,pmid,rpsid,pmidlink,components_type,rna_id,rna_id_interface,rnas,rna_length,rna_sequence,rna_classification,source,protein_sequence,protein_name,protein_region,protein_modification,protein_sequence_length,Uniprot ID,mark,link,IDR,low complexity domain,In_vitrovivo,solute_concentration,salt_concentration,buffer,temperature,incubation_time,other_requirement,detection_method,morphology,description
0,PMID: 22398450,RNAPS0000051,https://pubmed.ncbi.nlm.nih.gov/22398450,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P26599|PTBP1_HUMAN Polypyrimidine tract-binding protein 1 OS=Homo sapiens OX=9606 GN=PTBP1 PE=1 SV=1|length=531aa|residues=1-531
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTI",PTBP1,-,-,531aa(1-531),P26599,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/",-,"[32-44],[162-179],[306-335]",In vitro,136 µM [PTBP1];|80 µM RNA,"170 mM NaCl, 30 mM KCl, 1 mM MgCl2","170 mM NaCl, 30 mM KCl, 1 mM MgCl2",RT,"imme diately,> 2day s",other_molecular:1 mM ATP,Differential interference contrast microscopy,liquid,"Analogous droplets were also observed for an unrelated SH35-ligand5 pair and for the tetravalent RNA binding protein PTB interacting with an RNA oligonucleotide. Thus, liquid-liquiddemixing phase transitions may occur in many multivalent intracellular systems."
1,PMID: 22579282,RNAPS0000052,https://pubmed.ncbi.nlm.nih.gov/22579282,RNA + protein,-;|-,-;|-,"MS2 hairpin RNA (Han,2012);|Saccharomyces cerevisiae tRNA",31nt;|-,UAGAAAACAUGAGGAUCACCCAUGUCUGCAG;|-,irregular RNA;|tRNA,-;|Saccharomyces cerevisiae,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,1 µM[RNA];|2.5 µM yeast tRNA,"50 mM KCl, 5 mM MgCl2","50 mM KCl, 5 mM MgCl2",0˚C,30 min,"other_molecular:0.5% NP-40, 20 mM BME, 1:500 Rnasin",Confocal microscopy,gel,"Gel retention assay performed with both CFP tagged protein and Cy5.5-labeled hairpin RNA. The MS2 RNA hairpin is only recruited into the hydrogel when incubated with CFP-FUS214-MS2, which contains both the capacity for binding RNA as well as LC elements required for gel retention."
2,PMID: 26015579,RNAPS0000090,https://pubmed.ncbi.nlm.nih.gov/26015579,RNA + protein,-,-,polyU(50),50nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|D0PV95|DDX3_CAEEL ATP-dependent RNA helicase laf-1 OS=Caenorhabditis elegans OX=6239 GN=laf-1 PE=1 SV=1|length=708aa|residues=1-708
MESNQSNNGGSGNAALNRGGRYVPPHLRGGDGGAAAAASAGGDDRRGGAGGGGYRRGGGN
SGGGGGGGYDRGYNDNRDDRDNRGGSGGYGRDRNYEDRGYNGGGGGGGNRGYNNNRGGGG
GGYNRQDRGDGGSSNFSRGGYNNRDEGSDNRGSGRSYNNDRRDNGGDGQNTRWNNLDAPP
SRGTSKWENRGARDERIEQELFSGQLSGINFDKYEEIPVEATGDDVPQPISLFSDLSLHE
WIEENIKTAGYDRPTPVQKYSIPALQGGRDLMSCAQTGSGKTAAFLVPLVNAILQDGPDA
VHRSVTSSGGRKKQYPSALVLSPTRELSLQIFNESRKFAYRTPITSALLYGGRENYKDQI
HKLRLGCHILIATPGRLIDVMDQGLIGMEGCRYLVLDEADRMLDMGFEPQIRQIVECNRM
PSKEERITAMFSATFPKEIQLLAQDFLKENYVFLAVGRVGSTSENIMQKIVWVEEDEKRS
YLMDLLDATGDSSLTLVFVETKRGASDLAYYLNRQNYEVVTIHGDLKQFEREKHLDLFRT
GTAPILVATAVAARGLDIPNVKHVINYDLPSDVDEYVHRIGRTGRVGNVGLATSFFNDKN
RNIARELMDLIVEANQELPDWLEGMSGDMRSGGGYRGRGGRGNGQRFGGRDHRYQGGSGN
GGGGNGGGGGFGGGGQRSGGGGGFQSGGGGGRQQQQQQRAQPQQDWWS",laf-1,-,-,708aa(1-708),D0PV95,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/D0PV95,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0337,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0001,http://db.phasep.pro/browse/",-,-,In vitro,0-8 µM [laf-1];|5 µM polyU,100-400 mM NaCl,"20 mM Tris, pH 7.4, 1 mM DTT",20˚C,> 1 h,-,FRAP,"solute, liquid","RNA is recruited to droplets but does not shift the phase boundary. Addition of 5 µM RNA has no effect on the phase diagram of LAF-1. RNA concentration in the dilute phase vs. total LAF-1 concentration at 250 mM NaCl. Unlike LAF-1, which is in equilibrium with a constant saturation concentration in the dilute phase (Fig. 2D), the RNA concentration in the dilute phase decreases as total protein concentration increases. RNA concentration was directly measured using absorbance at A260 in the bulk phase after centrifugation of droplets."
3,PMID: 26351690,RNAPS0000159,https://pubmed.ncbi.nlm.nih.gov/26351690,RNAs + protein,-,-,Caenorhabditis elegans rRNA,50nt,-,rRNA,Caenorhabditis elegans,"sp|Q22053|FBRL_CAEEL rRNA 2'-O-methyltransferase fibrillarin OS=Caenorhabditis elegans OX=6239 GN=fib-1 PE=2 SV=1|length=352aa|residues=1-352
MGRPEFNRGGGGGGFRGGRGGDRGGSRGGFGGGGRGGYGGGDRGSFGGGDRGGFRGGRGG
GDRGGFRGGRGGGDRGGFGGRGSPRGGFGGRGSPRGGRGSPRGGRGGAGGMRGGKTVVVE
PHRLGGVFIVKGKEDALATKNMVVGESVYGEKRVSVDDGAGSIEYRVWNPFRSKLAASIM
GGLENTHIKPGTKLLYLGAASGTTVSHCSDVVGPEGIVYAVEFSHRSGRDLLGVAKKRPN
VVPIVEDARHPHKYRMLVGMVDVIFSDVAQPDQARIVALNAQNFLRNGGHAVISIKANCI
DSTAEPEAVFAGEVNKLKEEKFKPLEQVTLEPYERDHAVVVAVYRPVKGKKV",fib-1,-,-,352aa(1-352),Q22053,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q22053,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0032,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0019,http://db.phasep.pro/browse/",[1-115],[8-114],In vitro,5.5 µM [fib1];|5 µM rRNA,250 mM NaCl,"20 mM Tris, pH 7.4, 1 mM DTT",RT,-,-,Microscopy,liquid,"RNA specificity did not increase the magnitude of phase separation. We found quantitatively similar results with an in vitro-transcribed segment of C. elegans rRNA that is a direct substrate of FIB-1. Moreover, in addition to shifting the phase boundary, RNA accelerated droplet coarsening."
4,PMID: 26351690,RNAPS0000160,https://pubmed.ncbi.nlm.nih.gov/26351690,RNA + protein,-,-,yeast RNA,-,-,total RNA,yeast,"sp|Q22053|FBRL_CAEEL rRNA 2'-O-methyltransferase fibrillarin OS=Caenorhabditis elegans OX=6239 GN=fib-1 PE=2 SV=1|length=352aa|residues=1-352
MGRPEFNRGGGGGGFRGGRGGDRGGSRGGFGGGGRGGYGGGDRGSFGGGDRGGFRGGRGG
GDRGGFRGGRGGGDRGGFGGRGSPRGGFGGRGSPRGGRGSPRGGRGGAGGMRGGKTVVVE
PHRLGGVFIVKGKEDALATKNMVVGESVYGEKRVSVDDGAGSIEYRVWNPFRSKLAASIM
GGLENTHIKPGTKLLYLGAASGTTVSHCSDVVGPEGIVYAVEFSHRSGRDLLGVAKKRPN
VVPIVEDARHPHKYRMLVGMVDVIFSDVAQPDQARIVALNAQNFLRNGGHAVISIKANCI
DSTAEPEAVFAGEVNKLKEEKFKPLEQVTLEPYERDHAVVVAVYRPVKGKKV",fib-1,-,-,352aa(1-352),Q22053,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q22053,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0032,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0019,http://db.phasep.pro/browse/",[1-115],[8-114],In vitro,1-10 µM [fib1];|5 µM RNA,50-350 mM NaCl,"20 mM Tris, pH 7.4, 1 mM DTT",RT,-,-,Microscopy,"solute, liquid","At a given salt concentration, we observed droplet formation at a lower protein concentration when RNA was present, indicating that RNA promotes condensation, possibly by stabilizing interactions between FIB-1 molecules."
5,PMID: 26406374,RNAPS0000173,https://pubmed.ncbi.nlm.nih.gov/26406374,RNA + protein,-,-,"a random oligonucleotide RNA (Molliex,2015)",44nt,GGGCCCCCGGGUACCGAGCUGCUAAUCAAAACAAAACAAAAGCU,irregular RNA,-,"sp|P09651-2|ROA1_HUMAN Isoform A1-A of Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens OX=9606 GN=HNRNPA1|length=135aa|residues=186-320
MASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRGGNFSGRGGFGGSRGGGGYGGSGDGYN
GFGNDGSNFGGGGSYNDFGNYNNQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY
GGSSSSSSYGSGRRF",HNRNPA1,LCD,-,135aa(186-320),P09651,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/P09651,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2438","[186-196],[197-208],[309-318]",[190-320],In vitro,100 µM [HNRNPA1 LCD];|100 µM RNA,150 mM NaCl,"50 mM HEPES(pH 7.5), 5 mM DTT",10˚C,-,crowding agent:150 mg/ml Ficoll,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"The two RRM domains and multiple binding motifs for RRMs on the RNA likely mediate weak multivalent interactions that lead to LLPS. Droplets formed by A1-LCD also recruited RNA (Figure 4C), indicating that the LCD of hnRNPA1 binds RNA, as shown previously."
6,PMID: 26406374,RNAPS0000173,https://pubmed.ncbi.nlm.nih.gov/26406374,RNA + protein,-,-,"a random oligonucleotide RNA (Molliex,2015)",44nt,GGGCCCCCGGGUACCGAGCUGCUAAUCAAAACAAAACAAAAGCU,irregular RNA,-,"sp|P09651-2|ROA1_HUMAN Isoform A1-A of Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens OX=9606 GN=HNRNPA1|length=320aa|residues=1-320
MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVMRDPNTKRSRGFGFV
TYATVEEVDAAMNARPHKVDGRVVEPKRAVSREDSQRPGAHLTVKKIFVGGIKEDTEEHH
LRDYFEQYGKIEVIEIMTDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGHNCEVRKA
LSKQEMASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRGGNFSGRGGFGGSRGGGGYGGS
GDGYNGFGNDGSNFGGGGSYNDFGNYNNQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPR
NQGGYGGSSSSSSYGSGRRF",HNRNPA1,-,-,320aa(1-320),P09651,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/P09651,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2438","[1-8],[92-102],[182-196],[197-208],[309-318]",[190-320],In vitro,0.05-100 µM [HNRNPA1];|0-100 µM RNA,150 mM NaCl,"50 mM HEPES(pH 7.5), 5 mM DTT",10˚C,-,crowding agent:150 mg/ml Ficoll,"Differential interference contrast microscopy,Fluorescence microscopy","solute, liquid","Fluorescently labeled RNA (flfl-RNA44) was recruited into the protein-dense droplets formed by hnRNPA1 (Figure 4A). Notably, the addition of RNA substantially decreased the hnRNPA1 concentration required for phase separation to as low as 500 nM, well within the estimated intracellular concentration of hnRNPA1."
7,PMID: 26406374,RNAPS0000173,https://pubmed.ncbi.nlm.nih.gov/26406374,RNA + protein,-,-,"a random oligonucleotide RNA (Molliex,2015)",44nt,GGGCCCCCGGGUACCGAGCUGCUAAUCAAAACAAAACAAAAGCU,irregular RNA,-,"sp|P09651-2|ROA1_HUMAN Isoform A1-A of Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens OX=9606 GN=HNRNPA1|length=186aa|residues=1-186
MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVMRDPNTKRSRGFGFV
TYATVEEVDAAMNARPHKVDGRVVEPKRAVSREDSQRPGAHLTVKKIFVGGIKEDTEEHH
LRDYFEQYGKIEVIEIMTDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGHNCEVRKA
LSKQEM",HNRNPA1,RRM,-,186aa(1-186),P09651,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/P09651,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2438","[1-8],[92-102],[182-186]",-,In vitro,100 µM [HNRNPA1 RRM];|100 µM RNA,150 mM NaCl,"50 mM HEPES(pH 7.5), 5 mM DTT",10˚C,-,crowding agent:150 mg/ml Ficoll,Fluorescence microscopy,liquid,"The increased propensity for LLPS in the presence of RNA suggested the formation of larger hetero-oligomers. Indeed, despite our previous results that A1-RRM alone was not able to undergo LLPS under any conditions when tested in isolation, it readily phase separated in the presence of RNA."
8,PMID: 26412307,RNAPS0000051,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P26599|PTBP1_HUMAN Polypyrimidine tract-binding protein 1 OS=Homo sapiens OX=9606 GN=PTBP1 PE=1 SV=1|length=531aa|residues=1-531
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTI",PTBP1,-,-,531aa(1-531),P26599,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/",-,"[32-44],[162-179],[306-335]",In vitro,2.5-12.5 µM [PTBP1];|0.4-2 µM RNA,100 mM NaCl,"20 mM imidazole, pH 7.0, 1 mM DTT, 10% glycerol",RT,> 12 h,-,Electron microscopy,liquid,"An important point is that, even when insufficient in themselves to promote LLPS, promiscuous IDRs can decrease the critical concentration for phase separation driven by more specific interactions. We demonstrate this phenomenon for phase separation of PTB and RNA in vitro (Figure 4) and for P-body assembly in vivo (Figure 6)."
9,PMID: 26412307,RNAPS0000175,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P39936|IF4F2_YEAST Eukaryotic initiation factor 4F subunit p130 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=TIF4632 PE=1 SV=1|length=85aa|residues=13-97
QQANGYKKFPPHDNQYSGANNSQPNNHYNENLYSAREPHNNKQYQSKNGKYGTNKYNNRN
NSQGNAQYYNNRFNNGYRLNNNDYN",elF4GII,IDR,-,85aa(13-97),P39936,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P39936,http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0420,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0006,http://db.phasep.pro/browse/","[14-15],[17-19],[32-44],[64-66],[86-97]",-,In vitro,30 µM [elF4GII IDR];|0.1-4 µM RNA,100 mM NaCl,"20 mM Tris pH 7.4, 1 mM DTT",RT,-,-,Electron microscopy,liquid,"A range of RNA concentrations (0.1–10 mM) did not promote phase separation of the IDR proteins up to protein concentrations of 10–30 uM, SNAP-eIF4GII IDR, which did phase separate upon addition of RNA (0.1~4 uM)."
10,PMID: 26412307,RNAPS0000175,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P39936|IF4F2_YEAST Eukaryotic initiation factor 4F subunit p130 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=TIF4632 PE=1 SV=1|length=85aa|residues=13-97
QQANGYKKFPPHDNQYSGANNSQPNNHYNENLYSAREPHNNKQYQSKNGKYGTNKYNNRN
NSQGNAQYYNNRFNNGYRLNNNDYN",elF4GII,IDR,-,85aa(13-97),P39936,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P39936,http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0420,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0006,http://db.phasep.pro/browse/","[14-15],[17-19],[32-44],[64-66],[86-97]",-,In vitro,30 µM [elF4GII IDR];|4-10 µM RNA,100 mM NaCl,"20 mM Tris pH 7.4, 1 mM DTT",RT,-,-,Electron microscopy,liquid,"A range of RNA concentrations (0.1–10 mM) did not promote phase separation of the IDR proteins up to protein concentrations of 10–30 uM, SNAP-eIF4GII IDR, which did phase separate upon addition of RNA (0.1~4 uM)."
11,PMID: 26412307,RNAPS0000176,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=237aa|residues=1-237
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSG",FUS,IDR,-,237aa(1-237),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[1-237],"[17-104],[106-237]",In vitro,30 µM [FUS IDR];|0.1-10 µM RNA,100 mM NaCl,"20 mM Tris pH 7.4, 1 mM DTT",RT,-,-,Electron microscopy,solid,"A range of RNA concentrations (0.1–10 mM) did not promote phase separation of the IDR proteins up to protein concentrations of 10–30 uM, SNAP-eIF4GII IDR, which did phase separate upon addition of RNA (0.1~4 uM)."
12,PMID: 26412307,RNAPS0000177,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P09651-2|ROA1_HUMAN Isoform A1-A of Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens OX=9606 GN=HNRNPA1|length=135aa|residues=186-320
MASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRGGNFSGRGGFGGSRGGGGYGGSGDGYN
GFGNDGSNFGGGGSYNDFGNYNNQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY
GGSSSSSSYGSGRRF",HNRNPA1,IDR,-,135aa(186-320),P09651,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/P09651,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2438","[186-196],[197-208],[309-318]",[190-320],In vitro,10 µM [HNRNPA1 IDR];|0.1-10 µM RNA,100 mM NaCl,"20 mM Tris pH 7.4, 1 mM DTT",RT,-,-,Electron microscopy,liquid,"A range of RNA concentrations (0.1–10 mM) did not promote phase separation of the IDR proteins up to protein concentrations of 10–30 uM, SNAP-eIF4GII IDR, which did phase separate upon addition of RNA (0.1~4 uM)."
13,PMID: 26412307,RNAPS0000179,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P40070|LSM4_YEAST U6 snRNA-associated Sm-like protein LSm4 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=LSM4 PE=1 SV=1|length=97aa|residues=91-187
QQINSNNNSNSNGPGHKRYYNNRDSNNNRGNYNRRNNNNGNSNRRPYSQNRQYNNSNSSN
INNSINSINSNNQNMNNGLGGSVQHHFNSSSPQKVEF",LSM4,IDR,-,97aa(91-187),P40070,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0005,http://db.phasep.pro/browse/",-,"[94-102],[108-135],[138-167]",In vitro,30 µM [Lsm4 IDR];|0.1-10 µM RNA,100 mM NaCl,"20 mM Tris pH 7.4, 1 mM DTT",RT,-,-,Electron microscopy,solid,"A range of RNA concentrations (0.1–10 mM) did not promote phase separation of the IDR proteins up to protein concentrations of 10–30 uM, SNAP-eIF4GII IDR, which did phase separate upon addition of RNA (0.1~4 uM)."
14,PMID: 26412307,RNAPS0000367,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTB]-[elF4GII IDR] with PTB residues 1-531 fused to elF4GII residues 13-97|Linker is missing|length=616aa|residues=1-531/13-97
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTIQQANGYKKF
PPHDNQYSGANNSQPNNHYNENLYSAREPHNNKQYQSKNGKYGTNKYNNRNNSQGNAQYY
NNRFNNGYRLNNNDYN",PTBP1-TIF4632,IDR,-,"616aa(1-531,13-97)","P26599,P39936","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
TIF4632:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/;https://phasepro.elte.hu/entry/P39936,http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0420,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0006,http://db.phasep.pro/browse/","-;|[14-15],[17-19],[32-44],[64-66],[86-97]","[32-44],[162-179],[306-335];|-",In vitro,1.25 µM [PTBP1]-[TIF4632 IDR];|0.4 µM RNA,100 mM NaCl,"20 mM imidazole, pH 7.0, 1 mM DTT, 10% glycerol",RT,> 1 h;24 h,-,Electron microscopy,liquid,"All six PTB-IDR fusions phase separated upon addition of RNA, producing droplets that concentrated both molecules. At 1 hr after RNA addition, droplets formed by the eIF4GII IDR, Pub1 IDR, and Fus IDR fusions were relatively large, round, and separated into discrete structures. By contrast, the Lsm4 IDR, Tia1 IDR, and hnRNPA1 IDR fusions created droplets that were smaller, and often attached to each other in long irregular chains, as though coalescence into larger structures had been aborted."
15,PMID: 26412307,RNAPS0000369,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTB]-[FUS IDR] with PTB residues 1-531 fused to FUS residues 1-237|Linker is missing|length=768aa|residues=1-531/1-237
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTIMASNDYTQQ
ATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQSQNTGYGTQ
STPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSSSYGQPQSGS
YSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQDQSSMSSGGG
SGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSG",PTBP1-FUS,IDR,-,"768aa(1-531,1-237)","P26599,P35637","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",-;|[1-237],"[32-44],[162-179],[306-335];|[17-104],[106-237]",In vitro,≥125 nM [PTBP1]-[FUS IDR];|≥20 nM RNA,100 mM NaCl,"20 mM imidazole, pH 7.0, 1 mM DTT, 10% glycerol",RT,> 12 h,-,Electron microscopy,liquid,"Adding BSA can greatly reduce the concentration threshold of proteins and RNA for phase transition.Performing the experiment in the presence of 100 mg/ml BSA to mimic protein-crowding effects within the cell allowed the detection of RNA-driven LLPS of the SNAP-PTB-FusIDR at concentrations below 10 nM (Figure 2D), which is below the cellular concentration of many of the abundant components of mRNP granules."
16,PMID: 26412307,RNAPS0000369,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTB]-[FUS IDR] with PTB residues 1-531 fused to FUS residues 1-237|Linker is missing|length=768aa|residues=1-531/1-237
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTIMASNDYTQQ
ATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQSQNTGYGTQ
STPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSSSYGQPQSGS
YSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQDQSSMSSGGG
SGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSG",PTBP1-FUS,IDR,-,"768aa(1-531,1-237)","P26599,P35637","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",-;|[1-237],"[32-44],[162-179],[306-335];|[17-104],[106-237]",In vitro,≤62.5 nM [PTBP1]-[FUS IDR];|≤10 nM RNA,100 mM NaCl,"20 mM imidazole, pH 7.0, 1 mM DTT, 10% glycerol",RT,> 12 h,-,Electron microscopy,solute,"Adding BSA can greatly reduce the concentration threshold of proteins and RNA for phase transition.Performing the experiment in the presence of 100 mg/ml BSA to mimic protein-crowding effects within the cell allowed the detection of RNA-driven LLPS of the SNAP-PTB-FusIDR at concentrations below 10 nM (Figure 2D), which is below the cellular concentration of many of the abundant components of mRNP granules."
17,PMID: 26412307,RNAPS0000369,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTB]-[FUS IDR] with PTB residues 1-531 fused to FUS residues 1-237|Linker is missing|length=768aa|residues=1-531/1-237
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTIMASNDYTQQ
ATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQSQNTGYGTQ
STPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSSSYGQPQSGS
YSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQDQSSMSSGGG
SGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSG",PTBP1-FUS,IDR,-,"768aa(1-531,1-237)","P26599,P35637","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",-;|[1-237],"[32-44],[162-179],[306-335];|[17-104],[106-237]",In vitro,1-250 nM [PTBP1]-[FUS IDR];|1-40 nM RNA,100 mM NaCl,"20 mM imidazole, pH 7.0, 1 mM DTT, 10% glycerol",RT,> 12 h,other_molecular:100 mg/ml BSA,Electron microscopy,liquid,"Adding BSA can greatly reduce the concentration threshold of proteins and RNA for phase transition.Performing the experiment in the presence of 100 mg/ml BSA to mimic protein-crowding effects within the cell allowed the detection of RNA-driven LLPS of the SNAP-PTB-FusIDR at concentrations below 10 nM (Figure 2D), which is below the cellular concentration of many of the abundant components of mRNP granules."
18,PMID: 26412307,RNAPS0000369,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTB]-[FUS IDR] with PTB residues 1-531 fused to FUS residues 1-237|Linker is missing|length=768aa|residues=1-531/1-237
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTIMASNDYTQQ
ATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQSQNTGYGTQ
STPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSSSYGQPQSGS
YSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQDQSSMSSGGG
SGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSG",PTBP1-FUS,IDR,-,"768aa(1-531,1-237)","P26599,P35637","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",-;|[1-237],"[32-44],[162-179],[306-335];|[17-104],[106-237]",In vitro,3 µM [PTBP1]-[FUS IDR];|0.5 µM RNA,100 mM NaCl,"20 mM imidazole, pH 7.0, 1 mM DTT, 10% glycerol",RT,-,-,Electron microscopy,liquid,"At 100 mM NaCl and protein concentrations of 1.25–2.5 mM, all six SNAP-PTB-IDR fusions phase separated upon addition of 0.4–0.8 mM RNA, producing droplets that concentrated both molecules (Figures 2 and S2A, showing RNA enrichment)."
19,PMID: 26412307,RNAPS0000369,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTB]-[FUS IDR] with PTB residues 1-531 fused to FUS residues 1-237|Linker is missing|length=768aa|residues=1-531/1-237
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTIMASNDYTQQ
ATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQSQNTGYGTQ
STPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSSSYGQPQSGS
YSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQDQSSMSSGGG
SGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSG",PTBP1-FUS,IDR,-,"768aa(1-531,1-237)","P26599,P35637","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",-;|[1-237],"[32-44],[162-179],[306-335];|[17-104],[106-237]",In vitro,0.5-12.5 µM [PTBP1]-[FUS IDR];|0.1-2 µM RNA,100 mM NaCl,"20 mM imidazole, pH 7.0, 1 mM DTT, 10% glycerol",RT,> 12 h,-,Electron microscopy,"solute, liquid","At 100 mM NaCl and protein concentrations of 1.25–2.5 mM, all six SNAP-PTB-IDR fusions phase separated upon addition of 0.4–0.8 mM RNA, producing droplets that concentrated both molecules (Figures 2 and S2A, showing RNA enrichment)."
20,PMID: 26412307,RNAPS0000369,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTB]-[FUS IDR] with PTB residues 1-531 fused to FUS residues 1-237|Linker is missing|length=768aa|residues=1-531/1-237
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTIMASNDYTQQ
ATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQSQNTGYGTQ
STPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSSSYGQPQSGS
YSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQDQSSMSSGGG
SGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSG",PTBP1-FUS,IDR,-,"768aa(1-531,1-237)","P26599,P35637","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",-;|[1-237],"[32-44],[162-179],[306-335];|[17-104],[106-237]",In vitro,1.25 µM [PTBP1]-[FUS IDR];|0.4 µM RNA,100 mM NaCl,"20 mM imidazole, pH 7.0, 1 mM DTT, 10% glycerol",RT,> 1 h;24 h,-,Electron microscopy,liquid,"All six PTB-IDR fusions phase separated upon addition of RNA, producing droplets that concentrated both molecules. At 1 hr after RNA addition, droplets formed by the eIF4GII IDR, Pub1 IDR, and Fus IDR fusions were relatively large, round, and separated into discrete structures. By contrast, the Lsm4 IDR, Tia1 IDR, and hnRNPA1 IDR fusions created droplets that were smaller, and often attached to each other in long irregular chains, as though coalescence into larger structures had been aborted."
21,PMID: 26412307,RNAPS0000048,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTB]-[Pub1 IDR] with PTB residues 1-531 fused to Pub1 residues 243-327|Linker is missing|length=616aa|residues=1-531;243-327
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTINNNNNNYQQ
RRNYGNNNRGGFRQYNSNNNNNMNMGMNMNMNMNMNNSRGMPPSSMGMPIGAMPLPSQGQ
PQQSQTIGLPPQVNPQ",PTBP1-PUB1,IDR,-,"616aa(1-531,243-327)","P26599,P32588","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/,https://phasepro.elte.hu/entry/P32588,http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0524,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0004,http://db.phasep.pro/browse/",-;|[243-262],"[32-44],[162-179],[306-335];|[243-297],[307-316]",In vitro,2.5 µM [PTBP1]-[PUB1 IDR];|0.8 µM RNA,100 mM NaCl,"20 mM imidazole, pH 7.0, 1 mM DTT, 10% glycerol",RT,> 1 h;24 h,-,Electron microscopy,liquid,"All six PTB-IDR fusions phase separated upon addition of RNA, producing droplets that concentrated both molecules. At 1 hr after RNA addition, droplets formed by the eIF4GII IDR, Pub1 IDR, and Fus IDR fusions were relatively large, round, and separated into discrete structures. By contrast, the Lsm4 IDR, Tia1 IDR, and hnRNPA1 IDR fusions created droplets that were smaller, and often attached to each other in long irregular chains, as though coalescence into larger structures had been aborted."
22,PMID: 26412307,RNAPS0000049,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P32588|PUB1_YEAST Nuclear and cytoplasmic polyadenylated RNA-binding protein PUB1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=PUB1 PE=1 SV=4|length=85aa|residues=243-327
NNNNNNYQQRRNYGNNNRGGFRQYNSNNNNNMNMGMNMNMNMNMNNSRGMPPSSMGMPIG
AMPLPSQGQPQQSQTIGLPPQVNPQ",PUB1,IDR,-,85aa(243-327),P32588,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P32588,http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0524,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0004,http://db.phasep.pro/browse/",[243-262],"[243-297],[307-316]",In vitro,30 µM [PUB1 IDR];|0.1-10 µM RNA,100 mM NaCl,"20 mM Tris pH 7.4, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"A range of RNA concentrations (0.1-10 mM) did not promote phase separation of the IDR proteins up to protein concentrations of 10-30 µM, SNAP-eIF4GII IDR, which did phase separate upon addition of RNA (0.1~4 µM)."
23,PMID: 26412307,RNAPS0000050,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,"hnRNPA1_ligand RNA (Lin,2015)",46nt,UAGGGACUUAGGGUUCUCUCUAGGGACUUAGGGUUCUCUCUAGGGA,irregular RNA,-,"sp|P09651-2|ROA1_HUMAN Isoform A1-A of Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens OX=9606 GN=HNRNPA1|length=320aa|residues=1-320
MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVMRDPNTKRSRGFGFV
TYATVEEVDAAMNARPHKVDGRVVEPKRAVSREDSQRPGAHLTVKKIFVGGIKEDTEEHH
LRDYFEQYGKIEVIEIMTDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGHNCEVRKA
LSKQEMASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRGGNFSGRGGFGGSRGGGGYGGS
GDGYNGFGNDGSNFGGGGSYNDFGNYNNQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPR
NQGGYGGSSSSSSYGSGRRF",HNRNPA1,-,-,320aa(1-320),P09651,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/P09651,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2438","[1-8],[92-102],[182-196],[197-208],[309-318]",[190-320],In vitro,50 µM [HNRNPA1];|100 µM RNA,300 mM NaCl,"20 mM Tris pH 7.4, 1 mM DTT",RT,> 1 h,crowding agent:100 mg/ml Ficoll400,Electron microscopy,liquid,"If we added PEG as a crowding agent, we observed phase separation of hnRNPA1 without RNA at high protein concentrations, and stimulation of LLPS with RNA addition at lower protein concentrations, demonstrating that RNA can promote LLPS of hnRNPA1. Similar results were observed with Ficoll as a crowding agent."
24,PMID: 26412307,RNAPS0000050,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,"hnRNPA1_ligand RNA (Lin,2015)",46nt,UAGGGACUUAGGGUUCUCUCUAGGGACUUAGGGUUCUCUCUAGGGA,irregular RNA,-,"sp|P09651-2|ROA1_HUMAN Isoform A1-A of Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens OX=9606 GN=HNRNPA1|length=320aa|residues=1-320
MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVMRDPNTKRSRGFGFV
TYATVEEVDAAMNARPHKVDGRVVEPKRAVSREDSQRPGAHLTVKKIFVGGIKEDTEEHH
LRDYFEQYGKIEVIEIMTDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGHNCEVRKA
LSKQEMASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRGGNFSGRGGFGGSRGGGGYGGS
GDGYNGFGNDGSNFGGGGSYNDFGNYNNQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPR
NQGGYGGSSSSSSYGSGRRF",HNRNPA1,-,-,320aa(1-320),P09651,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/P09651,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2438","[1-8],[92-102],[182-196],[197-208],[309-318]",[190-320],In vitro,5 µM [HNRNPA1];|10 µM RNA,175 mM NaCl,"20 mM Tris pH 7.4, 1 mM DTT",RT,-,crowding agent:100 mg/ml PEG 3350,Electron microscopy,liquid,"If we added PEG as a crowding agent, we observed phase separation of hnRNPA1 without RNA at high protein concentrations, and stimulation of LLPS with RNA addition at lower protein concentrations, demonstrating that RNA can promote LLPS of hnRNPA1. Similar results were observed with Ficoll as a crowding agent."
25,PMID: 26412307,RNAPS0000050,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,"hnRNPA1_ligand RNA (Lin,2015)",46nt,UAGGGACUUAGGGUUCUCUCUAGGGACUUAGGGUUCUCUCUAGGGA,irregular RNA,-,"sp|P09651-2|ROA1_HUMAN Isoform A1-A of Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens OX=9606 GN=HNRNPA1|length=320aa|residues=1-320
MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVMRDPNTKRSRGFGFV
TYATVEEVDAAMNARPHKVDGRVVEPKRAVSREDSQRPGAHLTVKKIFVGGIKEDTEEHH
LRDYFEQYGKIEVIEIMTDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGHNCEVRKA
LSKQEMASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRGGNFSGRGGFGGSRGGGGYGGS
GDGYNGFGNDGSNFGGGGSYNDFGNYNNQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPR
NQGGYGGSSSSSSYGSGRRF",HNRNPA1,-,-,320aa(1-320),P09651,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/P09651,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2438","[1-8],[92-102],[182-196],[197-208],[309-318]",[190-320],In vitro,30 µM [HNRNPA1];|60 µM RNA,175 mM NaCl,"20 mM Tris pH 7.4, 1 mM DTT",RT,-,crowding agent:100 mg/ml PEG 3350,Electron microscopy,liquid,"If we added PEG as a crowding agent, we observed phase separation of hnRNPA1 without RNA at high protein concentrations, and stimulation of LLPS with RNA addition at lower protein concentrations, demonstrating that RNA can promote LLPS of hnRNPA1. Similar results were observed with Ficoll as a crowding agent."
26,PMID: 26474065,RNAPS0000014,https://pubmed.ncbi.nlm.nih.gov/26474065,RNA + protein,NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/1201,CLN3,1879nt(1-1879),GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA,Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,370-7400nM [Whi3];|0.5-134 nM CLN3,150 mM NaCl,"50 mM Tris pH8, 1 mM DTT",RT,> 12 h,-,Fluorescence microscopy,"solute, liquid","Remarkably, CLN3 RNA can promote detectable formation of droplets at Whi3 concentrations as low as 200 nM. This is in the same order of magnitude of soluble Whi3 in Ashbya cytosol that we have measured by fluorescence correlation spectroscopy (57±14 nM)."
27,PMID: 26474065,RNAPS0000014,https://pubmed.ncbi.nlm.nih.gov/26474065,RNA + protein,NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/1201,CLN3,1879nt(1-1879),GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA,Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,9 µM [Whi3];|50 nM CLN3,150 mM NaCl,"50 mM Tris pH8, 1 mM DTT",RT,-,-,Confocal microscopy,liquid,"We see that BNI1 mRNA can drive Whi3 phase separation at 150 mM salt in a similar fashion as CLN3 RNA, in that for a given protein concentration, the apparent droplet volume fraction increases then decreases with increasing RNA concentration. We also found that BNI1 droplets fuse faster than CLN3 droplets."
28,PMID: 26474065,RNAPS0000014,https://pubmed.ncbi.nlm.nih.gov/26474065,RNA + protein,NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/1201,CLN3,1879nt(1-1879),GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA,Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,3.7 µM [Whi3];|53 nM CLN3,150 mM NaCl,"50 mM Tris pH8, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"We found that droplets consisting of Whi3 and RNA were indeed readily formed. In contrast, adding the same amount of DNA, yeast total RNA or heparin did not promote Whi3 droplets. This indicates that CLN3 mRNA can shift the phase boundary to lower protein concentration and high salt concentration, enabling Whi3 phase separation in physiological conditions."
29,PMID: 26474065,RNAPS0000014,https://pubmed.ncbi.nlm.nih.gov/26474065,RNA + protein,NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/1201,CLN3,1879nt(1-1879),GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA,Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,7.4 µM [Whi3];|53 nM CLN3,150 mM NaCl,"50 mM Tris pH8, 1 mM DTT",RT,> 4 h,-,Fluorescence microscopy,liquid,"Individual single-point mutations showed minimal effect on droplet formation with or without mRNA. However, the RRM double mutant demonstrates a marked reduction in mRNA-mediated assembly. Thus, direct binding of the RRM domain with CLN3 mRNA is necessary for mRNA-mediated assembly of droplets. Purified individual RRM domain, polyQ domain, and RRM-polyQ domains are also not able to form droplets, neither by lowering salt nor by adding CLN3 mRNA."
30,PMID: 26474065,RNAPS0000014,https://pubmed.ncbi.nlm.nih.gov/26474065,RNA + protein,NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/1201,CLN3,1879nt(1-1879),GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA,Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729|mutation=F653A
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCAVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,protein_mutation:F653A,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[654-676],[698-718],[728-729]",-,In vitro,7.4 µM [Whi3];|53 nM CLN3,150 mM NaCl,"50 mM Tris pH8, 1 mM DTT",RT,> 4 h,-,Fluorescence microscopy,liquid,"Individual single-point mutations showed minimal effect on droplet formation with or without mRNA. However, the RRM double mutant demonstrates a marked reduction in mRNA-mediated assembly. Thus, direct binding of the RRM domain with CLN3 mRNA is necessary for mRNA-mediated assembly of droplets. Purified individual RRM domain, polyQ domain, and RRM-polyQ domains are also not able to form droplets, neither by lowering salt nor by adding CLN3 mRNA."
31,PMID: 26474065,RNAPS0000014,https://pubmed.ncbi.nlm.nih.gov/26474065,RNA + protein,NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/1201,CLN3,1879nt(1-1879),GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA,Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729|mutation=Y610A
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLAVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,protein_mutation:Y610A,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,7.4 µM [Whi3];|53 nM CLN3,150 mM NaCl,"50 mM Tris pH8, 1 mM DTT",RT,> 4 h,-,Fluorescence microscopy,liquid,"Individual single-point mutations showed minimal effect on droplet formation with or without mRNA. However, the RRM double mutant demonstrates a marked reduction in mRNA-mediated assembly. Thus, direct binding of the RRM domain with CLN3 mRNA is necessary for mRNA-mediated assembly of droplets. Purified individual RRM domain, polyQ domain, and RRM-polyQ domains are also not able to form droplets, neither by lowering salt nor by adding CLN3 mRNA."
32,PMID: 26474065,RNAPS0000014,https://pubmed.ncbi.nlm.nih.gov/26474065,RNA + protein,NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/1201,CLN3,1879nt(1-1879),GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA,Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729|mutation=Y610A,F653A
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLAVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCAVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,"protein_mutation:Y610A,F653A",729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[654-676],[698-718],[728-729]",-,In vitro,7.4 µM [Whi3];|53 nM CLN3,150 mM NaCl,"50 mM Tris pH8, 1 mM DTT",RT,> 4 h,-,Fluorescence microscopy,liquid,"Individual single-point mutations showed minimal effect on droplet formation with or without mRNA. However, the RRM double mutant demonstrates a marked reduction in mRNA-mediated assembly. Thus, direct binding of the RRM domain with CLN3 mRNA is necessary for mRNA-mediated assembly of droplets. Purified individual RRM domain, polyQ domain, and RRM-polyQ domains are also not able to form droplets, neither by lowering salt nor by adding CLN3 mRNA."
33,PMID: 26474065,RNAPS0000014,https://pubmed.ncbi.nlm.nih.gov/26474065,RNA + protein,NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/1201,CLN3,1879nt(1-1879),GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA,Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=640aa|residues=1-605,695-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPPLGVRGPNSRRGGATNNTSNAGTTNYSYAAAFGKS",Whi3,△RRM,-,"640aa(1-605,695-729)",Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-605],[695-718],[728]-[729]      ",-,In vitro,7.4 µM [Whi3△RRM];|53 nM CLN3,150 mM NaCl,"50 mM Tris pH8, 1 mM DTT",RT,> 4 h,-,Fluorescence microscopy,solute,"Individual single-point mutations showed minimal effect on droplet formation with or without mRNA. However, the RRM double mutant demonstrates a marked reduction in mRNA-mediated assembly. Thus, direct binding of the RRM domain with CLN3 mRNA is necessary for mRNA-mediated assembly of droplets. Purified individual RRM domain, polyQ domain, and RRM-polyQ domains are also not able to form droplets, neither by lowering salt nor by adding CLN3 mRNA."
34,PMID: 26474065,RNAPS0000014,https://pubmed.ncbi.nlm.nih.gov/26474065,RNA + protein,NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/1201,CLN3,1879nt(1-1879),GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA,Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=636aa|residues=1-460,554-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHGSSRNSISKTLQVNGPKNAA
AALQNTNGISQVDLSLLAKVPPPANPADQNPPCNTLYVGNLPPDATEQELRQLFSSQKGF
RRLSFRNKNNNGNGHGPMCFVEFEDVAHATRALAELYGSQLARTSGTHNNKGGIRLSFSK
NPLGVRGPNSRRGGATNNTSNAGTTNYSYAAAFGKS",Whi3,△polyQ,-,"636aa(1-460,554-729)",Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-460],[554-623],[668-676],[698-718],[728-729]",-,In vitro,7.4 µM [whi3△polyQ];|53 nM CLN3,150 mM NaCl,"50 mM Tris pH8, 1 mM DTT",RT,> 4 h,-,Fluorescence microscopy,liquid,"Individual single-point mutations showed minimal effect on droplet formation with or without mRNA. However, the RRM double mutant demonstrates a marked reduction in mRNA-mediated assembly. Thus, direct binding of the RRM domain with CLN3 mRNA is necessary for mRNA-mediated assembly of droplets. Purified individual RRM domain, polyQ domain, and RRM-polyQ domains are also not able to form droplets, neither by lowering salt nor by adding CLN3 mRNA."
35,PMID: 26474065,RNAPS0000014,https://pubmed.ncbi.nlm.nih.gov/26474065,RNA + protein,NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/1201,CLN3,1879nt(1-1879),GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA,Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,5 µM [Whi3];|53 nM CLN3,60 mM NaCl,"50 mM Tris pH8, 1 mM DTT",RT,≤ 15 min,-,Fluorescence microscopy,liquid,"The first indication that mRNA can promote droplets is clear when an endogenous Whi3-interacting mRNA, CLN3, is added to Whi3-protein droplets. Before adding RNA, the bulk concentration outside the protein droplet is the saturation concentration in these conditions. Shortly after adding CLN3 mRNA, new droplets consisting of Whi3 and RNA start to form and enlarge. Meanwhile, old protein-only droplets begin shrinking and eventually dissolve completely as Whi3 leaves the protein-only droplets and goes into the new protein-RNA droplets. Notably, the new droplets do not fuse with the preformed Whi3-only droplets."
36,PMID: 26474065,RNAPS0000015,https://pubmed.ncbi.nlm.nih.gov/26474065,RNA + protein,NCBI ID:855450,https://www.ncbi.nlm.nih.gov/gene/855450,BNI1,5862nt(1-5862),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA,mRNA,Saccharomyces cerevisiae,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,9 µM [Whi3];|50 nM BNI1,150 mM NaCl,"50 mM Tris pH8, 1 mM DTT",RT,-,-,Confocal microscopy,liquid,"We see that BNI1 mRNA can drive Whi3 phase separation at 150 mM salt in a similar fashion as CLN3 RNA, in that for a given protein concentration, the apparent droplet volume fraction increases then decreases with increasing RNA concentration. We also found that BNI1 droplets fuse faster than CLN3 droplets."
37,PMID: 26474065,RNAPS0000015,https://pubmed.ncbi.nlm.nih.gov/26474065,RNA + protein,NCBI ID:855450,https://www.ncbi.nlm.nih.gov/gene/855450,BNI1,5862nt(1-5862),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA,mRNA,Saccharomyces cerevisiae,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,1850-7400nM [Whi3];|5/27/53/134/268nM BNI1,150 mM NaCl,"50 mM Tris pH8, 1 mM DTT",RT,> 4 h,-,Fluorescence microscopy,liquid,"We see that BNI1 mRNA can drive Whi3 phase separation at 150 mM salt in a similar fashion as CLN3 RNA, in that for a given protein concentration, the apparent droplet volume fraction increases then decreases with increasing RNA concentration. We also found that BNI1 droplets fuse faster than CLN3 droplets."
38,PMID: 26474065,RNAPS0000053,https://pubmed.ncbi.nlm.nih.gov/26474065,RNA + protein,-,-,yeast RNA,-,-,total RNA,Triticum aestivum,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,3.7 µM [Whi3];|total yeast RNA that are normalized to 53 nM CLN3 RNA by charge,150 mM NaCl,"50 mM Tris pH8, 1 mM DTT",RT,-,-,Fluorescence microscopy,solute,"We found that droplets consisting of Whi3 and RNA were indeed readily formed. In contrast, adding the same amount of DNA, yeast total RNA or heparin did not promote Whi3 droplets."
39,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASLRRASL,RRASL,-,-,15aa,-,-,-,-,-,In vitro,1 mM [RRASL]3;|0.05 % (w/w) polyU,"150 mM NaCl, 4 mM MgCl2","50 mM HEPES buffer, pH 7.4, 1.6 mM DTT",37˚C,> 10 min,"other_molecular:0.01 mg/ml PKA,3.2 mM ATP",Turbidity measurement,solute,"The sequence was inspired by the peptide LRRASLG or ‘Kemptide’, which is a model synthetic substrate for PKA37,38. Addition of RRASLRRASL to a buffered solution of 0.05% (wt/wt) (∼0.06 mg ml–1) polyU resulted in complex coacervation."
40,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASLRRASL,RRASL,-,-,15aa,-,-,-,-,-,In vitro,1 mM [RRASL]3;|0.05 % (w/w) polyU,"150 mM NaCl, 4 mM MgCl2, 1 mM MnCl2","50 mM HEPES buffer, pH 7.4, 1.6 mM DTT",37˚C,> 5 min,"other_molecular:0.01 mg/ml PKA,3.2 mM ATP0.004 mg/ml LPP","Turbidity measurement,Confocal microscopy,Fluorescence microscopy",liquid,We monitored coacervate formation in the polyU/RRASLRRASL system by confocal microscopy. Figure 2e and Supplementary Movies 1-5 show differential interference contrast (DIC) and fluorescence images throughout the course of the reaction.
41,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASLRRASL,RRASL,-,-,15aa,-,-,-,-,-,In vitro,1 mM [RRASL]3;|0.05 % (w/w) polyU,"150 mM NaCl, 4 mM MgCl2","50 mM HEPES, pH 7.4, 1.6 mM DTT",37˚C,≤ 60 min,"other_molecular:0.01 mg/ml PKA,3.2 mM ATP",Turbidity measurement,solute,PKA activity was able to cause dissolution of polyU/triple RRASL coacervates in 150 mM NaCl buffered solution. Addition of 0.01 mg/mL PKA resulted in coacervate dissolution as we observed with the poly U/RRASLRRASL system.
42,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASLRRASL,RRASL,-,-,15aa,-,-,-,-,-,In vitro,1 mM [RRASL]3;|0.05 % (w/w) polyU,"150 mM NaCl, 4 mM MgCl2","50 mM HEPES, pH 7.4, 1.6 mM DTT",37˚C,≤ 60 min,"other_molecular:0.01 mg/ml PKA,3.2 mM ADP",Turbidity measurement,liquid,PKA activity was able to cause dissolution of polyU/triple RRASL coacervates in 150 mM NaCl buffered solution. Addition of 0.01 mg/mL PKA resulted in coacervate dissolution as we observed with the poly U/RRASLRRASL system.
43,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASLRRASL,RRASL,-,-,15aa,-,-,-,-,-,In vitro,1 mM [RRASL]3;|0.05 % (w/w) polyU,"150 mM NaCl, 4 mM MgCl2","50 mM HEPES, pH 7.4, 1.6 mM DTT",37˚C,> 10 min,other_molecular:3.2 mM ATP,Turbidity measurement,liquid,PKA activity was able to cause dissolution of polyU/triple RRASL coacervates in 150 mM NaCl buffered solution. Addition of 0.01 mg/mL PKA resulted in coacervate dissolution as we observed with the poly U/RRASLRRASL system.
44,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASLRRASL,RRASL,-,-,15aa,-,-,-,-,-,In vitro,<100 µM [RRASL]3;|0.05% (w/w) polyU,4 mM MgCl2,"50 mM HEPES, pH 7.4, 1.6 mM dithiothreitol",37˚C,> 5 min,other_molecular:2.25 mM ATP,"Turbidity measurement,Confocal microscopy,Fluorescence microscopy",solute,"For polyU/RRASLRRASLRRASL (triple RRASL) coacervates, the CCC shifts to 100 µM peptide (Fig. 1b, dashed line). These coacervates were stable at 150 mM NaCl (physiological salt concentration) and did not show an appreciable decrease in turbidity until 300 mM NaCl was reached; they dissolved at 350 mM NaCl."
45,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASLRRASL,RRASL,-,-,15aa,-,-,-,-,-,In vitro,>100 µM [RRASL]3;|0.05% (w/w) polyU,4 mM MgCl2,"50 mM HEPES, pH 7.4, 1.6 mM dithiothreitol",37˚C,> 5 min,other_molecular:2.25 mM ATP,"Turbidity measurement,Confocal microscopy,Fluorescence microscopy",liquid,"For polyU/RRASLRRASLRRASL (triple RRASL) coacervates, the CCC shifts to 100 µM peptide (Fig. 1b, dashed line). These coacervates were stable at 150 mM NaCl (physiological salt concentration) and did not show an appreciable decrease in turbidity until 300 mM NaCl was reached; they dissolved at 350 mM NaCl."
46,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASL,RRASL,-,-,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.05% (w/w) polyU,"4 mM MgCl2, NaCl<50 mM","50 mM HEPES, pH 7.4, 1.6 mM dithiothreitol",37˚C,> 5 min,other_molecular:2.25 mM ATP,Turbidity measurement,liquid,"Charge screening with additional NaCl decreased the turbidity to ∼35% at 50 mM NaCl, and the coacervates dissolved at 100 mM NaCl. For polyU/RRASLRRASLRRASL (triple RRASL) coacervates, the CCC shifts to 100 µM peptide. These coacervates were stable at 150 mM NaCl (physiological salt concentration) and did not show an appreciable decrease in turbidity until 300 mM NaCl was reached; they dissolved at 350 mM NaCl."
47,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASL,RRASL,-,-,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.05% (w/w) polyU,"4 mM MgCl2, NaCl>100 mM","50 mM HEPES, pH 7.4, 1.6 mM dithiothreitol",37˚C,> 5 min,other_molecular:2.25 mM ATP,Turbidity measurement,solute,"Charge screening with additional NaCl decreased the turbidity to ∼35% at 50 mM NaCl, and the coacervates dissolved at 100 mM NaCl. For polyU/RRASLRRASLRRASL (triple RRASL) coacervates, the CCC shifts to 100 µM peptide. These coacervates were stable at 150 mM NaCl (physiological salt concentration) and did not show an appreciable decrease in turbidity until 300 mM NaCl was reached; they dissolved at 350 mM NaCl."
48,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASL,RRASL,-,-,10aa,-,-,-,-,-,In vitro,<250 µM [RRASL]2;|0.05% (w/w) polyU,4 mM MgCl2,"50 mM HEPES, pH 7.4, 1.6 mM dithiothreitol",37˚C,> 5 min,other_molecular:2.25 mM ATP,"Turbidity measurement,Confocal microscopy,Fluorescence microscopy",solute,"Addition of RRASLRRASL to a buffered solution of 0.05% (wt/wt) (∼0.06 mg ml–1) polyU resulted in complex coacervation. The minimum concentration necessary for coacervate formation, or the critical coacervate concentration (CCC), was 250 µM RRASLRRASL."
49,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASL,RRASL,-,-,10aa,-,-,-,-,-,In vitro,>250 µM [RRASL]2;|0.05% (w/w) polyU,4 mM MgCl2,"50 mM HEPES, pH 7.4, 1.6 mM dithiothreitol",37˚C,> 5 min,other_molecular:2.25 mM ATP,"Turbidity measurement,Confocal microscopy,Fluorescence microscopy",liquid,"Addition of RRASLRRASL to a buffered solution of 0.05% (wt/wt) (∼0.06 mg ml–1) polyU resulted in complex coacervation. The minimum concentration necessary for coacervate formation, or the critical coacervate concentration (CCC), was 250 µM RRASLRRASL."
50,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASLRRASL,RRASL,-,-,15aa,-,-,-,-,-,In vitro,1 mM [RRASL]3;|0.05% (w/w) polyU,"4 mM MgCl2, <300 mM NaCl","50 mM HEPES, pH 7.4, 1.6 mM dithiothreitol",37˚C,> 5 min,other_molecular:2.25 mM ATP,Turbidity measurement,liquid,"For polyU/RRASLRRASLRRASL (triple RRASL) coacervates, the critical coacervate concentration (CCC) shifts to 100 µM peptide. These coacervates were stable at 150 mM NaCl (physiological salt concentration) and did not show an appreciable decrease in turbidity until 300 mM NaCl was reached; they dissolved at 350 mM NaCl."
51,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASLRRASL,RRASL,-,-,15aa,-,-,-,-,-,In vitro,1 mM [RRASL]3;|0.05% (w/w) polyU,"4 mM MgCl2, >350 mM NaCl","50 mM HEPES, pH 7.4, 1.6 mM dithiothreitol",37˚C,> 5 min,other_molecular:2.25 mM ATP,Turbidity measurement,solute,"For polyU/RRASLRRASLRRASL (triple RRASL) coacervates, the critical coacervate concentration (CCC) shifts to 100 µM peptide. These coacervates were stable at 150 mM NaCl (physiological salt concentration) and did not show an appreciable decrease in turbidity until 300 mM NaCl was reached; they dissolved at 350 mM NaCl."
52,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASL,RRASL,-,protein_ptm:Phosphorylation,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.05% (w/w) polyU,"4 mM MgCl2, 1 mM MnCl2","50 mM HEPES, pH 7.4, 1.6 mM dithiothreitol",37˚C,> 15 min,other_molecular:0.040 µM LPP,Turbidity measurement,liquid,"Addition of 0.001 mg/ml–1 LPP (800 U ml–1, 0.040 µM) to a solution containing polyU and RRApSLRRApSL resulted in a turbid solution after 10 min. Without LPP or Mn2+ for LPP activity, the solution did not become turbid. Dephosphorylation of RRApSLRRApSL by LPP was able to produce RRASLRRASL, and coacervation was subsequently observed."
53,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASL,RRASL,-,protein_ptm:Phosphorylation,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.05% (w/w) polyU,"4 mM MgCl2, 1 mM MnCl2","50 mM HEPES, pH 7.4, 1.6 mM dithiothreitol",37˚C,≤ 60 min,-,Turbidity measurement,solute,"Addition of 0.001 mg/ml–1 LPP (800 U ml–1, 0.040 µM) to a solution containing polyU and RRApSLRRApSL resulted in a turbid solution after 10 min. Without LPP or Mn2+ for LPP activity, the solution did not become turbid. Dephosphorylation of RRApSLRRApSL by LPP was able to produce RRASLRRASL, and coacervation was subsequently observed."
54,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASL,RRASL,-,protein_ptm:Phosphorylation,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.05% (w/w) polyU,4 mM MgCl2 ,"50 mM HEPES, pH 7.4, 1.6 mM dithiothreitol",37˚C,≤ 60 min,other_molecular:0.040 µM LPP,Turbidity measurement,solute,"Addition of 0.001 mg/ml–1 LPP (800 U ml–1, 0.040 µM) to a solution containing polyU and RRApSLRRApSL resulted in a turbid solution after 10 min. Without LPP or Mn2+ for LPP activity, the solution did not become turbid. Dephosphorylation of RRApSLRRApSL by LPP was able to produce RRASLRRASL, and coacervation was subsequently observed."
55,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASLRRASL,RRASL,-,-,15aa,-,-,-,-,-,In vitro,1 mM [RRASL]3;|0.05 % (w/w) polyU,"150 mM NaCl, 4 mM MgCl2, 1 mM MnCl2","50 mM HEPES buffer, pH 7.4, 1.6 mM DTT",37˚C,≤ 40 min,"other_molecular:0.01 mg/ml PKA,3.2 mM ATP",Turbidity measurement,solute,"Dephosphorylation of RRApSLRRApSL by LPP was able to produce RRASLRRASL, and coacervation was subsequently observed. Coacervate formation by phosphatase activity was not limited to just polyU and RRASLRRASL. LPP activity also triggered coacervation with polyU and triple RRApSL in 150 mM NaCl buffered solution and with tRNA and RRApSLRRApSL in buffered solution."
56,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASLRRASL,RRASL,-,-,15aa,-,-,-,-,-,In vitro,1 mM [RRASL]3;|0.05 % (w/w) polyU,"150 mM NaCl, 4 mM MgCl2","50 mM HEPES buffer, pH 7.4, 1.6 mM DTT",37˚C,≤ 40 min,"other_molecular:0.01 mg/ml PKA,3.2 mM ATP0.004 mg/ml LPP",Turbidity measurement,solute,"Dephosphorylation of RRApSLRRApSL by LPP was able to produce RRASLRRASL, and coacervation was subsequently observed. Coacervate formation by phosphatase activity was not limited to just polyU and RRASLRRASL. LPP activity also triggered coacervation with polyU and triple RRApSL in 150 mM NaCl buffered solution and with tRNA and RRApSLRRApSL in buffered solution."
57,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASL,RRASL,-,-,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.05% (w/w) polyU,4 mM MgCl2,"50 mM HEPES, pH 7.4,  1.6 mM dithiothreitol",37˚C,> 6 min,other_molecular:0.24 µM PKA2.25 mM ATP,Turbidity measurement,solute,"Addition of protein kinase A resulted in a transparent solution after ~6 min. Dissolution was rapid, and the sample went from turbid to transparent in ~2 min. Turbidity persisted in controls lacking kinase and in those with adenosine diphosphate (ADP) substituted for ATP. PolyU/RRASLRRASL coacervates could be reversibly formed and dissolved in the same solution by controlling phosphatase and kinase activity through the addition of reagents. The coacervate formation/dissolution was the result of RRASLRRASL concentration rather than changes in the solution ionic strength/composition from adding the reagents."
58,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASL,RRASL,-,-,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.05% (w/w) polyU,4 mM MgCl2,"50 mM HEPES, pH 7.4,  1.6 mM dithiothreitol",37˚C,≤ 60 min,other_molecular:2.25 mM ATP,Turbidity measurement,liquid,"Addition of protein kinase A resulted in a transparent solution after ~6 min. Dissolution was rapid, and the sample went from turbid to transparent in ~2 min. Turbidity persisted in controls lacking kinase and in those with adenosine diphosphate (ADP) substituted for ATP. PolyU/RRASLRRASL coacervates could be reversibly formed and dissolved in the same solution by controlling phosphatase and kinase activity through the addition of reagents. The coacervate formation/dissolution was the result of RRASLRRASL concentration rather than changes in the solution ionic strength/composition from adding the reagents."
59,PMID: 26791895,RNAPS0000054,https://pubmed.ncbi.nlm.nih.gov/26791895,RNA + protein,-,-,polyU,"-(600–1,000 kDa)",-,poly RNA,-,RRASLRRASL,RRASL,-,-,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.05% (w/w) polyU,4 mM MgCl2,"50 mM HEPES, pH 7.4,  1.6 mM dithiothreitol",37˚C,≤ 60 min,other_molecular:0.24 µM PKA2.25 mM ADP,Turbidity measurement,liquid,"Addition of protein kinase A resulted in a transparent solution after ~6 min. Dissolution was rapid, and the sample went from turbid to transparent in ~2 min. Turbidity persisted in controls lacking kinase and in those with adenosine diphosphate (ADP) substituted for ATP. PolyU/RRASLRRASL coacervates could be reversibly formed and dissolved in the same solution by controlling phosphatase and kinase activity through the addition of reagents. The coacervate formation/dissolution was the result of RRASLRRASL concentration rather than changes in the solution ionic strength/composition from adding the reagents."
60,PMID: 26791895,RNAPS0000161,https://pubmed.ncbi.nlm.nih.gov/26791895,RNAs + protein,-,-,Saccharomyces cerevisiae tRNA,-(23–27 kDa),-,tRNA,Saccharomyces cerevisiae,RRASLRRASL,RRASL,-,-,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.05 % (w/w) tRNA,4 mM MgCl2,"50 mM HEPES buffer, pH 7.4, 1.6 mM DTT",37˚C,> 50 min,other_molecular:2.25 mM ATP,Turbidity measurement,liquid,"Turbidity persisted in controls lacking kinase (red trace, Fig. 3b) and in those with adenosine diphosphate (ADP) substituted for ATP (blue trace, Fig. 3b). We also found that PKA activity was able to cause dissolution of polyU/triple RRASL coacervates in 150 mM NaCl buffered solution (Supplementary Fig. 10) and tRNA/RRASLRRASL coacervates in buffered solution (Supplementary Fig. 11)."
61,PMID: 26791895,RNAPS0000161,https://pubmed.ncbi.nlm.nih.gov/26791895,RNAs + protein,-,-,Saccharomyces cerevisiae tRNA,-(23–27 kDa),-,tRNA,Saccharomyces cerevisiae,RRASLRRASL,RRASL,-,-,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.05 % (w/w) tRNA,4 mM MgCl2,"50 mM HEPES buffer, pH 7.4, 1.6 mM DTT",37˚C,≤ 60 min,"other_molecular:0.005 mg/ml PKA,2.25 mM ATP",Turbidity measurement,solute,"Turbidity persisted in controls lacking kinase (red trace, Fig. 3b) and in those with adenosine diphosphate (ADP) substituted for ATP (blue trace, Fig. 3b). We also found that PKA activity was able to cause dissolution of polyU/triple RRASL coacervates in 150 mM NaCl buffered solution (Supplementary Fig. 10) and tRNA/RRASLRRASL coacervates in buffered solution (Supplementary Fig. 11)."
62,PMID: 26791895,RNAPS0000161,https://pubmed.ncbi.nlm.nih.gov/26791895,RNAs + protein,-,-,Saccharomyces cerevisiae tRNA,-(23–27 kDa),-,tRNA,Saccharomyces cerevisiae,RRASLRRASL,RRASL,-,-,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.05 % (w/w) tRNA,4 mM MgCl2,"50 mM HEPES buffer, pH 7.4, 1.6 mM DTT",37˚C,≤ 60 min,"other_molecular:0.005 mg/ml PKA,2.25 mM ADP",Turbidity measurement,liquid,"Turbidity persisted in controls lacking kinase (red trace, Fig. 3b) and in those with adenosine diphosphate (ADP) substituted for ATP (blue trace, Fig. 3b). We also found that PKA activity was able to cause dissolution of polyU/triple RRASL coacervates in 150 mM NaCl buffered solution (Supplementary Fig. 10) and tRNA/RRASLRRASL coacervates in buffered solution (Supplementary Fig. 11)."
63,PMID: 26791895,RNAPS0000161,https://pubmed.ncbi.nlm.nih.gov/26791895,RNAs + protein,-,-,Saccharomyces cerevisiae tRNA,-(23–27 kDa),-,tRNA,Saccharomyces cerevisiae,RRASLRRASL,RRASL,-,protein_ptm:Phosphorylation,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.15% (w/w) tRNA,"4 mM MgCl2, 1 mM MnCl2","50 mM HEPES, pH 7.4, 1.6 mM DTT",37˚C,> 20 min,other_molecular:0.040 µM LPP,Turbidity measurement,liquid,"Dephosphorylation of RRApSLRRApSL by LPP was able to produce RRASLRRASL, and coacervation was subsequently observed. Coacervate formation by phosphatase activity was not limited to just polyU and RRASLRRASL. LPP activity also triggered coacervation with polyU and triple RRApSL in 150 mM NaCl buffered solution and with tRNA and RRApSLRRApSL in buffered solution."
64,PMID: 26791895,RNAPS0000161,https://pubmed.ncbi.nlm.nih.gov/26791895,RNAs + protein,-,-,Saccharomyces cerevisiae tRNA,-(23–27 kDa),-,tRNA,Saccharomyces cerevisiae,RRASLRRASL,RRASL,-,protein_ptm:Phosphorylation,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.15% (w/w) tRNA,"4 mM MgCl2, 1 mM MnCl2","50 mM HEPES, pH 7.4, 1.6 mM DTT",37˚C,> 5 min,-,Turbidity measurement,solute,"Dephosphorylation of RRApSLRRApSL by LPP was able to produce RRASLRRASL, and coacervation was subsequently observed. Coacervate formation by phosphatase activity was not limited to just polyU and RRASLRRASL. LPP activity also triggered coacervation with polyU and triple RRApSL in 150 mM NaCl buffered solution and with tRNA and RRApSLRRApSL in buffered solution."
65,PMID: 26791895,RNAPS0000161,https://pubmed.ncbi.nlm.nih.gov/26791895,RNAs + protein,-,-,Saccharomyces cerevisiae tRNA,-(23–27 kDa),-,tRNA,Saccharomyces cerevisiae,RRASLRRASL,RRASL,-,protein_ptm:Phosphorylation,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.15% (w/w) tRNA,4 mM MgCl2,"50 mM HEPES, pH 7.4, 1.6 mM DTT",37˚C,≤ 80 min.,other_molecular:0.040 µM LPP,Turbidity measurement,solute,"Dephosphorylation of RRApSLRRApSL by LPP was able to produce RRASLRRASL, and coacervation was subsequently observed. Coacervate formation by phosphatase activity was not limited to just polyU and RRASLRRASL. LPP activity also triggered coacervation with polyU and triple RRApSL in 150 mM NaCl buffered solution and with tRNA and RRApSLRRApSL in buffered solution."
66,PMID: 26791895,RNAPS0000161,https://pubmed.ncbi.nlm.nih.gov/26791895,RNAs + protein,-,-,Saccharomyces cerevisiae tRNA,-(23–27 kDa),-,tRNA,Saccharomyces cerevisiae,RRASLRRASL,RRASL,-,-,10aa,-,-,-,-,-,In vitro,1 mM [RRASL]2;|0.05% (w/w) tRNA,4 mM MgCl2,"50 mM HEPES, pH 7.4, 1.6 mM dithiothreitol",37˚C,> 2 min,other_molecular:2.25 mM ATP,"Confocal microscopy,Fluorescence microscopy",liquid,These coacervates were similar in size to the polyU coacervates (1.8 ± 0.6 µM). We conclude that coacervation in these systems is not RNA sequence dependent and is largely driven by electrostatic attraction between the negatively charged RNAs and the positively charged peptides.
67,PMID: 26836305,RNAPS0000162,https://pubmed.ncbi.nlm.nih.gov/26836305,RNAs + protein,-,-,Triticum aestivum germ rRNA,-,-,rRNA,Triticum aestivum,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|length=174aa|residues=121-294
EDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDD
FDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKG
PSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL",NPM1,△N,-,174aa(121-294),P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/",[121-259],-,In vitro,0-50 µM [NPM1△N];|50 µg/ml rRNA,150 mM NaCl,"10 mM Tris, 2 mM DTT, pH 7.5",RT,> 5 min,-,Turbidity measurement,solute,"Neither of these truncated constructs (NPM1 N240, NPM1△N) experienced phase separation in the presence of rRNA, confirming that multivalent display of the NBD is required for the co-localization of rRNA with NPM1 within liquid-like droplets."
68,PMID: 26836305,RNAPS0000162,https://pubmed.ncbi.nlm.nih.gov/26836305,RNAs + protein,-,-,Triticum aestivum germ rRNA,-,-,rRNA,Triticum aestivum,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|length=240aa|residues=1-240
MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIV
EAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVE
EDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDD
FDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKG",NPM1,N240,-,240aa(1-240),P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/",[1-240],-,In vitro,0-50 µM [NPM1 N240];|50 µg/ml rRNA,150 mM NaCl,"10 mM Tris, 2 mM DTT, pH 7.5",RT,> 5 min,-,Turbidity measurement,solute,"Neither of these truncated constructs (NPM1 N240, NPM1△N) experienced phase separation in the presence of rRNA, confirming that multivalent display of the NBD is required for the co-localization of rRNA with NPM1 within liquid-like droplets."
69,PMID: 26836305,RNAPS0000162,https://pubmed.ncbi.nlm.nih.gov/26836305,RNAs + protein,-,-,Triticum aestivum germ rRNA,-,-,rRNA,Triticum aestivum,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|length=294aa|residues=1-294
MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIV
EAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVE
EDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDD
FDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKG
PSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL",NPM1,-,-,294aa(1-294),P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/",[1-259],-,In vitro,10-50 µM [NPM1];|50 µg/mL rRNA,150 mM NaCl,"10 mM Tris, 2 mM DTT, pH 7.5",RT,> 5 min,-,"Turbidity measurement,Fluorescence microscopy",liquid,"We tested and confirmed the ability of full length NPM1 (N294) to phase separate with either wheat germ rRNA or rpL5 using light scattering and fluorescence microscopy. Binary mixtures of NPM1 with either rpL5 or rRNA formed droplets that increased in size over time; those with rpL5 fused more rapidly and were larger in size than those with rRNA. Furthermore, droplets of NPM1 with rpL5 formed at ~5-fold lower concentrations of both components than were required for phase separation with N130 and rpL5 due to the higher valency of acidic tracts within the full-length protein."
70,PMID: 27212236,RNAPS0000058,https://pubmed.ncbi.nlm.nih.gov/27212236,RNA + protein,-,-,polyU(50),50nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|Q22053|FBRL_CAEEL rRNA 2'-O-methyltransferase fibrillarin OS=Caenorhabditis elegans OX=6239 GN=fib-1 PE=2 SV=1|length=352aa|residues=1-352
MGRPEFNRGGGGGGFRGGRGGDRGGSRGGFGGGGRGGYGGGDRGSFGGGDRGGFRGGRGG
GDRGGFRGGRGGGDRGGFGGRGSPRGGFGGRGSPRGGRGSPRGGRGGAGGMRGGKTVVVE
PHRLGGVFIVKGKEDALATKNMVVGESVYGEKRVSVDDGAGSIEYRVWNPFRSKLAASIM
GGLENTHIKPGTKLLYLGAASGTTVSHCSDVVGPEGIVYAVEFSHRSGRDLLGVAKKRPN
VVPIVEDARHPHKYRMLVGMVDVIFSDVAQPDQARIVALNAQNFLRNGGHAVISIKANCI
DSTAEPEAVFAGEVNKLKEEKFKPLEQVTLEPYERDHAVVVAVYRPVKGKKV",fib1,-,-,352aa(1-352),Q22053,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q22053,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0032,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0019,http://db.phasep.pro/browse/",[1-115],[8-114],In vitro,600 nM [fib1];|5 µM polyU,150 mM NaCl,"20 mM Tris, pH 7.5, 1 mM DTT",RT,> 30 min,-,Microscopy,liquid,"Indeed, in the presence of 5 mg/ml rRNA and 150 mM NaCl, FIB1 condenses into droplets at a protein concentration of 600 nM. FIB1 can phase separate even in the presence of non-specific poly-U50 and heparin, suggesting that electrostatic interactions contribute to droplet assembly."
71,PMID: 27212236,RNAPS0000164,https://pubmed.ncbi.nlm.nih.gov/27212236,RNAs + protein,-,-,Xenopus laevis  rRNA,-,-,rRNA,Xenopus laevis,"sp|Q22053|FBRL_CAEEL rRNA 2'-O-methyltransferase fibrillarin OS=Caenorhabditis elegans OX=6239 GN=fib-1 PE=2 SV=1|length=100aa|residues=1-100
MGRPEFNRGGGGGGFRGGRGGDRGGSRGGFGGGGRGGYGGGDRGSFGGGDRGGFRGGRGG
GDRGGFRGGRGGGDRGGFGGRGSPRGGFGGRGSPRGGRGS",fib1,△C,-,100aa(1-100),Q22053,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q22053,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0032,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0019,http://db.phasep.pro/browse/",[1-100],[8-100],In vitro,1 µM [fib1△C];|5 µg/ml rRNA,150 mM NaCl,"20 mM Tris, pH 7.5, 1 mM DTT",RT,> 30 min,-,FRAP,liquid,"The R/G domain (FIB1△C) is sufficient to form liquid-like droplets in vitro, while the MD alone (FIB1△N) is unable to form droplets in vitro. Interestingly, FIB1△C can phase separate into liquid-like droplets in vitro, even in the absence of RNA. By contrast, full-length FIB1 requires rRNA; however, this may be a non-specific consequence of the polyanionic nature of rRNA since heparin can also drive phase separation of full-length FIB1. FIB1△C droplets also exhibit faster dynamics than full-length FIB1."
72,PMID: 27212236,RNAPS0000164,https://pubmed.ncbi.nlm.nih.gov/27212236,RNAs + protein,-,-,Xenopus laevis  rRNA,-,-,rRNA,Xenopus laevis,"sp|Q22053|FBRL_CAEEL rRNA 2'-O-methyltransferase fibrillarin OS=Caenorhabditis elegans OX=6239 GN=fib-1 PE=2 SV=1|length=252aa|residues=101-352
PRGGRGGAGGMRGGKTVVVEPHRLGGVFIVKGKEDALATKNMVVGESVYGEKRVSVDDGA
GSIEYRVWNPFRSKLAASIMGGLENTHIKPGTKLLYLGAASGTTVSHCSDVVGPEGIVYA
VEFSHRSGRDLLGVAKKRPNVVPIVEDARHPHKYRMLVGMVDVIFSDVAQPDQARIVALN
AQNFLRNGGHAVISIKANCIDSTAEPEAVFAGEVNKLKEEKFKPLEQVTLEPYERDHAVV
VAVYRPVKGKKV",fib1,-,-,252aa(101-352),Q22053,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q22053,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0032,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0019,http://db.phasep.pro/browse/",[101-115],[101-114],In vitro,1 µM [fib1△N];|5 µg/ml rRNA,150 mM NaCl,"20 mM Tris, pH 7.5, 1 mM DTT",RT,> 30 min,-,FRAP,solute,"The R/G domain (FIB1△C) is sufficient to form liquid-like droplets in vitro, while the MD alone (FIB1△N) is unable to form droplets in vitro. Interestingly, FIB1△C can phase separate into liquid-like droplets in vitro, even in the absence of RNA. By contrast, full-length FIB1 requires rRNA; however, this may be a non-specific consequence of the polyanionic nature of rRNA since heparin can also drive phase separation of full-length FIB1. FIB1△C droplets also exhibit faster dynamics than full-length FIB1."
73,PMID: 27212236,RNAPS0000164,https://pubmed.ncbi.nlm.nih.gov/27212236,RNAs + protein,-,-,Xenopus laevis  rRNA,-,-,rRNA,Xenopus laevis,"sp|Q22053|FBRL_CAEEL rRNA 2'-O-methyltransferase fibrillarin OS=Caenorhabditis elegans OX=6239 GN=fib-1 PE=2 SV=1|length=352aa|residues=1-352
MGRPEFNRGGGGGGFRGGRGGDRGGSRGGFGGGGRGGYGGGDRGSFGGGDRGGFRGGRGG
GDRGGFRGGRGGGDRGGFGGRGSPRGGFGGRGSPRGGRGSPRGGRGGAGGMRGGKTVVVE
PHRLGGVFIVKGKEDALATKNMVVGESVYGEKRVSVDDGAGSIEYRVWNPFRSKLAASIM
GGLENTHIKPGTKLLYLGAASGTTVSHCSDVVGPEGIVYAVEFSHRSGRDLLGVAKKRPN
VVPIVEDARHPHKYRMLVGMVDVIFSDVAQPDQARIVALNAQNFLRNGGHAVISIKANCI
DSTAEPEAVFAGEVNKLKEEKFKPLEQVTLEPYERDHAVVVAVYRPVKGKKV",fib1,-,-,352aa(1-352),Q22053,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q22053,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0032,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0019,http://db.phasep.pro/browse/",[1-115],[8-114],In vitro,0.25-1 µM [fib1];|5 µg/ml rRNA,50-250 mM NaCl,"20 mM Tris, pH 7.5, 1 mM DTT",RT,≤ 2 h,-,FRAP,"liquid, solid","FIB1 can phase separate in vitro under near physiological protein and salt concentrations, giving rise to condensed liquid-phase droplets that are ~50-fold more concentrated with protein than the surrounding dilute phase. FIB1 droplets typically take roughly a hundred times longer than NPM1 droplets of comparable size to coalesce and relax into a single larger sphere. FIB1 FRAP dynamics are strongly impacted by the droplet age. By 2 hr, these droplets become increasingly solid-like with time, potentially due to the formation of fibers. Liquid-like FIB1 droplets evolve into sticky gel structures over a 2-hr time period."
74,PMID: 27212236,RNAPS0000165,https://pubmed.ncbi.nlm.nih.gov/27212236,RNAs + protein,-,-,Xenopus laevis  rRNA,-,-,rRNA,Xenopus laevis,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|length=175aa|residues=120-294
EEDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDD
DFDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPK
GPSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL",NPM1,△N,-,175aa(120-294),P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/",[120-259],-,In vitro,5 µM [NPM1△N];|100 µg/mL rRNA,150 mM NaCl,"20 mM Tris, pH 7.5, 1 mM DTT",RT,> 30 min,-,FRAP,solute,"Neither mutants of NPM1 is able to form droplets in vitro, consistent with phase separation of NPM1 requiring the oligomerization of NPM1 into multivalent pentamers that can bind to rRNA. Phase transition of a disordered nuage protein generates environmentally responsive membraneless organelles."
75,PMID: 27212236,RNAPS0000165,https://pubmed.ncbi.nlm.nih.gov/27212236,RNAs + protein,-,-,Xenopus laevis  rRNA,-,-,rRNA,Xenopus laevis,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|length=240aa|residues=1-240
MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIV
EAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVE
EDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDD
FDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKG",NPM1,N240,-,240aa(1-240),P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/",[1-240],-,In vitro,5 µM [NPM1△C];|100 µg/mL rRNA,150 mM NaCl,"20 mM Tris, pH 7.5, 1 mM DTT",RT,> 30 min,-,FRAP,solute,"Neither mutants of NPM1 is able to form droplets in vitro, consistent with phase separation of NPM1 requiring the oligomerization of NPM1 into multivalent pentamers that can bind to rRNA. Phase transition of a disordered nuage protein generates environmentally responsive membraneless organelles."
76,PMID: 27212236,RNAPS0000165,https://pubmed.ncbi.nlm.nih.gov/27212236,RNAs + protein,-,-,Xenopus laevis  rRNA,-,-,rRNA,Xenopus laevis,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|length=294aa|residues=1-294
MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIV
EAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVE
EDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDD
FDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKG
PSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL",NPM1,-,-,294aa(1-294),P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/",[1-259],-,In vitro,2-8 µM [NPM1];|100 µg/ml rRNA,100-250 mM NaCl,"20 mM Tris, pH 7.5, 1 mM DTT",RT,≤ 2 h,-,FRAP,"solute, liquid","NPM1 has also recently been demonstrated to undergo phase separation into liquid-like droplets. However, at 150 mM NaCl, NPM1 requires significantly higher concentrations of protein and rRNA. Moreover, phase separation of NPM1 required rRNA and cannot be induced by the addition of heparin or poly-U50. After 30 min of initiating phase separation, we find that NPM1 always exhibits a near complete recovery, even for droplets that have been sitting for several hours."
77,PMID: 27545621,RNAPS0000167,https://pubmed.ncbi.nlm.nih.gov/27545621,RNAs + protein,-,-,yeast RNA,-,-,total RNA,yeast,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|length=148aa|residues=267-414
NRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAA
QAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWG
SASNAGSGSGFNGGFGSSMDSKSSGWGM",TDP-43,CTD,-,148aa(267-414),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[267-414],"[272-314],[321-329],[342-358],[368-404]",In vitro,3-90 µg/mL RNA;|20 µM [TDP-43 CTD],-,"20 mM MES (pH 6.1), 1M DTT",22˚C,-,-,Turbidity measurement,liquid,"TDP-43 CTD LLPS peaks in the presence of increasing amounts of RNA, possibly due to saturation of the protein-RNA interactions."
78,PMID: 27545621,RNAPS0000167,https://pubmed.ncbi.nlm.nih.gov/27545621,RNAs + protein,-,-,yeast RNA,-,-,total RNA,yeast,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|length=148aa|residues=267-414
NRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAA
QAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWG
SASNAGSGSGFNGGFGSSMDSKSSGWGM",TDP-43,CTD,-,148aa(267-414),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[267-414],"[272-314],[321-329],[342-358],[368-404]",In vitro,3 µg/mL RNA;|20 µM [TDP-43 CTD],-,20 mM MES (pH 6.1),22˚C,-,-,"Differential interference contrast microscopy,FRAP",liquid,"At low salt concentration (0 M NaCl), 20 uM CTD remains monomeric. However, upon addition of 150 mM NaCl, the domain rapidly undergoes LLPS. These assemblies appear as dynamic, high protein concentration liquid droplets that flow and fuse and show effectively complete fluorescence recovery after photobleaching (FRAP), highlighting their liquid-like character. Addition of yeast RNA as low as 3 ug/mL resulted in phase separation. As previously observed for full-length FUS aggregation and phase separation, TDP-43 CTD LLPS peaks in the presence of increasing amounts of RNA, possibly due to saturation of the protein-RNA interactions."
79,PMID: 27594427,RNAPS0000170,https://pubmed.ncbi.nlm.nih.gov/27594427,RNAs + protein,-,-,Caenorhabditis elegans mRNA,-,-,mRNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1|length=693aa|residues=1-693
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,10 ng/µl mRNA;|0.6 µM [pgl-3],150 mM KCl,"25 mM HEPES pH 7.5, 1 mM DTT",RT,≤ 30-40 min,-,Microscopy,liquid,"In contrast, addition of total mRNA significantly increased both the number of PGL-3 drops and fraction of total PGL-3 that concentrated within these drops. Therefore, we conclude that mRNA rather than rRNA drives the formation of PGL-3 drops."
80,PMID: 27594427,RNAPS0000170,https://pubmed.ncbi.nlm.nih.gov/27594427,RNAs + protein,-,-,Caenorhabditis elegans mRNA,-,-,mRNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1|length=693aa|residues=1-693|mutation=R634L,R638G,R650L,R661G,R665G,R690G
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGLGGDGGGRGAYGGDRGLGGSGDGSRGY
GGGDGGGRGSYGEGSRGYQGGRAGFFGGSGGGS",pgl-3,-,"protein_mutation:R634L,R638G,R650L,R661G,R665G,R690G",693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[1-6],[51-70],[107-107],[112-134],[149-157],[181-194],[219-254],[279-287],[342-353],[368-381],[438-473],[484-487],[516-533],[551-594],[626-674],[683-693]",-,In vitro,10 ng/µl mRNA;|0.6 µM [pgl-3],150 mM KCl,"25 mM HEPES pH 7.5, 1 mM DTT",RT,≤ 30-40 min,-,Microscopy,solute,"Total mRNA failed to promote assembly of drops at physiological protein concentrations of a PGL-3 construct where the arginines in all the six RGG repeats have been mutated to glycine or leucine (RGG_mut). Therefore, P granule assembly is promoted by the presence of mRNA, and mRNA requires RGG repeats in PGL-3 in order to promote drop formation. Consistent with this result, mRNA concentrated within PGL-3 drops."
81,PMID: 27594427,RNAPS0000067,https://pubmed.ncbi.nlm.nih.gov/27594427,RNA + protein,-,-,luciferase(lacking 50 cap and polyA tail),-,-,mRNA,Photinus pyralis,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1|length=693aa|residues=1-693
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,10 ng/µl mRNA;|0.6 µM [pgl-3],150 mM KCl,"25 mM HEPES pH 7.5, 1 mM DTT",RT,≤ 30-40 min,-,Microscopy,liquid,"Drop assembly on addition of different kinds of RNA to PGL-3-mEGFP (0.6 mM).circles: total C. elegans mRNA (10 ng/ml), or in-vitro-transcribed luciferase mRNA lacking 50 cap and poly(A) tail (10 ng/ml)"
82,PMID: 27594427,RNAPS0000068,https://pubmed.ncbi.nlm.nih.gov/27594427,RNA + protein,-,-,Mus musculus brain mRNA,-,-,mRNA,Mus musculus,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1|length=693aa|residues=1-693
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,50 ng/µl mRNA;|0.6 µM [pgl-3],"150 mM KCl, 2 mM ZnCl2","25 mM HEPES pH 7.5, 2 mM DTT",RT,> 15 min,-,Microscopy,liquid,"Physiological concentration of mRNA (100 nM, or 50 ng/ml assuming average length of mRNA is 1.5 kb) can promote assembly of drops at physiological concentrations of PGL-3."
83,PMID: 27594427,RNAPS0000068,https://pubmed.ncbi.nlm.nih.gov/27594427,RNA + protein,-,-,Mus musculus brain mRNA,-,-,mRNA,Mus musculus,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1|length=693aa|residues=1-693
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,50 ng/µl mRNA;|0.1-100 µM [pgl-3],150 mM KCl,"25 mM HEPES pH 7.5, 1 mM DTT",RT,≤ 30-40 min,-,Microscopy,liquid,"Plot of the fraction of total GFP fluorescence found in phase-separated drops as a function of total PGL-3-mEGFP concentration in presence or absence of 50 ng/ml mouse brain mRNA. For each concentration of PGL-3, drops in R12 observation volumes were scored."
84,PMID: 27594427,RNAPS0000171,https://pubmed.ncbi.nlm.nih.gov/27594427,RNAs + protein,-,-,18S,1754nt(1-1754),AUACCUGAUUGAUUCUGUCAGCGCGAUAUGCUCAAGUAAAAGAUUAAGCCAUGCAUGCUUUGAUUCAUCAAUGAAAUUGCGUACGGCUCAUUAGAGCAGAUAUCACCUUAUCCGGGAUCCUCAUAUGGAUAACUGCGGAAAUACUGGAGCUAAUACAUGCAACUAUACCCCAACGCAAGGCGGGGUGCAAUUAUUAGAACAGACCAAACGUUUUCGGACGUUGUUUGUUGACUCUGAAUAAAGCAGUUUACUGUCAGUUUCGACUGACUCUAUCCGGAAAGGGUGUCUGCCCUUUCAACUAGAUGGUAGUUUAUUGGACUACCAUGGUUGUUACGGGUAACGGAGAAUAAGGGUUCGACUCCGGAGAGGGAGCCUUAGAAACGGCUACCACGUCCAAGGAAGGCAGCAGGCGCGAAACUUAUCCACUGUUGAGUAUGAGAUAGUGACUAAAAAUAUAAAGACUCAUCCUUUUGGAUGAGUUAUUUCAAUGAGUUGAAUACAAAUGAUUCUUCGAGUAGCAAGGAGAGGGCAAGUCUGGUGCCAGCAGCCGCGGUAAUUCCAGCUCUCCUAGUGUAUCUCGUUAUUGCUGCGGUUAAAAAGCUCGUAGUUGGAUCUAGGUUACGUGCCGCAGUUCGCAAUUUGCGUCAACUGUGGUCGUGACUUCUAAUUUGCUGGUUUGAGGUUGGGUUCGCCCUUCAACUGCCAGCAGGUUUACCUUGAAUAAAUCAGAGUGCUCAAUACAAGCGCUUGCUUGAAUAGCUCAUCAUGGAAUAAUGAAACAGGACUUCGGUUCUUUUUGUUGGUUCUAGAACUGAUUUAAUGGUUAAGAGGGACAAACCGGGGGCAUUCGUAUCAUUACGCGAGAGGUGAAAUUCGUGGACCGUAGUGAGACGCCCAACAGCGAAAGCAUUUGCCAAGAAUGUCUUCAUUAAUCAAGAACGAAAGUCAGAGGUUCGAAGGCGAUUAGAUACCGCCCUAGUUCUGACCGUAAACGAUGCCAUCUCGCGAUUCGGAGGGUUUUUGCCCUGCCGAGGAGCUAUCCGGAAACGAAAGUCUUUCGGUUCCGGGGGUAGUAUGGUUGCAAAGCUGAAACUUAAAGAAAUUGACGGAAGGGCACCACAAGGCGUGGAGCUUGCGGCUUAAUUUGACUCAACACGGGAAAACUCACCCGGUCCGGACACCAUUAGGACUGACAGAUUGAAAGCUCUUUCUCGAUUUGGUGGUUGGUGGUGCAUGGCCGUUCUUAGUUGGUGGAGUGAUUUGUCUGGUUUAUUCCGAUAACGAGCGAGACUCUAGCCUGCUAAAUAGUUGGCGAAUCUUCGGGUUCGUAUAACUUCUUAGAGGGAUAAGCGGUGUUUAGCCGCACGAGAUUGAGCGAUAACAGGUCUGUGAUGCCCUUAGAUGUCCGGGGCUGCACGCGUGCUACACUGGUGGAGUCAGCGGGUUUUUCCUAUGCCGAAAGGUAUCGGUAAACCGUUGAAAUUCUUCCAUGUCCGGGAUAGGGUAUUGUAAUUAUUGCCCUUAAACGAGGAAUGCCUAGUAAGUGUGAGUCAUCAGCUCACGUUGAUUACGUCCCUGCCCUUUGUACACACCGCCCGUCGCUAUCCGGGACUGAACUGAUUCGAGAAGAGUGGGGACUGUCGCUUCGAGGUUUAACGACUUCGUUGUUGCGGAAACCAUUUUUAUCGCAUUGGUUUGAACCGGGUAAAAGUCGUAACAAGGUAGCUGUAGGUGAACCUGCAGCUGGAUCAUCG,rRNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1|length=693aa|residues=1-693
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,10-100 ng/µl rRNA;|0.6 µM [pgl-3],150 mM KCl,"25 mM HEPES pH 7.5, 1 mM DTT",RT,≤ 30-40 min,-,Microscopy,solute,"In-vitro-transcribed 18S rRNA did not promote assembly of PGL-3 drops over a broad range of concentrations (10–100 ng/ml). Heating the rRNA made it assembly competent, which suggests that the complex structures of rRNA attenuate its ability to promote PGL-3 drops."
85,PMID: 27594427,RNAPS0000171,https://pubmed.ncbi.nlm.nih.gov/27594427,RNAs + protein,-,-,18S,1754nt(1-1754),AUACCUGAUUGAUUCUGUCAGCGCGAUAUGCUCAAGUAAAAGAUUAAGCCAUGCAUGCUUUGAUUCAUCAAUGAAAUUGCGUACGGCUCAUUAGAGCAGAUAUCACCUUAUCCGGGAUCCUCAUAUGGAUAACUGCGGAAAUACUGGAGCUAAUACAUGCAACUAUACCCCAACGCAAGGCGGGGUGCAAUUAUUAGAACAGACCAAACGUUUUCGGACGUUGUUUGUUGACUCUGAAUAAAGCAGUUUACUGUCAGUUUCGACUGACUCUAUCCGGAAAGGGUGUCUGCCCUUUCAACUAGAUGGUAGUUUAUUGGACUACCAUGGUUGUUACGGGUAACGGAGAAUAAGGGUUCGACUCCGGAGAGGGAGCCUUAGAAACGGCUACCACGUCCAAGGAAGGCAGCAGGCGCGAAACUUAUCCACUGUUGAGUAUGAGAUAGUGACUAAAAAUAUAAAGACUCAUCCUUUUGGAUGAGUUAUUUCAAUGAGUUGAAUACAAAUGAUUCUUCGAGUAGCAAGGAGAGGGCAAGUCUGGUGCCAGCAGCCGCGGUAAUUCCAGCUCUCCUAGUGUAUCUCGUUAUUGCUGCGGUUAAAAAGCUCGUAGUUGGAUCUAGGUUACGUGCCGCAGUUCGCAAUUUGCGUCAACUGUGGUCGUGACUUCUAAUUUGCUGGUUUGAGGUUGGGUUCGCCCUUCAACUGCCAGCAGGUUUACCUUGAAUAAAUCAGAGUGCUCAAUACAAGCGCUUGCUUGAAUAGCUCAUCAUGGAAUAAUGAAACAGGACUUCGGUUCUUUUUGUUGGUUCUAGAACUGAUUUAAUGGUUAAGAGGGACAAACCGGGGGCAUUCGUAUCAUUACGCGAGAGGUGAAAUUCGUGGACCGUAGUGAGACGCCCAACAGCGAAAGCAUUUGCCAAGAAUGUCUUCAUUAAUCAAGAACGAAAGUCAGAGGUUCGAAGGCGAUUAGAUACCGCCCUAGUUCUGACCGUAAACGAUGCCAUCUCGCGAUUCGGAGGGUUUUUGCCCUGCCGAGGAGCUAUCCGGAAACGAAAGUCUUUCGGUUCCGGGGGUAGUAUGGUUGCAAAGCUGAAACUUAAAGAAAUUGACGGAAGGGCACCACAAGGCGUGGAGCUUGCGGCUUAAUUUGACUCAACACGGGAAAACUCACCCGGUCCGGACACCAUUAGGACUGACAGAUUGAAAGCUCUUUCUCGAUUUGGUGGUUGGUGGUGCAUGGCCGUUCUUAGUUGGUGGAGUGAUUUGUCUGGUUUAUUCCGAUAACGAGCGAGACUCUAGCCUGCUAAAUAGUUGGCGAAUCUUCGGGUUCGUAUAACUUCUUAGAGGGAUAAGCGGUGUUUAGCCGCACGAGAUUGAGCGAUAACAGGUCUGUGAUGCCCUUAGAUGUCCGGGGCUGCACGCGUGCUACACUGGUGGAGUCAGCGGGUUUUUCCUAUGCCGAAAGGUAUCGGUAAACCGUUGAAAUUCUUCCAUGUCCGGGAUAGGGUAUUGUAAUUAUUGCCCUUAAACGAGGAAUGCCUAGUAAGUGUGAGUCAUCAGCUCACGUUGAUUACGUCCCUGCCCUUUGUACACACCGCCCGUCGCUAUCCGGGACUGAACUGAUUCGAGAAGAGUGGGGACUGUCGCUUCGAGGUUUAACGACUUCGUUGUUGCGGAAACCAUUUUUAUCGCAUUGGUUUGAACCGGGUAAAAGUCGUAACAAGGUAGCUGUAGGUGAACCUGCAGCUGGAUCAUCG,rRNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1|length=693aa|residues=1-693
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,＞100 ng/µl rRNA;|0.6 µM [pgl-3],150 mM KCl,"25 mM HEPES pH 7.5, 1 mM DTT",RT,≤ 30-40 min,-,Microscopy,liquid,"In-vitro-transcribed 18S rRNA did not promote assembly of PGL-3 drops over a broad range of concentrations (10–100 ng/ml). Heating the rRNA made it assembly competent, which suggests that the complex structures of rRNA attenuate its ability to promote PGL-3 drops."
86,PMID: 27594427,RNAPS0000172,https://pubmed.ncbi.nlm.nih.gov/27594427,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1|length=693aa|residues=1-693
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,[pgl-3]:693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,200 ng/µl RNA;|0.6 µM [pgl-3],150 mM KCl,"25 mM HEPES pH 7.5, 1 mM DTT",RT,≤ 30-40 min,-,Microscopy,liquid,we looked at the role of RNA in triggering PGL-3 phase separation in vitro. We found that total RNA purified from C. elegans (200 ng/ml) promoted PGL-3 drop assembly
87,PMID: 27594427,RNAPS0000172,https://pubmed.ncbi.nlm.nih.gov/27594427,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1|length=693aa|residues=1-693
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,[pgl-3]:693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,10 ng/µl RNA;|0.6 µM [pgl-3],150 mM KCl,"25 mM HEPES pH 7.5, 1 mM DTT",RT,≤ 30-40 min,-,Microscopy,liquid,"Consistent with the estimated in vivo concentration of mRNA in C. elegans embryos, we found that physiological concentration of mRNA (100 nM, or 50 ng/ml assuming average length of mRNA is 1.5 kb) can promote assembly of drops at physiological concentrations of PGL-3"
88,PMID: 29932899,RNAPS0000032,https://pubmed.ncbi.nlm.nih.gov/29932899,RNA + protein,NCBI ID:283131,https://www.ncbi.nlm.nih.gov/gene/283131,NEAT1_antisense,1531nt(9.7-11.1k),GGGCGAAUUGGGCCCUCUAGAUGCAUGCUCGAGCGGCCGCCAGUGUGAUGGAUAUCUGCAGAAUUCGCCCUUGGGUGGCAGGAGGCGGCAGGGGAGGCGGGUGGUGUGGGACCACAUAAGUGGAAGGUGUAGUAAAAUCUCAGACUUCACUACUGUAGAACUCAUAUAUAUGACCAAAAGCCAUUUGUACCCCAAAAGCCAUUGAAAUUAAAUAUAUAUAUAUACACACACACACACACACAUAAAGAAAAAAAAAGAAAAUUAUAAGAAGUUAAUAUUGACAGACCUGGAACAAAAAAUCAAAGACAGUAUUUAGUCAUUAAAAUUUUGCUAUUUCAAUUUCAUCAGUGUAAAUAAUUAAUUUAAGUGGAGAGGAGUGUUCAUUGUAACCAUAGGAGUUACUGUCUGUAUUGUCCUAGUUUUUGUAUUGGAUAGGAGAUUCAGAAAUGCUUACCACAUUAUUAAAAAACAAUUAAAGAAAGCAAGUAAAAGAGAGCCAUGUUGUGUCCUGAAUCAAAGAUUAAGAUUGAGAUUUACCCAGUUCUGUGUAUUUGAGUUCCAACAGAGAGAAUAUUCUUGCCUUACAGGAGUGUUCUAGCCUCCAUUUACCAGAUUUUAAAGCAUAAUGAAAAGUGAUGAUCAUUACAUUCCAUUGCAUUUUAUUAACAACAACAACAAAAACUGGAGCCUAAAAUUUCCAGAAAUAGAUCCAGAGAGAAAAUGUUAAGAACCAUUUGAUCUAGCAAUCCCACUCCUGGGUAUCUACCCAAAGGAAAAGAAGUCAUUAUACCAGAAAGACACUUGAUGGCAGUACAAGUCACAAUUGCAAAGAUGUGGAACCAACCCAUCAACCAGUGAGUGGAUAAAUAAAAUGUGGUAUCUCUACACCAUGGAAUAUGACUUAGCAAUAAAAAAGAACAAAAUAAUGUUUGUGGUUUUUUUUUUUUUUGCAGCAAUUUUGGAUGGAGCUGGAGGAUAUUAUUCUAAGUGAAGCAACUCAGGAAUGGAAAACCAAAUACUGUGUGUUCUCACUUAUAAGUGAGAGCUAACUUAUGGGUACAAAAAGGUAUACAGAGUGACAUAAUGGACACUAGAGACUCAAAGUGGGGAGGGUAAGAGGGGGGCAAGGUAUAAAAAACCACAUAUUGGGUACAAUGUACACUACUCAGGUGACCGGUGCAGUAAAAUCUCAGACUUCACUACUGUAGAAUUCAUCUAUAUGACCAAAAGCCAUUUGUACCCCAAAAGCCAUUGAAAUUAAAAAAAAAAAAAUACACACACACACACACAUAAAGAAAAAAAAGAAAAUUAUAAGAAGUUAAUAUUGACUGACCUGGAACGAAAAAACCAAGACAGUAUUUAGUCAUUAACAUUUUGCUAUUUCAUCAAUGUAAAUAAUUAAUUUAAAUGGAGAGGAGUGUUCAUUGUAAUCAUAGGAGUACAUACAUGUUUAGCUACUAAAGAAAAAGUAAUCAGAAGCAAAUUCAAUGGACAAGGGCGAAUUCCAGCACACUGGCGGCCGUUACUAGUG,lncRNA,Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,-,-,-,-,-,-,Immunoblotting,liquid,"Immunoblotting analysis revealed that three essential PSPs (NONO, SFPQ, and RBM14) were specifically precipitated with the sense RNA. Interestingly, FUS nonspecifically bound both to the sense and antisense RNAs (Figure 7B)."
89,PMID: 27692063,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/27692063,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1|length=506aa|residues=1-506
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,6.2 µM [DHH1];|0.075 mg/ml polyU,"150 mM KCl, 2 mM MgCl2",30 mM HEPES-KOH pH 7.4,4˚C,> 20 min,-,Wide-field fluorescence microscopy,solute,"Dhh1 liquid droplet formation requires ATP binding. Dhh1 droplets did not form in the absence of ATP, demonstrating that Dhh1 in its ATP-bound form promotes liquid droplet formation."
90,PMID: 27692063,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/27692063,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1|length=506aa|residues=1-506|mutation=F66R
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGREKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,protein_mutation:F66R,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/","[22-39],[61-85],[323-328],[411-453],[464-504]",-,In vitro,6.2 µM [DHH1];|0.075 mg/ml polyU,"150 mM KCl, 2 mM MgCl2",30 mM HEPES-KOH pH 7.4,4˚C,> 1 h,other_molecular:5 mM ATP,Wide-field fluorescence microscopy,solute,"Dhh1_M(F66R) showed only a minor defect in PB localization following glucose starvation, this mutant showed a dramatic loss of droplet formation in vitro."
91,PMID: 27692063,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/27692063,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1|length=506aa|residues=1-506
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,6.2 µM [DHH1];|0.075 mg/ml polyU,"150 mM KCl, 2 mM MgCl2",30 mM HEPES-KOH pH 7.4,4˚C,≤ 20 min,"other_molecular:5 mM ATP,5 μM RNase A",Wide-field fluorescence microscopy,liquid,"Remarkably, recombinant Dhh1, in the presence of RNA and ATP, readily formed droplets in solution. These droplets showed hallmarks of liquid-liquid phase separation, undergoing growth and fusion events and reversible deformation, consistent with the reported biophysical behavior of PBs. Dhh1 droplet formation was RNA-dependent, as no droplets formed when RNA was omitted, and the number and size of droplets rapidly decreased upon addition of RNase A, but not with buffer alone."
92,PMID: 27692063,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/27692063,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1|length=506aa|residues=1-506
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,1.5-12.5 µM [DHH1];|0.075 mg/ml polyU,"150 mM KCl, 2 mM MgCl2",30 mM HEPES-KOH pH 7.4,4˚C,> 1 h,other_molecular:5 mM ATP,Wide-field fluorescence microscopy,liquid,"Remarkably, recombinant Dhh1, in the presence of RNA and ATP, readily formed droplets in solution. These droplets showed hallmarks of liquid-liquid phase separation, undergoing growth and fusion events and reversible deformation, consistent with the reported biophysical behavior of PBs. Dhh1 droplet formation was RNA-dependent, as no droplets formed when RNA was omitted, and the number and size of droplets rapidly decreased upon addition of RNase A, but not with buffer alone. Dhh1 droplets did not form in the absence of ATP, demonstrating that Dhh1 in its ATP-bound form promotes liquid droplet formation."
93,PMID: 27791212,RNAPS0000015,https://pubmed.ncbi.nlm.nih.gov/27791212,RNA + protein,NCBI ID:855450,https://www.ncbi.nlm.nih.gov/gene/855450,BNI1,5862nt(1-5862),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA,mRNA,Saccharomyces cerevisiae,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,53 nM [BNI1];|-,150 mM KCl,-,RT,≤ 2 h,-,Confocal microscopy,liquid,"The MSD versus lag time for LAF-1 at high salt (250 mM NaCl), Whi3 at physiological salt (150 mM KCl) in the presence of 53 nM BNI1 mRNA, LAF-1 at low salt (125 mM NaCl), GAR-1DN at low salt (150 mM NaCl), and the noise floor is shown in Fig. 2c."
94,PMID: 27791212,RNAPS0000015,https://pubmed.ncbi.nlm.nih.gov/27791212,RNA + protein,NCBI ID:855450,https://www.ncbi.nlm.nih.gov/gene/855450,BNI1,5862nt(1-5862),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA,mRNA,Saccharomyces cerevisiae,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,9 µM [Whi3];|50 nM BNI1,150 mM KCl,"20 mM Tris, pH 7.4, 1 mM DTT",RT,-,-,Confocal microscopy,liquid,"In the case of Whi3, specific mRNA binding partners (i.e., cyclin transcripts, CLN3, and formin transcripts, BNI1) shifts the droplet phase boundary down, approaching physiological protein concentrations at physiological salt concentration. Such protein droplets appear to be liquid-like, exhibiting round morphologies after coalescence."
95,PMID: 27914198,RNAPS0000091,https://pubmed.ncbi.nlm.nih.gov/27914198,RNA + protein,-,-,polyU(30),30nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1|length=544aa|residues=1-544
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSS",meg-3,IDR,-,544aa(1-544),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492]",In vitro,0.1-5 µM [MEG3 IDR];|0.1-10 µM polyU,150 mM NaCl,"25 mM HEPES, pH7.4",RT,≤ 10 min,-,Confocal microscopy,liquid,"MEG-3 and MEG-3IDR behaved similarly to each other, except that in the low concentration range (<5 mM), MEG-3 formed more condensates than MEG-3IDR, and in the high concentration range (>5 mM) MEG-3IDR tended to form larger condensates."
96,PMID: 27914198,RNAPS0000091,https://pubmed.ncbi.nlm.nih.gov/27914198,RNA + protein,-,-,polyU(30),30nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1|length=862aa|residues=1-862
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,0.1-5 µM [MEG3];|0.1-10 µM polyU,150 mM NaCl,"25 mM HEPES, pH7.4",RT,≤ 10 min,-,Confocal microscopy,liquid,"We pre-incubated recombinant MEX-5 with poly-U in buffer for 30 min before adding MEG-3. We found that MEX-5 strongly inhibited MEG-3 phase separation induced by RNA. Addition of excess RNA (3-fold increase) restored robust phase separation in the presence of MEX-5. Additionally, MEX-5 had no effect on the phase separation of MEG-3 in the absence of RNA. MEG-3 and MEG-3IDR behaved similarly to each other, except that in the low concentration range (<5 mM), MEG-3 formed more condensates than MEG-3IDR, and in the high concentration range (>5 mM) MEG-3IDR tended to form larger condensates."
97,PMID: 28283059,RNAPS0000093,https://pubmed.ncbi.nlm.nih.gov/28283059,RNA + protein,-,-,polyA(19),19nt,AAAAAAAAAAAAAAAAAAA,poly RNA,-,"sp|P04147|PABP_YEAST Polyadenylate-binding protein, cytoplasmic and nuclear OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=PAB1 PE=1 SV=4|length=597aa|residues=2-577
MGSSHHHHHHHHASENLYFQSADITDKTAEQLENLNIQDDQKQAATGSESQSVENSSASL
YVGDLEPSVSEAHLYDIFSPIGSVSSIRVCRDAITKTSLGYAYVNFNDHEAGRKAIEQLN
YTPIKGRLCRIMWSQRDPSLRKKGSGNIFIKNLHPDIDNKALYDTFSVFGDILSSKIATD
ENGKSKGFGFVHFEEEGAAKEAIDALNGMLLNGQEIYVAPHLSRKERDSQLEETKAHYTN
LYVKNINSETTDEQFQELFAKFGPIVSASLEKDADGKLKGFGFVNYEKHEDAVKAVEALN
DSELNGEKLYVGRAQKKNERMHVLKKQYEAYRLEKMAKYQGVNLFVKNLDDSVDDEKLEE
EFAPYGTITSAKVMRTENGKSKGFGFVCFSTPEEATKAITEKNQQIVAGKPLYVAIAQRK
DVRRSQLAQQIQARNQMRYQQATAAAAAAAAGMPGQFMPPMFYGVMPPRGVPFNGPNPQQ
MNPMGGMPKNGMPPQFRNGPVYGVPPQGGFPRNANDNNQFYQQKQRQALGEQLYKKVSAK
TSNEEAAGKITGMILDLPPQEVFPLLESDELFEQHYKEASAAYESFKKEQEQQTEQA",Pab1,-,-,597aa(1-597),P04147,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P04147,http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0254,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0048,http://db.phasep.pro/browse/","[1-12],[29-65],[118-118],[130-143],[199-207],[217-231],[307-327],[357-357],[414-450],[471-501],[549-566],[588-596]",-,In vitro,15 µM [Pab1 2-577];|100 µg/ml polyA,"150 mM KCl, 2.5 mM MgCl2",20 mM HEPES pH 6.4,46˚C,> 30 min,-,Gel filtration,solute,"Adding RNA increasingly inhibited Pab1 demixing. Pab1 releases RNA and demixes, forming particles stabilized by protein-protein interactions, consistent with its behavior in vivo."
98,PMID: 28306503,RNAPS0000094,https://pubmed.ncbi.nlm.nih.gov/28306503,RNA + protein,-,-,polyU(30),30nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)20,-,-,[PR]20:40aa,-,-,-,-,-,In vitro,0-250 µM [PR]20;|0-1 µg/µl polyU,-,100mM K2HPO4/KH2PO4 buffer,RT,-,-,"Turbidity measurement,FRAP,Cryo-EM",liquid,"This raised the idea that biological anions could support PR LLPS as well. Indeed, addition of polyU RNA promoted LLPS in a dose-dependent manner even without molecular crowders being present."
99,PMID: 28306503,RNAPS0000095,https://pubmed.ncbi.nlm.nih.gov/28306503,RNA + protein,-,-,polyU(30),30nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|Q96LT7|CI072_HUMAN Guanine nucleotide exchange C9orf72 OS=Homo sapiens OX=9606 GN=C9orf72 PE=1 SV=2
MSTLCPPPSPAVAKTEIALSGKSPLLAATFAYWDNILGPRVRHIWAPKTEQVLLSDGEIT
FLANHTLNGEILRNAESGAIDVKFFVLSEKGVIIVSLIFDGNWNGDRSTYGLSIILPQTE
LSFYLPLHRVCVDRLTHIIRKGRIWMHKERQENVQKIILEGTERMEDQGQSIIPMLTGEV
IPVMELLSSMKSHSVPEEIDIADTVLNDDDIGDSCHEGFLLNAISSHLQTCGCSVVVGSS
AEKVNKIVRTLCLFLTPAERKCSRLCEAESSFKYESGLFVQGLLKDSTGSFVLPFRQVMY
APYPTTHIDVDVNTVKQMPPCHEHIYNQRRYMRSELTAFWRATSEEDMAQDTIIYTDESF
TPDLNIFQDVLHRDTLVKAFLDQVFQLKPGLSLRSTFLAQFLLVLHRKALTLIKYIEDDT
QKGKKPFKSLRNLKIDLDLTAEGDLNIIMALAEKIKPGLHSFIFGRPFYTSVQERDVLMT
F",C9orf72,-,-,481aa(1-481),Q96LT7,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0616,http://db.phasep.pro/browse/",-,-,In vitro,0.05-0.25 µg/µL [polyU];|20 µM [C9orf72],200 µM NaCl,"50mM MES,pH 5",RT,≤ 200 min,-,FRAP,liquid,"Similar to the PEG-induced LLPS, PR20-RNA droplets were highly circular (Figure 4A). They also continuously increased in size over time, as measured by dynamic light scattering (DLS)."
100,PMID: 28306503,RNAPS0000095,https://pubmed.ncbi.nlm.nih.gov/28306503,RNA + protein,-,-,polyU(30),30nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|Q96LT7|CI072_HUMAN Guanine nucleotide exchange C9orf72 OS=Homo sapiens OX=9606 GN=C9orf72 PE=1 SV=2
MSTLCPPPSPAVAKTEIALSGKSPLLAATFAYWDNILGPRVRHIWAPKTEQVLLSDGEIT
FLANHTLNGEILRNAESGAIDVKFFVLSEKGVIIVSLIFDGNWNGDRSTYGLSIILPQTE
LSFYLPLHRVCVDRLTHIIRKGRIWMHKERQENVQKIILEGTERMEDQGQSIIPMLTGEV
IPVMELLSSMKSHSVPEEIDIADTVLNDDDIGDSCHEGFLLNAISSHLQTCGCSVVVGSS
AEKVNKIVRTLCLFLTPAERKCSRLCEAESSFKYESGLFVQGLLKDSTGSFVLPFRQVMY
APYPTTHIDVDVNTVKQMPPCHEHIYNQRRYMRSELTAFWRATSEEDMAQDTIIYTDESF
TPDLNIFQDVLHRDTLVKAFLDQVFQLKPGLSLRSTFLAQFLLVLHRKALTLIKYIEDDT
QKGKKPFKSLRNLKIDLDLTAEGDLNIIMALAEKIKPGLHSFIFGRPFYTSVQERDVLMT
F",C9orf72,-,-,481aa(1-481),Q96LT7,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0616,http://db.phasep.pro/browse/",-,-,In vitro,0-1 µg/µL [polyU];|0-250 µm [C9orf72],-,"100mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Turbidity measurement,FRAP,Cryo-EM",liquid,"This raised the idea that biological anions could support PR LLPS as well. Indeed, addition of polyU RNA promoted LLPS in a dose-dependent manner even without molecular crowders being present (Figures 3F, 4A, and S1E); and this was also the case for other arginine-rich peptides."
101,PMID: 28472520,RNAPS0000097,https://pubmed.ncbi.nlm.nih.gov/28472520,RNA + protein,-,-,(GA-rich U5)30,30nt,GGAGUGAGAGGAAGGAAGGGAAGAAAGAAG,nucleotide rich RNA,-,"sp|O94752|EDC3_SCHPO Enhancer of mRNA-decapping protein 3 OS=Schizosaccharomyces pombe (strain 972 / ATCC 24843) OX=284812 GN=edc3 PE=1 SV=1|length=331aa|residues=1-71,195-454
MSVADFYGSNVEVLLNNDSKARGVITNFDSSNSILQLRLANDSTKSIVTKDIKDLRILPK
NEIMPKNGTKSKPFVDENIPAELHTTTGDILKPITPEQLSQGIALAIAKTSTDIVVENAA
QLLSQFVFSVLGGHKRLSSRNHNSQPLVCILVGSHDHASAAVAAGRRLCAIGIKVVLRLL
TPFNVDNRQLLMFQAAGGYIPTENFDQFLNKLTSPIELVVDVLTGFHPSIDKNSHALIQW
ANDLNVLILSVDIPSGYTVQKKNTAILPKWTLALGAVTTTLAQAALVKQAAGVSVFVGNL
GTGSQTWAELGILESQVTGQYLAQISCTSTN",edc3,-,-,"331aa(1-71,195-454)",O94752,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/O94752,http://llps.biocuckoo.cn/view.php?id=LLPS-Scp-0071,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0103,http://db.phasep.pro/browse/",-,[394-415],In vitro,0-60 µM [edc3△IDR];|0.00-15.0 µM RNA,125 mM NaCl,"25 mM HEPES, pH 7.3, 1 mM DTT",30˚C,immediately,-,Turbidity measurement,solute,"This effect is even more prominent in RNA:Edc3 phase diagrams, where the removal of the IDR results in the almost complete loss of LLPS (Figure4B). These data indicate that the IDR in Edc3 is an important RNA interaction site."
102,PMID: 28472520,RNAPS0000097,https://pubmed.ncbi.nlm.nih.gov/28472520,RNA + protein,-,-,(GA-rich U5)30,30nt,GGAGUGAGAGGAAGGAAGGGAAGAAAGAAG,nucleotide rich RNA,-,"sp|O94752|EDC3_SCHPO Enhancer of mRNA-decapping protein 3 OS=Schizosaccharomyces pombe (strain 972 / ATCC 24843) OX=284812 GN=edc3 PE=1 SV=1|length=454aa|residues=1-454
MSVADFYGSNVEVLLNNDSKARGVITNFDSSNSILQLRLANDSTKSIVTKDIKDLRILPK
NEIMPKNGTKSPSTNSTKLKSAETYSSKNKWSMDCDEEFDFAANLEKFDKKQVFAEFREK
DKKDPAKLLVSHNKSPNRNYHHKQNVLGPSVKDEFVDLPSAGSQINGIDAVLSSSSNGHV
TPGSKKGSRETLKKKPFVDENIPAELHTTTGDILKPITPEQLSQGIALAIAKTSTDIVVE
NAAQLLSQFVFSVLGGHKRLSSRNHNSQPLVCILVGSHDHASAAVAAGRRLCAIGIKVVL
RLLTPFNVDNRQLLMFQAAGGYIPTENFDQFLNKLTSPIELVVDVLTGFHPSIDKNSHAL
IQWANDLNVLILSVDIPSGYTVQKKNTAILPKWTLALGAVTTTLAQAALVKQAAGVSVFV
GNLGTGSQTWAELGILESQVTGQYLAQISCTSTN",edc3,-,-,454aa(1-454),O94752,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/O94752,http://llps.biocuckoo.cn/view.php?id=LLPS-Scp-0071,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0103,http://db.phasep.pro/browse/",[173-192],[394-415],In vitro,0-60 µM [edc3];|0.00-15.0 µM RNA,125 mM NaCl,"25 mM HEPES, pH 7.3, 1 mM DTT",30˚C,immediately,-,Turbidity measurement,"solute, liquid","This effect is even more prominent in RNA:Edc3 phase diagrams, where the removal of the IDR results in the almost complete loss of LLPS (Figure4B). These data indicate that the IDR in Edc3 is an important RNA interaction site."
103,PMID: 28556382,RNAPS0000103,https://pubmed.ncbi.nlm.nih.gov/28556382,RNA + protein,-,-,polyU,2400-3100nt,-,poly RNA,-,RRxxxRRxxxRRxxx,RP3,-,-,15aa,-,-,-,-,-,In vitro,200 µM[RP3];|400µM[polyU],50 mM NaCl,"10mM Tris-HCl,pH 7.9",RT,≤ 60 min,other_molecular:1 µM T7 RNA polymerase,Confocal fluorescence microscopy,liquid,"RNA transcription by T7 RNA polymerase in presence of RLMs leads to the formation of phase-separated RLM/RNA droplets, while further increase in [RNA] by transcription leads to a subsequent mixing phase transition and dissolves the RLM/RNA droplets"
104,PMID: 28556382,RNAPS0000103,https://pubmed.ncbi.nlm.nih.gov/28556382,RNA + protein,-,-,polyU,2400-3100nt,-,poly RNA,-,RRxxxRRxxxRRxxx,RP3,-,-,15aa,-,-,-,-,-,In vitro,2~2000µM [RNA];|200 µM [RP3],25-225 nm NACl,"10mM Tris-HCl,pH 7.9",RT,-,-,Confocal fluorescence microscopy,"solute, liquid","We observe that RP3 and SR8 undergo sequential demixing and mixing phase transitions in response to increasing RNA concentration. These data suggest a window-like behavior for immiscibility, which is a hallmark for a reentrant phase transition. Within this window, the peptide/RNA microdroplets display liquid-like properties such as circular appearance (aspect ratio = 0.97±0.04; n =15), facile fusion, and rapid recovery of fluorescence after photobleaching."
105,PMID: 28556382,RNAPS0000104,https://pubmed.ncbi.nlm.nih.gov/28556382,RNA + protein,-,-,polyU,2400-3100nt,-,poly RNA,-,sRsRsRsRxxxxxsRsRsRsR,SR8,-,-,21aa,-,-,-,-,-,In vitro,200µM[polyU];|200 µM[SR8],50 mM NaCl,"10mM Tris-HCl,pH 7.9",RT,-,-,Confocal fluorescence microscopy,liquid,"We observe that RP3 and SR8 undergo sequential demixing and mixing phase transitions in response to increasing RNA concentration. These data suggest a window-like behavior for immiscibility, which is a hallmark for a reentrant phase transition. Within this window, the peptide/RNA microdroplets display liquid-like properties such as circular appearance (aspect ratio = 0.97±0.04; n =15), facile fusion, and rapid recovery of fluorescence after photobleaching."
106,PMID: 28556382,RNAPS0000105,https://pubmed.ncbi.nlm.nih.gov/28556382,RNA + protein,-,-,polyU,2400-3100nt,-,poly RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,0.3 µM[polyU];|10 µM[FUS],50 mM NaCl,"10mM Tris-HCl,pH 7.9",RT,-,-,Confocal fluorescence microscopy,liquid,"Below the threshold concentration for homologous LLPS, FUS titrated with RNA not only triggers a demixing transition into liquid droplets but also leads to droplet dissolution, which is analogous to the phase behavior of RP3 and SR8 peptides."
107,PMID: 28683104,RNAPS0000117,https://pubmed.ncbi.nlm.nih.gov/28683104,RNA + protein,-,-,polyA,-(66-660 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=187aa|residues=255-441|mutation=C291S
NVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSKDNIKHVPGGGSVQIVYKPVD
LSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETH
KLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSA
SLAKQGL",MAPT,C,protein_mutation:C291S,187aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[257-264],[280-282],[284-286],[291-299],[340-350],[396-436]",-,In vitro,400 µM [Tau C];|800 µg/ml polyA,20 mM NaCl,"20 mM ammonium acetate at pH 7, 30% glycerol",RT,> 10 min,-,Confocal microscopy,liquid,"Confocal microscopy images of fluorescence-labeled tau verified that tau was predominantly contained within the droplet (Fig 4B). Depending on the specific condition, we were able to observe droplet formation with total Δtau187 protein concentration ranging between 2-400 µM, as will be discussed in greater detail next."
108,PMID: 28683104,RNAPS0000117,https://pubmed.ncbi.nlm.nih.gov/28683104,RNA + protein,-,-,polyA,-(66-660 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=187aa|residues=255-441|mutation=C291S
NVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSKDNIKHVPGGGSVQIVYKPVD
LSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETH
KLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSA
SLAKQGL",MAPT,C,protein_mutation:C291S,187aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[257-264],[280-282],[284-286],[291-299],[340-350],[396-436]",-,In vitro,400 µM [Tau C];|[Tau C]:polyA were maintained at a mass ratio of 7:1 (corresponding to a charge ratio of 1.2:1) and a total mass concentration of 2 mg/ml,0-100 mM NaCl,20 mM ammonium acetate at pH 7,RT,> 10 min,-,Bright-field microscopy,liquid,"The systematic increase in salt concentration decreased the amount of tau-RNA droplet. This high salt concentration inhibition trend was observed repeatedly under a range of experimental conditions, including the use of different RNA types. Droplets formed in the presence of polyA and poly(U) tolerated higher than 100 mM salt concentration compared to tRNA."
109,PMID: 28683104,RNAPS0000117,https://pubmed.ncbi.nlm.nih.gov/28683104,RNA + protein,-,-,polyA,-(66-660 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=187aa|residues=255-441|mutation=C291S
NVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSKDNIKHVPGGGSVQIVYKPVD
LSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETH
KLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSA
SLAKQGL",MAPT,C,protein_mutation:C291S,187aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[257-264],[280-282],[284-286],[291-299],[340-350],[396-436]",-,In vitro,400 µM [Tau C];|[Tau C]:polyA were maintained at a mass ratio of 7:1 (corresponding to a charge ratio of 1.2:1) and a total mass concentration of 2 mg/ml,≥150 mM NaCl,20 mM ammonium acetate at pH 7,RT,> 10 min,-,Bright-field microscopy,solute,"The systematic increase in salt concentration decreased the amount of tau-RNA droplet. This high salt concentration inhibition trend was observed repeatedly under a range of experimental conditions, including the use of different RNA types. Droplets formed in the presence of polyA and poly(U) tolerated higher than 100 mM salt concentration compared to tRNA."
110,PMID: 28683104,RNAPS0000117,https://pubmed.ncbi.nlm.nih.gov/28683104,RNA + protein,-,-,polyA,-(66-660 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=187aa|residues=255-441
NVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVD
LSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETH
KLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSA
SLAKQGL",MAPT,C,-,187aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[255-375],[395-441]","[323-340],[380-403]",In vitro,400 µM [Tau C];|800 µg/ml polyA,-,"20 mM ammonium acetate at pH 7, 30% glycerol",RT,> 10 min,-,Bright-field microscopy,liquid,"Mixing of 4R2N or Δtau187 (similar to K18) with tRNA (25 kDa), polyA RNA (66~660 kDa), or poly(U) RNA (800~1000 kDa) reliably produced a turbid solution under a wide range of tau:RNA mass ratios and salt concentrations. According to bright-field microscopy, droplets formed and phase separated from the bulk aqueous phase with a clearly visible and highly spherical boundary. Tau droplets were capable of merging into a single droplet with the complete and nearly instantaneous loss of any boundary at the fusion interface, indicating that the droplets are fluidic with a relatively low interfacial tension."
111,PMID: 28683104,RNAPS0000118,https://pubmed.ncbi.nlm.nih.gov/28683104,RNA + protein,-,-,polyU,-(800-1000 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=187aa|residues=255-441|mutation=C291S
NVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSKDNIKHVPGGGSVQIVYKPVD
LSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETH
KLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSA
SLAKQGL",MAPT,C,protein_mutation:C291S,187aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[257-264],[280-282],[284-286],[291-299],[340-350],[396-436]",-,In vitro,80 mM [Tau C];|120 mg/ml polyU,-,"20 mM ammonium acetate at pH 7, 0-50% glycerol",RT,> 10 min,-,Bright-field microscopy,liquid,"Specifically, at room temperature, a total protein concentration of 80 µM and in the presence of tRNA, the droplets reproducibly disappeared when the salt concentration was increased to 100 mM or higher."
112,PMID: 28683104,RNAPS0000118,https://pubmed.ncbi.nlm.nih.gov/28683104,RNA + protein,-,-,polyU,-(800-1000 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=187aa|residues=255-441|mutation=C291S
NVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSKDNIKHVPGGGSVQIVYKPVD
LSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETH
KLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSA
SLAKQGL",MAPT,C,protein_mutation:C291S,187aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[257-264],[280-282],[284-286],[291-299],[340-350],[396-436]",-,In vitro,2.5 µM [Tau C];|7.5 µg/ml polyU,100 mM NaCl,20 mM ammonium acetate at pH 7,37˚C,> 10 min,-,Bright-field microscopy,liquid,"This observation is illustrated in a series of images presented in Fig 5E—droplets are observed at NaCl concentration as high as 100 mM and tau concentrations as low as 2.5 µM when the temperature is elevated to 37˚C, while maintaining the tau:RNA molar ratios. The quantity of droplets decreased with decreasing total tau concentration, and disappeared when tau concentration dropped from 2.5 to 1 µM."
113,PMID: 28683104,RNAPS0000118,https://pubmed.ncbi.nlm.nih.gov/28683104,RNA + protein,-,-,polyU,-(800-1000 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=187aa|residues=255-441|mutation=C291S
NVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSKDNIKHVPGGGSVQIVYKPVD
LSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETH
KLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSA
SLAKQGL",MAPT,C,protein_mutation:C291S,187aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[257-264],[280-282],[284-286],[291-299],[340-350],[396-436]",-,In vitro,1 µM [Tau C];|3 µg/ml polyU,100 mM NaCl,20 mM ammonium acetate at pH 7,37˚C,> 10 min,-,Bright-field microscopy,solute,"This observation is illustrated in a series of images presented in Fig 5E—droplets are observed at NaCl concentration as high as 100 mM and tau concentrations as low as 2.5 µM when the temperature is elevated to 37˚C, while maintaining the tau:RNA molar ratios. The quantity of droplets decreased with decreasing total tau concentration, and disappeared when tau concentration dropped from 2.5 to 1 µM."
114,PMID: 28683104,RNAPS0000118,https://pubmed.ncbi.nlm.nih.gov/28683104,RNA + protein,-,-,polyU,-(800-1000 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=187aa|residues=255-441|mutation=C291S
NVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSKDNIKHVPGGGSVQIVYKPVD
LSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETH
KLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSA
SLAKQGL",MAPT,C,protein_mutation:C291S,187aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[257-264],[280-282],[284-286],[291-299],[340-350],[396-436]",-,In vitro,100 µM [Tau C];|[Tau C]:polyU were maintained at approximately 1:1 charge ratio,30 mM NaCl,20 mM ammonium acetate at pH 7,≤22˚C,> 10 min,-,Bright-field microscopy,solute,The amount of tau-RNA droplet was also found to be sensitively and reversibly tunable by temperature. Droplets dissolve below 22˚C and appear at and above 23˚C.
115,PMID: 28683104,RNAPS0000118,https://pubmed.ncbi.nlm.nih.gov/28683104,RNA + protein,-,-,polyU,-(800-1000 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=187aa|residues=255-441|mutation=C291S
NVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSKDNIKHVPGGGSVQIVYKPVD
LSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETH
KLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSA
SLAKQGL",MAPT,C,protein_mutation:C291S,187aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[257-264],[280-282],[284-286],[291-299],[340-350],[396-436]",-,In vitro,100 µM [Tau C];|[Tau C]:polyU were maintained at approximately 1:1 charge ratio,30 mM NaCl,20 mM ammonium acetate at pH 7,≥23˚C,> 10 min,-,Bright-field microscopy,liquid,The amount of tau-RNA droplet was also found to be sensitively and reversibly tunable by temperature. Droplets dissolve below 22˚C and appear at and above 23˚C.
116,PMID: 28683104,RNAPS0000118,https://pubmed.ncbi.nlm.nih.gov/28683104,RNA + protein,-,-,polyU,-(800-1000 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=187aa|residues=255-441|mutation=C291S
NVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSKDNIKHVPGGGSVQIVYKPVD
LSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETH
KLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSA
SLAKQGL",MAPT,C,protein_mutation:C291S,187aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[257-264],[280-282],[284-286],[291-299],[340-350],[396-436]",-,In vitro,400 µM [Tau C];|[Tau C]:polyU were maintained at a mass ratio of 7:1 (corresponding to a charge ratio of 1.2:1) and a total mass concentration of 2 mg/ml,0-100 mM NaCl,20 mM ammonium acetate at pH 7,RT,> 10 min,-,Bright-field microscopy,liquid,"This high salt concentration inhibition trend was observed repeatedly under a range of experimental conditions, including the use of different RNA types. Droplets formed in the presence of polyA and poly(U) tolerated higher than 100 mM salt concentration compared to tRNA."
117,PMID: 28683104,RNAPS0000118,https://pubmed.ncbi.nlm.nih.gov/28683104,RNA + protein,-,-,polyU,-(800-1000 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=187aa|residues=255-441|mutation=C291S
NVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSKDNIKHVPGGGSVQIVYKPVD
LSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETH
KLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSA
SLAKQGL",MAPT,C,protein_mutation:C291S,187aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[257-264],[280-282],[284-286],[291-299],[340-350],[396-436]",-,In vitro,5 µM [Tau C];|15 µg/ml polyU,-,20 mM ammonium acetate at pH 7,37˚C,> 10 min,-,Bright-field microscopy,liquid,"This general trend was observed repeatedly under a range of experimental conditions, including the use of different RNA types (Fig 5B and S6A Fig, left panel). Interestingly, droplets formed in the presence of poly(A) and poly(U) tolerated higher than 100 mM salt concentration compared to tRNA."
118,PMID: 28683104,RNAPS0000118,https://pubmed.ncbi.nlm.nih.gov/28683104,RNA + protein,-,-,polyU,-(800-1000 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=187aa|residues=255-441|mutation=C291S
NVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSKDNIKHVPGGGSVQIVYKPVD
LSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETH
KLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSA
SLAKQGL",MAPT,C,protein_mutation:C291S,187aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[257-264],[280-282],[284-286],[291-299],[340-350],[396-436]",-,In vitro,5 µM [Tau C];|15 µg/ml polyU,100 mM NaCl,20 mM ammonium acetate at pH 7,37˚C,> 10 min,-,Bright-field microscopy,liquid,"This general trend was observed repeatedly under a range of experimental conditions, including the use of different RNA types (Fig 5B and S6A Fig, left panel). Interestingly, droplets formed in the presence of poly(A) and poly(U) tolerated higher than 100 mM salt concentration compared to tRNA."
119,PMID: 28683104,RNAPS0000402,https://pubmed.ncbi.nlm.nih.gov/28683104,RNAs + protein,-,-,yeast tRNA,-(25 kDa),-,tRNA,yeast,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=187aa|residues=255-441|mutation=C291S
NVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSKDNIKHVPGGGSVQIVYKPVD
LSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETH
KLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSA
SLAKQGL",MAPT,C,protein_mutation:C291S,187aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[257-264],[280-282],[284-286],[291-299],[340-350],[396-436]",-,In vitro,400 µM [Tau C];|[Tau C]:tRNA were maintained at a mass ratio of 7:1 (corresponding to a charge ratio of 1.2:1) and a total mass concentration of 2 mg/ml,0-50 NaCl,20 mM ammonium acetate at pH 7,RT,> 10 min,-,Bright-field microscopy,liquid,"The systematic increase in salt concentration decreased the amount of tau-RNA droplet, the droplets reproducibly disappeared when the salt concentration was increased to 100 mM or higher"
120,PMID: 28683104,RNAPS0000402,https://pubmed.ncbi.nlm.nih.gov/28683104,RNAs + protein,-,-,yeast tRNA,-(25 kDa),-,tRNA,yeast,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=187aa|residues=255-441|mutation=C291S
NVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSKDNIKHVPGGGSVQIVYKPVD
LSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETH
KLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSA
SLAKQGL",MAPT,C,protein_mutation:C291S,187aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[257-264],[280-282],[284-286],[291-299],[340-350],[396-436]",-,In vitro,400 µM [Tau C];|[Tau C]:tRNA were maintained at a mass ratio of 7:1 (corresponding to a charge ratio of 1.2:1) and a total mass concentration of 2 mg/ml,≥100 mM NaCl,20 mM ammonium acetate at pH 7,RT,> 10 min,-,Bright-field microscopy,solute,"The systematic increase in salt concentration decreased the amount of tau-RNA droplet, the droplets reproducibly disappeared when the salt concentration was increased to 100 mM or higher"
121,PMID: 28790177,RNAPS0000403,https://pubmed.ncbi.nlm.nih.gov/28790177,RNAs + protein,-,-,Triticum aestivum RNA,-,-,total RNA,Triticum aestivum,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526|mutation=S or T26,30,68,84,87,117E
MASNDYTQQATQSYGAYPTQPGQGYEQQSEQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGEQSTPQGYGSTGGYGSEQSEQSSYGQQSSYPGYGQQPAPSSTSGSYGSSEQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,"protein_mutation:S or T26,30,68,84,87,117E
MASNDYTQQATQSYGAYPTQPGQGYEQQSEQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ",526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[3-254],[284-292],[332-338],[375-415],[451-499],[501-501],[503-505],[507-526]",-,In vitro,5 µM [FUS];|0.05-0.5 mg/mL RNA,150 mM NaCl,20 mM Tris pH 7.4,25˚C,> 45 min,-,Turbidity measurement,liquid,"Addition of RNA to full-length FUS 6E and 12E disrupted LLPS, while LLPS appeared consistent for wild-type FUS at all RNA conditions. LLPS was dramatically suppressed for FUS 6E with increasing RNA levels, and no LLPS was observed for FUS 12E at high RNA:FUS ratios."
122,PMID: 28790177,RNAPS0000403,https://pubmed.ncbi.nlm.nih.gov/28790177,RNAs + protein,-,-,Triticum aestivum RNA,-,-,total RNA,Triticum aestivum,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526|mutation=S or T7,11,19,68,26,30,42,61,84,87,117,131E
MASNDYEQQAEQSYGAYPEQPGQGYEQQSEQPYGQQSYSGYEQSTDTSGYGQSSYSSYGQ
EQNTGYGEQSTPQGYGSTGGYGSEQSEQSSYGQQSSYPGYGQQPAPSSTSGSYGSSEQSS
SYGQPQSGSYEQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,"protein_mutation:S or T7,11,19,68,26,30,42,61,84,87,117,131E",526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[2-10],[26-28],[40-254],[284-292],[332-338],[375-415],[451-499],[501-501],[503-505],[507-526]",-,In vitro,5 µM [FUS];|≤0.1 mg/mL RNA,150 mM NaCl,20 mM Tris pH 7.4,25˚C,> 45 min,-,Turbidity measurement,liquid,"Addition of RNA to full-length FUS 6E and 12E disrupted LLPS, while LLPS appeared consistent for wild-type FUS at all RNA conditions. LLPS was dramatically suppressed for FUS 6E with increasing RNA levels, and no LLPS was observed for FUS 12E at high RNA:FUS ratios."
123,PMID: 28790177,RNAPS0000403,https://pubmed.ncbi.nlm.nih.gov/28790177,RNAs + protein,-,-,Triticum aestivum RNA,-,-,total RNA,Triticum aestivum,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526|mutation=S or T7,11,19,68,26,30,42,61,84,87,117,131E
MASNDYEQQAEQSYGAYPEQPGQGYEQQSEQPYGQQSYSGYEQSTDTSGYGQSSYSSYGQ
EQNTGYGEQSTPQGYGSTGGYGSEQSEQSSYGQQSSYPGYGQQPAPSSTSGSYGSSEQSS
SYGQPQSGSYEQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,"protein_mutation:S or T7,11,19,68,26,30,42,61,84,87,117,131E",526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[2-10],[26-28],[40-254],[284-292],[332-338],[375-415],[451-499],[501-501],[503-505],[507-526]",-,In vitro,5 µM [FUS];|≥0.27 mg/mL RNA,150 mM NaCl,20 mM Tris pH 7.4,25˚C,> 45 min,-,Turbidity measurement,solute,"Addition of RNA to full-length FUS 6E and 12E disrupted LLPS, while LLPS appeared consistent for wild-type FUS at all RNA conditions. LLPS was dramatically suppressed for FUS 6E with increasing RNA levels, and no LLPS was observed for FUS 12E at high RNA:FUS ratios."
124,PMID: 28790177,RNAPS0000403,https://pubmed.ncbi.nlm.nih.gov/28790177,RNAs + protein,-,-,Triticum aestivum RNA,-,-,total RNA,Triticum aestivum,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|0-0.5 mg/mL RNA,150 mM NaCl,20 mM Tris pH 7.4,25˚C,> 45 min,-,Turbidity measurement,liquid,"Addition of RNA to full-length FUS 6E and 12E disrupted LLPS, while LLPS appeared consistent for wild-type FUS at all RNA conditions. LLPS was dramatically suppressed for FUS 6E with increasing RNA levels, and no LLPS was observed for FUS 12E at high RNA:FUS ratios."
125,PMID: 28790177,RNAPS0000403,https://pubmed.ncbi.nlm.nih.gov/28790177,RNAs + protein,-,-,Triticum aestivum RNA,-,-,total RNA,Triticum aestivum,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526|mutation=S or T26,30,68,84,87,117E
MASNDYTQQATQSYGAYPTQPGQGYEQQSEQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGEQSTPQGYGSTGGYGSEQSEQSSYGQQSSYPGYGQQPAPSSTSGSYGSSEQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,"protein_mutation:S or T26,30,68,84,87,117E",526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[3-254],[284-292],[332-338],[375-415],[451-499],[501-501],[503-505],[507-526]",-,In vitro,5 µM [FUS];|0.1 mg/mL RNA,150 mM NaCl,20 mM Tris pH 7.4,25˚C,≤ 1 d,other_molecular:agitation 1200 rpm,Differential interference contrast microscopy,liquid,"Non-agitated FUS WT, 6E, and 12E formed similar liquid-like droplets, as observed by DIC microscopy up to 1 day. However, agitation 1,200 rpm, 25°C, 1 day induces wild-type to form irregular aggregate, while assemblies of 6E and 12E remained spherical, with or without RNA (0.4:1 FUS, by mass)."
126,PMID: 28790177,RNAPS0000403,https://pubmed.ncbi.nlm.nih.gov/28790177,RNAs + protein,-,-,Triticum aestivum RNA,-,-,total RNA,Triticum aestivum,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526|mutation=S or T7,11,19,68,26,30,42,61,84,87,117,131E
MASNDYEQQAEQSYGAYPEQPGQGYEQQSEQPYGQQSYSGYEQSTDTSGYGQSSYSSYGQ
EQNTGYGEQSTPQGYGSTGGYGSEQSEQSSYGQQSSYPGYGQQPAPSSTSGSYGSSEQSS
SYGQPQSGSYEQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,"protein_mutation:S or T7,11,19,68,26,30,42,61,84,87,117,131E",526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[2-10],[26-28],[40-254],[284-292],[332-338],[375-415],[451-499],[501-501],[503-505],[507-526]",-,In vitro,5 µM [FUS];|0.1 mg/mL RNA,150 mM NaCl,20 mM Tris pH 7.4,25˚C,≤ 1 d,other_molecular:agitation 1200 rpm,Differential interference contrast microscopy,liquid,"Non-agitated FUS WT, 6E, and 12E formed similar liquid-like droplets, as observed by DIC microscopy up to 1 day. However, agitation 1,200 rpm, 25°C, 1 day induces wild-type to form irregular aggregate, while assemblies of 6E and 12E remained spherical, with or without RNA (0.4:1 FUS, by mass)."
127,PMID: 28790177,RNAPS0000403,https://pubmed.ncbi.nlm.nih.gov/28790177,RNAs + protein,-,-,Triticum aestivum RNA,-,-,total RNA,Triticum aestivum,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|0.1 mg/mL RNA,150 mM NaCl,20 mM Tris pH 7.4,25˚C,≤ 1 d,other_molecular:agitation 1200 rpm,Differential interference contrast microscopy,"liquid, solid","Non-agitated FUS WT, 6E, and 12E formed similar liquid-like droplets, as observed by DIC microscopy up to 1 day. However, agitation 1,200 rpm, 25°C, 1 day induces wild-type to form irregular aggregate, while assemblies of 6E and 12E remained spherical, with or without RNA (0.4:1 FUS, by mass)."
128,PMID: 28877466,RNAPS0000121,https://pubmed.ncbi.nlm.nih.gov/28877466,RNAs + protein,-,-,Sf9 RNA,-,-,total RNA,Sf9 cell line(Spodoptera frugiperda),"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=441aa|residues=1-441
MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPG
SETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAG
HVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPK
TPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAK
SRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHV
PGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNI
THVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMV
DSPQLATLADEVSASLAKQGL",MAPT,-,-,441aa(1-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[125-375],[395-441]","[216-226],[323-340],[380-403]",In vitro,25 µM [Tau];|150 ng/µl RNA,150 mM KCl,"25 mM HEPES, pH 7.4",RT,-,crowding agent:0-4% dextran,Total internal reflection fluorescence microscopy,solute,"Because drop formation seems to be driven by electrostatic interaction and tau-tubulin interaction is also mediated by charge, we wondered whether RNA could also enhance the formation of tau drops (Saha et al., 2016)."
129,PMID: 28877466,RNAPS0000121,https://pubmed.ncbi.nlm.nih.gov/28877466,RNAs + protein,-,-,Sf9 RNA,-,-,total RNA,Sf9 cell line(Spodoptera frugiperda),"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=441aa|residues=1-441
MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPG
SETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAG
HVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPK
TPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAK
SRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHV
PGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNI
THVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMV
DSPQLATLADEVSASLAKQGL",MAPT,-,-,441aa(1-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[125-375],[395-441]","[216-226],[323-340],[380-403]",In vitro,25 µM [Tau];|150 ng/µl RNA,150 mM KCl,"25 mM HEPES, pH 7.4",RT,-,crowding agent:6-10% dextran,Total internal reflection fluorescence microscopy,liquid,"Because drop formation seems to be driven by electrostatic interaction and tau-tubulin interaction is also mediated by charge, we wondered whether RNA could also enhance the formation of tau drops (Saha et al., 2016)."
130,PMID: 28924037,RNAPS0000051,https://pubmed.ncbi.nlm.nih.gov/28924037,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P26599|PTBP1_HUMAN Polypyrimidine tract-binding protein 1 OS=Homo sapiens OX=9606 GN=PTBP1 PE=1 SV=1|length=533aa|residues=1-531
GHMDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPS
RVIHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVT
PVLRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMA
GQSPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAK
LSLDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFG
LSVPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILF
GVYGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPR
EGQEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNG
GVVKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTI",PTBP1,-,-,531aa(1-531),P26599,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/",-,"[32-44],[162-179],[306-335]",In vitro,3.75-6.25 µM [PTBP1];|0.2-1.0 µM RNA,"150 mM KCl, 1 mM MgCl2","10 mM imidazole (pH 7.0), 1 mM EGTA, 1 mM DTT",22˚C,-,-,"Fluorescence microscopy,Turbidity measurement",liquid,"PTB undergoes LLPS when mixed with RNA and that fusion of PTB to FUS(WT) promotes this behavior. In contrast, attachment of FUS(27S) opposed LLPS of PTB + RNA. FUS(27S) is not a highly specific LLPS inhibitor but may be able to generally reduce the self-association of tethered proteins and thus oppose their LLPS."
131,PMID: 28924037,RNAPS0000369,https://pubmed.ncbi.nlm.nih.gov/28924037,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTBP1]-[FUS IDR] with PTBP1 residues 1-531 fused to FUS residues 1-214||length=756aa|residues=1-531/1-214|mutation= FUS IDR(27S)
GHMDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPS
RVIHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVT
PVLRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMA
GQSPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAK
LSLDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFG
LSVPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILF
GVYGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPR
EGQEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNG
GVVKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTIGGSAAAG
GSMASNDSTQQATQSSGASPTQPGQGSSQQSSQPSGQQSSSGSSQSTDTSGSGQSSSSSS
GQSQNTGSGTQSTPQGSGSTGGSGSSQSSQSSSGQQSSSPGSGQQPAPSSTSGSSGSSSQ
SSSSGQPQSGSSSQQPSSGGQQQSSGQQQSSNPPQGSGQQNQSNSSSGGGGGGGGGGNSG
QDQSSMSSGGGSGGGSGNQDQSGGGGSGGSGQQDRG",PTBP1-FUS,IDR,protein_mutation:FUS IDR(27S),"756aa(1-531,1-214)","P26599,P35637","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",-;|[1-214],"[32-44],[162-179],[306-335];|-",In vitro,3.75-6.25 µM [PTBP1]-[FUS IDR];|0-1.0 µM RNA,"150 mM KCl, 1 mM MgCl2","10 mM imidazole (pH 7.0), 1 mM EGTA, 1 mM DTT",22˚C,-,-,"Fluorescence microscopy,Turbidity measurement",solute,"PTB undergoes LLPS when mixed with RNA and that fusion of PTB to FUS(WT) promotes this behavior. In contrast, attachment of FUS(27S) opposed LLPS of PTB + RNA. FUS(27S) is not a highly specific LLPS inhibitor but may be able to generally reduce the self-association of tethered proteins and thus oppose their LLPS."
132,PMID: 29064502,RNAPS0000015,https://pubmed.ncbi.nlm.nih.gov/29064502,RNA + protein,NCBI ID:855450,https://www.ncbi.nlm.nih.gov/gene/855450,BNI1,5862nt(1-5862),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA,mRNA,Saccharomyces cerevisiae,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,9 µM [Whi3];|50 nM BNI1,150 mM KCl,"20 mM Tris, pH 7.4, 1 mM DTT",RT,-,crowding agent:0.01-0.07 mg/ml dextran 10-155 kD,Confocal microscopy,liquid,"The smaller 10 kDa dextranpartitions favourably into P granules, while the larger 155 kDa dextran is significantly excluded; similar in vivo results have beenreported for P granules and for nucleoli. Moreover, we see similar size-dependent exclusionin vitro for two other well-known droplet forming proteins, WHI3 and NPM1. These results suggest that the semidilute, void-rich nature of droplets is likely a feature of many liquid-phase organelles that are driven by the sequence encoded conformational fluctuations of IDRs."
133,PMID: 29064502,RNAPS0000123,https://pubmed.ncbi.nlm.nih.gov/29064502,RNA + protein,-,-,polyA(3000),3000nt,AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,poly RNA,-,"sp|D0PV95|DDX3_CAEEL ATP-dependent RNA helicase laf-1 OS=Caenorhabditis elegans OX=6239 GN=laf-1 PE=1 SV=1|length=708aa|residues=1-708
MESNQSNNGGSGNAALNRGGRYVPPHLRGGDGGAAAAASAGGDDRRGGAGGGGYRRGGGN
SGGGGGGGYDRGYNDNRDDRDNRGGSGGYGRDRNYEDRGYNGGGGGGGNRGYNNNRGGGG
GGYNRQDRGDGGSSNFSRGGYNNRDEGSDNRGSGRSYNNDRRDNGGDGQNTRWNNLDAPP
SRGTSKWENRGARDERIEQELFSGQLSGINFDKYEEIPVEATGDDVPQPISLFSDLSLHE
WIEENIKTAGYDRPTPVQKYSIPALQGGRDLMSCAQTGSGKTAAFLVPLVNAILQDGPDA
VHRSVTSSGGRKKQYPSALVLSPTRELSLQIFNESRKFAYRTPITSALLYGGRENYKDQI
HKLRLGCHILIATPGRLIDVMDQGLIGMEGCRYLVLDEADRMLDMGFEPQIRQIVECNRM
PSKEERITAMFSATFPKEIQLLAQDFLKENYVFLAVGRVGSTSENIMQKIVWVEEDEKRS
YLMDLLDATGDSSLTLVFVETKRGASDLAYYLNRQNYEVVTIHGDLKQFEREKHLDLFRT
GTAPILVATAVAARGLDIPNVKHVINYDLPSDVDEYVHRIGRTGRVGNVGLATSFFNDKN
RNIARELMDLIVEANQELPDWLEGMSGDMRSGGGYRGRGGRGNGQRFGGRDHRYQGGSGN
GGGGNGGGGGFGGGGQRSGGGGGFQSGGGGGRQQQQQQRAQPQQDWWS",laf-1,-,-,708aa(1-708),D0PV95,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/D0PV95,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0337,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0001,http://db.phasep.pro/browse/",-,-,In vitro,0-9 mg/ml [laf-1];|75 nM polyA,0-500 mM NaCl,"20 mM Tris, pH 7.4, 1 mM DTT",RT,-,-,Confocal microscopy,"solute, liquid","In the presence of polyadenylate RNA (poly-rA) of various lengths, the low-concentration arm of the LAF-1 binodal and the concentrations corresponding to the critical region remain essentially invariant. However, upon addition of RNA we observe a marked shift of the high-concentration arm of the LAF-1 binodal, toward lower values of dense phase concentration."
134,PMID: 29064502,RNAPS0000124,https://pubmed.ncbi.nlm.nih.gov/29064502,RNA + protein,-,-,polyA(30),30nt,AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,poly RNA,-,"sp|D0PV95|DDX3_CAEEL ATP-dependent RNA helicase laf-1 OS=Caenorhabditis elegans OX=6239 GN=laf-1 PE=1 SV=1|length=708aa|residues=1-708
MESNQSNNGGSGNAALNRGGRYVPPHLRGGDGGAAAAASAGGDDRRGGAGGGGYRRGGGN
SGGGGGGGYDRGYNDNRDDRDNRGGSGGYGRDRNYEDRGYNGGGGGGGNRGYNNNRGGGG
GGYNRQDRGDGGSSNFSRGGYNNRDEGSDNRGSGRSYNNDRRDNGGDGQNTRWNNLDAPP
SRGTSKWENRGARDERIEQELFSGQLSGINFDKYEEIPVEATGDDVPQPISLFSDLSLHE
WIEENIKTAGYDRPTPVQKYSIPALQGGRDLMSCAQTGSGKTAAFLVPLVNAILQDGPDA
VHRSVTSSGGRKKQYPSALVLSPTRELSLQIFNESRKFAYRTPITSALLYGGRENYKDQI
HKLRLGCHILIATPGRLIDVMDQGLIGMEGCRYLVLDEADRMLDMGFEPQIRQIVECNRM
PSKEERITAMFSATFPKEIQLLAQDFLKENYVFLAVGRVGSTSENIMQKIVWVEEDEKRS
YLMDLLDATGDSSLTLVFVETKRGASDLAYYLNRQNYEVVTIHGDLKQFEREKHLDLFRT
GTAPILVATAVAARGLDIPNVKHVINYDLPSDVDEYVHRIGRTGRVGNVGLATSFFNDKN
RNIARELMDLIVEANQELPDWLEGMSGDMRSGGGYRGRGGRGNGQRFGGRDHRYQGGSGN
GGGGNGGGGGFGGGGQRSGGGGGFQSGGGGGRQQQQQQRAQPQQDWWS",laf-1,-,-,708aa(1-708),D0PV95,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/D0PV95,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0337,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0001,http://db.phasep.pro/browse/",-,-,In vitro,0-9 mg/ml [laf-1];|7.5 µM polyA,0-500 mM NaCl,"20 mM Tris, pH 7.4, 1 mM DTT",RT,-,-,Confocal microscopy,"solute, liquid","In the presence of polyadenylate RNA (poly-rA) of various lengths, the low-concentration arm of the LAF-1 binodal and the concentrations corresponding to the critical region remain essentially invariant. However, upon addition of RNA we observe a marked shift of the high-concentration arm of the LAF-1 binodal, toward lower values of dense phase concentration."
135,PMID: 29064502,RNAPS0000125,https://pubmed.ncbi.nlm.nih.gov/29064502,RNA + protein,-,-,polyA(15),15nt,AAAAAAAAAAAAAAA,poly RNA,-,"sp|D0PV95|DDX3_CAEEL ATP-dependent RNA helicase laf-1 OS=Caenorhabditis elegans OX=6239 GN=laf-1 PE=1 SV=1|length=708aa|residues=1-708
MESNQSNNGGSGNAALNRGGRYVPPHLRGGDGGAAAAASAGGDDRRGGAGGGGYRRGGGN
SGGGGGGGYDRGYNDNRDDRDNRGGSGGYGRDRNYEDRGYNGGGGGGGNRGYNNNRGGGG
GGYNRQDRGDGGSSNFSRGGYNNRDEGSDNRGSGRSYNNDRRDNGGDGQNTRWNNLDAPP
SRGTSKWENRGARDERIEQELFSGQLSGINFDKYEEIPVEATGDDVPQPISLFSDLSLHE
WIEENIKTAGYDRPTPVQKYSIPALQGGRDLMSCAQTGSGKTAAFLVPLVNAILQDGPDA
VHRSVTSSGGRKKQYPSALVLSPTRELSLQIFNESRKFAYRTPITSALLYGGRENYKDQI
HKLRLGCHILIATPGRLIDVMDQGLIGMEGCRYLVLDEADRMLDMGFEPQIRQIVECNRM
PSKEERITAMFSATFPKEIQLLAQDFLKENYVFLAVGRVGSTSENIMQKIVWVEEDEKRS
YLMDLLDATGDSSLTLVFVETKRGASDLAYYLNRQNYEVVTIHGDLKQFEREKHLDLFRT
GTAPILVATAVAARGLDIPNVKHVINYDLPSDVDEYVHRIGRTGRVGNVGLATSFFNDKN
RNIARELMDLIVEANQELPDWLEGMSGDMRSGGGYRGRGGRGNGQRFGGRDHRYQGGSGN
GGGGNGGGGGFGGGGQRSGGGGGFQSGGGGGRQQQQQQRAQPQQDWWS",laf-1,-,-,708aa(1-708),D0PV95,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/D0PV95,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0337,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0001,http://db.phasep.pro/browse/",-,-,In vitro,0-9 mg/ml [laf-1];|15 µM polyA,0-500 mM NaCl,"20 mM Tris, pH 7.4, 1 mM DTT",RT,-,-,Confocal microscopy,"solute, liquid","In the presence of polyadenylate RNA (poly-rA) of various lengths, the low-concentration arm of the LAF-1 binodal and the concentrations corresponding to the critical region remain essentially invariant. However, upon addition of RNA we observe a marked shift of the high-concentration arm of the LAF-1 binodal, toward lower values of dense phase concentration."
136,PMID: 29064502,RNAPS0000126,https://pubmed.ncbi.nlm.nih.gov/29064502,RNA + protein,-,-,Caenorhabditis elegans rRNA,-,-,rRNA,Caenorhabditis elegans,"sp|P07222|NPM_XENLA Nucleophosmin OS=Xenopus laevis OX=8355 GN=npm1 PE=1 SV=1|length=299aa|residues=1-299
MEDSMDMDNIAPLRPQNFLFGCELKADKKEYSFKVEDDENEHQLSLRTVSLGASAKDELH
VVEAEGINYEGKTIKIALASLKPSVQPTVSLGGFEITPPVILRLKSGSGPVYVSGQHLVA
LEDLESSDDEDEEHEPSPKNAKRIAPDSASKVPRKKTRLEEEEEDSDEDDDDDEDDDDED
DDEEEEETPVKKTDSTKSKAAQKLNHNGKASALSTTQKTPKTPEQKGKQDTKPQTPKTPK
TPLSSEEIKAKMQTYLEKGNVLPKVEVKFANYVKNCFRTENQKVIEDLWKWRQSLKDGK",npm1,-,-,299aa(1-299),P07222,"LLPSDB,PhaSepDB","http://bio-comp.org.cn/llpsdb/protein.php?protein=p0225,http://db.phasep.pro/browse/",-,-,In vitro,25 µM [npm1];|0.1 mg/ml rRNA,150 mM NaCl,"20 mM Tris, pH 7.4, 1 mM DTT",RT,-,crowding agent:0.01-0.07 mg/ml dextran 10-155 kD,Confocal microscopy,liquid,"The smaller 10 kDa dextranpartitions favourably into P granules, while the larger 155 kDa dextran is significantly excluded; similar in vivo results have beenreported for P granules and for nucleoli. Moreover, we see similar size-dependent exclusionin vitro for two other well-known droplet forming proteins, WHI3 and NPM1. These results suggest that the semidilute, void-rich nature of droplets is likely a feature of many liquid-phase organelles that are driven by the sequence encoded conformational fluctuations of IDRs."
137,PMID: 29210575,RNAPS0000410,https://pubmed.ncbi.nlm.nih.gov/29210575,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P42212|GFP_AEQVI Green fluorescent protein OS=Aequorea victoria OX=6100 GN=GFP PE=1 SV=1|length=238aa|residues=1-238|mutation=E34K,T105K,E142R,N149K
MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGKGDATYGKLTLKFICTTGKLPVPWPTL
VTTFSYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKKRAEVKFEGDTLV
NRIELKGIDFKEDGNILGHKLRYNYNSHKVYIMADKQKNGIKVNFKIRHNIEDGSVQLAD
HYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITHGMDELYK",GFP,-,"protein_mutation:E34K,T105K,E142R,N149K",238aa(1-238),P42212,"LLPSDB,PhaSepDB","http://bio-comp.org.cn/llpsdb/protein.php?protein=p0171,http://db.phasep.pro/browse/","[1-7],[114-121],[179-219]",-,In vitro,[GFP] and RNA solutions were mixed together at protein mass fractions centered on 0.68 with 0.2 mg mL-1 total concentration.,-,10 mM Tris (pH 7.4),25˚C,-,-,Phase contrast microscopy,liquid,"Since GFP/RNA pairs phase separated as liquid-liquid rather than solid-liquid like most of the other GFP/polyanion pairs, we hypothesized GFP/synthetic polyanion pairs may also phase separate as liquid-liquid at other protein mass fractions. GFP/polyanion were mixed at varying ratios in 10 mM Tris (pH 7.4) at 0.2 mg mL-1 total macromolecular concentration, incubated at 25 ⁰C, then imaged by phase contrast microscopy. Each of the GFP/synthetic polyanion pairs formed liquid-liquid and not solid-liquid phase separations at protein mass fractions lower than the midpoint of turbidity, while at protein mass fractions greater than the midpoint of turbidity both GFP/PAA and GFP/PSS formed solid-liquid phase separations. Interestingly, DNA/GFP pairs formed only solid-liquid phase separations at each protein mass fraction, while RNA/GFP formed only liquid-liquid phase separations."
138,PMID: 29210575,RNAPS0000410,https://pubmed.ncbi.nlm.nih.gov/29210575,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P42212|GFP_AEQVI Green fluorescent protein OS=Aequorea victoria OX=6100 GN=GFP PE=1 SV=1|length=238aa|residues=1-238|mutation=D19K,E32K,D133K
MSKGEELFTGVVPILVELKGDVNGHKFSVSGKGEGDATYGKLTLKFICTTGKLPVPWPTL
VTTFSYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLV
NRIELKGIDFKEKGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLAD
HYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITHGMDELYK",GFP,-,"protein_mutation:D19K,E32K,D133K",238aa(1-238),P42212,"LLPSDB,PhaSepDB","http://bio-comp.org.cn/llpsdb/protein.php?protein=p0171,http://db.phasep.pro/browse/","[1-7],[115-118],[179-219]",-,In vitro,[GFP] and RNA solutions were mixed together at protein mass fractions centered on 0.64 with 0.2 mg mL-1 total concentration.,-,10 mM Tris (pH 7.4),25˚C,-,-,Phase contrast microscopy,liquid,"Since GFP/RNA pairs phase separated as liquid-liquid rather than solid-liquid like most of the other GFP/polyanion pairs, we hypothesized GFP/synthetic polyanion pairs may also phase separate as liquid-liquid at other protein mass fractions. GFP/polyanion were mixed at varying ratios in 10 mM Tris (pH 7.4) at 0.2 mg mL-1 total macromolecular concentration, incubated at 25 ⁰C, then imaged by phase contrast microscopy. Each of the GFP/synthetic polyanion pairs formed liquid-liquid and not solid-liquid phase separations at protein mass fractions lower than the midpoint of turbidity, while at protein mass fractions greater than the midpoint of turbidity both GFP/PAA and GFP/PSS formed solid-liquid phase separations. Interestingly, DNA/GFP pairs formed only solid-liquid phase separations at each protein mass fraction, while RNA/GFP formed only liquid-liquid phase separations."
139,PMID: 29210575,RNAPS0000410,https://pubmed.ncbi.nlm.nih.gov/29210575,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P42212|GFP_AEQVI Green fluorescent protein OS=Aequorea victoria OX=6100 GN=GFP PE=1 SV=1|length=238aa|residues=1-238|mutation=V11K,E124K,Q157R,D190R
MSKGEELFTGKVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTL
VTTFSYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLV
NRIKLKGIDFKEDGNILGHKLEYNYNSHNVYIMADKRKNGIKVNFKIRHNIEDGSVQLAD
HYQQNTPIGRGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITHGMDELYK",GFP,-,"protein_mutation:V11K,E124K,Q157R,D190R",238aa(1-238),P42212,"LLPSDB,PhaSepDB","http://bio-comp.org.cn/llpsdb/protein.php?protein=p0171,http://db.phasep.pro/browse/","[1-10],[23-29],[114-118],[161-166],[179-219]",-,In vitro,[GFP] and RNA solutions were mixed together at protein mass fractions 0.60 with 1 mg mL-1 total concentration.,400-500 mM NaCl,10 mM Tris (pH 7.4),25˚C,-,-,Phase contrast microscopy,liquid,"Effect of NaCl on GFP(+26)/RNA phase separation morphology. NaCl was titrated into GFP(+26)/RNA after intial mixing in 10 mM Tris (pH 7.4) with 0 mM NaCl. Similar to GFP/PAA pairs, the GFP(+26)/RNA dense phase transitioned from solid to liquid at NaCl concentrations corresponding to the plateau in salt titration experiments."
140,PMID: 29314832,RNAPS0000142,https://pubmed.ncbi.nlm.nih.gov/29314832,RNA + protein,-,-,luciferase_antisense_siRNA,21nt,UCGAAGUACUCAGCGUAAGUU,siRNA,Photinus pyralis,KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK,50 aa pLys,-,-,50aa,-,-,-,[1-50],-,In vitro,5 mM([RNA phosphate] + [pLys amine]),18.2 MΩ water and concentrated NaCl solutions,pH 7,RT,4 h,-,-,liquid,"Single- and double-stranded RNA oligonucleotides displayed the same phase behavior as DNA: single-stranded RNA formed coacervates and double-stranded RNA formed precipitates. When mixed with 50 aa pLys, ssRNA forms coacervates while dsRNA forms solid precipitates, just as for DNA."
141,PMID: 29314832,RNAPS0000143,https://pubmed.ncbi.nlm.nih.gov/29314832,RNA + protein,-,-,luciferase_dsRNA_siRNA,42nt,UCGAAGUACUCAGCGUAAGUUUUAGCUUCAUGAGUCGCAUUC,siRNA,Photinus pyralis,KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK,50 aa pLys,-,-,50aa,-,-,-,[1-50],-,In vitro,5 mM([RNA phosphate] + [pLys amine]),18.2 MΩ water and concentrated NaCl solutions,pH 7,RT,4 h,-,-,solid,"Single- and double-stranded RNA oligonucleotides displayed the same phase behavior as DNA: single-stranded RNA formed coacervates and double-stranded RNA formed precipitates. When mixed with 50 aa pLys, ssRNA forms coacervates while dsRNA forms solid precipitates, just as for DNA."
142,PMID: 29425497,RNAPS0000051,https://pubmed.ncbi.nlm.nih.gov/29425497,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P26599|PTBP1_HUMAN Polypyrimidine tract-binding protein 1 OS=Homo sapiens OX=9606 GN=PTBP1 PE=1 SV=1|length=531aa|residues=1-531
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTI",PTBP1,-,-,531aa(1-531),P26599,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/",-,"[32-44],[162-179],[306-335]",In vitro,20 µM [PTBP1];|1.6 µM RNA ,100 mM NaCl,"20 mM imidazole pH 7.0, 1 mM DTT, 10% glycerol",RT,-,other_molecular:100 mg/ml BSA,Confocal microscopy,liquid,"While SNAP-tagged PTB and RNA showed limited assembly when mixed together at concentrations of 20 mM and 1.6 mM, respectively, the addition of 100 mg/mL BSA induced robust phase separation at these concentrations. Consistent with this effect being due to molecular crowding, PTB-RNA LLPS is also stimulated by PEG or Ficoll, additional crowding agents."
143,PMID: 29425497,RNAPS0000051,https://pubmed.ncbi.nlm.nih.gov/29425497,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P26599|PTBP1_HUMAN Polypyrimidine tract-binding protein 1 OS=Homo sapiens OX=9606 GN=PTBP1 PE=1 SV=1|length=531aa|residues=1-531
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTI",PTBP1,-,-,531aa(1-531),P26599,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/",-,"[32-44],[162-179],[306-335]",In vitro,20 µM [PTBP1];|1.6 µM RNA ,100 mM NaCl,"20 mM imidazole pH 7.0, 1 mM DTT, 10% glycerol",RT,-,crowding agent:100 mg/ml Ficoll,Confocal microscopy,liquid,"While SNAP-tagged PTB and RNA showed limited assembly when mixed together at concentrations of 20 mM and 1.6 mM, respectively, the addition of 100 mg/mL BSA induced robust phase separation at these concentrations. Consistent with this effect being due to molecular crowding, PTB-RNA LLPS is also stimulated by PEG or Ficoll, additional crowding agents."
144,PMID: 29425497,RNAPS0000051,https://pubmed.ncbi.nlm.nih.gov/29425497,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P26599|PTBP1_HUMAN Polypyrimidine tract-binding protein 1 OS=Homo sapiens OX=9606 GN=PTBP1 PE=1 SV=1|length=531aa|residues=1-531
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTI",PTBP1,-,-,531aa(1-531),P26599,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/",-,"[32-44],[162-179],[306-335]",In vitro,20 µM [PTBP1];|1.6 µM RNA ,100 mM NaCl,"20 mM imidazole pH 7.0, 1 mM DTT, 10% glycerol",RT,-,crowding agent:100 mg/ml PEG,Confocal microscopy,liquid,"While SNAP-tagged PTB and RNA showed limited assembly when mixed together at concentrations of 20 mM and 1.6 mM, respectively, the addition of 100 mg/mL BSA induced robust phase separation at these concentrations. Consistent with this effect being due to molecular crowding, PTB-RNA LLPS is also stimulated by PEG or Ficoll, additional crowding agents."
145,PMID: 29425497,RNAPS0000051,https://pubmed.ncbi.nlm.nih.gov/29425497,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P26599|PTBP1_HUMAN Polypyrimidine tract-binding protein 1 OS=Homo sapiens OX=9606 GN=PTBP1 PE=1 SV=1|length=531aa|residues=1-531
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTI",PTBP1,-,-,531aa(1-531),P26599,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/",-,"[32-44],[162-179],[306-335]",In vitro,4 µM [PTBP1];|0.32 µM RNA ,100 mM NaCl,"20 mM imidazole pH 7.0, 1 mM DTT, 10% glycerol",RT,-,other_molecular:100 mg/ml BSA,Confocal microscopy,solute,"4 µM PTB and 0.32 µM RNA do not phase separate in 100 mg/mL BSA. However, we observed LLPS with identical concentrations of RNA and PTB, when PTB was fused to either the FUS or Pub1 IDRs. PTB fused to either IDR showed an increase in both the number and size of the assemblies visualized. Therefore, weak interactions of IDRs can enhance phase separation in the presence of competitor proteins, when present in molecules that also contain specific interactions which are less susceptible to competition from cellular macromolecules."
146,PMID: 29425497,RNAPS0000369,https://pubmed.ncbi.nlm.nih.gov/29425497,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTBP1]-[FUS IDR] with PTBP1 residues 1-531 fused to FUS residues 1-237|Linker is missing|length=768aa|residues=1-531/1-237
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTIMASNDYTQQ
ATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQSQNTGYGTQ
STPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSSSYGQPQSGS
YSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQDQSSMSSGGG
SGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSG",PTBP1-FUS,IDR,-,"768aa(1-531,1-237)","P26599,P35637","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",-;|[1-237],"[32-44],[162-179],[306-335];|[17-104],[106-237]",In vitro,4 µM [PTBP1]-[FUS IDR];|0.32 µM RNA,100 mM NaCl,"20 mM imidazole pH 7.0, 1 mM DTT, 10% glycerol",RT,-,other_molecular:100 mg/ml BSA,Confocal microscopy,liquid,"4 uM PTB and 0.32 μM RNA do not phase separate in 100 mg/mL BSA. However, we observed LLPS with identical concentrations of RNA and PTB, when PTB was fused to either the FUS or Pub1 IDRs. PTB fused to either IDR showed an increase in both the number and size of the assemblies visualized. Therefore, weak interactions of IDRs can enhance phase separation in the presence of competitor proteins, when present in molecules that also contain specific interactions which are less susceptible to competition from cellular macromolecules."
147,PMID: 29425497,RNAPS0000048,https://pubmed.ncbi.nlm.nih.gov/29425497,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTB]-[Pub1 IDR] with PTB residues 1-531 fused to Pub1 residues 243-327|Linker is missing|length=616aa|residues=1-531;243-327
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTINNNNNNYQQ
RRNYGNNNRGGFRQYNSNNNNNMNMGMNMNMNMNMNNSRGMPPSSMGMPIGAMPLPSQGQ
PQQSQTIGLPPQVNPQ",PTBP1-PUB1,IDR,-,"616aa(1-531,243-327)","P26599,P32588","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/,https://phasepro.elte.hu/entry/P32588,http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0524,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0004,http://db.phasep.pro/browse/",-;|[243-262],"[32-44],[162-179],[306-335];|[243-297],[307-316]",In vitro,4 µM [PTBP1]-[PUB1 IDR];|0.32 µM RNA,100 mM NaCl,"20 mM imidazole pH 7.0, 1 mM DTT, 10% glycerol",RT,-,other_molecular:100 mg/ml BSA,Confocal microscopy,liquid,"4 µM PTB and 0.32 µM RNA do not phase separate in 100 mg/mL BSA. However, we observed LLPS with identical concentrations of RNA and PTB, when PTB was fused to either the FUS or Pub1 IDRs. PTB fused to either IDR showed an increase in both the number and size of the assemblies visualized. Therefore, weak interactions of IDRs can enhance phase separation in the presence of competitor proteins, when present in molecules that also contain specific interactions which are less susceptible to competition from cellular macromolecules."
148,PMID: 29472250,RNAPS0000477,https://pubmed.ncbi.nlm.nih.gov/29472250,RNAs + protein,-,-,Homo sapiens brain RNA,-,-,total RNA,Homo sapiens,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=441aa|residues=1-441
MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPG
SETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAG
HVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPK
TPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAK
SRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHV
PGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNI
THVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMV
DSPQLATLADEVSASLAKQGL",MAPT,-,protein_ptm:Phosphorylation,441aa(1-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[125-375],[395-441]","[216-226],[323-340],[380-403]",In vitro,2 µM [Tau];|0.5 mg/ml RNA,50 mM NaCl,10 mM HEPES pH 7.4,RT,> 0 min,-,"Electron microscopy,FRAP,Atomic force microscopy",liquid,"The addition of heparin or RNA to phosphorylated p-tau441 led to spontaneous formation of p-tau441 droplets, even in the absence of PEG. While, Non-phosphorylated tau441 did not show LLPS with heparin and RNA at the same low protein concentration (2 uM) and in the same buffer conditions."
149,PMID: 29483575,RNAPS0000604,https://pubmed.ncbi.nlm.nih.gov/29483575,RNAs + protein,-,-,Triticum aestivum germ rRNA,-,-,rRNA,Triticum aestivum,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|llength=297aa|residues=1-294|mutation=A3 to GGS repeats
GSHMEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDEL
HIVEAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLV
AVEEDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAAGGSGGSGGSGGSGGSGG
SGGSGGSGGSGKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKT
PKGPSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL",hNPM1,-,protein_mutation:IDR [A3 tract] to GGS repeats,297aa,P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/","[1-14],[44-62],[80-81],[117-233],[294-294],[297-297]",-,In vitro,≥1 µM [hNPM1];|100 µg/ml rRNA,150 mM NaCl,"10 mM Tris, 2 mM DTT, pH 7.5",RT,> 15 min,-,Turbidity measurement,liquid,"Mutations in the A3- and B2-tracts severely affected LLPS with SURF6 N and rRNA, respectively, via the two different heterotypic scaffolding mechanisms (e.g., A-tracts of NPM1 interacting with R-motifs of SURF6 N, and the B2-tract & CTD of NPM1 interacting with rRNA). NPM1_M(mutA3) exhibited a ~ten fold decrease in the threshold concentration for LLPS with rRNA, supporting the mechanistic model wherein binding of the B2-tract (to rRNA) is partially inhibited by its interaction with the A3-tract. NPM1_M(mutB2) exhibited an increase in the concentration threshold for LLPS. The increase observed in the concentration threshold for LLPS of NPM1_M(mutB2) with SURF6 N is due, primarily, to disruption of the homotypic mechanism."
150,PMID: 29483575,RNAPS0000604,https://pubmed.ncbi.nlm.nih.gov/29483575,RNAs + protein,-,-,Triticum aestivum germ rRNA,-,-,rRNA,Triticum aestivum,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|llength=296aa|residues=1-294|mutation=B1 R/K to A
GSHMEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDEEHQLSLRTVSLGAGAKDELH
IVEAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVA
VEEDAESEDEEEEDVALLSISGARSAPGGGSAVPQAAVALAADEDDDDDDEEDDDEDDDD
DDFDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTP
KGPSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL",hNPM1,-,protein_mutation: [moderately charged basic tracts B1] R/K to A,296aa,P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/","[1-14],[44-61],[79-80],[116-232],[293-293],[296-296]",-,In vitro,≥10 µM [hNPM1];|100 µg/ml rRNA,150 mM NaCl,"10 mM Tris, 2 mM DTT, pH 7.5",RT,> 15 min,-,Turbidity measurement,liquid,"Mutations in the A3- and B2-tracts severely affected LLPS with SURF6 N and rRNA, respectively, via the two different heterotypic scaffolding mechanisms (e.g., A-tracts of NPM1 interacting with R-motifs of SURF6 N, and the B2-tract & CTD of NPM1 interacting with rRNA). NPM1_M(mutA3) exhibited a ~ten fold decrease in the threshold concentration for LLPS with rRNA, supporting the mechanistic model wherein binding of the B2-tract (to rRNA) is partially inhibited by its interaction with the A3-tract. NPM1_M(mutB2) exhibited an increase in the concentration threshold for LLPS. The increase observed in the concentration threshold for LLPS of NPM1_M(mutB2) with SURF6 N is due, primarily, to disruption of the homotypic mechanism."
151,PMID: 29483575,RNAPS0000604,https://pubmed.ncbi.nlm.nih.gov/29483575,RNAs + protein,-,-,Triticum aestivum germ rRNA,-,-,rRNA,Triticum aestivum,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|llength=297aa|residues=1-294|mutation=B2 R/K to A
GSHMEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDEL
HIVEAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLV
AVEEDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDD
DDDFDDEEAEEAAPVAASIRDTPAANAQASNQNGADSAPSSTPRSAGQESFAAQEATPAT
PAGPSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL",hNPM1,-,protein_mutation: [moderately charged basic tracts B2] R/K to A,297aa,P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/","[1-14],[44-62],[80-81],[117-251],[294-294],[297-297]",-,In vitro,0.1-100 µM [hNPM1];|100 µg/ml rRNA,150 mM NaCl,"10 mM Tris, 2 mM DTT, pH 7.5",RT,> 15 min,-,Turbidity measurement,solute,"Mutations in the A3- and B2-tracts severely affected LLPS with SURF6 N and rRNA, respectively, via the two different heterotypic scaffolding mechanisms (e.g., A-tracts of NPM1 interacting with R-motifs of SURF6 N, and the B2-tract & CTD of NPM1 interacting with rRNA). NPM1_M(mutA3) exhibited a ~ten fold decrease in the threshold concentration for LLPS with rRNA, supporting the mechanistic model wherein binding of the B2-tract (to rRNA) is partially inhibited by its interaction with the A3-tract. NPM1_M(mutB2) exhibited an increase in the concentration threshold for LLPS. The increase observed in the concentration threshold for LLPS of NPM1_M(mutB2) with SURF6 N is due, primarily, to disruption of the homotypic mechanism."
152,PMID: 29483575,RNAPS0000604,https://pubmed.ncbi.nlm.nih.gov/29483575,RNAs + protein,-,-,Triticum aestivum germ rRNA,-,-,rRNA,Triticum aestivum,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|length=296aa|residues=1-294
GSMEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELH
IVEAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVA
VEEDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDD
DDFDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTP
KGPSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL",hNPM1,-,-,296aa,P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/",[1-259],-,In vitro,≥10 µM [hNPM1];|100 µg/ml rRNA,150 mM NaCl,"10 mM Tris, 2 mM DTT, pH 7.5",RT,> 15 min,-,Turbidity measurement,liquid,"Mutations in the A3- and B2-tracts severely affected LLPS with SURF6 N and rRNA, respectively, via the two different heterotypic scaffolding mechanisms (e.g., A-tracts of NPM1 interacting with R-motifs of SURF6 N, and the B2-tract & CTD of NPM1 interacting with rRNA). NPM1_M(mutA3) exhibited a ~ten fold decrease in the threshold concentration for LLPS with rRNA, supporting the mechanistic model wherein binding of the B2-tract (to rRNA) is partially inhibited by its interaction with the A3-tract. NPM1_M(mutB2) exhibited an increase in the concentration threshold for LLPS. The increase observed in the concentration threshold for LLPS of NPM1_M(mutB2) with SURF6 N is due, primarily, to disruption of the homotypic mechanism."
153,PMID: 29650702,RNAPS0000151,https://pubmed.ncbi.nlm.nih.gov/29650702,RNA + protein,NCBI ID:283131,https://www.ncbi.nlm.nih.gov/gene/283131,NEAT1,3756nt(1-3756),GGAGUUAGCGACAGGGAGGGAUGCGCGCCUGGGUGUAGUUGUGGGGGAGGAAGUGGCUAGCUCAGGGCUUCAGGGGACAGACAGGGAGAGAUGACUGAGUUAGAUGAGACGAGGGGGCGGGCUGGGGGUGCGAGAAGGAAGCUUGGCAAGGAGACUAGGUCUAGGGGGACCACAGUGGGGCAGGCUGCAUGGAAAAUAUCCGCAGGGUCCCCCAGGCAGAACAGCCACGCUCCAGGCCAGGCUGUCCCUACUGCCUGGUGGAGGGGGAACUUGACCUCUGGGAGGGCGCCGCUCUUGCAUAGCUGAGCGAGCCCGGGUGCGCUGGUCUGUGUGGAAGGAGGAAGGCAGGGAGAGGUAGAAGGGGUGGAGGAGUCAGGAGGAAUAGGCCGCAGCAGCCCUGGAAAUGAUCAGGAAGGCAGGCAGUGGGUGCAGGGCUGCAGGAGGGCCGGGAGGGCUAAUCUUCAACUUGUCCAUGCCAGCAGCCCCUUUUUUUCCAGACCAAGGGCUGUGAACCCGCCUGGGGAUGAGGCCUGGUCUUGUGGAACUGAACUUAGCUCGACGGGGCUGACCGCUCUGGCCCAGGGUGGUAUGUAAUUUUCGCUCGGCCUGGGACGGGGCCCAGGCCGGGCCCAGCCUGGUGGAGCGUCCAGGUCUGGGUGCGAAGCCAGGCCCCUGGGCGGAGGUGAGGGGUGGUCUGAGGAGUGAUGUGGAGUUAAGGCGCCAUCCUCACCGGUGACUGGUGCGGCACCUAGCAUGUUUGACAGGCGGGGACUGCGAGGCACGCUGCUCGGGUGUUGGGGACAACAUUGACCAACGCUUUAUUUUCCAGGUGGCAGUGCUCCUUUUGGACUUUUCUCUAGGUUUGGCGCUAAACUCUUCUUGUGAGCUCACUCCACCCCUUCUUCCUCCCUUUAACUUAUCCAUUCACUUAAAACAUUACCUGGUCAUCUGGUAAGCCCGGGACAGUAAGCCGAGUGGCUGUUGGAGUCGGUAUUGUUGGUAAUGGUGGAGGAAGAGAGGCCUUCCCGCUGAGGCUGGGGUGGGGCGGAUCGGUGUUGCUUGCCUGCAGAGAGGGUGGGGAGUGAAUGUGCACCCUUGGGUGGGCCUGCAGCCAUCCAGCUGAAAGUUACAAAAAUGCUUCAUGGACCGUGGUUUGUUACUAUAGUGUUCCUCAUGGCGAGCAGAUGGAACCGGGAGACAUGGAGUCCCUGGCCAGUGUGAGUCCUAGCAUUGCAGGAGGGGAGACCCUGGAGGAGAGAGCCCGCCUCAAUUGAUGCCUGCAGAUUGAAUUUCCAGAGGCUUAGGAGGAGGAAGUUCUCCAAUGUUCUGUUUCCAGGCCUUGCUCAGGAAGCCCUGUAUUCAGGAGGCUACCAUUUAAAGUUUGCAGAUGAGCUUAUGGGGGGCAAUCUUAAAAAGUCCACAGCAGAUGCAUCCGGCUCGAGGGGCCAUCAGCUUUGAAUAAAUGCUUGUUCCAGAGCCCAUGAAUGCCAGCAGGCACCCCUCCUUUCCUGGGGUAAAGGUUUUCAGAUGCUGCAUCUUCUAAAUUGAGCCUCCGGUCAUACUAGUUUUGUGCUUGGAACCUUGCUUCAAGAAGAUCCCUAAGCUGUAGAACAUUUUAACGUUGAUGCCACAACGCAGAUUGAUGCCUUGUAGAUGGAGCUUGCAGAUGGAGCCCCGUGACCUCUCACCUACCCACCUGUUUGCCUGCCUUCUUGUGCGUUUCUCGGAGAAGUUCUUAGCCUGAUGAAAUAACUUGGGGCGUUGAAGAGCUGUUUAAUUUUAAAUGCCUUAGACUGGGGAUAUAUUAGAGGAAGCAGAUUGUCAAAUUAAGGGUGUCAUUGUGUUGUGCUAAACGCUGGGAGGGUACAAGUUGGUCAUUCCUAAAUCUGUGUGUGAGAAAUGGCAGGUCUAGUUUGGGCAUUGUGAUUGCAUUGCAGAUUACUAGGAGAAGGGAAUGGUGGGUACACCGGUAGUGCUCUUUUGUUCUUGCUUCGUUUUUUUAAACUUGAACUUUACUUCGUUAGAUUUCAUAAUACUUUCUUGGCAUUCUAGUAAGAGGACCCUGAGGUGGGAGUUGUGGGGGACGGGGAGAAGGGGACAGCUUGGCACCGGUCCCGUGGGCGUUGCAGUGUGGGGGAUGGGGGUAUGCAGCUUGGCACUGGUACUGGGAGGGAUGAGGGUGAAGAAGGGGAGAGGGUUGGUUAGAGAUACAGUGUGGGUGGUGGGGGUGGUAGGAAAUGCAGGUUGAAGGGAAUUCUCUGGGGCUUUGGGGAAUUUAGUGCGUGGGUGAGCCAAGAAAAUACUAAUUAAUAAUAGUAAGUUGUUAGUGUUGGUUAAGUUGUUGCUUGGAAGUGAGAAGUUGCUUAGAAACUUUCCAAAGUGCUUAGAACUUUAAGUGCAAACAGACAAACUAACAAACAAAAAUUGUUUUGCUUUGCUACAAGGUGGGGAAGACUGAAGAAGUGUUAACUGAAAACAGGUGACACAGAGUCACCAGUUUUCCGAGAACCAAAGGGAGGGGUGUGUGAUGCCAUCUCACAGGCAGGGGAAAUGUCUUUACCAGCUUCCUCCUGGUGGCCAAGACAGCCUGUUUCAGAGGGUUGUUUUGUUUGGGGUGUGGGUGUUAUCAAGUGAAUUAGUCACUUGAAAGAUGGGCGUCAGACUUGCAUACGCAGCAGAUCAGCAUCCUUCGCUGCCCCUUAGCAACUUAGGUGGUUGAUUUGAAACUGUGAAGGUGUGAUUUUUUCAGGAGCUGGAAGUCUUAGAAAAGCCUUGUAAAUGCCUAUAUUGUGGGCUUUUAACGUAUUUAAGGGACCACUUAAGACGAGAUUAGAUGGGCUCUUCUGGAUUUGUUCCUCAUUUGUCACAGGUGUCUUGUGAUUGAAAAUCAUGAGCGAAGUGAAAUUGCAUUGAAUUUCAAGGGAAUUUAGUAUGUAAAUCGUGCCUUAGAAACACAUCUGUUGUCUUUUCUGUGUUUGGUCGAUAUUAAUAAUGGCAAAAUUUUUGCCUAUCUAGUAUCUUCAAAUUGUAGUCUUUGUAACAACCAAAUAACCUUUUGUGGUCACUGUAAAAUUAAUAUUUGGUAGACAGAAUCCAUGUACCUUUGCUAAGGUUAGAAUGAAUAAUUUAUUGUAUUUUUAAUUUGAAUGUUUGUGCUUUUUAAAUGAGCCAAGACUAGAGGGGAAACUAUCACCUAAAAUCAGUUUGGAAAACAAGACCUAAAAAGGGAAGGGGAUGGGGAUUGUGGGGAGAGAGUGGGCGAGGUGCCUUUACUACAUGUGUGAUCUGAAAACCCUGCUUGGUUCUGAGCUGCGUCUAUUGAAUUGGUAAAGUAAUACCAAUGGCUUUUUAUCAUUUCCUUCUUCCCUUUAAGUUUCACUUGAAAUUUUAAAAAUCAUGGUUAUUUUUAUCGUUGGGAUCUUUCUGUCUUCUGGGUUCCAUUUUUUAAAUGUUUAAAAAUAUGUUGACAUGGUAGUUCAGUUCUUAACCAAUGACUUGGGGAUGAUGCAAACAAUUACUGUCGUUGGGAUUUAGAGUGUAUUAGUCACGCAUGUAUGGGGAAGUAGUCUCGGGUAUGCUGUUGUGAAAUUGAAACUGUAAAAGUAGAUGGUUGAAAGUACUGGUAUGUUGCUCUGUAUGGUAAGAACUAAUUCUGUUACGUCAUGUACAUAAUUACUAAUCACUUUUCUUCCCCUUUACAGCACAAAUAAAGUUUGAGUUCUAAACUCAUUAGAAAAAAAAAAAAAAAAAAAAAAA,lncRNA,Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|0-800 ng/µl Neat1 ,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,liquid,"rRNA, tRNA, and a noncoding RNA that is known to bind to FUS (Neat1) were all able to solubilize FUS droplets, suggesting a general effect, but smaller RNAs were more potent than larger ones. The FUS droplets re-appear after RNase A induced RNA degradation."
154,PMID: 29650702,RNAPS0000151,https://pubmed.ncbi.nlm.nih.gov/29650702,RNA + protein,NCBI ID:283131,https://www.ncbi.nlm.nih.gov/gene/283131,NEAT1,3756nt(1-3756),GGAGUUAGCGACAGGGAGGGAUGCGCGCCUGGGUGUAGUUGUGGGGGAGGAAGUGGCUAGCUCAGGGCUUCAGGGGACAGACAGGGAGAGAUGACUGAGUUAGAUGAGACGAGGGGGCGGGCUGGGGGUGCGAGAAGGAAGCUUGGCAAGGAGACUAGGUCUAGGGGGACCACAGUGGGGCAGGCUGCAUGGAAAAUAUCCGCAGGGUCCCCCAGGCAGAACAGCCACGCUCCAGGCCAGGCUGUCCCUACUGCCUGGUGGAGGGGGAACUUGACCUCUGGGAGGGCGCCGCUCUUGCAUAGCUGAGCGAGCCCGGGUGCGCUGGUCUGUGUGGAAGGAGGAAGGCAGGGAGAGGUAGAAGGGGUGGAGGAGUCAGGAGGAAUAGGCCGCAGCAGCCCUGGAAAUGAUCAGGAAGGCAGGCAGUGGGUGCAGGGCUGCAGGAGGGCCGGGAGGGCUAAUCUUCAACUUGUCCAUGCCAGCAGCCCCUUUUUUUCCAGACCAAGGGCUGUGAACCCGCCUGGGGAUGAGGCCUGGUCUUGUGGAACUGAACUUAGCUCGACGGGGCUGACCGCUCUGGCCCAGGGUGGUAUGUAAUUUUCGCUCGGCCUGGGACGGGGCCCAGGCCGGGCCCAGCCUGGUGGAGCGUCCAGGUCUGGGUGCGAAGCCAGGCCCCUGGGCGGAGGUGAGGGGUGGUCUGAGGAGUGAUGUGGAGUUAAGGCGCCAUCCUCACCGGUGACUGGUGCGGCACCUAGCAUGUUUGACAGGCGGGGACUGCGAGGCACGCUGCUCGGGUGUUGGGGACAACAUUGACCAACGCUUUAUUUUCCAGGUGGCAGUGCUCCUUUUGGACUUUUCUCUAGGUUUGGCGCUAAACUCUUCUUGUGAGCUCACUCCACCCCUUCUUCCUCCCUUUAACUUAUCCAUUCACUUAAAACAUUACCUGGUCAUCUGGUAAGCCCGGGACAGUAAGCCGAGUGGCUGUUGGAGUCGGUAUUGUUGGUAAUGGUGGAGGAAGAGAGGCCUUCCCGCUGAGGCUGGGGUGGGGCGGAUCGGUGUUGCUUGCCUGCAGAGAGGGUGGGGAGUGAAUGUGCACCCUUGGGUGGGCCUGCAGCCAUCCAGCUGAAAGUUACAAAAAUGCUUCAUGGACCGUGGUUUGUUACUAUAGUGUUCCUCAUGGCGAGCAGAUGGAACCGGGAGACAUGGAGUCCCUGGCCAGUGUGAGUCCUAGCAUUGCAGGAGGGGAGACCCUGGAGGAGAGAGCCCGCCUCAAUUGAUGCCUGCAGAUUGAAUUUCCAGAGGCUUAGGAGGAGGAAGUUCUCCAAUGUUCUGUUUCCAGGCCUUGCUCAGGAAGCCCUGUAUUCAGGAGGCUACCAUUUAAAGUUUGCAGAUGAGCUUAUGGGGGGCAAUCUUAAAAAGUCCACAGCAGAUGCAUCCGGCUCGAGGGGCCAUCAGCUUUGAAUAAAUGCUUGUUCCAGAGCCCAUGAAUGCCAGCAGGCACCCCUCCUUUCCUGGGGUAAAGGUUUUCAGAUGCUGCAUCUUCUAAAUUGAGCCUCCGGUCAUACUAGUUUUGUGCUUGGAACCUUGCUUCAAGAAGAUCCCUAAGCUGUAGAACAUUUUAACGUUGAUGCCACAACGCAGAUUGAUGCCUUGUAGAUGGAGCUUGCAGAUGGAGCCCCGUGACCUCUCACCUACCCACCUGUUUGCCUGCCUUCUUGUGCGUUUCUCGGAGAAGUUCUUAGCCUGAUGAAAUAACUUGGGGCGUUGAAGAGCUGUUUAAUUUUAAAUGCCUUAGACUGGGGAUAUAUUAGAGGAAGCAGAUUGUCAAAUUAAGGGUGUCAUUGUGUUGUGCUAAACGCUGGGAGGGUACAAGUUGGUCAUUCCUAAAUCUGUGUGUGAGAAAUGGCAGGUCUAGUUUGGGCAUUGUGAUUGCAUUGCAGAUUACUAGGAGAAGGGAAUGGUGGGUACACCGGUAGUGCUCUUUUGUUCUUGCUUCGUUUUUUUAAACUUGAACUUUACUUCGUUAGAUUUCAUAAUACUUUCUUGGCAUUCUAGUAAGAGGACCCUGAGGUGGGAGUUGUGGGGGACGGGGAGAAGGGGACAGCUUGGCACCGGUCCCGUGGGCGUUGCAGUGUGGGGGAUGGGGGUAUGCAGCUUGGCACUGGUACUGGGAGGGAUGAGGGUGAAGAAGGGGAGAGGGUUGGUUAGAGAUACAGUGUGGGUGGUGGGGGUGGUAGGAAAUGCAGGUUGAAGGGAAUUCUCUGGGGCUUUGGGGAAUUUAGUGCGUGGGUGAGCCAAGAAAAUACUAAUUAAUAAUAGUAAGUUGUUAGUGUUGGUUAAGUUGUUGCUUGGAAGUGAGAAGUUGCUUAGAAACUUUCCAAAGUGCUUAGAACUUUAAGUGCAAACAGACAAACUAACAAACAAAAAUUGUUUUGCUUUGCUACAAGGUGGGGAAGACUGAAGAAGUGUUAACUGAAAACAGGUGACACAGAGUCACCAGUUUUCCGAGAACCAAAGGGAGGGGUGUGUGAUGCCAUCUCACAGGCAGGGGAAAUGUCUUUACCAGCUUCCUCCUGGUGGCCAAGACAGCCUGUUUCAGAGGGUUGUUUUGUUUGGGGUGUGGGUGUUAUCAAGUGAAUUAGUCACUUGAAAGAUGGGCGUCAGACUUGCAUACGCAGCAGAUCAGCAUCCUUCGCUGCCCCUUAGCAACUUAGGUGGUUGAUUUGAAACUGUGAAGGUGUGAUUUUUUCAGGAGCUGGAAGUCUUAGAAAAGCCUUGUAAAUGCCUAUAUUGUGGGCUUUUAACGUAUUUAAGGGACCACUUAAGACGAGAUUAGAUGGGCUCUUCUGGAUUUGUUCCUCAUUUGUCACAGGUGUCUUGUGAUUGAAAAUCAUGAGCGAAGUGAAAUUGCAUUGAAUUUCAAGGGAAUUUAGUAUGUAAAUCGUGCCUUAGAAACACAUCUGUUGUCUUUUCUGUGUUUGGUCGAUAUUAAUAAUGGCAAAAUUUUUGCCUAUCUAGUAUCUUCAAAUUGUAGUCUUUGUAACAACCAAAUAACCUUUUGUGGUCACUGUAAAAUUAAUAUUUGGUAGACAGAAUCCAUGUACCUUUGCUAAGGUUAGAAUGAAUAAUUUAUUGUAUUUUUAAUUUGAAUGUUUGUGCUUUUUAAAUGAGCCAAGACUAGAGGGGAAACUAUCACCUAAAAUCAGUUUGGAAAACAAGACCUAAAAAGGGAAGGGGAUGGGGAUUGUGGGGAGAGAGUGGGCGAGGUGCCUUUACUACAUGUGUGAUCUGAAAACCCUGCUUGGUUCUGAGCUGCGUCUAUUGAAUUGGUAAAGUAAUACCAAUGGCUUUUUAUCAUUUCCUUCUUCCCUUUAAGUUUCACUUGAAAUUUUAAAAAUCAUGGUUAUUUUUAUCGUUGGGAUCUUUCUGUCUUCUGGGUUCCAUUUUUUAAAUGUUUAAAAAUAUGUUGACAUGGUAGUUCAGUUCUUAACCAAUGACUUGGGGAUGAUGCAAACAAUUACUGUCGUUGGGAUUUAGAGUGUAUUAGUCACGCAUGUAUGGGGAAGUAGUCUCGGGUAUGCUGUUGUGAAAUUGAAACUGUAAAAGUAGAUGGUUGAAAGUACUGGUAUGUUGCUCUGUAUGGUAAGAACUAAUUCUGUUACGUCAUGUACAUAAUUACUAAUCACUUUUCUUCCCCUUUACAGCACAAAUAAAGUUUGAGUUCUAAACUCAUUAGAAAAAAAAAAAAAAAAAAAAAAA,lncRNA,Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|1200-2500 ng/µl Neat1 ,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,solute,"rRNA, tRNA, and a noncoding RNA that is known to bind to FUS (Neat1) were all able to solubilize FUS droplets, suggesting a general effect, but smaller RNAs were more potent than larger ones. The FUS droplets re-appear after RNase A induced RNA degradation."
155,PMID: 29650702,RNAPS0000151,https://pubmed.ncbi.nlm.nih.gov/29650702,RNA + protein,NCBI ID:283131,https://www.ncbi.nlm.nih.gov/gene/283131,NEAT1,3756nt(1-3756),GGAGUUAGCGACAGGGAGGGAUGCGCGCCUGGGUGUAGUUGUGGGGGAGGAAGUGGCUAGCUCAGGGCUUCAGGGGACAGACAGGGAGAGAUGACUGAGUUAGAUGAGACGAGGGGGCGGGCUGGGGGUGCGAGAAGGAAGCUUGGCAAGGAGACUAGGUCUAGGGGGACCACAGUGGGGCAGGCUGCAUGGAAAAUAUCCGCAGGGUCCCCCAGGCAGAACAGCCACGCUCCAGGCCAGGCUGUCCCUACUGCCUGGUGGAGGGGGAACUUGACCUCUGGGAGGGCGCCGCUCUUGCAUAGCUGAGCGAGCCCGGGUGCGCUGGUCUGUGUGGAAGGAGGAAGGCAGGGAGAGGUAGAAGGGGUGGAGGAGUCAGGAGGAAUAGGCCGCAGCAGCCCUGGAAAUGAUCAGGAAGGCAGGCAGUGGGUGCAGGGCUGCAGGAGGGCCGGGAGGGCUAAUCUUCAACUUGUCCAUGCCAGCAGCCCCUUUUUUUCCAGACCAAGGGCUGUGAACCCGCCUGGGGAUGAGGCCUGGUCUUGUGGAACUGAACUUAGCUCGACGGGGCUGACCGCUCUGGCCCAGGGUGGUAUGUAAUUUUCGCUCGGCCUGGGACGGGGCCCAGGCCGGGCCCAGCCUGGUGGAGCGUCCAGGUCUGGGUGCGAAGCCAGGCCCCUGGGCGGAGGUGAGGGGUGGUCUGAGGAGUGAUGUGGAGUUAAGGCGCCAUCCUCACCGGUGACUGGUGCGGCACCUAGCAUGUUUGACAGGCGGGGACUGCGAGGCACGCUGCUCGGGUGUUGGGGACAACAUUGACCAACGCUUUAUUUUCCAGGUGGCAGUGCUCCUUUUGGACUUUUCUCUAGGUUUGGCGCUAAACUCUUCUUGUGAGCUCACUCCACCCCUUCUUCCUCCCUUUAACUUAUCCAUUCACUUAAAACAUUACCUGGUCAUCUGGUAAGCCCGGGACAGUAAGCCGAGUGGCUGUUGGAGUCGGUAUUGUUGGUAAUGGUGGAGGAAGAGAGGCCUUCCCGCUGAGGCUGGGGUGGGGCGGAUCGGUGUUGCUUGCCUGCAGAGAGGGUGGGGAGUGAAUGUGCACCCUUGGGUGGGCCUGCAGCCAUCCAGCUGAAAGUUACAAAAAUGCUUCAUGGACCGUGGUUUGUUACUAUAGUGUUCCUCAUGGCGAGCAGAUGGAACCGGGAGACAUGGAGUCCCUGGCCAGUGUGAGUCCUAGCAUUGCAGGAGGGGAGACCCUGGAGGAGAGAGCCCGCCUCAAUUGAUGCCUGCAGAUUGAAUUUCCAGAGGCUUAGGAGGAGGAAGUUCUCCAAUGUUCUGUUUCCAGGCCUUGCUCAGGAAGCCCUGUAUUCAGGAGGCUACCAUUUAAAGUUUGCAGAUGAGCUUAUGGGGGGCAAUCUUAAAAAGUCCACAGCAGAUGCAUCCGGCUCGAGGGGCCAUCAGCUUUGAAUAAAUGCUUGUUCCAGAGCCCAUGAAUGCCAGCAGGCACCCCUCCUUUCCUGGGGUAAAGGUUUUCAGAUGCUGCAUCUUCUAAAUUGAGCCUCCGGUCAUACUAGUUUUGUGCUUGGAACCUUGCUUCAAGAAGAUCCCUAAGCUGUAGAACAUUUUAACGUUGAUGCCACAACGCAGAUUGAUGCCUUGUAGAUGGAGCUUGCAGAUGGAGCCCCGUGACCUCUCACCUACCCACCUGUUUGCCUGCCUUCUUGUGCGUUUCUCGGAGAAGUUCUUAGCCUGAUGAAAUAACUUGGGGCGUUGAAGAGCUGUUUAAUUUUAAAUGCCUUAGACUGGGGAUAUAUUAGAGGAAGCAGAUUGUCAAAUUAAGGGUGUCAUUGUGUUGUGCUAAACGCUGGGAGGGUACAAGUUGGUCAUUCCUAAAUCUGUGUGUGAGAAAUGGCAGGUCUAGUUUGGGCAUUGUGAUUGCAUUGCAGAUUACUAGGAGAAGGGAAUGGUGGGUACACCGGUAGUGCUCUUUUGUUCUUGCUUCGUUUUUUUAAACUUGAACUUUACUUCGUUAGAUUUCAUAAUACUUUCUUGGCAUUCUAGUAAGAGGACCCUGAGGUGGGAGUUGUGGGGGACGGGGAGAAGGGGACAGCUUGGCACCGGUCCCGUGGGCGUUGCAGUGUGGGGGAUGGGGGUAUGCAGCUUGGCACUGGUACUGGGAGGGAUGAGGGUGAAGAAGGGGAGAGGGUUGGUUAGAGAUACAGUGUGGGUGGUGGGGGUGGUAGGAAAUGCAGGUUGAAGGGAAUUCUCUGGGGCUUUGGGGAAUUUAGUGCGUGGGUGAGCCAAGAAAAUACUAAUUAAUAAUAGUAAGUUGUUAGUGUUGGUUAAGUUGUUGCUUGGAAGUGAGAAGUUGCUUAGAAACUUUCCAAAGUGCUUAGAACUUUAAGUGCAAACAGACAAACUAACAAACAAAAAUUGUUUUGCUUUGCUACAAGGUGGGGAAGACUGAAGAAGUGUUAACUGAAAACAGGUGACACAGAGUCACCAGUUUUCCGAGAACCAAAGGGAGGGGUGUGUGAUGCCAUCUCACAGGCAGGGGAAAUGUCUUUACCAGCUUCCUCCUGGUGGCCAAGACAGCCUGUUUCAGAGGGUUGUUUUGUUUGGGGUGUGGGUGUUAUCAAGUGAAUUAGUCACUUGAAAGAUGGGCGUCAGACUUGCAUACGCAGCAGAUCAGCAUCCUUCGCUGCCCCUUAGCAACUUAGGUGGUUGAUUUGAAACUGUGAAGGUGUGAUUUUUUCAGGAGCUGGAAGUCUUAGAAAAGCCUUGUAAAUGCCUAUAUUGUGGGCUUUUAACGUAUUUAAGGGACCACUUAAGACGAGAUUAGAUGGGCUCUUCUGGAUUUGUUCCUCAUUUGUCACAGGUGUCUUGUGAUUGAAAAUCAUGAGCGAAGUGAAAUUGCAUUGAAUUUCAAGGGAAUUUAGUAUGUAAAUCGUGCCUUAGAAACACAUCUGUUGUCUUUUCUGUGUUUGGUCGAUAUUAAUAAUGGCAAAAUUUUUGCCUAUCUAGUAUCUUCAAAUUGUAGUCUUUGUAACAACCAAAUAACCUUUUGUGGUCACUGUAAAAUUAAUAUUUGGUAGACAGAAUCCAUGUACCUUUGCUAAGGUUAGAAUGAAUAAUUUAUUGUAUUUUUAAUUUGAAUGUUUGUGCUUUUUAAAUGAGCCAAGACUAGAGGGGAAACUAUCACCUAAAAUCAGUUUGGAAAACAAGACCUAAAAAGGGAAGGGGAUGGGGAUUGUGGGGAGAGAGUGGGCGAGGUGCCUUUACUACAUGUGUGAUCUGAAAACCCUGCUUGGUUCUGAGCUGCGUCUAUUGAAUUGGUAAAGUAAUACCAAUGGCUUUUUAUCAUUUCCUUCUUCCCUUUAAGUUUCACUUGAAAUUUUAAAAAUCAUGGUUAUUUUUAUCGUUGGGAUCUUUCUGUCUUCUGGGUUCCAUUUUUUAAAUGUUUAAAAAUAUGUUGACAUGGUAGUUCAGUUCUUAACCAAUGACUUGGGGAUGAUGCAAACAAUUACUGUCGUUGGGAUUUAGAGUGUAUUAGUCACGCAUGUAUGGGGAAGUAGUCUCGGGUAUGCUGUUGUGAAAUUGAAACUGUAAAAGUAGAUGGUUGAAAGUACUGGUAUGUUGCUCUGUAUGGUAAGAACUAAUUCUGUUACGUCAUGUACAUAAUUACUAAUCACUUUUCUUCCCCUUUACAGCACAAAUAAAGUUUGAGUUCUAAACUCAUUAGAAAAAAAAAAAAAAAAAAAAAAA,lncRNA,Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|2500 ng/µl Neat1 ,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,other_molecular:5 ng/µl RNase A,Confocal Laser scanning microscopy,liquid,"rRNA, tRNA, and a noncoding RNA that is known to bind to FUS (Neat1) were all able to solubilize FUS droplets, suggesting a general effect, but smaller RNAs were more potent than larger ones. The FUS droplets re-appear after RNase A induced RNA degradation."
156,PMID: 29650702,RNAPS0000152,https://pubmed.ncbi.nlm.nih.gov/29650702,RNA + protein,-,-,Hela rRNA,-,-,rRNA,Hela cell line(Homo sapiens),"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|1200-2500 ng/µl rRNA,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,solute,"rRNA, tRNA, and a noncoding RNA that is known to bind to FUS (Neat1) were all able to solubilize FUS droplets, suggesting a general effect, but smaller RNAs were more potent than larger ones. The FUS droplets re-appear after RNase A induced RNA degradation."
157,PMID: 29650702,RNAPS0000152,https://pubmed.ncbi.nlm.nih.gov/29650702,RNA + protein,-,-,Hela rRNA,-,-,rRNA,Hela cell line(Homo sapiens),"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|2500 ng/µl rRNA,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,other_molecular:5 ng/µl RNase A,Confocal Laser scanning microscopy,liquid,"rRNA, tRNA, and a noncoding RNA that is known to bind to FUS (Neat1) were all able to solubilize FUS droplets, suggesting a general effect, but smaller RNAs were more potent than larger ones. The FUS droplets re-appear after RNase A induced RNA degradation."
158,PMID: 29650702,RNAPS0000153,https://pubmed.ncbi.nlm.nih.gov/29650702,RNA + protein,-,-,Hela tRNA,-,-,tRNA,Hela cell line(Homo sapiens),"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|800-2500 ng/µl tRNA,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,solute,"rRNA, tRNA, and a noncoding RNA that is known to bind to FUS (Neat1) were all able to solubilize FUS droplets, suggesting a general effect, but smaller RNAs were more potent than larger ones. The FUS droplets re-appear after RNase A induced RNA degradation."
159,PMID: 29650702,RNAPS0000153,https://pubmed.ncbi.nlm.nih.gov/29650702,RNA + protein,-,-,Hela tRNA,-,-,tRNA,Hela cell line(Homo sapiens),"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|2500 ng/µl tRNA,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,other_molecular:5 ng/µl RNase A,Confocal Laser scanning microscopy,liquid,"rRNA, tRNA, and a noncoding RNA that is known to bind to FUS (Neat1) were all able to solubilize FUS droplets, suggesting a general effect, but smaller RNAs were more potent than larger ones. The FUS droplets re-appear after RNase A induced RNA degradation."
160,PMID: 29650702,RNAPS0000605,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526|mutation=G156E
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYEQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,"protein_mutation:D19K,E32K,D133K",526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[3-254],[284-292],[332-338],[375-415],[451-499],[501-501],[503-505],[507-526]",-,In vitro,5 µM [FUS];|100 ng/µl RNA ,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,> 24 h,-,Confocal Laser scanning microscopy,liquid,"Thus,we next tested whether the addition of RNA prevents the formation of fibrils in vitro. The addition of RNA kept the droplets in a soluble state, and fibers were not seen (Fig. 4A). We next investigated whether RNA also changes the material properties of FUS assemblies in vivo."
161,PMID: 29650702,RNAPS0000605,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|0-800 ng/µl rRNA,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,liquid,"rRNA, tRNA, and a noncoding RNA that is known to bind to FUS (Neat1) were all able to solubilize FUS droplets, suggesting a general effect, but smaller RNAs were more potent than larger ones. The FUS droplets re-appear after RNase A induced RNA degradation."
162,PMID: 29650702,RNAPS0000605,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|0-400 ng/µl tRNA,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,liquid,"rRNA, tRNA, and a noncoding RNA that is known to bind to FUS (Neat1) were all able to solubilize FUS droplets, suggesting a general effect, but smaller RNAs were more potent than larger ones. The FUS droplets re-appear after RNase A induced RNA degradation."
163,PMID: 29650702,RNAPS0000605,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,0-3 µM [FUS];|50 ng/µl RNA ,"50-300 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,liquid,"We estimated that the nuclear RNA concentration is ~10.6 times as high as that required for droplet dissolution in vitro (fig. S7 and supplementary methods). However, ~1% of nuclear FUS formed condensates (paraspeckles) (Fig. 1E) by binding to the noncoding RNA Neat1. To test whether Neat1 could nucleate FUS droplets in the presence of a high background concentration of RNA, we added Neat1 RNA to a FUS sample that had been solubilized with tRNA. This led to a reappearance of FUS droplets"
164,PMID: 29650702,RNAPS0000605,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|100-200 ng/µl RNA ,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,liquid,"Small amounts of RNA promoted liquid droplet formation. RNA-containing droplets contained a higher FUS concentration than RNA-free droplets, and they appeared slightly more viscous. However, upon further increase in the RNA/protein concentration ratio, the droplets became smaller and finally dissolved. The addition of RNase A resulted in droplet reappearance, indicating that droplet solubilization depends on intact RNA. Similar results were obtained for EWSR1, TAF15, hnRNPA1, and TDP43. Thus, we conclude that high RNA/protein ratios prevent phase separation and that low ratios promote phase separation."
165,PMID: 29650702,RNAPS0000605,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|300 ng/µl RNA ,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,solute,"Small amounts of RNA promoted liquid droplet formation. RNA-containing droplets contained a higher FUS concentration than RNA-free droplets, and they appeared slightly more viscous. However, upon further increase in the RNA/protein concentration ratio, the droplets became smaller and finally dissolved. The addition of RNase A resulted in droplet reappearance, indicating that droplet solubilization depends on intact RNA. Similar results were obtained for EWSR1, TAF15, hnRNPA1, and TDP43. Thus, we conclude that high RNA/protein ratios prevent phase separation and that low ratios promote phase separation."
166,PMID: 29650702,RNAPS0000605,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|300 ng/µl RNA ,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,other_molecular:5 ng/µl RNase A,Confocal Laser scanning microscopy,liquid,"Small amounts of RNA promoted liquid droplet formation. RNA-containing droplets contained a higher FUS concentration than RNA-free droplets, and they appeared slightly more viscous. However, upon further increase in the RNA/protein concentration ratio, the droplets became smaller and finally dissolved. The addition of RNase A resulted in droplet reappearance, indicating that droplet solubilization depends on intact RNA. Similar results were obtained for EWSR1, TAF15, hnRNPA1, and TDP43. Thus, we conclude that high RNA/protein ratios prevent phase separation and that low ratios promote phase separation."
167,PMID: 29650702,RNAPS0000155,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P09651-2|ROA1_HUMAN Isoform A1-A of Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens OX=9606 GN=HNRNPA1|length=320aa|residues=1-320
MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVMRDPNTKRSRGFGFV
TYATVEEVDAAMNARPHKVDGRVVEPKRAVSREDSQRPGAHLTVKKIFVGGIKEDTEEHH
LRDYFEQYGKIEVIEIMTDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGHNCEVRKA
LSKQEMASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRGGNFSGRGGFGGSRGGGGYGGS
GDGYNGFGNDGSNFGGGGSYNDFGNYNNQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPR
NQGGYGGSSSSSSYGSGRRF",HNRNPA1,-,-,320aa(1-320),P09651,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/P09651,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2438","[1-8],[92-102],[182-196],[197-208],[309-318]",[190-320],In vitro,12.5 µM [HNRNPA1];|100-800 ng/µl RNA,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,liquid,"Small amounts of RNA promoted liquid droplet formation. RNA-containing droplets contained a higher FUS concentration than RNA-free droplets, and they appeared slightly more viscous. However, upon further increase in the RNA/protein concentration ratio, the droplets became smaller and finally dissolved. The addition of RNase A resulted in droplet reappearance, indicating that droplet solubilization depends on intact RNA. Similar results were obtained for EWSR1, TAF15, hnRNPA1, and TDP43. Thus, we conclude that high RNA/protein ratios prevent phase separation and that low ratios promote phase separation."
168,PMID: 29650702,RNAPS0000156,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|length=414aa|residues=1-414
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG
NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQ
REPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM",TDP-43,-,-,414aa(1-414),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-414],"[272-314],[321-329],[342-358],[368-404]",In vitro,10 µM [TDP-43];|100-800 ng/µl RNA,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,liquid,"Small amounts of RNA promoted liquid droplet formation. RNA-containing droplets contained a higher FUS concentration than RNA-free droplets, and they appeared slightly more viscous. However, upon further increase in the RNA/protein concentration ratio, the droplets became smaller and finally dissolved. The addition of RNase A resulted in droplet reappearance, indicating that droplet solubilization depends on intact RNA. Similar results were obtained for EWSR1, TAF15, hnRNPA1, and TDP43. Thus, we conclude that high RNA/protein ratios prevent phase separation and that low ratios promote phase separation."
169,PMID: 29650702,RNAPS0000157,https://pubmed.ncbi.nlm.nih.gov/29650702,RNA + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|Q01844|EWS_HUMAN RNA-binding protein EWS OS=Homo sapiens OX=9606 GN=EWSR1 PE=1 SV=1|length=656aa|residues=1-656
MASTDYSTYSQAAAQQGYSAYTAQPTQGYAQTTQAYGQQSYGTYGQPTDVSYTQAQTTAT
YGQTAYATSYGQPPTGYTTPTAPQAYSQPVQGYGTGAYDTTTATVTTTQASYAAQSAYGT
QPAYPAYGQQPAATAPTRPQDGNKPTETSQPQSSTGGYNQPSLGYGQSNYSYPQVPGSYP
MQPVTAPPSYPPTSYSSTQPTSYDQSSYSQQNTYGQPSSYGQQSSYGQQSSYGQQPPTSY
PPQTGSYSQAPSQYSQQSSSYGQQSSFRQDHPSSMGVYGQESGGFSGPGENRSMSGPDNR
GRGRGGFDRGGMSRGGRGGGRGGMGSAGERGGFNKPGGPMDEGPDLDLGPPVDPDEDSDN
SAIYVQGLNDSVTLDDLADFFKQCGVVKMNKRTGQPMIHIYLDKETGKPKGDATVSYEDP
PTAKAAVEWFDGKDFQGSKLKVSLARKKPPMNSMRGGLPPREGRGMPPPLRGGPGGPGGP
GGPMGRMGGRGGDRGGFPPRGPRGSRGNPSGGGNVQHRAGDWQCPNPGCGNQNFAWRTEC
NQCKAPKPEGFLPPPFPPPGGDRGRGGPGGMRGGRGGLMDRGGPGGMFRGGRGGDRGGFR
GGRGMDRGGFGGGRRGGPGGPPGPLMEQMGGRRGGRGGPGKMDKGEHRQERRDRPY",EWSR1,-,-,656aa(1-656),Q01844,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q01844,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0808,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0149,http://db.phasep.pro/browse/","[1-264],[265-352],[454-525],[547-656]","[6-24],[51-85],[91-137],[182-266],[300-332],[336-357],[454-513],[550-624],[630-640]",In vitro,2 µM [EWSR1];|100-800 ng/µl RNA,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,liquid,"Small amounts of RNA promoted liquid droplet formation. RNA-containing droplets contained a higher FUS concentration than RNA-free droplets, and they appeared slightly more viscous. However, upon further increase in the RNA/protein concentration ratio, the droplets became smaller and finally dissolved. The addition of RNase A resulted in droplet reappearance, indicating that droplet solubilization depends on intact RNA. Similar results were obtained for EWSR1, TAF15, hnRNPA1, and TDP43. Thus, we conclude that high RNA/protein ratios prevent phase separation and that low ratios promote phase separation."
170,PMID: 29650702,RNAPS0000158,https://pubmed.ncbi.nlm.nih.gov/29650702,RNA + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|Q92804-2|RBP56_HUMAN Isoform Short of TATA-binding protein-associated factor 2N OS=Homo sapiens OX=9606 GN=TAF15|length=589aa|residues=1-589
MSDSGSYGQSGGEQQSYSTYGNPGSQGYGQASQSYSGYGQTTDSSYGQNYSGYSSYGQSY
SQSYGGYENQKQSSYSQQPYNNQGQQQNMESSGSQGGRAPSYDQPDYGQQDSYDQQSGYD
QHQGSYDEQSNYDQQHDSYSQNQQSYHSQRENYSHHTQDDRRDVSRYGEDNRGYGGSQGG
GRGRGGYDKDGRGPMTGSSGGDRGGFKNFGGHRDYGPRTDADSESDNSDNNTIFVQGLGE
GVSTDQVGEFFKQIGIIKTNKKTGKPMINLYTDKDTGKPKGEATVSFDDPPSAKAAIDWF
DGKEFHGNIIKVSFATRRPEFMRGGGSGGGRRGRGGYRGRGGFQGRGGDPKSGDWVCPNP
SCGNMNFARRNSCNQCNEPRPEDSRPSGGDFRGRGYGGERGYRGRGGRGGDRGGYGGDRS
GGGYGGDRSSGGGYSGDRSGGGYGGDRSGGGYGGDRGGGYGGDRGGGYGGDRGGGYGGDR
GGYGGDRGGGYGGDRGGYGGDRGGYGGDRGGYGGDRGGYGGDRSRGGYGGDRGGGSGYGG
DRSGGYGGDRSGGGYGGDRGGGYGGDRGGYGGKMGGRNDYRNDQRNRPY",TAF15,-,-,589aa(1-589),Q92804,"PhaSePro,DrLLPS,PhaSepDB","https://phasepro.elte.hu/entry/Q92804,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1528,http://db.phasep.pro/browse/","[1-230],[324-356],[373-589]","[4-21],[24-40],[44-70],[72-91],[104-129],[135-152],[175-196],[203-214],[225-234],[255-268],[326-351],[390-575]",In vitro,4 µM [TAF15];|100-800 ng/µl RNA,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,liquid,"Small amounts of RNA promoted liquid droplet formation. RNA-containing droplets contained a higher FUS concentration than RNA-free droplets, and they appeared slightly more viscous. However, upon further increase in the RNA/protein concentration ratio, the droplets became smaller and finally dissolved. The addition of RNase A resulted in droplet reappearance, indicating that droplet solubilization depends on intact RNA. Similar results were obtained for EWSR1, TAF15, hnRNPA1, and TDP43. Thus, we conclude that high RNA/protein ratios prevent phase separation and that low ratios promote phase separation."
171,PMID: 29650702,RNAPS0000027,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-;|NCBI ID:283131,-;|https://www.ncbi.nlm.nih.gov/gene/283131,Hela RNA;|NEAT1,-;|-,-;|-,total RNA;|lncRNA,Hela cell line(Homo sapiens);|Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|2500 ng/µl rRNA;|100 ng/µl Neat1,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,liquid,"To test whether Neat1 could nucleate FUS droplets in the presence of a high background concentration of RNA, we added Neat1 RNA to a FUS sample that had been solubilized with tRNA or rRNA. This led to a reappearance of FUS droplets. We attribute this result to the ability of Neat1 to form large RNA assemblies, which subsequently recruit FUS. This observation suggests that highly structured RNAs such as Neat1 act as scaffolds that promote the nucleation of condensates in the high-RNA concentration environment of the nucleus. A similar scenario may apply for stress granules in the cytoplasm, which contain large amounts of structured polyadenylated mRNA."
172,PMID: 29650702,RNAPS0000027,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-;|NCBI ID:283131,-;|https://www.ncbi.nlm.nih.gov/gene/283131,Hela RNA;|NEAT1,-;|-,-;|-,total RNA;|lncRNA,Hela cell line(Homo sapiens);|Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|2500 ng/µl tRNA;|100 ng/µl Neat1 ,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,liquid,"To test whether Neat1 could nucleate FUS droplets in the presence of a high background concentration of RNA, we added Neat1 RNA to a FUS sample that had been solubilized with tRNA or rRNA. This led to a reappearance of FUS droplets. We attribute this result to the ability of Neat1 to form large RNA assemblies, which subsequently recruit FUS. This observation suggests that highly structured RNAs such as Neat1 act as scaffolds that promote the nucleation of condensates in the high-RNA concentration environment of the nucleus. A similar scenario may apply for stress granules in the cytoplasm, which contain large amounts of structured polyadenylated mRNA."
173,PMID: 29650702,RNAPS0000027,https://pubmed.ncbi.nlm.nih.gov/29650702,RNAs + protein,-;|NCBI ID:283131,-;|https://www.ncbi.nlm.nih.gov/gene/283131,Hela RNA;|NEAT1,-;|-,-;|-,total RNA;|lncRNA,Hela cell line(Homo sapiens);|Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [FUS];|2500 ng/µl Neat1;|100 ng/µl tRNA ,"75 mM KCl, 1 mM MgCl2","25 mM Tris/HCl buffer (pH 7.4), 1 mM TCEP",RT,-,-,Confocal Laser scanning microscopy,solute,"To test whether Neat1 could nucleate FUS droplets in the presence of a high background concentration of RNA, we added Neat1 RNA to a FUS sample that had been solubilized with tRNA or rRNA. This led to a reappearance of FUS droplets. We attribute this result to the ability of Neat1 to form large RNA assemblies, which subsequently recruit FUS. This observation suggests that highly structured RNAs such as Neat1 act as scaffolds that promote the nucleation of condensates in the high-RNA concentration environment of the nucleus. A similar scenario may apply for stress granules in the cytoplasm, which contain large amounts of structured polyadenylated mRNA."
174,PMID: 29650703,RNAPS0000015,https://pubmed.ncbi.nlm.nih.gov/29650703,RNA + protein,NCBI ID:855450,https://www.ncbi.nlm.nih.gov/gene/855450,BNI1,5862nt(1-5862),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA,mRNA,Saccharomyces cerevisiae,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,2 µM [Whi3];|2.5 nM BNI1,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,> 30 min,-,Fluorescence microscopy,liquid,"CLN3 mRNA is not efficiently recruited, but BNI1 or SPA2 mRNA are recruited into preformed Whi3-BNI1 droplets based on fluorescence microscopy."
175,PMID: 29650703,RNAPS0000028,https://pubmed.ncbi.nlm.nih.gov/29650703,RNA + protein,NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/1201,CLN3_scr,1879nt(1-1879),GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA,Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,8 µM [Whi3];|5 nM CLN3 scr,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"An mRNA with scrambled CLN3 coding sequence (cln3 scr) with intact Whi3-binding sites formed Whi3 droplets, but no longer showed specificity. Fluorescence microscopy images showing the recruitment of cln3 scrambled mRNA into droplets with Whi3."
176,PMID: 29650703,RNAPS0000055,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:850639,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/850639,BNI1;|SPA2,5862nt(1-5862);|4401nt(1-4401),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|AUGGGUACGUCAAGCGAGGUUUCUCUCGCACAUCAUAGAGAUAUCUUCCAUUACUACGUCUCACUGAAGACUUUUUUCGAGGUGACUGGCGAAAAUCGUGACAGGUCAAAUUCGACACGAGCUCAAAAGGCCAGAGCCAAGCUGUUGAAGCUAUCUUCUUCGCAAUUUUACGAGCUGAGUACAGACGUGUCCGAUGAGCUGCAGAGGAGAAUCGGUGAAGAUGCUAACCAACCAGAUUACCUUUUGCCGAAGGCAAAUUUCCACAUGAAAAGGAACCAGGCUAGACAGAAACUGGCCAAUCUAUCACAAACUCGAUUUAAUGAUUUGUUGGACGAUAUCCUUUUUGAGAUCAAGAGAAGAGGGUUCGACAAGGAUUUGGAUGCUCCACGGCCCCCAUUACCGCAGCCGAUGAAACAAGAGGUCAGCAAAGACAGCGAUGAUACUGCAAGAACAUCCACAAAUUCUUCCUCUGUGACUCAAGUAGCUCCAAACGUCUCCGUACAACCUUCUUUGGUCAUUCCUAAGAUGGCAUCUAUCGAUUGGUCUUCUGAGGAAGAAGAAGAGGAGCAAGUAAAGGAGAAGCCAAAUGAACCGGAGGGAAAACAAACAAGCAUGGAUGAAAAGAAAGAGGCUAAACCUGCUCUAAACCCCAUAGUUACAGAUUCUGAUCUGCCUGACUCCCAAGUGCUCGCUCGUGAUAUCACAUCAAUGGCAAGGACUCCAACAACGACGCAUAAAAAUUACUGGGACGUUAAUGAUUCUCCAAUUAUCAAGGUAGAUAAAGAUAUCGAUAACGAAAAGGGUCCCGAACAGUUGAAGAGCCCUGAAGUACAACGGGCUGAGAACAAUAACCCUAACUCAGAGAUGGAAGACAAGGUUAAAGAACUGACUGAUUUAAACAGCGACUUACAUUUGCAAAUUGAAGAUUUGAAUGCUAAGUUAGCAUCUUUAACCAGCGAGAAGGAAAAGGAGAAGAAGGAAGAGAAGGAGGAAAAAGAAAAGGAAAAGAACUUAAAGAUUAACUACACCAUUGAUGAAAGUUUUCAGAAAGAAUUGCUGUCAUUAAACUCUCAAAUCGGUGAAUUAUCAAUUGAGAAUGAAAAUUUGAAGCAGAAAAUUUCAGAAUUCGAACUGCAUCAAAAAAAGAAUGACAACCAUAAUGAUUUGAAAAUCACUGACGGUUUUAUUAGCAAGUACUCUUCUGCCGAUGGGCUCAUUCCAGCUCAAUACAUCUUAAACGCUAACAACUUGAUAAUUCAAUUUACUACUAGGCUUUCCGCAGUACCCAUAGGCGACUCCACGGCAAUUUCCCAUCAAAUUGGCGAAGAGUUAUUUCAAAUAUUAUCCCAGUUAUCGAACCUAAUCUCCCAGCUAUUACUAUCGGCCGACCUAUUACAGUACAAAGAUCAGGUCAUUUUACUGAAGGCAUCAUUAUCGCAUGCGAUCACAUCGAUAAGAUAUUUCUCUGUUUACGGUCCCGUAUUAAUUCCGAAAAUAACUGUGCAAGCUGCUGUUUCAGAGGUUUGUUUUGCCAUGUGUAAUCUAAUUGAUUCAGCGAAAAUAAAAUCCGAUUCAAAUGGUGAGAGCACCACCUCUAAUGAAGGUAACCGACAGGUAUUAGAAUAUUCUUCACCAACUGCUACCACCCCAAUGACGCCAACUUUCCCCUCGACUUCUGGAAUAAAUAUGAAGAAGGGGUUUAUAAACCCAAGAAAACCAGCAUCUUUCUUGAAUGAUGUGGAGGAAGAAGAAUCUCCAGUCAAGCCAUUGAAAAUUACACAAAAGGCAAUUAACAGUCCGAUCAUAAGACCGUCAUCGUCUAAUGGAGUUCCAACAACCUCAAGAAAACCUUCAGGAACGGGGCUAUUUAGUUUAAUGAUUGAUUCAUCAAUUGCUAAGAAUAGCUCCCAUAAAGAGGAUAAUGAUAAAUAUGUCUCGCCCAUAAAGGCAGUAACAUCGGCCUCCAAUUCUGCAAGUAGCAAUAUUUCCGAAAUUCCUAAACUAACACUACCUCCACAAGCCAAAAUCGGUACUGUUAUUCCACCGUCAGAGAAUCAAGUUCCCAAUAUUAAAAUCGAGAAUACAGAAGAGGAUAAUAAAAGGAGUGACAUAACAAAUGAAAUCUCUGUUAAACCAACUUCUAGCAUUGCUGAUAAACUGAAACAAUUUGAGCAAAGUUCCGAAAAGAAAUCAUCACCAAAGGAAAAUCCUAUAGCAAAAGAAGAAAUGGAUUCAAAACCAAAACUAUCCAAUAAAUUUAUCACUUCAAUGAAUGAUGUGUCCACAGAUGAUUCAAGCUCUGAUGGUAACGAAAAUGACGAUGCAGACGAUGAUGAUGAUUUUACCUAUAUGGCAUUGAAACAAACAAUGAAGAGAGAAGGUUCAAAAAUUGAAAAAAAUAAUGACAGCAAACUACCUGCAAAUAUAGUGGAACUUGAUUUACAUGAGUCACCGGAGUCCGUGAAGAUUGAAUCUCCUGAAUCGAUAAAGGAAAUCACGUCAUCUGAAAUGUCUUCAGAAAUGCCAAGUAGUUCGCUGCCUAAGAGAUUAGUAGAGGAUGUUGAGCCUUCAGAAAUGCCAGAGAAGGGCGCAUCUGUAGAAUCAGUCAGGAAGAAAAAUUUUCAAGAACCACUUGGUAAUGUCGAAUCUCCGGAUAUGACGCAGAAGGUCAAGUCUUUGGGUAUGACAGGAAAGGCUGUAGGCCCAGAAUCAGAUAGUAGGGUCGAAUCUCCGGGCAUGACAGGACAGAUUAAAUCUUUGAAUAUGGCAGGAAAAGUUGUAGGCCCAGAAGCAGAUAGUAGGGUCGAAUCUCCGGGCAUGAAAGAGCAGAUUAAGUCUUUGGGUAUGACAGGAAAAAUUACAGCUCAAGAAUCAAUCAAGUCCCCGGAAGCGGCUAGGAAGUUGGCGUCAUCAGGAGAAGUUGACAAAAUUGAAUCUCCAAGAAUGGUAAGGGAAAGCGAGUCCUUGGAGGCAGUAGGCAAUACUAUCCCCUCAAACAUGACAGUGAAAAUGGAAUCCCCAAAUUUAAAGGGAAAUACUGUGUCUGAACCUCAAGAAAUAAGGAGAGACAUUGCCUCCUCAGAGCCGAUAGAGAAUGUUGACCCCCCAAAAGUACUAAAAAAGAUUGUCUUUCCAAAGGCUGUUAAUAGAACUGGAUCACCAAAAUCAGUCGAAAAGACUCCAUCUUCAGCUACACUGAAAAAGAGCGGGCUCCCAGAACCGAAUAGCCAAAUUGUUUCUCCUGAAUUGGCAAAAAAUUCACCUCUAGCACCGAUAAAGAAAAAUGUCGAGUUACGAGAAACUAAUAAACCACAUACUGAGACUAUCACUUCUGUGGAACCAACAAACAAGGAUGCCAAUACUUCUUGGAGAGACGCCGACUUAAACCGUACGAUCAAACGAGAGGAGGAGGACGAAGAUUUUGAUAGAGUGAACCACAAUAUCCAGAUCACUGGUGCAUAUACGAAAACUGGAAAAAUUGAUUAUCAUAAAAUACCUGUUGAUCGUAAAGCAAAAAGCGAAGCAGAAGUGCAUACUUCCGAGGAAGAUAUUGAUGAAUCAAAUAAUGUUAAUGGAAAAAGAGCUGAUGCCCAAAUACACAUCACUGAAAGAAAGCAUGCUUUCGUAAAUCCAACUGAAAAUUCACAGGUAAAAAAGACGAGCCACUCACCAUUUUUAAACAGUAAACCGGUUCAAUACGAGAACUCAGAGUCGAACGGCGGCAUUAACAACCACAUAAAGAUAAAAAAUACUGGAGAAACUACGGCACAUGACGAGAAACAUUAUAGUGAUGAUGAUGAUUCUAGCUAUCAAUUUGUUCCCAUGAAACAUGAAGAACAAGAACAAGAACAAAACAGAAGUGAGGAAGAGGAAAGUGAAGAUGACGAUGAAGAGGAAGAAGACAGUGAUUUUGAUGUGGAUACAUUUGACAUUGAAAAUCCGGAUAAUACACUAUCAGAGUUACUAUUGUAUUUAGAACAUCAAACAAUGGACGUCAUAUCCACGAUUCAAUCGCUUUUGACAUCGAUCAAGAAACCACAGGUGACGAAGGGUAAUUUGAGGGGAGAAUCGAAUGCAAUCAACCAAGUCAUAGGUCAAAUGGUGGACGCUACUAGCAUAUCAAUGGAGCAAAGCAGAAAUGCCAAUUUGAAGAAACACGGUGAUUGGGUGGUGCAAAGUCUAAGAGACUGUUCGCGUAGAAUGACAAUUUUGUGCCAAUUAACUGGCGAUGGAAUACUAGCGAAGGAAAAGAGCGAUCAAGAUUAUGCUGACAAAAACUUCAAACAGCGGUUGGCAGGGAUUGCGUUUGAUGUUGCCAAAUGUACAAAGGAGCUGGUAAAAACUGUAGAAGAGGCAAGUUUGAAGGACGAAAUAAAUUAUUUGAAUUCGAAGUUGAAGUAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Saccharomyces cerevisiae,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,2 µM [Whi3];|1.25 nM BNI1;|1.25 nM SPA2,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,> 30 min,-,Fluorescence microscopy,liquid,"Fluorescence microscopy images and quantification show SPA2 mRNA incubated with oligos to target the complement nucleotide regions of BNI1 (5 nM) is less recruited into preformed Whi3-BNI1 droplets (8 µM Whi3, 5 nM BNI1) compared to native SPA2 alone."
177,PMID: 29650703,RNAPS0000055,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:850639,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/850639,BNI1;|SPA2,5862nt(1-5862);|4401nt(1-4401),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|AUGGGUACGUCAAGCGAGGUUUCUCUCGCACAUCAUAGAGAUAUCUUCCAUUACUACGUCUCACUGAAGACUUUUUUCGAGGUGACUGGCGAAAAUCGUGACAGGUCAAAUUCGACACGAGCUCAAAAGGCCAGAGCCAAGCUGUUGAAGCUAUCUUCUUCGCAAUUUUACGAGCUGAGUACAGACGUGUCCGAUGAGCUGCAGAGGAGAAUCGGUGAAGAUGCUAACCAACCAGAUUACCUUUUGCCGAAGGCAAAUUUCCACAUGAAAAGGAACCAGGCUAGACAGAAACUGGCCAAUCUAUCACAAACUCGAUUUAAUGAUUUGUUGGACGAUAUCCUUUUUGAGAUCAAGAGAAGAGGGUUCGACAAGGAUUUGGAUGCUCCACGGCCCCCAUUACCGCAGCCGAUGAAACAAGAGGUCAGCAAAGACAGCGAUGAUACUGCAAGAACAUCCACAAAUUCUUCCUCUGUGACUCAAGUAGCUCCAAACGUCUCCGUACAACCUUCUUUGGUCAUUCCUAAGAUGGCAUCUAUCGAUUGGUCUUCUGAGGAAGAAGAAGAGGAGCAAGUAAAGGAGAAGCCAAAUGAACCGGAGGGAAAACAAACAAGCAUGGAUGAAAAGAAAGAGGCUAAACCUGCUCUAAACCCCAUAGUUACAGAUUCUGAUCUGCCUGACUCCCAAGUGCUCGCUCGUGAUAUCACAUCAAUGGCAAGGACUCCAACAACGACGCAUAAAAAUUACUGGGACGUUAAUGAUUCUCCAAUUAUCAAGGUAGAUAAAGAUAUCGAUAACGAAAAGGGUCCCGAACAGUUGAAGAGCCCUGAAGUACAACGGGCUGAGAACAAUAACCCUAACUCAGAGAUGGAAGACAAGGUUAAAGAACUGACUGAUUUAAACAGCGACUUACAUUUGCAAAUUGAAGAUUUGAAUGCUAAGUUAGCAUCUUUAACCAGCGAGAAGGAAAAGGAGAAGAAGGAAGAGAAGGAGGAAAAAGAAAAGGAAAAGAACUUAAAGAUUAACUACACCAUUGAUGAAAGUUUUCAGAAAGAAUUGCUGUCAUUAAACUCUCAAAUCGGUGAAUUAUCAAUUGAGAAUGAAAAUUUGAAGCAGAAAAUUUCAGAAUUCGAACUGCAUCAAAAAAAGAAUGACAACCAUAAUGAUUUGAAAAUCACUGACGGUUUUAUUAGCAAGUACUCUUCUGCCGAUGGGCUCAUUCCAGCUCAAUACAUCUUAAACGCUAACAACUUGAUAAUUCAAUUUACUACUAGGCUUUCCGCAGUACCCAUAGGCGACUCCACGGCAAUUUCCCAUCAAAUUGGCGAAGAGUUAUUUCAAAUAUUAUCCCAGUUAUCGAACCUAAUCUCCCAGCUAUUACUAUCGGCCGACCUAUUACAGUACAAAGAUCAGGUCAUUUUACUGAAGGCAUCAUUAUCGCAUGCGAUCACAUCGAUAAGAUAUUUCUCUGUUUACGGUCCCGUAUUAAUUCCGAAAAUAACUGUGCAAGCUGCUGUUUCAGAGGUUUGUUUUGCCAUGUGUAAUCUAAUUGAUUCAGCGAAAAUAAAAUCCGAUUCAAAUGGUGAGAGCACCACCUCUAAUGAAGGUAACCGACAGGUAUUAGAAUAUUCUUCACCAACUGCUACCACCCCAAUGACGCCAACUUUCCCCUCGACUUCUGGAAUAAAUAUGAAGAAGGGGUUUAUAAACCCAAGAAAACCAGCAUCUUUCUUGAAUGAUGUGGAGGAAGAAGAAUCUCCAGUCAAGCCAUUGAAAAUUACACAAAAGGCAAUUAACAGUCCGAUCAUAAGACCGUCAUCGUCUAAUGGAGUUCCAACAACCUCAAGAAAACCUUCAGGAACGGGGCUAUUUAGUUUAAUGAUUGAUUCAUCAAUUGCUAAGAAUAGCUCCCAUAAAGAGGAUAAUGAUAAAUAUGUCUCGCCCAUAAAGGCAGUAACAUCGGCCUCCAAUUCUGCAAGUAGCAAUAUUUCCGAAAUUCCUAAACUAACACUACCUCCACAAGCCAAAAUCGGUACUGUUAUUCCACCGUCAGAGAAUCAAGUUCCCAAUAUUAAAAUCGAGAAUACAGAAGAGGAUAAUAAAAGGAGUGACAUAACAAAUGAAAUCUCUGUUAAACCAACUUCUAGCAUUGCUGAUAAACUGAAACAAUUUGAGCAAAGUUCCGAAAAGAAAUCAUCACCAAAGGAAAAUCCUAUAGCAAAAGAAGAAAUGGAUUCAAAACCAAAACUAUCCAAUAAAUUUAUCACUUCAAUGAAUGAUGUGUCCACAGAUGAUUCAAGCUCUGAUGGUAACGAAAAUGACGAUGCAGACGAUGAUGAUGAUUUUACCUAUAUGGCAUUGAAACAAACAAUGAAGAGAGAAGGUUCAAAAAUUGAAAAAAAUAAUGACAGCAAACUACCUGCAAAUAUAGUGGAACUUGAUUUACAUGAGUCACCGGAGUCCGUGAAGAUUGAAUCUCCUGAAUCGAUAAAGGAAAUCACGUCAUCUGAAAUGUCUUCAGAAAUGCCAAGUAGUUCGCUGCCUAAGAGAUUAGUAGAGGAUGUUGAGCCUUCAGAAAUGCCAGAGAAGGGCGCAUCUGUAGAAUCAGUCAGGAAGAAAAAUUUUCAAGAACCACUUGGUAAUGUCGAAUCUCCGGAUAUGACGCAGAAGGUCAAGUCUUUGGGUAUGACAGGAAAGGCUGUAGGCCCAGAAUCAGAUAGUAGGGUCGAAUCUCCGGGCAUGACAGGACAGAUUAAAUCUUUGAAUAUGGCAGGAAAAGUUGUAGGCCCAGAAGCAGAUAGUAGGGUCGAAUCUCCGGGCAUGAAAGAGCAGAUUAAGUCUUUGGGUAUGACAGGAAAAAUUACAGCUCAAGAAUCAAUCAAGUCCCCGGAAGCGGCUAGGAAGUUGGCGUCAUCAGGAGAAGUUGACAAAAUUGAAUCUCCAAGAAUGGUAAGGGAAAGCGAGUCCUUGGAGGCAGUAGGCAAUACUAUCCCCUCAAACAUGACAGUGAAAAUGGAAUCCCCAAAUUUAAAGGGAAAUACUGUGUCUGAACCUCAAGAAAUAAGGAGAGACAUUGCCUCCUCAGAGCCGAUAGAGAAUGUUGACCCCCCAAAAGUACUAAAAAAGAUUGUCUUUCCAAAGGCUGUUAAUAGAACUGGAUCACCAAAAUCAGUCGAAAAGACUCCAUCUUCAGCUACACUGAAAAAGAGCGGGCUCCCAGAACCGAAUAGCCAAAUUGUUUCUCCUGAAUUGGCAAAAAAUUCACCUCUAGCACCGAUAAAGAAAAAUGUCGAGUUACGAGAAACUAAUAAACCACAUACUGAGACUAUCACUUCUGUGGAACCAACAAACAAGGAUGCCAAUACUUCUUGGAGAGACGCCGACUUAAACCGUACGAUCAAACGAGAGGAGGAGGACGAAGAUUUUGAUAGAGUGAACCACAAUAUCCAGAUCACUGGUGCAUAUACGAAAACUGGAAAAAUUGAUUAUCAUAAAAUACCUGUUGAUCGUAAAGCAAAAAGCGAAGCAGAAGUGCAUACUUCCGAGGAAGAUAUUGAUGAAUCAAAUAAUGUUAAUGGAAAAAGAGCUGAUGCCCAAAUACACAUCACUGAAAGAAAGCAUGCUUUCGUAAAUCCAACUGAAAAUUCACAGGUAAAAAAGACGAGCCACUCACCAUUUUUAAACAGUAAACCGGUUCAAUACGAGAACUCAGAGUCGAACGGCGGCAUUAACAACCACAUAAAGAUAAAAAAUACUGGAGAAACUACGGCACAUGACGAGAAACAUUAUAGUGAUGAUGAUGAUUCUAGCUAUCAAUUUGUUCCCAUGAAACAUGAAGAACAAGAACAAGAACAAAACAGAAGUGAGGAAGAGGAAAGUGAAGAUGACGAUGAAGAGGAAGAAGACAGUGAUUUUGAUGUGGAUACAUUUGACAUUGAAAAUCCGGAUAAUACACUAUCAGAGUUACUAUUGUAUUUAGAACAUCAAACAAUGGACGUCAUAUCCACGAUUCAAUCGCUUUUGACAUCGAUCAAGAAACCACAGGUGACGAAGGGUAAUUUGAGGGGAGAAUCGAAUGCAAUCAACCAAGUCAUAGGUCAAAUGGUGGACGCUACUAGCAUAUCAAUGGAGCAAAGCAGAAAUGCCAAUUUGAAGAAACACGGUGAUUGGGUGGUGCAAAGUCUAAGAGACUGUUCGCGUAGAAUGACAAUUUUGUGCCAAUUAACUGGCGAUGGAAUACUAGCGAAGGAAAAGAGCGAUCAAGAUUAUGCUGACAAAAACUUCAAACAGCGGUUGGCAGGGAUUGCGUUUGAUGUUGCCAAAUGUACAAAGGAGCUGGUAAAAACUGUAGAAGAGGCAAGUUUGAAGGACGAAAUAAAUUAUUUGAAUUCGAAGUUGAAGUAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Saccharomyces cerevisiae,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,20 µM [Whi3];|5 nM BNI1;|5 nM SPA2,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"Fluorescence microscopy images and quantification show SPA2 mRNA incubated with oligos to target the complement nucleotide regions of BNI1 (5 nM) is less recruited into preformed Whi3-BNI1 droplets (8 µM Whi3, 5 nM BNI1) compared to native SPA2 alone."
178,PMID: 29650703,RNAPS0000056,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201,BNI1;|CLN3_refold,5862nt(1-5862);|1879nt(1-1879),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,8 µM [Whi3];|5 nM BNI1;|5 nM CLN3 refold,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"Melted CLN3 mRNA that was slowly refolded (CLN3 refold) showed significantly less recruitment than melted, but more than native CLN3 (Fig. 3A and C). Mixing between melted CLN3 and melted BNI1 occurred in the presence of Whi3 and in RNA-only reactions, suggesting mixing is initiated by RNA-RNA interactions."
179,PMID: 29650703,RNAPS0000057,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201,BNI1;|CLN3_scr,5862nt(1-5862);|1879nt(1-1879),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,8 µM [Whi3];|5 nM BNI1;|5 nM CLN3 scr,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"CLN3 mRNA heated to 95°C to disrupt secondary structure also readily incorporated into Whi3-BNI1 droplets (Fig. 3, A and C). Melted CLN3 mRNA that was slowly refolded (CLN3 refold) showed significantly less recruitment than melted, but more than native CLN3."
180,PMID: 29650703,RNAPS0000059,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201,BNI1;|CLN3_ml,5862nt(1-5862);|1879nt(1-1879),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,8 µM [Whi3];|5 nM BNI1;|5 nM CLN3 ml,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,We next investigated which features of the mRNA sequence generate specificity. An mRNA with scrambled CLN3 coding sequence (cln3 scr) with intact Whi3-binding sites formed Whi3 droplets.
181,PMID: 29650703,RNAPS0000060,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201,BNI1;|CLN3_sm,5862nt(1-5862);|1879nt(1-1879),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,8 µM [Whi3];|5 nM BNI1;|5 nM CLN3 sm,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"Additionally, cln3sm, a mutant perturbing structure and exposing complementarity, co-localized with BNI1 transcripts in vitro and at polarity sites in cells (Fig. 3F, S5, >60% tips co-localized). Thus, secondary structure can regulate RNA sorting into distinct droplets through altering the capacity to form intermolecular interactions."
182,PMID: 29650703,RNAPS0000061,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201,BNI1;|CLN3,5862nt(1-5862);|1879nt(1-1879),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,2 µM [Whi3];|1.25 nM BNI1;|1.25 nM CLN3,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,> 30 min,-,Fluorescence microscopy,liquid,Fluorescence microscopy images showing CLN3 is excluded from Whi3-BNI1 droplets in a variety of protein and RNA concentrations.
183,PMID: 29650703,RNAPS0000061,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201,BNI1;|CLN3,5862nt(1-5862);|1879nt(1-1879),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,20 µM [Whi3];|5 nM BNI1;|5 nM CLN3,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,> 30 min,-,Fluorescence microscopy,liquid,Fluorescence microscopy images showing CLN3 is excluded from Whi3-BNI1 droplets in a variety of protein and RNA concentrations.
184,PMID: 29650703,RNAPS0000063,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:850639;|NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/850639;|https://www.ncbi.nlm.nih.gov/gene/1201,SPA2;|CLN3,4401nt(1-4401);|1879nt(1-1879),AUGGGUACGUCAAGCGAGGUUUCUCUCGCACAUCAUAGAGAUAUCUUCCAUUACUACGUCUCACUGAAGACUUUUUUCGAGGUGACUGGCGAAAAUCGUGACAGGUCAAAUUCGACACGAGCUCAAAAGGCCAGAGCCAAGCUGUUGAAGCUAUCUUCUUCGCAAUUUUACGAGCUGAGUACAGACGUGUCCGAUGAGCUGCAGAGGAGAAUCGGUGAAGAUGCUAACCAACCAGAUUACCUUUUGCCGAAGGCAAAUUUCCACAUGAAAAGGAACCAGGCUAGACAGAAACUGGCCAAUCUAUCACAAACUCGAUUUAAUGAUUUGUUGGACGAUAUCCUUUUUGAGAUCAAGAGAAGAGGGUUCGACAAGGAUUUGGAUGCUCCACGGCCCCCAUUACCGCAGCCGAUGAAACAAGAGGUCAGCAAAGACAGCGAUGAUACUGCAAGAACAUCCACAAAUUCUUCCUCUGUGACUCAAGUAGCUCCAAACGUCUCCGUACAACCUUCUUUGGUCAUUCCUAAGAUGGCAUCUAUCGAUUGGUCUUCUGAGGAAGAAGAAGAGGAGCAAGUAAAGGAGAAGCCAAAUGAACCGGAGGGAAAACAAACAAGCAUGGAUGAAAAGAAAGAGGCUAAACCUGCUCUAAACCCCAUAGUUACAGAUUCUGAUCUGCCUGACUCCCAAGUGCUCGCUCGUGAUAUCACAUCAAUGGCAAGGACUCCAACAACGACGCAUAAAAAUUACUGGGACGUUAAUGAUUCUCCAAUUAUCAAGGUAGAUAAAGAUAUCGAUAACGAAAAGGGUCCCGAACAGUUGAAGAGCCCUGAAGUACAACGGGCUGAGAACAAUAACCCUAACUCAGAGAUGGAAGACAAGGUUAAAGAACUGACUGAUUUAAACAGCGACUUACAUUUGCAAAUUGAAGAUUUGAAUGCUAAGUUAGCAUCUUUAACCAGCGAGAAGGAAAAGGAGAAGAAGGAAGAGAAGGAGGAAAAAGAAAAGGAAAAGAACUUAAAGAUUAACUACACCAUUGAUGAAAGUUUUCAGAAAGAAUUGCUGUCAUUAAACUCUCAAAUCGGUGAAUUAUCAAUUGAGAAUGAAAAUUUGAAGCAGAAAAUUUCAGAAUUCGAACUGCAUCAAAAAAAGAAUGACAACCAUAAUGAUUUGAAAAUCACUGACGGUUUUAUUAGCAAGUACUCUUCUGCCGAUGGGCUCAUUCCAGCUCAAUACAUCUUAAACGCUAACAACUUGAUAAUUCAAUUUACUACUAGGCUUUCCGCAGUACCCAUAGGCGACUCCACGGCAAUUUCCCAUCAAAUUGGCGAAGAGUUAUUUCAAAUAUUAUCCCAGUUAUCGAACCUAAUCUCCCAGCUAUUACUAUCGGCCGACCUAUUACAGUACAAAGAUCAGGUCAUUUUACUGAAGGCAUCAUUAUCGCAUGCGAUCACAUCGAUAAGAUAUUUCUCUGUUUACGGUCCCGUAUUAAUUCCGAAAAUAACUGUGCAAGCUGCUGUUUCAGAGGUUUGUUUUGCCAUGUGUAAUCUAAUUGAUUCAGCGAAAAUAAAAUCCGAUUCAAAUGGUGAGAGCACCACCUCUAAUGAAGGUAACCGACAGGUAUUAGAAUAUUCUUCACCAACUGCUACCACCCCAAUGACGCCAACUUUCCCCUCGACUUCUGGAAUAAAUAUGAAGAAGGGGUUUAUAAACCCAAGAAAACCAGCAUCUUUCUUGAAUGAUGUGGAGGAAGAAGAAUCUCCAGUCAAGCCAUUGAAAAUUACACAAAAGGCAAUUAACAGUCCGAUCAUAAGACCGUCAUCGUCUAAUGGAGUUCCAACAACCUCAAGAAAACCUUCAGGAACGGGGCUAUUUAGUUUAAUGAUUGAUUCAUCAAUUGCUAAGAAUAGCUCCCAUAAAGAGGAUAAUGAUAAAUAUGUCUCGCCCAUAAAGGCAGUAACAUCGGCCUCCAAUUCUGCAAGUAGCAAUAUUUCCGAAAUUCCUAAACUAACACUACCUCCACAAGCCAAAAUCGGUACUGUUAUUCCACCGUCAGAGAAUCAAGUUCCCAAUAUUAAAAUCGAGAAUACAGAAGAGGAUAAUAAAAGGAGUGACAUAACAAAUGAAAUCUCUGUUAAACCAACUUCUAGCAUUGCUGAUAAACUGAAACAAUUUGAGCAAAGUUCCGAAAAGAAAUCAUCACCAAAGGAAAAUCCUAUAGCAAAAGAAGAAAUGGAUUCAAAACCAAAACUAUCCAAUAAAUUUAUCACUUCAAUGAAUGAUGUGUCCACAGAUGAUUCAAGCUCUGAUGGUAACGAAAAUGACGAUGCAGACGAUGAUGAUGAUUUUACCUAUAUGGCAUUGAAACAAACAAUGAAGAGAGAAGGUUCAAAAAUUGAAAAAAAUAAUGACAGCAAACUACCUGCAAAUAUAGUGGAACUUGAUUUACAUGAGUCACCGGAGUCCGUGAAGAUUGAAUCUCCUGAAUCGAUAAAGGAAAUCACGUCAUCUGAAAUGUCUUCAGAAAUGCCAAGUAGUUCGCUGCCUAAGAGAUUAGUAGAGGAUGUUGAGCCUUCAGAAAUGCCAGAGAAGGGCGCAUCUGUAGAAUCAGUCAGGAAGAAAAAUUUUCAAGAACCACUUGGUAAUGUCGAAUCUCCGGAUAUGACGCAGAAGGUCAAGUCUUUGGGUAUGACAGGAAAGGCUGUAGGCCCAGAAUCAGAUAGUAGGGUCGAAUCUCCGGGCAUGACAGGACAGAUUAAAUCUUUGAAUAUGGCAGGAAAAGUUGUAGGCCCAGAAGCAGAUAGUAGGGUCGAAUCUCCGGGCAUGAAAGAGCAGAUUAAGUCUUUGGGUAUGACAGGAAAAAUUACAGCUCAAGAAUCAAUCAAGUCCCCGGAAGCGGCUAGGAAGUUGGCGUCAUCAGGAGAAGUUGACAAAAUUGAAUCUCCAAGAAUGGUAAGGGAAAGCGAGUCCUUGGAGGCAGUAGGCAAUACUAUCCCCUCAAACAUGACAGUGAAAAUGGAAUCCCCAAAUUUAAAGGGAAAUACUGUGUCUGAACCUCAAGAAAUAAGGAGAGACAUUGCCUCCUCAGAGCCGAUAGAGAAUGUUGACCCCCCAAAAGUACUAAAAAAGAUUGUCUUUCCAAAGGCUGUUAAUAGAACUGGAUCACCAAAAUCAGUCGAAAAGACUCCAUCUUCAGCUACACUGAAAAAGAGCGGGCUCCCAGAACCGAAUAGCCAAAUUGUUUCUCCUGAAUUGGCAAAAAAUUCACCUCUAGCACCGAUAAAGAAAAAUGUCGAGUUACGAGAAACUAAUAAACCACAUACUGAGACUAUCACUUCUGUGGAACCAACAAACAAGGAUGCCAAUACUUCUUGGAGAGACGCCGACUUAAACCGUACGAUCAAACGAGAGGAGGAGGACGAAGAUUUUGAUAGAGUGAACCACAAUAUCCAGAUCACUGGUGCAUAUACGAAAACUGGAAAAAUUGAUUAUCAUAAAAUACCUGUUGAUCGUAAAGCAAAAAGCGAAGCAGAAGUGCAUACUUCCGAGGAAGAUAUUGAUGAAUCAAAUAAUGUUAAUGGAAAAAGAGCUGAUGCCCAAAUACACAUCACUGAAAGAAAGCAUGCUUUCGUAAAUCCAACUGAAAAUUCACAGGUAAAAAAGACGAGCCACUCACCAUUUUUAAACAGUAAACCGGUUCAAUACGAGAACUCAGAGUCGAACGGCGGCAUUAACAACCACAUAAAGAUAAAAAAUACUGGAGAAACUACGGCACAUGACGAGAAACAUUAUAGUGAUGAUGAUGAUUCUAGCUAUCAAUUUGUUCCCAUGAAACAUGAAGAACAAGAACAAGAACAAAACAGAAGUGAGGAAGAGGAAAGUGAAGAUGACGAUGAAGAGGAAGAAGACAGUGAUUUUGAUGUGGAUACAUUUGACAUUGAAAAUCCGGAUAAUACACUAUCAGAGUUACUAUUGUAUUUAGAACAUCAAACAAUGGACGUCAUAUCCACGAUUCAAUCGCUUUUGACAUCGAUCAAGAAACCACAGGUGACGAAGGGUAAUUUGAGGGGAGAAUCGAAUGCAAUCAACCAAGUCAUAGGUCAAAUGGUGGACGCUACUAGCAUAUCAAUGGAGCAAAGCAGAAAUGCCAAUUUGAAGAAACACGGUGAUUGGGUGGUGCAAAGUCUAAGAGACUGUUCGCGUAGAAUGACAAUUUUGUGCCAAUUAACUGGCGAUGGAAUACUAGCGAAGGAAAAGAGCGAUCAAGAUUAUGCUGACAAAAACUUCAAACAGCGGUUGGCAGGGAUUGCGUUUGAUGUUGCCAAAUGUACAAAGGAGCUGGUAAAAACUGUAGAAGAGGCAAGUUUGAAGGACGAAAUAAAUUAUUUGAAUUCGAAGUUGAAGUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,8 µM [Whi3];|5 nM SPA2;|5 nM CLN3,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,> 30 min,-,Fluorescence microscopy,liquid,Fluorescence microscopy images show cy3 labeled cln3 mRNA is not efficiently recruited into whi3-spa2 droplets.
185,PMID: 29650703,RNAPS0000064,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201,BNI1_ml;|CLN3,5862nt(1-5862);|1879nt(1-1879),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,8 µM [Whi3];|5 nM BNI1 ml;|5 nM CLN3,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"Fluorescence microscopy images and recruitment coefficients show CLN3 mRNA (5 nM) is modestly recruited into preformed Whi3 droplets made with melted BNI1 (8 µM Whi3, 5 nM BNI1) unless complement regions of CLN3 are also exposed through melting (CLN3ml).In contrast, recruitment of CLN3 ml is lost when the mRNA is mixed with oligos targeting the sequence on CLN3 with complementarity to BNI1 mRNA (CLN3 ml + oligos). Outliers are indicated with (•) marks."
186,PMID: 29650703,RNAPS0000065,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201,BNI1_ml;|CLN3_ml,5862nt(1-5862);|1879nt(1-1879),AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA,mRNA;|mRNA,Saccharomyces cerevisiae;|Homo sapiens,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,8 µM [Whi3];|5 nM BNI1 ml;|5 nM CLN3 ml,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"Fluorescence microscopy images and recruitment coefficients show CLN3 mRNA (5 nM) is modestly recruited into preformed Whi3 droplets made with melted BNI1 (8 µM Whi3, 5 nM BNI1) unless complement regions of CLN3 are also exposed through melting (CLN3ml).In contrast, recruitment of CLN3 ml is lost when the mRNA is mixed with oligos targeting the sequence on CLN3 with complementarity to BNI1 mRNA (CLN3 ml + oligos). Outliers are indicated with (•) marks."
187,PMID: 29650703,RNAPS0000066,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201;|-,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201;|-,BNI1;|CLN3_ml;|Oligos_Blend,5862nt(1-5862);|1879nt(1-1879);|-,AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA;|-,mRNA;|mRNA;|-,Saccharomyces cerevisiae;|Homo sapiens;|-,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,8 µM [Whi3];|5 nM BNI1;|5 nM CLN3;|100 nM Oligos,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"Oligonucleotides (i.e., oligos) complementary to these regions were added to melted CLN3 and significantly decreased the coassembly with BNI1, restoring the formation of distinct CLN3 droplets."
188,PMID: 29650703,RNAPS0000069,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201;|-,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201;|-,BNI1;|CLN3;|Oligos_Blend,5862nt(1-5862);|1879nt(1-1879);|-,AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA;|-,mRNA;|mRNA;|-,Saccharomyces cerevisiae;|Homo sapiens;|-,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,20 µM [Whi3];|5 nM BNI1;|5 nM SPA2;|100 nM Oligos,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"Fluorescence microscopy images and quantification show SPA2 mRNA incubated with oligos to target the complement nucleotide regions of BNI1 (5 nM) is less recruited into preformed Whi3-BNI1 droplets (8 µM Whi3, 5 nM BNI1) compared to native SPA2 alone."
189,PMID: 29650703,RNAPS0000070,https://pubmed.ncbi.nlm.nih.gov/29650703,RNAs + protein,NCBI ID:855450;|NCBI ID:1201;|-,https://www.ncbi.nlm.nih.gov/gene/855450;|https://www.ncbi.nlm.nih.gov/gene/1201;|-,BNI1;|CLN3;|Oligos,5862nt(1-5862);|1879nt(1-1879);|-,AUGUUGAAGAAUUCAGGCUCCAAACAUUCGAACUCAAAGGAAAGUCAUUCGAAUUCGAGUUCUGGUAUAUUCCAAAAUUUGAAGCGUUUGGCUAACUCAAAUGCAACGAAUAGCAAUACGGGUUCUCCGACCUAUGCAUCCCAACAACAGCACUCUCCAGUGGGAAACGAAGUGUCCACUUCACCUGCAUCUUCGUCAUCUUUUAGAAAACUGAAUGCACCUUCUAGGUCUACAUCUACUGAGGCGAGGCCGUUGAAUAAAAAAUCGACAUUAAACACACAAAACUUGUCUCAAUAUAUGAAUGGUAAAUUAAGUGGAGAUGUUCCCGUAUCCUCACAGCACGCAAGGUCGCAUUCAAUGCAAUCGAAAUAUUCGUAUUCCAAGAGGAAUUCUUCACAGGCGUCCAAUAAGCUAACAAGGCAGCAUACCGGGCAAAGUCACUCCGCAUCAAGUCUUCUCUCUCAAGGUUCGCUAACUAACUUGAGCAAAUUCACUACACCCGAUGGUAAAAUUUAUUUAGAAAUGCCGUCGGACCCAUACGAGGUGGAAGUUUUGUUUGAAGAUAUUAUGUAUAAAAGAAAUAUUUUUCAGUCUUUAUCAGAGGACAAACAAGAAGCUCUGAUGGGCUACAGCAUUGAGAAGAAAUGGCUGAUUGUUAAGCAGGAUUUACAAAAUGAGCUAAAAAAAAUGCGAGCAAACACUACAUCUUCUUCCACUGCCUCCAGAACUUCGAUGGCGUCGGACCAUCAUCCUAUCCUUACGGCUAAUUCAUCUCUUUCGUCUCCCAAAUCUGUUUUGAUGACAAGCGCCUCUUCUCCCACCUCAACUGUAUACAGCAACAGUUUAAAUCAUUCUACUACUCUUUCAUCGGUAGGUACGUCAACCUCGAAGGGGAAAAAAUUAGUGAGCGGGAGUUUGAAAAAGCAGCCAUCUCUAAACAAUAUUUAUAGAGGUGGGGCUGAGAACAAUACGAGUGCAUCUACUCUUCCAGGAGACAGAACAAACAGACCACCGAUACAUUAUGUGCAACGAAUCCUGGCAGACAAACUUACUAGCGAUGAGAUGAAAGAUUUAUGGGUAACUUUAAGAACUGAACAGUUAGACUGGGUAGACGCUUUUAUAGACCAUCAGGGUCACAUUGCUAUGGCUAAUGUACUAAUGAACUCUAUUUAUAAGACUGCACCCCGAGAAAACUUGACUAAAGAAUUAUUAGAGAAAGAAAAUUCAUUUUUUAAAUGCUUCAGAGUCUUAUCAAUGCUCUCACAAGGUUUGUAUGAGUUCAGUACACAUAGGUUAAUGACUGAUACUGUUGCAGAAGGUUUAUUCUCUACGAAACUGGCCACAAGGAAAAUGGCCACUGAAAUUUUUGUUUGUAUGCUAGAAAAAAAAAAUAAAAGCAGAUUCGAAGCAGUUCUUACCUCACUAGAUAAAAAGUUUAGGAUAGGGCAAAAUCUUCAUAUGAUUCAAAACUUCAAAAAAAUGCCCCAGUAUUUCUCUCAUUUAACCUUGGAAAGUCAUUUGAAAAUUAUUCAAGCCUGGUUAUUUGCCGUUGAACAAACUUUAGAUGGAAGAGGAAAAAUGGGUUCCUUAGUAGGCGCGUCGGAUGAAUUUAAAAAUGGUGGGGGUGAAAAUGCGAUUCUAGAAUACUGCCAAUGGACAAUGGUUUUUAUCAAUCAUUUAUGCUCUUGCUCUGAUAACAUAAAUCAAAGAAUGCUAUUAAGGACGAAACUAGAAAAUUGUGGAAUUUUACGAAUUAUGAACAAAAUAAAACUGCUAGAUUACGACAAGGUAAUUGACCAAAUUGAGUUAUAUGACAAUAAUAAACUUGACGAUUUUAACGUUAAAUUAGAGGCCAACAAUAAGGCUUUUAAUGUAGAUUUACACGAUCCACUAUCAUUAUUAAAAAACCUUUGGGAUAUAUGUAAAGGUACCGAGAAUGAAAAGCUUUUAGUAUCUUUAGUUCAACAUCUUUUCCUUUCUAGUUCAAAGUUAAUAGAAGAAAACCAAAAUUCCUCUAAACUUACUAAGCAAUUGAAACUUAUGGAUUCUUUGGUGACUAAUGUUAGUGUUGCCUCAACUUCUGAUGAAGAAACUAAUAUGAAUAUGGCUAUCCAGCGGCUUUACGAUGCCAUGCAGACUGAUGAAGUUGCACGUCGAGCUAUAUUAGAAAGUAGAGCUCUAACGAAGAAAUUGGAAGAAAUUCAGGCAGAAAGGGAUUCUUUAAGUGAAAAGUUAAGCAAGGCGGAGCACGGACUCGUUGGACAGUUAGAAGAUGAGUUGCAUGAGAGAGAUCGUAUUUUAGCUAAGAAUCAGAGAGUUAUGCAGCAGCUGGAAGCUGAGUUAGAAGAGUUGAAAAAGAAGCAUCUUUUGGAAAAGCAUCAGCAAGAGGUAGAAUUGAGAAAAAUGUUGACUAUAUUGAAUUCGAGGCCUGAAGAAAGCUUCAAUAAGAAUGAAGGCACCAGAGGUAUGAACUCGAGCCUAAAUUCUUCAGAGAAAGCGAAUAUCCAAAAGGUGUUACAGGACGGAUUAUCAAGAGCAAAAAAGGAUUACAAGGAUGAUUCAAAAAAAUUCGGCAUGACACUUCAACCUAAUAAGAGAUUAAAAAUGUUAAGAAUGCAAAUGGAAAAUAUUGAAAAUGAAGCCAGGCAACUAGAGAUGACAAAUUUUGCUGAAUUUGAGAAAGAUCGUCUUGAACCUCCAAUACAUAUUAAGAAGCCCAAAGUGAAGAAGAUGAAAAAUAAGGAUAGGAAACCUUUAGUCAAGCCUCAAGAGGCGGACGUAAAUAAACUAAAUGACCUAAGGCGGGCUUUGGCUGAAAUCCAAAUGGAAAGUAAUGAUAUUUCCAAAUUUAACGUCGAAGAACGUGUUAAUGAGCUAUUUAAUGAAAAGAAAUCUCUGGCUUUAAAGAGACUGAAAGAACUAGAAACAAAAUACAAAGGAUUUGGUAUUGACUUUAAUGUCGACGAGAUUAUGGACAGUCCAAAGAAAAAUACUGGGGACGUGGAAACGGAAGAAGACGCUAACUAUGCCAGUCUUGACCCUAAGACAUAUCAGAAAAAGUUAGACGAGAUUAAUAGAAUAACGGACCAGUUGUUAGAUAUUCAGACUCAAACCGAACACGAAAUACAAGUAGAAGAAGAUGGGGAAAGCGAUCUUUCCUCUUCAAGUUCUGAUGAUGAAAGUGAGGAAAUAUACCAAGACGCAUCUCCAACUCAAGAACUAAGGAGCGAACACUCAGAGCUAUCUUCAGGAUCAGGUCCUGGGUCUUUUCUCGAUGCCUUAUCUCAAAAAUAUGGUACUGGUCAAAAUGUUACUGCAUCGGCUGCUUUUGGAGAGAACAAUAACGGUUCGGGUAUUGGACCUCUACAUAGUAAAGUUGAAAAGACCUUUAUGAACAGACUCAGAAAAUCCACCGUGUCUUCUGCUCCAUAUUUAGAGGAGUUAACACAGAAGGUAAAUAAAGUUGAACCAUAUGAACAAAAUGAAGAUGAAGGUCUAGAUAAAAAAUCUUUACCGGAAAACAGCACGGCAAGUGCAGCUUCCGCCUUUGACAAAGCUGAGAAAGACAUGAGACAACAUGUGGAAAACGGAAAGCAAGGGCGUGUGGUAAAUCAUGAAGAAGAUAAAACAGCGGAUUUCAGCGCUGUGAGUAAACUGAAUAAUACAGAUGGCGCAGAAGAUCUCUCUACUCAAUCAUCUGUACUCUCCUCACAGCCGCCACCGCCUCCUCCUCCUCCUCCUCCAGUUCCCGCCAAAUUGUUCGGUGAAUCGUUGGAGAAAGAGAAAAAGUCGGAAGACGACACUGUCAAGCAAGAAACUACUGGGGAUUCUCCUGCUCCUCCCCCUCCACCACCACCACCUCCUCCUCCACCCAUGGCAUUGUUCGGCAAACCCAAGGGAGAAACACCACCACCGCCGCCGCUACCAUCUGUAUUAUCUUCAUCUACUGAUGGCGUCAUUCCGCCAGCUCCACCUAUGAUGCCGGCAUCGCAAAUCAAAUCAGCUGUAACAUCACCAUUACUUCCUCAAUCGCCCUCAUUAUUUGAAAAGUAUCCUCGUCCACACAAGAAAUUAAAGCAACUGCAUUGGGAAAAAUUAGAUUGUACUGAUAAUUCUAUUUGGGGUACAGGUAAAGCUGAGAAGUUCGCAGAUGACUUAUACGAAAAGGGUGUUCUUGCUGAUUUAGAAAAGGCCUUUGCCGCUAGGGAAAUUAAAUCAUUAGCAAGCAAGCGCAAGGAAGAUCUGCAGAAAAUUACAUUUUUAUCCAGGGAUAUUUCUCAACAGUUUGGUAUCAAUUUGCAUAUGUAUUCAUCACUUUCGGUUGCCGAUCUGGUGAAAAAGAUUCUAAACUGCGAUAGGGAUUUUUUGCAAACACCGAGUGUUGUUGAGUUUUUGUCAAAAUCUGAAAUAAUUGAAGUUUCUGUUAAUUUAGCUAGGAAUUACGCCCCGUAUUCGACAGACUGGGAGGGCGUGAGGAAUCUCGAAGAUGCCAAGCCCCCUGAAAAAGAUCCAAACGAUUUACAGAGGGCUGACCAAAUUUAUUUGCAAUUGAUGGUUAAUCUAGAAUCAUACUGGGGUUCACGUAUGAGAGCUCUCACAGUGGUUACUUCGUAUGAAAGAGAAUAUAAUGAGUUAUUGGCAAAGUUAAGAAAAGUCGACAAAGCUGUUAGCGCGCUUCAAGAAUCAGAUAACUUGCGCAAUGUCUUUAAUGUUAUCUUAGCAGUUGGUAAUUUCAUGAACGACACUUCUAAGCAGGCACAAGGUUUCAAACUUUCAACCUUGCAGAGGUUGACGUUUAUCAAGGAUACUACCAAUAGCAUGACCUUUCUAAAUUACGUCGAAAAAAUUGUCAGGUUAAAUUAUCCAAGCUUCAAUGACUUUCUAAGUGAAUUAGAACCUGUAUUGGAUGUCGUGAAAGUUUCCAUUGAGCAGUUAGUUAACGACUGUAAGGACUUUAGCCAAUCGAUUGUAAACGUAGAGCGUUCAGUUGAAAUUGGUAAUUUAAGCGAUUCCUCAAAGUUUCAUCCAUUAGAUAAAGUUUUGAUAAAAACAUUGCCCGUGUUACCGGAAGCCAGAAAAAAGGGGGACUUGUUAGAAGACGAAGUUAAGCUGACUAUCAUGGAAUUUGAAAGUCUGAUGCAUACGUACGGUGAAGAUUCUGGUGAUAAGUUUGCAAAAAUCUCAUUCUUUAAGAAAUUUGCAGAUUUUAUAAAUGAAUACAAAAAAGCUCAAGCGCAAAAUCUAGCCGCGGAAGAAGAAGAAAGACUUUAUAUAAAGCAUAAGAAAAUAGUGGAAGAACAGCAAAAAAGGGCACAAGAAAAGGAAAAACAAAAAGAGAACAGCAAUUCGCCUUCAUCUGAAGGAAAUGAAGAGGAUGAAGCAGAAGAUAGGCGCGCUGUUAUGGAUAAACUAUUAGAACAGUUGAAAAAUGCAGGUCCUGCUAAAAGUGACCCAUCUUCCGCCAGAAAGAGAGCCCUAGUGAGGAAAAAAUAUCUUUCUGAAAAAGACAACGCUCCACAAUUACUCAACGAUUUGGAUACUGAAGAAGGGUCUAUUCUUUAUUCUCCAGAAGCUAUGGACCCUACUGCCGAUACAGUGAUUCACGCUGAAUCACCCACUCCGCUUGCCACAAGGGGUGUUAUGAAUACCUCUGAAGAUUUACCAUCGCCAUCCAAGACAUCUGCGCUGGAAGAUCAAGAGGAAAUUAGUGACAGAGCUAGAAUGUUAUUAAAGGAGCUAAGAGGCUCUGACACACCAGUAAAGCAAAAUUCCAUACUCGAUGAACAUCUAGAAAAAUUGAGGGCCCGCAAGGAAAGAUCCAUAGGUGAGGCUAGCACAGGUAACAGGCUAAGUUUCAAAUAA;|GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUCUUAAAGGUACAGGCCUCAGGGUCCCUGCUGUAGACGGGGCGGGGGAGAGUACGAUGGGUGGGGCGUGGUGGGUCGUAGGGCGCUCGAGAUGGAGCCCCCAGCUUCCUUGAUGGAUCGCGGGGCGCGAGUGCCCUAGACAAGCCGGAGCUGGGACCGGCAAUCGGGCGUUGAUCCUUGUCACCUGUCGCAGACCCUCAUCCCUCCCGUGGGAGCCCCCUUUGGACACUCUAUGACCCUGGACCCUCGGGGGACCUGAACUUGAUGCGAUGGGAGGCUGUGCAGGCUCGCGGCGGCGCUUUUCGGAUUCCGAGGGGGAGGAGACCGUCCCGGAGCCCCGGCUCCCUCUGUUGGACCAUCAGGGCGCGCAUUGGAAGAACGCGGUGGGCUUCUGGCUGCUGGGCCUUUGCAACAACUUCUCUUAUGUGGUGAUGCUGAGUGCCGCCCACGACAUCCUUAGCCACAAGAGGACAUCGGGAAACCAGAGCCAUGUGGACCCAGGCCCAACGCCGAUCCCCCACAACAGCUCAUCACGAUUUGACUGCAACUCUGUCUCUACGGCUGCUGUGCUCCUGGCGGACAUCCUCCCCACACUCGUCAUCAAAUUGUUGGCUCCUCUUGGCCUUCACCUGCUGCCCUACAGCCCCCGGGUUCUCGUCAGUGGGAUUUGUGCUGCUGGAAGCUUCGUCCUGGUUGCCUUUUCUCAUUCUGUGGGGACCAGCCUGUGUGGUGUGGUCUUCGCUAGCAUCUCAUCAGGCCUUGGGGAGGUCACCUUCCUCUCCCUCACUGCCUUCUACCCCAGGGCCGUGAUCUCCUGGUGGUCCUCAGGGACUGGGGGAGCUGGGCUGCUGGGGGCCCUGUCCUACCUGGGCCUCACCCAGGCCGGCCUCUCCCCUCAGCAGACCCUGCUGUCCAUGCUGGGUAUCCCUGCCCUGCUGCUGGCCAGCUAUUUCUUGUUGCUCACAUCUCCUGAGGCCCAGGACCCUGGAGGGGAAGAAGAAGCAGAGAGCGCAGCCCGGCAGCCCCUCAUAAGAACCGAGGCCCCGGAGUCGAAGCCAGGCUCCAGCUCCAGCCUCUCCCUUCGGGAAAGGUGGACAGUGUUCAAGGGUCUGCUGUGGUACAUUGUUCCCUUGGUCGUAGUUUACUUUGCCGAGUAUUUCAUUAACCAGGGACUUUUUGAACUCCUCUUUUUCUGGAACACUUCCCUGAGUCACGCUCAGCAAUACCGCUGGUACCAGAUGCUGUACCAGGCUGGCGUCUUUGCCUCCCGCUCUUCUCUCCGCUGCUGUCGCAUCCGUUUCACCUGGGCCCUGGCCCUGCUGCAGUGCCUCAACCUGGUGUUCCUGCUGGCAGACGUGUGGUUCGGCUUUCUGCCAAGCAUCUACCUCGUCUUCCUGAUCAUUCUGUAUGAGGGGCUCCUGGGAGGCGCAGCCUACGUGAACACCUUCCACAACAUCGCCCUGGAGACCAGUGAUGAGCACCGGGAGUUUGCAAUGGCGGCCACCUGCAUCUCUGACACACUGGGGAUCUCCCUGUCGGGGCUCCUGGCUUUGCCUCUGCAUGACUUCCUCUGCCAGCUCUCCUGAUACUCGGGAUCCUCAGGACGCAGGUCACAUUCACCUGUGGGCAGAGGGACAGGUCAGACACCCAGGCCCACCCCAGAGACCCUCCAUGAACUGUGCUCCCAGCCUUCCCGGCAGGUCUGGGAGUAGGGAAGGGCUGAAGCCUUGUUUCCCUUGCAGGGGGGCCAGCCAUUGUCUCCCACUUGGGGAGUUUCUUCCUGGCAUCAUGCCUUCUGAAUAAAUGCCGAUUUUAUCCAUGGAAA;|-,mRNA;|mRNA;|-,Saccharomyces cerevisiae;|Homo sapiens;|-,"tr|Q75E28|Q75E28_ASHGO ABL158Cp OS=Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) OX=284811 GN=AGOS_ABL158C PE=4 SV=1|length=729aa|residues=1-729
MSLVNSHSSASVENAAYNLHRAFSSSTENVGHMTPSNSSPLHHSTVVAMGAESQGGGASN
NNNNPANPGSTANNNSNNVNMNSIGGGASLGAGSGATGSISGTKGMNNSHSPLHIATMLN
TLSMNSNPPSQQQSNVQGPYLVRLQNVPKDTTLRECHALFALAHGVLSIELSSFQQYAER
SQTSGQESTNYIVAKFDSLHLACQYATILDEKAQIFGPSFPFKTYVEVVDELTQQQIPFQ
TQMQMHQGSPPAPTHVTAYQQPLLSASGVVSPPQSASSVKRPSLLVQRSRFSFTDPFSSE
QTNMGSQQPDLITTPLKGHQDTGKSFLLMESDEINDSIWGNGTGIPSSISGLTTSQPPTP
HLEWGTTGRRQSSTFYPSQSNTEIPPMHLTGQVQSSQLATGLQQPLPQPQRQSLSYNLVT
PLSSDMNLPPQSSQGGILPHQAPAQTQPQSQALQHHQHLHHQQQQLQQQQHHLQQQQHQQ
QQQSLSQQPQQQQSQQSQAHSQQHQQQHQQQQQQQQPQQQQPQQHPPQQPQQQNSQQAIV
GQSQQQVTSGQQKGSSRNSISKTLQVNGPKNAAAALQNTNGISQVDLSLLAKVPPPANPA
DQNPPCNTLYVGNLPPDATEQELRQLFSSQKGFRRLSFRNKNNNGNGHGPMCFVEFEDVA
HATRALAELYGSQLARTSGTHNNKGGIRLSFSKNPLGVRGPNSRRGGATNNTSNAGTTNY
SYAAAFGKS",Whi3,-,-,729aa(1-729),Q75E28,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q75E28,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0003,http://db.phasep.pro/browse/","[19-20],[29-144],[173-186],[237-282],[302-314],[337-364],[376-459],[469-623],[668-676],[698-718],[728-729]",-,In vitro,8 µM [Whi3];|5 nM BNI1 ml;|5 nM CLN3 ml;|100 nM Oligos,150 mM KCl,"50 mM Tris pH 8.0, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"Fluorescence microscopy images and recruitment coefficients show CLN3 mRNA (5 nM) is modestly recruited into preformed Whi3 droplets made with melted BNI1 (8 µM Whi3, 5 nM BNI1) unless complement regions of CLN3 are also exposed through melting (CLN3ml). In contrast, recruitment of CLN3 ml is lost when the mRNA is mixed with oligos targeting the sequence on CLN3 with complementarity to BNI1 mRNA (CLN3 ml + oligos). Outliers are indicated with (•) marks."
190,PMID: 29677514,RNAPS0000029,https://pubmed.ncbi.nlm.nih.gov/29677514,RNA + protein,NCBI ID:4137,https://www.ncbi.nlm.nih.gov/gene/4137,MAPT,6644nt(1-6644),GCAGUCACCGCCACCCACCAGCUCCGGCACCAACAGCAGCGCCGCUGCCACCGCCCACCUUCUGCCGCCGCCACCACAGCCACCUUCUCCUCCUCCGCUGUCCUCUCCCGUCCUCGCCUCUGUCGACUAUCAGGUGAACUUUGAACCAGGAUGGCUGAGCCCCGCCAGGAGUUCGAAGUGAUGGAAGAUCACGCUGGGACGUACGGGUUGGGGGACAGGAAAGAUCAGGGGGGCUACACCAUGCACCAAGACCAAGAGGGUGACACGGACGCUGGCCUGAAAGAAUCUCCCCUGCAGACCCCCACUGAGGACGGAUCUGAGGAACCGGGCUCUGAAACCUCUGAUGCUAAGAGCACUCCAACAGCGGAAGAUGUGACAGCACCCUUAGUGGAUGAGGGAGCUCCCGGCAAGCAGGCUGCCGCGCAGCCCCACACGGAGAUCCCAGAAGGAACCACAGCUGAAGAAGCAGGCAUUGGAGACACCCCCAGCCUGGAAGACGAAGCUGCUGGUCACGUGACCCAAGAGCCUGAAAGUGGUAAGGUGGUCCAGGAAGGCUUCCUCCGAGAGCCAGGCCCCCCAGGUCUGAGCCACCAGCUCAUGUCCGGCAUGCCUGGGGCUCCCCUCCUGCCUGAGGGCCCCAGAGAGGCCACACGCCAACCUUCGGGGACAGGACCUGAGGACACAGAGGGCGGCCGCCACGCCCCUGAGCUGCUCAAGCACCAGCUUCUAGGAGACCUGCACCAGGAGGGGCCGCCGCUGAAGGGGGCAGGGGGCAAAGAGAGGCCGGGGAGCAAGGAGGAGGUGGAUGAAGACCGCGACGUCGAUGAGUCCUCCCCCCAAGACUCCCCUCCCUCCAAGGCCUCCCCAGCCCAAGAUGGGCGGCCUCCCCAGACAGCCGCCAGAGAAGCCACCAGCAUCCCAGGCUUCCCAGCGGAGGGUGCCAUCCCCCUCCCUGUGGAUUUCCUCUCCAAAGUUUCCACAGAGAUCCCAGCCUCAGAGCCCGACGGGCCCAGUGUAGGGCGGGCCAAAGGGCAGGAUGCCCCCCUGGAGUUCACGUUUCACGUGGAAAUCACACCCAACGUGCAGAAGGAGCAGGCGCACUCGGAGGAGCAUUUGGGAAGGGCUGCAUUUCCAGGGGCCCCUGGAGAGGGGCCAGAGGCCCGGGGCCCCUCUUUGGGAGAGGACACAAAAGAGGCUGACCUUCCAGAGCCCUCUGAAAAGCAGCCUGCUGCUGCUCCGCGGGGGAAGCCCGUCAGCCGGGUCCCUCAACUCAAAGCUCGCAUGGUCAGUAAAAGCAAAGACGGGACUGGAAGCGAUGACAAAAAAGCCAAGACAUCCACACGUUCCUCUGCUAAAACCUUGAAAAAUAGGCCUUGCCUUAGCCCCAAACACCCCACUCCUGGUAGCUCAGACCCUCUGAUCCAACCCUCCAGCCCUGCUGUGUGCCCAGAGCCACCUUCCUCUCCUAAAUACGUCUCUUCUGUCACUUCCCGAACUGGCAGUUCUGGAGCAAAGGAGAUGAAACUCAAGGGGGCUGAUGGUAAAACGAAGAUCGCCACACCGCGGGGAGCAGCCCCUCCAGGCCAGAAGGGCCAGGCCAACGCCACCAGGAUUCCAGCAAAAACCCCGCCCGCUCCAAAGACACCACCCAGCUCUGCGACUAAGCAAGUCCAGAGAAGACCACCCCCUGCAGGGCCCAGAUCUGAGAGAGGUGAACCUCCAAAAUCAGGGGAUCGCAGCGGCUACAGCAGCCCCGGCUCCCCAGGCACUCCCGGCAGCCGCUCCCGCACCCCGUCCCUUCCAACCCCACCCACCCGGGAGCCCAAGAAGGUGGCAGUGGUCCGUACUCCACCCAAGUCGCCGUCUUCCGCCAAGAGCCGCCUGCAGACAGCCCCCGUGCCCAUGCCAGACCUGAAGAAUGUCAAGUCCAAGAUCGGCUCCACUGAGAACCUGAAGCACCAGCCGGGAGGCGGGAAGGUGCAGAUAAUUAAUAAGAAGCUGGAUCUUAGCAACGUCCAGUCCAAGUGUGGCUCAAAGGAUAAUAUCAAACACGUCCCGGGAGGCGGCAGUGUGCAAAUAGUCUACAAACCAGUUGACCUGAGCAAGGUGACCUCCAAGUGUGGCUCAUUAGGCAACAUCCAUCAUAAACCAGGAGGUGGCCAGGUGGAAGUAAAAUCUGAGAAGCUUGACUUCAAGGACAGAGUCCAGUCGAAGAUUGGGUCCCUGGACAAUAUCACCCACGUCCCUGGCGGAGGAAAUAAAAAGAUUGAAACCCACAAGCUGACCUUCCGCGAGAACGCCAAAGCCAAGACAGACCACGGGGCGGAGAUCGUGUACAAGUCGCCAGUGGUGUCUGGGGACACGUCUCCACGGCAUCUCAGCAAUGUCUCCUCCACCGGCAGCAUCGACAUGGUAGACUCGCCCCAGCUCGCCACGCUAGCUGACGAGGUGUCUGCCUCCCUGGCCAAGCAGGGUUUGUGAUCAGGCCCCUGGGGCGGUCAAUAAUUGUGGAGAGGAGAGAAUGAGAGAGUGUGGAAAAAAAAAGAAUAAUGACCCGGCCCCCGCCCUCUGCCCCCAGCUGCUCCUCGCAGUUCGGUUAAUUGGUUAAUCACUUAACCUGCUUUUGUCACUCGGCUUUGGCUCGGGACUUCAAAAUCAGUGAUGGGAGUAAGAGCAAAUUUCAUCUUUCCAAAUUGAUGGGUGGGCUAGUAAUAAAAUAUUUAAAAAAAAACAUUCAAAAACAUGGCCACAUCCAACAUUUCCUCAGGCAAUUCCUUUUGAUUCUUUUUUCUUCCCCCUCCAUGUAGAAGAGGGAGAAGGAGAGGCUCUGAAAGCUGCUUCUGGGGGAUUUCAAGGGACUGGGGGUGCCAACCACCUCUGGCCCUGUUGUGGGGGUGUCACAGAGGCAGUGGCAGCAACAAAGGAUUUGAAACUUGGUGUGUUCGUGGAGCCACAGGCAGACGAUGUCAACCUUGUGUGAGUGUGACGGGGGUUGGGGUGGGGCGGGAGGCCACGGGGGAGGCCGAGGCAGGGGCUGGGCAGAGGGGAGAGGAAGCACAAGAAGUGGGAGUGGGAGAGGAAGCCACGUGCUGGAGAGUAGACAUCCCCCUCCUUGCCGCUGGGAGAGCCAAGGCCUAUGCCACCUGCAGCGUCUGAGCGGCCGCCUGUCCUUGGUGGCCGGGGGUGGGGGCCUGCUGUGGGUCAGUGUGCCACCCUCUGCAGGGCAGCCUGUGGGAGAAGGGACAGCGGGUAAAAAGAGAAGGCAAGCUGGCAGGAGGGUGGCACUUCGUGGAUGACCUCCUUAGAAAAGACUGACCUUGAUGUCUUGAGAGCGCUGGCCUCUUCCUCCCUCCCUGCAGGGUAGGGGGCCUGAGUUGAGGGGCUUCCCUCUGCUCCACAGAAACCCUGUUUUAUUGAGUUCUGAAGGUUGGAACUGCUGCCAUGAUUUUGGCCACUUUGCAGACCUGGGACUUUAGGGCUAACCAGUUCUCUUUGUAAGGACUUGUGCCUCUUGGGAGACGUCCACCCGUUUCCAAGCCUGGGCCACUGGCAUCUCUGGAGUGUGUGGGGGUCUGGGAGGCAGGUCCCGAGCCCCCUGUCCUUCCCACGGCCACUGCAGUCACCCCGUCUGCGCCGCUGUGCUGUUGUCUGCCGUGAGAGCCCAAUCACUGCCUAUACCCCUCAUCACACGUCACAAUGUCCCGAAUUCCCAGCCUCACCACCCCUUCUCAGUAAUGACCCUGGUUGGUUGCAGGAGGUACCUACUCCAUACUGAGGGUGAAAUUAAGGGAAGGCAAAGUCCAGGCACAAGAGUGGGACCCCAGCCUCUCACUCUCAGUUCCACUCAUCCAACUGGGACCCUCACCACGAAUCUCAUGAUCUGAUUCGGUUCCCUGUCUCCUCCUCCCGUCACAGAUGUGAGCCAGGGCACUGCUCAGCUGUGACCCUAGGUGUUUCUGCCUUGUUGACAUGGAGAGAGCCCUUUCCCCUGAGAAGGCCUGGCCCCUUCCUGUGCUGAGCCCACAGCAGCAGGCUGGGUGUCUUGGUUGUCAGUGGUGGCACCAGGAUGGAAGGGCAAGGCACCCAGGGCAGGCCCACAGUCCCGCUGUCCCCCACUUGCACCCUAGCUUGUAGCUGCCAACCUCCCAGACAGCCCAGCCCGCUGCUCAGCUCCACAUGCAUAGUAUCAGCCCUCCACACCCGACAAAGGGGAACACACCCCCUUGGAAAUGGUUCUUUUCCCCCAGUCCCAGCUGGAAGCCAUGCUGUCUGUUCUGCUGGAGCAGCUGAACAUAUACAUAGAUGUUGCCCUGCCCUCCCCAUCUGCACCCUGUUGAGUUGUAGUUGGAUUUGUCUGUUUAUGCUUGGAUUCACCAGAGUGACUAUGAUAGUGAAAAGAAAAAAAAAAAAAAAAAAGGACGCAUGUAUCUUGAAAUGCUUGUAAAGAGGUUUCUAACCCACCCUCACGAGGUGUCUCUCACCCCCACACUGGGACUCGUGUGGCCUGUGUGGUGCCACCCUGCUGGGGCCUCCCAAGUUUUGAAAGGCUUUCCUCAGCACCUGGGACCCAACAGAGACCAGCUUCUAGCAGCUAAGGAGGCCGUUCAGCUGUGACGAAGGCCUGAAGCACAGGAUUAGGACUGAAGCGAUGAUGUCCCCUUCCCUACUUCCCCUUGGGGCUCCCUGUGUCAGGGCACAGACUAGGUCUUGUGGCUGGUCUGGCUUGCGGCGCGAGGAUGGUUCUCUCUGGUCAUAGCCCGAAGUCUCAUGGCAGUCCCAAAGGAGGCUUACAACUCCUGCAUCACAAGAAAAAGGAAGCCACUGCCAGCUGGGGGGAUCUGCAGCUCCCAGAAGCUCCGUGAGCCUCAGCCACCCCUCAGACUGGGUUCCUCUCCAAGCUCGCCCUCUGGAGGGGCAGCGCAGCCUCCCACCAAGGGCCCUGCGACCACAGCAGGGAUUGGGAUGAAUUGCCUGUCCUGGAUCUGCUCUAGAGGCCCAAGCUGCCUGCCUGAGGAAGGAUGACUUGACAAGUCAGGAGACACUGUUCCCAAAGCCUUGACCAGAGCACCUCAGCCCGCUGACCUUGCACAAACUCCAUCUGCUGCCAUGAGAAAAGGGAAGCCGCCUUUGCAAAACAUUGCUGCCUAAAGAAACUCAGCAGCCUCAGGCCCAAUUCUGCCACUUCUGGUUUGGGUACAGUUAAAGGCAACCCUGAGGGACUUGGCAGUAGAAAUCCAGGGCCUCCCCUGGGGCUGGCAGCUUCGUGUGCAGCUAGAGCUUUACCUGAAAGGAAGUCUCUGGGCCCAGAACUCUCCACCAAGAGCCUCCCUGCCGUUCGCUGAGUCCCAGCAAUUCUCCUAAGUUGAAGGGAUCUGAGAAGGAGAAGGAAAUGUGGGGUAGAUUUGGUGGUGGUUAGAGAUAUGCCCCCCUCAUUACUGCCAACAGUUUCGGCUGCAUUUCUUCACGCACCUCGGUUCCUCUUCCUGAAGUUCUUGUGCCCUGCUCUUCAGCACCAUGGGCCUUCUUAUACGGAAGGCUCUGGGAUCUCCCCCUUGUGGGGCAGGCUCUUGGGGCCAGCCUAAGAUCAUGGUUUAGGGUGAUCAGUGCUGGCAGAUAAAUUGAAAAGGCACGCUGGCUUGUGAUCUUAAAUGAGGACAAUCCCCCCAGGGCUGGGCACUCCUCCCCUCCCCUCACUUCUCCCACCUGCAGAGCCAGUGUCCUUGGGUGGGCUAGAUAGGAUAUACUGUAUGCCGGCUCCUUCAAGCUGCUGACUCACUUUAUCAAUAGUUCCAUUUAAAUUGACUUCAGUGGUGAGACUGUAUCCUGUUUGCUAUUGCUUGUUGUGCUAUGGGGGGAGGGGGGAGGAAUGUGUAAGAUAGUUAACAUGGGCAAAGGGAGAUCUUGGGGUGCAGCACUUAAACUGCCUCGUAACCCUUUUCAUGAUUUCAACCACAUUUGCUAGAGGGAGGGAGCAGCCACGGAGUUAGAGGCCCUUGGGGUUUCUCUUUUCCACUGACAGGCUUUCCCAGGCAGCUGGCUAGUUCAUUCCCUCCCCAGCCAGGUGCAGGCGUAGGAAUAUGGACAUCUGGUUGCUUUGGCCUGCUGCCCUCUUUCAGGGGUCCUAAGCCCACAAUCAUGCCUCCCUAAGACCUUGGCAUCCUUCCCUCUAAGCCGUUGGCACCUCUGUGCCACCUCUCACACUGGCUCCAGACACACAGCCUGUGCUUUUGGAGCUGAGAUCACUCGCUUCACCCUCCUCAUCUUUGUUCUCCAAGUAAAGCCACGAGGUCGGGGCGAGGGCAGAGGUGAUCACCUGCGUGUCCCAUCUACAGACCUGCAGCUUCAUAAAACUUCUGAUUUCUCUUCAGCUUUGAAAAGGGUUACCCUGGGCACUGGCCUAGAGCCUCACCUCCUAAUAGACUUAGCCCCAUGAGUUUGCCAUGUUGAGCAGGACUAUUUCUGGCACUUGCAAGUCCCAUGAUUUCUUCGGUAAUUCUGAGGGUGGGGGGAGGGACAUGAAAUCAUCUUAGCUUAGCUUUCUGUCUGUGAAUGUCUAUAUAGUGUAUUGUGUGUUUUAACAAAUGAUUUACACUGACUGUUGCUGUAAAAGUGAAUUUGGAAAUAAAGUUAUUACUCUGAUUAAA,mRNA,Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=73aa|residues=454-526
GPGGGPGGSHMGGNYGDDRRGGRGGYDRGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDS
RGEHRQDRRERPY",FUS,RGG3-PY,-,73aa(454-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[454-507],[508-512]",[454-507],In vitro,15-90 µM [FUS RGG3-PY];|add MAPT at a molar ratio of 1:50,75-300 µM NaCl ,"20 mM Na2HPO4/NaH2PO4, pH 7.5, 2.5% glycerol, 1 mM DTT",25˚C,-,-,Microscopy,"liquid, solute","In the presence of substoichiometric amounts of RNA, RGG3-PY formed liquid droplets in a concentration- and temperature-dependent manner, similar to the N-terminal SYGQ-rich domain (Burke et al., 2015). Formation of RGG3-PY droplets was enhanced at lower salt concentrations, suggesting that electrostatic interactions involving RGG/RG motifs drive LLPS of this domain."
191,PMID: 29677514,RNAPS0000029,https://pubmed.ncbi.nlm.nih.gov/29677514,RNA + protein,NCBI ID:4137,https://www.ncbi.nlm.nih.gov/gene/4137,MAPT,6644nt(1-6644),GCAGUCACCGCCACCCACCAGCUCCGGCACCAACAGCAGCGCCGCUGCCACCGCCCACCUUCUGCCGCCGCCACCACAGCCACCUUCUCCUCCUCCGCUGUCCUCUCCCGUCCUCGCCUCUGUCGACUAUCAGGUGAACUUUGAACCAGGAUGGCUGAGCCCCGCCAGGAGUUCGAAGUGAUGGAAGAUCACGCUGGGACGUACGGGUUGGGGGACAGGAAAGAUCAGGGGGGCUACACCAUGCACCAAGACCAAGAGGGUGACACGGACGCUGGCCUGAAAGAAUCUCCCCUGCAGACCCCCACUGAGGACGGAUCUGAGGAACCGGGCUCUGAAACCUCUGAUGCUAAGAGCACUCCAACAGCGGAAGAUGUGACAGCACCCUUAGUGGAUGAGGGAGCUCCCGGCAAGCAGGCUGCCGCGCAGCCCCACACGGAGAUCCCAGAAGGAACCACAGCUGAAGAAGCAGGCAUUGGAGACACCCCCAGCCUGGAAGACGAAGCUGCUGGUCACGUGACCCAAGAGCCUGAAAGUGGUAAGGUGGUCCAGGAAGGCUUCCUCCGAGAGCCAGGCCCCCCAGGUCUGAGCCACCAGCUCAUGUCCGGCAUGCCUGGGGCUCCCCUCCUGCCUGAGGGCCCCAGAGAGGCCACACGCCAACCUUCGGGGACAGGACCUGAGGACACAGAGGGCGGCCGCCACGCCCCUGAGCUGCUCAAGCACCAGCUUCUAGGAGACCUGCACCAGGAGGGGCCGCCGCUGAAGGGGGCAGGGGGCAAAGAGAGGCCGGGGAGCAAGGAGGAGGUGGAUGAAGACCGCGACGUCGAUGAGUCCUCCCCCCAAGACUCCCCUCCCUCCAAGGCCUCCCCAGCCCAAGAUGGGCGGCCUCCCCAGACAGCCGCCAGAGAAGCCACCAGCAUCCCAGGCUUCCCAGCGGAGGGUGCCAUCCCCCUCCCUGUGGAUUUCCUCUCCAAAGUUUCCACAGAGAUCCCAGCCUCAGAGCCCGACGGGCCCAGUGUAGGGCGGGCCAAAGGGCAGGAUGCCCCCCUGGAGUUCACGUUUCACGUGGAAAUCACACCCAACGUGCAGAAGGAGCAGGCGCACUCGGAGGAGCAUUUGGGAAGGGCUGCAUUUCCAGGGGCCCCUGGAGAGGGGCCAGAGGCCCGGGGCCCCUCUUUGGGAGAGGACACAAAAGAGGCUGACCUUCCAGAGCCCUCUGAAAAGCAGCCUGCUGCUGCUCCGCGGGGGAAGCCCGUCAGCCGGGUCCCUCAACUCAAAGCUCGCAUGGUCAGUAAAAGCAAAGACGGGACUGGAAGCGAUGACAAAAAAGCCAAGACAUCCACACGUUCCUCUGCUAAAACCUUGAAAAAUAGGCCUUGCCUUAGCCCCAAACACCCCACUCCUGGUAGCUCAGACCCUCUGAUCCAACCCUCCAGCCCUGCUGUGUGCCCAGAGCCACCUUCCUCUCCUAAAUACGUCUCUUCUGUCACUUCCCGAACUGGCAGUUCUGGAGCAAAGGAGAUGAAACUCAAGGGGGCUGAUGGUAAAACGAAGAUCGCCACACCGCGGGGAGCAGCCCCUCCAGGCCAGAAGGGCCAGGCCAACGCCACCAGGAUUCCAGCAAAAACCCCGCCCGCUCCAAAGACACCACCCAGCUCUGCGACUAAGCAAGUCCAGAGAAGACCACCCCCUGCAGGGCCCAGAUCUGAGAGAGGUGAACCUCCAAAAUCAGGGGAUCGCAGCGGCUACAGCAGCCCCGGCUCCCCAGGCACUCCCGGCAGCCGCUCCCGCACCCCGUCCCUUCCAACCCCACCCACCCGGGAGCCCAAGAAGGUGGCAGUGGUCCGUACUCCACCCAAGUCGCCGUCUUCCGCCAAGAGCCGCCUGCAGACAGCCCCCGUGCCCAUGCCAGACCUGAAGAAUGUCAAGUCCAAGAUCGGCUCCACUGAGAACCUGAAGCACCAGCCGGGAGGCGGGAAGGUGCAGAUAAUUAAUAAGAAGCUGGAUCUUAGCAACGUCCAGUCCAAGUGUGGCUCAAAGGAUAAUAUCAAACACGUCCCGGGAGGCGGCAGUGUGCAAAUAGUCUACAAACCAGUUGACCUGAGCAAGGUGACCUCCAAGUGUGGCUCAUUAGGCAACAUCCAUCAUAAACCAGGAGGUGGCCAGGUGGAAGUAAAAUCUGAGAAGCUUGACUUCAAGGACAGAGUCCAGUCGAAGAUUGGGUCCCUGGACAAUAUCACCCACGUCCCUGGCGGAGGAAAUAAAAAGAUUGAAACCCACAAGCUGACCUUCCGCGAGAACGCCAAAGCCAAGACAGACCACGGGGCGGAGAUCGUGUACAAGUCGCCAGUGGUGUCUGGGGACACGUCUCCACGGCAUCUCAGCAAUGUCUCCUCCACCGGCAGCAUCGACAUGGUAGACUCGCCCCAGCUCGCCACGCUAGCUGACGAGGUGUCUGCCUCCCUGGCCAAGCAGGGUUUGUGAUCAGGCCCCUGGGGCGGUCAAUAAUUGUGGAGAGGAGAGAAUGAGAGAGUGUGGAAAAAAAAAGAAUAAUGACCCGGCCCCCGCCCUCUGCCCCCAGCUGCUCCUCGCAGUUCGGUUAAUUGGUUAAUCACUUAACCUGCUUUUGUCACUCGGCUUUGGCUCGGGACUUCAAAAUCAGUGAUGGGAGUAAGAGCAAAUUUCAUCUUUCCAAAUUGAUGGGUGGGCUAGUAAUAAAAUAUUUAAAAAAAAACAUUCAAAAACAUGGCCACAUCCAACAUUUCCUCAGGCAAUUCCUUUUGAUUCUUUUUUCUUCCCCCUCCAUGUAGAAGAGGGAGAAGGAGAGGCUCUGAAAGCUGCUUCUGGGGGAUUUCAAGGGACUGGGGGUGCCAACCACCUCUGGCCCUGUUGUGGGGGUGUCACAGAGGCAGUGGCAGCAACAAAGGAUUUGAAACUUGGUGUGUUCGUGGAGCCACAGGCAGACGAUGUCAACCUUGUGUGAGUGUGACGGGGGUUGGGGUGGGGCGGGAGGCCACGGGGGAGGCCGAGGCAGGGGCUGGGCAGAGGGGAGAGGAAGCACAAGAAGUGGGAGUGGGAGAGGAAGCCACGUGCUGGAGAGUAGACAUCCCCCUCCUUGCCGCUGGGAGAGCCAAGGCCUAUGCCACCUGCAGCGUCUGAGCGGCCGCCUGUCCUUGGUGGCCGGGGGUGGGGGCCUGCUGUGGGUCAGUGUGCCACCCUCUGCAGGGCAGCCUGUGGGAGAAGGGACAGCGGGUAAAAAGAGAAGGCAAGCUGGCAGGAGGGUGGCACUUCGUGGAUGACCUCCUUAGAAAAGACUGACCUUGAUGUCUUGAGAGCGCUGGCCUCUUCCUCCCUCCCUGCAGGGUAGGGGGCCUGAGUUGAGGGGCUUCCCUCUGCUCCACAGAAACCCUGUUUUAUUGAGUUCUGAAGGUUGGAACUGCUGCCAUGAUUUUGGCCACUUUGCAGACCUGGGACUUUAGGGCUAACCAGUUCUCUUUGUAAGGACUUGUGCCUCUUGGGAGACGUCCACCCGUUUCCAAGCCUGGGCCACUGGCAUCUCUGGAGUGUGUGGGGGUCUGGGAGGCAGGUCCCGAGCCCCCUGUCCUUCCCACGGCCACUGCAGUCACCCCGUCUGCGCCGCUGUGCUGUUGUCUGCCGUGAGAGCCCAAUCACUGCCUAUACCCCUCAUCACACGUCACAAUGUCCCGAAUUCCCAGCCUCACCACCCCUUCUCAGUAAUGACCCUGGUUGGUUGCAGGAGGUACCUACUCCAUACUGAGGGUGAAAUUAAGGGAAGGCAAAGUCCAGGCACAAGAGUGGGACCCCAGCCUCUCACUCUCAGUUCCACUCAUCCAACUGGGACCCUCACCACGAAUCUCAUGAUCUGAUUCGGUUCCCUGUCUCCUCCUCCCGUCACAGAUGUGAGCCAGGGCACUGCUCAGCUGUGACCCUAGGUGUUUCUGCCUUGUUGACAUGGAGAGAGCCCUUUCCCCUGAGAAGGCCUGGCCCCUUCCUGUGCUGAGCCCACAGCAGCAGGCUGGGUGUCUUGGUUGUCAGUGGUGGCACCAGGAUGGAAGGGCAAGGCACCCAGGGCAGGCCCACAGUCCCGCUGUCCCCCACUUGCACCCUAGCUUGUAGCUGCCAACCUCCCAGACAGCCCAGCCCGCUGCUCAGCUCCACAUGCAUAGUAUCAGCCCUCCACACCCGACAAAGGGGAACACACCCCCUUGGAAAUGGUUCUUUUCCCCCAGUCCCAGCUGGAAGCCAUGCUGUCUGUUCUGCUGGAGCAGCUGAACAUAUACAUAGAUGUUGCCCUGCCCUCCCCAUCUGCACCCUGUUGAGUUGUAGUUGGAUUUGUCUGUUUAUGCUUGGAUUCACCAGAGUGACUAUGAUAGUGAAAAGAAAAAAAAAAAAAAAAAAGGACGCAUGUAUCUUGAAAUGCUUGUAAAGAGGUUUCUAACCCACCCUCACGAGGUGUCUCUCACCCCCACACUGGGACUCGUGUGGCCUGUGUGGUGCCACCCUGCUGGGGCCUCCCAAGUUUUGAAAGGCUUUCCUCAGCACCUGGGACCCAACAGAGACCAGCUUCUAGCAGCUAAGGAGGCCGUUCAGCUGUGACGAAGGCCUGAAGCACAGGAUUAGGACUGAAGCGAUGAUGUCCCCUUCCCUACUUCCCCUUGGGGCUCCCUGUGUCAGGGCACAGACUAGGUCUUGUGGCUGGUCUGGCUUGCGGCGCGAGGAUGGUUCUCUCUGGUCAUAGCCCGAAGUCUCAUGGCAGUCCCAAAGGAGGCUUACAACUCCUGCAUCACAAGAAAAAGGAAGCCACUGCCAGCUGGGGGGAUCUGCAGCUCCCAGAAGCUCCGUGAGCCUCAGCCACCCCUCAGACUGGGUUCCUCUCCAAGCUCGCCCUCUGGAGGGGCAGCGCAGCCUCCCACCAAGGGCCCUGCGACCACAGCAGGGAUUGGGAUGAAUUGCCUGUCCUGGAUCUGCUCUAGAGGCCCAAGCUGCCUGCCUGAGGAAGGAUGACUUGACAAGUCAGGAGACACUGUUCCCAAAGCCUUGACCAGAGCACCUCAGCCCGCUGACCUUGCACAAACUCCAUCUGCUGCCAUGAGAAAAGGGAAGCCGCCUUUGCAAAACAUUGCUGCCUAAAGAAACUCAGCAGCCUCAGGCCCAAUUCUGCCACUUCUGGUUUGGGUACAGUUAAAGGCAACCCUGAGGGACUUGGCAGUAGAAAUCCAGGGCCUCCCCUGGGGCUGGCAGCUUCGUGUGCAGCUAGAGCUUUACCUGAAAGGAAGUCUCUGGGCCCAGAACUCUCCACCAAGAGCCUCCCUGCCGUUCGCUGAGUCCCAGCAAUUCUCCUAAGUUGAAGGGAUCUGAGAAGGAGAAGGAAAUGUGGGGUAGAUUUGGUGGUGGUUAGAGAUAUGCCCCCCUCAUUACUGCCAACAGUUUCGGCUGCAUUUCUUCACGCACCUCGGUUCCUCUUCCUGAAGUUCUUGUGCCCUGCUCUUCAGCACCAUGGGCCUUCUUAUACGGAAGGCUCUGGGAUCUCCCCCUUGUGGGGCAGGCUCUUGGGGCCAGCCUAAGAUCAUGGUUUAGGGUGAUCAGUGCUGGCAGAUAAAUUGAAAAGGCACGCUGGCUUGUGAUCUUAAAUGAGGACAAUCCCCCCAGGGCUGGGCACUCCUCCCCUCCCCUCACUUCUCCCACCUGCAGAGCCAGUGUCCUUGGGUGGGCUAGAUAGGAUAUACUGUAUGCCGGCUCCUUCAAGCUGCUGACUCACUUUAUCAAUAGUUCCAUUUAAAUUGACUUCAGUGGUGAGACUGUAUCCUGUUUGCUAUUGCUUGUUGUGCUAUGGGGGGAGGGGGGAGGAAUGUGUAAGAUAGUUAACAUGGGCAAAGGGAGAUCUUGGGGUGCAGCACUUAAACUGCCUCGUAACCCUUUUCAUGAUUUCAACCACAUUUGCUAGAGGGAGGGAGCAGCCACGGAGUUAGAGGCCCUUGGGGUUUCUCUUUUCCACUGACAGGCUUUCCCAGGCAGCUGGCUAGUUCAUUCCCUCCCCAGCCAGGUGCAGGCGUAGGAAUAUGGACAUCUGGUUGCUUUGGCCUGCUGCCCUCUUUCAGGGGUCCUAAGCCCACAAUCAUGCCUCCCUAAGACCUUGGCAUCCUUCCCUCUAAGCCGUUGGCACCUCUGUGCCACCUCUCACACUGGCUCCAGACACACAGCCUGUGCUUUUGGAGCUGAGAUCACUCGCUUCACCCUCCUCAUCUUUGUUCUCCAAGUAAAGCCACGAGGUCGGGGCGAGGGCAGAGGUGAUCACCUGCGUGUCCCAUCUACAGACCUGCAGCUUCAUAAAACUUCUGAUUUCUCUUCAGCUUUGAAAAGGGUUACCCUGGGCACUGGCCUAGAGCCUCACCUCCUAAUAGACUUAGCCCCAUGAGUUUGCCAUGUUGAGCAGGACUAUUUCUGGCACUUGCAAGUCCCAUGAUUUCUUCGGUAAUUCUGAGGGUGGGGGGAGGGACAUGAAAUCAUCUUAGCUUAGCUUUCUGUCUGUGAAUGUCUAUAUAGUGUAUUGUGUGUUUUAACAAAUGAUUUACACUGACUGUUGCUGUAAAAGUGAAUUUGGAAAUAAAGUUAUUACUCUGAUUAAA,mRNA,Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=73aa|residues=454-526
GPGGGPGGSHMGGNYGDDRRGGRGGYDRGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDS
RGEHRQDRRERPY",FUS,RGG3-PY,-,73aa(454-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[454-507],[508-512]",[454-507],In vitro,30 µM [FUS RGG3-PY];|in presence of different amounts(0:1/1:100/1:75/1:50/1:25/1:10) of MAPT RNA,75 mM NaCl,"20 mM Na2HPO4/NaH2PO4, pH 7.5, 2.5% glycerol, 1 mM DTT",RT,-,-,Turbidity measurement,liquid,"Enhanced phase separation was also observed for the unmethylated RGG3-PY domain, which reached higher turbidity values than methylated RGG3-PY upon addition of RNA. This difference was not due to altered RNA binding, as filter binding experiments demonstrated equal affinity of unmethylated and methylated RGG3-PY for RNA."
192,PMID: 29677514,RNAPS0000029,https://pubmed.ncbi.nlm.nih.gov/29677514,RNA + protein,NCBI ID:4137,https://www.ncbi.nlm.nih.gov/gene/4137,MAPT,6644nt(1-6644),GCAGUCACCGCCACCCACCAGCUCCGGCACCAACAGCAGCGCCGCUGCCACCGCCCACCUUCUGCCGCCGCCACCACAGCCACCUUCUCCUCCUCCGCUGUCCUCUCCCGUCCUCGCCUCUGUCGACUAUCAGGUGAACUUUGAACCAGGAUGGCUGAGCCCCGCCAGGAGUUCGAAGUGAUGGAAGAUCACGCUGGGACGUACGGGUUGGGGGACAGGAAAGAUCAGGGGGGCUACACCAUGCACCAAGACCAAGAGGGUGACACGGACGCUGGCCUGAAAGAAUCUCCCCUGCAGACCCCCACUGAGGACGGAUCUGAGGAACCGGGCUCUGAAACCUCUGAUGCUAAGAGCACUCCAACAGCGGAAGAUGUGACAGCACCCUUAGUGGAUGAGGGAGCUCCCGGCAAGCAGGCUGCCGCGCAGCCCCACACGGAGAUCCCAGAAGGAACCACAGCUGAAGAAGCAGGCAUUGGAGACACCCCCAGCCUGGAAGACGAAGCUGCUGGUCACGUGACCCAAGAGCCUGAAAGUGGUAAGGUGGUCCAGGAAGGCUUCCUCCGAGAGCCAGGCCCCCCAGGUCUGAGCCACCAGCUCAUGUCCGGCAUGCCUGGGGCUCCCCUCCUGCCUGAGGGCCCCAGAGAGGCCACACGCCAACCUUCGGGGACAGGACCUGAGGACACAGAGGGCGGCCGCCACGCCCCUGAGCUGCUCAAGCACCAGCUUCUAGGAGACCUGCACCAGGAGGGGCCGCCGCUGAAGGGGGCAGGGGGCAAAGAGAGGCCGGGGAGCAAGGAGGAGGUGGAUGAAGACCGCGACGUCGAUGAGUCCUCCCCCCAAGACUCCCCUCCCUCCAAGGCCUCCCCAGCCCAAGAUGGGCGGCCUCCCCAGACAGCCGCCAGAGAAGCCACCAGCAUCCCAGGCUUCCCAGCGGAGGGUGCCAUCCCCCUCCCUGUGGAUUUCCUCUCCAAAGUUUCCACAGAGAUCCCAGCCUCAGAGCCCGACGGGCCCAGUGUAGGGCGGGCCAAAGGGCAGGAUGCCCCCCUGGAGUUCACGUUUCACGUGGAAAUCACACCCAACGUGCAGAAGGAGCAGGCGCACUCGGAGGAGCAUUUGGGAAGGGCUGCAUUUCCAGGGGCCCCUGGAGAGGGGCCAGAGGCCCGGGGCCCCUCUUUGGGAGAGGACACAAAAGAGGCUGACCUUCCAGAGCCCUCUGAAAAGCAGCCUGCUGCUGCUCCGCGGGGGAAGCCCGUCAGCCGGGUCCCUCAACUCAAAGCUCGCAUGGUCAGUAAAAGCAAAGACGGGACUGGAAGCGAUGACAAAAAAGCCAAGACAUCCACACGUUCCUCUGCUAAAACCUUGAAAAAUAGGCCUUGCCUUAGCCCCAAACACCCCACUCCUGGUAGCUCAGACCCUCUGAUCCAACCCUCCAGCCCUGCUGUGUGCCCAGAGCCACCUUCCUCUCCUAAAUACGUCUCUUCUGUCACUUCCCGAACUGGCAGUUCUGGAGCAAAGGAGAUGAAACUCAAGGGGGCUGAUGGUAAAACGAAGAUCGCCACACCGCGGGGAGCAGCCCCUCCAGGCCAGAAGGGCCAGGCCAACGCCACCAGGAUUCCAGCAAAAACCCCGCCCGCUCCAAAGACACCACCCAGCUCUGCGACUAAGCAAGUCCAGAGAAGACCACCCCCUGCAGGGCCCAGAUCUGAGAGAGGUGAACCUCCAAAAUCAGGGGAUCGCAGCGGCUACAGCAGCCCCGGCUCCCCAGGCACUCCCGGCAGCCGCUCCCGCACCCCGUCCCUUCCAACCCCACCCACCCGGGAGCCCAAGAAGGUGGCAGUGGUCCGUACUCCACCCAAGUCGCCGUCUUCCGCCAAGAGCCGCCUGCAGACAGCCCCCGUGCCCAUGCCAGACCUGAAGAAUGUCAAGUCCAAGAUCGGCUCCACUGAGAACCUGAAGCACCAGCCGGGAGGCGGGAAGGUGCAGAUAAUUAAUAAGAAGCUGGAUCUUAGCAACGUCCAGUCCAAGUGUGGCUCAAAGGAUAAUAUCAAACACGUCCCGGGAGGCGGCAGUGUGCAAAUAGUCUACAAACCAGUUGACCUGAGCAAGGUGACCUCCAAGUGUGGCUCAUUAGGCAACAUCCAUCAUAAACCAGGAGGUGGCCAGGUGGAAGUAAAAUCUGAGAAGCUUGACUUCAAGGACAGAGUCCAGUCGAAGAUUGGGUCCCUGGACAAUAUCACCCACGUCCCUGGCGGAGGAAAUAAAAAGAUUGAAACCCACAAGCUGACCUUCCGCGAGAACGCCAAAGCCAAGACAGACCACGGGGCGGAGAUCGUGUACAAGUCGCCAGUGGUGUCUGGGGACACGUCUCCACGGCAUCUCAGCAAUGUCUCCUCCACCGGCAGCAUCGACAUGGUAGACUCGCCCCAGCUCGCCACGCUAGCUGACGAGGUGUCUGCCUCCCUGGCCAAGCAGGGUUUGUGAUCAGGCCCCUGGGGCGGUCAAUAAUUGUGGAGAGGAGAGAAUGAGAGAGUGUGGAAAAAAAAAGAAUAAUGACCCGGCCCCCGCCCUCUGCCCCCAGCUGCUCCUCGCAGUUCGGUUAAUUGGUUAAUCACUUAACCUGCUUUUGUCACUCGGCUUUGGCUCGGGACUUCAAAAUCAGUGAUGGGAGUAAGAGCAAAUUUCAUCUUUCCAAAUUGAUGGGUGGGCUAGUAAUAAAAUAUUUAAAAAAAAACAUUCAAAAACAUGGCCACAUCCAACAUUUCCUCAGGCAAUUCCUUUUGAUUCUUUUUUCUUCCCCCUCCAUGUAGAAGAGGGAGAAGGAGAGGCUCUGAAAGCUGCUUCUGGGGGAUUUCAAGGGACUGGGGGUGCCAACCACCUCUGGCCCUGUUGUGGGGGUGUCACAGAGGCAGUGGCAGCAACAAAGGAUUUGAAACUUGGUGUGUUCGUGGAGCCACAGGCAGACGAUGUCAACCUUGUGUGAGUGUGACGGGGGUUGGGGUGGGGCGGGAGGCCACGGGGGAGGCCGAGGCAGGGGCUGGGCAGAGGGGAGAGGAAGCACAAGAAGUGGGAGUGGGAGAGGAAGCCACGUGCUGGAGAGUAGACAUCCCCCUCCUUGCCGCUGGGAGAGCCAAGGCCUAUGCCACCUGCAGCGUCUGAGCGGCCGCCUGUCCUUGGUGGCCGGGGGUGGGGGCCUGCUGUGGGUCAGUGUGCCACCCUCUGCAGGGCAGCCUGUGGGAGAAGGGACAGCGGGUAAAAAGAGAAGGCAAGCUGGCAGGAGGGUGGCACUUCGUGGAUGACCUCCUUAGAAAAGACUGACCUUGAUGUCUUGAGAGCGCUGGCCUCUUCCUCCCUCCCUGCAGGGUAGGGGGCCUGAGUUGAGGGGCUUCCCUCUGCUCCACAGAAACCCUGUUUUAUUGAGUUCUGAAGGUUGGAACUGCUGCCAUGAUUUUGGCCACUUUGCAGACCUGGGACUUUAGGGCUAACCAGUUCUCUUUGUAAGGACUUGUGCCUCUUGGGAGACGUCCACCCGUUUCCAAGCCUGGGCCACUGGCAUCUCUGGAGUGUGUGGGGGUCUGGGAGGCAGGUCCCGAGCCCCCUGUCCUUCCCACGGCCACUGCAGUCACCCCGUCUGCGCCGCUGUGCUGUUGUCUGCCGUGAGAGCCCAAUCACUGCCUAUACCCCUCAUCACACGUCACAAUGUCCCGAAUUCCCAGCCUCACCACCCCUUCUCAGUAAUGACCCUGGUUGGUUGCAGGAGGUACCUACUCCAUACUGAGGGUGAAAUUAAGGGAAGGCAAAGUCCAGGCACAAGAGUGGGACCCCAGCCUCUCACUCUCAGUUCCACUCAUCCAACUGGGACCCUCACCACGAAUCUCAUGAUCUGAUUCGGUUCCCUGUCUCCUCCUCCCGUCACAGAUGUGAGCCAGGGCACUGCUCAGCUGUGACCCUAGGUGUUUCUGCCUUGUUGACAUGGAGAGAGCCCUUUCCCCUGAGAAGGCCUGGCCCCUUCCUGUGCUGAGCCCACAGCAGCAGGCUGGGUGUCUUGGUUGUCAGUGGUGGCACCAGGAUGGAAGGGCAAGGCACCCAGGGCAGGCCCACAGUCCCGCUGUCCCCCACUUGCACCCUAGCUUGUAGCUGCCAACCUCCCAGACAGCCCAGCCCGCUGCUCAGCUCCACAUGCAUAGUAUCAGCCCUCCACACCCGACAAAGGGGAACACACCCCCUUGGAAAUGGUUCUUUUCCCCCAGUCCCAGCUGGAAGCCAUGCUGUCUGUUCUGCUGGAGCAGCUGAACAUAUACAUAGAUGUUGCCCUGCCCUCCCCAUCUGCACCCUGUUGAGUUGUAGUUGGAUUUGUCUGUUUAUGCUUGGAUUCACCAGAGUGACUAUGAUAGUGAAAAGAAAAAAAAAAAAAAAAAAGGACGCAUGUAUCUUGAAAUGCUUGUAAAGAGGUUUCUAACCCACCCUCACGAGGUGUCUCUCACCCCCACACUGGGACUCGUGUGGCCUGUGUGGUGCCACCCUGCUGGGGCCUCCCAAGUUUUGAAAGGCUUUCCUCAGCACCUGGGACCCAACAGAGACCAGCUUCUAGCAGCUAAGGAGGCCGUUCAGCUGUGACGAAGGCCUGAAGCACAGGAUUAGGACUGAAGCGAUGAUGUCCCCUUCCCUACUUCCCCUUGGGGCUCCCUGUGUCAGGGCACAGACUAGGUCUUGUGGCUGGUCUGGCUUGCGGCGCGAGGAUGGUUCUCUCUGGUCAUAGCCCGAAGUCUCAUGGCAGUCCCAAAGGAGGCUUACAACUCCUGCAUCACAAGAAAAAGGAAGCCACUGCCAGCUGGGGGGAUCUGCAGCUCCCAGAAGCUCCGUGAGCCUCAGCCACCCCUCAGACUGGGUUCCUCUCCAAGCUCGCCCUCUGGAGGGGCAGCGCAGCCUCCCACCAAGGGCCCUGCGACCACAGCAGGGAUUGGGAUGAAUUGCCUGUCCUGGAUCUGCUCUAGAGGCCCAAGCUGCCUGCCUGAGGAAGGAUGACUUGACAAGUCAGGAGACACUGUUCCCAAAGCCUUGACCAGAGCACCUCAGCCCGCUGACCUUGCACAAACUCCAUCUGCUGCCAUGAGAAAAGGGAAGCCGCCUUUGCAAAACAUUGCUGCCUAAAGAAACUCAGCAGCCUCAGGCCCAAUUCUGCCACUUCUGGUUUGGGUACAGUUAAAGGCAACCCUGAGGGACUUGGCAGUAGAAAUCCAGGGCCUCCCCUGGGGCUGGCAGCUUCGUGUGCAGCUAGAGCUUUACCUGAAAGGAAGUCUCUGGGCCCAGAACUCUCCACCAAGAGCCUCCCUGCCGUUCGCUGAGUCCCAGCAAUUCUCCUAAGUUGAAGGGAUCUGAGAAGGAGAAGGAAAUGUGGGGUAGAUUUGGUGGUGGUUAGAGAUAUGCCCCCCUCAUUACUGCCAACAGUUUCGGCUGCAUUUCUUCACGCACCUCGGUUCCUCUUCCUGAAGUUCUUGUGCCCUGCUCUUCAGCACCAUGGGCCUUCUUAUACGGAAGGCUCUGGGAUCUCCCCCUUGUGGGGCAGGCUCUUGGGGCCAGCCUAAGAUCAUGGUUUAGGGUGAUCAGUGCUGGCAGAUAAAUUGAAAAGGCACGCUGGCUUGUGAUCUUAAAUGAGGACAAUCCCCCCAGGGCUGGGCACUCCUCCCCUCCCCUCACUUCUCCCACCUGCAGAGCCAGUGUCCUUGGGUGGGCUAGAUAGGAUAUACUGUAUGCCGGCUCCUUCAAGCUGCUGACUCACUUUAUCAAUAGUUCCAUUUAAAUUGACUUCAGUGGUGAGACUGUAUCCUGUUUGCUAUUGCUUGUUGUGCUAUGGGGGGAGGGGGGAGGAAUGUGUAAGAUAGUUAACAUGGGCAAAGGGAGAUCUUGGGGUGCAGCACUUAAACUGCCUCGUAACCCUUUUCAUGAUUUCAACCACAUUUGCUAGAGGGAGGGAGCAGCCACGGAGUUAGAGGCCCUUGGGGUUUCUCUUUUCCACUGACAGGCUUUCCCAGGCAGCUGGCUAGUUCAUUCCCUCCCCAGCCAGGUGCAGGCGUAGGAAUAUGGACAUCUGGUUGCUUUGGCCUGCUGCCCUCUUUCAGGGGUCCUAAGCCCACAAUCAUGCCUCCCUAAGACCUUGGCAUCCUUCCCUCUAAGCCGUUGGCACCUCUGUGCCACCUCUCACACUGGCUCCAGACACACAGCCUGUGCUUUUGGAGCUGAGAUCACUCGCUUCACCCUCCUCAUCUUUGUUCUCCAAGUAAAGCCACGAGGUCGGGGCGAGGGCAGAGGUGAUCACCUGCGUGUCCCAUCUACAGACCUGCAGCUUCAUAAAACUUCUGAUUUCUCUUCAGCUUUGAAAAGGGUUACCCUGGGCACUGGCCUAGAGCCUCACCUCCUAAUAGACUUAGCCCCAUGAGUUUGCCAUGUUGAGCAGGACUAUUUCUGGCACUUGCAAGUCCCAUGAUUUCUUCGGUAAUUCUGAGGGUGGGGGGAGGGACAUGAAAUCAUCUUAGCUUAGCUUUCUGUCUGUGAAUGUCUAUAUAGUGUAUUGUGUGUUUUAACAAAUGAUUUACACUGACUGUUGCUGUAAAAGUGAAUUUGGAAAUAAAGUUAUUACUCUGAUUAAA,mRNA,Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=73aa|residues=454-526
GPGGGPGGSHMGGNYGDDRRGGRGGYDRGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDS
RGEHRQDRRERPY",FUS,RGG3-PY,protein_ptm:Methylation,73aa(454-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[454-507],[508-512]",[454-507],In vitro,30 µM [FUS RGG3-PY];|in presence of different amounts(0:1/1:100/1:75/1:50/1:25/1:10) of MAPT RNA,75 mM NaCl,"20 mM Na2HPO4/NaH2PO4, pH 7.5, 2.5% glycerol, 1 mM DTT",RT,-,-,Turbidity measurement,liquid,"Enhanced phase separation was also observed for the unmethylated RGG3-PY domain, which reached higher turbidity values than methylated RGG3-PY upon addition of RNA. This difference was not due to altered RNA binding, as filter binding experiments demonstrated equal affinity of unmethylated and methylated RGG3-PY for RNA."
193,PMID: 29677514,RNAPS0000029,https://pubmed.ncbi.nlm.nih.gov/29677514,RNA + protein,NCBI ID:4137,https://www.ncbi.nlm.nih.gov/gene/4137,MAPT,6644nt(1-6644),GCAGUCACCGCCACCCACCAGCUCCGGCACCAACAGCAGCGCCGCUGCCACCGCCCACCUUCUGCCGCCGCCACCACAGCCACCUUCUCCUCCUCCGCUGUCCUCUCCCGUCCUCGCCUCUGUCGACUAUCAGGUGAACUUUGAACCAGGAUGGCUGAGCCCCGCCAGGAGUUCGAAGUGAUGGAAGAUCACGCUGGGACGUACGGGUUGGGGGACAGGAAAGAUCAGGGGGGCUACACCAUGCACCAAGACCAAGAGGGUGACACGGACGCUGGCCUGAAAGAAUCUCCCCUGCAGACCCCCACUGAGGACGGAUCUGAGGAACCGGGCUCUGAAACCUCUGAUGCUAAGAGCACUCCAACAGCGGAAGAUGUGACAGCACCCUUAGUGGAUGAGGGAGCUCCCGGCAAGCAGGCUGCCGCGCAGCCCCACACGGAGAUCCCAGAAGGAACCACAGCUGAAGAAGCAGGCAUUGGAGACACCCCCAGCCUGGAAGACGAAGCUGCUGGUCACGUGACCCAAGAGCCUGAAAGUGGUAAGGUGGUCCAGGAAGGCUUCCUCCGAGAGCCAGGCCCCCCAGGUCUGAGCCACCAGCUCAUGUCCGGCAUGCCUGGGGCUCCCCUCCUGCCUGAGGGCCCCAGAGAGGCCACACGCCAACCUUCGGGGACAGGACCUGAGGACACAGAGGGCGGCCGCCACGCCCCUGAGCUGCUCAAGCACCAGCUUCUAGGAGACCUGCACCAGGAGGGGCCGCCGCUGAAGGGGGCAGGGGGCAAAGAGAGGCCGGGGAGCAAGGAGGAGGUGGAUGAAGACCGCGACGUCGAUGAGUCCUCCCCCCAAGACUCCCCUCCCUCCAAGGCCUCCCCAGCCCAAGAUGGGCGGCCUCCCCAGACAGCCGCCAGAGAAGCCACCAGCAUCCCAGGCUUCCCAGCGGAGGGUGCCAUCCCCCUCCCUGUGGAUUUCCUCUCCAAAGUUUCCACAGAGAUCCCAGCCUCAGAGCCCGACGGGCCCAGUGUAGGGCGGGCCAAAGGGCAGGAUGCCCCCCUGGAGUUCACGUUUCACGUGGAAAUCACACCCAACGUGCAGAAGGAGCAGGCGCACUCGGAGGAGCAUUUGGGAAGGGCUGCAUUUCCAGGGGCCCCUGGAGAGGGGCCAGAGGCCCGGGGCCCCUCUUUGGGAGAGGACACAAAAGAGGCUGACCUUCCAGAGCCCUCUGAAAAGCAGCCUGCUGCUGCUCCGCGGGGGAAGCCCGUCAGCCGGGUCCCUCAACUCAAAGCUCGCAUGGUCAGUAAAAGCAAAGACGGGACUGGAAGCGAUGACAAAAAAGCCAAGACAUCCACACGUUCCUCUGCUAAAACCUUGAAAAAUAGGCCUUGCCUUAGCCCCAAACACCCCACUCCUGGUAGCUCAGACCCUCUGAUCCAACCCUCCAGCCCUGCUGUGUGCCCAGAGCCACCUUCCUCUCCUAAAUACGUCUCUUCUGUCACUUCCCGAACUGGCAGUUCUGGAGCAAAGGAGAUGAAACUCAAGGGGGCUGAUGGUAAAACGAAGAUCGCCACACCGCGGGGAGCAGCCCCUCCAGGCCAGAAGGGCCAGGCCAACGCCACCAGGAUUCCAGCAAAAACCCCGCCCGCUCCAAAGACACCACCCAGCUCUGCGACUAAGCAAGUCCAGAGAAGACCACCCCCUGCAGGGCCCAGAUCUGAGAGAGGUGAACCUCCAAAAUCAGGGGAUCGCAGCGGCUACAGCAGCCCCGGCUCCCCAGGCACUCCCGGCAGCCGCUCCCGCACCCCGUCCCUUCCAACCCCACCCACCCGGGAGCCCAAGAAGGUGGCAGUGGUCCGUACUCCACCCAAGUCGCCGUCUUCCGCCAAGAGCCGCCUGCAGACAGCCCCCGUGCCCAUGCCAGACCUGAAGAAUGUCAAGUCCAAGAUCGGCUCCACUGAGAACCUGAAGCACCAGCCGGGAGGCGGGAAGGUGCAGAUAAUUAAUAAGAAGCUGGAUCUUAGCAACGUCCAGUCCAAGUGUGGCUCAAAGGAUAAUAUCAAACACGUCCCGGGAGGCGGCAGUGUGCAAAUAGUCUACAAACCAGUUGACCUGAGCAAGGUGACCUCCAAGUGUGGCUCAUUAGGCAACAUCCAUCAUAAACCAGGAGGUGGCCAGGUGGAAGUAAAAUCUGAGAAGCUUGACUUCAAGGACAGAGUCCAGUCGAAGAUUGGGUCCCUGGACAAUAUCACCCACGUCCCUGGCGGAGGAAAUAAAAAGAUUGAAACCCACAAGCUGACCUUCCGCGAGAACGCCAAAGCCAAGACAGACCACGGGGCGGAGAUCGUGUACAAGUCGCCAGUGGUGUCUGGGGACACGUCUCCACGGCAUCUCAGCAAUGUCUCCUCCACCGGCAGCAUCGACAUGGUAGACUCGCCCCAGCUCGCCACGCUAGCUGACGAGGUGUCUGCCUCCCUGGCCAAGCAGGGUUUGUGAUCAGGCCCCUGGGGCGGUCAAUAAUUGUGGAGAGGAGAGAAUGAGAGAGUGUGGAAAAAAAAAGAAUAAUGACCCGGCCCCCGCCCUCUGCCCCCAGCUGCUCCUCGCAGUUCGGUUAAUUGGUUAAUCACUUAACCUGCUUUUGUCACUCGGCUUUGGCUCGGGACUUCAAAAUCAGUGAUGGGAGUAAGAGCAAAUUUCAUCUUUCCAAAUUGAUGGGUGGGCUAGUAAUAAAAUAUUUAAAAAAAAACAUUCAAAAACAUGGCCACAUCCAACAUUUCCUCAGGCAAUUCCUUUUGAUUCUUUUUUCUUCCCCCUCCAUGUAGAAGAGGGAGAAGGAGAGGCUCUGAAAGCUGCUUCUGGGGGAUUUCAAGGGACUGGGGGUGCCAACCACCUCUGGCCCUGUUGUGGGGGUGUCACAGAGGCAGUGGCAGCAACAAAGGAUUUGAAACUUGGUGUGUUCGUGGAGCCACAGGCAGACGAUGUCAACCUUGUGUGAGUGUGACGGGGGUUGGGGUGGGGCGGGAGGCCACGGGGGAGGCCGAGGCAGGGGCUGGGCAGAGGGGAGAGGAAGCACAAGAAGUGGGAGUGGGAGAGGAAGCCACGUGCUGGAGAGUAGACAUCCCCCUCCUUGCCGCUGGGAGAGCCAAGGCCUAUGCCACCUGCAGCGUCUGAGCGGCCGCCUGUCCUUGGUGGCCGGGGGUGGGGGCCUGCUGUGGGUCAGUGUGCCACCCUCUGCAGGGCAGCCUGUGGGAGAAGGGACAGCGGGUAAAAAGAGAAGGCAAGCUGGCAGGAGGGUGGCACUUCGUGGAUGACCUCCUUAGAAAAGACUGACCUUGAUGUCUUGAGAGCGCUGGCCUCUUCCUCCCUCCCUGCAGGGUAGGGGGCCUGAGUUGAGGGGCUUCCCUCUGCUCCACAGAAACCCUGUUUUAUUGAGUUCUGAAGGUUGGAACUGCUGCCAUGAUUUUGGCCACUUUGCAGACCUGGGACUUUAGGGCUAACCAGUUCUCUUUGUAAGGACUUGUGCCUCUUGGGAGACGUCCACCCGUUUCCAAGCCUGGGCCACUGGCAUCUCUGGAGUGUGUGGGGGUCUGGGAGGCAGGUCCCGAGCCCCCUGUCCUUCCCACGGCCACUGCAGUCACCCCGUCUGCGCCGCUGUGCUGUUGUCUGCCGUGAGAGCCCAAUCACUGCCUAUACCCCUCAUCACACGUCACAAUGUCCCGAAUUCCCAGCCUCACCACCCCUUCUCAGUAAUGACCCUGGUUGGUUGCAGGAGGUACCUACUCCAUACUGAGGGUGAAAUUAAGGGAAGGCAAAGUCCAGGCACAAGAGUGGGACCCCAGCCUCUCACUCUCAGUUCCACUCAUCCAACUGGGACCCUCACCACGAAUCUCAUGAUCUGAUUCGGUUCCCUGUCUCCUCCUCCCGUCACAGAUGUGAGCCAGGGCACUGCUCAGCUGUGACCCUAGGUGUUUCUGCCUUGUUGACAUGGAGAGAGCCCUUUCCCCUGAGAAGGCCUGGCCCCUUCCUGUGCUGAGCCCACAGCAGCAGGCUGGGUGUCUUGGUUGUCAGUGGUGGCACCAGGAUGGAAGGGCAAGGCACCCAGGGCAGGCCCACAGUCCCGCUGUCCCCCACUUGCACCCUAGCUUGUAGCUGCCAACCUCCCAGACAGCCCAGCCCGCUGCUCAGCUCCACAUGCAUAGUAUCAGCCCUCCACACCCGACAAAGGGGAACACACCCCCUUGGAAAUGGUUCUUUUCCCCCAGUCCCAGCUGGAAGCCAUGCUGUCUGUUCUGCUGGAGCAGCUGAACAUAUACAUAGAUGUUGCCCUGCCCUCCCCAUCUGCACCCUGUUGAGUUGUAGUUGGAUUUGUCUGUUUAUGCUUGGAUUCACCAGAGUGACUAUGAUAGUGAAAAGAAAAAAAAAAAAAAAAAAGGACGCAUGUAUCUUGAAAUGCUUGUAAAGAGGUUUCUAACCCACCCUCACGAGGUGUCUCUCACCCCCACACUGGGACUCGUGUGGCCUGUGUGGUGCCACCCUGCUGGGGCCUCCCAAGUUUUGAAAGGCUUUCCUCAGCACCUGGGACCCAACAGAGACCAGCUUCUAGCAGCUAAGGAGGCCGUUCAGCUGUGACGAAGGCCUGAAGCACAGGAUUAGGACUGAAGCGAUGAUGUCCCCUUCCCUACUUCCCCUUGGGGCUCCCUGUGUCAGGGCACAGACUAGGUCUUGUGGCUGGUCUGGCUUGCGGCGCGAGGAUGGUUCUCUCUGGUCAUAGCCCGAAGUCUCAUGGCAGUCCCAAAGGAGGCUUACAACUCCUGCAUCACAAGAAAAAGGAAGCCACUGCCAGCUGGGGGGAUCUGCAGCUCCCAGAAGCUCCGUGAGCCUCAGCCACCCCUCAGACUGGGUUCCUCUCCAAGCUCGCCCUCUGGAGGGGCAGCGCAGCCUCCCACCAAGGGCCCUGCGACCACAGCAGGGAUUGGGAUGAAUUGCCUGUCCUGGAUCUGCUCUAGAGGCCCAAGCUGCCUGCCUGAGGAAGGAUGACUUGACAAGUCAGGAGACACUGUUCCCAAAGCCUUGACCAGAGCACCUCAGCCCGCUGACCUUGCACAAACUCCAUCUGCUGCCAUGAGAAAAGGGAAGCCGCCUUUGCAAAACAUUGCUGCCUAAAGAAACUCAGCAGCCUCAGGCCCAAUUCUGCCACUUCUGGUUUGGGUACAGUUAAAGGCAACCCUGAGGGACUUGGCAGUAGAAAUCCAGGGCCUCCCCUGGGGCUGGCAGCUUCGUGUGCAGCUAGAGCUUUACCUGAAAGGAAGUCUCUGGGCCCAGAACUCUCCACCAAGAGCCUCCCUGCCGUUCGCUGAGUCCCAGCAAUUCUCCUAAGUUGAAGGGAUCUGAGAAGGAGAAGGAAAUGUGGGGUAGAUUUGGUGGUGGUUAGAGAUAUGCCCCCCUCAUUACUGCCAACAGUUUCGGCUGCAUUUCUUCACGCACCUCGGUUCCUCUUCCUGAAGUUCUUGUGCCCUGCUCUUCAGCACCAUGGGCCUUCUUAUACGGAAGGCUCUGGGAUCUCCCCCUUGUGGGGCAGGCUCUUGGGGCCAGCCUAAGAUCAUGGUUUAGGGUGAUCAGUGCUGGCAGAUAAAUUGAAAAGGCACGCUGGCUUGUGAUCUUAAAUGAGGACAAUCCCCCCAGGGCUGGGCACUCCUCCCCUCCCCUCACUUCUCCCACCUGCAGAGCCAGUGUCCUUGGGUGGGCUAGAUAGGAUAUACUGUAUGCCGGCUCCUUCAAGCUGCUGACUCACUUUAUCAAUAGUUCCAUUUAAAUUGACUUCAGUGGUGAGACUGUAUCCUGUUUGCUAUUGCUUGUUGUGCUAUGGGGGGAGGGGGGAGGAAUGUGUAAGAUAGUUAACAUGGGCAAAGGGAGAUCUUGGGGUGCAGCACUUAAACUGCCUCGUAACCCUUUUCAUGAUUUCAACCACAUUUGCUAGAGGGAGGGAGCAGCCACGGAGUUAGAGGCCCUUGGGGUUUCUCUUUUCCACUGACAGGCUUUCCCAGGCAGCUGGCUAGUUCAUUCCCUCCCCAGCCAGGUGCAGGCGUAGGAAUAUGGACAUCUGGUUGCUUUGGCCUGCUGCCCUCUUUCAGGGGUCCUAAGCCCACAAUCAUGCCUCCCUAAGACCUUGGCAUCCUUCCCUCUAAGCCGUUGGCACCUCUGUGCCACCUCUCACACUGGCUCCAGACACACAGCCUGUGCUUUUGGAGCUGAGAUCACUCGCUUCACCCUCCUCAUCUUUGUUCUCCAAGUAAAGCCACGAGGUCGGGGCGAGGGCAGAGGUGAUCACCUGCGUGUCCCAUCUACAGACCUGCAGCUUCAUAAAACUUCUGAUUUCUCUUCAGCUUUGAAAAGGGUUACCCUGGGCACUGGCCUAGAGCCUCACCUCCUAAUAGACUUAGCCCCAUGAGUUUGCCAUGUUGAGCAGGACUAUUUCUGGCACUUGCAAGUCCCAUGAUUUCUUCGGUAAUUCUGAGGGUGGGGGGAGGGACAUGAAAUCAUCUUAGCUUAGCUUUCUGUCUGUGAAUGUCUAUAUAGUGUAUUGUGUGUUUUAACAAAUGAUUUACACUGACUGUUGCUGUAAAAGUGAAUUUGGAAAUAAAGUUAUUACUCUGAUUAAA,mRNA,Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=73aa|residues=454-526
GPGGGPGGSHMGGNYGDDRRGGRGGYDRGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDS
RGEHRQDRRERPY",FUS,RGG3-PY,-,73aa(454-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[454-507],[508-512]",[454-507],In vitro,15-60 µM [FUS RGG3-PY];|add MAPT at a molar ratio of 1:50,75 mM NaCl,"20 mM Na2HPO4/NaH2PO4, pH 7.5, 2.5% glycerol, 1 mM DTT",25˚C,-,-,Confocal microscopy,liquid,"In the presence of substoichiometric amounts of RNA, RGG3-PY formed liquid droplets in a concentration- and temperature-dependent manner. KGG3-PY remained completely dispersed and did not form any visible droplets under conditions that induced large RGG3-PY droplets. This demonstrates that arginines in RGG motifs are crucial for LLPS of the RGG3-PY domain."
194,PMID: 29677514,RNAPS0000029,https://pubmed.ncbi.nlm.nih.gov/29677514,RNA + protein,NCBI ID:4137,https://www.ncbi.nlm.nih.gov/gene/4137,MAPT,6644nt(1-6644),GCAGUCACCGCCACCCACCAGCUCCGGCACCAACAGCAGCGCCGCUGCCACCGCCCACCUUCUGCCGCCGCCACCACAGCCACCUUCUCCUCCUCCGCUGUCCUCUCCCGUCCUCGCCUCUGUCGACUAUCAGGUGAACUUUGAACCAGGAUGGCUGAGCCCCGCCAGGAGUUCGAAGUGAUGGAAGAUCACGCUGGGACGUACGGGUUGGGGGACAGGAAAGAUCAGGGGGGCUACACCAUGCACCAAGACCAAGAGGGUGACACGGACGCUGGCCUGAAAGAAUCUCCCCUGCAGACCCCCACUGAGGACGGAUCUGAGGAACCGGGCUCUGAAACCUCUGAUGCUAAGAGCACUCCAACAGCGGAAGAUGUGACAGCACCCUUAGUGGAUGAGGGAGCUCCCGGCAAGCAGGCUGCCGCGCAGCCCCACACGGAGAUCCCAGAAGGAACCACAGCUGAAGAAGCAGGCAUUGGAGACACCCCCAGCCUGGAAGACGAAGCUGCUGGUCACGUGACCCAAGAGCCUGAAAGUGGUAAGGUGGUCCAGGAAGGCUUCCUCCGAGAGCCAGGCCCCCCAGGUCUGAGCCACCAGCUCAUGUCCGGCAUGCCUGGGGCUCCCCUCCUGCCUGAGGGCCCCAGAGAGGCCACACGCCAACCUUCGGGGACAGGACCUGAGGACACAGAGGGCGGCCGCCACGCCCCUGAGCUGCUCAAGCACCAGCUUCUAGGAGACCUGCACCAGGAGGGGCCGCCGCUGAAGGGGGCAGGGGGCAAAGAGAGGCCGGGGAGCAAGGAGGAGGUGGAUGAAGACCGCGACGUCGAUGAGUCCUCCCCCCAAGACUCCCCUCCCUCCAAGGCCUCCCCAGCCCAAGAUGGGCGGCCUCCCCAGACAGCCGCCAGAGAAGCCACCAGCAUCCCAGGCUUCCCAGCGGAGGGUGCCAUCCCCCUCCCUGUGGAUUUCCUCUCCAAAGUUUCCACAGAGAUCCCAGCCUCAGAGCCCGACGGGCCCAGUGUAGGGCGGGCCAAAGGGCAGGAUGCCCCCCUGGAGUUCACGUUUCACGUGGAAAUCACACCCAACGUGCAGAAGGAGCAGGCGCACUCGGAGGAGCAUUUGGGAAGGGCUGCAUUUCCAGGGGCCCCUGGAGAGGGGCCAGAGGCCCGGGGCCCCUCUUUGGGAGAGGACACAAAAGAGGCUGACCUUCCAGAGCCCUCUGAAAAGCAGCCUGCUGCUGCUCCGCGGGGGAAGCCCGUCAGCCGGGUCCCUCAACUCAAAGCUCGCAUGGUCAGUAAAAGCAAAGACGGGACUGGAAGCGAUGACAAAAAAGCCAAGACAUCCACACGUUCCUCUGCUAAAACCUUGAAAAAUAGGCCUUGCCUUAGCCCCAAACACCCCACUCCUGGUAGCUCAGACCCUCUGAUCCAACCCUCCAGCCCUGCUGUGUGCCCAGAGCCACCUUCCUCUCCUAAAUACGUCUCUUCUGUCACUUCCCGAACUGGCAGUUCUGGAGCAAAGGAGAUGAAACUCAAGGGGGCUGAUGGUAAAACGAAGAUCGCCACACCGCGGGGAGCAGCCCCUCCAGGCCAGAAGGGCCAGGCCAACGCCACCAGGAUUCCAGCAAAAACCCCGCCCGCUCCAAAGACACCACCCAGCUCUGCGACUAAGCAAGUCCAGAGAAGACCACCCCCUGCAGGGCCCAGAUCUGAGAGAGGUGAACCUCCAAAAUCAGGGGAUCGCAGCGGCUACAGCAGCCCCGGCUCCCCAGGCACUCCCGGCAGCCGCUCCCGCACCCCGUCCCUUCCAACCCCACCCACCCGGGAGCCCAAGAAGGUGGCAGUGGUCCGUACUCCACCCAAGUCGCCGUCUUCCGCCAAGAGCCGCCUGCAGACAGCCCCCGUGCCCAUGCCAGACCUGAAGAAUGUCAAGUCCAAGAUCGGCUCCACUGAGAACCUGAAGCACCAGCCGGGAGGCGGGAAGGUGCAGAUAAUUAAUAAGAAGCUGGAUCUUAGCAACGUCCAGUCCAAGUGUGGCUCAAAGGAUAAUAUCAAACACGUCCCGGGAGGCGGCAGUGUGCAAAUAGUCUACAAACCAGUUGACCUGAGCAAGGUGACCUCCAAGUGUGGCUCAUUAGGCAACAUCCAUCAUAAACCAGGAGGUGGCCAGGUGGAAGUAAAAUCUGAGAAGCUUGACUUCAAGGACAGAGUCCAGUCGAAGAUUGGGUCCCUGGACAAUAUCACCCACGUCCCUGGCGGAGGAAAUAAAAAGAUUGAAACCCACAAGCUGACCUUCCGCGAGAACGCCAAAGCCAAGACAGACCACGGGGCGGAGAUCGUGUACAAGUCGCCAGUGGUGUCUGGGGACACGUCUCCACGGCAUCUCAGCAAUGUCUCCUCCACCGGCAGCAUCGACAUGGUAGACUCGCCCCAGCUCGCCACGCUAGCUGACGAGGUGUCUGCCUCCCUGGCCAAGCAGGGUUUGUGAUCAGGCCCCUGGGGCGGUCAAUAAUUGUGGAGAGGAGAGAAUGAGAGAGUGUGGAAAAAAAAAGAAUAAUGACCCGGCCCCCGCCCUCUGCCCCCAGCUGCUCCUCGCAGUUCGGUUAAUUGGUUAAUCACUUAACCUGCUUUUGUCACUCGGCUUUGGCUCGGGACUUCAAAAUCAGUGAUGGGAGUAAGAGCAAAUUUCAUCUUUCCAAAUUGAUGGGUGGGCUAGUAAUAAAAUAUUUAAAAAAAAACAUUCAAAAACAUGGCCACAUCCAACAUUUCCUCAGGCAAUUCCUUUUGAUUCUUUUUUCUUCCCCCUCCAUGUAGAAGAGGGAGAAGGAGAGGCUCUGAAAGCUGCUUCUGGGGGAUUUCAAGGGACUGGGGGUGCCAACCACCUCUGGCCCUGUUGUGGGGGUGUCACAGAGGCAGUGGCAGCAACAAAGGAUUUGAAACUUGGUGUGUUCGUGGAGCCACAGGCAGACGAUGUCAACCUUGUGUGAGUGUGACGGGGGUUGGGGUGGGGCGGGAGGCCACGGGGGAGGCCGAGGCAGGGGCUGGGCAGAGGGGAGAGGAAGCACAAGAAGUGGGAGUGGGAGAGGAAGCCACGUGCUGGAGAGUAGACAUCCCCCUCCUUGCCGCUGGGAGAGCCAAGGCCUAUGCCACCUGCAGCGUCUGAGCGGCCGCCUGUCCUUGGUGGCCGGGGGUGGGGGCCUGCUGUGGGUCAGUGUGCCACCCUCUGCAGGGCAGCCUGUGGGAGAAGGGACAGCGGGUAAAAAGAGAAGGCAAGCUGGCAGGAGGGUGGCACUUCGUGGAUGACCUCCUUAGAAAAGACUGACCUUGAUGUCUUGAGAGCGCUGGCCUCUUCCUCCCUCCCUGCAGGGUAGGGGGCCUGAGUUGAGGGGCUUCCCUCUGCUCCACAGAAACCCUGUUUUAUUGAGUUCUGAAGGUUGGAACUGCUGCCAUGAUUUUGGCCACUUUGCAGACCUGGGACUUUAGGGCUAACCAGUUCUCUUUGUAAGGACUUGUGCCUCUUGGGAGACGUCCACCCGUUUCCAAGCCUGGGCCACUGGCAUCUCUGGAGUGUGUGGGGGUCUGGGAGGCAGGUCCCGAGCCCCCUGUCCUUCCCACGGCCACUGCAGUCACCCCGUCUGCGCCGCUGUGCUGUUGUCUGCCGUGAGAGCCCAAUCACUGCCUAUACCCCUCAUCACACGUCACAAUGUCCCGAAUUCCCAGCCUCACCACCCCUUCUCAGUAAUGACCCUGGUUGGUUGCAGGAGGUACCUACUCCAUACUGAGGGUGAAAUUAAGGGAAGGCAAAGUCCAGGCACAAGAGUGGGACCCCAGCCUCUCACUCUCAGUUCCACUCAUCCAACUGGGACCCUCACCACGAAUCUCAUGAUCUGAUUCGGUUCCCUGUCUCCUCCUCCCGUCACAGAUGUGAGCCAGGGCACUGCUCAGCUGUGACCCUAGGUGUUUCUGCCUUGUUGACAUGGAGAGAGCCCUUUCCCCUGAGAAGGCCUGGCCCCUUCCUGUGCUGAGCCCACAGCAGCAGGCUGGGUGUCUUGGUUGUCAGUGGUGGCACCAGGAUGGAAGGGCAAGGCACCCAGGGCAGGCCCACAGUCCCGCUGUCCCCCACUUGCACCCUAGCUUGUAGCUGCCAACCUCCCAGACAGCCCAGCCCGCUGCUCAGCUCCACAUGCAUAGUAUCAGCCCUCCACACCCGACAAAGGGGAACACACCCCCUUGGAAAUGGUUCUUUUCCCCCAGUCCCAGCUGGAAGCCAUGCUGUCUGUUCUGCUGGAGCAGCUGAACAUAUACAUAGAUGUUGCCCUGCCCUCCCCAUCUGCACCCUGUUGAGUUGUAGUUGGAUUUGUCUGUUUAUGCUUGGAUUCACCAGAGUGACUAUGAUAGUGAAAAGAAAAAAAAAAAAAAAAAAGGACGCAUGUAUCUUGAAAUGCUUGUAAAGAGGUUUCUAACCCACCCUCACGAGGUGUCUCUCACCCCCACACUGGGACUCGUGUGGCCUGUGUGGUGCCACCCUGCUGGGGCCUCCCAAGUUUUGAAAGGCUUUCCUCAGCACCUGGGACCCAACAGAGACCAGCUUCUAGCAGCUAAGGAGGCCGUUCAGCUGUGACGAAGGCCUGAAGCACAGGAUUAGGACUGAAGCGAUGAUGUCCCCUUCCCUACUUCCCCUUGGGGCUCCCUGUGUCAGGGCACAGACUAGGUCUUGUGGCUGGUCUGGCUUGCGGCGCGAGGAUGGUUCUCUCUGGUCAUAGCCCGAAGUCUCAUGGCAGUCCCAAAGGAGGCUUACAACUCCUGCAUCACAAGAAAAAGGAAGCCACUGCCAGCUGGGGGGAUCUGCAGCUCCCAGAAGCUCCGUGAGCCUCAGCCACCCCUCAGACUGGGUUCCUCUCCAAGCUCGCCCUCUGGAGGGGCAGCGCAGCCUCCCACCAAGGGCCCUGCGACCACAGCAGGGAUUGGGAUGAAUUGCCUGUCCUGGAUCUGCUCUAGAGGCCCAAGCUGCCUGCCUGAGGAAGGAUGACUUGACAAGUCAGGAGACACUGUUCCCAAAGCCUUGACCAGAGCACCUCAGCCCGCUGACCUUGCACAAACUCCAUCUGCUGCCAUGAGAAAAGGGAAGCCGCCUUUGCAAAACAUUGCUGCCUAAAGAAACUCAGCAGCCUCAGGCCCAAUUCUGCCACUUCUGGUUUGGGUACAGUUAAAGGCAACCCUGAGGGACUUGGCAGUAGAAAUCCAGGGCCUCCCCUGGGGCUGGCAGCUUCGUGUGCAGCUAGAGCUUUACCUGAAAGGAAGUCUCUGGGCCCAGAACUCUCCACCAAGAGCCUCCCUGCCGUUCGCUGAGUCCCAGCAAUUCUCCUAAGUUGAAGGGAUCUGAGAAGGAGAAGGAAAUGUGGGGUAGAUUUGGUGGUGGUUAGAGAUAUGCCCCCCUCAUUACUGCCAACAGUUUCGGCUGCAUUUCUUCACGCACCUCGGUUCCUCUUCCUGAAGUUCUUGUGCCCUGCUCUUCAGCACCAUGGGCCUUCUUAUACGGAAGGCUCUGGGAUCUCCCCCUUGUGGGGCAGGCUCUUGGGGCCAGCCUAAGAUCAUGGUUUAGGGUGAUCAGUGCUGGCAGAUAAAUUGAAAAGGCACGCUGGCUUGUGAUCUUAAAUGAGGACAAUCCCCCCAGGGCUGGGCACUCCUCCCCUCCCCUCACUUCUCCCACCUGCAGAGCCAGUGUCCUUGGGUGGGCUAGAUAGGAUAUACUGUAUGCCGGCUCCUUCAAGCUGCUGACUCACUUUAUCAAUAGUUCCAUUUAAAUUGACUUCAGUGGUGAGACUGUAUCCUGUUUGCUAUUGCUUGUUGUGCUAUGGGGGGAGGGGGGAGGAAUGUGUAAGAUAGUUAACAUGGGCAAAGGGAGAUCUUGGGGUGCAGCACUUAAACUGCCUCGUAACCCUUUUCAUGAUUUCAACCACAUUUGCUAGAGGGAGGGAGCAGCCACGGAGUUAGAGGCCCUUGGGGUUUCUCUUUUCCACUGACAGGCUUUCCCAGGCAGCUGGCUAGUUCAUUCCCUCCCCAGCCAGGUGCAGGCGUAGGAAUAUGGACAUCUGGUUGCUUUGGCCUGCUGCCCUCUUUCAGGGGUCCUAAGCCCACAAUCAUGCCUCCCUAAGACCUUGGCAUCCUUCCCUCUAAGCCGUUGGCACCUCUGUGCCACCUCUCACACUGGCUCCAGACACACAGCCUGUGCUUUUGGAGCUGAGAUCACUCGCUUCACCCUCCUCAUCUUUGUUCUCCAAGUAAAGCCACGAGGUCGGGGCGAGGGCAGAGGUGAUCACCUGCGUGUCCCAUCUACAGACCUGCAGCUUCAUAAAACUUCUGAUUUCUCUUCAGCUUUGAAAAGGGUUACCCUGGGCACUGGCCUAGAGCCUCACCUCCUAAUAGACUUAGCCCCAUGAGUUUGCCAUGUUGAGCAGGACUAUUUCUGGCACUUGCAAGUCCCAUGAUUUCUUCGGUAAUUCUGAGGGUGGGGGGAGGGACAUGAAAUCAUCUUAGCUUAGCUUUCUGUCUGUGAAUGUCUAUAUAGUGUAUUGUGUGUUUUAACAAAUGAUUUACACUGACUGUUGCUGUAAAAGUGAAUUUGGAAAUAAAGUUAUUACUCUGAUUAAA,mRNA,Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=73aa|residues=454-526
GPGGGPGGSHMGGNYGDDRRGGRGGYDRGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDS
RGEHRQDRRERPY",FUS,RGG3-PY,-,73aa(454-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[454-507],[508-512]",[454-507],In vitro,2.5-30 µM [FUS RGG3-PY];|add MAPT at a molar ratio of 1:50,75 mM NaCl,"20 mM Na2HPO4/NaH2PO4, pH 7.5, 2.5% glycerol, 1 mM DTT",0-40˚C,-,-,Microscopy,"liquid, solute","In the presence of substoichiometric amounts of RNA, RGG3-PY formed liquid droplets in a concentration- and temperature-dependent manner. KGG3-PY remained completely dispersed and did not form any visible droplets under conditions that induced large RGG3-PY droplets. This demonstrates that arginines in RGG motifs are crucial for LLPS of the RGG3-PY domain."
195,PMID: 29677514,RNAPS0000029,https://pubmed.ncbi.nlm.nih.gov/29677514,RNA + protein,NCBI ID:4137,https://www.ncbi.nlm.nih.gov/gene/4137,MAPT,6644nt(1-6644),GCAGUCACCGCCACCCACCAGCUCCGGCACCAACAGCAGCGCCGCUGCCACCGCCCACCUUCUGCCGCCGCCACCACAGCCACCUUCUCCUCCUCCGCUGUCCUCUCCCGUCCUCGCCUCUGUCGACUAUCAGGUGAACUUUGAACCAGGAUGGCUGAGCCCCGCCAGGAGUUCGAAGUGAUGGAAGAUCACGCUGGGACGUACGGGUUGGGGGACAGGAAAGAUCAGGGGGGCUACACCAUGCACCAAGACCAAGAGGGUGACACGGACGCUGGCCUGAAAGAAUCUCCCCUGCAGACCCCCACUGAGGACGGAUCUGAGGAACCGGGCUCUGAAACCUCUGAUGCUAAGAGCACUCCAACAGCGGAAGAUGUGACAGCACCCUUAGUGGAUGAGGGAGCUCCCGGCAAGCAGGCUGCCGCGCAGCCCCACACGGAGAUCCCAGAAGGAACCACAGCUGAAGAAGCAGGCAUUGGAGACACCCCCAGCCUGGAAGACGAAGCUGCUGGUCACGUGACCCAAGAGCCUGAAAGUGGUAAGGUGGUCCAGGAAGGCUUCCUCCGAGAGCCAGGCCCCCCAGGUCUGAGCCACCAGCUCAUGUCCGGCAUGCCUGGGGCUCCCCUCCUGCCUGAGGGCCCCAGAGAGGCCACACGCCAACCUUCGGGGACAGGACCUGAGGACACAGAGGGCGGCCGCCACGCCCCUGAGCUGCUCAAGCACCAGCUUCUAGGAGACCUGCACCAGGAGGGGCCGCCGCUGAAGGGGGCAGGGGGCAAAGAGAGGCCGGGGAGCAAGGAGGAGGUGGAUGAAGACCGCGACGUCGAUGAGUCCUCCCCCCAAGACUCCCCUCCCUCCAAGGCCUCCCCAGCCCAAGAUGGGCGGCCUCCCCAGACAGCCGCCAGAGAAGCCACCAGCAUCCCAGGCUUCCCAGCGGAGGGUGCCAUCCCCCUCCCUGUGGAUUUCCUCUCCAAAGUUUCCACAGAGAUCCCAGCCUCAGAGCCCGACGGGCCCAGUGUAGGGCGGGCCAAAGGGCAGGAUGCCCCCCUGGAGUUCACGUUUCACGUGGAAAUCACACCCAACGUGCAGAAGGAGCAGGCGCACUCGGAGGAGCAUUUGGGAAGGGCUGCAUUUCCAGGGGCCCCUGGAGAGGGGCCAGAGGCCCGGGGCCCCUCUUUGGGAGAGGACACAAAAGAGGCUGACCUUCCAGAGCCCUCUGAAAAGCAGCCUGCUGCUGCUCCGCGGGGGAAGCCCGUCAGCCGGGUCCCUCAACUCAAAGCUCGCAUGGUCAGUAAAAGCAAAGACGGGACUGGAAGCGAUGACAAAAAAGCCAAGACAUCCACACGUUCCUCUGCUAAAACCUUGAAAAAUAGGCCUUGCCUUAGCCCCAAACACCCCACUCCUGGUAGCUCAGACCCUCUGAUCCAACCCUCCAGCCCUGCUGUGUGCCCAGAGCCACCUUCCUCUCCUAAAUACGUCUCUUCUGUCACUUCCCGAACUGGCAGUUCUGGAGCAAAGGAGAUGAAACUCAAGGGGGCUGAUGGUAAAACGAAGAUCGCCACACCGCGGGGAGCAGCCCCUCCAGGCCAGAAGGGCCAGGCCAACGCCACCAGGAUUCCAGCAAAAACCCCGCCCGCUCCAAAGACACCACCCAGCUCUGCGACUAAGCAAGUCCAGAGAAGACCACCCCCUGCAGGGCCCAGAUCUGAGAGAGGUGAACCUCCAAAAUCAGGGGAUCGCAGCGGCUACAGCAGCCCCGGCUCCCCAGGCACUCCCGGCAGCCGCUCCCGCACCCCGUCCCUUCCAACCCCACCCACCCGGGAGCCCAAGAAGGUGGCAGUGGUCCGUACUCCACCCAAGUCGCCGUCUUCCGCCAAGAGCCGCCUGCAGACAGCCCCCGUGCCCAUGCCAGACCUGAAGAAUGUCAAGUCCAAGAUCGGCUCCACUGAGAACCUGAAGCACCAGCCGGGAGGCGGGAAGGUGCAGAUAAUUAAUAAGAAGCUGGAUCUUAGCAACGUCCAGUCCAAGUGUGGCUCAAAGGAUAAUAUCAAACACGUCCCGGGAGGCGGCAGUGUGCAAAUAGUCUACAAACCAGUUGACCUGAGCAAGGUGACCUCCAAGUGUGGCUCAUUAGGCAACAUCCAUCAUAAACCAGGAGGUGGCCAGGUGGAAGUAAAAUCUGAGAAGCUUGACUUCAAGGACAGAGUCCAGUCGAAGAUUGGGUCCCUGGACAAUAUCACCCACGUCCCUGGCGGAGGAAAUAAAAAGAUUGAAACCCACAAGCUGACCUUCCGCGAGAACGCCAAAGCCAAGACAGACCACGGGGCGGAGAUCGUGUACAAGUCGCCAGUGGUGUCUGGGGACACGUCUCCACGGCAUCUCAGCAAUGUCUCCUCCACCGGCAGCAUCGACAUGGUAGACUCGCCCCAGCUCGCCACGCUAGCUGACGAGGUGUCUGCCUCCCUGGCCAAGCAGGGUUUGUGAUCAGGCCCCUGGGGCGGUCAAUAAUUGUGGAGAGGAGAGAAUGAGAGAGUGUGGAAAAAAAAAGAAUAAUGACCCGGCCCCCGCCCUCUGCCCCCAGCUGCUCCUCGCAGUUCGGUUAAUUGGUUAAUCACUUAACCUGCUUUUGUCACUCGGCUUUGGCUCGGGACUUCAAAAUCAGUGAUGGGAGUAAGAGCAAAUUUCAUCUUUCCAAAUUGAUGGGUGGGCUAGUAAUAAAAUAUUUAAAAAAAAACAUUCAAAAACAUGGCCACAUCCAACAUUUCCUCAGGCAAUUCCUUUUGAUUCUUUUUUCUUCCCCCUCCAUGUAGAAGAGGGAGAAGGAGAGGCUCUGAAAGCUGCUUCUGGGGGAUUUCAAGGGACUGGGGGUGCCAACCACCUCUGGCCCUGUUGUGGGGGUGUCACAGAGGCAGUGGCAGCAACAAAGGAUUUGAAACUUGGUGUGUUCGUGGAGCCACAGGCAGACGAUGUCAACCUUGUGUGAGUGUGACGGGGGUUGGGGUGGGGCGGGAGGCCACGGGGGAGGCCGAGGCAGGGGCUGGGCAGAGGGGAGAGGAAGCACAAGAAGUGGGAGUGGGAGAGGAAGCCACGUGCUGGAGAGUAGACAUCCCCCUCCUUGCCGCUGGGAGAGCCAAGGCCUAUGCCACCUGCAGCGUCUGAGCGGCCGCCUGUCCUUGGUGGCCGGGGGUGGGGGCCUGCUGUGGGUCAGUGUGCCACCCUCUGCAGGGCAGCCUGUGGGAGAAGGGACAGCGGGUAAAAAGAGAAGGCAAGCUGGCAGGAGGGUGGCACUUCGUGGAUGACCUCCUUAGAAAAGACUGACCUUGAUGUCUUGAGAGCGCUGGCCUCUUCCUCCCUCCCUGCAGGGUAGGGGGCCUGAGUUGAGGGGCUUCCCUCUGCUCCACAGAAACCCUGUUUUAUUGAGUUCUGAAGGUUGGAACUGCUGCCAUGAUUUUGGCCACUUUGCAGACCUGGGACUUUAGGGCUAACCAGUUCUCUUUGUAAGGACUUGUGCCUCUUGGGAGACGUCCACCCGUUUCCAAGCCUGGGCCACUGGCAUCUCUGGAGUGUGUGGGGGUCUGGGAGGCAGGUCCCGAGCCCCCUGUCCUUCCCACGGCCACUGCAGUCACCCCGUCUGCGCCGCUGUGCUGUUGUCUGCCGUGAGAGCCCAAUCACUGCCUAUACCCCUCAUCACACGUCACAAUGUCCCGAAUUCCCAGCCUCACCACCCCUUCUCAGUAAUGACCCUGGUUGGUUGCAGGAGGUACCUACUCCAUACUGAGGGUGAAAUUAAGGGAAGGCAAAGUCCAGGCACAAGAGUGGGACCCCAGCCUCUCACUCUCAGUUCCACUCAUCCAACUGGGACCCUCACCACGAAUCUCAUGAUCUGAUUCGGUUCCCUGUCUCCUCCUCCCGUCACAGAUGUGAGCCAGGGCACUGCUCAGCUGUGACCCUAGGUGUUUCUGCCUUGUUGACAUGGAGAGAGCCCUUUCCCCUGAGAAGGCCUGGCCCCUUCCUGUGCUGAGCCCACAGCAGCAGGCUGGGUGUCUUGGUUGUCAGUGGUGGCACCAGGAUGGAAGGGCAAGGCACCCAGGGCAGGCCCACAGUCCCGCUGUCCCCCACUUGCACCCUAGCUUGUAGCUGCCAACCUCCCAGACAGCCCAGCCCGCUGCUCAGCUCCACAUGCAUAGUAUCAGCCCUCCACACCCGACAAAGGGGAACACACCCCCUUGGAAAUGGUUCUUUUCCCCCAGUCCCAGCUGGAAGCCAUGCUGUCUGUUCUGCUGGAGCAGCUGAACAUAUACAUAGAUGUUGCCCUGCCCUCCCCAUCUGCACCCUGUUGAGUUGUAGUUGGAUUUGUCUGUUUAUGCUUGGAUUCACCAGAGUGACUAUGAUAGUGAAAAGAAAAAAAAAAAAAAAAAAGGACGCAUGUAUCUUGAAAUGCUUGUAAAGAGGUUUCUAACCCACCCUCACGAGGUGUCUCUCACCCCCACACUGGGACUCGUGUGGCCUGUGUGGUGCCACCCUGCUGGGGCCUCCCAAGUUUUGAAAGGCUUUCCUCAGCACCUGGGACCCAACAGAGACCAGCUUCUAGCAGCUAAGGAGGCCGUUCAGCUGUGACGAAGGCCUGAAGCACAGGAUUAGGACUGAAGCGAUGAUGUCCCCUUCCCUACUUCCCCUUGGGGCUCCCUGUGUCAGGGCACAGACUAGGUCUUGUGGCUGGUCUGGCUUGCGGCGCGAGGAUGGUUCUCUCUGGUCAUAGCCCGAAGUCUCAUGGCAGUCCCAAAGGAGGCUUACAACUCCUGCAUCACAAGAAAAAGGAAGCCACUGCCAGCUGGGGGGAUCUGCAGCUCCCAGAAGCUCCGUGAGCCUCAGCCACCCCUCAGACUGGGUUCCUCUCCAAGCUCGCCCUCUGGAGGGGCAGCGCAGCCUCCCACCAAGGGCCCUGCGACCACAGCAGGGAUUGGGAUGAAUUGCCUGUCCUGGAUCUGCUCUAGAGGCCCAAGCUGCCUGCCUGAGGAAGGAUGACUUGACAAGUCAGGAGACACUGUUCCCAAAGCCUUGACCAGAGCACCUCAGCCCGCUGACCUUGCACAAACUCCAUCUGCUGCCAUGAGAAAAGGGAAGCCGCCUUUGCAAAACAUUGCUGCCUAAAGAAACUCAGCAGCCUCAGGCCCAAUUCUGCCACUUCUGGUUUGGGUACAGUUAAAGGCAACCCUGAGGGACUUGGCAGUAGAAAUCCAGGGCCUCCCCUGGGGCUGGCAGCUUCGUGUGCAGCUAGAGCUUUACCUGAAAGGAAGUCUCUGGGCCCAGAACUCUCCACCAAGAGCCUCCCUGCCGUUCGCUGAGUCCCAGCAAUUCUCCUAAGUUGAAGGGAUCUGAGAAGGAGAAGGAAAUGUGGGGUAGAUUUGGUGGUGGUUAGAGAUAUGCCCCCCUCAUUACUGCCAACAGUUUCGGCUGCAUUUCUUCACGCACCUCGGUUCCUCUUCCUGAAGUUCUUGUGCCCUGCUCUUCAGCACCAUGGGCCUUCUUAUACGGAAGGCUCUGGGAUCUCCCCCUUGUGGGGCAGGCUCUUGGGGCCAGCCUAAGAUCAUGGUUUAGGGUGAUCAGUGCUGGCAGAUAAAUUGAAAAGGCACGCUGGCUUGUGAUCUUAAAUGAGGACAAUCCCCCCAGGGCUGGGCACUCCUCCCCUCCCCUCACUUCUCCCACCUGCAGAGCCAGUGUCCUUGGGUGGGCUAGAUAGGAUAUACUGUAUGCCGGCUCCUUCAAGCUGCUGACUCACUUUAUCAAUAGUUCCAUUUAAAUUGACUUCAGUGGUGAGACUGUAUCCUGUUUGCUAUUGCUUGUUGUGCUAUGGGGGGAGGGGGGAGGAAUGUGUAAGAUAGUUAACAUGGGCAAAGGGAGAUCUUGGGGUGCAGCACUUAAACUGCCUCGUAACCCUUUUCAUGAUUUCAACCACAUUUGCUAGAGGGAGGGAGCAGCCACGGAGUUAGAGGCCCUUGGGGUUUCUCUUUUCCACUGACAGGCUUUCCCAGGCAGCUGGCUAGUUCAUUCCCUCCCCAGCCAGGUGCAGGCGUAGGAAUAUGGACAUCUGGUUGCUUUGGCCUGCUGCCCUCUUUCAGGGGUCCUAAGCCCACAAUCAUGCCUCCCUAAGACCUUGGCAUCCUUCCCUCUAAGCCGUUGGCACCUCUGUGCCACCUCUCACACUGGCUCCAGACACACAGCCUGUGCUUUUGGAGCUGAGAUCACUCGCUUCACCCUCCUCAUCUUUGUUCUCCAAGUAAAGCCACGAGGUCGGGGCGAGGGCAGAGGUGAUCACCUGCGUGUCCCAUCUACAGACCUGCAGCUUCAUAAAACUUCUGAUUUCUCUUCAGCUUUGAAAAGGGUUACCCUGGGCACUGGCCUAGAGCCUCACCUCCUAAUAGACUUAGCCCCAUGAGUUUGCCAUGUUGAGCAGGACUAUUUCUGGCACUUGCAAGUCCCAUGAUUUCUUCGGUAAUUCUGAGGGUGGGGGGAGGGACAUGAAAUCAUCUUAGCUUAGCUUUCUGUCUGUGAAUGUCUAUAUAGUGUAUUGUGUGUUUUAACAAAUGAUUUACACUGACUGUUGCUGUAAAAGUGAAUUUGGAAAUAAAGUUAUUACUCUGAUUAAA,mRNA,Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=73aa|residues=454-526|mutation=R473,476,481,487,491,495,498,503K
GPGGGPGGSHMGGNYGDDRKGGKGGYDKGGYRGKGGDKGGFKGGKGGGDKGGFGPGKMDS
RGEHRQDRRERPY",FUS,RGG3-PY,"protein_mutation:R473,476,481,487,491,495,498,503K",73aa(454-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[454-470],[475-485],[491-492],[505-526]",-,In vitro,60 µM [FUS KGG3-PY];|add MAPT at a molar ratio of 1:50,75 mM NaCl,"20 mM Na2HPO4/NaH2PO4, pH 7.5, 2.5% glycerol, 1 mM DTT",25˚C,-,-,Confocal microscopy,solute,"In the presence of substoichiometric amounts of RNA, RGG3-PY formed liquid droplets in a concentration- and temperature-dependent manner. KGG3-PY remained completely dispersed and did not form any visible droplets under conditions that induced large RGG3-PY droplets. This demonstrates that arginines in RGG motifs are crucial for LLPS of the RGG3-PY domain."
196,PMID: 29772202,RNAPS0000174,https://pubmed.ncbi.nlm.nih.gov/29772202,RNA + protein,-,-,AU rich RNA,-,-,nucleotide rich RNA,Escherichia coli,"sp|Q8SWR8|ATX2_DROME Ataxin-2 homolog OS=Drosophila melanogaster OX=7227 GN=Atx2 PE=1 SV=1|length=400aa|residues=351-750
DGSMMMQSGGGSGQGGSTQSTAALMLAGGLKGVGPAPSANASADSSSKYSGGSMVKRKTV
PQGGKVMRNNVPTGGSNVSVSQGGNGNSVGQNKGGYQPSMGMPSQYSYQGNSQIMHGSSQ
YRNQSHMGGANKLNGDSNANTNKPLPQRQMRQYQGSQSNSSLNYGGEPQSLGKPVHGSHG
GHPGQNSNSPPLQTAGPQQQQQQQQQQQQQQQQQQPPQQQQHQNIQPQGQNTQPARQVRT
RDNQMQELRQFGQDFQLAPSNTSPPQQQQQQQQQQQQHQVQQQQQRALQQSASPPQQQQQ
QQQQQQHVVLHQVPQTHLHQAALSQPHYVPQQQPQQAPLPQQQHVPHHMQQKAQQQQLVE
TQHQHVQKQHQSQPQVQQPPPQLLQDPSQQPLPIYHTMPP",Atx2,mIDR,-,400aa(351-750),Q8SWR8,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q8SWR8,http://llps.biocuckoo.cn/view.php?id=LLPS-Drm-0117,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0290,http://db.phasep.pro/browse/",[351-750],"[351-371],[384-403],[424-445],[540-584],[613-670],[675-743],[749-750]",In vitro,10 µM [Atx2 mIDR];|2 µM RNA,300mM NaCl,20 mM Tris pH 8.0 and 1mM DTT,RT,> 1 h,crowding agent:10% PEG3350,Confocal microscopy,liquid,"Purified mIDR of Atx2 protein did not show LLPSs at 10 μM concentration (300 mM NaCl and 10% PEG3350). In the presence of 2 μM AU-rich RNA, the mIDR-containing fragment showed robust phase separation, consistent with a model in which RNA serves to stabilize and template multivalent interactions required for LLPS. If the PD and pQ elements are deleted, then this protein fragment fails to show LLPS with or without RNA, demonstrating that the predicted prion and pQ sequences of the protein affect the RNA-dependent phase separation. We also observed that the cIDR polypeptide showed robust RNA-independent LLPS in vitro, suggesting that this region is also capable of mediating protein-protein interactions that contribute to RNP-granule formation."
197,PMID: 29772202,RNAPS0000174,https://pubmed.ncbi.nlm.nih.gov/29772202,RNA + protein,-,-,AU rich RNA,-,-,nucleotide rich RNA,Escherichia coli,"sp|Q8SWR8|ATX2_DROME Ataxin-2 homolog OS=Drosophila melanogaster OX=7227 GN=Atx2 PE=1 SV=1|length=181aa|residues=900-1080
PPAANQPIYVMQPQHPFPPQTHPQAGQPPRLRRSNYPPMAASQMHVSASAATGQPLITAG
PIPQFIQYGHAPHQQQFQSHTYAPMQMRVYPDQPQQLQFMTQTPQSTTPSPGQPHQQFHP
PPQPSPAGGGPQPAFTPPTQAATYQLMCVHPQSLLANHYFPPPTPQHPQQNQQQYQIVMQ
Q",Atx2,cIDR,-,181aa(900-1080),Q8SWR8,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q8SWR8,http://llps.biocuckoo.cn/view.php?id=LLPS-Drm-0117,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0290,http://db.phasep.pro/browse/","[900-936],[1000-1037],[1057-1080]","[911-923],[1000-1044],[1060-1080]",In vitro,10 µM [Atx2 cIDR];|2 µM RNA,300mM NaCl,20 mM Tris pH 8.0 and 1mM DTT,RT,> 1 h,crowding agent:10% PEG3350,Confocal microscopy,liquid,"Purified mIDR of Atx2 protein did not show LLPSs at 10 μM concentration (300 mM NaCl and 10% PEG3350). In the presence of 2 μM AU-rich RNA, the mIDR-containing fragment showed robust phase separation, consistent with a model in which RNA serves to stabilize and template multivalent interactions required for LLPS. If the PD and pQ elements are deleted, then this protein fragment fails to show LLPS with or without RNA, demonstrating that the predicted prion and pQ sequences of the protein affect the RNA-dependent phase separation. We also observed that the cIDR polypeptide showed robust RNA-independent LLPS in vitro, suggesting that this region is also capable of mediating protein-protein interactions that contribute to RNP-granule formation."
198,PMID: 29772202,RNAPS0000174,https://pubmed.ncbi.nlm.nih.gov/29772202,RNA + protein,-,-,AU rich RNA,-,-,nucleotide rich RNA,Escherichia coli,"sp|Q8SWR8|ATX2_DROME Ataxin-2 homolog OS=Drosophila melanogaster OX=7227 GN=Atx2 PE=1 SV=1|length=270aa|residues=351-419,441-547,657-750
DGSMMMQSGGGSGQGGSTQSTAALMLAGGLKGVGPAPSANASADSSSKYSGGSMVKRKTV
PQGGKVMRNQNKGGYQPSMGMPSQYSYQGNSQIMHGSSQYRNQSHMGGANKLNGDSNANT
NKPLPQRQMRQYQGSQSNSSLNYGGEPQSLGKPVHGSHGGHPGQNSNSPPLQTAGPHVVL
HQVPQTHLHQAALSQPHYVPQQQPQQAPLPQQQHVPHHMQQKAQQQQLVETQHQHVQKQH
QSQPQVQQPPPQLLQDPSQQPLPIYHTMPP",Atx2,mIDR△PDPQ,-,"270aa(351-419,441-547,657-750)",Q8SWR8,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q8SWR8,http://llps.biocuckoo.cn/view.php?id=LLPS-Drm-0117,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0290,http://db.phasep.pro/browse/","[351-419],[441-547],[657-750]","[351-371],[384-403],[441-445],[540-547],[657-670],[675-743],[749-750]",In vitro,10 µM [Atx2 mIDR△PDPQ];|2 µM RNA,300mM NaCl,20 mM Tris pH 8.0 and 1mM DTT,RT,> 1 h,crowding agent:10% PEG3350,Confocal microscopy,solute,"Purified mIDR of Atx2 protein did not show LLPSs at 10 μM concentration (300 mM NaCl and 10% PEG3350). In the presence of 2 μM AU-rich RNA, the mIDR-containing fragment showed robust phase separation, consistent with a model in which RNA serves to stabilize and template multivalent interactions required for LLPS. If the PD and pQ elements are deleted, then this protein fragment fails to show LLPS with or without RNA, demonstrating that the predicted prion and pQ sequences of the protein affect the RNA-dependent phase separation. We also observed that the cIDR polypeptide showed robust RNA-independent LLPS in vitro, suggesting that this region is also capable of mediating protein-protein interactions that contribute to RNP-granule formation."
199,PMID: 29898402,RNAPS0000030,https://pubmed.ncbi.nlm.nih.gov/29898402,RNA + protein,NCBI ID: 850499,https://www.ncbi.nlm.nih.gov/gene/850499,SEC53,350nt(416-765),CUAUAAGUUGAAUAGUUCAGUCAAAAUUUUGACGGUGUCAUCAGGGGAUUGUACUGAAUGUCCGAUGGUUCUUUCAUCGACAAAAAUUUCGUAAUCGUUACCACCGACCAUAGUCUUGUCACCAAAGAAAUGAAUUUCCUUGAAACCAUCUUUUUCAACGUGUUGCAAACAGUAGGUCUUAUCCCAACCAGCGGGGAAAACGUCGAAAGAGAUUUGGCCACCAAUGGAGAAAGUCAAACCGUAGUCUGGGAAUUCCUUUUUCAAAGCUUCAACGAACUUGGCUCUGAUUUGGUGUUCCUUAUCGUAUCUUUCGAAUUCGUUUCUUUCCUCAGUAGAAGCAUUUCUACCAA,mRNA,yeast,"sp|P32588|PUB1_YEAST Nuclear and cytoplasmic polyadenylated RNA-binding protein PUB1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=PUB1 PE=1 SV=4|length=453aa|residues=1-453
MSENNEEQHQQQQQQQPVAVETPSAVEAPASADPSSEQSVAVEGNSEQAEDNQGENDPSV
VPANAITGGRETSDRVLYVGNLDKAITEDILKQYFQVGGPIANIKIMIDKNNKNVNYAFV
EYHQSHDANIALQTLNGKQIENNIVKINWAFQSQQSSSDDTFNLFVGDLNVNVDDETLRN
AFKDFPSYLSGHVMWDMQTGSSRGYGFVSFTSQDDAQNAMDSMQGQDLNGRPLRINWAAK
RDNNNNNNYQQRRNYGNNNRGGFRQYNSNNNNNMNMGMNMNMNMNMNNSRGMPPSSMGMP
IGAMPLPSQGQPQQSQTIGLPPQVNPQAVDHIIRSAPPRVTTAYIGNIPHFATEADLIPL
FQNFGFILDFKHYPEKGCCFIKYDTHEQAAVCIVALANFPFQGRNLRTGWGKERSNFMPQ
QQQQGGQPLIMNDQQQPVMSEQQQQQQQQQQQQ",PUB1,-,-,453aa(1-453),P32588,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P32588,http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0524,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0004,http://db.phasep.pro/browse/","[1-67],[241-262],[418-453]","[8-16],[103-116],[152-158],[243-297],[307-316],[420-427],[434-452]",In vitro,20 µM [PUB1];|0-183 nM mRNA,183 mM NaCl,"200 mM phosphate buffer (with pH 6.5), 1 mM TCEP",46˚C,> 10 min,crowding agent:20% Ficoll,Fluorescence microscopy,liquid,"When we mixed Pub1 with this RNA and induced phase separation by lowering the pH, we observed that the RNA reduced the number and size of Pub1 condensates (Figures S2J and S2L). Similar findings were made for heat-induced Pub1 assemblies (Figures S2K and S2L)."
200,PMID: 29898402,RNAPS0000030,https://pubmed.ncbi.nlm.nih.gov/29898402,RNA + protein,NCBI ID: 850499,https://www.ncbi.nlm.nih.gov/gene/850499,SEC53,350nt(416-765),CUAUAAGUUGAAUAGUUCAGUCAAAAUUUUGACGGUGUCAUCAGGGGAUUGUACUGAAUGUCCGAUGGUUCUUUCAUCGACAAAAAUUUCGUAAUCGUUACCACCGACCAUAGUCUUGUCACCAAAGAAAUGAAUUUCCUUGAAACCAUCUUUUUCAACGUGUUGCAAACAGUAGGUCUUAUCCCAACCAGCGGGGAAAACGUCGAAAGAGAUUUGGCCACCAAUGGAGAAAGUCAAACCGUAGUCUGGGAAUUCCUUUUUCAAAGCUUCAACGAACUUGGCUCUGAUUUGGUGUUCCUUAUCGUAUCUUUCGAAUUCGUUUCUUUCCUCAGUAGAAGCAUUUCUACCAA,mRNA,yeast,"sp|P32588|PUB1_YEAST Nuclear and cytoplasmic polyadenylated RNA-binding protein PUB1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=PUB1 PE=1 SV=4|length=453aa|residues=1-453
MSENNEEQHQQQQQQQPVAVETPSAVEAPASADPSSEQSVAVEGNSEQAEDNQGENDPSV
VPANAITGGRETSDRVLYVGNLDKAITEDILKQYFQVGGPIANIKIMIDKNNKNVNYAFV
EYHQSHDANIALQTLNGKQIENNIVKINWAFQSQQSSSDDTFNLFVGDLNVNVDDETLRN
AFKDFPSYLSGHVMWDMQTGSSRGYGFVSFTSQDDAQNAMDSMQGQDLNGRPLRINWAAK
RDNNNNNNYQQRRNYGNNNRGGFRQYNSNNNNNMNMGMNMNMNMNMNNSRGMPPSSMGMP
IGAMPLPSQGQPQQSQTIGLPPQVNPQAVDHIIRSAPPRVTTAYIGNIPHFATEADLIPL
FQNFGFILDFKHYPEKGCCFIKYDTHEQAAVCIVALANFPFQGRNLRTGWGKERSNFMPQ
QQQQGGQPLIMNDQQQPVMSEQQQQQQQQQQQQ",PUB1,-,-,453aa(1-453),P32588,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P32588,http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0524,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0004,http://db.phasep.pro/browse/","[1-67],[241-262],[418-453]","[8-16],[103-116],[152-158],[243-297],[307-316],[420-427],[434-452]",In vitro,20 µM [PUB1];|0-183 nM mRNA,183 mM NaCl,"200 mM phosphate buffer (with pH 6.2), 1 mM TCEP",25˚C,-,crowding agent:20% Ficoll,Fluorescence microscopy,liquid,"When we mixed Pub1 with this RNA and induced phase separation by lowering the pH, we observed that the RNA reduced the number and size of Pub1 condensates (Figures S2J and S2L). Similar findings were made for heat-induced Pub1 assemblies (Figures S2K and S2L)."
201,PMID: 29932899,RNAPS0000034,https://pubmed.ncbi.nlm.nih.gov/29932899,RNA + protein,NCBI ID:283131,https://www.ncbi.nlm.nih.gov/gene/283131,NEAT1_antisense,1079nt(12-13k),AGAAUACUCAAGCUAUGCAUCAAGCUUGGUACCGAGGUAACGGCCGCCAGUGUGCUGGAAUUCGCCCUUUUCCGGUAUGGACAGGCAGCUGCAGCCACUACGCAGUUUUACCCCAGUUCCACGGCACAUGAGGAGAGGACCAACAUUAUUCUAUUUUGGCAGCACGUGCUUUCAACCCAUCUCACAAAACAGUGUCACCAACCAGAUGUGCCAAGAGCCAGAGCAGGUGAAGACACCUACAGAUGCUGCCUCCUCUGGACACUGCCUCUGGGUGCCUCAGCUCUGCACCCAGAGGGAUGCAAAAGAGAUCCCCGCAGCACACUUUGAGAUGGCUAGGAAACUGCAAAUAACCUCAAAGCCAUCACUAGAAAAAUGGUUAAAAUGACCAUACCAACACGUACAAUAUGACAUGUUAUAGAGCCAUAAAAAUAACAGUACACCUUGUAUGAUUCCAUUUUAGGGCAGAGAAUAAUAGGAUACAUUUUAGUACAUCCACAGCCAGAAAAUGUCUGAAGGAAUAUAAAUGAAGUUGUCAUUAGUAGUUAUCUUAGGGGUCCGGGAUUAUAGAGGAACUUUUAUCUUCUACAUGGCCUUUUUCUAUAGUGUUUGAAUUUUAAUUACAAGACCAGUGAUUUAUAAAUUCAUACACUCCACAGCCCCAUCCAUUACAAUAGCACAUAAUAUAAUAACAUUAGCCAUGGACUUACCUAAAUCUGCAUAAUUUUGGUCUCUUCAGGACAGUUGCUGCAAUGCAGGCAUAAGCAGAGGACAAAGCCACAGUGUGACCUGGGUGCAGAGCACUGGGUUGGGCAUCACCAGCAGACACAUGACAAAAGCAAUUUAAAAAAUUAUACCUUGACAAAAUUAUACAUGAUUAUAUGUCUUGGACCCUGGGGGCCUUGUCAGCAUUAAGCCCAUGAAUGCUAAAUUCACACACAGAUGACAAGAAUCUACUGUACCAAUUACAGUCUUAGUAGGUCACUGCAUACAUGAUAGAUCAAAGAUGGCAACUAGCAGAAACUUAAGUUUCAUAUAUGGAGCGUCGAAGGGCGAAUUCUGCAGAUAUCCAUCACACUGGC,lncRNA,Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,-,-,-,-,-,-,Immunoblotting,liquid,"Immunoblotting analysis revealed that three essential PSPs (NONO, SFPQ, and RBM14) were specifically precipitated with the sense RNA. Interestingly, FUS nonspecifically bound both to the sense and antisense RNAs (Figure 7B)."
202,PMID: 30100264,RNAPS0000235,https://pubmed.ncbi.nlm.nih.gov/30100264,RNAs + protein,-,-,Saccharomyces cerevisiae RNA,-,-,total RNA,Saccharomyces cerevisiae,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|length=414aa|residues=1-414
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG
NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQ
REPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM",TDP-43,-,-,414aa(1-414),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-414],"[272-314],[321-329],[342-358],[368-404]",In vitro,5 µM [TDP-43];|5 µM RNA,50 mM NaCl,"50 mM HEPES-NaOH (pH 7.5), 5% (v/v) glycerol, 5 mM DTT, 10 mM Tris, pH8, 1mM EDTA",RT,≤ 10 min,crowding agent:100 mg/ml dextran,Microscopy,solute, 
203,PMID: 30110628,RNAPS0000236,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,(UC-rich A4)50,50nt,UUUAUUUCCUUCCUUCCUUCCUUCCUUCCUUCCUUCCUUCCCUCCUUCCU,nucleotide rich RNA,-,RRRR,poly(R)4,-,-,4aa,-,-,-,-,-,In vitro,25 µM [polyR];|1 µM (UC-rich A4)50,150 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,liquid,"In vitro, R4 peptide formed droplets in the presence of low-, but not high-, complexity rIGSRNA (Figure 3E). Increasing [NaCl] to 250 mM was sufficient to rapidly dissolve R4-GFP nucleolar foci and R4 peptide droplets in vivo and in vitro (Figures 3F and S3H)."
204,PMID: 30110628,RNAPS0000236,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,(UC-rich A4)50,50nt,UUUAUUUCCUUCCUUCCUUCCUUCCUUCCUUCCUUCCUUCCCUCCUUCCU,nucleotide rich RNA,-,RRRR,poly(R)4,-,-,4aa,-,-,-,-,-,In vitro,25 µM [polyR];|1 µM (UC-rich A4)50,250 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,solute,"In vitro, R4 peptide formed droplets in the presence of low-, but not high-, complexity rIGSRNA (Figure 3E). Increasing [NaCl] to 250 mM was sufficient to rapidly dissolve R4-GFP nucleolar foci and R4 peptide droplets in vivo and in vitro (Figures 3F and S3H)."
205,PMID: 30110628,RNAPS0000237,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,(CU-rich)100,100nt,UCUGUCUCUGUCUUUGUCUCUCUCUCUCCCUCUCUGCCUGUCUCACUGUGUCUGUCUUCUGUCUUACUCUCUUUCUCUCCCCGUCUGUCUCUCUCUCUCU,nucleotide rich RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=16aa|residues=104-119
GTGRRIHSYRGHLWLF",APP,ACM,-,16aa(104-119),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",-,-,In vitro,25 µM [APP ACM];|1 µM (CU-rich)100,150 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,liquid,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro."
206,PMID: 30110628,RNAPS0000237,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,(CU-rich)100,100nt,UCUGUCUCUGUCUUUGUCUCUCUCUCUCCCUCUCUGCCUGUCUCACUGUGUCUGUCUUCUGUCUUACUCUCUUUCUCUCCCCGUCUGUCUCUCUCUCUCU,nucleotide rich RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=16aa|residues=104-119
GTGRRIHSYRGHLWLF",APP,ACM,-,16aa(104-119),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",-,-,In vitro,25 µM [APP ACM];|1 µM (CU-rich)100,250 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,solute,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro."
207,PMID: 30110628,RNAPS0000238,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,(AG-rich U89)100,100nt,AGAGAGAGAGACAGAGAGAGACAGAGAGAGAGAGAGAGGAGGGAGAGAGAAAAAAGAAAGAAAAAAAGAAAAGAAAAGAAAGAGAAAAUGAAAGAAAAGG,nucleotide rich RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=16aa|residues=104-119
GTGRRIHSYRGHLWLF",APP,ACM,-,16aa(104-119),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",-,-,In vitro,25 µM [APP ACM];|1 µM (AG-rich U89)100,150 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,liquid,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro."
208,PMID: 30110628,RNAPS0000238,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,(AG-rich U89)100,100nt,AGAGAGAGAGACAGAGAGAGACAGAGAGAGAGAGAGAGGAGGGAGAGAGAAAAAAGAAAGAAAAAAAGAAAAGAAAAGAAAGAGAAAAUGAAAGAAAAGG,nucleotide rich RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=16aa|residues=104-119
GTGRRIHSYRGHLWLF",APP,ACM,-,16aa(104-119),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",-,-,In vitro,25 µM [APP ACM];|1 µM (AG-rich U89)100,250 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,solute,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro."
209,PMID: 30110628,RNAPS0000239,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,(CU-rich)100,100nt,UCUGUCUCUGUCUUUGUCUCUCUCUCUCCCUCUCUGCCUGUCUCACUGUGUCUGUCUUCUGUCUUACUCUCUUUCUCUCCCCGUCUGUCUCUCUCUCUCU,nucleotide rich RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=17aa|residues=672-688
DAEFRHDSGYEVHHQKL",β-amyloid,ACM,-,17aa(672-688),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",[672-688],-,In vitro,25 µM [β-amyloid 672-688];|1 µM (CU-rich)100,150 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,liquid,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro."
210,PMID: 30110628,RNAPS0000239,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,(CU-rich)100,100nt,UCUGUCUCUGUCUUUGUCUCUCUCUCUCCCUCUCUGCCUGUCUCACUGUGUCUGUCUUCUGUCUUACUCUCUUUCUCUCCCCGUCUGUCUCUCUCUCUCU,nucleotide rich RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=17aa|residues=672-688
DAEFRHDSGYEVHHQKL",β-amyloid,ACM,-,17aa(672-688),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",[672-688],-,In vitro,25 µM [β-amyloid 672-688];|1 µM (CU-rich)100,250 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,solute,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro."
211,PMID: 30110628,RNAPS0000240,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,(AG-rich U89)100,100nt,AGAGAGAGAGACAGAGAGAGACAGAGAGAGAGAGAGAGGAGGGAGAGAGAAAAAAGAAAGAAAAAAAGAAAAGAAAAGAAAGAGAAAAUGAAAGAAAAGG,nucleotide rich RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=17aa|residues=672-688
DAEFRHDSGYEVHHQKL",β-amyloid,ACM,-,17aa(672-688),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",[672-688],-,In vitro,25 µM [β-amyloid 672-688];|1 µM (AG-rich U89)100,150 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,liquid,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro."
212,PMID: 30110628,RNAPS0000240,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,(AG-rich U89)100,100nt,AGAGAGAGAGACAGAGAGAGACAGAGAGAGAGAGAGAGGAGGGAGAGAGAAAAAAGAAAGAAAAAAAGAAAAGAAAAGAAAGAGAAAAUGAAAGAAAAGG,nucleotide rich RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=17aa|residues=672-688
DAEFRHDSGYEVHHQKL",β-amyloid,ACM,-,17aa(672-688),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",[672-688],-,In vitro,25 µM [β-amyloid 672-688];|1 µM (AG-rich U89)100,250 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,solute,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro."
213,PMID: 30110628,RNAPS0000241,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,"rIGS16RNA-Low complexity (Wang,2018)",50nt,CGAUUGAUUGCGAUCUCAAUUGCCUUUUAGCUUCAUUCAUACCCUGUUAU,irregular RNA,-,RRRR,poly(R)4,-,-,4aa,-,-,-,-,-,In vitro,25 µM [polyR];|1 µM irregular RNA 12,150 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,solute,"In vitro, R4 peptide formed droplets in the presence of low-, but not high-, complexity rIGSRNA (Figure 3E). Increasing [NaCl] to 250 mM was sufficient to rapidly dissolve R4-GFP nucleolar foci and R4 peptide droplets in vivo and in vitro (Figures 3F and S3H)."
214,PMID: 30110628,RNAPS0000242,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,"High complexity-rIGSRNA2 (Wang,2018)",100nt,CCGGGAUUUCAGCCUUUAAAAGCGCGGGCCCUGCCACCUUUCGCUGUGGCCCUUACGCUCAGAAUGACGUGUCCUCUCUGCCGUAGGUUGACUCCUUGAG,irregular RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=16aa|residues=104-119
GTGRRIHSYRGHLWLF",APP,ACM,-,16aa(104-119),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",-,-,In vitro,25 µM [APP ACM];|1 µM irregular RNA 18,150 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,solute,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro."
215,PMID: 30110628,RNAPS0000243,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,"High complexity-rIGSRNA2 (Wang,2018)",100nt,CCGGGAUUUCAGCCUUUAAAAGCGCGGGCCCUGCCACCUUUCGCUGUGGCCCUUACGCUCAGAAUGACGUGUCCUCUCUGCCGUAGGUUGACUCCUUGAG,irregular RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=17aa|residues=672-688
DAEFRHDSGYEVHHQKL",β-amyloid,ACM,-,17aa(672-688),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",[672-688],-,In vitro,25 µM [β-amyloid 672-688];|1 µM irregular RNA 18,150 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,solute,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro."
216,PMID: 30110628,RNAPS0000244,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,"UC RNA(Loughlin,2021)",100nt,CCGGCCCGCCUGGUCUUCUGUCUCUGCGCUCUGGUGACCUCAGCCUCCCAAAUAGCUGGGACUACAGGGAUCUCUUAAGCCCGGGAGGGAGAGGUUAACG,nucleotide rich RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=16aa|residues=104-119
GTGRRIHSYRGHLWLF",APP,ACM,-,16aa(104-119),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",-,-,In vitro,"25 µM [APP ACM];|1 µM UC RNA(Loughlin,2021)",150 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,solute,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro."
217,PMID: 30110628,RNAPS0000245,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,"UC RNA(Loughlin,2021)",100nt,CCGGCCCGCCUGGUCUUCUGUCUCUGCGCUCUGGUGACCUCAGCCUCCCAAAUAGCUGGGACUACAGGGAUCUCUUAAGCCCGGGAGGGAGAGGUUAACG,nucleotide rich RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=17aa|residues=672-688
DAEFRHDSGYEVHHQKL",β-amyloid,ACM,-,17aa(672-688),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",[672-688],-,In vitro,"25 µM [β-amyloid 672-688];|1 µM UC RNA(Loughlin,2021)",150 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,solute,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro."
218,PMID: 30197298,RNAPS0000246,https://pubmed.ncbi.nlm.nih.gov/30197298,RNA + protein,-,-,polyA,-,-,poly RNA,-,"tr|Q9A749|Q9A749_CAUVC Ribonuclease E OS=Caulobacter vibrioides (strain ATCC 19089 / CB15) OX=190650 GN=rne PE=1 SV=1|length=448aa|residues=451-898
TGVLEGTTHVCEHCEGTGRVRSVESSALAALRAVEAEALKGSGSVILKVSRSVGLYILNE
KRDYLQRLLTTHGLFVSVVVDDSLHAGDQEIERTELGERIAVAPPPFVEEDDDFDPNAYD
DEEEEDDVILDDEDDTDREDTDDDDATTRKSARDDERGDRKGRRGRRDRNRGRGRRDERD
GETESEDEDVVAEGADEDRGEFGDDDEGGRRRRRRGRRGGRRGGREDGDRPTDAFVWIRP
RVPFGENVFTWHDPAALVGGGESRRQAPEPRVDAATEAAPRPERAEREERPGRERGRRGR
DRGRRQRDEAPVAEMTSVESATVEAAEPFEAPILAPPVIAGPPADVWVELPEVEEAPKKP
KRSRARGKKATETSVEAIDTVTEVAAEAPAPETAEPEAVEVAPPAPTVEAAPEPGPVVEA
VEEAQPAEPDPNEITAPPEKPRRGWWRR",rne,CTD,-,448aa(451-898),Q9A749,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9A749,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0174,http://db.phasep.pro/browse/","[545-686],[706-774],[802-828],[856-884],[890-892],[898-898]","[469-489],[554-680],[727-761],[830-879]",In vitro,12.4 µM [rne CTD];|10 µg/mL polyA,≤25 mM NaCl,20 mM Tris-Cl pH 7.4,4˚C,≤ 1 h,-,Microscopy,solute,"Because in vivo RNase E foci required the presence of RNA, whether addition of RNA could induce LLPS of the CTD-YFP protein in vitro was tested. Addition of 5–175 mg/mL poly-A RNA at a low concentration (12.4 mM) of CTD-YFP induced LLPS condensates and broadened the range in salt concentration over which they assemble"
219,PMID: 30197298,RNAPS0000246,https://pubmed.ncbi.nlm.nih.gov/30197298,RNA + protein,-,-,polyA,-,-,poly RNA,-,"tr|Q9A749|Q9A749_CAUVC Ribonuclease E OS=Caulobacter vibrioides (strain ATCC 19089 / CB15) OX=190650 GN=rne PE=1 SV=1|length=448aa|residues=451-898
TGVLEGTTHVCEHCEGTGRVRSVESSALAALRAVEAEALKGSGSVILKVSRSVGLYILNE
KRDYLQRLLTTHGLFVSVVVDDSLHAGDQEIERTELGERIAVAPPPFVEEDDDFDPNAYD
DEEEEDDVILDDEDDTDREDTDDDDATTRKSARDDERGDRKGRRGRRDRNRGRGRRDERD
GETESEDEDVVAEGADEDRGEFGDDDEGGRRRRRRGRRGGRRGGREDGDRPTDAFVWIRP
RVPFGENVFTWHDPAALVGGGESRRQAPEPRVDAATEAAPRPERAEREERPGRERGRRGR
DRGRRQRDEAPVAEMTSVESATVEAAEPFEAPILAPPVIAGPPADVWVELPEVEEAPKKP
KRSRARGKKATETSVEAIDTVTEVAAEAPAPETAEPEAVEVAPPAPTVEAAPEPGPVVEA
VEEAQPAEPDPNEITAPPEKPRRGWWRR",rne,CTD,-,448aa(451-898),Q9A749,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9A749,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0174,http://db.phasep.pro/browse/","[545-686],[706-774],[802-828],[856-884],[890-892],[898-898]","[469-489],[554-680],[727-761],[830-879]",In vitro,12.4 µM [rne CTD];|10 µg/mL polyA,≥200 mM NaCl,20 mM Tris-Cl pH 7.4,4˚C,≤ 1 h,-,Microscopy,solute,"Because in vivo RNase E foci required the presence of RNA, whether addition of RNA could induce LLPS of the CTD-YFP protein in vitro was tested. Addition of 5–175 mg/mL poly-A RNA at a low concentration (12.4 mM) of CTD-YFP induced LLPS condensates and broadened the range in salt concentration over which they assemble"
220,PMID: 30197298,RNAPS0000246,https://pubmed.ncbi.nlm.nih.gov/30197298,RNA + protein,-,-,polyA,-,-,poly RNA,-,"tr|Q9A749|Q9A749_CAUVC Ribonuclease E OS=Caulobacter vibrioides (strain ATCC 19089 / CB15) OX=190650 GN=rne PE=1 SV=1|length=448aa|residues=451-898
TGVLEGTTHVCEHCEGTGRVRSVESSALAALRAVEAEALKGSGSVILKVSRSVGLYILNE
KRDYLQRLLTTHGLFVSVVVDDSLHAGDQEIERTELGERIAVAPPPFVEEDDDFDPNAYD
DEEEEDDVILDDEDDTDREDTDDDDATTRKSARDDERGDRKGRRGRRDRNRGRGRRDERD
GETESEDEDVVAEGADEDRGEFGDDDEGGRRRRRRGRRGGRRGGREDGDRPTDAFVWIRP
RVPFGENVFTWHDPAALVGGGESRRQAPEPRVDAATEAAPRPERAEREERPGRERGRRGR
DRGRRQRDEAPVAEMTSVESATVEAAEPFEAPILAPPVIAGPPADVWVELPEVEEAPKKP
KRSRARGKKATETSVEAIDTVTEVAAEAPAPETAEPEAVEVAPPAPTVEAAPEPGPVVEA
VEEAQPAEPDPNEITAPPEKPRRGWWRR",rne,CTD,-,448aa(451-898),Q9A749,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9A749,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0174,http://db.phasep.pro/browse/","[545-686],[706-774],[802-828],[856-884],[890-892],[898-898]","[469-489],[554-680],[727-761],[830-879]",In vitro,12.4 µM [rne CTD];|5-175 µg/mL polyA,100 mM NaCl,20 mM Tris-Cl pH 7.4,4˚C,≤ 1 h,-,Microscopy,liquid,"Addition of 5-175 µg/mL poly-A RNA at a low concentration (12.4 µM) of CTD-YFP induced LLPS condensates and broadened the range in salt concentration over which they assemble. Interestingly, addition of excess poly-A RNA above 175 µg/mL prevented the assembly of condensates."
221,PMID: 30197298,RNAPS0000246,https://pubmed.ncbi.nlm.nih.gov/30197298,RNA + protein,-,-,polyA,-,-,poly RNA,-,"tr|Q9A749|Q9A749_CAUVC Ribonuclease E OS=Caulobacter vibrioides (strain ATCC 19089 / CB15) OX=190650 GN=rne PE=1 SV=1|length=448aa|residues=451-898
TGVLEGTTHVCEHCEGTGRVRSVESSALAALRAVEAEALKGSGSVILKVSRSVGLYILNE
KRDYLQRLLTTHGLFVSVVVDDSLHAGDQEIERTELGERIAVAPPPFVEEDDDFDPNAYD
DEEEEDDVILDDEDDTDREDTDDDDATTRKSARDDERGDRKGRRGRRDRNRGRGRRDERD
GETESEDEDVVAEGADEDRGEFGDDDEGGRRRRRRGRRGGRRGGREDGDRPTDAFVWIRP
RVPFGENVFTWHDPAALVGGGESRRQAPEPRVDAATEAAPRPERAEREERPGRERGRRGR
DRGRRQRDEAPVAEMTSVESATVEAAEPFEAPILAPPVIAGPPADVWVELPEVEEAPKKP
KRSRARGKKATETSVEAIDTVTEVAAEAPAPETAEPEAVEVAPPAPTVEAAPEPGPVVEA
VEEAQPAEPDPNEITAPPEKPRRGWWRR",rne,CTD,-,448aa(451-898),Q9A749,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9A749,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0174,http://db.phasep.pro/browse/","[545-686],[706-774],[802-828],[856-884],[890-892],[898-898]","[469-489],[554-680],[727-761],[830-879]",In vitro,12.4 µM [rne CTD];|0-5 µg/mL polyA,100 mM NaCl,20 mM Tris-Cl pH 7.4,4˚C,≤ 1 h,-,Microscopy,solute,"Addition of 5-175 µg/mL poly-A RNA at a low concentration (12.4 µM) of CTD-YFP induced LLPS condensates and broadened the range in salt concentration over which they assemble. Interestingly, addition of excess poly-A RNA above 175 µg/mL prevented the assembly of condensates."
222,PMID: 30197298,RNAPS0000246,https://pubmed.ncbi.nlm.nih.gov/30197298,RNA + protein,-,-,polyA,-,-,poly RNA,-,"tr|Q9A749|Q9A749_CAUVC Ribonuclease E OS=Caulobacter vibrioides (strain ATCC 19089 / CB15) OX=190650 GN=rne PE=1 SV=1|length=448aa|residues=451-898
TGVLEGTTHVCEHCEGTGRVRSVESSALAALRAVEAEALKGSGSVILKVSRSVGLYILNE
KRDYLQRLLTTHGLFVSVVVDDSLHAGDQEIERTELGERIAVAPPPFVEEDDDFDPNAYD
DEEEEDDVILDDEDDTDREDTDDDDATTRKSARDDERGDRKGRRGRRDRNRGRGRRDERD
GETESEDEDVVAEGADEDRGEFGDDDEGGRRRRRRGRRGGRRGGREDGDRPTDAFVWIRP
RVPFGENVFTWHDPAALVGGGESRRQAPEPRVDAATEAAPRPERAEREERPGRERGRRGR
DRGRRQRDEAPVAEMTSVESATVEAAEPFEAPILAPPVIAGPPADVWVELPEVEEAPKKP
KRSRARGKKATETSVEAIDTVTEVAAEAPAPETAEPEAVEVAPPAPTVEAAPEPGPVVEA
VEEAQPAEPDPNEITAPPEKPRRGWWRR",rne,CTD,-,448aa(451-898),Q9A749,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9A749,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0174,http://db.phasep.pro/browse/","[545-686],[706-774],[802-828],[856-884],[890-892],[898-898]","[469-489],[554-680],[727-761],[830-879]",In vitro,12.4 µM [rne CTD];|175-250 µg/mL polyA,100 mM NaCl,20 mM Tris-Cl pH 7.4,4˚C,≤ 1 h,-,Microscopy,solute,"Addition of 5-175 µg/mL poly-A RNA at a low concentration (12.4 µM) of CTD-YFP induced LLPS condensates and broadened the range in salt concentration over which they assemble. Interestingly, addition of excess poly-A RNA above 175 µg/mL prevented the assembly of condensates."
223,PMID: 30197298,RNAPS0000246,https://pubmed.ncbi.nlm.nih.gov/30197298,RNA + protein,-,-,polyA,-,-,poly RNA,-,"tr|Q9A749|Q9A749_CAUVC Ribonuclease E OS=Caulobacter vibrioides (strain ATCC 19089 / CB15) OX=190650 GN=rne PE=1 SV=1|length=448aa|residues=451-898
TGVLEGTTHVCEHCEGTGRVRSVESSALAALRAVEAEALKGSGSVILKVSRSVGLYILNE
KRDYLQRLLTTHGLFVSVVVDDSLHAGDQEIERTELGERIAVAPPPFVEEDDDFDPNAYD
DEEEEDDVILDDEDDTDREDTDDDDATTRKSARDDERGDRKGRRGRRDRNRGRGRRDERD
GETESEDEDVVAEGADEDRGEFGDDDEGGRRRRRRGRRGGRRGGREDGDRPTDAFVWIRP
RVPFGENVFTWHDPAALVGGGESRRQAPEPRVDAATEAAPRPERAEREERPGRERGRRGR
DRGRRQRDEAPVAEMTSVESATVEAAEPFEAPILAPPVIAGPPADVWVELPEVEEAPKKP
KRSRARGKKATETSVEAIDTVTEVAAEAPAPETAEPEAVEVAPPAPTVEAAPEPGPVVEA
VEEAQPAEPDPNEITAPPEKPRRGWWRR",rne,CTD,-,448aa(451-898),Q9A749,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9A749,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0174,http://db.phasep.pro/browse/","[545-686],[706-774],[802-828],[856-884],[890-892],[898-898]","[469-489],[554-680],[727-761],[830-879]",In vitro,12.4 µM [rne CTD];|10 µg/mL polyA,50-175 mM NaCl,20 mM Tris-Cl pH 7.4,4˚C,≤ 1 h,-,Microscopy,liquid,"Because in vivo RNase E foci required the presence of RNA, whether addition of RNA could induce LLPS of the CTD-YFP protein in vitro was tested. Addition of 5–175 mg/mL poly-A RNA at a low concentration (12.4 mM) of CTD-YFP induced LLPS condensates and broadened the range in salt concentration over which they assemble"
224,PMID: 30371865,RNAPS0000253,https://pubmed.ncbi.nlm.nih.gov/30371865,RNAs + protein,-,-,Mus musculus brain RNA,-,-,total RNA,Mus musculus,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|length=414aa|residues=1-414
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG
NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQ
REPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM",TDP-43,-,-,414aa(1-414),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-414],"[272-314],[321-329],[342-358],[368-404]",In vitro,5 µM [TDP-43],100 mM NaCl,10 mM HEPES pH7.4,24˚C,≤ 2 h,crowding agent:1% PEG,Microscopy,solute,"Phase separation of 5 µM TDP-43 did not occur over a 2 hour experiment using 100 mM NaCl, 1% PEG (a crowding reagent) and 20 ng/µl total murine brain RNA. However, addition of lead (II) acetate trihydrate to the reaction mix promoted TDP-43 LLPS in a dose dependent manner with an EC50 of 160 µM. Interestingly, at low concentrations of lead, TDP-43 formed small single droplets, while at higher concentrations of lead, TDP-43 phase separates into large amorphous consolidates. Neither nickel (II) sulfate nor cobalt (II) chloride induced TDP-43 LLPS at the highest concentration. However, zinc (II) sulfate triggered robust phase separation in a dose dependent manner with a lower EC50 of 79.3 µM."
225,PMID: 30371865,RNAPS0000253,https://pubmed.ncbi.nlm.nih.gov/30371865,RNAs + protein,-,-,Mus musculus brain RNA,-,-,total RNA,Mus musculus,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|length=414aa|residues=1-414
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG
NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQ
REPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM",TDP-43,-,-,414aa(1-414),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-414],"[272-314],[321-329],[342-358],[368-404]",In vitro,5 µM [TDP-43],100 mM NaCl,10 mM HEPES pH7.4,24˚C,≤ 2 h,crowding agent:1% PEG;other_molecular:160-640 µM Pb,Microscopy,"liquid, solid","Phase separation of 5 µM TDP-43 did not occur over a 2 hour experiment using 100 mM NaCl, 1% PEG (a crowding reagent) and 20 ng/µl total murine brain RNA. However, addition of lead (II) acetate trihydrate to the reaction mix promoted TDP-43 LLPS in a dose dependent manner with an EC50 of 160 µM. Interestingly, at low concentrations of lead, TDP-43 formed small single droplets, while at higher concentrations of lead, TDP-43 phase separates into large amorphous consolidates. Neither nickel (II) sulfate nor cobalt (II) chloride induced TDP-43 LLPS at the highest concentration. However, zinc (II) sulfate triggered robust phase separation in a dose dependent manner with a lower EC50 of 79.3 µM."
226,PMID: 30371865,RNAPS0000253,https://pubmed.ncbi.nlm.nih.gov/30371865,RNAs + protein,-,-,Mus musculus brain RNA,-,-,total RNA,Mus musculus,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|length=414aa|residues=1-414
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG
NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQ
REPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM",TDP-43,-,-,414aa(1-414),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-414],"[272-314],[321-329],[342-358],[368-404]",In vitro,5 µM [TDP-43],100 mM NaCl,10 mM HEPES pH7.4,24˚C,≤ 2 h,crowding agent:1% PEG;other_molecular:10-640 µM Zn,Microscopy,liquid,"Phase separation of 5 µM TDP-43 did not occur over a 2 hour experiment using 100 mM NaCl, 1% PEG (a crowding reagent) and 20 ng/µl total murine brain RNA. However, addition of lead (II) acetate trihydrate to the reaction mix promoted TDP-43 LLPS in a dose dependent manner with an EC50 of 160 µM. Interestingly, at low concentrations of lead, TDP-43 formed small single droplets, while at higher concentrations of lead, TDP-43 phase separates into large amorphous consolidates. Neither nickel (II) sulfate nor cobalt (II) chloride induced TDP-43 LLPS at the highest concentration. However, zinc (II) sulfate triggered robust phase separation in a dose dependent manner with a lower EC50 of 79.3 µM."
227,PMID: 30371865,RNAPS0000253,https://pubmed.ncbi.nlm.nih.gov/30371865,RNAs + protein,-,-,Mus musculus brain RNA,-,-,total RNA,Mus musculus,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|length=414aa|residues=1-414
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG
NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQ
REPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM",TDP-43,-,-,414aa(1-414),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-414],"[272-314],[321-329],[342-358],[368-404]",In vitro,5 µM [TDP-43],100 mM NaCl,10 mM HEPES pH7.4,24˚C,≤ 2 h,crowding agent:1% PEG;other_molecular:10-640 µM Ni,Microscopy,solute,"Phase separation of 5 µM TDP-43 did not occur over a 2 hour experiment using 100 mM NaCl, 1% PEG (a crowding reagent) and 20 ng/µl total murine brain RNA. However, addition of lead (II) acetate trihydrate to the reaction mix promoted TDP-43 LLPS in a dose dependent manner with an EC50 of 160 µM. Interestingly, at low concentrations of lead, TDP-43 formed small single droplets, while at higher concentrations of lead, TDP-43 phase separates into large amorphous consolidates. Neither nickel (II) sulfate nor cobalt (II) chloride induced TDP-43 LLPS at the highest concentration. However, zinc (II) sulfate triggered robust phase separation in a dose dependent manner with a lower EC50 of 79.3 µM."
228,PMID: 30371865,RNAPS0000253,https://pubmed.ncbi.nlm.nih.gov/30371865,RNAs + protein,-,-,Mus musculus brain RNA,-,-,total RNA,Mus musculus,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|length=414aa|residues=1-414
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG
NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQ
REPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM",TDP-43,-,-,414aa(1-414),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-414],"[272-314],[321-329],[342-358],[368-404]",In vitro,5 µM [TDP-43],100 mM NaCl,10 mM HEPES pH7.4,24˚C,≤ 2 h,crowding agent:1% PEG;other_molecular:10-640 µM Co,Microscopy,solute,"Phase separation of 5 µM TDP-43 did not occur over a 2 hour experiment using 100 mM NaCl, 1% PEG (a crowding reagent) and 20 ng/µl total murine brain RNA. However, addition of lead (II) acetate trihydrate to the reaction mix promoted TDP-43 LLPS in a dose dependent manner with an EC50 of 160 µM. Interestingly, at low concentrations of lead, TDP-43 formed small single droplets, while at higher concentrations of lead, TDP-43 phase separates into large amorphous consolidates. Neither nickel (II) sulfate nor cobalt (II) chloride induced TDP-43 LLPS at the highest concentration. However, zinc (II) sulfate triggered robust phase separation in a dose dependent manner with a lower EC50 of 79.3 µM."
229,PMID: 30442662,RNAPS0000254,https://pubmed.ncbi.nlm.nih.gov/30442662,RNA + protein,-,-,polyU(40),40nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526|mutation=R244C
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGCGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,protein_mutation:R244C,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[3-251],[284-292],[332-338],[375-415],[451-499],[501-501],[503-505],[507-526]",-,In vitro,1 µM [FUS];|1 µM polyU,100 mM NaCl,"50 mM Tris·HCl (pH 7.4), 1 mM EDTA, 1 mM DTT",RT,≤ 20 h,-,Microscopy,"liquid, solid","Within a period of 20 h, FUS_M(R244C)-RNA droplets formed and increased in both size and number. When UBQLN2 was present, the FUS_M(R244C)-RNA droplets formed were smaller in size but more numerous compared with those formed in the absence of UBQLN2. Notably, the FUS_M(R244C)-RNA droplets in the absence of UBQLN2 displayed nonspherical, irregular patterns, whereas those in the presence of UBQLN2 remained highly spherical over the entire time course. These nonspherical irregular droplets may represent the transition from the reversible liquid-like, phase-separated state of FUS to a more stable, solid state of FUS."
230,PMID: 30648970,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/30648970,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1|length=506aa|residues=1-506
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,2 µM [DHH1];|0.1 mg/ml polyU,"150 mM KCl, 2 mM MgCl2",30 mM HEPES-KOH pH 7.4,RT,> 20 min,other_molecular:5 mM ATP,Fluorescence microscopy,liquid,"We found a stoichiometric ratio of 2.7:1 ± 0.13 of Dhh1 to Pat1 in the in vitro phase-separated droplets, closely resembling the Dhh1:Pat1 ratio of mature PBs in vivo."
231,PMID: 30648970,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/30648970,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1|length=506aa|residues=1-506
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,4 µM [DHH1];|0.2 mg/ml polyU,"150 mM KCl, 2 mM MgCl2",30 mM HEPES-KOH pH 7.4,RT,> 20 min,other_molecular:3.2 mM ATP,Fluorescence microscopy,liquid,"We therefore next analyzed whether the Pat1-Dhh1 droplets are still responsive to Not1. Similar to what we observed in vivo (Figure 5), Not1MIF4G also diminishes formation Dhh1 droplets in the presence of Pat1 in vitro (Figure 6B)."
232,PMID: 30648970,RNAPS0000257,https://pubmed.ncbi.nlm.nih.gov/30648970,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P25644|PAT1_YEAST DNA topoisomerase 2-associated protein PAT1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=PAT1 PE=1 SV=4|length=419aa|residues=5-79,456-787|mutation=D39A,E40A,T41A,F42A
GLENSGNARDGPLDFEESYKGYGEHELEENDYLNAAAAGDNVQVGTDFDFGNPHSSGSSG
NAIGGNGVGATARSYGGSGGSGGSGGSSSYAFNNGNGATNLNKSGGKKFILELIETVYEE
ILDLEANLRNGQQTDSTAMWEALHIDDSSYDVNPFISMLSFDKGIKIMPRIFNFLDKQQK
LKILQKIFNELSHLQIIILSSYKTTPKPTLTQLKKVDLFQMIILKIIVSFLSNNSNFIEI
MGLLLQLIRNNNVSFLTTSKIGLNLITILISRAALIKQDSSRSNILSSPEISTWNEIYDK
LFTSLESKIQLIFPPREYNDHIMRLQNDKFMDEAYIWQFLASLALSGKLNHQRIIIDEVR
DEIFATINEAETLQKKEKELSVLPQRSQELDTELKSIIYNKEKLYQDLNLFLNVMGLVY",PAT1,NC,"protein_mutation:D39A,E40A,T41A,F42A","419aa(5-79,456-787)",P25644,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0330,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0246,http://db.phasep.pro/browse/","[5-16],[63-79],[456-475],[501-510],[660-667],[742-748],[756-771]",-,In vitro,2-8 µM [PAT1 NC];|0.2 mg/ml polyU,"150 mM KCl, 2 mM MgCl2",30 mM HEPES-KOH pH 7.4,RT,> 20 min,other_molecular:3.2 mM ATP,Fluorescence microscopy,solute,"While no LLPS of Pat1 NC alone was detected, addition of increasing concentrations of wild-type Pat1 NC strongly enhanced the LLPS of Dhh1 in the presence of ATP and RNA as judged by an increase in the area * intensity of Dhh1 droplets. Furthermore, Pat1 NC itself enriched in Dhh1 droplets, suggesting that Pat1 and Dhh1 co-oligomerize with RNA to form a composite phase-separated compartment. Dhh1-RNA droplet formation was either not at all or only mildly stimulated upon addition of these Pat1 variants."
233,PMID: 30648970,RNAPS0000257,https://pubmed.ncbi.nlm.nih.gov/30648970,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P25644|PAT1_YEAST DNA topoisomerase 2-associated protein PAT1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=PAT1 PE=1 SV=4|length=419aa|residues=5-79,456-787|mutation=S456E,S457E
GLENSGNARDGPLDFEESYKGYGEHELEENDYLNDETFGDNVQVGTDFDFGNPHSSGSSG
NAIGGNGVGATARSYGGSGGSGGSGGSAAYAFNNGNGATNLNKSGGKKFILELIETVYEE
ILDLEANLRNGQQTDSTAMWEALHIDDSSYDVNPFISMLSFDKGIKIMPRIFNFLDKQQK
LKILQKIFNELSHLQIIILSSYKTTPKPTLTQLKKVDLFQMIILKIIVSFLSNNSNFIEI
MGLLLQLIRNNNVSFLTTSKIGLNLITILISRAALIKQDSSRSNILSSPEISTWNEIYDK
LFTSLESKIQLIFPPREYNDHIMRLQNDKFMDEAYIWQFLASLALSGKLNHQRIIIDEVR
DEIFATINEAETLQKKEKELSVLPQRSQELDTELKSIIYNKEKLYQDLNLFLNVMGLVY",PAT1,NC,"protein_mutation:S456E,S457E","419aa(5-79,456-787)",P25644,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0330,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0246,http://db.phasep.pro/browse/","[5-16],[63-79],[456-473],[501-510],[660-667],[742-748],[756-771]",-,In vitro,2-8 µM [PAT1 NC];|0.2 mg/ml polyU,"150 mM KCl, 2 mM MgCl2",30 mM HEPES-KOH pH 7.4,RT,> 20 min,other_molecular:3.2 mM ATP,Fluorescence microscopy,solute,"While no LLPS of Pat1 NC alone was detected, addition of increasing concentrations of wild-type Pat1 NC strongly enhanced the LLPS of Dhh1 in the presence of ATP and RNA as judged by an increase in the area * intensity of Dhh1 droplets. Furthermore, Pat1 NC itself enriched in Dhh1 droplets, suggesting that Pat1 and Dhh1 co-oligomerize with RNA to form a composite phase-separated compartment. Dhh1-RNA droplet formation was either not at all or only mildly stimulated upon addition of these Pat1 variants."
234,PMID: 30648970,RNAPS0000257,https://pubmed.ncbi.nlm.nih.gov/30648970,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P25644|PAT1_YEAST DNA topoisomerase 2-associated protein PAT1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=PAT1 PE=1 SV=4|length=419aa|residues=5-79,456-787
GLENSGNARDGPLDFEESYKGYGEHELEENDYLNDETFGDNVQVGTDFDFGNPHSSGSSG
NAIGGNGVGATARSYGGSGGSGGSGGSSSYAFNNGNGATNLNKSGGKKFILELIETVYEE
ILDLEANLRNGQQTDSTAMWEALHIDDSSYDVNPFISMLSFDKGIKIMPRIFNFLDKQQK
LKILQKIFNELSHLQIIILSSYKTTPKPTLTQLKKVDLFQMIILKIIVSFLSNNSNFIEI
MGLLLQLIRNNNVSFLTTSKIGLNLITILISRAALIKQDSSRSNILSSPEISTWNEIYDK
LFTSLESKIQLIFPPREYNDHIMRLQNDKFMDEAYIWQFLASLALSGKLNHQRIIIDEVR
DEIFATINEAETLQKKEKELSVLPQRSQELDTELKSIIYNKEKLYQDLNLFLNVMGLVY",PAT1,NC,-,"419aa(5-79,456-787)",P25644,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0330,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0246,http://db.phasep.pro/browse/","[5-24],[55-79],[456-469]","[59-74],[545-555],[571-583]",In vitro,2-8 µM [PAT1 NC];|0.2 mg/ml polyU,"150 mM KCl, 2 mM MgCl2",30 mM HEPES-KOH pH 7.4,RT,> 20 min,other_molecular:3.2 mM ATP,Fluorescence microscopy,solute,"While no LLPS of Pat1 NC alone was detected, addition of increasing concentrations of wild-type Pat1 NC strongly enhanced the LLPS of Dhh1 in the presence of ATP and RNA as judged by an increase in the area * intensity of Dhh1 droplets. Furthermore, Pat1 NC itself enriched in Dhh1 droplets, suggesting that Pat1 and Dhh1 co-oligomerize with RNA to form a composite phase-separated compartment. Dhh1-RNA droplet formation was either not at all or only mildly stimulated upon addition of these Pat1 variants."
235,PMID: 30765518,RNAPS0000036,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,NCBI ID:4609,https://www.ncbi.nlm.nih.gov/gene/4609,MYC,4515nt(1-4515),GGAGUUUAUUCAUAACGCGCUCUCCAAGUAUACGUGGCAAUGCGUUGCUGGGUUAUUUUAAUCAUUCUAGGCAUCGUUUUCCUCCUUAUGCCUCUAUCAUUCCUCCCUAUCUACACUAACAUCCCACGCUCUGAACGCGCGCCCAUUAAUACCCUUCUUUCCUCCACUCUCCCUGGGACUCUUGAUCAAAGCGCGGCCCUUUCCCCAGCCUUAGCGAGGCGCCCUGCAGCCUGGUACGCGCGUGGCGUGGCGGUGGGCGCGCAGUGCGUUCUCGGUGUGGAGGGCAGCUGUUCCGCCUGCGAUGAUUUAUACUCACAGGACAAGGAUGCGGUUUGUCAAACAGUACUGCUACGGAGGAGCAGCAGAGAAAGGGAGAGGGUUUGAGAGGGAGCAAAAGAAAAUGGUAGGCGCGCGUAGUUAAUUCAUGCGGCUCUCUUACUCUGUUUACAUCCUAGAGCUAGAGUGCUCGGCUGCCCGGCUGAGUCUCCUCCCCACCUUCCCCACCCUCCCCACCCUCCCCAUAAGCGCCCCUCCCGGGUUCCCAAAGCAGAGGGCGUGGGGGAAAAGAAAAAAGAUCCUCUCUCGCUAAUCUCCGCCCACCGGCCCUUUAUAAUGCGAGGGUCUGGACGGCUGAGGACCCCCGAGCUGUGCUGCUCGCGGCCGCCACCGCCGGGCCCCGGCCGUCCCUGGCUCCCCUCCUGCCUCGAGAAGGGCAGGGCUUCUCAGAGGCUUGGCGGGAAAAAGAACGGAGGGAGGGAUCGCGCUGAGUAUAAAAGCCGGUUUUCGGGGCUUUAUCUAACUCGCUGUAGUAAUUCCAGCGAGAGGCAGAGGGAGCGAGCGGGCGGCCGGCUAGGGUGGAAGAGCCGGGCGAGCAGAGCUGCGCUGCGGGCGUCCUGGGAAGGGAGAUCCGGAGCGAAUAGGGGGCUUCGCCUCUGGCCCAGCCCUCCCGCUGAUCCCCCAGCCAGCGGUCCGCAACCCUUGCCGCAUCCACGAAACUUUGCCCAUAGCAGCGGGCGGGCACUUUGCACUGGAACUUACAACACCCGAGCAAGGACGCGACUCUCCCGACGCGGGGAGGCUAUUCUGCCCAUUUGGGGACACUUCCCCGCCGCUGCCAGGACCCGCUUCUCUGAAAGGCUCUCCUUGCAGCUGCUUAGACGCUGGAUUUUUUUCGGGUAGUGGAAAACCAGCCUCCCGCGACGAUGCCCCUCAACGUUAGCUUCACCAACAGGAACUAUGACCUCGACUACGACUCGGUGCAGCCGUAUUUCUACUGCGACGAGGAGGAGAACUUCUACCAGCAGCAGCAGCAGAGCGAGCUGCAGCCCCCGGCGCCCAGCGAGGAUAUCUGGAAGAAAUUCGAGCUGCUGCCCACCCCGCCCCUGUCCCCUAGCCGCCGCUCCGGGCUCUGCUCGCCCUCCUACGUUGCGGUCACACCCUUCUCCCUUCGGGGAGACAACGACGGCGGUGGCGGGAGCUUCUCCACGGCCGACCAGCUGGAGAUGGUGACCGAGCUGCUGGGAGGAGACAUGGUGAACCAGAGUUUCAUCUGCGACCCGGACGACGAGACCUUCAUCAAAAACAUCAUCAUCCAGGACUGUAUGUGGAGCGGCUUCUCGGCCGCCGCCAAGCUCGUCUCAGAGAAGCUGGCCUCCUACCAGGCUGCGCGCAAAGACAGCGGCAGCCCGAACCCCGCCCGCGGCCACAGCGUCUGCUCCACCUCCAGCUUGUACCUGCAGGAUCUGAGCGCCGCCGCCUCAGAGUGCAUCGACCCCUCGGUGGUCUUCCCCUACCCUCUCAACGACAGCAGCUCGCCCAAGUCCUGCGCCUCGCAAGACUCCAGCGCCUUCUCUCCGUCCUCGGAUUCUCUGCUCUCCUCGACGGAGUCCUCCCCGCAGGGCAGCCCCGAGCCCCUGGUGCUCCAUGAGGAGACACCGCCCACCACCAGCAGCGACUCUGAGGAGGAACAAGAAGAUGAGGAAGAAAUCGAUGUUGUUUCUGUGGAAAAGAGGCAGGCUCCUGGCAAAAGGUCAGAGUCUGGAUCACCUUCUGCUGGAGGCCACAGCAAACCUCCUCACAGCCCACUGGUCCUCAAGAGGUGCCACGUCUCCACACAUCAGCACAACUACGCAGCGCCUCCCUCCACUCGGAAGGACUAUCCUGCUGCCAAGAGGGUCAAGUUGGACAGUGUCAGAGUCCUGAGACAGAUCAGCAACAACCGAAAAUGCACCAGCCCCAGGUCCUCGGACACCGAGGAGAAUGUCAAGAGGCGAACACACAACGUCUUGGAGCGCCAGAGGAGGAACGAGCUAAAACGGAGCUUUUUUGCCCUGCGUGACCAGAUCCCGGAGUUGGAAAACAAUGAAAAGGCCCCCAAGGUAGUUAUCCUUAAAAAAGCCACAGCAUACAUCCUGUCCGUCCAAGCAGAGGAGCAAAAGCUCAUUUCUGAAGAGGACUUGUUGCGGAAACGACGAGAACAGUUGAAACACAAACUUGAACAGCUACGGAACUCUUGUGCGUAAGGAAAAGUAAGGAAAACGAUUCCUUCUAACAGAAAUGUCCUGAGCAAUCACCUAUGAACUUGUUUCAAAUGCAUGAUCAAAUGCAACCUCACAACCUUGGCUGAGUCUUGAGACUGAAAGAUUUAGCCAUAAUGUAAACUGCCUCAAAUUGGACUUUGGGCAUAAAAGAACUUUUUUAUGCUUACCAUCUUUUUUUUUUCUUUAACAGAUUUGUAUUUAAGAAUUGUUUUUAAAAAAUUUUAAGAUUUACACAAUGUUUCUCUGUAAAUAUUGCCAUUAAAUGUAAAUAACUUUAAUAAAACGUUUAUAGCAGUUACACAGAAUUUCAAUCCUAGUAUAUAGUACCUAGUAUUAUAGGUACUAUAAACCCUAAUUUUUUUUAUUUAAGUACAUUUUGCUUUUUAAAGUUGAUUUUUUUCUAUUGUUUUUAGAAAAAAUAAAAUAACUGGCAAAUAUAUCAUUGAGCCAAAUCUUAAGUUGUGAAUGUUUUGUUUCGUUUCUUCCCCCUCCCAACCACCACCAUCCCUGUUUGUUUUCAUCAAUUGCCCCUUCAGAGGGUGGUCUUAAGAAAGGCAAGAGUUUUCCUCUGUUGAAAUGGGUCUGGGGGCCUUAAGGUCUUUAAGUUCUUGGAGGUUCUAAGAUGCUUCCUGGAGACUAUGAUAACAGCCAGAGUUGACAGUUAGAAGGAAUGGCAGAAGGCAGGUGAGAAGGUGAGAGGUAGGCAAAGGAGAUACAAGAGGUCAAAGGUAGCAGUUAAGUACACAAAGAGGCAUAAGGACUGGGGAGUUGGGAGGAAGGUGAGGAAGAAACUCCUGUUACUUUAGUUAACCAGUGCCAGUCCCCUGCUCACUCCAAACCCAGGAAUUCUGCCCAGUUGAUGGGGACACGGUGGGAACCAGCUUCUGCUGCCUUCACAACCAGGCGCCAGUCCUGUCCAUGGGUUAUCUCGCAAACCCCAGAGGAUCUCUGGGAGGAAUGCUACUAUUAACCCUAUUUCACAAACAAGGAAAUAGAAGAGCUCAAAGAGGUUAUGUAACUUAUCUGUAGCCACGCAGAUAAUACAAAGCAGCAAUCUGGACCCAUUCUGUUCAAAACACUUAACCCUUCGCUAUCAUGCCUUGGUUCAUCUGGGUCUAAUGUGCUGAGAUCAAGAAGGUUUAGGACCUAAUGGACAGACUCAAGUCAUAACAAUGCUAAGCUCUAUUUGUGUCCCAAGCACUCCUAAGCAUUUUAUCCCUAACUCUACAUCAACCCCAUGAAGGAGAUACUGUUGAUUUCCCCAUAUUAGAAGUAGAGAGGGAAGCUGAGGCACACAAAGACUCAUCCACAUGCCCAAGAUUCACUGAUAGGGAAAAGUGGAAGCGAGAUUUGAACCCAGGCUGUUUACUCCUAACCUGUCCAAGCCACCUCUCAGACGACGGUAGGAAUCAGCUGGCUGCUUGUGAGUACAGGAGUUACAGUCCAGUGGGUUAUGUUUUUUAAGUCUCAACAUCUAAGCCUGGUCAGGCAUCAGUUCCCCUUUUUUUGUGAUUUAUUUUGUUUUUAUUUUGUUGUUCAUUGUUUAAUUUUUCCUUUUACAAUGAGAAGGUCACCAUCUUGACUCCUACCUUAGCCAUUUGUUGAAUCAGACUCAUGACGGCUCCUGGGAAGAAGCCAGUUCAGAUCAUAAAAUAAAACAUAUUUAUUCUUUGUCAUGGGAGUCAUUAUUUUAGAAACUACAAACUCUCCUUGCUUCCAUCCUUUUUUACAUACUCAUGACACAUGCUCAUCCUGAGUCCUUGAAAAGGUAUUUUUGAACAUGUGUAUUAAUUAUAAGCCUCUGAAAACCUAUGGCCCAAACCAGAAAUGAUGUUGAUUAUAUAGGUAAAUGAAGGAUGCUAUUGCUGUUCUAAUUACCUCAUUGUCUCAGUCUCAAAGUAGGUCUUCAGCUCCCUGUACUUUGGGAUUUUAAUCUACCACCACCCAUAAAUCAAUAAAUAAUUACUUUCUUUGA,mRNA,Homo sapiens,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,125 µM [FMR1 LCR];|0.05 mg/mL c-Myc RNA,30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Microscopy,liquid,"By mixing different RNA sequences with FMRP LCR, we showed that FMRP LCR-RNA phase separation is not sequence-specific and does not require sequences capable of G-quadruplex formation. FMRPLCR:RNA phase separation is not dependent on RNA sequence or structure but is likely driven by protein:RNA electrostatic and pi-pi interactions."
236,PMID: 30765518,RNAPS0000260,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,luciferase RNA,1857nt(1-1857),UCCGUUUAGUUACCUAUACCUGAUUUUAUUAUUCGUUAAAAUAGUACAGUGACCCACAAUUACAAAAUUACCAUUCAUCAAUUUGCAUAUAAUAUUACAAUAGCUAAGAAUUUCGUCAUCGCUGAAUACAGUUACAUUUUACAAUUUGGACUUUCCGCCCUUCUUGGCCUUUAUGAGGAUCUCUCUGAUUUUUCUUGCGUCGAGUUUUCCGGUAAGACCUUUCGGUACUUCGUCCACAAACACAACUCCUCCGCGCAACUUUUUCGCGGUUGUUACUUGACUGGCGACGUAAUCCACGAUCUCUUUUUCCGUCAUCGUCUUUCCGUGCUCCAAAACAACAACGGCGGCGGGAAGUUCACCGGCGUCAUCGUCGGGAAGACCUGCCACGCCCGCGUCGAAGAUGUUGGGGUGUUGUAACAAUAUCGAUUCCAAUUCAGCGGGGGCCACCUGAUAUCCUUUGUAUUUAAUUAAAGACUUCAAGCGGUCAACUAUGAAGAAGUGUUCGUCUUCGUCCCAGUAAGCUAUGUCUCCAGAAUGUAGCCAUCCAUCCUUGUCAAUCAAGGCGUUGGUCGCUUCCGGAUUGUUUACAUAACCGGACAUAAUCAUAGGUCCUCUGACACAUAAUUCGCCUCUCUGAUUAACGCCCAGCGUUUUCCCGGUAUCCAGAUCCACAACCUUCGCUUCAAAAAAUGGAACAACUUUACCGACCGCGCCCGGUUUAUCAUCCCCCUCGGGUGUAAUCAGAAUAGCUGAUGUAGUCUCAGUGAGCCCAUAUCCUUGUCGUAUCCCUGGAAGAUGGAAGCGUUUUGCAACCGCUUCCCCGACUUCUUUCGAAAGAGGUGCGCCCCCAGAAGCAAUUUCGUGUAAAUUAGAUAAAUCGUAUUUGUCAAUCAGAGUGCUUUUGGCGAAGAAUGAAAAUAGGGUUGGUACUAGCAACGCACUUUGAAUUUUGUAAUCCUGAAGGGAUCGUAAAAACAGCUCUUCUUCAAAUCUAUACAUUAAGACGACUCGAAAUCCACAUAUCAAAUAUCCGAGUGUAGUAAACAUUCCAAAACCGUGAUGGAAUGGAACAACACUUAAAAUCGCAGUAUCCGGAAUGAUUUGAUUGCCAAAAAUAGGAUCUCUGGCAUGCGAGAAUCUGACGCAGGCAGUUCUAUGCGGAAGGGCCACACCCUUAGGUAACCCAGUAGAUCCAGAGGAAUUCAUUAUCAGUGCAAUUGUUUUGUCACGAUCAAAGGACUCUGGUACAAAAUCGUAUUCAUUAAAACCGGGAGGUAGAUGAGAUGUGACGAACGUGUACAUCGACUGAAAUCCCUGGUAAUCCGUUUUAGAAUCCAUGAUAAUAAUUUUCUGGAUUAUUGGUAAUUUUUUUUGCACGUUCAAAAUUUUUUGCAACCCCUUUUUGGAAACAAACACUACGGUAGGCUGCGAAAUGUUCAUACUGUUGAGCAAUUCACGUUCAUUAUAAAUGUCGUUCGCGGGCGCAACUGCAACUCCGAUAAAUAACGCGCCCAACACCGGCAUAAAGAAUUGAAGAGAGUUUUCACUGCAUACGACGAUUCUGUGAUUUGUAUUCAGCCCAUAUCGUUUCAUAGCUUCUGCCAACCGAACGGACAUUUCGAAGUAUUCCGCGUACGUGAUGUUCACCUCGAUAUGUGCAUCUGUAAAAGCAAUUGUUCCAGGAACCAGGGCGUAUCUCUUCAUAGCCUUAUGCAGUUGCUCUCCAGCGGUUCCAUCCUCUAGAGGAUAGAAUGGCGCCGGGCCUUUCUUUAUGUUUUUGGCGUCUUCCAUUUUACCAACAGUACCGGAAUGCUAAUGUCACUGCGAGCGACAUUCAAGAAUGUAACACAAAGGAAU,mRNA,Photinus pyralis,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,125 µM [FMR1 LCR];|0.05 mg/mL luciferase RNA,30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Microscopy,liquid,"By mixing different RNA sequences with FMRP LCR, we showed that FMRP LCR-RNA phase separation is not sequence-specific and does not require sequences capable of G-quadruplex formation. FMRPLCR:RNA phase separation is not dependent on RNA sequence or structure but is likely driven by protein:RNA electrostatic and pi-pi interactions."
237,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"150 µM [FMR1 LCR];|5 µM sc1 G quadruplex RNA (Tsang,2019)",30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",RT,-,-,"Differential interference contrast microscopy,FRAP",liquid,"This suggests that binding between FMRPLCR and sc1 RNA may be more dynamic than the stable interaction depicted by the crystal structure of a small RGG peptide in complex with sc1 (Protein Data Bank ID codes 5DE5, 5DE8, and 5DEA)"
238,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"10-500 µM [FMR1 LCR];|5 µM sc1 G quadruplex RNA (Tsang,2019)",0-150 mM NaCl,"10 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Differential interference contrast microscopy,"solute, liquid","By using DIC microscopy to map a phase diagram in varying protein and salt concentrations, we found that increasing salt concentrations disfavor FMRPLCR droplet formation in the presence of sc1 RNA."
239,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,protein_ptm:Methylation,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"100 µM [FMR1 LCR];|≥2.5 µM sc1 G quadruplex RNA (Tsang,2019)",30 mM KCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Microscopy,liquid,Me-FMRP LCR and FMRP LCR_M(RtoK) have a dramatic decrease in phase-separation propensity compared with FMRP LCR.
240,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632|mutation=all R to K
GASSKPPPNKTDKEKSYVTDDGQGMGKGSKPYKNKGHGKKGPGYTSGTNSEASNASETES
DHKDELSDWSLAPTEEEKESFLKKGDGKKKGGGGKGQGGKGKGGGFKGNDDHSKTDNKPK
NPKEAKGKTTDGSLQIKVDCNNEKSVHTKTLQNTSSEGSKLKTGKDKNQKKEKPDSVDGQ
QPLVNGVP",FMR1,-,protein_mutation:all R to K,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-458],[473-488],[490-515],[530-544],[558-570],[606-631]",-,In vitro,"100 µM [FMR1 LCR];|≥1.5 µM sc1 G quadruplex RNA (Tsang,2019)",30 mM KCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Microscopy,liquid,Me-FMRP LCR and FMRP LCR_M(RtoK) have a dramatic decrease in phase-separation propensity compared with FMRP LCR.
241,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"100 µM [FMR1 LCR];|≥0.15 µM sc1 G quadruplex RNA (Tsang,2019)",30 mM KCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Microscopy,liquid,Me-FMRP LCR and FMRP LCR_M(RtoK) have a dramatic decrease in phase-separation propensity compared with FMRP LCR.
242,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=632aa|residues=1-632
MEELVVEVRGSNGAFYKAFVKDVHEDSITVAFENNWQPDRQIPFHDVRFPPPVGYNKDIN
ESDEVEVYSRANEKEPCCWWLAKVRMIKGEFYVIEYAACDATYNEIVTIERLRSVNPNKP
ATKDTFHKIKLDVPEDLRQMCAKEAAHKDFKKAVGAFSVTYDPENYQLVILSINEVTSKR
AHMLIDMHFRSLRTKLSLIMRNEEASKQLESSRQLASRFHEQFIVREDLMGLAIGTHGAN
IQQARKVPGVTAIDLDEDTCTFHIYGEDQDAVKKARSFLEFAEDVIQVPRNLVGKVIGKN
GKLIQEIVDKSGVVRVRIEAENEKNVPQEEEIMPPNSLPSNNSRVGPNAPEEKKHLDIKE
NSTHFSQPNSTKVQRVLVASSVVAGESQKPELKAWQGMVPFVFVGTKDSIANATVLLDYH
LNYLKEVDQLRLERLQIDEQLRQIGASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRG
HGRRGPGYTSGTNSEASNASETESDHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRG
QGGRGRGGGFKGNDDHSRTDNRPRNPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSS
EGSRLRTGKDRNQKKEKPDSVDGQQPLVNGVP",FMR1,-,-,632aa(1-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[281-422],[443-515],[516-632]","[492-504],[527-549]",In vitro,"50-250 µM [FMR1];|5 µM sc1 G quadruplex RNA (Tsang,2019)",30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",RT,-,-,Microscopy,"liquid, gel","Representative images of increasing FMRP concentration from 50 to 250 μM in the presence of Cy3-labeled sc1 RNA (5 μM) at room temperature, showing spherical droplets at the lower FMRP concentration and non-spherical gel assemblies enriched with sc1 RNA at the higher concentrations."
243,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"25 µM [FMR1 LCR];|5 µM sc1 G quadruplex RNA (Tsang,2019)",-,"10 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Differential interference contrast microscopy,liquid,FMRP LCR phase separates without any additives and that addition of RNA increases its phase-separation propensity at protein concentrations closer to physiological levels
244,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"500 µM [FMR1 LCR];|5 µM sc1 G quadruplex RNA (Tsang,2019)",-,"10 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Differential interference contrast microscopy,liquid,FMRP LCR phase separates without any additives and that addition of RNA increases its phase-separation propensity at protein concentrations closer to physiological levels
245,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"100 µM [FMR1 LCR];|2.5 µM sc1 G quadruplex RNA (Tsang,2019)","30 mM NaCl, 10-200 mM NaCl","25 mM Na2PO4 pH 7.4, 2 mM DTT",RT,-,-,Differential interference contrast microscopy,liquid,"Identical ionic strengths of different salt solutions disrupt droplet formation to a similar degree. However, the divalent ions Mg2+ and Ca2+ qualitatively appear to have a slightly stronger ability to disrupt droplet formation."
246,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"100 µM [FMR1 LCR];|2.5 µM sc1 G quadruplex RNA (Tsang,2019)","30 mM NaCl, 300 mM NaCl","25 mM Na2PO4 pH 7.4, 2 mM DTT",RT,-,-,Differential interference contrast microscopy,solute,"Identical ionic strengths of different salt solutions disrupt droplet formation to a similar degree. However, the divalent ions Mg2+ and Ca2+ qualitatively appear to have a slightly stronger ability to disrupt droplet formation."
247,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"100 µM [FMR1 LCR];|2.5 µM sc1 G quadruplex RNA (Tsang,2019)","30 mM NaCl, 10-200 mM KCl","25 mM Na2PO4 pH 7.4, 2 mM DTT",RT,-,-,Differential interference contrast microscopy,liquid,"Identical ionic strengths of different salt solutions disrupt droplet formation to a similar degree. However, the divalent ions Mg2+ and Ca2+ qualitatively appear to have a slightly stronger ability to disrupt droplet formation."
248,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"100 µM [FMR1 LCR];|2.5 µM sc1 G quadruplex RNA (Tsang,2019)","30 mM NaCl, 300 mM KCl","25 mM Na2PO4 pH 7.4, 2 mM DTT",RT,-,-,Differential interference contrast microscopy,solute,"Identical ionic strengths of different salt solutions disrupt droplet formation to a similar degree. However, the divalent ions Mg2+ and Ca2+ qualitatively appear to have a slightly stronger ability to disrupt droplet formation."
249,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"100 µM [FMR1 LCR];|2.5 µM sc1 G quadruplex RNA (Tsang,2019)","30 mM NaCl, 10-200 mM MgCl2","25 mM Na2PO4 pH 7.4, 2 mM DTT",RT,-,-,Differential interference contrast microscopy,liquid,"Identical ionic strengths of different salt solutions disrupt droplet formation to a similar degree. However, the divalent ions Mg2+ and Ca2+ qualitatively appear to have a slightly stronger ability to disrupt droplet formation."
250,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"100 µM [FMR1 LCR];|2.5 µM sc1 G quadruplex RNA (Tsang,2019)","30 mM NaCl, 300 mM MgCl2","25 mM Na2PO4 pH 7.4, 2 mM DTT",RT,-,-,Differential interference contrast microscopy,solute,"Identical ionic strengths of different salt solutions disrupt droplet formation to a similar degree. However, the divalent ions Mg2+ and Ca2+ qualitatively appear to have a slightly stronger ability to disrupt droplet formation."
251,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"100 µM [FMR1 LCR];|2.5 µM sc1 G quadruplex RNA (Tsang,2019)","30 mM NaCl, 10-150 mM CaCl2","25 mM Na2PO4 pH 7.4, 2 mM DTT",RT,-,-,Differential interference contrast microscopy,liquid,"Identical ionic strengths of different salt solutions disrupt droplet formation to a similar degree. However, the divalent ions Mg2+ and Ca2+ qualitatively appear to have a slightly stronger ability to disrupt droplet formation."
252,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"100 µM [FMR1 LCR];|2.5 µM sc1 G quadruplex RNA (Tsang,2019)","30 mM NaCl, 200-300 mM CaCl2","25 mM Na2PO4 pH 7.4, 2 mM DTT",RT,-,-,Differential interference contrast microscopy,solute,"Identical ionic strengths of different salt solutions disrupt droplet formation to a similar degree. However, the divalent ions Mg2+ and Ca2+ qualitatively appear to have a slightly stronger ability to disrupt droplet formation."
253,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"250 µM [FMR1 LCR];|5 µM sc1 G quadruplex RNA (Tsang,2019)",-,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 30 min,other_molecular:500 nM Cy3 dye,Sedimentation assay,liquid,"Cy3-labeled sc1 G quadruplex RNA (Tsang,2019) and miRNA125b are nearly completely sequestered into droplets (>90%), whereas 4EBP2 strongly partitions into the droplet (∼60%). In contrast, the free Cy3 dye and Cy3- BSA exhibit negligible partitioning."
254,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"250 µM [FMR1 LCR];|5 µM sc1 G quadruplex RNA (Tsang,2019)",-,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 30 min,other_molecular:500 nM Cy3 BSA,Sedimentation assay,liquid,"Cy3-labeled sc1 G quadruplex RNA (Tsang,2019) and miRNA125b are nearly completely sequestered into droplets (>90%), whereas 4EBP2 strongly partitions into the droplet (∼60%). In contrast, the free Cy3 dye and Cy3- BSA exhibit negligible partitioning."
255,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=455aa|residues=1-455
MEELVVEVRGSNGAFYKAFVKDVHEDSITVAFENNWQPDRQIPFHDVRFPPPVGYNKDIN
ESDEVEVYSRANEKEPCCWWLAKVRMIKGEFYVIEYAACDATYNEIVTIERLRSVNPNKP
ATKDTFHKIKLDVPEDLRQMCAKEAAHKDFKKAVGAFSVTYDPENYQLVILSINEVTSKR
AHMLIDMHFRSLRTKLSLIMRNEEASKQLESSRQLASRFHEQFIVREDLMGLAIGTHGAN
IQQARKVPGVTAIDLDEDTCTFHIYGEDQDAVKKARSFLEFAEDVIQVPRNLVGKVIGKN
GKLIQEIVDKSGVVRVRIEAENEKNVPQEEEIMPPNSLPSNNSRVGPNAPEEKKHLDIKE
NSTHFSQPNSTKVQRVLVASSVVAGESQKPELKAWQGMVPFVFVGTKDSIANATVLLDYH
LNYLKEVDQLRLERLQIDEQLRQIGASSRPPPNRT",FMR1,△LCR,-,455aa(1-455),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[281-422],[443-455]",-,In vitro,"50 µM [FMR1△LCR];|5 µM sc1 G quadruplex RNA (Tsang,2019)",30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,"Differential interference contrast microscopy,Fluorescence microscopy",solute,"Upon addition of Cy3-labeled sc1 G quadruplex RNA (Tsang,2019), droplets were formed with FMRP and FMRP LCR, but not with FMRPΔLCR. Our results show that FMRP LCR alone is necessary and sufficient to drive phase separation with sc1 G quadruplex RNA (Tsang,2019) in vitro. After 30 minutes of incubation on ice, FMRP wild type gel assemblies stick together with non-spherical morphology."
256,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"50 µM [FMR1 LCR];|5 µM sc1 G quadruplex RNA (Tsang,2019)",30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"Upon addition of Cy3-labeled sc1 G quadruplex RNA (Tsang,2019), droplets were formed with FMRP and FMRP LCR, but not with FMRPΔLCR. Our results show that FMRP LCR alone is necessary and sufficient to drive phase separation with sc1 G quadruplex RNA (Tsang,2019) in vitro. After 30 minutes of incubation on ice, FMRP wild type gel assemblies stick together with non-spherical morphology."
257,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=632aa|residues=1-632
MEELVVEVRGSNGAFYKAFVKDVHEDSITVAFENNWQPDRQIPFHDVRFPPPVGYNKDIN
ESDEVEVYSRANEKEPCCWWLAKVRMIKGEFYVIEYAACDATYNEIVTIERLRSVNPNKP
ATKDTFHKIKLDVPEDLRQMCAKEAAHKDFKKAVGAFSVTYDPENYQLVILSINEVTSKR
AHMLIDMHFRSLRTKLSLIMRNEEASKQLESSRQLASRFHEQFIVREDLMGLAIGTHGAN
IQQARKVPGVTAIDLDEDTCTFHIYGEDQDAVKKARSFLEFAEDVIQVPRNLVGKVIGKN
GKLIQEIVDKSGVVRVRIEAENEKNVPQEEEIMPPNSLPSNNSRVGPNAPEEKKHLDIKE
NSTHFSQPNSTKVQRVLVASSVVAGESQKPELKAWQGMVPFVFVGTKDSIANATVLLDYH
LNYLKEVDQLRLERLQIDEQLRQIGASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRG
HGRRGPGYTSGTNSEASNASETESDHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRG
QGGRGRGGGFKGNDDHSRTDNRPRNPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSS
EGSRLRTGKDRNQKKEKPDSVDGQQPLVNGVP",FMR1,-,-,632aa(1-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[281-422],[443-515],[516-632]","[492-504],[527-549]",In vitro,"50 µM [FMR1];|5 µM sc1 G quadruplex RNA (Tsang,2019)",30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,≤ 30 min,-,"Differential interference contrast microscopy,Fluorescence microscopy","liquid, gel","Upon addition of Cy3-labeled sc1 G quadruplex RNA (Tsang,2019), droplets were formed with FMRP and FMRP LCR, but not with FMRPΔLCR. Our results show that FMRP LCR alone is necessary and sufficient to drive phase separation with sc1 G quadruplex RNA (Tsang,2019) in vitro. After 30 minutes of incubation on ice, FMRP wild type gel assemblies stick together with non-spherical morphology."
258,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"0-300 µM [FMR1 LCR];|0-5 µM sc1 G quadruplex RNA (Tsang,2019)",100 mM KCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",RT,-,-,Microscopy,"solute, liquid","At room temperature, and in the absence of RNA and crowding reagents, we observed that phospho-FMRP LCR (containing 8–10 phosphate groups added) readily phase separates at ∼250 μM, whereas FMRP LCR does not. Furthermore, by using microscopy to map and compare the phase diagrams of phospho-FMRP LCR and FMRP LCR (pH 7.4 and 150 mM KCl), we found that moderately phosphorylated FMRP LCR (ranging from three to five groups, reflective of the phosphorylation state in vivo) increases its propensity to form liquid-like droplets with sc1 G quadruplex RNA (Tsang,2019) at lower protein concentrations."
259,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,protein_ptm:Phosphorylation,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"0-300 µM [FMR1 LCR];|0-5 µM sc1 G quadruplex RNA (Tsang,2019)",100 mM KCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",RT,-,-,Microscopy,"solute, liquid","At room temperature, and in the absence of RNA and crowding reagents, we observed that phospho-FMRP LCR (containing 8–10 phosphate groups added) readily phase separates at ∼250 μM, whereas FMRP LCR does not. Furthermore, by using microscopy to map and compare the phase diagrams of phospho-FMRP LCR and FMRP LCR (pH 7.4 and 150 mM KCl), we found that moderately phosphorylated FMRP LCR (ranging from three to five groups, reflective of the phosphorylation state in vivo) increases its propensity to form liquid-like droplets with sc1 G quadruplex RNA (Tsang,2019) at lower protein concentrations."
260,PMID: 30765518,RNAPS0000263,https://pubmed.ncbi.nlm.nih.gov/30765518,RNAs + protein,-;|-,-;|-,"sc1 G quadruplex RNA (Tsang,2019);|miR-125b",36nt;|22nt(1-22),GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG;|UCACAAGUUAGGGUCUCAGGGA,irregular RNA;|miRNA,-;|Mus musculus,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"250 µM [FMR1 LCR];|5 µM sc1 G quadruplex RNA (Tsang,2019);|500 nM miRNA125b",-,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 30 min,-,Sedimentation assay,liquid,"Cy3-labeled sc1 G quadruplex RNA (Tsang,2019) and miRNA125b are nearly completely sequestered into droplets (>90%), whereas 4EBP2 strongly partitions into the droplet (∼60%). In contrast, the free Cy3 dye and Cy3- BSA exhibit negligible partitioning."
261,PMID: 30765518,RNAPS0000264,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,polyA,-,-,poly RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,125 µM [FMR1 LCR];|0.05 mg/mL polyA,30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Microscopy,liquid,"By mixing different RNA sequences with FMRP LCR, we showed that FMRP LCR-RNA phase separation is not sequence-specific and does not require sequences capable of G-quadruplex formation. FMRPLCR:RNA phase separation is not dependent on RNA sequence or structure but is likely driven by protein:RNA electrostatic and pi-pi interactions."
262,PMID: 30765518,RNAPS0000265,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,125 µM [FMR1 LCR];|0.05 mg/mL polyU,30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Microscopy,liquid,"By mixing different RNA sequences with FMRP LCR, we showed that FMRP LCR-RNA phase separation is not sequence-specific and does not require sequences capable of G-quadruplex formation. FMRPLCR:RNA phase separation is not dependent on RNA sequence or structure but is likely driven by protein:RNA electrostatic and pi-pi interactions."
263,PMID: 30765518,RNAPS0000266,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,polyC,-,-,poly RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,125 µM [FMR1 LCR];|0.05 mg/mL polyC,30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Microscopy,liquid,"By mixing different RNA sequences with FMRP LCR, we showed that FMRP LCR-RNA phase separation is not sequence-specific and does not require sequences capable of G-quadruplex formation. FMRPLCR:RNA phase separation is not dependent on RNA sequence or structure but is likely driven by protein:RNA electrostatic and pi-pi interactions."
264,PMID: 30765518,RNAPS0000267,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,polyG,-,-,poly RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,125 µM [FMR1 LCR];|0.05 mg/mL polyG,30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Microscopy,liquid,"By mixing different RNA sequences with FMRP LCR, we showed that FMRP LCR-RNA phase separation is not sequence-specific and does not require sequences capable of G-quadruplex formation. FMRPLCR:RNA phase separation is not dependent on RNA sequence or structure but is likely driven by protein:RNA electrostatic and pi-pi interactions."
265,PMID: 30765518,RNAPS0000268,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,yeast RNA,-,-,total RNA,yeast,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,125 µM [FMR1 LCR];|0.05 mg/mL RNA,30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Microscopy,liquid,"By mixing different RNA sequences with FMRP LCR, we showed that FMRP LCR-RNA phase separation is not sequence-specific and does not require sequences capable of G-quadruplex formation. FMRPLCR:RNA phase separation is not dependent on RNA sequence or structure but is likely driven by protein:RNA electrostatic and pi-pi interactions."
266,PMID: 30826182,RNAPS0000269,https://pubmed.ncbi.nlm.nih.gov/30826182,RNAs + protein,-,-,yeast RNA,-,-,total RNA,yeast,"A fusion protein construct [TDP-43]-[MBP] with TDP-43 residues 1-414 fused to MBP residues 1-396|Linker is missing|length=810aa|residues=1-414/1-396
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG
NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQ
REPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGMMKIKTG
ARILALSALTTMMFSASALAKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHP
DKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYN
GKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPL
IAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKG
ETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFL
ENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFW
YAVRTAVINAASGRQTVDEALKDAQTRITK",TDP-43-MBP,-,-,"810aa(1-414,1-396)","Q13148,P02686","TDP-34:PhaSePro,DrLLPS,LLPSDB,PhaSepDB,
MBP:DrLLPS,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-a1103,http://db.phasep.pro/browse/","[9-28],[84-104],[179-194],[263-269],[296-304],[326-389],[412-422],[485-490],[749-768],[794-805],[807-807]",-,In vitro,5 µM [TDP-43]-[MBP];|0-2.5 µg RNA,150 mM NaCl,"15mM HEPES (pH 7.4), 1mM DTT",RT,> 2 h,-,Differential interference contrast microscopy,liquid,"In the absence of RNA, C-terminal MBP-tagged TDP-43 WT and 5FL formed liquid-like droplets at physiological salt concentrations that did not form in the presence of 1,6 hexanediol, which disrupts weak contacts between LCDs that drive LLPS. However, in the presence of increasing concentrations of total RNA, WT TDP-43 LLPS was inhibited in a dose-dependent manner. In contrast, the RNA-binding-deficient TDP-43 5FL species was unaffected by exogenous RNA. Upon selective cleavage of the MBP tag with TEV protease, TDP-43 WT and 5FL form solid-phase aggregate."
267,PMID: 30826182,RNAPS0000269,https://pubmed.ncbi.nlm.nih.gov/30826182,RNAs + protein,-,-,yeast RNA,-,-,total RNA,yeast,"A fusion protein construct [TDP-43]-[MBP] with TDP-43 residues 1-414 fused to MBP residues 1-396|Linker is missing|length=810aa|residues=1-414/1-396
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG
NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQ
REPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGMMKIKTG
ARILALSALTTMMFSASALAKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHP
DKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYN
GKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPL
IAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKG
ETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFL
ENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFW
YAVRTAVINAASGRQTVDEALKDAQTRITK",TDP-43-MBP,-,-,"810aa(1-414,1-396)","Q13148,P02686","TDP-34:PhaSePro,DrLLPS,LLPSDB,PhaSepDB,
MBP:DrLLPS,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-a1103,http://db.phasep.pro/browse/","[9-28],[84-104],[179-194],[263-269],[296-304],[326-389],[412-422],[485-490],[749-768],[794-805],[807-807]",-,In vitro,5 µM [TDP-43]-[MBP];|12.5-25 µg RNA,150 mM NaCl,"15mM HEPES (pH 7.4), 1mM DTT",RT,> 2 h,-,Differential interference contrast microscopy,solute,"In the absence of RNA, C-terminal MBP-tagged TDP-43 WT and 5FL formed liquid-like droplets at physiological salt concentrations that did not form in the presence of 1,6 hexanediol, which disrupts weak contacts between LCDs that drive LLPS. However, in the presence of increasing concentrations of total RNA, WT TDP-43 LLPS was inhibited in a dose-dependent manner. In contrast, the RNA-binding-deficient TDP-43 5FL species was unaffected by exogenous RNA. Upon selective cleavage of the MBP tag with TEV protease, TDP-43 WT and 5FL form solid-phase aggregate."
268,PMID: 30826182,RNAPS0000269,https://pubmed.ncbi.nlm.nih.gov/30826182,RNAs + protein,-,-,yeast RNA,-,-,total RNA,yeast,"A fusion protein construct [TDP-43]-[MBP] with TDP-43 residues 1-414 fused to MBP residues 1-396|Linker is missing||length=810aa|residues=1-414/1-396|mutation=TDP-43 F147,149,194,229,231L
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGLGLVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVLVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRALALVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG
NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQ
REPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGMMKIKTG
ARILALSALTTMMFSASALAKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHP
DKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYN
GKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPL
IAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKG
ETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFL
ENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFW
YAVRTAVINAASGRQTVDEALKDAQTRITK",TDP-43-MBP,-,-,"810aa(1-414,1-396)","Q13148,P02686","TDP-34:PhaSePro,DrLLPS,LLPSDB,PhaSepDB,
MBP:DrLLPS,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-a1103,http://db.phasep.pro/browse/","[9-28],[84-104],[179-202],[206-206],[263-269],[296-304],[326-389],[412-422],[485-490],[749-768],[794-805],[807-807]",-,In vitro,5 µM [TDP-43]-[MBP];|0-25 µg RNA,150 mM NaCl,"15mM HEPES (pH 7.4), 1mM DTT",RT,> 2 h,-,Differential interference contrast microscopy,liquid,"In the absence of RNA, C-terminal MBP-tagged TDP-43 WT and 5FL formed liquid-like droplets at physiological salt concentrations that did not form in the presence of 1,6 hexanediol, which disrupts weak contacts between LCDs that drive LLPS. However, in the presence of increasing concentrations of total RNA, WT TDP-43 LLPS was inhibited in a dose-dependent manner. In contrast, the RNA-binding-deficient TDP-43 5FL species was unaffected by exogenous RNA. Upon selective cleavage of the MBP tag with TEV protease, TDP-43 WT and 5FL form solid-phase aggregate."
269,PMID: 30833787,RNAPS0000172,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,1.8 µM [pgl-3];|0.3 µM [total C. elegans RNA],"1M NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,30 min,-,"Microscopy,FRAP",-,"PGL-3 condensates dissolve almost completely in 1 M NaCl, but persisted partially in the co-condensates."
270,PMID: 30833787,RNAPS0000172,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,1.8 µM [pgl-3];|0.3 µM [total C. elegans RNA],"150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,30 min,other_molecular:7 mM ATP/Mg,"Microscopy,FRAP",-,"PGL-3 condensates dissolve almost completely in 1 M NaCl, but persisted partially in the co-condensates."
271,PMID: 30833787,RNAPS0000172,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,1.8 µM [pgl-3];|0.3 µM [total C. elegans RNA],"150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,30 min,"other_molecular:5% 2,5 or 1,6-Hexanediol","Microscopy,FRAP",-,"PGL-3 condensates dissolve almost completely in 1 M NaCl, but persisted partially in the co-condensates."
272,PMID: 30833787,RNAPS0000172,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,1.8 µM [pgl-3];|0.3 µM [total C. elegans RNA],"150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,30 min,other_molecular:0.5% SDS,"Microscopy,FRAP",-,"PGL-3 condensates dissolve almost completely in 1 M NaCl, but persisted partially in the co-condensates."
273,PMID: 30833787,RNAPS0000172,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,1.8 µM [pgl-3];|0.3 µM [total C. elegans RNA],"150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,0.5-30 min,-,"Microscopy,FRAP",-,"As reported previously, when incubated separately in condensate buffer, MEG-3 and PGL-3 readily formed condensates"
274,PMID: 30833787,RNAPS0000172,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"sp|G5EBV6|PGL3_CAEEL Guanyl-specific ribonuclease pgl-3 OS=Caenorhabditis elegans OX=6239 GN=pgl-3 PE=1 SV=1|length=693aa|residues=1-693
MEANKRQIVEVDGIKSYFFPHLAHYLASNDELLVNNIAQANKLAAFVLGATDKRPSNEEI
AEMILPNDSSAYVLAAGMDVCLILGDDFRPKFDSGAEKLSQLGQAHDLAPIIDDEKKISM
LARKTKLKKSNDAKILQVLLKVLGAEEAEEKFVELSELSSALDLDFDVYVLAKLLGFASE
ELQEEIEIIRDNVTDAFEACKPLLKKLMIEGPKIDSVDPFTQLLLTPQEESIEKAVSHIV
ARFEEASAVEDDESLVLKSQLGYQLIFLVVRSLADGKRDASRTIQSLMPSSVRAEVFPGL
QRSVFKSAVFLASHIIQVFLGSMKSFEDWAFVGLAEDLESTWRRRAIAELLKKFRISVLE
QCFSQPIPLLPQSELNNETVIENVNNALQFALWITEFYGSESEKKSLNQLQFLSPKSKNL
LVDSFKKFAQGLDSKDHVNRIIESLEKSSSSEPSATAKQTTTSNGPTTVSTAAQVVTVEK
MPFSRQTIPCEGTDLANVLNSAKIIGESVTVAAHDVIPEKLNAEKNDNTPSTASPVQFSS
DGWDSPTKSVALPPKISTLEEEQEEDTTITKVSPQPQERTGTAWGSGDATPVPLATPVNE
YKVSGFGAAPVASGFGQFASSNGTSGRGSYGGGRGGDRGGRGAYGGDRGRGGSGDGSRGY
RGGDRGGRGSYGEGSRGYQGGRAGFFGGSRGGS",pgl-3,-,-,693aa(1-693),G5EBV6,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/G5EBV6,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2109,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0049,http://db.phasep.pro/browse/","[445-468],[523-591],[620-693]","[154-165],[443-454],[460-478],[625-692]",In vitro,1.8 µM [pgl-3];|150ng/µl RNA,150 mM NaCl,25mM HEPES (pH 7.4),RT,> 30 min,-,"Microscopy,FRAP",liquid,"PGL-3 formed dynamic condensates with a recovery rate of 0.034±0.001 s−1 that increased in intensity and decreased in number over time, as expected for a liquid phase growing by Ostwald ripening and fusion."
275,PMID: 30833787,RNAPS0000271,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1|length=862aa|residues=1-862
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,0.15 µM [meg-3];|0.3 µM [total C. elegans RNA],"150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,30 min,other_molecular:7 mM ATP/Mg,"Microscopy,FRAP",-,"As reported previously, when incubated separately in condensate buffer, MEG-3 and PGL-3 readily formed condensates"
276,PMID: 30833787,RNAPS0000271,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1|length=862aa|residues=1-862
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,0.15 µM [meg-3];|0.3 µM [total C. elegans RNA],"150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,30 min,"other_molecular:5% 2,5 or 1,6-Hexanediol","Microscopy,FRAP",-,"As reported previously, when incubated separately in condensate buffer, MEG-3 and PGL-3 readily formed condensates"
277,PMID: 30833787,RNAPS0000271,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1|length=862aa|residues=1-862
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,0.15 µM [meg-3];|0.3 µM [total C. elegans RNA],"150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,30 min,other_molecular:0.5% SDS,"Microscopy,FRAP",-,"As reported previously, when incubated separately in condensate buffer, MEG-3 and PGL-3 readily formed condensates"
278,PMID: 30833787,RNAPS0000271,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1|length=862aa|residues=1-862
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,0.15 µM [meg-3];|0.3 µM [total C. elegans RNA],"1M NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,30 min,-,"Microscopy,FRAP",-,"As reported previously, when incubated separately in condensate buffer, MEG-3 and PGL-3 readily formed condensates"
279,PMID: 30833787,RNAPS0000271,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1|length=862aa|residues=1-862
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,[meg-3]:IDR;|[PGL-3]:-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,0.15 µM [meg-3];|0.3 µM [total C. elegans RNA],"150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,0.5-30 min,-,"Microscopy,FRAP",-,"As reported previously, when incubated separately in condensate buffer, MEG-3 and PGL-3 readily formed condensates"
280,PMID: 30833787,RNAPS0000271,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1|length=544aa|residues=1-544
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSS",meg-3,IDR,-,544aa(1-544),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492]",In vitro,0.15 µM [meg-3-IDR];|0.3 µM [total C. elegans RNA],"150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,30 min,-,"Microscopy,FRAP",-,"We found, however, that at 0.15 μM, the MEG-3 IDR does not form visible condensates even in the presence of RNA."
281,PMID: 30833787,RNAPS0000271,https://pubmed.ncbi.nlm.nih.gov/30833787,RNAs + protein,-,-,Caenorhabditis elegans RNA,-,-,total RNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1|length=544aa|residues=1-544
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSS",meg-3,IDR,-,544aa(1-544),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492]",In vitro,0.15 µM [meg-3-IDR];|0.3 µM [total C. elegans RNA],"1M NaCl, 2 mM CaCl2, 2 mM MgCl2",25 mM HEPES pH 7,-,30 min,-,"Microscopy,FRAP",-,"We have shown previously that the IDR readily phase separates  in vitro at concentrations greater than 1 µM18. We found, however,  that at 0.15µM, the MEG-3 IDR does not form visible condensates  even in the presence of RNA (Fig. 5b and Supplementary Fig. 6a)."
282,PMID: 30926670,RNAPS0000272,https://pubmed.ncbi.nlm.nih.gov/30926670,RNA + protein,-,-,polyrU,-,-,poly RNA,-,PKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPK,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|0-1.5 µg/µL [poly-rU],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,"crowding agent:,30%PEG","Microscopy,FRAP",liquid,"Increasing the concentration of poly-rU in PEG-induced PR droplets decreases PR dynamics, even at lower RNA concentrations than used for PR-RNA droplet formation in the absence of PEG."
283,PMID: 30926670,RNAPS0000272,https://pubmed.ncbi.nlm.nih.gov/30926670,RNA + protein,-,-,polyrU,-,-,poly RNA,-,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|0.5-8 µg/µL [poly-rU],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",liquid,"As can be seen in Fig. 2 A and B (and Movie S1), mixing of PR with homopolymeric RNAs (except poly-rG) results in the formation of liquid-like condensates."
284,PMID: 30926670,RNAPS0000273,https://pubmed.ncbi.nlm.nih.gov/30926670,RNA + protein,-,-,polyrA,-,-,poly RNA,-,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|1 µg/µL [poly-rA],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",liquid,"As can be seen in Fig. 2 A and B (and Movie S1), mixing of PR with homopolymeric RNAs (except poly-rG) results in the formation of liquid-like condensates."
285,PMID: 30926670,RNAPS0000274,https://pubmed.ncbi.nlm.nih.gov/30926670,RNA + protein,-,-,polyrC,-,-,poly RNA,-,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|1 µg/µL [poly-rC],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",liquid,"As can be seen in Fig. 2 A and B (and Movie S1), mixing of PR with homopolymeric RNAs (except poly-rG) results in the formation of liquid-like condensates."
286,PMID: 30926670,RNAPS0000275,https://pubmed.ncbi.nlm.nih.gov/30926670,RNA + protein,-,-,polyrG,-,-,poly RNA,-,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|1 µg/µL [poly-rG],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",-,"In contrast, poly-rG is known to form G quadruplexes, and these structural elements are highly stable. Interestingly, unlike the spherical coacervates formed by complexation of each of poly-rA, poly-rC, and poly-rU with PR, the assemblies formed by poly-rG and PR peptides are characterized by an open, fractal-like network structure that is resistant to thermal denaturation at high salt concentrations."
287,PMID: 30926670,RNAPS0000279,https://pubmed.ncbi.nlm.nih.gov/30926670,RNA + protein,-,-,polyrA,-,-,poly RNA,-,PKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPK,poly(proline-lysine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PK30];|1 µg/µL [poly-rA],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",liquid,PK−polynucleotide droplets are uniformly less viscous than PR−polynucleotide droplets as assayed by spontaneous fusion events
288,PMID: 30926670,RNAPS0000280,https://pubmed.ncbi.nlm.nih.gov/30926670,RNA + protein,-,-,polyrU,-,-,poly RNA,-,PKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPK,poly(proline-lysine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PK30];|1 µg/µL [poly-rU],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",liquid,PK−polynucleotide droplets are uniformly less viscous than PR−polynucleotide droplets as assayed by spontaneous fusion events
289,PMID: 30926670,RNAPS0000281,https://pubmed.ncbi.nlm.nih.gov/30926670,RNA + protein,-,-,polyrC,-,-,poly RNA,-,PKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPK,poly(proline-lysine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PK30];|1 µg/µL [poly-rC],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",liquid,PK−polynucleotide droplets are uniformly less viscous than PR−polynucleotide droplets as assayed by spontaneous fusion events
290,PMID: 30926670,RNAPS0000282,https://pubmed.ncbi.nlm.nih.gov/30926670,RNAs + protein,-;|-,-;|-,polyrG;|polyrC,-;|-,-;|-,poly RNA;|poly RNA,-;|-,PKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPK,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|1 µg/µL [poly-rG+poly-rC],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",-,"In contrast, poly-rG is known to form G quadruplexes, and these structural elements are highly stable. Interestingly, unlike the spherical coacervates formed by complexation of each of poly-rA, poly-rC, and poly-rU with PR, the assemblies formed by poly-rG and PR peptides are characterized by an open, fractal-like network structure that is resistant to thermal denaturation at high salt concentrations."
291,PMID: 30926670,RNAPS0000283,https://pubmed.ncbi.nlm.nih.gov/30926670,RNAs + protein,-;|-,-;|-,polyrA;|polyrU,-;|-,-;|-,poly RNA;|poly RNA,-;|-,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|1 µg/µL [poly-rA:poly-rU=60:40],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,drug:2M-6M Urea,"Microscopy,FRAP",solid,"Addition of urea to open network assemblies helped prevent the formation of networked structures, but this did not result in droplet formation (Fig. 2D). However, thermal denaturation of the poly-rA:rU-PR assemblies followed by an annealing reaction helped convert preformed open networks into spherical assemblies."
292,PMID: 30926670,RNAPS0000283,https://pubmed.ncbi.nlm.nih.gov/30926670,RNAs + protein,-;|-,-;|-,polyrA;|polyrU,-;|-,-;|-,poly RNA;|poly RNA,-;|-,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|1 µg/µL [poly-rA+poly-rU],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP","liquid, solid","Interestingly, when preformed PR−poly-rA and PR−poly-rU condensates/coacervates were mixed together, we did not observe the formation of filamentous structures. Instead, small spherical assemblies are observed"
293,PMID: 30926670,RNAPS0000284,https://pubmed.ncbi.nlm.nih.gov/30926670,RNAs + protein,-;|-,-;|-,polyrA;|polyrC,-;|-,-;|-,poly RNA;|poly RNA,-;|-,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|1 µg/µL [poly-rA+poly-rC],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",liquid,"Interestingly, when preformed PR−poly-rA and PR−poly-rU condensates/coacervates were mixed together, we did not observe the formation of filamentous structures. Instead, small spherical assemblies are observed"
294,PMID: 30926670,RNAPS0000285,https://pubmed.ncbi.nlm.nih.gov/30926670,RNAs + protein,-;|-,-;|-,polyrU;|polyrC,-;|-,-;|-,poly RNA;|poly RNA,-;|-,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|1 µg/µL [poly-rC+poly-rU],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",liquid,"Interestingly, when preformed PR−poly-rA and PR−poly-rU condensates/coacervates were mixed together, we did not observe the formation of filamentous structures. Instead, small spherical assemblies are observed"
295,PMID: 30926670,RNAPS0000286,https://pubmed.ncbi.nlm.nih.gov/30926670,RNAs + protein,-,-,yeast rRNA,-,-,rRNA,yeast,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|1 µg/µL [rRNA],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",-,"The morphologies of the resulting condensates were dependent on the specific type of polyanion and their assembly state: Micro tubule asters or filaments provided a solid scaffold for PR re cruitment, while flexible polyanions such as total yeast RNA or polyphosphate lead to the formation of spherical droplets, in dicative of a minimization of the surface energy that is consistent with liquid−liquid phase separation driven by complex coacervation."
296,PMID: 30926670,RNAPS0000287,https://pubmed.ncbi.nlm.nih.gov/30926670,RNAs + protein,-,-,Saccharomyces cerevisiae RNA,-,-,total RNA,Saccharomyces cerevisiae,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|1 µg/µL [total yeast RNA],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",liquid,"The morphologies of the resulting condensates were dependent on the specific type of polyanion and their assembly state: Micro tubule asters or filaments provided a solid scaffold for PR re cruitment, while flexible polyanions such as total yeast RNA or polyphosphate lead to the formation of spherical droplets, in dicative of a minimization of the surface energy that is consistent with liquid−liquid phase separation driven by complex coacervation."
297,PMID: 30950394,RNAPS0000118,https://pubmed.ncbi.nlm.nih.gov/30950394,RNA + protein,-,-,polyU,-(800-1000 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=207aa|residues=255-441|mutation=C291S
MGSSHHHHHHSSGLVPRGSHMVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSK
DNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKI
GSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSST
GSIDMVDSPQLATLADEVSASLAKQGL",MAPT,C,protein_mutation:C291S,207aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[255-277],[300-302],[304-306],[311-319],[360-370],[416-456]",-,In vitro,20 µM [Tau C];|60 µg/mL polyU,30 mM NaCl,"20 mM ammonium acetate buffer, pH 7.0",10-17˚C,-,-,Turbidity measurement,solute,"The turbidity-temperature curves show that at high temperature, samples became turbid with Abs500~1.5 and abundance of complex coacervations (CCs), while at low temperature, samples became transparent with Abs500~0 and absence of CCs. This demonstrates tau187-RNA CC formation is favored at higher temperature, following clearly a lower critical solution temperature behavior (LCST). By cycling the temperature, we robustly and reversibly changed the tau187-RNA mixture between a turbid state to a completely transparent state. The transition temperatures at which the turbidity emerged during heating and vanished during cooling stay invariant with repeated heating-cooling cycles. The method of extracting a cloud point for the LCST transition temperature from such data will be described in detail in the next section. Importantly, the history of temperature change does not affect the resulting state. Hence the formation and dissolution of tau187-RNA CCs are reversible and consistent with a path-independent equilibrium process. The Thioflavin T (ThT) fluorescence curves of the same sample system as a function of time confirms the absence of amyloid aggregate formation in tau187-RNA CCs. These results together suggest that tau187-RNA CCs are in an equilibrium state, in which tau retains its solution-like dynamics."
298,PMID: 30950394,RNAPS0000118,https://pubmed.ncbi.nlm.nih.gov/30950394,RNA + protein,-,-,polyU,-(800-1000 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=207aa|residues=255-441|mutation=C291S
MGSSHHHHHHSSGLVPRGSHMVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSK
DNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKI
GSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSST
GSIDMVDSPQLATLADEVSASLAKQGL",MAPT,C,protein_mutation:C291S,207aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[255-277],[300-302],[304-306],[311-319],[360-370],[416-456]",-,In vitro,20 µM [Tau C];|60 µg/mL polyU,30 mM NaCl,"20 mM ammonium acetate buffer, pH 7.0",18-25˚C,-,-,Turbidity measurement,liquid,"The turbidity-temperature curves show that at high temperature, samples became turbid with Abs500~1.5 and abundance of complex coacervations (CCs), while at low temperature, samples became transparent with Abs500~0 and absence of CCs. This demonstrates tau187-RNA CC formation is favored at higher temperature, following clearly a lower critical solution temperature behavior (LCST). By cycling the temperature, we robustly and reversibly changed the tau187-RNA mixture between a turbid state to a completely transparent state. The transition temperatures at which the turbidity emerged during heating and vanished during cooling stay invariant with repeated heating-cooling cycles. The method of extracting a cloud point for the LCST transition temperature from such data will be described in detail in the next section. Importantly, the history of temperature change does not affect the resulting state. Hence the formation and dissolution of tau187-RNA CCs are reversible and consistent with a path-independent equilibrium process. The Thioflavin T (ThT) fluorescence curves of the same sample system as a function of time confirms the absence of amyloid aggregate formation in tau187-RNA CCs. These results together suggest that tau187-RNA CCs are in an equilibrium state, in which tau retains its solution-like dynamics."
299,PMID: 30950394,RNAPS0000118,https://pubmed.ncbi.nlm.nih.gov/30950394,RNA + protein,-,-,polyU,-(800-1000 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=207aa|residues=255-441|mutation=C291S
MGSSHHHHHHSSGLVPRGSHMVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSK
DNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKI
GSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSST
GSIDMVDSPQLATLADEVSASLAKQGL",MAPT,C,protein_mutation:C291S,207aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[255-277],[300-302],[304-306],[311-319],[360-370],[416-456]",-,In vitro,100 µM [Tau C];|300 µg/mL polyU,30 mM NaCl,"20 mM ammonium acetate buffer, pH 7.0",RT,-,-,Microscopy,liquid,"The turbidity-temperature curves show that at high temperature, samples became turbid with Abs500~1.5 and abundance of complex coacervations (CCs), while at low temperature, samples became transparent with Abs500~0 and absence of CCs. This demonstrates tau187-RNA CC formation is favored at higher temperature, following clearly a lower critical solution temperature behavior (LCST). By cycling the temperature, we robustly and reversibly changed the tau187-RNA mixture between a turbid state to a completely transparent state. The transition temperatures at which the turbidity emerged during heating and vanished during cooling stay invariant with repeated heating-cooling cycles. The method of extracting a cloud point for the LCST transition temperature from such data will be described in detail in the next section. Importantly, the history of temperature change does not affect the resulting state. Hence the formation and dissolution of tau187-RNA CCs are reversible and consistent with a path-independent equilibrium process. The Thioflavin T (ThT) fluorescence curves of the same sample system as a function of time confirms the absence of amyloid aggregate formation in tau187-RNA CCs. These results together suggest that tau187-RNA CCs are in an equilibrium state, in which tau retains its solution-like dynamics."
300,PMID: 30950394,RNAPS0000118,https://pubmed.ncbi.nlm.nih.gov/30950394,RNA + protein,-,-,polyU,-(800-1000 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=207aa|residues=255-441|mutation=C291S
MGSSHHHHHHSSGLVPRGSHMVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSK
DNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKI
GSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSST
GSIDMVDSPQLATLADEVSASLAKQGL",MAPT,C,protein_mutation:C291S,207aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[255-277],[300-302],[304-306],[311-319],[360-370],[416-456]",-,In vitro,20 µM [Tau C];|60 µg/mL polyU,0-131 mM NaCl,"20 mM ammonium acetate buffer, pH 7.0",20˚C,-,-,Turbidity measurement,liquid,"Titrating RNA to tau187, the turbidity was found to be peaked when [RNA]:[tau] reached charge matching condition at which the charge ratio between net positive and negative charges was 1:1 (which for tau187 and RNA used in this study corresponded to [tau187]:[RNA]=1 µM: 3 µg/mL), validating once more that LLPS is driven by complex coacervation (CC). Henceforth, all phase diagram data are acquired at a charge matching condition between RNA and tau. Titrating NaCl to tau187-RNA, CC formation showed a steady decrease of turbidity. Combined, these demonstrate that tau187-RNA CC favors the condition of charge balance and low ionic strength, which is consistent with known properties of CC and previous findings. Increasing [tau] lowers Tcp, favoring CC formation, while increasing [NaCl] raises Tcp, disfavoring CC formation. Such trends were observed at two [NaCl] and two [tau] values, respectively. Tau187-RNA complex coacervation (CC) and tau114-RNA CC were prepared with 20 µM tau187 and 28 µM tau114, so that the total concentration of polymer, that is tau and RNA, reaches 0.5 mg/mL. Turbidity was recorded at varying [NaCl]. Similar to the observation with tau187-RNA CC, tau114-RNA CC showed decreasing turbidity at increasing [NaCl]. The [NaCl] values where turbidity reaches 0 were estimated as 131 mM and 150 mM for tau187 and tau114, respectively, implying CC formation is more favorable with tau114 that hence can sustain higher [NaCl]. Based on this, 20 µM of tau187, 131 mM of NaCl and room temperature, 20˚C, were used as the phase separation conditions ([tau], [NaCl] and Tcp) for tau187, and 28 µM, 150 mM and 20˚C for tau114. Comparison of the two constructs shows that tau114-RNA CC has a lower Tcp than tau187-RNA CC, suggesting it is more favorable to phase separation. This qualitatively agrees with experimental observations. Notice that the shorter tau114 has a slightly higher propensity to form CC as compared to the longer tau187 fragment, an observation that is opposite of what one would expect from purely entropic considerations based on the mixing of homopolymers or simple coacervation."
301,PMID: 30950394,RNAPS0000118,https://pubmed.ncbi.nlm.nih.gov/30950394,RNA + protein,-,-,polyU,-(800-1000 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=207aa|residues=255-441|mutation=C291S
MGSSHHHHHHSSGLVPRGSHMVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSK
DNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKI
GSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSST
GSIDMVDSPQLATLADEVSASLAKQGL",MAPT,C,protein_mutation:C291S,207aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[255-277],[300-302],[304-306],[311-319],[360-370],[416-456]",-,In vitro,2-240 µM [Tau C];|6-720 µg/mL polyU,30 mM NaCl,"20 mM ammonium acetate buffer, pH 7.0",RT,-,-,Turbidity measurement,liquid,"Titrating RNA to tau187, the turbidity was found to be peaked when [RNA]:[tau] reached charge matching condition at which the charge ratio between net positive and negative charges was 1:1 (which for tau187 and RNA used in this study corresponded to [tau187]:[RNA]=1 µM: 3 µg/mL), validating once more that LLPS is driven by complex coacervation (CC). Henceforth, all phase diagram data are acquired at a charge matching condition between RNA and tau. Titrating NaCl to tau187-RNA, CC formation showed a steady decrease of turbidity. Combined, these demonstrate that tau187-RNA CC favors the condition of charge balance and low ionic strength, which is consistent with known properties of CC and previous findings. Increasing [tau] lowers Tcp, favoring CC formation, while increasing [NaCl] raises Tcp, disfavoring CC formation. Such trends were observed at two [NaCl] and two [tau] values, respectively. Tau187-RNA complex coacervation (CC) and tau114-RNA CC were prepared with 20 µM tau187 and 28 µM tau114, so that the total concentration of polymer, that is tau and RNA, reaches 0.5 mg/mL. Turbidity was recorded at varying [NaCl]. Similar to the observation with tau187-RNA CC, tau114-RNA CC showed decreasing turbidity at increasing [NaCl]. The [NaCl] values where turbidity reaches 0 were estimated as 131 mM and 150 mM for tau187 and tau114, respectively, implying CC formation is more favorable with tau114 that hence can sustain higher [NaCl]. Based on this, 20 µM of tau187, 131 mM of NaCl and room temperature, 20˚C, were used as the phase separation conditions ([tau], [NaCl] and Tcp) for tau187, and 28 µM, 150 mM and 20˚C for tau114. Comparison of the two constructs shows that tau114-RNA CC has a lower Tcp than tau187-RNA CC, suggesting it is more favorable to phase separation. This qualitatively agrees with experimental observations. Notice that the shorter tau114 has a slightly higher propensity to form CC as compared to the longer tau187 fragment, an observation that is opposite of what one would expect from purely entropic considerations based on the mixing of homopolymers or simple coacervation."
302,PMID: 30950394,RNAPS0000118,https://pubmed.ncbi.nlm.nih.gov/30950394,RNA + protein,-,-,polyU,-(800-1000 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=207aa|residues=255-441|mutation=C291S
MGSSHHHHHHSSGLVPRGSHMVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSK
DNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKI
GSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSST
GSIDMVDSPQLATLADEVSASLAKQGL",MAPT,C,protein_mutation:C291S,207aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[255-277],[300-302],[304-306],[311-319],[360-370],[416-456]",-,In vitro,1-120 µM [Tau C];|3-360 µg/mL polyU,30 mM NaCl,"20 mM ammonium acetate buffer, pH 7.0",RT,-,-,Turbidity measurement,"solute, liquid","Titrating RNA to tau187, the turbidity was found to be peaked when [RNA]:[tau] reached charge matching condition at which the charge ratio between net positive and negative charges was 1:1 (which for tau187 and RNA used in this study corresponded to [tau187]:[RNA]=1 µM: 3 µg/mL), validating once more that LLPS is driven by complex coacervation (CC). Henceforth, all phase diagram data are acquired at a charge matching condition between RNA and tau. Titrating NaCl to tau187-RNA, CC formation showed a steady decrease of turbidity. Combined, these demonstrate that tau187-RNA CC favors the condition of charge balance and low ionic strength, which is consistent with known properties of CC and previous findings. Increasing [tau] lowers Tcp, favoring CC formation, while increasing [NaCl] raises Tcp, disfavoring CC formation. Such trends were observed at two [NaCl] and two [tau] values, respectively. Tau187-RNA complex coacervation (CC) and tau114-RNA CC were prepared with 20 µM tau187 and 28 µM tau114, so that the total concentration of polymer, that is tau and RNA, reaches 0.5 mg/mL. Turbidity was recorded at varying [NaCl]. Similar to the observation with tau187-RNA CC, tau114-RNA CC showed decreasing turbidity at increasing [NaCl]. The [NaCl] values where turbidity reaches 0 were estimated as 131 mM and 150 mM for tau187 and tau114, respectively, implying CC formation is more favorable with tau114 that hence can sustain higher [NaCl]. Based on this, 20 µM of tau187, 131 mM of NaCl and room temperature, 20˚C, were used as the phase separation conditions ([tau], [NaCl] and Tcp) for tau187, and 28 µM, 150 mM and 20˚C for tau114. Comparison of the two constructs shows that tau114-RNA CC has a lower Tcp than tau187-RNA CC, suggesting it is more favorable to phase separation. This qualitatively agrees with experimental observations. Notice that the shorter tau114 has a slightly higher propensity to form CC as compared to the longer tau187 fragment, an observation that is opposite of what one would expect from purely entropic considerations based on the mixing of homopolymers or simple coacervation."
303,PMID: 30950394,RNAPS0000118,https://pubmed.ncbi.nlm.nih.gov/30950394,RNA + protein,-,-,polyU,-(800-1000 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=207aa|residues=255-441|mutation=C291S
MGSSHHHHHHSSGLVPRGSHMVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSK
DNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKI
GSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSST
GSIDMVDSPQLATLADEVSASLAKQGL",MAPT,C,protein_mutation:C291S,207aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[255-277],[300-302],[304-306],[311-319],[360-370],[416-456]",-,In vitro,1-120 µM [Tau C];|3-360 µg/mL polyU,120 mM NaCl,"20 mM ammonium acetate buffer, pH 7.0",RT,-,-,Turbidity measurement,"solute, liquid","Titrating RNA to tau187, the turbidity was found to be peaked when [RNA]:[tau] reached charge matching condition at which the charge ratio between net positive and negative charges was 1:1 (which for tau187 and RNA used in this study corresponded to [tau187]:[RNA]=1 µM: 3 µg/mL), validating once more that LLPS is driven by complex coacervation (CC). Henceforth, all phase diagram data are acquired at a charge matching condition between RNA and tau. Titrating NaCl to tau187-RNA, CC formation showed a steady decrease of turbidity. Combined, these demonstrate that tau187-RNA CC favors the condition of charge balance and low ionic strength, which is consistent with known properties of CC and previous findings. Increasing [tau] lowers Tcp, favoring CC formation, while increasing [NaCl] raises Tcp, disfavoring CC formation. Such trends were observed at two [NaCl] and two [tau] values, respectively. Tau187-RNA complex coacervation (CC) and tau114-RNA CC were prepared with 20 µM tau187 and 28 µM tau114, so that the total concentration of polymer, that is tau and RNA, reaches 0.5 mg/mL. Turbidity was recorded at varying [NaCl]. Similar to the observation with tau187-RNA CC, tau114-RNA CC showed decreasing turbidity at increasing [NaCl]. The [NaCl] values where turbidity reaches 0 were estimated as 131 mM and 150 mM for tau187 and tau114, respectively, implying CC formation is more favorable with tau114 that hence can sustain higher [NaCl]. Based on this, 20 µM of tau187, 131 mM of NaCl and room temperature, 20˚C, were used as the phase separation conditions ([tau], [NaCl] and Tcp) for tau187, and 28 µM, 150 mM and 20˚C for tau114. Comparison of the two constructs shows that tau114-RNA CC has a lower Tcp than tau187-RNA CC, suggesting it is more favorable to phase separation. This qualitatively agrees with experimental observations. Notice that the shorter tau114 has a slightly higher propensity to form CC as compared to the longer tau187 fragment, an observation that is opposite of what one would expect from purely entropic considerations based on the mixing of homopolymers or simple coacervation."
304,PMID: 30950394,RNAPS0000118,https://pubmed.ncbi.nlm.nih.gov/30950394,RNA + protein,-,-,polyU,-(800-1000 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=207aa|residues=255-441|mutation=C291S
MGSSHHHHHHSSGLVPRGSHMVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSK
DNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKI
GSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSST
GSIDMVDSPQLATLADEVSASLAKQGL",MAPT,C,protein_mutation:C291S,207aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[255-277],[300-302],[304-306],[311-319],[360-370],[416-456]",-,In vitro,5 µM [Tau C];|15 µg/mL polyU,10-300 mM NaCl,"20 mM ammonium acetate buffer, pH 7.0",RT,-,-,Turbidity measurement,"solute, liquid","Titrating RNA to tau187, the turbidity was found to be peaked when [RNA]:[tau] reached charge matching condition at which the charge ratio between net positive and negative charges was 1:1 (which for tau187 and RNA used in this study corresponded to [tau187]:[RNA]=1 µM: 3 µg/mL), validating once more that LLPS is driven by complex coacervation (CC). Henceforth, all phase diagram data are acquired at a charge matching condition between RNA and tau. Titrating NaCl to tau187-RNA, CC formation showed a steady decrease of turbidity. Combined, these demonstrate that tau187-RNA CC favors the condition of charge balance and low ionic strength, which is consistent with known properties of CC and previous findings. Increasing [tau] lowers Tcp, favoring CC formation, while increasing [NaCl] raises Tcp, disfavoring CC formation. Such trends were observed at two [NaCl] and two [tau] values, respectively. Tau187-RNA complex coacervation (CC) and tau114-RNA CC were prepared with 20 µM tau187 and 28 µM tau114, so that the total concentration of polymer, that is tau and RNA, reaches 0.5 mg/mL. Turbidity was recorded at varying [NaCl]. Similar to the observation with tau187-RNA CC, tau114-RNA CC showed decreasing turbidity at increasing [NaCl]. The [NaCl] values where turbidity reaches 0 were estimated as 131 mM and 150 mM for tau187 and tau114, respectively, implying CC formation is more favorable with tau114 that hence can sustain higher [NaCl]. Based on this, 20 µM of tau187, 131 mM of NaCl and room temperature, 20˚C, were used as the phase separation conditions ([tau], [NaCl] and Tcp) for tau187, and 28 µM, 150 mM and 20˚C for tau114. Comparison of the two constructs shows that tau114-RNA CC has a lower Tcp than tau187-RNA CC, suggesting it is more favorable to phase separation. This qualitatively agrees with experimental observations. Notice that the shorter tau114 has a slightly higher propensity to form CC as compared to the longer tau187 fragment, an observation that is opposite of what one would expect from purely entropic considerations based on the mixing of homopolymers or simple coacervation."
305,PMID: 30950394,RNAPS0000118,https://pubmed.ncbi.nlm.nih.gov/30950394,RNA + protein,-,-,polyU,-(800-1000 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=207aa|residues=255-441|mutation=C291S
MGSSHHHHHHSSGLVPRGSHMVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSK
DNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKI
GSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSST
GSIDMVDSPQLATLADEVSASLAKQGL",MAPT,C,protein_mutation:C291S,207aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[255-277],[300-302],[304-306],[311-319],[360-370],[416-456]",-,In vitro,20 µM [Tau C];|60 µg/mL polyU,10-300 mM NaCl,"20 mM ammonium acetate buffer, pH 7.0",RT,-,-,Turbidity measurement,"solute, liquid","Titrating RNA to tau187, the turbidity was found to be peaked when [RNA]:[tau] reached charge matching condition at which the charge ratio between net positive and negative charges was 1:1 (which for tau187 and RNA used in this study corresponded to [tau187]:[RNA]=1 µM: 3 µg/mL), validating once more that LLPS is driven by complex coacervation (CC). Henceforth, all phase diagram data are acquired at a charge matching condition between RNA and tau. Titrating NaCl to tau187-RNA, CC formation showed a steady decrease of turbidity. Combined, these demonstrate that tau187-RNA CC favors the condition of charge balance and low ionic strength, which is consistent with known properties of CC and previous findings. Increasing [tau] lowers Tcp, favoring CC formation, while increasing [NaCl] raises Tcp, disfavoring CC formation. Such trends were observed at two [NaCl] and two [tau] values, respectively. Tau187-RNA complex coacervation (CC) and tau114-RNA CC were prepared with 20 µM tau187 and 28 µM tau114, so that the total concentration of polymer, that is tau and RNA, reaches 0.5 mg/mL. Turbidity was recorded at varying [NaCl]. Similar to the observation with tau187-RNA CC, tau114-RNA CC showed decreasing turbidity at increasing [NaCl]. The [NaCl] values where turbidity reaches 0 were estimated as 131 mM and 150 mM for tau187 and tau114, respectively, implying CC formation is more favorable with tau114 that hence can sustain higher [NaCl]. Based on this, 20 µM of tau187, 131 mM of NaCl and room temperature, 20˚C, were used as the phase separation conditions ([tau], [NaCl] and Tcp) for tau187, and 28 µM, 150 mM and 20˚C for tau114. Comparison of the two constructs shows that tau114-RNA CC has a lower Tcp than tau187-RNA CC, suggesting it is more favorable to phase separation. This qualitatively agrees with experimental observations. Notice that the shorter tau114 has a slightly higher propensity to form CC as compared to the longer tau187 fragment, an observation that is opposite of what one would expect from purely entropic considerations based on the mixing of homopolymers or simple coacervation."
306,PMID: 30950394,RNAPS0000118,https://pubmed.ncbi.nlm.nih.gov/30950394,RNA + protein,-,-,polyU,-(800-1000 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=134aa|residues=255-368|mutation=C291S
MGSSHHHHHHSSGLVPRGSHMVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSK
DNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKI
GSLDNITHVPGGGN",MAPT,-,-,134aa(255-368),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[255-277],[300-302],[304-306],[311-319],[360-370],[384-384],[386-388]  254",-,In vitro,28 µM [Tau 255-368];|the total concentration of tau and polyU RNA reaches 0.5 mg/mL,0-150 mM NaCl,"20 mM ammonium acetate buffer, pH 7.0",20˚C,-,-,Turbidity measurement,liquid,"Titrating RNA to tau187, the turbidity was found to be peaked when [RNA]:[tau] reached charge matching condition at which the charge ratio between net positive and negative charges was 1:1 (which for tau187 and RNA used in this study corresponded to [tau187]:[RNA]=1 µM: 3 µg/mL), validating once more that LLPS is driven by complex coacervation (CC). Henceforth, all phase diagram data are acquired at a charge matching condition between RNA and tau. Titrating NaCl to tau187-RNA, CC formation showed a steady decrease of turbidity. Combined, these demonstrate that tau187-RNA CC favors the condition of charge balance and low ionic strength, which is consistent with known properties of CC and previous findings. Increasing [tau] lowers Tcp, favoring CC formation, while increasing [NaCl] raises Tcp, disfavoring CC formation. Such trends were observed at two [NaCl] and two [tau] values, respectively. Tau187-RNA complex coacervation (CC) and tau114-RNA CC were prepared with 20 µM tau187 and 28 µM tau114, so that the total concentration of polymer, that is tau and RNA, reaches 0.5 mg/mL. Turbidity was recorded at varying [NaCl]. Similar to the observation with tau187-RNA CC, tau114-RNA CC showed decreasing turbidity at increasing [NaCl]. The [NaCl] values where turbidity reaches 0 were estimated as 131 mM and 150 mM for tau187 and tau114, respectively, implying CC formation is more favorable with tau114 that hence can sustain higher [NaCl]. Based on this, 20 µM of tau187, 131 mM of NaCl and room temperature, 20˚C, were used as the phase separation conditions ([tau], [NaCl] and Tcp) for tau187, and 28 µM, 150 mM and 20˚C for tau114. Comparison of the two constructs shows that tau114-RNA CC has a lower Tcp than tau187-RNA CC, suggesting it is more favorable to phase separation. This qualitatively agrees with experimental observations. Notice that the shorter tau114 has a slightly higher propensity to form CC as compared to the longer tau187 fragment, an observation that is opposite of what one would expect from purely entropic considerations based on the mixing of homopolymers or simple coacervation."
307,PMID: 30950394,RNAPS0000118,https://pubmed.ncbi.nlm.nih.gov/30950394,RNA + protein,-,-,polyU,-(800-1000 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=134aa|residues=255-368|mutation=C291S
MGSSHHHHHHSSGLVPRGSHMVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSK
DNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKI
GSLDNITHVPGGGN",MAPT,-,protein_mutation:C291S,134aa(255-368),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[255-277],[300-302],[304-306],[311-319],[360-370],[384-384],[386-388]  254",-,In vitro,1-300 µM [Tau 255-368];|the total concentration of tau and polyU RNA reaches 0.5 mg/mL,30 mM NaCl,"20 mM ammonium acetate buffer, pH 7.0",RT,-,-,Turbidity measurement,"solute, liquid","Titrating RNA to tau187, the turbidity was found to be peaked when [RNA]:[tau] reached charge matching condition at which the charge ratio between net positive and negative charges was 1:1 (which for tau187 and RNA used in this study corresponded to [tau187]:[RNA]=1 µM: 3 µg/mL), validating once more that LLPS is driven by complex coacervation (CC). Henceforth, all phase diagram data are acquired at a charge matching condition between RNA and tau. Titrating NaCl to tau187-RNA, CC formation showed a steady decrease of turbidity. Combined, these demonstrate that tau187-RNA CC favors the condition of charge balance and low ionic strength, which is consistent with known properties of CC and previous findings. Increasing [tau] lowers Tcp, favoring CC formation, while increasing [NaCl] raises Tcp, disfavoring CC formation. Such trends were observed at two [NaCl] and two [tau] values, respectively. Tau187-RNA complex coacervation (CC) and tau114-RNA CC were prepared with 20 µM tau187 and 28 µM tau114, so that the total concentration of polymer, that is tau and RNA, reaches 0.5 mg/mL. Turbidity was recorded at varying [NaCl]. Similar to the observation with tau187-RNA CC, tau114-RNA CC showed decreasing turbidity at increasing [NaCl]. The [NaCl] values where turbidity reaches 0 were estimated as 131 mM and 150 mM for tau187 and tau114, respectively, implying CC formation is more favorable with tau114 that hence can sustain higher [NaCl]. Based on this, 20 µM of tau187, 131 mM of NaCl and room temperature, 20˚C, were used as the phase separation conditions ([tau], [NaCl] and Tcp) for tau187, and 28 µM, 150 mM and 20˚C for tau114. Comparison of the two constructs shows that tau114-RNA CC has a lower Tcp than tau187-RNA CC, suggesting it is more favorable to phase separation. This qualitatively agrees with experimental observations. Notice that the shorter tau114 has a slightly higher propensity to form CC as compared to the longer tau187 fragment, an observation that is opposite of what one would expect from purely entropic considerations based on the mixing of homopolymers or simple coacervation."
308,PMID: 30950394,RNAPS0000118,https://pubmed.ncbi.nlm.nih.gov/30950394,RNA + protein,-,-,polyU,-(800-1000 kDa),-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|length=134aa|residues=255-368|mutation=C291S
MGSSHHHHHHSSGLVPRGSHMVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSK
DNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKI
GSLDNITHVPGGGN",MAPT,-,protein_mutation:C291S,134aa(255-368),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[255-277],[300-302],[304-306],[311-319],[360-370],[384-384],[386-388]  254",-,In vitro,1-300 µM [Tau 255-368];|the total concentration of tau and polyU RNA reaches 0.5 mg/mL,120 mM NaCl,"20 mM ammonium acetate buffer, pH 7.0",RT,-,-,Turbidity measurement,"solute, liquid","Titrating RNA to tau187, the turbidity was found to be peaked when [RNA]:[tau] reached charge matching condition at which the charge ratio between net positive and negative charges was 1:1 (which for tau187 and RNA used in this study corresponded to [tau187]:[RNA]=1 µM: 3 µg/mL), validating once more that LLPS is driven by complex coacervation (CC). Henceforth, all phase diagram data are acquired at a charge matching condition between RNA and tau. Titrating NaCl to tau187-RNA, CC formation showed a steady decrease of turbidity. Combined, these demonstrate that tau187-RNA CC favors the condition of charge balance and low ionic strength, which is consistent with known properties of CC and previous findings. Increasing [tau] lowers Tcp, favoring CC formation, while increasing [NaCl] raises Tcp, disfavoring CC formation. Such trends were observed at two [NaCl] and two [tau] values, respectively. Tau187-RNA complex coacervation (CC) and tau114-RNA CC were prepared with 20 µM tau187 and 28 µM tau114, so that the total concentration of polymer, that is tau and RNA, reaches 0.5 mg/mL. Turbidity was recorded at varying [NaCl]. Similar to the observation with tau187-RNA CC, tau114-RNA CC showed decreasing turbidity at increasing [NaCl]. The [NaCl] values where turbidity reaches 0 were estimated as 131 mM and 150 mM for tau187 and tau114, respectively, implying CC formation is more favorable with tau114 that hence can sustain higher [NaCl]. Based on this, 20 µM of tau187, 131 mM of NaCl and room temperature, 20˚C, were used as the phase separation conditions ([tau], [NaCl] and Tcp) for tau187, and 28 µM, 150 mM and 20˚C for tau114. Comparison of the two constructs shows that tau114-RNA CC has a lower Tcp than tau187-RNA CC, suggesting it is more favorable to phase separation. This qualitatively agrees with experimental observations. Notice that the shorter tau114 has a slightly higher propensity to form CC as compared to the longer tau187 fragment, an observation that is opposite of what one would expect from purely entropic considerations based on the mixing of homopolymers or simple coacervation."
309,PMID: 32901111,RNAPS0000294,https://pubmed.ncbi.nlm.nih.gov/32901111,RNA + protein,-,-,SARS-CoV-2 N1541 RNA,1541nt,GGGGAAUUGUGAGCGGAUAACAAUUCCCCUCUAGAAAUAAUUUUGUUUAACUUUAAGAAGGAGAUAUACCAUGGGCAGCAGCCAUCAUCAUCAUCAUCACCACCACCACCAUAGCAGCGGCCUGGUGCCGCGCGGCAGCGCUAGCAUGUCUGAUAAUGGACCCCAAAAUCAGCGAAAUGCACCCCGCAUUACGUUUGGUGGACCCUCAGAUUCAACUGGCAGUAACCAGAAUGGAGAACGCAGUGGGGCGCGAUCAAAACAACGUCGGCCCCAAGGUUUACCCAAUAAUACUGCGUCUUGGUUCACCGCUCUCACUCAACAUGGCAAGGAAGACCUUAAAUUCCCUCGAGGACAAGGCGUUCCAAUUAACACCAAUAGCAGUCCAGAUGACCAAAUUGGCUACUACCGAAGAGCUACCAGACGAAUUCGUGGUGGUGACGGUAAAAUGAAAGAUCUCAGUCCAAGAUGGUAUUUCUACUACCUAGGAACUGGGCCAGAAGCUGGACUUCCCUAUGGUGCUAACAAAGACGGCAUCAUAUGGGUUGCAACUGAGGGAGCCUUGAAUACACCAAAAGAUCACAUUGGCACCCGCAAUCCUGCUAACAAUGCUGCAAUCGUGCUACAACUUCCUCAAGGAACAACAUUGCCAAAAGGCUUCUACGCAGAAGGGAGCAGAGGCGGCAGUCAAGCCUCUUCUCGUUCCUCAUCACGUAGUCGCAACAGUUCAAGAAAUUCAACUCCAGGCAGCAGUAGGGGAACUUCUCCUGCUAGAAUGGCUGGCAAUGGCGGUGAUGCUGCUCUUGCUUUGCUGCUGCUUGACAGAUUGAACCAGCUUGAGAGCAAAAUGUCUGGUAAAGGCCAACAACAACAAGGCCAAACUGUCACUAAGAAAUCUGCUGCUGAGGCUUCUAAGAAGCCUCGGCAAAAACGUACUGCCACUAAAGCAUACAAUGUAACACAAGCUUUCGGCAGACGUGGUCCAGAACAAACCCAAGGAAAUUUUGGGGACCAGGAACUAAUCAGACAAGGAACUGAUUACAAACAUUGGCCGCAAAUUGCACAAUUUGCCCCCAGCGCUUCAGCGUUCUUCGGAAUGUCGCGCAUUGGCAUGGAAGUCACACCUUCGGGAACGUGGUUGACCUACACAGGUGCCAUCAAAUUGGAUGACAAAGAUCCAAAUUUCAAAGAUCAAGUCAUUUUGCUGAAUAAGCAUAUUGACGCAUACAAAACAUUCCCACCAACAGAGCCUAAAAAGGACAAAAAGAAGAAGGCUGAUGAAACUCAAGCCUUACCGCAGAGACAGAAGAAACAGCAAACUGUGACUCUUCUUCCUGCUGCAGAUUUGGAUGAUUUCUCCAAACAAUUGCAACAAUCCAUGAGCAGUGCUGACUCAACUCAGGCCUGUUGAGGAUCCUGUGAAUUCGAGCUCCGUCGACAAGCUUGCGGCCGCACUCGAGCACCACCACCACCACCACUGAGAUCCGGCUGCUAACAAAGCCCGAAAGGAAGCUGAGUUGGCUGCUGCCACCGCUGAGCAAUAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.1-5µM [A85];|20µM [N protein],-,"1× PBS, pH 7.4",RT,> 1 h,crowding agent:2.5% PEG8000,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"Representative fluorescence and DIC images of LLPS formed by N protein (green) with 85-nt RNA A85 at the indicated concentrations. Representative fluorescence and DIC images of LLPS formed by N protein (red) with the positive strand RNA of N protein (N1541, 1541 nt) at the indicated concentrations."
310,PMID: 33290746,RNAPS0000420,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,"H20 RNA(Chen,2020)",20nt,AGAUUCAACUGGCAGUAACC,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,4 µM[SARS-CoV-2 N protein],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,"liquid, solute","Pure N-protein demixed into droplets (consistent with results from the Morgan [Carlson et al., 2020] and Fawzi [Myrto Perdikari et al., 2020] labs) and LLPS was enhanced by RNA extracted from the culture medium supernatant of infected cells containing full-length SARS-CoV-2 genome"
311,PMID: 30981631,RNAPS0000296,https://pubmed.ncbi.nlm.nih.gov/30981631,RNAs + protein,-,-,Escherichia coli RNA,-,-,total RNA,Escherichia coli,"sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens OX=9606 GN=NPM1 PE=1 SV=2|length=294aa|residues=1-294
MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIV
EAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVE
EDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDD
FDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKG
PSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL",NPM1,-,-,294aa(1-294),P06748,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P06748,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2486,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0020,http://db.phasep.pro/browse/",[1-259],-,In vitro,15 µM [NPM1];|50 ng/mL RNA,150 mM NaCl,"10 mM Tris, pH 7.5, 2 mM DTT",RT,> 30 min,-,"Microscopy,FRAP",liquid,"(PR)23 initially infiltrated NPM1/rRNA droplets as observed in protein only droplets. NPM1 within these droplets showed no change in mobility as compared to droplets formed in the absence of (PR)23, while the recovery time of (PR)23 increased ~2-fold between the 0.253 and 0.53 additions. Upon further titration of (PR)23, droplets dissolved, leaving rRNA/(PR)23 puncta that displayed drastically reduced recovery of (PR)23, similar to (PR)23/rRNA puncta formed in the absence of NPM1. NPM1 did associate with these puncta, but not so as to cause phase separation. Further titration of (PR)23 yielded new phase separated NPM1/(PR)23 droplets that engulfed the rRNA/(PR)23 puncta. NPM1 was excluded from the rRNA/(PR)23 puncta in phase 3 droplets and had reduced mobility compared with phase 1 and NPM1/rRNA-only droplets. (PR)23 had comparatively rapid recovery in the NPM1-containing liquid droplet regions surrounding (PR)23/rRNA puncta and significantly diminished recovery within puncta. Finally, continued titration of (PR)23 resulted in the dissolution of the reformed NPM1/(PR)23 droplets, while the rRNA/(PR)23 puncta persisted."
312,PMID: 31188823,RNAPS0000300,https://pubmed.ncbi.nlm.nih.gov/31188823,RNA + protein,-,-,"12-mer RNA (Kang,2019)",12nt,UAGUUUGGUGAU,irregular RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=267aa|residues=1-267
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGG",FUS,NTD,-,267aa(1-267),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[1-267],"[17-104],[106-261]",In vitro,20µM [FUS NTD];|40 µM RNA,"150 mM NaCl, 1 mM MgCl2, 4 mM ZnCl2",5 mM sodium phosphate buffer at pH 6.0,25˚C,-,-,Differential interference contrast microscopy,liquid,"Like ATP, RNA and two ssDNA molecules also induced the same monotonic dissolution of LLPS of NTD. Briefly, a ratio of 1:2 was required for RNA, but only a ratio of 1:1 was sufficient for two ssDNA molecules to significantly disrupt LLPS to reduce the sizes of droplets, with the maximal diameter reduced from approximately 7.6 to < 3.0 μm. Furthermore, a ratio of 1:5 was required for RNA (0.1 mM), but only a ratio of 1:2 was sufficient for two ssDNA molecules (0.04 mM) to completely dissolve LLPS of the NTD."
313,PMID: 31188823,RNAPS0000300,https://pubmed.ncbi.nlm.nih.gov/31188823,RNA + protein,-,-,"12-mer RNA (Kang,2019)",12nt,UAGUUUGGUGAU,irregular RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=267aa|residues=1-267
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGG",FUS,NTD,-,267aa(1-267),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[1-267],"[17-104],[106-261]",In vitro,20µM [FUS NTD];|100 µM RNA,"150 mM NaCl, 1 mM MgCl2, 4 mM ZnCl2",5 mM sodium phosphate buffer at pH 6.0,25˚C,-,-,Differential interference contrast microscopy,solute,"Like ATP, RNA and two ssDNA molecules also induced the same monotonic dissolution of LLPS of NTD. Briefly, a ratio of 1:2 was required for RNA, but only a ratio of 1:1 was sufficient for two ssDNA molecules to significantly disrupt LLPS to reduce the sizes of droplets, with the maximal diameter reduced from approximately 7.6 to < 3.0 μm. Furthermore, a ratio of 1:5 was required for RNA (0.1 mM), but only a ratio of 1:2 was sufficient for two ssDNA molecules (0.04 mM) to completely dissolve LLPS of the NTD."
314,PMID: 31188823,RNAPS0000300,https://pubmed.ncbi.nlm.nih.gov/31188823,RNA + protein,-,-,"12-mer RNA (Kang,2019)",12nt,UAGUUUGGUGAU,irregular RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=156aa|residues=371-526
RRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQQRAGDWKCPN
PTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYDRGGYRGRGGD
RGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,CTD,-,156aa(371-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[371-507],[508-512]","[371-425],[450-507]",In vitro,20µM [FUS CTD];|40 µM RNA,"150 mM NaCl, 1 mM MgCl2, 4 mM ZnCl2",5 mM sodium phosphate buffer at pH 6.0,25˚C,-,-,Differential interference contrast microscopy,liquid,"Upon adding RNA at a molar ratio of 1:2, many small droplets formed with a maximal diameter of approximately 1.1 μm. However, at 1:5, droplets were significantly dissolved, with only a small number of droplets left with a maximal diameter <1.0 μm, and at 1:10, all droplets dissolved. Interestingly, for TssDNA, even at 1:1, many large droplets formed with a maximal diameter of approximately 4.0 μm, while at 1:2, droplets were significantly dissolved, with only several droplets left with a maximal diameter <1.0 μm. At 1:5, all droplets were dissolved. T24 has a similar effect as TssDNA: at 1:1, many large droplets formed with a maximal diameter of approximately 5.0 μm, while at 1:2, droplets were significantly dissolved, with several droplets left with a maximal diameter <1.0 μm. Strikingly, three oligonucleic acids also have the same two-stage effect on the FUS U-CTD."
315,PMID: 31188823,RNAPS0000300,https://pubmed.ncbi.nlm.nih.gov/31188823,RNA + protein,-,-,"12-mer RNA (Kang,2019)",12nt,UAGUUUGGUGAU,irregular RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=156aa|residues=371-526
RRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQQRAGDWKCPN
PTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYDRGGYRGRGGD
RGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,CTD,-,156aa(371-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[371-507],[508-512]","[371-425],[450-507]",In vitro,20µM [FUS CTD];|100 µM RNA,"150 mM NaCl, 1 mM MgCl2, 4 mM ZnCl2",5 mM sodium phosphate buffer at pH 6.0,25˚C,-,-,Differential interference contrast microscopy,liquid,"Upon adding RNA at a molar ratio of 1:2, many small droplets formed with a maximal diameter of approximately 1.1 μm. However, at 1:5, droplets were significantly dissolved, with only a small number of droplets left with a maximal diameter <1.0 μm, and at 1:10, all droplets dissolved. Interestingly, for TssDNA, even at 1:1, many large droplets formed with a maximal diameter of approximately 4.0 μm, while at 1:2, droplets were significantly dissolved, with only several droplets left with a maximal diameter <1.0 μm. At 1:5, all droplets were dissolved. T24 has a similar effect as TssDNA: at 1:1, many large droplets formed with a maximal diameter of approximately 5.0 μm, while at 1:2, droplets were significantly dissolved, with several droplets left with a maximal diameter <1.0 μm. Strikingly, three oligonucleic acids also have the same two-stage effect on the FUS U-CTD."
316,PMID: 31188823,RNAPS0000300,https://pubmed.ncbi.nlm.nih.gov/31188823,RNA + protein,-,-,"12-mer RNA (Kang,2019)",12nt,UAGUUUGGUGAU,irregular RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=156aa|residues=371-526
RRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQQRAGDWKCPN
PTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYDRGGYRGRGGD
RGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,CTD,-,156aa(371-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[371-507],[508-512]","[371-425],[450-507]",In vitro,20µM [FUS CTD];|200 µM RNA,"150 mM NaCl, 1 mM MgCl2, 4 mM ZnCl2",5 mM sodium phosphate buffer at pH 6.0,25˚C,-,-,Differential interference contrast microscopy,solute,"Upon adding RNA at a molar ratio of 1:2, many small droplets formed with a maximal diameter of approximately 1.1 μm. However, at 1:5, droplets were significantly dissolved, with only a small number of droplets left with a maximal diameter <1.0 μm, and at 1:10, all droplets dissolved. Interestingly, for TssDNA, even at 1:1, many large droplets formed with a maximal diameter of approximately 4.0 μm, while at 1:2, droplets were significantly dissolved, with only several droplets left with a maximal diameter <1.0 μm. At 1:5, all droplets were dissolved. T24 has a similar effect as TssDNA: at 1:1, many large droplets formed with a maximal diameter of approximately 5.0 μm, while at 1:2, droplets were significantly dissolved, with several droplets left with a maximal diameter <1.0 μm. Strikingly, three oligonucleic acids also have the same two-stage effect on the FUS U-CTD."
317,PMID: 31188823,RNAPS0000300,https://pubmed.ncbi.nlm.nih.gov/31188823,RNA + protein,-,-,"12-mer RNA (Kang,2019)",12nt,UAGUUUGGUGAU,irregular RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,20µM [FUS];|40 µM RNA,"150 mM NaCl, 1 mM MgCl2, 4 mM ZnCl2",5 mM sodium phosphate buffer at pH 6.0,25˚C,-,-,Differential interference contrast microscopy,liquid,"In the absence of nucleic acids, FUS itself was able to undergo LLPS to form only a small number of droplets with a maximal diameter of approximately 3.7 μm. By contrast, addition of RNA at a ratio of 1:2 significantly enhanced LLPS by mainly increasing the numbers of droplets with a maximal diameter of approximately 4.0 μm. Further addition to 1:10 led to significant dissolution of liquid droplets by reducing both numbers and sizes of droplets with a maximal diameter of only approximately 2.5 μm.  For TssDNA, at a molar ratio of 1:1 (FUS:TssDNA), LLPS of FUS appeared to be significantly enhanced by forming a large number of droplets with a maximal diameter up to 5.4 μm. Further addition to 1:5 led to significant dissolution of droplets with the maximal diameter reduced to only approximately 1.6 μm, and at 1:10, all droplets were completely dissolved. Interestingly, T24 showed the same two stage effect on LLPS of FUS as TssDNA. At a molar ratio of 1:1, LLPS of FUS was significantly enhanced by forming a large number of droplets with a maximal diameter up to approximately 6.2 μm. Similarly, addition to 1:5 led to significant dissolution of droplets with the maximal diameter reduced to approximately 1.2 μm, and at 1:10, all droplets were also dissolved."
318,PMID: 31188823,RNAPS0000300,https://pubmed.ncbi.nlm.nih.gov/31188823,RNA + protein,-,-,"12-mer RNA (Kang,2019)",12nt,UAGUUUGGUGAU,irregular RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,20µM [FUS];|200 µM RNA,"150 mM NaCl, 1 mM MgCl2, 4 mM ZnCl2",5 mM sodium phosphate buffer at pH 6.0,25˚C,-,-,Differential interference contrast microscopy,liquid,"In the absence of nucleic acids, FUS itself was able to undergo LLPS to form only a small number of droplets with a maximal diameter of approximately 3.7 μm. By contrast, addition of RNA at a ratio of 1:2 significantly enhanced LLPS by mainly increasing the numbers of droplets with a maximal diameter of approximately 4.0 μm. Further addition to 1:10 led to significant dissolution of liquid droplets by reducing both numbers and sizes of droplets with a maximal diameter of only approximately 2.5 μm.  For TssDNA, at a molar ratio of 1:1 (FUS:TssDNA), LLPS of FUS appeared to be significantly enhanced by forming a large number of droplets with a maximal diameter up to 5.4 μm. Further addition to 1:5 led to significant dissolution of droplets with the maximal diameter reduced to only approximately 1.6 μm, and at 1:10, all droplets were completely dissolved. Interestingly, T24 showed the same two stage effect on LLPS of FUS as TssDNA. At a molar ratio of 1:1, LLPS of FUS was significantly enhanced by forming a large number of droplets with a maximal diameter up to approximately 6.2 μm. Similarly, addition to 1:5 led to significant dissolution of droplets with the maximal diameter reduced to approximately 1.2 μm, and at 1:10, all droplets were also dissolved."
319,PMID: 31266957,RNAPS0000301,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,KKASLKKASLKKASL,K3,-,-,15aa,-,-,-,-,-,In vitro,0.5 mg/ml [polyU RNA];|1 mM.[K3],-,"25 mM HEPES,pH 7.4",RT,-,-,Differential interference contrast microscopy,liquid,DIC image of a pair of K3/RNA liquid droplets undergoing fusion. The concentration of polyU RNA was 0.5 mg ml−1 and K3 was 1 mM.
320,PMID: 31266957,RNAPS0000301,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,KKASLKKASLKKASL,K3,-,-,15aa,-,-,-,-,-,In vitro,1 mg/ml[polyU RNA];|1 mM[K3],-,"25 mM HEPES,PH 5.4 or 7.4 or 9.4",RT,5 min-20 min,-,Fluorescence microscopy,"solute, liquid",Distribution of droplet diameters after 5 and 20 min with the corresponding fluorescence images.The K3 droplets grew in time at the expense of smaller droplets
321,PMID: 31266957,RNAPS0000301,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,KKASLKKASLKKASL,K3,-,-,15aa,-,-,-,-,-,In vitro,0.5 mg/ml[polyU RNA];|1 mM[K3],-,"25 mM HEPES,pH 7.4",RT,≤ 90 min,other_molecular:CREB/p300,Turbidity measurement,liquid,"The specificity of acetylation-dependent complex coacervation was further supported by KAT reactions with lysine- and arginine-rich peptide/RNA-coacervates (Fig. 6e), demonstrating that R3/RNA-coacervates are not dissolved in the presence of CREB or p300."
322,PMID: 31266957,RNAPS0000301,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,KKASLKKASLKKASL,K3,-,-,15aa,-,-,-,-,-,In vitro,0.5 mg/ml[polyU RNA];|1 mM[K3],-,"25 mM HEPES,pH 7.4",RT,≤ 90 min,other_molecular:AcCoA,Turbidity measurement,liquid,"The specificity of acetylation-dependent complex coacervation was further supported by KAT reactions with lysine- and arginine-rich peptide/RNA-coacervates (Fig. 6e), demonstrating that R3/RNA-coacervates are not dissolved in the presence of CREB or p300."
323,PMID: 31266957,RNAPS0000301,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,KKASLKKASLKKASL,K3,-,-,15aa,-,-,-,-,-,In vitro,0.5 mg/ml[polyU RNA];|1 mM[K3],-,"25 mM HEPES,pH 7.4",RT,≤ 90 min,other_molecular:both the enzyme and AcCoA.,Turbidity measurement,liquid,"The specificity of acetylation-dependent complex coacervation was further supported by KAT reactions with lysine- and arginine-rich peptide/RNA-coacervates (Fig. 6e), demonstrating that R3/RNA-coacervates are not dissolved in the presence of CREB or p300."
324,PMID: 31266957,RNAPS0000302,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,KKASLKKASLRRASL,K2R1,-,-,15aa,-,-,-,-,-,In vitro,1 mg/ml[polyU RNA ];|1 mM[K2R1R3],-,"25 mM HEPES,pH 7.4",RT,≤ 25 min,-,"FRAP,Differential interference contrast microscopy,Fluorescence microscopy",-,"The concentration of K3, K2R1, R3, and polyU RNA in DIC, fluorescence imaging, and FRAP were identical and equal to 1 mM K3/K2R1/ R3 and 1 mg ml−1 polyU RNA, in 50 mM HEPES, pH 7.4."
325,PMID: 31266957,RNAPS0000303,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,KKKKKKKKKKKKKKKKKKKKR,K18,-,-,21aa,-,-,-,-,-,In vitro,50 µM[K18];|125 µg/ml[polyU RNA],-,-,RT,≤ 20 min,-,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"DIC and fluorescence micrographs of hTau40, K25, and K18 solutions in the presence of different co-factors/buffer conditions. The concentration of the proteins was 50 μM."
326,PMID: 31266957,RNAPS0000303,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,KKKKKKKKKKKKKKKKKKKKR,K18,-,-,21aa,-,-,-,-,-,In vitro,50 µM[K18];|125 µg/ml[polyU RNA],-,"25 mM HEPES,pH 7.4",RT,≤ 20 min,-,"Differential interference contrast microscopy,Fluorescence microscopy",solute,"DIC and fluorescence micrographs of hTau40, K25, and K18 solutions in the presence of different co-factors/buffer conditions. The concentration of the proteins was 50 μM."
327,PMID: 31266957,RNAPS0000303,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,KKKKKKKKKKKKKKKKKKKKR,K18,-,-,21aa,-,-,-,-,-,In vitro,50 µM[K18];|125 µg/ml[polyU RNA],-,-,RT,≤ 20 min,crowding agent:10% dextran,"Differential interference contrast microscopy,Fluorescence microscopy",solute,"DIC and fluorescence micrographs of hTau40, K25, and K18 solutions in the presence of different co-factors/buffer conditions. The concentration of the proteins was 50 μM."
328,PMID: 31266957,RNAPS0000303,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,KKKKKKKKKKKKKKKKKKKKR,K18,-,-,21aa,-,-,-,-,-,In vitro,125 µg/ml[RNA];|50 µM[K18],-,"25 mM HEPES,pH 7.4",RT,≤ 1 h,other_molecular:CREB/p300,Turbidity measurement,liquid,"The specificity of acetylation-dependent complex coacervation was further supported by KAT reactions with lysine- and arginine-rich peptide/RNA-coacervates (Fig. 6e), demonstrating that R3/RNA-coacervates are not dissolved in the presence of CREB or p300."
329,PMID: 31266957,RNAPS0000303,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,KKKKKKKKKKKKKKKKKKKKR,K18,-,-,21aa,-,-,-,-,-,In vitro,125 µg/ml[RNA];|50 µM[K18],-,"25 mM HEPES,pH 7.4",RT,≤ 1 h,other_molecular:AcCoA,Turbidity measurement,liquid,"The specificity of acetylation-dependent complex coacervation was further supported by KAT reactions with lysine- and arginine-rich peptide/RNA-coacervates (Fig. 6e), demonstrating that R3/RNA-coacervates are not dissolved in the presence of CREB or p300."
330,PMID: 31266957,RNAPS0000303,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,KKKKKKKKKKKKKKKKKKKKR,K18,-,-,21aa,-,-,-,-,-,In vitro,125 µg/ml[RNA];|50 µM[K18],-,"25 mM HEPES,pH 7.4",RT,≤ 1 h,other_molecular:both the enzyme and AcCoA.,Turbidity measurement,liquid,"The specificity of acetylation-dependent complex coacervation was further supported by KAT reactions with lysine- and arginine-rich peptide/RNA-coacervates (Fig. 6e), demonstrating that R3/RNA-coacervates are not dissolved in the presence of CREB or p300."
331,PMID: 31266957,RNAPS0000304,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,"SKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSKDNIKHVPGGGSVQIVYKPVD
LSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETH
KLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSA
SLAKQGL",K25,-,-,184aa,-,-,-,"[1-10],[23-25],[27-29],[34-42],[83-93],[139-179]",-,In vitro,50 µM[K25];|100 µg/ml[polyU RNA],-,-,RT,≤ 20 min,-,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"DIC and fluorescence micrographs of hTau40, K25, and K18 solutions in the presence of different co-factors/buffer conditions. The concentration of the proteins was 50μM."
332,PMID: 31266957,RNAPS0000304,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,"SKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSKDNIKHVPGGGSVQIVYKPVD
LSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETH
KLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSA
SLAKQGL",K25,-,-,184aa,-,-,-,"[1-10],[23-25],[27-29],[34-42],[83-93],[139-179]",-,In vitro,50 µM[K25];|100 µg/ml[polyU RNA],-,"25 mM HEPES,pH 7.4",RT,≤ 20 min,-,"Differential interference contrast microscopy,Fluorescence microscopy",solute,"DIC and fluorescence micrographs of hTau40, K25, and K18 solutions in the presence of different co-factors/buffer conditions. The concentration of the proteins was 50μM."
333,PMID: 31266957,RNAPS0000304,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,"SKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKSGSKDNIKHVPGGGSVQIVYKPVD
LSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETH
KLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSA
SLAKQGL",K25,-,-,184aa,-,-,-,"[1-10],[23-25],[27-29],[34-42],[83-93],[139-179]",-,In vitro,50 µM[K25];|100 µg/ml[polyU RNA],-,-,RT,≤ 20 min,crowding agent:10% dextran,"Differential interference contrast microscopy,Fluorescence microscopy",solute,"DIC and fluorescence micrographs of hTau40, K25, and K18 solutions in the presence of different co-factors/buffer conditions. The concentration of the proteins was 50μM."
334,PMID: 31266957,RNAPS0000305,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT
MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPG
SETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAG
HVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPK
TPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAK
SRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHV
PGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNI
THVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMV
DSPQLATLADEVSASLAKQGL",MAPT,-,-,441aa(1-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[125-375],[395-441]","[216-226],[323-340],[380-403]",In vitro,50 µM[hTau40];|40 µg/ml[polyU RNA],-,-,RT,≤ 20 min,-,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"DIC and fluorescence micrographs of hTau40, K25, and K18 solutions in the presence of different co-factors/buffer conditions. The concentration of the proteins was 52 μM."
335,PMID: 31266957,RNAPS0000305,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT
MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPG
SETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAG
HVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPK
TPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAK
SRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHV
PGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNI
THVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMV
DSPQLATLADEVSASLAKQGL",MAPT,-,-,441aa(1-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[125-375],[395-441]","[216-226],[323-340],[380-403]",In vitro,50 µM[hTau40];|40 µg/ml[polyU RNA],-,"25 mM HEPES,pH 7.4",RT,≤ 20 min,-,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"DIC and fluorescence micrographs of hTau40, K25, and K18 solutions in the presence of different co-factors/buffer conditions. The concentration of the proteins was 52 μM."
336,PMID: 31266957,RNAPS0000305,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT
MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPG
SETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAG
HVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPK
TPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAK
SRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHV
PGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNI
THVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMV
DSPQLATLADEVSASLAKQGL",MAPT,-,-,441aa(1-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[125-375],[395-441]","[216-226],[323-340],[380-403]",In vitro,50 µM[hTau40];|40 µg/ml[polyU RNA],-,-,RT,≤ 20 min,crowding agent:10% dextran,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"DIC and fluorescence micrographs of hTau40, K25, and K18 solutions in the presence of different co-factors/buffer conditions. The concentration of the proteins was 52 μM."
337,PMID: 31266957,RNAPS0000306,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,RRASLRRASLRRASL,R3,-,-,15aa,-,-,-,-,-,In vitro,0.5 mg/ml[polyU RNA];|1 mM[R3],-,"25 mM HEPES,pH 7.4",RT,≤ 90 min,other_molecular:CREB/p300,Turbidity measurement,liquid,"The specificity of acetylation-dependent complex coacervation was further supported by KAT reactions with lysine- and arginine-rich peptide/RNA-coacervates (Fig. 6e), demonstrating that R3/RNA-coacervates are not dissolved in the presence of CREB or p300."
338,PMID: 31266957,RNAPS0000306,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,RRASLRRASLRRASL,R3,-,-,15aa,-,-,-,-,-,In vitro,0.5 mg/ml[polyU RNA];|1 mM[R3],-,"25 mM HEPES,pH 7.4",RT,≤ 90 min,other_molecular:AcCoA,Turbidity measurement,liquid,"The specificity of acetylation-dependent complex coacervation was further supported by KAT reactions with lysine- and arginine-rich peptide/RNA-coacervates (Fig. 6e), demonstrating that R3/RNA-coacervates are not dissolved in the presence of CREB or p300."
339,PMID: 31266957,RNAPS0000306,https://pubmed.ncbi.nlm.nih.gov/31266957,RNA + protein,-,-,polyU,2000–3300nt,-,poly RNA,-,RRASLRRASLRRASL,R3,-,-,15aa,-,-,-,-,-,In vitro,0.5 mg/ml[polyU RNA];|1 mM[R3],-,"25 mM HEPES,pH 7.4",RT,≤ 90 min,other_molecular:both the enzyme and AcCoA.,Turbidity measurement,liquid,"The specificity of acetylation-dependent complex coacervation was further supported by KAT reactions with lysine- and arginine-rich peptide/RNA-coacervates (Fig. 6e), demonstrating that R3/RNA-coacervates are not dissolved in the presence of CREB or p300."
340,PMID: 31266957,RNAPS0000307,https://pubmed.ncbi.nlm.nih.gov/31266957,RNAs + protein,-,-,yeast tRNA,-,-,tRNA,yeast,KKASLKKASLKKASL,K3,-,-,15aa,-,-,-,-,-,In vitro,0.5 mg/ml[tRNA];|0.5mM[K3],-,"50 mM HEPES,pH 7.4 or 9.4",RT,-,-,Turbidity measurement,-,"We then prepared peptide solutions with transfer RNA (tRNA) or polyU RNA (Fig. 2b) at different peptide concentrations and pH values and found that the mixtures underwent phase separation when K3/R3 concentrations reached ~ 0.5 mM (Fig. 2b, c and Supplementary Fig. 2b). The condensation-transition led to the occurrence of spherical droplets that fused with each other."
341,PMID: 31266957,RNAPS0000307,https://pubmed.ncbi.nlm.nih.gov/31266957,RNAs + protein,-,-,yeast tRNA,-,-,tRNA,yeast,KKASLKKASLKKASL,K3,-,-,15aa,-,-,-,-,-,In vitro,0.5 mg/ml[tRNA];|1 mM[K3],-,"50 mM HEPES,pH 7.4 or 9.4",RT,-,-,Turbidity measurement,-,"Turbidity of K3 with tRNA (0.5 mg ml−1) and R3 with tRNA (0.5 mg ml−1) samples at different pH values and peptide concentrations (0.1 mM, 0.5 mM, and 1 mM). Reported turbidity values represent the average of a triplicate of measurements for each sample."
342,PMID: 31266957,RNAPS0000307,https://pubmed.ncbi.nlm.nih.gov/31266957,RNAs + protein,-,-,yeast tRNA,-,-,tRNA,yeast,KKASLKKASLKKASL,K3,-,-,15aa,-,-,-,-,-,In vitro,1 mg/ml[tRNA];|2mM[K3],0 or 30 mM NaCl,"50 mM HEPES,PH 7.4",RT,-,-,Fluorescence microscopy,-,"Turbidity of K3 with tRNA (0.5 mg ml−1) and R3 with tRNA (0.5 mg ml−1) samples at different pH values and peptide concentrations (0.1 mM, 0.5 mM, and 1 mM). Reported turbidity values represent the average of a triplicate of measurements for each sample."
343,PMID: 31266957,RNAPS0000308,https://pubmed.ncbi.nlm.nih.gov/31266957,RNAs + protein,-,-,yeast tRNA,-,-,tRNA,yeast,RRASLRRASLRRASL,R3,-,-,15aa,-,-,-,-,-,In vitro,0.5 mg/ml[tRNA];|0.5mM or 1mM[R3],-,"50 mM HEPES,PH 5.4 or 7.4 or 9.4",RT,-,-,Turbidity measurement,-,"Turbidity of K3 with tRNA (0.5 mg ml−1) and R3 with tRNA (0.5 mg ml−1) samples at different pH values and peptide concentrations (0.1 mM, 0.5 mM, and 1 mM). Reported turbidity values represent the average of a triplicate of measurements for each sample."
344,PMID: 31271494,RNAPS0000037,https://pubmed.ncbi.nlm.nih.gov/31271494,RNA + protein,NCBI ID:7082,https://www.ncbi.nlm.nih.gov/gene/7082,TJP1,8024nt(1-8024),GCCGCCGGGCCACGGCCUGCAGGGGUGGAAGGGGCGGCGGCGGCGGGAGCUGCGGGCCACGCACGGCGGCGGCGGCGGGAGCGGCCGGGCACGCACGGCGACGGCGGCGGCGGGAGCGGGAGCCCGGGCCACGCACGGCCGCAGCUGCGGGUGCGGCGGGCGCGGGAGCGGUGGGAGCUGUGGUGGCGGCGGAUGGCCCAGAGCUGAUCUAUGCGGCGCCUGGAGGGGCUGUGUCUGCGGCGGCGGCGGAGGCGGCGGGGCCCUGCCCGCGAGCGGAGCGGGGACAAGAUGAAGUACCAGAAAUACCUGACGGUGCUGCAGAUGGCCAUCGGCGUCACCCCCUCCAACCGCGGCAGCCUCCUGCCGCUCAAGAGGAAGCUGUGGGUAACGCCAUCCUCUGAAAAUCCUAAUGGUGCUACUUCUAGUGUCAGCCAAGGAAAACCCUCUUUAAGACGAAUUAAAGGGAGAUUACACAGAAGCAAAAGCCUUGAUAGCAUGGAUUUCUGUGAGCUCACUAGCACAGCAAUGGAGGAAACAGCUAUAUGGGAACAACAUACAGUGACGCUUCACAGGGCUCCUGGAUUUGGAUUUGGAAUUGCAAUAUCUGGUGGACGAGAUAAUCCUCAUUUUCAGAGUGGGGAAACGUCAAUAGUGAUUUCAGAUGUGCUGAAAGGAGGACCAGCUGAAGGACAGCUACAGGAAAAUGACCGAGUUGCAAUGGUUAACGGAGUUUCAAUGGAUAAUGUUGAACAUGCUUUUGCUGUUCAGCAACUAAGGAAAAGUGGGAAAAAUGCAAAAAUUACAAUUAGAAGGAAGAAGAAAGUUCAAAUACCAGUAAGUCGUCCUGAUCCUGAACCAGUAUCUGAUAAUGAAGAAGAUAGUUAUGAUGAGGAAAUACAUGAUCCAAGAAGUGGCCGGAGUGGUGUGGUUAACAGAAGGAGUGAGAAGAUUUGGCCGAGGGAUAGAAGUGCAAGUAGAGAGAGGAGCUUGUCCCCGCGGUCAGACAGGCGGUCAGUGGCUUCCAGCCAGCCUGCUAAACCUACUAAAGUCACACUGGUGAAAUCCCGGAAAAAUGAAGAAUAUGGUCUUCGAUUGGCAAGCCAUAUAUUUGUUAAGGAAAUUUCACAAGAUAGUUUGGCAGCAAGAGAUGGCAAUAUUCAAGAAGGUGAUGUUGUAUUGAAGAUAAAUGGUACUGUGACAGAAAAUAUGUCAUUGACAGAUGCAAAGACAUUGAUAGAAAGGUCUAAAGGCAAAUUAAAAAUGGUAGUUCAAAGAGAUGAACGGGCUACGCUAUUGAAUGUCCCUGAUCUUUCUGACAGCAUCCACUCUGCUAAUGCCUCUGAGAGAGACGACAUUUCAGAAAUUCAGUCACUGGCAUCAGAUCAUUCUGGUCGAUCACACGAUAGGCCUCCCCGCCGCAGCCGGUCACGAUCUCCUGACCAGCGGUCAGAGCCUUCUGAUCAUUCCAGGCACUCGCCGCAGCAGCCAAGCAAUGGCAGUCUCCGGAGUAGAGAUGAAGAGAGAAUUUCUAAACCUGGGGCUGUCUCAACUCCUGUAAAGCAUGCUGAUGAUCACACACCUAAAACAGUGGAAGAAGUUACAGUUGAAAGAAAUGAGAAACAAACACCUUCUCUUCCAGAACCAAAGCCUGUGUAUGCCCAAGUUGGGCAACCAGAUGUGGAUUUACCUGUCAGUCCAUCUGAUGGUGUCCUACCUAAUUCAACUCAUGAAGAUGGGAUUCUUCGGCCCAGCAUGAAAUUGGUAAAAUUCAGAAAAGGAGAUAGUGUGGGUUUGCGGCUGGCUGGUGGAAAUGAUGUUGGAAUAUUUGUAGCUGGCGUUCUAGAAGAUAGCCCUGCAGCCAAGGAAGGCUUAGAGGAAGGUGAUCAAAUUCUCAGGGUAAACAACGUAGAUUUUACAAAUAUCAUAAGAGAAGAAGCCGUCCUUUUCCUGCUUGACCUCCCUAAAGGAGAAGAAGUGACCAUAUUGGCUCAGAAGAAGAAGGAUGUUUAUCGUCGCAUUGUAGAAUCAGAUGUAGGAGAUUCUUUCUAUAUUAGAACCCAUUUUGAAUAUGAAAAGGAAUCUCCCUAUGGACUUAGUUUUAACAAAGGAGAGGUGUUCCGUGUUGUGGAUACCUUGUACAAUGGAAAACUGGGCUCUUGGCUUGCUAUUCGAAUUGGUAAAAAUCAUAAGGAGGUAGAACGAGGCAUCAUCCCUAAUAAGAACAGAGCUGAGCAGCUAGCCAGUGUACAGUAUACACUUCCAAAAACAGCAGGCGGAGACCGUGCUGACUUCUGGAGAUUCAGAGGUCUUCGCAGCUCCAAGAGAAAUCUUCGAAAAAGCAGAGAGGAUUUGUCCGCUCAGCCUGUUCAAACAAAGUUUCCAGCUUAUGAAAGAGUGGUUCUUCGAGAAGCUGGAUUUCUGAGGCCUGUAACCAUUUUUGGACCAAUAGCUGAUGUUGCCAGAGAAAAGCUGGCAAGAGAAGAACCAGAUAUUUAUCAAAUUGCAAAGAGUGAACCACGAGACGCUGGAACUGACCAACGUAGCUCUGGCAUUAUUCGCCUGCAUACAAUAAAGCAAAUCAUAGAUCAAGACAAACAUGCUUUAUUAGAUGUAACACCAAAUGCAGUUGAUCGUCUUAACUAUGCCCAGUGGUAUCCAAUUGUUGUAUUUCUUAACCCUGAUUCUAAGCAAGGAGUAAAAACAAUGAGAAUGAGGUUAUGUCCAGAAUCUCGGAAAAGUGCCAGGAAGUUAUACGAGCGAUCUCAUAAACUUCGUAAAAAUAAUCACCAUCUUUUUACAACUACAAUUAACUUAAAUUCAAUGAAUGAUGGUUGGUAUGGUGCGCUGAAAGAAGCAAUUCAACAACAGCAAAACCAGCUGGUAUGGGUUUCCGAGGGAAAGGCGGAUGGUGCUACAAGUGAUGACCUUGAUUUGCAUGAUGAUCGUCUGUCCUACCUGUCAGCUCCAGGUAGUGAAUACUCAAUGUAUAGCACGGACAGUAGACACACUUCUGACUAUGAAGACACAGACACAGAAGGCGGGGCCUACACUGAUCAAGAACUAGAUGAAACUCUUAAUGAUGAGGUUGGGACUCCACCGGAGUCUGCCAUUACACGGUCCUCUGAGCCUGUAAGAGAGGACUCCUCUGGAAUGCAUCAUGAAAACCAAACAUAUCCUCCUUACUCACCACAAGCGCAGCCACAACCAAUUCAUAGAAUAGACUCCCCUGGAUUUAAGCCAGCCUCUCAACAGAAAGCAGAAGCUUCAUCUCCAGUCCCUUACCUUUCGCCUGAAACAAACCCAGCAUCAUCAACCUCUGCUGUUAAUCAUAAUGUAAAUUUAACUAAUGUCAGACUGGAGGAGCCCACCCCAGCUCCUUCCACCUCUUACUCACCACAAGCUGAUUCUUUAAGAACACCAAGUACUGAGGCAGCUCACAUAAUGCUAAGAGAUCAAGAACCAUCAUUGUCGUCGCAUGUAGAUCCAACAAAGGUGUAUAGAAAGGAUCCAUAUCCCGAGGAAAUGAUGAGGCAGAACCAUGUUUUGAAACAGCCAGCCGUUAGUCACCCAGGGCACAGGCCAGACAAAGAGCCUAAUCUGACCUAUGAACCCCAACUCCCAUACGUAGAGAAACAAGCCAGCAGAGACCUCGAGCAGCCCACAUACAGAUACGAGUCCUCAAGCUAUACGGACCAGUUUUCUCGAAACUAUGAACAUCGUCUGCGAUACGAAGAUCGCGUCCCCAUGUAUGAAGAACAGUGGUCAUAUUAUGAUGACAAACAGCCCUACCCAUCUCGGCCACCUUUUGAUAAUCAGCACUCUCAAGACCUUGACUCCAGACAGCAUCCCGAAGAGUCCUCAGAACGAGGGUACUUUCCACGUUUUGAAGAGCCAGCCCCUCUGUCUUACGACAGCAGACCACGUUACGAACAGGCACCUAGAGCAUCCGCCCUGCGGCACGAAGAGCAGCCAGCUCCUGGGUAUGACACACAUGGUAGACUCAGACCGGAAGCCCAGCCCCACCCUUCAGCAGGGCCCAAGCCUGCAGAGUCCAAGCAGUAUUUUGAGCAAUAUUCACGCAGUUACGAGCAAGUACCACCCCAAGGAUUUACCUCUAGAGCAGGUCAUUUUGAGCCUCUCCAUGGUGCUGCAGCUGUCCCUCCGCUGAUACCUUCAUCUCAGCAUAAGCCAGAAGCUCUGCCUUCAAACACCAAACCACUGCCUCCACCCCCAACUCAAACCGAAGAAGAGGAAGAUCCAGCAAUGAAGCCACAGUCUGUACUCACCAGAGUUAAGAUGUUUGAAAACAAAAGAUCUGCAUCCUUAGAGACCAAGAAGGAUGUAAAUGACACUGGCAGUUUUAAGCCUCCAGAAGUAGCAUCUAAACCUUCAGGUGCUCCCAUCAUUGGUCCCAAACCCACUUCUCAGAAUCAAUUCAGUGAACAUGACAAAACUCUGUACAGGAUCCCAGAACCUCAAAAACCUCAACUGAAGCCACCUGAAGAUAUUGUUCGGUCCAAUCAUUAUGACCCUGAAGAAGAUGAAGAAUAUUAUCGAAAACAGCUGUCAUACUUUGACCGAAGAAGUUUUGAGAAUAAGCCUCCUGCACACAUUGCCGCCAGCCAUCUCUCCGAGCCUGCAAAGCCAGCGCAUUCUCAGAAUCAAUCAAAUUUUUCUAGUUAUUCUUCAAAGGGAAAGCCUCCUGAAGCUGAUGGUGUGGAUAGAUCAUUUGGCGAGAAACGCUAUGAACCCAUCCAGGCCACUCCCCCUCCUCCUCCAUUGCCCUCGCAGUAUGCCCAGCCAUCUCAGCCUGUCACCAGCGCGUCUCUCCACAUACAUUCUAAGGGAGCACAUGGUGAAGGUAAUUCAGUGUCAUUGGAUUUUCAGAAUUCCUUAGUGUCCAAACCAGACCCACCUCCAUCUCAGAAUAAGCCAGCAACUUUCAGACCACCAAACCGAGAAGAUACUGCUCAGGCAGCUUUCUAUCCCCAGAAAAGUUUUCCAGAUAAAGCCCCAGUUAAUGGAACUGAACAGACUCAGAAAACAGUCACUCCAGCAUACAAUCGAUUCACACCAAAACCAUAUACAAGUUCUGCCCGACCAUUUGAACGCAAGUUUGAAAGUCCUAAAUUCAAUCACAAUCUUCUGCCAAGUGAAACUGCACAUAAACCUGACUUGUCUUCAAAAACUCCCACUUCUCCAAAAACUCUUGUGAAAUCGCACAGUUUGGCACAGCCUCCUGAGUUUGACAGUGGAGUUGAAACUUUCUCUAUCCAUGCAGAGAAGCCUAAAUAUCAAAUAAAUAAUAUCAGCACAGUGCCUAAAGCUAUUCCUGUGAGUCCUUCAGCUGUGGAAGAGGAUGAAGAUGAAGAUGGUCAUACUGUGGUGGCCACAGCCCGAGGCAUAUUUAACAGCAAUGGGGGCGUGCUGAGUUCCAUAGAAACUGGUGUUAGUAUAAUUAUCCCUCAAGGAGCCAUUCCCGAAGGAGUUGAGCAGGAAAUCUAUUUCAAGGUCUGCCGGGACAACAGCAUCCUUCCACCUUUAGAUAAAGAGAAAGGUGAAACACUGCUGAGUCCUUUGGUGAUGUGUGGUCCCCAUGGCCUCAAGUUCCUGAAGCCUGUGGAGCUGCGCUUACCACACUGUGCGUCCAUGACUCCUGACGGUUGGUCUUUUGCUCUAAAAUCAUCCGACUCCUCGUCGGGUGAUCCUAAAACCUGGCAAAACAAGUGUCUUCCCGGAGAUCCAAAUUAUCUCGUUGGAGCAAACUGUGUUUCUGUCCUUAUUGACCACUUUUAACUCUUGAAAUAUAGGAACUUAAAUAAUGUGAAACUGGAUUAAACUUAAUCUAAAUGGAACCACUCUAUCAAGUAUUAUACCUUUUUUAGAGUUGAUACUACAGUUUGUUAGUAUGAGGCAUUUGUUUGAACUGAUAAAGAUGAGUGAGCAUGCCCCUGAACCAUGGUCGGAAAACAUGCUACACACUGCAUGUUUGUGAUUGACGGGACUGUUGGUAUUGGCUAGAGGUUCAAAGAUAUUUUGCUUUGUGAUUUUUGUAAUUUUUUUAUCGUCACUGCUUAACUUCACAUAUUGAUUUCCGUUAAAAUACCAGCCAGUAAAUGGGGGUGCAUUUGAGGUCUGUUCUUUCCAAAGUACACUGUUUCAAACUUUACUAUGGCCCUGGCCUAGCAUACGUACACAUUUUAUUUUAUUAUGCAUGAAGUAAUAUGCACACAUUUUUUAAAUGCACCUGGAAUAUAUAACCAGUGUUGUGGAUUUAACAGAAAUGUACAGCAAGGAGAUUUACAACUGGGGGAGGGUGAAGUGAAGACAAUGACUUACUGUACAUGAAAACACAUUUUUCUUAGGGAAGGAUACAAAAGCAUGUGAGACUGGUUCCAUGGCCUCUUCAGAUCUCUAACUUCACCAUAUUACCACAGACAUACUAACCAGCAGAAAUGCCUUACCCUCAUGUUCUUAAUUCUUAGCUCAUUCUCCUUGUGUUACUAAGUUUUUAUGGCUUUUGUGCAUUAUCUAGAUACUGUAUCAUGACAAAGACUGAGUACGUUGUGCAUUUGGUGGUUUCAGAAAUGUGUUAUCACCCAGAAGAAAAUAGUGGUGUGAUUUGGGGAUAUUUUUUUCUUUUCUUUUCUUUUCUUUUUUUUUUUUUUUGACAAGGGGCAGUGGUGGUUUUCUGUUCUUUCUGGCUAUGCAUUUGAAAAUUUUGAUGUUUUAAGGAUGCUUGUACAUAAUGCGUGCAUACCACUUUUGUUCUUGGUUUGUAAAUUAACUUUUAUAAACUUUACCUUUUUUAUACAUAAACAAGACCACGUUUCUAAAGGCUACCUUUGUAUUCUCUCCUGUACCUCUUGAGCCUUGAACUUUGACCUCUGCAGCAAUAAAGCAGCGUUUCUAUGACACAUGCAAGGUCAUUUUUUUUAAGAAAAAGGAUGCACAGAGUUGUUACAUUUUUAAGUGCUGCAUUUAAAAGAUACAGUUACUCAGAAUUCUCUAGUUUGAUUAAAUUCUUGCAAAGUAUCCCUACUGUAAUUUGUGAUACAAUGCUGUGCCCUAAAGUGUAUUUUUUUACUAAUAGACAAUUUAUUAUGGCACAUCAGCACGAUUUCUGUUUAGAUAAUACACCACUACAUUCUGUUAAUCAUUAGGUGUGACUGAAUUUCUUUUGCCGUUAUUAAAAAUCUCAAAUUUCUAAAUCUCCAAAAUAAAACUUUUUAAAAUAAAGUGCUGGCUUGGUCUGUUUGCCCACUGUUUUCUAGUUUCAUGCAGCUUUAUAAUCCUGUUUUAAAAUCCUGCACACAAAUCCCUAUCACCCAGCGUCACCUACCACCUCGUCGUCUGGUGUUGCAUGCAGAAUUUCUCCCCUUGGCCAGCAUGUACAGAUGGGUGGGCAGUGCUCAUCUGAAGGGCUCAGACUGAAGUGGGGCAGAAGGACCUGGAGACAGAGUGGGAGAAGGCAGCAGGCCGACUUCCCCCUGUGGGUAAACACACACCCCUGCGUGGAGAAACACCCCUGCAUGGGGACACACGUGCGUUUGUGUGUGUGCGUGUAACCAUUUGUAUAUGGUUUUAUUCCCCAGAUAAAUAGCACGGGCAUUGUUUAAUGUCACCCACAUUUGGGGGAAGAAAAUGGGUUUAGUGAGCAUAAAUAUUCCAUUGUGGACAUCCUACUUACUUAACUGCCACCCCUGUUGACAUUUGGAUUAUUGCUAUAGUGUUUCAGUAAACACCUUUGUGGACUGAAUCCAUCUAUGUGGAUUUUAUUUUUUUCAUCUUUGUUAAGGUAUAAUUUACAUAGAGUAAGUUACUGUUUUUAAAAUGUAUAGUUCAAAUUUUGACAAACACAUACUGUUUAUUUACCACGGUUAAUACAUACAACAGUUUCUUUAUCUUCUCUAAUCAUUUGUACCCCUUUAUACUCAACCCUUCUUCCAGCCCCUGGCAGGAUGAUCUCUUCUGUUUCUAUAGUUGCCUUUUUGACAGUGUCAUAUAAAUGGAAUCAUACAAUA,mRNA,Homo sapiens,"sp|P26368|U2AF2_HUMAN Splicing factor U2AF 65 kDa subunit OS=Homo sapiens OX=9606 GN=U2AF2 PE=1 SV=4
MSDFDEFERQLNENKQERDKENRHRKRSHSRSRSRDRKRRSRSRDRRNRDQRSASRDRRR
RSKPLTRGAKEEHGGLIRSPRHEKKKKVRKYWDVPPPGFEHITPMQYKAMQAAGQIPATA
LLPTMTPDGLAVTPTPVPVVGSQMTRQARRLYVGNIPFGITEEAMMDFFNAQMRLGGLTQ
APGNPVLAVQINQDKNFAFLEFRSVDETTQAMAFDGIIFQGQSLKIRRPHDYQPLPGMSE
NPSVYVPGVVSTVVPDSAHKLFIGGLPNYLNDDQVKELLTSFGPLKAFNLVKDSATGLSK
GYAFCEYVDINVTDQAIAGLNGMQLGDKKLLVQRASVGAKNATLVSPPSTINQTPVTLQV
PGLMSSQVQMGGHPTEVLCLMNMVLPEELLDDEEYEEIVEDVRDECSKYGLVKSIEIPRP
VDGVEVPGCGKIFVEFTSVFDCQKAMQGLTGRKFANRVVVTKYCDPDSYHRRDFW",U2AF65,-,-,475aa(1-475),P26368,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/P26368,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0481",-,"[157-178],[248-259],[365-376]",In vitro,1 µg [TJP1];|2µM [U2AF65],150 mM NaCl,Hepes 20 mM pH 7.5,RT,-,-,Sedimentation assay,-,"Furthermore, this SPY-rich RNA partly cosedimented with U2AF65 assemblies (Fig 5C, compare lanes 3 and 4 with lanes 5 and 6). Analyses of four additional RNAs confirmed the correlation between SPY content and the ability of an RNA to exacerbate U2AF65 sedimentation."
345,PMID: 31271494,RNAPS0000365,https://pubmed.ncbi.nlm.nih.gov/31271494,RNA + protein,NCBI ID:1785,https://www.ncbi.nlm.nih.gov/gene/1785,DNM2,3633nt(1-3633),GAGAACCGGAUGAGGCGGCGACCGUGAGGCCGAGCCGGGAGCGGGCGUCUUGCCGAGGCCCGGGCGGGCGGGGAGCAACGGCUACAGACGCCGCGGGGCCAGGUCGUUGAGGGUCGGCGGCGGGCGAGGAGCGCAGGGCGCUCGGGCCGGGGGCCGCCGGCGCCAUGGGCAACCGCGGGAUGGAAGAGCUGAUCCCGCUGGUCAACAAACUGCAGGACGCCUUCAGCUCCAUCGGCCAGAGCUGCCACCUGGACCUGCCGCAGAUCGCUGUAGUGGGCGGCCAGAGCGCCGGCAAGAGCUCGGUGCUGGAGAACUUCGUGGGCCGGGACUUCCUUCCCCGCGGUUCAGGAAUCGUCACCCGGCGGCCUCUCAUUCUGCAGCUCAUCUUCUCAAAAACAGAACAUGCCGAGUUUUUGCACUGCAAGUCCAAAAAGUUUACAGACUUUGAUGAAGUCCGGCAGGAGAUUGAAGCAGAGACCGACAGGGUCACGGGGACCAACAAAGGCAUCUCCCCAGUGCCCAUCAACCUUCGAGUCUACUCGCCACACGUGUUGAACUUGACCCUCAUCGACCUCCCGGGUAUCACCAAGGUGCCUGUGGGCGACCAGCCUCCAGACAUCGAGUACCAGAUCAAGGACAUGAUCCUGCAGUUCAUCAGCCGGGAGAGCAGCCUCAUUCUGGCUGUCACGCCCGCCAACAUGGACCUGGCCAACUCCGACGCCCUCAAGCUGGCCAAGGAAGUCGAUCCCCAAGGCCUACGGACCAUCGGUGUCAUCACCAAGCUUGACCUGAUGGACGAGGGCACCGACGCCAGGGACGUCUUGGAGAACAAGUUGCUCCCGUUGAGAAGAGGCUACAUUGGCGUGGUGAACCGCAGCCAGAAGGAUAUUGAGGGCAAGAAGGACAUCCGUGCAGCACUGGCAGCUGAGAGGAAGUUCUUCCUCUCCCACCCGGCCUACCGGCACAUGGCCGACCGCAUGGGCACGCCACAUCUGCAGAAGACGCUGAAUCAGCAACUGACCAACCACAUCCGGGAGUCGCUGCCGGCCCUACGUAGCAAACUACAGAGCCAGCUGCUGUCCCUGGAGAAGGAGGUGGAGGAGUACAAGAACUUUCGGCCCGACGACCCCACCCGCAAAACCAAAGCCCUGCUGCAGAUGGUCCAGCAGUUUGGGGUGGAUUUUGAGAAGAGGAUCGAGGGCUCAGGAGAUCAGGUGGACACUCUGGAGCUCUCCGGGGGCGCCCGAAUCAAUCGCAUCUUCCACGAGCGGUUCCCAUUUGAGCUGGUGAAGAUGGAGUUUGACGAGAAGGACUUACGACGGGAGAUCAGCUAUGCCAUUAAGAACAUCCAUGGAGUCAGGACCGGGCUUUUCACCCCGGACUUGGCAUUCGAGGCCAUUGUGAAAAAGCAGGUCGUCAAGCUGAAAGAGCCCUGUCUGAAAUGUGUCGACCUGGUUAUCCAGGAGCUAAUCAAUACAGUUAGGCAGUGUACCAGUAAGCUCAGUUCCUACCCCCGGUUGCGAGAGGAGACAGAGCGAAUCGUCACCACUUACAUCCGGGAACGGGAGGGGAGAACGAAGGACCAGAUUCUUCUGCUGAUCGACAUUGAGCAGUCCUACAUCAACACGAACCAUGAGGACUUCAUCGGGUUUGCCAAUGCCCAGCAGAGGAGCACGCAGCUGAACAAGAAGAGAGCCAUCCCCAAUCAGGGGGAGAUCCUGGUGAUCCGCAGGGGCUGGCUGACCAUCAACAACAUCAGCCUGAUGAAAGGCGGCUCCAAGGAGUACUGGUUUGUGCUGACUGCCGAGUCACUGUCCUGGUACAAGGAUGAGGAGGAGAAAGAGAAGAAGUACAUGCUGCCUCUGGACAACCUCAAGAUCCGUGAUGUGGAGAAGGGCUUCAUGUCCAACAAGCACGUCUUCGCCAUCUUCAACACGGAGCAGAGAAACGUCUACAAGGACCUGCGGCAGAUCGAGCUGGCCUGUGACUCCCAGGAAGACGUGGACAGCUGGAAGGCCUCGUUCCUCCGAGCUGGCGUCUACCCCGAGAAGGACCAGGCAGAAAACGAGGAUGGGGCCCAGGAGAACACCUUCUCCAUGGACCCCCAACUGGAGCGGCAGGUGGAGACCAUUCGCAACCUGGUGGACUCAUACGUGGCCAUCAUCAACAAGUCCAUCCGCGACCUCAUGCCAAAGACCAUCAUGCACCUCAUGAUCAACAAUACGAAGGCCUUCAUCCACCACGAGCUGCUGGCCUACCUAUACUCCUCGGCAGACCAGAGCAGCCUCAUGGAGGAGUCGGCUGACCAGGCACAGCGGCGGGACGACAUGCUGCGCAUGUACCAUGCCCUCAAGGAGGCGCUCAACAUCAUCGGUGACAUCAGCACCAGCACUGUGUCCACGCCUGUACCCCCGCCUGUCGAUGACACCUGGCUCCAGAGCGCCAGCAGCCACAGCCCCACUCCACAGCGCCGACCGGUGUCCAGCAUACACCCCCCUGGCCGGCCCCCAGCAGUGAGGGGCCCCACUCCAGGGCCCCCCCUGAUUCCUGUUCCCGUGGGGGCAGCAGCCUCCUUCUCGGCGCCCCCAAUCCCAUCCCGGCCUGGACCCCAGAGCGUGUUUGCCAACAGUGACCUCUUCCCAGCCCCGCCUCAGAUCCCAUCUCGGCCAGUUCGGAUCCCCCCAGGGAUUCCCCCAGGAGUGCCCAGCAGAAGACCCCCUGCUGCGCCCAGCCGGCCCACCAUUAUCCGCCCAGCCGAGCCAUCCCUGCUCGACUAGGCCUCGAGGGGGGCGUGCUCUCGGGGGGGCCUCACGCACCCGCGGCGCAGGAGCUUCAGUGGUCUGGGGCCCUCCGCCGCCCCUAUGCUGGGACCAGGCUCCCAGUGGGCAGCCCUGGCCUCUUCCUUAACGCUGGCCCCGGUCCAGGGCCGGCCCCUGUGCCUGGCUGGACACCGCACUGCGCAAAGGGGCCCUGGAGCUCCAGGCAGGGGGCGCUGGGGUGUUGCACUUUGGGGGAUGGAGUCUCAGGGUGGCAGAGGGGGGACCAGAACCCUUGACACCAUCCUGAAUGAGGGGUCCAGCCUGGGGGGGACUCUACCAAGGUCUUCUUGGGCUGGGAAAGCCCAUGUAGGGCAGGCCUUCUAUAAGUGCGGGCACCAAGGGCGCCUACAUCCCCAGGCCUUGCUGGGGUGCAGGGGUAUAUCAACUUCCCAUUAGCAGGAGCUCCCCAGCGGCAAGCCUGGCCCAGUGGGCUCGGUAGUGCCCAGCUGGCAGGCCUGAGGUGUACAUAGUCCUUCCCGGCCAUAUUAACCACACAGCCUGAGCCUGGCCCAGCCUCGGCUGCCAGAGGUGCCUUUGCUAGGCCCGGAGCCGUUGGCCCGGGCCGGCCUUGCCCUAUUCCUCUCCUCCUCCUCCUCCUGGGUCCCCCAGGGUGGCUGGGCUUGGGCUAUGUGGGUGGUGGUGGCGGGGGGUCUUGGGGGCCUCUCAGCUCCCGCCCAUGCCUCCCUGAUGGGUGGGCCCAGGGCGGCCUCUCUCUGAGGAGACCUCACCCACUCCUCGCUCAGUUUGACCACUGUAAGUGCCUGCACUCUGUAUUCUAUUAAUAAACUAAAAUAAAGGGAAGACGCUGCUGGUG,mRNA,Homo sapiens,"sp|P26368|U2AF2_HUMAN Splicing factor U2AF 65 kDa subunit OS=Homo sapiens OX=9606 GN=U2AF2 PE=1 SV=4
MSDFDEFERQLNENKQERDKENRHRKRSHSRSRSRDRKRRSRSRDRRNRDQRSASRDRRR
RSKPLTRGAKEEHGGLIRSPRHEKKKKVRKYWDVPPPGFEHITPMQYKAMQAAGQIPATA
LLPTMTPDGLAVTPTPVPVVGSQMTRQARRLYVGNIPFGITEEAMMDFFNAQMRLGGLTQ
APGNPVLAVQINQDKNFAFLEFRSVDETTQAMAFDGIIFQGQSLKIRRPHDYQPLPGMSE
NPSVYVPGVVSTVVPDSAHKLFIGGLPNYLNDDQVKELLTSFGPLKAFNLVKDSATGLSK
GYAFCEYVDINVTDQAIAGLNGMQLGDKKLLVQRASVGAKNATLVSPPSTINQTPVTLQV
PGLMSSQVQMGGHPTEVLCLMNMVLPEELLDDEEYEEIVEDVRDECSKYGLVKSIEIPRP
VDGVEVPGCGKIFVEFTSVFDCQKAMQGLTGRKFANRVVVTKYCDPDSYHRRDFW",U2AF65,-,-,475aa(1-475),P26368,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/P26368,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0481",-,"[157-178],[248-259],[365-376]",In vitro,1 µg [DNM2];|2µM [U2AF65],150 mM NaCl,Hepes 20 mM pH 7.5,RT,-,-,Sedimentation assay,-,"Furthermore, this SPY-rich RNA partly cosedimented with U2AF65 assemblies (Fig 5C, compare lanes 3 and 4 with lanes 5 and 6). Analyses of four additional RNAs confirmed the correlation between SPY content and the ability of an RNA to exacerbate U2AF65 sedimentation."
346,PMID: 31292544,RNAPS0000315,https://pubmed.ncbi.nlm.nih.gov/31292544,RNA + protein,-,-,"m6A RNA(Ries,2019)",65nt,CCAGAGCCAGAACCAGAGACCAGAAACCAGAACCAGAACCAGAAGCCAGAGCCAGAAACCAGA,irregular RNA,-,"sp|Q9Y5A9|YTHD2_HUMAN YTH domain-containing family protein 2 OS=Homo sapiens OX=9606 GN=YTHDF2 PE=1 SV=2
MSASSLLEQRPKGQGNKVQNGSVHQKDGLNDDDFEPYLSPQARPNNAYTAMSDSYLPSYY
SPSIGFSYSLGEAAWSTGGDTAMPYLTSYGQLSNGEPHFLPDAMFGQPGALGSTPFLGQH
GFNFFPSGIDFSAWGNNSSQGQSTQSSGYSSNYAYAPSSLGGAMIDGQSAFANETLNKAP
GMNTIDQGMAALKLGSTEVASNVPKVVGSAVGSGSITSNIVASNSLPPATIAPPKPASWA
DIASKPAKQQPKLKTKNGIAGSSLPPPPIKHNMDIGTWDNKGPVAKAPSQALVQNIGQPT
QGSPQPVGQQANNSPPVAQASVGQQTQPLPPPPPQPAQLSVQQQAAQPTRWVAPRNRGSG
FGHNGVDGNGVGQSQAGSGSTPSEPHPVLEKLRSINNYNPKDFDWNLKHGRVFIIKSYSE
DDIHRSIKYNIWCSTEHGNKRLDAAYRSMNGKGPVYLLFSVNGSGHFCGVAEMKSAVDYN
TCAGVWSQDKWKGRFDVRWIFVKDVPNSQLRHIRLENNENKPVTNSRDTQEVPLEKAKQV
LKIIASYKHTTSIFDDFSHYEKRQEEEESVKKERQGRGK",YTHDF2,-,-,579aa(1-579),Q9Y5A9,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/Q9Y5A9,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1477","[1-45],[247-382]","[52-63],[135-153],[324-349]",In vitro,570 nM [RNA];|25  µM [DF2],-,-,-,-,-,Differential interference contrast microscopy,solute,"We next asked whether the binding of m6 A-RNA to the YTH domain  regulates LLPS of DF proteins. We chose a buffer and protein concen tration in which LLPS does not occur. Addition of a 65-nucleotide-long  RNA containing either zero m6 A nucleotides or one m6 A nucleotide  did not induce LLPS of DF2 (Fig. 1f, Extended Data Fig. 1f). However,  an RNA that contained ten m6 A nucleotides triggered LLPS within  minutes"
347,PMID: 31292544,RNAPS0000315,https://pubmed.ncbi.nlm.nih.gov/31292544,RNA + protein,-,-,"m6A RNA(Ries,2019)",65nt,CCUGAGCCUGAACCUGAGACCUGAAACCUGAACCUGAACCUGAAGCCUGAGCCUGAAACCUGA,irregular RNA,-,"sp|Q9Y5A9|YTHD2_HUMAN YTH domain-containing family protein 2 OS=Homo sapiens OX=9606 GN=YTHDF2 PE=1 SV=2
MSASSLLEQRPKGQGNKVQNGSVHQKDGLNDDDFEPYLSPQARPNNAYTAMSDSYLPSYY
SPSIGFSYSLGEAAWSTGGDTAMPYLTSYGQLSNGEPHFLPDAMFGQPGALGSTPFLGQH
GFNFFPSGIDFSAWGNNSSQGQSTQSSGYSSNYAYAPSSLGGAMIDGQSAFANETLNKAP
GMNTIDQGMAALKLGSTEVASNVPKVVGSAVGSGSITSNIVASNSLPPATIAPPKPASWA
DIASKPAKQQPKLKTKNGIAGSSLPPPPIKHNMDIGTWDNKGPVAKAPSQALVQNIGQPT
QGSPQPVGQQANNSPPVAQASVGQQTQPLPPPPPQPAQLSVQQQAAQPTRWVAPRNRGSG
FGHNGVDGNGVGQSQAGSGSTPSEPHPVLEKLRSINNYNPKDFDWNLKHGRVFIIKSYSE
DDIHRSIKYNIWCSTEHGNKRLDAAYRSMNGKGPVYLLFSVNGSGHFCGVAEMKSAVDYN
TCAGVWSQDKWKGRFDVRWIFVKDVPNSQLRHIRLENNENKPVTNSRDTQEVPLEKAKQV
LKIIASYKHTTSIFDDFSHYEKRQEEEESVKKERQGRGK",YTHDF2,-,-,579aa(1-579),Q9Y5A9,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/Q9Y5A9,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1477","[1-45],[247-382]","[52-63],[135-153],[324-349]",In vitro,570 nM [RNA];|25  µM [DF2],-,-,-,≤ min,-,Differential interference contrast microscopy,liquid,"We next asked whether the binding of m6 A-RNA to the YTH domain  regulates LLPS of DF proteins. We chose a buffer and protein concen tration in which LLPS does not occur. Addition of a 65-nucleotide-long  RNA containing either zero m6 A nucleotides or one m6 A nucleotide  did not induce LLPS of DF2 (Fig. 1f, Extended Data Fig. 1f). However,  an RNA that contained ten m6 A nucleotides triggered LLPS within  minutes"
348,PMID: 31334587,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/31334587,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1|length=506aa|residues=1-506
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,0.2 mg/ml[polyU];|5µM[DHH1],2 mM MgCl2,30 mM HEPES-KOH pH 7.4,RT,60-200 s,other_molecular:50 mM ATP,Turbidity measurement,"solute, liquid","In the first junction, liquid-liquid phase separation (LLPS) is triggered by mixing a one-phase protein solution of Dhh1 with ATP and polyU."
349,PMID: 31435012,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,1.25 µl 1mg/ml[polyU](final concentration 0.05 mg/ml);|3 µl[DHH1],-,"13.4 µl LSB-100(100 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),2.1 µl 0.5M KCl (final KCl concentration 100mM) ,1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）mix ,1.25 µl 100mM ATP/MgCl2 (final concentration 5mM) ,1 µl 10 mg/ml BSA, 2 µl 1M Hepes of the respective pH ,3 µl mix of MH200G and Dhh1 stock to the final concentration as indicated,pH=6.2-7.2",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",-,Phase separation behaviour of full-length and tail-less (core) Dhh1 in different pH conditions.
350,PMID: 31435012,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,1.25 µl 1mg/ml[polyU];|3 µl[DHH1],-,"12.5 µl LSB-100(100 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),3 µl mix of 0.5M KCl / water to the final KCl concentration as indicated ,1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）mix ,1.25 µl 100mM ATP/MgCl2 (final concentration 5 mM) ,1 µl 10 mg/ml BSA, 2 µl 1M Hepes of the respective pH ,3 µl mix of MH200G and Dhh1 stock to the final concentration as indicated,0-15mM ATP",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",-,Phase separation behaviour of full-length and tail-less (core) Dhh1 in different ATP concentrations.
351,PMID: 31435012,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,0.05-0.5mg/ml[polyU](final concentration 0.05 mg/ml);|3 µl[DHH1],-,"13.4 µl LSB-100(100 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),2.1 µl 0.5M KCl (final KCl concentration 100 mM) ,1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）mix .1.25 µl 100mM ATP/MgCl2 (final concentration 5 mM) ,1 µl 10 mg/ml BSA, 2 µl 1M Hepes ofthe respective pH .1.25 µl mix of water / 10mg/ml polyU to the final concentration as indicated ,3 µl mix of MH200G and Dhh1 stock to the final concentration as indicate",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",-,Phase separation behaviour of full-length and tail-less (core) Dhh1 in different polyU concentrations
352,PMID: 31435012,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,1.25 µl 1mg/ml[polyU](final concentration 0.05 mg/ml);|3 µl[DHH1],-,"13.4 µl LSB-100(100 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),2.1 µl 0.5M KCl (final KCl concentration 100mM) ,1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）mix ,1.5 µl mix of ATP/MgCl2 (250mM stock) and H2O to the final concentration as indicated ,1 µl 10 mg/ml BSA ,2 µl 1M Hepes of the respective pH ,3 µl mix of MH200G and Dhh1 stock to the final concentration as indicated",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",-,Phase separation behaviour of full-length and tail-less (core) Dhh1 in different salt concentrations.
353,PMID: 31435012,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,0.25µl 10mg/ml[polyU];|5.25µl 50µM[DHH1],-,"15.75 µl LSB-150 (150 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1 µl 10 mg/ml BSA,1 µl Hepes,pH 6.4 ",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",liquid,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA. To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human, both recombinant DDX6 and DDX3X still form phase separated droplets in vitro."
354,PMID: 31435012,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1|residue=48-425
FEDFYLKRELLMGIFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATI
",DHH1,-,-,378aa(48-425),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,0.25µl 10mg/ml[polyU];|5.25µl 50µM[DHH1-core],-,"15.75 µl LSB-150 (150 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1 µl 10 mg/ml BSA,1 µl Hepes,pH 6.4 ",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",liquid,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA. To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human, both recombinant DDX6 and DDX3X still form phase separated droplets in vitro."
355,PMID: 31435012,RNAPS0000326,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P06634|DED1_YEAST ATP-dependent RNA helicase DED1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DED1 PE=1 SV=2
MAELSEQVQNLSINDNNENGYVPPHLRGKPRSARNNSSNYNNNNGGYNGGRGGGSFFSNN
RRGGYGNGGFFGGNNGGSRSNGRSGGRWIDGKHVPAPRNEKAEIAIFGVPEDPNFQSSGI
NFDNYDDIPVDASGKDVPEPITEFTSPPLDGLLLENIKLARFTKPTPVQKYSVPIVANGR
DLMACAQTGSGKTGGFLFPVLSESFKTGPSPQPESQGSFYQRKAYPTAVIMAPTRELATQ
IFDEAKKFTYRSWVKACVVYGGSPIGNQLREIERGCDLLVATPGRLNDLLERGKISLANV
KYLVLDEADRMLDMGFEPQIRHIVEDCDMTPVGERQTLMFSATFPADIQHLARDFLSDYI
FLSVGRVGSTSENITQKVLYVENQDKKSALLDLLSASTDGLTLIFVETKRMADQLTDFLI
MQNFRATAIHGDRTQSERERALAAFRSGAATLLVATAVAARGLDIPNVTHVINYDLPSDV
DDYVHRIGRTGRAGNTGLATAFFNSENSNIVKGLHEILTEANQEVPSFLKDAMMSAPGSR
SNSRRGGFGRNNNRDYRKAGGASAGGWGSSRSRDNSFRGGSGWGSDSKSSGWGNSGGSNN
SSWW",DED1,-,-,604aa(1-604),P06634,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0016,http://db.phasep.pro/browse/",-,"[34-87],[385-403],[449-460],[538-554],[559-570],[579-604]",In vitro,1.5µl 1mg/ml[polyU];|2.5µl 50µM[DED1],-,"13ul LSB-50(50 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),1ul CK mix,2ul Hepes pH 6.8,1ul 10mg/ml BSA",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",liquid,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro."
356,PMID: 31435012,RNAPS0000327,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P24784|DBP1_YEAST ATP-dependent RNA helicase DBP1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DBP1 PE=1 SV=2
MADLPQKVSNLSINNKENGGGGGKSSYVPPHLRSRGKPSFERSTPKQEDKVTGGDFFRRA
GRQTGNNGGFFGFSKERNGGTSANYNRGGSSNYKSSGNRWVNGKHIPGPKNAKLEAELFG
VHDDPDYHSSGIKFDNYDNIPVDASGKDVPEPILDFSSPPLDELLMENIKLASFTKPTPV
QKYSIPIVTKGRDLMACAQTGSGKTGGFLFPLFTELFRSGPSPVPEKAQSFYSRKGYPSA
LVLAPTRELATQIFEEARKFTYRSWVRPCVVYGGAPIGNQMREVDRGCDLLVATPGRLND
LLERGKVSLANIKYLVLDEADRMLDMGFEPQIRHIVEECDMPSVENRQTLMFSATFPVDI
QHLARDFLDNYIFLSVGRVGSTSENITQRILYVDDMDKKSALLDLLSAEHKGLTLIFVET
KRMADQLTDFLIMQNFKATAIHGDRTQAERERALSAFKANVADILVATAVAARGLDIPNV
THVINYDLPSDIDDYVHRIGRTGRAGNTGVATSFFNSNNQNIVKGLMEILNEANQEVPTF
LSDLSRQNSRGGRTRGGGGFFNSRNNGSRDYRKHGGNGSFGSTRPRNTGTSNWGSIGGGF
RNDNEKNGYGNSNASWW",DBP1,-,-,617aa(1-617),P24784,"LLPSDB,PhaSepDB","http://bio-comp.org.cn/llpsdb/protein.php?protein=p0221,http://db.phasep.pro/browse/",-,"[19-23],[545-569]",In vitro,1µl 1mg/ml[polyU];|3µl 50µM[DBP1],-,"14 µl LSB-50(50 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,2 µl Hepes pH 6.4,1 µl 10mg/ml BSA",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",liquid,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro."
357,PMID: 31435012,RNAPS0000328,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P24783|DBP2_YEAST ATP-dependent RNA helicase DBP2 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DBP2 PE=1 SV=1
MTYGGRDQQYNKTNYKSRGGDFRGGRNSDRNSYNDRPQGGNYRGGFGGRSNYNQPQELIK
PNWDEELPKLPTFEKNFYVEHESVRDRSDSEIAQFRKENEMTISGHDIPKPITTFDEAGF
PDYVLNEVKAEGFDKPTGIQCQGWPMALSGRDMVGIAATGSGKTLSYCLPGIVHINAQPL
LAPGDGPIVLVLAPTRELAVQIQTECSKFGHSSRIRNTCVYGGVPKSQQIRDLSRGSEIV
IATPGRLIDMLEIGKTNLKRVTYLVLDEADRMLDMGFEPQIRKIVDQIRPDRQTLMWSAT
WPKEVKQLAADYLNDPIQVQVGSLELSASHNITQIVEVVSDFEKRDRLNKYLETASQDNE
YKTLIFASTKRMCDDITKYLREDGWPALAIHGDKDQRERDWVLQEFRNGRSPIMVATDVA
ARGIDVKGINYVINYDMPGNIEDYVHRIGRTGRAGATGTAISFFTEQNKGLGAKLISIMR
EANQNIPPELLKYDRRSYGGGHPRYGGGRGGRGGYGRRGGYGGGRGGYGGNRQRDGGWGN
RGRSNY",DBP2,-,-,546aa(1-546),P24783,DrLLPS,http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0566,-,"[39-53],[447-461],[495-543]",In vitro,1µl 1mg/ml[polyU];|2.5µl 50µM[DBP2],-,"11.5 µl MH200G,1 µl 1M phosphate pH 6.0,1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,2 µl Hepes pH 6.0,1 µl 10mg/ml BSA",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",liquid,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro."
358,PMID: 31435012,RNAPS0000329,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P60842|IF4A1_HUMAN Eukaryotic initiation factor 4A-I OS=Homo sapiens OX=9606 GN=EIF4A1 PE=1 SV=1
MSASQDSRSRDNGPDGMEPEGVIESNWNEIVDSFDDMNLSESLLRGIYAYGFEKPSAIQQ
RAILPCIKGYDVIAQAQSGTGKTATFAISILQQIELDLKATQALVLAPTRELAQQIQKVV
MALGDYMGASCHACIGGTNVRAEVQKLQMEAPHIIVGTPGRVFDMLNRRYLSPKYIKMFV
LDEADEMLSRGFKDQIYDIFQKLNSNTQVVLLSATMPSDVLEVTKKFMRDPIRILVKKEE
LTLEGIRQFYINVEREEWKLDTLCDLYETLTITQAVIFINTRRKVDWLTEKMHARDFTVS
AMHGDMDQKERDVIMREFRSGSSRVLITTDLLARGIDVQQVSLVINYDLPTNRENYIHRI
GRGGRFGRKGVAINMVTEEDKRTLRDIETFYNTSIEEMPLNVADLI",EIF4A1,-,-,406aa(1-406),P60842,DrLLPS,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2247,[20-21],[359-370],In vitro,2µl 1mg/ml[polyU];|2µl 500µM[EIF4A1],100 mM NaCl,"9µl LSB-150(150 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),2µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1µl BSA 10mg/ml,1µl Hepes pH 6.6,3µl 1x ATPase buffer(30 mM HEPES-KOH pH 7.5, 100 mM NaCl, 2 mM MgCl2)",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",solute,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro."
359,PMID: 31435012,RNAPS0000330,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q07478|SUB2_YEAST ATP-dependent RNA helicase SUB2 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=SUB2 PE=1 SV=1
MSHEGEEDLLEYSDNEQEIQIDASKAAEAGETGAATSATEGDNNNNTAAGDKKGSYVGIH
STGFKDFLLKPELSRAIIDCGFEHPSEVQQHTIPQSIHGTDVLCQAKSGLGKTAVFVLST
LQQLDPVPGEVAVVVICNARELAYQIRNEYLRFSKYMPDVKTAVFYGGTPISKDAELLKN
KDTAPHIVVATPGRLKALVREKYIDLSHVKNFVIDECDKVLEELDMRRDVQEIFRATPRD
KQVMMFSATLSQEIRPICRRFLQNPLEIFVDDEAKLTLHGLQQYYIKLEEREKNRKLAQL
LDDLEFNQVIIFVKSTTRANELTKLLNASNFPAITVHGHMKQEERIARYKAFKDFEKRIC
VSTDVFGRGIDIERINLAINYDLTNEADQYLHRVGRAGRFGTKGLAISFVSSKEDEEVLA
KIQERFDVKIAEFPEEGIDPSTYLNN",SUB2,-,-,446aa(1-446),Q07478,PhaSepDB,http://db.phasep.pro/browse/,-,[23-41],In vitro,2µl 1mg/ml[polyU];|2µl 500µM[SUB2],100 mM NaCl,"9µl LSB-150(150 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),2µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1µl BSA 10mg/ml,1µl Hepes pH 6.6,3µl 1x ATPase buffer(30 mM HEPES-KOH pH 7.5, 100 mM NaCl, 2 mM MgCl2)",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",solute,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro."
360,PMID: 31435012,RNAPS0000331,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P20449|DBP5_YEAST ATP-dependent RNA helicase DBP5 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DBP5 PE=1 SV=2
MSDTKRDPADLLASLKIDNEKEDTSEVSTKETVKSQPEKTADSIKPAEKLVPKVEEKKTK
QEDSNLISSEYEVKVKLADIQADPNSPLYSAKSFDELGLAPELLKGIYAMKFQKPSKIQE
RALPLLLHNPPRNMIAQSQSGTGKTAAFSLTMLTRVNPEDASPQAICLAPSRELARQTLE
VVQEMGKFTKITSQLIVPDSFEKNKQINAQVIVGTPGTVLDLMRRKLMQLQKIKIFVLDE
ADNMLDQQGLGDQCIRVKRFLPKDTQLVLFSATFADAVRQYAKKIVPNANTLELQTNEVN
VDAIKQLYMDCKNEADKFDVLTELYGLMTIGSSIIFVATKKTANVLYGKLKSEGHEVSIL
HGDLQTQERDRLIDDFREGRSKVLITTNVLARGIDIPTVSMVVNYDLPTLANGQADPATY
IHRIGRTGRFGRKGVAISFVHDKNSFNILSAIQKYFGDIEMTRVPTDDWDEVEKIVKKVL
KD",DBP5,-,-,482aa(1-482),P20449,-,-,-,-,In vitro,2µl 1mg/ml[polyU];|2µl 500µM[DBP5],100 mM NaCl,"9µl LSB-150(150 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),2µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1µl BSA 10mg/ml,1µl Hepes pH 6.6,3µl 1x ATPase buffer(30 mM HEPES-KOH pH 7.5, 100 mM NaCl, 2 mM MgCl2)",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",solute,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro."
361,PMID: 31435012,RNAPS0000332,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P26196|DDX6_HUMAN Probable ATP-dependent RNA helicase DDX6 OS=Homo sapiens OX=9606 GN=DDX6 PE=1 SV=2
MSTARTENPVIMGLSSQNGQLRGPVKPTGGPGGGGTQTQQQMNQLKNTNTINNGTQQQAQ
SMTTTIKPGDDWKKTLKLPPKDLRIKTSDVTSTKGNEFEDYCLKRELLMGIFEMGWEKPS
PIQEESIPIALSGRDILARAKNGTGKSGAYLIPLLERLDLKKDNIQAMVIVPTRELALQV
SQICIQVSKHMGGAKVMATTGGTNLRDDIMRLDDTVHVVIATPGRILDLIKKGVAKVDHV
QMIVLDEADKLLSQDFVQIMEDIILTLPKNRQILLYSATFPLSVQKFMNSHLQKPYEINL
MEELTLKGVTQYYAYVTERQKVHCLNTLFSRLQINQSIIFCNSSQRVELLAKKISQLGYS
CFYIHAKMRQEHRNRVFHDFRNGLCRNLVCTDLFTRGIDIQAVNVVINFDFPKLAETYLH
RIGRSGRFGHLGLAINLITYDDRFNLKSIEEQLGTEIKPIPSNIDKSLYVAEYHSEPVED
EKP",DDX6,-,-,483aa(1-483),P26196,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0982,http://db.phasep.pro/browse/",-,-,In vitro,3µl 2mg/ml[polyU];|2.5µl 50µM[DDX6],-,"14.5 µl LSB-50(50 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),2 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1 µl BSA 10mg/ml,1 µl Hepes pH 6.4",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",liquid,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro."
362,PMID: 31435012,RNAPS0000333,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|O00571|DDX3X_HUMAN ATP-dependent RNA helicase DDX3X OS=Homo sapiens OX=9606 GN=DDX3X PE=1 SV=3
MSHVAVENALGLDQQFAGLDLNSSDNQSGGSTASKGRYIPPHLRNREATKGFYDKDSSGW
SSSKDKDAYSSFGSRSDSRGKSSFFSDRGSGSRGRFDDRGRSDYDGIGSRGDRSGFGKFE
RGGNSRWCDKSDEDDWSKPLPPSERLEQELFSGGNTGINFEKYDDIPVEATGNNCPPHIE
SFSDVEMGEIIMGNIELTRYTRPTPVQKHAIPIIKEKRDLMACAQTGSGKTAAFLLPILS
QIYSDGPGEALRAMKENGRYGRRKQYPISLVLAPTRELAVQIYEEARKFSYRSRVRPCVV
YGGADIGQQIRDLERGCHLLVATPGRLVDMMERGKIGLDFCKYLVLDEADRMLDMGFEPQ
IRRIVEQDTMPPKGVRHTMMFSATFPKEIQMLARDFLDEYIFLAVGRVGSTSENITQKVV
WVEESDKRSFLLDLLNATGKDSLTLVFVETKKGADSLEDFLYHEGYACTSIHGDRSQRDR
EEALHQFRSGKSPILVATAVAARGLDISNVKHVINFDLPSDIEEYVHRIGRTGRVGNLGL
ATSFFNERNINITKDLLDLLVEAKQEVPSWLENMAYEHHYKGSSRGRSKSSRFSGGFGAR
DYRQSSGASSSSFSSSRASSSRSGGGGHGSSRGFGGGGYGGFYNSDGYGGNYNSQGVDWW
GN",DDX3X,-,-,662aa(1-662),O00571,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/O00571,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1500,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0261,http://db.phasep.pro/browse/","[1-167],[256-263],[407-411],[437-437],[439-441],[473-480],[500-506],[535-536],[576-584]",-,In vitro,2µl 2mg/ml[polyU];|3µl 50µM[DDX3X],-,"14 µl LSB-50(50 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),2 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1 µl BSA 10mg/ml,1 µl Hepes pH 6.8",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",liquid,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro."
363,PMID: 31435012,RNAPS0000334,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P21693|DBPA_ECOLI ATP-dependent RNA helicase DbpA OS=Escherichia coli (strain K12) OX=83333 GN=dbpA PE=1 SV=2
MTAFSTLNVLPPAQLTNLNELGYLTMTPVQAAALPAILAGKDVRVQAKTGSGKTAAFGLG
LLQQIDASLFQTQALVLCPTRELADQVAGELRRLARFLPNTKILTLCGGQPFGMQRDSLQ
HAPHIIVATPGRLLDHLQKGTVSLDALNTLVMDEADRMLDMGFSDAIDDVIRFAPASRQT
LLFSATWPEAIAAISGRVQRDPLAIEIDSTDALPPIEQQFYETSSKGKIPLLQRLLSLHQ
PSSCVVFCNTKKDCQAVCDALNEVGQSALSLHGDLEQRDRDQTLVRFANGSARVLVATDV
AARGLDIKSLELVVNFELAWDPEVHVHRIGRTARAGNSGLAISFCAPEEAQRANIISDML
QIKLNWQTPPANSSIATLEAEMATLCIDGGKKAKMRPGDVLGALTGDIGLDGADIGKIAV
HPAHVYVAVRQAVAHKAWKQLQGGKIKGKTCRVRLLK",dbpA,-,-,457aa(1-457),P21693,-,-,-,-,In vitro,2µl 2mg/ml[polyU];|3µl 50µM[dbpA],-,"16 µl LSB-100(100 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),2 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1 µl BSA 10 mg/ml,1 µl 1M Hepes pH 6.4",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",solute,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro."
364,PMID: 31435012,RNAPS0000335,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P0A8J8|RHLB_ECOLI ATP-dependent RNA helicase RhlB OS=Escherichia coli (strain K12) OX=83333 GN=rhlB PE=1 SV=2
MSKTHLTEQKFSDFALHPKVVEALEKKGFHNCTPIQALALPLTLAGRDVAGQAQTGTGKT
MAFLTSTFHYLLSHPAIADRKVNQPRALIMAPTRELAVQIHADAEPLAEATGLKLGLAYG
GDGYDKQLKVLESGVDILIGTTGRLIDYAKQNHINLGAIQVVVLDEADRMYDLGFIKDIR
WLFRRMPPANQRLNMLFSATLSYRVRELAFEQMNNAEYIEVEPEQKTGHRIKEELFYPSN
EEKMRLLQTLIEEEWPDRAIIFANTKHRCEEIWGHLAADGHRVGLLTGDVAQKKRLRILD
EFTRGDLDILVATDVAARGLHIPAVTHVFNYDLPDDCEDYVHRIGRTGRAGASGHSISLA
CEEYALNLPAIETYIGHSIPVSKYNPDALMTDLPKPLRLTRPRTGNGPRRTGAPRNRRRS
G",RhlB,-,-,421aa(1-421),P0A8J8,PhaSepDB,http://db.phasep.pro/browse/,-,[398-419],In vitro,2µl 2mg/ml[polyU];|3µl 50µM[RhlB],-,"16 µl LSB-100(100 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),2 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1 µl BSA 10 mg/ml,1 µl 1M Hepes pH 6.4",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",solute,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro."
365,PMID: 31435012,RNAPS0000336,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P0A9P6|DEAD_ECOLI ATP-dependent RNA helicase DeaD OS=Escherichia coli (strain K12) OX=83333 GN=deaD PE=1 SV=2
MAEFETTFADLGLKAPILEALNDLGYEKPSPIQAECIPHLLNGRDVLGMAQTGSGKTAAF
SLPLLQNLDPELKAPQILVLAPTRELAVQVAEAMTDFSKHMRGVNVVALYGGQRYDVQLR
ALRQGPQIVVGTPGRLLDHLKRGTLDLSKLSGLVLDEADEMLRMGFIEDVETIMAQIPEG
HQTALFSATMPEAIRRITRRFMKEPQEVRIQSSVTTRPDISQSYWTVWGMRKNEALVRFL
EAEDFDAAIIFVRTKNATLEVAEALERNGYNSAALNGDMNQALREQTLERLKDGRLDILI
ATDVAARGLDVERISLVVNYDIPMDSESYVHRIGRTGRAGRAGRALLFVENRERRLLRNI
ERTMKLTIPEVELPNAELLGKRRLEKFAAKVQQQLESSDLDQYRALLSKIQPTAEGEELD
LETLAAALLKMAQGERTLIVPPDAPMRPKREFRDRDDRGPRDRNDRGPRGDREDRPRRER
RDVGDMQLYRIEVGRDDGVEVRHIVGAIANEGDISSRYIGNIKLFASHSTIELPKGMPGE
VLQHFTRTRILNKPMNMQLLGDAQPHTGGERRGGGRGFGGERREGGRNFSGERREGGRGD
GRRFSGERREGRAPRRDDSTGRRRFGGDA",DeaD,-,-,629aa(1-629),P0A9P6,-,-,-,-,In vitro,1.5µl 2mg/ml[polyU];|3µl 50µM[DeaD],-,"17.5 µl LSB-100(100 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1 µl BSA 10mg/ml,1 µl Hepes pH 6.4",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",liquid,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro."
366,PMID: 31435012,RNAPS0000337,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P21507|SRMB_ECOLI ATP-dependent RNA helicase SrmB OS=Escherichia coli (strain K12) OX=83333 GN=srmB PE=1 SV=1
MTVTTFSELELDESLLEALQDKGFTRPTAIQAAAIPPALDGRDVLGSAPTGTGKTAAYLL
PALQHLLDFPRKKSGPPRILILTPTRELAMQVSDHARELAKHTHLDIATITGGVAYMNHA
EVFSENQDIVVATTGRLLQYIKEENFDCRAVETLILDEADRMLDMGFAQDIEHIAGETRW
RKQTLLFSATLEGDAIQDFAERLLEDPVEVSANPSTRERKKIHQWYYRADDLEHKTALLV
HLLKQPEATRSIVFVRKRERVHELANWLREAGINNCYLEGEMVQGKRNEAIKRLTEGRVN
VLVATDVAARGIDIPDVSHVFNFDMPRSGDTYLHRIGRTARAGRKGTAISLVEAHDHLLL
GKVGRYIEEPIKARVIDELRPKTRAPSEKQTGKPSKKVLAKRAEKKKAKEKEKPRVKKRH
RDTKNIGKRRKPSGTGVPPQTTEE",SrmB,-,-,444aa(1-444),P21507,PhaSepDB,http://db.phasep.pro/browse/,[389-444],"[7-17],[29-38],[396-419]",In vitro,1.5µl 2mg/ml[polyU];|3µl 50µM[SrmB],-,"18.5 µl LSB-50(50 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1 µl BSA 10mg/ml",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",liquid,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro."
367,PMID: 31435012,RNAPS0000338,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P25888|RHLE_ECOLI ATP-dependent RNA helicase RhlE OS=Escherichia coli (strain K12) OX=83333 GN=rhlE PE=1 SV=3
MSFDSLGLSPDILRAVAEQGYREPTPIQQQAIPAVLEGRDLMASAQTGTGKTAGFTLPLL
QHLITRQPHAKGRRPVRALILTPTRELAAQIGENVRDYSKYLNIRSLVVFGGVSINPQMM
KLRGGVDVLVATPGRLLDLEHQNAVKLDQVEILVLDEADRMLDMGFIHDIRRVLTKLPAK
RQNLLFSATFSDDIKALAEKLLHNPLEIEVARRNTASDQVTQHVHFVDKKRKRELLSHMI
GKGNWQQVLVFTRTKHGANHLAEQLNKDGIRSAAIHGNKSQGARTRALADFKSGDIRVLV
ATDIAARGLDIEELPHVVNYELPNVPEDYVHRIGRTGRAAATGEALSLVCVDEHKLLRDI
EKLLKKEIPRIAIPGYEPDPSIKAEPIQNGRQQRGGGGRGQGGGRGQQQPRRGEGGAKSA
SAKPAEKPSRRLGDAKPAGEQQRRRRPRKPAAA",RhlE,-,-,453aa(1-453),P25888,-,-,-,"[334-343],[390-430],[441-453]",In vitro,1.5µl 2mg/ml[polyU];|2µl 50µM[RhlE],-,"18.5 µl LSB-100(100 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1 µl BSA 10mg/ml,1 µl Hepes 1M pH 6.8",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",liquid,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase-separated droplets in vitro."
368,PMID: 31586050,RNAPS0000339,https://pubmed.ncbi.nlm.nih.gov/31586050,RNA + protein,-,-,(GA-rich)30,30nt,GGAGGAGAGGAAGGUAAGGGAAGAAAGAAG,nucleotide rich RNA,-,"sp|Q96F86|EDC3_HUMAN Enhancer of mRNA-decapping protein 3 OS=Homo sapiens OX=9606 GN=EDC3 PE=1 SV=1
MATDWLGSIVSINCGDSLGVYQGRVSAVDQVSQTISLTRPFHNGVKCLVPEVTFRAGDIT
ELKILEIPGPGDNQHFGDLHQTELGPSGAGCQVGINQNGTGKFVKKPASSSSAPQNIPKR
TDVKSQDVAVSPQQQQCSKSYVDRHMESLSQSKSFRRRHNSWSSSSRHPNQATPKKSGLK
NGQMKNKDDECFGDDIEEIPDTDFDFEGNLALFDKAAVFEEIDTYERRSGTRSRGIPNER
PTRYRHDENILESEPIVYRRIIVPHNVSKEFCTDSGLVVPSISYELHKKLLSVAEKHGLT
LERRLEMTGVCASQMALTLLGGPNRLNPKNVHQRPTVALLCGPHVKGAQGISCGRHLANH
DVQVILFLPNFVKMLESITNELSLFSKTQGQQVSSLKDLPTSPVDLVINCLDCPENVFLR
DQPWYKAAVAWANQNRAPVLSIDPPVHEVEQGIDAKWSLALGLPLPLGEHAGRIYLCDIG
IPQQVFQEVGINYHSPFGCKFVIPLHSA",EDC3,-,-,508aa(1-508),Q96F86,DrLLPS,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1241,"[95-189],[192-192],[203-258],[",[154-167],In vitro,150 µM Edc3 protein,25 mM NaCl,"25 mM HEPES, pH 7.3",RT,≤ 180 min,-,ssNMR,liquid,"In conclusion, our ssNMR data suggest that RNA is recruited to the dynamic and unstructured IDR in Edc3, which results in decreased internal mobility."
369,PMID: 31630970,RNAPS0000340,https://pubmed.ncbi.nlm.nih.gov/31630970,RNA + protein,-,-,polyrU(40),40nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,1µM poly(rU)40;|1µM FUS,100mM NaCl,"100mM Tris-HCl,pH 7.5,1mM EDTA,1mM DTT",RT,≤ 6 h,-,FRAP,"solute, liquid","The size of condensates was determined over the course of six hours; whereas WT-FUS, NLS, and G mutant FUS form small droplets (area of ~1.5μm2, R) R mutants grow much larger (area ~ 3-6 μm2) (Fig. 6B). Even after three hours, a stark difference in droplet size is observed (Fig 6C)."
370,PMID: 31677973,RNAPS0000342,https://pubmed.ncbi.nlm.nih.gov/31677973,RNA + protein,-,-,"MajSAT RNA (Huo,2020)",231nt,GGACCUGGAAUAUGGCGAGAAAACUGAAAAUCACGGAAAAUGAGAAAUACACACUUUAGGACGUGAAAUAUGGCGAGGAAAACUGAAAAAGGUGGAAAAUUUAGAAAUGUCCACUGUAGGUCGUGGAAUAUGGCAAGAAAACUGAAAAUCAUGGAAAAUGAGAAACAUCCACUUGACGACUUGAAAAAUGACGAAAUCACUAAAAAACGUGAAAAAUGAGAAAUGCACACUGAA,irregular RNA,-,"sp|Q15424|SAFB1_HUMAN Scaffold attachment factor B1 OS=Homo sapiens OX=9606 GN=SAFB PE=1 SV=4
MAETLSGLGDSGAAGAAALSSASSETGTRRLSDLRVIDLRAELRKRNVDSSGNKSVLMER
LKKAIEDEGGNPDEIEITSEGNKKTSKRSSKGRKPEEEGVEDNGLEENSGDGQEDVETSL
ENLQDIDIMDISVLDEAEIDNGSVADCVEDDDADNLQESLSDSRELVEGEMKELPEQLQE
HAIEDKETINNLDTSSSDFTILQEIEEPSLEPENEKILDILGETCKSEPVKEESSELEQP
FAQDTSSVGPDRKLAEEEDLFDSAHPEEGDLDLASESTAHAQSSKADSLLAVVKREPAEQ
PGDGERTDCEPVGLEPAVEQSSAASELAEASSEELAEAPTEAPSPEARDSKEDGRKFDFD
ACNEVPPAPKESSTSEGADQKMSSPEDDSDTKRLSKEEKGRSSCGRNFWVSGLSSTTRAT
DLKNLFSKYGKVVGAKVVTNARSPGARCYGFVTMSTAEEATKCINHLHKTELHGKMISVE
KAKNEPVGKKTSDKRDSDGKKEKSSNSDRSTNLKRDDKCDRKDDAKKGDDGSGEKSKDQD
DQKPGPSERSRATKSGSRGTERTVVMDKSKGVPVISVKTSGSKERASKSQDRKSASREKR
SVVSFDKVKEPRKSRDSESHSRVRERSEREQRMQAQWEREERERLEIARERLAFQRQRLE
RERMERERLERERMHVEHERRREQERIHREREELRRQQELRYEQERRPAVRRPYDLDRRD
DAYWPEAKRAALDERYHSDFNRQDRFHDFDHRDRGRYPDHSVDRREGSRSMMGEREGQHY
PERHGGPERHGRDSRDGWGGYGSDKRMSEGRGLPPPPRRDWGDHGRREDDRSWQGTADGG
MMDRDHKRWQGGERSMSGHSGPGHMMNRGGMSGRGSFAPGGASRGHPIPHGGMQGGFGGQ
SRGSRPSDARFTRRY",SAFB,-,-,915aa(1-915),Q15424,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2609,http://db.phasep.pro/browse/",-,"[5-24],[83-94],[96-108],[201-215],[319-347],[514-541],[614-707],[739-756],[863-876],[891-905]",In vitro,0-3.75µM MajSAT RNA;|5µM SAFB-GEP,50mM NaCl,"50mM Tris pH 7.5, 5mM DTT",25˚C,10 min,"other_molecular:10% 1,6-hexanediol, 0.1% Triton",FRAP,"solute, liquid","When no RNAs were added, SAFB-GFP formed condensed droplets under 50 mM NaCl concentration. Surprisingly, by adding MajSAT RNAs, SAFB-GFP formed larger “droplet clusters,” whose sizes enlarged with the increase in concentrations of MajSAT RNAs (Figures 6E and 6F)."
371,PMID: 31677973,RNAPS0000343,https://pubmed.ncbi.nlm.nih.gov/31677973,RNA + protein,-,-,"U1 RNA (Huo,2020)",156nt,AUACUUACCUGGCAGGGGAGAUACCAUGAUCACGAAGGUGGUUUUCCCAGGGCGAGGCUUAUCCAUUGCACUCCGGAUGUGCUGACCCCUGCGAUUUCCCCAAAUGCGGGAAACUCGACUGCAUAAUUUGUGGUAGUGGGGGACUGCGUUCGCGCU,irregular RNA,-,"sp|Q15424|SAFB1_HUMAN Scaffold attachment factor B1 OS=Homo sapiens OX=9606 GN=SAFB PE=1 SV=4
MAETLSGLGDSGAAGAAALSSASSETGTRRLSDLRVIDLRAELRKRNVDSSGNKSVLMER
LKKAIEDEGGNPDEIEITSEGNKKTSKRSSKGRKPEEEGVEDNGLEENSGDGQEDVETSL
ENLQDIDIMDISVLDEAEIDNGSVADCVEDDDADNLQESLSDSRELVEGEMKELPEQLQE
HAIEDKETINNLDTSSSDFTILQEIEEPSLEPENEKILDILGETCKSEPVKEESSELEQP
FAQDTSSVGPDRKLAEEEDLFDSAHPEEGDLDLASESTAHAQSSKADSLLAVVKREPAEQ
PGDGERTDCEPVGLEPAVEQSSAASELAEASSEELAEAPTEAPSPEARDSKEDGRKFDFD
ACNEVPPAPKESSTSEGADQKMSSPEDDSDTKRLSKEEKGRSSCGRNFWVSGLSSTTRAT
DLKNLFSKYGKVVGAKVVTNARSPGARCYGFVTMSTAEEATKCINHLHKTELHGKMISVE
KAKNEPVGKKTSDKRDSDGKKEKSSNSDRSTNLKRDDKCDRKDDAKKGDDGSGEKSKDQD
DQKPGPSERSRATKSGSRGTERTVVMDKSKGVPVISVKTSGSKERASKSQDRKSASREKR
SVVSFDKVKEPRKSRDSESHSRVRERSEREQRMQAQWEREERERLEIARERLAFQRQRLE
RERMERERLERERMHVEHERRREQERIHREREELRRQQELRYEQERRPAVRRPYDLDRRD
DAYWPEAKRAALDERYHSDFNRQDRFHDFDHRDRGRYPDHSVDRREGSRSMMGEREGQHY
PERHGGPERHGRDSRDGWGGYGSDKRMSEGRGLPPPPRRDWGDHGRREDDRSWQGTADGG
MMDRDHKRWQGGERSMSGHSGPGHMMNRGGMSGRGSFAPGGASRGHPIPHGGMQGGFGGQ
SRGSRPSDARFTRRY",SAFB,-,-,915aa(1-915),Q15424,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2609,http://db.phasep.pro/browse/",-,"[5-24],[83-94],[96-108],[201-215],[319-347],[514-541],[614-707],[739-756],[863-876],[891-905]",In vitro,"0-3.75µM U1 RNA (Huo,2020);|5µM SAFB-GEP",50mM NaCl,"50mM Tris pH 7.5, 5mM DTT",25˚C,10 min,"other_molecular:10% 1,6-hexanediol, 0.1% Triton",FRAP,"liquid, solute","When no RNAs were added, SAFB-GFP formed condensed droplets under 50 mM NaCl concentration. Surprisingly, by adding MajSAT RNAs, SAFB-GFP formed larger “droplet clusters,” whose sizes enlarged with the increase in concentrations of MajSAT RNAs (Figures 6E and 7F)."
372,PMID: 31975687,RNAPS0000038,https://pubmed.ncbi.nlm.nih.gov/31975687,RNA + protein,NCBI ID:245998,https://www.ncbi.nlm.nih.gov/gene/245998,Y51F10.2,1073nt(1-1073),UUCCUGUUCUCUGUGGACAAAAAUGUACAGUUUCAAAAGCAGCACCGACGUGAAGACUUAUAUCAGCACCCCGUCGUGCCGGAUAUGUCUUGAGCCAUUUGACGAAGGACAACAUCUUCCGAAAAUCCUGCAAUGUGCCCACACGGUCUGCGAGAGAUGCAUCGGUUUGCUCGACGAGCAGAGCCGAAUCAACCACAAUCGGCCGCCGAUCGACCGCUCGUUUGUGCACAUUAGAUGUCCAGUUUGCAGGGCAGUCACCCAGACUCCACGCAACUACAUUCGAUCCAACUACCAGCUAAUCGAAUUGAUGGAUUCGAUGCGUGGAGAAGCCGAUCAUAAUAUUUCAUUCCUCGCGUGUGUCGGCUGUAAUGGCGUUUAUCACGAGAAAGACACCAAUAUUUGCACUACAUGCUCCCCAAUCAUCAAGGAUGCUCAUCCCACUGAACUCAUCGAGCAAGGAGUAAUUCUGAAUCAGUACGCGUUGUGUUCGACGUGUCUCCUCAGAGAUCACAUCAAAAAGAACCACGUGUCGAUCAGUCUGCAGCCUCUUCGCGUCGAAAUGCAACGCCAGGAGAAUCAGCGGCGGAUAGUCGGCUUGCAGGACAAUUUGCACAAAGUGCAACGCGAUUUUCGUGAGCAGCUUAACGCGACUAUGGAGCGAUGGGCCGGAUGGAAUGGGAGCCACGAUUUGUCGAUGGAUAAAUUCCGUGAGCUUGGUGAUACGUACAAUCAGAAGAAGGUUUAUGAUGCGUUCGUGCAUCAGCUGAGAGGCAAGACCGCUAAGAUUGAGAAGCUCGCCGAGCACGUUUUGCGAUGGAAUGAUGAGCUGGACAGGGAGAUGGAAAGACCACCAGCUCAUCGUUUGCCACGUAGCUCAACUCCAGCGCCAGCACCACCAUUCGACAACUCCGUCGCCUACUAUUUUGAGCACCAAUUUUGAGCUUUUAUAUUUUUUUUUCUCAUCCCACCACCACAUUAAAACAGAGUUUUUAUAUAUACAGUACCCAUUAUUCGAACACAAUUUGUUCUAAAAGAGCCCCCAAGAAUCAGAUUUAAUAAAGAAUGCUCUCACC,mRNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,20 ng/µL [polyU(30)];|500 nM [meg-3],"150 mM (37.5 mM
KCl, 112.5 mM NaCl)",25 mM HEPES (pH 7.4),RT,30 min,-,"FISH,FRAP",liquid,"To determine whether RNA length affects MEG-3 condensation behavior, we tested RNAs of varying sizes in the condensation assay. We found that short RNAs (30 and 100 nt) were not as efficient as longer RNAs at stimulating MEG-3 condensation."
373,PMID: 31975687,RNAPS0000039,https://pubmed.ncbi.nlm.nih.gov/31975687,RNA + protein,NCBI ID:174158,https://www.ncbi.nlm.nih.gov/gene/174158,polyU(30),30nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,20 ng/µL [nos-2];|500 nM [meg-3],"150 mM (37.5 mM
KCl, 112.5 mM NaCl)",25 mM HEPES (pH 7.4),RT,30 min,-,"FISH,FRAP",liquid,"To determine whether RNA length affects MEG-3 condensation behavior, we tested RNAs of varying sizes in the condensation assay. We found that short RNAs (30 and 100 nt) were not as efficient as longer RNAs at stimulating MEG-3 condensation."
374,PMID: 31975687,RNAPS0000039,https://pubmed.ncbi.nlm.nih.gov/31975687,RNA + protein,NCBI ID:174158,https://www.ncbi.nlm.nih.gov/gene/174158,nos-2,1242nt(1-1242),CACAGACGACGGAAAGGGGAAAUUCAAGCCAUUUGAGUUUUUGUUCUUCUUGAAAGAUGUCUCUGGGUACUCCAAGUGAACCGACUUCGACUCUCGAAUCAGACAUUUUUGACGAUCUUUCGUUGUAUUAUCUAGAGGAUGUAUUCCUUUCCGCCACAACGCCGUCGCCAACAUUUGAUUUGAGUGAUCCAUCGGAUCCAUCACUUUCGGAUUCGUUUGACAGUGAAUGGUCACCAAUGACUCCAUGCUCAAUAGAAAGACCGGAGACCUCAACAUCAUCAAUCUUCUCGUUUGAAGCUAGACCCAUCAAAACGCCGCCACCUGCCGAAUAUCUUCGACUUCCGACAUUCCUGUCAACGAAUAAUUCCGGAUUUUUCGAUUCAGUUGUCGCUUCGGAUUUCAAUUUGUACGGGAAGUUCAAUGAUUGGUUGAAUGACAGCAAGCCUCGCAGUGGAUCGUUUGCGAUUGAAUCUGCUGAAGAGCUCGCGAGGAAUCCAAGAGAAACUCGCUCCGAGCCCGAAGUGCCAUCAUUGUUCAAAAGGCGUGAAUAUGGAUGUGGAUACUGUCGUUCCGUUGGAUAUAUGCGAUGGGAAACGCAUACACGUAAGAAAUGCGACAAGCUCAGCUCAUUGGCUCCAUGUAAAAUUUGUGGAGCUCGCGGUGAAAUGAAUCACACCGAGACGUACUGCCCAAUGAAGCCGUCGAGCCAGUUGUUCUUCAAUGAGGAUUUCAGCCGAGACUUCGAAAACCGACGAUUCCAGCGCAGUCGUUAUCAAUUUUACAAGCAUUCCUCAUUAAUUCAGAAGAUCUACGCAUCAUCCGAAGAUUCUUUCUAGAAGAUCCAAUUUCUCAAUACUUUUUUAUAUCGGGUCCAACCCGUUUAUUUUCUACAAGCUUUCACAAACAGAUAGUUUAUUGAGUUACCCGUUCAUAGCCUUUAUUGAUUCCAAAUUUCCCAUCUCACACUUUUCUACGGUAUACCAUUUACUUUUUCUGCUAAUAAUCAAUUAUUAAUACCGUAUAAUGGUCCUCUAUAUUGUCCACGUAACAACUUGUGCUUUUUCGUCGAAUUUUCAUCAGUUUGUGGAAGAAAGUGAUAACUGAAAGAAAGAAGUUUUGAAAGGAAUAGUUGUAGAAGUAAAUCACUUGUCAAUUGCAUUUGAAUAGUUGGCGAGAGCCGCAAUAUCGAGAAAAUGUGUAGCCAGGAAGGUAUAGCUCUGAAAAUAAAAAUUUACAAUUCGU,mRNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,20 ng/µL [nos-2];|500 nM [meg-3],"150 mM (37.5 mM
KCl, 112.5 mM NaCl)",25 mM HEPES (pH 7.4),RT,30 min,-,"FISH,FRAP",liquid,"To investigate whether MEG-3 shows any bias when presented with specific sequences, we synthesized nine fluorescently labeled RNAs (800-1300nt size range) corresponding to embryonic transcripts with strong, minimal, or no localization to P granules in vivo under normal culture conditions. Each transcript (20 ng/mL) was combined with recombinant His-tagged MEG-3 (500 nM; ) in condensation buffer containing 150 mM salt. In the absence of RNA, MEG-3 formed irregular assemblies with a broad size range."
375,PMID: 31975687,RNAPS0000040,https://pubmed.ncbi.nlm.nih.gov/31975687,RNA + protein,NCBI ID:172773,https://www.ncbi.nlm.nih.gov/gene/172773,skr-2,758nt(1-758),CGUUAGUGACCCUGUCACAACUAAUUUUAAUUCCAGUCAACUACAACACGAUGGCUGACCAAAAGGAAGCAUCCGAAGCAGCAAAGAACCGCGAAAUCAAGAUCUCGUCUUCGGAUGAUGAAAUCUUCUUGGUCCCACGCAAUGUGAUCCGUCUCUCAAACACUCUCAACACUCUUCUUGUGGACCUCGGGCUCGACGACGAUGAAGGAACCAACGCUGAGCCAAUUCCAGUGCAAAACGUCACUGCCUCGAUUUUGAAGAAGGUUAUCAACUGGUGCACCAAACACCAGUCCGACCCAAUUCCAACUGAAGACAGUGAGAAGAAAACGGAUGGUUCCAUCCAAGACUGGGACAAAAAAUUUCUCGAUAUUGACCAAGGAACCCUUUUCGAGCUCAUUUUGGCUGCCAACUAUUUGGACAUCAAAGGACUUCUUGAUGUCGCCUGCCAGUCUGUCGCCAACAUGAUCAAGGGAAAAUCUCCAGAUGAAAUUCGUCGUGCUUUCAACAUCAAGGACGACUUCACUGCAGAGGAGAGAGAGCAAAUCCGUAAGGAAAACGCCUGGUGCGAUGAUUAAAUCUCCAUCUUUUCCCCUGUUAAACUUUCAAUUACCUUGUUUUCUAAAUGUUUCACAUCAUCCACCAUAUCUUUCCCCUUAUUAAACGCACUUUUUAAUUGUUAACAAAUUUCUUCACUGCCAGCUGACACAACUGUGUACAGUUCUGUUUUUCAUUCAAUAAAGUUGAUGUGAACAUGAAAA,mRNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,20 ng/µL [skr-2];|500 nM [meg-3],"150 mM (37.5 mM
KCl, 112.5 mM NaCl)",25 mM HEPES (pH 7.4),RT,30 min,-,"FISH,FRAP",liquid,"To investigate whether MEG-3 shows any bias when presented with specific sequences, we synthesized nine fluorescently labeled RNAs (800-1300nt size range) corresponding to embryonic transcripts with strong, minimal, or no localization to P granules in vivo under normal culture conditions. Each transcript (20 ng/mL) was combined with recombinant His-tagged MEG-3 (500 nM; ) in condensation buffer containing 150 mM salt. In the absence of RNA, MEG-3 formed irregular assemblies with a broad size range."
376,PMID: 31975687,RNAPS0000041,https://pubmed.ncbi.nlm.nih.gov/31975687,RNA + protein,NCBI ID:181451,https://www.ncbi.nlm.nih.gov/gene/181451,R04D3.2,951nt(1-951),CUAAAGUCUGAAUGUUCUAUUUGUCUUUGCUUUUCUUGAUGGCGUGUGUCUUCUCGUCAUUGUUGGUGGUGCAGUUGGUGUGGAUGGAUUUUCAUUCUUAUCUGCAUCGAAUGUCUCCGUCUCCUUUUGCUUUUCCUCUUUCUUUUUGGCAGAAGUACGACGAGAGGUCGAUAGUUUCUCGAUGCGAACUGAUGUUCCUCGUUUUCUUCCGCGUGUUUUCUUUGUACUUUGUACCGGCUCUUUGAAAACAAUUUCGCCACCAUCUCCAAGCUCAGAUUUGGUCUUUUCAUCUGUCUCUUGGUCAUUUUCAAUCGGAUCAUUUGUGGGAGACUUAUCUUUUCUGAAAAUCCAAUCACCGGAAGCUUGAUUUCUCUCAUUUACAUCAAUGUCUCCGGCAAUAGUUGUAUUGAAGAGUACGGUAGUGUCAUCAAAAGAAGAGAAAAACAGUGGGAAAUCUCUAUUUUUCGGCGACUCUGUUAUUUGUGAUGUUCCUUCUCCAUGGUUACGAUGGUCAAUACGGAAUGUUGAGUUAAGUAGAUCUCCAGAACCUGCAUCGCGAGGAUAGUCAGUGUCGAAAAGCCAAUUGAGUCCCAAUGUCUCGUCACAAUCUACCACUGGUUCUCCUGUUUUGAUCAUCACUUCAGUGUCAUUUCUCUGAAAUUUUCUUCGUCUUUCAGAUAAUUGAAUUUUUGGCGUUUUUGCUGGAGUUGCGGUUUCAAGAACAGUGGACGAGCGUCUUUUUGCAACUUUCAGGAACGUCGGAAGAUCAACAAGCUGAUCGGAAAUAUCAAUGAUAGACGAUUGUGAAGGCGUAUGAAACACCGACACUGGGGUCGUUGGGACUGAUUCUUGAACUUCAAUACUGUGACCGUCGACCAUGUCGUAAUCUGAACUUUCAUCAGCUUCUUCUUCGGGGCCAACACCCAACAUCCACCAAGGAAGCGGCAACAU,mRNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,20 ng/µL [RO4D3.2];|500 nM [meg-3],"150 mM (37.5 mM
KCl, 112.5 mM NaCl)",25 mM HEPES (pH 7.4),RT,30 min,-,"FISH,FRAP",liquid,"To investigate whether MEG-3 shows any bias when presented with specific sequences, we synthesized nine fluorescently labeled RNAs (800-1300nt size range) corresponding to embryonic transcripts with strong, minimal, or no localization to P granules in vivo under normal culture conditions. Each transcript (20 ng/mL) was combined with recombinant His-tagged MEG-3 (500 nM; ) in condensation buffer containing 150 mM salt. In the absence of RNA, MEG-3 formed irregular assemblies with a broad size range."
377,PMID: 31975687,RNAPS0000042,https://pubmed.ncbi.nlm.nih.gov/31975687,RNA + protein,NCBI ID:183500,https://www.ncbi.nlm.nih.gov/gene/183500,C46A5.6,1084nt(1-1084),GGUAAAAUGUUGCCGCUUCCUUGGUGGAUGUUGGGUGUUGGCCCCGAAGAAGAAGCUGAUGAAAGUUCAGAUUACGACAUGGUCGACGGUCACAGUAUUGAAGUUCAAGAAUCAGUCCCAACGACCCCAGUGUCGGUGUUUCAUACGCCUUCACAAUCGUCUAUCAUUGAUAUUUCCGAUCAGCUUGUUGAUCUUCCGACGUUCCUGAAAGUUGCAAAAAGACGCUCGUCCACUGUUCUUGAAACCGCAACUCCAGCAAAAACGCCAAAAAUUCAAUUAUCUGAAAGACGAAGAAAAUUUCAGAGAAAUGACACUGAAGUGAUGAUCAAAACAGGAGAACCAGUGGUAGAUUGUGACGAGACAUUGGGACUCAAUUGGCUUUUCGACACUGACUAUCCUCGCGAUGCAGGUUCUGGAGAUCUACUUAACUCAACAUUCCGUAUUGACCAUCGUAACCAUGGAGAAGGAACAUCACAAAUAACAGAGUCGCCGAAAAAUAGAGAUUUCCCACUGUUUUUCUCUUCUUUUGAUGACACUACCGUACUCUUCAAUACAACUAUUGCCGGAGACAUUGAUGUAAAUGAGAGAAAUCAAGCUUCCGGUGAUUGGAUUUUCAGAAAAGAUAAGUCUCCCACAAAUGAUCCGAUUGAAAAUGACCAAGAGACAGAUGAAAAGACCAAAUCUGAGCUUGGAGAUGGUGGCGAAAUUGUUUUCAAAGAGCCGGUACAAAGUACAAAGAAAACACGCGGAAGAAAACGAGGAACAUCAGUUCGCAUCGAGAAACUAUCGACCUCUCGUCGUACUUCUGCCAAAAAGAAAGAGGAAAAGCAAAAGGAGACGGAGACAUUCGAUGCAGAUAAGAAUGAAAAUCCAUCCACACCAACUGCACCACCAACAAUGACGAGAAGACACACGCCAUCAAGAAAAGCAAAGACAAAUAGAACAUUCAGACUUUAGAUUUGUUCUGUAAAAUUGUUAAUCCUCUGUUAGUUUUUCUUCAACGUUGUAGUUGUUUCUGUUAAAUUUGACUGUCUAUUUAAAGUUUUUUGUUGUUGUUCUUUUUUGCAUAAAAUGCUUAGUAUUA,mRNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,20 ng/µL [C46A5.6];|500 nM [meg-3],"150 mM (37.5 mM
KCl, 112.5 mM NaCl)",25 mM HEPES (pH 7.4),RT,30 min,-,"FISH,FRAP",liquid,"To investigate whether MEG-3 shows any bias when presented with specific sequences, we synthesized nine fluorescently labeled RNAs (800-1300nt size range) corresponding to embryonic transcripts with strong, minimal, or no localization to P granules in vivo under normal culture conditions. Each transcript (20 ng/mL) was combined with recombinant His-tagged MEG-3 (500 nM; ) in condensation buffer containing 150 mM salt. In the absence of RNA, MEG-3 formed irregular assemblies with a broad size range."
378,PMID: 31975687,RNAPS0000043,https://pubmed.ncbi.nlm.nih.gov/31975687,RNA + protein,NCBI ID:172674,https://www.ncbi.nlm.nih.gov/gene/172674,pbs-7,878nt(1-878),AGAACCAAAAUGAAUGCUCACGACGAAGUCCAGCGCACACUGAAUCCUACUUGUACCGGAACAUCGGUUAUCGCUCUCCAGUAUAAAACUGGGGUUGUUGUCCUUACUGAUCGAGUUGUUUCCUAUGGAAAAAUGGCUCGUUACAAGAAUGUUUCUCGUCAAUACAAGGUCAAUGAUAAUGUUCUCAUUGCCUUCGGAGGAGAUCACGCUGACUUCCACUGGCUUCAAAAUGUGAUCGAGCGUCAGGUUCUUCUCUGGAAGCGCUUCGAUCAGGAUAUUGGACCAAAAGCUCUCCACGGAUACCUCACAAGCCUUCUCUACGCCAAACGUUGCAAGAUGAACCCAGUGUGGAACACACUUGUUGUCGCCGGAGUCGAAGAGGAGGAGAAGAACAACAAGGAGACUAGCACACCUUUCAUCGGUGUCAUUACUCAGAAGGGAUGCGCAUAUCAAGUGAAGCACAUUGCAACUGGACUUGGAGCGUUCCUCCUCAACCAAGCUGUUGAAGAUGAGUGGAGAAAGAAGGGAGAAGACCUCUCCCGUGAAGAGGCAGAAGCCGUGCUUCGCAAAUCGCUUGAACUUACUCUCUACCACGACUGCGUCGCUGACAAUGAGUUCGAAAUCGGACGUGUUGAUGCGACAGAAGGUGUCGUUUUGGGUAAAGAAGAGAAGAUUAUUGGUGACUGGUCGAUUGCCGAGACUAACUGUCAAUAUGAAUAAGUUUUCCCCGGUGUGCAGGAUGCGUUUCAGUAUCUCCAUGUUUAACUUAUUUGUAUCCUUCUUUUCAAAACAUUUUACUCUCUCCAACCCACGUUUUCGGUGUAAAUUUUAUUUAUUUUCGCGUGAAGUCGAUAAAUAAACUUCCAUUUAAUCCUUCU,mRNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,20 ng/µL [pbs-7];|500 nM [meg-3],"150 mM (37.5 mM
KCl, 112.5 mM NaCl)",25 mM HEPES (pH 7.4),RT,30 min,-,"FISH,FRAP",liquid,"To investigate whether MEG-3 shows any bias when presented with specific sequences, we synthesized nine fluorescently labeled RNAs (800-1300nt size range) corresponding to embryonic transcripts with strong, minimal, or no localization to P granules in vivo under normal culture conditions. Each transcript (20 ng/mL) was combined with recombinant His-tagged MEG-3 (500 nM; ) in condensation buffer containing 150 mM salt. In the absence of RNA, MEG-3 formed irregular assemblies with a broad size range."
379,PMID: 31975687,RNAPS0000044,https://pubmed.ncbi.nlm.nih.gov/31975687,RNA + protein,NCBI ID:178881,https://www.ncbi.nlm.nih.gov/gene/178881,T19H12.2,891nt(1-891),ACCAGCUCACGAAACUAACAAUGCCGUCGAUGGAGGAAGUCUACGCCAGCGAGCUCAGAGGACGUGAGCCGGAAACCGUCGACACACUUUUCCUCGACAACACCCAAGGAGGAGUGAUCGGAGGAAUCAACGAAAAACUCACCAAACUGGAGUUGCUGAGCAUGGUCAAGUGCGGGUUGACCACUCUCAAAGGGAUGCCGGUUCUCCCAGCGCUCAACUACUUGGAUCUCAGCGACAACGAGCUUGGAGACGAUGCUUCGUUUGACGUCCUCAUCAAAUGUGCUCCGGAGAUCAAGAAAAUCACGCUUUCCGGAAACCGCCUCACUCUGGACAACGUUCGGACGCUGAAGAUGCUCCCCAAUCUCAUGGAGCUCGACCUGUCGAACAAUUCAAGCCUCGGACUUCUCGACGACUAUCGUGUCAAGAUGUUCGAGAUGAUCCCGUCGCUGAAGAUUCUCGAUGGAUGCGACGUCGAUGGAGAGGAGGUUGAGGAGGAGUUCGCCGCCGGCGAGGGAGCCGAGGACAGCGACGAGGGAGACAGCGAUGAAGAUGGCCCAGGGCUCAGCUACCUCAACAAGAGCCAGUUCUCAGAUGACGAGACCGACGACUACGUCGUUCCAGAAGCGGGAGAUGCUGAGACUCGUGGAGCCAAGAGAGCCGCUUCUGCUGACUGCGACGAGCCGGAGGCCAAGAAGUCGGCCGAGUAACAAGGGAUGCUCCACUGCUCCACGCCACCACCAUCGUCAAUUUCUCCCGUCUAUUUUUCAAUUCAACUUUCUUAUAUUUUCAAUACUCAAUCAUUCCCUUCCACGUGUGUGCCCAAUAUUUAAAUUUCACCCAAGCGAUCUCGGCGAAAAACGCCUCCUGUAAAAUAAAAUUUCUUUCGCUUUC,mRNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,20 ng/µL [T19H12.2];|500 nM [meg-3],"150 mM (37.5 mM
KCl, 112.5 mM NaCl)",25 mM HEPES (pH 7.4),RT,30 min,-,"FISH,FRAP",liquid,"To investigate whether MEG-3 shows any bias when presented with specific sequences, we synthesized nine fluorescently labeled RNAs (800-1300nt size range) corresponding to embryonic transcripts with strong, minimal, or no localization to P granules in vivo under normal culture conditions. Each transcript (20 ng/mL) was combined with recombinant His-tagged MEG-3 (500 nM; ) in condensation buffer containing 150 mM salt. In the absence of RNA, MEG-3 formed irregular assemblies with a broad size range."
380,PMID: 31975687,RNAPS0000373,https://pubmed.ncbi.nlm.nih.gov/31975687,RNA + protein,NCBI ID:172242,https://www.ncbi.nlm.nih.gov/gene/172242,hil-5,867nt(1-867),ACUAUCACUUUUCAAGUGUUUGUUCAUCGUUUAACAAUGUCCGACGUCGCCGUUGCCGAGACUCCAGCAGUCAAGACCCCAACCAAAGCUUCAAAAGCCACGAAGGCCAAGGCUACCAAGAUUCCGAAGGUGAAGGUCGUUGCCGCCCAUCCGCCAUUCAUCAACAUGAUCACCGAAGCCGUCAGCAACCUCAAGGACCGCAAGGGAUCAUCCAGGGUCGCCAUUUUCAAGUUCAUCACUGCCAAAUACACGCUUGGAGAUCAAGUUAACAAGACCAACGCUCACCUUCGCUCUGCACUUAAAAAAGGAGUCGUCAGCAAGGUCCUCGUCCAGACUAACGGAAUCGGAGCCAACGGACGAUUCCGUCUUGCCGUUGCCGAGAAGCCACCAGCAGUGAAGAAGGCUGCCACUGGAGAGCAAAAGGUUAUGAAGACCGUCGCCAAGAAGGCUGUCAGCGGAGACAAGGCUAAGAAAACUGUCGCCAAAAAGACCGGAGACAAGGUGAAGAAGGUCAAGUCACCGAAGAGGAUCGCUAAGCCAGCUGUCAAGAAGGUCACUAAGAAAGCCGCCGCUCCAACGAAGUCUGCUGCCAAUGAAACCGCUCCAAAGAAGGCUGCUGCCACUGAAGCCGCUCCAAAGAAGGCUGCUGUCACGAAAGCUGCUACAAAGAAGACUCCUGCCAGGAAGGCCGUUGGUACUGCCCCAAAAGCCUAAUAACACUGUGUGAAAUUCAAAUUUAAUUCGAUCUCACCAUUGUAAUAUACCUCCUCCUUGAAGGUGUCCCGGGUACCGGUUUUUUCUUCCCAUUUAAUCAUAAUUUGUUCCAUUUUAACAAAUAUACCUUCCAAUAAACCAUUAAUAGAUUCU,mRNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,20 ng/µL [hil-5];|500 nM [meg-3],"150 mM (37.5 mM
KCl, 112.5 mM NaCl)",25 mM HEPES (pH 7.4),RT,30 min,-,"FISH,FRAP",liquid,"To investigate whether MEG-3 shows any bias when presented with specific sequences, we synthesized nine fluorescently labeled RNAs (800-1300nt size range) corre sponding to embryonic transcripts with strong, minimal, or no localization to P granules in vivo under normal culture conditions. Each transcript (20 ng/mL) was combined with recombinant His-tagged MEG-3 (500 nM; ) in condensation buffer containing 150 mM salt. In the absence of RNA, MEG-3 formed irregular assemblies with a broad size range ."
381,PMID: 31975687,RNAPS0000045,https://pubmed.ncbi.nlm.nih.gov/31975687,RNA + protein,NCBI ID:266845,https://www.ncbi.nlm.nih.gov/gene/266845,dao-5,3158nt(1-3158),GGUACCCCUGAUCGCUAUGAGUUCCGACUUGUAUGCGAAUGCUGUUCUCUACAGCGAAAUUUCACAAAGAAACCCGGAGUUGGUAUCGAAAAUGUUCAAUGAAGCAACACGGAAAAAGUUGGAUGCGUUUUUAAAAGACAAUGAAGCGCCAAAGCUCAAAGACAUCGUCACCGACAAUGUAUUCAAGAAGAGAAAGCGUAUAGCUUCUUCUUCCGGAAACGAGCCACCUGUUAAAAAAAUGGCAGCAAAGGACUCGUCUGACUCAGAUUCUUCAGACGAUGGAGCUGUGAAGAAGAAUGGUGUGCAAAAACCUGUCAAUGUUGCGGCCAAAAAAUCGGCGACUCCUGUUCAAAAGAAGGCUGAAUCUAGCAGCAGUUCGGAUAGUGAUGCUCCUGCCAAGAAAUUGACUCCAGUUAAGAAACCGGCCCAAACUCCUGCACAGAAGAAAGCUGCGUCAAGCUCUGAUAGCGAUAGCGAUGAUGAACCUCCGAAGAAAGCUCCAGCUGUUACAACCAAAGUUGCUCCAAAGCCAAUGGCAAAGAAGCAGGAUACCAGUGAUUCCGACAGUGAUAGCGAGGAUAGCGACGAUGGCAAAAGCAAGAAAGCAAAUCCAGUAAAGGUUACUCCAGUUGCGAAUGUUCUCCAGAAAGUUGUUGCCAAGAAAGCCGCUUCUUCAUCUUCCGAUUCCUCUGACGACGAAAAGAAGCCAGCUGCCAAACCAACUCCAGCUAAACCUACUCCAAAGCCUGUUGUCAAGAAGGCCGAGUCCUCUUCGGAUUCAAGCGAUGACGAGAAGAAGCCAGUUGCCAAGCCAGCACCAGCUAAAGCAACUCCAAAGCCUGCUGCCAAGAAGGCCGAUUCAUCUUCUGAUUCUUCUGAUGAUGAAGCUCCAGCGAAAAAGACUCCAGCUAAAGCUGCUCCAAAGCCUGUUGCCAAGAAGGCCGAGUCCUCUUCGGAUUCAAGCGAUGACGAGAAGAAGCCAGCUGCCAAGCCAACGCCGGCUAAAGCUACUCCAAAGCCUGUUGCAAAGAAGGCCGAAUCCUCUUCGGAUUCAUCCGAUGACGAGAAGAAACCAGUUGCCAAGCCAGCACCAGCUAAAGCUACUCCAAAGCCUGUUGCCAAGAAGGCCGAGUCCUCUUCGGAUUCAAGCGAUGACGAGAAGAAGCCAGCUGCCAAGCCAACGCCGGCUAAAGCUACUCCAAAGCCUGUUGCAAAGAAGGCCGAAUCCUCUUCGGAUUCAUCCGAUGACGAGAAGAAACCAGUUGCCAAGCCAACAUCAGCUAAAGCAACUCCAAAGCCUGCUGCCAAGAAGGCCGAUUCAUCUUCUGAUUCUUCUGAUGAUGAAGCUCCAGCGAAAAAGACUCCAGCUAAAGCUGCUCCAAAGCCUGCUUCCAAGAAGGCCGAAUCCUCUUCGGAUUCAUCCGAUGACGAGAAGCCAGCUGCCAAGUCAACACCGGCUAAGAUCACUCCAAAGCCUACUGCCAAGAAGGUCGCCUCCUCAUCUUCUGAUUCCUCCGACGACGAGAAAAAACCAGCUGCCAAGCCAACUCCAGCCAACGCUACUCCAAAGCCUGUUGCCAAGAAGGCCGAGUCCUCUUCGGAUUCAAGCGAUGACGAGAAGAAACCAGUUGCCAAGCCAACAUCAGCUAAAGCAACUCCAAAGCCUGCUGCCAAGAAGGCCGAUUUAUCUUCUGAUUUUUCUGAUGAUGAAGCUCCAGCGAAAAAGACUCCAGCUAAAGCUGCUCCAAAGCCUGCUUCCAAGAAGGCCGAAUCCUCUUCGGAUUCAUCCGAUGACGAGAAGCCAGCUGCCAAGUCAACACCGGCUAAGACCACUCCAAAGCCUACUGCCAAGAAGGCCGCCUCCUCAUCUUCUGAUUCCUCCGACGACGAGAAGAAACCAGUUGCCAAGCCAACAUCAGCUAAAGCAACUCCAAAGCCUGCUGCCAAGAAGGCCGAUUCAUCUUCUGAUUCUUCUGAUGAUGAGGCUCCAGCGAAAAAGACUCCAGUUAAGCCAACUCCAGUCAAGAUUGUAGCGAAGAAAGUUGAUUCGUCUUCUGAUUCAUCCGAUGAUGAGAAGAAGCCUACAAAGGCAACUCCUGUCAAAGUCACCCCGAAGUCAGUUACAAAGAAAGCAGCAGCAUCGUCUUCGGACUCAUCCGAUGAUGAAAAGAAACCAGUGGUGAAACAAACUCCUAACGUUGUCCCGAAAAAAGAGAAAGCGGCUUCAAGUUCAGAUGAUUCUUCUGACGAUGAAAAGAAGCCGACUGCCAAGCCAACACCAAAAGCUACUCCUAAGCAAUCUGCCAAAAAAGCUGAUUCAUCCGAUGAUUCUUCUGAUGACGAGGCACCGGCUAAGAAGACACCAGCCAAGUCAACACCUGCAAAAACCGCUGUGAAAAAAGAAGCCUCUUCAUCGUCAGACGAUUCUUCGGAUGAUGAGAAAACGAAAAAGAAGUCUGCCACCACACCAGCAAAAUCAACUCCAAAGACUGCACUAAAGAAAGCUGAAUCUUCUGAUUCCUCUGAUGACGACGAAGAUCUUCCAAAACCAUCUAAGGCUGUCACUCCAAGACCACAACGUGCUGACUCUGAAGAAUCCGCCGAGACCGAGGAGAGCAGUUCAAGAACACCGGCUUUGAAGGCAAAACCAUUGGCUACCUCGACUGAAAAGGCGGUCUAUGAAAACCGAAAAAGAAAGUCUUCACCAUUCCGACGCGUGCAAAUGACAAAGGAUAGCGUUUCUGAAAAAUUUAGAAACAACCAGCAUGAUUCGCACUUCGAUCAAUGGGGACAGCGUGCCAAUGAAAGCCUAGGAAAAGUUGUUGGAAAAGCAUUCCGUCAUGAGAAAACUAAGAAGAAGAAGGGAAGCUACGGAGGUGGUCCAAUCAACCAAUCUAUUAAUUCUAUCAAGUUCUCUGACUCUGACGAUUAGUUUCUUAACUUUAUCCUUAAGUUAAUUUGUUUCCAAAAUUGUUUCUCACCCCCGUCUACACUUCGUUUUUUAUCUGUUGUCUGUUGCUUUCCUUUUUGUUUCCCCUUUAAAUUUAUAAUCCUGAGUUGAUCCAAAACAAAUGUUUUGUAUACUUUUGUUACUUCAAAUAUAACUUGUUAUGUUUCCGUUUUUCUCCCUCUUGUCUCAUCCAUAAAAUGUUUGGUCC,mRNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,20 ng/µL [dao-5];|500 nM [meg-3],"150 mM (37.5 mM
KCl, 112.5 mM NaCl)",25 mM HEPES (pH 7.4),RT,30 min,-,"FISH,FRAP",liquid,"To investigate whether MEG-3 shows any bias when presented with specific sequences, we synthesized nine fluorescently labeled RNAs (800-1300nt size range) corresponding to embryonic transcripts with strong, minimal, or no localization to P granules in vivo under normal culture conditions. Each transcript (20 ng/mL) was combined with recombinant His-tagged MEG-3 (500 nM; ) in condensation buffer containing 150 mM salt. In the absence of RNA, MEG-3 formed irregular assemblies with a broad size range."
382,PMID: 31975687,RNAPS0000091,https://pubmed.ncbi.nlm.nih.gov/31975687,RNA + protein,-,-,polyU(30),30nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,20 ng/µL [U30];|500 nM [meg-3],"150 mM (37.5 mM
KCl, 112.5 mM NaCl)",25 mM HEPES (pH 7.4),RT,30 min,-,"FISH,FRAP",liquid,"To determine whether RNA length affects MEG-3 condensation behavior, we tested RNAs of varying sizes in the condensation assay. We found that short RNAs (30 and 100 nt) were not as efficient as longer RNAs at stimulating MEG-3 condensation."
383,PMID: 31975687,RNAPS0000377,https://pubmed.ncbi.nlm.nih.gov/31975687,RNA + protein,-,-,polyU(100),100nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,20 ng/µL [U100];|500 nM [meg-3],"150 mM (37.5 mM
KCl, 112.5 mM NaCl)",25 mM HEPES (pH 7.4),RT,30 min,-,"FISH,FRAP",liquid,"To determine whether RNA length affects MEG-3 condensation behavior, we tested RNAs of varying sizes in the condensation assay. We found that short RNAs (30 and 100 nt) were not as effi cient as longer RNAs at stimulating MEG-3 condensation"
384,PMID: 31975687,RNAPS0000378,https://pubmed.ncbi.nlm.nih.gov/31975687,RNA + protein,-,-,polyU(200),200nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,20 ng/µL [U200];|500 nM [meg-3],"150 mM (37.5 mM
KCl, 112.5 mM NaCl)",25 mM HEPES (pH 7.4),RT,30 min,-,"FISH,FRAP",liquid,"To determine whether RNA length affects MEG-3 condensation behavior, we tested RNAs of varying sizes in the condensation assay. We found that short RNAs (30 and 100 nt) were not as effi cient as longer RNAs at stimulating MEG-3 condensation"
385,PMID: 31975687,RNAPS0000379,https://pubmed.ncbi.nlm.nih.gov/31975687,RNA + protein,-,-,polyU(300),300nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,20 ng/µL [U300];|500 nM [meg-3],"150 mM (37.5 mM
KCl, 112.5 mM NaCl)",25 mM HEPES (pH 7.4),RT,30 min,-,"FISH,FRAP",liquid,"To determine whether RNA length affects MEG-3 condensation behavior, we tested RNAs of varying sizes in the condensation assay. We found that short RNAs (30 and 100 nt) were not as effi cient as longer RNAs at stimulating MEG-3 condensation"
386,PMID: 31975687,RNAPS0000380,https://pubmed.ncbi.nlm.nih.gov/31975687,RNA + protein,-,-,polyU(600),600nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,20 ng/µL [U600];|500 nM [meg-3],"150 mM (37.5 mM
KCl, 112.5 mM NaCl)",25 mM HEPES (pH 7.4),RT,30 min,-,"FISH,FRAP",liquid,"To determine whether RNA length affects MEG-3 condensation behavior, we tested RNAs of varying sizes in the condensation assay. We found that short RNAs (30 and 100 nt) were not as effi cient as longer RNAs at stimulating MEG-3 condensation"
387,PMID: 32513655,RNAPS0000391,https://pubmed.ncbi.nlm.nih.gov/32513655,RNA + protein,-,-,polyA(15),15nt,AAAAAAAAAAAAAAA,poly RNA,-,"sp|P25644|PAT1_YEAST DNA topoisomerase 2-associated protein PAT1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=PAT1 PE=1 SV=4|residues=296-754
TEDPYNEDFYFQVYKIIQRGGITSESNKGLIARAYLEHSGHRLGGRYKRTDIALQRMQSQVEKA
VTVAKERPSKLKDQQAAAGNSSQDNKQANTVLGKISSTLNSKNPRRQLQIPRQQPSDPDA
LKDVTDSLTNVDLASSGSSSTGSSAAAVASKQRRRSSYAFNNGNGATNLNKSGGKKFILE
LIETVYEEILDLEANLRNGQQTDSTAMWEALHIDDSSYDVNPFISMLSFDKGIKIMPRIF
NFLDKQQKLKILQKIFNELSHLQIIILSSYKTTPKPTLTQLKKVDLFQMIILKIIVSFLS
NNSNFIEIMGLLLQLIRNNNVSFLTTSKIGLNLITILISRAALIKQDSSRSNILSSPEIS
TWNEIYDKLFTSLESKIQLIFPPREYNDHIMRLQNDKFMDEAYIWQFLASLALSGKLNHQ
RIIIDEVRDEIFATINEAETLQKKEKELSVLPQR;|-",PAT1;|Dcp1-Dcp2,M+C-term,-;|-,458aa(296-754),"P25644;Q12517,P53550 ","DrLLPS,LLPSDB,PhaSepDB;Dcp-1:DrLLPS,PhaSepDB,
Dcp-2:PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0330,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0246,http://db.phasep.pro/browse/;http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0754,http://db.phasep.pro/browse/;http://db.phasep.pro/browse/","[1-4],[5-24],[55-79],[164-200],[365-421],[422-469];|-","[59-74],[111-137],[149-157],[165-183],[187-224],[404-415],[434-450],[545-555],[571-583];|-",In vitro,13.4 ng/µl [polyA];|2.5µM [Pat1];|2.5µM Dcp1/Dcp2Ext,60 mM NaCl,"20 mM HEPES pH 7.0, 1 mM DTT",RT,20 min,-,"Bright-field microscopy,Fluorescence microscopy",liquid,"PatMC and Dcp2 both weakly interact with RNA, which can trigger or potentiate liquid-liquid phase separation with oligomeric RNA binding proteins (RBPs)The PatMC/Dcp1/Dcp2Ext droplets were able to incorporate A15 RNA,though A15 RNA did not change the critical concentration required for phase separation However, neither short A15 RNAs nor polyA RNA promoted droplet formation with either PatMC"
388,PMID: 32513655,RNAPS0000391,https://pubmed.ncbi.nlm.nih.gov/32513655,RNA + protein,-,-,polyA(15),15nt,AAAAAAAAAAAAAAA,poly RNA,-,"sp|P25644|PAT1_YEAST DNA topoisomerase 2-associated protein PAT1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=PAT1 PE=1 SV=4|residues=296-754
TEDPYNEDFYFQVYKIIQRGGITSESNKGLIARAYLEHSGHRLGGRYKRTDIALQRMQSQVEKA
VTVAKERPSKLKDQQAAAGNSSQDNKQANTVLGKISSTLNSKNPRRQLQIPRQQPSDPDA
LKDVTDSLTNVDLASSGSSSTGSSAAAVASKQRRRSSYAFNNGNGATNLNKSGGKKFILE
LIETVYEEILDLEANLRNGQQTDSTAMWEALHIDDSSYDVNPFISMLSFDKGIKIMPRIF
NFLDKQQKLKILQKIFNELSHLQIIILSSYKTTPKPTLTQLKKVDLFQMIILKIIVSFLS
NNSNFIEIMGLLLQLIRNNNVSFLTTSKIGLNLITILISRAALIKQDSSRSNILSSPEIS
TWNEIYDKLFTSLESKIQLIFPPREYNDHIMRLQNDKFMDEAYIWQFLASLALSGKLNHQ
RIIIDEVRDEIFATINEAETLQKKEKELSVLPQR",PAT1,M+C-term,-,458aa(296-754),P25644,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0330,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0246,http://db.phasep.pro/browse/","[1-4],[5-24],[55-79],[164-200],[365-421],[422-469]","[59-74],[111-137],[149-157],[165-183],[187-224],[404-415],[434-450],[545-555],[571-583]",In vitro,13.4 ng/µl [polyA];|2.5µM [Pat1],60 mM NaCl,"20 mM HEPES pH 7.0, 1 mM DTT",RT,20 min,-,"Bright-field microscopy,Fluorescence microscopy",solute,"PatMC and Dcp2 both weakly interact with RNA, which can trigger or potentiate liquid-liquid phase separation with oligomeric RNA binding proteins (RBPs)The PatMC/Dcp1/Dcp2Ext droplets were able to incorporate A15 RNA,though A15 RNA did not change the critical concentration required for phase separation However, neither short A15 RNAs nor polyA RNA promoted droplet formation with either PatMC"
389,PMID: 32561643,RNAPS0000392,https://pubmed.ncbi.nlm.nih.gov/32561643,RNA + protein,-,-,polyU,-,-,poly RNA,-,OIOOASVEELTEVPGIGPOLAOOILEOLA,Precursor-Orn,-,-,29aa,-,-,-,-,-,In vitro,1.2 mg/mL [polyU];|240 µM [Precursor-Orn];|1.2 µM [fluorescein-labeled Precursor-Orn],-,50 mM MES pH 5.6,RT,-,-,Fluorescence microscopy,liquid,"On mixing with polyU, both Precursor-Orn and -Arg formed coacervates  as did Ancestor- (HhH)2 (SI Appendix, Fig. S10). Neither polypeptide formed droplets in the absence of polyU. Further, precursor-Arg consistently made larger droplets than Precursor-Orn, and at lower concen trations. Thus, by increasing the coacervate forming potential, statistical modification of ornithine to arginine could also provide an advantage at this early stage"
390,PMID: 32561643,RNAPS0000393,https://pubmed.ncbi.nlm.nih.gov/32561643,RNA + protein,-,-,polyU,-,-,poly RNA,-,RIRRASVEELTEVPGIGPRLARRILERLA,Precursor-Arg,-,-,29aa,-,-,-,-,-,In vitro,1.4 mg/mL [polyU];|190 µM [Precursor-Arg];|20 µM [fluorescein-labeled Precursor-Arg],-,50 mM MES pH 5.6,RT,-,-,Fluorescence microscopy,liquid,"On mixing with polyU, both Precursor-Orn and -Arg formed coacervates  as did Ancestor- (HhH)2 (SI Appendix, Fig. S10). Neither polypeptide formed droplets in the absence of polyU. Further, precursor-Arg consistently made larger droplets than Precursor-Orn, and at lower concen trations. Thus, by increasing the coacervate forming potential, statistical modification of ornithine to arginine could also provide an advantage at this early stage"
391,PMID: 32561643,RNAPS0000394,https://pubmed.ncbi.nlm.nih.gov/32561643,RNA + protein,-,-,polyU,-,-,poly RNA,-,GRVRRSEIPLGIELEAGTLRLARRPEIRVA,all residues except arginine(Scrambled),-,-,30aa,-,-,-,"[1-2],[4-6],[8-8],[12-30]",-,In vitro,1 mg/mL [polyU];|200 µM [Scrambled];|8 µM [fluorescein-labeled Scrambled],-,50 mM MES pH 5.6,RT,-,-,Fluorescence microscopy,solid,"Phase separation of these polypeptides is perhaps un surprising, given that arginine-rich peptides have been shown to phase-separate on the addition of RNA or crowding agents . However, scrambling the sequence of the Precursor-Arg—either completely or while preserving only the positions of the arginine residues (scrambled 1 and 2, respectively)—resulted in amor phous aggregate on polyU addition (Fig. 4B). Thus, basic amino acids are likely necessary but not sufficient to encode phase separation."
392,PMID: 32561643,RNAPS0000395,https://pubmed.ncbi.nlm.nih.gov/32561643,RNA + protein,-,-,polyU,-,-,poly RNA,-,GEPAIRSEPIRLRLEGVRALRTEVGLRIRA,Precursor-Arg(Scrambled),-,-,30aa,-,-,-,"[1-10],[16-26],[28-30]",-,In vitro,1 mg/mL [polyU];|200 µM [Scrambled];|8 µM [fluorescein-labeled Scrambled],-,50 mM MES pH 5.6,RT,-,-,Fluorescence microscopy,solid,"Phase separation of these polypeptides is perhaps un surprising, given that arginine-rich peptides have been shown to phase-separate on the addition of RNA or crowding agents . However, scrambling the sequence of the Precursor-Arg—either completely or while preserving only the positions of the arginine residues (scrambled 1 and 2, respectively)—resulted in amor phous aggregate on polyU addition (Fig. 4B). Thus, basic amino acids are likely necessary but not sufficient to encode phase separation."
393,PMID: 32571937,RNAPS0000396,https://pubmed.ncbi.nlm.nih.gov/32571937,RNA + protein,-,-,polyU,-(600-1000 kDa),-,poly RNA,-,"sp|P04554|PRM2_HUMAN Protamine-2 OS=Homo sapiens OX=9606 GN=PRM2 PE=1 SV=3
MVRYRVRSLSERSHEVYRQQLHGQEQGHHGQEEQGLSPEHVEVYERTHGQSHYRRRHCSR
RRLHRIHRRQHRSCRRRKRRSCRHRRRHRRGCRTRKRTCRRH",PRM2,-,-,102aa(1-102),P04554,PhaSepDB,http://db.phasep.pro/browse/,-,"[19-36],[52-101]",In vitro,1.1-22 mg/mL [polyU];|4.4 mg/mL [PRM2];|,-,"25 mM Tris-HCl, pH 7.5",RT,-,-,Fluorescence microscopy,liquid,"Remarkably, we observed that micrometer-sized hollow condensates are readily formed by mixing 4.4 mg/mL PRM with 22 mg/mL RNA. These hollow condensates closely resemble lipid vesicles in their appearance. Furthermore, we observed that these hollow condensates are relatively stable across a wide range of temperature and salt concentrations."
394,PMID: 32571937,RNAPS0000396,https://pubmed.ncbi.nlm.nih.gov/32571937,RNA + protein,-,-,polyU,-(600-1000 kDa),-,poly RNA,-,"sp|P04554|PRM2_HUMAN Protamine-2 OS=Homo sapiens OX=9606 GN=PRM2 PE=1 SV=3
MVRYRVRSLSERSHEVYRQQLHGQEQGHHGQEEQGLSPEHVEVYERTHGQSHYRRRHCSR
RRLHRIHRRQHRSCRRRKRRSCRHRRRHRRGCRTRKRTCRRH",PRM2,-,-,102aa(1-102),P04554,PhaSepDB,http://db.phasep.pro/browse/,-,"[19-36],[52-101]",In vitro,2.2 mg/mL [polyU];|4.4 mg/mL [PRM2];|,-,"25 mM Tris-HCl, pH 7.5",RT,-,-,"Fluorescence microscopy,Differential interference contrast microscopy",liquid,"Remarkably, we observed that micrometer-sized hollow condensates are readily formed by mixing 4.4 mg/mL PRM with 22 mg/mL RNA. These hollow condensates closely resemble lipid vesicles in their appearance. Furthermore, we observed that these hollow condensates are relatively stable across a wide range of temperature and salt concentrations."
395,PMID: 32571937,RNAPS0000397,https://pubmed.ncbi.nlm.nih.gov/32571937,RNA + protein,-,-,polyU,-(600-1000 kDa),-,poly RNA,-,"sp|P04554|PRM2_HUMAN Protamine-2 OS=Homo sapiens OX=9606 GN=PRM2 PE=1 SV=3
MVRYRVRSLSERSHEVYRQQLHGQEQGHHGQEEQGLSPEHVEVYERTHGQSHYRRRHCSR
RRLHRIHRRQHRSCRRRKRRSCRHRRRHRRGCRTRKRTCRRH",PRM2,-,-,102aa(1-102),P04554,PhaSepDB,http://db.phasep.pro/browse/,-,"[19-36],[52-101]",In vitro,22 mg/mL [polyU];|4.4 mg/mL [PRM2];|,-,"25 mM Tris-HCl, pH 7.5",RT,-,-,"Fluorescence microscopy,Differential interference contrast microscopy",liquid,"Remarkably, we observed that micrometer-sized hollow condensates are readily formed by mixing 4.4 mg/mL PRM with 22 mg/mL RNA. These hollow condensates closely resemble lipid vesicles in their appearance. Furthermore, we observed that these hollow condensates are relatively stable across a wide range of temperature and salt concentrations."
396,PMID: 32571937,RNAPS0000398,https://pubmed.ncbi.nlm.nih.gov/32571937,RNA + protein,-,-,polyU,-(600-1000 kDa),-,poly RNA,-,-,poly(acrylic acid),-,-,-,-,-,-,-,-,In vitro,4 mg/mL [polyU];|40 mg/mL [poly(acrylic acid)],-,"25 mM Tris-HCl, pH 7.5",RT,-,-,"Fluorescence microscopy,Differential interference contrast microscopy",liquid,"Second, we changed the polycation, keeping the polyanionic RNA unchanged. Similar to the PRM−poly(U) system, we observed that RNA can also form hollow condensates upon interaction with a synthetic cationic poly electrolyte, poly(Allylamine) (PAH) under similar conditions"
397,PMID: 32571937,RNAPS0000399,https://pubmed.ncbi.nlm.nih.gov/32571937,RNAs + protein,-,-,Saccharomyces cerevisiae RNA,-,-,total RNA,Saccharomyces cerevisiae,RGRGGRGRGGRGRGGRGRGGRGRGG,[RGRGG]5,-,-,25aa,-,-,-,-,-,In vitro,8.9 mg/mL [Cellular RNA];|0.024mg/mL [[RGRGG]5],-,"5 mM Tris-HCl, pH 7.5",RT,-,-,"Fluorescence microscopy,Differential interference contrast microscopy",liquid,"Finally, we tested whether cellular RNA, a mixture that contains both structured and unstructured RNAs, can form vesicular assem blies. Indeed, we observed that total RNA from Saccharomyces cerevisiae can form micrometer-sized hollow condensates upon interacting with an R/G-rich polypeptide at excess RNA condi tion"
398,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",MBP-N,-,-,-,P0DTC9,-,-,-,-,In vitro,0-50 µM [ total torula yeast RNA];|50 µM [N protein],50 mM NaCl,"50 mM Tris,pH 7.4",RT,20 min,-,"Turbidity measurement,Differential interference contrast microscopy",-,"We conducted turbidity and microscopy experiments with fixed protein concentration and varying protein:RNA mass ratios in low salt conditions. In low salt conditions in the absence of RNA, there is an increase in turbidity along the formation of small, spherical droplets, suggesting that N is able to undergo LLPS even in the absence of RNA."
399,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0-50 µM [ total torula yeast RNA];|50 µM [N protein],50 mM NaCl,"50 mM Tris,pH 7.4",RT,20 min,other_molecular:+ TEV protease,"Turbidity measurement,Differential interference contrast microscopy","liquid, solute","We conducted turbidity and microscopy experiments with fixed protein concentration and varying protein:RNA mass ratios in low salt conditions. In low salt conditions in the absence of RNA, there is an increase in turbidity along the formation of small, spherical droplets, suggesting that N is able to undergo LLPS even in the absence of RNA."
400,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",MBP-N,-,-,-,P0DTC9,-,-,-,-,In vitro,0.3 mg/mL [ total torula yeast RNA];|50 µM [N protein],183 mM NaCl,"50 mM Tris,pH 7.4",RT,20 min,-,"Turbidity measurement,Differential interference contrast microscopy",solute,"This increase in turbidity is coupled with the appearance of small, spherical droplets visible by microscopy Interestingly, at lower pH conditions the turbidity of the reaction increases and  persists over time as has been observed for protein aggregate or gels"
401,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.3 mg/mL [ total torula yeast RNA];|50 µM [N protein],183 mM NaCl,"50 mM Tris,pH 7.4",RT,20 min,other_molecular:+ TEV protease,"Turbidity measurement,Differential interference contrast microscopy",liquid,"This increase in turbidity is coupled with the appearance of small, spherical droplets visible by microscopy Interestingly, at lower pH conditions the turbidity of the reaction increases and  persists over time as has been observed for protein aggregate or gels"
402,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",MBP-N,-,-,-,P0DTC9,-,-,-,-,In vitro,0.3 mg/mL [ total torula yeast RNA];|50 µM [N protein],183 mM NaCl,"20 mM MES,pH 5.5",RT,20 min,-,"Turbidity measurement,Differential interference contrast microscopy",solute,"At pH 5.5, the droplets still appear spherical; however, the persistent turbidity  suggests that the droplets may be less fluid (more “gel”) in these conditions.  Consistent with this hypothesis, at lower pH conditions the assemblies no longer remain  spherical and resemble droplets that were unable to complete fusion"
403,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.3 mg/mL [ total torula yeast RNA];|50 µM [N protein],183 mM NaCl,"20 mM MES,pH 5.5",RT,20 min,other_molecular:+ TEV protease,"Turbidity measurement,Differential interference contrast microscopy",gel,"At pH 5.5, the droplets still appear spherical; however, the persistent turbidity  suggests that the droplets may be less fluid (more “gel”) in these conditions.  Consistent with this hypothesis, at lower pH conditions the assemblies no longer remain  spherical and resemble droplets that were unable to complete fusion"
404,PMID: 32615218,RNAPS0000401,https://pubmed.ncbi.nlm.nih.gov/32615218,RNAs + protein,-,-,Escherichia coli RNA,-,-,total RNA,Escherichia coli,"sp|P54397|FKB39_DROME 39 kDa FK506-binding nuclear protein OS=Drosophila melanogaster OX=7227 GN=FK506-bp1 PE=1 SV=2
MSMFWGLNMKPERKYSQTIIKSFHISGVALDKGQEAKLYLAAEKQEYIVATVTKAIPQVA
LDLNFSKGDRIMFYTAGDASVSLLGYLHDIDSEDDEDDDQMTIENLLNSKAIKNSKKSED
DEDENESGEEDEEDTDDDSQIIEEYESFLENGEEEDDDDVDEDNEESGEEDEQDSDDSEA
EEEQPKAKVAKLSPGASAKKSGKEQNGVAKKEEAKQQQKKKEKPEAKKEQPKAKEPAKQQ
PASKDPRTITGGVKIVDQVVGKGEEAKQGKRVSVYYIGRLQSNNKTFDSLLKGKPFKFAL
GGGEVIKGWDVGVAGMKVGGKRVITCPPHMAYGARGAPPKIGPNSTLVFEVELKAVH",FKBP39,-,-,357aa(1-357),P54397,-,-,[113-251],"[89-99],[118-139],[150-184],[209-242]",In vitro,0.005-0.5 µg [RNA_Blend];|0.5 µg [FKBP39],300 mM NaCl,-,4˚C,2 min,-,Differential interference contrast microscopy,liquid,"Based on this knowledge, we decided to examine the  propensity of FKBP39 to promote phase transition in the presence of RNA. The FKBP39 was  tested in 200 µg/ml (2.5 µl total volume containing 0.5 µg of the protein) in buffer  supplemented with 300 mM NaCl. As presented in Figure 8, FKBP39 can lead to LLPS in the presence of RNA."
405,PMID: 32627867,RNAPS0000119,https://pubmed.ncbi.nlm.nih.gov/32627867,RNAs + protein,-,-,P19 RNA,-,-,total RNA,P19 cell line(Mus musculus),"tr|A0A0G2K0Y1|A0A0G2K0Y1_RAT TMF1-regulated nuclear protein 1 OS=Rattus norvegicus OX=10116 GN=Trnp1 PE=4 SV=1
MPGCRISACGPGAQEGTAEPGSPPPPPREPLPSLQPPSSSPTSTPTSTQSPQLPEAAETP
VEGQELQRWRQGASGGSGGASPAGIGGAGAAAGAGGRALELAEARRRLLEVEGRRRLVSE
LESRVLQLHRVFLAAELRLAHRAESLSRLSGGVAQAELYLAAHGSRLKKGARRGRRGRPP
ALLASALGLGSCVPWGAGRLRRGQGPEPDSPFRRSPPRGPASPQR",Trnp1,△95-223,-,94aa(1-94),A0A0G2K0Y1,-,-,-,"[19-55],[72-94]",In vitro,50 ng [RNA_Blend];|5 µM [YFP],150 mM salt,"50 mM Sorenson’s buffer,2 mM DTT,pH 7.6",25˚C,-,-,Phase contrast microscopy,solute,"Notably, however, deletion of the first N-terminal 16 aa (D1-16) still allowed binding to WT Trnp1. To test the behavior of these deletion constructs in phase separation, we produced the recombinant MBP-D1-16, MBP-D1-140 (C-term IDR), and MBP-D95-223 (N-term IDR) Trnp1 proteins and tested their LLPS capacity."
406,PMID: 32627867,RNAPS0000119,https://pubmed.ncbi.nlm.nih.gov/32627867,RNAs + protein,-,-,P19 RNA,-,-,total RNA,P19 cell line(Mus musculus),"tr|A0A0G2K0Y1|A0A0G2K0Y1_RAT TMF1-regulated nuclear protein 1 OS=Rattus norvegicus OX=10116 GN=Trnp1 PE=4 SV=1
MPGCRISACGPGAQEGTAEPGSPPPPPREPLPSLQPPSSSPTSTPTSTQSPQLPEAAETP
VEGQELQRWRQGASGGSGGASPAGIGGAGAAAGAGGRALELAEARRRLLEVEGRRRLVSE
LESRVLQLHRVFLAAELRLAHRAESLSRLSGGVAQAELYLAAHGSRLKKGARRGRRGRPP
ALLASALGLGSCVPWGAGRLRRGQGPEPDSPFRRSPPRGPASPQR",Trnp1,-,-,225aa(1-225),A0A0G2K0Y1,-,-,-,"[19-55],[72-126],[133-146],[166-191]",In vitro,50 ng [RNA_Blend];|5 µM [YFP],150 mM salt,"50 mM Sorenson’s buffer,2 mM DTT,pH 7.6",25˚C,-,-,Phase contrast microscopy,solute,"Notably, addition of dextran (used here as a crowding agent) caused formation of fibrillary solid aggregate, while RNA addition had very little effects on Trnp1 LLPS and aggregation (Fig 1E). These results indicate that Trnp1 drives phase separation and hence may play a role in the formation of MLOs."
407,PMID: 32627867,RNAPS0000119,https://pubmed.ncbi.nlm.nih.gov/32627867,RNAs + protein,-,-,P19 RNA,-,-,total RNA,P19 cell line(Mus musculus),"tr|A0A0G2K0Y1|A0A0G2K0Y1_RAT TMF1-regulated nuclear protein 1 OS=Rattus norvegicus OX=10116 GN=Trnp1 PE=4 SV=1
MPGCRISACGPGAQEGTAEPGSPPPPPREPLPSLQPPSSSPTSTPTSTQSPQLPEAAETP
VEGQELQRWRQGASGGSGGASPAGIGGAGAAAGAGGRALELAEARRRLLEVEGRRRLVSE
LESRVLQLHRVFLAAELRLAHRAESLSRLSGGVAQAELYLAAHGSRLKKGARRGRRGRPP
ALLASALGLGSCVPWGAGRLRRGQGPEPDSPFRRSPPRGPASPQR",Trnp1,△1-140,-,83aa(141-223),A0A0G2K0Y1,-,-,-,"[141-146],[166-191]",In vitro,50 ng [RNA_Blend];|5 µM [YFP],150 mM salt,"50 mM Sorenson’s buffer,2 mM DTT,pH 7.6",25˚C,-,-,Phase contrast microscopy,solid,"Notably, however, deletion of the first N-terminal 16 aa (D1-16) still allowed binding to WT Trnp1. To test the behavior of these deletion constructs in phase separation, we produced the recombinant MBP-D1-16, MBP-D1-140 (C-term IDR), and MBP-D95-223 (N-term IDR) Trnp1 proteins and tested their LLPS capacity."
408,PMID: 32627867,RNAPS0000119,https://pubmed.ncbi.nlm.nih.gov/32627867,RNAs + protein,-,-,P19 RNA,-,-,total RNA,P19 cell line(Mus musculus),"tr|A0A0G2K0Y1|A0A0G2K0Y1_RAT TMF1-regulated nuclear protein 1 OS=Rattus norvegicus OX=10116 GN=Trnp1 PE=4 SV=1
MPGCRISACGPGAQEGTAEPGSPPPPPREPLPSLQPPSSSPTSTPTSTQSPQLPEAAETP
VEGQELQRWRQGASGGSGGASPAGIGGAGAAAGAGGRALELAEARRRLLEVEGRRRLVSE
LESRVLQLHRVFLAAELRLAHRAESLSRLSGGVAQAELYLAAHGSRLKKGARRGRRGRPP
ALLASALGLGSCVPWGAGRLRRGQGPEPDSPFRRSPPRGPASPQR",Trnp1,△1-16,-,207aa(17-223),A0A0G2K0Y1,-,-,-,"[19-55],[72-126],[133-146],[166-191]",In vitro,50 ng [RNA_Blend];|5 µM [YFP],150 mM salt,"50 mM Sorenson’s buffer,2 mM DTT,pH 7.6",25˚C,-,-,Phase contrast microscopy,solid,"Notably, however, deletion of the first N-terminal 16 aa (D1-16) still allowed binding to WT Trnp1. To test the behavior of these deletion constructs in phase separation, we produced the recombinant MBP-D1-16, MBP-D1-140 (C-term IDR), and MBP-D95-223 (N-term IDR) Trnp1 proteins and tested their LLPS capacity."
409,PMID: 32627867,RNAPS0000120,https://pubmed.ncbi.nlm.nih.gov/32627867,RNAs + protein,-,-,P19 RNA,-,-,total RNA,P19 cell line(Mus musculus),-,YFP,-,-,-,-,-,-,-,-,In vitro,50 ng [RNA_Blend];|5 µM [Trnp1],150 mM salt,"50 mM Sorenson’s buffer,2 mM DTT,pH 7.6",25˚C,-,-,Phase contrast microscopy,solid,"Notably, addition of dextran (used here as a crowding agent) caused formation of fibrillary solid aggregate, while RNA addition had very little effects on Trnp1 LLPS and aggregation (Fig 1E). These results indicate that Trnp1 drives phase separation and hence may play a role in the formation of MLOs."
410,PMID: 32637943,RNAPS0000404,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,luciferase RNA,1857nt(1-1857),UCCGUUUAGUUACCUAUACCUGAUUUUAUUAUUCGUUAAAAUAGUACAGUGACCCACAAUUACAAAAUUACCAUUCAUCAAUUUGCAUAUAAUAUUACAAUAGCUAAGAAUUUCGUCAUCGCUGAAUACAGUUACAUUUUACAAUUUGGACUUUCCGCCCUUCUUGGCCUUUAUGAGGAUCUCUCUGAUUUUUCUUGCGUCGAGUUUUCCGGUAAGACCUUUCGGUACUUCGUCCACAAACACAACUCCUCCGCGCAACUUUUUCGCGGUUGUUACUUGACUGGCGACGUAAUCCACGAUCUCUUUUUCCGUCAUCGUCUUUCCGUGCUCCAAAACAACAACGGCGGCGGGAAGUUCACCGGCGUCAUCGUCGGGAAGACCUGCCACGCCCGCGUCGAAGAUGUUGGGGUGUUGUAACAAUAUCGAUUCCAAUUCAGCGGGGGCCACCUGAUAUCCUUUGUAUUUAAUUAAAGACUUCAAGCGGUCAACUAUGAAGAAGUGUUCGUCUUCGUCCCAGUAAGCUAUGUCUCCAGAAUGUAGCCAUCCAUCCUUGUCAAUCAAGGCGUUGGUCGCUUCCGGAUUGUUUACAUAACCGGACAUAAUCAUAGGUCCUCUGACACAUAAUUCGCCUCUCUGAUUAACGCCCAGCGUUUUCCCGGUAUCCAGAUCCACAACCUUCGCUUCAAAAAAUGGAACAACUUUACCGACCGCGCCCGGUUUAUCAUCCCCCUCGGGUGUAAUCAGAAUAGCUGAUGUAGUCUCAGUGAGCCCAUAUCCUUGUCGUAUCCCUGGAAGAUGGAAGCGUUUUGCAACCGCUUCCCCGACUUCUUUCGAAAGAGGUGCGCCCCCAGAAGCAAUUUCGUGUAAAUUAGAUAAAUCGUAUUUGUCAAUCAGAGUGCUUUUGGCGAAGAAUGAAAAUAGGGUUGGUACUAGCAACGCACUUUGAAUUUUGUAAUCCUGAAGGGAUCGUAAAAACAGCUCUUCUUCAAAUCUAUACAUUAAGACGACUCGAAAUCCACAUAUCAAAUAUCCGAGUGUAGUAAACAUUCCAAAACCGUGAUGGAAUGGAACAACACUUAAAAUCGCAGUAUCCGGAAUGAUUUGAUUGCCAAAAAUAGGAUCUCUGGCAUGCGAGAAUCUGACGCAGGCAGUUCUAUGCGGAAGGGCCACACCCUUAGGUAACCCAGUAGAUCCAGAGGAAUUCAUUAUCAGUGCAAUUGUUUUGUCACGAUCAAAGGACUCUGGUACAAAAUCGUAUUCAUUAAAACCGGGAGGUAGAUGAGAUGUGACGAACGUGUACAUCGACUGAAAUCCCUGGUAAUCCGUUUUAGAAUCCAUGAUAAUAAUUUUCUGGAUUAUUGGUAAUUUUUUUUGCACGUUCAAAAUUUUUUGCAACCCCUUUUUGGAAACAAACACUACGGUAGGCUGCGAAAUGUUCAUACUGUUGAGCAAUUCACGUUCAUUAUAAAUGUCGUUCGCGGGCGCAACUGCAACUCCGAUAAAUAACGCGCCCAACACCGGCAUAAAGAAUUGAAGAGAGUUUUCACUGCAUACGACGAUUCUGUGAUUUGUAUUCAGCCCAUAUCGUUUCAUAGCUUCUGCCAACCGAACGGACAUUUCGAAGUAUUCCGCGUACGUGAUGUUCACCUCGAUAUGUGCAUCUGUAAAAGCAAUUGUUCCAGGAACCAGGGCGUAUCUCUUCAUAGCCUUAUGCAGUUGCUCUCCAGCGGUUCCAUCCUCUAGAGGAUAGAAUGGCGCCGGGCCUUUCUUUAUGUUUUUGGCGUCUUCCAUUUUACCAACAGUACCGGAAUGCUAAUGUCACUGCGAGCGACAUUCAAGAAUGUAACACAAAGGAAU,mRNA,Photinus pyralis,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,100 nM [Luc];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,"liquid, solid","We first analyzed the effects of three mid-sized viral RNA fragments: (1) 5’-400, containing the 400 nt at the 5’ end of the SARS-CoV-2 genome, which is thought to include multiple secondary  structure elements and the leader TRS; (2) PS-318, a sequence near the end of ORF1b in  SARS-CoV, proposed as a packaging sequence but of unknown function; and (3) N- 1260, containing the open reading frame of the N gene near the 3’ end of the SARS-CoV-2  genome. RNA encoding firefly luciferase (Luc-1710) was a nonviral control. N protein structures were analyzed by microscopy 30 minutes after addition of RNA at room temperature"
411,PMID: 32637943,RNAPS0000405,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,318nt(PS-318),UAGCUUGUGCUGGUCCCUUUGAAGGUGUUAGACCUUUGACUGAACCUUCUGUUAUUAAAACACCAUUACGGGCGUUUCUAAAAAGGUCUACCUGUCCUUCCACUCUACCAUCAAACAAGACAGUAAGUGAAGAACAAGCACUCUCAGUAGGUUUCUUGGCAAUGUCAGUCAUUGUGCAGACACCUAUUGUAGAUACAUGUGCUGGGGCUUCUCUUUUGUAGUCCCAGAUGUACAGUAUUAGCAGCGAUAUCAACACCCAAAUUAUUGAGUAUCUUAAUCUCUGGCACUGGUUUAAUGUUACGCUUAGCCCAAAGCUCA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|mutation:R10D
MSDNGPQNQDNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,protein_mutation:R10D,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,1 µM [SARS-CoV-2];|10 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,15 min,-,Negative-stain electron microscopy,solid,"We used negative-stain electron microscopy to further analyze mixtures of 10 µM N protein and  1 µM RNA.These images represent the saturated protein-RNA solution surrounding  condensates. Unmodified wild-type protein and viral RNA formed uniform particles of ~20 nm diameter, reminiscent of structures seen in previous studies of partially disrupted MHV  nucleocapsids.Thus, the gel filamentous condensates of the unmodified protein – and possibly the nucleocapsid – are likely to be assembled on a foundation of discrete structural  building blocks. In contrast, the mixture of 10D mutant and RNA formed nonuniform, diffuse chains"
412,PMID: 32637943,RNAPS0000405,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,318nt(PS-318),UAGCUUGUGCUGGUCCCUUUGAAGGUGUUAGACCUUUGACUGAACCUUCUGUUAUUAAAACACCAUUACGGGCGUUUCUAAAAAGGUCUACCUGUCCUUCCACUCUACCAUCAAACAAGACAGUAAGUGAAGAACAAGCACUCUCAGUAGGUUUCUUGGCAAUGUCAGUCAUUGUGCAGACACCUAUUGUAGAUACAUGUGCUGGGGCUUCUCUUUUGUAGUCCCAGAUGUACAGUAUUAGCAGCGAUAUCAACACCCAAAUUAUUGAGUAUCUUAAUCUCUGGCACUGGUUUAAUGUUACGCUUAGCCCAAAGCUCA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,1 µM [SARS-CoV-2];|10 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,15 min,-,Negative-stain electron microscopy,gel,"We used negative-stain electron microscopy to further analyze mixtures of 10 µM N protein and  1 µM RNA.These images represent the saturated protein-RNA solution surrounding  condensates. Unmodified wild-type protein and viral RNA formed uniform particles of ~20 nm diameter, reminiscent of structures seen in previous studies of partially disrupted MHV  nucleocapsids.Thus, the gel filamentous condensates of the unmodified protein – and possibly the nucleocapsid – are likely to be assembled on a foundation of discrete structural  building blocks. In contrast, the mixture of 10D mutant and RNA formed nonuniform, diffuse chains"
413,PMID: 32637943,RNAPS0000405,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,318nt(PS-318),UAGCUUGUGCUGGUCCCUUUGAAGGUGUUAGACCUUUGACUGAACCUUCUGUUAUUAAAACACCAUUACGGGCGUUUCUAAAAAGGUCUACCUGUCCUUCCACUCUACCAUCAAACAAGACAGUAAGUGAAGAACAAGCACUCUCAGUAGGUUUCUUGGCAAUGUCAGUCAUUGUGCAGACACCUAUUGUAGAUACAUGUGCUGGGGCUUCUCUUUUGUAGUCCCAGAUGUACAGUAUUAGCAGCGAUAUCAACACCCAAAUUAUUGAGUAUCUUAAUCUCUGGCACUGGUUUAAUGUUACGCUUAGCCCAAAGCUCA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|mutation:R10D
MSDNGPQNQDNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,liquid,"We first analyzed the effects of three mid-sized viral RNA fragments: (1) 5’-400, containing the 400 nt at the 5’ end of the SARS-CoV-2 genome, which is thought to include multiple secondary  structure elements and the leader TRS51-53; (2) PS-318, a sequence near the end of ORF1b in  SARS-CoV, proposed as a packaging sequence54,55 but of unknown function51,56; and (3) N- 1260, containing the open reading frame of the N gene near the 3’ end of the SARS-CoV-2  genome. RNA encoding firefly luciferase (Luc-1710) was a nonviral control. N protein structures were analyzed by microscopy 30 minutes after addition of RNA at room temperature"
414,PMID: 32637943,RNAPS0000406,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,10nt(TRS),UCUAAACGAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|mutation:R10D
MSDNGPQNQDNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,protein_mutation:R10D,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,10 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,"solute, solid","We explored the role of phosphorylation in depth with studies of a phosphomimetic mutant in  which the ten serines and threonines in the SR region were replaced with aspartate (the 10D  mutant). When combined with the 5’-400 viral RNA, the 10D protein rapidly formed condensates with a spherical droplet morphology that was clearly distinct from the filamentous structures of  the wild-type protein"
415,PMID: 32637943,RNAPS0000406,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,10nt(TRS),UCUAAACGAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,10 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,"liquid, solid","We tested the importance of multivalent RNA binding by measuring the effects of a 10- nucleotide RNA carrying the TRS sequence of SARS-CoV-2. The TRS sequence is thought to  bind primarily to the NTD, with some contribution from the adjacent SR region57,58. Surprisingly,  addition of the TRS RNA triggered the rapid formation of droplets, without the filamentous  structures seen with longer viral RNAs"
416,PMID: 32637943,RNAPS0000406,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,10nt(TRS),UCUAAACGAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,1.25-20 µM [SARS-CoV-2];|10 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,liquid,"We tested the importance of multivalent RNA binding by measuring the effects of a 10- nucleotide RNA carrying the TRS sequence of SARS-CoV-2. The TRS sequence is thought to  bind primarily to the NTD, with some contribution from the adjacent SR region57,58. Surprisingly,  addition of the TRS RNA triggered the rapid formation of droplets, without the filamentous  structures seen with longer viral RNAs"
417,PMID: 32637943,RNAPS0000406,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,10nt(TRS),UCUAAACGAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=1-246,280-419
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△CBP,-,"386aa(1-246,280-419)",P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-246],[365-391]","[175-208],[211-230],[236-246],[361-379]",In vitro,10 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,"Turbidity measurement,Microscopy",liquid,"When combined with viral 5’-400 RNA, none of the deletions completely prevented droplet  formation at high protein concentrations (Fig. 2a), indicating that no single disordered segment  is essential for the interactions that mediate droplet formation. CTE deletion stimulated the  formation of abundant filaments, suggesting that this region normally inhibits interactions.  Deletion of the NTE or CBP abolished filaments. Droplets were also observed after deletion of  both the NTE and CTE, showing that the central regions are sufficient for droplet formation."
418,PMID: 32637943,RNAPS0000406,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,10nt(TRS),UCUAAACGAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=1-364
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFP",SARS-CoV-2 Nucleoprotein,△CTE,-,364aa(1-364),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256]","[175-208],[211-230],[236-249],[361-364]",In vitro,10 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,"Turbidity measurement,Microscopy",liquid,"When combined with viral 5’-400 RNA, none of the deletions completely prevented droplet  formation at high protein concentrations (Fig. 2a), indicating that no single disordered segment  is essential for the interactions that mediate droplet formation. CTE deletion stimulated the  formation of abundant filaments, suggesting that this region normally inhibits interactions.  Deletion of the NTE or CBP abolished filaments. Droplets were also observed after deletion of  both the NTE and CTE, showing that the central regions are sufficient for droplet formation."
419,PMID: 32637943,RNAPS0000406,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,10nt(TRS),UCUAAACGAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=45-419
LPNNTASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△NTE,-,375aa(45-419),P0DTC9,-,-,"[45-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,10 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,"Turbidity measurement,Microscopy","solute, liquid","When combined with viral 5’-400 RNA, none of the deletions completely prevented droplet  formation at high protein concentrations (Fig. 2a), indicating that no single disordered segment  is essential for the interactions that mediate droplet formation. CTE deletion stimulated the  formation of abundant filaments, suggesting that this region normally inhibits interactions.  Deletion of the NTE or CBP abolished filaments. Droplets were also observed after deletion of  both the NTE and CTE, showing that the central regions are sufficient for droplet formation."
420,PMID: 32637943,RNAPS0000406,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,10nt(TRS),UCUAAACGAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=45-364
LPNNTASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFP",SARS-CoV-2 Nucleoprotein,△NTE+△CTE,-,320aa(45-364),P0DTC9,-,-,"[45-49],[174-174],[181-212],[233-247],[249-256]","[175-208],[211-230],[236-249],[361-364]",In vitro,10 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,"Turbidity measurement,Microscopy","solute, liquid","When combined with viral 5’-400 RNA, none of the deletions completely prevented droplet  formation at high protein concentrations (Fig. 2a), indicating that no single disordered segment  is essential for the interactions that mediate droplet formation. CTE deletion stimulated the  formation of abundant filaments, suggesting that this region normally inhibits interactions.  Deletion of the NTE or CBP abolished filaments. Droplets were also observed after deletion of  both the NTE and CTE, showing that the central regions are sufficient for droplet formation."
421,PMID: 32637943,RNAPS0000406,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,10nt(TRS),UCUAAACGAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=1-175,207-419
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEG
PARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△SR,-,"388aa(1-175,207-419)",P0DTC9,-,-,"[1-40],[44-49],[174-174],[207-212],[233-247],[249-256],[365-391]","[175-175],[207-207],[211-230],[236-249],[361-379]",In vitro,10 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,"Turbidity measurement,Microscopy",solid,"When combined with viral 5’-400 RNA, none of the deletions completely prevented droplet  formation at high protein concentrations (Fig. 2a), indicating that no single disordered segment  is essential for the interactions that mediate droplet formation. CTE deletion stimulated the  formation of abundant filaments, suggesting that this region normally inhibits interactions.  Deletion of the NTE or CBP abolished filaments. Droplets were also observed after deletion of  both the NTE and CTE, showing that the central regions are sufficient for droplet formation."
422,PMID: 32637943,RNAPS0000407,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 N1260 RNA,1260nt,UGUCGACGGAGCUCGAAUUCUUAGGCCUGAGUUGAGUCAGCACUGCUCAUGGAUUGUUGCAAUUGUUUGGAGAAAUCAUCCAAAUCUGCAGCAGGAAGAAGAGUCACAGUUUGCUGUUUCUUCUGUCUCUGCGGUAAGGCUUGAGUUUCAUCAGCCUUCUUCUUUUUGUCCUUUUUAGGCUCUGUUGGUGGGAAUGUUUUGUAUGCGUCAAUAUGCUUAUUCAGCAAAAUGACUUGAUCUUUGAAAUUUGGAUCUUUGUCAUCCAAUUUGAUGGCACCUGUGUAGGUCAACCACGUUCCCGAAGGUGUGACUUCCAUGCCAAUGCGCGACAUUCCGAAGAACGCUGAAGCGCUGGGGGCAAAUUGUGCAAUUUGCGGCCAAUGUUUGUAAUCAGUUCCUUGUCUGAUUAGUUCCUGGUCCCCAAAAUUUCCUUGGGUUUGUUCUGGACCACGUCUGCCGAAAGCUUGUGUUACAUUGUAUGCUUUAGUGGCAGUACGUUUUUGCCGAGGCUUCUUAGAAGCCUCAGCAGCAGAUUUCUUAGUGACAGUUUGGCCUUGUUGUUGUUGGCCUUUACCAGACAUUUUGCUCUCAAGCUGGUUCAAUCUGUCAAGCAGCAGCAAAGCAAGAGCAGCAUCACCGCCAUUGCCAGCCAUUCUAGCAGGAGAAGUUCCCCUACUGCUGCCUGGAGUUGAAUUUCUUGAACUGUUGCGACUACGUGAUGAGGAACGAGAAGAGGCUUGACUGCCGCCUCUGCUCCCUUCUGCGUAGAAGCCUUUUGGCAAUGUUGUUCCUUGAGGAAGUUGUAGCACGAUUGCAGCAUUGUUAGCAGGAUUGCGGGUGCCAAUGUGAUCUUUUGGUGUAUUCAAGGCUCCCUCAGUUGCAACCCAUAUGAUGCCGUCUUUGUUAGCACCAUAGGGAAGUCCAGCUUCUGGCCCAGUUCCUAGGUAGUAGAAAUACCAUCUUGGACUGAGAUCUUUCAUUUUACCGUCACCACCACGAAUUCGUCUGGUAGCUCUUCGGUAGUAGCCAAUUUGGUCAUCUGGACUGCUAUUGGUGUUAAUUGGAACGCCUUGUCCUCGAGGGAAUUUAAGGUCUUCCUUGCCAUGUUGAGUGAGAGCGGUGAACCAAGACGCAGUAUUAUUGGGUAAACCUUGGGGCCGACGUUGUUUUGAUCGCGCCCCACUGCGUUCUCCAUUCUGGUUACUGCCAGUUGAAUCUGAGGGUCCACCAAACGUAAUGCGGGGUGCAUUUCGCUGAUUUUGGGGUCCAUUAUCAGACAUGGAUCCCUGAAAAUACAGGUUUUCCGUGGUACCGCGCGGCACCAGGCCGCUGCUGUGAUGAUGAUGAUGAUGGCUGCUGCCCAUGGUAUAUCUCCUUCUUAAAGUUAAACAAAAUUAUUUCUAGAGGGGAAUUGUUAUCCGCUCACAAUUCCC,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,200 nM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,liquid,"We first analyzed the effects of three mid-sized viral RNA fragments: (1) 5’-400, containing the 400 nt at the 5’ end of the SARS-CoV-2 genome, which is thought to include multiple secondary  structure elements and the leader TRS51-53; (2) PS-318, a sequence near the end of ORF1b in  SARS-CoV, proposed as a packaging sequence54,55 but of unknown function51,56; and (3) N- 1260, containing the open reading frame of the N gene near the 3’ end of the SARS-CoV-2  genome. RNA encoding firefly luciferase (Luc-1710) was a nonviral control. N protein structures were analyzed by microscopy 30 minutes after addition of RNA at room temperature"
423,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=1-364|mutation:R10D
MSDNGPQNQDNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFP",SARS-CoV-2 Nucleoprotein,△CTE,protein_mutation:R10D,364aa(1-364),P0DTC9,-,-,"[1-43],[73-102],[145-149],[152-160],[172-215],[235-271]",-,In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,liquid,"All three large viral RNAs were effective in driving droplet  formation, although N-1260 appeared to reduce the saturating concentration (Extended Data  Fig. 4a). NTE deletion in the 10D protein reduced droplet formation, showing once again the  positive role of this region"
424,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=45-419|mutation:T10D
LPNNTASWFDALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△NTE,protein_mutation:T10D,375aa(45-419),P0DTC9,-,-,"[45-46],[73-102],[145-149],[152-160],[172-215],[235-271],[365-387],[409-419]",-,In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,liquid,"All three large viral RNAs were effective in driving droplet  formation, although N-1260 appeared to reduce the saturating concentration (Extended Data  Fig. 4a). NTE deletion in the 10D protein reduced droplet formation, showing once again the  positive role of this region"
425,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=45-364|mutation:T10D
LPNNTASWFDALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFP",SARS-CoV-2 Nucleoprotein,△NTE+△CTE,protein_mutation:T10D,320aa(45-364),P0DTC9,-,-,"[45-46],[73-102],[145-149],[152-160],[172-215],[235-271]",-,In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,liquid,"All three large viral RNAs were effective in driving droplet  formation, although N-1260 appeared to reduce the saturating concentration (Extended Data  Fig. 4a). NTE deletion in the 10D protein reduced droplet formation, showing once again the  positive role of this region"
426,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|mutation:R10D
MSDNGPQNQDNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,protein_mutation:R10D,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,"solute, liquid","We explored the role of phosphorylation in depth with studies of a phosphomimetic mutant in  which the ten serines and threonines in the SR region were replaced with aspartate (the 10D  mutant). When combined with the 5’-400 viral RNA, the 10D protein rapidly formed condensates with a spherical droplet morphology that was clearly distinct from the filamentous structures of  the wild-type protein"
427,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.125-2 µM [SARS-CoV-2];|10 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,"liquid, solid","We tested the importance of multivalent RNA binding by measuring the effects of a 10- nucleotide RNA carrying the TRS sequence of SARS-CoV-2. The TRS sequence is thought to  bind primarily to the NTD, with some contribution from the adjacent SR region57,58. Surprisingly,  addition of the TRS RNA triggered the rapid formation of droplets, without the filamentous  structures seen with longer viral RNAs"
428,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=1-246,280-419
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△CBP,-,"386aa(1-246,280-419)",P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-246],[365-391]","[175-208],[211-230],[236-246],[361-379]",In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,"Turbidity measurement,Microscopy",liquid,"When combined with viral 5’-400 RNA, none of the deletions completely prevented droplet  formation at high protein concentrations (Fig. 2a), indicating that no single disordered segment  is essential for the interactions that mediate droplet formation. CTE deletion stimulated the  formation of abundant filaments, suggesting that this region normally inhibits interactions.  Deletion of the NTE or CBP abolished filaments. Droplets were also observed after deletion of  both the NTE and CTE, showing that the central regions are sufficient for droplet formation."
429,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=1-364
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFP",SARS-CoV-2 Nucleoprotein,△CTE,-,364aa(1-364),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256]","[175-208],[211-230],[236-249],[361-364]",In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,"Turbidity measurement,Microscopy","liquid, solid","When combined with viral 5’-400 RNA, none of the deletions completely prevented droplet  formation at high protein concentrations (Fig. 2a), indicating that no single disordered segment  is essential for the interactions that mediate droplet formation. CTE deletion stimulated the  formation of abundant filaments, suggesting that this region normally inhibits interactions.  Deletion of the NTE or CBP abolished filaments. Droplets were also observed after deletion of  both the NTE and CTE, showing that the central regions are sufficient for droplet formation."
430,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=45-419
LPNNTASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△NTE,-,375aa(45-419),P0DTC9,-,-,"[45-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,"Turbidity measurement,Microscopy",liquid,"When combined with viral 5’-400 RNA, none of the deletions completely prevented droplet  formation at high protein concentrations (Fig. 2a), indicating that no single disordered segment  is essential for the interactions that mediate droplet formation. CTE deletion stimulated the  formation of abundant filaments, suggesting that this region normally inhibits interactions.  Deletion of the NTE or CBP abolished filaments. Droplets were also observed after deletion of  both the NTE and CTE, showing that the central regions are sufficient for droplet formation."
431,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=45-364
LPNNTASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFP",SARS-CoV-2 Nucleoprotein,△NTE+△CTE,-,320aa(45-364),P0DTC9,-,-,"[45-49],[174-174],[181-212],[233-247],[249-256]","[175-208],[211-230],[236-249],[361-364]",In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,"Turbidity measurement,Microscopy",liquid,"When combined with viral 5’-400 RNA, none of the deletions completely prevented droplet  formation at high protein concentrations (Fig. 2a), indicating that no single disordered segment  is essential for the interactions that mediate droplet formation. CTE deletion stimulated the  formation of abundant filaments, suggesting that this region normally inhibits interactions.  Deletion of the NTE or CBP abolished filaments. Droplets were also observed after deletion of  both the NTE and CTE, showing that the central regions are sufficient for droplet formation."
432,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=1-175,207-419
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEG
PARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△SR,-,"388aa(1-175,207-419)",P0DTC9,-,-,"[1-40],[44-49],[174-174],[207-212],[233-247],[249-256],[365-391]","[175-175],[207-207],[211-230],[236-249],[361-379]",In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,"Turbidity measurement,Microscopy",liquid,"When combined with viral 5’-400 RNA, none of the deletions completely prevented droplet  formation at high protein concentrations (Fig. 2a), indicating that no single disordered segment  is essential for the interactions that mediate droplet formation. CTE deletion stimulated the  formation of abundant filaments, suggesting that this region normally inhibits interactions.  Deletion of the NTE or CBP abolished filaments. Droplets were also observed after deletion of  both the NTE and CTE, showing that the central regions are sufficient for droplet formation."
433,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,liquid,"We first analyzed the effects of three mid-sized viral RNA fragments: (1) 5’-400, containing the 400 nt at the 5’ end of the SARS-CoV-2 genome, which is thought to include multiple secondary  structure elements and the leader TRS51-53; (2) PS-318, a sequence near the end of ORF1b in  SARS-CoV, proposed as a packaging sequence54,55 but of unknown function51,56; and (3) N- 1260, containing the open reading frame of the N gene near the 3’ end of the SARS-CoV-2  genome. RNA encoding firefly luciferase (Luc-1710) was a nonviral control. N protein structures were analyzed by microscopy 30 minutes after addition of RNA at room temperature"
434,PMID: 32649883,RNAPS0000409,https://pubmed.ncbi.nlm.nih.gov/32649883,RNA + protein,NCBI ID:283131,https://www.ncbi.nlm.nih.gov/gene/283131,NEAT1,3756nt(1-3756),GGAGUUAGCGACAGGGAGGGAUGCGCGCCUGGGUGUAGUUGUGGGGGAGGAAGUGGCUAGCUCAGGGCUUCAGGGGACAGACAGGGAGAGAUGACUGAGUUAGAUGAGACGAGGGGGCGGGCUGGGGGUGCGAGAAGGAAGCUUGGCAAGGAGACUAGGUCUAGGGGGACCACAGUGGGGCAGGCUGCAUGGAAAAUAUCCGCAGGGUCCCCCAGGCAGAACAGCCACGCUCCAGGCCAGGCUGUCCCUACUGCCUGGUGGAGGGGGAACUUGACCUCUGGGAGGGCGCCGCUCUUGCAUAGCUGAGCGAGCCCGGGUGCGCUGGUCUGUGUGGAAGGAGGAAGGCAGGGAGAGGUAGAAGGGGUGGAGGAGUCAGGAGGAAUAGGCCGCAGCAGCCCUGGAAAUGAUCAGGAAGGCAGGCAGUGGGUGCAGGGCUGCAGGAGGGCCGGGAGGGCUAAUCUUCAACUUGUCCAUGCCAGCAGCCCCUUUUUUUCCAGACCAAGGGCUGUGAACCCGCCUGGGGAUGAGGCCUGGUCUUGUGGAACUGAACUUAGCUCGACGGGGCUGACCGCUCUGGCCCAGGGUGGUAUGUAAUUUUCGCUCGGCCUGGGACGGGGCCCAGGCCGGGCCCAGCCUGGUGGAGCGUCCAGGUCUGGGUGCGAAGCCAGGCCCCUGGGCGGAGGUGAGGGGUGGUCUGAGGAGUGAUGUGGAGUUAAGGCGCCAUCCUCACCGGUGACUGGUGCGGCACCUAGCAUGUUUGACAGGCGGGGACUGCGAGGCACGCUGCUCGGGUGUUGGGGACAACAUUGACCAACGCUUUAUUUUCCAGGUGGCAGUGCUCCUUUUGGACUUUUCUCUAGGUUUGGCGCUAAACUCUUCUUGUGAGCUCACUCCACCCCUUCUUCCUCCCUUUAACUUAUCCAUUCACUUAAAACAUUACCUGGUCAUCUGGUAAGCCCGGGACAGUAAGCCGAGUGGCUGUUGGAGUCGGUAUUGUUGGUAAUGGUGGAGGAAGAGAGGCCUUCCCGCUGAGGCUGGGGUGGGGCGGAUCGGUGUUGCUUGCCUGCAGAGAGGGUGGGGAGUGAAUGUGCACCCUUGGGUGGGCCUGCAGCCAUCCAGCUGAAAGUUACAAAAAUGCUUCAUGGACCGUGGUUUGUUACUAUAGUGUUCCUCAUGGCGAGCAGAUGGAACCGGGAGACAUGGAGUCCCUGGCCAGUGUGAGUCCUAGCAUUGCAGGAGGGGAGACCCUGGAGGAGAGAGCCCGCCUCAAUUGAUGCCUGCAGAUUGAAUUUCCAGAGGCUUAGGAGGAGGAAGUUCUCCAAUGUUCUGUUUCCAGGCCUUGCUCAGGAAGCCCUGUAUUCAGGAGGCUACCAUUUAAAGUUUGCAGAUGAGCUUAUGGGGGGCAAUCUUAAAAAGUCCACAGCAGAUGCAUCCGGCUCGAGGGGCCAUCAGCUUUGAAUAAAUGCUUGUUCCAGAGCCCAUGAAUGCCAGCAGGCACCCCUCCUUUCCUGGGGUAAAGGUUUUCAGAUGCUGCAUCUUCUAAAUUGAGCCUCCGGUCAUACUAGUUUUGUGCUUGGAACCUUGCUUCAAGAAGAUCCCUAAGCUGUAGAACAUUUUAACGUUGAUGCCACAACGCAGAUUGAUGCCUUGUAGAUGGAGCUUGCAGAUGGAGCCCCGUGACCUCUCACCUACCCACCUGUUUGCCUGCCUUCUUGUGCGUUUCUCGGAGAAGUUCUUAGCCUGAUGAAAUAACUUGGGGCGUUGAAGAGCUGUUUAAUUUUAAAUGCCUUAGACUGGGGAUAUAUUAGAGGAAGCAGAUUGUCAAAUUAAGGGUGUCAUUGUGUUGUGCUAAACGCUGGGAGGGUACAAGUUGGUCAUUCCUAAAUCUGUGUGUGAGAAAUGGCAGGUCUAGUUUGGGCAUUGUGAUUGCAUUGCAGAUUACUAGGAGAAGGGAAUGGUGGGUACACCGGUAGUGCUCUUUUGUUCUUGCUUCGUUUUUUUAAACUUGAACUUUACUUCGUUAGAUUUCAUAAUACUUUCUUGGCAUUCUAGUAAGAGGACCCUGAGGUGGGAGUUGUGGGGGACGGGGAGAAGGGGACAGCUUGGCACCGGUCCCGUGGGCGUUGCAGUGUGGGGGAUGGGGGUAUGCAGCUUGGCACUGGUACUGGGAGGGAUGAGGGUGAAGAAGGGGAGAGGGUUGGUUAGAGAUACAGUGUGGGUGGUGGGGGUGGUAGGAAAUGCAGGUUGAAGGGAAUUCUCUGGGGCUUUGGGGAAUUUAGUGCGUGGGUGAGCCAAGAAAAUACUAAUUAAUAAUAGUAAGUUGUUAGUGUUGGUUAAGUUGUUGCUUGGAAGUGAGAAGUUGCUUAGAAACUUUCCAAAGUGCUUAGAACUUUAAGUGCAAACAGACAAACUAACAAACAAAAAUUGUUUUGCUUUGCUACAAGGUGGGGAAGACUGAAGAAGUGUUAACUGAAAACAGGUGACACAGAGUCACCAGUUUUCCGAGAACCAAAGGGAGGGGUGUGUGAUGCCAUCUCACAGGCAGGGGAAAUGUCUUUACCAGCUUCCUCCUGGUGGCCAAGACAGCCUGUUUCAGAGGGUUGUUUUGUUUGGGGUGUGGGUGUUAUCAAGUGAAUUAGUCACUUGAAAGAUGGGCGUCAGACUUGCAUACGCAGCAGAUCAGCAUCCUUCGCUGCCCCUUAGCAACUUAGGUGGUUGAUUUGAAACUGUGAAGGUGUGAUUUUUUCAGGAGCUGGAAGUCUUAGAAAAGCCUUGUAAAUGCCUAUAUUGUGGGCUUUUAACGUAUUUAAGGGACCACUUAAGACGAGAUUAGAUGGGCUCUUCUGGAUUUGUUCCUCAUUUGUCACAGGUGUCUUGUGAUUGAAAAUCAUGAGCGAAGUGAAAUUGCAUUGAAUUUCAAGGGAAUUUAGUAUGUAAAUCGUGCCUUAGAAACACAUCUGUUGUCUUUUCUGUGUUUGGUCGAUAUUAAUAAUGGCAAAAUUUUUGCCUAUCUAGUAUCUUCAAAUUGUAGUCUUUGUAACAACCAAAUAACCUUUUGUGGUCACUGUAAAAUUAAUAUUUGGUAGACAGAAUCCAUGUACCUUUGCUAAGGUUAGAAUGAAUAAUUUAUUGUAUUUUUAAUUUGAAUGUUUGUGCUUUUUAAAUGAGCCAAGACUAGAGGGGAAACUAUCACCUAAAAUCAGUUUGGAAAACAAGACCUAAAAAGGGAAGGGGAUGGGGAUUGUGGGGAGAGAGUGGGCGAGGUGCCUUUACUACAUGUGUGAUCUGAAAACCCUGCUUGGUUCUGAGCUGCGUCUAUUGAAUUGGUAAAGUAAUACCAAUGGCUUUUUAUCAUUUCCUUCUUCCCUUUAAGUUUCACUUGAAAUUUUAAAAAUCAUGGUUAUUUUUAUCGUUGGGAUCUUUCUGUCUUCUGGGUUCCAUUUUUUAAAUGUUUAAAAAUAUGUUGACAUGGUAGUUCAGUUCUUAACCAAUGACUUGGGGAUGAUGCAAACAAUUACUGUCGUUGGGAUUUAGAGUGUAUUAGUCACGCAUGUAUGGGGAAGUAGUCUCGGGUAUGCUGUUGUGAAAUUGAAACUGUAAAAGUAGAUGGUUGAAAGUACUGGUAUGUUGCUCUGUAUGGUAAGAACUAAUUCUGUUACGUCAUGUACAUAAUUACUAAUCACUUUUCUUCCCCUUUACAGCACAAAUAAAGUUUGAGUUCUAAACUCAUUAGAAAAAAAAAAAAAAAAAAAAAAA;|-,lncRNA,Homo sapiens,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|length=274aa|residues=1-274|mutation=D169G
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIGGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSG",TDP-43,-,protein_mutation:D169G,274aa(1-274),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/","[9-28],[84-104],[180-194],[261-274]",-,In vitro,0-500ng/µl siNEAT1;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,-,Differential interference contrast microscopy,"solute, liquid","Suppression of TDP-43 LLPS by total RNAs showed no marked difference between D169G and WT TDP-431-274 (Figures 7C and 7D). In contrast, the induction of TDP-43 LLPS by NEAT1 RNA was drastically reduced by D169G (Figures 7E and 7F)."
435,PMID: 32649883,RNAPS0000409,https://pubmed.ncbi.nlm.nih.gov/32649883,RNA + protein,NCBI ID:283131,https://www.ncbi.nlm.nih.gov/gene/283131,NEAT1,3756nt(1-3756),GGAGUUAGCGACAGGGAGGGAUGCGCGCCUGGGUGUAGUUGUGGGGGAGGAAGUGGCUAGCUCAGGGCUUCAGGGGACAGACAGGGAGAGAUGACUGAGUUAGAUGAGACGAGGGGGCGGGCUGGGGGUGCGAGAAGGAAGCUUGGCAAGGAGACUAGGUCUAGGGGGACCACAGUGGGGCAGGCUGCAUGGAAAAUAUCCGCAGGGUCCCCCAGGCAGAACAGCCACGCUCCAGGCCAGGCUGUCCCUACUGCCUGGUGGAGGGGGAACUUGACCUCUGGGAGGGCGCCGCUCUUGCAUAGCUGAGCGAGCCCGGGUGCGCUGGUCUGUGUGGAAGGAGGAAGGCAGGGAGAGGUAGAAGGGGUGGAGGAGUCAGGAGGAAUAGGCCGCAGCAGCCCUGGAAAUGAUCAGGAAGGCAGGCAGUGGGUGCAGGGCUGCAGGAGGGCCGGGAGGGCUAAUCUUCAACUUGUCCAUGCCAGCAGCCCCUUUUUUUCCAGACCAAGGGCUGUGAACCCGCCUGGGGAUGAGGCCUGGUCUUGUGGAACUGAACUUAGCUCGACGGGGCUGACCGCUCUGGCCCAGGGUGGUAUGUAAUUUUCGCUCGGCCUGGGACGGGGCCCAGGCCGGGCCCAGCCUGGUGGAGCGUCCAGGUCUGGGUGCGAAGCCAGGCCCCUGGGCGGAGGUGAGGGGUGGUCUGAGGAGUGAUGUGGAGUUAAGGCGCCAUCCUCACCGGUGACUGGUGCGGCACCUAGCAUGUUUGACAGGCGGGGACUGCGAGGCACGCUGCUCGGGUGUUGGGGACAACAUUGACCAACGCUUUAUUUUCCAGGUGGCAGUGCUCCUUUUGGACUUUUCUCUAGGUUUGGCGCUAAACUCUUCUUGUGAGCUCACUCCACCCCUUCUUCCUCCCUUUAACUUAUCCAUUCACUUAAAACAUUACCUGGUCAUCUGGUAAGCCCGGGACAGUAAGCCGAGUGGCUGUUGGAGUCGGUAUUGUUGGUAAUGGUGGAGGAAGAGAGGCCUUCCCGCUGAGGCUGGGGUGGGGCGGAUCGGUGUUGCUUGCCUGCAGAGAGGGUGGGGAGUGAAUGUGCACCCUUGGGUGGGCCUGCAGCCAUCCAGCUGAAAGUUACAAAAAUGCUUCAUGGACCGUGGUUUGUUACUAUAGUGUUCCUCAUGGCGAGCAGAUGGAACCGGGAGACAUGGAGUCCCUGGCCAGUGUGAGUCCUAGCAUUGCAGGAGGGGAGACCCUGGAGGAGAGAGCCCGCCUCAAUUGAUGCCUGCAGAUUGAAUUUCCAGAGGCUUAGGAGGAGGAAGUUCUCCAAUGUUCUGUUUCCAGGCCUUGCUCAGGAAGCCCUGUAUUCAGGAGGCUACCAUUUAAAGUUUGCAGAUGAGCUUAUGGGGGGCAAUCUUAAAAAGUCCACAGCAGAUGCAUCCGGCUCGAGGGGCCAUCAGCUUUGAAUAAAUGCUUGUUCCAGAGCCCAUGAAUGCCAGCAGGCACCCCUCCUUUCCUGGGGUAAAGGUUUUCAGAUGCUGCAUCUUCUAAAUUGAGCCUCCGGUCAUACUAGUUUUGUGCUUGGAACCUUGCUUCAAGAAGAUCCCUAAGCUGUAGAACAUUUUAACGUUGAUGCCACAACGCAGAUUGAUGCCUUGUAGAUGGAGCUUGCAGAUGGAGCCCCGUGACCUCUCACCUACCCACCUGUUUGCCUGCCUUCUUGUGCGUUUCUCGGAGAAGUUCUUAGCCUGAUGAAAUAACUUGGGGCGUUGAAGAGCUGUUUAAUUUUAAAUGCCUUAGACUGGGGAUAUAUUAGAGGAAGCAGAUUGUCAAAUUAAGGGUGUCAUUGUGUUGUGCUAAACGCUGGGAGGGUACAAGUUGGUCAUUCCUAAAUCUGUGUGUGAGAAAUGGCAGGUCUAGUUUGGGCAUUGUGAUUGCAUUGCAGAUUACUAGGAGAAGGGAAUGGUGGGUACACCGGUAGUGCUCUUUUGUUCUUGCUUCGUUUUUUUAAACUUGAACUUUACUUCGUUAGAUUUCAUAAUACUUUCUUGGCAUUCUAGUAAGAGGACCCUGAGGUGGGAGUUGUGGGGGACGGGGAGAAGGGGACAGCUUGGCACCGGUCCCGUGGGCGUUGCAGUGUGGGGGAUGGGGGUAUGCAGCUUGGCACUGGUACUGGGAGGGAUGAGGGUGAAGAAGGGGAGAGGGUUGGUUAGAGAUACAGUGUGGGUGGUGGGGGUGGUAGGAAAUGCAGGUUGAAGGGAAUUCUCUGGGGCUUUGGGGAAUUUAGUGCGUGGGUGAGCCAAGAAAAUACUAAUUAAUAAUAGUAAGUUGUUAGUGUUGGUUAAGUUGUUGCUUGGAAGUGAGAAGUUGCUUAGAAACUUUCCAAAGUGCUUAGAACUUUAAGUGCAAACAGACAAACUAACAAACAAAAAUUGUUUUGCUUUGCUACAAGGUGGGGAAGACUGAAGAAGUGUUAACUGAAAACAGGUGACACAGAGUCACCAGUUUUCCGAGAACCAAAGGGAGGGGUGUGUGAUGCCAUCUCACAGGCAGGGGAAAUGUCUUUACCAGCUUCCUCCUGGUGGCCAAGACAGCCUGUUUCAGAGGGUUGUUUUGUUUGGGGUGUGGGUGUUAUCAAGUGAAUUAGUCACUUGAAAGAUGGGCGUCAGACUUGCAUACGCAGCAGAUCAGCAUCCUUCGCUGCCCCUUAGCAACUUAGGUGGUUGAUUUGAAACUGUGAAGGUGUGAUUUUUUCAGGAGCUGGAAGUCUUAGAAAAGCCUUGUAAAUGCCUAUAUUGUGGGCUUUUAACGUAUUUAAGGGACCACUUAAGACGAGAUUAGAUGGGCUCUUCUGGAUUUGUUCCUCAUUUGUCACAGGUGUCUUGUGAUUGAAAAUCAUGAGCGAAGUGAAAUUGCAUUGAAUUUCAAGGGAAUUUAGUAUGUAAAUCGUGCCUUAGAAACACAUCUGUUGUCUUUUCUGUGUUUGGUCGAUAUUAAUAAUGGCAAAAUUUUUGCCUAUCUAGUAUCUUCAAAUUGUAGUCUUUGUAACAACCAAAUAACCUUUUGUGGUCACUGUAAAAUUAAUAUUUGGUAGACAGAAUCCAUGUACCUUUGCUAAGGUUAGAAUGAAUAAUUUAUUGUAUUUUUAAUUUGAAUGUUUGUGCUUUUUAAAUGAGCCAAGACUAGAGGGGAAACUAUCACCUAAAAUCAGUUUGGAAAACAAGACCUAAAAAGGGAAGGGGAUGGGGAUUGUGGGGAGAGAGUGGGCGAGGUGCCUUUACUACAUGUGUGAUCUGAAAACCCUGCUUGGUUCUGAGCUGCGUCUAUUGAAUUGGUAAAGUAAUACCAAUGGCUUUUUAUCAUUUCCUUCUUCCCUUUAAGUUUCACUUGAAAUUUUAAAAAUCAUGGUUAUUUUUAUCGUUGGGAUCUUUCUGUCUUCUGGGUUCCAUUUUUUAAAUGUUUAAAAAUAUGUUGACAUGGUAGUUCAGUUCUUAACCAAUGACUUGGGGAUGAUGCAAACAAUUACUGUCGUUGGGAUUUAGAGUGUAUUAGUCACGCAUGUAUGGGGAAGUAGUCUCGGGUAUGCUGUUGUGAAAUUGAAACUGUAAAAGUAGAUGGUUGAAAGUACUGGUAUGUUGCUCUGUAUGGUAAGAACUAAUUCUGUUACGUCAUGUACAUAAUUACUAAUCACUUUUCUUCCCCUUUACAGCACAAAUAAAGUUUGAGUUCUAAACUCAUUAGAAAAAAAAAAAAAAAAAAAAAAA;|-,lncRNA,Homo sapiens,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSG",TDP-43,-,-,274aa(1-274),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,0-500ng/µl siNEAT1;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,-,Differential interference contrast microscopy,"solute, liquid","We found that the PS scaffolding RNA NEAT1 promoted TDP-43 de-mixing in a dose-dependent manner (Figure 5I), which involved both RRM1 and RRM2 (Figures 5J and 5K). Furthermore, we demonstrated that increasing concentrations of NEAT1 antagonized the suppressive environment generated by tRNA in the in vitro LLPS assay of TDP-43 (Figure 5L), which was markedly reduced by DRRM1 but enhanced by DRRM2 (Figures 5M and 5N)."
436,PMID: 32649883,RNAPS0000409,https://pubmed.ncbi.nlm.nih.gov/32649883,RNA + protein,NCBI ID:283131,https://www.ncbi.nlm.nih.gov/gene/283131,NEAT1,3756nt(1-3756),GGAGUUAGCGACAGGGAGGGAUGCGCGCCUGGGUGUAGUUGUGGGGGAGGAAGUGGCUAGCUCAGGGCUUCAGGGGACAGACAGGGAGAGAUGACUGAGUUAGAUGAGACGAGGGGGCGGGCUGGGGGUGCGAGAAGGAAGCUUGGCAAGGAGACUAGGUCUAGGGGGACCACAGUGGGGCAGGCUGCAUGGAAAAUAUCCGCAGGGUCCCCCAGGCAGAACAGCCACGCUCCAGGCCAGGCUGUCCCUACUGCCUGGUGGAGGGGGAACUUGACCUCUGGGAGGGCGCCGCUCUUGCAUAGCUGAGCGAGCCCGGGUGCGCUGGUCUGUGUGGAAGGAGGAAGGCAGGGAGAGGUAGAAGGGGUGGAGGAGUCAGGAGGAAUAGGCCGCAGCAGCCCUGGAAAUGAUCAGGAAGGCAGGCAGUGGGUGCAGGGCUGCAGGAGGGCCGGGAGGGCUAAUCUUCAACUUGUCCAUGCCAGCAGCCCCUUUUUUUCCAGACCAAGGGCUGUGAACCCGCCUGGGGAUGAGGCCUGGUCUUGUGGAACUGAACUUAGCUCGACGGGGCUGACCGCUCUGGCCCAGGGUGGUAUGUAAUUUUCGCUCGGCCUGGGACGGGGCCCAGGCCGGGCCCAGCCUGGUGGAGCGUCCAGGUCUGGGUGCGAAGCCAGGCCCCUGGGCGGAGGUGAGGGGUGGUCUGAGGAGUGAUGUGGAGUUAAGGCGCCAUCCUCACCGGUGACUGGUGCGGCACCUAGCAUGUUUGACAGGCGGGGACUGCGAGGCACGCUGCUCGGGUGUUGGGGACAACAUUGACCAACGCUUUAUUUUCCAGGUGGCAGUGCUCCUUUUGGACUUUUCUCUAGGUUUGGCGCUAAACUCUUCUUGUGAGCUCACUCCACCCCUUCUUCCUCCCUUUAACUUAUCCAUUCACUUAAAACAUUACCUGGUCAUCUGGUAAGCCCGGGACAGUAAGCCGAGUGGCUGUUGGAGUCGGUAUUGUUGGUAAUGGUGGAGGAAGAGAGGCCUUCCCGCUGAGGCUGGGGUGGGGCGGAUCGGUGUUGCUUGCCUGCAGAGAGGGUGGGGAGUGAAUGUGCACCCUUGGGUGGGCCUGCAGCCAUCCAGCUGAAAGUUACAAAAAUGCUUCAUGGACCGUGGUUUGUUACUAUAGUGUUCCUCAUGGCGAGCAGAUGGAACCGGGAGACAUGGAGUCCCUGGCCAGUGUGAGUCCUAGCAUUGCAGGAGGGGAGACCCUGGAGGAGAGAGCCCGCCUCAAUUGAUGCCUGCAGAUUGAAUUUCCAGAGGCUUAGGAGGAGGAAGUUCUCCAAUGUUCUGUUUCCAGGCCUUGCUCAGGAAGCCCUGUAUUCAGGAGGCUACCAUUUAAAGUUUGCAGAUGAGCUUAUGGGGGGCAAUCUUAAAAAGUCCACAGCAGAUGCAUCCGGCUCGAGGGGCCAUCAGCUUUGAAUAAAUGCUUGUUCCAGAGCCCAUGAAUGCCAGCAGGCACCCCUCCUUUCCUGGGGUAAAGGUUUUCAGAUGCUGCAUCUUCUAAAUUGAGCCUCCGGUCAUACUAGUUUUGUGCUUGGAACCUUGCUUCAAGAAGAUCCCUAAGCUGUAGAACAUUUUAACGUUGAUGCCACAACGCAGAUUGAUGCCUUGUAGAUGGAGCUUGCAGAUGGAGCCCCGUGACCUCUCACCUACCCACCUGUUUGCCUGCCUUCUUGUGCGUUUCUCGGAGAAGUUCUUAGCCUGAUGAAAUAACUUGGGGCGUUGAAGAGCUGUUUAAUUUUAAAUGCCUUAGACUGGGGAUAUAUUAGAGGAAGCAGAUUGUCAAAUUAAGGGUGUCAUUGUGUUGUGCUAAACGCUGGGAGGGUACAAGUUGGUCAUUCCUAAAUCUGUGUGUGAGAAAUGGCAGGUCUAGUUUGGGCAUUGUGAUUGCAUUGCAGAUUACUAGGAGAAGGGAAUGGUGGGUACACCGGUAGUGCUCUUUUGUUCUUGCUUCGUUUUUUUAAACUUGAACUUUACUUCGUUAGAUUUCAUAAUACUUUCUUGGCAUUCUAGUAAGAGGACCCUGAGGUGGGAGUUGUGGGGGACGGGGAGAAGGGGACAGCUUGGCACCGGUCCCGUGGGCGUUGCAGUGUGGGGGAUGGGGGUAUGCAGCUUGGCACUGGUACUGGGAGGGAUGAGGGUGAAGAAGGGGAGAGGGUUGGUUAGAGAUACAGUGUGGGUGGUGGGGGUGGUAGGAAAUGCAGGUUGAAGGGAAUUCUCUGGGGCUUUGGGGAAUUUAGUGCGUGGGUGAGCCAAGAAAAUACUAAUUAAUAAUAGUAAGUUGUUAGUGUUGGUUAAGUUGUUGCUUGGAAGUGAGAAGUUGCUUAGAAACUUUCCAAAGUGCUUAGAACUUUAAGUGCAAACAGACAAACUAACAAACAAAAAUUGUUUUGCUUUGCUACAAGGUGGGGAAGACUGAAGAAGUGUUAACUGAAAACAGGUGACACAGAGUCACCAGUUUUCCGAGAACCAAAGGGAGGGGUGUGUGAUGCCAUCUCACAGGCAGGGGAAAUGUCUUUACCAGCUUCCUCCUGGUGGCCAAGACAGCCUGUUUCAGAGGGUUGUUUUGUUUGGGGUGUGGGUGUUAUCAAGUGAAUUAGUCACUUGAAAGAUGGGCGUCAGACUUGCAUACGCAGCAGAUCAGCAUCCUUCGCUGCCCCUUAGCAACUUAGGUGGUUGAUUUGAAACUGUGAAGGUGUGAUUUUUUCAGGAGCUGGAAGUCUUAGAAAAGCCUUGUAAAUGCCUAUAUUGUGGGCUUUUAACGUAUUUAAGGGACCACUUAAGACGAGAUUAGAUGGGCUCUUCUGGAUUUGUUCCUCAUUUGUCACAGGUGUCUUGUGAUUGAAAAUCAUGAGCGAAGUGAAAUUGCAUUGAAUUUCAAGGGAAUUUAGUAUGUAAAUCGUGCCUUAGAAACACAUCUGUUGUCUUUUCUGUGUUUGGUCGAUAUUAAUAAUGGCAAAAUUUUUGCCUAUCUAGUAUCUUCAAAUUGUAGUCUUUGUAACAACCAAAUAACCUUUUGUGGUCACUGUAAAAUUAAUAUUUGGUAGACAGAAUCCAUGUACCUUUGCUAAGGUUAGAAUGAAUAAUUUAUUGUAUUUUUAAUUUGAAUGUUUGUGCUUUUUAAAUGAGCCAAGACUAGAGGGGAAACUAUCACCUAAAAUCAGUUUGGAAAACAAGACCUAAAAAGGGAAGGGGAUGGGGAUUGUGGGGAGAGAGUGGGCGAGGUGCCUUUACUACAUGUGUGAUCUGAAAACCCUGCUUGGUUCUGAGCUGCGUCUAUUGAAUUGGUAAAGUAAUACCAAUGGCUUUUUAUCAUUUCCUUCUUCCCUUUAAGUUUCACUUGAAAUUUUAAAAAUCAUGGUUAUUUUUAUCGUUGGGAUCUUUCUGUCUUCUGGGUUCCAUUUUUUAAAUGUUUAAAAAUAUGUUGACAUGGUAGUUCAGUUCUUAACCAAUGACUUGGGGAUGAUGCAAACAAUUACUGUCGUUGGGAUUUAGAGUGUAUUAGUCACGCAUGUAUGGGGAAGUAGUCUCGGGUAUGCUGUUGUGAAAUUGAAACUGUAAAAGUAGAUGGUUGAAAGUACUGGUAUGUUGCUCUGUAUGGUAAGAACUAAUUCUGUUACGUCAUGUACAUAAUUACUAAUCACUUUUCUUCCCCUUUACAGCACAAAUAAAGUUUGAGUUCUAAACUCAUUAGAAAAAAAAAAAAAAAAAAAAAAA;|-,lncRNA,Homo sapiens,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-103,201-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTDMTEDELREFFSQ
YGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSG",TDP-43,△RRM1,-,"317aa(1-103,201-274)",Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,0-500ng/µl siNEAT1;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,-,Differential interference contrast microscopy,"liquid, solute","We found that the PS scaffolding RNA NEAT1 promoted TDP-43 de-mixing in a dose-dependent manner (Figure 5I), which involved both RRM1 and RRM2 (Figures 5J and 5K). Furthermore, we demonstrated that increasing concentrations of NEAT1 antagonized the suppressive environment generated by tRNA in the in vitro LLPS assay of TDP-43 (Figure 5L), which was markedly reduced by DRRM1 but enhanced by DRRM2 (Figures 5M and 5N)."
437,PMID: 32649883,RNAPS0000409,https://pubmed.ncbi.nlm.nih.gov/32649883,RNA + protein,NCBI ID:283131,https://www.ncbi.nlm.nih.gov/gene/283131,NEAT1,3756nt(1-3756),GGAGUUAGCGACAGGGAGGGAUGCGCGCCUGGGUGUAGUUGUGGGGGAGGAAGUGGCUAGCUCAGGGCUUCAGGGGACAGACAGGGAGAGAUGACUGAGUUAGAUGAGACGAGGGGGCGGGCUGGGGGUGCGAGAAGGAAGCUUGGCAAGGAGACUAGGUCUAGGGGGACCACAGUGGGGCAGGCUGCAUGGAAAAUAUCCGCAGGGUCCCCCAGGCAGAACAGCCACGCUCCAGGCCAGGCUGUCCCUACUGCCUGGUGGAGGGGGAACUUGACCUCUGGGAGGGCGCCGCUCUUGCAUAGCUGAGCGAGCCCGGGUGCGCUGGUCUGUGUGGAAGGAGGAAGGCAGGGAGAGGUAGAAGGGGUGGAGGAGUCAGGAGGAAUAGGCCGCAGCAGCCCUGGAAAUGAUCAGGAAGGCAGGCAGUGGGUGCAGGGCUGCAGGAGGGCCGGGAGGGCUAAUCUUCAACUUGUCCAUGCCAGCAGCCCCUUUUUUUCCAGACCAAGGGCUGUGAACCCGCCUGGGGAUGAGGCCUGGUCUUGUGGAACUGAACUUAGCUCGACGGGGCUGACCGCUCUGGCCCAGGGUGGUAUGUAAUUUUCGCUCGGCCUGGGACGGGGCCCAGGCCGGGCCCAGCCUGGUGGAGCGUCCAGGUCUGGGUGCGAAGCCAGGCCCCUGGGCGGAGGUGAGGGGUGGUCUGAGGAGUGAUGUGGAGUUAAGGCGCCAUCCUCACCGGUGACUGGUGCGGCACCUAGCAUGUUUGACAGGCGGGGACUGCGAGGCACGCUGCUCGGGUGUUGGGGACAACAUUGACCAACGCUUUAUUUUCCAGGUGGCAGUGCUCCUUUUGGACUUUUCUCUAGGUUUGGCGCUAAACUCUUCUUGUGAGCUCACUCCACCCCUUCUUCCUCCCUUUAACUUAUCCAUUCACUUAAAACAUUACCUGGUCAUCUGGUAAGCCCGGGACAGUAAGCCGAGUGGCUGUUGGAGUCGGUAUUGUUGGUAAUGGUGGAGGAAGAGAGGCCUUCCCGCUGAGGCUGGGGUGGGGCGGAUCGGUGUUGCUUGCCUGCAGAGAGGGUGGGGAGUGAAUGUGCACCCUUGGGUGGGCCUGCAGCCAUCCAGCUGAAAGUUACAAAAAUGCUUCAUGGACCGUGGUUUGUUACUAUAGUGUUCCUCAUGGCGAGCAGAUGGAACCGGGAGACAUGGAGUCCCUGGCCAGUGUGAGUCCUAGCAUUGCAGGAGGGGAGACCCUGGAGGAGAGAGCCCGCCUCAAUUGAUGCCUGCAGAUUGAAUUUCCAGAGGCUUAGGAGGAGGAAGUUCUCCAAUGUUCUGUUUCCAGGCCUUGCUCAGGAAGCCCUGUAUUCAGGAGGCUACCAUUUAAAGUUUGCAGAUGAGCUUAUGGGGGGCAAUCUUAAAAAGUCCACAGCAGAUGCAUCCGGCUCGAGGGGCCAUCAGCUUUGAAUAAAUGCUUGUUCCAGAGCCCAUGAAUGCCAGCAGGCACCCCUCCUUUCCUGGGGUAAAGGUUUUCAGAUGCUGCAUCUUCUAAAUUGAGCCUCCGGUCAUACUAGUUUUGUGCUUGGAACCUUGCUUCAAGAAGAUCCCUAAGCUGUAGAACAUUUUAACGUUGAUGCCACAACGCAGAUUGAUGCCUUGUAGAUGGAGCUUGCAGAUGGAGCCCCGUGACCUCUCACCUACCCACCUGUUUGCCUGCCUUCUUGUGCGUUUCUCGGAGAAGUUCUUAGCCUGAUGAAAUAACUUGGGGCGUUGAAGAGCUGUUUAAUUUUAAAUGCCUUAGACUGGGGAUAUAUUAGAGGAAGCAGAUUGUCAAAUUAAGGGUGUCAUUGUGUUGUGCUAAACGCUGGGAGGGUACAAGUUGGUCAUUCCUAAAUCUGUGUGUGAGAAAUGGCAGGUCUAGUUUGGGCAUUGUGAUUGCAUUGCAGAUUACUAGGAGAAGGGAAUGGUGGGUACACCGGUAGUGCUCUUUUGUUCUUGCUUCGUUUUUUUAAACUUGAACUUUACUUCGUUAGAUUUCAUAAUACUUUCUUGGCAUUCUAGUAAGAGGACCCUGAGGUGGGAGUUGUGGGGGACGGGGAGAAGGGGACAGCUUGGCACCGGUCCCGUGGGCGUUGCAGUGUGGGGGAUGGGGGUAUGCAGCUUGGCACUGGUACUGGGAGGGAUGAGGGUGAAGAAGGGGAGAGGGUUGGUUAGAGAUACAGUGUGGGUGGUGGGGGUGGUAGGAAAUGCAGGUUGAAGGGAAUUCUCUGGGGCUUUGGGGAAUUUAGUGCGUGGGUGAGCCAAGAAAAUACUAAUUAAUAAUAGUAAGUUGUUAGUGUUGGUUAAGUUGUUGCUUGGAAGUGAGAAGUUGCUUAGAAACUUUCCAAAGUGCUUAGAACUUUAAGUGCAAACAGACAAACUAACAAACAAAAAUUGUUUUGCUUUGCUACAAGGUGGGGAAGACUGAAGAAGUGUUAACUGAAAACAGGUGACACAGAGUCACCAGUUUUCCGAGAACCAAAGGGAGGGGUGUGUGAUGCCAUCUCACAGGCAGGGGAAAUGUCUUUACCAGCUUCCUCCUGGUGGCCAAGACAGCCUGUUUCAGAGGGUUGUUUUGUUUGGGGUGUGGGUGUUAUCAAGUGAAUUAGUCACUUGAAAGAUGGGCGUCAGACUUGCAUACGCAGCAGAUCAGCAUCCUUCGCUGCCCCUUAGCAACUUAGGUGGUUGAUUUGAAACUGUGAAGGUGUGAUUUUUUCAGGAGCUGGAAGUCUUAGAAAAGCCUUGUAAAUGCCUAUAUUGUGGGCUUUUAACGUAUUUAAGGGACCACUUAAGACGAGAUUAGAUGGGCUCUUCUGGAUUUGUUCCUCAUUUGUCACAGGUGUCUUGUGAUUGAAAAUCAUGAGCGAAGUGAAAUUGCAUUGAAUUUCAAGGGAAUUUAGUAUGUAAAUCGUGCCUUAGAAACACAUCUGUUGUCUUUUCUGUGUUUGGUCGAUAUUAAUAAUGGCAAAAUUUUUGCCUAUCUAGUAUCUUCAAAUUGUAGUCUUUGUAACAACCAAAUAACCUUUUGUGGUCACUGUAAAAUUAAUAUUUGGUAGACAGAAUCCAUGUACCUUUGCUAAGGUUAGAAUGAAUAAUUUAUUGUAUUUUUAAUUUGAAUGUUUGUGCUUUUUAAAUGAGCCAAGACUAGAGGGGAAACUAUCACCUAAAAUCAGUUUGGAAAACAAGACCUAAAAAGGGAAGGGGAUGGGGAUUGUGGGGAGAGAGUGGGCGAGGUGCCUUUACUACAUGUGUGAUCUGAAAACCCUGCUUGGUUCUGAGCUGCGUCUAUUGAAUUGGUAAAGUAAUACCAAUGGCUUUUUAUCAUUUCCUUCUUCCCUUUAAGUUUCACUUGAAAUUUUAAAAAUCAUGGUUAUUUUUAUCGUUGGGAUCUUUCUGUCUUCUGGGUUCCAUUUUUUAAAUGUUUAAAAAUAUGUUGACAUGGUAGUUCAGUUCUUAACCAAUGACUUGGGGAUGAUGCAAACAAUUACUGUCGUUGGGAUUUAGAGUGUAUUAGUCACGCAUGUAUGGGGAAGUAGUCUCGGGUAUGCUGUUGUGAAAUUGAAACUGUAAAAGUAGAUGGUUGAAAGUACUGGUAUGUUGCUCUGUAUGGUAAGAACUAAUUCUGUUACGUCAUGUACAUAAUUACUAAUCACUUUUCUUCCCCUUUACAGCACAAAUAAAGUUUGAGUUCUAAACUCAUUAGAAAAAAAAAAAAAAAAAAAAAAA;|-,lncRNA,Homo sapiens,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-190,263-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSKHNSNRQLERSG",TDP-43,△RRM2,-,"202aa(1-190,263-274)",Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,0-500ng/µl siNEAT1;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,-,Differential interference contrast microscopy,"liquid, solute","We found that the PS scaffolding RNA NEAT1 promoted TDP-43 de-mixing in a dose-dependent manner (Figure 5I), which involved both RRM1 and RRM2 (Figures 5J and 5K). Furthermore, we demonstrated that increasing concentrations of NEAT1 antagonized the suppressive environment generated by tRNA in the in vitro LLPS assay of TDP-43 (Figure 5L), which was markedly reduced by DRRM1 but enhanced by DRRM2 (Figures 5M and 5N)."
438,PMID: 32649883,RNAPS0000129,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,NCBI ID:283131;|-,https://www.ncbi.nlm.nih.gov/gene/283131;|-,NEAT1;|yeast tRNA,3756nt(1-3756);|-,GGAGUUAGCGACAGGGAGGGAUGCGCGCCUGGGUGUAGUUGUGGGGGAGGAAGUGGCUAGCUCAGGGCUUCAGGGGACAGACAGGGAGAGAUGACUGAGUUAGAUGAGACGAGGGGGCGGGCUGGGGGUGCGAGAAGGAAGCUUGGCAAGGAGACUAGGUCUAGGGGGACCACAGUGGGGCAGGCUGCAUGGAAAAUAUCCGCAGGGUCCCCCAGGCAGAACAGCCACGCUCCAGGCCAGGCUGUCCCUACUGCCUGGUGGAGGGGGAACUUGACCUCUGGGAGGGCGCCGCUCUUGCAUAGCUGAGCGAGCCCGGGUGCGCUGGUCUGUGUGGAAGGAGGAAGGCAGGGAGAGGUAGAAGGGGUGGAGGAGUCAGGAGGAAUAGGCCGCAGCAGCCCUGGAAAUGAUCAGGAAGGCAGGCAGUGGGUGCAGGGCUGCAGGAGGGCCGGGAGGGCUAAUCUUCAACUUGUCCAUGCCAGCAGCCCCUUUUUUUCCAGACCAAGGGCUGUGAACCCGCCUGGGGAUGAGGCCUGGUCUUGUGGAACUGAACUUAGCUCGACGGGGCUGACCGCUCUGGCCCAGGGUGGUAUGUAAUUUUCGCUCGGCCUGGGACGGGGCCCAGGCCGGGCCCAGCCUGGUGGAGCGUCCAGGUCUGGGUGCGAAGCCAGGCCCCUGGGCGGAGGUGAGGGGUGGUCUGAGGAGUGAUGUGGAGUUAAGGCGCCAUCCUCACCGGUGACUGGUGCGGCACCUAGCAUGUUUGACAGGCGGGGACUGCGAGGCACGCUGCUCGGGUGUUGGGGACAACAUUGACCAACGCUUUAUUUUCCAGGUGGCAGUGCUCCUUUUGGACUUUUCUCUAGGUUUGGCGCUAAACUCUUCUUGUGAGCUCACUCCACCCCUUCUUCCUCCCUUUAACUUAUCCAUUCACUUAAAACAUUACCUGGUCAUCUGGUAAGCCCGGGACAGUAAGCCGAGUGGCUGUUGGAGUCGGUAUUGUUGGUAAUGGUGGAGGAAGAGAGGCCUUCCCGCUGAGGCUGGGGUGGGGCGGAUCGGUGUUGCUUGCCUGCAGAGAGGGUGGGGAGUGAAUGUGCACCCUUGGGUGGGCCUGCAGCCAUCCAGCUGAAAGUUACAAAAAUGCUUCAUGGACCGUGGUUUGUUACUAUAGUGUUCCUCAUGGCGAGCAGAUGGAACCGGGAGACAUGGAGUCCCUGGCCAGUGUGAGUCCUAGCAUUGCAGGAGGGGAGACCCUGGAGGAGAGAGCCCGCCUCAAUUGAUGCCUGCAGAUUGAAUUUCCAGAGGCUUAGGAGGAGGAAGUUCUCCAAUGUUCUGUUUCCAGGCCUUGCUCAGGAAGCCCUGUAUUCAGGAGGCUACCAUUUAAAGUUUGCAGAUGAGCUUAUGGGGGGCAAUCUUAAAAAGUCCACAGCAGAUGCAUCCGGCUCGAGGGGCCAUCAGCUUUGAAUAAAUGCUUGUUCCAGAGCCCAUGAAUGCCAGCAGGCACCCCUCCUUUCCUGGGGUAAAGGUUUUCAGAUGCUGCAUCUUCUAAAUUGAGCCUCCGGUCAUACUAGUUUUGUGCUUGGAACCUUGCUUCAAGAAGAUCCCUAAGCUGUAGAACAUUUUAACGUUGAUGCCACAACGCAGAUUGAUGCCUUGUAGAUGGAGCUUGCAGAUGGAGCCCCGUGACCUCUCACCUACCCACCUGUUUGCCUGCCUUCUUGUGCGUUUCUCGGAGAAGUUCUUAGCCUGAUGAAAUAACUUGGGGCGUUGAAGAGCUGUUUAAUUUUAAAUGCCUUAGACUGGGGAUAUAUUAGAGGAAGCAGAUUGUCAAAUUAAGGGUGUCAUUGUGUUGUGCUAAACGCUGGGAGGGUACAAGUUGGUCAUUCCUAAAUCUGUGUGUGAGAAAUGGCAGGUCUAGUUUGGGCAUUGUGAUUGCAUUGCAGAUUACUAGGAGAAGGGAAUGGUGGGUACACCGGUAGUGCUCUUUUGUUCUUGCUUCGUUUUUUUAAACUUGAACUUUACUUCGUUAGAUUUCAUAAUACUUUCUUGGCAUUCUAGUAAGAGGACCCUGAGGUGGGAGUUGUGGGGGACGGGGAGAAGGGGACAGCUUGGCACCGGUCCCGUGGGCGUUGCAGUGUGGGGGAUGGGGGUAUGCAGCUUGGCACUGGUACUGGGAGGGAUGAGGGUGAAGAAGGGGAGAGGGUUGGUUAGAGAUACAGUGUGGGUGGUGGGGGUGGUAGGAAAUGCAGGUUGAAGGGAAUUCUCUGGGGCUUUGGGGAAUUUAGUGCGUGGGUGAGCCAAGAAAAUACUAAUUAAUAAUAGUAAGUUGUUAGUGUUGGUUAAGUUGUUGCUUGGAAGUGAGAAGUUGCUUAGAAACUUUCCAAAGUGCUUAGAACUUUAAGUGCAAACAGACAAACUAACAAACAAAAAUUGUUUUGCUUUGCUACAAGGUGGGGAAGACUGAAGAAGUGUUAACUGAAAACAGGUGACACAGAGUCACCAGUUUUCCGAGAACCAAAGGGAGGGGUGUGUGAUGCCAUCUCACAGGCAGGGGAAAUGUCUUUACCAGCUUCCUCCUGGUGGCCAAGACAGCCUGUUUCAGAGGGUUGUUUUGUUUGGGGUGUGGGUGUUAUCAAGUGAAUUAGUCACUUGAAAGAUGGGCGUCAGACUUGCAUACGCAGCAGAUCAGCAUCCUUCGCUGCCCCUUAGCAACUUAGGUGGUUGAUUUGAAACUGUGAAGGUGUGAUUUUUUCAGGAGCUGGAAGUCUUAGAAAAGCCUUGUAAAUGCCUAUAUUGUGGGCUUUUAACGUAUUUAAGGGACCACUUAAGACGAGAUUAGAUGGGCUCUUCUGGAUUUGUUCCUCAUUUGUCACAGGUGUCUUGUGAUUGAAAAUCAUGAGCGAAGUGAAAUUGCAUUGAAUUUCAAGGGAAUUUAGUAUGUAAAUCGUGCCUUAGAAACACAUCUGUUGUCUUUUCUGUGUUUGGUCGAUAUUAAUAAUGGCAAAAUUUUUGCCUAUCUAGUAUCUUCAAAUUGUAGUCUUUGUAACAACCAAAUAACCUUUUGUGGUCACUGUAAAAUUAAUAUUUGGUAGACAGAAUCCAUGUACCUUUGCUAAGGUUAGAAUGAAUAAUUUAUUGUAUUUUUAAUUUGAAUGUUUGUGCUUUUUAAAUGAGCCAAGACUAGAGGGGAAACUAUCACCUAAAAUCAGUUUGGAAAACAAGACCUAAAAAGGGAAGGGGAUGGGGAUUGUGGGGAGAGAGUGGGCGAGGUGCCUUUACUACAUGUGUGAUCUGAAAACCCUGCUUGGUUCUGAGCUGCGUCUAUUGAAUUGGUAAAGUAAUACCAAUGGCUUUUUAUCAUUUCCUUCUUCCCUUUAAGUUUCACUUGAAAUUUUAAAAAUCAUGGUUAUUUUUAUCGUUGGGAUCUUUCUGUCUUCUGGGUUCCAUUUUUUAAAUGUUUAAAAAUAUGUUGACAUGGUAGUUCAGUUCUUAACCAAUGACUUGGGGAUGAUGCAAACAAUUACUGUCGUUGGGAUUUAGAGUGUAUUAGUCACGCAUGUAUGGGGAAGUAGUCUCGGGUAUGCUGUUGUGAAAUUGAAACUGUAAAAGUAGAUGGUUGAAAGUACUGGUAUGUUGCUCUGUAUGGUAAGAACUAAUUCUGUUACGUCAUGUACAUAAUUACUAAUCACUUUUCUUCCCCUUUACAGCACAAAUAAAGUUUGAGUUCUAAACUCAUUAGAAAAAAAAAAAAAAAAAAAAAAA;|-,lncRNA;|tRNA,Homo sapiens;|yeast,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSG",TDP-43,-,-,274aa(1-274),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,1.25µg/µl tRNA;|0-400ng/µl siNEAT1;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:5%PEG8000,Differential interference contrast microscopy,"liquid, solute","We found that the PS scaffolding RNA NEAT1 promoted TDP-43 de-mixing in a dose-dependent manner (Figure 5I), which involved both RRM1 and RRM2 (Figures 5J and 5K). Furthermore, we demonstrated that increasing concentrations of NEAT1 antagonized the suppressive environment generated by tRNA in the in vitro LLPS assay of TDP-43 (Figure 5L), which was markedly reduced by DRRM1 but enhanced by DRRM2 (Figures 5M and 5N)."
439,PMID: 32649883,RNAPS0000129,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,NCBI ID:283131;|-,https://www.ncbi.nlm.nih.gov/gene/283131;|-,NEAT1;|yeast tRNA,3756nt(1-3756);|-,GGAGUUAGCGACAGGGAGGGAUGCGCGCCUGGGUGUAGUUGUGGGGGAGGAAGUGGCUAGCUCAGGGCUUCAGGGGACAGACAGGGAGAGAUGACUGAGUUAGAUGAGACGAGGGGGCGGGCUGGGGGUGCGAGAAGGAAGCUUGGCAAGGAGACUAGGUCUAGGGGGACCACAGUGGGGCAGGCUGCAUGGAAAAUAUCCGCAGGGUCCCCCAGGCAGAACAGCCACGCUCCAGGCCAGGCUGUCCCUACUGCCUGGUGGAGGGGGAACUUGACCUCUGGGAGGGCGCCGCUCUUGCAUAGCUGAGCGAGCCCGGGUGCGCUGGUCUGUGUGGAAGGAGGAAGGCAGGGAGAGGUAGAAGGGGUGGAGGAGUCAGGAGGAAUAGGCCGCAGCAGCCCUGGAAAUGAUCAGGAAGGCAGGCAGUGGGUGCAGGGCUGCAGGAGGGCCGGGAGGGCUAAUCUUCAACUUGUCCAUGCCAGCAGCCCCUUUUUUUCCAGACCAAGGGCUGUGAACCCGCCUGGGGAUGAGGCCUGGUCUUGUGGAACUGAACUUAGCUCGACGGGGCUGACCGCUCUGGCCCAGGGUGGUAUGUAAUUUUCGCUCGGCCUGGGACGGGGCCCAGGCCGGGCCCAGCCUGGUGGAGCGUCCAGGUCUGGGUGCGAAGCCAGGCCCCUGGGCGGAGGUGAGGGGUGGUCUGAGGAGUGAUGUGGAGUUAAGGCGCCAUCCUCACCGGUGACUGGUGCGGCACCUAGCAUGUUUGACAGGCGGGGACUGCGAGGCACGCUGCUCGGGUGUUGGGGACAACAUUGACCAACGCUUUAUUUUCCAGGUGGCAGUGCUCCUUUUGGACUUUUCUCUAGGUUUGGCGCUAAACUCUUCUUGUGAGCUCACUCCACCCCUUCUUCCUCCCUUUAACUUAUCCAUUCACUUAAAACAUUACCUGGUCAUCUGGUAAGCCCGGGACAGUAAGCCGAGUGGCUGUUGGAGUCGGUAUUGUUGGUAAUGGUGGAGGAAGAGAGGCCUUCCCGCUGAGGCUGGGGUGGGGCGGAUCGGUGUUGCUUGCCUGCAGAGAGGGUGGGGAGUGAAUGUGCACCCUUGGGUGGGCCUGCAGCCAUCCAGCUGAAAGUUACAAAAAUGCUUCAUGGACCGUGGUUUGUUACUAUAGUGUUCCUCAUGGCGAGCAGAUGGAACCGGGAGACAUGGAGUCCCUGGCCAGUGUGAGUCCUAGCAUUGCAGGAGGGGAGACCCUGGAGGAGAGAGCCCGCCUCAAUUGAUGCCUGCAGAUUGAAUUUCCAGAGGCUUAGGAGGAGGAAGUUCUCCAAUGUUCUGUUUCCAGGCCUUGCUCAGGAAGCCCUGUAUUCAGGAGGCUACCAUUUAAAGUUUGCAGAUGAGCUUAUGGGGGGCAAUCUUAAAAAGUCCACAGCAGAUGCAUCCGGCUCGAGGGGCCAUCAGCUUUGAAUAAAUGCUUGUUCCAGAGCCCAUGAAUGCCAGCAGGCACCCCUCCUUUCCUGGGGUAAAGGUUUUCAGAUGCUGCAUCUUCUAAAUUGAGCCUCCGGUCAUACUAGUUUUGUGCUUGGAACCUUGCUUCAAGAAGAUCCCUAAGCUGUAGAACAUUUUAACGUUGAUGCCACAACGCAGAUUGAUGCCUUGUAGAUGGAGCUUGCAGAUGGAGCCCCGUGACCUCUCACCUACCCACCUGUUUGCCUGCCUUCUUGUGCGUUUCUCGGAGAAGUUCUUAGCCUGAUGAAAUAACUUGGGGCGUUGAAGAGCUGUUUAAUUUUAAAUGCCUUAGACUGGGGAUAUAUUAGAGGAAGCAGAUUGUCAAAUUAAGGGUGUCAUUGUGUUGUGCUAAACGCUGGGAGGGUACAAGUUGGUCAUUCCUAAAUCUGUGUGUGAGAAAUGGCAGGUCUAGUUUGGGCAUUGUGAUUGCAUUGCAGAUUACUAGGAGAAGGGAAUGGUGGGUACACCGGUAGUGCUCUUUUGUUCUUGCUUCGUUUUUUUAAACUUGAACUUUACUUCGUUAGAUUUCAUAAUACUUUCUUGGCAUUCUAGUAAGAGGACCCUGAGGUGGGAGUUGUGGGGGACGGGGAGAAGGGGACAGCUUGGCACCGGUCCCGUGGGCGUUGCAGUGUGGGGGAUGGGGGUAUGCAGCUUGGCACUGGUACUGGGAGGGAUGAGGGUGAAGAAGGGGAGAGGGUUGGUUAGAGAUACAGUGUGGGUGGUGGGGGUGGUAGGAAAUGCAGGUUGAAGGGAAUUCUCUGGGGCUUUGGGGAAUUUAGUGCGUGGGUGAGCCAAGAAAAUACUAAUUAAUAAUAGUAAGUUGUUAGUGUUGGUUAAGUUGUUGCUUGGAAGUGAGAAGUUGCUUAGAAACUUUCCAAAGUGCUUAGAACUUUAAGUGCAAACAGACAAACUAACAAACAAAAAUUGUUUUGCUUUGCUACAAGGUGGGGAAGACUGAAGAAGUGUUAACUGAAAACAGGUGACACAGAGUCACCAGUUUUCCGAGAACCAAAGGGAGGGGUGUGUGAUGCCAUCUCACAGGCAGGGGAAAUGUCUUUACCAGCUUCCUCCUGGUGGCCAAGACAGCCUGUUUCAGAGGGUUGUUUUGUUUGGGGUGUGGGUGUUAUCAAGUGAAUUAGUCACUUGAAAGAUGGGCGUCAGACUUGCAUACGCAGCAGAUCAGCAUCCUUCGCUGCCCCUUAGCAACUUAGGUGGUUGAUUUGAAACUGUGAAGGUGUGAUUUUUUCAGGAGCUGGAAGUCUUAGAAAAGCCUUGUAAAUGCCUAUAUUGUGGGCUUUUAACGUAUUUAAGGGACCACUUAAGACGAGAUUAGAUGGGCUCUUCUGGAUUUGUUCCUCAUUUGUCACAGGUGUCUUGUGAUUGAAAAUCAUGAGCGAAGUGAAAUUGCAUUGAAUUUCAAGGGAAUUUAGUAUGUAAAUCGUGCCUUAGAAACACAUCUGUUGUCUUUUCUGUGUUUGGUCGAUAUUAAUAAUGGCAAAAUUUUUGCCUAUCUAGUAUCUUCAAAUUGUAGUCUUUGUAACAACCAAAUAACCUUUUGUGGUCACUGUAAAAUUAAUAUUUGGUAGACAGAAUCCAUGUACCUUUGCUAAGGUUAGAAUGAAUAAUUUAUUGUAUUUUUAAUUUGAAUGUUUGUGCUUUUUAAAUGAGCCAAGACUAGAGGGGAAACUAUCACCUAAAAUCAGUUUGGAAAACAAGACCUAAAAAGGGAAGGGGAUGGGGAUUGUGGGGAGAGAGUGGGCGAGGUGCCUUUACUACAUGUGUGAUCUGAAAACCCUGCUUGGUUCUGAGCUGCGUCUAUUGAAUUGGUAAAGUAAUACCAAUGGCUUUUUAUCAUUUCCUUCUUCCCUUUAAGUUUCACUUGAAAUUUUAAAAAUCAUGGUUAUUUUUAUCGUUGGGAUCUUUCUGUCUUCUGGGUUCCAUUUUUUAAAUGUUUAAAAAUAUGUUGACAUGGUAGUUCAGUUCUUAACCAAUGACUUGGGGAUGAUGCAAACAAUUACUGUCGUUGGGAUUUAGAGUGUAUUAGUCACGCAUGUAUGGGGAAGUAGUCUCGGGUAUGCUGUUGUGAAAUUGAAACUGUAAAAGUAGAUGGUUGAAAGUACUGGUAUGUUGCUCUGUAUGGUAAGAACUAAUUCUGUUACGUCAUGUACAUAAUUACUAAUCACUUUUCUUCCCCUUUACAGCACAAAUAAAGUUUGAGUUCUAAACUCAUUAGAAAAAAAAAAAAAAAAAAAAAAA;|-,lncRNA;|tRNA,Homo sapiens;|yeast,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-103,201-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTDMTEDELREFFSQ
YGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSG",TDP-43,△RRM1,-,"317aa(1-103,201-274)",Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,1.25µg/µl tRNA;|0-400ng/µl siNEAT1;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:5%PEG8000,Differential interference contrast microscopy,"liquid, solute","We found that the PS scaffolding RNA NEAT1 promoted TDP-43 de-mixing in a dose-dependent manner (Figure 5I), which involved both RRM1 and RRM2 (Figures 5J and 5K). Furthermore, we demonstrated that increasing concentrations of NEAT1 antagonized the suppressive environment generated by tRNA in the in vitro LLPS assay of TDP-43 (Figure 5L), which was markedly reduced by DRRM1 but enhanced by DRRM2 (Figures 5M and 5N)."
440,PMID: 32649883,RNAPS0000129,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,NCBI ID:283131;|-,https://www.ncbi.nlm.nih.gov/gene/283131;|-,NEAT1;|yeast tRNA,3756nt(1-3756);|-,GGAGUUAGCGACAGGGAGGGAUGCGCGCCUGGGUGUAGUUGUGGGGGAGGAAGUGGCUAGCUCAGGGCUUCAGGGGACAGACAGGGAGAGAUGACUGAGUUAGAUGAGACGAGGGGGCGGGCUGGGGGUGCGAGAAGGAAGCUUGGCAAGGAGACUAGGUCUAGGGGGACCACAGUGGGGCAGGCUGCAUGGAAAAUAUCCGCAGGGUCCCCCAGGCAGAACAGCCACGCUCCAGGCCAGGCUGUCCCUACUGCCUGGUGGAGGGGGAACUUGACCUCUGGGAGGGCGCCGCUCUUGCAUAGCUGAGCGAGCCCGGGUGCGCUGGUCUGUGUGGAAGGAGGAAGGCAGGGAGAGGUAGAAGGGGUGGAGGAGUCAGGAGGAAUAGGCCGCAGCAGCCCUGGAAAUGAUCAGGAAGGCAGGCAGUGGGUGCAGGGCUGCAGGAGGGCCGGGAGGGCUAAUCUUCAACUUGUCCAUGCCAGCAGCCCCUUUUUUUCCAGACCAAGGGCUGUGAACCCGCCUGGGGAUGAGGCCUGGUCUUGUGGAACUGAACUUAGCUCGACGGGGCUGACCGCUCUGGCCCAGGGUGGUAUGUAAUUUUCGCUCGGCCUGGGACGGGGCCCAGGCCGGGCCCAGCCUGGUGGAGCGUCCAGGUCUGGGUGCGAAGCCAGGCCCCUGGGCGGAGGUGAGGGGUGGUCUGAGGAGUGAUGUGGAGUUAAGGCGCCAUCCUCACCGGUGACUGGUGCGGCACCUAGCAUGUUUGACAGGCGGGGACUGCGAGGCACGCUGCUCGGGUGUUGGGGACAACAUUGACCAACGCUUUAUUUUCCAGGUGGCAGUGCUCCUUUUGGACUUUUCUCUAGGUUUGGCGCUAAACUCUUCUUGUGAGCUCACUCCACCCCUUCUUCCUCCCUUUAACUUAUCCAUUCACUUAAAACAUUACCUGGUCAUCUGGUAAGCCCGGGACAGUAAGCCGAGUGGCUGUUGGAGUCGGUAUUGUUGGUAAUGGUGGAGGAAGAGAGGCCUUCCCGCUGAGGCUGGGGUGGGGCGGAUCGGUGUUGCUUGCCUGCAGAGAGGGUGGGGAGUGAAUGUGCACCCUUGGGUGGGCCUGCAGCCAUCCAGCUGAAAGUUACAAAAAUGCUUCAUGGACCGUGGUUUGUUACUAUAGUGUUCCUCAUGGCGAGCAGAUGGAACCGGGAGACAUGGAGUCCCUGGCCAGUGUGAGUCCUAGCAUUGCAGGAGGGGAGACCCUGGAGGAGAGAGCCCGCCUCAAUUGAUGCCUGCAGAUUGAAUUUCCAGAGGCUUAGGAGGAGGAAGUUCUCCAAUGUUCUGUUUCCAGGCCUUGCUCAGGAAGCCCUGUAUUCAGGAGGCUACCAUUUAAAGUUUGCAGAUGAGCUUAUGGGGGGCAAUCUUAAAAAGUCCACAGCAGAUGCAUCCGGCUCGAGGGGCCAUCAGCUUUGAAUAAAUGCUUGUUCCAGAGCCCAUGAAUGCCAGCAGGCACCCCUCCUUUCCUGGGGUAAAGGUUUUCAGAUGCUGCAUCUUCUAAAUUGAGCCUCCGGUCAUACUAGUUUUGUGCUUGGAACCUUGCUUCAAGAAGAUCCCUAAGCUGUAGAACAUUUUAACGUUGAUGCCACAACGCAGAUUGAUGCCUUGUAGAUGGAGCUUGCAGAUGGAGCCCCGUGACCUCUCACCUACCCACCUGUUUGCCUGCCUUCUUGUGCGUUUCUCGGAGAAGUUCUUAGCCUGAUGAAAUAACUUGGGGCGUUGAAGAGCUGUUUAAUUUUAAAUGCCUUAGACUGGGGAUAUAUUAGAGGAAGCAGAUUGUCAAAUUAAGGGUGUCAUUGUGUUGUGCUAAACGCUGGGAGGGUACAAGUUGGUCAUUCCUAAAUCUGUGUGUGAGAAAUGGCAGGUCUAGUUUGGGCAUUGUGAUUGCAUUGCAGAUUACUAGGAGAAGGGAAUGGUGGGUACACCGGUAGUGCUCUUUUGUUCUUGCUUCGUUUUUUUAAACUUGAACUUUACUUCGUUAGAUUUCAUAAUACUUUCUUGGCAUUCUAGUAAGAGGACCCUGAGGUGGGAGUUGUGGGGGACGGGGAGAAGGGGACAGCUUGGCACCGGUCCCGUGGGCGUUGCAGUGUGGGGGAUGGGGGUAUGCAGCUUGGCACUGGUACUGGGAGGGAUGAGGGUGAAGAAGGGGAGAGGGUUGGUUAGAGAUACAGUGUGGGUGGUGGGGGUGGUAGGAAAUGCAGGUUGAAGGGAAUUCUCUGGGGCUUUGGGGAAUUUAGUGCGUGGGUGAGCCAAGAAAAUACUAAUUAAUAAUAGUAAGUUGUUAGUGUUGGUUAAGUUGUUGCUUGGAAGUGAGAAGUUGCUUAGAAACUUUCCAAAGUGCUUAGAACUUUAAGUGCAAACAGACAAACUAACAAACAAAAAUUGUUUUGCUUUGCUACAAGGUGGGGAAGACUGAAGAAGUGUUAACUGAAAACAGGUGACACAGAGUCACCAGUUUUCCGAGAACCAAAGGGAGGGGUGUGUGAUGCCAUCUCACAGGCAGGGGAAAUGUCUUUACCAGCUUCCUCCUGGUGGCCAAGACAGCCUGUUUCAGAGGGUUGUUUUGUUUGGGGUGUGGGUGUUAUCAAGUGAAUUAGUCACUUGAAAGAUGGGCGUCAGACUUGCAUACGCAGCAGAUCAGCAUCCUUCGCUGCCCCUUAGCAACUUAGGUGGUUGAUUUGAAACUGUGAAGGUGUGAUUUUUUCAGGAGCUGGAAGUCUUAGAAAAGCCUUGUAAAUGCCUAUAUUGUGGGCUUUUAACGUAUUUAAGGGACCACUUAAGACGAGAUUAGAUGGGCUCUUCUGGAUUUGUUCCUCAUUUGUCACAGGUGUCUUGUGAUUGAAAAUCAUGAGCGAAGUGAAAUUGCAUUGAAUUUCAAGGGAAUUUAGUAUGUAAAUCGUGCCUUAGAAACACAUCUGUUGUCUUUUCUGUGUUUGGUCGAUAUUAAUAAUGGCAAAAUUUUUGCCUAUCUAGUAUCUUCAAAUUGUAGUCUUUGUAACAACCAAAUAACCUUUUGUGGUCACUGUAAAAUUAAUAUUUGGUAGACAGAAUCCAUGUACCUUUGCUAAGGUUAGAAUGAAUAAUUUAUUGUAUUUUUAAUUUGAAUGUUUGUGCUUUUUAAAUGAGCCAAGACUAGAGGGGAAACUAUCACCUAAAAUCAGUUUGGAAAACAAGACCUAAAAAGGGAAGGGGAUGGGGAUUGUGGGGAGAGAGUGGGCGAGGUGCCUUUACUACAUGUGUGAUCUGAAAACCCUGCUUGGUUCUGAGCUGCGUCUAUUGAAUUGGUAAAGUAAUACCAAUGGCUUUUUAUCAUUUCCUUCUUCCCUUUAAGUUUCACUUGAAAUUUUAAAAAUCAUGGUUAUUUUUAUCGUUGGGAUCUUUCUGUCUUCUGGGUUCCAUUUUUUAAAUGUUUAAAAAUAUGUUGACAUGGUAGUUCAGUUCUUAACCAAUGACUUGGGGAUGAUGCAAACAAUUACUGUCGUUGGGAUUUAGAGUGUAUUAGUCACGCAUGUAUGGGGAAGUAGUCUCGGGUAUGCUGUUGUGAAAUUGAAACUGUAAAAGUAGAUGGUUGAAAGUACUGGUAUGUUGCUCUGUAUGGUAAGAACUAAUUCUGUUACGUCAUGUACAUAAUUACUAAUCACUUUUCUUCCCCUUUACAGCACAAAUAAAGUUUGAGUUCUAAACUCAUUAGAAAAAAAAAAAAAAAAAAAAAAA;|-,lncRNA;|tRNA,Homo sapiens;|yeast,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-190,263-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSKHNSNRQLERSG",TDP-43,△RRM2,-,"202aa(1-190,263-274)",Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,1.25µg/µl tRNA;|0-400ng/µl siNEAT1;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:5%PEG8000,Differential interference contrast microscopy,liquid,"We found that the PS scaffolding RNA NEAT1 promoted TDP-43 de-mixing in a dose-dependent manner (Figure 5I), which involved both RRM1 and RRM2 (Figures 5J and 5K). Furthermore, we demonstrated that increasing concentrations of NEAT1 antagonized the suppressive environment generated by tRNA in the in vitro LLPS assay of TDP-43 (Figure 5L), which was markedly reduced by DRRM1 but enhanced by DRRM2 (Figures 5M and 5N)."
441,PMID: 32649883,RNAPS0000156,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-274
MSEYIRVTED ENDEPIEIPS EDDGTVLLST VTAQFPGACG LRYRNPVSQC MRGVRLVEGI LHAPDAGWGN LVYVVNYPKD NKRKMDETDA SSAVKVKRAV QKTSDLIVLG LPWKTTEQDL KEYFSTFGEV LMVQVKKDLK TGHSKGFGFV RFTEYETQVK VMSQRHMIDG RWCDCKLPNS KQSQDEPLRS RKVFVGRCTE DMTEDELREF FSQYGDVMDV FIPKPFRAFA FVTFADDQIA QSLCGEDLII KGISVHISNA EPKHNSNRQL ERSG",TDP-43,-,protein_mutation:D169G,274aa(1-274),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,0-500ng/µl total RNA;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:10%PEG8000,Differential interference contrast microscopy,"solute, liquid","Suppression of TDP-43 LLPS by total RNAs showed no marked difference between D169G and WT TDP-431-274 (Figures 7C and 7D). In contrast, the induction of TDP-43 LLPS by NEAT1 RNA was drastically reduced by D169G (Figures 7E and 7F)."
442,PMID: 32649883,RNAPS0000156,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-274
MSEYIRVTED ENDEPIEIPS EDDGTVLLST VTAQFPGACG LRYRNPVSQC MRGVRLVEGI LHAPDAGWGN LVYVVNYPKD NKRKMDETDA SSAVKVKRAV QKTSDLIVLG LPWKTTEQDL KEYFSTFGEV LMVQVKKDLK TGHSKGFGFV RFTEYETQVK VMSQRHMIDG RWCDCKLPNS KQSQDEPLRS RKVFVGRCTE DMTEDELREF FSQYGDVMDV FIPKPFRAFA FVTFADDQIA QSLCGEDLII KGISVHISNA EPKHNSNRQL ERSG",TDP-43,-,-,274aa(1-274),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,0-500ng/µl total RNA;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:10%PEG8000,Differential interference contrast microscopy,"liquid, solute","In vitro LLPS assay of WT, DRRM1, and DRRM2 TDP-431-273 with total RNA extracts added as indicated. A higher concentration of DRRM1 with large LDs as WT TDP-43 is also tested. The concentrations of NaCl, the crowding agent PEG, TDP-43 proteins, and RNAs used in the in vitro assays are indicated."
443,PMID: 32649883,RNAPS0000156,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-103,201-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTDMTEDELREFFSQ
YGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSG",TDP-43,△RRM1,-,"317aa(1-103,201-274)",Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,0-500ng/µl total RNA;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:10%PEG8000,Differential interference contrast microscopy,liquid,"In vitro LLPS assay of WT, DRRM1, and DRRM2 TDP-431-273 with total RNA extracts added as indicated. A higher concentration of DRRM1 with large LDs as WT TDP-43 is also tested. The concentrations of NaCl, the crowding agent PEG, TDP-43 proteins, and RNAs used in the in vitro assays are indicated."
444,PMID: 32649883,RNAPS0000156,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-103,201-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTDMTEDELREFFSQ
YGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSG",TDP-43,△RRM1,-,"317aa(1-103,201-274)",Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,0-500ng/µl total RNA;|100 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:10%PEG8000,Differential interference contrast microscopy,liquid,"In vitro LLPS assay of WT, DRRM1, and DRRM2 TDP-431-273 with total RNA extracts added as indicated. A higher concentration of DRRM1 with large LDs as WT TDP-43 is also tested. The concentrations of NaCl, the crowding agent PEG, TDP-43 proteins, and RNAs used in the in vitro assays are indicated."
445,PMID: 32649883,RNAPS0000156,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-190,263-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSKHNSNRQLERSG",TDP-43,△RRM2,-,"202aa(1-190,263-274)",Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,0-500ng/µl total RNA;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:10%PEG8000,Differential interference contrast microscopy,liquid,"In vitro LLPS assay of WT, DRRM1, and DRRM2 TDP-431-273 with total RNA extracts added as indicated. A higher concentration of DRRM1 with large LDs as WT TDP-43 is also tested. The concentrations of NaCl, the crowding agent PEG, TDP-43 proteins, and RNAs used in the in vitro assays are indicated."
446,PMID: 32649883,RNAPS0000411,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,-,-,yeast tRNA,-,-,tRNA,yeast,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA
QSLCGEDLIIKGISVHISNAEPKHNSNRQLERSG",TDP-43,-,-,274aa(1-274),Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,0-5µg/µl tRNA;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:5%PEG8000,Microscopy,"liquid, solute","WT and DRRM1 TDP-431-274 showed  similar sensitivity to tRNA (R1.25 mg/ml) (Figures 5E and 5F),  whereas DRRM2 required a higher concentration of tRNA  (R2.5 mg/ml) (Figure 5G)."
447,PMID: 32649883,RNAPS0000411,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,-,-,yeast tRNA,-,-,tRNA,yeast,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-103,201-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTDMTEDELREFFSQ
YGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSG",TDP-43,△RRM1,-,"317aa(1-103,201-274)",Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,0-5µg/µl tRNA;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:5%PEG8000,Microscopy,"liquid, solute","WT and DRRM1 TDP-431-274 showed  similar sensitivity to tRNA (R1.25 mg/ml) (Figures 5E and 5F),  whereas DRRM2 required a higher concentration of tRNA  (R2.5 mg/ml) (Figure 6G)."
448,PMID: 32649883,RNAPS0000411,https://pubmed.ncbi.nlm.nih.gov/32649883,RNAs + protein,-,-,yeast tRNA,-,-,tRNA,yeast,"sp|Q13148|TADBP_HUMAN TAR DNA-binding protein 43 OS=Homo sapiens OX=9606 GN=TARDBP PE=1 SV=1|residues=1-190,263-274
MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGI
LHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDL
KEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNS
KQSQDEPLRSKHNSNRQLERSG",TDP-43,△RRM2,-,"202aa(1-190,263-274)",Q13148,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q13148,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2689,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0023,http://db.phasep.pro/browse/",[266-274],[272-274],In vitro,0-5µg/µl tRNA;|50 µM TDP-43,100 mM NaCl,"50 mM Tris-HCl, pH 7.5",RT,1 min,crowding agent:5%PEG8000,Microscopy,"liquid, solute","WT and DRRM1 TDP-431-274 showed  similar sensitivity to tRNA (R1.25 mg/ml) (Figures 5E and 5F),  whereas DRRM2 required a higher concentration of tRNA  (R2.5 mg/ml) (Figure 7G)."
449,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,2µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Turbidity measurement,Differential interference contrast microscopy,Electron microscopy",liquid,"With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation."
450,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=1-364
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFP",SARS-CoV-2 Nucleoprotein,-,-,364aa(1-364),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256]","[175-208],[211-230],[236-249],[361-364]",In vitro,2µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Turbidity measurement,Differential interference contrast microscopy,Electron microscopy",liquid,"With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation."
451,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=49-419
TASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,370aa(49-419),P0DTC9,-,-,"[49-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,2µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Turbidity measurement,Differential interference contrast microscopy,Electron microscopy",liquid,"With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation."
452,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=49-364
TASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKK",SARS-CoV-2 Nucleoprotein,-,-,316aa(49-364),P0DTC9,-,-,"[49-49],[174-174],[181-212],[233-247],[249-256]","[175-208],[211-230],[236-249],[361-364]",In vitro,2µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Turbidity measurement,Differential interference contrast microscopy,Electron microscopy",liquid,"With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation."
453,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=1-246
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTV
",SARS-CoV-2 Nucleoprotein,-,-,246aa(1-246),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-246]","[175-208],[211-230],[236-246]",In vitro,2µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Turbidity measurement,Differential interference contrast microscopy,Electron microscopy",liquid,"With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation."
454,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=247-419
TKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,173aa(247-419),P0DTC9,-,-,"[247-247],[249-256],[365-391]","[247-249],[361-379]",In vitro,2µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Turbidity measurement,Differential interference contrast microscopy,Electron microscopy",solute,"With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation."
455,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=49-264
TASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTV",SARS-CoV-2 Nucleoprotein,-,-,198aa(49-246),P0DTC9,-,-,"[49-49],[174-174],[181-212],[233-246]","[175-208],[211-230],[236-246]",In vitro,2µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Turbidity measurement,Differential interference contrast microscopy,Electron microscopy",liquid,"With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation."
456,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=49-209
TASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPAR",SARS-CoV-2 Nucleoprotein,-,-,161aa(49-209),P0DTC9,-,-,"[49-49],[174-174],[181-209]",[175-208],In vitro,2µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Turbidity measurement,Differential interference contrast microscopy,Electron microscopy",solute,"With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation."
457,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=1-174
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAE
",SARS-CoV-2 Nucleoprotein,-,-,174aa(1-174),P0DTC9,-,-,"[1-40],[44-49],[174-174]",-,In vitro,2µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Turbidity measurement,Differential interference contrast microscopy,Electron microscopy",solute,"With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation."
458,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=49-174
TASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAE
",SARS-CoV-2 Nucleoprotein,-,-,126aa(49-174),P0DTC9,-,-,"[49-49],[174-174]",-,In vitro,2µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Turbidity measurement,Differential interference contrast microscopy,Electron microscopy",solute,"With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation."
459,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]",-,In vitro,0-5µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Differential interference contrast microscopy,FRAP","solute, liquid","With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation."
460,PMID: 32870271,RNAPS0000414,https://pubmed.ncbi.nlm.nih.gov/32870271,RNA + protein,-,-,"rA2RE11 cis-acting element RNA (H. Ryan,2020)",11nt,GCCAAGGAGCC,irregular RNA,Homo sapiens,"sp|P22626|ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens OX=9606 GN=HNRNPA2B1 PE=1 SV=2
MEKTLETVPLERKKREKEQFRKLFIGGLSFETTEESLRNYYEQWGKLTDCVVMRDPASKR
SRGFGFVTFSSMAEVDAAMAARPHSIDGRVVEPKRAVAREESGKPGAHVTVKKLFVGGIK
EDTEEHHLRDYFEEYGKIDTIEIITDRQSGKKRGFGFVTFDDHDPVDKIVLQKYHTINGH
NAEVRKALSRQEMQEVQSSRSGRGGNFGFGDSRGGGGNFGPGPGSNFRGGSDGYGSGRGF
GDGYNGYGGGPGGGNFGGSPGYGGGRGGYGGGGPGYGNQGGGYGGGYDNYGGGNYGSGNY
NDFGNYNQQPSNYGPMKSGNFGGSRNMGGPYGGGNYGPGGSGGSGGYGGRSRY",HNRNPA2B1,C,-,-,P22626,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2608,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0117,http://db.phasep.pro/browse/","[190-341],[342-353]","[11-22],[198-307],[322-352]",In vitro,15 µM [A2RE];|15 µM [HNRNPA2B1],50mM NaCl or 150mM NaCl,20 mM Tris pH 7.5,RT,≤ 120 min,-,Differential interference contrast microscopy,solute,"rA2RE11 and rA2RE21 prevent phase separation and aggregation of full-length hnRNPA2 WT and mutants.After cleavage of a C-terminal maltose binding protein solubility tag by TEV protease, hnRNPA2 FL D290V (B) and P298L (C) undergo LLPS followed by aggregation. In the presence of either rA2RE11 or rA2RE21, neither phase separation nor aggregation occur."
461,PMID: 32870271,RNAPS0000414,https://pubmed.ncbi.nlm.nih.gov/32870271,RNA + protein,-,-,"rA2RE11 cis-acting element RNA (H. Ryan,2020)",11nt,GCCAAGGAGCC,irregular RNA,Homo sapiens,"sp|P22626|ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens OX=9606 GN=HNRNPA2B1 PE=1 SV=2
MEKTLETVPLERKKREKEQFRKLFIGGLSFETTEESLRNYYEQWGKLTDCVVMRDPASKR
SRGFGFVTFSSMAEVDAAMAARPHSIDGRVVEPKRAVAREESGKPGAHVTVKKLFVGGIK
EDTEEHHLRDYFEEYGKIDTIEIITDRQSGKKRGFGFVTFDDHDPVDKIVLQKYHTINGH
NAEVRKALSRQEMQEVQSSRSGRGGNFGFGDSRGGGGNFGPGPGSNFRGGSDGYGSGRGF
GDGYNGYGGGPGGGNFGGSPGYGGGRGGYGGGGPGYGNQGGGYGGGYDNYGGGNYGSGNY
NDFGNYNQQPSNYGPMKSGNFGGSRNMGGPYGGGNYGPGGSGGSGGYGGRSRY",HNRNPA2B1,C,protein_mutation:D290V,-,P22626,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2608,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0117,http://db.phasep.pro/browse/","[190-341],[342-353]","[11-22],[198-307],[322-352]",In vitro,15 µM [A2RE];|15 µM [HNRNPA2B1],50mM NaCl or 150mM NaCl,20 mM Tris pH 7.5,RT,≤ 120 min,-,Differential interference contrast microscopy,solute,"rA2RE11 and rA2RE21 prevent phase separation and aggregation of full-length hnRNPA2 WT and mutants.After cleavage of a C-terminal maltose binding protein solubility tag by TEV protease, hnRNPA2 FL D290V (B) and P298L (C) undergo LLPS followed by aggregation. In the presence of either rA2RE11 or rA2RE21, neither phase separation nor aggregation occur."
462,PMID: 32870271,RNAPS0000414,https://pubmed.ncbi.nlm.nih.gov/32870271,RNA + protein,-,-,"rA2RE11 cis-acting element RNA (H. Ryan,2020)",11nt,GCCAAGGAGCC,irregular RNA,Homo sapiens,"sp|P22626|ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens OX=9606 GN=HNRNPA2B1 PE=1 SV=2
MEKTLETVPLERKKREKEQFRKLFIGGLSFETTEESLRNYYEQWGKLTDCVVMRDPASKR
SRGFGFVTFSSMAEVDAAMAARPHSIDGRVVEPKRAVAREESGKPGAHVTVKKLFVGGIK
EDTEEHHLRDYFEEYGKIDTIEIITDRQSGKKRGFGFVTFDDHDPVDKIVLQKYHTINGH
NAEVRKALSRQEMQEVQSSRSGRGGNFGFGDSRGGGGNFGPGPGSNFRGGSDGYGSGRGF
GDGYNGYGGGPGGGNFGGSPGYGGGRGGYGGGGPGYGNQGGGYGGGYDNYGGGNYGSGNY
NDFGNYNQQPSNYGPMKSGNFGGSRNMGGPYGGGNYGPGGSGGSGGYGGRSRY",HNRNPA2B1,C,protein_mutation:D298L,-,P22626,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2608,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0117,http://db.phasep.pro/browse/","[190-341],[342-353]","[11-22],[198-307],[322-352]",In vitro,15 µM [A2RE];|15 µM [HNRNPA2B1],50mM NaCl or 150mM NaCl,20 mM Tris pH 7.5,RT,≤ 120 min,-,Differential interference contrast microscopy,solute,"rA2RE11 and rA2RE21 prevent phase separation and aggregation of full-length hnRNPA2 WT and mutants.After cleavage of a C-terminal maltose binding protein solubility tag by TEV protease, hnRNPA2 FL D290V (B) and P298L (C) undergo LLPS followed by aggregation. In the presence of either rA2RE11 or rA2RE21, neither phase separation nor aggregation occur."
463,PMID: 32870271,RNAPS0000415,https://pubmed.ncbi.nlm.nih.gov/32870271,RNA + protein,-,-,"rA2RE21 two overlapping tandem A2REs RNA (H. Ryan,2020)",21nt,GCCAAGGAGCCAGAGAGCAUG,irregular RNA,Homo sapiens,"sp|P22626|ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens OX=9606 GN=HNRNPA2B1 PE=1 SV=2
MEKTLETVPLERKKREKEQFRKLFIGGLSFETTEESLRNYYEQWGKLTDCVVMRDPASKR
SRGFGFVTFSSMAEVDAAMAARPHSIDGRVVEPKRAVAREESGKPGAHVTVKKLFVGGIK
EDTEEHHLRDYFEEYGKIDTIEIITDRQSGKKRGFGFVTFDDHDPVDKIVLQKYHTINGH
NAEVRKALSRQEMQEVQSSRSGRGGNFGFGDSRGGGGNFGPGPGSNFRGGSDGYGSGRGF
GDGYNGYGGGPGGGNFGGSPGYGGGRGGYGGGGPGYGNQGGGYGGGYDNYGGGNYGSGNY
NDFGNYNQQPSNYGPMKSGNFGGSRNMGGPYGGGNYGPGGSGGSGGYGGRSRY",HNRNPA2B1,C,-,-,P22626,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2608,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0117,http://db.phasep.pro/browse/","[190-341],[342-353]","[11-22],[198-307],[322-352]",In vitro,15 µM [A2RE];|15 µM [HNRNPA2B1],50mM NaCl or 150mM NaCl,20 mM Tris pH 7.5,RT,≤ 120 min,-,Differential interference contrast microscopy,solute,"rA2RE11 and rA2RE21 prevent phase separation and aggregation of full-length hnRNPA2 WT and mutants.After cleavage of a C-terminal maltose binding protein solubility tag by TEV protease, hnRNPA2 FL D290V (B) and P298L (C) undergo LLPS followed by aggregation. In the presence of either rA2RE11 or rA2RE21, neither phase separation nor aggregation occur."
464,PMID: 32870271,RNAPS0000415,https://pubmed.ncbi.nlm.nih.gov/32870271,RNA + protein,-,-,"rA2RE21 two overlapping tandem A2REs RNA (H. Ryan,2020)",21nt,GCCAAGGAGCCAGAGAGCAUG,irregular RNA,Homo sapiens,"sp|P22626|ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens OX=9606 GN=HNRNPA2B1 PE=1 SV=2
MEKTLETVPLERKKREKEQFRKLFIGGLSFETTEESLRNYYEQWGKLTDCVVMRDPASKR
SRGFGFVTFSSMAEVDAAMAARPHSIDGRVVEPKRAVAREESGKPGAHVTVKKLFVGGIK
EDTEEHHLRDYFEEYGKIDTIEIITDRQSGKKRGFGFVTFDDHDPVDKIVLQKYHTINGH
NAEVRKALSRQEMQEVQSSRSGRGGNFGFGDSRGGGGNFGPGPGSNFRGGSDGYGSGRGF
GDGYNGYGGGPGGGNFGGSPGYGGGRGGYGGGGPGYGNQGGGYGGGYDNYGGGNYGSGNY
NDFGNYNQQPSNYGPMKSGNFGGSRNMGGPYGGGNYGPGGSGGSGGYGGRSRY",HNRNPA2B1,C,protein_mutation:D290V,-,P22626,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2608,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0117,http://db.phasep.pro/browse/","[190-341],[342-353]","[11-22],[198-307],[322-352]",In vitro,15 µM [A2RE];|15 µM [HNRNPA2B1],50mM NaCl or 150mM NaCl,20 mM Tris pH 7.5,RT,≤ 120 min,-,Differential interference contrast microscopy,solute,"rA2RE11 and rA2RE21 prevent phase separation and aggregation of full-length hnRNPA2 WT and mutants.After cleavage of a C-terminal maltose binding protein solubility tag by TEV protease, hnRNPA2 FL D290V (B) and P298L (C) undergo LLPS followed by aggregation. In the presence of either rA2RE11 or rA2RE21, neither phase separation nor aggregation occur."
465,PMID: 32870271,RNAPS0000415,https://pubmed.ncbi.nlm.nih.gov/32870271,RNA + protein,-,-,"rA2RE21 two overlapping tandem A2REs RNA (H. Ryan,2020)",21nt,GCCAAGGAGCCAGAGAGCAUG,irregular RNA,Homo sapiens,"sp|P22626|ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens OX=9606 GN=HNRNPA2B1 PE=1 SV=2
MEKTLETVPLERKKREKEQFRKLFIGGLSFETTEESLRNYYEQWGKLTDCVVMRDPASKR
SRGFGFVTFSSMAEVDAAMAARPHSIDGRVVEPKRAVAREESGKPGAHVTVKKLFVGGIK
EDTEEHHLRDYFEEYGKIDTIEIITDRQSGKKRGFGFVTFDDHDPVDKIVLQKYHTINGH
NAEVRKALSRQEMQEVQSSRSGRGGNFGFGDSRGGGGNFGPGPGSNFRGGSDGYGSGRGF
GDGYNGYGGGPGGGNFGGSPGYGGGRGGYGGGGPGYGNQGGGYGGGYDNYGGGNYGSGNY
NDFGNYNQQPSNYGPMKSGNFGGSRNMGGPYGGGNYGPGGSGGSGGYGGRSRY",HNRNPA2B1,C,"protein_mutation:D298L,",-,P22626,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2608,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0117,http://db.phasep.pro/browse/","[190-341],[342-353]","[11-22],[198-307],[322-352]",In vitro,15 µM [A2RE];|15 µM [HNRNPA2B1],50mM NaCl or 150mM NaCl,20 mM Tris pH 7.5,RT,≤ 120 min,-,Differential interference contrast microscopy,solute,"rA2RE11 and rA2RE21 prevent phase separation and aggregation of full-length hnRNPA2 WT and mutants.After cleavage of a C-terminal maltose binding protein solubility tag by TEV protease, hnRNPA2 FL D290V (B) and P298L (C) undergo LLPS followed by aggregation. In the presence of either rA2RE11 or rA2RE21, neither phase separation nor aggregation occur."
466,PMID: 32895492,RNAPS0000416,https://pubmed.ncbi.nlm.nih.gov/32895492,RNA + protein,NCBI ID:108868751,https://www.ncbi.nlm.nih.gov/gene/108868751,DIGIT,2226nt(1-2226),AAAUUCAUUGUGGACGAUUUUACUUUGGGGCUACUUUUUUCCCCCUUUCGGAAUUGGUUUUGUUUUAGAAAAUGUGAGGGGCUGCAUCCCCUCUCAAGCAGGAUUGAAAAUUCCACCACUCCUCCGCGCCCCCACGUACUCACCGCCUGAUUUACCUCUUUUUUAAAUCUUGAGUUUCUCUCCCGAAUGGAACUUGUUAACCCCCCCAAAAAACUUUUGGUUUUGUAAAAUCCAAAUUUUGUAAAGGCAAAAACGACUAAAGGAGGGGUGCAUCGUGCUUCUUAAAAAGAUUUUUUUUUCCAGCCACUCUGGGUCUGAAAACUACCAUGGCAGUCCCUAGGUCCUACACAGCGAAGACCAAAUUCAGCCGCUCUUUAAAAUUCGCCACCAAGAGUUGCAGUCUGAAGCGGUGCUUCUAGCUGCUCCCAGCGUGGGUGUCGGUAGUUUUUGUGCUUUUAAAAAAUUAGUUUUGGAAAUGUGGUGCCUUCUCUCCCAAACUAUUUUUUUGAUUUUCAAUCCAGAUGGGGUCUUUGGGACUUCCCUAUCUUCUUCCCCAAUAAUUGGGUCGCAUUUUUCCUUACGACCUGCUGGCUGCCGGUAGGCCUGCCCUUCCGCCUGGCAGGCCCAGAGUGGAUUCCCUGGGCCGCAGUGGCCUGGACGAUGGCCGGGUCUGAUAGCGGCAGGCGGCCGCGAUGAUUUGCGGGAUUCUCGGCAUGGCACGGCCAGCCUGCCCGAGCCACGGGAGGCGCAGCCAGCCCACCACUCACGGCAAGCAGGCGGCCGAGCGCCCUUCGAGAAGAGACUUAAGUCACCAUGCUCCAGGGCAGAUACUCCCCCACCAAUCUUUCCCAGGUUUAAAGCUACAGGGCAGUUGAUGGACGACAACUAGAGGCUGCAACUUAUCAGUGACUGCCUGCGUUUGUGUUGGAGGCUGGGUGUGCGCUGCGGUGCGCGUGUGAGUGGAUCUUUUAAGACCUUUGUCUGAGCCGGGCAGAGGCACAAGUGCCACCUGACGCUUGGGGCAGAUUCCUCGUCCUGUUCUUGCAAAGAUGCCAAAUCAGGAGAGUGUCAAGAUUUCAACCGCAGACCUAAAAAAAGUGUCUCCAUGUUUUUAAAAGUAUCAGACAACCACCUCCACACACCCCUCCGUCUCCCCUUCCACCUGGAACAUUGUUCUUUUUAAUAACCAGGUUUAGCAAACUGCUAUACUGCGCCUGUGCUUUCCUGCAGCCCUCCGCUGUACCAGCUGAGCCCUGUACAGAAUCUGAGCGUCAGAGUUGCAGACCCAACCUUGCCACCUUGCAAAUCAUCCCUUCUCUGGAGGCCUCAGGAUUUUAGUUGAUCAAACCAACACCAACAUUCAUUGGGUCCCUUUGCAACCCUAACAUUUAAUGAGACUUGGUAAUUGUCAUCCGUUCGCCAAGGAGGUUGGGGAUGAACUUGGGGGCAUUUUCUUGUUUAUUUUUCAUUGAGACAAAGGAGUGUGCUGUCCCCACCUCCGCCCCCAGACAAGGACAGGGUUCCUACAUCAGCUGGGUCUAAAAUAAGGAAAAGCGAGUGCUGCCGCAGAGGGGACUUUCCGGGAAGGGGGUCACAGGAACCCCAAGGCCACACAGCUCCAGACACUCUGCCGGAGCUCUAGGGGAGCUCACCCCUGCGCGGCGGGACCUCCCCCAUCGGGUUGCCCCUUCAAUCUGCAGCCGCGCGGAGGCAGGCCCCGGGAAAGGCAGUCGGCGCUCGGUGCUCGCACUGCGCCUCGGCGGGCGGAAACUCACAAGUGUCCUCAACGUGCUAAACAAACCAUCAGGGCCCCGCAUCGCCUGGCGCAAUUGGAAUAACAAAUGCGACGCACGCAAAUUGUCCACCUCGUGUUGCUAAGCGAUUGUUUGUCGGCCCCGCACGCACAGCUCAGCAUGGGAGGACCGCGAGCGUCCAGAGGCAGCCGGCGAGCGCUUAGGUCGGAAAUGCAGUAAACAUGCCGCUGAUUUUCCCUAUUAUCACCCAAACACGAUUUCACACAAAGCAAUCACCACGCAGAAGUCUAUGAAAAUGUGUUUGUUGAGGAGUCACUCGCCCCAGUAAUAGUCCUCAUUUUUAAGAUAUUAAAGAAUAGCUCAGCGGAUUCCACAUGCAUAAGGUCUAUUUGCCGUUCGGCAUCUGUCACGGCGCUUUUGCACUGCGGUCAUCACUAAAUUGAUUCAUAGAGUGUAGAUUAAAUUGCUUCUC,lncRNA,Homo sapiens,"sp|Q15059|BRD3_HUMAN Bromodomain-containing protein 3 OS=Homo sapiens OX=9606 GN=BRD3 PE=1 SV=1
MSTATTVAPAGIPATPGPVNPPPPEVSNPSKPGRKTNQLQYMQNVVVKTLWKHQFAWPFY
QPVDAIKLNLPDYHKIIKNPMDMGTIKKRLENNYYWSASECMQDFNTMFTNCYIYNKPTD
DIVLMAQALEKIFLQKVAQMPQEEVELLPPAPKGKGRKPAAGAQSAGTQQVAAVSSVSPA
TPFQSVPPTVSQTPVIAATPVPTITANVTSVPVPPAAAPPPPATPIVPVVPPTPPVVKKK
GVKRKADTTTPTTSAITASRSESPPPLSDPKQAKVVARRESGGRPIKPPKKDLEDGEVPQ
HAGKKGKLSEHLRYCDSILREMLSKKHAAYAWPFYKPVDAEALELHDYHDIIKHPMDLST
VKRKMDGREYPDAQGFAADVRLMFSNCYKYNPPDHEVVAMARKLQDVFEMRFAKMPDEPV
EAPALPAPAAPMVSKGAESSRSSEESSSDSGSSDSEEERATRLAELQEQLKAVHEQLAAL
SQAPVNKPKKKKEKKEKEKKKKDKEKEKEKHKVKAEEEKKAKVAPPAKQAQQKKAPAKKA
NSTTTAGRQLKKGGKQASASYDSEEEEEGLPMSYDEKRQLSLDINRLPGEKLGRVVHIIQ
SREPSLRDSNPDEIEIDFETLKPTTLRELERYVKSCLQKKQRKPFSASGKKQAAKSKEEL
AQEKKKELEKRLQDVSGQLSSSKKPARKEKPGSAPSGGPSRLSSSSSSESGSSSSSGSSS
DSSDSE",BRD3,-,-,726aa(1-726),Q15059,PhaSepDB,http://db.phasep.pro/browse/,"[1-35],[156-169],[237-244],[251-251],[254-305],[421-462],[478-556],[645-726]","[16-33],[149-163],[208-261],[419-431],[436-460],[463-540],[564-568],[646-678],[692-725]",In vitro,100nM [DIGIT];|0.5-2µM [BRD3],200mM NaCl,"50mM Tris-HCl pH7.5, 10% glycerol and 1mM DTT",RT,-,crowding agent:1.5% PEG-6000,Fluorescence microscopy,liquid,"Droplet assay showing the formation of mEGFP–BRD3 droplets in the presence of 100 nM DIGIT (top), 100 nM scrambled DIGIT (SCRM; middle) or no RNA (bottom). The NaCl concentration is  200 mM. PEG-6000 (1.5%) was added to each reaction."
467,PMID: 32895492,RNAPS0000417,https://pubmed.ncbi.nlm.nih.gov/32895492,RNA + protein,NCBI ID:108868751,https://www.ncbi.nlm.nih.gov/gene/108868751,DIGIT_scr,2226nt(1-2226),AAAUUCAUUGUGGACGAUUUUACUUUGGGGCUACUUUUUUCCCCCUUUCGGAAUUGGUUUUGUUUUAGAAAAUGUGAGGGGCUGCAUCCCCUCUCAAGCAGGAUUGAAAAUUCCACCACUCCUCCGCGCCCCCACGUACUCACCGCCUGAUUUACCUCUUUUUUAAAUCUUGAGUUUCUCUCCCGAAUGGAACUUGUUAACCCCCCCAAAAAACUUUUGGUUUUGUAAAAUCCAAAUUUUGUAAAGGCAAAAACGACUAAAGGAGGGGUGCAUCGUGCUUCUUAAAAAGAUUUUUUUUUCCAGCCACUCUGGGUCUGAAAACUACCAUGGCAGUCCCUAGGUCCUACACAGCGAAGACCAAAUUCAGCCGCUCUUUAAAAUUCGCCACCAAGAGUUGCAGUCUGAAGCGGUGCUUCUAGCUGCUCCCAGCGUGGGUGUCGGUAGUUUUUGUGCUUUUAAAAAAUUAGUUUUGGAAAUGUGGUGCCUUCUCUCCCAAACUAUUUUUUUGAUUUUCAAUCCAGAUGGGGUCUUUGGGACUUCCCUAUCUUCUUCCCCAAUAAUUGGGUCGCAUUUUUCCUUACGACCUGCUGGCUGCCGGUAGGCCUGCCCUUCCGCCUGGCAGGCCCAGAGUGGAUUCCCUGGGCCGCAGUGGCCUGGACGAUGGCCGGGUCUGAUAGCGGCAGGCGGCCGCGAUGAUUUGCGGGAUUCUCGGCAUGGCACGGCCAGCCUGCCCGAGCCACGGGAGGCGCAGCCAGCCCACCACUCACGGCAAGCAGGCGGCCGAGCGCCCUUCGAGAAGAGACUUAAGUCACCAUGCUCCAGGGCAGAUACUCCCCCACCAAUCUUUCCCAGGUUUAAAGCUACAGGGCAGUUGAUGGACGACAACUAGAGGCUGCAACUUAUCAGUGACUGCCUGCGUUUGUGUUGGAGGCUGGGUGUGCGCUGCGGUGCGCGUGUGAGUGGAUCUUUUAAGACCUUUGUCUGAGCCGGGCAGAGGCACAAGUGCCACCUGACGCUUGGGGCAGAUUCCUCGUCCUGUUCUUGCAAAGAUGCCAAAUCAGGAGAGUGUCAAGAUUUCAACCGCAGACCUAAAAAAAGUGUCUCCAUGUUUUUAAAAGUAUCAGACAACCACCUCCACACACCCCUCCGUCUCCCCUUCCACCUGGAACAUUGUUCUUUUUAAUAACCAGGUUUAGCAAACUGCUAUACUGCGCCUGUGCUUUCCUGCAGCCCUCCGCUGUACCAGCUGAGCCCUGUACAGAAUCUGAGCGUCAGAGUUGCAGACCCAACCUUGCCACCUUGCAAAUCAUCCCUUCUCUGGAGGCCUCAGGAUUUUAGUUGAUCAAACCAACACCAACAUUCAUUGGGUCCCUUUGCAACCCUAACAUUUAAUGAGACUUGGUAAUUGUCAUCCGUUCGCCAAGGAGGUUGGGGAUGAACUUGGGGGCAUUUUCUUGUUUAUUUUUCAUUGAGACAAAGGAGUGUGCUGUCCCCACCUCCGCCCCCAGACAAGGACAGGGUUCCUACAUCAGCUGGGUCUAAAAUAAGGAAAAGCGAGUGCUGCCGCAGAGGGGACUUUCCGGGAAGGGGGUCACAGGAACCCCAAGGCCACACAGCUCCAGACACUCUGCCGGAGCUCUAGGGGAGCUCACCCCUGCGCGGCGGGACCUCCCCCAUCGGGUUGCCCCUUCAAUCUGCAGCCGCGCGGAGGCAGGCCCCGGGAAAGGCAGUCGGCGCUCGGUGCUCGCACUGCGCCUCGGCGGGCGGAAACUCACAAGUGUCCUCAACGUGCUAAACAAACCAUCAGGGCCCCGCAUCGCCUGGCGCAAUUGGAAUAACAAAUGCGACGCACGCAAAUUGUCCACCUCGUGUUGCUAAGCGAUUGUUUGUCGGCCCCGCACGCACAGCUCAGCAUGGGAGGACCGCGAGCGUCCAGAGGCAGCCGGCGAGCGCUUAGGUCGGAAAUGCAGUAAACAUGCCGCUGAUUUUCCCUAUUAUCACCCAAACACGAUUUCACACAAAGCAAUCACCACGCAGAAGUCUAUGAAAAUGUGUUUGUUGAGGAGUCACUCGCCCCAGUAAUAGUCCUCAUUUUUAAGAUAUUAAAGAAUAGCUCAGCGGAUUCCACAUGCAUAAGGUCUAUUUGCCGUUCGGCAUCUGUCACGGCGCUUUUGCACUGCGGUCAUCACUAAAUUGAUUCAUAGAGUGUAGAUUAAAUUGCUUCUC,lncRNA,Homo sapiens,"sp|Q15059|BRD3_HUMAN Bromodomain-containing protein 3 OS=Homo sapiens OX=9606 GN=BRD3 PE=1 SV=1
MSTATTVAPAGIPATPGPVNPPPPEVSNPSKPGRKTNQLQYMQNVVVKTLWKHQFAWPFY
QPVDAIKLNLPDYHKIIKNPMDMGTIKKRLENNYYWSASECMQDFNTMFTNCYIYNKPTD
DIVLMAQALEKIFLQKVAQMPQEEVELLPPAPKGKGRKPAAGAQSAGTQQVAAVSSVSPA
TPFQSVPPTVSQTPVIAATPVPTITANVTSVPVPPAAAPPPPATPIVPVVPPTPPVVKKK
GVKRKADTTTPTTSAITASRSESPPPLSDPKQAKVVARRESGGRPIKPPKKDLEDGEVPQ
HAGKKGKLSEHLRYCDSILREMLSKKHAAYAWPFYKPVDAEALELHDYHDIIKHPMDLST
VKRKMDGREYPDAQGFAADVRLMFSNCYKYNPPDHEVVAMARKLQDVFEMRFAKMPDEPV
EAPALPAPAAPMVSKGAESSRSSEESSSDSGSSDSEEERATRLAELQEQLKAVHEQLAAL
SQAPVNKPKKKKEKKEKEKKKKDKEKEKEKHKVKAEEEKKAKVAPPAKQAQQKKAPAKKA
NSTTTAGRQLKKGGKQASASYDSEEEEEGLPMSYDEKRQLSLDINRLPGEKLGRVVHIIQ
SREPSLRDSNPDEIEIDFETLKPTTLRELERYVKSCLQKKQRKPFSASGKKQAAKSKEEL
AQEKKKELEKRLQDVSGQLSSSKKPARKEKPGSAPSGGPSRLSSSSSSESGSSSSSGSSS
DSSDSE",BRD3,-,-,726aa(1-726),Q15059,PhaSepDB,http://db.phasep.pro/browse/,"[1-35],[156-169],[237-244],[251-251],[254-305],[421-462],[478-556],[645-726]","[16-33],[149-163],[208-261],[419-431],[436-460],[463-540],[564-568],[646-678],[692-725]",In vitro,100nM [scrambled DIGIT (SCRM)];|1-2µM [BRD3],200mM NaCl,"50mM Tris-HCl pH7.5, 10% glycerol and 1mM DTT",RT,-,crowding agent:1.5% PEG-6000,Fluorescence microscopy,liquid,"Droplet assay showing the formation of mEGFP–BRD3 droplets in the presence of 100 nM DIGIT (top), 100 nM scrambled DIGIT (SCRM; middle) or no RNA (bottom). The NaCl concentration is  200 mM. PEG-6000 (1.5%) was added to each reaction."
468,PMID: 32901111,RNAPS0000294,https://pubmed.ncbi.nlm.nih.gov/32901111,RNA + protein,-,-,SARS-CoV-2 N1541 RNA,1541nt,GGGGAAUUGUGAGCGGAUAACAAUUCCCCUCUAGAAAUAAUUUUGUUUAACUUUAAGAAGGAGAUAUACCAUGGGCAGCAGCCAUCAUCAUCAUCAUCACCACCACCACCAUAGCAGCGGCCUGGUGCCGCGCGGCAGCGCUAGCAUGUCUGAUAAUGGACCCCAAAAUCAGCGAAAUGCACCCCGCAUUACGUUUGGUGGACCCUCAGAUUCAACUGGCAGUAACCAGAAUGGAGAACGCAGUGGGGCGCGAUCAAAACAACGUCGGCCCCAAGGUUUACCCAAUAAUACUGCGUCUUGGUUCACCGCUCUCACUCAACAUGGCAAGGAAGACCUUAAAUUCCCUCGAGGACAAGGCGUUCCAAUUAACACCAAUAGCAGUCCAGAUGACCAAAUUGGCUACUACCGAAGAGCUACCAGACGAAUUCGUGGUGGUGACGGUAAAAUGAAAGAUCUCAGUCCAAGAUGGUAUUUCUACUACCUAGGAACUGGGCCAGAAGCUGGACUUCCCUAUGGUGCUAACAAAGACGGCAUCAUAUGGGUUGCAACUGAGGGAGCCUUGAAUACACCAAAAGAUCACAUUGGCACCCGCAAUCCUGCUAACAAUGCUGCAAUCGUGCUACAACUUCCUCAAGGAACAACAUUGCCAAAAGGCUUCUACGCAGAAGGGAGCAGAGGCGGCAGUCAAGCCUCUUCUCGUUCCUCAUCACGUAGUCGCAACAGUUCAAGAAAUUCAACUCCAGGCAGCAGUAGGGGAACUUCUCCUGCUAGAAUGGCUGGCAAUGGCGGUGAUGCUGCUCUUGCUUUGCUGCUGCUUGACAGAUUGAACCAGCUUGAGAGCAAAAUGUCUGGUAAAGGCCAACAACAACAAGGCCAAACUGUCACUAAGAAAUCUGCUGCUGAGGCUUCUAAGAAGCCUCGGCAAAAACGUACUGCCACUAAAGCAUACAAUGUAACACAAGCUUUCGGCAGACGUGGUCCAGAACAAACCCAAGGAAAUUUUGGGGACCAGGAACUAAUCAGACAAGGAACUGAUUACAAACAUUGGCCGCAAAUUGCACAAUUUGCCCCCAGCGCUUCAGCGUUCUUCGGAAUGUCGCGCAUUGGCAUGGAAGUCACACCUUCGGGAACGUGGUUGACCUACACAGGUGCCAUCAAAUUGGAUGACAAAGAUCCAAAUUUCAAAGAUCAAGUCAUUUUGCUGAAUAAGCAUAUUGACGCAUACAAAACAUUCCCACCAACAGAGCCUAAAAAGGACAAAAAGAAGAAGGCUGAUGAAACUCAAGCCUUACCGCAGAGACAGAAGAAACAGCAAACUGUGACUCUUCUUCCUGCUGCAGAUUUGGAUGAUUUCUCCAAACAAUUGCAACAAUCCAUGAGCAGUGCUGACUCAACUCAGGCCUGUUGAGGAUCCUGUGAAUUCGAGCUCCGUCGACAAGCUUGCGGCCGCACUCGAGCACCACCACCACCACCACUGAGAUCCGGCUGCUAACAAAGCCCGAAAGGAAGCUGAGUUGGCUGCUGCCACCGCUGAGCAAUAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.05-0.5µM [N1541];|20µM [N protein],-,"1× PBS, pH 7.4",RT,> 1 h,crowding agent:2.5% PEG8000,"Differential interference contrast microscopy,Fluorescence microscopy","liquid, solid","Representative fluorescence and DIC images of LLPS formed by N protein (green) with 85-nt RNA A85 at the indicated concentrations. Representative fluorescence and DIC images of LLPS formed by N protein (red) with the positive strand RNA of N protein (N1541, 1541 nt) at the indicated concentrations."
469,PMID: 32901111,RNAPS0000420,https://pubmed.ncbi.nlm.nih.gov/32901111,RNA + protein,-,-,"H20 RNA(Chen,2020)",20nt,AGAUUCAACUGGCAGUAACC,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.2-10µM [H20];|1-40µM [N protein],-,"1× PBS, pH 7.4",RT,> 1 h,crowding agent:2.5% PEG8000,"Differential interference contrast microscopy,Fluorescence microscopy","liquid, solute","To further quantify the properties of N protein/RNA LLPS, we established the phase diagram of Alexa-647-labeled N protein (647-N) with another 20-nt ssRNA labeled with HEX (H20). Phase diagram of a 20-nt RNA H20 separating with N protein of SARS CoV-2. The histogram shows the percentage of area occupied by N protein/H20 droplets."
470,PMID: 32901111,RNAPS0000421,https://pubmed.ncbi.nlm.nih.gov/32901111,RNA + protein,-,-,"A20 RNA(Chen,2020)A20 RNA(Chen,2020)",20nt,UAGCUUAUCAGACUGAUGUU,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.2-10µM [A20];|1-40µM [N protein],-,"1× PBS, pH 7.4",RT,> 1 h,crowding agent:2.5% PEG8000,Fluorescence microscopy,"liquid, solute","We observed formation of liquid-like droplets when N protein or RNA concentration was higher than certain thresholds.Phase diagram of N protei-20 RNA LLPS in the presence of 2.5% PEG8000, N protein is labeled with Alexa-488."
471,PMID: 32901111,RNAPS0000422,https://pubmed.ncbi.nlm.nih.gov/32901111,RNA + protein,-,-,"A85 RNA(Chen,2020)",85nt,GGCGCAUAAAGAUGAGACGCGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGUUCG,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.1-5µM [A85];|20µM [N protein],-,"1× PBS, pH 7.4",RT,> 1 h,crowding agent:2.5% PEG8000,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"Representative fluorescence and DIC images of LLPS formed by N protein (green) with 85-nt RNA A85 at the indicated concentrations. Representative fluorescence and DIC images of LLPS formed by N protein (red) with the positive strand RNA of N protein (N1541, 1541 nt) at the indicated concentrations."
472,PMID: 32901111,RNAPS0000423,https://pubmed.ncbi.nlm.nih.gov/32901111,RNA + protein,-,-,polyU(10),10nt,UUUUUUUUUU,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,10µM[U10];|20µM [N protein],-,"1× PBS, pH 7.4",RT,> 1 h,crowding agent:2.5% PEG8000,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"Representative fluorescence images of LLPS formed by RNA (orange) of different lengths mixed  with N protein (red). In the experiments, the RNA oligoes of the same mass were used, and the  corresponding molar concentrations are also indicated"
473,PMID: 32901111,RNAPS0000424,https://pubmed.ncbi.nlm.nih.gov/32901111,RNA + protein,-,-,polyU(20),20nt,UUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5µM[U20];|20µM [N protein],-,"1× PBS, pH 7.4",RT,> 1 h,crowding agent:2.5% PEG8000,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"When inducing N protein/RNA LLPS by using these poly-U oligos with the same mass and the same concentrations of N protein, we found that the longest ssRNA, U60, could phase separate with N protein to form much larger droplets compared with other shorter oligoes (Supplementary information, Fig. S5a), confirming that the LLPS is indeed dependent on ssRNA length.Representative fluorescence images of LLPS formed by RNA (orange) of different lengths mixed  with N protein (red). In the experiments, the RNA oligoes of the same mass were used, and the  corresponding molar concentrations are also indicated."
474,PMID: 32901111,RNAPS0000425,https://pubmed.ncbi.nlm.nih.gov/32901111,RNA + protein,-,-,polyU(40),40nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,2.5µM[U40];|20µM [N protein],-,"1× PBS, pH 7.4",RT,> 1 h,crowding agent:2.5% PEG8000,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"When inducing N protein/RNA LLPS by using these poly-U oligos with the same mass and the same concentrations of N protein, we found that the longest ssRNA, U60, could phase separate with N protein to form much larger droplets compared with other shorter oligoes (Supplementary information, Fig. S5a), confirming that the LLPS is indeed dependent on ssRNA length.Representative fluorescence images of LLPS formed by RNA (orange) of different lengths mixed  with N protein (red). In the experiments, the RNA oligoes of the same mass were used, and the  corresponding molar concentrations are also indicated."
475,PMID: 32901111,RNAPS0000426,https://pubmed.ncbi.nlm.nih.gov/32901111,RNA + protein,-,-,polyU(60),60nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,1.67µM[U60];|20µM [N protein],-,"1× PBS, pH 7.4",RT,> 1 h,crowding agent:2.5% PEG8000,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"When inducing N protein/RNA LLPS by using these poly-U oligos with the same mass and the same concentrations of N protein, we found that the longest ssRNA, U60, could phase separate with N protein to form much larger droplets compared with other shorter oligoes (Supplementary information, Fig. S5a), confirming that the LLPS is indeed dependent on ssRNA length.Representative fluorescence images of LLPS formed by RNA (orange) of different lengths mixed  with N protein (red). In the experiments, the RNA oligoes of the same mass were used, and the  corresponding molar concentrations are also indicated."
476,PMID: 32909564,RNAPS0000427,https://pubmed.ncbi.nlm.nih.gov/32909564,RNA + protein,-,-,polyU(20),20nt,UUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|D0PV95|DDX3_CAEEL ATP-dependent RNA helicase laf-1 OS=Caenorhabditis elegans OX=6239 GN=laf-1 PE=1 SV=1
MESNQSNNGGSGNAALNRGGRYVPPHLRGGDGGAAAAASAGGDDRRGGAGGGGYRRGGGN
SGGGGGGGYDRGYNDNRDDRDNRGGSGGYGRDRNYEDRGYNGGGGGGGNRGYNNNRGGGG
GGYNRQDRGDGGSSNFSRGGYNNRDEGSDNRGSGRSYNNDRRDNGGDGQNTRWNNLDAPP
SRGTSKWENRGARDERIEQELFSGQLSGINFDKYEEIPVEATGDDVPQPISLFSDLSLHE
WIEENIKTAGYDRPTPVQKYSIPALQGGRDLMSCAQTGSGKTAAFLVPLVNAILQDGPDA
VHRSVTSSGGRKKQYPSALVLSPTRELSLQIFNESRKFAYRTPITSALLYGGRENYKDQI
HKLRLGCHILIATPGRLIDVMDQGLIGMEGCRYLVLDEADRMLDMGFEPQIRQIVECNRM
PSKEERITAMFSATFPKEIQLLAQDFLKENYVFLAVGRVGSTSENIMQKIVWVEEDEKRS
YLMDLLDATGDSSLTLVFVETKRGASDLAYYLNRQNYEVVTIHGDLKQFEREKHLDLFRT
GTAPILVATAVAARGLDIPNVKHVINYDLPSDVDEYVHRIGRTGRVGNVGLATSFFNDKN
RNIARELMDLIVEANQELPDWLEGMSGDMRSGGGYRGRGGRGNGQRFGGRDHRYQGGSGN
GGGGNGGGGGFGGGGQRSGGGGGFQSGGGGGRQQQQQQRAQPQQDWWS",laf-1,-,-,708aa(1-708),D0PV95,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/D0PV95,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0337,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0001,http://db.phasep.pro/browse/",-,-,In vitro,5 or 10 µM[polyU];|5 µM[laf-1],-,"20 mM Tris–HCl, 5 mM TCEP, pH 7.4",25˚C,-,-,Microscopy,liquid,"Light microscopy snapshots of (A) LAF-1 (5 μM) + polyU20 RNA (5 μM), (B) LAF-1 (5 μM) + polyU20 RNA (10 μM), (C) LAF-1 (5 μM) + polyU20 RNA (5 μM) + LL-III (50 μM), (D) LAF-1 (5 μM) + polyU20 RNA (5 μM) + LL-III (500 μM), at 25˚C in buffer (20 mM Tris–HCl, 5 mM TCEP, pH 7.4). (Scale bar, 30 µm)."
477,PMID: 32909564,RNAPS0000427,https://pubmed.ncbi.nlm.nih.gov/32909564,RNA + protein,-,-,polyU(20),20nt,UUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|D0PV95|DDX3_CAEEL ATP-dependent RNA helicase laf-1 OS=Caenorhabditis elegans OX=6239 GN=laf-1 PE=1 SV=1
MESNQSNNGGSGNAALNRGGRYVPPHLRGGDGGAAAAASAGGDDRRGGAGGGGYRRGGGN
SGGGGGGGYDRGYNDNRDDRDNRGGSGGYGRDRNYEDRGYNGGGGGGGNRGYNNNRGGGG
GGYNRQDRGDGGSSNFSRGGYNNRDEGSDNRGSGRSYNNDRRDNGGDGQNTRWNNLDAPP
SRGTSKWENRGARDERIEQELFSGQLSGINFDKYEEIPVEATGDDVPQPISLFSDLSLHE
WIEENIKTAGYDRPTPVQKYSIPALQGGRDLMSCAQTGSGKTAAFLVPLVNAILQDGPDA
VHRSVTSSGGRKKQYPSALVLSPTRELSLQIFNESRKFAYRTPITSALLYGGRENYKDQI
HKLRLGCHILIATPGRLIDVMDQGLIGMEGCRYLVLDEADRMLDMGFEPQIRQIVECNRM
PSKEERITAMFSATFPKEIQLLAQDFLKENYVFLAVGRVGSTSENIMQKIVWVEEDEKRS
YLMDLLDATGDSSLTLVFVETKRGASDLAYYLNRQNYEVVTIHGDLKQFEREKHLDLFRT
GTAPILVATAVAARGLDIPNVKHVINYDLPSDVDEYVHRIGRTGRVGNVGLATSFFNDKN
RNIARELMDLIVEANQELPDWLEGMSGDMRSGGGYRGRGGRGNGQRFGGRDHRYQGGSGN
GGGGNGGGGGFGGGGQRSGGGGGFQSGGGGGRQQQQQQRAQPQQDWWS",laf-1,-,-,708aa(1-708),D0PV95,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/D0PV95,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0337,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0001,http://db.phasep.pro/browse/",-,-,In vitro,5 or 10 µM[polyU];|5 µM[laf-1],-,"20 mM Tris–HCl, 5 mM TCEP, pH 7.4",25˚C,-,other_molecular:50 μM LL-III200 μM LL-III500 μM LL-III,Microscopy,liquid,"Light microscopy snapshots of (A) LAF-1 (5 μM) + polyU20 RNA (5 μM), (B) LAF-1 (5 μM) + polyU20 RNA (10 μM), (C) LAF-1 (5 μM) + polyU20 RNA (5 μM) + LL-III (50 μM), (D) LAF-1 (5 μM) + polyU20 RNA (5 μM) + LL-III (500 μM), at 25˚C in buffer (20 mM Tris–HCl, 5 mM TCEP, pH 7.4). (Scale bar, 30 µm)."
478,PMID: 32995779,RNAPS0000428,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,SARS-CoV-2 virus RNA,5000nt(1-5000),GGUUAAUGUUGUCUACUGUUGUAAACACCUUAAUAGUCCUCACUUCUCUCAAAGAAAGAAGUGUCUUAAGAUUGUCAAAGGUGAUAACUUCACCAUCUAGGUGGAAUGUGGUAGGAUUACUAGUGUAAUAUACACUUUUAUCACCUCUCUUAAGAAAUUCUAUACCUAGUUGUGUAGAUUGUCCAGAAUAGGACCAAUCUUUAUAGGAACCAGCAAGUGAGAUGGUUUCAAUAAAAUGUUCUUCAGGUGUUUUAGAAGAAGAAGUAAGAUAACCAUUAUACGCUGUAACAGCAUCAGGUGAAGAAACAGAAACUGUAGCUGGCACUUUGAGAGAUCUCAUAUACCGAGCAGCUUCUUCCAAAUUUAAGCCAUGUGUUACAUAGCCAAGUGGCAUUGUAACAAGAGUUUCAUUUAGAUCGUUAAGUGUGUUGAUAAGUGACGCUACAGUUGUUUUACUGGUGUAAAAGUAAAAUCUAGCACCAUAAUCAACCACACCCUCUUGUAUUUUAAUACCCUUAUAUUUACGCUGUAUAGUUGAAACUAUGGCUUUAGUUUCCACACAGACAGGCAUUAAUUUGCGUGUUUCUUCUGCAUGUGCAAGCAUUUCUCGCAAAUUCCAAGAAACAGUUCCAAGAAUUUCUUGCUUCUCAUUAGAGAUAAUAGAUGGUAGAAUGUAAAAGGCACUUUUACACUUUUUAAGCACUGUCUUUGCCUCCUCUACAGUGUAACCAUUUAAACCCUGACCCGGGUAAGUGGUUAUAUAAUUGUCUGUUGGCACUUUUCUCAAAGCUUUCGCUAGCAUUUCAGUAGUGCCACCAGCCUUUUUAGUAGGUAUAACCACAGCAGUUAAAACACCCUCUUGAACAACAUCACCCACUAUAUAUGGAGCAUCUUUCUUUAAGAAAGUGAUGUCAAUGUCACUAACAAGAGUGGCAGAAUCUGGAUGAAGAUUGCCAUUAAUGUCAAUAUAAAGUAACAAGUUUUCUGUGAGGAACUUAGUUUCUUCCAGAGUUGUUGUAACUUCUUCAACACAAGCUUUGAUUUUCUUAUCAUCUUGUUUUCUCUGUUCAACUGAAGGUUUACUUUCAGUUAUAAAUGGCUUAACUUCCUCUUUAGGAAUCUCAGCGAUCUUUUGUUCAACUUGCUUUUCACUCUUCAUUUCCAAAAAGCUUGAAACAAGUUUGUCAUAGAGAUUUUUAUCAAAGACAGCUAAGUAGACAUUUGUGCGAACAGUAUCUACACAAACUCUUAAAGAAUGUAUAGGGUCAGCACCAAAAAUACCAGCUGAUAAUAAUGGUGCAAGUAGAACUUCGUGCUGAUUAAAAUUUUCAUAAGCACUCUUAAGAAGUUGAAUGUCUUCACCUUUGUUAACAUUUGGGCCGACAACAUGAAGACAGUGUUUAGCAAGAUUGUGUCCGCUUAAAACACAACUACCACCCACUUUAAGUGGUCCAUUAGUAGCUAUGUAAUCAUCAGAUUCAACUUGCAUGGCAUUGUUAGUAGCCUUAUUUAAGGCUCCUGCAACACCUCCUCCAUGUUUAAGGUAAACAUUGGCUGCAUUAACAACCACUGUUGGUUUUACCUUUUUAGCUUCUUCCACAAUGUCUGCAUUUUUAAUGUAUACAUUGUCAGUAAGUUUUAAAUAACCACUAAAACUAUUCACUUCAAUAGUCUGAACAACUGGUGUAAGUUCCAUCUCUAAUUGAGGUUGAACCUCAACAAUUGUUUGAAUAGUAGUUGUCUGAUUGUCCUCACUGCCGUCUUGUUGACCAACAGUUUGUUGACUAUCAUCAUCUAACCAAUCUUCUUCUUGCUCUUCUUCAGGUUGAAGAGCAGCAGAAGUGGCACCAAAUUCCAAAGGUUUACCUUGGUAAUCAUCUUCAGUACCAUACUCAUAUUGAGUUGAUGGCUCAAACUCUUCUUCUUCACAAUCACCUUCUUCUUCAUCCUCAUCUGGAGGGUAGAAAGAACAAUACAUAUGUGAAGCCAAUUUAAACUCACCAGACUCAUCAAAUAAGUAGUAUGUAGCCAUACUCCACUCAUCUAAAUCAAUGCCCAGUGGUGUAAGUAAUUCAGAUACUGGUUGCAAAGUUUUUAUGACAGCAUCUGCCACAACACAGGCGAACUCAUUUACUUCUGUACCGAGUUCAACUGUAUAGGCAGAGCACUUCUCAUUAAGUACUUUAUCAAUCCUUUCAUCAAGUUCAAAAGUGAUAUUCACACUCUUGUAACCUUGCACUUCUAUCACAGUGUCAUCACCAAAAGUAACCUUUGUUGGUGCACCGCCUUUGAGUGUGAAGGUAUUGUUUGUUACCAUCAUAUUAGGUGCAAGGGCACAGUACUUUUCUGUGUCUUUGAUUUCGAGCAACAUAAGCCCGUUAAUACAAACUGGUGUACCAACCAAUGGAGCUUCAACAGCUUCACUAGUAGGUUGUUCUAAUGGUUGUAAAUCACCAGUUUUCAAGACAACUUCCUCUGUUAACACUUCUGUGGGAAGUGUUUCUCCCUCUAAGAAGAUAAUUUCUUUUGGGGCUUUUAGAGGCAUGAGUAGGCCAGUUUCUUCUCUGGAUUUAACACACUUUCUGUACAAUCCCUUUGAGUGCGUGACAAAUGUUUCACCUAAAUUCAAGGCUUUAAGUUUAGCUCCACCAAUAAUGAUAGAGUCAGCACACAAAGCCAAAAAUUUAUUUACAAGCUUAAAGAAUGUCUGAACACUCUCCUUAAUUUCCUUUGCACAGGUGACAAUUUGUCCACCGACAAUUUCACAAGCACAGGUUGAGAUAAAUUUAACAAUUUCCCAACCGUCUCUAAGAAACUCUACACCUUCCUUAAACUUCUCUUCAAGCCAAUCAAGGACGGGUUUGAGUUUUUCAUAAACAGUGCCAAAGAUGUUAGUUAGCCACUGCGAAGUCAACUGAACAACACCACCUGUAAUGUAGGCCAUUACAACUAGAUUGUUAGUAGCCAAAUCAGAUGUGAACAUCAUAGCAUCAAUGAGUCUCAGUGAAUACUGUGAAAUUCCAUCUAGUAUUGUUAUAGCGGCCUUCUGUAAAACACGCACAGAAUUUUGAGCAGUUUCAAGAGUGCGGGAGAAAAUUGAUCGUACAACACGAGCAGCCUCUGAUGCAAAUGCAUAAAGAGGACUCAGUAUUGAUUUCUGUUCACCAAUAUUCCAGGCACCUUUUUUAGCUUUUCCUUUUGUAACUUUAAAAUUACCACAGGAUUCAACAAUUUGUUUGAAUGCUUUAUAAUCCAAACCUUUCACAGUUUCCACAAAAGCACUUGUGGAAGCAGAAAAAGAUGCCAAAAUAAUGGCGAUCUCUUCAUUAAGUUUAAAGUCACCAACAAUAUUGAUGUUGACUUUCUCUUUUUGGAGUAUUUCAAGAAGGUUGUCAUUAAGACCUUCGGAACCUUCUCCAACAACACCUGUAUGGUUACAACCUAUGUUAGCGCUAGCACGUGGAACCCAAUAGGCACACUUGUUAUGGCAACCAACAUAAGAGAACACACAGCCUCCAAAGGCAAUAGUGCGACCACCCUUACGAAGAAUGGUUUUCAAGCCAGAUUCAUUAUGGUAUUCGGCAAGACUAUGCUCAGGUCCUACUUCUGAAUUGUGACAUGCUGGACAAUAAAUUUUAACAACAGCAUUUUGGGGUAAGUAACCACAAGUAGUGGCACCUUCUUUAGUCAAAUUCUCAGUGCCACAAAAUUCGCAAGUGGCUUUAACAAAAUCGCCCGUCUGCCAUGAAGUUUCACCACAAUGAUCACACUUCAUGAGAGUUGAAAGGCACAUUUGGUUGCAUUCAUUUGGUGACGCAACUGGAUAGACAGAUCGAAUUCUACCCAUAAAGCCAUCAAGCUUUUUCUUUUCAACCCUUGGUUGAAUAGUCUUGAUUAUGGAAUUUAAGGGAAAUACAAAAUUUGGACAUUCCCCAUUGAAGGUGUCAAAUUUCUUUGCCAAUUUAAUUUCAAAAGGUGUCUGCAAUUCAUAGCUCUUUUCAGAACGUUCCGUGUACCAAGCAAUUUCAUGCUCAUGUUCACGGCAGCAGUAUACACCCCUCUUAGUGUCAAUAAAGUCCAGUUGUUCGGACAAAGUGCAUGAAGCUUUACCAGCACGUGCUAGAAGGUCUUUAAUGCACUCAAGAGGGUAGCCAUCAGGGCCACAGAAGUUGUUAUCGACAUAGCGAGUGUAUGCCCCUCCGUUAAGCUCACGCAUGAGUUCACGGGUAACACCACUGCUAUGUUUAGUGUUCCAGUUUUCUUGAAAAUCUUCAUAAGGAUCAGUGCCAAGCUCGUCGCCUAAGUCAAAUGACUUUAGAUCGGCGCCGUAACUAUGGCCACCAGCUCCUUUAUUACCGUUCUUACGAAGAAGAACCUUGCGGUAAGCCACUGGUAUUUCGCCCACAUGAGGGACAAGGACACCAAGUGUCUCACCACUACGACCGUACUGAAUGCCUUCGAGUUCUGCUACCAGCUCAACCAUAACAUGACCAUGAGGUGCAGUUCGAGCAUCCGAACGUUUGAUGAACACAUAGGGCUGUUCAAGUUGAGGCAAAACGCCUUUUUCAACUUCUACUAAGCCACAAGUGCCAUCUUUAAGAUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,"1.7,17,170 nM[SARS-CoV-2];|18.5 µM [N protein]","150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Electron microscopy,solid,"Unlike polyC, in silico methods predict that these RNA fragments can form intra- and inter-molecular base-pairing interactions and contain extensive secondary structure elements. Similar to synthetic RNA substrates that form base-pair interactions, the N protein formed non-spherical condensates with viral RNA fragments in vitro."
479,PMID: 32995779,RNAPS0000428,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,SARS-CoV-2 virus RNA,5000nt(1-5000),GGUUAAUGUUGUCUACUGUUGUAAACACCUUAAUAGUCCUCACUUCUCUCAAAGAAAGAAGUGUCUUAAGAUUGUCAAAGGUGAUAACUUCACCAUCUAGGUGGAAUGUGGUAGGAUUACUAGUGUAAUAUACACUUUUAUCACCUCUCUUAAGAAAUUCUAUACCUAGUUGUGUAGAUUGUCCAGAAUAGGACCAAUCUUUAUAGGAACCAGCAAGUGAGAUGGUUUCAAUAAAAUGUUCUUCAGGUGUUUUAGAAGAAGAAGUAAGAUAACCAUUAUACGCUGUAACAGCAUCAGGUGAAGAAACAGAAACUGUAGCUGGCACUUUGAGAGAUCUCAUAUACCGAGCAGCUUCUUCCAAAUUUAAGCCAUGUGUUACAUAGCCAAGUGGCAUUGUAACAAGAGUUUCAUUUAGAUCGUUAAGUGUGUUGAUAAGUGACGCUACAGUUGUUUUACUGGUGUAAAAGUAAAAUCUAGCACCAUAAUCAACCACACCCUCUUGUAUUUUAAUACCCUUAUAUUUACGCUGUAUAGUUGAAACUAUGGCUUUAGUUUCCACACAGACAGGCAUUAAUUUGCGUGUUUCUUCUGCAUGUGCAAGCAUUUCUCGCAAAUUCCAAGAAACAGUUCCAAGAAUUUCUUGCUUCUCAUUAGAGAUAAUAGAUGGUAGAAUGUAAAAGGCACUUUUACACUUUUUAAGCACUGUCUUUGCCUCCUCUACAGUGUAACCAUUUAAACCCUGACCCGGGUAAGUGGUUAUAUAAUUGUCUGUUGGCACUUUUCUCAAAGCUUUCGCUAGCAUUUCAGUAGUGCCACCAGCCUUUUUAGUAGGUAUAACCACAGCAGUUAAAACACCCUCUUGAACAACAUCACCCACUAUAUAUGGAGCAUCUUUCUUUAAGAAAGUGAUGUCAAUGUCACUAACAAGAGUGGCAGAAUCUGGAUGAAGAUUGCCAUUAAUGUCAAUAUAAAGUAACAAGUUUUCUGUGAGGAACUUAGUUUCUUCCAGAGUUGUUGUAACUUCUUCAACACAAGCUUUGAUUUUCUUAUCAUCUUGUUUUCUCUGUUCAACUGAAGGUUUACUUUCAGUUAUAAAUGGCUUAACUUCCUCUUUAGGAAUCUCAGCGAUCUUUUGUUCAACUUGCUUUUCACUCUUCAUUUCCAAAAAGCUUGAAACAAGUUUGUCAUAGAGAUUUUUAUCAAAGACAGCUAAGUAGACAUUUGUGCGAACAGUAUCUACACAAACUCUUAAAGAAUGUAUAGGGUCAGCACCAAAAAUACCAGCUGAUAAUAAUGGUGCAAGUAGAACUUCGUGCUGAUUAAAAUUUUCAUAAGCACUCUUAAGAAGUUGAAUGUCUUCACCUUUGUUAACAUUUGGGCCGACAACAUGAAGACAGUGUUUAGCAAGAUUGUGUCCGCUUAAAACACAACUACCACCCACUUUAAGUGGUCCAUUAGUAGCUAUGUAAUCAUCAGAUUCAACUUGCAUGGCAUUGUUAGUAGCCUUAUUUAAGGCUCCUGCAACACCUCCUCCAUGUUUAAGGUAAACAUUGGCUGCAUUAACAACCACUGUUGGUUUUACCUUUUUAGCUUCUUCCACAAUGUCUGCAUUUUUAAUGUAUACAUUGUCAGUAAGUUUUAAAUAACCACUAAAACUAUUCACUUCAAUAGUCUGAACAACUGGUGUAAGUUCCAUCUCUAAUUGAGGUUGAACCUCAACAAUUGUUUGAAUAGUAGUUGUCUGAUUGUCCUCACUGCCGUCUUGUUGACCAACAGUUUGUUGACUAUCAUCAUCUAACCAAUCUUCUUCUUGCUCUUCUUCAGGUUGAAGAGCAGCAGAAGUGGCACCAAAUUCCAAAGGUUUACCUUGGUAAUCAUCUUCAGUACCAUACUCAUAUUGAGUUGAUGGCUCAAACUCUUCUUCUUCACAAUCACCUUCUUCUUCAUCCUCAUCUGGAGGGUAGAAAGAACAAUACAUAUGUGAAGCCAAUUUAAACUCACCAGACUCAUCAAAUAAGUAGUAUGUAGCCAUACUCCACUCAUCUAAAUCAAUGCCCAGUGGUGUAAGUAAUUCAGAUACUGGUUGCAAAGUUUUUAUGACAGCAUCUGCCACAACACAGGCGAACUCAUUUACUUCUGUACCGAGUUCAACUGUAUAGGCAGAGCACUUCUCAUUAAGUACUUUAUCAAUCCUUUCAUCAAGUUCAAAAGUGAUAUUCACACUCUUGUAACCUUGCACUUCUAUCACAGUGUCAUCACCAAAAGUAACCUUUGUUGGUGCACCGCCUUUGAGUGUGAAGGUAUUGUUUGUUACCAUCAUAUUAGGUGCAAGGGCACAGUACUUUUCUGUGUCUUUGAUUUCGAGCAACAUAAGCCCGUUAAUACAAACUGGUGUACCAACCAAUGGAGCUUCAACAGCUUCACUAGUAGGUUGUUCUAAUGGUUGUAAAUCACCAGUUUUCAAGACAACUUCCUCUGUUAACACUUCUGUGGGAAGUGUUUCUCCCUCUAAGAAGAUAAUUUCUUUUGGGGCUUUUAGAGGCAUGAGUAGGCCAGUUUCUUCUCUGGAUUUAACACACUUUCUGUACAAUCCCUUUGAGUGCGUGACAAAUGUUUCACCUAAAUUCAAGGCUUUAAGUUUAGCUCCACCAAUAAUGAUAGAGUCAGCACACAAAGCCAAAAAUUUAUUUACAAGCUUAAAGAAUGUCUGAACACUCUCCUUAAUUUCCUUUGCACAGGUGACAAUUUGUCCACCGACAAUUUCACAAGCACAGGUUGAGAUAAAUUUAACAAUUUCCCAACCGUCUCUAAGAAACUCUACACCUUCCUUAAACUUCUCUUCAAGCCAAUCAAGGACGGGUUUGAGUUUUUCAUAAACAGUGCCAAAGAUGUUAGUUAGCCACUGCGAAGUCAACUGAACAACACCACCUGUAAUGUAGGCCAUUACAACUAGAUUGUUAGUAGCCAAAUCAGAUGUGAACAUCAUAGCAUCAAUGAGUCUCAGUGAAUACUGUGAAAUUCCAUCUAGUAUUGUUAUAGCGGCCUUCUGUAAAACACGCACAGAAUUUUGAGCAGUUUCAAGAGUGCGGGAGAAAAUUGAUCGUACAACACGAGCAGCCUCUGAUGCAAAUGCAUAAAGAGGACUCAGUAUUGAUUUCUGUUCACCAAUAUUCCAGGCACCUUUUUUAGCUUUUCCUUUUGUAACUUUAAAAUUACCACAGGAUUCAACAAUUUGUUUGAAUGCUUUAUAAUCCAAACCUUUCACAGUUUCCACAAAAGCACUUGUGGAAGCAGAAAAAGAUGCCAAAAUAAUGGCGAUCUCUUCAUUAAGUUUAAAGUCACCAACAAUAUUGAUGUUGACUUUCUCUUUUUGGAGUAUUUCAAGAAGGUUGUCAUUAAGACCUUCGGAACCUUCUCCAACAACACCUGUAUGGUUACAACCUAUGUUAGCGCUAGCACGUGGAACCCAAUAGGCACACUUGUUAUGGCAACCAACAUAAGAGAACACACAGCCUCCAAAGGCAAUAGUGCGACCACCCUUACGAAGAAUGGUUUUCAAGCCAGAUUCAUUAUGGUAUUCGGCAAGACUAUGCUCAGGUCCUACUUCUGAAUUGUGACAUGCUGGACAAUAAAUUUUAACAACAGCAUUUUGGGGUAAGUAACCACAAGUAGUGGCACCUUCUUUAGUCAAAUUCUCAGUGCCACAAAAUUCGCAAGUGGCUUUAACAAAAUCGCCCGUCUGCCAUGAAGUUUCACCACAAUGAUCACACUUCAUGAGAGUUGAAAGGCACAUUUGGUUGCAUUCAUUUGGUGACGCAACUGGAUAGACAGAUCGAAUUCUACCCAUAAAGCCAUCAAGCUUUUUCUUUUCAACCCUUGGUUGAAUAGUCUUGAUUAUGGAAUUUAAGGGAAAUACAAAAUUUGGACAUUCCCCAUUGAAGGUGUCAAAUUUCUUUGCCAAUUUAAUUUCAAAAGGUGUCUGCAAUUCAUAGCUCUUUUCAGAACGUUCCGUGUACCAAGCAAUUUCAUGCUCAUGUUCACGGCAGCAGUAUACACCCCUCUUAGUGUCAAUAAAGUCCAGUUGUUCGGACAAAGUGCAUGAAGCUUUACCAGCACGUGCUAGAAGGUCUUUAAUGCACUCAAGAGGGUAGCCAUCAGGGCCACAGAAGUUGUUAUCGACAUAGCGAGUGUAUGCCCCUCCGUUAAGCUCACGCAUGAGUUCACGGGUAACACCACUGCUAUGUUUAGUGUUCCAGUUUUCUUGAAAAUCUUCAUAAGGAUCAGUGCCAAGCUCGUCGCCUAAGUCAAAUGACUUUAGAUCGGCGCCGUAACUAUGGCCACCAGCUCCUUUAUUACCGUUCUUACGAAGAAGAACCUUGCGGUAAGCCACUGGUAUUUCGCCCACAUGAGGGACAAGGACACCAAGUGUCUCACCACUACGACCGUACUGAAUGCCUUCGAGUUCUGCUACCAGCUCAACCAUAACAUGACCAUGAGGUGCAGUUCGAGCAUCCGAACGUUUGAUGAACACAUAGGGCUGUUCAAGUUGAGGCAAAACGCCUUUUUCAACUUCUACUAAGCCACAAGUGCCAUCUUUAAGAUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,18 nM[SARS-CoV-2 virus Sec1];|7.8 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,"other_molecular:0,10 mM lipoic acid",Electron microscopy,solid,"The  condensates formed by the N protein in the absence or presence of polyC or viral RNA dissolve with the  addition of 10% 1,6 hexanediol, indicating that phase separation is driven, at least partially, by hydrophobic  interactions (Figure 5A). In comparison, lipoic acid that increases the liquidity of stress granules did  not affect phase separation"
480,PMID: 32995779,RNAPS0000428,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,SARS-CoV-2 virus RNA,5000nt(1-5000),GGUUAAUGUUGUCUACUGUUGUAAACACCUUAAUAGUCCUCACUUCUCUCAAAGAAAGAAGUGUCUUAAGAUUGUCAAAGGUGAUAACUUCACCAUCUAGGUGGAAUGUGGUAGGAUUACUAGUGUAAUAUACACUUUUAUCACCUCUCUUAAGAAAUUCUAUACCUAGUUGUGUAGAUUGUCCAGAAUAGGACCAAUCUUUAUAGGAACCAGCAAGUGAGAUGGUUUCAAUAAAAUGUUCUUCAGGUGUUUUAGAAGAAGAAGUAAGAUAACCAUUAUACGCUGUAACAGCAUCAGGUGAAGAAACAGAAACUGUAGCUGGCACUUUGAGAGAUCUCAUAUACCGAGCAGCUUCUUCCAAAUUUAAGCCAUGUGUUACAUAGCCAAGUGGCAUUGUAACAAGAGUUUCAUUUAGAUCGUUAAGUGUGUUGAUAAGUGACGCUACAGUUGUUUUACUGGUGUAAAAGUAAAAUCUAGCACCAUAAUCAACCACACCCUCUUGUAUUUUAAUACCCUUAUAUUUACGCUGUAUAGUUGAAACUAUGGCUUUAGUUUCCACACAGACAGGCAUUAAUUUGCGUGUUUCUUCUGCAUGUGCAAGCAUUUCUCGCAAAUUCCAAGAAACAGUUCCAAGAAUUUCUUGCUUCUCAUUAGAGAUAAUAGAUGGUAGAAUGUAAAAGGCACUUUUACACUUUUUAAGCACUGUCUUUGCCUCCUCUACAGUGUAACCAUUUAAACCCUGACCCGGGUAAGUGGUUAUAUAAUUGUCUGUUGGCACUUUUCUCAAAGCUUUCGCUAGCAUUUCAGUAGUGCCACCAGCCUUUUUAGUAGGUAUAACCACAGCAGUUAAAACACCCUCUUGAACAACAUCACCCACUAUAUAUGGAGCAUCUUUCUUUAAGAAAGUGAUGUCAAUGUCACUAACAAGAGUGGCAGAAUCUGGAUGAAGAUUGCCAUUAAUGUCAAUAUAAAGUAACAAGUUUUCUGUGAGGAACUUAGUUUCUUCCAGAGUUGUUGUAACUUCUUCAACACAAGCUUUGAUUUUCUUAUCAUCUUGUUUUCUCUGUUCAACUGAAGGUUUACUUUCAGUUAUAAAUGGCUUAACUUCCUCUUUAGGAAUCUCAGCGAUCUUUUGUUCAACUUGCUUUUCACUCUUCAUUUCCAAAAAGCUUGAAACAAGUUUGUCAUAGAGAUUUUUAUCAAAGACAGCUAAGUAGACAUUUGUGCGAACAGUAUCUACACAAACUCUUAAAGAAUGUAUAGGGUCAGCACCAAAAAUACCAGCUGAUAAUAAUGGUGCAAGUAGAACUUCGUGCUGAUUAAAAUUUUCAUAAGCACUCUUAAGAAGUUGAAUGUCUUCACCUUUGUUAACAUUUGGGCCGACAACAUGAAGACAGUGUUUAGCAAGAUUGUGUCCGCUUAAAACACAACUACCACCCACUUUAAGUGGUCCAUUAGUAGCUAUGUAAUCAUCAGAUUCAACUUGCAUGGCAUUGUUAGUAGCCUUAUUUAAGGCUCCUGCAACACCUCCUCCAUGUUUAAGGUAAACAUUGGCUGCAUUAACAACCACUGUUGGUUUUACCUUUUUAGCUUCUUCCACAAUGUCUGCAUUUUUAAUGUAUACAUUGUCAGUAAGUUUUAAAUAACCACUAAAACUAUUCACUUCAAUAGUCUGAACAACUGGUGUAAGUUCCAUCUCUAAUUGAGGUUGAACCUCAACAAUUGUUUGAAUAGUAGUUGUCUGAUUGUCCUCACUGCCGUCUUGUUGACCAACAGUUUGUUGACUAUCAUCAUCUAACCAAUCUUCUUCUUGCUCUUCUUCAGGUUGAAGAGCAGCAGAAGUGGCACCAAAUUCCAAAGGUUUACCUUGGUAAUCAUCUUCAGUACCAUACUCAUAUUGAGUUGAUGGCUCAAACUCUUCUUCUUCACAAUCACCUUCUUCUUCAUCCUCAUCUGGAGGGUAGAAAGAACAAUACAUAUGUGAAGCCAAUUUAAACUCACCAGACUCAUCAAAUAAGUAGUAUGUAGCCAUACUCCACUCAUCUAAAUCAAUGCCCAGUGGUGUAAGUAAUUCAGAUACUGGUUGCAAAGUUUUUAUGACAGCAUCUGCCACAACACAGGCGAACUCAUUUACUUCUGUACCGAGUUCAACUGUAUAGGCAGAGCACUUCUCAUUAAGUACUUUAUCAAUCCUUUCAUCAAGUUCAAAAGUGAUAUUCACACUCUUGUAACCUUGCACUUCUAUCACAGUGUCAUCACCAAAAGUAACCUUUGUUGGUGCACCGCCUUUGAGUGUGAAGGUAUUGUUUGUUACCAUCAUAUUAGGUGCAAGGGCACAGUACUUUUCUGUGUCUUUGAUUUCGAGCAACAUAAGCCCGUUAAUACAAACUGGUGUACCAACCAAUGGAGCUUCAACAGCUUCACUAGUAGGUUGUUCUAAUGGUUGUAAAUCACCAGUUUUCAAGACAACUUCCUCUGUUAACACUUCUGUGGGAAGUGUUUCUCCCUCUAAGAAGAUAAUUUCUUUUGGGGCUUUUAGAGGCAUGAGUAGGCCAGUUUCUUCUCUGGAUUUAACACACUUUCUGUACAAUCCCUUUGAGUGCGUGACAAAUGUUUCACCUAAAUUCAAGGCUUUAAGUUUAGCUCCACCAAUAAUGAUAGAGUCAGCACACAAAGCCAAAAAUUUAUUUACAAGCUUAAAGAAUGUCUGAACACUCUCCUUAAUUUCCUUUGCACAGGUGACAAUUUGUCCACCGACAAUUUCACAAGCACAGGUUGAGAUAAAUUUAACAAUUUCCCAACCGUCUCUAAGAAACUCUACACCUUCCUUAAACUUCUCUUCAAGCCAAUCAAGGACGGGUUUGAGUUUUUCAUAAACAGUGCCAAAGAUGUUAGUUAGCCACUGCGAAGUCAACUGAACAACACCACCUGUAAUGUAGGCCAUUACAACUAGAUUGUUAGUAGCCAAAUCAGAUGUGAACAUCAUAGCAUCAAUGAGUCUCAGUGAAUACUGUGAAAUUCCAUCUAGUAUUGUUAUAGCGGCCUUCUGUAAAACACGCACAGAAUUUUGAGCAGUUUCAAGAGUGCGGGAGAAAAUUGAUCGUACAACACGAGCAGCCUCUGAUGCAAAUGCAUAAAGAGGACUCAGUAUUGAUUUCUGUUCACCAAUAUUCCAGGCACCUUUUUUAGCUUUUCCUUUUGUAACUUUAAAAUUACCACAGGAUUCAACAAUUUGUUUGAAUGCUUUAUAAUCCAAACCUUUCACAGUUUCCACAAAAGCACUUGUGGAAGCAGAAAAAGAUGCCAAAAUAAUGGCGAUCUCUUCAUUAAGUUUAAAGUCACCAACAAUAUUGAUGUUGACUUUCUCUUUUUGGAGUAUUUCAAGAAGGUUGUCAUUAAGACCUUCGGAACCUUCUCCAACAACACCUGUAUGGUUACAACCUAUGUUAGCGCUAGCACGUGGAACCCAAUAGGCACACUUGUUAUGGCAACCAACAUAAGAGAACACACAGCCUCCAAAGGCAAUAGUGCGACCACCCUUACGAAGAAUGGUUUUCAAGCCAGAUUCAUUAUGGUAUUCGGCAAGACUAUGCUCAGGUCCUACUUCUGAAUUGUGACAUGCUGGACAAUAAAUUUUAACAACAGCAUUUUGGGGUAAGUAACCACAAGUAGUGGCACCUUCUUUAGUCAAAUUCUCAGUGCCACAAAAUUCGCAAGUGGCUUUAACAAAAUCGCCCGUCUGCCAUGAAGUUUCACCACAAUGAUCACACUUCAUGAGAGUUGAAAGGCACAUUUGGUUGCAUUCAUUUGGUGACGCAACUGGAUAGACAGAUCGAAUUCUACCCAUAAAGCCAUCAAGCUUUUUCUUUUCAACCCUUGGUUGAAUAGUCUUGAUUAUGGAAUUUAAGGGAAAUACAAAAUUUGGACAUUCCCCAUUGAAGGUGUCAAAUUUCUUUGCCAAUUUAAUUUCAAAAGGUGUCUGCAAUUCAUAGCUCUUUUCAGAACGUUCCGUGUACCAAGCAAUUUCAUGCUCAUGUUCACGGCAGCAGUAUACACCCCUCUUAGUGUCAAUAAAGUCCAGUUGUUCGGACAAAGUGCAUGAAGCUUUACCAGCACGUGCUAGAAGGUCUUUAAUGCACUCAAGAGGGUAGCCAUCAGGGCCACAGAAGUUGUUAUCGACAUAGCGAGUGUAUGCCCCUCCGUUAAGCUCACGCAUGAGUUCACGGGUAACACCACUGCUAUGUUUAGUGUUCCAGUUUUCUUGAAAAUCUUCAUAAGGAUCAGUGCCAAGCUCGUCGCCUAAGUCAAAUGACUUUAGAUCGGCGCCGUAACUAUGGCCACCAGCUCCUUUAUUACCGUUCUUACGAAGAAGAACCUUGCGGUAAGCCACUGGUAUUUCGCCCACAUGAGGGACAAGGACACCAAGUGUCUCACCACUACGACCGUACUGAAUGCCUUCGAGUUCUGCUACCAGCUCAACCAUAACAUGACCAUGAGGUGCAGUUCGAGCAUCCGAACGUUUGAUGAACACAUAGGGCUGUUCAAGUUGAGGCAAAACGCCUUUUUCAACUUCUACUAAGCCACAAGUGCCAUCUUUAAGAUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,18 nM[SARS-CoV-2 virus Sec1];|7.8 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,"other_molecular:10% 1,6-hexanediol",Electron microscopy,liquid,"The  condensates formed by the N protein in the absence or presence of polyC or viral RNA dissolve with the  addition of 10% 1,6 hexanediol, indicating that phase separation is driven, at least partially, by hydrophobic  interactions (Figure 5A). In comparison, lipoic acid that increases the liquidity of stress granules did  not affect phase separation"
481,PMID: 32995779,RNAPS0000429,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,SARS-CoV-2 virus RNA,5000nt(5001-10000),ACCUGAGUUACUGAAGUCAUUGAGAGCCUUUGCGAGAUGACAACAAGCAGCUUCUCUGUAGCUAGUUGUAUCCAUUGCUCCACUAAAAUACUUGUACUUAUUAUAAAGAGCUAAGUAUCUAUUAUAUUGCGUAAGAGGUAAUAGCACAUCACUACGCAACUUUAGAUACAUUUCUUUAUUUAACAAAAAGGUGCACAGCGCAGCUUCUUCAAAAGUACUAAAGGAAACACCAUUAAAGACUACACGUCUCUUUAGGUAAUUACUAAAGAACCAAUAGAAAUGCUUUGUGGAAAUACAAAUGAUAUAAGCAAUUGUUAUCCAGAAAGGUACUAAAGGUGUGAACAUAACCAUCCACUGAAUAUGUGCUAAAAAAGAAACAUCAUUAGUAAGAUAAAAUGUCAAGUACAAGUAAAUAACAGAAUAAACACCAGGUAAGAAUGAGUAAACUGGUGUUAAACAGAGUACAGUGAAUGACAUAAGGAAUAGUAAAGUAUUAAAGGCAACUACAUGACUGUAUUCACCAAAAGCUCUUCUAAACCUCAUAAAAUAGUAGGCAAGGCAUGUUACUACGAUAGCUACAAUACCACCAGCUACUAUAGAUGCUGAUAUGUCCAAAGCACCAAUAGGUUGAAUUAGUGGUGUAAACAUAUUAGUAAGUAAAUUUACAGCAUCUACACCACAGAAAACUCCUGGUAAAGAUCUGUAAUAAUCAUUGUUAAGUACCCAUCUACCACUAGUAGAUACACAAACACCAGCUUCUGAUCUUUCACAAGUGCCGUGCCUACAGUACUCAGAAUCAAAAGUUGUUACCACUCUAACAGAACCUUCAAGGUAGGUGUUAGGAAAUUGAAUAAUAGAGCCAUCCAUGAGCACAUAACGUGUGUCAGGGCGUAAACUUUCAUAAGCAACAGAACCUUCUAGUACAUUGGUAUCAUAACAAUAUGGUACUGGCUUACCAGAAGCAUCUUUAAAAAUUGUACAUUCAGCAGCCAAAACACAAGCUGAUGUUGCAAAGUCAGUGUACUCUAUAAGUUUUGAUGGUGUGUAACAGAUGUUACCAACUGCACUAAAAACUCUAGGUAAGAAAUGCAAAAAGUCACCAUUAGUUGUGCGUAAUAUCGUGCCAGGCAAACCAGGCACGACAAAACCCACUUCUCUUGUUAUGACUGCAGCAAUCAAUGGGCAAGCUUUGUCAUUAGUAUAACUACCACCACGCUGGCUAAACCAUGUGUCAAAAUCAGCAUGUUUGUUAGCAAAACAAGUAUCUGUAGAUGCUAUGUCACGAGUGACACCACCAUCAAUAGCCUUGUAUCCUAUGAUUUCACUUGAAAAGUCAGUAUGUUUAGACAUGACAUGAACAGGUGUUAUUAAAUAGAAAAUAGCAGCAACAAAAAGGAACACAAGUGUAACUUUAAUUAACUGCUUCAACCAAUUAUUAACAAUUUUACCACCCUUAAGUGCUAUCUUUGUUGUUACAACAUUAACAACUUGUCUAGUAGUUGCACAUGUCAACUUAAAAGGUAAGUUAUUCUUUUUAGCAGCACUACGUAUUUGUUUUCGUAGUUGUUCAGACAAUGACAUGAAAUCUUUAACGUUCCAUAUCAAAGCAAUGUUGUGACUUUUUGCUACCUGCGCAUUAAUAUGACGCGCACUACAGUCAAUACAAGCACCAAGGUCACGGGGUGUCAUGUUUUCAACUUUGUUAUAGGUGAGCAUAUAGUUAUUACAACUAUCGCCAGUAACUUCUAUGUCAGAUUGAUGUGACAAUUUAAGACAUUCAACAACAUCUUUAGUUUCUACAUCUGAAUCAACAAACCCUUGCCGAGCUGCUGAAAUAAAAGUAGAUAAGACAUUGUCUAAGGACACAUUCUUUGCAAGUUCAGCUUCUGCAGUUGCAACUAGUGUUUUGAGUUUUUCCAUUGGUACGUUAAAAGUUGAUGAAAACGUAUUAACGUAAGCAUCAAACAUUUUAACUGCAACUUCCGCACUAUCACCAACAUCAGACACUAAUGCCUGAUCUAGUAACAGUAUAGGUUGACACAUAAGCUGACUGUAGUAAACAGACGCUGAUUUUGCAGAUGAUUCUUCACAUUUUGAUUUACCAUCAAAAACUAUAACAUUAAUAGGCAAUGAACCUUUAGUGUUAUUAGCUCUCAGGUUGUCUAAGUUAACAAAAUGAGAGAGAGAAUGUCUUUCAUAAGUCUUUUGACCAGCUUUAUCAAAGUAAAGAUGGAUGGAACCAUUCUUCACUGUAACACUAUCAACGAUGUAAGAAGACUGGUCAGUAGGAUUUAUUGGUCUUUUAAACUGUAGUGACAAGUCUCUCGCAACUUCAUCACUAAUAAAUGUACUACCAGCACAGAAUGUAUCACAAUUAACACAAUUCCAAUUGUGUAGUUUGCAAAAGCCUUUACCUCCAUUAGCAUAGACAUAAAAGGACCUUCUAACACCAUUAACAAUAGUUGUACAUUCGACUCUUGUUGCUCUAUUACGUUUGUAACACAUCAUACAAGUUGAUGAAUUACAACCGUCUACAACAUGCACAUAACUUUUCCAUACAUAAUAAAAUGAUGCAAAGAAGAUGUACAUUCUAACCAUAGCUGAAAUCGGGGCCAUUUGUACAAGAUUAAUUAUUAACCACAUAAGCCAAGAAUUACUAAUAAAAUGUACUGCAAAAUAGCUGAAAAACAAUUGCAUGAUUGCAGCCAAUCCAAGUACAUAGAAAAACCUAGUGAAAAGAAUAUAUGCCAAAAACCACUCUGCAACUAAGCCAAAAGCAGUUAAAUCCCAUUUAAAAGAUGAAAUGGUAAUUUGUAUAGUUUCUAAAGAAGGAUAGGUGUCUAAAGAAUCUAAACCACUAAGACAAACACUACAAGGUAUAGAACCAGUACAGUAGGUUGCAAUAGUGACAUUAGUAGAGUUCAAAUAGCCUUCUCUGUAACCAGUACAGUAAGAAGGCAUGCCUAAAUUAGACAUUAAAACACCUAAAGCAGCGGUUGAGUAGAUUAAAGAACCUAGGCAAACACUUAAUAGUAAAAACCAAAUUAUAAUAUUUAUCAGUUUAGAAAAAUUAGGUGACUUCAAAUAAUUAAAUGAAGCCUCUAGACAAAAUUUACCGACACUCUUAACAGUAUUCUUUGCUAUAGUAGUCGGCAUAGAUGCUUUAAUUCUAGAAUUUGUACUUCUAGUAAAAGUACACAAUUGUAGCAAUAAAGUAAAGAAAUAAGGCAUAUAAUUAGUACAAACACGGUUUAAACACCGUGUAACUAUGUUAGUAGUUGUACUAACAACUUUGUUAAGAAAAGGCUUAGCAUAAUUAGCUAUAGUAUCCCAAGGGACACUAUUAACAGCAGCUAAACCAUGAGUAGCAAGGGUUUUCAAACCUAAUACUCUAGAUAAUUCAUUAGGUUUCUUAAUAGUAAGACUAGAAUUGUCUACAUAAGCAGCCAUUAGAUCUGUGUGGCCAACCUCUUCUGUAAUUUUUAAACUAUUAUUUGCUGGUUUAAGUAUAAUGUCUCCUACAACUUCGGUAGUUUUCACAUUACACUCAAGAACGUCUUUCUGUAUGGUAGGAUUUUCCACUACUUCUUCAGAGACUGGUUUUAGAUCUUCGCAGGCAAGAUUAUCCAUUCCCUGCGCGUCCUCUGACUUCAGUACAUCAAACGAAUUUGAUGUUUCAACUGGUUUUGUGCUCCAAAGACAACGUAUACACCAGGUAUUUGGUUUAUACGUGGCUUUAUUAGUUGCAUUGUUAACAUGCCAAACAAUAGGUUUAUGUAACAAUUUAGCUCCUUUCUUAAAAGAGGGUGUGUAGUGUUUAUAAUCAAUAGCCACCACAUCACCAUUUAAGUCAGGGAAAAAUGUAACUUUAAGCUCUCUUGAAGCAGGUUUCUUAUAACCAGUUAACUGGUUUAAAUCAUCAGCAAAUUUGAUAUUAUCACAUACAAACUUAAAAUUAUCGAAGCUUGCGUUUGGAUAUGGUUGGUUUGGUACAAGAUCAAUUGGUUGCUCUGUGAAAUAAGAAUUGUCUUUCUUAUAAUAAUUGUCCAACUUAGGGUCAAUUUCUGUACAAACAACACCAUCCAAUUUAUAAGUAACUGGUUUUAUGGUUGUUGUGUAACUGUUUUCUUUGUAGAAAACAUCCGUAAUAGGACCUUUGUAUUCUGAGGACUUUGUAAGUAAAGCACCGUCUAUGCAAUACAAAGUUUCUUUAGAAGUUAUAUGUUUAUAGUGACCACACUGGUAAUUACCAGUGUACUCACUAGCACAAGUAAAUGUACCAUGCUUAAGUUCAUACUGAGCAGGUGGUGCUGACAUCAUAACAAAAGGUGACUCCUGUUGUACUAGAUAUUUUGUAGCUUGUUUACCACACGUACAAGGUAUCUGAACACCUUUCUUAAAUUGUUCAUAAGAAAGUGUGCCCAUGUACAUAACAGCUUCUACACCCUUAAGGGUUGUCUGCUGUUGUCCACAAGUUUUACACACCACGUUCAAGACUCUUUUGCAAGAAUCUAAAUUGGCAUGUUGAAACAAGUAACUCAUUGUUUCUCUAACAUCACCUAACUCACCUACUGUCUUAUUACAGUAGGCUAAGAUAAGUGCACAAAAGUUAGCAGCUUCACCAGCCCUUGCUCUGUAAUAAGCAUCUUGUAGAGCAGGUGGAUUAAACUUCAACUCUAUUUGUUGGAGUGUUAACAAUGCAGUGGCAAGAUAACAGUUGUUAUCUGCCCAUUUAAUAGAAGUUAAACCAUUAACUUGUGGGUAUUUCCACUUUUUAGUGUGAUUUAAUGCUGACAUGUACCUACCCAGAAAACUAGGAUCAGUUGUGUGGUAGUACUCAAAAGCCUCAACACGUAGAGUGUCAUCAUUAGGUAAAACAUAAAAUGUUUUACCUUCAUGUGAAUUAUGAGGUUUUAUUUUAGUAACAUCAGCUCCAUCCAAAUAAGUUGGACCAAACUGUUGUCCAUAUGUCAUUGACAUGUCCACAACUUGCGUGUGGA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,"1.9,18,190 nM[SARS-CoV-2];|18.5 µM [N protein]","150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Electron microscopy,solid,"Unlike polyC, in silico methods predict that these RNA fragments can form intra- and inter-molecular base-pairing interactions and contain extensive secondary structure elements. Similar to synthetic RNA substrates that form base-pair interactions, the N protein formed non-spherical condensates with viral RNA fragments in vitro."
482,PMID: 32995779,RNAPS0000430,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,SARS-CoV-2 virus RNA,5000nt(10001-15000),ACUCAUUGAAUCAUAAUAAAGUCUAGCCUUACCCCAUUUAUUAAAUGGAAAACCAGCUGAUUUGUCUAGGUUGUUGACGAUGACUUGGUUAGCAUUAAUACAGCCACCAUCGUAACAAUCAAAGUACUUAUCAACAACUUCAACUACAAAUAGUAGUUGUCUGAUAUCACACAUUGUUGGUAGAUUAUAACGAUAGUAGUCAUAAUCGCUGAUAGCAGCAUUACCAUCCUGAGCAAAGAAGAAGUGUUUUAAUUCAACAGAACUUCCUUCCUUAAAGAAACCCUUAGACACAGCAAAGUCAUAGAAGUCUUUGUUAAAAUUACCGGGUUUGACAGUUUGAAAAGCAACAUUGUUAGUAAGUGCAGCUACUGAAAAGCACGUAGUGCGUUUAUCUAGUAAUAGAUUACCAGAAGCAGCGUGCAUAGCAGGGUCAGCAGCAUACACAAGUAAUUCCUUAAAACUAAGUCUAGAGCUAUGUAAGUUUACAUCCUGAUUAUGUACAACACCUAGCUCUCUGAAGUGGUAUCCAGUUGAAACUACAAAUGGAACACCAUCAACAAAUAUUUUUCUCACUAGUGGUCCAAAACUUGUAGGUGGGAACACUGUAGAGAAUAAAACAUUAAAGUUUGCACAAUGCAGAAUGCAUCUGUCAUCCAAACAGUUAACACAAUUUGGGUGGUAUGUCUGAUCCCAAUAUUUAAAAUAACGGUCAAAGAGUUUUAACCUCUCUUCCGUGAAGUCAUAUUUUAACAAAUCCCACUUAAUGUAAGGCUUUGUUAAGUCAGUGUCAACAUGUGACUCUGCAGUUAAAGCCCUGGUCAAGGUUAAUAUAGGCAUUAACAAUGAAUAAUAAGAAUCUACAACAGGAACUCCACUACCUGGCGUGGUUUGUAUGAAAUCACCGAAAUCAUACCAGUUACCAUUGAGAUCUUGAUUAUCUAAUGUCAGUACACCAACAAUACCAGCAUUUCGCAUGGCAUCACAGAAUUGUACUGUUUUUAACAAAGCUUGGCGUACACGUUCACCUAAGUUGGCGUAUACGCGUAAUAUAUCUGGGUUUUCUACAAAAUCAUACCAGUCCUUUUUAUUGAAAUAAUCAUCAUCACAACAAUUGUAUGUGACAAGUAUUUCUUUUAAUGUGUCACAAUUACCUUCAUCAAAAUGCCUUAAAGCAUAGACGAGGUCUGCCAUUGUGUAUUUAGUAAGACGUUGACGUGAUAUAUGUGGUACCAUGUCACCGUCUAUUCUAAACUUAAAGAAGUCAUGUUUAGCAACAGCUGGACAAUCCUUAAGUAAAUUAUAAAUUGUUUCUUCAUGUUGGUAGUUAGAGAAAGUGUGUCUCUUAACUACAAAGUAAGAAUCAAUUAAAUUGUCAUCUUCGUCCUUUUCUUGGAAGCGACAACAAUUAGUUUUUAGGAAUUUAGCAAAACCAGCUACUUUAUCAUUGUAGAUGUCAAAAGCCCUGUAUACGACAUCAGUACUAGUGCCUGUGCCGCACGGUGUAAGACGGGCUGCACUUACACCGCAAACCCGUUUAAAAACGAUUGUGCAUCAGCUGACUGAAGCAUGGGUUCGCGGAGUUGAUCACAACUACAGCCAUAACCUUUCCACAUACCGCAGACGGUACAGACUGUGUUUUUAAGUGUAAAACCCACAGGGUCAUUAGCACAAGUUGUAGGUAUUUGUACAUACUUACCUUUUAAGUCACAAAAUCCUUUAGGAUUUGGAUGAUCUAUGUGGCAACGGCAGUACAGACAACACGAUGCACCACCAAAGGAUUCUUGAUCCAUAUUGGCUUCCGGUGUAACUGUUAUUGCCUGACCAGUACCAGUGUGUGUACACAACAUCUUAACACAAUUAGUGAUUGGUUGUCCCCCACUAGCUAGAUAAUCUUUGUAAGCUUUAGCAGCAUCUACAGCAAAAGCACAGAAAGAUAAUACAGUUGAAUUGGCAGGCACUUCUGUUGCAUUACCAGCUUGUAGACGUACUGUGGCAGCUAAACUACCAAGUACCAUACCUCUAUUUAGGUUGUUUAAUCCUUUAAUAAAGUAUAAAUACUUCACUUUAGGACCUUUAGGUGUGUCUGUAACAAACCUACAAGGUGGUUCCAGUUCUGUAUAGAUAGUACCAGUUCCAUCACUCUUAGGGAAUCUAGCCCAUUUCAAAUCCUGUAAAUCGGAUAACAGUGCAAGUACAAACCUACCUCCCUUUGUUGUGUUGUAGUAAGCUAACGCAUUGUCAUCAGUGCAAGCAGUUUGUGUAGUACCGGCAGCACAAGACAUCUGUCGUAGUGCAACAGGACUAAGCUCAUUAUUCUGUAAUUUGACAGCAGAAUUGGCCCUUAAAGCUGUUACAAUAAGAGGCCAUGCUAAAUUAGGUGAAUUGUCCAUACUAAUUUCACUAAGUUGAACAAUUUUACUAUCUGCAUCUACAACCUGUUGGAUUUCCCACAAUGCUGAUGCAUAAGUAAAUGUUGUACCAUCACACGUAUUUUUAUAUGUGUUAUAGUCUGGUAUGACAACCAUUAGUUUGGCUGCUGUUGUAAGAGGUAUUAUGUUCAAGGGAACACAACCAUCUCUUGCAUUGUUGAUAAUGUUGUUGAGUGCAUCAUUAUCCAACUUUCUAAGCAUAGUGAAAAGCAUUGUCUGCAUAGCACUAGUAACUUUUGCCCUCUUGUCCUCAGAUCUAGCCUGUUUAUACAUUUGGGUCAUAGCUUGAUCAGCCAUCUUUUCCAACUUACGUUGCAUGGCUGCAUCACGGUCAAAUUCAGAUUUAGCCACAUUCAAAGACUUCUUCAACUUUUUAAGAACAACUUCAGAAUCACCAUUAGCAACAGCCUGCUCAUAAGCUUCUUGAGCAGUAGCAAAAGCUGCAUAUGAUGGAAGGGAACUAAACUCUGAGGCUAUAGCUUGUAAGGUUGCCCUGUUGUCCAGCAUUUCUUCACAAAGCUUGUUUAUGUCUACAGCACCCUGCAUGGAAAGCAAAACAGAAAGUAGUGAAACCAUUUUUUCAAAGGCUUCAGUAGUAUCUUUAGCUAAGAGAAUGUCAUUGUGUAACUGGACACAUUGAGCCCACAAUUUAGAUGAUGAUUCUACUCUGAGUUGUUGCAAAACUGAGAGUAAGACUACUGAUGUGCACUUUACAUCUGACAUUUUAGACUGUACAGUGGCUACUUUGAUACAAGGUUUGCCACCAACACCCAACAAUUUAAUGUUGAGUUUGAAGGCAUCUAUGCUAUUCUUGGGUGGGAGUAGUCCCUGUGAAUUCAUAUAUCUAAACUCCUGUGUAGAAACUAAGUAAUCAUAAACACCAAGAGUCAGUCUAAAGUAGCGGUUGAGUAAACAAAAGAGGCCAAAGUAACAAGUACAAAAAUAGCCUAAGAAACAAUAAACUAGCAUUAUACACUGAAGUGUAUUACCAGUUAUGAAGAAAAUAGGGCAAUACUCAACACACAUAAAAACAAUACCUCUGGCCAAAAACAUGACAGUUGUAACUACACCUGAGUAGUUAGAAGUAACAGAGAUUAUAAGAGCCCACAUGGAAAUGGCUUGAUCUAAAGCAUUACCAUAAUAAACUUUAUAAACGAGUGUCAAGACAUUCAUAAGUGUCCACACUCUCCUAGCACCAUCAUCAUACACAGUUCUUGCUGUCAUAAGGAUUAGUAACACUACAGCUGAUGCAUACAUAACACAGUCUUUUAGCUUAAAACCAGACAAACUAGUAUCAACCAUAUCCAACCAUGUCAUAAUACGCAUCACCCAACUAGCAGGCAUAUAGACCAUAUUAAAAUAAGCUACAGUGGCAAGAGAAGGUAACAAAAACAAACAGAGAAAUGCAUGCUUAUGUUUGACAAACAUCAUUGCAAAAGCAGACAUAGCAAUAAUACCCAUAGCAAAAGGUAAAAAGGCAUUUUCAUACAAAAAAAAGAACAAAGACCAUUGAGUACUCUGGACUAAAACUAAAAGUGAAGUCAAAAUUGUGAGUAACAACCAGUGGUGUGUACCCUUGAUUGUUCUUUUCACUGCACUUUGGAAAGUAACACCUGAGCAUUGUCUAACAACAUCAAAAGGUGUAAAUUCAUCUUCUAAUAAAGCACUACCCAAUAUGGUACGUCCAUUCAUACCAUUUUGCAGUAAUUCUUUUAAUGAAGCACACAUAUCUAAAACGGCAAUUCCAGUUUGAGCAGAAAGAGGUCCUAGUAUGUCAACAUGGUCUUGUGUUAGAGGUUCAUAAUUGUACUUCAUAGCCACAAGGUUAAAGUCAUUAAGAGUUGUGGUAAAUCGAUUGAGAAACCACCUGUCUCCAUUUAUAACAGCAGCGUACAACCAAGCUAAAACAUUAACUGUAAUAGUUGUGUCCGUACCAGCUGCUUGUGCUGUUUGCCUGUCAACAAAAGGUCCAUAAAAGUUACCUUCUAAGUCUGUGCCAGCAUGAACUCCAGUUGGUAAUUCCAUAUGGUGCAUGUAACAAAAAGAGACACAGUCAUAAUCUAUGUUAAAACCAACACUACCACAUGAACCAUUAAGGAAUGAACCCUUAAUAGUGAAAUUGGGCCUCAUAGCACAUUGGUAAACACCAGAUGGUGAACCAUUGUAACAAGCUAACACUGAAAAAGUCUGUCCUGGUUGAAUGCGAACAAACUUAUACUUAGGUGUCUUAGGAUUGGCUGUAUCAACCUUAAGCUUAAGUACACAAUUUUGCAUAGAAUGUCCAAUAACCCUGAGUUGAACAUUACCAGCCUGUACCAAGAAAUUAUGAUUAGACUUACGAAUGAGUAAAUCUUCAUAAUUAGGGUUAAGCAUGUCUUCAGAGGUGCAGAUCACAUGUCUUGGACAGUAAACUACGUCAUCAAGCCAAAGACCGUUAAGUGUAGUUGUACCACAAGUUACUUGUACCAUACAACCCUCAACUUUACCAGAUGGGAAUGCCAUUUUUCUAAAACCACUCUGCAAAACAGCUGAGGUGAUAGAGGUUUGUGGUGGUUGGUAAAGAACAUCAGA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,"1.8,18,180 nM[SARS-CoV-2];|18.5 µM [N protein]","150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Electron microscopy,solid,"Unlike polyC, in silico methods predict that these RNA fragments can form intra- and inter-molecular base-pairing interactions and contain extensive secondary structure elements. Similar to synthetic RNA substrates that form base-pair interactions, the N protein formed non-spherical condensates with viral RNA fragments in vitro."
483,PMID: 32995779,RNAPS0000431,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,SARS-CoV-2 virus RNA,5000nt(15001-20000),ACUCUACCAUCAAAAAAGACAGUGAGUGGUGCACAAAUCGUUUCAGUUGGUUUCUUGGCUAUGUCAGUCAUAGAACAAACACCAAUAGUAGAUAUAUGUGCUGGAGCAUCUCUUUUGUAGUCCCAGAUCACAGUAUUAGCAGCAAUGUCCACACCCAAAUUAUUGAGUAUUUUCACCUCUGGUACUGGUUUAAUGUUGCGCUUAGCCCAAAGCUCAAAUGCUACAUUAACAGGUAAUGUUGUUUUAUUUUCAAACAAUUCUACAUCAACACCAUCAACUUUUGUGUAAACAGUGUUAUUAAUGAUAGAAACUGGUACUUCACCCUGUUGUCCAUCAAAGUGUCCCUUAUUUACAACAUUAAAAGCCACAUUUUCUAAACUCUGAAGUCUUGUAAAAGUGUUCCAGAGGUUAUAAGUAUCAAAUUGUUUGUAAACCCACAAGCUAAAGCCAGCUGAGAUCAUCAUGUUAUAAGCAUCGAGAUACAAUCUGUACUCAUUAGCAUGAUGUCUACAGACAGCACCACCUAAAUUGCAACGUGUUAUACACGUAGCAGACUUUAGUGGUACAUAAUCUAUAUCUGACACUACUUGUUUUCCAUGAGACUCACAUGGACUGUCAGAGUAAUAGAAAAAUGGUAAUUGUUUUAAAUUAACAAAAGCACUUUUAUCAAAAGCUGGUGUGUGGAAUGCAUGUUUAUUUACAUACAAACUGCCACCAUCACAACCAGGCAAGUUAAGGUUAGAUAGCACUCUAGUGUCAAAUCUACAAACAAUGGAAUUAGCAGGAUAUCUAUCGACAUUGCAAUUCCAAAAUAGGCAUACACCAUCUGUGAAUUUGUCAGAAUGUGUGGCAUAAGAAUAGAAUAAUUCUUCUAUUUUAUAAGCUUUGUCACUACAAGGCUGUGCAUCAUAGAACUUCCAUUCUACAUCAGCUUGAGGUACACACUUAAUAGCUUUAGGGUUACCAAUGUCGUGAAGAACUGGGAAUUUGUCUGCUAAUAAUGCAGCUUUAACAACCAUGUGUUGAACCUUUCUACAAGCCGCAUUAAUCUUCAGUUCAUCACCAAUUAUAGGAUAUUCAAUAGUCCAGUCAACACGCUUAACAAAGCACUCGUGGACAGCUAGACACCUAGUCAUGAUUGCAUCACAACUAGCUACAUGUGCAUUACCAUGGACUUGACAAUACAGAUCAUGGUUGCUUUGUAGGUUACCUGUAAAACCCCAUUGUUGAACAUCAAUCAUAAACGGAUUAUAGACGUAAUCAAAUCCAAUAGAAUGAUGCCAACAGGCAUAAGUGUCUGAAGCAGUGGAAAAGCAUGUGGCACGUCUAUCACAUAGACAACAGGUGCGCUCAGGUCCUAUUUUCACAAAAUACUUCAUAGAUGUCAACUCAAAGCCAUGUGCCCAUAAGACAAAUACGACUCUGUCAGAGAGAUUUUUAAGUGUGUCACUUAACAUUUGUACAAUCUUUAUACGCACUACAUUCCAAGGAAGUCCUUUGUACAUAAGUGGUAUGAGGUGUUUAAAUUGAUCUCCAGGCGGUGGUUUAGCACUAACUCUGGAAAAAUCUGUAUUAUUAGGUGUAUCAACAUAACCUGUAGGUACAGCAACUAGGUUAACACCUGUAGAAAAACCUAGCUGUAAAGGUAAAUUGGUACCAACAGCUUCUCUAGUAGCAUGACACCCCUCGACAUCGAAGCCAAUCCAUGCACGUACAUGUCUUAUAGCUUCUUCGCGGGUGAUAAACAUGUUAGGGUAACCAUUAACUUGAUAAUUCAUUUUAAAACCCAUCAUAGAGAUGAGUCUUCUAUAGGUCAUGUCCUUAGGUAUGCCAGGUAUGUCAACACAUAAACCUUCAGUUUUGAAUUUAGUGUCAACACUGAGGUGUGUAGGUGCCUGUGUAGGAUGUAACCCAGUGAUUACCUUACUACAAUCUUUAAAGAGUCCUGUUACAUUUUCAGCUUGUAAAGUUGCCACAUUCCUACGUGGAAUUUCAAGACUUGUAAAUUGCAACUUGUCAUAAAGGUCUCUAUCAGACAUUAUGCAAAGUAUGCCUACUUUUGCUCUGGUAAUAGCAACAUUAAAUCUGUUUACAUUACAAGAGUGAGCUGUUUCAGUGGUUUGAGUGAAUAUGACAUAGUCAUAUUCUGAGCCCUGUGAUGAAUCAACAGUUUGAGUUGGUAGUCCCAAAAUCUUUGAGGCUACAGCAUUCUGUGAAUUAUAAGGUGAAAUAAAGACAGCUUUUCUCCAAGCAGGGUUACGUGUAAGGAAUUCUCUUACCACGCCUAUUUGUGGCCUGUUAAUUGCAGAUGAAACAUCAUGCGUGAUAACACCCUUAUAAAACAUUUUAAAGCAUUGAGCUGAUUUGUCUUUAUGUGCUUUAAGCUUAUUAUCAUAAACCAAAGCACUCACAGUGUCAACAAUUUCAGCAGGACAACGCCGACAAGUUCCGAGGAACAUGUCUGGACCUAUAGUUUUCAUAAGUCUACACACUGAAUUGAAAUAUUCUGGUUCUAGUGUGCCCUUAGUUAGCAAUGUGCGUGGUGCAGGUAAUUGAGCAGGGUCGCCAAUGUACACAUAGUGCUUAGCACGUAAUCUGGCAUUGACAACACUCAAAUCAUAAUUUGUGGCCAUUGAAAUUUCAUCAAAGACAACUAUAUCUGCUGUCGUCUCAGGCAAUGCAUUUACAGUACAAAAGACAUACUGUUCUAAUGUUGAAUUCACUUUGAAUUUAUCAAAACACUCUACACGAGCACGUGCAGGUAUAAUUCUACUACAUUUAUCUAUAGGCAAAUAUUUUAAUGCCUUCUCACAUAGUGCAUCAACAGCGGCAUGAGAGCAAGCUGUAUACACUAUGCGAGCAGAAGGGUAGUAGAGAGCUAGGCCAAUAGCAAAAUGACUCUUACCAGUACCAGGUGGUCCCUGGAGUGUAGAAUACUUUUGCAUACCAACCUUUUGAUAAUUUGCAACAUUGCUAGAAAACUCAUCUGAGAUAUUGAGUGUUGGGUAUAAGCCAGUAAUUCUAACAUAGUGCUCUUGUGGCACUAGUGUAGGUGCACUUAAUGGCAUUACUGUAUGUGAUGUCAGCACAAAAUAAUCACCAACAUUUAAUUUGUAAGUUGUUGUACCUCGGUAAACAACAGCAUCACCAUAGUCACCUUUUUCAAAGGUGUACUCUCCUAUUUGUACUUUACUGUUUUUAGUUACACGAUAACCAGUAAAGACAUAAUUUCGGUUAAGUGGUGGUCUAGGUUUACCAACUUCCCAUGAAAGAUGUAAUUCUCUGUCAGACAGCACUUCACGUACAGUAGCAAUACCAUAAGACAGUUUAAAUGUCUCCUCAGUAGCUUUGAGCGUUUCUGCUGCAAAAAGCUUGAGUCUUUCAGUACAGGUGUUAGCUAAAAUGUAAUCACCAGCAUUUGUCCAGUCACAUGUUGCAAUUGCAUUAAAGUCAGUAACAUUAUCGCUACCAACACAUGUAUUUUUAUAUAAACCAAAAACUUGUCCAUUAGCACACAAUGGAAAACUAAUGGGUGGUUUAUGUGAUUUACAAUAAUAGCUCAUACCUCCUAAGUAAAGUUGAGUCACAUCUGUGACAUCACAACCUGGAGCAUUGCAAACAUACGGAUUAACAGACAAGACUAAUUUAUGUGAUGUUGAUAUGACAUGGUCGUAACAGCAUUUACAACAUAAGAAUGGUCUACGUAUGCAAGCACCACAUCUUAAUGAAGUCUGUGAAUUGCAAAGAACACAAGCCCCAACAGCCUGUAAGACUGUAUGCGGUGUGUACAUAGCCUCAUAAAACUCAGGUUCCCAAUACCUUGAAGUGUUAUCAUUAGUAAGCAUAACAGAAUACAUGUCUAACAUGUGUCCUGUUAACUCAUCAUGUAGCUUUCUUAUGUAUUGUAAGUACAAAUGAAAGACAUCAGCAUACUCCUGAUUAGGAUGUUUAGUAAGUGGGUAAGCAUCUAUAGCUAAAGACACGAACCGUUCAAUCAUAAGUGUACCAUCUGUUUUUACGAUAUCAUCUACAAAACAGCCGGCCCCUAGGAUUCUUGAUGGAUCUGGGUAAGGAAGGUACACAUAAUCAUCACCCUGUUUAACUAGCAUUGUAUGUUGAGAGCAAAAUUCAUGAGGUCCUUUAGUAAGGUCAGUCUCAGUCCAACAUUUUGCUUCAGACAUAAAAACAUUGUUUUGAUAAUAAAGAACUGACUUAAAGUUCUUUAUGCUAGCCACUAGACCUUGAGAUGCAUAAGUGCUAUUGAAACACACAACAGCAUCGUCAGAGAGUAUCAUCAUUGAGAAAUGUUUACGCAAAUAUGCGUAAAACUCAUUCACAAAGUCUGUGUCAACAUCUCUAUUUCUAUAGAGACACUCAUAAAGUCUGUGUUGUAAAUUGCGGACAUACUUAUCGGCAAUUUUGUUACCAUCAGUAGAUAAAAGUGCAUUAACAUUGGCCGUGACAGCUUGACAAAUGUUAAAAACACUAUUAGCAUAAGCAGUUGUGGCAUCUCCUGAUGAGGUUCCACCUGGUUUAACAUAUAGUGAACCGCCACACAUGACCAUUUCACUCAAUACUUGAGCACACUCAUUAGCUAAUCUAUAGAAACGGUGUGACAAGCUACAACACGUUGUAUGUUUGCGAGCAAGAACAAGUGAGGCCAUAAUUCUAAGCAUGUUAGGCAUGGCUCUAUCACAUUUAGGAUAAUCCCAACCCAUAAGGUGAGGGUUUUCUACAUCACUAUAAACAGUUUUUAACAUGUUGUGCCAACCACCAUAGAAUUUGCUUGUUCCAAUUACUACAGUAGCUCCUCUAGUGGCGGCUAUUGAUUUCAAUAAUUUUUGAUGAAACUGUCUAUUGGUCAUAGUACUACAGAUAGAGACACCAGCUACGGUGCGAGCUCUAUUCUUUGCACUAAUGGCAUACUUAAGAUUCAUUUGAGUUAUAGUAGGGAUGACAUUACGUUUUGUAUAUGCGAAAAGUGCAUCUUGAUCCUCAUA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,"1.8,18,52 nM[SARS-CoV-2];|18.5 µM [N protein]","150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Electron microscopy,solid,"Unlike polyC, in silico methods predict that these RNA fragments can form intra- and inter-molecular base-pairing interactions and contain extensive secondary structure elements. Similar to synthetic RNA substrates that form base-pair interactions, the N protein formed non-spherical condensates with viral RNA fragments in vitro."
484,PMID: 32995779,RNAPS0000432,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,SARS-CoV-2 virus RNA,5000nt(20001-25000),GUCUAAUUCAGGUUGCAAAGGAUCAUAAACUGUGUUGUUGACAAUUCCUAUUACAACAUCACAGUUACCAGACACAAAUGUGUUGUCUGUAGUAAUGAUUUGUGGUUCAUAAAAAUUCCUUUGUGUUACAAACCAGUGUGUGCCAUUUGAAACAAAGACACCUUCACGAGGAAAGUGUGCUUUUCCAUCAUGACAAAUGGCAGGAGCAGUUGUGAAGUUCUUUUCUUGUGCAGGGACAUAAGUCACAUGCAAGAAGACUACACCAUGAGGUGCUGACUGAGGGAAGGACAUAAGAUGAUAGCCCUUUCCACAAAAAUCAACUCUUUUUGAUUGUCCAAGUACACACUCUGACAUUUUAGUAGCAGCAAGAUUAGCAGAAGCUCUGAUUUCUGCAGCUCUAAUUAAUUGUUGAGUCACAUAUGUCUGCAAACUUUGAAGUCUGCCUGUGAUCAACCUAUCAAUUUGCACUUCAGCCUCAACUUUGUCAAGACGUGAAAGGAUAUCAUUUAAAACACUUGAAAUUGCACCAAAAUUGGAGCUAAGUUGUUUAACAAGCGUGUUUAAAGCUUGUGCAUUUUGGUUGACCACAUCUUGAAGUUUUCCAAGUGCACUUGCUGUGGAAGAAAGUGAGUCUUGAAUUUUGCCAAUAGCACUAUUAAAUUGGUUGGCAAUCAAUUUUUGGUUCUCAUAGAGAACAUUCUGUGUAACUCCAAUACCAUUAAACCUAUAAGCCAUUUGCAUAGCAAAUGGUAUUUGUAAUGCAGCACCUGCACCAAAGGUCCAACCAGAAGUGAUUGUACCCGCUAACAGUGCAGAAGUGUAUUGAGCAAUCAUUUCAUCUGUGAGCAAAGGUGGCAAAACAGUAAGGCCGUUAAACUUUUGUGCACAAAUGAGGUCUCUAGCAGCAAUAUCACCAAGGCAAUCACCAUAUUGUUUGAUGAAGCCAGCAUCUGCAAGUGUCACUUUGUUGAAAAGUAGAUCUUCAAUAAAUGACCUCUUGCUUGGUUUUGAUGGAUCUGGUAAUAUUUGUGAAAAAUUAAAACCACCAAAAUCUUUAAUUGGUGGUGUUUUGUAAAUUUGUUUGACUUGUGCAAAAACUUCUUGGGUGUUUUUGUCUUGUUCAACAGCUAUUCCAGUUAAAGCACGGUUUAAUUGUGUACAAAAACUGCCAUAUUGCAACAAAAGAUUGCUGCAUUCAGUUGAAUCACCACAAAUGUACAUUGUACAAUCUACUGAUGUCUUGGUCAUAGACACUGGUAGAAUUUCUGUGGUAACACUAAUAGUAAAAUUUGUGGGUAUGGCAAUAGAGUUAUUAGAGUAAGCAACUGAAUUUUCUGCACCAAGUGACAUAGUGUAGGCAAUGAUGGAUUGACUAGCUACACUACGUGCCCGCCGAGGAGAAUUAGUCUGAGUCUGAUAACUAGCGCAUAUACCUGCACCAAUGGGUAUGUCACACUCAUAUGAGUUGUUGACAUGUUCAGCCCCUAUUAAACAGCCUGCACGUGUUUGAAAAACAUUAGAACCUGUAGAAUAAACACGCCAAGUAGGAGUAAGUUGAUCUGCAUGAAUAGCAACAGGGACUUCUGUGCAGUUAACAUCCUGAUAAAGAACAGCAACCUGGUUAGAAGUAUUUGUUCCUGGUGUUAUAACACUGACACCACCAAAAGAACAUGGUGUAAUGUCAAGAAUCUCAAGUGUCUGUGGAUCACGGACAGCAUCAGUAGUGUCAGCAAUGUCUCUGCCAAAUUGUUGGAAAGGCAGAAACUUUUUGUUAGACUCAGUAAGAACACCUGUGCCUGUUAAACCAUUGAAGUUGAAAUUGACACAUUUGUUUUUAACCAAAUUAGUAGACUUUUUAGGUCCACAAACAGUUGCUGGUGCAUGUAGAAGUUCAAAAGAAAGUACUACUACUCUGUAUGGUUGGUAACCAACACCAUUAGUGGGUUGGAAACCAUAUGAUUGUAAAGGAAAGUAACAAUUAAAACCUUCAACACCAUUACAAGGUGUGCUACCGGCCUGAUAGAUUUCAGUUGAAAUAUCUCUCUCAAAAGGUUUGAGAUUAGACUUCCUAAACAAUCUAUACAGGUAAUUAUAAUUACCACCAACCUUAGAAUCAAGAUUGUUAGAAUUCCAAGCUAUAACGCAGCCUGUAAAAUCAUCUGGUAAUUUAUAAUUAUAAUCAGCAAUCUUUCCAGUUUGCCCUGGAGCGAUUUGUCUGACUUCAUCACCUCUAAUUACAAAUGAAUCUGCAUAGACAUUAGUAAAGCAGAGAUCAUUUAAUUUAGUAGGAGACACUCCAUAACACUUAAAAGUGGAAAAUGAUGCGGAAUUAUAUAGGACAGAAUAAUCAGCAACACAGUUGCUGAUUCUCUUCCUGUUCCAAGCAUAAACAGAUGCAAAUCUGGUGGCGUUAAAAACUUCACCAAAAGGGCACAAGUUUGUAAUAUUAGGAAAUCUAACAAUAGAUUCUGUUGGUUGGACUCUAAAGUUAGAAGUUUGAUAGAUUCCUUUUUCUACAGUGAAGGAUUUCAACGUACACUUUGUUUCUGAGAGAGGGUCAAGUGCACAGUCUACAGCAUCUGUAAUGGUUCCAUUUUCAUUAUAUUUUAAUAGAAAAGUCCUAGGUUGAAGAUAACCCACAUAAUAAGCUGCAGCACCAGCUGUCCAACCUGAAGAAGAAUCACCAGGAGUCAAAUAACUUCUAUGUAAAGCAAGUAAAGUUUGAAACCUAGUGAUGUUAAUACCUAUUGGCAAAUCUACCAAUGGUUCUAAAGCCGAAAAACCCUGAGGGAGAUCACGCACUAAAUUAAUAGGCGUGUGCUUAGAAUAUAUUUUAAAAUAACCAUCAAUAUUCUUAAACACAAAUUCCCUAAGAUUUUUGAAAUUACCCUGUUUUCCUUCAAGGUCCAUAAGAAAAGGCUGAGAGACAUAUUCAAAAGUGCAAUUAUUCGCACUAGAAUAAACUCUGAACUCACUUUCCAUCCAACUUUUGUUGUUUUUGUGGUAAUAAACACCCAAAAAUGGAUCAUUACAAAAUUGAAAUUCACAGACUUUAAUAACAACAUUAGUAGCGUUAUUAACAAUAAGUAGGGACUGGGUCUUCGAAUCUAAAGUAGUACCAAAAAUCCAGCCUCUUAUUAUGUUAGACUUCUCAGUGGAAGCAAAAUAAACACCAUCAUUAAAUGGUAGGACAGGGUUAUCAAACCUCUUAGUACCAUUGGUCCCAGAGACAUGUAUAGCAUGGAACCAAGUAACAUUGGAAAAGAAAGGUAAGAACAAGUCCUGAGUUGAAUGUAAAACUGAGGAUCUGAAAACUUUGUCAGGGUAAUAAACACCACGUGUGAAAGAAUUAGUGUAUGCAGGGGGUAAUUGAGUUCUGGUUGUAAGAUUAACACACUGACUAGAGACUAGUGGCAAUAAAACAAGAAAAACAAACAUUGUUCGUUUAGUUGUUAACAAGAACAUCACUAGAAAUAACAACUCUGUUGUUUUCUCUAAUUAUAAGUCUACCUUUACUAAGAAGAGAUAAAAUCAUAUCAUUGAUUUGACCUUCUUUUAAAGACAUAACAGCAGUACCCCUUAAUUUAAGGGGAAAUUUACUCAUGUCAAAUAAAGAAUAGGAAGACAACUGAAUUGGAUUUGUAUUCCUCCAAAAUAUGUAAUUUGCAUGCAUGACAUAACCAUCUAUUUGUUCGCGUGGUUUGCCAAGAUAAUUACAUCCAAUUAAAAAUGCUUCAGAUGAUGACGCAUUCACAUUAGUAACAAAGGCUGUCCACCAUGCGAAGUGUCCCAUGAGCUUAUAAAGAUCAGCAUUCCAAGAAUGUUCUGUUAUCUUUAUAGCCACGGAACCUCCAAGAGCUAGCUUUUGUUGUAUAAACCCACAAAUGUAAGUGAAAAAACCCUCUUUAGAGUCAUUUUCUUUUGUAACAUUUUUAGUCUUAGGGUCGUACAUAUCACUAAUAAUGAGAUCCCAUUUAUUAGCUGUAUGUACAGUUGCACAAUCACCAAUCAAAGUUGAAUCUGCAUCAGAGACAAAGUCAUUAAGAUCUGAAUCGACAAGCAGCGUACCCGUAGGCAACCACUGUCUUAAAACAGCUGUACCUGGUGCAACUCCUUUAUCAGAACCAGCACCAAAAUGUAUAACUCUCAUAUUAUAGGGUACAGCUAAUGUUAAUGUGUUUAAAUAUUGACACAGUUGAGUAUAUUUUGCGACAUUCAUCAUUAUGCCUUUAGGUAAUGUUGCACUAUCACCAUAAUUUUGAAGGUCACACUUUUCUAAUAGCAUUCUUUGCAUUUUGUAAAGAUUAGGCAUAGCAACACCCGGUUGCCACGCUUGACUAGAUUGUAAUUUUGGGUAAAAUGUUUCUACAUGGCCAUCUUUACACCAAAGCAUAAAUGAAAUUUCUGUAUAGUCAAUAGUCACUUUGACAACCUUAGAAACUACAGAUAAAUCUUGGGAUUUUAUUAUUUCAACAAAAUCAUCAAGUAAUAAAUCAAUAACAGAACACACACACUUAGAUGAACCUGUUUGCGCAUCUGUUAUGAAAUAGUUUUUAACUGUACUGUCCAUAGGAAUAAAAUCUUCUAAUUCAAAAGGUGAUUCCUUAAAACGUUUAGCUAGUCCAAUCAGUAGAUGUAAACCACCUAACUGACUAUGACUAAAAUCUCCAUAAACGAUAUGUUCGAAGGCAUAGCCUUCUAAUUUAUACCGUUCAAUGAAUUCAUCCAUAGCUAAUUCUAAGAAAUCAAUUUCCAUUUGACUCCUGGGUUUAAAUUCUUGUAAAUUUCUACUCUGAGUAAAGUAAGUUUCAGGUAAUUGUUGGACAACACCAUCAACUUUCUUAUAAUAAUUGAACUGUGUUUUUACGGCUUCUCCAAUUAAUGUGACUCCAUUAAGACUAGCUUGUUUGGGACCUACAGAUGGUUGUAAACCUUUAACACUACCUUCUGUAAUAAGAACACCAUUACGGGCAUUUCUAAAUAAGUCUACUUGACCAUCA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,"1.8,18,265 nM[SARS-CoV-2];|18.5 µM [N protein]","150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Electron microscopy,solid,"Unlike polyC, in silico methods predict that these RNA fragments can form intra- and inter-molecular base-pairing interactions and contain extensive secondary structure elements. Similar to synthetic RNA substrates that form base-pair interactions, the N protein formed non-spherical condensates with viral RNA fragments in vitro."
485,PMID: 32995779,RNAPS0000433,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,SARS-CoV-2 virus RNA,4903nt(25001-29903),UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGUCAUUCUCCUAAGAAGCUAUUAAAAUCACAUGGGGAUAGCACUACUAAAAUUAAUUUUACACAUUAGGGCUCUUCCAUAUAGGCAGCUCUCCCUAGCAUUGUUCACUGUACACUCGAUCGUACUCCGCGUGGCCUCGGUGAAAAUGUGGUGGCUCUUUCAAGUCCUCCCUAAUGUUACACACUGAUUAAAGAUUGCUAUGUGAGAUUAAAGUUAACUACAUCUACUUGUGCUAUGUAGUUACGAGAAUUCAUUCUGCACAAGAGUAGACUAUAUAUCGUAAACGGAAAAGCGAAAACGUUUAUAUAGCCCAUCUGCCUUGUGUGGUCUGCAUGAGUUUAGGCCUGAGUUGAGUCAGCACUGCUCAUGGAUUGUUGCAAUUGUUUGGAGAAAUCAUCCAAAUCUGCAGCAGGAAGAAGAGUCACAGUUUGCUGUUUCUUCUGUCUCUGCGGUAAGGCUUGAGUUUCAUCAGCCUUCUUCUUUUUGUCCUUUUUAGGCUCUGUUGGUGGGAAUGUUUUGUAUGCGUCAAUAUGCUUAUUCAGCAAAAUGACUUGAUCUUUGAAAUUUGGAUCUUUGUCAUCCAAUUUGAUGGCACCUGUGUAGGUCAACCACGUUCCCGAAGGUGUGACUUCCAUGCCAAUGCGCGACAUUCCGAAGAACGCUGAAGCGCUGGGGGCAAAUUGUGCAAUUUGCGGCCAAUGUUUGUAAUCAGUUCCUUGUCUGAUUAGUUCCUGGUCCCCAAAAUUUCCUUGGGUUUGUUCUGGACCACGUCUGCCGAAAGCUUGUGUUACAUUGUAUGCUUUAGUGGCAGUACGUUUUUGCCGAGGCUUCUUAGAAGCCUCAGCAGCAGAUUUCUUAGUGACAGUUUGGCCUUGUUGUUGUUGGCCUUUACCAGACAUUUUGCUCUCAAGCUGGUUCAAUCUGUCAAGCAGCAGCAAAGCAAGAGCAGCAUCACCGCCAUUGCCAGCCAUUCUAGCAGGAGAAGUUCCCCUACUGCUGCCUGGAGUUGAAUUUCUUGAACUGUUGCGACUACGUGAUGAGGAACGAGAAGAGGCUUGACUGCCGCCUCUGCUCCCUUCUGCGUAGAAGCCUUUUGGCAAUGUUGUUCCUUGAGGAAGUUGUAGCACGAUUGCAGCAUUGUUAGCAGGAUUGCGGGUGCCAAUGUGAUCUUUUGGUGUAUUCAAGGCUCCCUCAGUUGCAACCCAUAUGAUGCCGUCUUUGUUAGCACCAUAGGGAAGUCCAGCUUCUGGCCCAGUUCCUAGGUAGUAGAAAUACCAUCUUGGACUGAGAUCUUUCAUUUUACCGUCACCACCACGAAUUCGUCUGGUAGCUCUUCGGUAGUAGCCAAUUUGGUCAUCUGGACUGCUAUUGGUGUUAAUUGGAACGCCUUGUCCUCGAGGGAAUUUAAGGUCUUCCUUGCCAUGUUGAGUGAGAGCGGUGAACCAAGACGCAGUAUUAUUGGGUAAACCUUGGGGCCGACGUUGUUUUGAUCGCGCCCCACUGCGUUCUCCAUUCUGGUUACUGCCAGUUGAAUCUGAGGGUCCACCAAACGUAAUGCGGGGUGCAUUUCGCUGAUUUUGGGGUCCAUUAUCAGACAUUUUAGUUUGUUCGUUUAGAUGAAAUCUAAAACAACACGAACGUCAUGAUACUCUAAAAAGUCUUCAUAGAACGAACAACGCACUACAAGACUACCCAAUUUAGGUUCCUGGCAAUUAAUUGUAAAAGGUAAACAGGAAACUGUAUAAUUACCGAUAUCGAUGUACUGAAUGGGUGAUUUAGAACCAGCCUCAUCCACGCACAAUUCAAUUAAAGGUGCUGAUUUUCUAGCUCCUACUCUAAUAUACCAUUUAGAAUAGAAGUGAAUAGGACACGGGUCAUCAACUACAUAUGGUUGAUGUUGAGUACAUGACUGUAAACUACAUUCUUGGUGAAAUGCAGCUACAGUUGUGAUGAUUCCUAAGAAAACAAGAAAUUUCAUGUUCGUUUAGGCGUGACAAGUUUCAUUAUGAUCUUGCAGUUCAAGUGAGAACCAAAAGAUAAUAAGCAUAAUUAAAACAAGGAAUAGCAGAAAGGCUAAAAAGCACAAAUAGAAGUCAAUUAAUGAAAGUUCAAUCAUUCUGUCUUUCUUUUGAGUGUGAAGCAAAGUGUUAUAAACACUAUUGCCGCAACAAUAAGAAAAAUUGGAGAGUAAAGUUCUUGAACUUCCUCUUGUCUGAUGAACAGUUUAGGUGAAACUGAUCUGGCACGUAACUGAUAGACGUGUUUUACGCCGUCAGGACAAGCAAAAGCAAAUUGAGUGCUAAAGCAAGUCAGUGCAAAUUUGUUAUCAGCUAGAGGAUGAAAUGGUGAAUUGCCCUCGUAUGUUCCAGAAGAGCAAGGUUCUUUUAAAAGUACUGUUGUACCUCUAACACACUCUUGGUAGUGAUAAAGCUCACAAGUAGCGAGUGUUAUCAGUGCCAAGAAAAGAAUAAUUUUCAUGUUCGUUUAAUCAAUCUCCAUUGGUUGCUCUUCAUCUAAUUGAGAAUAUUUAUUCUCAGUUAGUGACUUAGAUAAAUUUUUAAUUAUGAGGUUUAUGAUGUAAUCAAGAUUCCAAAUGGAAACUUUAAAAGUCCUCAUAAUAAUUAGUAAUAUCUCUGCUAUAGUAACCUGAAAGUCAACGAGAUGAAACAUCUGUUGUCACUUACUGUACAAGCAAAGCAAUAUUGUCACUGCUACUGGAAUGGUCUGUGUUUAAUUUAUAGUUGCCAAUCCUGUAGCGACUGUAUGCAGCAAAACCUGAGUCACCUGCUACACGCUGCGAAGCUCCCAAUUUGUAAUAAGAAAGCGUUCGUGAUGUAGCAACAGUGAUUUCUUUAGGCAGGUCCUUGAUGUCACAGCGUCCUAGAUGGUGUCCAGCAAUACGAAGAUGUCCACGAAGGAUCACAGCUCCGAUUACGAGUUCACUUUCUAGAAGCGGUCUGGUCAGAAUAGUGCCAUGGAGUGGCACGUUGAGAAGAAUGUUAGUUUCUGGAUUGAAUGACCACAUGGAACGCGUACGCGCAAACAGUCUGAAAGAAGCAAUGAAGUAGCUGAGCCACAUCAAGCCUACAAGACAAGCCAUUGCGAUAGCAAUUCCACCGGUGAUCCAAUUUAUUCUGUAAACAGCAGCAAGCACAAAACAAGCUAAAGUUACUGGCCAUAACAGCCAGAGGAAAAUUAACUUAAUUAUAUACAAAAACCUAUUCCUGUUGGCAUAGGCAAAUUGUAGAAGACAAAUCCAUGUAAGGAAUAGGAAACCUAUUACUAGGUUCCAUUGUUCAAGGAGCUUUUUAAGCUCUUCAACGGUAAUAGUACCGUUGGAAUCUGCCAUGGCUAAAAUUAAAGUUCCAAACAGAAAAACUAAUAUAAUAUUUAGUUCGUUUAGACCAGAAGAUCAGGAACUCUAGAAGAAUUCAGAUUUUUAACACGAGAGUAAACGUAAAAAGAAGGUUUUACAAGACUCACGUUAACAAUAUUGCAGCAGUACGCACACAAUCGAAGCGCAGUAAGGAUGGCUAGUGUAACUAGCAAGAAUACCACGAAAGCAAGAAAAAGAAGUACGCUAUUAACUAUUAACGUACCUGUCUCUUCCGAAACGAAUGAGUACAUAAGUUCGUACUCAUCAGCUUGUGCUUACAAAGGCACGCUAGUAGUCGUCGUCGGUUCAUCAUAAAUUGGUUCCAUUACUGGAUUAACAACUCCGGAUGAACCGUCGAUUGUGUGAAUUUGGACAUGUUCUUCAGGCUCAUCAACAAUUUUAUUGUAGAUGAAGAAGGUAACAUGUUCAACACCAGUGUCUGUACUCAAUUGAGUUGAGUACAGCUGGUAAUAGUCUGAAGUGAAGUAACUGUGUAAUACAACACAGUCUUUUACUCCAGAUUCCCAUUUUUCAGUAUAACCACCAAUCUGGUAGUCAUGUUCAGAAAUAGGACUUGUUGUGCCAUCACCUGAAGUAAUGACAAUUGAAGAAGUUACACUAUUGUAAGGUAUACAAUAGUCGUAACAAUUAGUAUGCCAGCAAAGAAAAUAGUUGGCAUCAUAAAGUAAUGGGUUUUUGGAACGGCAUUUCCAGCAAAGCCAAAGCCUCAUUAUUAUUCUUACAAAGUUUAUACUCUGCAAGAAGUAGACUAAAGCAUAAAGAUAGAGAAAAGGGGCUUCAAGGCCAGCAGCAACGAGCAAAAGGUGUGAGUAAACUGUUACAAACAACAACAGCAAGUUGCAAACAAAGUGAACACCCUUGGAGAGUGCUAGUUGCCAUCUCUUUUUGAGGGUUAUGAUUUUGGAAGCGCUCUGAAAAACAGCAAGAAGUGCAACGCCAACAAUAAGCCAUCCGAAAGGGAGUGAGGCUUGUAUCGGUAUCGUUGCAGUAGCGCGAACAAAAUCUGAAGGAGUAGCAUCCUUGAUUUCACCUUGCUUCAAAGUUACAGUUCCAAUUGUGAAGAUUCUCAUAAACAAAUCCAUAAGUUCGUUUAUGUGUAAUGUAAUUUGACUCCUUUGAGCACUGGCUCAGAGUCGUCUUCAUCAAAUUUGCAGCAGGAUCCACAAGAACAACAGCCCUUGAGACAACUACAGCAACUGGUCAUACAGCAAAGCAUAAUUGUCACCAUUACUAUGGCAAUCAAGCCAGCUAUAAAACCUAGCCAAAUGUACCAUGGCCAUUUUAUAUACUGCUCAUACUUUCCAAGUUCUUGGAGAUCGAUGAGAGAUUCAUUUAAAUUCUUGGCAACCUCAUUGAGGCGGUCAAUUUCUUUUUGAAUGUUUACAACUGAAGCAUUAAUGCCAGAGAUGUCACCUAAAUCAACAUCUGGUGAUGUAUGAUUCUUAAAAUAUUUAUCUAACUCCUCCUUGAAUGA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,"1.8,18,103 nM[SARS-CoV-2];|18.5 µM [N protein]","150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Electron microscopy,solid,"Unlike polyC, in silico methods predict that these RNA fragments can form intra- and inter-molecular base-pairing interactions and contain extensive secondary structure elements. Similar to synthetic RNA substrates that form base-pair interactions, the N protein formed non-spherical condensates with viral RNA fragments in vitro."
486,PMID: 32995779,RNAPS0000434,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyC(2000),2000nt,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,50 ng/µL [polyC];|2.3-18 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,≤ 25 min,-,Electron microscopy,"liquid, solute","Mixing of 50 ng/µL polyC RNA and the N protein resulted in the formation of condensates in 150 mM NaCl. The analysis of the condensates settled on the coverslip revealed a saturation concentration (csat) of 3.3 ± 1.3 µM for N protein in the presence of 50 ng/µL polyC RNA (± s.e.), consistent with the abundance of N protein in infected cells (43). The partition coefficient of N protein into condensates was 13 ± 2 (±s.d.)."
487,PMID: 32995779,RNAPS0000434,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyC(2000),2000nt,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=1,31-419
MERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△PLD,-,"390aa(1,31-419)",P0DTC9,-,-,"[1-1],[31-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.5-5000 ng/µL[polyC];|18 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Electron microscopy,"liquid, solute","Phase separation was only moderately reduced in the ΔSR, ΔPLD, and ΔR1 mutants, suggesting that these regions are not essential for phase separation. In comparison, deletion of the R2 sequence fully abolished the formation of condensates with polyC RNA."
488,PMID: 32995779,RNAPS0000434,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyC(2000),2000nt,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△R1,-,"397aa(1-234,257-419)",P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-234],[365-391]","[175-208],[211-230],[361-379]",In vitro,0.5-5000 ng/µL[polyC];|18 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Electron microscopy,"liquid, solute","Phase separation was only moderately reduced in the ΔSR, ΔPLD, and ΔR1 mutants, suggesting that these regions are not essential for phase separation. In comparison, deletion of the R2 sequence fully abolished the formation of condensates with polyC RNA."
489,PMID: 32995779,RNAPS0000434,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyC(2000),2000nt,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=1-368,391-419
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△R2,-,"397aa(1-368,391-419)",P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-368],[391-391]","[175-208],[211-230],[236-249],[361-368]",In vitro,0.5-5000 ng/µL[polyC];|18 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Electron microscopy,"solute, liquid","Phase separation was only moderately reduced in the ΔSR, ΔPLD, and ΔR1 mutants, suggesting that these regions are not essential for phase separation. In comparison, deletion of the R2 sequence fully abolished the formation of condensates with polyC RNA."
490,PMID: 32995779,RNAPS0000434,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyC(2000),2000nt,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,protein_ptm:phosphorylated or dePhosphorylated,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,50 ng/µL[polyC];|1.9-60 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Electron microscopy,"liquid, solute","Phase separation was only moderately reduced in the ΔSR, ΔPLD, and ΔR1 mutants, suggesting that these regions are not essential for phase separation. In comparison, deletion of the R2 sequence fully abolished the formation of condensates with polyC RNA."
491,PMID: 32995779,RNAPS0000434,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyC(2000),2000nt,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=1-182,196-419
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△SR,-,"406aa(1-182,196-419)",P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-182],[196-212],[233-247],[249-256],[365-391]","[175-182],[196-208],[211-230],[236-249],[361-379]",In vitro,0.5-5000 ng/µL[polyC];|18 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Electron microscopy,"liquid, solute","Phase separation was only moderately reduced in the ΔSR, ΔPLD, and ΔR1 mutants, suggesting that these regions are not essential for phase separation. In comparison, deletion of the R2 sequence fully abolished the formation of condensates with polyC RNA."
492,PMID: 32995779,RNAPS0000434,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyC(2000),2000nt,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=1-368,391-419
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△R2,protein_ptm:dePhosphorylated,"397aa(1-368,391-419)",P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-368],[391-391]","[175-208],[211-230],[236-249],[361-368]",In vitro,50 ng/µL[polyC];|1.9-60 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Electron microscopy,"liquid, solute","Phase separation was only moderately reduced in the ΔSR, ΔPLD, and ΔR1 mutants, suggesting that these regions are not essential for phase separation. In comparison, deletion of the R2 sequence fully abolished the formation of condensates with polyC RNA."
493,PMID: 32995779,RNAPS0000434,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyC(2000),2000nt,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,50 ng/µL [polyC];|24 µM [N protein],"50-200 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Electron microscopy,"solute, liquid","Although N protein is unable to phase separate without RNA in 150 mM salt, 24 µM N protein efficiently formed condensates at lower salt with a half-maximal inhibition constant (IC50) of 90 ± 1 µM NaCl (±s.e.). The addition of 50 ng/µL polyC RNA increased IC50 to 152 ± 6 mM NaCl."
494,PMID: 32995779,RNAPS0000434,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyC(2000),2000nt,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,50 ng/µL [polyC];|7.8 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,"other_molecular:0,10 mM lipoic acid",Electron microscopy,liquid,"The condensates formed by the N protein in the absence or presence of polyC or viral RNA dissolve with the  addition of 10% 1,6 hexanediol, indicating that phase separation is driven, at least partially, by hydrophobic  interactions (Figure 5A). In comparison, lipoic acid that increases the liquidity of stress granules  did  not affect phase separation"
495,PMID: 32995779,RNAPS0000434,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyC(2000),2000nt,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,50 ng/µL [polyC];|7.8 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,"other_molecular:10% 1,6-hexanediol",Electron microscopy,"solute, liquid","The condensates formed by the N protein in the absence or presence of polyC or viral RNA dissolve with the  addition of 10% 1,6 hexanediol, indicating that phase separation is driven, at least partially, by hydrophobic  interactions (Figure 5A). In comparison, lipoic acid that increases the liquidity of stress granules  did  not affect phase separation"
496,PMID: 32995779,RNAPS0000434,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyC(2000),2000nt,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.5-5000 ng/µL [polyC];|18.5 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Electron microscopy,"liquid, solute","Condensate formation of N protein and RNA was dependent on protein-RNA stoichiometry. At 18 µM N  protein, condensate formation was not observed in the presence of 0-5 ng/µL polyC RNA. Increasing the RNA  concentration promoted phase separation with an optimal RNA concentration of 100-500 ng/µL, in which  charge neutralization occurs with the positively-charged N protein"
497,PMID: 32995779,RNAPS0000434,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyC(2000),2000nt,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,50 µg/µL[polyC];|7.8 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,"drug:2.5,40 µM Nelfinavir Mesylate",Electron microscopy,liquid,"Nelfinavir mesylate and LDK378 produced larger but  fewer condensates, whereas crystal violet, tolcapone, and chlorhexidine enhanced phase separation by  increasing the number and size of the condensates (Figure 5B, Figure 5_figure supplement 1A-B). Nilotinib  resulted in a 50% increase in condensate volume and altered the shape of the condensates (Figure 5B), which  may be due to changes in condensate fusion or maturation"
498,PMID: 32995779,RNAPS0000434,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyC(2000),2000nt,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,50 µg/µL[polyC];|7.8 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,"drug:2.5,40 µM Tolcapone",Electron microscopy,liquid,"Nelfinavir mesylate and LDK378 produced larger but  fewer condensates, whereas crystal violet, tolcapone, and chlorhexidine enhanced phase separation by  increasing the number and size of the condensates (Figure 5B, Figure 5_figure supplement 1A-B). Nilotinib  resulted in a 50% increase in condensate volume and altered the shape of the condensates (Figure 5B), which  may be due to changes in condensate fusion or maturation"
499,PMID: 32995779,RNAPS0000434,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyC(2000),2000nt,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,50 µg/µL[polyC];|7.8 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,"drug:2.5,40 µM Nilotinib",Electron microscopy,liquid,"Nelfinavir mesylate and LDK378 produced larger but  fewer condensates, whereas crystal violet, tolcapone, and chlorhexidine enhanced phase separation by  increasing the number and size of the condensates (Figure 5B, Figure 5_figure supplement 1A-B). Nilotinib  resulted in a 50% increase in condensate volume and altered the shape of the condensates (Figure 5B), which  may be due to changes in condensate fusion or maturation"
500,PMID: 32995779,RNAPS0000435,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5-5000 ng/µL [polyU];|18.5 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Microscopy,"liquid, solute","Similar to polyC RNA, polyA and polyU RNA substrates produced spherical condensates at micromolar  concentrations of the N protein (Figure 2A). However, combining N protein with polyG that forms G quadruplexes or polyAU that forms base-pair interactions led to the formation of non-spherical condensates"
501,PMID: 32995779,RNAPS0000436,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyG,-,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5-5000 ng/µL [polyG];|18.5 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Microscopy,solid,"Similar to polyC RNA, polyA and polyU RNA substrates produced spherical condensates at micromolar  concentrations of the N protein (Figure 2A). However, combining N protein with polyG that forms G quadruplexes or polyAU that forms base-pair interactions led to the formation of non-spherical condensates"
502,PMID: 32995779,RNAPS0000437,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyA,-,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5-5000 ng/µL [polyA];|18.5 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Microscopy,"liquid, solute","Similar to polyC RNA, polyA and polyU RNA substrates produced spherical condensates at micromolar  concentrations of the N protein (Figure 2A). However, combining N protein with polyG that forms G quadruplexes or polyAU that forms base-pair interactions led to the formation of non-spherical condensates"
503,PMID: 32995779,RNAPS0000438,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyAU,-,-,repeat RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5-5000 ng/µL [polyAU];|18.5 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Microscopy,solid,"Similar to polyC RNA, polyA and polyU RNA substrates produced spherical condensates at micromolar  concentrations of the N protein (Figure 2A). However, combining N protein with polyG that forms G quadruplexes or polyAU that forms base-pair interactions led to the formation of non-spherical condensates"
504,PMID: 33056997,RNAPS0000439,https://pubmed.ncbi.nlm.nih.gov/33056997,RNA + protein,-,-,polyU(2200),2200nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,FRGRGRGD,Ac-FRGRGRGD-OH (precursor),-,-,8aa,-,-,-,-,-,In vitro,4.1 mM [polyU];|23 mM[Ac-FRGRGRGD-OH],-,MES buffer (500-1000 mM),25˚C,≤ 40 min,other_molecular:0-100 mM EDC,Turbidity measurement,"liquid, solute",We dissolved 23 mM of the peptide precursor in an aqueous 200 mM MES buffer solution at pH 5.3 with 4.1 mM RNA (expressed in [Uracil nucleotides]).We performed the same experiments with various fuel concentrations to make a phase diagram
505,PMID: 33056997,RNAPS0000439,https://pubmed.ncbi.nlm.nih.gov/33056997,RNA + protein,-,-,polyU(2200),2200nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,FRGRGRGD,Ac-FRGRGRGD-OH (precursor),-,-,8aa,-,-,-,-,-,In vitro,0-5 mM [polyU];|23 mM[Ac-FRGRGRGD-OH],-,MES buffer (500-1000 mM),25˚C,≤ 40 min,other_molecular:0-60 mM EDC,Turbidity measurement,"liquid, solute","We found that more than 7.5 mM fuel was required to induce an increase in turbidity, which corresponds to 0.9 mM product. This result suggests a critical coacervation concentration of 0.9 mM anhydride product. Between 7.5 mM and 40 mM fuel, we found dynamic droplets. Above 40 mM of fuel, the droplets were metastable. We tested the effect of the RNA concentration on the droplet’s behavior"
506,PMID: 33200826,RNAPS0000435,https://pubmed.ncbi.nlm.nih.gov/33200826,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.5 mg/ml[ploy-U];|50 µM [N protein],70 mM NaCl,50 mM Tris pH 7.4,25˚C,≤ 2 h,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"To compare the effect of homopolymeric RNAs on nucleocapsid phase separation, we first performed turbidity measurements at condi tions where N phase separates alone. Importantly, the homopoly meric RNA stock solutions are all buffer exchanged via a spin desalting column and therefore are soluble in these conditions alone. Like torula yeast RNA, all homopolymeric RNAs enhanced the turbidity of solutions of N (Fig 6A), suggesting that particular sequences or RNA structures are not essential for interaction with N."
507,PMID: 33200826,RNAPS0000436,https://pubmed.ncbi.nlm.nih.gov/33200826,RNA + protein,-,-,polyG,-,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.5 mg/ml[ploy-G];|50 µM [N protein],70 mM NaCl,50 mM Tris pH 7.4,25˚C,≤ 2 h,-,"Turbidity measurement,Differential interference contrast microscopy",solid,"To compare the effect of homopolymeric RNAs on nucleocapsid phase separation, we first performed turbidity measurements at condi tions where N phase separates alone. Importantly, the homopoly meric RNA stock solutions are all buffer exchanged via a spin desalting column and therefore are soluble in these conditions alone. Like torula yeast RNA, all homopolymeric RNAs enhanced the turbidity of solutions of N (Fig 6A), suggesting that particular sequences or RNA structures are not essential for interaction with N."
508,PMID: 33200826,RNAPS0000437,https://pubmed.ncbi.nlm.nih.gov/33200826,RNA + protein,-,-,polyA,-,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.5 mg/ml[ploy-A];|50 µM [N protein],70 mM NaCl,50 mM Tris pH 7.4,25˚C,≤ 2 h,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"To compare the effect of homopolymeric RNAs on nucleocapsid phase separation, we first performed turbidity measurements at condi tions where N phase separates alone. Importantly, the homopoly meric RNA stock solutions are all buffer exchanged via a spin desalting column and therefore are soluble in these conditions alone. Like torula yeast RNA, all homopolymeric RNAs enhanced the turbidity of solutions of N (Fig 6A), suggesting that particular sequences or RNA structures are not essential for interaction with N."
509,PMID: 33200826,RNAPS0000440,https://pubmed.ncbi.nlm.nih.gov/33200826,RNA + protein,-,-,polyC,-,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.5 mg/ml[ploy-C;|50 µM [N protein],70 mM NaCl,50 mM Tris pH 7.4,25˚C,≤ 2 h,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"To compare the effect of homopolymeric RNAs on nucleocapsid phase separation, we first performed turbidity measurements at condi tions where N phase separates alone. Importantly, the homopoly meric RNA stock solutions are all buffer exchanged via a spin desalting column and therefore are soluble in these conditions alone. Like torula yeast RNA, all homopolymeric RNAs enhanced the turbidity of solutions of N (Fig 6A), suggesting that particular sequences or RNA structures are not essential for interaction with N."
510,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△CIDR,-,-,P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.5 mg/ml [torula yeast RNA];|50 µM [N protein],70 mM NaCl,50 mM Tris  pH 7.4,RT,-,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"After cleavage of the solubilizing MBP fusion where full-length N robustly phase separates (50 lΜ protein, 0.5 mg/ml RNA, 70 mM NaCl), we observed that deletion of the N-terminal domain had little effect on LLPS"
511,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△CTD,-,-,P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.5 mg/ml [torula yeast RNA];|50 µM [N protein],70 mM NaCl,50 mM Tris  pH 7.4,RT,-,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"After cleavage of the solubilizing MBP fusion where full-length N robustly phase separates (50 lΜ protein, 0.5 mg/ml RNA, 70 mM NaCl), we observed that deletion of the N-terminal domain had little effect on LLPS"
512,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△linker,-,-,P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.5 mg/ml [torula yeast RNA];|50 µM [N protein],70 mM NaCl,50 mM Tris  pH 7.4,RT,-,-,"Turbidity measurement,Differential interference contrast microscopy",solute,"After cleavage of the solubilizing MBP fusion where full-length N robustly phase separates (50 lΜ protein, 0.5 mg/ml RNA, 70 mM NaCl), we observed that deletion of the N-terminal domain had little effect on LLPS"
513,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△NIDR,-,-,P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.5 mg/ml [torula yeast RNA];|50 µM [N protein],70 mM NaCl,50 mM Tris  pH 7.4,RT,-,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"After cleavage of the solubilizing MBP fusion where full-length N robustly phase separates (50 lΜ protein, 0.5 mg/ml RNA, 70 mM NaCl), we observed that deletion of the N-terminal domain had little effect on LLPS"
514,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△NTD,-,-,P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.5 mg/ml [torula yeast RNA];|50 µM [N protein],70 mM NaCl,50 mM Tris  pH 7.4,RT,-,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"After cleavage of the solubilizing MBP fusion where full-length N robustly phase separates (50 lΜ protein, 0.5 mg/ml RNA, 70 mM NaCl), we observed that deletion of the N-terminal domain had little effect on LLPS"
515,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.3 mg/ml [torula yeast RNA];|50 µM [N protein],183 mM NaCl,50 mM Tris pH 7.4 ,RT,-,-,Differential interference contrast microscopy,liquid,"The fact that no phase separation is observed in the absence of TEV cleavage suggests that interactions at these conditions are not mediated by artifactual contacts between MBP and N, as these should be enhanced when the proteins are fused."
516,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.3 mg/ml [torula yeast RNA];|50 µM [N protein],183 mM NaCl,pH 5.5,RT,-,-,Differential interference contrast microscopy,liquid,"The fact that no phase separation is observed in the absence of TEV cleavage suggests that interactions at these conditions are not mediated by artifactual contacts between MBP and N, as these should be enhanced when the proteins are fused."
517,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,12.5 µM [torula yeast RNA];|50 µM [N protein],100 mM NaCl,50 mM Tris pH 7.4,RT,-,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"At conditions of 1:0.25 MBP-N:RNA, the turbidity of the solution and the apparent number and size of the liquid droplets are enhanced compared to without RNA (Fig 4A and C). Interestingly, at higher RNA concentrations turbidity and droplet formation are diminished"
518,PMID: 33200826,RNAPS0000400,https://pubmed.ncbi.nlm.nih.gov/33200826,RNAs + protein,-,-,Torula yeast RNA,-,-,total RNA,Torula yeast,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.3 mg/ml [desalted totaltorula yeast RNA];|50µM [N protein],70 mM NaCl,50 mM Tris  pH 7.4,RT,-,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"To compare the effect of homopolymeric RNAs on nucleocapsid phase separation, we first performed turbidity measurements at condi tions where N phase separates alone. Importantly, the homopoly meric RNA stock solutions are all buffer exchanged via a spin desalting column and therefore are soluble in these conditions alone. Like torula yeast RNA, all homopolymeric RNAs enhanced the turbidity of solutions of N (Fig 6A), suggesting that particular sequences or RNA structures are not essential for interaction with N."
519,PMID: 33247108,RNAPS0000441,https://pubmed.ncbi.nlm.nih.gov/33247108,RNA + protein,-,-,polyU,-(800 kDa),-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein;|non-structural protein (nsp) 12 of SARS-CoV-2,-,-,419aa(1-419);|42aa,P0DTC9;P0DTC9,-;-,-;-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391];|-","[175-208],[211-230],[236-249],[361-379];|-",In vitro,1 µM[polyU];|50 µM [N protein],-,"20 mM NaPi, pH 7.5",RT,-,-,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"Next,nsp12, nsp7, and nsp8 were reconstituted in a 1:1:2 stoichiometry together with a RNA template-product duplex, which carried fluorescein at the 5’ end29. The RdRp/RNA-complex was added to preformed NSARS-CoV-2/polyU droplets into which the RdRp/ RNA-complex was recruited"
520,PMID: 33247108,RNAPS0000442,https://pubmed.ncbi.nlm.nih.gov/33247108,RNA + protein,-,-,polyU,-(800 kDa),-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,1 µM[polyU];|50 µM [N protein],50-200 mM NaCl,"20 mM NaPi, pH 7.5",RT,-,"other_molecular:5-20% 1,6-hexanediol",Fluorescence microscopy,"liquid, solute","NSARS-CoV-2/polyU droplets were robust against the presence of the aliphatic alcohol 1,6-hexanediol. In contrast, the addition of increasing amounts of NaCl dissolved the droplets, indicating an important role of electrostatic interactions for RNA induced LLPS of NSARS-CoV-2. Fluorescence microscopy of droplets formed by 50 µM NSARS-CoV-2 and 1 µM polyU in 20 mM NaPi, pH 7.5, at increasing concentrations of 1,6-hexanediol (a) or NaCl (b)."
521,PMID: 33279579,RNAPS0000443,https://pubmed.ncbi.nlm.nih.gov/33279579,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|residues=255-441
NVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHV
PGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNI
THVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMV
DSPQLATLADEVSASLAKQGL",MAPT,-,-,187aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[257-264],[280-282],[284-286],[291-299],[340-350],[396-436]",-,In vitro,20 µM[2N4R];|40 µg/mL[polyU],5 mM NaCl,-,RT,10 min,"other_molecular:0 or 4 wt% 1,6-hexanediol",Transmission electron microscopy,liquid,"We prepared tau LLPS-ED in two ways: by mixing tau187 with  RNA by the complex coacervation mechanism, or by lowering the ionic strength of the solution  containing 2N4R (< 10 mM, referred to as low-salt droplets) that induces simple coacervation  (Figure 1D). When adding 4% 1,6-HD, neither form of tau LLPS-ED, tau-RNA droplets formed  by complex coacervation or tau low-salt droplets formed by simple coacervation, dissolved  (Figure 1D)."
522,PMID: 33279579,RNAPS0000443,https://pubmed.ncbi.nlm.nih.gov/33279579,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|residues=255-441
NVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHV
PGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNI
THVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMV
DSPQLATLADEVSASLAKQGL",MAPT,-,-,187aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[257-264],[280-282],[284-286],[291-299],[340-350],[396-436]",-,In vitro,100 µM[tau];|40 µg/mL[polyU],4.75M NaCl,-,RT,10 min,-,Transmission electron microscopy,liquid,"We prepared tau LLPS-ED in two ways: by mixing tau187 with  RNA by the complex coacervation mechanism, or by lowering the ionic strength of the solution  containing 2N4R (< 10 mM, referred to as low-salt droplets) that induces simple coacervation  (Figure 1D). When adding 4% 1,6-HD, neither form of tau LLPS-ED, tau-RNA droplets formed  by complex coacervation or tau low-salt droplets formed by simple coacervation, dissolved  (Figure 1D)."
523,PMID: 33290746,RNAPS0000445,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,SARS-CoV-2 virus RNA,1000nt(1-1000),AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGCACCUCAUGGUCAUGUUAUGGUUGAGCUGGUAGCAGAACUCGAAGGCAUUCAGUACGGUCGUAGUGGUGAGACACUUGGUGUCCUUGUCCCUCAUGUGGGCGAAAUACCAGUGGCUUACCGCAAGGUUCUUCUUCGUAAGAACGGUAAUAAAGGAGCUGGUGGCCAUAGUUACGGCGCCGAUCUAAAGUCAUUUGACUUAGGCGACGAGCUUGGCACUGAUCCUUAUGAAGAUUUUCAAGAAAACUGGAACACUAAACAUAGCAGUGGUGUUACCCGUGAACUCAUGCGUGAGCUUAACGGAGGGGCAUACACUCGCUAUGUCGAUAACAACUUCUGUGGCCCUGAUGGCUACCCUCUUGAGUGCAUUAAAGACCUUCUAGCACGUGCUGGUAAAGCUUCAUGCACUUUGUCCGAACAACUGGACUUUAUUGACACUAAGAGGGGUGUAUACUGCUGCCGUGAACAUGAGCAUGAAAUUGCUUGGUACACGGAACGUUCU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,25 nM[SARS-CoV-2 frameshifting];|4 µM[N protein],150 mM NaCl,20 mM Tris pH 7.5,22-40˚C,20 min,-,Fluorescence microscopy,liquid,"N-protein alone demixed into droplets in a temperature-dependent manner, highly pronounced at fever temperature (40℃) and above (45℃). Addition of the 50 end RNA lowered the most effficient condensation temper_x0002atures to 37℃and 33℃(which correspond to the exterior lung and upper airway temperatures, respectively) (McFadden et al., 1985)."
524,PMID: 33290746,RNAPS0000445,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,SARS-CoV-2 virus RNA,1000nt(1-1000),AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGCACCUCAUGGUCAUGUUAUGGUUGAGCUGGUAGCAGAACUCGAAGGCAUUCAGUACGGUCGUAGUGGUGAGACACUUGGUGUCCUUGUCCCUCAUGUGGGCGAAAUACCAGUGGCUUACCGCAAGGUUCUUCUUCGUAAGAACGGUAAUAAAGGAGCUGGUGGCCAUAGUUACGGCGCCGAUCUAAAGUCAUUUGACUUAGGCGACGAGCUUGGCACUGAUCCUUAUGAAGAUUUUCAAGAAAACUGGAACACUAAACAUAGCAGUGGUGUUACCCGUGAACUCAUGCGUGAGCUUAACGGAGGGGCAUACACUCGCUAUGUCGAUAACAACUUCUGUGGCCCUGAUGGCUACCCUCUUGAGUGCAUUAAAGACCUUCUAGCACGUGCUGGUAAAGCUUCAUGCACUUUGUCCGAACAACUGGACUUUAUUGACACUAAGAGGGGUGUAUACUGCUGCCGUGAACAUGAGCAUGAAAUUGCUUGGUACACGGAACGUUCU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0-15 nM[SARS-CoV-2 frameshifting];|0.5-2 µM[N protein],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,"liquid, solute","The 5'end and frameshifting region, which have the same length, displayed consistent near-opposing behaviors across a range of RNA and protein concentrations. The 5'end generally drives N-protein condensation, whereas the frameshifting region solubilized condensates and promoted LLPS only within a narrow protein and RNA concentration range."
525,PMID: 33290746,RNAPS0000445,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,SARS-CoV-2 virus RNA,1000nt(1-1000),AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGCACCUCAUGGUCAUGUUAUGGUUGAGCUGGUAGCAGAACUCGAAGGCAUUCAGUACGGUCGUAGUGGUGAGACACUUGGUGUCCUUGUCCCUCAUGUGGGCGAAAUACCAGUGGCUUACCGCAAGGUUCUUCUUCGUAAGAACGGUAAUAAAGGAGCUGGUGGCCAUAGUUACGGCGCCGAUCUAAAGUCAUUUGACUUAGGCGACGAGCUUGGCACUGAUCCUUAUGAAGAUUUUCAAGAAAACUGGAACACUAAACAUAGCAGUGGUGUUACCCGUGAACUCAUGCGUGAGCUUAACGGAGGGGCAUACACUCGCUAUGUCGAUAACAACUUCUGUGGCCCUGAUGGCUACCCUCUUGAGUGCAUUAAAGACCUUCUAGCACGUGCUGGUAAAGCUUCAUGCACUUUGUCCGAACAACUGGACUUUAUUGACACUAAGAGGGGUGUAUACUGCUGCCGUGAACAUGAGCAUGAAAUUGCUUGGUACACGGAACGUUCU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5 nM[SARS-CoV-2];|1 µM[N protein],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,liquid,"N-protein LLPS varied as a function of the specific RNA co component (Figure 1E). The 5’ end and the nucleocapsid RNAs promoted LLPS. In contrast, at the same concentration, the fra meshifting region and the PS region RNAs reduced LLPS relative to N-protein alone"
526,PMID: 33290746,RNAPS0000445,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,SARS-CoV-2 virus RNA,1000nt(1-1000),AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGCACCUCAUGGUCAUGUUAUGGUUGAGCUGGUAGCAGAACUCGAAGGCAUUCAGUACGGUCGUAGUGGUGAGACACUUGGUGUCCUUGUCCCUCAUGUGGGCGAAAUACCAGUGGCUUACCGCAAGGUUCUUCUUCGUAAGAACGGUAAUAAAGGAGCUGGUGGCCAUAGUUACGGCGCCGAUCUAAAGUCAUUUGACUUAGGCGACGAGCUUGGCACUGAUCCUUAUGAAGAUUUUCAAGAAAACUGGAACACUAAACAUAGCAGUGGUGUUACCCGUGAACUCAUGCGUGAGCUUAACGGAGGGGCAUACACUCGCUAUGUCGAUAACAACUUCUGUGGCCCUGAUGGCUACCCUCUUGAGUGCAUUAAAGACCUUCUAGCACGUGCUGGUAAAGCUUCAUGCACUUUGUCCGAACAACUGGACUUUAUUGACACUAAGAGGGGUGUAUACUGCUGCCGUGAACAUGAGCAUGAAAUUGCUUGGUACACGGAACGUUCU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5 nM[SARS-CoV-2 frameshifting];|2 µM[N protein],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,liquid,"Addition of 0.3 kb or 2.4 kb of non-viral sequence to the 1 kb 5’ end or frameshifting re gion RNAs resulted in progressive increase in condensate size/ number, with the 5’ end driving enhanced condensates relative to the frameshifting region at all lengths tested"
527,PMID: 33290746,RNAPS0000445,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,SARS-CoV-2 virus RNA,1000nt(1-1000),AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGCACCUCAUGGUCAUGUUAUGGUUGAGCUGGUAGCAGAACUCGAAGGCAUUCAGUACGGUCGUAGUGGUGAGACACUUGGUGUCCUUGUCCCUCAUGUGGGCGAAAUACCAGUGGCUUACCGCAAGGUUCUUCUUCGUAAGAACGGUAAUAAAGGAGCUGGUGGCCAUAGUUACGGCGCCGAUCUAAAGUCAUUUGACUUAGGCGACGAGCUUGGCACUGAUCCUUAUGAAGAUUUUCAAGAAAACUGGAACACUAAACAUAGCAGUGGUGUUACCCGUGAACUCAUGCGUGAGCUUAACGGAGGGGCAUACACUCGCUAUGUCGAUAACAACUUCUGUGGCCCUGAUGGCUACCCUCUUGAGUGCAUUAAAGACCUUCUAGCACGUGCUGGUAAAGCUUCAUGCACUUUGUCCGAACAACUGGACUUUAUUGACACUAAGAGGGGUGUAUACUGCUGCCGUGAACAUGAGCAUGAAAUUGCUUGGUACACGGAACGUUCU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|mutation:Y109A
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWAFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,protein_mutation:Y109A,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5-50 nM [SARS-CoV-2];|,150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,liquid,"Y109A mutation eliminates 5’ end RNA-driven condensation (Fig ure 5A) and interactions between N-pro tein Y109A and the 5’ end are diminished relative to the WT sequence, in both 203 (40% average binding decrease in N binding intensity) and 1603 (50% N bind ing decrease) conditions"
528,PMID: 33290746,RNAPS0000445,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,SARS-CoV-2 virus RNA,1000nt(1-1000),AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGCACCUCAUGGUCAUGUUAUGGUUGAGCUGGUAGCAGAACUCGAAGGCAUUCAGUACGGUCGUAGUGGUGAGACACUUGGUGUCCUUGUCCCUCAUGUGGGCGAAAUACCAGUGGCUUACCGCAAGGUUCUUCUUCGUAAGAACGGUAAUAAAGGAGCUGGUGGCCAUAGUUACGGCGCCGAUCUAAAGUCAUUUGACUUAGGCGACGAGCUUGGCACUGAUCCUUAUGAAGAUUUUCAAGAAAACUGGAACACUAAACAUAGCAGUGGUGUUACCCGUGAACUCAUGCGUGAGCUUAACGGAGGGGCAUACACUCGCUAUGUCGAUAACAACUUCUGUGGCCCUGAUGGCUACCCUCUUGAGUGCAUUAAAGACCUUCUAGCACGUGCUGGUAAAGCUUCAUGCACUUUGUCCGAACAACUGGACUUUAUUGACACUAAGAGGGGUGUAUACUGCUGCCGUGAACAUGAGCAUGAAAUUGCUUGGUACACGGAACGUUCU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,50 nM [SARS-CoV-2 5‘end];|50 nM [SARS-CoV-2 N protein],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,liquid,"We mixed frameshifting re gion RNA with either 5’ end or nucleocapsid RNA. Mixtures con taining the 5’ end and frameshifting region produced droplets of intermediate properties, including smaller size and more numerous assemblies. Similarly, frameshifting region RNA made nucleocapsid RNA condensates less flocculated and smaller"
529,PMID: 33290746,RNAPS0000445,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,SARS-CoV-2 virus RNA,1000nt(1-1000),AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGCACCUCAUGGUCAUGUUAUGGUUGAGCUGGUAGCAGAACUCGAAGGCAUUCAGUACGGUCGUAGUGGUGAGACACUUGGUGUCCUUGUCCCUCAUGUGGGCGAAAUACCAGUGGCUUACCGCAAGGUUCUUCUUCGUAAGAACGGUAAUAAAGGAGCUGGUGGCCAUAGUUACGGCGCCGAUCUAAAGUCAUUUGACUUAGGCGACGAGCUUGGCACUGAUCCUUAUGAAGAUUUUCAAGAAAACUGGAACACUAAACAUAGCAGUGGUGUUACCCGUGAACUCAUGCGUGAGCUUAACGGAGGGGCAUACACUCGCUAUGUCGAUAACAACUUCUGUGGCCCUGAUGGCUACCCUCUUGAGUGCAUUAAAGACCUUCUAGCACGUGCUGGUAAAGCUUCAUGCACUUUGUCCGAACAACUGGACUUUAUUGACACUAAGAGGGGUGUAUACUGCUGCCGUGAACAUGAGCAUGAAAUUGCUUGGUACACGGAACGUUCU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,7.5-50 nM[SARS-CoV-2 frameshifting];|4µM[N protein],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,liquid,"The 5‘ end and frameshifting region, which have the same length, displayed consistent near-opposing behaviors across a range of RNA and protein concentrations. The 5’ end generally drives N-protein condensation, whereas the frameshifting region solubilized condensates and promoted LLPS only within a narrow protein and RNA concentration range"
530,PMID: 33290746,RNAPS0000446,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,SARS-CoV-2 virus RNA,996nt(13404-14400),GCUGUAGUUGUGAUCAACUCCGCGAACCCAUGCUUCAGUCAGCUGAUGCACAAUCGUUUUUAAACGGGUUUGCGGUGUAAGUGCAGCCCGUCUUACACCGUGCGGCACAGGCACUAGUACUGAUGUCGUAUACAGGGCUUUUGACAUCUACAAUGAUAAAGUAGCUGGUUUUGCUAAAUUCCUAAAAACUAAUUGUUGUCGCUUCCAAGAAAAGGACGAAGAUGACAAUUUAAUUGAUUCUUACUUUGUAGUUAAGAGACACACUUUCUCUAACUACCAACAUGAAGAAACAAUUUAUAAUUUACUUAAGGAUUGUCCAGCUGUUGCUAAACAUGACUUCUUUAAGUUUAGAAUAGACGGUGACAUGGUACCACAUAUAUCACGUCAACGUCUUACUAAAUACACAAUGGCAGACCUCGUCUAUGCUUUAAGGCAUUUUGAUGAAGGUAAUUGUGACACAUUAAAAGAAAUACUUGUCACAUACAAUUGUUGUGAUGAUGAUUAUUUCAAUAAAAAGGACUGGUAUGAUUUUGUAGAAAACCCAGAUAUAUUACGCGUAUACGCCAACUUAGGUGAACGUGUACGCCAAGCUUUGUUAAAAACAGUACAAUUCUGUGAUGCCAUGCGAAAUGCUGGUAUUGUUGGUGUACUGACAUUAGAUAAUCAAGAUCUCAAUGGUAACUGGUAUGAUUUCGGUGAUUUCAUACAAACCACGCCAGGUAGUGGAGUUCCUGUUGUAGAUUCUUAUUAUUCAUUGUUAAUGCCUAUAUUAACCUUGACCAGGGCUUUAACUGCAGAGUCACAUGUUGACACUGACUUAACAAAGCCUUACAUUAAGUGGGAUUUGUUAAAAUAUGACUUCACGGAAGAGAGGUUAAAACUCUUUGACCGUUAUUUUAAAUAUUGGGAUCAGACAUACCACCCAAAUUGUGUUAACUGUUUGGAUGACAGAUGCAUUCUGCAUUGUGCAAACUUUAAUGUUUUAUUCUCUACAGUG,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,50 nM [SARS-CoV-2 frameshifting];|50 nM [SARS-CoV-2 N protein],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,solute,"We mixed frameshifting re gion RNA with either 5’ end or nucleocapsid RNA. Mixtures con taining the 5’ end and frameshifting region produced droplets of intermediate properties, including smaller size and more numerous assemblies. Similarly, frameshifting region RNA made nucleocapsid RNA condensates less flocculated and smaller"
531,PMID: 33290746,RNAPS0000446,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,SARS-CoV-2 virus RNA,1000nt(1-1000),AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGCACCUCAUGGUCAUGUUAUGGUUGAGCUGGUAGCAGAACUCGAAGGCAUUCAGUACGGUCGUAGUGGUGAGACACUUGGUGUCCUUGUCCCUCAUGUGGGCGAAAUACCAGUGGCUUACCGCAAGGUUCUUCUUCGUAAGAACGGUAAUAAAGGAGCUGGUGGCCAUAGUUACGGCGCCGAUCUAAAGUCAUUUGACUUAGGCGACGAGCUUGGCACUGAUCCUUAUGAAGAUUUUCAAGAAAACUGGAACACUAAACAUAGCAGUGGUGUUACCCGUGAACUCAUGCGUGAGCUUAACGGAGGGGCAUACACUCGCUAUGUCGAUAACAACUUCUGUGGCCCUGAUGGCUACCCUCUUGAGUGCAUUAAAGACCUUCUAGCACGUGCUGGUAAAGCUUCAUGCACUUUGUCCGAACAACUGGACUUUAUUGACACUAAGAGGGGUGUAUACUGCUGCCGUGAACAUGAGCAUGAAAUUGCUUGGUACACGGAACGUUCU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,50 nM [SARS-CoV-2 frameshifting];|50 nM [SARS-CoV-2 frameshifting],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,solute,"We mixed frameshifting re gion RNA with either 5’ end or nucleocapsid RNA. Mixtures con taining the 5’ end and frameshifting region produced droplets of intermediate properties, including smaller size and more numerous assemblies. Similarly, frameshifting region RNA made nucleocapsid RNA condensates less flocculated and smaller"
532,PMID: 33290746,RNAPS0000446,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,SARS-CoV-2 virus RNA,996nt(13404-14400),GCUGUAGUUGUGAUCAACUCCGCGAACCCAUGCUUCAGUCAGCUGAUGCACAAUCGUUUUUAAACGGGUUUGCGGUGUAAGUGCAGCCCGUCUUACACCGUGCGGCACAGGCACUAGUACUGAUGUCGUAUACAGGGCUUUUGACAUCUACAAUGAUAAAGUAGCUGGUUUUGCUAAAUUCCUAAAAACUAAUUGUUGUCGCUUCCAAGAAAAGGACGAAGAUGACAAUUUAAUUGAUUCUUACUUUGUAGUUAAGAGACACACUUUCUCUAACUACCAACAUGAAGAAACAAUUUAUAAUUUACUUAAGGAUUGUCCAGCUGUUGCUAAACAUGACUUCUUUAAGUUUAGAAUAGACGGUGACAUGGUACCACAUAUAUCACGUCAACGUCUUACUAAAUACACAAUGGCAGACCUCGUCUAUGCUUUAAGGCAUUUUGAUGAAGGUAAUUGUGACACAUUAAAAGAAAUACUUGUCACAUACAAUUGUUGUGAUGAUGAUUAUUUCAAUAAAAAGGACUGGUAUGAUUUUGUAGAAAACCCAGAUAUAUUACGCGUAUACGCCAACUUAGGUGAACGUGUACGCCAAGCUUUGUUAAAAACAGUACAAUUCUGUGAUGCCAUGCGAAAUGCUGGUAUUGUUGGUGUACUGACAUUAGAUAAUCAAGAUCUCAAUGGUAACUGGUAUGAUUUCGGUGAUUUCAUACAAACCACGCCAGGUAGUGGAGUUCCUGUUGUAGAUUCUUAUUAUUCAUUGUUAAUGCCUAUAUUAACCUUGACCAGGGCUUUAACUGCAGAGUCACAUGUUGACACUGACUUAACAAAGCCUUACAUUAAGUGGGAUUUGUUAAAAUAUGACUUCACGGAAGAGAGGUUAAAACUCUUUGACCGUUAUUUUAAAUAUUGGGAUCAGACAUACCACCCAAAUUGUGUUAACUGUUUGGAUGACAGAUGCAUUCUGCAUUGUGCAAACUUUAAUGUUUUAUUCUCUACAGUG,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,7.5-50 nM[SARS-CoV-2 5'end];|4µM[N protein],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,"solute, liquid","The 5‘ end and frameshifting region, which have the same length, displayed consistent near-opposing behaviors across a range of RNA and protein concentrations. The 5’ end generally drives N-protein condensation, whereas the frameshifting region solubilized condensates and promoted LLPS only within a narrow protein and RNA concentration range"
533,PMID: 33290746,RNAPS0000446,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,SARS-CoV-2 virus RNA,996nt(13404-14400),GCUGUAGUUGUGAUCAACUCCGCGAACCCAUGCUUCAGUCAGCUGAUGCACAAUCGUUUUUAAACGGGUUUGCGGUGUAAGUGCAGCCCGUCUUACACCGUGCGGCACAGGCACUAGUACUGAUGUCGUAUACAGGGCUUUUGACAUCUACAAUGAUAAAGUAGCUGGUUUUGCUAAAUUCCUAAAAACUAAUUGUUGUCGCUUCCAAGAAAAGGACGAAGAUGACAAUUUAAUUGAUUCUUACUUUGUAGUUAAGAGACACACUUUCUCUAACUACCAACAUGAAGAAACAAUUUAUAAUUUACUUAAGGAUUGUCCAGCUGUUGCUAAACAUGACUUCUUUAAGUUUAGAAUAGACGGUGACAUGGUACCACAUAUAUCACGUCAACGUCUUACUAAAUACACAAUGGCAGACCUCGUCUAUGCUUUAAGGCAUUUUGAUGAAGGUAAUUGUGACACAUUAAAAGAAAUACUUGUCACAUACAAUUGUUGUGAUGAUGAUUAUUUCAAUAAAAAGGACUGGUAUGAUUUUGUAGAAAACCCAGAUAUAUUACGCGUAUACGCCAACUUAGGUGAACGUGUACGCCAAGCUUUGUUAAAAACAGUACAAUUCUGUGAUGCCAUGCGAAAUGCUGGUAUUGUUGGUGUACUGACAUUAGAUAAUCAAGAUCUCAAUGGUAACUGGUAUGAUUUCGGUGAUUUCAUACAAACCACGCCAGGUAGUGGAGUUCCUGUUGUAGAUUCUUAUUAUUCAUUGUUAAUGCCUAUAUUAACCUUGACCAGGGCUUUAACUGCAGAGUCACAUGUUGACACUGACUUAACAAAGCCUUACAUUAAGUGGGAUUUGUUAAAAUAUGACUUCACGGAAGAGAGGUUAAAACUCUUUGACCGUUAUUUUAAAUAUUGGGAUCAGACAUACCACCCAAAUUGUGUUAACUGUUUGGAUGACAGAUGCAUUCUGCAUUGUGCAAACUUUAAUGUUUUAUUCUCUACAGUG,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0-15 nM[SARS-CoV-2 5'end];|0.5-2 µM[N protein],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,"liquid, solute","The 5'end and frameshifting region, which have the same length, displayed consistent near-opposing behaviors across a range of RNA and protein concentrations. The 5'end generally drives N-protein condensation, whereas the frameshifting region solubilized condensates and promoted LLPS only within a narrow protein and RNA concentration range."
534,PMID: 33290746,RNAPS0000446,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,SARS-CoV-2 virus RNA,996nt(13404-14400),GCUGUAGUUGUGAUCAACUCCGCGAACCCAUGCUUCAGUCAGCUGAUGCACAAUCGUUUUUAAACGGGUUUGCGGUGUAAGUGCAGCCCGUCUUACACCGUGCGGCACAGGCACUAGUACUGAUGUCGUAUACAGGGCUUUUGACAUCUACAAUGAUAAAGUAGCUGGUUUUGCUAAAUUCCUAAAAACUAAUUGUUGUCGCUUCCAAGAAAAGGACGAAGAUGACAAUUUAAUUGAUUCUUACUUUGUAGUUAAGAGACACACUUUCUCUAACUACCAACAUGAAGAAACAAUUUAUAAUUUACUUAAGGAUUGUCCAGCUGUUGCUAAACAUGACUUCUUUAAGUUUAGAAUAGACGGUGACAUGGUACCACAUAUAUCACGUCAACGUCUUACUAAAUACACAAUGGCAGACCUCGUCUAUGCUUUAAGGCAUUUUGAUGAAGGUAAUUGUGACACAUUAAAAGAAAUACUUGUCACAUACAAUUGUUGUGAUGAUGAUUAUUUCAAUAAAAAGGACUGGUAUGAUUUUGUAGAAAACCCAGAUAUAUUACGCGUAUACGCCAACUUAGGUGAACGUGUACGCCAAGCUUUGUUAAAAACAGUACAAUUCUGUGAUGCCAUGCGAAAUGCUGGUAUUGUUGGUGUACUGACAUUAGAUAAUCAAGAUCUCAAUGGUAACUGGUAUGAUUUCGGUGAUUUCAUACAAACCACGCCAGGUAGUGGAGUUCCUGUUGUAGAUUCUUAUUAUUCAUUGUUAAUGCCUAUAUUAACCUUGACCAGGGCUUUAACUGCAGAGUCACAUGUUGACACUGACUUAACAAAGCCUUACAUUAAGUGGGAUUUGUUAAAAUAUGACUUCACGGAAGAGAGGUUAAAACUCUUUGACCGUUAUUUUAAAUAUUGGGAUCAGACAUACCACCCAAAUUGUGUUAACUGUUUGGAUGACAGAUGCAUUCUGCAUUGUGCAAACUUUAAUGUUUUAUUCUCUACAGUG,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5 nM[SARS-CoV-2];|1 µM[N protein],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,liquid,"N-protein LLPS varied as a function of the specific RNA co component (Figure 1E). The 5’ end and the nucleocapsid RNAs promoted LLPS. In contrast, at the same concentration, the fra meshifting region and the PS region RNAs reduced LLPS relative to N-protein alone"
535,PMID: 33290746,RNAPS0000446,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,SARS-CoV-2 virus RNA,996nt(13404-14400),GCUGUAGUUGUGAUCAACUCCGCGAACCCAUGCUUCAGUCAGCUGAUGCACAAUCGUUUUUAAACGGGUUUGCGGUGUAAGUGCAGCCCGUCUUACACCGUGCGGCACAGGCACUAGUACUGAUGUCGUAUACAGGGCUUUUGACAUCUACAAUGAUAAAGUAGCUGGUUUUGCUAAAUUCCUAAAAACUAAUUGUUGUCGCUUCCAAGAAAAGGACGAAGAUGACAAUUUAAUUGAUUCUUACUUUGUAGUUAAGAGACACACUUUCUCUAACUACCAACAUGAAGAAACAAUUUAUAAUUUACUUAAGGAUUGUCCAGCUGUUGCUAAACAUGACUUCUUUAAGUUUAGAAUAGACGGUGACAUGGUACCACAUAUAUCACGUCAACGUCUUACUAAAUACACAAUGGCAGACCUCGUCUAUGCUUUAAGGCAUUUUGAUGAAGGUAAUUGUGACACAUUAAAAGAAAUACUUGUCACAUACAAUUGUUGUGAUGAUGAUUAUUUCAAUAAAAAGGACUGGUAUGAUUUUGUAGAAAACCCAGAUAUAUUACGCGUAUACGCCAACUUAGGUGAACGUGUACGCCAAGCUUUGUUAAAAACAGUACAAUUCUGUGAUGCCAUGCGAAAUGCUGGUAUUGUUGGUGUACUGACAUUAGAUAAUCAAGAUCUCAAUGGUAACUGGUAUGAUUUCGGUGAUUUCAUACAAACCACGCCAGGUAGUGGAGUUCCUGUUGUAGAUUCUUAUUAUUCAUUGUUAAUGCCUAUAUUAACCUUGACCAGGGCUUUAACUGCAGAGUCACAUGUUGACACUGACUUAACAAAGCCUUACAUUAAGUGGGAUUUGUUAAAAUAUGACUUCACGGAAGAGAGGUUAAAACUCUUUGACCGUUAUUUUAAAUAUUGGGAUCAGACAUACCACCCAAAUUGUGUUAACUGUUUGGAUGACAGAUGCAUUCUGCAUUGUGCAAACUUUAAUGUUUUAUUCUCUACAGUG,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5 nM[SARS-CoV-2 5'end];|2 µM[N protein],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,liquid,"Addition of 0.3 kb or 2.4 kb of non-viral sequence to the 1 kb 5’ end or frameshifting re gion RNAs resulted in progressive increase in condensate size/ number, with the 5’ end driving enhanced condensates relative to the frameshifting region at all lengths tested"
536,PMID: 33290746,RNAPS0000447,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,SARS-CoV-2 virus RNA,1300nt(5' end region),-,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5 nM[SARS-CoV-2 5'end];|2 µM[N protein],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,liquid,"Addition of 0.3 kb or 2.4 kb of non-viral sequence to the 1 kb 5’ end or frameshifting re gion RNAs resulted in progressive increase in condensate size/ number, with the 5’ end driving enhanced condensates relative to the frameshifting region at all lengths tested"
537,PMID: 33290746,RNAPS0000447,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,SARS-CoV-2 virus RNA,1300nt(frameshift region),-,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5 nM[SARS-CoV-2 frameshifting];|2 µM[N protein],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,liquid,"Addition of 0.3 kb or 2.4 kb of non-viral sequence to the 1 kb 5’ end or frameshifting re gion RNAs resulted in progressive increase in condensate size/ number, with the 5’ end driving enhanced condensates relative to the frameshifting region at all lengths tested"
538,PMID: 33290746,RNAPS0000448,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,SARS-CoV-2 virus RNA,582nt(19782–20363),AUUUGAGCUUUGGGCUAAGCGCAACAUUAAACCAGUACCAGAGGUGAAAAUACUCAAUAAUUUGGGUGUGGACAUUGCUGCUAAUACUGUGAUCUGGGACUACAAAAGAGAUGCUCCAGCACAUAUAUCUACUAUUGGUGUUUGUUCUAUGACUGACAUAGCCAAGAAACCAACUGAAACGAUUUGUGCACCACUCACUGUCUUUUUUGAUGGUAGAGUUGAUGGUCAAGUAGACUUAUUUAGAAAUGCCCGUAAUGGUGUUCUUAUUACAGAAGGUAGUGUUAAAGGUUUACAACCAUCUGUAGGUCCCAAACAAGCUAGUCUUAAUGGAGUCACAUUAAUUGGAGAAGCCGUAAAAACACAGUUCAAUUAUUAUAAGAAAGUUGAUGGUGUUGUCCAACAAUUACCUGAAACUUACUUUACUCAGAGUAGAAAUUUACAAGAAUUUAAACCCAGGAGUCAAAUGGAAAUUGAUUUCUUAGAAUUAGCUAUGGAUGAAUUCAUUGAACGGUAUAAAUUAGAAGGCUAUGCCUUCGAACAUAUCGUUUAUGGAGAUUUUAGUCAUAGUCAGUUAGGUGGUUU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5 nM[SARS-CoV-2];|1 µM[N protein],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,liquid,"N-protein LLPS varied as a function of the specific RNA co component (Figure 1E). The 5’ end and the nucleocapsid RNAs promoted LLPS. In contrast, at the same concentration, the fra meshifting region and the PS region RNAs reduced LLPS relative to N-protein alone"
539,PMID: 33290746,RNAPS0000449,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,SARS-CoV-2 virus RNA,1336nt(1–75 + 28273–29533),AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACGGUGCUAACAAAGACGGCAUCAUAUGGGUUGCAACUGAGGGAGCCUUGAAUACACCAAAAGAUCACAUUGGCACCCGCAAUCCUGCUAACAAUGCUGCAAUCGUGCUACAACUUCCUCAAGGAACAACAUUGCCAAAAGGCUUCUACGCAGAAGGGAGCAGAGGCGGCAGUCAAGCCUCUUCUCGUUCCUCAUCACGUAGUCGCAACAGUUCAAGAAAUUCAACUCCAGGCAGCAGUAGGGGAACUUCUCCUGCUAGAAUGGCUGGCAAUGGCGGUGAUGCUGCUCUUGCUUUGCUGCUGCUUGACAGAUUGAACCAGCUUGAGAGCAAAAUGUCUGGUAAAGGCCAACAACAACAAGGCCAAACUGUCACUAAGAAAUCUGCUGCUGAGGCUUCUAAGAAGCCUCGGCAAAAACGUACUGCCACUAAAGCAUACAAUGUAACACAAGCUUUCGGCAGACGUGGUCCAGAACAAACCCAAGGAAAUUUUGGGGACCAGGAACUAAUCAGACAAGGAACUGAUUACAAACAUUGGCCGCAAAUUGCACAAUUUGCCCCCAGCGCUUCAGCGUUCUUCGGAAUGUCGCGCAUUGGCAUGGAAGUCACACCUUCGGGAACGUGGUUGACCUACACAGGUGCCAUCAAAUUGGAUGACAAAGAUCCAAAUUUCAAAGAUCAAGUCAUUUUGCUGAAUAAGCAUAUUGACGCAUACAAAACAUUCCCACCAACAGAGCCUAAAAAGGACAAAAAGAAGAAGGCUGAUGAAACUCAAGCCUUACCGCAGAGACAGAAGAAACAGCAAACUGUGACUCUUCUUCCUGCUGCAGAUUUGGAUGAUUUCUCCAAACAAUUGCAACAAUCCAUGAGCAGUGCUGACUCAACUCAGGCCUAAACUCAUGCAGACCACACAAGGCAGAUGGGCUAUAUAAACGUUUUCGCUUUUCCGUUUACGAUAUAUAGUCUACUCUUGUGCAGAAUGAAUUCUCGUAACUACAUAGCACAAGUAGAUGUAGUUAACUUUAAUCUCACAUAGCAAUCUUUAAUCAGUGUGUAACAUUAGGGAGGACUUGAAAGAGCCACCACAUUUUCACCGAGGCCACGCGGAGUACGAUCGAGUGUACAGUGAACAAUGCUAGGGAGAGCUGCCUAUAUGGAAGAGCCCUAAUGUGUAAAAUUAAUUUUAGUAGUGCUAUCCCCAUGUGAUUUUAAUAGCUUCUUAGGAGAAUGACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5 nM[SARS-CoV-2];|1 µM[N protein],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,liquid,"N-protein LLPS varied as a function of the specific RNA co component (Figure 1E). The 5’ end and the nucleocapsid RNAs promoted LLPS. In contrast, at the same concentration, the fra meshifting region and the PS region RNAs reduced LLPS relative to N-protein alone"
540,PMID: 33290746,RNAPS0000450,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,SARS-CoV-2 virus RNA,29903nt(1-29903),AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGCACCUCAUGGUCAUGUUAUGGUUGAGCUGGUAGCAGAACUCGAAGGCAUUCAGUACGGUCGUAGUGGUGAGACACUUGGUGUCCUUGUCCCUCAUGUGGGCGAAAUACCAGUGGCUUACCGCAAGGUUCUUCUUCGUAAGAACGGUAAUAAAGGAGCUGGUGGCCAUAGUUACGGCGCCGAUCUAAAGUCAUUUGACUUAGGCGACGAGCUUGGCACUGAUCCUUAUGAAGAUUUUCAAGAAAACUGGAACACUAAACAUAGCAGUGGUGUUACCCGUGAACUCAUGCGUGAGCUUAACGGAGGGGCAUACACUCGCUAUGUCGAUAACAACUUCUGUGGCCCUGAUGGCUACCCUCUUGAGUGCAUUAAAGACCUUCUAGCACGUGCUGGUAAAGCUUCAUGCACUUUGUCCGAACAACUGGACUUUAUUGACACUAAGAGGGGUGUAUACUGCUGCCGUGAACAUGAGCAUGAAAUUGCUUGGUACACGGAACGUUCUGAAAAGAGCUAUGAAUUGCAGACACCUUUUGAAAUUAAAUUGGCAAAGAAAUUUGACACCUUCAAUGGGGAAUGUCCAAAUUUUGUAUUUCCCUUAAAUUCCAUAAUCAAGACUAUUCAACCAAGGGUUGAAAAGAAAAAGCUUGAUGGCUUUAUGGGUAGAAUUCGAUCUGUCUAUCCAGUUGCGUCACCAAAUGAAUGCAACCAAAUGUGCCUUUCAACUCUCAUGAAGUGUGAUCAUUGUGGUGAAACUUCAUGGCAGACGGGCGAUUUUGUUAAAGCCACUUGCGAAUUUUGUGGCACUGAGAAUUUGACUAAAGAAGGUGCCACUACUUGUGGUUACUUACCCCAAAAUGCUGUUGUUAAAAUUUAUUGUCCAGCAUGUCACAAUUCAGAAGUAGGACCUGAGCAUAGUCUUGCCGAAUACCAUAAUGAAUCUGGCUUGAAAACCAUUCUUCGUAAGGGUGGUCGCACUAUUGCCUUUGGAGGCUGUGUGUUCUCUUAUGUUGGUUGCCAUAACAAGUGUGCCUAUUGGGUUCCACGUGCUAGCGCUAACAUAGGUUGUAACCAUACAGGUGUUGUUGGAGAAGGUUCCGAAGGUCUUAAUGACAACCUUCUUGAAAUACUCCAAAAAGAGAAAGUCAACAUCAAUAUUGUUGGUGACUUUAAACUUAAUGAAGAGAUCGCCAUUAUUUUGGCAUCUUUUUCUGCUUCCACAAGUGCUUUUGUGGAAACUGUGAAAGGUUUGGAUUAUAAAGCAUUCAAACAAAUUGUUGAAUCCUGUGGUAAUUUUAAAGUUACAAAAGGAAAAGCUAAAAAAGGUGCCUGGAAUAUUGGUGAACAGAAAUCAAUACUGAGUCCUCUUUAUGCAUUUGCAUCAGAGGCUGCUCGUGUUGUACGAUCAAUUUUCUCCCGCACUCUUGAAACUGCUCAAAAUUCUGUGCGUGUUUUACAGAAGGCCGCUAUAACAAUACUAGAUGGAAUUUCACAGUAUUCACUGAGACUCAUUGAUGCUAUGAUGUUCACAUCUGAUUUGGCUACUAACAAUCUAGUUGUAAUGGCCUACAUUACAGGUGGUGUUGUUCAGUUGACUUCGCAGUGGCUAACUAACAUCUUUGGCACUGUUUAUGAAAAACUCAAACCCGUCCUUGAUUGGCUUGAAGAGAAGUUUAAGGAAGGUGUAGAGUUUCUUAGAGACGGUUGGGAAAUUGUUAAAUUUAUCUCAACCUGUGCUUGUGAAAUUGUCGGUGGACAAAUUGUCACCUGUGCAAAGGAAAUUAAGGAGAGUGUUCAGACAUUCUUUAAGCUUGUAAAUAAAUUUUUGGCUUUGUGUGCUGACUCUAUCAUUAUUGGUGGAGCUAAACUUAAAGCCUUGAAUUUAGGUGAAACAUUUGUCACGCACUCAAAGGGAUUGUACAGAAAGUGUGUUAAAUCCAGAGAAGAAACUGGCCUACUCAUGCCUCUAAAAGCCCCAAAAGAAAUUAUCUUCUUAGAGGGAGAAACACUUCCCACAGAAGUGUUAACAGAGGAAGUUGUCUUGAAAACUGGUGAUUUACAACCAUUAGAACAACCUACUAGUGAAGCUGUUGAAGCUCCAUUGGUUGGUACACCAGUUUGUAUUAACGGGCUUAUGUUGCUCGAAAUCAAAGACACAGAAAAGUACUGUGCCCUUGCACCUAAUAUGAUGGUAACAAACAAUACCUUCACACUCAAAGGCGGUGCACCAACAAAGGUUACUUUUGGUGAUGACACUGUGAUAGAAGUGCAAGGUUACAAGAGUGUGAAUAUCACUUUUGAACUUGAUGAAAGGAUUGAUAAAGUACUUAAUGAGAAGUGCUCUGCCUAUACAGUUGAACUCGGUACAGAAGUAAAUGAGUUCGCCUGUGUUGUGGCAGAUGCUGUCAUAAAAACUUUGCAACCAGUAUCUGAAUUACUUACACCACUGGGCAUUGAUUUAGAUGAGUGGAGUAUGGCUACAUACUACUUAUUUGAUGAGUCUGGUGAGUUUAAAUUGGCUUCACAUAUGUAUUGUUCUUUCUACCCUCCAGAUGAGGAUGAAGAAGAAGGUGAUUGUGAAGAAGAAGAGUUUGAGCCAUCAACUCAAUAUGAGUAUGGUACUGAAGAUGAUUACCAAGGUAAACCUUUGGAAUUUGGUGCCACUUCUGCUGCUCUUCAACCUGAAGAAGAGCAAGAAGAAGAUUGGUUAGAUGAUGAUAGUCAACAAACUGUUGGUCAACAAGACGGCAGUGAGGACAAUCAGACAACUACUAUUCAAACAAUUGUUGAGGUUCAACCUCAAUUAGAGAUGGAACUUACACCAGUUGUUCAGACUAUUGAAGUGAAUAGUUUUAGUGGUUAUUUAAAACUUACUGACAAUGUAUACAUUAAAAAUGCAGACAUUGUGGAAGAAGCUAAAAAGGUAAAACCAACAGUGGUUGUUAAUGCAGCCAAUGUUUACCUUAAACAUGGAGGAGGUGUUGCAGGAGCCUUAAAUAAGGCUACUAACAAUGCCAUGCAAGUUGAAUCUGAUGAUUACAUAGCUACUAAUGGACCACUUAAAGUGGGUGGUAGUUGUGUUUUAAGCGGACACAAUCUUGCUAAACACUGUCUUCAUGUUGUCGGCCCAAAUGUUAACAAAGGUGAAGACAUUCAACUUCUUAAGAGUGCUUAUGAAAAUUUUAAUCAGCACGAAGUUCUACUUGCACCAUUAUUAUCAGCUGGUAUUUUUGGUGCUGACCCUAUACAUUCUUUAAGAGUUUGUGUAGAUACUGUUCGCACAAAUGUCUACUUAGCUGUCUUUGAUAAAAAUCUCUAUGACAAACUUGUUUCAAGCUUUUUGGAAAUGAAGAGUGAAAAGCAAGUUGAACAAAAGAUCGCUGAGAUUCCUAAAGAGGAAGUUAAGCCAUUUAUAACUGAAAGUAAACCUUCAGUUGAACAGAGAAAACAAGAUGAUAAGAAAAUCAAAGCUUGUGUUGAAGAAGUUACAACAACUCUGGAAGAAACUAAGUUCCUCACAGAAAACUUGUUACUUUAUAUUGACAUUAAUGGCAAUCUUCAUCCAGAUUCUGCCACUCUUGUUAGUGACAUUGACAUCACUUUCUUAAAGAAAGAUGCUCCAUAUAUAGUGGGUGAUGUUGUUCAAGAGGGUGUUUUAACUGCUGUGGUUAUACCUACUAAAAAGGCUGGUGGCACUACUGAAAUGCUAGCGAAAGCUUUGAGAAAAGUGCCAACAGACAAUUAUAUAACCACUUACCCGGGUCAGGGUUUAAAUGGUUACACUGUAGAGGAGGCAAAGACAGUGCUUAAAAAGUGUAAAAGUGCCUUUUACAUUCUACCAUCUAUUAUCUCUAAUGAGAAGCAAGAAAUUCUUGGAACUGUUUCUUGGAAUUUGCGAGAAAUGCUUGCACAUGCAGAAGAAACACGCAAAUUAAUGCCUGUCUGUGUGGAAACUAAAGCCAUAGUUUCAACUAUACAGCGUAAAUAUAAGGGUAUUAAAAUACAAGAGGGUGUGGUUGAUUAUGGUGCUAGAUUUUACUUUUACACCAGUAAAACAACUGUAGCGUCACUUAUCAACACACUUAACGAUCUAAAUGAAACUCUUGUUACAAUGCCACUUGGCUAUGUAACACAUGGCUUAAAUUUGGAAGAAGCUGCUCGGUAUAUGAGAUCUCUCAAAGUGCCAGCUACAGUUUCUGUUUCUUCACCUGAUGCUGUUACAGCGUAUAAUGGUUAUCUUACUUCUUCUUCUAAAACACCUGAAGAACAUUUUAUUGAAACCAUCUCACUUGCUGGUUCCUAUAAAGAUUGGUCCUAUUCUGGACAAUCUACACAACUAGGUAUAGAAUUUCUUAAGAGAGGUGAUAAAAGUGUAUAUUACACUAGUAAUCCUACCACAUUCCACCUAGAUGGUGAAGUUAUCACCUUUGACAAUCUUAAGACACUUCUUUCUUUGAGAGAAGUGAGGACUAUUAAGGUGUUUACAACAGUAGACAACAUUAACCUCCACACGCAAGUUGUGGACAUGUCAAUGACAUAUGGACAACAGUUUGGUCCAACUUAUUUGGAUGGAGCUGAUGUUACUAAAAUAAAACCUCAUAAUUCACAUGAAGGUAAAACAUUUUAUGUUUUACCUAAUGAUGACACUCUACGUGUUGAGGCUUUUGAGUACUACCACACAACUGAUCCUAGUUUUCUGGGUAGGUACAUGUCAGCAUUAAAUCACACUAAAAAGUGGAAAUACCCACAAGUUAAUGGUUUAACUUCUAUUAAAUGGGCAGAUAACAACUGUUAUCUUGCCACUGCAUUGUUAACACUCCAACAAAUAGAGUUGAAGUUUAAUCCACCUGCUCUACAAGAUGCUUAUUACAGAGCAAGGGCUGGUGAAGCUGCUAACUUUUGUGCACUUAUCUUAGCCUACUGUAAUAAGACAGUAGGUGAGUUAGGUGAUGUUAGAGAAACAAUGAGUUACUUGUUUCAACAUGCCAAUUUAGAUUCUUGCAAAAGAGUCUUGAACGUGGUGUGUAAAACUUGUGGACAACAGCAGACAACCCUUAAGGGUGUAGAAGCUGUUAUGUACAUGGGCACACUUUCUUAUGAACAAUUUAAGAAAGGUGUUCAGAUACCUUGUACGUGUGGUAAACAAGCUACAAAAUAUCUAGUACAACAGGAGUCACCUUUUGUUAUGAUGUCAGCACCACCUGCUCAGUAUGAACUUAAGCAUGGUACAUUUACUUGUGCUAGUGAGUACACUGGUAAUUACCAGUGUGGUCACUAUAAACAUAUAACUUCUAAAGAAACUUUGUAUUGCAUAGACGGUGCUUUACUUACAAAGUCCUCAGAAUACAAAGGUCCUAUUACGGAUGUUUUCUACAAAGAAAACAGUUACACAACAACCAUAAAACCAGUUACUUAUAAAUUGGAUGGUGUUGUUUGUACAGAAAUUGACCCUAAGUUGGACAAUUAUUAUAAGAAAGACAAUUCUUAUUUCACAGAGCAACCAAUUGAUCUUGUACCAAACCAACCAUAUCCAAACGCAAGCUUCGAUAAUUUUAAGUUUGUAUGUGAUAAUAUCAAAUUUGCUGAUGAUUUAAACCAGUUAACUGGUUAUAAGAAACCUGCUUCAAGAGAGCUUAAAGUUACAUUUUUCCCUGACUUAAAUGGUGAUGUGGUGGCUAUUGAUUAUAAACACUACACACCCUCUUUUAAGAAAGGAGCUAAAUUGUUACAUAAACCUAUUGUUUGGCAUGUUAACAAUGCAACUAAUAAAGCCACGUAUAAACCAAAUACCUGGUGUAUACGUUGUCUUUGGAGCACAAAACCAGUUGAAACAUCAAAUUCGUUUGAUGUACUGAAGUCAGAGGACGCGCAGGGAAUGGAUAAUCUUGCCUGCGAAGAUCUAAAACCAGUCUCUGAAGAAGUAGUGGAAAAUCCUACCAUACAGAAAGACGUUCUUGAGUGUAAUGUGAAAACUACCGAAGUUGUAGGAGACAUUAUACUUAAACCAGCAAAUAAUAGUUUAAAAAUUACAGAAGAGGUUGGCCACACAGAUCUAAUGGCUGCUUAUGUAGACAAUUCUAGUCUUACUAUUAAGAAACCUAAUGAAUUAUCUAGAGUAUUAGGUUUGAAAACCCUUGCUACUCAUGGUUUAGCUGCUGUUAAUAGUGUCCCUUGGGAUACUAUAGCUAAUUAUGCUAAGCCUUUUCUUAACAAAGUUGUUAGUACAACUACUAACAUAGUUACACGGUGUUUAAACCGUGUUUGUACUAAUUAUAUGCCUUAUUUCUUUACUUUAUUGCUACAAUUGUGUACUUUUACUAGAAGUACAAAUUCUAGAAUUAAAGCAUCUAUGCCGACUACUAUAGCAAAGAAUACUGUUAAGAGUGUCGGUAAAUUUUGUCUAGAGGCUUCAUUUAAUUAUUUGAAGUCACCUAAUUUUUCUAAACUGAUAAAUAUUAUAAUUUGGUUUUUACUAUUAAGUGUUUGCCUAGGUUCUUUAAUCUACUCAACCGCUGCUUUAGGUGUUUUAAUGUCUAAUUUAGGCAUGCCUUCUUACUGUACUGGUUACAGAGAAGGCUAUUUGAACUCUACUAAUGUCACUAUUGCAACCUACUGUACUGGUUCUAUACCUUGUAGUGUUUGUCUUAGUGGUUUAGAUUCUUUAGACACCUAUCCUUCUUUAGAAACUAUACAAAUUACCAUUUCAUCUUUUAAAUGGGAUUUAACUGCUUUUGGCUUAGUUGCAGAGUGGUUUUUGGCAUAUAUUCUUUUCACUAGGUUUUUCUAUGUACUUGGAUUGGCUGCAAUCAUGCAAUUGUUUUUCAGCUAUUUUGCAGUACAUUUUAUUAGUAAUUCUUGGCUUAUGUGGUUAAUAAUUAAUCUUGUACAAAUGGCCCCGAUUUCAGCUAUGGUUAGAAUGUACAUCUUCUUUGCAUCAUUUUAUUAUGUAUGGAAAAGUUAUGUGCAUGUUGUAGACGGUUGUAAUUCAUCAACUUGUAUGAUGUGUUACAAACGUAAUAGAGCAACAAGAGUCGAAUGUACAACUAUUGUUAAUGGUGUUAGAAGGUCCUUUUAUGUCUAUGCUAAUGGAGGUAAAGGCUUUUGCAAACUACACAAUUGGAAUUGUGUUAAUUGUGAUACAUUCUGUGCUGGUAGUACAUUUAUUAGUGAUGAAGUUGCGAGAGACUUGUCACUACAGUUUAAAAGACCAAUAAAUCCUACUGACCAGUCUUCUUACAUCGUUGAUAGUGUUACAGUGAAGAAUGGUUCCAUCCAUCUUUACUUUGAUAAAGCUGGUCAAAAGACUUAUGAAAGACAUUCUCUCUCUCAUUUUGUUAACUUAGACAACCUGAGAGCUAAUAACACUAAAGGUUCAUUGCCUAUUAAUGUUAUAGUUUUUGAUGGUAAAUCAAAAUGUGAAGAAUCAUCUGCAAAAUCAGCGUCUGUUUACUACAGUCAGCUUAUGUGUCAACCUAUACUGUUACUAGAUCAGGCAUUAGUGUCUGAUGUUGGUGAUAGUGCGGAAGUUGCAGUUAAAAUGUUUGAUGCUUACGUUAAUACGUUUUCAUCAACUUUUAACGUACCAAUGGAAAAACUCAAAACACUAGUUGCAACUGCAGAAGCUGAACUUGCAAAGAAUGUGUCCUUAGACAAUGUCUUAUCUACUUUUAUUUCAGCAGCUCGGCAAGGGUUUGUUGAUUCAGAUGUAGAAACUAAAGAUGUUGUUGAAUGUCUUAAAUUGUCACAUCAAUCUGACAUAGAAGUUACUGGCGAUAGUUGUAAUAACUAUAUGCUCACCUAUAACAAAGUUGAAAACAUGACACCCCGUGACCUUGGUGCUUGUAUUGACUGUAGUGCGCGUCAUAUUAAUGCGCAGGUAGCAAAAAGUCACAACAUUGCUUUGAUAUGGAACGUUAAAGAUUUCAUGUCAUUGUCUGAACAACUACGAAAACAAAUACGUAGUGCUGCUAAAAAGAAUAACUUACCUUUUAAGUUGACAUGUGCAACUACUAGACAAGUUGUUAAUGUUGUAACAACAAAGAUAGCACUUAAGGGUGGUAAAAUUGUUAAUAAUUGGUUGAAGCAGUUAAUUAAAGUUACACUUGUGUUCCUUUUUGUUGCUGCUAUUUUCUAUUUAAUAACACCUGUUCAUGUCAUGUCUAAACAUACUGACUUUUCAAGUGAAAUCAUAGGAUACAAGGCUAUUGAUGGUGGUGUCACUCGUGACAUAGCAUCUACAGAUACUUGUUUUGCUAACAAACAUGCUGAUUUUGACACAUGGUUUAGCCAGCGUGGUGGUAGUUAUACUAAUGACAAAGCUUGCCCAUUGAUUGCUGCAGUCAUAACAAGAGAAGUGGGUUUUGUCGUGCCUGGUUUGCCUGGCACGAUAUUACGCACAACUAAUGGUGACUUUUUGCAUUUCUUACCUAGAGUUUUUAGUGCAGUUGGUAACAUCUGUUACACACCAUCAAAACUUAUAGAGUACACUGACUUUGCAACAUCAGCUUGUGUUUUGGCUGCUGAAUGUACAAUUUUUAAAGAUGCUUCUGGUAAGCCAGUACCAUAUUGUUAUGAUACCAAUGUACUAGAAGGUUCUGUUGCUUAUGAAAGUUUACGCCCUGACACACGUUAUGUGCUCAUGGAUGGCUCUAUUAUUCAAUUUCCUAACACCUACCUUGAAGGUUCUGUUAGAGUGGUAACAACUUUUGAUUCUGAGUACUGUAGGCACGGCACUUGUGAAAGAUCAGAAGCUGGUGUUUGUGUAUCUACUAGUGGUAGAUGGGUACUUAACAAUGAUUAUUACAGAUCUUUACCAGGAGUUUUCUGUGGUGUAGAUGCUGUAAAUUUACUUACUAAUAUGUUUACACCACUAAUUCAACCUAUUGGUGCUUUGGACAUAUCAGCAUCUAUAGUAGCUGGUGGUAUUGUAGCUAUCGUAGUAACAUGCCUUGCCUACUAUUUUAUGAGGUUUAGAAGAGCUUUUGGUGAAUACAGUCAUGUAGUUGCCUUUAAUACUUUACUAUUCCUUAUGUCAUUCACUGUACUCUGUUUAACACCAGUUUACUCAUUCUUACCUGGUGUUUAUUCUGUUAUUUACUUGUACUUGACAUUUUAUCUUACUAAUGAUGUUUCUUUUUUAGCACAUAUUCAGUGGAUGGUUAUGUUCACACCUUUAGUACCUUUCUGGAUAACAAUUGCUUAUAUCAUUUGUAUUUCCACAAAGCAUUUCUAUUGGUUCUUUAGUAAUUACCUAAAGAGACGUGUAGUCUUUAAUGGUGUUUCCUUUAGUACUUUUGAAGAAGCUGCGCUGUGCACCUUUUUGUUAAAUAAAGAAAUGUAUCUAAAGUUGCGUAGUGAUGUGCUAUUACCUCUUACGCAAUAUAAUAGAUACUUAGCUCUUUAUAAUAAGUACAAGUAUUUUAGUGGAGCAAUGGAUACAACUAGCUACAGAGAAGCUGCUUGUUGUCAUCUCGCAAAGGCUCUCAAUGACUUCAGUAACUCAGGUUCUGAUGUUCUUUACCAACCACCACAAACCUCUAUCACCUCAGCUGUUUUGCAGAGUGGUUUUAGAAAAAUGGCAUUCCCAUCUGGUAAAGUUGAGGGUUGUAUGGUACAAGUAACUUGUGGUACAACUACACUUAACGGUCUUUGGCUUGAUGACGUAGUUUACUGUCCAAGACAUGUGAUCUGCACCUCUGAAGACAUGCUUAACCCUAAUUAUGAAGAUUUACUCAUUCGUAAGUCUAAUCAUAAUUUCUUGGUACAGGCUGGUAAUGUUCAACUCAGGGUUAUUGGACAUUCUAUGCAAAAUUGUGUACUUAAGCUUAAGGUUGAUACAGCCAAUCCUAAGACACCUAAGUAUAAGUUUGUUCGCAUUCAACCAGGACAGACUUUUUCAGUGUUAGCUUGUUACAAUGGUUCACCAUCUGGUGUUUACCAAUGUGCUAUGAGGCCCAAUUUCACUAUUAAGGGUUCAUUCCUUAAUGGUUCAUGUGGUAGUGUUGGUUUUAACAUAGAUUAUGACUGUGUCUCUUUUUGUUACAUGCACCAUAUGGAAUUACCAACUGGAGUUCAUGCUGGCACAGACUUAGAAGGUAACUUUUAUGGACCUUUUGUUGACAGGCAAACAGCACAAGCAGCUGGUACGGACACAACUAUUACAGUUAAUGUUUUAGCUUGGUUGUACGCUGCUGUUAUAAAUGGAGACAGGUGGUUUCUCAAUCGAUUUACCACAACUCUUAAUGACUUUAACCUUGUGGCUAUGAAGUACAAUUAUGAACCUCUAACACAAGACCAUGUUGACAUACUAGGACCUCUUUCUGCUCAAACUGGAAUUGCCGUUUUAGAUAUGUGUGCUUCAUUAAAAGAAUUACUGCAAAAUGGUAUGAAUGGACGUACCAUAUUGGGUAGUGCUUUAUUAGAAGAUGAAUUUACACCUUUUGAUGUUGUUAGACAAUGCUCAGGUGUUACUUUCCAAAGUGCAGUGAAAAGAACAAUCAAGGGUACACACCACUGGUUGUUACUCACAAUUUUGACUUCACUUUUAGUUUUAGUCCAGAGUACUCAAUGGUCUUUGUUCUUUUUUUUGUAUGAAAAUGCCUUUUUACCUUUUGCUAUGGGUAUUAUUGCUAUGUCUGCUUUUGCAAUGAUGUUUGUCAAACAUAAGCAUGCAUUUCUCUGUUUGUUUUUGUUACCUUCUCUUGCCACUGUAGCUUAUUUUAAUAUGGUCUAUAUGCCUGCUAGUUGGGUGAUGCGUAUUAUGACAUGGUUGGAUAUGGUUGAUACUAGUUUGUCUGGUUUUAAGCUAAAAGACUGUGUUAUGUAUGCAUCAGCUGUAGUGUUACUAAUCCUUAUGACAGCAAGAACUGUGUAUGAUGAUGGUGCUAGGAGAGUGUGGACACUUAUGAAUGUCUUGACACUCGUUUAUAAAGUUUAUUAUGGUAAUGCUUUAGAUCAAGCCAUUUCCAUGUGGGCUCUUAUAAUCUCUGUUACUUCUAACUACUCAGGUGUAGUUACAACUGUCAUGUUUUUGGCCAGAGGUAUUGUUUUUAUGUGUGUUGAGUAUUGCCCUAUUUUCUUCAUAACUGGUAAUACACUUCAGUGUAUAAUGCUAGUUUAUUGUUUCUUAGGCUAUUUUUGUACUUGUUACUUUGGCCUCUUUUGUUUACUCAACCGCUACUUUAGACUGACUCUUGGUGUUUAUGAUUACUUAGUUUCUACACAGGAGUUUAGAUAUAUGAAUUCACAGGGACUACUCCCACCCAAGAAUAGCAUAGAUGCCUUCAAACUCAACAUUAAAUUGUUGGGUGUUGGUGGCAAACCUUGUAUCAAAGUAGCCACUGUACAGUCUAAAAUGUCAGAUGUAAAGUGCACAUCAGUAGUCUUACUCUCAGUUUUGCAACAACUCAGAGUAGAAUCAUCAUCUAAAUUGUGGGCUCAAUGUGUCCAGUUACACAAUGACAUUCUCUUAGCUAAAGAUACUACUGAAGCCUUUGAAAAAAUGGUUUCACUACUUUCUGUUUUGCUUUCCAUGCAGGGUGCUGUAGACAUAAACAAGCUUUGUGAAGAAAUGCUGGACAACAGGGCAACCUUACAAGCUAUAGCCUCAGAGUUUAGUUCCCUUCCAUCAUAUGCAGCUUUUGCUACUGCUCAAGAAGCUUAUGAGCAGGCUGUUGCUAAUGGUGAUUCUGAAGUUGUUCUUAAAAAGUUGAAGAAGUCUUUGAAUGUGGCUAAAUCUGAAUUUGACCGUGAUGCAGCCAUGCAACGUAAGUUGGAAAAGAUGGCUGAUCAAGCUAUGACCCAAAUGUAUAAACAGGCUAGAUCUGAGGACAAGAGGGCAAAAGUUACUAGUGCUAUGCAGACAAUGCUUUUCACUAUGCUUAGAAAGUUGGAUAAUGAUGCACUCAACAACAUUAUCAACAAUGCAAGAGAUGGUUGUGUUCCCUUGAACAUAAUACCUCUUACAACAGCAGCCAAACUAAUGGUUGUCAUACCAGACUAUAACACAUAUAAAAAUACGUGUGAUGGUACAACAUUUACUUAUGCAUCAGCAUUGUGGGAAAUCCAACAGGUUGUAGAUGCAGAUAGUAAAAUUGUUCAACUUAGUGAAAUUAGUAUGGACAAUUCACCUAAUUUAGCAUGGCCUCUUAUUGUAACAGCUUUAAGGGCCAAUUCUGCUGUCAAAUUACAGAAUAAUGAGCUUAGUCCUGUUGCACUACGACAGAUGUCUUGUGCUGCCGGUACUACACAAACUGCUUGCACUGAUGACAAUGCGUUAGCUUACUACAACACAACAAAGGGAGGUAGGUUUGUACUUGCACUGUUAUCCGAUUUACAGGAUUUGAAAUGGGCUAGAUUCCCUAAGAGUGAUGGAACUGGUACUAUCUAUACAGAACUGGAACCACCUUGUAGGUUUGUUACAGACACACCUAAAGGUCCUAAAGUGAAGUAUUUAUACUUUAUUAAAGGAUUAAACAACCUAAAUAGAGGUAUGGUACUUGGUAGUUUAGCUGCCACAGUACGUCUACAAGCUGGUAAUGCAACAGAAGUGCCUGCCAAUUCAACUGUAUUAUCUUUCUGUGCUUUUGCUGUAGAUGCUGCUAAAGCUUACAAAGAUUAUCUAGCUAGUGGGGGACAACCAAUCACUAAUUGUGUUAAGAUGUUGUGUACACACACUGGUACUGGUCAGGCAAUAACAGUUACACCGGAAGCCAAUAUGGAUCAAGAAUCCUUUGGUGGUGCAUCGUGUUGUCUGUACUGCCGUUGCCACAUAGAUCAUCCAAAUCCUAAAGGAUUUUGUGACUUAAAAGGUAAGUAUGUACAAAUACCUACAACUUGUGCUAAUGACCCUGUGGGUUUUACACUUAAAAACACAGUCUGUACCGUCUGCGGUAUGUGGAAAGGUUAUGGCUGUAGUUGUGAUCAACUCCGCGAACCCAUGCUUCAGUCAGCUGAUGCACAAUCGUUUUUAAACGGGUUUGCGGUGUAAGUGCAGCCCGUCUUACACCGUGCGGCACAGGCACUAGUACUGAUGUCGUAUACAGGGCUUUUGACAUCUACAAUGAUAAAGUAGCUGGUUUUGCUAAAUUCCUAAAAACUAAUUGUUGUCGCUUCCAAGAAAAGGACGAAGAUGACAAUUUAAUUGAUUCUUACUUUGUAGUUAAGAGACACACUUUCUCUAACUACCAACAUGAAGAAACAAUUUAUAAUUUACUUAAGGAUUGUCCAGCUGUUGCUAAACAUGACUUCUUUAAGUUUAGAAUAGACGGUGACAUGGUACCACAUAUAUCACGUCAACGUCUUACUAAAUACACAAUGGCAGACCUCGUCUAUGCUUUAAGGCAUUUUGAUGAAGGUAAUUGUGACACAUUAAAAGAAAUACUUGUCACAUACAAUUGUUGUGAUGAUGAUUAUUUCAAUAAAAAGGACUGGUAUGAUUUUGUAGAAAACCCAGAUAUAUUACGCGUAUACGCCAACUUAGGUGAACGUGUACGCCAAGCUUUGUUAAAAACAGUACAAUUCUGUGAUGCCAUGCGAAAUGCUGGUAUUGUUGGUGUACUGACAUUAGAUAAUCAAGAUCUCAAUGGUAACUGGUAUGAUUUCGGUGAUUUCAUACAAACCACGCCAGGUAGUGGAGUUCCUGUUGUAGAUUCUUAUUAUUCAUUGUUAAUGCCUAUAUUAACCUUGACCAGGGCUUUAACUGCAGAGUCACAUGUUGACACUGACUUAACAAAGCCUUACAUUAAGUGGGAUUUGUUAAAAUAUGACUUCACGGAAGAGAGGUUAAAACUCUUUGACCGUUAUUUUAAAUAUUGGGAUCAGACAUACCACCCAAAUUGUGUUAACUGUUUGGAUGACAGAUGCAUUCUGCAUUGUGCAAACUUUAAUGUUUUAUUCUCUACAGUGUUCCCACCUACAAGUUUUGGACCACUAGUGAGAAAAAUAUUUGUUGAUGGUGUUCCAUUUGUAGUUUCAACUGGAUACCACUUCAGAGAGCUAGGUGUUGUACAUAAUCAGGAUGUAAACUUACAUAGCUCUAGACUUAGUUUUAAGGAAUUACUUGUGUAUGCUGCUGACCCUGCUAUGCACGCUGCUUCUGGUAAUCUAUUACUAGAUAAACGCACUACGUGCUUUUCAGUAGCUGCACUUACUAACAAUGUUGCUUUUCAAACUGUCAAACCCGGUAAUUUUAACAAAGACUUCUAUGACUUUGCUGUGUCUAAGGGUUUCUUUAAGGAAGGAAGUUCUGUUGAAUUAAAACACUUCUUCUUUGCUCAGGAUGGUAAUGCUGCUAUCAGCGAUUAUGACUACUAUCGUUAUAAUCUACCAACAAUGUGUGAUAUCAGACAACUACUAUUUGUAGUUGAAGUUGUUGAUAAGUACUUUGAUUGUUACGAUGGUGGCUGUAUUAAUGCUAACCAAGUCAUCGUCAACAACCUAGACAAAUCAGCUGGUUUUCCAUUUAAUAAAUGGGGUAAGGCUAGACUUUAUUAUGAUUCAAUGAGUUAUGAGGAUCAAGAUGCACUUUUCGCAUAUACAAAACGUAAUGUCAUCCCUACUAUAACUCAAAUGAAUCUUAAGUAUGCCAUUAGUGCAAAGAAUAGAGCUCGCACCGUAGCUGGUGUCUCUAUCUGUAGUACUAUGACCAAUAGACAGUUUCAUCAAAAAUUAUUGAAAUCAAUAGCCGCCACUAGAGGAGCUACUGUAGUAAUUGGAACAAGCAAAUUCUAUGGUGGUUGGCACAACAUGUUAAAAACUGUUUAUAGUGAUGUAGAAAACCCUCACCUUAUGGGUUGGGAUUAUCCUAAAUGUGAUAGAGCCAUGCCUAACAUGCUUAGAAUUAUGGCCUCACUUGUUCUUGCUCGCAAACAUACAACGUGUUGUAGCUUGUCACACCGUUUCUAUAGAUUAGCUAAUGAGUGUGCUCAAGUAUUGAGUGAAAUGGUCAUGUGUGGCGGUUCACUAUAUGUUAAACCAGGUGGAACCUCAUCAGGAGAUGCCACAACUGCUUAUGCUAAUAGUGUUUUUAACAUUUGUCAAGCUGUCACGGCCAAUGUUAAUGCACUUUUAUCUACUGAUGGUAACAAAAUUGCCGAUAAGUAUGUCCGCAAUUUACAACACAGACUUUAUGAGUGUCUCUAUAGAAAUAGAGAUGUUGACACAGACUUUGUGAAUGAGUUUUACGCAUAUUUGCGUAAACAUUUCUCAAUGAUGAUACUCUCUGACGAUGCUGUUGUGUGUUUCAAUAGCACUUAUGCAUCUCAAGGUCUAGUGGCUAGCAUAAAGAACUUUAAGUCAGUUCUUUAUUAUCAAAACAAUGUUUUUAUGUCUGAAGCAAAAUGUUGGACUGAGACUGACCUUACUAAAGGACCUCAUGAAUUUUGCUCUCAACAUACAAUGCUAGUUAAACAGGGUGAUGAUUAUGUGUACCUUCCUUACCCAGAUCCAUCAAGAAUCCUAGGGGCCGGCUGUUUUGUAGAUGAUAUCGUAAAAACAGAUGGUACACUUAUGAUUGAACGGUUCGUGUCUUUAGCUAUAGAUGCUUACCCACUUACUAAACAUCCUAAUCAGGAGUAUGCUGAUGUCUUUCAUUUGUACUUACAAUACAUAAGAAAGCUACAUGAUGAGUUAACAGGACACAUGUUAGACAUGUAUUCUGUUAUGCUUACUAAUGAUAACACUUCAAGGUAUUGGGAACCUGAGUUUUAUGAGGCUAUGUACACACCGCAUACAGUCUUACAGGCUGUUGGGGCUUGUGUUCUUUGCAAUUCACAGACUUCAUUAAGAUGUGGUGCUUGCAUACGUAGACCAUUCUUAUGUUGUAAAUGCUGUUACGACCAUGUCAUAUCAACAUCACAUAAAUUAGUCUUGUCUGUUAAUCCGUAUGUUUGCAAUGCUCCAGGUUGUGAUGUCACAGAUGUGACUCAACUUUACUUAGGAGGUAUGAGCUAUUAUUGUAAAUCACAUAAACCACCCAUUAGUUUUCCAUUGUGUGCUAAUGGACAAGUUUUUGGUUUAUAUAAAAAUACAUGUGUUGGUAGCGAUAAUGUUACUGACUUUAAUGCAAUUGCAACAUGUGACUGGACAAAUGCUGGUGAUUACAUUUUAGCUAACACCUGUACUGAAAGACUCAAGCUUUUUGCAGCAGAAACGCUCAAAGCUACUGAGGAGACAUUUAAACUGUCUUAUGGUAUUGCUACUGUACGUGAAGUGCUGUCUGACAGAGAAUUACAUCUUUCAUGGGAAGUUGGUAAACCUAGACCACCACUUAACCGAAAUUAUGUCUUUACUGGUUAUCGUGUAACUAAAAACAGUAAAGUACAAAUAGGAGAGUACACCUUUGAAAAAGGUGACUAUGGUGAUGCUGUUGUUUACCGAGGUACAACAACUUACAAAUUAAAUGUUGGUGAUUAUUUUGUGCUGACAUCACAUACAGUAAUGCCAUUAAGUGCACCUACACUAGUGCCACAAGAGCACUAUGUUAGAAUUACUGGCUUAUACCCAACACUCAAUAUCUCAGAUGAGUUUUCUAGCAAUGUUGCAAAUUAUCAAAAGGUUGGUAUGCAAAAGUAUUCUACACUCCAGGGACCACCUGGUACUGGUAAGAGUCAUUUUGCUAUUGGCCUAGCUCUCUACUACCCUUCUGCUCGCAUAGUGUAUACAGCUUGCUCUCAUGCCGCUGUUGAUGCACUAUGUGAGAAGGCAUUAAAAUAUUUGCCUAUAGAUAAAUGUAGUAGAAUUAUACCUGCACGUGCUCGUGUAGAGUGUUUUGAUAAAUUCAAAGUGAAUUCAACAUUAGAACAGUAUGUCUUUUGUACUGUAAAUGCAUUGCCUGAGACGACAGCAGAUAUAGUUGUCUUUGAUGAAAUUUCAAUGGCCACAAAUUAUGAUUUGAGUGUUGUCAAUGCCAGAUUACGUGCUAAGCACUAUGUGUACAUUGGCGACCCUGCUCAAUUACCUGCACCACGCACAUUGCUAACUAAGGGCACACUAGAACCAGAAUAUUUCAAUUCAGUGUGUAGACUUAUGAAAACUAUAGGUCCAGACAUGUUCCUCGGAACUUGUCGGCGUUGUCCUGCUGAAAUUGUUGACACUGUGAGUGCUUUGGUUUAUGAUAAUAAGCUUAAAGCACAUAAAGACAAAUCAGCUCAAUGCUUUAAAAUGUUUUAUAAGGGUGUUAUCACGCAUGAUGUUUCAUCUGCAAUUAACAGGCCACAAAUAGGCGUGGUAAGAGAAUUCCUUACACGUAACCCUGCUUGGAGAAAAGCUGUCUUUAUUUCACCUUAUAAUUCACAGAAUGCUGUAGCCUCAAAGAUUUUGGGACUACCAACUCAAACUGUUGAUUCAUCACAGGGCUCAGAAUAUGACUAUGUCAUAUUCACUCAAACCACUGAAACAGCUCACUCUUGUAAUGUAAACAGAUUUAAUGUUGCUAUUACCAGAGCAAAAGUAGGCAUACUUUGCAUAAUGUCUGAUAGAGACCUUUAUGACAAGUUGCAAUUUACAAGUCUUGAAAUUCCACGUAGGAAUGUGGCAACUUUACAAGCUGAAAAUGUAACAGGACUCUUUAAAGAUUGUAGUAAGGUAAUCACUGGGUUACAUCCUACACAGGCACCUACACACCUCAGUGUUGACACUAAAUUCAAAACUGAAGGUUUAUGUGUUGACAUACCUGGCAUACCUAAGGACAUGACCUAUAGAAGACUCAUCUCUAUGAUGGGUUUUAAAAUGAAUUAUCAAGUUAAUGGUUACCCUAACAUGUUUAUCACCCGCGAAGAAGCUAUAAGACAUGUACGUGCAUGGAUUGGCUUCGAUGUCGAGGGGUGUCAUGCUACUAGAGAAGCUGUUGGUACCAAUUUACCUUUACAGCUAGGUUUUUCUACAGGUGUUAACCUAGUUGCUGUACCUACAGGUUAUGUUGAUACACCUAAUAAUACAGAUUUUUCCAGAGUUAGUGCUAAACCACCGCCUGGAGAUCAAUUUAAACACCUCAUACCACUUAUGUACAAAGGACUUCCUUGGAAUGUAGUGCGUAUAAAGAUUGUACAAAUGUUAAGUGACACACUUAAAAAUCUCUCUGACAGAGUCGUAUUUGUCUUAUGGGCACAUGGCUUUGAGUUGACAUCUAUGAAGUAUUUUGUGAAAAUAGGACCUGAGCGCACCUGUUGUCUAUGUGAUAGACGUGCCACAUGCUUUUCCACUGCUUCAGACACUUAUGCCUGUUGGCAUCAUUCUAUUGGAUUUGAUUACGUCUAUAAUCCGUUUAUGAUUGAUGUUCAACAAUGGGGUUUUACAGGUAACCUACAAAGCAACCAUGAUCUGUAUUGUCAAGUCCAUGGUAAUGCACAUGUAGCUAGUUGUGAUGCAAUCAUGACUAGGUGUCUAGCUGUCCACGAGUGCUUUGUUAAGCGUGUUGACUGGACUAUUGAAUAUCCUAUAAUUGGUGAUGAACUGAAGAUUAAUGCGGCUUGUAGAAAGGUUCAACACAUGGUUGUUAAAGCUGCAUUAUUAGCAGACAAAUUCCCAGUUCUUCACGACAUUGGUAACCCUAAAGCUAUUAAGUGUGUACCUCAAGCUGAUGUAGAAUGGAAGUUCUAUGAUGCACAGCCUUGUAGUGACAAAGCUUAUAAAAUAGAAGAAUUAUUCUAUUCUUAUGCCACACAUUCUGACAAAUUCACAGAUGGUGUAUGCCUAUUUUGGAAUUGCAAUGUCGAUAGAUAUCCUGCUAAUUCCAUUGUUUGUAGAUUUGACACUAGAGUGCUAUCUAACCUUAACUUGCCUGGUUGUGAUGGUGGCAGUUUGUAUGUAAAUAAACAUGCAUUCCACACACCAGCUUUUGAUAAAAGUGCUUUUGUUAAUUUAAAACAAUUACCAUUUUUCUAUUACUCUGACAGUCCAUGUGAGUCUCAUGGAAAACAAGUAGUGUCAGAUAUAGAUUAUGUACCACUAAAGUCUGCUACGUGUAUAACACGUUGCAAUUUAGGUGGUGCUGUCUGUAGACAUCAUGCUAAUGAGUACAGAUUGUAUCUCGAUGCUUAUAACAUGAUGAUCUCAGCUGGCUUUAGCUUGUGGGUUUACAAACAAUUUGAUACUUAUAACCUCUGGAACACUUUUACAAGACUUCAGAGUUUAGAAAAUGUGGCUUUUAAUGUUGUAAAUAAGGGACACUUUGAUGGACAACAGGGUGAAGUACCAGUUUCUAUCAUUAAUAACACUGUUUACACAAAAGUUGAUGGUGUUGAUGUAGAAUUGUUUGAAAAUAAAACAACAUUACCUGUUAAUGUAGCAUUUGAGCUUUGGGCUAAGCGCAACAUUAAACCAGUACCAGAGGUGAAAAUACUCAAUAAUUUGGGUGUGGACAUUGCUGCUAAUACUGUGAUCUGGGACUACAAAAGAGAUGCUCCAGCACAUAUAUCUACUAUUGGUGUUUGUUCUAUGACUGACAUAGCCAAGAAACCAACUGAAACGAUUUGUGCACCACUCACUGUCUUUUUUGAUGGUAGAGUUGAUGGUCAAGUAGACUUAUUUAGAAAUGCCCGUAAUGGUGUUCUUAUUACAGAAGGUAGUGUUAAAGGUUUACAACCAUCUGUAGGUCCCAAACAAGCUAGUCUUAAUGGAGUCACAUUAAUUGGAGAAGCCGUAAAAACACAGUUCAAUUAUUAUAAGAAAGUUGAUGGUGUUGUCCAACAAUUACCUGAAACUUACUUUACUCAGAGUAGAAAUUUACAAGAAUUUAAACCCAGGAGUCAAAUGGAAAUUGAUUUCUUAGAAUUAGCUAUGGAUGAAUUCAUUGAACGGUAUAAAUUAGAAGGCUAUGCCUUCGAACAUAUCGUUUAUGGAGAUUUUAGUCAUAGUCAGUUAGGUGGUUUACAUCUACUGAUUGGACUAGCUAAACGUUUUAAGGAAUCACCUUUUGAAUUAGAAGAUUUUAUUCCUAUGGACAGUACAGUUAAAAACUAUUUCAUAACAGAUGCGCAAACAGGUUCAUCUAAGUGUGUGUGUUCUGUUAUUGAUUUAUUACUUGAUGAUUUUGUUGAAAUAAUAAAAUCCCAAGAUUUAUCUGUAGUUUCUAAGGUUGUCAAAGUGACUAUUGACUAUACAGAAAUUUCAUUUAUGCUUUGGUGUAAAGAUGGCCAUGUAGAAACAUUUUACCCAAAAUUACAAUCUAGUCAAGCGUGGCAACCGGGUGUUGCUAUGCCUAAUCUUUACAAAAUGCAAAGAAUGCUAUUAGAAAAGUGUGACCUUCAAAAUUAUGGUGAUAGUGCAACAUUACCUAAAGGCAUAAUGAUGAAUGUCGCAAAAUAUACUCAACUGUGUCAAUAUUUAAACACAUUAACAUUAGCUGUACCCUAUAAUAUGAGAGUUAUACAUUUUGGUGCUGGUUCUGAUAAAGGAGUUGCACCAGGUACAGCUGUUUUAAGACAGUGGUUGCCUACGGGUACGCUGCUUGUCGAUUCAGAUCUUAAUGACUUUGUCUCUGAUGCAGAUUCAACUUUGAUUGGUGAUUGUGCAACUGUACAUACAGCUAAUAAAUGGGAUCUCAUUAUUAGUGAUAUGUACGACCCUAAGACUAAAAAUGUUACAAAAGAAAAUGACUCUAAAGAGGGUUUUUUCACUUACAUUUGUGGGUUUAUACAACAAAAGCUAGCUCUUGGAGGUUCCGUGGCUAUAAAGAUAACAGAACAUUCUUGGAAUGCUGAUCUUUAUAAGCUCAUGGGACACUUCGCAUGGUGGACAGCCUUUGUUACUAAUGUGAAUGCGUCAUCAUCUGAAGCAUUUUUAAUUGGAUGUAAUUAUCUUGGCAAACCACGCGAACAAAUAGAUGGUUAUGUCAUGCAUGCAAAUUACAUAUUUUGGAGGAAUACAAAUCCAAUUCAGUUGUCUUCCUAUUCUUUAUUUGACAUGAGUAAAUUUCCCCUUAAAUUAAGGGGUACUGCUGUUAUGUCUUUAAAAGAAGGUCAAAUCAAUGAUAUGAUUUUAUCUCUUCUUAGUAAAGGUAGACUUAUAAUUAGAGAAAACAACAGAGUUGUUAUUUCUAGUGAUGUUCUUGUUAACAACUAAACGAACAAUGUUUGUUUUUCUUGUUUUAUUGCCACUAGUCUCUAGUCAGUGUGUUAAUCUUACAACCAGAACUCAAUUACCCCCUGCAUACACUAAUUCUUUCACACGUGGUGUUUAUUACCCUGACAAAGUUUUCAGAUCCUCAGUUUUACAUUCAACUCAGGACUUGUUCUUACCUUUCUUUUCCAAUGUUACUUGGUUCCAUGCUAUACAUGUCUCUGGGACCAAUGGUACUAAGAGGUUUGAUAACCCUGUCCUACCAUUUAAUGAUGGUGUUUAUUUUGCUUCCACUGAGAAGUCUAACAUAAUAAGAGGCUGGAUUUUUGGUACUACUUUAGAUUCGAAGACCCAGUCCCUACUUAUUGUUAAUAACGCUACUAAUGUUGUUAUUAAAGUCUGUGAAUUUCAAUUUUGUAAUGAUCCAUUUUUGGGUGUUUAUUACCACAAAAACAACAAAAGUUGGAUGGAAAGUGAGUUCAGAGUUUAUUCUAGUGCGAAUAAUUGCACUUUUGAAUAUGUCUCUCAGCCUUUUCUUAUGGACCUUGAAGGAAAACAGGGUAAUUUCAAAAAUCUUAGGGAAUUUGUGUUUAAGAAUAUUGAUGGUUAUUUUAAAAUAUAUUCUAAGCACACGCCUAUUAAUUUAGUGCGUGAUCUCCCUCAGGGUUUUUCGGCUUUAGAACCAUUGGUAGAUUUGCCAAUAGGUAUUAACAUCACUAGGUUUCAAACUUUACUUGCUUUACAUAGAAGUUAUUUGACUCCUGGUGAUUCUUCUUCAGGUUGGACAGCUGGUGCUGCAGCUUAUUAUGUGGGUUAUCUUCAACCUAGGACUUUUCUAUUAAAAUAUAAUGAAAAUGGAACCAUUACAGAUGCUGUAGACUGUGCACUUGACCCUCUCUCAGAAACAAAGUGUACGUUGAAAUCCUUCACUGUAGAAAAAGGAAUCUAUCAAACUUCUAACUUUAGAGUCCAACCAACAGAAUCUAUUGUUAGAUUUCCUAAUAUUACAAACUUGUGCCCUUUUGGUGAAGUUUUUAACGCCACCAGAUUUGCAUCUGUUUAUGCUUGGAACAGGAAGAGAAUCAGCAACUGUGUUGCUGAUUAUUCUGUCCUAUAUAAUUCCGCAUCAUUUUCCACUUUUAAGUGUUAUGGAGUGUCUCCUACUAAAUUAAAUGAUCUCUGCUUUACUAAUGUCUAUGCAGAUUCAUUUGUAAUUAGAGGUGAUGAAGUCAGACAAAUCGCUCCAGGGCAAACUGGAAAGAUUGCUGAUUAUAAUUAUAAAUUACCAGAUGAUUUUACAGGCUGCGUUAUAGCUUGGAAUUCUAACAAUCUUGAUUCUAAGGUUGGUGGUAAUUAUAAUUACCUGUAUAGAUUGUUUAGGAAGUCUAAUCUCAAACCUUUUGAGAGAGAUAUUUCAACUGAAAUCUAUCAGGCCGGUAGCACACCUUGUAAUGGUGUUGAAGGUUUUAAUUGUUACUUUCCUUUACAAUCAUAUGGUUUCCAACCCACUAAUGGUGUUGGUUACCAACCAUACAGAGUAGUAGUACUUUCUUUUGAACUUCUACAUGCACCAGCAACUGUUUGUGGACCUAAAAAGUCUACUAAUUUGGUUAAAAACAAAUGUGUCAAUUUCAACUUCAAUGGUUUAACAGGCACAGGUGUUCUUACUGAGUCUAACAAAAAGUUUCUGCCUUUCCAACAAUUUGGCAGAGACAUUGCUGACACUACUGAUGCUGUCCGUGAUCCACAGACACUUGAGAUUCUUGACAUUACACCAUGUUCUUUUGGUGGUGUCAGUGUUAUAACACCAGGAACAAAUACUUCUAACCAGGUUGCUGUUCUUUAUCAGGAUGUUAACUGCACAGAAGUCCCUGUUGCUAUUCAUGCAGAUCAACUUACUCCUACUUGGCGUGUUUAUUCUACAGGUUCUAAUGUUUUUCAAACACGUGCAGGCUGUUUAAUAGGGGCUGAACAUGUCAACAACUCAUAUGAGUGUGACAUACCCAUUGGUGCAGGUAUAUGCGCUAGUUAUCAGACUCAGACUAAUUCUCCUCGGCGGGCACGUAGUGUAGCUAGUCAAUCCAUCAUUGCCUACACUAUGUCACUUGGUGCAGAAAAUUCAGUUGCUUACUCUAAUAACUCUAUUGCCAUACCCACAAAUUUUACUAUUAGUGUUACCACAGAAAUUCUACCAGUGUCUAUGACCAAGACAUCAGUAGAUUGUACAAUGUACAUUUGUGGUGAUUCAACUGAAUGCAGCAAUCUUUUGUUGCAAUAUGGCAGUUUUUGUACACAAUUAAACCGUGCUUUAACUGGAAUAGCUGUUGAACAAGACAAAAACACCCAAGAAGUUUUUGCACAAGUCAAACAAAUUUACAAAACACCACCAAUUAAAGAUUUUGGUGGUUUUAAUUUUUCACAAAUAUUACCAGAUCCAUCAAAACCAAGCAAGAGGUCAUUUAUUGAAGAUCUACUUUUCAACAAAGUGACACUUGCAGAUGCUGGCUUCAUCAAACAAUAUGGUGAUUGCCUUGGUGAUAUUGCUGCUAGAGACCUCAUUUGUGCACAAAAGUUUAACGGCCUUACUGUUUUGCCACCUUUGCUCACAGAUGAAAUGAUUGCUCAAUACACUUCUGCACUGUUAGCGGGUACAAUCACUUCUGGUUGGACCUUUGGUGCAGGUGCUGCAUUACAAAUACCAUUUGCUAUGCAAAUGGCUUAUAGGUUUAAUGGUAUUGGAGUUACACAGAAUGUUCUCUAUGAGAACCAAAAAUUGAUUGCCAACCAAUUUAAUAGUGCUAUUGGCAAAAUUCAAGACUCACUUUCUUCCACAGCAAGUGCACUUGGAAAACUUCAAGAUGUGGUCAACCAAAAUGCACAAGCUUUAAACACGCUUGUUAAACAACUUAGCUCCAAUUUUGGUGCAAUUUCAAGUGUUUUAAAUGAUAUCCUUUCACGUCUUGACAAAGUUGAGGCUGAAGUGCAAAUUGAUAGGUUGAUCACAGGCAGACUUCAAAGUUUGCAGACAUAUGUGACUCAACAAUUAAUUAGAGCUGCAGAAAUCAGAGCUUCUGCUAAUCUUGCUGCUACUAAAAUGUCAGAGUGUGUACUUGGACAAUCAAAAAGAGUUGAUUUUUGUGGAAAGGGCUAUCAUCUUAUGUCCUUCCCUCAGUCAGCACCUCAUGGUGUAGUCUUCUUGCAUGUGACUUAUGUCCCUGCACAAGAAAAGAACUUCACAACUGCUCCUGCCAUUUGUCAUGAUGGAAAAGCACACUUUCCUCGUGAAGGUGUCUUUGUUUCAAAUGGCACACACUGGUUUGUAACACAAAGGAAUUUUUAUGAACCACAAAUCAUUACUACAGACAACACAUUUGUGUCUGGUAACUGUGAUGUUGUAAUAGGAAUUGUCAACAACACAGUUUAUGAUCCUUUGCAACCUGAAUUAGACUCAUUCAAGGAGGAGUUAGAUAAAUAUUUUAAGAAUCAUACAUCACCAGAUGUUGAUUUAGGUGACAUCUCUGGCAUUAAUGCUUCAGUUGUAAACAUUCAAAAAGAAAUUGACCGCCUCAAUGAGGUUGCCAAGAAUUUAAAUGAAUCUCUCAUCGAUCUCCAAGAACUUGGAAAGUAUGAGCAGUAUAUAAAAUGGCCAUGGUACAUUUGGCUAGGUUUUAUAGCUGGCUUGAUUGCCAUAGUAAUGGUGACAAUUAUGCUUUGCUGUAUGACCAGUUGCUGUAGUUGUCUCAAGGGCUGUUGUUCUUGUGGAUCCUGCUGCAAAUUUGAUGAAGACGACUCUGAGCCAGUGCUCAAAGGAGUCAAAUUACAUUACACAUAAACGAACUUAUGGAUUUGUUUAUGAGAAUCUUCACAAUUGGAACUGUAACUUUGAAGCAAGGUGAAAUCAAGGAUGCUACUCCUUCAGAUUUUGUUCGCGCUACUGCAACGAUACCGAUACAAGCCUCACUCCCUUUCGGAUGGCUUAUUGUUGGCGUUGCACUUCUUGCUGUUUUUCAGAGCGCUUCCAAAAUCAUAACCCUCAAAAAGAGAUGGCAACUAGCACUCUCCAAGGGUGUUCACUUUGUUUGCAACUUGCUGUUGUUGUUUGUAACAGUUUACUCACACCUUUUGCUCGUUGCUGCUGGCCUUGAAGCCCCUUUUCUCUAUCUUUAUGCUUUAGUCUACUUCUUGCAGAGUAUAAACUUUGUAAGAAUAAUAAUGAGGCUUUGGCUUUGCUGGAAAUGCCGUUCCAAAAACCCAUUACUUUAUGAUGCCAACUAUUUUCUUUGCUGGCAUACUAAUUGUUACGACUAUUGUAUACCUUACAAUAGUGUAACUUCUUCAAUUGUCAUUACUUCAGGUGAUGGCACAACAAGUCCUAUUUCUGAACAUGACUACCAGAUUGGUGGUUAUACUGAAAAAUGGGAAUCUGGAGUAAAAGACUGUGUUGUAUUACACAGUUACUUCACUUCAGACUAUUACCAGCUGUACUCAACUCAAUUGAGUACAGACACUGGUGUUGAACAUGUUACCUUCUUCAUCUACAAUAAAAUUGUUGAUGAGCCUGAAGAACAUGUCCAAAUUCACACAAUCGACGGUUCAUCCGGAGUUGUUAAUCCAGUAAUGGAACCAAUUUAUGAUGAACCGACGACGACUACUAGCGUGCCUUUGUAAGCACAAGCUGAUGAGUACGAACUUAUGUACUCAUUCGUUUCGGAAGAGACAGGUACGUUAAUAGUUAAUAGCGUACUUCUUUUUCUUGCUUUCGUGGUAUUCUUGCUAGUUACACUAGCCAUCCUUACUGCGCUUCGAUUGUGUGCGUACUGCUGCAAUAUUGUUAACGUGAGUCUUGUAAAACCUUCUUUUUACGUUUACUCUCGUGUUAAAAAUCUGAAUUCUUCUAGAGUUCCUGAUCUUCUGGUCUAAACGAACUAAAUAUUAUAUUAGUUUUUCUGUUUGGAACUUUAAUUUUAGCCAUGGCAGAUUCCAACGGUACUAUUACCGUUGAAGAGCUUAAAAAGCUCCUUGAACAAUGGAACCUAGUAAUAGGUUUCCUAUUCCUUACAUGGAUUUGUCUUCUACAAUUUGCCUAUGCCAACAGGAAUAGGUUUUUGUAUAUAAUUAAGUUAAUUUUCCUCUGGCUGUUAUGGCCAGUAACUUUAGCUUGUUUUGUGCUUGCUGCUGUUUACAGAAUAAAUUGGAUCACCGGUGGAAUUGCUAUCGCAAUGGCUUGUCUUGUAGGCUUGAUGUGGCUCAGCUACUUCAUUGCUUCUUUCAGACUGUUUGCGCGUACGCGUUCCAUGUGGUCAUUCAAUCCAGAAACUAACAUUCUUCUCAACGUGCCACUCCAUGGCACUAUUCUGACCAGACCGCUUCUAGAAAGUGAACUCGUAAUCGGAGCUGUGAUCCUUCGUGGACAUCUUCGUAUUGCUGGACACCAUCUAGGACGCUGUGACAUCAAGGACCUGCCUAAAGAAAUCACUGUUGCUACAUCACGAACGCUUUCUUAUUACAAAUUGGGAGCUUCGCAGCGUGUAGCAGGUGACUCAGGUUUUGCUGCAUACAGUCGCUACAGGAUUGGCAACUAUAAAUUAAACACAGACCAUUCCAGUAGCAGUGACAAUAUUGCUUUGCUUGUACAGUAAGUGACAACAGAUGUUUCAUCUCGUUGACUUUCAGGUUACUAUAGCAGAGAUAUUACUAAUUAUUAUGAGGACUUUUAAAGUUUCCAUUUGGAAUCUUGAUUACAUCAUAAACCUCAUAAUUAAAAAUUUAUCUAAGUCACUAACUGAGAAUAAAUAUUCUCAAUUAGAUGAAGAGCAACCAAUGGAGAUUGAUUAAACGAACAUGAAAAUUAUUCUUUUCUUGGCACUGAUAACACUCGCUACUUGUGAGCUUUAUCACUACCAAGAGUGUGUUAGAGGUACAACAGUACUUUUAAAAGAACCUUGCUCUUCUGGAACAUACGAGGGCAAUUCACCAUUUCAUCCUCUAGCUGAUAACAAAUUUGCACUGACUUGCUUUAGCACUCAAUUUGCUUUUGCUUGUCCUGACGGCGUAAAACACGUCUAUCAGUUACGUGCCAGAUCAGUUUCACCUAAACUGUUCAUCAGACAAGAGGAAGUUCAAGAACUUUACUCUCCAAUUUUUCUUAUUGUUGCGGCAAUAGUGUUUAUAACACUUUGCUUCACACUCAAAAGAAAGACAGAAUGAUUGAACUUUCAUUAAUUGACUUCUAUUUGUGCUUUUUAGCCUUUCUGCUAUUCCUUGUUUUAAUUAUGCUUAUUAUCUUUUGGUUCUCACUUGAACUGCAAGAUCAUAAUGAAACUUGUCACGCCUAAACGAACAUGAAAUUUCUUGUUUUCUUAGGAAUCAUCACAACUGUAGCUGCAUUUCACCAAGAAUGUAGUUUACAGUCAUGUACUCAACAUCAACCAUAUGUAGUUGAUGACCCGUGUCCUAUUCACUUCUAUUCUAAAUGGUAUAUUAGAGUAGGAGCUAGAAAAUCAGCACCUUUAAUUGAAUUGUGCGUGGAUGAGGCUGGUUCUAAAUCACCCAUUCAGUACAUCGAUAUCGGUAAUUAUACAGUUUCCUGUUUACCUUUUACAAUUAAUUGCCAGGAACCUAAAUUGGGUAGUCUUGUAGUGCGUUGUUCGUUCUAUGAAGACUUUUUAGAGUAUCAUGACGUUCGUGUUGUUUUAGAUUUCAUCUAAACGAACAAACUAAAAUGUCUGAUAAUGGACCCCAAAAUCAGCGAAAUGCACCCCGCAUUACGUUUGGUGGACCCUCAGAUUCAACUGGCAGUAACCAGAAUGGAGAACGCAGUGGGGCGCGAUCAAAACAACGUCGGCCCCAAGGUUUACCCAAUAAUACUGCGUCUUGGUUCACCGCUCUCACUCAACAUGGCAAGGAAGACCUUAAAUUCCCUCGAGGACAAGGCGUUCCAAUUAACACCAAUAGCAGUCCAGAUGACCAAAUUGGCUACUACCGAAGAGCUACCAGACGAAUUCGUGGUGGUGACGGUAAAAUGAAAGAUCUCAGUCCAAGAUGGUAUUUCUACUACCUAGGAACUGGGCCAGAAGCUGGACUUCCCUAUGGUGCUAACAAAGACGGCAUCAUAUGGGUUGCAACUGAGGGAGCCUUGAAUACACCAAAAGAUCACAUUGGCACCCGCAAUCCUGCUAACAAUGCUGCAAUCGUGCUACAACUUCCUCAAGGAACAACAUUGCCAAAAGGCUUCUACGCAGAAGGGAGCAGAGGCGGCAGUCAAGCCUCUUCUCGUUCCUCAUCACGUAGUCGCAACAGUUCAAGAAAUUCAACUCCAGGCAGCAGUAGGGGAACUUCUCCUGCUAGAAUGGCUGGCAAUGGCGGUGAUGCUGCUCUUGCUUUGCUGCUGCUUGACAGAUUGAACCAGCUUGAGAGCAAAAUGUCUGGUAAAGGCCAACAACAACAAGGCCAAACUGUCACUAAGAAAUCUGCUGCUGAGGCUUCUAAGAAGCCUCGGCAAAAACGUACUGCCACUAAAGCAUACAAUGUAACACAAGCUUUCGGCAGACGUGGUCCAGAACAAACCCAAGGAAAUUUUGGGGACCAGGAACUAAUCAGACAAGGAACUGAUUACAAACAUUGGCCGCAAAUUGCACAAUUUGCCCCCAGCGCUUCAGCGUUCUUCGGAAUGUCGCGCAUUGGCAUGGAAGUCACACCUUCGGGAACGUGGUUGACCUACACAGGUGCCAUCAAAUUGGAUGACAAAGAUCCAAAUUUCAAAGAUCAAGUCAUUUUGCUGAAUAAGCAUAUUGACGCAUACAAAACAUUCCCACCAACAGAGCCUAAAAAGGACAAAAAGAAGAAGGCUGAUGAAACUCAAGCCUUACCGCAGAGACAGAAGAAACAGCAAACUGUGACUCUUCUUCCUGCUGCAGAUUUGGAUGAUUUCUCCAAACAAUUGCAACAAUCCAUGAGCAGUGCUGACUCAACUCAGGCCUAAACUCAUGCAGACCACACAAGGCAGAUGGGCUAUAUAAACGUUUUCGCUUUUCCGUUUACGAUAUAUAGUCUACUCUUGUGCAGAAUGAAUUCUCGUAACUACAUAGCACAAGUAGAUGUAGUUAACUUUAAUCUCACAUAGCAAUCUUUAAUCAGUGUGUAACAUUAGGGAGGACUUGAAAGAGCCACCACAUUUUCACCGAGGCCACGCGGAGUACGAUCGAGUGUACAGUGAACAAUGCUAGGGAGAGCUGCCUAUAUGGAAGAGCCCUAAUGUGUAAAAUUAAUUUUAGUAGUGCUAUCCCCAUGUGAUUUUAAUAGCUUCUUAGGAGAAUGACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.3nM-7.5 nM[SARS-CoV-2];|4 µM[SARS-CoV-2 N protein],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,"liquid, solute","Pure N-protein demixed into droplets (consistent with results from the Morgan [Carlson et al., 2020] and Fawzi [Myrto Perdikari et al., 2020] labs) and LLPS was enhanced by RNA extracted from the culture medium supernatant of infected cells containing full-length SARS-CoV-2 genome"
541,PMID: 33290746,RNAPS0000451,https://pubmed.ncbi.nlm.nih.gov/33290746,RNAs + protein,-;|-,-;|-,SARS-CoV-2 virus RNA;|SARS-CoV-2 virus RNA,996nt(13404-14400);|1000nt(1-1000),ACUGAAGUGUAUUACCAGUUAUGAAGAAAAUAGGGCAAUACUCAACACACAUAAAAACAAUACCUCUGGCCAAAAACAUGACAGUUGUAACUACACCUGAGUAGUUAGAAGUAACAGAGAUUAUAAGAGCCCACAUGGAAAUGGCUUGAUCUAAAGCAUUACCAUAAUAAACUUUAUAAACGAGUGUCAAGACAUUCAUAAGUGUCCACACUCUCCUAGCACCAUCAUCAUACACAGUUCUUGCUGUCAUAAGGAUUAGUAACACUACAGCUGAUGCAUACAUAACACAGUCUUUUAGCUUAAAACCAGACAAACUAGUAUCAACCAUAUCCAACCAUGUCAUAAUACGCAUCACCCAACUAGCAGGCAUAUAGACCAUAUUAAAAUAAGCUACAGUGGCAAGAGAAGGUAACAAAAACAAACAGAGAAAUGCAUGCUUAUGUUUGACAAACAUCAUUGCAAAAGCAGACAUAGCAAUAAUACCCAUAGCAAAAGGUAAAAAGGCAUUUUCAUACAAAAAAAAGAACAAAGACCAUUGAGUACUCUGGACUAAAACUAAAAGUGAAGUCAAAAUUGUGAGUAACAACCAGUGGUGUGUACCCUUGAUUGUUCUUUUCACUGCACUUUGGAAAGUAACACCUGAGCAUUGUCUAACAACAUCAAAAGGUGUAAAUUCAUCUUCUAAUAAAGCACUACCCAAUAUGGUACGUCCAUUCAUACCAUUUUGCAGUAAUUCUUUUAAUGAAGCACACAUAUCUAAAACGGCAAUUCCAGUUUGAGCAGAAAGAGGUCCUAGUAUGUCAACAUGGUCUUGUGUUAGAGGUUCAUAAUUGUACUUCAUAGCCACAAGGUUAAAGUCAUUAAGAGUUGUGGUAAAUCGAUUGAGAAACCACCUGUCUCCAUUUAUAACAGCAGCGUACAACCAAGCUAAAACAUUAACUGUAAUAGUUGUGUCCGUACCAGCUGCUUGUGCUGUUUGCCUGUCAACAAAAGGUC;|GGUUAAUGUUGUCUACUGUUGUAAACACCUUAAUAGUCCUCACUUCUCUCAAAGAAAGAAGUGUCUUAAGAUUGUCAAAGGUGAUAACUUCACCAUCUAGGUGGAAUGUGGUAGGAUUACUAGUGUAAUAUACACUUUUAUCACCUCUCUUAAGAAAUUCUAUACCUAGUUGUGUAGAUUGUCCAGAAUAGGACCAAUCUUUAUAGGAACCAGCAAGUGAGAUGGUUUCAAUAAAAUGUUCUUCAGGUGUUUUAGAAGAAGAAGUAAGAUAACCAUUAUACGCUGUAACAGCAUCAGGUGAAGAAACAGAAACUGUAGCUGGCACUUUGAGAGAUCUCAUAUACCGAGCAGCUUCUUCCAAAUUUAAGCCAUGUGUUACAUAGCCAAGUGGCAUUGUAACAAGAGUUUCAUUUAGAUCGUUAAGUGUGUUGAUAAGUGACGCUACAGUUGUUUUACUGGUGUAAAAGUAAAAUCUAGCACCAUAAUCAACCACACCCUCUUGUAUUUUAAUACCCUUAUAUUUACGCUGUAUAGUUGAAACUAUGGCUUUAGUUUCCACACAGACAGGCAUUAAUUUGCGUGUUUCUUCUGCAUGUGCAAGCAUUUCUCGCAAAUUCCAAGAAACAGUUCCAAGAAUUUCUUGCUUCUCAUUAGAGAUAAUAGAUGGUAGAAUGUAAAAGGCACUUUUACACUUUUUAAGCACUGUCUUUGCCUCCUCUACAGUGUAACCAUUUAAACCCUGACCCGGGUAAGUGGUUAUAUAAUUGUCUGUUGGCACUUUUCUCAAAGCUUUCGCUAGCAUUUCAGUAGUGCCACCAGCCUUUUUAGUAGGUAUAACCACAGCAGUUAAAACACCCUCUUGAACAACAUCACCCACUAUAUAUGGAGCAUCUUUCUUUAAGAAAGUGAUGUCAAUGUCACUAACAAGAGUGGCAGAAUCUGGAUGAAGAUUGCCAUUAAUGUCAAUAUAAAGUAACAAGUUUUCUGUGAGGAACUUAGU,virus RNA;|virus RNA,SARS-CoV-2 virus;|SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,50 nM [SARS-CoV-2 5‘end];|50 nM [SARS-CoV-2 frameshifting],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,solute,"We mixed frameshifting region RNA with either 5’ end or nucleocapsid RNA. Mixtures con taining the 5’ end and frameshifting region produced droplets of intermediate properties, including smaller size and more numerous assemblies. Similarly, frameshifting region RNA made nucleocapsid RNA condensates less flocculated and smaller"
542,PMID: 33290746,RNAPS0000452,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,SARS-CoV-2 virus RNA,3000nt(5' end region),-,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5 nM[SARS-CoV-2 5'end];|2 µM[N protein],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,liquid,"Addition of 0.3 kb or 2.4 kb of non-viral sequence to the 1 kb 5’ end or frameshifting re gion RNAs resulted in progressive increase in condensate size/ number, with the 5’ end driving enhanced condensates relative to the frameshifting region at all lengths tested"
543,PMID: 33290746,RNAPS0000452,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,SARS-CoV-2 virus RNA,3000nt(frameshift region),-,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5 nM[SARS-CoV-2 frameshifting];|2 µM[N protein],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,liquid,"Addition of 0.3 kb or 2.4 kb of non-viral sequence to the 1 kb 5’ end or frameshifting re gion RNAs resulted in progressive increase in condensate size/ number, with the 5’ end driving enhanced condensates relative to the frameshifting region at all lengths tested"
544,PMID: 33376791,RNAPS0000454,https://pubmed.ncbi.nlm.nih.gov/33376791,RNAs + protein,-,-,Escherichia coli RNA,-,-,total RNA,Escherichia coli,"sp|P42212|GFP_AEQVI Green fluorescent protein OS=Aequorea victoria OX=6100 GN=GFP PE=1 SV=1
MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTL
VTTFSYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLV
NRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLAD
HYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITHGMDELYK",GFP,-,-,238aa(1-238),P42212,"LLPSDB,PhaSepDB","http://bio-comp.org.cn/llpsdb/protein.php?protein=p0171,http://db.phasep.pro/browse/",-,-,In vitro,0.001-1 mg/ml [total cellular RNA];|0.001-1 mg/ml [GFP],"60 mM KCl, 40 mM NaCl",70 mM K2HPO4(pH 7.4),RT,-,-,"Turbidity measurement,Fluorescence microscopy",-,Variants with an expected net charge below +18 did not phase separate with RNA under simulated physiological conditions (Supplemen tary Figure 3). We next explored the phase boundary for each GFP variant (≥+18) that phase separated in this initial assay
545,PMID: 33452693,RNAPS0000443,https://pubmed.ncbi.nlm.nih.gov/33452693,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|
MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPG
SETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAG
HVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPK
TPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAK
SRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHV
PGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNI
THVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMV
DSPQLATLADEVSASLAKQGL",MAPT,-,-,441aa(1-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[125-375],[395-441]","[216-226],[323-340],[380-403]",In vitro,60nM[polyU];|60µM[tau],50 mM KCl ,"50 mM HEPES pH 7.4, 1 mM DTT",RT,immediately or 20 - 30 min,other_molecular:2.5% dextran,"Differential interference contrast microscopy,FRAP",liquid,"We therefore formed droplets by mixing tau (50 μM) with polyU RNA (60 nM). To increase the stabil ity of the droplets, we additionally added 2.5% dextranWe then added 10 μM of aSyn to the preformed tau droplets such that the tau concentration was fivefold higher when compared to aSyn. aSyn alone did not form droplets (Figure S1). Fluorescence microscopy showed that aSyn concentrates inside the tau droplets independent of the presence of RNA"
546,PMID: 33477032,RNAPS0000456,https://pubmed.ncbi.nlm.nih.gov/33477032,RNA + protein,-,-,polyA(24),24nt,AAAAAAAAAAAAAAAAAAAAAAAA,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,Molar Ratio of N protein and A24 from 1:0.5 to 1:1000,70 mM KCl,25 mM HEPES pH 7.5,RT,-,-,Turbidity measurement,liquid,"Indeed, here we found that A24 also biphasically modulated LLPS of the N protein as ATP but the ratios required to induce and dissolve droplets were much lower than those of ATP. Addition of A24 even at 1:0.5 resulted a turbidity value of 0.97 (Fig. 1C)"
547,PMID: 33477032,RNAPS0000456,https://pubmed.ncbi.nlm.nih.gov/33477032,RNA + protein,-,-,polyA(24),24nt,AAAAAAAAAAAAAAAAAAAAAAAA,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,10 µM[polyA];|20 µM[SARS-CoV-2 Nucleoprotein],70 mM KCl,25 mM HEPES pH 7.5,RT,-,other_molecular:0-8000 µM ATP,Differential interference contrast microscopy,-,"Indeed, here we found that A24 also biphasically  modulated LLPS of the N protein as ATP but the ratios required to  induce and dissolve droplets were much lower than those of ATP.  Addition of A24 even at 1:0.5 resulted a turbidity value of 0.97 as well as the formation of a large number of dynamic  droplets with the diameter of some even close to ~2 mm"
548,PMID: 33495715,RNAPS0000459,https://pubmed.ncbi.nlm.nih.gov/33495715,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0-150 µM [Total HeLa cellular RNA];|0-30 µM[N protein],150 mmol/L NaCl,pH 8.0,RT,5 min,-,FRAP,"liquid, solute","Because the N protein binds to genomic RNA to participate in viral genome replication and subgenomic mRNA transcription [31], we next characterized the effect of RNA on LLPS of the N protein, found that HeLa RNA strongly promoted the N protein LLPS without impacting mCherry"
549,PMID: 33495715,RNAPS0000459,https://pubmed.ncbi.nlm.nih.gov/33495715,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△SR,-,-,P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,100 ng/µL [Total HeLa cellular RNA];|15 µM/L [N protein],150 mmol/L NaCl,pH 8.0,RT,-,-,FRAP,liquid,"We found that aa 1– 175 (containing IDR 1 and RNA binding domain) is necessary and  suffificient for RNA-stimulated LLPS (Fig. 3b), with IDR1 being abso  lutely required (Fig. 3b, fragment 51–C), while deletion of HDD and  IDR3 or the SR domain only attenuated LLPS (Fig. 3b)."
550,PMID: 33495715,RNAPS0000459,https://pubmed.ncbi.nlm.nih.gov/33495715,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=1-175
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEG
",SARS-CoV-2 Nucleoprotein,1-175,-,175aa(1-175),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,100 ng/µL [Total HeLa cellular RNA];|15 µM/L [N protein],150 mmol/L NaCl,pH 8.0,RT,-,-,FRAP,liquid,"We found that aa 1– 175 (containing IDR 1 and RNA binding domain) is necessary and  suffificient for RNA-stimulated LLPS (Fig. 3b), with IDR1 being abso  lutely required (Fig. 3b, fragment 51–C), while deletion of HDD and  IDR3 or the SR domain only attenuated LLPS (Fig. 3b)."
551,PMID: 33495715,RNAPS0000459,https://pubmed.ncbi.nlm.nih.gov/33495715,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=1-210
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARM",SARS-CoV-2 Nucleoprotein,1-210,-,210aa(1-210),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,100 ng/µL [Total HeLa cellular RNA];|15 µM/L [N protein],150 mmol/L NaCl,pH 8.0,RT,-,-,FRAP,liquid,"We found that aa 1– 175 (containing IDR 1 and RNA binding domain) is necessary and  suffificient for RNA-stimulated LLPS (Fig. 3b), with IDR1 being abso  lutely required (Fig. 3b, fragment 51–C), while deletion of HDD and  IDR3 or the SR domain only attenuated LLPS (Fig. 3b)."
552,PMID: 33495715,RNAPS0000459,https://pubmed.ncbi.nlm.nih.gov/33495715,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|51-419
SWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,51-C,-,369aa(51-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,100 ng/µL [Total HeLa cellular RNA];|15 µM/L [N protein],150 mmol/L NaCl,pH 8.0,RT,-,-,FRAP,solute,"We found that aa 1– 175 (containing IDR 1 and RNA binding domain) is necessary and  suffificient for RNA-stimulated LLPS (Fig. 3b), with IDR1 being abso  lutely required (Fig. 3b, fragment 51–C), while deletion of HDD and  IDR3 or the SR domain only attenuated LLPS (Fig. 3b)."
553,PMID: 33495715,RNAPS0000459,https://pubmed.ncbi.nlm.nih.gov/33495715,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,100 ng/µL [Total HeLa cellular RNA];|15 µM/L [N protein],150 mmol/L NaCl,pH 8.0,RT,-,-,FRAP,liquid,"We found that aa 1– 175 (containing IDR 1 and RNA binding domain) is necessary and  suffificient for RNA-stimulated LLPS (Fig. 3b), with IDR1 being abso  lutely required (Fig. 3b, fragment 51–C), while deletion of HDD and  IDR3 or the SR domain only attenuated LLPS (Fig. 3b)."
554,PMID: 33523882,RNAPS0000460,https://pubmed.ncbi.nlm.nih.gov/33523882,RNA + protein,-,-,(CGG)99,297nt,CGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG,repeat RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1
MEELVVEVRGSNGAFYKAFVKDVHEDSITVAFENNWQPDRQIPFHDVRFPPPVGYNKDIN
ESDEVEVYSRANEKEPCCWWLAKVRMIKGEFYVIEYAACDATYNEIVTIERLRSVNPNKP
ATKDTFHKIKLDVPEDLRQMCAKEAAHKDFKKAVGAFSVTYDPENYQLVILSINEVTSKR
AHMLIDMHFRSLRTKLSLIMRNEEASKQLESSRQLASRFHEQFIVREDLMGLAIGTHGAN
IQQARKVPGVTAIDLDEDTCTFHIYGEDQDAVKKARSFLEFAEDVIQVPRNLVGKVIGKN
GKLIQEIVDKSGVVRVRIEAENEKNVPQEEEIMPPNSLPSNNSRVGPNAPEEKKHLDIKE
NSTHFSQPNSTKVQRVLVASSVVAGESQKPELKAWQGMVPFVFVGTKDSIANATVLLDYH
LNYLKEVDQLRLERLQIDEQLRQIGASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRG
HGRRGPGYTSGTNSEASNASETESDHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRG
QGGRGRGGGFKGNDDHSRTDNRPRNPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSS
EGSRLRTGKDRNQKKEKPDSVDGQQPLVNGVP",FMR1,-,-,632aa(1-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[281-422],[443-515],[516-632]","[492-504],[527-549]",In vitro,20 ng/µl [(CGG)99];|9 µM [FMRpolyG],"25 mM NaCl, 10 mM MgCl2","10 mM tris-HCl buffer pH 7.5,12% (w/v) glycerol",23˚C,1 h,-,FRAP,liquid,We next investigated whether PpIX affects the LLPS of FMRpolyG  in vitro. The phase-separated liquid droplets and hydrogels of com plexes of fluorescein-FMRpolyG and CX rhodamine–CGG99 formed  substantially smaller droplets after PpIX treatment compared to un treated controls
555,PMID: 33523882,RNAPS0000460,https://pubmed.ncbi.nlm.nih.gov/33523882,RNA + protein,-,-,(CGG)99,297nt,CGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG,repeat RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1
MEELVVEVRGSNGAFYKAFVKDVHEDSITVAFENNWQPDRQIPFHDVRFPPPVGYNKDIN
ESDEVEVYSRANEKEPCCWWLAKVRMIKGEFYVIEYAACDATYNEIVTIERLRSVNPNKP
ATKDTFHKIKLDVPEDLRQMCAKEAAHKDFKKAVGAFSVTYDPENYQLVILSINEVTSKR
AHMLIDMHFRSLRTKLSLIMRNEEASKQLESSRQLASRFHEQFIVREDLMGLAIGTHGAN
IQQARKVPGVTAIDLDEDTCTFHIYGEDQDAVKKARSFLEFAEDVIQVPRNLVGKVIGKN
GKLIQEIVDKSGVVRVRIEAENEKNVPQEEEIMPPNSLPSNNSRVGPNAPEEKKHLDIKE
NSTHFSQPNSTKVQRVLVASSVVAGESQKPELKAWQGMVPFVFVGTKDSIANATVLLDYH
LNYLKEVDQLRLERLQIDEQLRQIGASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRG
HGRRGPGYTSGTNSEASNASETESDHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRG
QGGRGRGGGFKGNDDHSRTDNRPRNPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSS
EGSRLRTGKDRNQKKEKPDSVDGQQPLVNGVP",FMR1,-,-,632aa(1-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[281-422],[443-515],[516-632]","[492-504],[527-549]",In vitro,20 ng/µl [(CGG)99];|9 µM [FMRpolyG],"25 mM NaCl, 10 mM MgCl2","10 mM tris-HCl buffer pH 7.5,12% (w/v) glycerol",23˚C,1 h,drug:PpIX (50µM),FRAP,liquid,We next investigated whether PpIX affects the LLPS of FMRpolyG  in vitro. The phase-separated liquid droplets and hydrogels of com plexes of fluorescein-FMRpolyG and CX rhodamine–CGG99 formed  substantially smaller droplets after PpIX treatment compared to un treated controls
556,PMID: 33558506,RNAPS0000465,https://pubmed.ncbi.nlm.nih.gov/33558506,RNA + protein,-,-,polyrU(40),40nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|residues=471-510
DRRGGRGGYDRGGYRGRGGDRGGFRGGRGGGDRGGFGPGK",FUS,RGG3,-,40aa(471-510),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,0.2 mg/ml µM[GLS1];|0.2 µM [GIRGL];|1 mg/ml µM [FUS],150 mM NaCl,"25 mM Tris-HCl (pH = 7.5), 20 mM DTT",RT,-,-,Confocal fluorescence microscopy,liquid,"MD simulations similar to those in Fig. 1d but now including π-rich FUSPLP as a client (Table S2) revealed enhanced surface recruitment of PLP chains into RRP-RNA droplets only at low-RNA conditions(Fig. 1f, Fig. S9), thereby lending support to this idea. To test this experimentally, we utilized PLPs from two different RNPs, EWS and FUS, and quantified their partitioning in FUSRGG3-poly(rU) condensates."
557,PMID: 33558506,RNAPS0000465,https://pubmed.ncbi.nlm.nih.gov/33558506,RNA + protein,-,-,polyrU(40),40nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,2.5 mg/ml µM[GLS1];|0.2 µM [GIRGL];|1 mg/ml µM [FUS],150 mM NaCl,"25 mM Tris-HCl (pH = 7.5), 20 mM DTT",RT,-,-,Confocal fluorescence microscopy,liquid,"MD simulations similar to those in Fig. 1d but now including π-rich FUSPLP as a client (Table S2) revealed enhanced surface recruitment of PLP chains into RRP-RNA droplets only at low-RNA conditions(Fig. 1f, Fig. S9), thereby lending support to this idea. To test this experimentally, we utilized PLPs from two different RNPs, EWS and FUS, and quantified their partitioning in FUSRGG3-poly(rU) condensates."
558,PMID: 33597515,RNAPS0000466,https://pubmed.ncbi.nlm.nih.gov/33597515,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,1.25 mg/mL [PolyU];|4.5 µM [FUS],2.7 M KCl,50 mM Tris-HCl (pH 7.2) ,RT,-,"other_molecular:10% 1,6-hexanediol,12.5 mM ATP",Fluorescence microscopy,"liquid, solute","To test this hypothesis, we probed the ability of pre-formed FUS condensates to dissociate when exposed to a range of additional components acting as phase separation disruptors, as shown in Fig. 3a. We selected a representative set of compounds with the ability to modulate both electrostatic interactions, such as poly-uridine (PolyU) RNA and ATP, both highly negatively charged molecules previously described to disrupt phase separation20,64,65, as well as 1,6-hexanediol, an aliphatic alcohol known to disrupt weak protein–protein hydrophobic interactions and selectively dissolve liquid condensates but not solid ones70. At low-salt concentrations, PolyU RNA, ATP, and 1,6-hexanediol were all able to dissolve FUS condensates, confirming that both hydrophobic and electrostatic interactions contribute to the stability of FUS condensates in the low-salt regime. At high-salt conditions, 1,6-hexanediol was the only disruptor that could dissolve FUS condensates, while the addition of PolyU RNA and ATP did not show any effects. These observations, summarized in Fig. 3b, suggest that reentrant high-salt phase separation of proteins is indeed primarily a hydrophobically driven process where electrostatics are screened out."
559,PMID: 33597515,RNAPS0000466,https://pubmed.ncbi.nlm.nih.gov/33597515,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,1.25 mg/mL [PolyU];|4.5 µM [FUS],50 mM KCl,50 mM Tris-HCl (pH 7.2) ,RT,-,"other_molecular:10% 1,6-hexanediol,12.5 mM ATP",Fluorescence microscopy,solute,"To test this hypothesis, we probed the ability of pre-formed FUS condensates to dissociate when exposed to a range of additional components acting as phase separation disruptors, as shown in Fig. 3a. We selected a representative set of compounds with the ability to modulate both electrostatic interactions, such as poly-uridine (PolyU) RNA and ATP, both highly negatively charged molecules previously described to disrupt phase separation20,64,65, as well as 1,6-hexanediol, an aliphatic alcohol known to disrupt weak protein–protein hydrophobic interactions and selectively dissolve liquid condensates but not solid ones70. At low-salt concentrations, PolyU RNA, ATP, and 1,6-hexanediol were all able to dissolve FUS condensates, confirming that both hydrophobic and electrostatic interactions contribute to the stability of FUS condensates in the low-salt regime. At high-salt conditions, 1,6-hexanediol was the only disruptor that could dissolve FUS condensates, while the addition of PolyU RNA and ATP did not show any effects. These observations, summarized in Fig. 3b, suggest that reentrant high-salt phase separation of proteins is indeed primarily a hydrophobically driven process where electrostatics are screened out."
560,PMID: 33621982,RNAPS0000467,https://pubmed.ncbi.nlm.nih.gov/33621982,RNA + protein,-,-,p53,14nt(site1),UUUUUUACCUUGUA,mRNA,Mus musculus,"sp|P31483|TIA1_HUMAN Nucleolysin TIA-1 isoform p40 OS=Homo sapiens OX=9606 GN=TIA1 PE=1 SV=3
MEDEMPKTLYVGNLSRDVTEALILQLFSQIGPCKNCKMIMDTAGNDPYCFVEFHEHRHAA
AALAAMNGRKIMGKEVKVNWATTPSSQKKDTSSSTVVSTQRSQDHFHVFVGDLSPEITTE
DIKAAFAPFGRISDARVVKDMATGKSKGYGFVSFFNKWDAENAIQQMGGQWLGGRQIRTN
WATRKPPAPKSTYESNTKQLSYDEVVNQSSPSNCTVYCGGVTSGLTEQLMRQTFSPFGQI
MEIRVFPDKGYSFVRFNSHESAAHAIVSVNGTTIEGHVVKCYWGKETLDMINPVQQQNQI
GYPQPYGQWGQWYGNAQQIGQYMPNGWQVPAYGMYGQAWNQQGFNQTQSSAPWMGPNYGV
QPPQGQNGSMLPNQPSGYRVAGYETQ",TIA-1,-,-,386aa(1-386),P31483,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P31483,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0303,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0007,http://db.phasep.pro/browse/",[354-386],"[59-65],[82-104]",In vitro,1 µM [p53];|5 µM [TIA-1],50 mM NaCl,"20 mM HEPES
pH 7, 40 mM Arginine",RT,≤ 20 min,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"We therefore tested whether these individual sites were sufficient for inducing TIA-1 condensation in vitro using oligonucleotides repre senting either the short 14-nt TIA-1 binding site (p53 site 1) or the longer 27-nt TIA-1 binding site (p53 site 2). P53 site 1 did not induce self-association of TIA-1 either through phase separation or fibril formation as shown by DIC, tur bidity and ThT fluorescence assay respectively.In con trast, the presence of UC5 resulted in a dramatic increase in ThT fluorescence, after a lag time of ∼6 h"
561,PMID: 33621982,RNAPS0000468,https://pubmed.ncbi.nlm.nih.gov/33621982,RNA + protein,-,-,p53,27nt(site2),UUUUUUUUUUUUUUACCCCUUUUUAUA,mRNA,Mus musculus,"sp|P31483|TIA1_HUMAN Nucleolysin TIA-1 isoform p40 OS=Homo sapiens OX=9606 GN=TIA1 PE=1 SV=3
MEDEMPKTLYVGNLSRDVTEALILQLFSQIGPCKNCKMIMDTAGNDPYCFVEFHEHRHAA
AALAAMNGRKIMGKEVKVNWATTPSSQKKDTSSSTVVSTQRSQDHFHVFVGDLSPEITTE
DIKAAFAPFGRISDARVVKDMATGKSKGYGFVSFFNKWDAENAIQQMGGQWLGGRQIRTN
WATRKPPAPKSTYESNTKQLSYDEVVNQSSPSNCTVYCGGVTSGLTEQLMRQTFSPFGQI
MEIRVFPDKGYSFVRFNSHESAAHAIVSVNGTTIEGHVVKCYWGKETLDMINPVQQQNQI
GYPQPYGQWGQWYGNAQQIGQYMPNGWQVPAYGMYGQAWNQQGFNQTQSSAPWMGPNYGV
QPPQGQNGSMLPNQPSGYRVAGYETQ",TIA-1,-,-,386aa(1-386),P31483,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P31483,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0303,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0007,http://db.phasep.pro/browse/",[354-386],"[59-65],[82-104]",In vitro,1 µM [p53];|5 µM [TIA-1],50 mM NaCl,"20 mM HEPES
pH 7, 40 mM Arginine",RT,≤ 20 min,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"We therefore tested whether these individual sites were sufficient for inducing TIA-1 condensation in vitro using oligonucleotides repre senting either the short 14-nt TIA-1 binding site (p53 site 1) or the longer 27-nt TIA-1 binding site (p53 site 2). P53 site 1 did not induce self-association of TIA-1 either through phase separation or fibril formation as shown by DIC, tur bidity and ThT fluorescence assay respectively.In con trast, the presence of UC5 resulted in a dramatic increase in ThT fluorescence, after a lag time of ∼6 h"
562,PMID: 33621982,RNAPS0000469,https://pubmed.ncbi.nlm.nih.gov/33621982,RNA + protein,-,-,p53,326nt(3'UTR),GGGUCCCUUCUGCUGCCUUUUUUACCUUGUAGCUAG GGCUCAGCCCCCUCUCUGAGUAGUGGUUCCUGGCCCAAGUUGGGGAAUAGGUUGAUAGUU GUCAGGUCUCUGCUGGCCCAGCGAAAUUCUAUCCAGCCAGUUGUUGGACCCUGGCACCUA CAAUGAAAUCUCACCCUACCCCACACCCUGUAAGAUUCUAUCUUGGGCCCUCAUAGGGUC CAUAUCCUCCAGGGCCUACUUUCCUUCCAUUCUGCAAAGCCUGUCUGCAUUUAUCCACCC CCCACCCUGUCUCCCUCUUUUUUUUUUUUUUACCCCUUUUUAUAUAUCAA,mRNA,Mus musculus,"sp|P31483|TIA1_HUMAN Nucleolysin TIA-1 isoform p40 OS=Homo sapiens OX=9606 GN=TIA1 PE=1 SV=3
MEDEMPKTLYVGNLSRDVTEALILQLFSQIGPCKNCKMIMDTAGNDPYCFVEFHEHRHAA
AALAAMNGRKIMGKEVKVNWATTPSSQKKDTSSSTVVSTQRSQDHFHVFVGDLSPEITTE
DIKAAFAPFGRISDARVVKDMATGKSKGYGFVSFFNKWDAENAIQQMGGQWLGGRQIRTN
WATRKPPAPKSTYESNTKQLSYDEVVNQSSPSNCTVYCGGVTSGLTEQLMRQTFSPFGQI
MEIRVFPDKGYSFVRFNSHESAAHAIVSVNGTTIEGHVVKCYWGKETLDMINPVQQQNQI
GYPQPYGQWGQWYGNAQQIGQYMPNGWQVPAYGMYGQAWNQQGFNQTQSSAPWMGPNYGV
QPPQGQNGSMLPNQPSGYRVAGYETQ",TIA-1,-,-,386aa(1-386),P31483,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P31483,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0303,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0007,http://db.phasep.pro/browse/",[354-386],"[59-65],[82-104]",In vitro,0.25 µM [p53];|2.5 µM [TIA-1],50 mM NaCl,"20 mM HEPES
pH 7, 40 mM Arginine",RT,10 min,-,Turbidity measurement,liquid,Next we tested whether these TIA-1 binding sites also drove TIA-1 condensation in the context of the p53 3  UTR. Wild type p53 3  UTR RNA induced phase separation of TIA-1 in turbidity assay and fibril formation in the ThT assay
563,PMID: 33621982,RNAPS0000470,https://pubmed.ncbi.nlm.nih.gov/33621982,RNA + protein,-,-,p53_mut,326nt(3'UTR),GGGUCCCUUCUGCUGCCUAUGUAACCUAGUAGCUAG GGCUCAGCCCCCUCUCUGAGUAGUGGUUCCUGGCCCAAGUUGGGGAAUAGGUUGAUAGUU GUCAGGUCUCUGCUGGCCCAGCGAAAUUCUAUCCAGCCAGUUGUUGGACCCUGGCACCUA CAAUGAAAUCUCACCCUACCCCACACCCUGUAAGAUUCUAUCUUGGGCCCUCAUAGGGUC CAUAUCCUCCAGGGCCUACUUUCCUUCCAUUCUGCAAAGCCUGUCUGCAUUUAUCCACCC CCCACCCUGUCUCCCUCUAUGUAUGUAUGUAACCCCUGAUUAUAUAUCAA,mRNA,Mus musculus,"sp|P31483|TIA1_HUMAN Nucleolysin TIA-1 isoform p40 OS=Homo sapiens OX=9606 GN=TIA1 PE=1 SV=3
MEDEMPKTLYVGNLSRDVTEALILQLFSQIGPCKNCKMIMDTAGNDPYCFVEFHEHRHAA
AALAAMNGRKIMGKEVKVNWATTPSSQKKDTSSSTVVSTQRSQDHFHVFVGDLSPEITTE
DIKAAFAPFGRISDARVVKDMATGKSKGYGFVSFFNKWDAENAIQQMGGQWLGGRQIRTN
WATRKPPAPKSTYESNTKQLSYDEVVNQSSPSNCTVYCGGVTSGLTEQLMRQTFSPFGQI
MEIRVFPDKGYSFVRFNSHESAAHAIVSVNGTTIEGHVVKCYWGKETLDMINPVQQQNQI
GYPQPYGQWGQWYGNAQQIGQYMPNGWQVPAYGMYGQAWNQQGFNQTQSSAPWMGPNYGV
QPPQGQNGSMLPNQPSGYRVAGYETQ",TIA-1,-,-,386aa(1-386),P31483,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P31483,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0303,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0007,http://db.phasep.pro/browse/",[354-386],"[59-65],[82-104]",In vitro,0.25 µM [p53];|2.5 µM [TIA-1],50 mM NaCl,"20 mM HEPES
pH 7, 40 mM Arginine",RT,10 min,-,Turbidity measurement,liquid,Next we tested whether these TIA-1 binding sites also drove TIA-1 condensation in the context of the p53 3  UTR. Wild type p53 3  UTR RNA induced phase separation of TIA-1 in turbidity assay and fibril formation in the ThT assay
564,PMID: 33621982,RNAPS0000471,https://pubmed.ncbi.nlm.nih.gov/33621982,RNA + protein,-,-,(UUUUUACUCCAA)4+UUUUUACUCC,58nt,UUUUUACUCCAAUUUUUACUCCAAUUUUUACUCCAAUUUUUACUCCAAUUUUUACUCC,repeat RNA,-,"sp|P31483|TIA1_HUMAN Nucleolysin TIA-1 isoform p40 OS=Homo sapiens OX=9606 GN=TIA1 PE=1 SV=3
MEDEMPKTLYVGNLSRDVTEALILQLFSQIGPCKNCKMIMDTAGNDPYCFVEFHEHRHAA
AALAAMNGRKIMGKEVKVNWATTPSSQKKDTSSSTVVSTQRSQDHFHVFVGDLSPEITTE
DIKAAFAPFGRISDARVVKDMATGKSKGYGFVSFFNKWDAENAIQQMGGQWLGGRQIRTN
WATRKPPAPKSTYESNTKQLSYDEVVNQSSPSNCTVYCGGVTSGLTEQLMRQTFSPFGQI
MEIRVFPDKGYSFVRFNSHESAAHAIVSVNGTTIEGHVVKCYWGKETLDMINPVQQQNQI
GYPQPYGQWGQWYGNAQQIGQYMPNGWQVPAYGMYGQAWNQQGFNQTQSSAPWMGPNYGV
QPPQGQNGSMLPNQPSGYRVAGYETQ",TIA-1,-,-,386aa(1-386),P31483,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P31483,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0303,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0007,http://db.phasep.pro/browse/",[354-386],"[59-65],[82-104]",In vitro,0.25 µM [RNA];|2.5 µM [TIA-1],50 mM NaCl,"20 mM HEPES
pH 7, 40 mM Arginine",RT,10 min,-,Turbidity measurement,liquid,"To directly test the ability of the oligonucleotide con centration with specific binding sites to modulate TIA-1 condensation, we varied the concentration of TC5 between 0.125 and 5  M and monitored spontaneous phase sepa ration and fibril formation over time of TIA-1 at 2.5  M"
565,PMID: 33621982,RNAPS0000472,https://pubmed.ncbi.nlm.nih.gov/33621982,RNA + protein,-,-,"UC RNA(Loughlin,2021)",10nt,UUUUUACUCC,irregular RNA,-,"sp|P31483|TIA1_HUMAN Nucleolysin TIA-1 isoform p40 OS=Homo sapiens OX=9606 GN=TIA1 PE=1 SV=3
MEDEMPKTLYVGNLSRDVTEALILQLFSQIGPCKNCKMIMDTAGNDPYCFVEFHEHRHAA
AALAAMNGRKIMGKEVKVNWATTPSSQKKDTSSSTVVSTQRSQDHFHVFVGDLSPEITTE
DIKAAFAPFGRISDARVVKDMATGKSKGYGFVSFFNKWDAENAIQQMGGQWLGGRQIRTN
WATRKPPAPKSTYESNTKQLSYDEVVNQSSPSNCTVYCGGVTSGLTEQLMRQTFSPFGQI
MEIRVFPDKGYSFVRFNSHESAAHAIVSVNGTTIEGHVVKCYWGKETLDMINPVQQQNQI
GYPQPYGQWGQWYGNAQQIGQYMPNGWQVPAYGMYGQAWNQQGFNQTQSSAPWMGPNYGV
QPPQGQNGSMLPNQPSGYRVAGYETQ",TIA-1,-,-,386aa(1-386),P31483,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P31483,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0303,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0007,http://db.phasep.pro/browse/",[354-386],"[59-65],[82-104]",In vitro,0.25 µM [RNA];|2.5 µM [TIA-1],50 mM NaCl,"20 mM HEPES
pH 7, 40 mM Arginine",RT,10 min,-,Turbidity measurement,liquid,"To directly test the ability of the oligonucleotide con centration with specific binding sites to modulate TIA-1 condensation, we varied the concentration of TC5 between 0.125 and 5  M and monitored spontaneous phase sepa ration and fibril formation over time of TIA-1 at 2.5  M"
566,PMID: 33649309,RNAPS0000473,https://pubmed.ncbi.nlm.nih.gov/33649309,RNA + protein,-,-,polyA,2100–10000nt,-,poly RNA,-,"sp|Q6ZN16|M3K15_HUMAN Mitogen-activated protein kinase kinase kinase 15 OS=Homo sapiens OX=9606 GN=MAP3K15 PE=1 SV=2
MESGGGNAPAGALGAASESPQCPPPPGVEGAAGPAEPDGAAEGAAGGSGEGESGGGPRRA
LRAVYVRSESSQGGAAGGPEAGARQCLLRACEAEGAHLTSVPFGELDFGETAVLDAFYDA
DVAVVDMSDVSRQPSLFYHLGVRESFDMANNVILYHDTDADTALSLKDMVTQKNTASSGN
YYFIPYIVTPCADYFCCESDAQRRASEYMQPNWDNILGPLCMPLVDRFISLLKDIHVTSC
VYYKETLLNDIRKAREKYQGEELAKELARIKLRMDNTEVLTSDIIINLLLSYRDIQDYDA
MVKLVETLEMLPTCDLADQHNIKFHYAFALNRRNSTGDREKALQIMLQVLQSCDHPGPDM
FCLCGRIYKDIFLDSDCKDDTSRDSAIEWYRKGFELQSSLYSGINLAVLLIVAGQQFETS
LELRKIGVRLNSLLGRKGSLEKMNNYWDVGQFFSVSMLAHDVGKAVQAAERLFKLKPPVW
YLRSLVQNLLLIRRFKKTIIEHSPRQERLNFWLDIIFEATNEVTNGLRFPVLVIEPTKVY
QPSYVSINNEAEERTVSLWHVSPTEMKQMHEWNFTASSIKGISLSKFDERCCFLYVHDNS
DDFQIYFSTEEQCSRFFSLVKEMITNTAGSTVELEGETDGDTLEYEYDHDANGERVVLGK
GTYGIVYAGRDLSNQVRIAIKEIPERDSRYSQPLHEEIALHKYLKHRNIVQYLGSVSENG
YIKIFMEQVPGGSLSALLRSKWGPMKEPTIKFYTKQILEGLKYLHENQIVHRDIKGDNVL
VNTYSGVVKISDFGTSKRLAGVNPCTETFTGTLQYMAPEIIDQGPRGYGAPADIWSLGCT
IIEMATSKPPFHELGEPQAAMFKVGMFKIHPEIPEALSAEARAFILSCFEPDPHKRATTA
ELLREGFLRQVNKGKKNRIAFKPSEGPRGVVLALPTQGEPMATSSSEHGSVSPDSDAQPD
ALFERTRAPRHHLGHLLSVPDESSALEDRGLASSPEDRDQGLFLLRKDSERRAILYKILW
EEQNQVASNLQECVAQSSEELHLSVGHIKQIIGILRDFIRSPEHRVMATTISKLKVDLDF
DSSSISQIHLVLFGFQDAVNKILRNHLIRPHWMFAMDNIIRRAVQAAVTILIPELRAHFE
PTCETEGVDKDMDEAEEGYPPATGPGQEAQPHQQHLSLQLGELRQETNRLLEHLVEKERE
YQNLLRQTLEQKTQELYHLQLKLKSNCITENPAGPYGQRTDKELIDWLRLQGADAKTIEK
IVEEGYTLSDILNEITKEDLRYLRLRGGLLCRLWSAVSQYRRAQEASETKDKA",ASK3,-,-,1313aa(1-1313),Q6ZN16,-,-,"[1-58],[939-958]","[4-16],[23-57],[73-83],[112-131],[1280-1293]",In vitro,2.5 µM[polyA],150 mM NaCl,"20 mM Tris (pH 7.5), 1 mM DTT",0˚C,15 min,crowding agent:20% PEG,Electron microscopy,solute,"Of note, we found that poly(A) RNA also inhibits the formation of solid-like ASK3 condensates in vitro, suggesting that the common physicochemical property between PAR and RNA is important for the liquidity maintenance of ASK3 condensates."
567,PMID: 33688654,RNAPS0000474,https://pubmed.ncbi.nlm.nih.gov/33688654,RNA + protein,-,-,SARS-CoV-2 virus RNA,211nt(84-294),CUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,LCD,-,-,P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,7.5µM [SARS-CoV-2];|30 µM [SARS-CoV-2 N protein],300 mM NaCl,"20 mM Tris, pH 8.0",37˚C,≤ 24 h,-,FRAP,"liquid, solid","The LCD segment, as opposed to the full length NCAP, form fibrils in lower protein:RNA ratios.  Whereas we observed no LLPS or amyloid formation of the LCD in the 40:1 protein: RNA (0.75  µM) molar ratio, ThS and PI positive LLPS droplets of roughly 3-10 µm in diameter appeared in  the 4:1 (7.5 µM RNA) molar ratio mixture during 17 h of incubation (Figure 4B & S4). 24 h of incubation led to the formation of gel particles of intense ThS signal"
568,PMID: 33688654,RNAPS0000474,https://pubmed.ncbi.nlm.nih.gov/33688654,RNA + protein,-,-,SARS-CoV-2 virus RNA,211nt(84-294),CUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.75 µM [SARS-CoV-2];|30 µM [SARS-CoV-2 N protein],300 mM NaCl,"20 mM Tris, pH 8.0",37˚C,17 h,-,Fluorescence microscopy,solid,"Amyloid and LLPS formation are correlated in mixtures of NCAP, and its LCD, with appropriate Site2hp RNA concentrations, as visualized in vitro by fluorescence microscopy with the amyloid  fluorescent dye Thioflavin-S (ThS). ThS positive LLPS droplets of ~2-5 µm in diameter were  observed of the NCAP protein when mixed with Site2hp RNA in 40:1 protein:RNA molar ratio (0.75 µM RNA). Those droplets were also positive to propidium iodide (PI), a nucleic acid  indicator, demonstrating that the protein fibrils and RNA are co-localized into those droplets"
569,PMID: 33688654,RNAPS0000474,https://pubmed.ncbi.nlm.nih.gov/33688654,RNA + protein,-,-,SARS-CoV-2 virus RNA,211nt(84-294),CUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,7.5 µM [SARS-CoV-2];|30 µM [SARS-CoV-2 N protein],300 mM NaCl,"20 mM Tris, pH 8.0",37˚C,17 h,-,Fluorescence microscopy,"liquid, solid","Amyloid and LLPS formation are correlated in mixtures of NCAP, and its LCD, with appropriate Site2hp RNA concentrations, as visualized in vitro by fluorescence microscopy with the amyloid  fluorescent dye Thioflavin-S (ThS). ThS positive LLPS droplets of ~2-5 µm in diameter were  observed of the NCAP protein when mixed with Site2hp RNA in 40:1 protein:RNA molar ratio (0.75 µM RNA). Those droplets were also positive to propidium iodide (PI), a nucleic acid  indicator, demonstrating that the protein fibrils and RNA are co-localized into those droplets"
570,PMID: 33762340,RNAPS0000475,https://pubmed.ncbi.nlm.nih.gov/33762340,RNA + protein,-,-,GIRGL,-,-,lncRNA,Homo sapiens,"sp|Q14444|CAPR1_HUMAN Caprin-1 OS=Homo sapiens OX=9606 GN=CAPRIN1 PE=1 SV=2
MPSATSHSGSGSKSSGPPPPSGSSGSEAAAGAGAAAPASQHPATGTGAVQTEAMKQILGV
IDKKLRNLEKKKGKLDDYQERMNKGERLNQDQLDAVSKYQEVTNNLEFAKELQRSFMALS
QDIQKTIKKTARREQLMREEAEQKRLKTVLELQYVLDKLGDDEVRTDLKQGLNGVPILSE
EELSLLDEFYKLVDPERDMSLRLNEQYEHASIHLWDLLEGKEKPVCGTTYKVLKEIVERV
FQSNYFDSTHNHQNGLCEEEEAASAPAVEDQVPEAEPEPAEEYTEQSEVESTEYVNRQFM
AETQFTSGEKEQVDEWTVETVEVVNSLQQQPQAASPSVPEPHSLTPVAQADPLVRRQRVQ
DLMAQMQGPYNFIQDSMLDFENQTLDPAIVSAQPMNPTQNMDMPQLVCPPVHSESRLAQP
NQVPVQPEATQVPLVSSTSEGYTASQPLYQPSHATEQRPQKEPIDQIQATISLNTDQTTA
SSSLPAASQPQVFQAGTSKPLHSSGINVNAAPFQSMQTVFNMNAPVPPVNEPETLKQQNQ
YQASYNQSFSSQPHQVEQTELQQEQLQTVVGTYHGSPDQSHQVTGNHQQPPQQNTGFPRS
NQPYYNSRGVSRGGSRGARGLMNGYRGPANGFRGGYDGYRPSFSNTPNSGYTQSQFSAPR
DYSGYQRDGYQQNFKRGSGQSGPRGAPRGRGGPPRPNRGMPQMNTQQVN",CAPRIN1,-,-,709aa(1-709),Q14444,DrLLPS,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0521,"[1-50],[251-251],[260-291],[417-446],[475-499],[524-709]","[2-43],[61-81],[178-188],[258-282],[311-324],[328-337],[477-491],[537-552],[555-570],[607-620],[676-704]",In vitro,0.2 µM [GLS1];|20 µM [CAPRIN1],30 mM NaCl,"25 mM Na2HPO4(pH 7.4), 2 mM DTT",RT,-,-,Epifluorescence microscopy,liquid,"SGs form through liquid-liquid phase separation, resulting from the aggregation of SG component proteins that interact through intrinsically disordered (ID) regions (45). This process can be modeled in vitro and, for example, has been used to show how posttranslational modifications of the fragile X mental retardation protein (FMRP) affect its phase separation with RNA (46). Using this approach, we observed the formation of visible droplets (phase-separated protein rich condensates) when Flag-CAPRIN1 was incubated with 3′UTR-1 of GLS1, but not with the GLS1 5′UTR."
571,PMID: 33762340,RNAPS0000144,https://pubmed.ncbi.nlm.nih.gov/33762340,RNAs + protein,NCBI ID:18870687;|-,https://www.ncbi.nlm.nih.gov/gene/18870687;|-,GLS1;|GIRGL,5926nt(1-5926);|-,CUUCUUUUAGUGUCGUAACAUCGAUUUAUACCUAACCAUCCAAUCCUUAUCAUCAUUGCCACUAACCACUGUCCUACCUUUUCUAAGAAAGCAGUAGUAAUAGCAAUAUAAAUAUAAGUCAGAUGUCGUAUAACGAUAAUAAUCACAAUUAUUAUGAUCCCAACCAACAGCCCAGUGGUGCUCCACUUCAGGGUGAUGGUUACUAUCAACAACCAUAUGAUGAUAUGAACCAACAACAACAAGAUUACUAUGAUCCAAAUGUUCAAUAUCAACAACAACCAUAUGAUAUGGAUGGAUACCAGGAUGGUGCCCAAUACGGUAGUCAACCUGCCCAAGGUUAUAAUGCUGAUCCAGAAGCCUUUUCUGAUUUCAGUUAUGGUGGUCAAACUCCAGGUGCUUCAUAUGAUCAAUAUGGUACCCAAUACACUCCUUCUCAAAUGAGUUAUGGUGGUGACCCAAGAUCUUCUGGUGCCUCAACUCCAAUUUAUGGAGGUCAAGGUCAAGGAUAUGAUCCAUCACAAUUCCAAAUGUCAUCUAACUUACCUUAUCCUGCUUGGUCUGCUGAUCCUCAAGCUCCAAUCAAGGUUGAGCAUAUUGAAGAUAUCUUUAUUGAUUUAACAAACAAGUUUGGUUUCCAAAGAGAUUCUAUGAGAAAUAUGUUUGAUUACUUUAUGACCUUGUUAGAUUCUAGAUCCUCAAGAAUGUCACCAGCUCAAGCACUUUUAAGUUUACACGCUGAUUAUAUUGGUGGUGAAAAUGCUAAUUAUAGAAAAUGGUUCUUUUCUUCCCAACAAGAUUUAGACGAUUCUCUCGGUUUUGCUAAUAUGGCCUUAGGUAAGAUUGGUAGAAAGGCUAGAAAAGCAUCCAAGAAGUCUAAGAAGGCAAGAAAGGCAGCCGAAGAACAUGGUGAAGAUGUUGAUGCUCUUGCUACUGAAUUAGAAGGUGAUUAUUCAUUGGAAGCUGCUGAAAUCAGAUGGAAAGCCAAGAUGAACACUUUAACUCCUGAAGAAAGAGUUCGUGAUAUUGCUCUUUACGUGUUAUUAUGGGGUGAAGCUAAUCAAGUUCGUUUUACUCCAGAAUGUUUAUGUUAUAUCUACAAGACUGCAUCUGAUUACUUGAACUCUCCAUUGUGUCAACAAAGACAAGAACCAGUUCCUGAAGGUGAUUAUUUGAACAGAGUUAUUACCCCAUUAUAUAGAUUCCUUAGAUCUCAAGUUUAUGAGAUUUACGAAGGUAAAUUCGUCAAACGUGAAAAGGAUCACAAUAAGGUUAUUGGUUAUGAUGAUGUUAAUCAAUUAUUUUGGUACCCAGAGGGUAUUUCCAGAAUCAUGUUUGAAGAUGGAACAAGAAUGGUGGAUAUUCCACAAGAAGAACGUUAUUUAAGACUUGGUGAAGUUGAAUGGAAUAAUGUAUUCUUCAAAACUUAUAAGGAAAUUAGAACUUGGUUACAUUUCAUUACUAAUUUCAAUAGAAUUUGGAUUAUCCAUGCAAGUAUUUACUGGAUGUAUACUGCUUACAACUCCCCAACCUUAUAUACCAAGAAUUACGUUCAAACCAGAAACCAACAACCUCUUGCUUCUUCAAGAUGGGCUGCUUGUGCUAUUGGUGGUGUCGUUGCUUCCCUUAUUCAAAUUUUUGCUACCCUUUUUGAAUGGAUGUUUGUUCCAAGAGAAUGGGCUGGUGCUCAACAUUUGACUCGUCGUUUAAUGUUUUUGAUUUUGAUUUUCUUUGUUAACUUGGCUCCUGUGGUUUAUACAUUCAAGAUUACUGGUUUAACAUUAUACUCCAAAUCUGCUUACGCGGUCUCAAUUGUUGGUUUCUUUAUUGCUGUUGCCACCAUUAUUUUCUUUGCCGUUAUGCCAUUGGGUGGGUUAUUCACUUCAUACAUGAACAAGAGAUCUAGAAGAUAUAUUUCAUCUCAAACUUUCACUGCUAAUUUCAUCAAGUUGAAGGGUUUGGAUAUGUGGAUGUCAUAUUUAUUAUGGUUCUUAGUUUUCCUUGCCAAGUUGGUCGAAUCUUAUUUCUUCUUGACCUUAUCUAUUAGAGAUCCUAUUAGAAUUUUGUCCACCACUACCAUGAGAUGUGUUGGUGAAGUUUGGUAUAAGGAAGCAGUUUGCAGAAACCAAGCUAAGAUUGUUUUGGGUUUGAUGUACCUUGUUGAUUUGUUAUUGUUCUUCUUGGAUACUUACAUGUGGUACAUUAUUUGUAACUGUAUCUUCUCCAUCGGUCGUUCCUUCUACUUGGGUAUUUCUAUCUUGACUCCAUGGAGAAACAUUUUCACCAGAUUGCCAAAGAGAAUCUACUCCAAGAUUUUAGCUACCACUGAAAUGGAAAUUAAGUAUAAGCCAAAGGUUUUGAUUUCCCAAAUCUGGAACGCUAUUGUGAUUUCUAUGUACAGAGAACAUUUGUUAGCCAUUGACCAUGUCCAAAAGUUAUUAUACCACCAAGUUCCUUCAGAAAUUGAAGGUAAGAGAACUUUGAGAGCUCCAACUUUCUUUGUUUCUCAAGAUGAUAACAACUUUGAAACUGAAUUCUUCCCAAGAAAUUCCGAAGCUGAAAGAAGAAUUUCUUUCUUUGCUCAAUCUUUAGCUACUCCAAUUCCAGAACCAUUACCAGUUGACAACAUGCCUACUUUUACUGUUUUCACUCCUCACUAUUCUGAAAAGAUUUUGUUAUCAUUGAGAGAAAUUAUUAGAGAAGAUGAUCAAUUCUCUAGAGUUACUUUAUUGGAAUACUUGAAACAAUUGCACCCAGUUGAAUGGGACUGUUUUGUCAAGGAUACUAAGAUUUUGGCUGAAGAAACUGCUGCCUACGAAAAUGGCGAUGAUUCCGAAAAGAUGUCUGAAGAUGGAUUGAAAUCUAAGAUUGAUGAUUUACCAUUCUACUGUAUUGGUUUCAAGUCUGCUGCCCCUGAAUAUACUUUAAGAACUAGAAUCUGGGCCUCUUUGAGAUCUCAAACUUUAUAUAGAACUGUUUCUGGUUUCAUGAAUUAUGCUAGAGCUAUCAAGUUGUUGUACAGAGUUGAAAACCCAGAAUUGGUUCAAUACUUUGGUGGCGAUCCAGAAGGUUUAGAAAUGGCUUUGGAAAAGAUGGCUAGAAGAAAGUUUAGAUUCUUGGUUUCUAUGCAAAGAUUGUCCAAGUUUAAGGAUGAUGAAAUGGAAAAUGCUGAAUUCUUGUUACGUGCUUACCCAGAUUUACAAAUUGCUUACUUAGAUGAAGAACCUGCUGAAGAAGGUGAAGACGCUAGAGUUUACUCCUCAUUGAUUGAUGGUCAUUGUGAAAUGUUAGAAAACGGAAGACGUCGUCCUAAGUUCAGAGUUCAAUUGUCUGGUAAUCCAAUUUUGGGUGAUGGUAAGUCUGAUAACCAAAAUCAUGCUGUUAUUUUCCACAGAGGUGAAUAUAUUCAAUUGAUUGAUGCUAACCAAGAUAACUAUUUGGAAGAAUGUUUGAAGAUUAGAUCUGUUUUGGCUGAAUUUGAAGAAUUGAAUGUUGAACAUGUUAACCCAUAUGCUCCAAACUUGAAGAGUGAAGAAUUGAAGGACAAAAAGGAACCUGUUGCUUUCUUGGGUGCUAGGGAAUAUAUUUUCUCUGAAAACUCUGGUGUUUUGGGUGAUGUUGCCGCUGGUAAAGAACAAACUUUUGGUACCUUGUUUGCUAGAACUUUGGCUCAAAUUGGUGGUAAAUUGCAUUAUGGUCACCCGGAUUUCUUAAAUGCUACAUUUAUGUUAACUAGAGGUGGUGUUUCUAAGGCUCAAAAGGGUUUACAUUUGAACGAAGAUAUUUAUGCUGGUAUGAAUGCUAUGAUGAGAGGUGGUAAGAUUAAGCAUUGUGAAUACUACCAAUGUGGUAAAGGUAGAGAUAUGGGUUUCGGCUCUAUUUUGAAUUUCACUACUAAGAUUGGUGCUGGUAUGGGUGAACAAAUGUUGUCCAGAGAAUACUACUACUUGUCUACUCAAUUACCAUUGGAUCGUUUCUUGUCUUUCUACUAUGGUCAUCCAGGUUUCCAUAUUAAUAACUUGUUCAUUCAAUUGUCUUUACAAGUUUUCAUUUUGGUUUUGGCUAACUUGAACUCUUUGGCUCAUGAAUCUAUUAUGUGUUCUUACAACAAGGAUGUUCCAAUUACUGAUGUUUUAUAUCCAUAUGGUUGUUACAACUUGGCUCCAGCUGUUGAUUGGGUUAGACGUUAUACUUUAUCCAUUUUCAUUGUCUUCUUUAUUUCCUUCAUCCCAUUGGUUGUUCAAGAAUUAAUUGAAAGAGGUGUUUGGAAGGCUUUCCAAAGAUUUGUUAGACAUUUCCUUUCCUUAUCACCAAUGUUUGAAGUUUUCGUUGCCCAAAUCUAUUCUUCAUCUGUUUUCACUGAUUUAACUGUUGGUGGUGCUAGAUAUAUUUCCACUGGUAGAGGUUUUGCCACUUCAAGAAUCCCAUUUUCAAUUUUGUACUCCCGUUUUGCUGAUUCUUCUAUUUACAUGGGUGCAAGAUUGAUGUUGAUUUUAUUAUUCGGUAGUGUUUCUAAAUGGCAAGCUCCAUUAUUGUGGUUCUGGGCUUCAUUGUCAUCAUUGAUGUUUUCACCAUUUAUUUUCAACCCUCAUCAAUUUGCUUGGGAAGAUUUCUUCAUUGAUUACAGAGAUUUCAUUAGAUGGUUAUCCAGAGGUAAUACCAAGUGGCACAGAAACUCAUGGAUUGGUUACAUUAGACUUUCUAGAUCUCGUGUUACUGGUUUCAAGAGGAAGAUGAUUGAUGAUAUUUCUGAAAAGUCUGCUGGUGAUGCAUCCAGAGCUCACAGAUCCAACAUCUUGUUUGCUGAUUUCAUUCCAUGUCUUCUUUACACUGCUGGUCUUUAUGUUGCCUUUGUUUUCAUUAAUGCCCAAACUGGGGUUACUGAAUAUCCAUAUGAAAUUUUGGGUUCUAGAAGGCCACAACCAGUCAAUGCUACUUUGAGAGUUGUUAUUUGUGCAUUAGCUCCUGUUGUUAUUGACAUGGGUAUUUUAGCUGUCUGUGUUGCCAUGGCCUGUUGUGCUGGUCCAAUGUUGGGUAUGUGUUGCAAGAAGACUGGUGCUGUUAUUGCUGGUGUUGCCCAUGGUGGUGCUGUCAUUGUUCACAUUGUUUUCUUUAUUGUCAUGUGGGUCUUGGAAGGUUUCAACUUUGCCAGAUUAUUAUUAGGAUUUGCCACUAUGAUUUACAUUCAAAGAUUAUUAUUCAAGUUUUUAACCUUGUGUUUCUUGACUAGAGAAUUCAAGAACGAUAAGGCCAACACUGCCUUCUGGACUGGUAAGUGGUAUAACACUGGUAUGGGAUGGAUGGCUUUCACUCAACCAUCUCGUGAAUUUGUUGCCAAGAUUAUUGAAAUGUCUGAAUUUGCCGGUGAUUUCGUAUUGGCUCAUAUCAUUUUAUUCUGUCAAUUACCAGUGUUGUGUAUUCCAUUGAUUGACAGAUGGCACUCUACUAUGUUAUUCUGGUUGAAACCAUCUAGAUUGAUUAGACCACCAAUUUACUCAUUGAAGCAAGCUAGAUUAAGAAAGAGAAUGGUUAGAAAAUACUGUACAUUAUACUUUGCCAUUUUGGUAUUAUUUGUUGUUAUUAUUGUUGCCCCAGCUGUUGGUUCCAGUCAAGUUGCUGUUGAUCAAUUUGCUAACAUUGGUGGUAAUGGAUCUAUCAUCAAUGGUUUGUUCCAACCAAGAAACAUCAGUAACAACGAUACUGGUCCAAACAGACCUAAAUCAUACACCUGGUCUUAUUUCAGUACUCCAGAAAAGGGUAAGACCAAGGGUUAUUCUACCAACCCAUUCUAGAGUAUUGGUUUAAAAAAAGAUGUGUAUCAUUAGAUAUUUUUGUUGCCGAUUAUCAUUUAACAUUUUGUUUAUUUUGUUUAUACAAGUUCUUUAUAUACUUUUUUUUAUAUUAAAUUCAUGGAUUAUUACUGUUAACU;|-,mRNA;|lncRNA,Spathaspora passalidarum;|Homo sapiens,"sp|Q14444|CAPR1_HUMAN Caprin-1 OS=Homo sapiens OX=9606 GN=CAPRIN1 PE=1 SV=2
MPSATSHSGSGSKSSGPPPPSGSSGSEAAAGAGAAAPASQHPATGTGAVQTEAMKQILGV
IDKKLRNLEKKKGKLDDYQERMNKGERLNQDQLDAVSKYQEVTNNLEFAKELQRSFMALS
QDIQKTIKKTARREQLMREEAEQKRLKTVLELQYVLDKLGDDEVRTDLKQGLNGVPILSE
EELSLLDEFYKLVDPERDMSLRLNEQYEHASIHLWDLLEGKEKPVCGTTYKVLKEIVERV
FQSNYFDSTHNHQNGLCEEEEAASAPAVEDQVPEAEPEPAEEYTEQSEVESTEYVNRQFM
AETQFTSGEKEQVDEWTVETVEVVNSLQQQPQAASPSVPEPHSLTPVAQADPLVRRQRVQ
DLMAQMQGPYNFIQDSMLDFENQTLDPAIVSAQPMNPTQNMDMPQLVCPPVHSESRLAQP
NQVPVQPEATQVPLVSSTSEGYTASQPLYQPSHATEQRPQKEPIDQIQATISLNTDQTTA
SSSLPAASQPQVFQAGTSKPLHSSGINVNAAPFQSMQTVFNMNAPVPPVNEPETLKQQNQ
YQASYNQSFSSQPHQVEQTELQQEQLQTVVGTYHGSPDQSHQVTGNHQQPPQQNTGFPRS
NQPYYNSRGVSRGGSRGARGLMNGYRGPANGFRGGYDGYRPSFSNTPNSGYTQSQFSAPR
DYSGYQRDGYQQNFKRGSGQSGPRGAPRGRGGPPRPNRGMPQMNTQQVN",CAPRIN1,-,-,709aa(1-709),Q14444,DrLLPS,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0521,"[1-50],[251-251],[260-291],[417-446],[475-499],[524-709]","[2-43],[61-81],[178-188],[258-282],[311-324],[328-337],[477-491],[537-552],[555-570],[607-620],[676-704]",In vitro,0.2 µM [GLS1];|0.2 µM [GIRGL];|20 µM [CAPRIN1],30 mM NaCl,"25 mM Na2HPO4(pH 7.4), 2 mM DTT",RT,-,-,Epifluorescence microscopy,liquid,"Formation of the CAPRIN1-containing condensates was dependent on the concentration of 3'UTR-1 GLS1 mRNA (fig. S5N), and moreover, these droplets were observed to undergo fusion events (fig. S5O), characteristic of protein droplets formed by liquid-liquid phase separation. Notably, the frequency of phase droplet formation between CAPRIN1 and GLS1 mRNA was comparatively increased when full-length sense, but not antisense, GIRGL was added to these assays."
572,PMID: 33782395,RNAPS0000479,https://pubmed.ncbi.nlm.nih.gov/33782395,RNA + protein,-,-,polyrU,200–250nt,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,10-1000 µM [poly(rU)];|0.5-20 µM [N protein],0 mM NaCl,"50 mM Tris, pH 7.5",RT,-,-,Turbidity measurement,"solute, liquid","In line with this expectation, we observed robust droplet formation with homopolymeric RNA (Fig. 5A, B) under aqueous buffer conditions, both at 50 mM Tris and at a higher salt concentration of 50 mM NaCl. Turbidity assays at different concentrations of protein and poly(rU) (200–250 nucleotides) demonstrate the classical re-entrant phase behavior expected for a system undergoing heterotypic interaction"
573,PMID: 33782395,RNAPS0000479,https://pubmed.ncbi.nlm.nih.gov/33782395,RNA + protein,-,-,polyrU,200–250nt,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,10-1000 µM [poly(rU)];|0.5-20 µM [N protein],50 mM NaCl,"50 mM Tris, pH 7.5",RT,-,-,Turbidity measurement,"solute, liquid","In line with this expectation, we observed robust droplet formation with homopolymeric RNA (Fig. 5A, B) under aqueous buffer conditions, both at 50 mM Tris and at a higher salt concentration of 50 mM NaCl. Turbidity assays at different concentrations of protein and poly(rU) (200–250 nucleotides) demonstrate the classical re-entrant phase behavior expected for a system undergoing heterotypic interaction"
574,PMID: 26455390,RNAPS0000517,https://pubmed.ncbi.nlm.nih.gov/26455390,RNA + protein,-,-,yeast RNA,-,-,total RNA,yeast,"A fusion protein construct [MBP]-[FUS] with PTB residues 1-396 fused to FUS residues 1-526
MKIKTGARILALSALTTMMFSASALAKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHP
DKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYN
GKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPL
IAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKG
ETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFL
ENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFW
YAVRTAVINAASGRQTVDEALKDAQTRITKMASNDYTQQATQSYGAYPTQPGQGYSQQS
SQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",MBP-FUS,-,-,"922aa(1-396,1-526)","P02686,P35637","MBP:DrLLPS,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-a1103,http://db.phasep.pro/browse/;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-133],[134-304];[1-507],[508-512]","-;[17-104],[106-261],[371-425],[450-507]",In vitro,5 µM [MBP-FUS];|2-20 µM torula yeast RNA,150 mM NaCl,20 mM Tris-HCl pH 7.4,RT,≤ 30 min,-,Turbidity measurement,-,"We observed the greatest extent of phase separation at an RNA:FUS ratio of 0.4:1 by mass (Fig 3A).The highest concentrations of RNA led to decreased phase separation, below that of FUS without RNA."
575,PMID: 27802129,RNAPS0000518,https://pubmed.ncbi.nlm.nih.gov/27802129,RNA + protein,NCBI ID:100101736,https://www.ncbi.nlm.nih.gov/gene/100101736,ccbn1,1315nt(1-1315),UGCAGUUUGUGUAAGACAAGAGGUUGUGGAUUUCCCCUAUGAUGGCACUGAUUAUGACUCGGAGUAUGCGGCUCAAUGUGGAGAAUGUGGAACCAGGCAUGGCUGGAAGGAAAGCCGCUGUGUCCAAGCCUGUGCUGAGGCCUAGGAAUGCACUGGGUGAUAUUGGGAACCAAAUAAGCAAGGCAAAAGUUCCCCUAAAGAGAGCAACAAAAGCACUUCGCAAACCCCCUGUAGAGAAAUCGGAGAAACUGAUUGUACCAGAUGAGAAUGACCCUAAGGAAGCACAGCCCGUGCCUGAUUCUCCUAACCGAAUGGAGACUUCUGUGUGUGUAAUAGAAGAGAUACCUCCUGCUUUCUCCAGUGCCCUAAUUCCAAUGAAAGAUGUAGAUGCAGAAGAUUCAGACAACCCAAUGCUGUGCAGUGACUAUGUGAAGGACAUCUACUGUUAUCUUAGGAACAUGGAGGCUAGACAAGCAAUCAGGCCACACUAUCUAGAUGGUCAGGAGAUCAAUGGAAACAUGAGGGCCAUAUUGGUAGACUGGCUUGUGCAGGUCCAUCUGAGGUUUAAACUGCUGCAGGAGACCAUGUCUAUGACCAUAGCUAUUCUGGAUCGUUUUCUGCAGGAAAAUCCUGUUCCCAAGAAACUGUUGCAGCUGGCUGGUGUGAGCGCAAUGUUCAUUGCAUGCAAAUAUGAAGAGAUCUAUUGUCCAACAAUUGGUGACUUUGCCUUUGUCACUGACCACACUUACACAAAGUCCCAAAUCAGAAACAUGGAAAUGCAAAUCCUUAGAGUUCUCAAAUUUGACAUUGGGAGGCCACUGCCACUGCAUUUCUUGAGAAGAGCAUCUAAAAUUGGGGAGGUGGACUCUGUACAUCACACACUGGCUAAAUACCUAAUAGAGCUGGUUAUGACAGACUAUGACAUGGUGCACGUACCUCCCUCCCAGUUGGCGGCAGCAGCUUUCUGUUUGGCAAUGAAGAUUCUUAAUAGUGGAGAAUGGACUCCUGUUCUUGAGCACUACAUGGCUUAUAAAGAGAGUUCCCUUAUGCCAGUCAUGCAGCACAUCGCAAAGAAUAUUGUAAAGGUCAAUGGAGGACACACAAAGUUCCUGUCUGUAAAAAGCAAAUACAGCAGCAGUCGACAGAUGAAGGUCAGCUGCCUGCCCCAUCUGAAGUCUGAGCUUGUGGAAAGCCUGGCAAAAGCUGCAUCAUAAGACUCCUGUUUAUAACACUUUUUACCAAUGCUCUUAACUGUAUUUUAUCCUUUUAAUAAAGAUUAUUUUAAGUGUGAAAAAAAAAAAAAAAAAAAAAAAAA,mRNA,Xenopus tropicalis,"tr|F7AUA0|F7AUA0_XENTR Cytoplasmic polyadenylation element-binding protein 4 OS=Xenopus tropicalis OX=8364 GN=cpeb4 PE=3 SV=4
MGDYGFGVLVQNNTGNKSAFPVRFHPHLQPPHHHQNTTPSPAAFINNTAANGSNAGSAWL
FPAPAAHNIQDEILGSEKSKSQQQQEQQESLEKQQLSPSQSQEAGILPDPEKVKSEENQG
DSSSENGNGKDKIRIESPVLTGFDYQEASGLGSSNQTLTSSASPLTGFSNWSAAIAPSSS
TMINEDASFFHQGGVPAASANNGALLFQNFPHHVSPGFGGSFSPQIGPLSQHHPHHPHFQ
HHHNQHQQQRRSPASPHPPPFTHRNAGFNQLPHLANNLNKPPSPWSSYQSPSPTPSSSWS
PGGSGYGGWGGSQGRDHRRGLNGGMPPLNSISPLKKNFGNNHIQLQKYGRPNSAFAPKSW
MDDSLNRADNIFPFADRTRAFDMHSLESSLIDIMRAENDSLKGQSSLFPMEDGFLDDGRS
DQPLHSGLGSPHCFPHQNGERVERYSRKVFVGGLPPDIDEDEITASFRRFGPLIVDWPHK
AESKSYFPPKGYAFLLFQDESSVQALIDACIEEDGKLYLCVSSPTIKDKPVQIRPWNLSD
SDFVMDGSQPLDPRKTIFVGGVPRPLRAVELAMIMDRLYGGVCYAGIDTDPELKYPKGAG
RVAFSNQQSYIAAISARFVQLQHGEIDKRVEVKPYVLDDQLCDECQGARCSGKFAPFFCA
NVTCLQYYCEYCWAAIHSRAGREFHKPLVKEGGDRPRHISFRWN",cpeb4,-,-,704aa(1-704),F7AUA0,-,-,-,[7-15],In vitro,4 µl [xCPEB4];|20 µg tRNA,-,-,RT,> 75 min,other_molecular: 200 μM ATP,-,-,"When tested for radiolabelled RNA binding, the membrane-bound FL-xCPEB4 was able to specifically retain the B1 RNA, but not the B1-123. This RNA-binding capacity of the liquid-like droplets required the RBD, as the NTD on its own did not retain the radiolabelled probe."
576,PMID: 31171700,RNAPS0000521,https://pubmed.ncbi.nlm.nih.gov/31171700,RNA + protein,NCBI ID:820229,https://www.ncbi.nlm.nih.gov/gene/820229,CAT7,2725nt(1-2725),CUGUUUCACCUUGUGUCUGAGCUGGUCUGAAGGCUGGUUGUUCAGACUGAGCUUCCUGCCUGCCUGUACCCCGCCAACAGCUUCAGAAGAAGGAGCAGCCCCUGGGUGCGUCCACUUUCUGGGCACGUGAGGUUGGGCCUUGGCCGCCUGAGCCCUUGAGUUGGUCACUUGAACCUUGGGAAUAUUGAGAUUAUAUUCUCCUGCCUUUUAAAAAGAUGGACUUCAGCAGAAAUCUUUAUGAUAUUGGGGAACAACUGGACAGUGAAGAUCUGGCCUCCCUCAAGUUCCUGAGCCUGGACUACAUUCCGCAAAGGAAGCAAGAACCCAUCAAGGAUGCCUUGAUGUUAUUCCAGAGACUCCAGGAAAAGAGAAUGUUGGAGGAAAGCAAUCUGUCCUUCCUGAAGGAGCUGCUCUUCCGAAUUAAUAGACUGGAUUUGCUGAUUACCUACCUAAACACUAGAAAGGAGGAGAUGGAAAGGGAACUUCAGACACCAGGCAGGGCUCAAAUUUCUGCCUACAGGGUCAUGCUCUAUCAGAUUUCAGAAGAAGUGAGCAGAUCAGAAUUGAGGUCUUUUAAGUUUCUUUUGCAAGAGGAAAUCUCCAAAUGCAAACUGGAUGAUGACAUGAACCUGCUGGAUAUUUUCAUAGAGAUGGAGAAGAGGGUCAUCCUGGGAGAAGGAAAGUUGGACAUCCUGAAAAGAGUCUGUGCCCAAAUCAACAAGAGCCUGCUGAAGAUAAUCAACGACUAUGAAGAAUUCAGCAAAGGGGAGGAGUUGUGUGGGGUAAUGACAAUCUCGGACUCUCCAAGAGAACAGGAUAGUGAAUCACAGACUUUGGACAAAGUUUACCAAAUGAAAAGCAAACCUCGGGGAUACUGUCUGAUCAUCAACAAUCACAAUUUUGCAAAAGCACGGGAGAAAGUGCCCAAACUUCACAGCAUUAGGGACAGGAAUGGAACACACUUGGAUGCAGGGGCUUUGACCACGACCUUUGAAGAGCUUCAUUUUGAGAUCAAGCCCCACGAUGACUGCACAGUAGAGCAAAUCUAUGAGAUUUUGAAAAUCUACCAACUCAUGGACCACAGUAACAUGGACUGCUUCAUCUGCUGUAUCCUCUCCCAUGGAGACAAGGGCAUCAUCUAUGGCACUGAUGGACAGGAGGCCCCCAUCUAUGAGCUGACAUCUCAGUUCACUGGUUUGAAGUGCCCUUCCCUUGCUGGAAAACCCAAAGUGUUUUUUAUUCAGGCUUGUCAGGGGGAUAACUACCAGAAAGGUAUACCUGUUGAGACUGAUUCAGAGGAGCAACCCUAUUUAGAAAUGGAUUUAUCAUCACCUCAAACGAGAUAUAUCCCGGAUGAGGCUGACUUUCUGCUGGGGAUGGCCACUGUGAAUAACUGUGUUUCCUACCGAAACCCUGCAGAGGGAACCUGGUACAUCCAGUCACUUUGCCAGAGCCUGAGAGAGCGAUGUCCUCGAGGCGAUGAUAUUCUCACCAUCCUGACUGAAGUGAACUAUGAAGUAAGCAACAAGGAUGACAAGAAAAACAUGGGGAAACAGAUGCCUCAGCCUACUUUCACACUAAGAAAAAAACUUGUCUUCCCUUCUGAUUGAUGGUGCUAUUUUGUUUGUUUUGUUUUGUUUUGUUUUUUUGAGACAGAAUCUCGCUCUGUCGCCCAGGCUGGAGUGCAGUGGCGUGAUCUCGGCUCACCGCAAGCUCCGCCUCCCGGGUUCAGGCCAUUCUCCUGCCUCAGCCUCCCGAGUAGCUGGGACUACAGGGGCCCGCCACCACACCUGGCUAAUUUUUUAAAAAUAUUUUUAGUAGAGACAGGGUUUCACUGUGUUAGCCAGGGUGGUCUUGAUCUCCUGACCUCGUGAUCCACCCACCUCGGCCUCCCAAAGUGCUGGGAUUACAGGCGUGAGCCACCGCGCCUGGCCGAUGGUACUAUUUAGAUAUAACACUAUGUUUAUUUACUAAUUUUCUAGAUUUUCUACUUUAUUAAUUGUUUUGCACUUUUUUAUAAGAGCUAAAGUUAAAUAGGAUAUUAACAACAAUAACACUGUCUCCUUUCUCUUAUGCUUAAGGCUUUGGGAAUGUUUUUAGCUGGUGGCAAUAAAUACCAGACACGUACAAAAUCCAGCUAUGAAUAUAGAGGGCUUAUGAUUCAGAUUGUUAUCUAUCAACUAUAAGCCCACUGUUAAUAUUCUAUUAACUUUAAUUCUCUUUCAAAGCUAAAUUCCACACUACCACAUUAAAAAAAUUAGAAAGUAGCCACGUAUGGUGGCUCAUGUCUAUAAUCCCAGCACUUUGGGAGGUUGAGGUGGGAGGAUUGCUUGAACCCAAGAGGUCAAGGCUGCAGUGAGCCAUGUUCACACCGCUGCACUCAAGCUUGGGUGACAGAACAAGACCCCGUCUCAAAAAAAAUUUUUUUUUUAAUAAAACAAAAUUUGUUUGAAAUCUUUUAAAAAUUCAAAUGAUUUUUACAAGUUUUAAAUAAGCUCUCCCCAAACUUGCUUUAUGCCUUCUUAUUGCUUUUAUGAUAUAUAUAUGCUUGGCUAACUAUAUUUGCUUUUUGCUAACAAUGCUCUGGGGUCUUUUUAUGCAUUUGCAUUUGCUCUUUCAUCUCUGCUUGGAUUAUUUUAAAUCAUUAGGAAUUAAGUUAUCUUUAAAAUUUAAGUAUCUUUUUUCAAAAACAUUUUUUAAUAGAAUAAAAUAUAAUUUGAUCUUA,mRNA,Homo sapiens,"sp|O43663|PRC1_HUMAN Protein regulator of cytokinesis 1 OS=Homo sapiens OX=9606 GN=PRC1 PE=1 SV=2
MRRSEVLAEESIVCLQKALNHLREIWELIGIPEDQRLQRTEVVKKHIKELLDMMIAEEES
LKERLIKSISVCQKELNTLCSELHVEPFQEEGETTILQLEKDLRTQVELMRKQKKERKQE
LKLLQEQDQELCEILCMPHYDIDSASVPSLEELNQFRQHVTTLRETKASRREEFVSIKRQ
IILCMEALDHTPDTSFERDVVCEDEDAFCLSLENIATLQKLLRQLEMQKSQNEAVCEGLR
TQIRELWDRLQIPEEEREAVATIMSGSKAKVRKALQLEVDRLEELKMQNMKKVIEAIRVE
LVQYWDQCFYSQEQRQAFAPFCAEDYTESLLQLHDAEIVRLKNYYEVHKELFEGVQKWEE
TWRLFLEFERKASDPNRFTNRGGNLLKEEKQRAKLQKMLPKLEEELKARIELWEQEHSKA
FMVNGQKFMEYVAEQWEMHRLEKERAKQERQLKNKKQTETEMLYGSAPRTPSKRRGLAPN
TPGKARKLNTTTMSNATANSSIRPIFGGTVYHSPVSRLPPSGSKPVAASTCSGKKTPRTG
RHGANKENLELNGSILSGGYPGSAPLQRNFSINSVASTYSEFAKDPSLSDSSTVGLQREL
SKASKSDATSGILNSTNIQS",PRC1,-,-,620aa(1-620),O43663,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0213,http://db.phasep.pro/browse/","[446-466],[467-620]","[107-131],[385-405],[438-458],[489-501]",In vitro,6.3 µM [mEGFP-PRC1];|0.3 µM CAT7 RNA,"100 mM KCl,1 mM MgSO4",20 mM HEPES pH 7.9,RT,-,-,Fluorescence microscopy,liquid,"We tested whether ligands of PRC1, including DNA, RNA, and nucleosomal arrays, could incorporate into PRC1 condensates in vitro. We also included Cy5-labeled 2.5-kb DNA alone as well as Cy5-labeled CAT7 RNA shown previously to associate with PRC1. All four ligands were incorporated into condensates formed by mEGFP-CBX2 + RING1b (Fig. 6A) and mEGFP-PRC1 (Fig. 6B), whereas free Cy5 dye or purified mCherry protein was not found within the condensate phase."
577,PMID: 31437398,RNAPS0000523,https://pubmed.ncbi.nlm.nih.gov/31437398,RNA + protein,-,-,polyA,-(100-500 kDa),-,poly RNA,Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|residue=211-421,454-526
DRGGRGRGGSGGGGGGGGGGYNRSSGGYEPRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIESVADYFKQIGIIKTNKKTGQPMINLYT
DRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFSGNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQQ
GPGGGPGGSHMGGNYGDDRRGGRGGYDRGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-, ,"284aa(211-421,454-526)",P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[211-421],[454-507],[508-512]","[211-261],[371-421],[454-507]",In vitro,-,-,"25 mM Tris-HCl pH 7.5,20 mM DTT",RT,≤ 2.4 s,-,"FRAP,Trap-induced fusion",liquid,"In presence of poly(A) RNA, FUSR/G-rich LCD condensates showed almost an order of magnitude slower fusion kinetics than condensates formed by poly(U) RNA. Simultaneously, FRAP measurements revealed ~ 2-fold decrease in protein diffusion rate within poly(A)-FUSR/G-rich LCD condensates as compared to the poly(U)-FUSR/G-rich LCD droplets."
578,PMID: 31437398,RNAPS0000524,https://pubmed.ncbi.nlm.nih.gov/31437398,RNA + protein,-,-,polyU,-(600-1000 kDa),-,poly RNA,Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|residue=472-505
RRGGRGGYD RGGYRGRGGD RGGFRGGRGGGDRGG",FUS,-, ,34aa(472-505),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[472-505],[472-505],In vitro,-,-,"25 mM Tris-HCl pH 7.5,20 mM DTT",RT,≤ 1.2 s,-,"FRAP,Trap-induced fusion",liquid,"In presence of poly(A) RNA, FUSR/G-rich LCD condensates showed almost an order of magnitude slower fusion kinetics than condensates formed by poly(U) RNA. Simultaneously, FRAP measurements revealed ~ 2-fold decrease in protein diffusion rate within poly(A)-FUSR/G-rich LCD condensates as compared to the poly(U)-FUSR/G-rich LCD droplets."
579,PMID: 31437398,RNAPS0000523,https://pubmed.ncbi.nlm.nih.gov/31437398,RNA + protein,-,-,polyA,-(100-500 kDa),-,poly RNA,Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|residue=211-421,454-526
DRGGRGRGGSGGGGGGGGGGYNRSSGGYEPRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIESVADYFKQIGIIKTNKKTGQPMINLYT
DRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFSGNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQQ
GPGGGPGGSHMGGNYGDDRRGGRGGYDRGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-, ,"284aa(211-421,454-526)",P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[211-421],[454-507],[508-512]","[211-261],[371-421],[454-507]",In vitro,-,-,"25 mM Tris-HCl pH 7.5,20 mM DTT",RT,≤ 11.4 s,-,"FRAP,Trap-induced fusion",liquid,"In presence of poly(A) RNA, FUSR/G-rich LCD condensates showed almost an order of magnitude slower fusion kinetics than condensates formed by poly(U) RNA. Simultaneously, FRAP measurements revealed ~ 2-fold decrease in protein diffusion rate within poly(A)-FUSR/G-rich LCD condensates as compared to the poly(U)-FUSR/G-rich LCD droplets."
580,PMID: 31437398,RNAPS0000524,https://pubmed.ncbi.nlm.nih.gov/31437398,RNA + protein,-,-,polyU,-(600-1000 kDa),-,poly RNA,Homo sapiens,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|residue=472-505
RRGGRGGYD RGGYRGRGGD RGGFRGGRGGGDRGG",FUS,-, ,34aa(472-505),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[472-505],[472-505],In vitro,-,-,"25 mM Tris-HCl pH 7.5,20 mM DTT",RT,≤ 1.8 s,-,"FRAP,Trap-induced fusion",liquid,"In presence of poly(A) RNA, FUSR/G-rich LCD condensates showed almost an order of magnitude slower fusion kinetics than condensates formed by poly(U) RNA. Simultaneously, FRAP measurements revealed ~ 2-fold decrease in protein diffusion rate within poly(A)-FUSR/G-rich LCD condensates as compared to the poly(U)-FUSR/G-rich LCD droplets."
581,PMID: 31894537,RNAPS0000525,https://pubmed.ncbi.nlm.nih.gov/31894537,RNA + protein,-,-,Purified RNAs from HeLa cells,-,-,total RNA,Caenorhabditis elegans,"sp|Q965H3|SOP2_CAEEL Polycomb protein sop-2 OS=Caenorhabditis elegans OX=6239 GN=sop-2 PE=1 SV=2
MSSNLTSNEMSSTSAIVEPPEAVKGNERDKSTRRSTSQVVRPEKHEVENALEDQCSSSSL
PKEAQYYAKLDKKLEGKDPRSQFYEAVRLSADIFAHKFEKAVCSRQTFEPTNSIIKVLNT
AEEEMLHEKVVPLPVSSKLQYYLNRGRYDTIFDRDEQLQRTADPMADEPDHVEKRVTSIL
EQASREMEEGEVEPVFYDGSDEDQELPIDLGAMRNLQRTNKFAARSSRMAARRGGRPGYR
GAFRGAARGAPSRRPAPAAEVAPETPVAAPMAPAAPAAPATPEAAPAAEVMDTSIATEMP
QESAVDLSNVSAATEMDTSKEGEASRPTSEKKKKIRTTEMDRLMSMDLGPKDGGRVGELG
HMWPESRRRPAAPLPETPAAQPRKSLPRRAAEKKKPEDSDAAEEQEVEMEVDNDASTSTP
RNARGGRGGGNRRGSRRGQKRTSGGSGKLVEPKKEPVDEPAEKIPKRSEAAPEVPATATT
KEAPPSTSSSPPDAPATPATPASSDSRDSPRKIRAMIFSLTGSPPESETPPVLQQEQVIS
TAAPTAGRHPNIIQQVPHINRIPPQPLRRLTAPQAPPASQPEEPPVQQTVPVVKVELASA
PAPIVRDPQSTEPVPPAMPTLVENNHEATLILPPNKTSDYTRWNAQDLINWVRLLITNNV
DSTIAIMVREEFDGETLACLVLDDDFRKEVPIPYGHYKKMKIYGTEVLNHYRTEKYQADL
RKFHEELAAWKAQQR",SOP-2,-,-,735aa(1-735),Q965H3,PhaSepDB,http://db.phasep.pro/browse/,-,"[222-288],[424-447],[468-506],[572-596]",In vitro,10µM/L [SOP-2],150 mM NaCl,25 mM HEPES pH 7.5,RT,≤ 15 min,crowding agent:20% PEG-8000,FRAP,"liquid, gel","Co-addition of RNA enlarged the size of SOP-2(IDR) and SOP-2(IDR&SAM) droplets (Figs. 1J, 1K, S3A and S3B). FRAP assays showed that co-addition of RNA increased the mobility in SOP-2(IDR) droplets formed immediately after LLPS induction (Figs. 1L, 1M and S3C), while decreasing the mobility in droplets formed 15 min after induction (Figs. 1N, 1O and S3D). Fifteen minutes after induction, SOP-2(IDR) droplets were spherical, while SOP-2(IDR)/RNA droplets became irregularly shaped (Fig. S3E and S3F), indicating slow relaxation of SOP-2(IDR)/RNA droplets after fusion."
582,PMID: 32234784,RNAPS0000526,https://pubmed.ncbi.nlm.nih.gov/32234784,RNA + protein,-,-,(UG)12,24nt,UGUGUGUGUGUGUGUGUGUGUGUG,repeat RNA,-,"sp|Q14011|CIRBP_HUMAN Cold-inducible RNA-binding protein OS=Homo sapiens OX=9606 GN=CIRBP PE=1 SV=1|residue=RGG 90-137
RGYRGGSAGGRGFFRGGRGRGRGFSRGGGDRGYGGNRFESRSGGYGG",CIRBP,RGG,-,47aa(90-137),Q14011,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0652,http://db.phasep.pro/browse/",[90-137],"[90-125],[130-137]",In vitro,30 µM [CIRBP];|10 µM (UG)12 RNA,75 mM NaCl,"20 mM Na2HPO4/NaH2PO4 pH 7.5,1 mM DTT,2.5% glycerol",25℃,≤ 30 min,-,Differential interference contrast microscopy,liquid,DIC microscopy showed that CIRBPRGG formed liquid-like condensates in the presence of RNA similar to the full-length protein.
583,PMID: 32234784,RNAPS0000526,https://pubmed.ncbi.nlm.nih.gov/32234784,RNA + protein,-,-,(UG)12,24nt,UGUGUGUGUGUGUGUGUGUGUGUG,repeat RNA,-,"sp|Q14011|CIRBP_HUMAN Cold-inducible RNA-binding protein OS=Homo sapiens OX=9606 GN=CIRBP PE=1 SV=1|residue=RSY 137-172
RSGGYGGSRDYYSSRSQSGGYSDRSSGGSYRDSYDSYATHNE",CIRBP,RSY,-,46aa(137-172),Q14011,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0652,http://db.phasep.pro/browse/",[137-172],[137-167],In vitro,30 µM [CIRBP];|10 µM (UG)12 RNA,75 mM NaCl,"20 mM Na2HPO4/NaH2PO4 pH 7.5,1 mM DTT,2.5% glycerol",25℃,≤ 30 min,-,Differential interference contrast microscopy,liquid,DIC microscopy showed that CIRBPRGG formed liquid-like condensates in the presence of RNA similar to the full-length protein.
584,PMID: 32234784,RNAPS0000526,https://pubmed.ncbi.nlm.nih.gov/32234784,RNA + protein,-,-,(UG)12,24nt,UGUGUGUGUGUGUGUGUGUGUGUG,repeat RNA,-,"sp|Q14011|CIRBP_HUMAN Cold-inducible RNA-binding protein OS=Homo sapiens OX=9606 GN=CIRBP PE=1 SV=1|residue=RRM 1-67
MASDEGKLFVGGLSFDTNEQSLEQVFSKYGQISEVVVVKDRETQRSRGFGFVTFENIDDA
KDAMMAM",CIRBP,RRM,-,67aa(1-67),Q14011,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0652,http://db.phasep.pro/browse/",-,-,In vitro,30 µM [CIRBP];|10 µM (UG)12 RNA,75 mM NaCl,"20 mM Na2HPO4/NaH2PO4 pH 7.5,1 mM DTT,2.5% glycerol",25℃,≤ 30 min,-,Differential interference contrast microscopy,liquid,DIC microscopy showed that CIRBPRGG formed liquid-like condensates in the presence of RNA similar to the full-length protein.
585,PMID: 32328638,RNAPS0000527,https://pubmed.ncbi.nlm.nih.gov/32328638,RNA + protein,-,-,luciferase siRNA,24nt,GCACUCUGAUUGACAAAUACGAUU,siRNA,Xenopus tropicalis,-,fxr1,-,-,539aa(isofromA),Q5BJ56,PhaSepDB,http://db.phasep.pro/browse/,-,"[404-421],[461-496],[523-539]",In vitro,4 µM [FXR1];|10 nM luciferase RNA,150 mM KCl,"20 mM Hepes and 1 mM β-mercaptoethanol, pH 7.4",RT,> 3 h,-,Fluorescence microscopy,liquid,"We observed that in the presence of luciferase RNA, both isoforms E and A had the tendency to slowly aggregate (Fig. 6 A; and Fig. S4 A)."
586,PMID: 32328638,RNAPS0000527,https://pubmed.ncbi.nlm.nih.gov/32328638,RNA + protein,-,-,luciferase siRNA,24nt,GCACUCUGAUUGACAAAUACGAUU,siRNA,Xenopus tropicalis,-,fxr1,-,-,677aa(iosformE),Q5BJ56,PhaSepDB,http://db.phasep.pro/browse/,-,"[404-421],[461-496],[523-545],[572-582]",In vitro,4 µM [FXR1];|10 nM luciferase RNA,150 mM KCl,"20 mM Hepes and 1 mM β-mercaptoethanol, pH 7.4",RT,> 3 h,-,Fluorescence microscopy,liquid,"We observed that in the presence of luciferase RNA, both isoforms E and A had the tendency to slowly aggregate (Fig. 6 A; and Fig. S4 A)."
587,PMID: 32328638,RNAPS0000527,https://pubmed.ncbi.nlm.nih.gov/32328638,RNA + protein,-,-,luciferase siRNA,24nt,GCACUCUGAUUGACAAAUACGAUU,siRNA,Xenopus tropicalis,-,fxr1,-,-,539aa(isofromA),Q5BJ56,PhaSepDB,http://db.phasep.pro/browse/,-,"[404-421],[461-496],[523-539]",In vitro,2 µM [FXR1];|10 nM luciferase RNA,150 mM KCl,"20 mM Hepes and 1 mM β-mercaptoethanol, pH 7.4",RT,> 3 h,-,Fluorescence microscopy,liquid,"We observed that in the presence of luciferase RNA, both isoforms E and A had the tendency to slowly aggregate (Fig. 6 A; and Fig. S4 A)."
588,PMID: 32328638,RNAPS0000527,https://pubmed.ncbi.nlm.nih.gov/32328638,RNA + protein,-,-,luciferase siRNA,24nt,GCACUCUGAUUGACAAAUACGAUU,siRNA,Xenopus tropicalis,-,fxr1,-,-,677aa(iosformE),Q5BJ56,PhaSepDB,http://db.phasep.pro/browse/,-,"[404-421],[461-496],[523-545],[572-582]",In vitro,2 µM [FXR1];|10 nM luciferase RNA,150 mM KCl,"20 mM Hepes and 1 mM β-mercaptoethanol, pH 7.4",RT,> 3 h,-,Fluorescence microscopy,liquid,"We observed that in the presence of luciferase RNA, both isoforms E and A had the tendency to slowly aggregate (Fig. 6 A; and Fig. S4 A)."
589,PMID: 32328638,RNAPS0000527,https://pubmed.ncbi.nlm.nih.gov/32328638,RNA + protein,-,-,luciferase siRNA,24nt,GCACUCUGAUUGACAAAUACGAUU,siRNA,Xenopus tropicalis,-,fxr1,-,-,677aa(iosformE),Q5BJ56,PhaSepDB,http://db.phasep.pro/browse/,-,"[404-421],[461-496],[523-545],[572-582]",In vitro,4 µM [FXR1];|10 nM luciferase RNA,150 mM KCl,"20 mM Hepes and 1 mM β-mercaptoethanol, pH 7.4",RT,≤ 24h,-,Fluorescence microscopy,liquid,"We observed that in the presence of luciferase RNA, both isoforms E and A had the tendency to slowly aggregate (Fig. 6 A; and Fig. S4 A)."
590,PMID: 32328638,RNAPS0000527,https://pubmed.ncbi.nlm.nih.gov/32328638,RNA + protein,-,-,luciferase siRNA,24nt,GCACUCUGAUUGACAAAUACGAUU,siRNA,Xenopus tropicalis,-,fxr1,-,-,677aa(iosformE),Q5BJ56,PhaSepDB,http://db.phasep.pro/browse/,-,"[404-421],[461-496],[523-545],[572-582]",In vitro,2 µM [FXR1];|10 nM luciferase RNA,150 mM KCl,"20 mM Hepes and 1 mM β-mercaptoethanol, pH 7.4",RT,≤ 24h,-,Fluorescence microscopy,liquid,"We observed that in the presence of luciferase RNA, both isoforms E and A had the tendency to slowly aggregate (Fig. 6 A; and Fig. S4 A)."
591,PMID: 32359423,RNAPS0000528,https://pubmed.ncbi.nlm.nih.gov/32359423,RNA + protein,-,-,Saccharomyces cerevisiae tRNA,-,-,tRNA,Saccharomyces cerevisiae,"sp|P06634|DED1_YEAST ATP-dependent RNA helicase DED1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DED1 PE=1 SV=2
MAELSEQVQNLSINDNNENGYVPPHLRGKPRSARNNSSNYNNNNGGYNGGRGGGSFFSNN
RRGGYGNGGFFGGNNGGSRSNGRSGGRWIDGKHVPAPRNEKAEIAIFGVPEDPNFQSSGI
NFDNYDDIPVDASGKDVPEPITEFTSPPLDGLLLENIKLARFTKPTPVQKYSVPIVANGR
DLMACAQTGSGKTGGFLFPVLSESFKTGPSPQPESQGSFYQRKAYPTAVIMAPTRELATQ
IFDEAKKFTYRSWVKACVVYGGSPIGNQLREIERGCDLLVATPGRLNDLLERGKISLANV
KYLVLDEADRMLDMGFEPQIRHIVEDCDMTPVGERQTLMFSATFPADIQHLARDFLSDYI
FLSVGRVGSTSENITQKVLYVENQDKKSALLDLLSASTDGLTLIFVETKRMADQLTDFLI
MQNFRATAIHGDRTQSERERALAAFRSGAATLLVATAVAARGLDIPNVTHVINYDLPSDV
DDYVHRIGRTGRAGNTGLATAFFNSENSNIVKGLHEILTEANQEVPSFLKDAMMSAPGSR
SNSRRGGFGRNNNRDYRKAGGASAGGWGSSRSRDNSFRGGSGWGSDSKSSGWGNSGGSNN
SSWW",DED1,-,-,604aa(1-604),P06634,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0016,http://db.phasep.pro/browse/",-,"[34-87],[385-403],[449-460],[538-554],[559-570],[579-604]",In vitro,2.5 µM [DED1];|45 ng/µL tRNA,200 mM KCl,20 mM PIPES/KOH pH 6.8,42°C,15  min,-,Microscopy,-,"Hence, we compared Ded1p condensates formed in the presence or absence of different RNAs. tRNA and rRNA did not affect Ded1p heat-induced condensates. In contrast, condensates formed in the presence of mRNA were spherical, and a substantial mRNA fraction became insoluble."
592,PMID: 32359423,RNAPS0000529,https://pubmed.ncbi.nlm.nih.gov/32359423,RNA + protein,-,-,Saccharomyces cerevisiae rRNA,-,-,rRNA,Saccharomyces cerevisiae,"sp|P06634|DED1_YEAST ATP-dependent RNA helicase DED1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DED1 PE=1 SV=2
MAELSEQVQNLSINDNNENGYVPPHLRGKPRSARNNSSNYNNNNGGYNGGRGGGSFFSNN
RRGGYGNGGFFGGNNGGSRSNGRSGGRWIDGKHVPAPRNEKAEIAIFGVPEDPNFQSSGI
NFDNYDDIPVDASGKDVPEPITEFTSPPLDGLLLENIKLARFTKPTPVQKYSVPIVANGR
DLMACAQTGSGKTGGFLFPVLSESFKTGPSPQPESQGSFYQRKAYPTAVIMAPTRELATQ
IFDEAKKFTYRSWVKACVVYGGSPIGNQLREIERGCDLLVATPGRLNDLLERGKISLANV
KYLVLDEADRMLDMGFEPQIRHIVEDCDMTPVGERQTLMFSATFPADIQHLARDFLSDYI
FLSVGRVGSTSENITQKVLYVENQDKKSALLDLLSASTDGLTLIFVETKRMADQLTDFLI
MQNFRATAIHGDRTQSERERALAAFRSGAATLLVATAVAARGLDIPNVTHVINYDLPSDV
DDYVHRIGRTGRAGNTGLATAFFNSENSNIVKGLHEILTEANQEVPSFLKDAMMSAPGSR
SNSRRGGFGRNNNRDYRKAGGASAGGWGSSRSRDNSFRGGSGWGSDSKSSGWGNSGGSNN
SSWW",DED1,-,-,604aa(1-604),P06634,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0016,http://db.phasep.pro/browse/",-,"[34-87],[385-403],[449-460],[538-554],[559-570],[579-604]",In vitro,2.5 µM [DED1];|45 ng/µL rRNA,200 mM KCl,20 mM PIPES/KOH pH 6.8,42°C,15  min,-,Microscopy,-,"Hence, we compared Ded1p condensates formed in the presence or absence of different RNAs. tRNA and rRNA did not affect Ded2p heat-induced condensates. In contrast, condensates formed in the presence of mRNA were spherical, and a substantial mRNA fraction became insoluble."
593,PMID: 32359423,RNAPS0000530,https://pubmed.ncbi.nlm.nih.gov/32359423,RNA + protein,-,-,Saccharomyces cerevisiae mRNA,-,-,mRNA,Saccharomyces cerevisiae,"sp|P06634|DED1_YEAST ATP-dependent RNA helicase DED1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DED1 PE=1 SV=2
MAELSEQVQNLSINDNNENGYVPPHLRGKPRSARNNSSNYNNNNGGYNGGRGGGSFFSNN
RRGGYGNGGFFGGNNGGSRSNGRSGGRWIDGKHVPAPRNEKAEIAIFGVPEDPNFQSSGI
NFDNYDDIPVDASGKDVPEPITEFTSPPLDGLLLENIKLARFTKPTPVQKYSVPIVANGR
DLMACAQTGSGKTGGFLFPVLSESFKTGPSPQPESQGSFYQRKAYPTAVIMAPTRELATQ
IFDEAKKFTYRSWVKACVVYGGSPIGNQLREIERGCDLLVATPGRLNDLLERGKISLANV
KYLVLDEADRMLDMGFEPQIRHIVEDCDMTPVGERQTLMFSATFPADIQHLARDFLSDYI
FLSVGRVGSTSENITQKVLYVENQDKKSALLDLLSASTDGLTLIFVETKRMADQLTDFLI
MQNFRATAIHGDRTQSERERALAAFRSGAATLLVATAVAARGLDIPNVTHVINYDLPSDV
DDYVHRIGRTGRAGNTGLATAFFNSENSNIVKGLHEILTEANQEVPSFLKDAMMSAPGSR
SNSRRGGFGRNNNRDYRKAGGASAGGWGSSRSRDNSFRGGSGWGSDSKSSGWGNSGGSNN
SSWW",DED1,-,-,604aa(1-604),P06634,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0016,http://db.phasep.pro/browse/",-,"[34-87],[385-403],[449-460],[538-554],[559-570],[579-604]",In vitro,2.5 µM [DED1];|45 ng/µL mRNA,200 mM KCl,20 mM PIPES/KOH pH 6.8,42°C,15  min,-,Microscopy,liquid,"Hence, we compared Ded1p condensates formed in the presence or absence of different RNAs. tRNA and rRNA did not affect Ded3p heat-induced condensates. In contrast, condensates formed in the presence of mRNA were spherical, and a substantial mRNA fraction became insoluble."
594,PMID: 32359423,RNAPS0000530,https://pubmed.ncbi.nlm.nih.gov/32359423,RNA + protein,-,-,Saccharomyces cerevisiae mRNA,-,-,mRNA,Saccharomyces cerevisiae,"sp|P06634|DED1_YEAST ATP-dependent RNA helicase DED1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DED1 PE=1 SV=2
MAELSEQVQNLSINDNNENGYVPPHLRGKPRSARNNSSNYNNNNGGYNGGRGGGSFFSNN
RRGGYGNGGFFGGNNGGSRSNGRSGGRWIDGKHVPAPRNEKAEIAIFGVPEDPNFQSSGI
NFDNYDDIPVDASGKDVPEPITEFTSPPLDGLLLENIKLARFTKPTPVQKYSVPIVANGR
DLMACAQTGSGKTGGFLFPVLSESFKTGPSPQPESQGSFYQRKAYPTAVIMAPTRELATQ
IFDEAKKFTYRSWVKACVVYGGSPIGNQLREIERGCDLLVATPGRLNDLLERGKISLANV
KYLVLDEADRMLDMGFEPQIRHIVEDCDMTPVGERQTLMFSATFPADIQHLARDFLSDYI
FLSVGRVGSTSENITQKVLYVENQDKKSALLDLLSASTDGLTLIFVETKRMADQLTDFLI
MQNFRATAIHGDRTQSERERALAAFRSGAATLLVATAVAARGLDIPNVTHVINYDLPSDV
DDYVHRIGRTGRAGNTGLATAFFNSENSNIVKGLHEILTEANQEVPSFLKDAMMSAPGSR
SNSRRGGFGRNNNRDYRKAGGASAGGWGSSRSRDNSFRGGSGWGSDSKSSGWGNSGGSNN
SSWW",DED1,-,-,604aa(1-604),P06634,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0016,http://db.phasep.pro/browse/",-,"[34-87],[385-403],[449-460],[538-554],[559-570],[579-604]",In vitro,2.5 µM [DED1];|45 ng/µL mRNA,"200 mM KCl,1 M NaCl",20 mM PIPES/KOH pH 6.8,42°C,5  min,-,Microscopy,solute,"Importantly, hardened mRNA-containing condensates dissolved upon increasing the salt concentration."
595,PMID: 32587965,RNAPS0000531,https://pubmed.ncbi.nlm.nih.gov/32587965,RNA + protein,-,-,SARS-CoV-2 virus RNA,-,-,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,4 µM [SARS-CoV-2 N protein];|0.3-7.5 nM [SARS-CoV-2 virus RNA],150 nM NaCl,20 mM Tris pH 7.5,37°C,≤ 20 min,-,Fluorescence microscopy,liquid,Pure N-protein demixed into droplets on its own and phase separation was enhanced by full-length genomic SARS-CoV-2 RNA (Figure 1B).
596,PMID: 34159327,RNAPS0000532,https://pubmed.ncbi.nlm.nih.gov/34159327,RNA + protein,-,-,SARS-CoV-2 virus RNA,267nt (5′UTR),GGGUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAG,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,15-50nM [SARS-CoV-2];|3.6 µM [SARS-CoV-2 N protein],150 mM NaCl,20 mM Tris pH 7.5,37°C,20h,-,Fluorescence microscopy,liquid,"We tested 1-1000nt, 1-267nt (the 5′UTR), 1-500nt, and 500-1000nt fragments at either 15, 25, or 50nM RNA and 3.6µM protein. All tested fragments could drive N-protein LLPS, however some fragments drove LLPS more readily (1-500 or 1-1000)."
597,PMID: 34159327,RNAPS0000533,https://pubmed.ncbi.nlm.nih.gov/34159327,RNA + protein,-,-,SARS-CoV-2 virus RNA,501nt(500-1000),GGGCACCUCAUGGUCAUGUUAUGGUUGAGCUGGUAGCAGAACUCGAAGGCAUUCAGUACGGUCGUAGUGGUGAGACACUUGGUGUCCUUGUCCCUCAUGUGGGCGAAAUACCAGUGGCUUACCGCAAGGUUCUUCUUCGUAAGAACGGUAAUAAAGGAGCUGGUGGCCAUAGUUACGGCGCCGAUCUAAAGUCAUUUGACUUAGGCGACGAGCUUGGCACUGAUCCUUAUGAAGAUUUUCAAGAAAACUGGAACACUAAACAUAGCAGUGGUGUUACCCGUGAACUCAUGCGUGAGCUUAACGGAGGGGCAUACACUCGCUAUGUCGAUAACAACUUCUGUGGCCCUGAUGGCUACCCUCUUGAGUGCAUUAAAGACCUUCUAGCACGUGCUGGUAAAGCUUCAUGCACUUUGUCCGAACAACUGGACUUUAUUGACACUAAGAGGGGUGUAUACUGCUGCCGUGAACAUGAGCAUGAAAUUGCUUGGUACACGGAACGUUCUGGGCCCUCGA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,15-50nM [SARS-CoV-2];|3.6 µM [SARS-CoV-2 N protein],150 mM NaCl,20 mM Tris pH 7.5,37°C,20h,-,Fluorescence microscopy,liquid,"We tested 1-1000nt, 1-267nt (the 5′UTR), 1-500nt, and 500-1000nt fragments at either 15, 25, or 50nM RNA and 3.6µM protein. All tested fragments could drive N-protein LLPS, however some fragments drove LLPS more readily (1-500 or 1-1000)."
598,PMID: 34159327,RNAPS0000534,https://pubmed.ncbi.nlm.nih.gov/34159327,RNA + protein,-,-,SARS-CoV-2 virus RNA,500nt(1-500),GGGUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGC,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=45-364
LPNNTASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFP",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,15-50nM [SARS-CoV-2];|3.6 µM [SARS-CoV-2 N protein],150 mM NaCl,20 mM Tris pH 7.5,37°C,20h,-,Fluorescence microscopy,liquid,"We tested 1-1000nt, 1-267nt (the 5′UTR), 1-500nt, and 500-1000nt fragments at either 15, 25, or 50nM RNA and 3.6µM protein. All tested fragments could drive N-protein LLPS, however some fragments drove LLPS more readily (1-500 or 1-1000)."
599,PMID: 34159327,RNAPS0000535,https://pubmed.ncbi.nlm.nih.gov/34159327,RNA + protein,-,-,SARS-CoV-2 virus RNA-dsRNAa,503nt(1-500+3),GGGUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGUAUUAAUUAUACUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGACAGUAAUUAGUUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGC,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,15 nM [SARS-CoV-2];|3.6 µM [SARS-CoV-2 N protein],150 mM NaCl,20 mM Tris pH 7.5,37°C,18h,-,Fluorescence microscopy,liquid,"We converted the single-stranded, principal site sequence to dsRNA (preserving the total RNA length, by recoding the sequence 5’ and 3′ to the stem-loops to pair with the principal site (+dsRNAa). Strikingly, this type of mutation resulted in enhanced LLPS in all three sequence contexts (Fig. 1D-F), with much larger droplets forming more quickly in identical protein and RNA concentrations. We next sought to induce the formation of additional double-stranded RNA in a different way. Thus, we converted the single stranded principal site region to double-stranded RNA by forcing the single stranded region to base pair by adding complementary sequence either 5′ of the first hairpin (+dsRNAb) or 3′ of the second hairpin (+dsRNAc) which flanked the single stranded principal sites. In all three sequence contexts, this type of mutation again enhanced LLPS (Fig.1 D-F).We next asked whether addition of 10 paired nucleotides (20nt per stem-loop) of dsRNA at the base of the principal site flanking stem-loops would also promote LLPS (+dsRNAd) as this mutant would preserve the ssRNA of the principal site while creating additional structure. We observed that these extended stem-loops indeed also enhanced LLPS relative to wildtype in all three sequence contexts."
600,PMID: 34159327,RNAPS0000536,https://pubmed.ncbi.nlm.nih.gov/34159327,RNA + protein,-,-,SARS-CoV-2 virus RNA-dsRNAb,525nt(1-500+25),GGGUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCAGUAAUUAGUUAUUAAUUAUACUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGC,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,15 nM [SARS-CoV-2];|3.6 µM [SARS-CoV-2 N protein],150 mM NaCl,20 mM Tris pH 7.5,37°C,18h,-,Fluorescence microscopy,liquid,"We converted the single-stranded, principal site sequence to dsRNA (preserving the total RNA length, by recoding the sequence 5’ and 3′ to the stem-loops to pair with the principal site (+dsRNAa). Strikingly, this type of mutation resulted in enhanced LLPS in all three sequence contexts (Fig. 1D-F), with much larger droplets forming more quickly in identical protein and RNA concentrations. We next sought to induce the formation of additional double-stranded RNA in a different way. Thus, we converted the single stranded principal site region to double-stranded RNA by forcing the single stranded region to base pair by adding complementary sequence either 5′ of the first hairpin (+dsRNAb) or 3′ of the second hairpin (+dsRNAc) which flanked the single stranded principal sites. In all three sequence contexts, this type of mutation again enhanced LLPS (Fig.1 D-F).We next asked whether addition of 10 paired nucleotides (20nt per stem-loop) of dsRNA at the base of the principal site flanking stem-loops would also promote LLPS (+dsRNAd) as this mutant would preserve the ssRNA of the principal site while creating additional structure. We observed that these extended stem-loops indeed also enhanced LLPS relative to wildtype in all three sequence contexts."
601,PMID: 34159327,RNAPS0000537,https://pubmed.ncbi.nlm.nih.gov/34159327,RNA + protein,-,-,SARS-CoV-2 virus RNA-dsRNAd,543nt(1-500+43),GGGUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCGAUUGCAUCCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGGAUGCAAUCGUAUAAUUAAUAACUAAUUACUGCGAUUGCAUCUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAUGCAAUCGGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGC,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,15 nM [SARS-CoV-2];|3.6 µM [SARS-CoV-2 N protein],150 mM NaCl,20 mM Tris pH 7.5,37°C,18h,-,Fluorescence microscopy,liquid,"We converted the single-stranded, principal site sequence to dsRNA (preserving the total RNA length, by recoding the sequence 5’ and 3′ to the stem-loops to pair with the principal site (+dsRNAa). Strikingly, this type of mutation resulted in enhanced LLPS in all three sequence contexts (Fig. 1D-F), with much larger droplets forming more quickly in identical protein and RNA concentrations. We next sought to induce the formation of additional double-stranded RNA in a different way. Thus, we converted the single stranded principal site region to double-stranded RNA by forcing the single stranded region to base pair by adding complementary sequence either 5′ of the first hairpin (+dsRNAb) or 3′ of the second hairpin (+dsRNAc) which flanked the single stranded principal sites. In all three sequence contexts, this type of mutation again enhanced LLPS (Fig.1 D-F).We next asked whether addition of 10 paired nucleotides (20nt per stem-loop) of dsRNA at the base of the principal site flanking stem-loops would also promote LLPS (+dsRNAd) as this mutant would preserve the ssRNA of the principal site while creating additional structure. We observed that these extended stem-loops indeed also enhanced LLPS relative to wildtype in all three sequence contexts."
602,PMID: 34159327,RNAPS0000536,https://pubmed.ncbi.nlm.nih.gov/34159327,RNA + protein,-,-,SARS-CoV-2 virus RNA-dsRNAc,525nt(1-500+25),GGGUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGACAGUAAUUAGUUAUUAAUUAUAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGC,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,15 nM [SARS-CoV-2];|3.6 µM [SARS-CoV-2 N protein],150 mM NaCl,20 mM Tris pH 7.5,37°C,18h,-,Fluorescence microscopy,liquid,"We converted the single-stranded, principal site sequence to dsRNA (preserving the total RNA length, by recoding the sequence 5’ and 3′ to the stem-loops to pair with the principal site (+dsRNAa). Strikingly, this type of mutation resulted in enhanced LLPS in all three sequence contexts (Fig. 1D-F), with much larger droplets forming more quickly in identical protein and RNA concentrations. We next sought to induce the formation of additional double-stranded RNA in a different way. Thus, we converted the single stranded principal site region to double-stranded RNA by forcing the single stranded region to base pair by adding complementary sequence either 5′ of the first hairpin (+dsRNAb) or 3′ of the second hairpin (+dsRNAc) which flanked the single stranded principal sites. In all three sequence contexts, this type of mutation again enhanced LLPS (Fig.1 D-F).We next asked whether addition of 10 paired nucleotides (20nt per stem-loop) of dsRNA at the base of the principal site flanking stem-loops would also promote LLPS (+dsRNAd) as this mutant would preserve the ssRNA of the principal site while creating additional structure. We observed that these extended stem-loops indeed also enhanced LLPS relative to wildtype in all three sequence contexts."
603,PMID: 32637943,RNAPS0000538,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,61nt(Rsndom-10),UCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUC,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,10 µM [SARS-CoV-2 N protein];|1.25-20 µM [Rsndom-10],70 mM KCl,25 mM HEPES pH 7.5,RT,> 30 min,-,Light microscopy,liquid,"We analyzed the formation and morphology of condensates over a wide range of N protein and 5′-400 RNA concentrations (Figures S3 and ​and1C,1C, top row). At low RNA concentrations, small spherical droplets were seen at multiple N protein concentrations. Higher RNA and protein concentrations led to filamentous structures. Interestingly, at RNA concentrations approaching those of N protein, no structures were formed. Droplets formed when TRS RNA was equimolar with or in excess of N protein (Figure 1C), suggesting that these droplets depend on the binding of a single TRS RNA to each N protein. A 10-nt RNA with a random sequence displayed similar behavior but at higher concentrations, suggesting that specific binding is not entirely responsible for the effects of TRS RNA (Figure 1C)."
604,PMID: 33479198,RNAPS0000539,https://pubmed.ncbi.nlm.nih.gov/33479198,RNA + protein,-,-,"17-mer ssRNA (Lu,2021)",34nt,CGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,10µM [SARS-CoV-2 N protein];|0-10µM [17 mer RNA-3'-6-FAM],80 mM KCl,5 mM HEPES pH 7.5,20 °C,≥ 10 min,-,"Fluorescence microscopy,Differential interference contrast microscopy","liquid, solute","We generated a variant N protein with an N-terminal cysteine for specific labeling, then mixed Cy5-labeled full-length N protein with a nonspecific 17-mer ssRNA labeled with fluorescein (6-FAM). After mixing, we observed formation of spherical phase-separated condensates containing both components (Fig. 1a). Condensates formed in a specific range of RNA concentration, above which phase separation was inhibited (Fig. 1a). This so-called reentrant phase separation behavior is commonly observed in two-component systems, including RNA–protein mixtures, and is related to the ratio of binding sites in the two components in the mixture. With 10 µM N protein, maximal phase separation occurred in the presence of 5 µM 17-mer RNA (85 µM nucleotide), above which phase separation was inhibited (Fig.1a)."
605,PMID: 33479219,RNAPS0000540,https://pubmed.ncbi.nlm.nih.gov/33479219,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAE",SARS-CoV-2 Nucleoprotein,-, ,174aa(1-174),P0DTC9,-,-,"[1-40],[44-49],[174-174]",-,In vitro,2.5-40 µM [SARS-CoV-2 N protein];| 6.25 ng/µL [total RNAs],50 mM NaCl,25 mM HEPES pH 7.5,RT,15-30 min,-,Confocal microscopy,liquid,"Considering the ability of N protein to bind RNAs, we added total RNAs extracted from HeLa cells into N protein solutions. Droplets appeared with the supplement of RNAs (Fig.1i). Moreover, the size of condensates increased with higher protein concentration meanwhile their numbers decreased (Fig.1i)."
606,PMID: 33479219,RNAPS0000540,https://pubmed.ncbi.nlm.nih.gov/33479219,RNAs + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=1-174
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAE
",SARS-CoV-2 Nucleoprotein,-, ,174aa(1-174),P0DTC9,-,-,"[1-40],[44-49],[174-174]",-,In vitro,10 µM [SARS-CoV-2 N protein];|0-50 ng/µL [total RNAs],50 mM NaCl,25 mM HEPES pH 7.5,RT,15-30 min,-,Confocal microscopy,"liquid, gel, solid","Next, with protein concentration fixed at 10 μΜ along with an increasing RNA gradient, we observed that N protein condensed into droplets, then gel structure and finally solid-like entanglement (Fig. 1j), suggesting RNAs play a crucial role in this process."
607,PMID: 33479219,RNAPS0000540,https://pubmed.ncbi.nlm.nih.gov/33479219,RNA + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=1-174
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAE
",SARS-CoV-2 Nucleoprotein,-, ,174aa(1-174),P0DTC9,-,-,"[1-40],[44-49],[174-174]",-,In vitro,2.5-10 µM [SARS-CoV-2 N protein];|25 ng/µL [total RNAs],50 mM NaCl,25 mM HEPES pH 7.5,RT,15-30 min,-,Confocal microscopy,liquid,"We also labeled purified N protein with FITC and observed its assembly at different protein concentrations in the presence and absence of RNAs (Fig.1k). These results were similar to those obtained with unlabeled protein, showing dependence on the concentration of protein and the addition of RNAs."
608,PMID: 33479219,RNAPS0000540,https://pubmed.ncbi.nlm.nih.gov/33479219,RNA + protein,-,-,Hela RNA,-,-,total RNA,Hela cell line(Homo sapiens),"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=1-174
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAE
",SARS-CoV-2 Nucleoprotein,-, ,174aa(1-174),P0DTC9,-,-,"[1-40],[44-49],[174-174]",-,In vitro,10 µM [SARS-CoV-2 N protein];|6.25 ng/µL [total RNAs],50 - 500 mM NaCl,25 mM HEPES pH 7.5,RT,15-30 min,-,Confocal microscopy,liquid,"Moreover, increased salt concentration led to the dissolution of droplets (Fig. ​1l), suggesting that the process is reversible."
609,PMID: 33650968,RNAPS0000544,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:961,https://www.ncbi.nlm.nih.gov/gene/961,CD47,4194nt(3'UTR),CUGAAGUGAAGUGAUGGACUCCGAUUUGGAGAGUAGUAAGACGUGAAAGGAAUACACUUGUGUUUAAGCACCAUGGCCUUGAUGAUUCACUGUUGGGGAGAAGAAACAAGAAAAGUAACUGGUUGUCACCUAUGAGACCCUUACGUGAUUGUUAGUUAAGUUUUUAUUCAAAGCAGCUGUAAUUUAGUUAAUAAAAUAAUUAUGAUCUAUGUUGUUUGCCCAAUUGAGAUCCAGUUUUUUGUUGUUAUUUUUAAUCAAUUAGGGGCAAUAGUAGAAUGGACAAUUUCCAAGAAUGAUGCCUUUCAGGUCCUAGGGCCUCUGGCCUCUAGGUAACCAGUUUAAAUUGGUUCAGGGUGAUAACUACUUAGCACUGCCCUGGUGAUUACCCAGAGAUAUCUAUGAAAACCAGUGGCUUCCAUCAAACCUUUGCCAACUCAGGUUCACAGCAGCUUUGGGCAGUUAUGGCAGUAUGGCAUUAGCUGAGAGGUGUCUGCCACUUCUGGGUCAAUGGAAUAAUAAAUUAAGUACAGGCAGGAAUUUGGUUGGGAGCAUCUUGUAUGAUCUCCGUAUGAUGUGAUAUUGAUGGAGAUAGUGGUCCUCAUUCUUGGGGGUUGCCAUUCCCACAUUCCCCCUUCAACAAACAGUGUAACAGGUCCUUCCCAGAUUUAGGGUACUUUUAUUGAUGGAUAUGUUUUCCUUUUAUUCACAUAACCCCUUGAAACCCUGUCUUGUCCUCCUGUUACUUGCUUCUGCUGUACAAGAUGUAGCACCUUUUCUCCUCUUUGAACAUGGUCUAGUGACACGGUAGCACCAGUUGCAGGAAGGAGCCAGACUUGUUCUCAGAGCACUGUGUUCACACUUUUCAGCAAAAAUAGCUAUGGUUGUAACAUAUGUAUUCCCUUCCUCUGAUUUGAAGGCAAAAAUCUACAGUGUUUCUUCACUUCUUUUCUGAUCUGGGGCAUGAAAAAAGCAAGAUUGAAAUUUGAACUAUGAGUCUCCUGCAUGGCAACAAAAUGUGUGUCACCAUCAGGCCAACAGGCCAGCCCUUGAAUGGGGAUUUAUUACUGUUGUAUCUAUGUUGCAUGAUAAACAUUCAUCACCUUCCUCCUGUAGUCCUGCCUCGUACUCCCCUUCCCCUAUGAUUGAAAAGUAAACAAAACCCACAUUUCCUAUCCUGGUUAGAAGAAAAUUAAUGUUCUGACAGUUGUGAUCGCCUGGAGUACUUUUAGACUUUUAGCAUUCGUUUUUUACCUGUUUGUGGAUGUGUGUUUGUAUGUGCAUACGUAUGAGAUAGGCACAUGCAUCUUCUGUAUGGACAAAGGUGGGGUACCUACAGGAGAGCAAAGGUUAAUUUUGUGCUUUUAGUAAAAACAUUUAAAUACAAAGUUCUUUAUUGGGUGGAAUUAUAUUUGAUGCAAAUAUUUGAUCACUUAAAACUUUUAAAACUUCUAGGUAAUUUGCCACGCUUUUUGACUGCUCACCAAUACCCUGUAAAAAUACGUAAUUCUUCCUGUUUGUGUAAUAAGAUAUUCAUAUUUGUAGUUGCAUUAAUAAUAGUUAUUUCUUAGUCCAUCAGAUGUUCCCGUGUGCCUCUUUUAUGCCAAAUUGAUUGUCAUAUUUCAUGUUGGGACCAAGUAGUUUGCCCAUGGCAAACCUAAAUUUAUGACCUGCUGAGGCCUCUCAGAAAACUGAGCAUACUAGCAAGACAGCUCUUCUUGAAAAAAAAAAUAUGUAUACACAAAUAUAUACGUAUAUCUAUAUAUACGUAUGUAUAUACACACAUGUAUAUUCUUCCUUGAUUGUGUAGCUGUCCAAAAUAAUAACAUAUAUAGAGGGAGCUGUAUUCCUUUAUACAAAUCUGAUGGCUCCUGCAGCACUUUUUCCUUCUGAAAAUAUUUACAUUUUGCUAACCUAGUUUGUUACUUUAAAAAUCAGUUUUGAUGAAAGGAGGGAAAAGCAGAUGGACUUGAAAAAGAUCCAAGCUCCUAUUAGAAAAGGUAUGAAAAUCUUUAUAGUAAAAUUUUUUAUAAACUAAAGUUGUACCUUUUAAUAUGUAGUAAACUCUCAUUUAUUUGGGGUUCGCUCUUGGAUCUCAUCCAUCCAUUGUGUUCUCUUUAAUGCUGCCUGCCUUUUGAGGCAUUCACUGCCCUAGACAAUGCCACCAGAGAUAGUGGGGGAAAUGCCAGAUGAAACCAACUCUUGCUCUCACUAGUUGUCAGCUUCUCUGGAUAAGUGACCACAGAAGCAGGAGUCCUCCUGCUUGGGCAUCAUUGGGCCAGUUCCUUCUCUUUAAAUCAGAUUUGUAAUGGCUCCCAAAUUCCAUCACAUCACAUUUAAAUUGCAGACAGUGUUUUGCACAUCAUGUAUCUGUUUUGUCCCAUAAUAUGCUUUUUACUCCCUGAUCCCAGUUUCUGCUGUUGACUCUUCCAUUCAGUUUUAUUUAUUGUGUGUUCUCACAGUGACACCAUUUGUCCUUUUCUGCAACAACCUUUCCAGCUACUUUUGCCAAAUUCUAUUUGUCUUCUCCUUCAAAACAUUCUCCUUUGCAGUUCCUCUUCAUCUGUGUAGCUGCUCUUUUGUCUCUUAACUUACCAUUCCUAUAGUACUUUAUGCAUCUCUGCUUAGUUCUAUUAGUUUUUUGGCCUUGCUCUUCUCCUUGAUUUUAAAAUUCCUUCUAUAGCUAGAGCUUUUCUUUCUUUCAUUCUCUCUUCCUGCAGUGUUUUGCAUACAUCAGAAGCUAGGUACAUAAGUUAAAUGAUUGAGAGUUGGCUGUAUUUAGAUUUAUCACUUUUUAAUAGGGUGAGCUUGAGAGUUUUCUUUCUUUCUGUUUUUUUUUUUUGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGACUAAUUUCACAUGCUCUAAAAACCUUCAAAGGUGAUUAUUUUUCUCCUGGAAACUCCAGGUCCAUUCUGUUUAAAUCCCUAAGAAUGUCAGAAUUAAAAUAACAGGGCUAUCCCGUAAUUGGAAAUAUUUCUUUUUUCAGGAUGCUAUAGUCAAUUUAGUAAGUGACCACCAAAUUGUUAUUUGCACUAACAAAGCUCAAAACACGAUAAGUUUACUCCUCCAUCUCAGUAAUAAAAAUUAAGCUGUAAUCAACCUUCUAGGUUUCUCUUGUCUUAAAAUGGGUAUUCAAAAAUGGGGAUCUGUGGUGUAUGUAUGGAAACACAUACUCCUUAAUUUACCUGUUGUUGGAAACUGGAGAAAUGAUUGUCGGGCAACCGUUUAUUUUUUAUUGUAUUUUAUUUGGUUGAGGGAUUUUUUUAUAAACAGUUUUACUUGUGUCAUAUUUUAAAAUUACUAACUGCCAUCACCUGCUGGGGUCCUUUGUUAGGUCAUUUUCAGUGACUAAUAGGGAUAAUCCAGGUAACUUUGAAGAGAUGAGCAGUGAGUGACCAGGCAGUUUUUCUGCCUUUAGCUUUGACAGUUCUUAAUUAAGAUCAUUGAAGACCAGCUUUCUCAUAAAUUUCUCUUUUUGAAAAAAAGAAAGCAUUUGUACUAAGCUCCUCUGUAAGACAACAUCUUAAAUCUUAAAAGUGUUGUUAUCAUGACUGGUGAGAGAAGAAAACAUUUUGUUUUUAUUAAAUGGAGCAUUAUUUACAAAAAGCCAUUGUUGAGAAUUAGAUCCCACAUCGUAUAAAUAUCUAUUAACCAUUCUAAAUAAAGAGAACUCCAGUGUUGCUAUGUGCAAGAUCCUCUCUUGGAGCUUUUUUGCAUAGCAAUUAAAGGUGUGCUAUUUGUCAGUAGCCAUUUUUUUGCAGUGAUUUGAAGACCAAAGUUGUUUUACAGCUGUGUUACCGUUAAAGGUUUUUUUUUUUAUAUGUAUUAAAUCAAUUUAUCACUGUUUAAAGCUUUGAAUAUCUGCAAUCUUUGCCAAGGUACUUUUUUAUUUAAAAAAAAACAUAACUUUGUAAAUAUUACCCUGUAAUAUUAUAUAUACUUAAUAAAACAUUUUAAGCUAUUUUGUUGGGCUAUUUCUAUUGCUGCUACAGCAGACCACAAGCACAUUUCUGAAAAAUUUAAUUUAUUAAUGUAUUUUUAAGUUGCUUAUAUUCUAGGUAACAAUGUAAAGAAUGAUUUAAAAUAUUAAUUAUGAAUUUUUUGAGUAUAAUACCCAAUAAGCUUUUAAUUAGAGCAGAGUUUUAAUUAAAAGUUUUAAAUCAGUC,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|3-200nM[CD47 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,2 h;16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,"However, when we added 30UTRs of TIS11B target mRNAs, including CD47, CD274 (PD-L1) or ELAVL1 (HuR) (Ma and Mayr, 2018), we observed formation of mesh-like FUS-TIS condensates (Figure 2A). "
610,PMID: 33650968,RNAPS0000545,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:1994,https://www.ncbi.nlm.nih.gov/gene/1994,ELAVL1,4909nt(3'UTR),-,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|3-200nM[ELAVL1 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,2 h;16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,"However, when we added 30UTRs of TIS11B target mRNAs, including CD47, CD274 (PD-L1) or ELAVL1 (HuR) (Ma and Mayr, 2018), we observed formation of mesh-like FUS-TIS condensates (Figure 2A). "
611,PMID: 33650968,RNAPS0000546,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:29126,https://www.ncbi.nlm.nih.gov/gene/29126,CD274,2705nt(3'UTR),-,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|5-500nM[CD274 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,2 h;16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,"However, when we added 30UTRs of TIS11B target mRNAs, including CD47, CD274 (PD-L1) or ELAVL1 (HuR) (Ma and Mayr, 2018), we observed formation of mesh-like FUS-TIS condensates (Figure 2A). "
612,PMID: 33650968,RNAPS0000547,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:2521,https://www.ncbi.nlm.nih.gov/gene/2521,FUS,1814nt(3'UTR),UUAGCCUGGCUCCCCAGGUUCUGGAACAGCUUUUUGUCCUGUACCCAGUGUUACCCUCGUUAUUUUGUAACCUUCCAAUUCCUGAUCACCCAAGGGUUUUUUUGUGUCGGACUAUGUAAUUGUAACUAUACCUCUGGUUCCCAUUAAAAGUGACCAUUUUAGUUAAAUUUUGUUCCUCUUCCCCCUUUUCACUUUCCUGGAAGAUCGAUGUCCCGAUCAGGAAGGUAGAGAGUUUUCCUGUUCAGAUUACCCUGCCCAGCAGGAACUGGAAUACAGUGUUCGGGGAGAAGGCCAAAUGAUAUCCUUGAGAGCAGAGAUUAAACUUUUCUGUCAUGGGGAAAGUUGGUGUAUAAAUGAGAAAUGAAGAACAUGGGAUGUCAUGAGUGUUGGCCUAAAUUUGCCCAGCUAUGGGGAAUUUUUCCUUUACCACAUUUAUUUGCAUACUGGUCUUAGUUUAUUUGCAGCAGUUUAUCCCUUUUUAAGAACUCUUUGAUCUUUUGGCCCUUUUAAUGGUGAGGCUCAAACAAACUACAUUUAAAUGGGGCAGUAUUCAGAUUUGACCAUGGUGGAGAGCGCUUAGCCACUCUGGGUCUUUCACAGGAAGGAGAGUAACUGAGUGCUGCAGGAGUUUGUGGAGUGGAGUCAGGAUCUAGGAGGUGAGUGACUCCCUUCCUAGCUGCCCUGGUGAACAGCGCUUGGGUAGAUACCUGCUAUAAGGAGACUGGUCUGGCUGGGUUACUUUCACAUCCUGCCUGUACUCAGAGGGCUUGAGGUCAUUGACAUUAUGAGAUUUUAGGCUUGAUCCCUUUUUGAUUGGAGGGUGGAAGGCCCUCCUAAGGGAAUGAUAAGUGAUAAGAGGGGGAAGGGGUUGCAGCCAAUGAGUUAAAACCUUAGAGCAGUGCUCCUCAGCCUCUUACCAUGUGGUUGUAAACUUGCACGUACCUGCCAACCAGUUAUUUAGCAUGCUUUUUAUUUUAGUUACACAGAGCGUAACAUUAACCCAAGAGCAGAAAGGUUUUAUUUACAGGGUUUUCGAACUUGGUUUGUAAGACAGCUGCCAUCACAAGCAUAGCUUACAAAUGUGCUGGGGACCCCUAAUUGGGAAGUGCUUUCCUCUCAAAUUUUUAUUUUUUAUUUUUAGAGACAGAGUCUUGCUCUGUCAUCCAGGCUGGAGUGCAGUGGCGUGAUCUCGGCUCACUGUAGCCUCUGCCUCCUGAGUUUAAGCGAUUCUCCUGCCUCAGGAGAAUCCCAGCUUCUGAGUAGCUGAGACUACAGGCGUGGGCCACCAUGCCCACCUAGUUUUUGCAUUUUUAGUGGAGGUGUGGUUUCACUGUGUUGGCCAGGCUGGUCUCUUAACUCCUGACCUCAGGUGAUCCACCUGCCUUGGCCUCCCAAAGUGCUGGAAUUACAGGCAUGAGCCGCUGCAUCUGGCCAUCCUCUCAAAUUUUCAAGUGUUCCACAAGUAUGUUCUCUACUGAAGAGUUGCUGCAUCCUUGAAUCUUGGGUGAUUUGAGGCACAGAAACUAUGACUUUAUUUUUUGAGAUGGAGUUUUGCUCUUGUUGCCCAGGCUGGAGUGCAAUGGCACGUUUUUCGGCUUACCGCAACUGCCGCCUCCUGGGUUCAAGCGAUAGCUGGGAUUACAGGCAUGCGCCACCAUGCCCAGCUAAUUUAUUUGUAUUUUUAGUAGAGACGGGGUUUCUCCAUGUUGGUCAGGCUGGUCUCGAACUCCCGACCUCAGGUGAUGUGCACACCUCAGCCUCCCAAUAAACCAUGACUUUUAAGAGGAAUAGCAGGUUUACUUCCCCUGCCAGCA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|10-500nM[FUS 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,2 h;16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,"We then added to FUS-TIS in vitro transcribed 30UTRs of mRNAs, which were recruited to FUSTIS condensates (Figure 2A). The addition of the FUS 30UTR did not change the morphology of the sphere-like condensates formed by FUS-TIS "
613,PMID: 33650968,RNAPS0000548,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:960,https://www.ncbi.nlm.nih.gov/gene/960,CD44,3069nt(3'UTR),CACCUACACCAUUAUCUUGGAAAGAAACAACCGUUGGAAACAUAACCAUUACAGGGAGCUGGGACACUUAACAGAUGCAAUGUGCUACUGAUUGUUUCAUUGCGAAUCUUUUUUAGCAUAAAAUUUUCUACUCUUUUUGUUUUUUGUGUUUUGUUCUUUAAAGUCAGGUCCAAUUUGUAAAAACAGCAUUGCUUUCUGAAAUUAGGGCCCAAUUAAUAAUCAGCAAGAAUUUGAUCGUUCCAGUUCCCACUUGGAGGCCUUUCAUCCCUCGGGUGUGCUAUGGAUGGCUUCUAACAAAAACUACACAUAUGUAUUCCUGAUCGCCAACCUUUCCCCCACCAGCUAAGGACAUUUCCCAGGGUUAAUAGGGCCUGGUCCCUGGGAGGAAAUUUGAAUGGGUCCAUUUUGCCCUUCCAUAGCCUAAUCCCUGGGCAUUGCUUUCCACUGAGGUUGGGGGUUGGGGUGUACUAGUUACACAUCUUCAACAGACCCCCUCUAGAAAUUUUUCAGAUGCUUCUGGGAGACACCCAAAGGGUGAAGCUAUUUAUCUGUAGUAAACUAUUUAUCUGUGUUUUUGAAAUAUUAAACCCUGGAUCAGUCCUUUGAUCAGUAUAAUUUUUUAAAGUUACUUUGUCAGAGGCACAAAAGGGUUUAAACUGAUUCAUAAUAAAUAUCUGUACUUCUUCGAUCUUCACCUUUUGUGCUGUGAUUCUUCAGUUUCUAAACCAGCACUGUCUGGGUCCCUACAAUGUAUCAGGAAGAGCUGAGAAUGGUAAGGAGACUCUUCUAAGUCUUCAUCUCAGAGACCCUGAGUUCCCACUCAGACCCACUCAGCCAAAUCUCAUGGAAGACCAAGGAGGGCAGCACUGUUUUUGUUUUUUGUUUUUUGUUUUUUUUUUUUGACACUGUCCAAAGGUUUUCCAUCCUGUCCUGGAAUCAGAGUUGGAAGCUGAGGAGCUUCAGCCUCUUUUAUGGUUUAAUGGCCACCUGUUCUCUCCUGUGAAAGGCUUUGCAAAGUCACAUUAAGUUUGCAUGACCUGUUAUCCCUGGGGCCCUAUUUCAUAGAGGCUGGCCCUAUUAGUGAUUUCCAAAAACAAUAUGGAAGUGCCUUUUGAUGUCUUACAAUAAGAGAAGAAGCCAAUGGAAAUGAAAGAGAUUGGCAAAGGGGAAGGAUGAUGCCAUGUAGAUCCUGUUUGACAUUUUUAUGGCUGUAUUUGUAAACUUAAACACACCAGUGUCUGUUCUUGAUGCAGUUGCUAUUUAGGAUGAGUUAAGUGCCUGGGGAGUCCCUCAAAAGGUUAAAGGGAUUCCCAUCAUUGGAAUCUUAUCACCAGAUAGGCAAGUUUAUGACCAAACAAGAGAGUACUGGCUUUAUCCUCUAACCUCAUAUUUUCUCCCACUUGGCAAGUCCUUUGUGGCAUUUAUUCAUCAGUCAGGGUGUCCGAUUGGUCCUAGAACUUCCAAAGGCUGCUUGUCAUAGAAGCCAUUGCAUCUAUAAAGCAACGGCUCCUGUUAAAUGGUAUCUCCUUUCUGAGGCUCCUACUAAAAGUCAUUUGUUACCUAAACUUAUGUGCUUAACAGGCAAUGCUUCUCAGACCACAAAGCAGAAAGAAGAAGAAAAGCUCCUGACUAAAUCAGGGCUGGGCUUAGACAGAGUUGAUCUGUAGAAUAUCUUUAAAGGAGAGAUGUCAACUUUCUGCACUAUUCCCAGCCUCUGCUCCUCCCUGUCUACCCUCUCCCCUCCCUCUCUCCCUCCACUUCACCCCACAAUCUUGAAAAACUUCCUUUCUCUUCUGUGAACAUCAUUGGCCAGAUCCAUUUUCAGUGGUCUGGAUUUCUUUUUAUUUUCUUUUCAACUUGAAAGAAACUGGACAUUAGGCCACUAUGUGUUGUUACUGCCACUAGUGUUCAAGUGCCUCUUGUUUUCCCAGAGAUUUCCUGGGUCUGCCAGAGGCCCAGACAGGCUCACUCAAGCUCUUUAACUGAAAAGCAACAAGCCACUCCAGGACAAGGUUCAAAAUGGUUACAACAGCCUCUACCUGUCGCCCCAGGGAGAAAGGGGUAGUGAUACAAGUCUCAUAGCCAGAGAUGGUUUUCCACUCCUUCUAGAUAUUCCCAAAAAGAGGCUGAGACAGGAGGUUAUUUUCAAUUUUAUUUUGGAAUUAAAUACUUUUUUCCCUUUAUUACUGUUGUAGUCCCUCACUUGGAUAUACCUCUGUUUUCACGAUAGAAAUAAGGGAGGUCUAGAGCUUCUAUUCCUUGGCCAUUGUCAACGGAGAGCUGGCCAAGUCUUCACAAACCCUUGCAACAUUGCCUGAAGUUUAUGGAAUAAGAUGUAUUCUCACUCCCUUGAUCUCAAGGGCGUAACUCUGGAAGCACAGCUUGACUACACGUCAUUUUUACCAAUGAUUUUCAGGUGACCUGGGCUAAGUCAUUUAAACUGGGUCUUUAUAAAAGUAAAAGGCCAACAUUUAAUUAUUUUGCAAAGCAACCUAAGAGCUAAAGAUGUAAUUUUUCUUGCAAUUGUAAAUCUUUUGUGUCUCCUGAAGACUUCCCUUAAAAUUAGCUCUGAGUGAAAAAUCAAAAGAGACAAAAGACAUCUUCGAAUCCAUAUUUCAAGCCUGGUAGAAUUGGCUUUUCUAGCAGAACCUUUCCAAAAGUUUUAUAUUGAGAUUCAUAACAACACCAAGAAUUGAUUUUGUAGCCAACAUUCAUUCAAUACUGUUAUAUCAGAGGAGUAGGAGAGAGGAAACAUUUGACUUAUCUGGAAAAGCAAAAUGUACUUAAGAAUAAGAAUAACAUGGUCCAUUCACCUUUAUGUUAUAGAUAUGUCUUUGUGUAAAUCAUUUGUUUUGAGUUUUCAAAGAAUAGCCCAUUGUUCAUUCUUGUGCUGUACAAUGACCACUGUUAUUGUUACUUUGACUUUUCAGAGCACACCCUUCCUCUGGUUUUUGUAUAUUUAUUGAUGGAUCAAUAAUAAUGAGGAAAGCAUGAUAUGUAUAUUGCUGAGUUGAAAGCACUUAUUGGAAAAUAUUAAAAGGCUAACAUUAAAAGACUAAAGGAAACAGA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|30-500nM[CD44 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,"liquid, gel","We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network"
614,PMID: 33650968,RNAPS0000549,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:54621,https://www.ncbi.nlm.nih.gov/gene/54621,VSIG10,3046nt(3'UTR),AGAAGAGGAUGGUCCAUGGUUGUCUUGCUCUGAAAGCUUGGAGAGCUACAUUGAAGACGAGCUCUUCAUUCAGCUUUGACUCCACCUGCACCCCUGGCGGGGGCUUGCACUAACAAUGUUUGGGUCUCAGCAAAAAACAAAACCAAGCACACACAUCUUUCCUUCCAUGUAUUGAAAAACAUUGGUUUGAUUUGCUCUAAGUUUUCCCAAUGAUGUUUAAAAGCUUUGAGAAGGAAAGCUGCUUUGGUGUCUGAGGUGCCACUUCUGCUGUGAAUCCUGGCUUUAUCCAGGUUGAUCUACUGUGAUAGAUGCUGAUUUAGAGGGAACAGAGGUCAGGGAAGCACUGGGUCUUGGUGCCUUUUGCCGCUUUUUUUUUUUUUUUUUUUUUUUUUUGAGACGGAGUCUCCCUCUAUUGCCCAGGCUGGAGUGCAAUGGCACGAUCUUGGCUCACCACAACUUCUGCCUCCCAGGUUCAAGCGAUUCUCCUGCCUCAGCCACGGCACCUUGCAAAUAUCAGCUCCUUGGAACAGGUGAAGUUCCAGGUACCAAUGCCAAUCAGAGGAAGGCAGUUUGGUUCAGGCUUUGGAGUUAGAAACACCUGAAGUUGAAUCUGGGCUCUGUUGCUUCCUUCUUUCAUGGGCUAGAGCACGACUCUUUACCUCUCUCUUGGCCUCAAUUUCCUCACCUGUAAAAUAGAUGAGGAAGCUGCUCACUUAUUAUUGUCUCGUUCUGAAAGCUUGGAAAGCUACAUCGAAGAUGAGCUCUUCAUUCAGCUUUGAUUUGACCUGUACCCCUGGUGGGGGAUUGCACUGGCAACAUUUGGGUCUCAGCAAAAAAACCAAGCACACACAUCUUUCCUUCCAUUUAUUGAAAAACAUCUUUGUAAGAUCCAUUCAUUGAAAAACAUAAUCCAUUUAUUGAAAAAUAUCUUUGUAAGAUCACCUGCUAAAUAUGAAAAUCUGACUUGAAUUUGUACUCUUUAAAGUUGCGUAUCUGCUCUAGUGGGCAGGACCUAGGGCUUAAAGGGGAACUUCCUUUCUCCAUUUCUAAGAACUGGGACUCUAAAAUGAGAAGCUGGUUGUCUGAAGUAACCCUGCAGGUGUGGUUGGGGAAGGUCUGUUUUCUUGGAUGAAGGAACUAAACUAAGCAUAUCAGAGCACUGUCUUAACCAGUUUUAUUUCCCUGGAGAUAGAAUUCUUUUAAAAAGAGUUAGGGAGCUGGUAAUAGGAAGUGCCUUUCAUUAUAACUACAUUUUGCAGAGCUUCAUAUUUAUAUACAAGCCUCCUAGGUGAUACACUGUUAGCUUGCAGACUUUCCUAUGCUUCAUUUCUCCUGUUGCUUUCAAAGAAGGCAGGAGACACGUUUAAUAACGGAGUAUCUGGUGAUAAGAAUUGCUUGGGCAAACCAGCUCAUCUGGACUCUUUCUCAGUCUUGGAAGUGGGAAGAGGAAAACUUGUUUCCUUCCUGCUUCUUAAGGAUAUUCUGAGGGUACACUGAUCAAUAACACUAAAUUUGGAAUGAAAAUACCAUGUGAUGAGUUUAGCCUGCUGAUGCUUCCAGUAGAUCCUUGUAUAGUUUCAAGAUUUAAGUUUUCCGAUUUCAUAUAAAUUUCUUAAAGUCGAGGACCUUAUAAGGGUGCAAUGGAUGUUUGCUAAAUAUGAAAAACUGACUUGAAUUUGCACUCUUUAAUGUUGCGUAUCUGCUCUAGUGGGCAGGACCUAGGGCUUAAAGGGGAACUUCCUUUCUCCAAUUCUAGGAACUGGGACUCUAAAAUGAGAAGCUGGUUGUCUGAAGUAACCCUGCAGGUGUGGUUGGGGAAGGUCUGUUUUCUUGGAUGAAGGGAUUAAACUGAGCAAAUCACUAGAAGUAUGCCCUGUCCCCUGCUCAGAACACUGGGGAGCUCAAGAGUGGGCUGCAAUGUGCACCCCUCAGGAAUAGCUGUGAAUUGCAGGUCUACUGGCUUUUUGCUUUUUGUCUUUUGCUGCAAGGUACCCCACGUACUUAACCAUUCUCAACAGUGUAAAUCAGUGUCAUUUUAGAAUGAGAUACUCAGCUUGCUUCUAAAGUCACUGAAUUACUGAGUGAGUCUCUCCUUUAGAGUCUUCGGCAACCAAAUUCCAGAAUUGAAGAGUCUACUACUCAGAGGCAACAAGAUUAAAAAAAGAAAACACAAAAACUGUUGAGGUGAAAAAAAAAAAAAACCCUAGCUAGGAACACAGAGAAUGUUUUGUAGGAUCACUGGGAUAUUUUCCACAACUUCCUCUUCUCUAGCACACACAUCUGUUGAUAGGAAAUAUUUGAGGGUUUUUCCACUACCAAAUGGGAGCUUCAUGGUCCUGGUGUCAAACACUAUAAACCUUUGACCAGCUGAGCUGUGACUGCUGUCACAUAUCUGAGUCCUGUGUGCACAGUAAUAUCCUGGGUCAGGUAAAAUCCAGGUCUUCAAGUUUUAAGGAUUUUUUGAAGAAUUCGGGCUUCUUUAAGACGAUCCAUGCCCAAAUCCACAAGCUUGUUGACAGUGGAUUACAGUUUGUGUGGCAAAGUCCAAGUUGUUACACUGUGCUUUAAAAAAAAUCUUAUCUGCAUGUAUUGUUAACUUAGAGACCAUGAGAUCUAUUUAUCAGGACCAGGAAGAUACACACUUCAGGUCCAUUGCAACUGACUUUUUUCUUGUUUUUCUCAAACCCUGGUGGAGCCUGGGAAGGGGGCCUCCACAAUUCUGUGGCUUUGAUAUUAGCCCCAAUUCUCACAAGCACAUACAAGCCCCAUAAUUGCCGCAGGAAAACACAAGAUGGAAAAUUGCAAUAACCCAUGCACUGAGACUUAGAAAAUCAUCCUUACUAGGCAAAAUGUAUUAUGAUGCAAUAAGUGCCAACUGAUAUUUCUCACGUUGGGACUGGCCAGGAACUGCUGCAAAGAAAAAUAAGCAGCUCCUUCUCCAUUAUUUACAUUUUAAGAUGUGGUGGGGGGAGGUUGGGAGAAAUUAGUUCUGAGGUUAUCAUAUGCCUUUUUUAAAAGAUAAUGGAAUAAAGCUAUUUUUAAGUAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|30-500nM[VSIG10 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,"liquid, gel","We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network"
615,PMID: 33650968,RNAPS0000550,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:1812,https://www.ncbi.nlm.nih.gov/gene/1812,DRD1,1723nt(3'UTR),ACUCGCAGAUGAAUCCUGCCACACAUGCUCAUCCCAAAAGCUAGAGGAGAUUGCUCUGGGGCUUGCUAUUAAGAAACUAAGGUACGGUGAGACUCUGAGGUGUCAGGAGAGCCCUCUGCUGCUUUCCAACACACAAUUAACUCCGUUUCCAAAUACAUUCCAGUGUAUUUUCUGUGUUGUUCAUAGUCAAUCAAACAGGGACACUACAAACAUGGGGAGCCAUAAGGGACAUGUCUUUGGCUUCAGAAUUGUUUUUAGAAAUUUAUUCUUAUCUUAGGAUUUACCAAAUAGGGCAAAGAAUCAACAGUGAACAGCUUCACUUAAAAUCAAAUUUUUCUGGGAAGAAAAUGAGAUGGGUUGAGUUUGCUGUAUACAAACAGGUGCUAACACUGUUCCCAGCAAAGUUUUCAGAUUGUAAAGGUAGGUGCAUGCCUUCAUAAAUUAUUUCUAAAACAUUAAUUGAGGCUUACAGUAGGAGUGAGAAAUUUUUUUCCAGAAUUGAGAGAUGUUUUGUUGAUAUUGGUUCUAUUUAUUUAUUGUAUAUAUGGAUAUUUUUAAUUUAUGAUAUAAUAAAUAUAUAUUUAUCAUAUUUAAUAGGAUAAAUUAAUGAGUUUUAUCCAAGACCUUACAACCACAUUUCUGGCCAUUUAACUAGCACUUUAUAAGCCAAUGAAGCAAACACACAGACUCUGUGAGAUUCUAAAUGUUCAUGUGUAACUUCUAGAAACACAGCAGAAACUGAUAGAUAAGGGAAUAAAGUUGAAAUGAUUCCUUAAAAUUCAUGGACACAGAUAAAUGCAAGGUGAGAAUUGACAAAUGCUAUAAAUGCUUUCUUUUUCUGAAAAGAUUUUGAAAAAUUUAAAAAAGUAUAGCUACUACUGUGUUCAAAACGUUUUAAAUGACAAAUGACUUUCCCAGGGGAAUUUGCAGUUCUGUAAAUAUCUUAAAUAAAAGCCAACUUAAGAAGAGCCCAGCAUUAAAUUUACGAUCUUAGGUGGUAAUGAAAAGUAUAUGCUGCUUUGUAUUUAUGUAAAAUAAUUGGCCCUCUCCAUCUUUUCUCAUUUCAUGUGUCAGGUAGUUUUUCUGAACCACACAAAUGGCUUUCCUGGAGAGAGAUCUGUAGCACAGACAGUGGGUUACAGCAGCCCCACUGAGGGACCAAACUCAAACCCUGCAUUUCCAUCUUACCAGGUCAAACCAAACCAGUCAGUGGGGCUACUUUUUAUAGUGCUUUAAUCUGAAUUUAGAGCUGAUUUUUAAAGGAGUCUUUAAAUGUUAAUGGUAUACUAACUAACGAAUAGUGCCUCAUUAUCAUUCUUGAGUCAGAUACUUCUGUUGAUGGGAGAAACAGAAGAAUCCUUCCCUUUGGGUGUGUUGAGCUCCCCCAAAGCCAUCAGCAUCUCUUUUGACAAAUGCUAGUCCUUUCUCUGUGCUUUGGAAUCAGGUUCCUGCAUCAUCACCCGGACUGUAAAAAGUAUCAUAAGCCUCCCUUGCCAGAUGCCAACUCGUGGGGCAUUUCAACAGAGUUUCUUUGAAAUGUUUACAACGUAUUCUUCUUGAUAAGCAAUGAACUUAACAUUUAGAUGCAAUCCGUGAAAAGAAAAAAAAAUCUGAAAAAUAUCUCCUGCAUCAGGUCUGUGUUAUUUAUGUAUUGUGAAUGUUUUCUUAAUUUUAUUGGCUGUAUGCUUUCUUACACAUAAUAAAAAUAUUUUGUGAACUCAAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|50-500nM[DRD1 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,"liquid, gel","We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network"
616,PMID: 33650968,RNAPS0000551,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:255231,https://www.ncbi.nlm.nih.gov/gene/255231,MCOLN2,1102nt(3'UTR),AGUUCUGCUAAAGAUGAUUAAAGUUCAGGCAUCCUUAUCCAGCGGCUGAGCAGAGGAACCCCAAAUGACUUGGACAAGCAGUUCCAAAAUGACUCUCUUAUUUAAUUGUGGAGUGGGAAAGAGGACUCACAGUUAGCCAGCUGACCAUGACUGAAGUUCCAGCUUUACUUUUUAUAAACUUGAAUGAUAAAGAAUAGACCAUGGGCUACUACUGGGCAUUAGUGCAAUAUAACAGCGAUAAUAAAAUUCUCUAUUAGUCUGUUAAUUUAUGACAUGAUCUCGGAAUGGAAAAAGAUCAUUUCAGAGUGUGCGAAAUAAUAGUCUUUAACCAUGUAAUUAAAUAUGUGUGUUUAUUGUCAAAUAAGGAUUUGUUUUAAAGGUGAUUCUUGGGUUUGAAGACAUUUGUUAAUUCAUGGUCUGUACAGAAAUGAAGCUGGUUGCAAUACCAAUCUAGAGAGUCCAAGCUGGUGAACUAUUAAGCUGUUUAAAGAUCACCCUUGGCCUGGCACAGUGGUUCACACCUGUAAUCCCAGCACUUUGGGAGGCCUAGGCAGGCAGACUGAGCUCAGGAGCUUGAGACCAGCCUGGGCAACAUGGCAAAAACCCACCUCUACAAAAAGUACAAAAAUUAGUCGGGCGUGAUGGCAGGCAUCUGUAGUCCCAGCUACUUGGGAAGCUGAAGUGGGAGGAUCACCUGAGCUCUGGAGGUGGAGGCUGCCAUGAGCCAUGAUCGUGCCACUACACUCCAGCCUGGGUGACAGAGUGAGAUCCUGUCUCAAAAAAAAAAAAAAAUCACCCUUAAAUCAACAAAAAGACCUCAUGCUCAUGCAGUGGACAUUUCUUGGCCUGUUUUCCUGUGGGUUUUCUUCAGCAUGAUAUGAAGCAACUGUUGGCAUAGCCAGUGGGAUAAAUAAGAAAUGGAAUCAUUUGGCUGCCUCGUCACUUGUGCUAAUGGUCAGUUGUACACACAUGACAUGUGGAAGUGACCUGUAGCAGCGGUCACUCAUUUUAACAAUUGAACUCUGCUGGGUUGGGUAUUUACCUUUGUCUAGAAAAGAAAUAUGAUAUAUUUUCUCUAAAUAAAUUUAUUUUCAUCAUUCCA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[MCOLN2 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,"liquid, gel","We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network"
617,PMID: 33650968,RNAPS0000552,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:653820,https://www.ncbi.nlm.nih.gov/gene/653820,FAM72B,1095nt(3'UTR),AUGGAAUUAUGAUAUAUAUGAUAUACAAACUUUUUUCUAUUUAAAAAUAUAUUAAUGGAUCAACUUUAAAAUUGUUAGUUGCCAGUGAUCUUUUUUGGAAAACAAAAAUGGGGCAUUUGUUGAUUUAUUUAUUUUCCGUCUCUAAUUAGUUACCUCAGUUUGAUUGAAGCCAGUGGAGUUGUGCUUUUCCUCUACUUCUACUUCCUCUCCCCCACCUUUUUCUGCCCAGUGUAGGUGUAUUCUUAAAUUCAGACGGGAAGAUUCUUUCACAUAUCACUCAGUUACCUCCCAAUCUGGGGGAGUUUUUCUUACAACUUGAUACCAGAUACCAUUAAUUUUACAUUCCUGAAUAAAGGCCUAGUACCCACGCAUAUUUCAACCAUGCAUAUAUCAAGUUCAACUGAGUUUUAAUAGGGGAUUAAAAAAACAAGCUGUUAGGUUUCCAUGGGCACUGGUUCUCAUAGGUUCUAUUGGUGAUAACUGCUUUAACAUGGAGCAAGAGUUUGUGAAUCAGGAAAUAGAAUAAAUUAAAAUUUAAAAUAUAUAGAGGAAUCCUCUUGAUUGCUCAGCAUGAUGUUAGAUAAAUGAGUUUGUCAGAAAAUAUCAGUAUACGCUGUUUACCAAUGUUAUUUAUUUACAUUCUUCUAAAGCCAUUAUGGAUAUUGUAUUAUGAGAGCUAAACCUAAAUAAGUUAUCCUGUUCCCUAGGACCUUCUCUGUAAAUAGUGAAUUUUAGACGAGUAGUCUGUCCUAAAUCUUAAAUAGAAAAAAAACUAAAGCGAUUUGCUUAAGCCAUUGUACAUUAUAAAGAGCUGUUUUGUUUUGCUUUGCUUUGCUUUGUUUUGUUUUUUUAAAGCUGCAUUCAGAGCCACAAAGGAAUAGGAAAGUAGGGUAGUGUUGGAUUCUGGUUUUAUGUAACUCUAAAAUAAAUGUAUCUCUUUAAUAUCUCAGUUGUAGGGAUUUUGUCAAUACCAAAGCAGACUGAGUUGUGGUUUUGUAAAUAAAGUUUUUUCUAAAAAUGACCAUUCUUCCUUUAAUUUUUUGUUAUGCCCACAUAUUGUAUGUAAAAAUAUAAAUAAAUAGUACUUAAAGUAUA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[FAM72B 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,"liquid, gel","We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network"
618,PMID: 33650968,RNAPS0000553,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:8600,https://www.ncbi.nlm.nih.gov/gene/8600,TNFSF11,1095nt(3'UTR),GCCCCAGUUUUUGGAGUGUUAUGUAUUUCCUGGAUGUUUGGAAACAUUUUUUAAAACAAGCCAAGAAAGAUGUAUAUAGGUGUGUGAGACUACUAAGAGGCAUGGCCCCAACGGUACACGACUCAGUAUCCAUGCUCUUGACCUUGUAGAGAACACGCGUAUUUACAGCCAGUGGGAGAUGUUAGACUCAUGGUGUGUUACACAAUGGUUUUUAAAUUUUGUAAUGAAUUCCUAGAAUUAAACCAGAUUGGAGCAAUUACGGGGUGACCUUAUGAGAAACUGCAUGUGGGCUAUGGGAGGGGUUGGUCCCUGGUCAUGUGCCCCUUCGCAGCUGAAGUGGAGAGGGUGUCAUCUAGCGCAAUUGAAGGAUCAUCUGAAGGGGCAAAUUCUUUUGAAUUGUUACAUCAUGCUGGAACCUGCAAAAAAUACUUUUUCUAAUGAGGAGAGAAAAUAUAUGUAUUUUUAUAUAAUAUCUAAAGUUAUAUUUCAGAUGUAAUGUUUUCUUUGCAAAGUAUUGUAAAUUAUAUUUGUGCUAUAGUAUUUGAUUCAAAAUAUUUAAAAAUGUCUUGCUGUUGACAUAUUUAAUGUUUUAAAUGUACAGACAUAUUUAACUGGUGCACUUUGUAAAUUCCCUGGGGAAAACUUGCAGCUAAGGAGGGGAAAAAAAUGUUGUUUCCUAAUAUCAAAUGCAGUAUAUUUCUUCGUUCUUUUUAAGUUAAUAGAUUUUUUCAGACUUGUCAAGCCUGUGCAAAAAAAUUAAAAUGGAUGCCUUGAAUAAUAAGCAGGAUGUUGGCCACCAGGUGCCUUUCAAAUUUAGAAACUAAUUGACUUUAGAAAGCUGACAUUGCCAAAAAGGAUACAUAAUGGGCCACUGAAAUCUGUCAAGAGUAGUUAUAUAAUUGUUGAACAGGUGUUUUUCCACAAGUGCCGCAAAUUGUACCUUUUUUGUUUUUUCAAAAUAGAAAAGUUAUUAGUGGUUUAUCAGCAAAAAAGUCCAAUUUUAAUUUAGUAAAUGUUAUCUUAUACUGUACAAUAAAAACAUUGCCUUUGAAUGUUAAUUUUUUGGUACAAAAAUAAAUUUAUAUGAAAACCUGC,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[TNFSF11 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,"liquid, gel","We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network"
619,PMID: 33650968,RNAPS0000554,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:27075,https://www.ncbi.nlm.nih.gov/gene/27075,TSPAN13,1045nt(3'UTR),UGAGAAAACAAGGAAGAUUUCCUUUCGUAUUAUGAUCUUGUUCACUUUCUGUAAUUUUCUGUUAAGCUCCAUUUGCCAGUUUAAGGAAGGAAACACUAUCUGGAAAAGUACCUUAUUGAUAGUGGAAUUAUAUAUUUUUACUCUAUGUUUCUCUACAUGUUUUUUUCUUUCCGUUGCUGAAAAAUAUUUGAAACUUGUGGUCUCUGAAGCUCGGUGGCACCUGGAAUUUACUGUAUUCAUUGUCGGGCACUGUCCACUGUGGCCUUUCUUAGCAUUUUUACCUGCAGAAAAACUUUGUAUGGUACCACUGUGUUGGUUAUAUGGUGAAUCUGAACGUACAUCUCACUGGUAUAAUUAUAUGUAGCACUGUGCUGUGUAGAUAGUUCCUACUGGAAAAAGAGUGGAAAUUUAUUAAAAUCAGAAAGUAUGAGAUCCUGUUAUGUUAAGGGAAAUCCAAAUUCCCAAUUUUUUUUGGUCUUUUUAGGAAAGAUUGUUGUGGUAAAAAGUGUUAGUAUAAAAAUGAUAAUUUACUUGUAGUCUUUUAUGAUUACACCAAUGUAUUCUAGAAAUAGUUAUGUCUUAGGAAAUUGUGGUUUAAUUUUUGACUUUUACAGGUAAGUGCAAAGGAGAAGUGGUUUCAUGAAAUGUUCUAAUGUAUAAUAACAUUUACCUUCAGCCUCCAUCAGAAUGGAACGAGUUUUGAGUAAUCAGGAAGUAUAUCUAUAUGAUCUUGAUAUUGUUUUAUAAUAAUUUGAAGUCUAAAAGACUGCAUUUUUAAACAAGUUAGUAUUAAUGCGUUGGCCCACGUAGCAAAAAGAUAUUUGAUUAUCUUAAAAAUUGUUAAAUACCGUUUUCAUGAAAUUUCUCAGUAUUGUAACAGCAACUUGUCAAACCUAAGCAUAUUUGAAUAUGAUCUCCCAUAAUUUGAAAUUGAAAUCGUAUUGUGUGGCUCUGUAUAUUCUGUUAAAAAAUUAAAGGACAGAAACCUUUCUUUGUGUAUGCAUGUUUGAAUUAAAAGAAAGUAAUGGAAGAAUUGAUCGAUGAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[TSPAN13 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,"liquid, gel","We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network"
620,PMID: 33650968,RNAPS0000555,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:10186,https://www.ncbi.nlm.nih.gov/gene/10186,LHFPL6,1044nt(3'UTR),GAUGGAGCUACCAAGAGCAGACAGAGGAGAAGAUGGGCCAAAGGGGCUUGGAGAGGUCAAAACAUCCACCUACCUUCAAAAGGUGGGAUAGUAGUUCUAAUCCAAUACAAUGCUAAUAAAAUGAAACCCGAUAAAAUCAGGAACAUGAUAUAGGAAGGAAGGAUUGUAGGAGAUUUGUGGGGGAAAAAAAAGGAGAGUAUAGAAUGAUGGAGAAAAAUGGACCAAAGGCUAAAAAUAUUGCAGGGCAUCGGGUGUUUCUAUUCCACAGAGUAUUGUUAAUGUACAACACACACACACACACACACACACACACACACACACACACACACACAACAAAUCUACAUAUACAAACAAGGGUUUGGGUUUUAGUUUUUUUUUUUUAAGGUGAGGACUCAGAAAAUCAAAGGGCUAGUAGAAACAGUGUUAUGUUGGGAAGCAGGGUACCCCCAAAGAUGUUCCCUGUAGGUCACGGCACUCCCAAAAGCACACAAGCACAUACAGACAUAUGCAUCCCCACACACGCCUAUGCACAAACGUGGAUUAUCGCACAGACUGGGAGGUUUAGUGGUGCAUUUCUCCUCUGUUUUCUUUUUAAUAUACAUUUAAAAUACAGUAUUAUCACUUUAUAAAACAUACAUUAAGCCUAAUAAAUGGACCAAUAAGCCAAACUAUCAGUAUUUUGUAUAUCCUGCAUAAACUCUAAUUUAGUUCCUCAACAUAUUUUCAGUGUUUAUGCAGACCUUUAGAGUUAAGCCUUUGUAUUUCCAUGUUAUUCCACAAUAUGCAAUAUUUCUCUGAGUAGCUUCUGCUAUGAUAUUCUUAUGAAGAAAAGGGGCAACUUUCUGUCCACUAUAGGAGAGAAUUCAGCCGAAGAUAUGAGAGUAAUGAGAGACAUUUUCCAGUCAUUGGAUCGUGUUUUCUUUUGUCCAUUAUUGUACUGUGCUGUACCACAUUUAUUUCUAUAUUCAUUUUGUAAAAAAUUUAAAAGUGCUAUUUUGUUUGUAUUUGAAAAUCUCUGUGAAUAAAUUCUCUCUUUGAUCAAUA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[LHFPL6 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,"liquid, gel","We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network"
621,PMID: 33650968,RNAPS0000556,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:3586,https://www.ncbi.nlm.nih.gov/gene/3586,IL10,1034nt(3'UTR),GACAUCAGGGUGGCGACUCUAUAGACUCUAGGACAUAAAUUAGAGGUCUCCAAAAUCGGAUCUGGGGCUCUGGGAUAGCUGACCCAGCCCCUUGAGAAACCUUAUUGUACCUCUCUUAUAGAAUAUUUAUUACCUCUGAUACCUCAACCCCCAUUUCUAUUUAUUUACUGAGCUUCUCUGUGAACGAUUUAGAAAGAAGCCCAAUAUUAUAAUUUUUUUCAAUAUUUAUUAUUUUCACCUGUUUUUAAGCUGUUUCCAUAGGGUGACACACUAUGGUAUUUGAGUGUUUUAAGAUAAAUUAUAAGUUACAUAAGGGAGGAAAAAAAAUGUUCUUUGGGGAGCCAACAGAAGCUUCCAUUCCAAGCCUGACCACGCUUUCUAGCUGUUGAGCUGUUUUCCCUGACCUCCCUCUAAUUUAUCUUGUCUCUGGGCUUGGGGCUUCCUAACUGCUACAAAUACUCUUAGGAAGAGAAACCAGGGAGCCCCUUUGAUGAUUAAUUCACCUUCCAGUGUCUCGGAGGGAUUCCCCUAACCUCAUUCCCCAACCACUUCAUUCUUGAAAGCUGUGGCCAGCUUGUUAUUUAUAACAACCUAAAUUUGGUUCUAGGCCGGGCGCGGUGGCUCACGCCUGUAAUCCCAGCACUUUGGGAGGCUGAGGCGGGUGGAUCACUUGAGGUCAGGAGUUCCUAACCAGCCUGGUCAACAUGGUGAAACCCCGUCUCUACUAAAAAUACAAAAAUUAGCCGGGCAUGGUGGCGCGCACCUGUAAUCCCAGCUACUUGGGAGGCUGAGGCAAGAGAAUUGCUUGAACCCAGGAGAUGGAAGUUGCAGUGAGCUGAUAUCAUGCCCCUGUACUCCAGCCUGGGUGACAGAGCAAGACUCUGUCUCAAAAAAUAAAAAUAAAAAUAAAUUUGGUUCUAAUAGAACUCAGUUUUAACUAGAAUUUAUUCAAUUCCUCUGGGAAUGUUACAUUGUUUGUCUGUCUUCAUAGCAGAUUUUAAUUUUGAAUAAAUAAAUGUAUCUUAUUCACAUCA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[IL10 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,"We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network"
622,PMID: 33650968,RNAPS0000557,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:51311,https://www.ncbi.nlm.nih.gov/gene/51311,TLR8,1003nt(3'UTR),CUGACGUUAAGUCAUGAUUUCGCGCCAUAAUAAAGAUGCAAAGGAAUGACAUUUCUGUAUUAGUUAUCUAUUGCUAUGUAACAAAUUAUCCCAAAACUUAGUGGUUUAAAACAACACAUUUGCUGGCCCACAGUUUUUGAGGGUCAGGAGUCCAGGCCCAGCAUAACUGGGUCCUCUGCUCAGGGUGUCUCAGAGGCUGCAAUGUAGGUGUUCACCAGAGACAUAGGCAUCACUGGGGUCACACUCAUGUGGUUGUUUUCUGGAUUCAAUUCCUCCUGGGCUAUUGGCCAAAGGCUAUACUCAUGUAAGCCAUGCGAGCCUCUCCCACAAGGCAGCUUGCUUCAUCAGAGCUAGCAAAAAAGAGAGGUUGCUAGCAAGAUGAAGUCACAAUCUUUUGUAAUCGAAUCAAAAAAGUGAUAUCUCAUCACUUUGGCCAUAUUCUAUUUGUUAGAAGUAAACCACAGGUCCCACCAGCUCCAUGGGAGUGACCACCUCAGUCCAGGGAAAACAGCUGAAGACCAAGAUGGUGAGCUCUGAUUGCUUCAGUUGGUCAUCAACUAUUUUCCCUUGACUGCUGUCCUGGGAUGGCCUGCUAUCUUGAUGAUAGAUUGUGAAUAUCAGGAGGCAGGGAUCACUGUGGACCAUCUUAGCAGUUGACCUAACACAUCUUCUUUUCAAUAUCUAAGAACUUUUGCCACUGUGACUAAUGGUCCUAAUAUUAAGCUGUUGUUUAUAUUUAUCAUAUAUCUAUGGCUACAUGGUUAUAUUAUGCUGUGGUUGCGUUCGGUUUUAUUUACAGUUGCUUUUACAAAUAUUUGCUGUAACAUUUGACUUCUAAGGUUUAGAUGCCAUUUAAGAACUGAGAUGGAUAGCUUUUAAAGCAUCUUUUACUUCUUACCAUUUUUUAAAAGUAUGCAGCUAAAUUCGAAGCUUUUGGUCUAUAUUGUUAAUUGCCAUUGCUGUAAAUCUUAAAAUGAAUGAAUAAAAAUGUUUCAUUUUACAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[TLR8 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,"We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network"
623,PMID: 33650968,RNAPS0000558,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:89801,https://www.ncbi.nlm.nih.gov/gene/89801,PPP1R3F,1000nt(3'UTR),GCUCUGCUUGUGGGAUCAGCAGAGGCUUAAGAUGGGAUACAUGGCCUGUGCAGUGAGGGGACCUGGGUCCUUUGCUUCUGAGAAUGCUCAACUGAAAGAGAGGCCUUCUCAUCCCCAAGCUCUCCAGUCAACACAGGGCUCCCUGUGGUGACACCAGUGGAGAUGAGGGAACGGGUAGAUGGUGUGAGUGAGGGGAACUUUUAGAGUGGAACUGGGCAUGUCCUCCGCCUACCCCCCGAGCCUGUAUUUAUUUUUGUAUAAUUCUCUGGAUGAGGGAGAGUGGUCGUGAGCUGGUCUUGGGGCACAAUUACCCAGAGAUAUAUUUAUUAACAGCCAACCUGUGCAACCUGCUGGAGCUUUAUUUUUAAUUUAAUUUAUAUAGAGUACCUAUUAUUAUAUGCCACAAUAGAGCUCUAUGAGAAACAGUGUCUUGCGGUGUAGUGUUCUCCUGUUUGGGCAUGAGUGUGCAGGGUGGUCACUUUCUGUGGGAGGAUCACAGUGGGGAGUUGGGGGUGGGACGUGGUCGCCUGCUGCUGCUUCAACAUGUCUUUCCUUGAAGAUGUGUGUCUCCUCGUCUCGUGGUCCUAAUCCAUAUGGUUCUUUGUCUUUUCCACAUUCUGCCUGUGGGACCCUACAGGUGUGUAUUUGGAUGGUGGUGGUGGGAGCCAGGGAGGAAGAGUGGCAGCCACAUGAGGGUUUGGUGUCAGUCACAUGGUUGCAGUGGUAGCUGUGGUCUCCUGUGGAUGUGGGGACAUCAGUUGUGAAUCAGCCACAAGGUUUUGAGGUUACUGAAAAAACAGCCUUUGACACCAGCAGGGAGACCCCUUAGUCCCUGAGAUAAGGAAGGCCUCAGAAAGGAAAGAGGAGUUAAUGUACUGCAGUACUUGGUAGCACAGUUGCUGUCCACAGACAUCACAUUUCUACUAAAAACAGGAAGCCCAGAAGCUUUGAAAGAAAGAUAUAUAUUUAUUGCAUGCAAAUAAAAAACUGCUCAACAAAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[PPP1R3F 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,"liquid, gel","We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network"
624,PMID: 33650968,RNAPS0000559,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:2863,https://www.ncbi.nlm.nih.gov/gene/2863,GPR39,976nt(3'UTR),AUGUCAAGCGAGGGAGCCUUGAGUGGGAACUGGCCCUCCAGCCCUAAGAAAACGUCACUCUCACUCUGCAGUCUCAAACUAUGCCCCCAUCAGGGAUGGAAUGGACACUGGAGGCUUUACAAAAGGCAGAUGCCCACCUCAGUGACUUCUAAGGACUGACUCUGCCAGCCUGGCCUUGACUCCGGUUACACAGACAUGGGGGUGAACUUUCACUCCACCUCCUUCCUUCAAGUACAUACUGAAAAUUCAGUCAGGCUGAAUUUAUUCAGAAUGCUUUACCGAGCUCUUUCAUUAUUUGCACAGGAACAAAAGAGAACACGGACUCCCGCUCCCUACCCAGAAUAAAAGGACACCCAGAAGAAACUCACUCAGGGAGGUGGGGGGUUGGGGGCGAGGGCUGGAAGAACAAUGCAGGAGGGGGUGGCAUCUCCUUCAGCUUCAGCAGUGUGCCGAGAAGAGGGCUAAUUUGAGGAACAGGAUGGUGGUGCGGAGCCCUGGCCUGAGGGCCGAGGCAGAACUUCCCCUUUUCUUGGGCCUUGGCCCGUUACAAAGAGGGGUGUUGCAGCAGCUGAUGCAAACUGAGUUCAGUUUCCCUGGGGAGCAGAAGGACUGGUACCCGGCAGAGGCGAUGAGACAGGCCGCUGAUGAUGCACAGGACUUGCGGUACAUGAUCCCUGUAACACAGACCCAAAGGAGCUGAGUUAACGUGCACCGGCAAAAGAAUAGCUGUCCCUCUCAGCCCAAAUCCAAACGGACAGCUCUUCCUUACUCCUCCCACAGCCCAGAGACUAGGUGAGGUCAGGGAAGUGCUUCGGAUUGUCUCAUUGAUAUUCAAGAUAGAUGGUGAAAGAGACAGGCACUAUUUCAUUAGUUUUAACAAAACUGUUCCAAAAGCGAUUUGAGAUGCCAAUACCUGUGAAUACCUGUUAAUAAAGAGCUGUUAAAUAGACUUAUUUACAUUUUAAGUCAGAGUUCA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[GPR39 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,"We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network"
625,PMID: 33650968,RNAPS0000560,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:54497,https://www.ncbi.nlm.nih.gov/gene/54497,HEATR5B,595nt(3'UTR),UUUGUAAUUUCAUUUAUUUGUAUUUAUGUUGUCAACUAGCCCCUAAUUAGUGAUGGCCACUGUAUCAUUCCAGGCUACCUAUGGGUUCUGUUUUAUUUGUAUAUUGGUAUUAUAGUGCUUCCAAGUAGGUUAAGUGAAAUAAUGCUCACACCACUUAUUGAUUUUUAAGGAGUGAUUUUUUUUAUCAUGUGGUGAAUAUGUUUUCAUUUUCCUCCUAAUAAUGUUUCUCUUUUGUUAACUUAUUUAUUUUUCAAACACUGAGCCAUAGUCUUAAAUUUAAAUGCUAAAAACAAUUGUAUCAUGUAGUCGGGCAGCCUAUUGAUACUGUCAGGGGAAAAAAAUGGGUCAGAACUCAGCAUCUGUCAUGAAAAAAAUCAAUUGAAAAACAAGCAGAUUUUAAAUUUUGAAGUAAUCAAAAUAAUGGAAAGUGUCUGUUUUGUGGUGUAUAUACUAUGAAUAAAAUCACAGCAUUUUCUAAGCAUUUCCCAAAAUGUCCUUAUCUUUCUGAUGGAUCUUUUAGCUUUCAUAUCAAAUUACUAAAUUAUGCUAUGUAUAUUUUAGUUGGUAACAAUUAAAAUUCUCAUUUAAAGGUUCA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[HEATR5B 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,"We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network"
626,PMID: 33650968,RNAPS0000561,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:345757,https://www.ncbi.nlm.nih.gov/gene/345757,FAM174A,557nt(3'UTR),GAAUGUGCCUUUUGAUGAAAGAACUUUAUCUUUCUACAAUGAAGAGUGGAAUUUCUAUGUUUAAGGAAUAAGAAGCCACUAUAUCAAUGUUGGGGGGGUAUUUAAGUUACAUAUAUUUUAACAACCUUUAAUUUGCUGUUGCAAUAAAUACCGUAUCCUUUUAUUAUAUCUUUAUAUGUAUAGAAGUACUCUGUUAAUGGGCUCAGAGAUGUUGGGGAUAAAGUAUACUGUAAUAAUUUAUCUGUUUGAAAAUUACUAUAAAACGGUGUUUUCUGAUCGGUUUUUGUUUCCUGCUUACCAUAUGAUUGUAAAUUGUUUUAUGUAUUAAUCAGUUAAUGCUAAUUAUUUUUGCUGAUGUCAUAUGUUAAAGAGCUAUAAAUUCCAACAACCAACUGGUGUGUAAAAAUAAUUUAAAAUUUCCUUUACUGAAAGGUAUUUCCCAUUUUUGUGGGGAAAAGAAGCCAAAUUUAUUACUUUGUGUUGGGGUUUUUAAAAUAUUAAGAAAUGUCUAAGUUAUUGUUUGCAAAACAAUAAAUAUGAUUUUAAAUUCUCUUAAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[FAM174A 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,"liquid, gel","We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network"
627,PMID: 33650968,RNAPS0000562,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:7130,https://www.ncbi.nlm.nih.gov/gene/7130,TNFAIP6,515nt(3'UTR),AAAAAAAAAAAAGGAUGAUCAAAACACACAGUGUUUAUGUUGGAAUCUUUUGGAACUCCUUUGAUCUCACUGUUAUUAUUAACAUUUAUUUAUUAUUUUUCUAAAUGUGAAAGCAAUACAUAAUUUAGGGAAAAUUGGAAAAUAUAGGAAACUUUAAACGAGAAAAUGAAACCUCUCAUAAUCCCACUGCAUAGAAAUAACAAGCGUUAACAUUUUCAUAUUUUUUUCUUUCAGUCAUUUUUCUAUUUGUGGUAUAUGUAUAUAUGUACCUAUAUGUAUUUGCAUUUGAAAUUUUGGAAUCCUGCUCUAUGUACAGUUUUGUAUUAUACUUUUUAAAUCUUGAACUUUAUAAACAUUUUCUGAAAUCAUUGAUUAUUCUACAAAAACAUGAUUUUAAACAGCUGUAAAAUAUUCUAUGAUAUGAAUGUUUUAUGCAUUAUUUAAGCCUGUCUCUAUUGUUGGAAUUUCAGGUCAUUUUCAUAAAUAUUGUUGCAAUAAAUAUCCUUGAACACA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[TNFAIP6 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,"We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network"
628,PMID: 33650968,RNAPS0000563,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:2857,https://www.ncbi.nlm.nih.gov/gene/2857,GPR34,496nt(3'UTR),GGUAAACAUACUAAAAUGAAUUAUAUAAUGCAGCCUCUUAAUUCUUUGAAGAACUAAAAAAUUAGGAAACAAAGUUCUAGCAUUUACAAAACUCAGAUCUCAAAGCUCUGCUUGUAUUUGUGAUAUUUCAUUUGCUUAACUGUAAACCAUUUCAAGGUACUAACUUUUAAAUCUGUAUGUAAAAUCUUUUCAAAAUACAUUUUUAAGCUAAUACUCUUAACAUAGAUUAUGAAGUUAAGUGAAAUUUAUGGCUCUAACAGCAAAAUAAUUAAAGUGCCAUAGUUUCUCAAGUGACUAAAGUAGUUAUUAAAAUCAAGCACUUGAUACUAAUUUGAAGUGUGUUUAAAAGUAAAUGAUUUGGGAACUGACAAUGUGUCAGAAAAUAUAUGUUCAUUUAUCAUUUUAAAAUCUUGUAUAAUUUGCCACUGUAUUCAUUUAUGCCUAAAUCUCUAUAACAGAUGAAAAGAUAAUUAAUAAAAUCCUAAUUAAAAAAUGA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[GPR34 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,"We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network"
629,PMID: 33650968,RNAPS0000564,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:51699,https://www.ncbi.nlm.nih.gov/gene/51699,VPS29,482nt(3'UTR),AGCCAGGCCUGUCUUGAUGAUUUUUGGUUUUUUUUCAUUGUCCUGUUGAAAUCAAGUAAUUAAACAUUUAAGAGCCACAAAAUUGUAUCACUUUUAUAAUAUUUUGCAGUAAAAUAUAAUACCAUCUUCUCUGUUAAUACAUAAUUGCUCCAAGCUUCCUGUAAACUAUAAGAAUAUAUUUAGUUUACAGUAUAUGGAUUCUAUGAAAAAAUGUCCACAACACAGUAAUUGGUCACUUGUUAAGAAAAAUUUAUCCUUGUAAGUAUCUUCAAAGUUGAUAUUUGGAACUUUAUUCCAAAAGUAGUGCAUGUGGAGAAAGAAUCUAGACUUUCUUGUAUACAUUUUUCUCUUCUCCAGUAAUAAACAAUUACCUUUCAUUUAUACUUUGAUAACCUGUAUUUAAUUUAAAAAAAAACAUAAAAAUGAGGAACCAAGUGAAACUACGGAUAUAAAUAUUAAAGUGGACGAGAUGACCUUUCAGA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[VPS29 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,"liquid, gel","We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network"
630,PMID: 33650968,RNAPS0000565,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:4609,https://www.ncbi.nlm.nih.gov/gene/4609,MYC,476nt(3'UTR),GGAAAAGUAAGGAAAACGAUUCCUUCUAACAGAAAUGUCCUGAGCAAUCACCUAUGAACUUGUUUCAAAUGCAUGAUCAAAUGCAACCUCACAACCUUGGCUGAGUCUUGAGACUGAAAGAUUUAGCCAUAAUGUAAACUGCCUCAAAUUGGACUUUGGGCAUAAAAGAACUUUUUUAUGCUUACCAUCUUUUUUUUUUCUUUAACAGAUUUGUAUUUAAGAAUUGUUUUUAAAAAAUUUUAAGAUUUACACAAUGUUUCUCUGUAAAUAUUGCCAUUAAAUGUAAAUAACUUUAAUAAAACGUUUAUAGCAGUUACACAGAAUUUCAAUCCUAGUAUAUAGUACCUAGUAUUAUAGGUACUAUAAACCCUAAUUUUUUUUAUUUAAGUACAUUUUGCUUUUUAAAGUUGAUUUUUUUCUAUUGUUUUUAGAAAAAAUAAAAUAACUGGCAAAUAUAUCAUUGAGCCAAAUCUUAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[MYC 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,"We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network"
631,PMID: 33650968,RNAPS0000566,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:5321,https://www.ncbi.nlm.nih.gov/gene/5321,PLA2G4A,473nt(3'UTR),UUCAUGUACUGGAAAUGGCAGCAGUUUCUGAUGCUGAGGCAGUUUGCAAUCCCAUGACAACUGGAUUUAAAAGUACAGUACAGAUAGUCGUACUGAUCAUGAGAGACUGGCUGAUACUCAAAGUUGCAGUUACUUAGCUGCAUGAGAAUAAUACUAUUAUAAGUUAGGUUGACAAAUGAUGUUGAUUAUGUAAGGAUAUACUUAGCUACAUUUUCAGUCAGUAUGAACUUCCUGAUACAAAUGUAGGGAUAUAUACUGUAUUUUUAAACAUUUCUCACCAACUUUCUUAUGUGUGUUCUUUUUAAAAAUUUUUUUUCUUUUAAAAUAUUUAACAGUUCAAUCUCAAUAAGACCUCGCAUUAUGUAUGAAUGUUAUUCACUGACUAGAUUUAUUCAUACCAUGAGACAACACUAUUUUUAUUUAUAUAUGCAUAUAUAUACAUACAUGAAAUAAAUACAUCAAUAUAAAAAUAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[PLA2G4A 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,"We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network"
632,PMID: 33650968,RNAPS0000567,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:83440,https://www.ncbi.nlm.nih.gov/gene/83440,ADPGK,1047nt(3'UTR),GAAGAUUCUUAGGGGUAAUUUUUCUGAGGAAGGAGAACUAGCCAACUUAAGAAUUACAGGAAGAAAGUGGUUUGGAAGACAGCCAAAGAAAUAAAAGCAGAUUAAACUGUAUCAGGUACAUUCCAGCCUGUUGGCAACUCCAUAAAAACAUUUCAGAUUUUAAUCCGAAUUUAGCUAAUGAGACUGGAUUUUUGUUUUUUAUGUUGUGUGUCACAGAGCUAAAAACUCAGUUCCCAAAUCCCCAGUUUAUGCAGCGCCAUCAGGUAUUUUAAGCUAAACUUCUUCACCCCUGAGAGCAUGUCAGCUGGAGAAAAGCAGUUCUUCCUUGCCCACUUGAGAAGUGCACGCCCACUCACCCAACAUCCUGGUCUCUAGGAAAGCCUCAUGUGAGGUUCCUCUUUCUUUCAGCUCAGUGCCCAUGGGCAAGGAUCAUGAUUUCCAUUCCGUGUUACAAUGACAAUAUUUAAUGAGCAUAACCUUCUCAGUCUCCUGCUCUCAAAUUUAGGACAGAGCCGCUAAGGACAAAACAAUCCCUCCCGUGCUUUAUGAUGGCAGCAGGGGCUGGGGAGCCUCUGAGGGACUCUUUCAUUCUGCAGUUGUCUGGAAGCCUGGGUGGCGUCAUGAGCUGAAGGAUCAUGCUUUCCUGUCCUGGCUCCAUAGGUUAUAGGCUGGCUGGUGAAAGGUUCACGUGGCCCAGGCUGAACUUCAUUGCCUAGCUUUGGAUGUGCUUUCUGCCAUAAAGACUGAUUUUUGUUCGUUCUGAGCCUUCAAGGAAUUUGUUUUUUACAACUGGAAUAUGCUCCUGUGUGUGUUAACAGAUCAUGGAUGUUUUAUGUUUUCACUGAUCAUUUAAAGAGUUUGACCUCAGAGCUCCAGGAUCAUCAGUAAAUUUGUCAUGUUAUAUAUUUAUUUUUUUAUAAAUCAAGACUUCUGUGUGCUCUUAAAUAUAUUAAAAACAAUUUACAUUUCAGGAAUUCUGUCUGUAAUUGAUUUUUGUCUCCAUCACCACUCUGGAACCAGAUAAGAUAAAAAUCAUUCUGAUCUUCA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[ADPGK 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
633,PMID: 33650968,RNAPS0000568,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:55761,https://www.ncbi.nlm.nih.gov/gene/55761,TTC17,1027nt(3'UTR),UGCACUUCUUCCUUCUCUCUUUCUCUUUACUCAUGCUCUAAAAAAAAAGAAUAAGAAAAGAAACCAAUCAUUGUCAGUAUCUACUAUUAAUGAUGUGUGUGAAAAUAACUAAGACUUAUAACAGGACUUUUACAUAUGUGGGAAUUGGUUUGUUUUUGUUUUUACGUUUCUCCUUUCCCCCAACCAACCUCAGAAGAGGCACCUUCAGAAACACACAUUUCUUAAAAGGAAAGUGCAGCUUCAAGAUAUUGUGUAAAUACUGAGCCAAGACAUUUCUGGAGCUGUGCUCUGUCUCCAAAAACCUCAAUGCCUUUAGGGCUUUUCUCAGUGGUCCAGCUAGCCUUCUCUUUGGAGGAGGAUGAAGCCGCAUUGCACAUUCUCUGCUUCCUGUCGUAGCCUCUGUUGUCAAUGGAAAUGCGGAAGCCCAUCUGGUGCCCGUCAGUGAGAAGCAACGUUCUGCGCUCUCUCCGUUAGACCUCCAUGCUGUCCCCAGUCUUGUCCAUUCCAUGCUGCUGUGUUACAAACUCUCAGAGGUAGUUUGCAGGGGAGGAAGGGGAAUAUGAUUUUAAAAACAAAAUAUUUACAACAACAAAAAUUCUUAGGAUCACCUGACCUUUGUAAUGUUAUUUAUGUUGGGGAGGGAGGGGGGCUGAGAAGGGGAAAUCAGCAGUGUGCAACAUCUUUAUAAUUUGUACUUUAAUUACAAAUCACAAGGAAACCAAUAAGUUGAAAUCCUAUAUAACAGGUUUAUAUAUAUAGAAUAUGUAUAUUUGAAGCCCUCUACAGACUGAGUCUAUGUUUUACUAAUUCUUUGUUCACUGUGUUACCCAUCUUGGAAUAAGUUGUGAAUGUCAGCUCCCUCUCUCUGAGGCCUCCAGACUUAGCUCCUCAGGAGGGUAAUGAGCCAAGGUUGAGUGUUUCCAUACAAUGCUUUUACCUUUGAUCCCAGGAGAAUCAGAAACUCCAACAUUUUGGAAUCUUCAAGGGCACAUACUGAGAAAAAAAAUAAAAUUGUUUAUGAGCAAAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[TTC17 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
634,PMID: 33650968,RNAPS0000569,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:8320,https://www.ncbi.nlm.nih.gov/gene/8320,EOMES,1117nt(3'UTR),AGAGUUAUUUUAACCUCAAAAAUUAGCUAACUUUUUGCAGAUGGACUUGGUGGUGUUUUUUGUUGUCUUCUUUGCCUAGGUUGCCAAAAAGAUGUUUGCCUUCCACCUUGAUGCAUCCUGUUUUGUGCAAUUCUCUAAAAGAAGGUGCCAAAGCUUUUUGAUUGCUGCAGGUAACUGAAACAAACCUAGCAUUUUUAAAAAAUAAGAUUAAUGGAAGACUUUAAGGUAUUUUAAAAUUCGAAGGGUAUCCAAGGUUCUGUAUUUAUUUAUUGGGGAGACACUAACCCUUCAAAGAAGCAGGCUGUGAACAUUGGGUGCCCAGUGCUAUCAGAUGAGUUAAAACCUUUGAUUCUCAUUUCUAUUUGUAAAUUCUUAAGCAAAUAGAAGCCGAGUGUUAAGGUGUUUUGCUUCUGAAAGAGGGCUGUGCCUUCCGUUUCAGAAGGAGACAUUUUGCUGUUACAUUCUGCCAGGGGCAAAAGAUACUAGGCCCAGGAGUCAAGAAAAGCUUUUGUGAAAGUGAUAGUUUCACCUGACUUUGAUUCCUUAACCCCCGGCUUUUGGAACAAGCCAUGUUUGCCCUAGUCCAGGAUUGCCUCACUUGAGACUUGCUAGGCCUCUGCUGUGUGCUGGGGUGGCCAGUGGGACUCAGGAGAGAGCAAGCUAAGGAGUCACCAAAAAAAAAAAAAAAAAAAAGGGAGAAUUUAAAAGUGUACAGUUGUGUGUUUAGAUACACUAUAGAAUAAUGUGGUAUAUAUUGUACAAAUAGUCUACAUAGGUGUCUGGGAUAAUGUAAAACUGGUGCUUUGGCUUUGUAAAGAAUUUGCAAAUCACUUAACAGCUGCAGGGGCAAGGGGAGAGUUUCAUCAUCCCCAUGAUAUUUGGGAAUAUUCUGUUUACUUCUUAGAUAGUUAAGAAUGUAUUCAGCUACUAUGUACUAACUUGAACCGUGUUUAAGGAAAACUCCUAUUUCAUCCUCUUCUUGCGCCAUCCCCUCUCCCUAACUUGGUAAUGUGAAGAAACUAAAACCUGAUACCACAGCUCCUAUAGGCAUUUUAGAGAUCUUGGAUUUUUAUGUACAGUCUUAGUCAUUUUUAAUAAAUGUGGUUCAGUAAGGGAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[EOMES 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
635,PMID: 33650968,RNAPS0000570,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:112817,https://www.ncbi.nlm.nih.gov/gene/112817,HOGA1,1143nt(3'UTR),GGGCAGGCAGGGUCCAUGGCUGGCCUGAGCCCAUCUCAGCCUCCUGCCUUGCACUUGCAGCCUGAAGCGGAGAGCACAGGGGGAUGAGGGUGGCAGGCAGCGGGGAGCCGAUAGAGGCUCCUUUGCCUGCUGUGGUCCUCCAGGCAGCCUUUCACAGGCACGCCCAUGCAUAUCUCCUAUUCUAACGGCCCCUGACCUCUCCCUUUUGGAUCCUAAACUGUGUCUCUGGUCUGAAGACUGGGAAGGAGCAAUUUCUCAAUUUAUCUUUCUACUGUGGAUGCUUUCCUACGCCCUGAGGCACAUGAAGUCAGAAAGGAAGGGCAGAGGGGCAAGUAGGCACAGUAAGGGAAUUUUCUUUUCUUUUUUUUUUUUUUUGAGACAGAGUUUCACUCUGUCACCCAGGCUGGAGUGCAAUGGCAUGAUCUCGCCUCCUGGGUUCAAGCGAUUCUCCUGCCUCAGCCUCCCGAGUAGCUGGGAUUACAGGCGCCUGCCACCACGCCCAGCUAAUUUUUGUAUUUUUAGCAGAGAUGGGGUUUCACCGUGUUGGCCAGGCUGGUCUUGAACUCCUGACCUCAGGUGAUCCAACUGCCUCGGCCUCCCAAAGUGCUGGGAUUACAGCUGUGAGCCACUGCACCCGGCCGGGAAUUUAUCAAAGGGGGGACUACUUAGAUUUGGGGCUUCAAACCUGAGUCUAGCACAAUGCAGCUGGAGGCCAGGGCUACUCCUACAAACCCAAGUUCUGACUCCUUCCAGGGAAGUAUCAGCUUAAGAAACUUGAUCAGGAAAGUGACACUGGUCUUUCAAAGAGCCCUCUUUACCCUCCCAUCCCUGCCCUCCACACUGCAAGCUGCAUUCCAGCCACAACGCCCUUUUCUAAAUCUAUUUUCAUUCAUCUCCUAUUCUGGUCUGUAGCCUUGAUUCCAACCAUUGAAUGCACGGAGACAGCCCAGUGGCUUGUCAGAUUGGUAAAUAAUGACACCUGGUGGAUAAAUGUUACAUUCUAGAAGACUAUUCUGGUCAGCCUAGGUCUGAAACACUAAGGAGACUUGGCCUGAGAUAGGGCCAUCCACUUGCCUACAGGCACUCUGCUUUUAUUAUUAAAAAUAGUCACUUUGUUACUAUAAUAAAAUUUAACAGAAAAAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[HOGA1 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
636,PMID: 33650968,RNAPS0000571,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:127018,https://www.ncbi.nlm.nih.gov/gene/127018,LYPLAL1,1130nt(3'UTR),AUGAAUCAAGAGUGAUUUGUUAAUGUAAGUGUAAUGUCUUUGUGAAAAGUGAUUUUUACUGCCAAAUUAUAAUGAUAAUUAAAAUAUUAAGAAAUAACACUUUCCUGACUUUUUUAUUAUUAAAAUGCUUAUCACUGUAGACAGUAGCUAAUCUUAUUAAUGAAAAACAAUAGACAAACAUCUGUGCAUAAUUUUUCAGACACAAUUCUGUAAAUAUUUGGAAACCUUUUAAGUAUUUAAACUUUUAAAUUUUUGAAAUAAAGUAUUCUAAACUAAUAUAAAUAAGGACAAUGAAAAAACAUGAAAGGACUUAGCAUAAUGUUAUUUUAUCUUUUCUACAACUUUGUUUAAAUUACCUUUCCAAAGAUAUUUGUGUUUAUGUAAUUUUCCACGGAAUAACAUUAAUACUCUAGGUUUAUAAACCGGUUUCACAUUAUUUCAUUUGAUCAUCACAAGAGCUUUGUGAAGUAAGCCGAGAAGUUGUUACUGGUAUUUAAUAAUAGCAAUAGAGGAGUUAAAGACUUUCCCACAGCUUGCAGGUCAAGACAAGAAAUUCAGGUCUCCUAAUUCUCAGUGGAGCUCUAUUUCUGUUAACCCAAAUUGCUGCUCUGUUUUAGGUCUCAAUUUCAUCUGUAAAAUGAUACUAAUAGUACUUAUCCCAUUGGAUUUUUGUUGAGAUUUAAAUAAAUAGCCAAAAGCCAAUACAUAAUAAACACUCAAUAAAGAUUAACCAUAAGGAGAGUCAUGAUCUGGUUCCAGGAAUACAUUGUUAGAUGACUGAAAAAUUGUAUUACUUCAAUGAAAAUACUAUAAAUAAUAACAUUUUCAUAUAUUAGUUGGUUCUCAUGCAUACAUAAUCUAAUUUUAUUUGAUCCUCACAACUGUUUAAGUUUUAUUAAAUAUACAUUAUCCCUAUUUGUAUAAAUAGAAUCAUACAAUACCUGCCUGCUUUCAUUCAACAAAAUUAUCAUGAGAUUUUUCCAUGUUGUGUACAUCAAUAGUUCAUCUAUUUUAUUGCUCAGUAAUAUUCCAUUGUGUGGAUGUAUCACUAUUUGUUUACACAUUCACCACUGAUAUAUAAGUUGCUUCCAGUGUGAGGCUGUUUUAAAUAAAGCUGCUAUGAAUAUUCA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[LYPLAL1 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
637,PMID: 33650968,RNAPS0000572,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:55164,https://www.ncbi.nlm.nih.gov/gene/55164,SHQ1,1007nt(3'UTR),CUCUUAGGUGGUUUUAUUCAUUGUUGAGAAAUAUGGUAGAUUGGGUUUCAUUUACCGAAUGAGAAUUCUUCAUUUUCACUUUGUAAUUUUUCUUAGUAUAUAGUCAGCCCACUGUAUUUGUGUGUUCCACAUCUGUGGAUUCAACCAACUGCAGAUCAAAAAUAUUGAAGAAAAAAUCGCAUCUGUACCAAACAUGUACAGACUUUUUUCUUGUUAUUAUUCUCUAAAUAAUACAGUAUGACAACUAUUUCCACAGCAUUUACAUUGUAUUGGGUAAUAUAAGUAAUCUAGUGAUGAUUUAAACUGUGCAGGAGGAUGUGGGUAGGUUAUAUGCAAAUACUGCACCAUUUUUUAUCAGGGGCUUGAGCAUCUGAGGAUUUUAGUAUCCUCAGGAGUCCUGGAACCAACCCCCCACAGAUACGGGGACAACUUUAUGACAUUGUUUUUCAACCAAUGAAUGUUUAUACCUUUUGUUUUCCUUGCCGCGACUGUGAAGAUAAAGUUCAAAAGUAUUUUUACCAAAGUGUAGCUAAUAUUUCAAGCUGAAAAUAAUAGUUCUACUGCCCGUGUCUCCAGAAUGUAGAGCCCAUCAAUAUUUUUAUUUUAGGAGGUGUACUUGACACCCAAUAAACUGCACGUAUCAAAAGUGUACAAUGUGUUGGCGUAUGUAUACCCUGCGUAAAACUAUCACCACAACUGAAGUGAGGAACGGACCCAUCAUUCCCAAGUGCCCUUGUGCCCUGUUAUUAGUUUGCAUGUCCUAGAAUUCUAUGUAAAUUGAAUCAUACAAUAUGUAUCCCUUUUUUGGUCAGGCAUAUUUUACUCAGUAUAGUUAUUUUGAGAUUCAUCCAUGUGGUAGCAUGUGUCACGAGUUUUUGUUUUUAUGUUUUUCAUUGCUGAGUACUGCUUCAUUGAAUAGAUUUGUUCAUUGACCUAUCGAUGGACACCUGGGUUGUUUCCAGUUUGGGGCUGUUAUAAAUAAAGCUGUUAUGAACAUUUGUGUACAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[SHQ1 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
638,PMID: 33650968,RNAPS0000573,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:132203,https://www.ncbi.nlm.nih.gov/gene/132203,SNTN,1117nt(3'UTR),ACAGUUUUAAAUAUGCUGUAUAAAAUAAUGGCAAAAGACAGUGUUAUUAAAAUGUUUCCAUCUUAUUUUUGAUUAAUUGAAUAUAUCUAUCAUGCAUCUGAAAUUGCCUAGGAUGGUUCUGAUUGCUGGUAUUCAGAUCCAAUGUAACUCCAAAUAUUUACCCAUACACUUCAAGAAUGUUUGAAUGAUAAGGUCUCUGUGUGCUUUACAAUAGGAUAGAUUUGAUACCACUGAAUAAUAAAUGGCUUUUGCUGAGUCAGUAGCGACCUAGAGCACUCUACUUAUAGUCAUUGAGUCACUCAUUUAUUCACUAAACAUUUGUUGAGCAUCUACUUGAUGGAACUGCUGAGGAUACAGUAAUGAAUUGGCCAGGCAAUUCCUUCCUUCAGACAUGUUUGCAGAAGUCUAGCAGAAGAGAUAGACAUUGAACAAUUUUUAAAUAAUUGCAUACACAGUAUAAUUAGAAUUGAAAUAAGGGCUAUAGGAUGCUAAAAGAGAUUAUCACCUGAUCGGAGUUCAAAGGUCAGAAAAGCUUUACUGACAUUCUAUAAAAAGCAAAAAAAAAAAAAUUGGUCCAUGGAUGCCAGGGAUAUGGGUGGGAAAUGGGGCUGUCCACAAAUGGCACAAGGGGAGUUUUUUAUUUUAUUUUAUUUUAUUUUAUUUUAUUUUAUUUUGAGACAGAGUUUUGCUCUUGUUGCCCAGGCUGGAGUGCAAUGGCACGAUCUCAGCUUACUGCAACCUCGAUCUCCCAGGUUCAAGUGAUUCUCCUGCCUCAGCCUCCUGAGUAGCUGGGAUUACAGGCGUGUGCCACGAUGCCAGGCUAAUUUUUUUUGUAUUUUUAGUGGAGACGGGGUUUCGCCAUGUCGGCCAGGCUGGUCUCGAACUCCUGACCUCAGGUGAUCCGCCCACAGCCUCCCAAAGUGCUGGGAUUACAGGCUUGAGCCACCAAGUCUGGCCAAGGGGACUUUUAAGGGGGCUGGAAAUGGUCUCCAUUUUGAUUGUGAGGUGGUGGCUACAAGAUUGCAUGCAUUUGUCAAACUCAUAGAACUGCACACUGAAAAGAGUGAAUUGUACUGUAUGUCAAUUAUACCUAAAUAAAUCUGACUUAACAAAAAAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[SNTN 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
639,PMID: 33650968,RNAPS0000574,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:5482,https://www.ncbi.nlm.nih.gov/gene/5482,ASPN,1083nt(3'UTR),UAAUUAGUAAUUGGUAAUGUCCAUUUAAUAUAAGAUUCAAAAAUCCCUACAUUUGGAAUACUUGAACUCUAUUAAUAAUGGUAGUAUUAUAUAUACAAGCAAAUAUCUAUUCUCAAGUGGUAAGUCCACUGACUUAUUUUAUGACAAGAAAUUUCAACGGAAUUUUGCCAAACUAUUGAUACAUAAGGGUUGAGAGAAACAAGCAUCUAUUGCAGUUUCUUUUUGCGUACAAAUGAUCUUACAUAAAUCUCAUGCUUGACCAUUCCUUUCUUCAUAACAAAAAAGUAAGAUAUUCGGUAUUUAACACUUUGUUAUCAAGCAUAUUUUAAAAAGAACUGUACUGUAAAUGGAAUGCUUGACUUAGCAAAAUUUGUGCUCUUUCAUUUGCUGUUAGAAAAACAGAAUUAACAAAGACAGUAAUGUGAAGAGUGCAUUACACUAUUCUUAUUCUUUAGUAACUUGGGUAGUACUGUAAUAUUUUUAAUCAUCUUAAAGUAUGAUUUGAUAUAAUCUUAUUGAAAUUACCUUAUCAUGUCUUAGAGCCCGUCUUUAUGUUUAAAACUAAUUUCUUAAAAUAAAGCCUUCAGUAAAUGUUCAUUACCAACUUGAUAAAUGCUACUCAUAAGAGCUGGUUUGGGGCUAUAGCAUAUGCUUUUUUUUUUUUAAUUAUUACCUGAUUUAAAAAUCUCUGUAAAAACGUGUAGUGUUUCAUAAAAUCUGUAACUCGCAUUUUAAUGAUCCGCUAUUAUAAGCUUUUAAUAGCAUGAAAAUUGUUAGGCUAUAUAACAUUGCCACUUCAACUCUAAGGAAUAUUUUUGAGAUAUCCCUUUGGAAGACCUUGCUUGGAAGAGCCUGGACACUAACAAUUCUACACCAAAUUGUCUCUUCAAAUACGUAUGGACUGGAUAACUCUGAGAAACACAUCUAGUAUAACUGAAUAAGCAGAGCAUCAAAUUAAACAGACAGAAACCGAAAGCUCUAUAUAAAUGCUCAGAGUUCUUUAUGUAUUUCUUAUUGGCAUUCAACAUAUGUAAAAUCAGAAAACAGGGAAAUUUUCAUUAAAAAUAUUGGUUUGAAAUAAAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[ASPN 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
640,PMID: 33650968,RNAPS0000575,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:24150,https://www.ncbi.nlm.nih.gov/gene/24150,TP53TG3,1024nt(3'UTR),GUACUGCACGACUACUCGCUUCUGAAACUGAUAGACACUGCCUCAGCUCCGUGCAGGGCAGACGCACAAGAGCAGAAUCUCCGUGGGACAUCUCUCUGGAGCAUCAAUAUUACUGCAGUAUUUGGAAGAAACAAAUUUAAAUAAGUUCUAAGGUGAAGAAUGGAACAUUUAAGACAAGUCUGGAAAGUCAUCUGCCUUUAAUAACUGUCGUUUGUCCUUAACGUCAGACUUUCUCCAAGACCAAAACUCUAAGAACUUAUUUCCAUUCUUACAAAUAGUAAAAAUGAUAAAUCAUAUCAAGUCAAUUGAAAGUCCUGCCUGCUGCUUUCCUAAAUUGCAAUAUGGCCUUGGUAUGGUUUUAUUUGUACUUUUGUGGGGGAUUCGUGGAUCUUUAGAUUAAAAAAAAAAAAAUAGGUUUUUGAACAAUUUUUGCAAGUUUGCAGCUGUUAGUUAUUGAUUUAUUUUUCCAACCCAUCUAAUUCUUCUGUCUCUCUCCUCUCCUCAGGCUCAAUAAUUCCAUGGGUCUCUAAGGCUGUGUUUAUUUUCUUUAAAUUUUGUUGAUUUACUUUUAUACUCCAUUUGAUUUUUUCUAUCUCUCACCUUUUCUCAGACUCAGUCAUCCCACAGGUCUGUAAGGCUCUGUUCAUUUUCUUUAAACUUCUUUUUUUUUUCCUCUCCUCAGAUUGGAUAAAUUAUAUUGCUAUGUCUCUGUUUCUGAACUAUAGAAAAGCUCAAAAUUAUUAUUUUUAUUUCUCAUUUUUUAUAUGGCUAUUUUUUCUCUGCUGAUGUUUCACAUCUAUUCAUUUAUGAGAAUAUUUUCCUUUGCCCUCAUGAGCGUGUUUAUAAUAGCUGCCUUCAAAUUCUUGUCUGCCGUUUACAUCUUGGACAUCUUGGAGAUGGCUACUGCCUGCUUUUUAUCUUGUGUAUUUAUUACAUUUUCACGUGUCUUCACGCAUCCCUUGAAUUGGAAAUUGUGCCCUGGAGACUGUAUACAAGACUGGAUUAAAAAGACUGGAUUCUGUUU,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[TP53TG3 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
641,PMID: 33650968,RNAPS0000576,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:2846,https://www.ncbi.nlm.nih.gov/gene/2846,LPAR4,1130nt(3'UTR),GUAUGAGAAAUGUGUUCAGGUCCAGAUAUGGUUUCUCCUAUAAUUUUUCCUAUGCUAUAAACUAAAGAUUUGAAGCUAAUGAUACUGAGAAUAAUGCACCAAAUCCAGUCAGAUACAUUUGUUUGAAGGUAUACUGUAGAGUUUUUAUUGCUGUUUUGUUCAGUAAUUAUAGGUCAAAUCUAAUUACAACAACCAAGAUGGAUUGCCAAACUCUUCUGCUUGGUUGGAAUUUCAUUGUAUCGCAUUAUCCAGGUGGCUAGUGGCAUUUGAUAAUAUAGAGAUGACUUUGAAACUUUCAAAAAGGUAUUUCUAUUCCAAUGAUAUUUGGUAAUUAGGUUGGGCCUAUAAAUAUAGAACAAAUUCAGGGAUUUUUAAAAAAUUGUGUUACUACUGAUAUAUGCUAGUUUUAUUUUAUUUUUUUGAACUGUCAUUGAGUUUAUUUUAGCACAAGAAUAUUUUUAGCCUAACAUUAUUAAUAAGAAAUGUGUCAAAUUUUUAACAUUGGUAAAAUAUGUUAUGUGCAUUUUGAAAACAGAAAACAAAUUGCGUUGGCAUGUACGUGGGUGGGAAGAAAAAGAAAAUUAACAGGAUUUACACAAUUAUAAUCACCAGCAGUGUGAGUUUAAAAAACUUCGUUGUUUUUACACCAAAUUAAAAUUUUCAUGUCAAACUUCAAAGCCAGAAAGCUGCUAAAUACGUGUCUGGCAGGUAAAAGCUGGAAAAUUACUUAAAACAGGAAAGUGUCAAUAAAAAAACUUGAGCAACACCAACAUAUUUUUUCUUAAAAUGUCACGUUAUCUUCAUUUUGGGAAACUAGGUUCUAUAAAAUAUUUAUCCUCCCUGUUAUACUUUGGAGCACAGCACAGCCAGAAAGGGGCUGCAUUUGUGCCCAGGUCAGGAGCAAAUUGAAAAAAAAAAUAAAGUAAUACAAAAAAAUCAAACUAUAAAGCAAAAACAUUUAUUAAAACCUGAAUUAAUCCUUUUUGGAGGGAGGAGUAGAGAUAUAUAACCUGAAAAUACUUAUUCUUUCUUAUCGAAUUUUGGAGCCUAAUAUAGCCAGGAGCUGCUGAAUUUGUGCCCCUGGAUUGGAAGCAAAUAAAAAAAAAAAACAACACAUAAACUAAACCAAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[LPAR4 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
642,PMID: 33650968,RNAPS0000577,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:389396,https://www.ncbi.nlm.nih.gov/gene/389396,GLYATL3,1164nt(3'UTR),CCCAGUAAAAAACUGCAGUGGUUUUAUUACUUUCCCUGAGCAUACACACACUCUUGGCUGCCAACGAGGGGAGAGUUAAAAUGGGAAUCAGGGGACUCUUGAGUUGUUGGAAAGGGUCUGGAGAAUAUAUACAGGAUCCACUUGAGAAGCCUUAAUUUUUCGUAUCUCAGGUUUCUCCAGUAAAUAGCUGUGGGGGUGAAGAGUAGCUGUGGCUGAAGACUGAGGACGAUUGUCCUCCUGUAGGAUCCACUGUAGGAGAAUAGGUUCUAAAGCCAGCAGUUUUAGUGUACUAGGAGAAAUUACUGCAUGAGAACAAAUGAUUUAACAGAGGACCACGUGGCUACUGCUUUUUGAUUGCUGCUUGGACCUCUGCUCUGUAUUCUUAAAGCCACACCGCUUCCCUACUGCCAUCAUAUUCCCCUGUCCCCACUGCUAUGUCUCAUCAACCUCUGUUCCUAACACCUCUGCCACCAAGUUCUCUGUAGAGUAACCUCCUUUUUCCCCUUUAAUUACUUGCUCUUUACUUCUGCCUAGGACUCUAGCCUAUAGUUCACUGCCCUGGGAAUGUUCAAAUAUAGUGGUUCUUACAUUUUAGUGUUUAUCAGAAUCACCCAGAGGGCAGGUUGCAACACACAUCACUAGGCCUCUCCUUCUACGAGGUAGGGCCCAAAAUUUGCAUUUCUAACAGCUUCCCACUGCUUAUUUGCCUUGGAUGAAUGACAAUAUGGGCAUUUUGAUGCUAUAAACAAAUGCUGUCACCAUAGAACUAGACUUUACCUAUAACCUAUUUCAGCCCCCUUAUUUAUAGUCUACUUUCCCAUAUAAAACUAAGAUUUAUAUAUAGGGGUGUUUGGGGGUAUGCAAAUGAAUAUAUAACAUAUAUGCAUACACAUAUAUAUACAUUCUCUUCAUUUCUUUUAUAUGUAUAGGUAUAUACUCAUAGAAUUUUGAUAAGAUAAUAAAUUUUAACCCUUUGAUUACAUAUGAAAAAUUUGAGGACCAGAGAAAAUAAAUGACUUUUUCAAGAUUAUAUUCUUUAUAAUCAGUACUGGAGGCAAAGCCAGAAUGCUGCCAUUUUAAUUCCAAUCUGUUAUUUUCACUAAAUCAUGUAUCCUUUUUUAUAAUGAAAAUUAAAAUGCUUACAUAAUUAAAAUAUUAAUUUUA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[GLYATL3 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
643,PMID: 33650968,RNAPS0000578,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:9635,https://www.ncbi.nlm.nih.gov/gene/9635,CLCA2,1026nt(3'UTR),AUAAAUAUCCAAAGUGUCUUCCUUCUUAGAUAUAAGACCCAUGGCCUUCGACUACAAAAACAUACUAACAAAGUCAAAUUAACAUCAAAACUGUAUUAAAAUGCAUUGAGUUUUUGUACAAUACAGAUAAGAUUUUUACAUGGUAGAUCAACAAAUUCUUUUUGGGGGUAGAUUAGAAAACCCUUACACUUUGGCUAUGAACAAAUAAUAAAAAUUAUUCUUUAAAGUAAUGUCUUUAAAGGCAAAGGGAAGGGUAAAGUCGGACCAGUGUCAAGGAAAGUUUGUUUUAUUGAGGUGGAAAAAUAGCCCCAAGCAGAGAAAAGGAGGGUAGGUCUGCAUUAUAACUGUCUGUGUGAAGCAAUCAUUUAGUUACUUUGAUUAAUUUUUCUUUUCUCCUUAUCUGUGCAGAACAGGUUGCUUGUUUACAACUGAAGAUCAUGCUAUAUUUUAUAUAUGAAGCCCCUAAUGCAAAGCUCUUUACCUCUUGCUAUUUUGUUAUAUAUAUUACAGAUGAAAUCUCACUGCUAAUGCUCAGAGAUCUUUUUUCACUGUAAGAGGUAACCUUUAACAAUAUGGGUAUUACCUUUGUCUCUUCAUACCGGUUUUAUGACAAAGGUCUAUUGAAUUUAUUUGUUUGUAAGUUUCUACUCCCAUCAAAGCAGCUUUCUAAGUUAUUGCCUUGGUUAUUAUGGAUGAUAGUUAUAGCCCUUAUAAUGCCUUAACUAAGGAAGAAAAGAUGUUAUUCUGAGUUUGUUUUAAUACAUAUAUGAACAUAUAGUUUUAUUCAAUUAAACCAAAGAAGAGGUCAGCAGGGAGAUACUAACCUUUGGAAAUGAUUAGCUGGCUCUGUUUUUUGGUUAAAUAAGAGUCUUUAAUCCUUUCUCCAUCAAGAGUUACUUACCAAGGGCAGGGGAAGGGGGAUAUAGAGGUCACAAGGAAAUAAAAAUCAUCUUUCAUCUUUAAUUUUACUCCUUCCUCUUAUUUUUUUAAAAGAUUAUCGAACAAUAAAAUCAUUUGCCUUUUUAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[CLCA2 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
644,PMID: 33650968,RNAPS0000579,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:3189,https://www.ncbi.nlm.nih.gov/gene/3189,HNRNPH3,1142nt(3'UTR),AAGCAAAAACACCAACAUACAAGUCUUGACAACAGCAUCUGGUCUACUAGACUUUCUUACAGAUUUAAUUUCUUUUGUAUUUUAAGAACUUUAUAAUGACUGAAGGAAUGUGUUUUCAAAAUAUUAUUUGGUAAAGCAACAGAUUGUGAUGGGAAAAUGUUUUCUGUAGGUUUAUUUGUUGCAUACUUUGACUUAAAAAUAAAUUUUUAUAUUCAAACCACUGAUGUUGAUACUUUUUAUAUACUAGUUACUCCUAAAGAUGUGCUGCCUUCAUAAGAUUUGGGUUGAUGUAUUUUACUAUUAGUUCUACAAGAAGUAGUGUGGUGUAAUUUUAGAGGAUAAUGGUUCACCUCUGCGUAAACUGCAAGUCUUAAGCAGACAUCUGGAAUAGAGCUUGACAAAUAAUUAGUGUAACUUUUUUCUUUAGUUCCUCCUGGACAACACUGUAAAUAUAAAGCCUAAAGAUGAAGUGGCUUCAGGAGUAUAAAUUCAGCUAAUUAUUUCUAUAUUAUUAUUUUUCAAAUGUCAUUUAUCAGGCAUAGCUCUGAAACAUUGAUGAUCUAAGAGGUAUUGAUUUCUGAAUAUUCAUAAUUGUGUUACCUGGGUAUGAGAGUGUUGGAAGCUGAAUUCUAGCCCUAGAUUUUGGAGUAAAACCCCUUCAGCACUUGACCGAAAUACCAAAAAUGUCUCCAAAAAAUUGAUAGUUGCAGGUUAUCGCAAGAUGUCUUAGAGUAGGGUUAAGGUUCUCAGUGACACAAGAAUUCAGUAUUAAGUACAUAGGUAUUUACUAUGGAGUAUAAUUCUCACAAUUGUAUUUUCAGUUUUCUGCCCAAUAGAGUUUAAAUAACUGUAUAAAUGAUGACUUUAAAAAAAUGUAAGCAACAAGUCCAUGUCAUAGUCAAUAAAAACAAUCCUGCAGUUGGGUUUUGUAUCUGAUCCCUGCUUGGAGUUUUAGUUUAAAGAAUCUAUAUGUAGCAAGGAAAAGGUGCUUUUUAAUUUUAAUCCCUUUGAUCAAUAUGGCUUUUUUCCAAAUUGGCUAAUGGAUCAAAAUGAAACCUGUUGAUGUGAAUUCAGUUAUUGAACUUGUUACUUGUUUUUGCCAGAAAUGUUAUUAAUAAAUGUCAUUGUGGGAGAUAAUAGUA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[HNRNPH3 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
645,PMID: 33650968,RNAPS0000580,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:5591,https://www.ncbi.nlm.nih.gov/gene/5591,PRKDC,1062nt(3'UTR),GUCUGUGGGAGUCUGCAGAUAGAAAGCAUUACAUUGUUUAAAGAAUCUACUAUACUUUGGUUGGCAGCAUUCCAUGAGCUGAUUUUCCUGAAACACUAAAGAGAAAUGUCUUUUGUGCUACAGUUUCGUAGCAUGAGUUUAAAUCAAGAUUAUGAUGAGUAAAUGUGUAUGGGUUAAAUCAAAGAUAAGGUUAUAGUAACAUCAAAGAUUAGGUGAGGUUUAUAGAAAGAUAGAUAUCCAGGCUUACCAAAGUAUUAAGUCAAGAAUAUAAUAUGUGAUCAGCUUUCAAAGCAUUUACAAGUGCUGCAAGUUAGUGAAACAGCUGUCUCCGUAAAUGGAGGAAAUGUGGGGAAGCCUUGGAAUGCCCUUCUGGUUCUGGCACAUUGGAAAGCACACUCAGAAGGCUUCAUCACCAAGAUUUUGGGAGAGUAAAGCUAAGUAUAGUUGAUGUAACAUUGUAGAAGCAGCAUAGGAACAAUAAGAACAAUAGGUAAAGCUAUAAUUAUGGCUUAUAUUUAGAAAUGACUGCAUUUGAUAUUUUAGGAUAUUUUUCUAGGUUUUUUCCUUUCAUUUUAUUCUCUUCUAGUUUUGACAUUUUAUGAUAGAUUUGCUCUCUAGAAGGAAACGUCUUUAUUUAGGAGGGCAAAAAUUUUGGUCAUAGCAUUCACUUUUGCUAUUCCAAUCUACAACUGGAAGAUACAUAAAAGUGCUUUGCAUUGAAUUUGGGAUAACUUCAAAAAUCCCAUGGUUGUUGUUAGGGAUAGUACUAAGCAUUUCAGUUCCAGGAGAAUAAAAGAAAUUCCUAUUUGAAAUGAAUUCCUCAUUUGGAGGAAAAAAAGCAUGCAUUCUAGCACAACAAGAUGAAAUUAUGGAAUACAAAAGUGGCUCCUUCCCAUGUGCAGUCCCUGUCCCCCCCCGCCAGUCCUCCACACCCAAACUGUUUCUGAUUGGCUUUUAGCUUUUUGUUGUUUUUUUUUUUCCUUCUAACACUUGUAUUUGGAGGCUCUUCUGUGAUUUUGAGAAGUAUACUCUUGAGUGUUUAAUAAAGUUUUUUUCCAAAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[PRKDC 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
646,PMID: 33650968,RNAPS0000581,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:387,https://www.ncbi.nlm.nih.gov/gene/387,RHOA,1064nt(3'UTR),AACCUUGCUGCAAGCACAGCCCUUAUGCGGUUAAUUUUGAAGUGCUGUUUAUUAAUCUUAGUGUAUGAUUACUGGCCUUUUUCAUUUAUCUAUAAUUUACCUAAGAUUACAAAUCAGAAGUCAUCUUGCUACCAGUAUUUAGAAGCCAACUAUGAUUAUUAACGAUGUCCAACCCGUCUGGCCCACCAGGGUCCUUUUGACACUGCUCUAACAGCCCUCCUCUGCACUCCCACCUGACACACCAGGCGCUAAUUCAAGGAAUUUCUUAACUUCUUGCUUCUUUCUAGAAAGAGAAACAGUUGGUAACUUUUGUGAAUUAGGCUGUAACUACUUUAUAACUAACAUGUCCUGCCUAUUAUCUGUCAGCUGCAAGGUACUCUGGUGAGUCACCACUUCAGGGCUUUACUCCGUAACAGAUUUUGUUGGCAUAGCUCUGGGGUGGGCAGUUUUUUGAAAAUGGGCUCAACCAGAAAAGCCCAAGUUCAUGCAGCUGUGGCAGAGUUACAGUUCUGUGGUUUCAUGUUAGUUACCUUAUAGUUACUGUGUAAUUAGUGCCACUUAAUGUAUGUUACCAAAAAUAAAUAUAUCUACCCCAGACUAGAUGUAGUAUUUUUUGUAUAAUUGGAUUUCCUAAUACUGUCAUCCUCAAAGAAAGUGUAUUGGUUUUUUAAAAAAGAAAGUGUAUUUGGAAAUAAAGUCAGAUGGAAAAUUCAUUUUUUAAAUUCCCGUUUUGUCACUUUUUCUGAUAAAAGAUGGCCAUAUUACCCCUUUUCGGCCCCAUGUAUCUCAGUACCCCAUGGAGCUGGGCUAAGUAAAUAGGAAUUGGUUUCACGCCUGAGGCAAUUAGACACUUUGGAAGAUGGCAUAACCUGUCUCACCUGGACUUAAGCAUCUGGCUCUAAUUCACAGUGCUCUUUUCUCCUCACUGUAUCCAGGUUCCCUCCCAGAGGAGCCACCAGUUCUCAUGGGUGGCACUCAGUCUCUCUUCUCUCCAGCUGACUAAACUUUUUUUCUGUACCAGUUAAUUUUUCCAACUACUAAUAGAAUAAAGGCAGUUUUCUAAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[RHOA 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
647,PMID: 33650968,RNAPS0000582,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:25800,https://www.ncbi.nlm.nih.gov/gene/25800,SLC39A6,1062nt(3'UTR),UUAAGGUUUAAAUGCUAGAGUAGCUUAAAAAGUUGUCAUAGUUUCAGUAGGUCAUAGGGAGAUGAGUUUGUAUGCUGUACUAUGCAGCGUUUAAAGUUAGUGGGUUUUGUGAUUUUUGUAUUGAAUAUUGCUGUCUGUUACAAAGUCAGUUAAAGGUACGUUUUAAUAUUUAAGUUAUUCUAUCUUGGAGAUAAAAUCUGUAUGUGCAAUUCACCGGUAUUACCAGUUUAUUAUGUAAACAAGAGAUUUGGCAUGACAUGUUCUGUAUGUUUCAGGGAAAAAUGUCUUUAAUGCUUUUUCAAGAACUAACACAGUUAUUCCUAUACUGGAUUUUAGGUCUCUGAAGAACUGCUGGUGUUUAGGAAUAAGAAUGUGCAUGAAGCCUAAAAUACCAAGAAAGCUUAUACUGAAUUUAAGCAAAGAAAUAAAGGAGAAAAGAGAAGAAUCUGAGAAUUGGGGAGGCAUAGAUUCUUAUAAAAAUCACAAAAUUUGUUGUAAAUUAGAGGGGAGAAAUUUAGAAUUAAGUAUAAAAAGGCAGAAUUAGUAUAGAGUACAUUCAUUAAACAUUUUUGUCAGGAUUAUUUCCCGUAAAAACGUAGUGAGCACUUUUCAUAUACUAAUUUAGUUGUACAUUUAACUUUGUAUAAUACAGAAAUCUAAAUAUAUUUAAUGAAUUCAAGCAAUAUAUCACUUGACCAAGAAAUUGGAAUUUCAAAAUGUUCGUGCGGGUAUAUACCAGAUGAGUACAGUGAGUAGUUUUAUGUAUCACCAGACUGGGUUAUUGCCAAGUUAUAUAUCACCAAAAGCUGUAUGACUGGAUGUUCUGGUUACCUGGUUUACAAAAUUAUCAGAGUAGUAAAACUUUGAUAUAUAUGAGGAUAUUAAAACUACACUAAGUAUCAUUUGAUUCGAUUCAGAAAGUACUUUGAUAUCUCUCAGUGCUUCAGUGCUAUCAUUGUGAGCAAUUGUCUUUUAUAUACGGUACUGUAGCCAUACUAGGCCUGUCUGUGGCAUUCUCUAGAUGUUUCUUUUUUACACAAUAAAUUCCUUAUAUCAGCUUGA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[SLC39A6 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
648,PMID: 33650968,RNAPS0000583,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:200010,https://www.ncbi.nlm.nih.gov/gene/200010,SLC5A9,1095nt(3'UTR),UUCCACAGACCUGGCUUCAGUGUAGACAGAUUAAACAAAGCCCAAGCCUGUCAGCCACAGAAACAGGCUCUCCUCUUACUUUGCUGUCUAAACUGGAGAUCACAGAAGUCAAGACUGCAAGCUCCCCUGAAGAGAAUCCAACUCAACCUGCACACUUGACAAGUGGAGAAACAGAAGCCCAGAGAGAGCACUGGGUUUGUUCAGGACCACCCAGAAGGUGUCACACGGGGUUUCCCCACUCUUUCUGAUAUAUUGCCUUACAGACCUACCUCAAACACACUGUUUCCACCCUCUUCUUGAAUGUAUUCAGUAGCCUUUACUGAAUGUGUGUCUUGAGAGUAGAAAAAUGGAGGAUACAAGAAAAGGAGCAGGAAGAAAUUUGCAAAAAUCCAAGAGCACCUUUGCUCCCCCUUAUCCUCCUUCCUCUUCCCCUUUCUAGUUCCCCUACCUCUCUAUCUUUCUAUUCUCACCAAUAAUCUCUUUGUUGCAUGAAUUUACCCAGGAGAGUCCUAUAUUUCCAUUGGUGGCUCCACAGUGGUGGCUGUCAGACCCGAAGGGGUGGGGAGCCAAGGGUGGACUUUAAGCAUGGUGACAGAUGGUAUUUUGGGCAGAAAGCUCUUAGACAAUGGACUAUCCAAAGCACUAUUUAAAUUCUGCCUCUUCCUACUCUCUAACCCAAAUAUGCACAAACUCUCUAUGGCCUUGAGAAGCAGUUGGAGAGACAUGACUUGUUAAAACCUCAAGGAAUCAAGACAUGUUACUCUGUAUUUAAGGGUAAGCCCCACAGCGGGCAGCACAAACAGCCUGGGAGCCACUGUGCCUGUGCUUCUCUGUCCUUCUCCCUUUGCUUGCCAUGAAUCCGCAUACCUUGGAAUACACUGUGACCCCAGUUAAGUGUCCCUUCGCCAGGAAGCUGCCGCAACGUCCAGACCUGGGUCAAGUUCCCACUCCUGCUCCCAUAGCCUUGACCUGCUUCUGUCACAGCACUGAUCACACUGAGAUGGAAGACUCCAGGGGGCAAGGACCAAGGGCCAUAUCCCAAGUGACUUUGUACCCAGAAAAUAACAGCUGUUCAAUAAAUGUGUAUUGAGUUAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[SLC39A6 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
649,PMID: 33650968,RNAPS0000584,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:85027,https://www.ncbi.nlm.nih.gov/gene/85027,SMIM3,1113nt(3'UTR),GAGCCUCCCAAGAGGGCCGGGUGAGGGAUGAGGACAGGCAUCCUAUCCCCAGCCUCUUCCUGUCUUCAGAAAAGCAGCAGGAGGGACUUUGGGGCAUGGACCUGAGUUCUGGUUUUGAUUCUGCCACGAGCCAGCUGUGUGAAUUUGGUCAAGGGACCUAACUCUCUGAGUUCCAGGUUCCUUAUCUUUCAAAUGGGGAUGGUGAUCCCUGCCCUUUCUACCUCAUAGGGAUGUGAGAACCACCUGACUUAGUGGAUGUGAAAGCUGUUUGUGAUCAGUAAAGCUACCACAGAUAUAAGGGUGUUAUGCUGAAUCCUGAGAAGCUUUCAAGAACCAGAGAACCUGAUUGCUGAUGAUGGCCUUAAAGGUGGUGAGGGAGAUACUGGGGGCAGAGCAGACUUUGCCAGUGCCCCUCAGGUCAAACCAAGCCAAGAGCACCCUGUCCCCAUUCCAAGGGGCCAGCAGCACUUUGGCCCAAAGUAUUUUCUUUAAGGUGCCAUUCCUUCAUGUUUUCUCAGUUUGGAGGGUGAUGGGUAGAGCUUUCCAGAACCUUCUCCAUUCCAGAAUCUCUGCCCCUGUGUAAUCUGAAGGAAGGCUGUGCCAUCUUUGGGCACUGCCAAGGGAGUUGGGGUGAUGGGCUUCUUUCUGCACUGGAGUCUCACAUCUGUUAGCUUUGACACUCAAGCAAUGUUGGAAAAUGCAGGGUGACUGAGUUCCCUGCCCAGCUUUCGGGAUCUCUGGCCCCCAUCCCCUUGUGUGUGUCCCUCUGCCCAGCUCCUGCUGUAAUUAGCUCCACGUGUACCCCCUUCACUCCCUCCCACCAGCUCUGCAGCCAGCCUAUGGCAAUUAUAUUUUAAGAGGUGUUCCCAGGACUUUUGGGACCUACUAAAACAAUGAUGGUUAUUUUAGAUGUGAUGAUUUAUAUUUAUGUAGAGAUAUUUCUGGACCACUCAAGCUCUUCGAUACCAAAAUCAGGAGCAUCUUGGGAUUUAUUAAAUUAUGUAAGAAGAUAGCACAGAUAUCGGGAUAUUAUUGUGUGAAAAUGCUGCUUUUACUUUGAUGUGAUCUCAUUGAUGUACACAACCAAGUUCCAAUAAAGUGCUAGAAUGUGCA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[SMIM3 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
650,PMID: 33650968,RNAPS0000585,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:25928,https://www.ncbi.nlm.nih.gov/gene/25928,SOSTDC1,1067nt(3'UTR),AACUCAGACUCCCAUAACUAGACUUACUAGUAACCAUCUGCUUUACAGAUUUGAUUGCUUGGAAGACUCAAGCCUGCCACUGCUGUUUUCUCACUUGAAAGUAUAUGCUUUCUGCUUUGAUCAAACCCAGCAAGCUGUCUUAAGUAUCAGGACCUUCUUUGGGAAUAGUUUUUCCUUUUCAAGUUUUUCAAGAUGUAGGUAUAUCCAUGAAUGCAAUUUGCAUUUAAAUUCCACGUAUCCUGUAGUUUUAAUUCCUCAUUGUUCUUAAAAGACUGUUGAUACUAUAAACAUCAGUGAAUCAUUAUAUUUUAAAACAGAAAAGGGCUUCUCAGAUACCCUCCAUCUACUGGCCCAUCCCCUCUCCUAAACAAAACUCCUUCAAAACAGGUUAAAAAAAAUAUGUUGUCAUGAAUCUUCACAGUAACAUUUCAGAAAGGUGCUUUUUUGGUACUCUUCAUGGGAACAGUUUAGCAGCCAUGAGUGAUCUUCCUUUGAAAGAGAAUGAAAGACCCUGUGACAUUUCACUUCAAAAAUAAGCCCUGUAGCUCUUUACGGUCGCAUAGUAUGAAAUUAUACCCUGCAUGCUGACCCUCGCUUGGAAUGGAAUGCCAGAAAUGCAUGGCAGCAGCUAAUAAGUAAAGCUGAUUAACUAUUUAUUUGUCAAUGUUAUUAUUUAAUGAGCUUUCACAUGUGAUUUGUUUCAAAACUUUAAUUUUUUAAUGUUUUGAAACUUUUUCAUGGACCUAAAUAUUUUCCUAUAUGAUUUGUGGUUGAUUAGAAAUAUGAAAUACAUGUUGUAGAUAUGUAAAAUGAAUAUUUUAGUCUCCUUAUUACAUAUAUGUUCAUGGUGAACUUUAUCAAUAGUAUGGAUCUUUUUAAAUCAAUAAGAUGCUUUGUAAAGUUGAAAUAAGUAAUACUUUCUUGUUUAAUCUGUGCAAUCAGAAGGUGUCUUGACCUUCAAUUCAAUUGGUUUCUUUUAACAAAAAUAAACACUGCUAAAAGUUAUUGUUGUUGCCUCUAACAUGUAUAAAGGGUGCAAAAAUUGUAGAAUAAAUGUAUAAGGGUAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[SOSTDC1 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
651,PMID: 33650968,RNAPS0000586,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:8987,https://www.ncbi.nlm.nih.gov/gene/8987,STBD1,1130nt(3'UTR),UUCAGUUUGCAAAGUAAUGGAGAAGCUGUAGAACAAUGUGGAAGAGGCUGAGGUUGUGGAACACACUGAAUAAAAUAAAGGCAGUGUGACUCCAAAUUCAGCCAUCUGAAUUGUUUAAAUUUGCUAGUGGAUUUUGUCUAAUGUGCAGAAAUAUAUAUGUCUAAUGUGCAGAAAUAUAUAUGUGUGUAUGUGUGUAUAUAUAUGCACACACACACAGAUAAUGCUUCCAGUGAAUGUGAACUUCUUUUCCCUGUGGCACUGAUUGACAGACUUGUGCUGAUCCAUUAUUACUUUAGGGCUUGAUUCUCUUGGGGAGUGACUUGGCUAAGCUUCAGGUGUAAACUGUGGUCACGGAGCAAAAACAUUAACCAGCUGCCCAGGGUUCAAGCUUGAGCCUUUAGGUGAUCUUUAAACUAUGGUAGUAAAAUAAGCCUCACUCAAACAUAGCUGACUUCCUAUUGGUACAGCUUGAAAAGCACUUUUUACUACAUACACAUUUUAUGCUUAAAAAGUUAACAUGAUACGAAACUGUGAUUAGAAAAUAUCUGGUCUGGAUGUGAUUAGUAAGGAUACAAGAUAAUGUUCUAAGACUGCCUAAUGCUUUUUGUUUGAUUUUCAUCUGCCAGGCGUUGUUAUGUGCUAUGAGGGUAGCAAGUACGUCUUUGUCUUAAUGAUCUAAGGCUGGUGUAGAAACAAAGGGCCUAAUGAGAACCAAUCAUCAUGGAAGUCAGUUGCGGGGGCAGCCCAUAAGGAAAGGGAAAGUGAGUGGGGUUGGGCAUAGGCUGAGUGAGGUGGCCUGAAUGACACCUCUUAGAGGACUGUGAAGUACAGGCACAGCCCGACUGCAGGGAGGGAUGCACCCAUCAUUUACCCAUGGGAGCAUCUGUAGGACCAUCUCUCUCCCACUUCUUCUCCCCUCCCCCACCGCAUCUGGCCAGAUGGACUGUCCUACAGCAAUCGUUUCCAUCUGUCACCCUCUUCCCUCUCCUUUCAUACCAGUCACUAUCUUGGGUAACAAAUUUAUACAGGACAGUGGUACAGAAAUACAUCUUUGCUCUGAGAAUACAGCAAAUAUUAACUUAAAUUAUUAUAACUGAACAAAUAAUAAAACCUGAAUUUUAAUAUCUUCA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[STBD1 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
652,PMID: 33650968,RNAPS0000587,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:841,https://www.ncbi.nlm.nih.gov/gene/841,CASP8,1117nt(3'UTR),UGGUGCUAUUUUGUUUGUUUUGUUUUGUUUUGUUUUUUUGAGACAGAAUCUCGCUCUGUCGCCCAGGCUGGAGUGCAGUGGCGUGAUCUCGGCUCACCGCAAGCUCCGCCUCCCGGGUUCAGGCCAUUCUCCUGCCUCAGCCUCCCGAGUAGCUGGGACUACAGGGGCCCGCCACCACACCUGGCUAAUUUUUUAAAAAUAUUUUUAGUAGAGACAGGGUUUCACUGUGUUAGCCAGGGUGGUCUUGAUCUCCUGACCUCGUGAUCCACCCACCUCGGCCUCCCAAAGUGCUGGGAUUACAGGCGUGAGCCACCGCGCCUGGCCGAUGGUACUAUUUAGAUAUAACACUAUGUUUAUUUACUAAUUUUCUAGAUUUUCUACUUUAUUAAUUGUUUUGCACUUUUUUAUAAGAGCUAAAGUUAAAUAGGAUAUUAACAACAAUAACACUGUCUCCUUUCUCUUAUGCUUAAGGCUUUGGGAAUGUUUUUAGCUGGUGGCAAUAAAUACCAGACACGUACAAAAUCCAGCUAUGAAUAUAGAGGGCUUAUGAUUCAGAUUGUUAUCUAUCAACUAUAAGCCCACUGUUAAUAUUCUAUUAACUUUAAUUCUCUUUCAAAGCUAAAUUCCACACUACCACAUUAAAAAAAUUAGAAAGUAGCCACGUAUGGUGGCUCAUGUCUAUAAUCCCAGCACUUUGGGAGGUUGAGGUGGGAGGAUUGCUUGAACCCAAGAGGUCAAGGCUGCAGUGAGCCAUGUUCACACCGCUGCACUCAAGCUUGGGUGACAGAACAAGACCCCGUCUCAAAAAAAAUUUUUUUUUUAAUAAAACAAAAUUUGUUUGAAAUCUUUUAAAAAUUCAAAUGAUUUUUACAAGUUUUAAAUAAGCUCUCCCCAAACUUGCUUUAUGCCUUCUUAUUGCUUUUAUGAUAUAUAUAUGCUUGGCUAACUAUAUUUGCUUUUUGCUAACAAUGCUCUGGGGUCUUUUUAUGCAUUUGCAUUUGCUCUUUCAUCUCUGCUUGGAUUAUUUUAAAUCAUUAGGAAUUAAGUUAUCUUUAAAAUUUAAGUAUCUUUUUUCAAAAACAUUUUUUAAUAGAAUAAAAUAUAAUUUGAUCUUAUU,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[CASP8 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
653,PMID: 33650968,RNAPS0000588,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:114799,https://www.ncbi.nlm.nih.gov/gene/114799,ESCO1,1059nt(3'UTR),AACAAAUUCUUGCCUACACCACUAGAAGACAUCUAUUGAAGAGAAUGGAUUGGUUGCUGACUUUAACCAGGAACUAGGGCCAUUUUUAUUACAAUGAACUCAGGACUGGCAACAACCAUAUGGUUGUUCCAUUUUCAUAAAAUUGGAAACAAUGCAGUAAUAGCUUAUUGUUUUGUUUUUUAAAGAAGAUAUUUUAUUAUCUUUUACAGAAAUUUAUGAUUGAUGUAUUUUAUCUAUAGUUAUUUAGACAUGUUUACAUGCAGCAGAUAAUUGUUCAUAGUGGACUGAAAACUAAUGCAAGGACUAUGGUCUCAGUGAUAAGUAUAUUUUGAAGUUCUUAAUAUGGAAAUAUACCAGUGUAGCUUGGUACUGUAUUUUUUUAUAUUGAUCUGCUGAUACCAGUGAUAGGCUUAAAGAUUGUAUUUUCACAGAGUGGAAACCAAUUUUUUUAGUUAUUGUUCAAGGAGGGUGCAAUAUUAAGUGUUUUGGAAUUUGAAGCUAAUUUUUAAAAGGCCUGAACUAUACUUUGAAGAAACCCCUAUAGAAAAGGAAAGCUCCAGCUAAAUAGGAAGAAUUAGAAUAUUGAGCUUUUUUUUCCUGAUUUUUCUCUUUCCUAUCUUUGAUGGAAGGAGGAAGUAGAAAGUGGUAAAGAAUUGAGGCUUUCCUUCUUGGAGAGCUGUAAAUGACAAGCAUUAGGAAAGGUACCCUCCUAGAUUCAUUAUUCUUUCAUUCUGGUUUCACUUUUAAAAUAAAUGGCAACUUGGCACACCUAGGCUGUUAACAAAUCUCAAAGAGGUUUAUAAAAACGUAUAGAAUACUUGGAAGCAAAGUAUGGAUGACUCGGUAUCUGCUUUGUUAUUCCUCAGAAAUACUGCACUGAGUAUAUGCCCUCAUUACUGGACUUCAUUUUGAUACUUGUCUAUCCUUCAUAGUGCCCUCUACUUUUAAAGGGUUUAUAUGUUGAAAAACUGCUGUGGCCUUUUAUGACCUGUAUAUAAUGUAGAAUAAAAAUAAUAAAAUACUUGAUAGCUUUUUCUAAGUGACCAAUGUACUAACUGA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[ESCO1 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
654,PMID: 33650968,RNAPS0000589,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:987,https://www.ncbi.nlm.nih.gov/gene/987,LRBA,1063nt(3'UTR),UGGUGACAGCUGUACAUCAACUCUGCCCCUAGGAUGAGCAGAAGUACCUGGAGCAUCAUUCUCUUCUACCACAUCUGAAUGUAACUUAAAUUUGCUCAAAGAAGCAAAAUAUUUUUUAAAGUUAUUAAUAAUUGCUAUUUUUGUAGUCUUUGCUUGACUUUUUUGGGGGGGAUUAGCAAAGCAGAAAACUGGCUGCUGGGUUCUGUAGUUUUAAAAAAUCUAUAUUUUUAGUCAUAAUGAGAAGUCUAUUUUCACCAAUUAUGGAAACAUACAGUGGAGCAAGUAAACCACUUAUUCCAGCUAUAAUAUUAUGAAGAACAUUUCCCAUGCAUCUACAAGCUUGAGAAAUAGGAUUUUCACAGUGGGGAAGUGGGUUACAAUAUUGGAAUAGGAAAAUUUGAUGCUGUAAUUUGGGUCCUGUAUUUUUCCAAACAACUGUGCUUCUUCAGCACUAAUAUUUCUGGGAUUUAAAUAGUAAUGUUUAAAUUAUGGUAAAUGUAAUUUAAAACAUCUCAAUUAAGUCUGUCUAUCAAUAUUGUUCUUCAAGCAUGUUUUAGACCUAGAAAAGUAUGGUUUGGGGGAGGCUAUUUUAUUGUGUGGUUAGCACAAGGAAUCUAAUUUAUAGCAAGUGUGAAAUAGUUACCAUUUUUUCCUGAUCUGUCAUCUUCAUAGCACAACAAAACGAAAUGAUGGAAAUGCUCUUGAGCUCACAACAUUUGUUUUUCUUUUAAAGUAAAUGCAAGUACCAAAGCUCACUACUGCGGUUUGCCUGUGCCUGGACAAUGAGGCGGAGCCACUGUUGUUUUGUUGGGGCACCCCCUUCCCUCCCCGGGUUUGCAAAUAGAGGCUACCGGGUGCUGUAUUCAGCAACACCUGUUUUACUAUUUGUUAUUAAACUAUCAUCUCCACCUUCCUUUUGAUUAGCAAUUUGUACUAAGAAACGAAACAAUGUUAUUUGGUGGUGUAUAAUUCUACUUUUCUAGUAGAUUACUGUGUGGAAUUCUGUGAAAAAUAUUUGAGAAAAGGCCUGUAUUGCAUAAAUAAAUUCUUUGUAUGUUGUGAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[LRBA 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
655,PMID: 33650968,RNAPS0000590,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:4957,https://www.ncbi.nlm.nih.gov/gene/4957,ODF2,1037nt(3'UTR),GGCCACUUAUCAGGGCCUGGAGCCCUGAUGGAAGCCAUAGGAACUCCAGAGUUGCCAAGCCAUAGCUGAGAAGCCUGGUGGUUUUCCUCUCCCAGUGAAAAAAUGGGUUCAGGGUCUUGUCCUUAGCUACUAGCUCUAGAAAAGUCCCAAAAGCAGCAGAAGGUGAAGCAGGAAGCACUUGGUUUUCUCCUUCCUGAUAUAGUCACCUGUUGGAAGUGUUAAAAUUUCCUCGACAGGCCUUAAAUUUACUACUACAUUAGGGUACCACAUUUUAACUUACCAUGACUUUGCUCCUUCCUUUCCUGAGAAAAUAUUUCCACUGGAUUUUUUCCACCAGUCCCCUUACAGCCCUCAUUGUUUUAGGAAUCUCUCUCAGGUUUUUUCUGACCUAAACCAGCAGGAAGUCGUCCUGGGCUGUAAGCACCAUCACUUGCUUUUUUUUUUUUUCUGAUUUCACAAGUGUGGUGUUUUCCCAAGGCUCCCUUCCCAAGCUCAGUGCAAACCUCUCACUCCCAAGUUUCUUUGAGGCCACUUGCCCCCAAGCACUUCACAAUAGACCCUCGAGGGCUUGUGUCCAUUUGGCCUUUUACAAGUGUAAUGCCAAUUUCAUUGAUUUUUGUUUCUUUUGGCCUGAUUUGUAUCUCUGGAAUGCAUUUAUUCUUGAAAUAUUUGUGUGAUUUUACAAAAAGCUUUUGUAAUCAGUUAUUUAAGGCUCCAUUUGAUGAUUUCCUUUACCCAACCAGUCCUCAUCCCUCCUCUAAAAAAUGAUUAAGUAAAAUGCUGCAGGACAGCCAGUAGACAUUUUUAAAGUACUUGGUGCCUGAAACAUCAGGCUUCUCAUUUCAUUUUAGCUCAGGUUGGUGCUUUCACAUUGUAAUCAAUGAACUGUCAGGAGGGAACAAACUGUAAGAAGGAUUGCUUGGUGUUUUAGGGUAGAUCACUUUAGCUAUUAGGAAGAGGAUGGGGUAGUGUACAGUAUAUAUUUUUAAAAUGUGAAUUGGUUUCUGAAUAAGAAUCUGGGCCAUUUUUGUUCACCA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[ODF2 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,The normalized ensemble diversity (NED) value of RNAs is highly predictive for their ability to form sphere- or mesh-like condensates.
656,PMID: 33650968,RNAPS0000591,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:8600,https://www.ncbi.nlm.nih.gov/gene/8600,TNFSF11,1125nt(3'UTR+2*15nt),GCCCCAGUUUUUGGAGUGUUAUGUAUUUCCUGGAUGUUUGGAAACAUUUUUUAAAACAAGCCAAGAAAGAUGUAUAUAGGUGUGUGAGACUACUAAGAGGCAUGGCCCCAACGGUACACGACUCAGUAUCCAUGCUCUUGACCUUGUAGAGAACACGCGUAUUUACAGCCAGUGGGAGAUGUUAGACUCAUGGUGUGUUACACAAUGGUUUUUAAAUUUUGUAAUGAAUUCCUAGAAUUAAACCAGAUUGGAGCAAUUACGGGGUGACCUUAUGAGAAACUGCAUGUGGGCUAUGGGAGGGGUUGGUCCCUGGUCAUGUGCCCCUUCGCAGCUGAAGUGGAGAGGGUGUCAUCUAGCGCAAUUGAAGGAUCAUCUGAAGGGGCAAAUUCUUUUGAAUUGUUACAUCAUGCUGGAACCUGCAAAAAAUACUUUUUCUAAUGAGGAGAGAAAAUAUAUGUAUUUUUAUAUAAUAUCUAAAGUUAUAUUUCAGAUGUAAUGUUUUCUUUGCAAAGUAUUGUAAAUUAUAUUUGUGCUAUAGUAUUUGAUUCAAAAUAUUUAAAAAUGUCUUGCUGUUGACAUAUUUAAUGUUUUAAAUGUACAGACAUAUUUAACUGGUGCACUUUGUCAGUUUCUCAUAAGGAAAUUCCCUGGGGAAAACUUGCAGCUAAGGAGGGGAAAAAAAUGUUGUUUCCUAAUAUCAAAUGCAGUAUAUUUCUUCGUUCUUUUUAAGUUAAUAGAUUUUUUCAGACUUGUCAAGCCUGUGCAAAAAAAUUAAAAUGGAUGCCUUGAAUAAUAAGCAGGAUGUUGGCCACCAGGUGCCUUUCAAAUUUAGAAACUAAUUGACUUUAGAAAGCUGACAUUGCCAAAAAGGAUACAUAAUGGGCCACUGAAAUCUGUCAAGAGUAGUUAUAUAAUUGUUGAACAGGUGUUUUUCCACAAGUGCCGCAAAUUGUACCUUUUUUGUUUUUUCAAAAUAGAAAAGUUAUUAGUGGUUUAUCAGCAAAAAAGUCCAAUUUUAAUUUAGUAAAUGUUAUCUUAUACUGUACAAUAAAAACAUUGCCUUUGAAUGUUAAUUUUUUGGUACAAAAAUAAAUUUAUAUGAAAACCUGCGCAGGUUUUCAUAUA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|150nM[TNFSF11 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,"The TNFSF11 3'UTR mutant has stronger local structures indicated by increased base-pairing and a lower NED value, and it has largely lost the ability for network formation"
657,PMID: 33650968,RNAPS0000592,https://pubmed.ncbi.nlm.nih.gov/33650968,RNAs + protein,NCBI ID:961;|NCBI ID:1994,https://www.ncbi.nlm.nih.gov/gene/961;|https://www.ncbi.nlm.nih.gov/gene/1994,CD47;|ELAVL1,4194nt(3'UTR);|4909nt(3'UTR),CUGAAGUGAAGUGAUGGACUCCGAUUUGGAGAGUAGUAAGACGUGAAAGGAAUACACUUGUGUUUAAGCACCAUGGCCUUGAUGAUUCACUGUUGGGGAGAAGAAACAAGAAAAGUAACUGGUUGUCACCUAUGAGACCCUUACGUGAUUGUUAGUUAAGUUUUUAUUCAAAGCAGCUGUAAUUUAGUUAAUAAAAUAAUUAUGAUCUAUGUUGUUUGCCCAAUUGAGAUCCAGUUUUUUGUUGUUAUUUUUAAUCAAUUAGGGGCAAUAGUAGAAUGGACAAUUUCCAAGAAUGAUGCCUUUCAGGUCCUAGGGCCUCUGGCCUCUAGGUAACCAGUUUAAAUUGGUUCAGGGUGAUAACUACUUAGCACUGCCCUGGUGAUUACCCAGAGAUAUCUAUGAAAACCAGUGGCUUCCAUCAAACCUUUGCCAACUCAGGUUCACAGCAGCUUUGGGCAGUUAUGGCAGUAUGGCAUUAGCUGAGAGGUGUCUGCCACUUCUGGGUCAAUGGAAUAAUAAAUUAAGUACAGGCAGGAAUUUGGUUGGGAGCAUCUUGUAUGAUCUCCGUAUGAUGUGAUAUUGAUGGAGAUAGUGGUCCUCAUUCUUGGGGGUUGCCAUUCCCACAUUCCCCCUUCAACAAACAGUGUAACAGGUCCUUCCCAGAUUUAGGGUACUUUUAUUGAUGGAUAUGUUUUCCUUUUAUUCACAUAACCCCUUGAAACCCUGUCUUGUCCUCCUGUUACUUGCUUCUGCUGUACAAGAUGUAGCACCUUUUCUCCUCUUUGAACAUGGUCUAGUGACACGGUAGCACCAGUUGCAGGAAGGAGCCAGACUUGUUCUCAGAGCACUGUGUUCACACUUUUCAGCAAAAAUAGCUAUGGUUGUAACAUAUGUAUUCCCUUCCUCUGAUUUGAAGGCAAAAAUCUACAGUGUUUCUUCACUUCUUUUCUGAUCUGGGGCAUGAAAAAAGCAAGAUUGAAAUUUGAACUAUGAGUCUCCUGCAUGGCAACAAAAUGUGUGUCACCAUCAGGCCAACAGGCCAGCCCUUGAAUGGGGAUUUAUUACUGUUGUAUCUAUGUUGCAUGAUAAACAUUCAUCACCUUCCUCCUGUAGUCCUGCCUCGUACUCCCCUUCCCCUAUGAUUGAAAAGUAAACAAAACCCACAUUUCCUAUCCUGGUUAGAAGAAAAUUAAUGUUCUGACAGUUGUGAUCGCCUGGAGUACUUUUAGACUUUUAGCAUUCGUUUUUUACCUGUUUGUGGAUGUGUGUUUGUAUGUGCAUACGUAUGAGAUAGGCACAUGCAUCUUCUGUAUGGACAAAGGUGGGGUACCUACAGGAGAGCAAAGGUUAAUUUUGUGCUUUUAGUAAAAACAUUUAAAUACAAAGUUCUUUAUUGGGUGGAAUUAUAUUUGAUGCAAAUAUUUGAUCACUUAAAACUUUUAAAACUUCUAGGUAAUUUGCCACGCUUUUUGACUGCUCACCAAUACCCUGUAAAAAUACGUAAUUCUUCCUGUUUGUGUAAUAAGAUAUUCAUAUUUGUAGUUGCAUUAAUAAUAGUUAUUUCUUAGUCCAUCAGAUGUUCCCGUGUGCCUCUUUUAUGCCAAAUUGAUUGUCAUAUUUCAUGUUGGGACCAAGUAGUUUGCCCAUGGCAAACCUAAAUUUAUGACCUGCUGAGGCCUCUCAGAAAACUGAGCAUACUAGCAAGACAGCUCUUCUUGAAAAAAAAAAUAUGUAUACACAAAUAUAUACGUAUAUCUAUAUAUACGUAUGUAUAUACACACAUGUAUAUUCUUCCUUGAUUGUGUAGCUGUCCAAAAUAAUAACAUAUAUAGAGGGAGCUGUAUUCCUUUAUACAAAUCUGAUGGCUCCUGCAGCACUUUUUCCUUCUGAAAAUAUUUACAUUUUGCUAACCUAGUUUGUUACUUUAAAAAUCAGUUUUGAUGAAAGGAGGGAAAAGCAGAUGGACUUGAAAAAGAUCCAAGCUCCUAUUAGAAAAGGUAUGAAAAUCUUUAUAGUAAAAUUUUUUAUAAACUAAAGUUGUACCUUUUAAUAUGUAGUAAACUCUCAUUUAUUUGGGGUUCGCUCUUGGAUCUCAUCCAUCCAUUGUGUUCUCUUUAAUGCUGCCUGCCUUUUGAGGCAUUCACUGCCCUAGACAAUGCCACCAGAGAUAGUGGGGGAAAUGCCAGAUGAAACCAACUCUUGCUCUCACUAGUUGUCAGCUUCUCUGGAUAAGUGACCACAGAAGCAGGAGUCCUCCUGCUUGGGCAUCAUUGGGCCAGUUCCUUCUCUUUAAAUCAGAUUUGUAAUGGCUCCCAAAUUCCAUCACAUCACAUUUAAAUUGCAGACAGUGUUUUGCACAUCAUGUAUCUGUUUUGUCCCAUAAUAUGCUUUUUACUCCCUGAUCCCAGUUUCUGCUGUUGACUCUUCCAUUCAGUUUUAUUUAUUGUGUGUUCUCACAGUGACACCAUUUGUCCUUUUCUGCAACAACCUUUCCAGCUACUUUUGCCAAAUUCUAUUUGUCUUCUCCUUCAAAACAUUCUCCUUUGCAGUUCCUCUUCAUCUGUGUAGCUGCUCUUUUGUCUCUUAACUUACCAUUCCUAUAGUACUUUAUGCAUCUCUGCUUAGUUCUAUUAGUUUUUUGGCCUUGCUCUUCUCCUUGAUUUUAAAAUUCCUUCUAUAGCUAGAGCUUUUCUUUCUUUCAUUCUCUCUUCCUGCAGUGUUUUGCAUACAUCAGAAGCUAGGUACAUAAGUUAAAUGAUUGAGAGUUGGCUGUAUUUAGAUUUAUCACUUUUUAAUAGGGUGAGCUUGAGAGUUUUCUUUCUUUCUGUUUUUUUUUUUUGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGACUAAUUUCACAUGCUCUAAAAACCUUCAAAGGUGAUUAUUUUUCUCCUGGAAACUCCAGGUCCAUUCUGUUUAAAUCCCUAAGAAUGUCAGAAUUAAAAUAACAGGGCUAUCCCGUAAUUGGAAAUAUUUCUUUUUUCAGGAUGCUAUAGUCAAUUUAGUAAGUGACCACCAAAUUGUUAUUUGCACUAACAAAGCUCAAAACACGAUAAGUUUACUCCUCCAUCUCAGUAAUAAAAAUUAAGCUGUAAUCAACCUUCUAGGUUUCUCUUGUCUUAAAAUGGGUAUUCAAAAAUGGGGAUCUGUGGUGUAUGUAUGGAAACACAUACUCCUUAAUUUACCUGUUGUUGGAAACUGGAGAAAUGAUUGUCGGGCAACCGUUUAUUUUUUAUUGUAUUUUAUUUGGUUGAGGGAUUUUUUUAUAAACAGUUUUACUUGUGUCAUAUUUUAAAAUUACUAACUGCCAUCACCUGCUGGGGUCCUUUGUUAGGUCAUUUUCAGUGACUAAUAGGGAUAAUCCAGGUAACUUUGAAGAGAUGAGCAGUGAGUGACCAGGCAGUUUUUCUGCCUUUAGCUUUGACAGUUCUUAAUUAAGAUCAUUGAAGACCAGCUUUCUCAUAAAUUUCUCUUUUUGAAAAAAAGAAAGCAUUUGUACUAAGCUCCUCUGUAAGACAACAUCUUAAAUCUUAAAAGUGUUGUUAUCAUGACUGGUGAGAGAAGAAAACAUUUUGUUUUUAUUAAAUGGAGCAUUAUUUACAAAAAGCCAUUGUUGAGAAUUAGAUCCCACAUCGUAUAAAUAUCUAUUAACCAUUCUAAAUAAAGAGAACUCCAGUGUUGCUAUGUGCAAGAUCCUCUCUUGGAGCUUUUUUGCAUAGCAAUUAAAGGUGUGCUAUUUGUCAGUAGCCAUUUUUUUGCAGUGAUUUGAAGACCAAAGUUGUUUUACAGCUGUGUUACCGUUAAAGGUUUUUUUUUUUAUAUGUAUUAAAUCAAUUUAUCACUGUUUAAAGCUUUGAAUAUCUGCAAUCUUUGCCAAGGUACUUUUUUAUUUAAAAAAAAACAUAACUUUGUAAAUAUUACCCUGUAAUAUUAUAUAUACUUAAUAAAACAUUUUAAGCUAUUUUGUUGGGCUAUUUCUAUUGCUGCUACAGCAGACCACAAGCACAUUUCUGAAAAAUUUAAUUUAUUAAUGUAUUUUUAAGUUGCUUAUAUUCUAGGUAACAAUGUAAAGAAUGAUUUAAAAUAUUAAUUAUGAAUUUUUUGAGUAUAAUACCCAAUAAGCUUUUAAUUAGAGCAGAGUUUUAAUUAAAAGUUUUAAAUCAGUC;|-,mRNA;|mRNA,Homo sapiens;|Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|CD47 3'UTR;|ELAVL1 3'UTR,"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,"Therefore, we tested whether two RNAs co-localize in the network. Labeling of several pairs of RNAs with two different fluorescent dyes showed that they colocalize"
658,PMID: 33650968,RNAPS0000593,https://pubmed.ncbi.nlm.nih.gov/33650968,RNAs + protein,NCBI ID:961;|NCBI ID:8600,https://www.ncbi.nlm.nih.gov/gene/961;|https://www.ncbi.nlm.nih.gov/gene/8600,CD47;|TNFSF11,4194nt(3'UTR);|1095nt(3'UTR),CUGAAGUGAAGUGAUGGACUCCGAUUUGGAGAGUAGUAAGACGUGAAAGGAAUACACUUGUGUUUAAGCACCAUGGCCUUGAUGAUUCACUGUUGGGGAGAAGAAACAAGAAAAGUAACUGGUUGUCACCUAUGAGACCCUUACGUGAUUGUUAGUUAAGUUUUUAUUCAAAGCAGCUGUAAUUUAGUUAAUAAAAUAAUUAUGAUCUAUGUUGUUUGCCCAAUUGAGAUCCAGUUUUUUGUUGUUAUUUUUAAUCAAUUAGGGGCAAUAGUAGAAUGGACAAUUUCCAAGAAUGAUGCCUUUCAGGUCCUAGGGCCUCUGGCCUCUAGGUAACCAGUUUAAAUUGGUUCAGGGUGAUAACUACUUAGCACUGCCCUGGUGAUUACCCAGAGAUAUCUAUGAAAACCAGUGGCUUCCAUCAAACCUUUGCCAACUCAGGUUCACAGCAGCUUUGGGCAGUUAUGGCAGUAUGGCAUUAGCUGAGAGGUGUCUGCCACUUCUGGGUCAAUGGAAUAAUAAAUUAAGUACAGGCAGGAAUUUGGUUGGGAGCAUCUUGUAUGAUCUCCGUAUGAUGUGAUAUUGAUGGAGAUAGUGGUCCUCAUUCUUGGGGGUUGCCAUUCCCACAUUCCCCCUUCAACAAACAGUGUAACAGGUCCUUCCCAGAUUUAGGGUACUUUUAUUGAUGGAUAUGUUUUCCUUUUAUUCACAUAACCCCUUGAAACCCUGUCUUGUCCUCCUGUUACUUGCUUCUGCUGUACAAGAUGUAGCACCUUUUCUCCUCUUUGAACAUGGUCUAGUGACACGGUAGCACCAGUUGCAGGAAGGAGCCAGACUUGUUCUCAGAGCACUGUGUUCACACUUUUCAGCAAAAAUAGCUAUGGUUGUAACAUAUGUAUUCCCUUCCUCUGAUUUGAAGGCAAAAAUCUACAGUGUUUCUUCACUUCUUUUCUGAUCUGGGGCAUGAAAAAAGCAAGAUUGAAAUUUGAACUAUGAGUCUCCUGCAUGGCAACAAAAUGUGUGUCACCAUCAGGCCAACAGGCCAGCCCUUGAAUGGGGAUUUAUUACUGUUGUAUCUAUGUUGCAUGAUAAACAUUCAUCACCUUCCUCCUGUAGUCCUGCCUCGUACUCCCCUUCCCCUAUGAUUGAAAAGUAAACAAAACCCACAUUUCCUAUCCUGGUUAGAAGAAAAUUAAUGUUCUGACAGUUGUGAUCGCCUGGAGUACUUUUAGACUUUUAGCAUUCGUUUUUUACCUGUUUGUGGAUGUGUGUUUGUAUGUGCAUACGUAUGAGAUAGGCACAUGCAUCUUCUGUAUGGACAAAGGUGGGGUACCUACAGGAGAGCAAAGGUUAAUUUUGUGCUUUUAGUAAAAACAUUUAAAUACAAAGUUCUUUAUUGGGUGGAAUUAUAUUUGAUGCAAAUAUUUGAUCACUUAAAACUUUUAAAACUUCUAGGUAAUUUGCCACGCUUUUUGACUGCUCACCAAUACCCUGUAAAAAUACGUAAUUCUUCCUGUUUGUGUAAUAAGAUAUUCAUAUUUGUAGUUGCAUUAAUAAUAGUUAUUUCUUAGUCCAUCAGAUGUUCCCGUGUGCCUCUUUUAUGCCAAAUUGAUUGUCAUAUUUCAUGUUGGGACCAAGUAGUUUGCCCAUGGCAAACCUAAAUUUAUGACCUGCUGAGGCCUCUCAGAAAACUGAGCAUACUAGCAAGACAGCUCUUCUUGAAAAAAAAAAUAUGUAUACACAAAUAUAUACGUAUAUCUAUAUAUACGUAUGUAUAUACACACAUGUAUAUUCUUCCUUGAUUGUGUAGCUGUCCAAAAUAAUAACAUAUAUAGAGGGAGCUGUAUUCCUUUAUACAAAUCUGAUGGCUCCUGCAGCACUUUUUCCUUCUGAAAAUAUUUACAUUUUGCUAACCUAGUUUGUUACUUUAAAAAUCAGUUUUGAUGAAAGGAGGGAAAAGCAGAUGGACUUGAAAAAGAUCCAAGCUCCUAUUAGAAAAGGUAUGAAAAUCUUUAUAGUAAAAUUUUUUAUAAACUAAAGUUGUACCUUUUAAUAUGUAGUAAACUCUCAUUUAUUUGGGGUUCGCUCUUGGAUCUCAUCCAUCCAUUGUGUUCUCUUUAAUGCUGCCUGCCUUUUGAGGCAUUCACUGCCCUAGACAAUGCCACCAGAGAUAGUGGGGGAAAUGCCAGAUGAAACCAACUCUUGCUCUCACUAGUUGUCAGCUUCUCUGGAUAAGUGACCACAGAAGCAGGAGUCCUCCUGCUUGGGCAUCAUUGGGCCAGUUCCUUCUCUUUAAAUCAGAUUUGUAAUGGCUCCCAAAUUCCAUCACAUCACAUUUAAAUUGCAGACAGUGUUUUGCACAUCAUGUAUCUGUUUUGUCCCAUAAUAUGCUUUUUACUCCCUGAUCCCAGUUUCUGCUGUUGACUCUUCCAUUCAGUUUUAUUUAUUGUGUGUUCUCACAGUGACACCAUUUGUCCUUUUCUGCAACAACCUUUCCAGCUACUUUUGCCAAAUUCUAUUUGUCUUCUCCUUCAAAACAUUCUCCUUUGCAGUUCCUCUUCAUCUGUGUAGCUGCUCUUUUGUCUCUUAACUUACCAUUCCUAUAGUACUUUAUGCAUCUCUGCUUAGUUCUAUUAGUUUUUUGGCCUUGCUCUUCUCCUUGAUUUUAAAAUUCCUUCUAUAGCUAGAGCUUUUCUUUCUUUCAUUCUCUCUUCCUGCAGUGUUUUGCAUACAUCAGAAGCUAGGUACAUAAGUUAAAUGAUUGAGAGUUGGCUGUAUUUAGAUUUAUCACUUUUUAAUAGGGUGAGCUUGAGAGUUUUCUUUCUUUCUGUUUUUUUUUUUUGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGACUAAUUUCACAUGCUCUAAAAACCUUCAAAGGUGAUUAUUUUUCUCCUGGAAACUCCAGGUCCAUUCUGUUUAAAUCCCUAAGAAUGUCAGAAUUAAAAUAACAGGGCUAUCCCGUAAUUGGAAAUAUUUCUUUUUUCAGGAUGCUAUAGUCAAUUUAGUAAGUGACCACCAAAUUGUUAUUUGCACUAACAAAGCUCAAAACACGAUAAGUUUACUCCUCCAUCUCAGUAAUAAAAAUUAAGCUGUAAUCAACCUUCUAGGUUUCUCUUGUCUUAAAAUGGGUAUUCAAAAAUGGGGAUCUGUGGUGUAUGUAUGGAAACACAUACUCCUUAAUUUACCUGUUGUUGGAAACUGGAGAAAUGAUUGUCGGGCAACCGUUUAUUUUUUAUUGUAUUUUAUUUGGUUGAGGGAUUUUUUUAUAAACAGUUUUACUUGUGUCAUAUUUUAAAAUUACUAACUGCCAUCACCUGCUGGGGUCCUUUGUUAGGUCAUUUUCAGUGACUAAUAGGGAUAAUCCAGGUAACUUUGAAGAGAUGAGCAGUGAGUGACCAGGCAGUUUUUCUGCCUUUAGCUUUGACAGUUCUUAAUUAAGAUCAUUGAAGACCAGCUUUCUCAUAAAUUUCUCUUUUUGAAAAAAAGAAAGCAUUUGUACUAAGCUCCUCUGUAAGACAACAUCUUAAAUCUUAAAAGUGUUGUUAUCAUGACUGGUGAGAGAAGAAAACAUUUUGUUUUUAUUAAAUGGAGCAUUAUUUACAAAAAGCCAUUGUUGAGAAUUAGAUCCCACAUCGUAUAAAUAUCUAUUAACCAUUCUAAAUAAAGAGAACUCCAGUGUUGCUAUGUGCAAGAUCCUCUCUUGGAGCUUUUUUGCAUAGCAAUUAAAGGUGUGCUAUUUGUCAGUAGCCAUUUUUUUGCAGUGAUUUGAAGACCAAAGUUGUUUUACAGCUGUGUUACCGUUAAAGGUUUUUUUUUUUAUAUGUAUUAAAUCAAUUUAUCACUGUUUAAAGCUUUGAAUAUCUGCAAUCUUUGCCAAGGUACUUUUUUAUUUAAAAAAAAACAUAACUUUGUAAAUAUUACCCUGUAAUAUUAUAUAUACUUAAUAAAACAUUUUAAGCUAUUUUGUUGGGCUAUUUCUAUUGCUGCUACAGCAGACCACAAGCACAUUUCUGAAAAAUUUAAUUUAUUAAUGUAUUUUUAAGUUGCUUAUAUUCUAGGUAACAAUGUAAAGAAUGAUUUAAAAUAUUAAUUAUGAAUUUUUUGAGUAUAAUACCCAAUAAGCUUUUAAUUAGAGCAGAGUUUUAAUUAAAAGUUUUAAAUCAGUC;|GCCCCAGUUUUUGGAGUGUUAUGUAUUUCCUGGAUGUUUGGAAACAUUUUUUAAAACAAGCCAAGAAAGAUGUAUAUAGGUGUGUGAGACUACUAAGAGGCAUGGCCCCAACGGUACACGACUCAGUAUCCAUGCUCUUGACCUUGUAGAGAACACGCGUAUUUACAGCCAGUGGGAGAUGUUAGACUCAUGGUGUGUUACACAAUGGUUUUUAAAUUUUGUAAUGAAUUCCUAGAAUUAAACCAGAUUGGAGCAAUUACGGGGUGACCUUAUGAGAAACUGCAUGUGGGCUAUGGGAGGGGUUGGUCCCUGGUCAUGUGCCCCUUCGCAGCUGAAGUGGAGAGGGUGUCAUCUAGCGCAAUUGAAGGAUCAUCUGAAGGGGCAAAUUCUUUUGAAUUGUUACAUCAUGCUGGAACCUGCAAAAAAUACUUUUUCUAAUGAGGAGAGAAAAUAUAUGUAUUUUUAUAUAAUAUCUAAAGUUAUAUUUCAGAUGUAAUGUUUUCUUUGCAAAGUAUUGUAAAUUAUAUUUGUGCUAUAGUAUUUGAUUCAAAAUAUUUAAAAAUGUCUUGCUGUUGACAUAUUUAAUGUUUUAAAUGUACAGACAUAUUUAACUGGUGCACUUUGUAAAUUCCCUGGGGAAAACUUGCAGCUAAGGAGGGGAAAAAAAUGUUGUUUCCUAAUAUCAAAUGCAGUAUAUUUCUUCGUUCUUUUUAAGUUAAUAGAUUUUUUCAGACUUGUCAAGCCUGUGCAAAAAAAUUAAAAUGGAUGCCUUGAAUAAUAAGCAGGAUGUUGGCCACCAGGUGCCUUUCAAAUUUAGAAACUAAUUGACUUUAGAAAGCUGACAUUGCCAAAAAGGAUACAUAAUGGGCCACUGAAAUCUGUCAAGAGUAGUUAUAUAAUUGUUGAACAGGUGUUUUUCCACAAGUGCCGCAAAUUGUACCUUUUUUGUUUUUUCAAAAUAGAAAAGUUAUUAGUGGUUUAUCAGCAAAAAAGUCCAAUUUUAAUUUAGUAAAUGUUAUCUUAUACUGUACAAUAAAAACAUUGCCUUUGAAUGUUAAUUUUUUGGUACAAAAAUAAAUUUAUAUGAAAACCUGC,mRNA;|mRNA,Homo sapiens;|Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|CD47 3'UTR;|TNFSF11 3'UTR,"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,"Therefore, we tested whether two RNAs co-localize in the network. Labeling of several pairs of RNAs with two different fluorescent dyes showed that they colocalize"
659,PMID: 33650968,RNAPS0000594,https://pubmed.ncbi.nlm.nih.gov/33650968,RNAs + protein,NCBI ID:961;|NCBI ID:51311,https://www.ncbi.nlm.nih.gov/gene/961;|https://www.ncbi.nlm.nih.gov/gene/51311,CD47;|TLR8,4194nt(3'UTR);|1003nt(3'UTR),CUGAAGUGAAGUGAUGGACUCCGAUUUGGAGAGUAGUAAGACGUGAAAGGAAUACACUUGUGUUUAAGCACCAUGGCCUUGAUGAUUCACUGUUGGGGAGAAGAAACAAGAAAAGUAACUGGUUGUCACCUAUGAGACCCUUACGUGAUUGUUAGUUAAGUUUUUAUUCAAAGCAGCUGUAAUUUAGUUAAUAAAAUAAUUAUGAUCUAUGUUGUUUGCCCAAUUGAGAUCCAGUUUUUUGUUGUUAUUUUUAAUCAAUUAGGGGCAAUAGUAGAAUGGACAAUUUCCAAGAAUGAUGCCUUUCAGGUCCUAGGGCCUCUGGCCUCUAGGUAACCAGUUUAAAUUGGUUCAGGGUGAUAACUACUUAGCACUGCCCUGGUGAUUACCCAGAGAUAUCUAUGAAAACCAGUGGCUUCCAUCAAACCUUUGCCAACUCAGGUUCACAGCAGCUUUGGGCAGUUAUGGCAGUAUGGCAUUAGCUGAGAGGUGUCUGCCACUUCUGGGUCAAUGGAAUAAUAAAUUAAGUACAGGCAGGAAUUUGGUUGGGAGCAUCUUGUAUGAUCUCCGUAUGAUGUGAUAUUGAUGGAGAUAGUGGUCCUCAUUCUUGGGGGUUGCCAUUCCCACAUUCCCCCUUCAACAAACAGUGUAACAGGUCCUUCCCAGAUUUAGGGUACUUUUAUUGAUGGAUAUGUUUUCCUUUUAUUCACAUAACCCCUUGAAACCCUGUCUUGUCCUCCUGUUACUUGCUUCUGCUGUACAAGAUGUAGCACCUUUUCUCCUCUUUGAACAUGGUCUAGUGACACGGUAGCACCAGUUGCAGGAAGGAGCCAGACUUGUUCUCAGAGCACUGUGUUCACACUUUUCAGCAAAAAUAGCUAUGGUUGUAACAUAUGUAUUCCCUUCCUCUGAUUUGAAGGCAAAAAUCUACAGUGUUUCUUCACUUCUUUUCUGAUCUGGGGCAUGAAAAAAGCAAGAUUGAAAUUUGAACUAUGAGUCUCCUGCAUGGCAACAAAAUGUGUGUCACCAUCAGGCCAACAGGCCAGCCCUUGAAUGGGGAUUUAUUACUGUUGUAUCUAUGUUGCAUGAUAAACAUUCAUCACCUUCCUCCUGUAGUCCUGCCUCGUACUCCCCUUCCCCUAUGAUUGAAAAGUAAACAAAACCCACAUUUCCUAUCCUGGUUAGAAGAAAAUUAAUGUUCUGACAGUUGUGAUCGCCUGGAGUACUUUUAGACUUUUAGCAUUCGUUUUUUACCUGUUUGUGGAUGUGUGUUUGUAUGUGCAUACGUAUGAGAUAGGCACAUGCAUCUUCUGUAUGGACAAAGGUGGGGUACCUACAGGAGAGCAAAGGUUAAUUUUGUGCUUUUAGUAAAAACAUUUAAAUACAAAGUUCUUUAUUGGGUGGAAUUAUAUUUGAUGCAAAUAUUUGAUCACUUAAAACUUUUAAAACUUCUAGGUAAUUUGCCACGCUUUUUGACUGCUCACCAAUACCCUGUAAAAAUACGUAAUUCUUCCUGUUUGUGUAAUAAGAUAUUCAUAUUUGUAGUUGCAUUAAUAAUAGUUAUUUCUUAGUCCAUCAGAUGUUCCCGUGUGCCUCUUUUAUGCCAAAUUGAUUGUCAUAUUUCAUGUUGGGACCAAGUAGUUUGCCCAUGGCAAACCUAAAUUUAUGACCUGCUGAGGCCUCUCAGAAAACUGAGCAUACUAGCAAGACAGCUCUUCUUGAAAAAAAAAAUAUGUAUACACAAAUAUAUACGUAUAUCUAUAUAUACGUAUGUAUAUACACACAUGUAUAUUCUUCCUUGAUUGUGUAGCUGUCCAAAAUAAUAACAUAUAUAGAGGGAGCUGUAUUCCUUUAUACAAAUCUGAUGGCUCCUGCAGCACUUUUUCCUUCUGAAAAUAUUUACAUUUUGCUAACCUAGUUUGUUACUUUAAAAAUCAGUUUUGAUGAAAGGAGGGAAAAGCAGAUGGACUUGAAAAAGAUCCAAGCUCCUAUUAGAAAAGGUAUGAAAAUCUUUAUAGUAAAAUUUUUUAUAAACUAAAGUUGUACCUUUUAAUAUGUAGUAAACUCUCAUUUAUUUGGGGUUCGCUCUUGGAUCUCAUCCAUCCAUUGUGUUCUCUUUAAUGCUGCCUGCCUUUUGAGGCAUUCACUGCCCUAGACAAUGCCACCAGAGAUAGUGGGGGAAAUGCCAGAUGAAACCAACUCUUGCUCUCACUAGUUGUCAGCUUCUCUGGAUAAGUGACCACAGAAGCAGGAGUCCUCCUGCUUGGGCAUCAUUGGGCCAGUUCCUUCUCUUUAAAUCAGAUUUGUAAUGGCUCCCAAAUUCCAUCACAUCACAUUUAAAUUGCAGACAGUGUUUUGCACAUCAUGUAUCUGUUUUGUCCCAUAAUAUGCUUUUUACUCCCUGAUCCCAGUUUCUGCUGUUGACUCUUCCAUUCAGUUUUAUUUAUUGUGUGUUCUCACAGUGACACCAUUUGUCCUUUUCUGCAACAACCUUUCCAGCUACUUUUGCCAAAUUCUAUUUGUCUUCUCCUUCAAAACAUUCUCCUUUGCAGUUCCUCUUCAUCUGUGUAGCUGCUCUUUUGUCUCUUAACUUACCAUUCCUAUAGUACUUUAUGCAUCUCUGCUUAGUUCUAUUAGUUUUUUGGCCUUGCUCUUCUCCUUGAUUUUAAAAUUCCUUCUAUAGCUAGAGCUUUUCUUUCUUUCAUUCUCUCUUCCUGCAGUGUUUUGCAUACAUCAGAAGCUAGGUACAUAAGUUAAAUGAUUGAGAGUUGGCUGUAUUUAGAUUUAUCACUUUUUAAUAGGGUGAGCUUGAGAGUUUUCUUUCUUUCUGUUUUUUUUUUUUGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGACUAAUUUCACAUGCUCUAAAAACCUUCAAAGGUGAUUAUUUUUCUCCUGGAAACUCCAGGUCCAUUCUGUUUAAAUCCCUAAGAAUGUCAGAAUUAAAAUAACAGGGCUAUCCCGUAAUUGGAAAUAUUUCUUUUUUCAGGAUGCUAUAGUCAAUUUAGUAAGUGACCACCAAAUUGUUAUUUGCACUAACAAAGCUCAAAACACGAUAAGUUUACUCCUCCAUCUCAGUAAUAAAAAUUAAGCUGUAAUCAACCUUCUAGGUUUCUCUUGUCUUAAAAUGGGUAUUCAAAAAUGGGGAUCUGUGGUGUAUGUAUGGAAACACAUACUCCUUAAUUUACCUGUUGUUGGAAACUGGAGAAAUGAUUGUCGGGCAACCGUUUAUUUUUUAUUGUAUUUUAUUUGGUUGAGGGAUUUUUUUAUAAACAGUUUUACUUGUGUCAUAUUUUAAAAUUACUAACUGCCAUCACCUGCUGGGGUCCUUUGUUAGGUCAUUUUCAGUGACUAAUAGGGAUAAUCCAGGUAACUUUGAAGAGAUGAGCAGUGAGUGACCAGGCAGUUUUUCUGCCUUUAGCUUUGACAGUUCUUAAUUAAGAUCAUUGAAGACCAGCUUUCUCAUAAAUUUCUCUUUUUGAAAAAAAGAAAGCAUUUGUACUAAGCUCCUCUGUAAGACAACAUCUUAAAUCUUAAAAGUGUUGUUAUCAUGACUGGUGAGAGAAGAAAACAUUUUGUUUUUAUUAAAUGGAGCAUUAUUUACAAAAAGCCAUUGUUGAGAAUUAGAUCCCACAUCGUAUAAAUAUCUAUUAACCAUUCUAAAUAAAGAGAACUCCAGUGUUGCUAUGUGCAAGAUCCUCUCUUGGAGCUUUUUUGCAUAGCAAUUAAAGGUGUGCUAUUUGUCAGUAGCCAUUUUUUUGCAGUGAUUUGAAGACCAAAGUUGUUUUACAGCUGUGUUACCGUUAAAGGUUUUUUUUUUUAUAUGUAUUAAAUCAAUUUAUCACUGUUUAAAGCUUUGAAUAUCUGCAAUCUUUGCCAAGGUACUUUUUUAUUUAAAAAAAAACAUAACUUUGUAAAUAUUACCCUGUAAUAUUAUAUAUACUUAAUAAAACAUUUUAAGCUAUUUUGUUGGGCUAUUUCUAUUGCUGCUACAGCAGACCACAAGCACAUUUCUGAAAAAUUUAAUUUAUUAAUGUAUUUUUAAGUUGCUUAUAUUCUAGGUAACAAUGUAAAGAAUGAUUUAAAAUAUUAAUUAUGAAUUUUUUGAGUAUAAUACCCAAUAAGCUUUUAAUUAGAGCAGAGUUUUAAUUAAAAGUUUUAAAUCAGUC;|CUGACGUUAAGUCAUGAUUUCGCGCCAUAAUAAAGAUGCAAAGGAAUGACAUUUCUGUAUUAGUUAUCUAUUGCUAUGUAACAAAUUAUCCCAAAACUUAGUGGUUUAAAACAACACAUUUGCUGGCCCACAGUUUUUGAGGGUCAGGAGUCCAGGCCCAGCAUAACUGGGUCCUCUGCUCAGGGUGUCUCAGAGGCUGCAAUGUAGGUGUUCACCAGAGACAUAGGCAUCACUGGGGUCACACUCAUGUGGUUGUUUUCUGGAUUCAAUUCCUCCUGGGCUAUUGGCCAAAGGCUAUACUCAUGUAAGCCAUGCGAGCCUCUCCCACAAGGCAGCUUGCUUCAUCAGAGCUAGCAAAAAAGAGAGGUUGCUAGCAAGAUGAAGUCACAAUCUUUUGUAAUCGAAUCAAAAAAGUGAUAUCUCAUCACUUUGGCCAUAUUCUAUUUGUUAGAAGUAAACCACAGGUCCCACCAGCUCCAUGGGAGUGACCACCUCAGUCCAGGGAAAACAGCUGAAGACCAAGAUGGUGAGCUCUGAUUGCUUCAGUUGGUCAUCAACUAUUUUCCCUUGACUGCUGUCCUGGGAUGGCCUGCUAUCUUGAUGAUAGAUUGUGAAUAUCAGGAGGCAGGGAUCACUGUGGACCAUCUUAGCAGUUGACCUAACACAUCUUCUUUUCAAUAUCUAAGAACUUUUGCCACUGUGACUAAUGGUCCUAAUAUUAAGCUGUUGUUUAUAUUUAUCAUAUAUCUAUGGCUACAUGGUUAUAUUAUGCUGUGGUUGCGUUCGGUUUUAUUUACAGUUGCUUUUACAAAUAUUUGCUGUAACAUUUGACUUCUAAGGUUUAGAUGCCAUUUAAGAACUGAGAUGGAUAGCUUUUAAAGCAUCUUUUACUUCUUACCAUUUUUUAAAAGUAUGCAGCUAAAUUCGAAGCUUUUGGUCUAUAUUGUUAAUUGCCAUUGCUGUAAAUCUUAAAAUGAAUGAAUAAAAAUGUUUCAUUUUACAA,mRNA;|mRNA,Homo sapiens;|Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|CD47 3'UTR;|TLR8 3'UTR,"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,"Therefore, we tested whether two RNAs co-localize in the network. Labeling of several pairs of RNAs with two different fluorescent dyes showed that they colocalize"
660,PMID: 33650968,RNAPS0000595,https://pubmed.ncbi.nlm.nih.gov/33650968,RNAs + protein,NCBI ID:961;|NCBI ID:919;|NCBI ID:8600;|NCBI ID:10186,https://www.ncbi.nlm.nih.gov/gene/961;|https://www.ncbi.nlm.nih.gov/gene/919;|https://www.ncbi.nlm.nih.gov/gene/8600;|https://www.ncbi.nlm.nih.gov/gene/10186,CD47;|CD274;|TNFSF11;|LHFPL6,4194nt(3'UTR);|2705nt(3'UTR);|1095nt(3'UTR);|1044nt(3'UTR),CUGAAGUGAAGUGAUGGACUCCGAUUUGGAGAGUAGUAAGACGUGAAAGGAAUACACUUGUGUUUAAGCACCAUGGCCUUGAUGAUUCACUGUUGGGGAGAAGAAACAAGAAAAGUAACUGGUUGUCACCUAUGAGACCCUUACGUGAUUGUUAGUUAAGUUUUUAUUCAAAGCAGCUGUAAUUUAGUUAAUAAAAUAAUUAUGAUCUAUGUUGUUUGCCCAAUUGAGAUCCAGUUUUUUGUUGUUAUUUUUAAUCAAUUAGGGGCAAUAGUAGAAUGGACAAUUUCCAAGAAUGAUGCCUUUCAGGUCCUAGGGCCUCUGGCCUCUAGGUAACCAGUUUAAAUUGGUUCAGGGUGAUAACUACUUAGCACUGCCCUGGUGAUUACCCAGAGAUAUCUAUGAAAACCAGUGGCUUCCAUCAAACCUUUGCCAACUCAGGUUCACAGCAGCUUUGGGCAGUUAUGGCAGUAUGGCAUUAGCUGAGAGGUGUCUGCCACUUCUGGGUCAAUGGAAUAAUAAAUUAAGUACAGGCAGGAAUUUGGUUGGGAGCAUCUUGUAUGAUCUCCGUAUGAUGUGAUAUUGAUGGAGAUAGUGGUCCUCAUUCUUGGGGGUUGCCAUUCCCACAUUCCCCCUUCAACAAACAGUGUAACAGGUCCUUCCCAGAUUUAGGGUACUUUUAUUGAUGGAUAUGUUUUCCUUUUAUUCACAUAACCCCUUGAAACCCUGUCUUGUCCUCCUGUUACUUGCUUCUGCUGUACAAGAUGUAGCACCUUUUCUCCUCUUUGAACAUGGUCUAGUGACACGGUAGCACCAGUUGCAGGAAGGAGCCAGACUUGUUCUCAGAGCACUGUGUUCACACUUUUCAGCAAAAAUAGCUAUGGUUGUAACAUAUGUAUUCCCUUCCUCUGAUUUGAAGGCAAAAAUCUACAGUGUUUCUUCACUUCUUUUCUGAUCUGGGGCAUGAAAAAAGCAAGAUUGAAAUUUGAACUAUGAGUCUCCUGCAUGGCAACAAAAUGUGUGUCACCAUCAGGCCAACAGGCCAGCCCUUGAAUGGGGAUUUAUUACUGUUGUAUCUAUGUUGCAUGAUAAACAUUCAUCACCUUCCUCCUGUAGUCCUGCCUCGUACUCCCCUUCCCCUAUGAUUGAAAAGUAAACAAAACCCACAUUUCCUAUCCUGGUUAGAAGAAAAUUAAUGUUCUGACAGUUGUGAUCGCCUGGAGUACUUUUAGACUUUUAGCAUUCGUUUUUUACCUGUUUGUGGAUGUGUGUUUGUAUGUGCAUACGUAUGAGAUAGGCACAUGCAUCUUCUGUAUGGACAAAGGUGGGGUACCUACAGGAGAGCAAAGGUUAAUUUUGUGCUUUUAGUAAAAACAUUUAAAUACAAAGUUCUUUAUUGGGUGGAAUUAUAUUUGAUGCAAAUAUUUGAUCACUUAAAACUUUUAAAACUUCUAGGUAAUUUGCCACGCUUUUUGACUGCUCACCAAUACCCUGUAAAAAUACGUAAUUCUUCCUGUUUGUGUAAUAAGAUAUUCAUAUUUGUAGUUGCAUUAAUAAUAGUUAUUUCUUAGUCCAUCAGAUGUUCCCGUGUGCCUCUUUUAUGCCAAAUUGAUUGUCAUAUUUCAUGUUGGGACCAAGUAGUUUGCCCAUGGCAAACCUAAAUUUAUGACCUGCUGAGGCCUCUCAGAAAACUGAGCAUACUAGCAAGACAGCUCUUCUUGAAAAAAAAAAUAUGUAUACACAAAUAUAUACGUAUAUCUAUAUAUACGUAUGUAUAUACACACAUGUAUAUUCUUCCUUGAUUGUGUAGCUGUCCAAAAUAAUAACAUAUAUAGAGGGAGCUGUAUUCCUUUAUACAAAUCUGAUGGCUCCUGCAGCACUUUUUCCUUCUGAAAAUAUUUACAUUUUGCUAACCUAGUUUGUUACUUUAAAAAUCAGUUUUGAUGAAAGGAGGGAAAAGCAGAUGGACUUGAAAAAGAUCCAAGCUCCUAUUAGAAAAGGUAUGAAAAUCUUUAUAGUAAAAUUUUUUAUAAACUAAAGUUGUACCUUUUAAUAUGUAGUAAACUCUCAUUUAUUUGGGGUUCGCUCUUGGAUCUCAUCCAUCCAUUGUGUUCUCUUUAAUGCUGCCUGCCUUUUGAGGCAUUCACUGCCCUAGACAAUGCCACCAGAGAUAGUGGGGGAAAUGCCAGAUGAAACCAACUCUUGCUCUCACUAGUUGUCAGCUUCUCUGGAUAAGUGACCACAGAAGCAGGAGUCCUCCUGCUUGGGCAUCAUUGGGCCAGUUCCUUCUCUUUAAAUCAGAUUUGUAAUGGCUCCCAAAUUCCAUCACAUCACAUUUAAAUUGCAGACAGUGUUUUGCACAUCAUGUAUCUGUUUUGUCCCAUAAUAUGCUUUUUACUCCCUGAUCCCAGUUUCUGCUGUUGACUCUUCCAUUCAGUUUUAUUUAUUGUGUGUUCUCACAGUGACACCAUUUGUCCUUUUCUGCAACAACCUUUCCAGCUACUUUUGCCAAAUUCUAUUUGUCUUCUCCUUCAAAACAUUCUCCUUUGCAGUUCCUCUUCAUCUGUGUAGCUGCUCUUUUGUCUCUUAACUUACCAUUCCUAUAGUACUUUAUGCAUCUCUGCUUAGUUCUAUUAGUUUUUUGGCCUUGCUCUUCUCCUUGAUUUUAAAAUUCCUUCUAUAGCUAGAGCUUUUCUUUCUUUCAUUCUCUCUUCCUGCAGUGUUUUGCAUACAUCAGAAGCUAGGUACAUAAGUUAAAUGAUUGAGAGUUGGCUGUAUUUAGAUUUAUCACUUUUUAAUAGGGUGAGCUUGAGAGUUUUCUUUCUUUCUGUUUUUUUUUUUUGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGACUAAUUUCACAUGCUCUAAAAACCUUCAAAGGUGAUUAUUUUUCUCCUGGAAACUCCAGGUCCAUUCUGUUUAAAUCCCUAAGAAUGUCAGAAUUAAAAUAACAGGGCUAUCCCGUAAUUGGAAAUAUUUCUUUUUUCAGGAUGCUAUAGUCAAUUUAGUAAGUGACCACCAAAUUGUUAUUUGCACUAACAAAGCUCAAAACACGAUAAGUUUACUCCUCCAUCUCAGUAAUAAAAAUUAAGCUGUAAUCAACCUUCUAGGUUUCUCUUGUCUUAAAAUGGGUAUUCAAAAAUGGGGAUCUGUGGUGUAUGUAUGGAAACACAUACUCCUUAAUUUACCUGUUGUUGGAAACUGGAGAAAUGAUUGUCGGGCAACCGUUUAUUUUUUAUUGUAUUUUAUUUGGUUGAGGGAUUUUUUUAUAAACAGUUUUACUUGUGUCAUAUUUUAAAAUUACUAACUGCCAUCACCUGCUGGGGUCCUUUGUUAGGUCAUUUUCAGUGACUAAUAGGGAUAAUCCAGGUAACUUUGAAGAGAUGAGCAGUGAGUGACCAGGCAGUUUUUCUGCCUUUAGCUUUGACAGUUCUUAAUUAAGAUCAUUGAAGACCAGCUUUCUCAUAAAUUUCUCUUUUUGAAAAAAAGAAAGCAUUUGUACUAAGCUCCUCUGUAAGACAACAUCUUAAAUCUUAAAAGUGUUGUUAUCAUGACUGGUGAGAGAAGAAAACAUUUUGUUUUUAUUAAAUGGAGCAUUAUUUACAAAAAGCCAUUGUUGAGAAUUAGAUCCCACAUCGUAUAAAUAUCUAUUAACCAUUCUAAAUAAAGAGAACUCCAGUGUUGCUAUGUGCAAGAUCCUCUCUUGGAGCUUUUUUGCAUAGCAAUUAAAGGUGUGCUAUUUGUCAGUAGCCAUUUUUUUGCAGUGAUUUGAAGACCAAAGUUGUUUUACAGCUGUGUUACCGUUAAAGGUUUUUUUUUUUAUAUGUAUUAAAUCAAUUUAUCACUGUUUAAAGCUUUGAAUAUCUGCAAUCUUUGCCAAGGUACUUUUUUAUUUAAAAAAAAACAUAACUUUGUAAAUAUUACCCUGUAAUAUUAUAUAUACUUAAUAAAACAUUUUAAGCUAUUUUGUUGGGCUAUUUCUAUUGCUGCUACAGCAGACCACAAGCACAUUUCUGAAAAAUUUAAUUUAUUAAUGUAUUUUUAAGUUGCUUAUAUUCUAGGUAACAAUGUAAAGAAUGAUUUAAAAUAUUAAUUAUGAAUUUUUUGAGUAUAAUACCCAAUAAGCUUUUAAUUAGAGCAGAGUUUUAAUUAAAAGUUUUAAAUCAGUC;|-;|GCCCCAGUUUUUGGAGUGUUAUGUAUUUCCUGGAUGUUUGGAAACAUUUUUUAAAACAAGCCAAGAAAGAUGUAUAUAGGUGUGUGAGACUACUAAGAGGCAUGGCCCCAACGGUACACGACUCAGUAUCCAUGCUCUUGACCUUGUAGAGAACACGCGUAUUUACAGCCAGUGGGAGAUGUUAGACUCAUGGUGUGUUACACAAUGGUUUUUAAAUUUUGUAAUGAAUUCCUAGAAUUAAACCAGAUUGGAGCAAUUACGGGGUGACCUUAUGAGAAACUGCAUGUGGGCUAUGGGAGGGGUUGGUCCCUGGUCAUGUGCCCCUUCGCAGCUGAAGUGGAGAGGGUGUCAUCUAGCGCAAUUGAAGGAUCAUCUGAAGGGGCAAAUUCUUUUGAAUUGUUACAUCAUGCUGGAACCUGCAAAAAAUACUUUUUCUAAUGAGGAGAGAAAAUAUAUGUAUUUUUAUAUAAUAUCUAAAGUUAUAUUUCAGAUGUAAUGUUUUCUUUGCAAAGUAUUGUAAAUUAUAUUUGUGCUAUAGUAUUUGAUUCAAAAUAUUUAAAAAUGUCUUGCUGUUGACAUAUUUAAUGUUUUAAAUGUACAGACAUAUUUAACUGGUGCACUUUGUAAAUUCCCUGGGGAAAACUUGCAGCUAAGGAGGGGAAAAAAAUGUUGUUUCCUAAUAUCAAAUGCAGUAUAUUUCUUCGUUCUUUUUAAGUUAAUAGAUUUUUUCAGACUUGUCAAGCCUGUGCAAAAAAAUUAAAAUGGAUGCCUUGAAUAAUAAGCAGGAUGUUGGCCACCAGGUGCCUUUCAAAUUUAGAAACUAAUUGACUUUAGAAAGCUGACAUUGCCAAAAAGGAUACAUAAUGGGCCACUGAAAUCUGUCAAGAGUAGUUAUAUAAUUGUUGAACAGGUGUUUUUCCACAAGUGCCGCAAAUUGUACCUUUUUUGUUUUUUCAAAAUAGAAAAGUUAUUAGUGGUUUAUCAGCAAAAAAGUCCAAUUUUAAUUUAGUAAAUGUUAUCUUAUACUGUACAAUAAAAACAUUGCCUUUGAAUGUUAAUUUUUUGGUACAAAAAUAAAUUUAUAUGAAAACCUGC;|GAUGGAGCUACCAAGAGCAGACAGAGGAGAAGAUGGGCCAAAGGGGCUUGGAGAGGUCAAAACAUCCACCUACCUUCAAAAGGUGGGAUAGUAGUUCUAAUCCAAUACAAUGCUAAUAAAAUGAAACCCGAUAAAAUCAGGAACAUGAUAUAGGAAGGAAGGAUUGUAGGAGAUUUGUGGGGGAAAAAAAAGGAGAGUAUAGAAUGAUGGAGAAAAAUGGACCAAAGGCUAAAAAUAUUGCAGGGCAUCGGGUGUUUCUAUUCCACAGAGUAUUGUUAAUGUACAACACACACACACACACACACACACACACACACACACACACACACACAACAAAUCUACAUAUACAAACAAGGGUUUGGGUUUUAGUUUUUUUUUUUUAAGGUGAGGACUCAGAAAAUCAAAGGGCUAGUAGAAACAGUGUUAUGUUGGGAAGCAGGGUACCCCCAAAGAUGUUCCCUGUAGGUCACGGCACUCCCAAAAGCACACAAGCACAUACAGACAUAUGCAUCCCCACACACGCCUAUGCACAAACGUGGAUUAUCGCACAGACUGGGAGGUUUAGUGGUGCAUUUCUCCUCUGUUUUCUUUUUAAUAUACAUUUAAAAUACAGUAUUAUCACUUUAUAAAACAUACAUUAAGCCUAAUAAAUGGACCAAUAAGCCAAACUAUCAGUAUUUUGUAUAUCCUGCAUAAACUCUAAUUUAGUUCCUCAACAUAUUUUCAGUGUUUAUGCAGACCUUUAGAGUUAAGCCUUUGUAUUUCCAUGUUAUUCCACAAUAUGCAAUAUUUCUCUGAGUAGCUUCUGCUAUGAUAUUCUUAUGAAGAAAAGGGGCAACUUUCUGUCCACUAUAGGAGAGAAUUCAGCCGAAGAUAUGAGAGUAAUGAGAGACAUUUUCCAGUCAUUGGAUCGUGUUUUCUUUUGUCCAUUAUUGUACUGUGCUGUACCACAUUUAUUUCUAUAUUCAUUUUGUAAAAAAUUUAAAAGUGCUAUUUUGUUUGUAUUUGAAAAUCUCUGUGAAUAAAUUCUCUCUUUGAUCAAUA,mRNA;|mRNA;|mRNA;|mRNA,Homo sapiens;|Homo sapiens;|Homo sapiens;|Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|3nM[CD47 3'UTR];|3nM[CD274 3'UTR];|50nM[TNFSF11 3'UTR];|50nM[LHFPL6 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,"Furthermore, the mixing of suboptimal amounts of four network-forming RNAs, together with FUS-TIS, resulted in network formation, indicating that the different RNAs have an additive effect"
661,PMID: 33650968,RNAPS0000596,https://pubmed.ncbi.nlm.nih.gov/33650968,RNAs + protein,NCBI ID:961;|NCBI ID:1994;|NCBI ID:29126;|NCBI ID:960;|NCBI ID:54621;|NCBI ID:1812;|NCBI ID:10186;|NCBI ID:8600;|NCBI ID:27075;|NCBI ID:127018,https://www.ncbi.nlm.nih.gov/gene/961;|https://www.ncbi.nlm.nih.gov/gene/1994;;|https://www.ncbi.nlm.nih.gov/gene/29126;|https://www.ncbi.nlm.nih.gov/gene/960;|https://www.ncbi.nlm.nih.gov/gene/54621;|https://www.ncbi.nlm.nih.gov/gene/1812;|https://www.ncbi.nlm.nih.gov/gene/10186;|https://www.ncbi.nlm.nih.gov/gene/8600;|https://www.ncbi.nlm.nih.gov/gene/27075;|https://www.ncbi.nlm.nih.gov/gene/127018,CD47;|ELAVL1;|CD274;|CD44;|VSIG10;|DRD1;|LHFPL6;|TNFSF11;|TSPAN13;|LYPLAL1,4194nt(3'UTR);|4909nt(3'UTR);|2705nt(3'UTR);|3069nt(3'UTR);|3046nt(3'UTR);|1723nt(3'UTR);|1044nt(3'UTR);|515nt(3'UTR);|1045nt(3'UTR);|1130nt(3'UTR),CUGAAGUGAAGUGAUGGACUCCGAUUUGGAGAGUAGUAAGACGUGAAAGGAAUACACUUGUGUUUAAGCACCAUGGCCUUGAUGAUUCACUGUUGGGGAGAAGAAACAAGAAAAGUAACUGGUUGUCACCUAUGAGACCCUUACGUGAUUGUUAGUUAAGUUUUUAUUCAAAGCAGCUGUAAUUUAGUUAAUAAAAUAAUUAUGAUCUAUGUUGUUUGCCCAAUUGAGAUCCAGUUUUUUGUUGUUAUUUUUAAUCAAUUAGGGGCAAUAGUAGAAUGGACAAUUUCCAAGAAUGAUGCCUUUCAGGUCCUAGGGCCUCUGGCCUCUAGGUAACCAGUUUAAAUUGGUUCAGGGUGAUAACUACUUAGCACUGCCCUGGUGAUUACCCAGAGAUAUCUAUGAAAACCAGUGGCUUCCAUCAAACCUUUGCCAACUCAGGUUCACAGCAGCUUUGGGCAGUUAUGGCAGUAUGGCAUUAGCUGAGAGGUGUCUGCCACUUCUGGGUCAAUGGAAUAAUAAAUUAAGUACAGGCAGGAAUUUGGUUGGGAGCAUCUUGUAUGAUCUCCGUAUGAUGUGAUAUUGAUGGAGAUAGUGGUCCUCAUUCUUGGGGGUUGCCAUUCCCACAUUCCCCCUUCAACAAACAGUGUAACAGGUCCUUCCCAGAUUUAGGGUACUUUUAUUGAUGGAUAUGUUUUCCUUUUAUUCACAUAACCCCUUGAAACCCUGUCUUGUCCUCCUGUUACUUGCUUCUGCUGUACAAGAUGUAGCACCUUUUCUCCUCUUUGAACAUGGUCUAGUGACACGGUAGCACCAGUUGCAGGAAGGAGCCAGACUUGUUCUCAGAGCACUGUGUUCACACUUUUCAGCAAAAAUAGCUAUGGUUGUAACAUAUGUAUUCCCUUCCUCUGAUUUGAAGGCAAAAAUCUACAGUGUUUCUUCACUUCUUUUCUGAUCUGGGGCAUGAAAAAAGCAAGAUUGAAAUUUGAACUAUGAGUCUCCUGCAUGGCAACAAAAUGUGUGUCACCAUCAGGCCAACAGGCCAGCCCUUGAAUGGGGAUUUAUUACUGUUGUAUCUAUGUUGCAUGAUAAACAUUCAUCACCUUCCUCCUGUAGUCCUGCCUCGUACUCCCCUUCCCCUAUGAUUGAAAAGUAAACAAAACCCACAUUUCCUAUCCUGGUUAGAAGAAAAUUAAUGUUCUGACAGUUGUGAUCGCCUGGAGUACUUUUAGACUUUUAGCAUUCGUUUUUUACCUGUUUGUGGAUGUGUGUUUGUAUGUGCAUACGUAUGAGAUAGGCACAUGCAUCUUCUGUAUGGACAAAGGUGGGGUACCUACAGGAGAGCAAAGGUUAAUUUUGUGCUUUUAGUAAAAACAUUUAAAUACAAAGUUCUUUAUUGGGUGGAAUUAUAUUUGAUGCAAAUAUUUGAUCACUUAAAACUUUUAAAACUUCUAGGUAAUUUGCCACGCUUUUUGACUGCUCACCAAUACCCUGUAAAAAUACGUAAUUCUUCCUGUUUGUGUAAUAAGAUAUUCAUAUUUGUAGUUGCAUUAAUAAUAGUUAUUUCUUAGUCCAUCAGAUGUUCCCGUGUGCCUCUUUUAUGCCAAAUUGAUUGUCAUAUUUCAUGUUGGGACCAAGUAGUUUGCCCAUGGCAAACCUAAAUUUAUGACCUGCUGAGGCCUCUCAGAAAACUGAGCAUACUAGCAAGACAGCUCUUCUUGAAAAAAAAAAUAUGUAUACACAAAUAUAUACGUAUAUCUAUAUAUACGUAUGUAUAUACACACAUGUAUAUUCUUCCUUGAUUGUGUAGCUGUCCAAAAUAAUAACAUAUAUAGAGGGAGCUGUAUUCCUUUAUACAAAUCUGAUGGCUCCUGCAGCACUUUUUCCUUCUGAAAAUAUUUACAUUUUGCUAACCUAGUUUGUUACUUUAAAAAUCAGUUUUGAUGAAAGGAGGGAAAAGCAGAUGGACUUGAAAAAGAUCCAAGCUCCUAUUAGAAAAGGUAUGAAAAUCUUUAUAGUAAAAUUUUUUAUAAACUAAAGUUGUACCUUUUAAUAUGUAGUAAACUCUCAUUUAUUUGGGGUUCGCUCUUGGAUCUCAUCCAUCCAUUGUGUUCUCUUUAAUGCUGCCUGCCUUUUGAGGCAUUCACUGCCCUAGACAAUGCCACCAGAGAUAGUGGGGGAAAUGCCAGAUGAAACCAACUCUUGCUCUCACUAGUUGUCAGCUUCUCUGGAUAAGUGACCACAGAAGCAGGAGUCCUCCUGCUUGGGCAUCAUUGGGCCAGUUCCUUCUCUUUAAAUCAGAUUUGUAAUGGCUCCCAAAUUCCAUCACAUCACAUUUAAAUUGCAGACAGUGUUUUGCACAUCAUGUAUCUGUUUUGUCCCAUAAUAUGCUUUUUACUCCCUGAUCCCAGUUUCUGCUGUUGACUCUUCCAUUCAGUUUUAUUUAUUGUGUGUUCUCACAGUGACACCAUUUGUCCUUUUCUGCAACAACCUUUCCAGCUACUUUUGCCAAAUUCUAUUUGUCUUCUCCUUCAAAACAUUCUCCUUUGCAGUUCCUCUUCAUCUGUGUAGCUGCUCUUUUGUCUCUUAACUUACCAUUCCUAUAGUACUUUAUGCAUCUCUGCUUAGUUCUAUUAGUUUUUUGGCCUUGCUCUUCUCCUUGAUUUUAAAAUUCCUUCUAUAGCUAGAGCUUUUCUUUCUUUCAUUCUCUCUUCCUGCAGUGUUUUGCAUACAUCAGAAGCUAGGUACAUAAGUUAAAUGAUUGAGAGUUGGCUGUAUUUAGAUUUAUCACUUUUUAAUAGGGUGAGCUUGAGAGUUUUCUUUCUUUCUGUUUUUUUUUUUUGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGACUAAUUUCACAUGCUCUAAAAACCUUCAAAGGUGAUUAUUUUUCUCCUGGAAACUCCAGGUCCAUUCUGUUUAAAUCCCUAAGAAUGUCAGAAUUAAAAUAACAGGGCUAUCCCGUAAUUGGAAAUAUUUCUUUUUUCAGGAUGCUAUAGUCAAUUUAGUAAGUGACCACCAAAUUGUUAUUUGCACUAACAAAGCUCAAAACACGAUAAGUUUACUCCUCCAUCUCAGUAAUAAAAAUUAAGCUGUAAUCAACCUUCUAGGUUUCUCUUGUCUUAAAAUGGGUAUUCAAAAAUGGGGAUCUGUGGUGUAUGUAUGGAAACACAUACUCCUUAAUUUACCUGUUGUUGGAAACUGGAGAAAUGAUUGUCGGGCAACCGUUUAUUUUUUAUUGUAUUUUAUUUGGUUGAGGGAUUUUUUUAUAAACAGUUUUACUUGUGUCAUAUUUUAAAAUUACUAACUGCCAUCACCUGCUGGGGUCCUUUGUUAGGUCAUUUUCAGUGACUAAUAGGGAUAAUCCAGGUAACUUUGAAGAGAUGAGCAGUGAGUGACCAGGCAGUUUUUCUGCCUUUAGCUUUGACAGUUCUUAAUUAAGAUCAUUGAAGACCAGCUUUCUCAUAAAUUUCUCUUUUUGAAAAAAAGAAAGCAUUUGUACUAAGCUCCUCUGUAAGACAACAUCUUAAAUCUUAAAAGUGUUGUUAUCAUGACUGGUGAGAGAAGAAAACAUUUUGUUUUUAUUAAAUGGAGCAUUAUUUACAAAAAGCCAUUGUUGAGAAUUAGAUCCCACAUCGUAUAAAUAUCUAUUAACCAUUCUAAAUAAAGAGAACUCCAGUGUUGCUAUGUGCAAGAUCCUCUCUUGGAGCUUUUUUGCAUAGCAAUUAAAGGUGUGCUAUUUGUCAGUAGCCAUUUUUUUGCAGUGAUUUGAAGACCAAAGUUGUUUUACAGCUGUGUUACCGUUAAAGGUUUUUUUUUUUAUAUGUAUUAAAUCAAUUUAUCACUGUUUAAAGCUUUGAAUAUCUGCAAUCUUUGCCAAGGUACUUUUUUAUUUAAAAAAAAACAUAACUUUGUAAAUAUUACCCUGUAAUAUUAUAUAUACUUAAUAAAACAUUUUAAGCUAUUUUGUUGGGCUAUUUCUAUUGCUGCUACAGCAGACCACAAGCACAUUUCUGAAAAAUUUAAUUUAUUAAUGUAUUUUUAAGUUGCUUAUAUUCUAGGUAACAAUGUAAAGAAUGAUUUAAAAUAUUAAUUAUGAAUUUUUUGAGUAUAAUACCCAAUAAGCUUUUAAUUAGAGCAGAGUUUUAAUUAAAAGUUUUAAAUCAGUC;|-;|-;|CACCUACACCAUUAUCUUGGAAAGAAACAACCGUUGGAAACAUAACCAUUACAGGGAGCUGGGACACUUAACAGAUGCAAUGUGCUACUGAUUGUUUCAUUGCGAAUCUUUUUUAGCAUAAAAUUUUCUACUCUUUUUGUUUUUUGUGUUUUGUUCUUUAAAGUCAGGUCCAAUUUGUAAAAACAGCAUUGCUUUCUGAAAUUAGGGCCCAAUUAAUAAUCAGCAAGAAUUUGAUCGUUCCAGUUCCCACUUGGAGGCCUUUCAUCCCUCGGGUGUGCUAUGGAUGGCUUCUAACAAAAACUACACAUAUGUAUUCCUGAUCGCCAACCUUUCCCCCACCAGCUAAGGACAUUUCCCAGGGUUAAUAGGGCCUGGUCCCUGGGAGGAAAUUUGAAUGGGUCCAUUUUGCCCUUCCAUAGCCUAAUCCCUGGGCAUUGCUUUCCACUGAGGUUGGGGGUUGGGGUGUACUAGUUACACAUCUUCAACAGACCCCCUCUAGAAAUUUUUCAGAUGCUUCUGGGAGACACCCAAAGGGUGAAGCUAUUUAUCUGUAGUAAACUAUUUAUCUGUGUUUUUGAAAUAUUAAACCCUGGAUCAGUCCUUUGAUCAGUAUAAUUUUUUAAAGUUACUUUGUCAGAGGCACAAAAGGGUUUAAACUGAUUCAUAAUAAAUAUCUGUACUUCUUCGAUCUUCACCUUUUGUGCUGUGAUUCUUCAGUUUCUAAACCAGCACUGUCUGGGUCCCUACAAUGUAUCAGGAAGAGCUGAGAAUGGUAAGGAGACUCUUCUAAGUCUUCAUCUCAGAGACCCUGAGUUCCCACUCAGACCCACUCAGCCAAAUCUCAUGGAAGACCAAGGAGGGCAGCACUGUUUUUGUUUUUUGUUUUUUGUUUUUUUUUUUUGACACUGUCCAAAGGUUUUCCAUCCUGUCCUGGAAUCAGAGUUGGAAGCUGAGGAGCUUCAGCCUCUUUUAUGGUUUAAUGGCCACCUGUUCUCUCCUGUGAAAGGCUUUGCAAAGUCACAUUAAGUUUGCAUGACCUGUUAUCCCUGGGGCCCUAUUUCAUAGAGGCUGGCCCUAUUAGUGAUUUCCAAAAACAAUAUGGAAGUGCCUUUUGAUGUCUUACAAUAAGAGAAGAAGCCAAUGGAAAUGAAAGAGAUUGGCAAAGGGGAAGGAUGAUGCCAUGUAGAUCCUGUUUGACAUUUUUAUGGCUGUAUUUGUAAACUUAAACACACCAGUGUCUGUUCUUGAUGCAGUUGCUAUUUAGGAUGAGUUAAGUGCCUGGGGAGUCCCUCAAAAGGUUAAAGGGAUUCCCAUCAUUGGAAUCUUAUCACCAGAUAGGCAAGUUUAUGACCAAACAAGAGAGUACUGGCUUUAUCCUCUAACCUCAUAUUUUCUCCCACUUGGCAAGUCCUUUGUGGCAUUUAUUCAUCAGUCAGGGUGUCCGAUUGGUCCUAGAACUUCCAAAGGCUGCUUGUCAUAGAAGCCAUUGCAUCUAUAAAGCAACGGCUCCUGUUAAAUGGUAUCUCCUUUCUGAGGCUCCUACUAAAAGUCAUUUGUUACCUAAACUUAUGUGCUUAACAGGCAAUGCUUCUCAGACCACAAAGCAGAAAGAAGAAGAAAAGCUCCUGACUAAAUCAGGGCUGGGCUUAGACAGAGUUGAUCUGUAGAAUAUCUUUAAAGGAGAGAUGUCAACUUUCUGCACUAUUCCCAGCCUCUGCUCCUCCCUGUCUACCCUCUCCCCUCCCUCUCUCCCUCCACUUCACCCCACAAUCUUGAAAAACUUCCUUUCUCUUCUGUGAACAUCAUUGGCCAGAUCCAUUUUCAGUGGUCUGGAUUUCUUUUUAUUUUCUUUUCAACUUGAAAGAAACUGGACAUUAGGCCACUAUGUGUUGUUACUGCCACUAGUGUUCAAGUGCCUCUUGUUUUCCCAGAGAUUUCCUGGGUCUGCCAGAGGCCCAGACAGGCUCACUCAAGCUCUUUAACUGAAAAGCAACAAGCCACUCCAGGACAAGGUUCAAAAUGGUUACAACAGCCUCUACCUGUCGCCCCAGGGAGAAAGGGGUAGUGAUACAAGUCUCAUAGCCAGAGAUGGUUUUCCACUCCUUCUAGAUAUUCCCAAAAAGAGGCUGAGACAGGAGGUUAUUUUCAAUUUUAUUUUGGAAUUAAAUACUUUUUUCCCUUUAUUACUGUUGUAGUCCCUCACUUGGAUAUACCUCUGUUUUCACGAUAGAAAUAAGGGAGGUCUAGAGCUUCUAUUCCUUGGCCAUUGUCAACGGAGAGCUGGCCAAGUCUUCACAAACCCUUGCAACAUUGCCUGAAGUUUAUGGAAUAAGAUGUAUUCUCACUCCCUUGAUCUCAAGGGCGUAACUCUGGAAGCACAGCUUGACUACACGUCAUUUUUACCAAUGAUUUUCAGGUGACCUGGGCUAAGUCAUUUAAACUGGGUCUUUAUAAAAGUAAAAGGCCAACAUUUAAUUAUUUUGCAAAGCAACCUAAGAGCUAAAGAUGUAAUUUUUCUUGCAAUUGUAAAUCUUUUGUGUCUCCUGAAGACUUCCCUUAAAAUUAGCUCUGAGUGAAAAAUCAAAAGAGACAAAAGACAUCUUCGAAUCCAUAUUUCAAGCCUGGUAGAAUUGGCUUUUCUAGCAGAACCUUUCCAAAAGUUUUAUAUUGAGAUUCAUAACAACACCAAGAAUUGAUUUUGUAGCCAACAUUCAUUCAAUACUGUUAUAUCAGAGGAGUAGGAGAGAGGAAACAUUUGACUUAUCUGGAAAAGCAAAAUGUACUUAAGAAUAAGAAUAACAUGGUCCAUUCACCUUUAUGUUAUAGAUAUGUCUUUGUGUAAAUCAUUUGUUUUGAGUUUUCAAAGAAUAGCCCAUUGUUCAUUCUUGUGCUGUACAAUGACCACUGUUAUUGUUACUUUGACUUUUCAGAGCACACCCUUCCUCUGGUUUUUGUAUAUUUAUUGAUGGAUCAAUAAUAAUGAGGAAAGCAUGAUAUGUAUAUUGCUGAGUUGAAAGCACUUAUUGGAAAAUAUUAAAAGGCUAACAUUAAAAGACUAAAGGAAACAGA;|AGAAGAGGAUGGUCCAUGGUUGUCUUGCUCUGAAAGCUUGGAGAGCUACAUUGAAGACGAGCUCUUCAUUCAGCUUUGACUCCACCUGCACCCCUGGCGGGGGCUUGCACUAACAAUGUUUGGGUCUCAGCAAAAAACAAAACCAAGCACACACAUCUUUCCUUCCAUGUAUUGAAAAACAUUGGUUUGAUUUGCUCUAAGUUUUCCCAAUGAUGUUUAAAAGCUUUGAGAAGGAAAGCUGCUUUGGUGUCUGAGGUGCCACUUCUGCUGUGAAUCCUGGCUUUAUCCAGGUUGAUCUACUGUGAUAGAUGCUGAUUUAGAGGGAACAGAGGUCAGGGAAGCACUGGGUCUUGGUGCCUUUUGCCGCUUUUUUUUUUUUUUUUUUUUUUUUUUGAGACGGAGUCUCCCUCUAUUGCCCAGGCUGGAGUGCAAUGGCACGAUCUUGGCUCACCACAACUUCUGCCUCCCAGGUUCAAGCGAUUCUCCUGCCUCAGCCACGGCACCUUGCAAAUAUCAGCUCCUUGGAACAGGUGAAGUUCCAGGUACCAAUGCCAAUCAGAGGAAGGCAGUUUGGUUCAGGCUUUGGAGUUAGAAACACCUGAAGUUGAAUCUGGGCUCUGUUGCUUCCUUCUUUCAUGGGCUAGAGCACGACUCUUUACCUCUCUCUUGGCCUCAAUUUCCUCACCUGUAAAAUAGAUGAGGAAGCUGCUCACUUAUUAUUGUCUCGUUCUGAAAGCUUGGAAAGCUACAUCGAAGAUGAGCUCUUCAUUCAGCUUUGAUUUGACCUGUACCCCUGGUGGGGGAUUGCACUGGCAACAUUUGGGUCUCAGCAAAAAAACCAAGCACACACAUCUUUCCUUCCAUUUAUUGAAAAACAUCUUUGUAAGAUCCAUUCAUUGAAAAACAUAAUCCAUUUAUUGAAAAAUAUCUUUGUAAGAUCACCUGCUAAAUAUGAAAAUCUGACUUGAAUUUGUACUCUUUAAAGUUGCGUAUCUGCUCUAGUGGGCAGGACCUAGGGCUUAAAGGGGAACUUCCUUUCUCCAUUUCUAAGAACUGGGACUCUAAAAUGAGAAGCUGGUUGUCUGAAGUAACCCUGCAGGUGUGGUUGGGGAAGGUCUGUUUUCUUGGAUGAAGGAACUAAACUAAGCAUAUCAGAGCACUGUCUUAACCAGUUUUAUUUCCCUGGAGAUAGAAUUCUUUUAAAAAGAGUUAGGGAGCUGGUAAUAGGAAGUGCCUUUCAUUAUAACUACAUUUUGCAGAGCUUCAUAUUUAUAUACAAGCCUCCUAGGUGAUACACUGUUAGCUUGCAGACUUUCCUAUGCUUCAUUUCUCCUGUUGCUUUCAAAGAAGGCAGGAGACACGUUUAAUAACGGAGUAUCUGGUGAUAAGAAUUGCUUGGGCAAACCAGCUCAUCUGGACUCUUUCUCAGUCUUGGAAGUGGGAAGAGGAAAACUUGUUUCCUUCCUGCUUCUUAAGGAUAUUCUGAGGGUACACUGAUCAAUAACACUAAAUUUGGAAUGAAAAUACCAUGUGAUGAGUUUAGCCUGCUGAUGCUUCCAGUAGAUCCUUGUAUAGUUUCAAGAUUUAAGUUUUCCGAUUUCAUAUAAAUUUCUUAAAGUCGAGGACCUUAUAAGGGUGCAAUGGAUGUUUGCUAAAUAUGAAAAACUGACUUGAAUUUGCACUCUUUAAUGUUGCGUAUCUGCUCUAGUGGGCAGGACCUAGGGCUUAAAGGGGAACUUCCUUUCUCCAAUUCUAGGAACUGGGACUCUAAAAUGAGAAGCUGGUUGUCUGAAGUAACCCUGCAGGUGUGGUUGGGGAAGGUCUGUUUUCUUGGAUGAAGGGAUUAAACUGAGCAAAUCACUAGAAGUAUGCCCUGUCCCCUGCUCAGAACACUGGGGAGCUCAAGAGUGGGCUGCAAUGUGCACCCCUCAGGAAUAGCUGUGAAUUGCAGGUCUACUGGCUUUUUGCUUUUUGUCUUUUGCUGCAAGGUACCCCACGUACUUAACCAUUCUCAACAGUGUAAAUCAGUGUCAUUUUAGAAUGAGAUACUCAGCUUGCUUCUAAAGUCACUGAAUUACUGAGUGAGUCUCUCCUUUAGAGUCUUCGGCAACCAAAUUCCAGAAUUGAAGAGUCUACUACUCAGAGGCAACAAGAUUAAAAAAAGAAAACACAAAAACUGUUGAGGUGAAAAAAAAAAAAAACCCUAGCUAGGAACACAGAGAAUGUUUUGUAGGAUCACUGGGAUAUUUUCCACAACUUCCUCUUCUCUAGCACACACAUCUGUUGAUAGGAAAUAUUUGAGGGUUUUUCCACUACCAAAUGGGAGCUUCAUGGUCCUGGUGUCAAACACUAUAAACCUUUGACCAGCUGAGCUGUGACUGCUGUCACAUAUCUGAGUCCUGUGUGCACAGUAAUAUCCUGGGUCAGGUAAAAUCCAGGUCUUCAAGUUUUAAGGAUUUUUUGAAGAAUUCGGGCUUCUUUAAGACGAUCCAUGCCCAAAUCCACAAGCUUGUUGACAGUGGAUUACAGUUUGUGUGGCAAAGUCCAAGUUGUUACACUGUGCUUUAAAAAAAAUCUUAUCUGCAUGUAUUGUUAACUUAGAGACCAUGAGAUCUAUUUAUCAGGACCAGGAAGAUACACACUUCAGGUCCAUUGCAACUGACUUUUUUCUUGUUUUUCUCAAACCCUGGUGGAGCCUGGGAAGGGGGCCUCCACAAUUCUGUGGCUUUGAUAUUAGCCCCAAUUCUCACAAGCACAUACAAGCCCCAUAAUUGCCGCAGGAAAACACAAGAUGGAAAAUUGCAAUAACCCAUGCACUGAGACUUAGAAAAUCAUCCUUACUAGGCAAAAUGUAUUAUGAUGCAAUAAGUGCCAACUGAUAUUUCUCACGUUGGGACUGGCCAGGAACUGCUGCAAAGAAAAAUAAGCAGCUCCUUCUCCAUUAUUUACAUUUUAAGAUGUGGUGGGGGGAGGUUGGGAGAAAUUAGUUCUGAGGUUAUCAUAUGCCUUUUUUAAAAGAUAAUGGAAUAAAGCUAUUUUUAAGUAA;|ACUCGCAGAUGAAUCCUGCCACACAUGCUCAUCCCAAAAGCUAGAGGAGAUUGCUCUGGGGCUUGCUAUUAAGAAACUAAGGUACGGUGAGACUCUGAGGUGUCAGGAGAGCCCUCUGCUGCUUUCCAACACACAAUUAACUCCGUUUCCAAAUACAUUCCAGUGUAUUUUCUGUGUUGUUCAUAGUCAAUCAAACAGGGACACUACAAACAUGGGGAGCCAUAAGGGACAUGUCUUUGGCUUCAGAAUUGUUUUUAGAAAUUUAUUCUUAUCUUAGGAUUUACCAAAUAGGGCAAAGAAUCAACAGUGAACAGCUUCACUUAAAAUCAAAUUUUUCUGGGAAGAAAAUGAGAUGGGUUGAGUUUGCUGUAUACAAACAGGUGCUAACACUGUUCCCAGCAAAGUUUUCAGAUUGUAAAGGUAGGUGCAUGCCUUCAUAAAUUAUUUCUAAAACAUUAAUUGAGGCUUACAGUAGGAGUGAGAAAUUUUUUUCCAGAAUUGAGAGAUGUUUUGUUGAUAUUGGUUCUAUUUAUUUAUUGUAUAUAUGGAUAUUUUUAAUUUAUGAUAUAAUAAAUAUAUAUUUAUCAUAUUUAAUAGGAUAAAUUAAUGAGUUUUAUCCAAGACCUUACAACCACAUUUCUGGCCAUUUAACUAGCACUUUAUAAGCCAAUGAAGCAAACACACAGACUCUGUGAGAUUCUAAAUGUUCAUGUGUAACUUCUAGAAACACAGCAGAAACUGAUAGAUAAGGGAAUAAAGUUGAAAUGAUUCCUUAAAAUUCAUGGACACAGAUAAAUGCAAGGUGAGAAUUGACAAAUGCUAUAAAUGCUUUCUUUUUCUGAAAAGAUUUUGAAAAAUUUAAAAAAGUAUAGCUACUACUGUGUUCAAAACGUUUUAAAUGACAAAUGACUUUCCCAGGGGAAUUUGCAGUUCUGUAAAUAUCUUAAAUAAAAGCCAACUUAAGAAGAGCCCAGCAUUAAAUUUACGAUCUUAGGUGGUAAUGAAAAGUAUAUGCUGCUUUGUAUUUAUGUAAAAUAAUUGGCCCUCUCCAUCUUUUCUCAUUUCAUGUGUCAGGUAGUUUUUCUGAACCACACAAAUGGCUUUCCUGGAGAGAGAUCUGUAGCACAGACAGUGGGUUACAGCAGCCCCACUGAGGGACCAAACUCAAACCCUGCAUUUCCAUCUUACCAGGUCAAACCAAACCAGUCAGUGGGGCUACUUUUUAUAGUGCUUUAAUCUGAAUUUAGAGCUGAUUUUUAAAGGAGUCUUUAAAUGUUAAUGGUAUACUAACUAACGAAUAGUGCCUCAUUAUCAUUCUUGAGUCAGAUACUUCUGUUGAUGGGAGAAACAGAAGAAUCCUUCCCUUUGGGUGUGUUGAGCUCCCCCAAAGCCAUCAGCAUCUCUUUUGACAAAUGCUAGUCCUUUCUCUGUGCUUUGGAAUCAGGUUCCUGCAUCAUCACCCGGACUGUAAAAAGUAUCAUAAGCCUCCCUUGCCAGAUGCCAACUCGUGGGGCAUUUCAACAGAGUUUCUUUGAAAUGUUUACAACGUAUUCUUCUUGAUAAGCAAUGAACUUAACAUUUAGAUGCAAUCCGUGAAAAGAAAAAAAAAUCUGAAAAAUAUCUCCUGCAUCAGGUCUGUGUUAUUUAUGUAUUGUGAAUGUUUUCUUAAUUUUAUUGGCUGUAUGCUUUCUUACACAUAAUAAAAAUAUUUUGUGAACUCAAA;|GAUGGAGCUACCAAGAGCAGACAGAGGAGAAGAUGGGCCAAAGGGGCUUGGAGAGGUCAAAACAUCCACCUACCUUCAAAAGGUGGGAUAGUAGUUCUAAUCCAAUACAAUGCUAAUAAAAUGAAACCCGAUAAAAUCAGGAACAUGAUAUAGGAAGGAAGGAUUGUAGGAGAUUUGUGGGGGAAAAAAAAGGAGAGUAUAGAAUGAUGGAGAAAAAUGGACCAAAGGCUAAAAAUAUUGCAGGGCAUCGGGUGUUUCUAUUCCACAGAGUAUUGUUAAUGUACAACACACACACACACACACACACACACACACACACACACACACACACAACAAAUCUACAUAUACAAACAAGGGUUUGGGUUUUAGUUUUUUUUUUUUAAGGUGAGGACUCAGAAAAUCAAAGGGCUAGUAGAAACAGUGUUAUGUUGGGAAGCAGGGUACCCCCAAAGAUGUUCCCUGUAGGUCACGGCACUCCCAAAAGCACACAAGCACAUACAGACAUAUGCAUCCCCACACACGCCUAUGCACAAACGUGGAUUAUCGCACAGACUGGGAGGUUUAGUGGUGCAUUUCUCCUCUGUUUUCUUUUUAAUAUACAUUUAAAAUACAGUAUUAUCACUUUAUAAAACAUACAUUAAGCCUAAUAAAUGGACCAAUAAGCCAAACUAUCAGUAUUUUGUAUAUCCUGCAUAAACUCUAAUUUAGUUCCUCAACAUAUUUUCAGUGUUUAUGCAGACCUUUAGAGUUAAGCCUUUGUAUUUCCAUGUUAUUCCACAAUAUGCAAUAUUUCUCUGAGUAGCUUCUGCUAUGAUAUUCUUAUGAAGAAAAGGGGCAACUUUCUGUCCACUAUAGGAGAGAAUUCAGCCGAAGAUAUGAGAGUAAUGAGAGACAUUUUCCAGUCAUUGGAUCGUGUUUUCUUUUGUCCAUUAUUGUACUGUGCUGUACCACAUUUAUUUCUAUAUUCAUUUUGUAAAAAAUUUAAAAGUGCUAUUUUGUUUGUAUUUGAAAAUCUCUGUGAAUAAAUUCUCUCUUUGAUCAAUA;|GCCCCAGUUUUUGGAGUGUUAUGUAUUUCCUGGAUGUUUGGAAACAUUUUUUAAAACAAGCCAAGAAAGAUGUAUAUAGGUGUGUGAGACUACUAAGAGGCAUGGCCCCAACGGUACACGACUCAGUAUCCAUGCUCUUGACCUUGUAGAGAACACGCGUAUUUACAGCCAGUGGGAGAUGUUAGACUCAUGGUGUGUUACACAAUGGUUUUUAAAUUUUGUAAUGAAUUCCUAGAAUUAAACCAGAUUGGAGCAAUUACGGGGUGACCUUAUGAGAAACUGCAUGUGGGCUAUGGGAGGGGUUGGUCCCUGGUCAUGUGCCCCUUCGCAGCUGAAGUGGAGAGGGUGUCAUCUAGCGCAAUUGAAGGAUCAUCUGAAGGGGCAAAUUCUUUUGAAUUGUUACAUCAUGCUGGAACCUGCAAAAAAUACUUUUUCUAAUGAGGAGAGAAAAUAUAUGUAUUUUUAUAUAAUAUCUAAAGUUAUAUUUCAGAUGUAAUGUUUUCUUUGCAAAGUAUUGUAAAUUAUAUUUGUGCUAUAGUAUUUGAUUCAAAAUAUUUAAAAAUGUCUUGCUGUUGACAUAUUUAAUGUUUUAAAUGUACAGACAUAUUUAACUGGUGCACUUUGUAAAUUCCCUGGGGAAAACUUGCAGCUAAGGAGGGGAAAAAAAUGUUGUUUCCUAAUAUCAAAUGCAGUAUAUUUCUUCGUUCUUUUUAAGUUAAUAGAUUUUUUCAGACUUGUCAAGCCUGUGCAAAAAAAUUAAAAUGGAUGCCUUGAAUAAUAAGCAGGAUGUUGGCCACCAGGUGCCUUUCAAAUUUAGAAACUAAUUGACUUUAGAAAGCUGACAUUGCCAAAAAGGAUACAUAAUGGGCCACUGAAAUCUGUCAAGAGUAGUUAUAUAAUUGUUGAACAGGUGUUUUUCCACAAGUGCCGCAAAUUGUACCUUUUUUGUUUUUUCAAAAUAGAAAAGUUAUUAGUGGUUUAUCAGCAAAAAAGUCCAAUUUUAAUUUAGUAAAUGUUAUCUUAUACUGUACAAUAAAAACAUUGCCUUUGAAUGUUAAUUUUUUGGUACAAAAAUAAAUUUAUAUGAAAACCUGC;|UGAGAAAACAAGGAAGAUUUCCUUUCGUAUUAUGAUCUUGUUCACUUUCUGUAAUUUUCUGUUAAGCUCCAUUUGCCAGUUUAAGGAAGGAAACACUAUCUGGAAAAGUACCUUAUUGAUAGUGGAAUUAUAUAUUUUUACUCUAUGUUUCUCUACAUGUUUUUUUCUUUCCGUUGCUGAAAAAUAUUUGAAACUUGUGGUCUCUGAAGCUCGGUGGCACCUGGAAUUUACUGUAUUCAUUGUCGGGCACUGUCCACUGUGGCCUUUCUUAGCAUUUUUACCUGCAGAAAAACUUUGUAUGGUACCACUGUGUUGGUUAUAUGGUGAAUCUGAACGUACAUCUCACUGGUAUAAUUAUAUGUAGCACUGUGCUGUGUAGAUAGUUCCUACUGGAAAAAGAGUGGAAAUUUAUUAAAAUCAGAAAGUAUGAGAUCCUGUUAUGUUAAGGGAAAUCCAAAUUCCCAAUUUUUUUUGGUCUUUUUAGGAAAGAUUGUUGUGGUAAAAAGUGUUAGUAUAAAAAUGAUAAUUUACUUGUAGUCUUUUAUGAUUACACCAAUGUAUUCUAGAAAUAGUUAUGUCUUAGGAAAUUGUGGUUUAAUUUUUGACUUUUACAGGUAAGUGCAAAGGAGAAGUGGUUUCAUGAAAUGUUCUAAUGUAUAAUAACAUUUACCUUCAGCCUCCAUCAGAAUGGAACGAGUUUUGAGUAAUCAGGAAGUAUAUCUAUAUGAUCUUGAUAUUGUUUUAUAAUAAUUUGAAGUCUAAAAGACUGCAUUUUUAAACAAGUUAGUAUUAAUGCGUUGGCCCACGUAGCAAAAAGAUAUUUGAUUAUCUUAAAAAUUGUUAAAUACCGUUUUCAUGAAAUUUCUCAGUAUUGUAACAGCAACUUGUCAAACCUAAGCAUAUUUGAAUAUGAUCUCCCAUAAUUUGAAAUUGAAAUCGUAUUGUGUGGCUCUGUAUAUUCUGUUAAAAAAUUAAAGGACAGAAACCUUUCUUUGUGUAUGCAUGUUUGAAUUAAAAGAAAGUAAUGGAAGAAUUGAUCGAUGAA;|AUGAAUCAAGAGUGAUUUGUUAAUGUAAGUGUAAUGUCUUUGUGAAAAGUGAUUUUUACUGCCAAAUUAUAAUGAUAAUUAAAAUAUUAAGAAAUAACACUUUCCUGACUUUUUUAUUAUUAAAAUGCUUAUCACUGUAGACAGUAGCUAAUCUUAUUAAUGAAAAACAAUAGACAAACAUCUGUGCAUAAUUUUUCAGACACAAUUCUGUAAAUAUUUGGAAACCUUUUAAGUAUUUAAACUUUUAAAUUUUUGAAAUAAAGUAUUCUAAACUAAUAUAAAUAAGGACAAUGAAAAAACAUGAAAGGACUUAGCAUAAUGUUAUUUUAUCUUUUCUACAACUUUGUUUAAAUUACCUUUCCAAAGAUAUUUGUGUUUAUGUAAUUUUCCACGGAAUAACAUUAAUACUCUAGGUUUAUAAACCGGUUUCACAUUAUUUCAUUUGAUCAUCACAAGAGCUUUGUGAAGUAAGCCGAGAAGUUGUUACUGGUAUUUAAUAAUAGCAAUAGAGGAGUUAAAGACUUUCCCACAGCUUGCAGGUCAAGACAAGAAAUUCAGGUCUCCUAAUUCUCAGUGGAGCUCUAUUUCUGUUAACCCAAAUUGCUGCUCUGUUUUAGGUCUCAAUUUCAUCUGUAAAAUGAUACUAAUAGUACUUAUCCCAUUGGAUUUUUGUUGAGAUUUAAAUAAAUAGCCAAAAGCCAAUACAUAAUAAACACUCAAUAAAGAUUAACCAUAAGGAGAGUCAUGAUCUGGUUCCAGGAAUACAUUGUUAGAUGACUGAAAAAUUGUAUUACUUCAAUGAAAAUACUAUAAAUAAUAACAUUUUCAUAUAUUAGUUGGUUCUCAUGCAUACAUAAUCUAAUUUUAUUUGAUCCUCACAACUGUUUAAGUUUUAUUAAAUAUACAUUAUCCCUAUUUGUAUAAAUAGAAUCAUACAAUACCUGCCUGCUUUCAUUCAACAAAAUUAUCAUGAGAUUUUUCCAUGUUGUGUACAUCAAUAGUUCAUCUAUUUUAUUGCUCAGUAAUAUUCCAUUGUGUGGAUGUAUCACUAUUUGUUUACACAUUCACCACUGAUAUAUAAGUUGCUUCCAGUGUGAGGCUGUUUUAAAUAAAGCUGCUAUGAAUAUUCA,mRNA;|mRNA;|mRNA;|mRNA;|mRNA;|mRNA;|mRNA;|mRNA;|mRNA;|mRNA,Homo sapiens;|Homo sapiens;|Homo sapiens;|Homo sapiens;|Homo sapiens;|Homo sapiens;|Homo sapiens;|Homo sapiens;|Homo sapiens;|Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|2nM[CD47 3'UTR];|2nM[ELAVL1 3'UTR];|2nM[CD274 3'UTR];|2nM[CD44 3'UTR];|2nM[VSIG10 3'UTR];|2nM[DRD1 3'UTR];|2nM[LHFPL6 3'UTR];|2nM[TNFSF11 3'UTR];|2nM[TSPAN13 3'UTR];|2nM[LYPLAL1 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,"Importantly, mixing 10 mRNAs together with FUS-TIS only required 2 nM (0.7–3.2 ng/ml) of each mRNA which is substantially lower than the average mRNA expression in cells (Figure 4B). "
662,PMID: 33650968,RNAPS0000597,https://pubmed.ncbi.nlm.nih.gov/33650968,RNAs + protein,NCBI ID:51311;|NCBI ID:4609,https://www.ncbi.nlm.nih.gov/gene/51311;|https://www.ncbi.nlm.nih.gov/gene/4609,TLR8;|MYC,1003nt(3'UTR);|476nt(3'UTR),CUGACGUUAAGUCAUGAUUUCGCGCCAUAAUAAAGAUGCAAAGGAAUGACAUUUCUGUAUUAGUUAUCUAUUGCUAUGUAACAAAUUAUCCCAAAACUUAGUGGUUUAAAACAACACAUUUGCUGGCCCACAGUUUUUGAGGGUCAGGAGUCCAGGCCCAGCAUAACUGGGUCCUCUGCUCAGGGUGUCUCAGAGGCUGCAAUGUAGGUGUUCACCAGAGACAUAGGCAUCACUGGGGUCACACUCAUGUGGUUGUUUUCUGGAUUCAAUUCCUCCUGGGCUAUUGGCCAAAGGCUAUACUCAUGUAAGCCAUGCGAGCCUCUCCCACAAGGCAGCUUGCUUCAUCAGAGCUAGCAAAAAAGAGAGGUUGCUAGCAAGAUGAAGUCACAAUCUUUUGUAAUCGAAUCAAAAAAGUGAUAUCUCAUCACUUUGGCCAUAUUCUAUUUGUUAGAAGUAAACCACAGGUCCCACCAGCUCCAUGGGAGUGACCACCUCAGUCCAGGGAAAACAGCUGAAGACCAAGAUGGUGAGCUCUGAUUGCUUCAGUUGGUCAUCAACUAUUUUCCCUUGACUGCUGUCCUGGGAUGGCCUGCUAUCUUGAUGAUAGAUUGUGAAUAUCAGGAGGCAGGGAUCACUGUGGACCAUCUUAGCAGUUGACCUAACACAUCUUCUUUUCAAUAUCUAAGAACUUUUGCCACUGUGACUAAUGGUCCUAAUAUUAAGCUGUUGUUUAUAUUUAUCAUAUAUCUAUGGCUACAUGGUUAUAUUAUGCUGUGGUUGCGUUCGGUUUUAUUUACAGUUGCUUUUACAAAUAUUUGCUGUAACAUUUGACUUCUAAGGUUUAGAUGCCAUUUAAGAACUGAGAUGGAUAGCUUUUAAAGCAUCUUUUACUUCUUACCAUUUUUUAAAAGUAUGCAGCUAAAUUCGAAGCUUUUGGUCUAUAUUGUUAAUUGCCAUUGCUGUAAAUCUUAAAAUGAAUGAAUAAAAAUGUUUCAUUUUACAA;|GGAAAAGUAAGGAAAACGAUUCCUUCUAACAGAAAUGUCCUGAGCAAUCACCUAUGAACUUGUUUCAAAUGCAUGAUCAAAUGCAACCUCACAACCUUGGCUGAGUCUUGAGACUGAAAGAUUUAGCCAUAAUGUAAACUGCCUCAAAUUGGACUUUGGGCAUAAAAGAACUUUUUUAUGCUUACCAUCUUUUUUUUUUCUUUAACAGAUUUGUAUUUAAGAAUUGUUUUUAAAAAAUUUUAAGAUUUACACAAUGUUUCUCUGUAAAUAUUGCCAUUAAAUGUAAAUAACUUUAAUAAAACGUUUAUAGCAGUUACACAGAAUUUCAAUCCUAGUAUAUAGUACCUAGUAUUAUAGGUACUAUAAACCCUAAUUUUUUUUAUUUAAGUACAUUUUGCUUUUUAAAGUUGAUUUUUUUCUAUUGUUUUUAGAAAAAAUAAAAUAACUGGCAAAUAUAUCAUUGAGCCAAAUCUUAA,mRNA;|mRNA,Homo sapiens;|Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100nM[TLR8 3'UTR];|100nM[MYC 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,"A phase separation experiment with FUS-TIS confirmed that the addition of the two predominantly structured 3'UTRs (TLR8 and MYC) generates sphere-like condensates, whereas the addition of RNAs capable of forming a crosslinked RNA network (D1-TLR8-D2 and D1-MYC-D2), which we call an RNA matrix, induces formation of mesh-like FUS-TIS condensates "
663,PMID: 33650968,RNAPS0000597,https://pubmed.ncbi.nlm.nih.gov/33650968,RNAs + protein,NCBI ID:51311;|NCBI ID:4609,https://www.ncbi.nlm.nih.gov/gene/51311;|https://www.ncbi.nlm.nih.gov/gene/4609,TLR8;|MYC,-(3'UTR+ two RNA dimerization elements);|-(3'UTR + two RNA dimerization elements),-;|-,mRNA;|mRNA,Homo sapiens;|Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100nM[TLR8 3'UTR];|100nM[MYC 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,gel,"A phase separation experiment with FUS-TIS confirmed that the addition of the two predominantly structured 3'UTRs (TLR8 and MYC) generates sphere-like condensates, whereas the addition of RNAs capable of forming a crosslinked RNA network (D1-TLR8-D2 and D1-MYC-D2), which we call an RNA matrix, induces formation of mesh-like FUS-TIS condensates "
664,PMID: 33762340,RNAPS0000602,https://pubmed.ncbi.nlm.nih.gov/33762340,RNA + protein,NCBI ID:18870687,https://www.ncbi.nlm.nih.gov/gene/18870687,GLS1,-(3'UTR),-,mRNA,Spathaspora passalidarum,"sp|Q14444|CAPR1_HUMAN Caprin-1 OS=Homo sapiens OX=9606 GN=CAPRIN1 PE=1 SV=2
MPSATSHSGSGSKSSGPPPPSGSSGSEAAAGAGAAAPASQHPATGTGAVQTEAMKQILGV
IDKKLRNLEKKKGKLDDYQERMNKGERLNQDQLDAVSKYQEVTNNLEFAKELQRSFMALS
QDIQKTIKKTARREQLMREEAEQKRLKTVLELQYVLDKLGDDEVRTDLKQGLNGVPILSE
EELSLLDEFYKLVDPERDMSLRLNEQYEHASIHLWDLLEGKEKPVCGTTYKVLKEIVERV
FQSNYFDSTHNHQNGLCEEEEAASAPAVEDQVPEAEPEPAEEYTEQSEVESTEYVNRQFM
AETQFTSGEKEQVDEWTVETVEVVNSLQQQPQAASPSVPEPHSLTPVAQADPLVRRQRVQ
DLMAQMQGPYNFIQDSMLDFENQTLDPAIVSAQPMNPTQNMDMPQLVCPPVHSESRLAQP
NQVPVQPEATQVPLVSSTSEGYTASQPLYQPSHATEQRPQKEPIDQIQATISLNTDQTTA
SSSLPAASQPQVFQAGTSKPLHSSGINVNAAPFQSMQTVFNMNAPVPPVNEPETLKQQNQ
YQASYNQSFSSQPHQVEQTELQQEQLQTVVGTYHGSPDQSHQVTGNHQQPPQQNTGFPRS
NQPYYNSRGVSRGGSRGARGLMNGYRGPANGFRGGYDGYRPSFSNTPNSGYTQSQFSAPR
DYSGYQRDGYQQNFKRGSGQSGPRGAPRGRGGPPRPNRGMPQMNTQQVN",CAPRIN1,-,-,709aa(1-709),Q14444,DrLLPS,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0521,"[1-50],[251-251],[260-291],[417-446],[475-499],[524-709]","[2-43],[61-81],[178-188],[258-282],[311-324],[328-337],[477-491],[537-552],[555-570],[607-620],[676-704]",In vitro,20µM[CAPRIN1];|0.2µM[GLS1 mRNA 3'UTR],30 mM NaCl,"25 mM Na2HPO4(pH 7.4),2 mM DTT",RT,immediately ,-,FRAP,liquid,"Using this approach, we observed the formation of visible droplets (phase-separated protein- rich condensates) when Flag-CAPRIN1 was incubated with 3′UTR-1 of GLS1, but not with the GLS1 5′UTR (Fig. 7H and fig. S5M)."
665,PMID: 33762340,RNAPS0000603,https://pubmed.ncbi.nlm.nih.gov/33762340,RNA + protein,NCBI ID:18870687,https://www.ncbi.nlm.nih.gov/gene/18870687,GLS1,-(5'UTR),-,mRNA,Spathaspora passalidarum,"sp|Q14444|CAPR1_HUMAN Caprin-1 OS=Homo sapiens OX=9606 GN=CAPRIN1 PE=1 SV=2
MPSATSHSGSGSKSSGPPPPSGSSGSEAAAGAGAAAPASQHPATGTGAVQTEAMKQILGV
IDKKLRNLEKKKGKLDDYQERMNKGERLNQDQLDAVSKYQEVTNNLEFAKELQRSFMALS
QDIQKTIKKTARREQLMREEAEQKRLKTVLELQYVLDKLGDDEVRTDLKQGLNGVPILSE
EELSLLDEFYKLVDPERDMSLRLNEQYEHASIHLWDLLEGKEKPVCGTTYKVLKEIVERV
FQSNYFDSTHNHQNGLCEEEEAASAPAVEDQVPEAEPEPAEEYTEQSEVESTEYVNRQFM
AETQFTSGEKEQVDEWTVETVEVVNSLQQQPQAASPSVPEPHSLTPVAQADPLVRRQRVQ
DLMAQMQGPYNFIQDSMLDFENQTLDPAIVSAQPMNPTQNMDMPQLVCPPVHSESRLAQP
NQVPVQPEATQVPLVSSTSEGYTASQPLYQPSHATEQRPQKEPIDQIQATISLNTDQTTA
SSSLPAASQPQVFQAGTSKPLHSSGINVNAAPFQSMQTVFNMNAPVPPVNEPETLKQQNQ
YQASYNQSFSSQPHQVEQTELQQEQLQTVVGTYHGSPDQSHQVTGNHQQPPQQNTGFPRS
NQPYYNSRGVSRGGSRGARGLMNGYRGPANGFRGGYDGYRPSFSNTPNSGYTQSQFSAPR
DYSGYQRDGYQQNFKRGSGQSGPRGAPRGRGGPPRPNRGMPQMNTQQVN",CAPRIN1,-,-,709aa(1-709),Q14444,DrLLPS,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0521,"[1-50],[251-251],[260-291],[417-446],[475-499],[524-709]","[2-43],[61-81],[178-188],[258-282],[311-324],[328-337],[477-491],[537-552],[555-570],[607-620],[676-704]",In vitro,20µM[CAPRIN1];|0.2µM[GLS1 mRNA 5'UTR],30 mM NaCl,"25 mM Na2HPO4(pH 7.4),2 mM DTT",RT,immediately ,-,FRAP,solute,"Using this approach, we observed the formation of visible droplets (phase-separated protein- rich condensates) when Flag-CAPRIN1 was incubated with 3′UTR-1 of GLS1, but not with the GLS1 5′UTR (Fig. 7H and fig. S5M)."
666,PMID: 33762340,RNAPS0000150,https://pubmed.ncbi.nlm.nih.gov/33762340,RNAs + protein,NCBI ID:18870687;|-,https://www.ncbi.nlm.nih.gov/gene/18870687,GLS1;|GIRGL,-(3'UTR);|740nt(1-740),-;|-,mRNA;|lncRNA,Spathaspora passalidarum;|Homo sapiens,"sp|Q14444|CAPR1_HUMAN Caprin-1 OS=Homo sapiens OX=9606 GN=CAPRIN1 PE=1 SV=2
MPSATSHSGSGSKSSGPPPPSGSSGSEAAAGAGAAAPASQHPATGTGAVQTEAMKQILGV
IDKKLRNLEKKKGKLDDYQERMNKGERLNQDQLDAVSKYQEVTNNLEFAKELQRSFMALS
QDIQKTIKKTARREQLMREEAEQKRLKTVLELQYVLDKLGDDEVRTDLKQGLNGVPILSE
EELSLLDEFYKLVDPERDMSLRLNEQYEHASIHLWDLLEGKEKPVCGTTYKVLKEIVERV
FQSNYFDSTHNHQNGLCEEEEAASAPAVEDQVPEAEPEPAEEYTEQSEVESTEYVNRQFM
AETQFTSGEKEQVDEWTVETVEVVNSLQQQPQAASPSVPEPHSLTPVAQADPLVRRQRVQ
DLMAQMQGPYNFIQDSMLDFENQTLDPAIVSAQPMNPTQNMDMPQLVCPPVHSESRLAQP
NQVPVQPEATQVPLVSSTSEGYTASQPLYQPSHATEQRPQKEPIDQIQATISLNTDQTTA
SSSLPAASQPQVFQAGTSKPLHSSGINVNAAPFQSMQTVFNMNAPVPPVNEPETLKQQNQ
YQASYNQSFSSQPHQVEQTELQQEQLQTVVGTYHGSPDQSHQVTGNHQQPPQQNTGFPRS
NQPYYNSRGVSRGGSRGARGLMNGYRGPANGFRGGYDGYRPSFSNTPNSGYTQSQFSAPR
DYSGYQRDGYQQNFKRGSGQSGPRGAPRGRGGPPRPNRGMPQMNTQQVN",CAPRIN1,-,-,709aa(1-709),Q14444,DrLLPS,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0521,"[1-50],[251-251],[260-291],[417-446],[475-499],[524-709]","[2-43],[61-81],[178-188],[258-282],[311-324],[328-337],[477-491],[537-552],[555-570],[607-620],[676-704]",In vitro,20µM[CAPRIN1];|0.2µM[GLS1 mRNA 3'UTR];|0.2µM[sense GIRGL],30 mM NaCl,"25 mM Na2HPO4(pH 7.4),2 mM DTT",RT,immediately ,-,FRAP,liquid,"Notably, the frequency of phase droplet formation between CAPRIN1 and GLS1 mRNA was comparatively increased when full-length sense, but not antisense, GIRGL was added to these assays."
667,PMID: 33762340,RNAPS0000154,https://pubmed.ncbi.nlm.nih.gov/33762340,RNAs + protein,NCBI ID:18870687;|-,https://www.ncbi.nlm.nih.gov/gene/18870687,GLS1;|GIRGL_antisense,-(3'UTR);|740nt(1-740),-;|-,mRNA;|lncRNA,Spathaspora passalidarum;|Homo sapiens,"sp|Q14444|CAPR1_HUMAN Caprin-1 OS=Homo sapiens OX=9606 GN=CAPRIN1 PE=1 SV=2
MPSATSHSGSGSKSSGPPPPSGSSGSEAAAGAGAAAPASQHPATGTGAVQTEAMKQILGV
IDKKLRNLEKKKGKLDDYQERMNKGERLNQDQLDAVSKYQEVTNNLEFAKELQRSFMALS
QDIQKTIKKTARREQLMREEAEQKRLKTVLELQYVLDKLGDDEVRTDLKQGLNGVPILSE
EELSLLDEFYKLVDPERDMSLRLNEQYEHASIHLWDLLEGKEKPVCGTTYKVLKEIVERV
FQSNYFDSTHNHQNGLCEEEEAASAPAVEDQVPEAEPEPAEEYTEQSEVESTEYVNRQFM
AETQFTSGEKEQVDEWTVETVEVVNSLQQQPQAASPSVPEPHSLTPVAQADPLVRRQRVQ
DLMAQMQGPYNFIQDSMLDFENQTLDPAIVSAQPMNPTQNMDMPQLVCPPVHSESRLAQP
NQVPVQPEATQVPLVSSTSEGYTASQPLYQPSHATEQRPQKEPIDQIQATISLNTDQTTA
SSSLPAASQPQVFQAGTSKPLHSSGINVNAAPFQSMQTVFNMNAPVPPVNEPETLKQQNQ
YQASYNQSFSSQPHQVEQTELQQEQLQTVVGTYHGSPDQSHQVTGNHQQPPQQNTGFPRS
NQPYYNSRGVSRGGSRGARGLMNGYRGPANGFRGGYDGYRPSFSNTPNSGYTQSQFSAPR
DYSGYQRDGYQQNFKRGSGQSGPRGAPRGRGGPPRPNRGMPQMNTQQVN",CAPRIN1,-,-,709aa(1-709),Q14444,DrLLPS,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0521,"[1-50],[251-251],[260-291],[417-446],[475-499],[524-709]","[2-43],[61-81],[178-188],[258-282],[311-324],[328-337],[477-491],[537-552],[555-570],[607-620],[676-704]",In vitro,20µM[CAPRIN1];|0.2µM[GLS1 mRNA 3'UTR];|0.2µM[antisense GIRGL],30 mM NaCl,"25 mM Na2HPO4(pH 7.4),2 mM DTT",RT,immediately ,-,FRAP,liquid,"Notably, the frequency of phase droplet formation between CAPRIN1 and GLS1 mRNA was comparatively increased when full-length sense, but not antisense, GIRGL was added to these assays."
668,PMID: 33762340,RNAPS0000602,https://pubmed.ncbi.nlm.nih.gov/33762340,RNA + protein,NCBI ID:18870687,https://www.ncbi.nlm.nih.gov/gene/18870687,GLS1,-(3'UTR),-,mRNA,Spathaspora passalidarum,"sp|Q14444|CAPR1_HUMAN Caprin-1 OS=Homo sapiens OX=9606 GN=CAPRIN1 PE=1 SV=2
MPSATSHSGSGSKSSGPPPPSGSSGSEAAAGAGAAAPASQHPATGTGAVQTEAMKQILGV
IDKKLRNLEKKKGKLDDYQERMNKGERLNQDQLDAVSKYQEVTNNLEFAKELQRSFMALS
QDIQKTIKKTARREQLMREEAEQKRLKTVLELQYVLDKLGDDEVRTDLKQGLNGVPILSE
EELSLLDEFYKLVDPERDMSLRLNEQYEHASIHLWDLLEGKEKPVCGTTYKVLKEIVERV
FQSNYFDSTHNHQNGLCEEEEAASAPAVEDQVPEAEPEPAEEYTEQSEVESTEYVNRQFM
AETQFTSGEKEQVDEWTVETVEVVNSLQQQPQAASPSVPEPHSLTPVAQADPLVRRQRVQ
DLMAQMQGPYNFIQDSMLDFENQTLDPAIVSAQPMNPTQNMDMPQLVCPPVHSESRLAQP
NQVPVQPEATQVPLVSSTSEGYTASQPLYQPSHATEQRPQKEPIDQIQATISLNTDQTTA
SSSLPAASQPQVFQAGTSKPLHSSGINVNAAPFQSMQTVFNMNAPVPPVNEPETLKQQNQ
YQASYNQSFSSQPHQVEQTELQQEQLQTVVGTYHGSPDQSHQVTGNHQQPPQQNTGFPRS
NQPYYNSRGVSRGGSRGARGLMNGYRGPANGFRGGYDGYRPSFSNTPNSGYTQSQFSAPR
DYSGYQRDGYQQNFKRGSGQSGPRGAPRGRGGPPRPNRGMPQMNTQQVN",CAPRIN1,-,-,709aa(1-709),Q14444,DrLLPS,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0521,"[1-50],[251-251],[260-291],[417-446],[475-499],[524-709]","[2-43],[61-81],[178-188],[258-282],[311-324],[328-337],[477-491],[537-552],[555-570],[607-620],[676-704]",In vitro,20µM[CAPRIN1];|0-0.4µM[GLS1 mRNA 3'UTR],30 mM NaCl,"25 mM Na2HPO4(pH 7.4),2 mM DTT",RT,immediately ,-,FRAP,liquid,"Formation of the CAPRIN1-containing condensates was dependent on the concentration of 3′UTR-1 GLS1 mRNA (fig. S5N), and moreover, these droplets were observed to undergo fusion events (fig. S5O)"
669,PMID: 33895773,RNAPS0000607,https://pubmed.ncbi.nlm.nih.gov/33895773,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,10µM[mCherry-N protein];|10 ng/mL[polyU],-,-,37˚C,20 min,-,FRAP,liquid,We further found that recombinant mCherry-fusion SARS-CoV-2 N protein formed micrometer-sized liquid droplets within 1 min when blended with poly(I:C) or polyU in vitro
670,PMID: 33895773,RNAPS0000607,https://pubmed.ncbi.nlm.nih.gov/33895773,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.25-5µM[mCherry-N protein];|0-50 ng/mL[polyU],-,-,37˚C,-,-,FRAP,"solute, liquid","N protein was able to form liquid-like droplets at the concentration of 1μM with the presence of poly(I: C) or polyU over 5 ng/mL (Fig. 3f, g). Small liquid droplets tended to coalesce and formed larger droplets over time, together with larger equivalent diameter in vitro (Fig. 3h). "
671,PMID: 33910901,RNAPS0000610,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q94BV4|RH6_ARATH DEAD-box ATP-dependent RNA helicase 6 OS=Arabidopsis thaliana OX=3702 GN=RH6 PE=2 SV=2
MNNNNNNRGRFPPGIGAAGPGPDPNFQSRNPNPPQPQQYLQSRTPFPQQPQPQPPQYLQS
QSDAQQYVQRGYPQQIQQQQQLQQQQQQQQQQQEQQWSRRAQLPGDPSYIDEVEKTVQSE
AISDSNNEDWKATLKLPPRDNRYQTEDVTATKGNEFEDYFLKRDLLRGIYEKGFEKPSPI
QEESIPIALTGSDILARAKNGTGKTGAFCIPTLEKIDPENNVIQAVILVPTRELALQTSQ
VCKELSKYLKIEVMVTTGGTSLRDDIMRLYQPVHLLVGTPGRILDLAKKGVCVLKDCAML
VMDEADKLLSVEFQPSIEELIQFLPESRQILMFSATFPVTVKSFKDRYLKKPYIINLMDQ
LTLMGVTQYYAFVEERQKVHCLNTLFSKLQINQSIIFCNSVNRVELLAKKITELGYSCFY
IHAKMVQDHRNRVFHDFRNGACRNLVCTDLFTRGIDIQAVNVVINFDFPRTSESYLHRVG
RSGRFGHLGLAVNLVTYEDRFKMYQTEQELGTEIKPIPSLIDKAIYCQ",RH6,-,-,528aa(1-528),Q94BV4,DrLLPS,http://llps.biocuckoo.cn/view.php?id=LLPS-Art-0517,-,"[2-41],[45-56],[65-97]",In vitro,300ng/µL[polyU];|8µM[RH6],200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,other_moleculer:5mM[ATP];crowding agent:2 μl of 50% PEG8000,"Fluorescence 
microscopy ",liquid,"In contrast, RH12, RH6, and RH8 remained dispersed in the absence of RNA or ATP, indicating that these helicases at high concentrations can undergo phase separation in an RNA- and ATP-dependent manner in vitro."
672,PMID: 33910901,RNAPS0000611,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q8RXK6|RH8_ARATH DEAD-box ATP-dependent RNA helicase 8 OS=Arabidopsis thaliana OX=3702 GN=RH8 PE=2 SV=1
MNNRGRYPPGIGAGRGAFNPNPNYQSRSGYQQHPPPQYVQRGNYAQNHQQQFQQAPSQPH
QYQQQQQQQQQWLRRGQIPGGNSNGDAVVEVEKTVQSEVIDPNSEDWKARLKLPAPDTRY
RTEDVTATKGNEFEDYFLKRELLMGIYEKGFERPSPIQEESIPIALTGRDILARAKNGTG
KTAAFCIPVLEKIDQDNNVIQAVIIVPTRELALQTSQVCKELGKHLKIQVMVTTGGTSLK
DDIMRLYQPVHLLVGTPGRILDLTKKGVCVLKDCSVLVMDEADKLLSQEFQPSVEHLISF
LPESRQILMFSATFPVTVKDFKDRFLTNPYVINLMDELTLKGITQFYAFVEERQKIHCLN
TLFSKLQINQSIIFCNSVNRVELLAKKITELGYSCFYIHAKMLQDHRNRVFHDFRNGACR
NLVCTDLFTRGIDIQAVNVVINFDFPKNAETYLHRVGRSGRFGHLGLAVNLITYEDRFNL
YRIEQELGTEIKQIPPHIDQAIYCQ",RH8,-,-,505aa(1-505),Q8RXK6,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Art-1431,http://db.phasep.pro/browse/",-,[43-72],In vitro,300ng/µL[polyU];|8µM[RH8],200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,other_moleculer:5mM[ATP];crowding agent:2 μl of 50% PEG8000,"Fluorescence 
microscopy ",liquid,"In contrast, RH12, RH6, and RH8 remained dispersed in the absence of RNA or ATP, indicating that these helicases at high concentrations can undergo phase separation in an RNA- and ATP-dependent manner in vitro."
673,PMID: 33910901,RNAPS0000612,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q9M2E0|RH12_ARATH DEAD-box ATP-dependent RNA helicase 12 OS=Arabidopsis thaliana OX=3702 GN=RH12 PE=2 SV=1
MNTNRGRYPPGVGTGRGAPPNPDYHQSYRQQQPPQDQQYVQRGYSQNPQQMQLQQQHQQQ
QQQQQWSRRPQLPGNASNANEVVQQTTQPEASSDANGQDWKATLRLPPPDTRYQTADVTA
TKGNEFEDYFLKRDLLKGIYEKGFEKPSPIQEESIPIALTGSDILARAKNGTGKTGAFCI
PVLEKIDPNNNVIQAMILVPTRELALQTSQVCKELSKYLNIQVMVTTGGTSLRDDIMRLH
QPVHLLVGTPGRILDLTKKGVCVLKDCAMLVMDEADKLLSAEFQPSLEELIQFLPQNRQF
LMFSATFPVTVKAFKDRHLRKPYVINLMDQLTLMGVTQYYAFVEERQKVHCLNTLFSKLQ
INQSIIFCNSVNRVELLAKKITELGYSCFYIHAKMVQDHRNRVFHEFRNGACRNLVCTDL
FTRGIDIQAVNVVINFDFPRTSESYLHRVGRSGRFGHLGLAVNLVTYEDRFKMYQTEQEL
GTEIKPIPSNIDQAIYCQ",RH12,-,-,498aa(1-498),Q9M2E0,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Art-1808,http://db.phasep.pro/browse/",-,"[26-42],[46-66]",In vitro,300ng/µL[polyU];|8µM[RH12],200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,other_moleculer:5mM[ATP];crowding agent:2 μl of 50% PEG8000,"Fluorescence 
microscopy ",liquid,"In contrast, RH12, RH6, and RH8 remained dispersed in the absence of RNA or ATP, indicating that these helicases at high concentrations can undergo phase separation in an RNA- and ATP-dependent manner in vitro."
674,PMID: 33910901,RNAPS0000610,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q94BV4|RH6_ARATH DEAD-box ATP-dependent RNA helicase 6 OS=Arabidopsis thaliana OX=3702 GN=RH6 PE=2 SV=2
MNNNNNNRGRFPPGIGAAGPGPDPNFQSRNPNPPQPQQYLQSRTPFPQQPQPQPPQYLQS
QSDAQQYVQRGYPQQIQQQQQLQQQQQQQQQQQEQQWSRRAQLPGDPSYIDEVEKTVQSE
AISDSNNEDWKATLKLPPRDNRYQTEDVTATKGNEFEDYFLKRDLLRGIYEKGFEKPSPI
QEESIPIALTGSDILARAKNGTGKTGAFCIPTLEKIDPENNVIQAVILVPTRELALQTSQ
VCKELSKYLKIEVMVTTGGTSLRDDIMRLYQPVHLLVGTPGRILDLAKKGVCVLKDCAML
VMDEADKLLSVEFQPSIEELIQFLPESRQILMFSATFPVTVKSFKDRYLKKPYIINLMDQ
LTLMGVTQYYAFVEERQKVHCLNTLFSKLQINQSIIFCNSVNRVELLAKKITELGYSCFY
IHAKMVQDHRNRVFHDFRNGACRNLVCTDLFTRGIDIQAVNVVINFDFPRTSESYLHRVG
RSGRFGHLGLAVNLVTYEDRFKMYQTEQELGTEIKPIPSLIDKAIYCQ",RH6,-,-,528aa(1-528),Q94BV4,DrLLPS,http://llps.biocuckoo.cn/view.php?id=LLPS-Art-0517,-,"[2-41],[45-56],[65-97]",In vitro,300ng/µL[polyU];|8µM[RH6],200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,crowding agent:2 μl of 50% PEG8000,"Fluorescence 
microscopy ",solute,"In contrast, RH12, RH6, and RH8 remained dispersed in the absence of RNA or ATP, indicating that these helicases at high concentrations can undergo phase separation in an RNA- and ATP-dependent manner in vitro."
675,PMID: 33910901,RNAPS0000611,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q8RXK6|RH8_ARATH DEAD-box ATP-dependent RNA helicase 8 OS=Arabidopsis thaliana OX=3702 GN=RH8 PE=2 SV=1
MNNRGRYPPGIGAGRGAFNPNPNYQSRSGYQQHPPPQYVQRGNYAQNHQQQFQQAPSQPH
QYQQQQQQQQQWLRRGQIPGGNSNGDAVVEVEKTVQSEVIDPNSEDWKARLKLPAPDTRY
RTEDVTATKGNEFEDYFLKRELLMGIYEKGFERPSPIQEESIPIALTGRDILARAKNGTG
KTAAFCIPVLEKIDQDNNVIQAVIIVPTRELALQTSQVCKELGKHLKIQVMVTTGGTSLK
DDIMRLYQPVHLLVGTPGRILDLTKKGVCVLKDCSVLVMDEADKLLSQEFQPSVEHLISF
LPESRQILMFSATFPVTVKDFKDRFLTNPYVINLMDELTLKGITQFYAFVEERQKIHCLN
TLFSKLQINQSIIFCNSVNRVELLAKKITELGYSCFYIHAKMLQDHRNRVFHDFRNGACR
NLVCTDLFTRGIDIQAVNVVINFDFPKNAETYLHRVGRSGRFGHLGLAVNLITYEDRFNL
YRIEQELGTEIKQIPPHIDQAIYCQ",RH8,-,-,505aa(1-505),Q8RXK6,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Art-1431,http://db.phasep.pro/browse/",-,[43-72],In vitro,300ng/µL[polyU];|8µM[RH8],200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,crowding agent:2 μl of 50% PEG8000,"Fluorescence 
microscopy ",solute,"In contrast, RH12, RH6, and RH8 remained dispersed in the absence of RNA or ATP, indicating that these helicases at high concentrations can undergo phase separation in an RNA- and ATP-dependent manner in vitro."
676,PMID: 33910901,RNAPS0000612,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q9M2E0|RH12_ARATH DEAD-box ATP-dependent RNA helicase 12 OS=Arabidopsis thaliana OX=3702 GN=RH12 PE=2 SV=1
MNTNRGRYPPGVGTGRGAPPNPDYHQSYRQQQPPQDQQYVQRGYSQNPQQMQLQQQHQQQ
QQQQQWSRRPQLPGNASNANEVVQQTTQPEASSDANGQDWKATLRLPPPDTRYQTADVTA
TKGNEFEDYFLKRDLLKGIYEKGFEKPSPIQEESIPIALTGSDILARAKNGTGKTGAFCI
PVLEKIDPNNNVIQAMILVPTRELALQTSQVCKELSKYLNIQVMVTTGGTSLRDDIMRLH
QPVHLLVGTPGRILDLTKKGVCVLKDCAMLVMDEADKLLSAEFQPSLEELIQFLPQNRQF
LMFSATFPVTVKAFKDRHLRKPYVINLMDQLTLMGVTQYYAFVEERQKVHCLNTLFSKLQ
INQSIIFCNSVNRVELLAKKITELGYSCFYIHAKMVQDHRNRVFHEFRNGACRNLVCTDL
FTRGIDIQAVNVVINFDFPRTSESYLHRVGRSGRFGHLGLAVNLVTYEDRFKMYQTEQEL
GTEIKPIPSNIDQAIYCQ",RH12,-,-,498aa(1-498),Q9M2E0,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Art-1808,http://db.phasep.pro/browse/",-,"[26-42],[46-66]",In vitro,300ng/µL[polyU];|8µM[RH12],200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,crowding agent:2 μl of 50% PEG8000,"Fluorescence 
microscopy ",solute,"In contrast, RH12, RH6, and RH8 remained dispersed in the absence of RNA or ATP, indicating that these helicases at high concentrations can undergo phase separation in an RNA- and ATP-dependent manner in vitro."
677,PMID: 33910901,RNAPS0000613,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,-,Turnip mosaic virus Vpg,-,-,-,-,-,-,-,-,In vitro,0-150ng/µL[polyU];|15µM[VPg],1 μl of 200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,-,"Fluorescence 
microscopy ",liquid,"we found that VPg protein undergoes LLPS in the absence of RNA, and ssRNA (polyU) decreases its phase separation (fig. S12, C to E). VPg directly interacts with RH12 in vitro (Fig. 5D). Although high concentration of RNA inhibits the phase separation of VPg, phase separation of RH12 is dependent on RNA "
678,PMID: 33910901,RNAPS0000613,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,-,Turnip mosaic virus Vpg,-,-,-,-,-,-,-,-,In vitro,8µM[VPg];|50ng/µL[polyU],1 μl of 200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,-,"Fluorescence 
microscopy ",liquid,"As expected, the droplet number and size of VPg proteins increased with the addition of RH8 or RH12 proteins under high concentration of RNAs"
679,PMID: 33910901,RNAPS0000611,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q8RXK6|RH8_ARATH DEAD-box ATP-dependent RNA helicase 8 OS=Arabidopsis thaliana OX=3702 GN=RH8 PE=2 SV=1
MNNRGRYPPGIGAGRGAFNPNPNYQSRSGYQQHPPPQYVQRGNYAQNHQQQFQQAPSQPH
QYQQQQQQQQQWLRRGQIPGGNSNGDAVVEVEKTVQSEVIDPNSEDWKARLKLPAPDTRY
RTEDVTATKGNEFEDYFLKRELLMGIYEKGFERPSPIQEESIPIALTGRDILARAKNGTG
KTAAFCIPVLEKIDQDNNVIQAVIIVPTRELALQTSQVCKELGKHLKIQVMVTTGGTSLK
DDIMRLYQPVHLLVGTPGRILDLTKKGVCVLKDCSVLVMDEADKLLSQEFQPSVEHLISF
LPESRQILMFSATFPVTVKDFKDRFLTNPYVINLMDELTLKGITQFYAFVEERQKIHCLN
TLFSKLQINQSIIFCNSVNRVELLAKKITELGYSCFYIHAKMLQDHRNRVFHDFRNGACR
NLVCTDLFTRGIDIQAVNVVINFDFPKNAETYLHRVGRSGRFGHLGLAVNLITYEDRFNL
YRIEQELGTEIKQIPPHIDQAIYCQ",RH8,-,-,505aa(1-505),Q8RXK6,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Art-1431,http://db.phasep.pro/browse/",-,[43-72],In vitro,8µM[RH8];|50ng/µL[polyU],1 μl of 200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,-,"Fluorescence 
microscopy ",liquid,"As expected, the droplet number and size of VPg proteins increased with the addition of RH8 or RH12 proteins under high concentration of RNAs"
680,PMID: 33910901,RNAPS0000612,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q9M2E0|RH12_ARATH DEAD-box ATP-dependent RNA helicase 12 OS=Arabidopsis thaliana OX=3702 GN=RH12 PE=2 SV=1
MNTNRGRYPPGVGTGRGAPPNPDYHQSYRQQQPPQDQQYVQRGYSQNPQQMQLQQQHQQQ
QQQQQWSRRPQLPGNASNANEVVQQTTQPEASSDANGQDWKATLRLPPPDTRYQTADVTA
TKGNEFEDYFLKRDLLKGIYEKGFEKPSPIQEESIPIALTGSDILARAKNGTGKTGAFCI
PVLEKIDPNNNVIQAMILVPTRELALQTSQVCKELSKYLNIQVMVTTGGTSLRDDIMRLH
QPVHLLVGTPGRILDLTKKGVCVLKDCAMLVMDEADKLLSAEFQPSLEELIQFLPQNRQF
LMFSATFPVTVKAFKDRHLRKPYVINLMDQLTLMGVTQYYAFVEERQKVHCLNTLFSKLQ
INQSIIFCNSVNRVELLAKKITELGYSCFYIHAKMVQDHRNRVFHEFRNGACRNLVCTDL
FTRGIDIQAVNVVINFDFPRTSESYLHRVGRSGRFGHLGLAVNLVTYEDRFKMYQTEQEL
GTEIKPIPSNIDQAIYCQ",RH12,-,-,498aa(1-498),Q9M2E0,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Art-1808,http://db.phasep.pro/browse/",-,"[26-42],[46-66]",In vitro,8µM[RH12];|50ng/µL[polyU],1 μl of 200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,-,"Fluorescence 
microscopy ",liquid,"As expected, the droplet number and size of VPg proteins increased with the addition of RH8 or RH12 proteins under high concentration of RNAs"
681,PMID: 33910901,RNAPS0000612,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q9M2E0|RH12_ARATH DEAD-box ATP-dependent RNA helicase 12 OS=Arabidopsis thaliana OX=3702 GN=RH12 PE=2 SV=1
MNTNRGRYPPGVGTGRGAPPNPDYHQSYRQQQPPQDQQYVQRGYSQNPQQMQLQQQHQQQ
QQQQQWSRRPQLPGNASNANEVVQQTTQPEASSDANGQDWKATLRLPPPDTRYQTADVTA
TKGNEFEDYFLKRDLLKGIYEKGFEKPSPIQEESIPIALTGSDILARAKNGTGKTGAFCI
PVLEKIDPNNNVIQAMILVPTRELALQTSQVCKELSKYLNIQVMVTTGGTSLRDDIMRLH
QPVHLLVGTPGRILDLTKKGVCVLKDCAMLVMDEADKLLSAEFQPSLEELIQFLPQNRQF
LMFSATFPVTVKAFKDRHLRKPYVINLMDQLTLMGVTQYYAFVEERQKVHCLNTLFSKLQ
INQSIIFCNSVNRVELLAKKITELGYSCFYIHAKMVQDHRNRVFHEFRNGACRNLVCTDL
FTRGIDIQAVNVVINFDFPRTSESYLHRVGRSGRFGHLGLAVNLVTYEDRFKMYQTEQEL
GTEIKPIPSNIDQAIYCQ",RH12,-,-,498aa(1-498),Q9M2E0,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Art-1808,http://db.phasep.pro/browse/",-,"[26-42],[46-66]",In vitro,8µM[RH12];|300ng/µL[polyU],200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,crowding agent:2μl of 50% PEG8000;other_moleculer:5mM[ATP],"Fluorescence 
microscopy ",liquid,"To evaluate whether VPg directly inhibits RH12 phase separation, we mixed VPg and RH12 under high concentration of RNA. VPg proteins remain dispersed at polyU"
682,PMID: 33910901,RNAPS0000613,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,-,Turnip mosaic virus Vpg,-,-,-,-,-,-,-,-,In vitro,10µM[VPg];|300ng/µL[polyU],200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,crowding agent:2μl of 50% PEG8000;other_moleculer:5mM[ATP],"Fluorescence 
microscopy ",solute,"To evaluate whether VPg directly inhibits RH12 phase separation, we mixed VPg and RH12 under high concentration of RNA. VPg proteins remain dispersed at polyU"
683,PMID: 33991007,RNAPS0000526,https://pubmed.ncbi.nlm.nih.gov/33991007,RNA + protein,-,-,(UG)12,24nt,UGUGUGUGUGUGUGUGUGUGUGUG,repeat RNA,-,"sp|Q14011|CIRBP_HUMAN Cold-inducible RNA-binding protein OS=Homo sapiens OX=9606 GN=CIRBP PE=1 SV=1
MASDEGKLFVGGLSFDTNEQSLEQVFSKYGQISEVVVVKDRETQRSRGFGFVTFENIDDA
KDAMMAMNGKSVDGRQIRVDQAGKSSDNRSRGYRGGSAGGRGFFRGGRGRGRGFSRGGGD
RGYGGNRFESRSGGYGGSRDYYSSRSQSGGYSDRSSGGSYRDSYDSYATHNE",CIRBP,-,-,172aa(1-172),Q14011,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0652,http://db.phasep.pro/browse/",[86-172],"[89-125],[130-167]",In vitro,17µM[CIRBP];|1-30µM[(UG)12],150 mM NaCl,"50 mM NaH2PO4/Na2HPO4,pH 6.5",-,-,-,Turbidity measurement,liquid,"titration of (UG)12RNA to a sample with a fixed CIRBP concentration (17 μM) led to a progressive turbidity increase at low RNA concentrations, whereas higher amounts of RNA had a suppressive effect on CIRBP LLPS"
684,PMID: 33991007,RNAPS0000526,https://pubmed.ncbi.nlm.nih.gov/33991007,RNA + protein,-,-,(UG)12,24nt,UGUGUGUGUGUGUGUGUGUGUGUG,repeat RNA,-,"sp|Q14011|CIRBP_HUMAN Cold-inducible RNA-binding protein OS=Homo sapiens OX=9606 GN=CIRBP PE=1 SV=1
MASDEGKLFVGGLSFDTNEQSLEQVFSKYGQISEVVVVKDRETQRSRGFGFVTFENIDDA
KDAMMAMNGKSVDGRQIRVDQAGKSSDNRSRGYRGGSAGGRGFFRGGRGRGRGFSRGGGD
RGYGGNRFESRSGGYGGSRDYYSSRSQSGGYSDRSSGGSYRDSYDSYATHNE",CIRBP,-,-,172aa(1-172),Q14011,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0652,http://db.phasep.pro/browse/",[86-172],"[89-125],[130-167]",In vitro,17µM[CIRBP];|7.5µM[(UG)12],150 mM NaCl,"50 mM NaH2PO4/Na2HPO4,pH 6.5",-,-,other_moleculer:0-10mM[ATP],Turbidity measurement,liquid,"Addition of increasing amounts of ATP to RNA-bound and phase separated CIRBP led to a concentration-dependent decrease in turbidity, demonstrating that ATP inhibits CIRBP LLPS "
685,PMID: 33991007,RNAPS0000526,https://pubmed.ncbi.nlm.nih.gov/33991007,RNA + protein,-,-,(UG)12,24nt,UGUGUGUGUGUGUGUGUGUGUGUG,repeat RNA,-,"sp|Q14011|CIRBP_HUMAN Cold-inducible RNA-binding protein OS=Homo sapiens OX=9606 GN=CIRBP PE=1 SV=1
MASDEGKLFVGGLSFDTNEQSLEQVFSKYGQISEVVVVKDRETQRSRGFGFVTFENIDDA
KDAMMAMNGKSVDGRQIRVDQAGKSSDNRSRGYRGGSAGGRGFFRGGRGRGRGFSRGGGD
RGYGGNRFESRSGGYGGSRDYYSSRSQSGGYSDRSSGGSYRDSYDSYATHNE",CIRBP,-,-,172aa(1-172),Q14011,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0652,http://db.phasep.pro/browse/",[86-172],"[89-125],[130-167]",In vitro,17µM[CIRBP];|7.5µM[(UG)12],150 mM NaCl,"50 mM NaH2PO4/Na2HPO4,pH 6.5",-,5-30 min,other_moleculer:5mM[ATP],Differential interference contrast microscopy,-,"In order to further validate these findings, we monitored CIRBP phase separation by DIC microscopy. In the presence of substoichiometric amounts of RNA, CIRBP immediately formed small condensates that increased in size over time, most likely due to fusion of condensates, and indicating their “liquid-like” behavior "
686,PMID: 33991007,RNAPS0000526,https://pubmed.ncbi.nlm.nih.gov/33991007,RNA + protein,-,-,(UG)12,24nt,UGUGUGUGUGUGUGUGUGUGUGUG,repeat RNA,-,"sp|Q14011|CIRBP_HUMAN Cold-inducible RNA-binding protein OS=Homo sapiens OX=9606 GN=CIRBP PE=1 SV=1
MASDEGKLFVGGLSFDTNEQSLEQVFSKYGQISEVVVVKDRETQRSRGFGFVTFENIDDA
KDAMMAMNGKSVDGRQIRVDQAGKSSDNRSRGYRGGSAGGRGFFRGGRGRGRGFSRGGGD
RGYGGNRFESRSGGYGGSRDYYSSRSQSGGYSDRSSGGSYRDSYDSYATHNE",CIRBP,-,-,172aa(1-172),Q14011,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0652,http://db.phasep.pro/browse/",[86-172],"[89-125],[130-167]",In vitro,17µM[CIRBP];|7.5µM[(UG)12],150 mM NaCl,"50 mM NaH2PO4/Na2HPO4,pH 6.5",-,5-30 min,-,Differential interference contrast microscopy,liquid,"In order to further validate these findings, we monitored CIRBP phase separation by DIC microscopy. In the presence of substoichiometric amounts of RNA, CIRBP immediately formed small condensates that increased in size over time, most likely due to fusion of condensates, and indicating their “liquid-like” behavior "
687,PMID: 34108682,RNAPS0000618,https://pubmed.ncbi.nlm.nih.gov/34108682,RNA + protein,NCBI ID: 647979,https://www.ncbi.nlm.nih.gov/gene/647979,NORAD,5378nt(1-5378),AGUUCCGGUCCGGCAGAGAUCGCGGAGAGACGCAGAACGCAGCCCGCUCCUCCAGGGCCCUCCAGGCCCUCCGGCCCCGGGCCGGCGGGUGAACUGGGGGGCCCCGGGACAGGCCGAGCCCUCUGCCCUGCAGAUAACGGAGGCCUCUGCUGUGGCUGCCCACUGGCUGUGCCCGCCCACUGGCUGUGCCCAGACCUUGAAGCCGCAGCGAACCUCUCUUUCCCACCCCACCUCGGUGACUAAUGGCGGCCGUGGCGUCUCCCAGCCCGGACCCCGCCGGCACCCGGGUCUCCCGACCCAAGCCUCGACGAAACCCCCGCAGAGCCGCCGGGACGCAGCGCCUUUGGGCGGCGCUGGGCGUGGUGGGCCGGGAAGUAUGGCGGCAGCUCGAACGCCGCGCGGCGGAGGCCAUUAAGGCGUGGACGGCCCGGGAAGGCGGCCUAGGGACGCAAGCAGGCUCGGCCGCCUCUUUAGGCCACGGAGCCGCGCAGAUCCGGUUCCCGGGUGACCACUCUGUCGCCAUUGGGCGAGACCUACCUAGUCCUGACGACAACGGACAAAGGCCUUAAGGGGCCUGGAAGGUGAGCGAAGUCCCGAACGACGACGGGUGGAACGGUUAGCGGCCAUCGGGCGGUUGGUCUUCAUUCUACCAGACUUUGCUGUCGGAAGAGAGAAAUGGUAGAAUGACAGGCCACGUUUGGCCCGUUGGAAAUGCCCACCACCCUCUGGGAAGAUUUACUGGCCGUUUAUGGAAGGCCUGUGUAUAUAAUAUGAAAAAGCUGCUCUCAACUCCACCCCAACCUUUUAAUAGAAAACAUUUGUCACAUCUAGCCCUUCUAGAUGGAAAGAGGUUGCCGACGUAUGAUAAAAUAGAGUUAGAAAGUUACACAUCUUGUAAAUUCUCAUUUGUUUAAAAGAAAUCAUAGAAAAUACAUGUCUUCUGGAGAUGACUUUUGGAAAUGGAGUUGUUAAGACGGCCUCUGGAAGCGAUACGUCCACGUUUGUUAAGUGGGUUAGAUGACAUGGAGCUGGAAGACCUGAGAAGGAAGAGAAGAAGGUUCUAUGCUAGACUGGUCAUAUUUAGAAGACAUUUUCAUAUUCUAUCCAUUGUUUUGUGUGCAUUUUAUUCCUCACUACUGUGUAUAUAGUUGACAAUGCUAAGCUUUUUUGAAAUGUCUCUUCUUUUUAGAUGUUCUGAAGUGCCUGAUAUGUUAAAAUUAGAGGUAGCAAAAUCACAUUUUGUAAAUACCUUUUUGUUACAAUUCAUAGGAAAUAUUUUUGGGGGGGAAUGGCCAAAUCACCUGUUGAGUAAUACUCAUUGUGUUUGUGCAGUGGUUCAGGGGAGGAGAGAGGAGGGGGAGGUGCAGAGAGCUCUAUGCCAUCCUGUUUACAGCGAGGCAAGAUGAAUCAUUAUGUCUGUGCAUUUUGUUUUACUUAUCUGUGUAUAUAGUGUACAUAAAGGACAGACGAGUCCUAAUUGACAACAUCUAGUCUUUCUGGAUGUUAAAGAGGUUGCCAGUGUAUGACAAAAGUAGAGUUAGUAAACUAAUAUAUUUUGUACAUUUUGUUUUACAAGUCCUAGGAAAGAUUGUCUUCUGAAAAUUUGAUGUCUUCUGGGUUGAUGGAGAUGGGAAGGGUUCUAGGCCAGAAUGUUCACAUUUGGAAGACUCUUUCAAAUUAUAACUGUUGUUACAUGUUUGCAGUUUAUUCAAGACUGCUGUAUACAUAGUAGACAAAUUAACUCCUUACUUGAAACAUCUAGUCUAUCUAGAUGUUUAGAAGUGCCCGAUGUAUGUUAAAUGUAUAGGUAGUAAAAUACCACUUUGUAAAUAUCUUUUUGCUAAAAUUCAUAGGAAAUGCUUUUGGAAAUUGAAUUGUGAAGCCACCUUUGUGAACAGUAUAGUAAUGUCUAUACUUGUUCAAUAGUUUAGAGGAGGUAGGAGGGAAGAAAUUGCAAAAGGUAAUAUUACUAGUGUGUUCAUACUUGGACAUUUUCAGACACCAUUUUUCUAUAUGUUUUGUGCAUUUUGUUUUGCUCUGUAUAUAGUAUAUAUAAUGGACAAAUAGUCCUAAUUUUUCAACAUCUAGUCUCUAGAUGUUAAAGAGGUUGCCAGUGUAUGACAAAGGAGUAAAAUUAGCAUAUUUUGUACACUUUGUGUUGAAAUUCGUAGGAAAACUUGUCUUCUGUAAAGACUUUUGCAUAGGAAUUUGUUUGACCAUCUCUAAGCAUUACACGUGCCUGUACUUGUCCACUGGAUUGAAGGCAGAGAAGGAAGGGAGGAGGGAAUGAUUCAAGGCCAAAAUGGCCACAUUUAGAAGAUACCUCAGAUGAUAACCAUUGUUAUGUGUGUGCAAUUUUAUUUAACAGUGCUGUGUAUGUGGUGGACAAGUUAUAUGAAAUAUCUAGUCUUUCUAGAUAUUUGGAAGUGCUUGAUGUAUUUAAAAGUGGUAGUAGAAUAACACUUUGUAAAUAGCUUUUAAAAACUGAUGGGAAAUGCUGUUUGGAAGUGGAAUUGUUGAACCACCUGGGAGGUGGGAGGGAAGAAAUUGCAAAUGGUGUUUUGCCAUUGUUUAUUAGAAAAUUUCAGCUUAAUCCAUUGUGUAUAUGUUACAUGCAUUUCAUUUAACUUUGCUAUACUGUAUAUAUUGUAUAUAUAACGGACAAAUUAGUCCCGAUUUUAUAAUAUCUAGUCUCUAGAUAUUAAAGAGGUUGCCAAUGUAUGACAGAAGUAGAGUUAGUAAACUAACACAUUUUGUACACUUUGUUAAAAUUUGUAGAAAGGCUGUCUUCUGAAAAGGACUUUUGGAAGUGAGAUAACAUCAGCUCUAAGUGACACGUGCCUAUAUCCAUCAGGUUGGUGGUGGAGAGGAGUUGGAAGGAAUGAAGGGUUCUAGACCAGAAUGUUCGUAUUUAGAAGACACUAUCAGAUAUAACCAUUGUUACAUGUGUGUAGUUUAUUCAACCCUACUGUGUAUAUAGCGGACAAACUUAAGUCCUUAUUUGAAACAUCUAGUCUUUCUAGAUGUUUAGAAGUGCACAAAGUAUGUUAAAAGUAGAGGUAGUAAAUAACACAUUUUGUAGCUAUCCUUUUGAUAUGAAAUAUUGUCUUGGAAAUUGAUCAAUUCUCUGAGCAGUACCCAUUUUGAUAUUUGUGCUGGUUCAGGGGGAAGGAGGAGCACAAAGUGCAAAGGGCUUUCUACCAGUGUCCAGUGUGUUUAUGAGGAGGCACAUUGACCAUUGUCCCUUAUGUCUGCAUUUUCAUUUACUGUGCUGUGUAUAUAGUGUAUAUAAGCGGACAUAGGAGUCCUAAUUUACGUCUAGUCGAUGUUAAAAAGGUUGCCAGUAUAUGACAAAAGUAGAAUUAGUAAACUACUACAUUGAGUACACUUUGUGUUAAAAUUCAUAGGGAAGACUUCUUAAAAACAAGUGAAAUUGUUAAAACCCCCCCUAAGCAUUACAGAUGGCUUAUAGCUGUCCACGGGGUUGGUAGAGGUGGGAAAGGGAAGGGUUCUAGGCCAGAAUGUUCCUAUUUAGAAGACACUCAAAUUACAGUCUGUGUUAUGUAUGUAUACCAUUUAUUCAAUGCUACUGUGUAUAUAAUGGAAAACUUAAGUCCAGUUUGAAACAUCUAGUCUUUCUAGGUGUUUAAAAGUGUACAACGGCCUGUCGCAGUGGCGCAUGCCUGUAAUCCCAGCACUUUGGGAGGCCGAGGCAGGCGGAUCACGAGGUCAAGAGAUCAGGACCAUCUUGGCCAACAUGGUGAAACCCCAUCUUUACUAAAAAUACAAAAAUUAGCUGGUCGUGGUGGUGCCCACCUGUAGCCCCAGUUACUCGAGAGGCUGAGGCAGGAGAAUCGCUUGAACUUGGGAGGCGGAAGUUGCAGUGAGCCAAGAUCGCACCACUGCACUCCAGCCUGGCGACAGAGCGAGGCUCCGUUUCAAAAAAAAAAGUGCACAAUGUAGGUUAACAGUAGAGGGCUUAAGUAACACCCCUCUAAGCAUUUGUUUUCAGUACUUCCUAGGAGUGGUUGCAUUUGGGAAUGGAAUUGUUAAAACUUGAUGCUUAGGAGCGAAUGCAGACUAUUCAUUGGGUGUUUGGGGUGGGGGAAGGGGGGGUGGGCAGAGGAGGUAUGCAGGGAGAGGGGUUCUGUGCUCCUGAGAUUAGUUCAGAUGGUCUAACCAUUGUUCUAUAUGUGCAUUUUAGUUAAUAUUGUGUAUUAAAGGAUAAGUCUUAAUGCUCAAAGUAUGUUAAAAAUAGAUGUAGUAAAUCAGUCCCUUUGUGAAUGUCCUUUUGUUAGUUUUUAGGAAGGCCUGUCCUCUGGGAGUGACCUUUAUUAGUCCACCCCUUGGAGCUAGACAUCCUGUACUUAGUCACGGGGAUGGUGGAAGAGGGAGAAGAGGAAGGGUGAAGGGAAGGGCUCUUUGCUAGUAUCUCCAUAUCUAGACGAUGGUUUUAGAUGAUAACCACAGGUCUACAAGAGCGUUUUUAGUAAAGUGCCUGUGUUCAUUGUGGACAAAGUUAUUAUUUUGCAACAUCUAAGCUUUACGAAUGGGGUGACAACUUAUGAUAAAAACUAGAGCUAGUGAAUUAGCCUAUUUGUAAAUACCUUUGUUAUAAUUGAUAGGAUACAUCUUGGACAUGGAAUUGUUAAGCCACCUCUGAGCAGUGUAUGUCAGGACUUGUUCAUUAGGUUGGCAGCAGAGGGGCAGAAGGAAUUAUACAGGUAGAGAUGUAUGCAGAUGUGUCCAUAUAUGUCCAUAUUUACAUUUUGAUAGCCAUUGAUGUAUGCAUCUCUUGGCUGUACUAUAAGAACACAUUAAUUCAAUGGAAAUACACUUUGCUAAUAUUUUAAUGGUAUAGAUCUGCUAAUGAAUUCUCUUAAAAACAUACUGUAUUCUGUUGCUGUGUGUUUCAUUUUAAAUUGAGCAUUAAGGGAAUGCAGCAUUUAAAUCAGAACUCUGCCAAUGCUUUUAUCUAGAGGCGUGUUGCCAUUUUUGUCUUAUAUGAAAUUUCUGUCCCAAGAAAGGCAGGAUUACAUCUUUUUUUUUUUUUUUAGCAGUUUGAGUUGGUGUAGUGUAUUCUUGGUUAUCAGAAUACUCAUAUAGCUUUGGGAUUUUGAAUUGGUAAAUAUUCAUGAUGUGUGAAAAAUCAUGAUACAUACUGUACAGUCUCAGUCCCAUAAAAUUGGAUGUUGUGCCUACACACAGGAUCUAGAAGAAUAUGUCAAACUAUAAACUGCUUGUGAUUGUGAAUGACUUUGUUCUUUGCUUGUGUUUUUCAAUUUCCUAUAAUGCACAUACUAACUUUUAAAAAAUAAAGGUUAUUUUAAAAGCCUGUAUUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,lncRNA,Homo sapiens,"sp|Q14671|PUM1_HUMAN Pumilio homolog 1 OS=Homo sapiens OX=9606 GN=PUM1 PE=1 SV=3
MSVACVLKRKAVLWQDSFSPHLKHHPQEPANPNMPVVLTSGTGSQAQPQPAANQALAAGT
HSSPVPGSIGVAGRSQDDAMVDYFFQRQHGEQLGGGGSGGGGYNNSKHRWPTGDNIHAEH
QVRSMDELNHDFQALALEGRAMGEQLLPGKKFWETDESSKDGPKGIFLGDQWRDSAWGTS
DHSVSQPIMVQRRPGQSFHVNSEVNSVLSPRSESGGLGVSMVEYVLSSSPGDSCLRKGGF
GPRDADSDENDKGEKKNKGTFDGDKLGDLKEEGDVMDKTNGLPVQNGIDADVKDFSRTPG
NCQNSANEVDLLGPNQNGSEGLAQLTSTNGAKPVEDFSNMESQSVPLDPMEHVGMEPLQF
DYSGTQVPVDSAAATVGLFDYNSQQQLFQRPNALAVQQLTAAQQQQYALAAAHQPHIGLA
PAAFVPNPYIISAAPPGTDPYTAGLAAAATLGPAVVPHQYYGVTPWGVYPASLFQQQAAA
AAAATNSANQQTTPQAQQGQQQVLRGGASQRPLTPNQNQQGQQTDPLVAAAAVNSALAFG
QGLAAGMPGYPVLAPAAYYDQTGALVVNAGARNGLGAPVRLVAPAPVIISSSAAQAAVAA
AAASANGAAGGLAGTTNGPFRPLGTQQPQPQPQQQPNNNLASSSFYGNNSLNSNSQSSSL
FSQGSAQPANTSLGFGSSSSLGATLGSALGGFGTAVANSNTGSGSRRDSLTGSSDLYKRT
SSSLTPIGHSFYNGLSFSSSPGPVGMPLPSQGPGHSQTPPPSLSSHGSSSSLNLGGLTNG
SGRYISAAPGAEAKYRSASSASSLFSPSSTLFSSSRLRYGMSDVMPSGRSRLLEDFRNNR
YPNLQLREIAGHIMEFSQDQHGSRFIQLKLERATPAERQLVFNEILQAAYQLMVDVFGNY
VIQKFFEFGSLEQKLALAERIRGHVLSLALQMYGCRVIQKALEFIPSDQQNEMVRELDGH
VLKCVKDQNGNHVVQKCIECVQPQSLQFIIDAFKGQVFALSTHPYGCRVIQRILEHCLPD
QTLPILEELHQHTEQLVQDQYGNYVIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHKFASN
VVEKCVTHASRTERAVLIDEVCTMNDGPHSALYTMMKDQYANYVVQKMIDVAEPGQRKIV
MHKIRPHIATLRKYTYGKHILAKLEKYYMKNGVDLGPICGPPNGII",PUM1,-,-,1186aa(1-1186),Q14671,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1307,http://db.phasep.pro/browse/","[22-73],[233-272],[485-524],[613-648],[742-773]","[45-58],[94-102],[393-414],[442-457],[475-502],[527-538],[583-614],[625-639],[647-665],[671-695],[762-782],[797-815]",In vitro,2.7 nM[NORAD];|5 µM [PUM1],"150 mM NaCl, 1 mM MgCl2","20 mM Tris HCl pH 7.5, 1 mM DTT, 10% glycerol",RT,30 min,crowding agent:5% PEG3350;other_molecular: 1 U TEV protease,"Differential interference contrast microscopy,FRAP",liquid,"Moreover, in vitro-transcribed NORAD RNA was incorporated into preformed PUM droplets and further increased PUM1 phase separation"
688,PMID: 34108682,RNAPS0000619,https://pubmed.ncbi.nlm.nih.gov/34108682,RNA + protein,NCBI ID: 647979,https://www.ncbi.nlm.nih.gov/gene/647979,NORAD,5378nt(1-5378),AGUUCCGGUCCGGCAGAGAUCGCGGAGAGACGCAGAACGCAGCCCGCUCCUCCAGGGCCCUCCAGGCCCUCCGGCCCCGGGCCGGCGGGUGAACUGGGGGGCCCCGGGACAGGCCGAGCCCUCUGCCCUGCAGAUAACGGAGGCCUCUGCUGUGGCUGCCCACUGGCUGUGCCCGCCCACUGGCUGUGCCCAGACCUUGAAGCCGCAGCGAACCUCUCUUUCCCACCCCACCUCGGUGACUAAUGGCGGCCGUGGCGUCUCCCAGCCCGGACCCCGCCGGCACCCGGGUCUCCCGACCCAAGCCUCGACGAAACCCCCGCAGAGCCGCCGGGACGCAGCGCCUUUGGGCGGCGCUGGGCGUGGUGGGCCGGGAAGUAUGGCGGCAGCUCGAACGCCGCGCGGCGGAGGCCAUUAAGGCGUGGACGGCCCGGGAAGGCGGCCUAGGGACGCAAGCAGGCUCGGCCGCCUCUUUAGGCCACGGAGCCGCGCAGAUCCGGUUCCCGGGUGACCACUCUGUCGCCAUUGGGCGAGACCUACCUAGUCCUGACGACAACGGACAAAGGCCUUAAGGGGCCUGGAAGGUGAGCGAAGUCCCGAACGACGACGGGUGGAACGGUUAGCGGCCAUCGGGCGGUUGGUCUUCAUUCUACCAGACUUUGCUGUCGGAAGAGAGAAAUGGUAGAAUGACAGGCCACGUUUGGCCCGUUGGAAAUGCCCACCACCCUCUGGGAAGAUUUACUGGCCGUUUAUGGAAGGCCUGUGUAUAUAAUAUGAAAAAGCUGCUCUCAACUCCACCCCAACCUUUUAAUAGAAAACAUUUGUCACAUCUAGCCCUUCUAGAUGGAAAGAGGUUGCCGACGUAUGAUAAAAUAGAGUUAGAAAGUUACACAUCUUGUAAAUUCUCAUUUGUUUAAAAGAAAUCAUAGAAAAUACAUGUCUUCUGGAGAUGACUUUUGGAAAUGGAGUUGUUAAGACGGCCUCUGGAAGCGAUACGUCCACGUUUGUUAAGUGGGUUAGAUGACAUGGAGCUGGAAGACCUGAGAAGGAAGAGAAGAAGGUUCUAUGCUAGACUGGUCAUAUUUAGAAGACAUUUUCAUAUUCUAUCCAUUGUUUUGUGUGCAUUUUAUUCCUCACUACUGUGUAUAUAGUUGACAAUGCUAAGCUUUUUUGAAAUGUCUCUUCUUUUUAGAUGUUCUGAAGUGCCUGAUAUGUUAAAAUUAGAGGUAGCAAAAUCACAUUUUGUAAAUACCUUUUUGUUACAAUUCAUAGGAAAUAUUUUUGGGGGGGAAUGGCCAAAUCACCUGUUGAGUAAUACUCAUUGUGUUUGUGCAGUGGUUCAGGGGAGGAGAGAGGAGGGGGAGGUGCAGAGAGCUCUAUGCCAUCCUGUUUACAGCGAGGCAAGAUGAAUCAUUAUGUCUGUGCAUUUUGUUUUACUUAUCUGUGUAUAUAGUGUACAUAAAGGACAGACGAGUCCUAAUUGACAACAUCUAGUCUUUCUGGAUGUUAAAGAGGUUGCCAGUGUAUGACAAAAGUAGAGUUAGUAAACUAAUAUAUUUUGUACAUUUUGUUUUACAAGUCCUAGGAAAGAUUGUCUUCUGAAAAUUUGAUGUCUUCUGGGUUGAUGGAGAUGGGAAGGGUUCUAGGCCAGAAUGUUCACAUUUGGAAGACUCUUUCAAAUUAUAACUGUUGUUACAUGUUUGCAGUUUAUUCAAGACUGCUGUAUACAUAGUAGACAAAUUAACUCCUUACUUGAAACAUCUAGUCUAUCUAGAUGUUUAGAAGUGCCCGAUGUAUGUUAAAUGUAUAGGUAGUAAAAUACCACUUUGUAAAUAUCUUUUUGCUAAAAUUCAUAGGAAAUGCUUUUGGAAAUUGAAUUGUGAAGCCACCUUUGUGAACAGUAUAGUAAUGUCUAUACUUGUUCAAUAGUUUAGAGGAGGUAGGAGGGAAGAAAUUGCAAAAGGUAAUAUUACUAGUGUGUUCAUACUUGGACAUUUUCAGACACCAUUUUUCUAUAUGUUUUGUGCAUUUUGUUUUGCUCUGUAUAUAGUAUAUAUAAUGGACAAAUAGUCCUAAUUUUUCAACAUCUAGUCUCUAGAUGUUAAAGAGGUUGCCAGUGUAUGACAAAGGAGUAAAAUUAGCAUAUUUUGUACACUUUGUGUUGAAAUUCGUAGGAAAACUUGUCUUCUGUAAAGACUUUUGCAUAGGAAUUUGUUUGACCAUCUCUAAGCAUUACACGUGCCUGUACUUGUCCACUGGAUUGAAGGCAGAGAAGGAAGGGAGGAGGGAAUGAUUCAAGGCCAAAAUGGCCACAUUUAGAAGAUACCUCAGAUGAUAACCAUUGUUAUGUGUGUGCAAUUUUAUUUAACAGUGCUGUGUAUGUGGUGGACAAGUUAUAUGAAAUAUCUAGUCUUUCUAGAUAUUUGGAAGUGCUUGAUGUAUUUAAAAGUGGUAGUAGAAUAACACUUUGUAAAUAGCUUUUAAAAACUGAUGGGAAAUGCUGUUUGGAAGUGGAAUUGUUGAACCACCUGGGAGGUGGGAGGGAAGAAAUUGCAAAUGGUGUUUUGCCAUUGUUUAUUAGAAAAUUUCAGCUUAAUCCAUUGUGUAUAUGUUACAUGCAUUUCAUUUAACUUUGCUAUACUGUAUAUAUUGUAUAUAUAACGGACAAAUUAGUCCCGAUUUUAUAAUAUCUAGUCUCUAGAUAUUAAAGAGGUUGCCAAUGUAUGACAGAAGUAGAGUUAGUAAACUAACACAUUUUGUACACUUUGUUAAAAUUUGUAGAAAGGCUGUCUUCUGAAAAGGACUUUUGGAAGUGAGAUAACAUCAGCUCUAAGUGACACGUGCCUAUAUCCAUCAGGUUGGUGGUGGAGAGGAGUUGGAAGGAAUGAAGGGUUCUAGACCAGAAUGUUCGUAUUUAGAAGACACUAUCAGAUAUAACCAUUGUUACAUGUGUGUAGUUUAUUCAACCCUACUGUGUAUAUAGCGGACAAACUUAAGUCCUUAUUUGAAACAUCUAGUCUUUCUAGAUGUUUAGAAGUGCACAAAGUAUGUUAAAAGUAGAGGUAGUAAAUAACACAUUUUGUAGCUAUCCUUUUGAUAUGAAAUAUUGUCUUGGAAAUUGAUCAAUUCUCUGAGCAGUACCCAUUUUGAUAUUUGUGCUGGUUCAGGGGGAAGGAGGAGCACAAAGUGCAAAGGGCUUUCUACCAGUGUCCAGUGUGUUUAUGAGGAGGCACAUUGACCAUUGUCCCUUAUGUCUGCAUUUUCAUUUACUGUGCUGUGUAUAUAGUGUAUAUAAGCGGACAUAGGAGUCCUAAUUUACGUCUAGUCGAUGUUAAAAAGGUUGCCAGUAUAUGACAAAAGUAGAAUUAGUAAACUACUACAUUGAGUACACUUUGUGUUAAAAUUCAUAGGGAAGACUUCUUAAAAACAAGUGAAAUUGUUAAAACCCCCCCUAAGCAUUACAGAUGGCUUAUAGCUGUCCACGGGGUUGGUAGAGGUGGGAAAGGGAAGGGUUCUAGGCCAGAAUGUUCCUAUUUAGAAGACACUCAAAUUACAGUCUGUGUUAUGUAUGUAUACCAUUUAUUCAAUGCUACUGUGUAUAUAAUGGAAAACUUAAGUCCAGUUUGAAACAUCUAGUCUUUCUAGGUGUUUAAAAGUGUACAACGGCCUGUCGCAGUGGCGCAUGCCUGUAAUCCCAGCACUUUGGGAGGCCGAGGCAGGCGGAUCACGAGGUCAAGAGAUCAGGACCAUCUUGGCCAACAUGGUGAAACCCCAUCUUUACUAAAAAUACAAAAAUUAGCUGGUCGUGGUGGUGCCCACCUGUAGCCCCAGUUACUCGAGAGGCUGAGGCAGGAGAAUCGCUUGAACUUGGGAGGCGGAAGUUGCAGUGAGCCAAGAUCGCACCACUGCACUCCAGCCUGGCGACAGAGCGAGGCUCCGUUUCAAAAAAAAAAGUGCACAAUGUAGGUUAACAGUAGAGGGCUUAAGUAACACCCCUCUAAGCAUUUGUUUUCAGUACUUCCUAGGAGUGGUUGCAUUUGGGAAUGGAAUUGUUAAAACUUGAUGCUUAGGAGCGAAUGCAGACUAUUCAUUGGGUGUUUGGGGUGGGGGAAGGGGGGGUGGGCAGAGGAGGUAUGCAGGGAGAGGGGUUCUGUGCUCCUGAGAUUAGUUCAGAUGGUCUAACCAUUGUUCUAUAUGUGCAUUUUAGUUAAUAUUGUGUAUUAAAGGAUAAGUCUUAAUGCUCAAAGUAUGUUAAAAAUAGAUGUAGUAAAUCAGUCCCUUUGUGAAUGUCCUUUUGUUAGUUUUUAGGAAGGCCUGUCCUCUGGGAGUGACCUUUAUUAGUCCACCCCUUGGAGCUAGACAUCCUGUACUUAGUCACGGGGAUGGUGGAAGAGGGAGAAGAGGAAGGGUGAAGGGAAGGGCUCUUUGCUAGUAUCUCCAUAUCUAGACGAUGGUUUUAGAUGAUAACCACAGGUCUACAAGAGCGUUUUUAGUAAAGUGCCUGUGUUCAUUGUGGACAAAGUUAUUAUUUUGCAACAUCUAAGCUUUACGAAUGGGGUGACAACUUAUGAUAAAAACUAGAGCUAGUGAAUUAGCCUAUUUGUAAAUACCUUUGUUAUAAUUGAUAGGAUACAUCUUGGACAUGGAAUUGUUAAGCCACCUCUGAGCAGUGUAUGUCAGGACUUGUUCAUUAGGUUGGCAGCAGAGGGGCAGAAGGAAUUAUACAGGUAGAGAUGUAUGCAGAUGUGUCCAUAUAUGUCCAUAUUUACAUUUUGAUAGCCAUUGAUGUAUGCAUCUCUUGGCUGUACUAUAAGAACACAUUAAUUCAAUGGAAAUACACUUUGCUAAUAUUUUAAUGGUAUAGAUCUGCUAAUGAAUUCUCUUAAAAACAUACUGUAUUCUGUUGCUGUGUGUUUCAUUUUAAAUUGAGCAUUAAGGGAAUGCAGCAUUUAAAUCAGAACUCUGCCAAUGCUUUUAUCUAGAGGCGUGUUGCCAUUUUUGUCUUAUAUGAAAUUUCUGUCCCAAGAAAGGCAGGAUUACAUCUUUUUUUUUUUUUUUAGCAGUUUGAGUUGGUGUAGUGUAUUCUUGGUUAUCAGAAUACUCAUAUAGCUUUGGGAUUUUGAAUUGGUAAAUAUUCAUGAUGUGUGAAAAAUCAUGAUACAUACUGUACAGUCUCAGUCCCAUAAAAUUGGAUGUUGUGCCUACACACAGGAUCUAGAAGAAUAUGUCAAACUAUAAACUGCUUGUGAUUGUGAAUGACUUUGUUCUUUGCUUGUGUUUUUCAAUUUCCUAUAAUGCACAUACUAACUUUUAAAAAAUAAAGGUUAUUUUAAAAGCCUGUAUUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,lncRNA,Homo sapiens,"sp|Q8TB72|PUM2_HUMAN Pumilio homolog 2 OS=Homo sapiens OX=9606 GN=PUM2 PE=1 SV=2
MNHDFQALALESRGMGELLPTKKFWEPDDSTKDGQKGIFLGDDEWRETAWGASHHSMSQP
IMVQRRSGQGFHGNSEVNAILSPRSESGGLGVSMVEYVLSSSPADKLDSRFRKGNFGTRD
AETDGPEKGDQKGKASPFEEDQNRDLKQGDDDDSKINGRGLPNGMDADCKDFNRTPGSRQ
ASPTEVVERLGPNTNPSEGLGPLPNPTANKPLVEEFSNPETQNLDAMEQVGLESLQFDYP
GNQVPMDSSGATVGLFDYNSQQQLFQRTNALTVQQLTAAQQQQYALAAAQQPHIAGVFSA
GLAPAAFVPNPYIISAAPPGTDPYTAAGLAAAATLAGPAVVPPQYYGVPWGVYPANLFQQ
QAAAAANNTASQQAASQAQPGQQQVLRAGAGQRPLTPNQGQQGQQAESLAAAAAANPTLA
FGQGLATGMPGYQVLAPTAYYDQTGALVVGPGARTGLGAPVRLMAPTPVLISSAAAQAAA
AAAAGGTASSLTGSTNGLFRPIGTQPPQQQQQQPSTNLQSNSFYGSSSLTNSSQSSSLFS
HGPGQPGSTSLGFGSGNSLGAAIGSALSGFGSSVGSSASSSATRRESLSTSSDLYKRSSS
SLAPIGQPFYNSLGFSSSPSPIGMPLPSQTPGHSLTPPPSLSSHGSSSSLHLGGLTNGSG
RYISAAPGAEAKYRSASSTSSLFSSSSQLFPPSRLRYNRSDIMPSGRSRLLEDFRNNRFP
NLQLRDLIGHIVEFSQDQHGSRFIQQKLERATPAERQMVFNEILQAAYQLMTDVFGNYVI
QKFFEFGSLDQKLALATRIRGHVLPLALQMYGCRVIQKALESISSDQQVISEMVKELDGH
VLKCVKDQNGNHVVQKCIECVQPQSLQFIIDAFKGQVFVLSTHPYGCRVIQRILEHCTAE
QTLPILEELHQHTEQLVQDQYGNYVIQHVLEHGRPEDKSKIVSEIRGKVLALSQHKFASN
VVEKCVTHASRAERALLIDEVCCQNDGPHSALYTMMKDQYANYVVQKMIDMAEPAQRKII
MHKIRPHITTLRKYTYGKHILAKLEKYYLKNSPDLGPIGGPPNGML",PUM2,-,-,1066(1-1066),Q8TB72,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0193,http://db.phasep.pro/browse/","[1-11],[20-20],[77-102],[108-159],[179-243],[277-288],[309-343],[363-412],[420-425],[431-492],[494-528],[534-543],[549-558],[565-599],[617-679],[697-704],[752-761],[823-832],[899-911],[934-945],[1018-1027],[1055-1062],[1064-1066]",-,In vitro,2.7 nM[NORAD];|5 µM [PUM2],"150 mM NaCl, 1 mM MgCl2","20 mM Tris HCl pH 7.5, 1 mM DTT, 10% glycerol",RT,30 min,crowding agent:5% PEG3350;other_molecular: 1 U TEV protease,"Differential interference contrast microscopy,FRAP",liquid,"Moreover, in vitro-transcribed NORAD RNA was incorporated into preformed PUM droplets and further increased PUM1 phase separation"
689,PMID: 34108682,RNAPS0000618,https://pubmed.ncbi.nlm.nih.gov/34108682,RNA + protein,NCBI ID: 647979,https://www.ncbi.nlm.nih.gov/gene/647979,NORAD,5378nt(1-5378),AGUUCCGGUCCGGCAGAGAUCGCGGAGAGACGCAGAACGCAGCCCGCUCCUCCAGGGCCCUCCAGGCCCUCCGGCCCCGGGCCGGCGGGUGAACUGGGGGGCCCCGGGACAGGCCGAGCCCUCUGCCCUGCAGAUAACGGAGGCCUCUGCUGUGGCUGCCCACUGGCUGUGCCCGCCCACUGGCUGUGCCCAGACCUUGAAGCCGCAGCGAACCUCUCUUUCCCACCCCACCUCGGUGACUAAUGGCGGCCGUGGCGUCUCCCAGCCCGGACCCCGCCGGCACCCGGGUCUCCCGACCCAAGCCUCGACGAAACCCCCGCAGAGCCGCCGGGACGCAGCGCCUUUGGGCGGCGCUGGGCGUGGUGGGCCGGGAAGUAUGGCGGCAGCUCGAACGCCGCGCGGCGGAGGCCAUUAAGGCGUGGACGGCCCGGGAAGGCGGCCUAGGGACGCAAGCAGGCUCGGCCGCCUCUUUAGGCCACGGAGCCGCGCAGAUCCGGUUCCCGGGUGACCACUCUGUCGCCAUUGGGCGAGACCUACCUAGUCCUGACGACAACGGACAAAGGCCUUAAGGGGCCUGGAAGGUGAGCGAAGUCCCGAACGACGACGGGUGGAACGGUUAGCGGCCAUCGGGCGGUUGGUCUUCAUUCUACCAGACUUUGCUGUCGGAAGAGAGAAAUGGUAGAAUGACAGGCCACGUUUGGCCCGUUGGAAAUGCCCACCACCCUCUGGGAAGAUUUACUGGCCGUUUAUGGAAGGCCUGUGUAUAUAAUAUGAAAAAGCUGCUCUCAACUCCACCCCAACCUUUUAAUAGAAAACAUUUGUCACAUCUAGCCCUUCUAGAUGGAAAGAGGUUGCCGACGUAUGAUAAAAUAGAGUUAGAAAGUUACACAUCUUGUAAAUUCUCAUUUGUUUAAAAGAAAUCAUAGAAAAUACAUGUCUUCUGGAGAUGACUUUUGGAAAUGGAGUUGUUAAGACGGCCUCUGGAAGCGAUACGUCCACGUUUGUUAAGUGGGUUAGAUGACAUGGAGCUGGAAGACCUGAGAAGGAAGAGAAGAAGGUUCUAUGCUAGACUGGUCAUAUUUAGAAGACAUUUUCAUAUUCUAUCCAUUGUUUUGUGUGCAUUUUAUUCCUCACUACUGUGUAUAUAGUUGACAAUGCUAAGCUUUUUUGAAAUGUCUCUUCUUUUUAGAUGUUCUGAAGUGCCUGAUAUGUUAAAAUUAGAGGUAGCAAAAUCACAUUUUGUAAAUACCUUUUUGUUACAAUUCAUAGGAAAUAUUUUUGGGGGGGAAUGGCCAAAUCACCUGUUGAGUAAUACUCAUUGUGUUUGUGCAGUGGUUCAGGGGAGGAGAGAGGAGGGGGAGGUGCAGAGAGCUCUAUGCCAUCCUGUUUACAGCGAGGCAAGAUGAAUCAUUAUGUCUGUGCAUUUUGUUUUACUUAUCUGUGUAUAUAGUGUACAUAAAGGACAGACGAGUCCUAAUUGACAACAUCUAGUCUUUCUGGAUGUUAAAGAGGUUGCCAGUGUAUGACAAAAGUAGAGUUAGUAAACUAAUAUAUUUUGUACAUUUUGUUUUACAAGUCCUAGGAAAGAUUGUCUUCUGAAAAUUUGAUGUCUUCUGGGUUGAUGGAGAUGGGAAGGGUUCUAGGCCAGAAUGUUCACAUUUGGAAGACUCUUUCAAAUUAUAACUGUUGUUACAUGUUUGCAGUUUAUUCAAGACUGCUGUAUACAUAGUAGACAAAUUAACUCCUUACUUGAAACAUCUAGUCUAUCUAGAUGUUUAGAAGUGCCCGAUGUAUGUUAAAUGUAUAGGUAGUAAAAUACCACUUUGUAAAUAUCUUUUUGCUAAAAUUCAUAGGAAAUGCUUUUGGAAAUUGAAUUGUGAAGCCACCUUUGUGAACAGUAUAGUAAUGUCUAUACUUGUUCAAUAGUUUAGAGGAGGUAGGAGGGAAGAAAUUGCAAAAGGUAAUAUUACUAGUGUGUUCAUACUUGGACAUUUUCAGACACCAUUUUUCUAUAUGUUUUGUGCAUUUUGUUUUGCUCUGUAUAUAGUAUAUAUAAUGGACAAAUAGUCCUAAUUUUUCAACAUCUAGUCUCUAGAUGUUAAAGAGGUUGCCAGUGUAUGACAAAGGAGUAAAAUUAGCAUAUUUUGUACACUUUGUGUUGAAAUUCGUAGGAAAACUUGUCUUCUGUAAAGACUUUUGCAUAGGAAUUUGUUUGACCAUCUCUAAGCAUUACACGUGCCUGUACUUGUCCACUGGAUUGAAGGCAGAGAAGGAAGGGAGGAGGGAAUGAUUCAAGGCCAAAAUGGCCACAUUUAGAAGAUACCUCAGAUGAUAACCAUUGUUAUGUGUGUGCAAUUUUAUUUAACAGUGCUGUGUAUGUGGUGGACAAGUUAUAUGAAAUAUCUAGUCUUUCUAGAUAUUUGGAAGUGCUUGAUGUAUUUAAAAGUGGUAGUAGAAUAACACUUUGUAAAUAGCUUUUAAAAACUGAUGGGAAAUGCUGUUUGGAAGUGGAAUUGUUGAACCACCUGGGAGGUGGGAGGGAAGAAAUUGCAAAUGGUGUUUUGCCAUUGUUUAUUAGAAAAUUUCAGCUUAAUCCAUUGUGUAUAUGUUACAUGCAUUUCAUUUAACUUUGCUAUACUGUAUAUAUUGUAUAUAUAACGGACAAAUUAGUCCCGAUUUUAUAAUAUCUAGUCUCUAGAUAUUAAAGAGGUUGCCAAUGUAUGACAGAAGUAGAGUUAGUAAACUAACACAUUUUGUACACUUUGUUAAAAUUUGUAGAAAGGCUGUCUUCUGAAAAGGACUUUUGGAAGUGAGAUAACAUCAGCUCUAAGUGACACGUGCCUAUAUCCAUCAGGUUGGUGGUGGAGAGGAGUUGGAAGGAAUGAAGGGUUCUAGACCAGAAUGUUCGUAUUUAGAAGACACUAUCAGAUAUAACCAUUGUUACAUGUGUGUAGUUUAUUCAACCCUACUGUGUAUAUAGCGGACAAACUUAAGUCCUUAUUUGAAACAUCUAGUCUUUCUAGAUGUUUAGAAGUGCACAAAGUAUGUUAAAAGUAGAGGUAGUAAAUAACACAUUUUGUAGCUAUCCUUUUGAUAUGAAAUAUUGUCUUGGAAAUUGAUCAAUUCUCUGAGCAGUACCCAUUUUGAUAUUUGUGCUGGUUCAGGGGGAAGGAGGAGCACAAAGUGCAAAGGGCUUUCUACCAGUGUCCAGUGUGUUUAUGAGGAGGCACAUUGACCAUUGUCCCUUAUGUCUGCAUUUUCAUUUACUGUGCUGUGUAUAUAGUGUAUAUAAGCGGACAUAGGAGUCCUAAUUUACGUCUAGUCGAUGUUAAAAAGGUUGCCAGUAUAUGACAAAAGUAGAAUUAGUAAACUACUACAUUGAGUACACUUUGUGUUAAAAUUCAUAGGGAAGACUUCUUAAAAACAAGUGAAAUUGUUAAAACCCCCCCUAAGCAUUACAGAUGGCUUAUAGCUGUCCACGGGGUUGGUAGAGGUGGGAAAGGGAAGGGUUCUAGGCCAGAAUGUUCCUAUUUAGAAGACACUCAAAUUACAGUCUGUGUUAUGUAUGUAUACCAUUUAUUCAAUGCUACUGUGUAUAUAAUGGAAAACUUAAGUCCAGUUUGAAACAUCUAGUCUUUCUAGGUGUUUAAAAGUGUACAACGGCCUGUCGCAGUGGCGCAUGCCUGUAAUCCCAGCACUUUGGGAGGCCGAGGCAGGCGGAUCACGAGGUCAAGAGAUCAGGACCAUCUUGGCCAACAUGGUGAAACCCCAUCUUUACUAAAAAUACAAAAAUUAGCUGGUCGUGGUGGUGCCCACCUGUAGCCCCAGUUACUCGAGAGGCUGAGGCAGGAGAAUCGCUUGAACUUGGGAGGCGGAAGUUGCAGUGAGCCAAGAUCGCACCACUGCACUCCAGCCUGGCGACAGAGCGAGGCUCCGUUUCAAAAAAAAAAGUGCACAAUGUAGGUUAACAGUAGAGGGCUUAAGUAACACCCCUCUAAGCAUUUGUUUUCAGUACUUCCUAGGAGUGGUUGCAUUUGGGAAUGGAAUUGUUAAAACUUGAUGCUUAGGAGCGAAUGCAGACUAUUCAUUGGGUGUUUGGGGUGGGGGAAGGGGGGGUGGGCAGAGGAGGUAUGCAGGGAGAGGGGUUCUGUGCUCCUGAGAUUAGUUCAGAUGGUCUAACCAUUGUUCUAUAUGUGCAUUUUAGUUAAUAUUGUGUAUUAAAGGAUAAGUCUUAAUGCUCAAAGUAUGUUAAAAAUAGAUGUAGUAAAUCAGUCCCUUUGUGAAUGUCCUUUUGUUAGUUUUUAGGAAGGCCUGUCCUCUGGGAGUGACCUUUAUUAGUCCACCCCUUGGAGCUAGACAUCCUGUACUUAGUCACGGGGAUGGUGGAAGAGGGAGAAGAGGAAGGGUGAAGGGAAGGGCUCUUUGCUAGUAUCUCCAUAUCUAGACGAUGGUUUUAGAUGAUAACCACAGGUCUACAAGAGCGUUUUUAGUAAAGUGCCUGUGUUCAUUGUGGACAAAGUUAUUAUUUUGCAACAUCUAAGCUUUACGAAUGGGGUGACAACUUAUGAUAAAAACUAGAGCUAGUGAAUUAGCCUAUUUGUAAAUACCUUUGUUAUAAUUGAUAGGAUACAUCUUGGACAUGGAAUUGUUAAGCCACCUCUGAGCAGUGUAUGUCAGGACUUGUUCAUUAGGUUGGCAGCAGAGGGGCAGAAGGAAUUAUACAGGUAGAGAUGUAUGCAGAUGUGUCCAUAUAUGUCCAUAUUUACAUUUUGAUAGCCAUUGAUGUAUGCAUCUCUUGGCUGUACUAUAAGAACACAUUAAUUCAAUGGAAAUACACUUUGCUAAUAUUUUAAUGGUAUAGAUCUGCUAAUGAAUUCUCUUAAAAACAUACUGUAUUCUGUUGCUGUGUGUUUCAUUUUAAAUUGAGCAUUAAGGGAAUGCAGCAUUUAAAUCAGAACUCUGCCAAUGCUUUUAUCUAGAGGCGUGUUGCCAUUUUUGUCUUAUAUGAAAUUUCUGUCCCAAGAAAGGCAGGAUUACAUCUUUUUUUUUUUUUUUAGCAGUUUGAGUUGGUGUAGUGUAUUCUUGGUUAUCAGAAUACUCAUAUAGCUUUGGGAUUUUGAAUUGGUAAAUAUUCAUGAUGUGUGAAAAAUCAUGAUACAUACUGUACAGUCUCAGUCCCAUAAAAUUGGAUGUUGUGCCUACACACAGGAUCUAGAAGAAUAUGUCAAACUAUAAACUGCUUGUGAUUGUGAAUGACUUUGUUCUUUGCUUGUGUUUUUCAAUUUCCUAUAAUGCACAUACUAACUUUUAAAAAAUAAAGGUUAUUUUAAAAGCCUGUAUUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,lncRNA,Homo sapiens,"sp|Q14671|PUM1_HUMAN Pumilio homolog 1 OS=Homo sapiens OX=9606 GN=PUM1 PE=1 SV=3
MSVACVLKRKAVLWQDSFSPHLKHHPQEPANPNMPVVLTSGTGSQAQPQPAANQALAAGT
HSSPVPGSIGVAGRSQDDAMVDYFFQRQHGEQLGGGGSGGGGYNNSKHRWPTGDNIHAEH
QVRSMDELNHDFQALALEGRAMGEQLLPGKKFWETDESSKDGPKGIFLGDQWRDSAWGTS
DHSVSQPIMVQRRPGQSFHVNSEVNSVLSPRSESGGLGVSMVEYVLSSSPGDSCLRKGGF
GPRDADSDENDKGEKKNKGTFDGDKLGDLKEEGDVMDKTNGLPVQNGIDADVKDFSRTPG
NCQNSANEVDLLGPNQNGSEGLAQLTSTNGAKPVEDFSNMESQSVPLDPMEHVGMEPLQF
DYSGTQVPVDSAAATVGLFDYNSQQQLFQRPNALAVQQLTAAQQQQYALAAAHQPHIGLA
PAAFVPNPYIISAAPPGTDPYTAGLAAAATLGPAVVPHQYYGVTPWGVYPASLFQQQAAA
AAAATNSANQQTTPQAQQGQQQVLRGGASQRPLTPNQNQQGQQTDPLVAAAAVNSALAFG
QGLAAGMPGYPVLAPAAYYDQTGALVVNAGARNGLGAPVRLVAPAPVIISSSAAQAAVAA
AAASANGAAGGLAGTTNGPFRPLGTQQPQPQPQQQPNNNLASSSFYGNNSLNSNSQSSSL
FSQGSAQPANTSLGFGSSSSLGATLGSALGGFGTAVANSNTGSGSRRDSLTGSSDLYKRT
SSSLTPIGHSFYNGLSFSSSPGPVGMPLPSQGPGHSQTPPPSLSSHGSSSSLNLGGLTNG
SGRYISAAPGAEAKYRSASSASSLFSPSSTLFSSSRLRYGMSDVMPSGRSRLLEDFRNNR
YPNLQLREIAGHIMEFSQDQHGSRFIQLKLERATPAERQLVFNEILQAAYQLMVDVFGNY
VIQKFFEFGSLEQKLALAERIRGHVLSLALQMYGCRVIQKALEFIPSDQQNEMVRELDGH
VLKCVKDQNGNHVVQKCIECVQPQSLQFIIDAFKGQVFALSTHPYGCRVIQRILEHCLPD
QTLPILEELHQHTEQLVQDQYGNYVIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHKFASN
VVEKCVTHASRTERAVLIDEVCTMNDGPHSALYTMMKDQYANYVVQKMIDVAEPGQRKIV
MHKIRPHIATLRKYTYGKHILAKLEKYYMKNGVDLGPICGPPNGII",PUM1,-,-,1186aa(1-1186),Q14671,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1307,http://db.phasep.pro/browse/","[22-73],[233-272],[485-524],[613-648],[742-773]","[45-58],[94-102],[393-414],[442-457],[475-502],[527-538],[583-614],[625-639],[647-665],[671-695],[762-782],[797-815]",In vitro,2 nM[NORAD];|5 µM [PUM1],"150 mM NaCl, 1 mM MgCl2","20 mM Tris HCl pH 7.5, 1 mM DTT, 10% glycerol",RT,30 min,crowding agent:5% PEG3350;other_molecular: 1 U TEV protease,FRAP,liquid,"Both RNA and protein components remained dynamic within these droplets, although NORAD exhibited slower FRAP recovery than PUM1, as observed in other RNA–protein condensates19 "
690,PMID: 34108682,RNAPS0000618,https://pubmed.ncbi.nlm.nih.gov/34108682,RNA + protein,NCBI ID: 647979,https://www.ncbi.nlm.nih.gov/gene/647979,NORAD,5378nt(1-5378),AGUUCCGGUCCGGCAGAGAUCGCGGAGAGACGCAGAACGCAGCCCGCUCCUCCAGGGCCCUCCAGGCCCUCCGGCCCCGGGCCGGCGGGUGAACUGGGGGGCCCCGGGACAGGCCGAGCCCUCUGCCCUGCAGAUAACGGAGGCCUCUGCUGUGGCUGCCCACUGGCUGUGCCCGCCCACUGGCUGUGCCCAGACCUUGAAGCCGCAGCGAACCUCUCUUUCCCACCCCACCUCGGUGACUAAUGGCGGCCGUGGCGUCUCCCAGCCCGGACCCCGCCGGCACCCGGGUCUCCCGACCCAAGCCUCGACGAAACCCCCGCAGAGCCGCCGGGACGCAGCGCCUUUGGGCGGCGCUGGGCGUGGUGGGCCGGGAAGUAUGGCGGCAGCUCGAACGCCGCGCGGCGGAGGCCAUUAAGGCGUGGACGGCCCGGGAAGGCGGCCUAGGGACGCAAGCAGGCUCGGCCGCCUCUUUAGGCCACGGAGCCGCGCAGAUCCGGUUCCCGGGUGACCACUCUGUCGCCAUUGGGCGAGACCUACCUAGUCCUGACGACAACGGACAAAGGCCUUAAGGGGCCUGGAAGGUGAGCGAAGUCCCGAACGACGACGGGUGGAACGGUUAGCGGCCAUCGGGCGGUUGGUCUUCAUUCUACCAGACUUUGCUGUCGGAAGAGAGAAAUGGUAGAAUGACAGGCCACGUUUGGCCCGUUGGAAAUGCCCACCACCCUCUGGGAAGAUUUACUGGCCGUUUAUGGAAGGCCUGUGUAUAUAAUAUGAAAAAGCUGCUCUCAACUCCACCCCAACCUUUUAAUAGAAAACAUUUGUCACAUCUAGCCCUUCUAGAUGGAAAGAGGUUGCCGACGUAUGAUAAAAUAGAGUUAGAAAGUUACACAUCUUGUAAAUUCUCAUUUGUUUAAAAGAAAUCAUAGAAAAUACAUGUCUUCUGGAGAUGACUUUUGGAAAUGGAGUUGUUAAGACGGCCUCUGGAAGCGAUACGUCCACGUUUGUUAAGUGGGUUAGAUGACAUGGAGCUGGAAGACCUGAGAAGGAAGAGAAGAAGGUUCUAUGCUAGACUGGUCAUAUUUAGAAGACAUUUUCAUAUUCUAUCCAUUGUUUUGUGUGCAUUUUAUUCCUCACUACUGUGUAUAUAGUUGACAAUGCUAAGCUUUUUUGAAAUGUCUCUUCUUUUUAGAUGUUCUGAAGUGCCUGAUAUGUUAAAAUUAGAGGUAGCAAAAUCACAUUUUGUAAAUACCUUUUUGUUACAAUUCAUAGGAAAUAUUUUUGGGGGGGAAUGGCCAAAUCACCUGUUGAGUAAUACUCAUUGUGUUUGUGCAGUGGUUCAGGGGAGGAGAGAGGAGGGGGAGGUGCAGAGAGCUCUAUGCCAUCCUGUUUACAGCGAGGCAAGAUGAAUCAUUAUGUCUGUGCAUUUUGUUUUACUUAUCUGUGUAUAUAGUGUACAUAAAGGACAGACGAGUCCUAAUUGACAACAUCUAGUCUUUCUGGAUGUUAAAGAGGUUGCCAGUGUAUGACAAAAGUAGAGUUAGUAAACUAAUAUAUUUUGUACAUUUUGUUUUACAAGUCCUAGGAAAGAUUGUCUUCUGAAAAUUUGAUGUCUUCUGGGUUGAUGGAGAUGGGAAGGGUUCUAGGCCAGAAUGUUCACAUUUGGAAGACUCUUUCAAAUUAUAACUGUUGUUACAUGUUUGCAGUUUAUUCAAGACUGCUGUAUACAUAGUAGACAAAUUAACUCCUUACUUGAAACAUCUAGUCUAUCUAGAUGUUUAGAAGUGCCCGAUGUAUGUUAAAUGUAUAGGUAGUAAAAUACCACUUUGUAAAUAUCUUUUUGCUAAAAUUCAUAGGAAAUGCUUUUGGAAAUUGAAUUGUGAAGCCACCUUUGUGAACAGUAUAGUAAUGUCUAUACUUGUUCAAUAGUUUAGAGGAGGUAGGAGGGAAGAAAUUGCAAAAGGUAAUAUUACUAGUGUGUUCAUACUUGGACAUUUUCAGACACCAUUUUUCUAUAUGUUUUGUGCAUUUUGUUUUGCUCUGUAUAUAGUAUAUAUAAUGGACAAAUAGUCCUAAUUUUUCAACAUCUAGUCUCUAGAUGUUAAAGAGGUUGCCAGUGUAUGACAAAGGAGUAAAAUUAGCAUAUUUUGUACACUUUGUGUUGAAAUUCGUAGGAAAACUUGUCUUCUGUAAAGACUUUUGCAUAGGAAUUUGUUUGACCAUCUCUAAGCAUUACACGUGCCUGUACUUGUCCACUGGAUUGAAGGCAGAGAAGGAAGGGAGGAGGGAAUGAUUCAAGGCCAAAAUGGCCACAUUUAGAAGAUACCUCAGAUGAUAACCAUUGUUAUGUGUGUGCAAUUUUAUUUAACAGUGCUGUGUAUGUGGUGGACAAGUUAUAUGAAAUAUCUAGUCUUUCUAGAUAUUUGGAAGUGCUUGAUGUAUUUAAAAGUGGUAGUAGAAUAACACUUUGUAAAUAGCUUUUAAAAACUGAUGGGAAAUGCUGUUUGGAAGUGGAAUUGUUGAACCACCUGGGAGGUGGGAGGGAAGAAAUUGCAAAUGGUGUUUUGCCAUUGUUUAUUAGAAAAUUUCAGCUUAAUCCAUUGUGUAUAUGUUACAUGCAUUUCAUUUAACUUUGCUAUACUGUAUAUAUUGUAUAUAUAACGGACAAAUUAGUCCCGAUUUUAUAAUAUCUAGUCUCUAGAUAUUAAAGAGGUUGCCAAUGUAUGACAGAAGUAGAGUUAGUAAACUAACACAUUUUGUACACUUUGUUAAAAUUUGUAGAAAGGCUGUCUUCUGAAAAGGACUUUUGGAAGUGAGAUAACAUCAGCUCUAAGUGACACGUGCCUAUAUCCAUCAGGUUGGUGGUGGAGAGGAGUUGGAAGGAAUGAAGGGUUCUAGACCAGAAUGUUCGUAUUUAGAAGACACUAUCAGAUAUAACCAUUGUUACAUGUGUGUAGUUUAUUCAACCCUACUGUGUAUAUAGCGGACAAACUUAAGUCCUUAUUUGAAACAUCUAGUCUUUCUAGAUGUUUAGAAGUGCACAAAGUAUGUUAAAAGUAGAGGUAGUAAAUAACACAUUUUGUAGCUAUCCUUUUGAUAUGAAAUAUUGUCUUGGAAAUUGAUCAAUUCUCUGAGCAGUACCCAUUUUGAUAUUUGUGCUGGUUCAGGGGGAAGGAGGAGCACAAAGUGCAAAGGGCUUUCUACCAGUGUCCAGUGUGUUUAUGAGGAGGCACAUUGACCAUUGUCCCUUAUGUCUGCAUUUUCAUUUACUGUGCUGUGUAUAUAGUGUAUAUAAGCGGACAUAGGAGUCCUAAUUUACGUCUAGUCGAUGUUAAAAAGGUUGCCAGUAUAUGACAAAAGUAGAAUUAGUAAACUACUACAUUGAGUACACUUUGUGUUAAAAUUCAUAGGGAAGACUUCUUAAAAACAAGUGAAAUUGUUAAAACCCCCCCUAAGCAUUACAGAUGGCUUAUAGCUGUCCACGGGGUUGGUAGAGGUGGGAAAGGGAAGGGUUCUAGGCCAGAAUGUUCCUAUUUAGAAGACACUCAAAUUACAGUCUGUGUUAUGUAUGUAUACCAUUUAUUCAAUGCUACUGUGUAUAUAAUGGAAAACUUAAGUCCAGUUUGAAACAUCUAGUCUUUCUAGGUGUUUAAAAGUGUACAACGGCCUGUCGCAGUGGCGCAUGCCUGUAAUCCCAGCACUUUGGGAGGCCGAGGCAGGCGGAUCACGAGGUCAAGAGAUCAGGACCAUCUUGGCCAACAUGGUGAAACCCCAUCUUUACUAAAAAUACAAAAAUUAGCUGGUCGUGGUGGUGCCCACCUGUAGCCCCAGUUACUCGAGAGGCUGAGGCAGGAGAAUCGCUUGAACUUGGGAGGCGGAAGUUGCAGUGAGCCAAGAUCGCACCACUGCACUCCAGCCUGGCGACAGAGCGAGGCUCCGUUUCAAAAAAAAAAGUGCACAAUGUAGGUUAACAGUAGAGGGCUUAAGUAACACCCCUCUAAGCAUUUGUUUUCAGUACUUCCUAGGAGUGGUUGCAUUUGGGAAUGGAAUUGUUAAAACUUGAUGCUUAGGAGCGAAUGCAGACUAUUCAUUGGGUGUUUGGGGUGGGGGAAGGGGGGGUGGGCAGAGGAGGUAUGCAGGGAGAGGGGUUCUGUGCUCCUGAGAUUAGUUCAGAUGGUCUAACCAUUGUUCUAUAUGUGCAUUUUAGUUAAUAUUGUGUAUUAAAGGAUAAGUCUUAAUGCUCAAAGUAUGUUAAAAAUAGAUGUAGUAAAUCAGUCCCUUUGUGAAUGUCCUUUUGUUAGUUUUUAGGAAGGCCUGUCCUCUGGGAGUGACCUUUAUUAGUCCACCCCUUGGAGCUAGACAUCCUGUACUUAGUCACGGGGAUGGUGGAAGAGGGAGAAGAGGAAGGGUGAAGGGAAGGGCUCUUUGCUAGUAUCUCCAUAUCUAGACGAUGGUUUUAGAUGAUAACCACAGGUCUACAAGAGCGUUUUUAGUAAAGUGCCUGUGUUCAUUGUGGACAAAGUUAUUAUUUUGCAACAUCUAAGCUUUACGAAUGGGGUGACAACUUAUGAUAAAAACUAGAGCUAGUGAAUUAGCCUAUUUGUAAAUACCUUUGUUAUAAUUGAUAGGAUACAUCUUGGACAUGGAAUUGUUAAGCCACCUCUGAGCAGUGUAUGUCAGGACUUGUUCAUUAGGUUGGCAGCAGAGGGGCAGAAGGAAUUAUACAGGUAGAGAUGUAUGCAGAUGUGUCCAUAUAUGUCCAUAUUUACAUUUUGAUAGCCAUUGAUGUAUGCAUCUCUUGGCUGUACUAUAAGAACACAUUAAUUCAAUGGAAAUACACUUUGCUAAUAUUUUAAUGGUAUAGAUCUGCUAAUGAAUUCUCUUAAAAACAUACUGUAUUCUGUUGCUGUGUGUUUCAUUUUAAAUUGAGCAUUAAGGGAAUGCAGCAUUUAAAUCAGAACUCUGCCAAUGCUUUUAUCUAGAGGCGUGUUGCCAUUUUUGUCUUAUAUGAAAUUUCUGUCCCAAGAAAGGCAGGAUUACAUCUUUUUUUUUUUUUUUAGCAGUUUGAGUUGGUGUAGUGUAUUCUUGGUUAUCAGAAUACUCAUAUAGCUUUGGGAUUUUGAAUUGGUAAAUAUUCAUGAUGUGUGAAAAAUCAUGAUACAUACUGUACAGUCUCAGUCCCAUAAAAUUGGAUGUUGUGCCUACACACAGGAUCUAGAAGAAUAUGUCAAACUAUAAACUGCUUGUGAUUGUGAAUGACUUUGUUCUUUGCUUGUGUUUUUCAAUUUCCUAUAAUGCACAUACUAACUUUUAAAAAAUAAAGGUUAUUUUAAAAGCCUGUAUUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,lncRNA,Homo sapiens,"sp|Q14671|PUM1_HUMAN Pumilio homolog 1 OS=Homo sapiens OX=9606 GN=PUM1 PE=1 SV=3
MSVACVLKRKAVLWQDSFSPHLKHHPQEPANPNMPVVLTSGTGSQAQPQPAANQALAAGT
HSSPVPGSIGVAGRSQDDAMVDYFFQRQHGEQLGGGGSGGGGYNNSKHRWPTGDNIHAEH
QVRSMDELNHDFQALALEGRAMGEQLLPGKKFWETDESSKDGPKGIFLGDQWRDSAWGTS
DHSVSQPIMVQRRPGQSFHVNSEVNSVLSPRSESGGLGVSMVEYVLSSSPGDSCLRKGGF
GPRDADSDENDKGEKKNKGTFDGDKLGDLKEEGDVMDKTNGLPVQNGIDADVKDFSRTPG
NCQNSANEVDLLGPNQNGSEGLAQLTSTNGAKPVEDFSNMESQSVPLDPMEHVGMEPLQF
DYSGTQVPVDSAAATVGLFDYNSQQQLFQRPNALAVQQLTAAQQQQYALAAAHQPHIGLA
PAAFVPNPYIISAAPPGTDPYTAGLAAAATLGPAVVPHQYYGVTPWGVYPASLFQQQAAA
AAAATNSANQQTTPQAQQGQQQVLRGGASQRPLTPNQNQQGQQTDPLVAAAAVNSALAFG
QGLAAGMPGYPVLAPAAYYDQTGALVVNAGARNGLGAPVRLVAPAPVIISSSAAQAAVAA
AAASANGAAGGLAGTTNGPFRPLGTQQPQPQPQQQPNNNLASSSFYGNNSLNSNSQSSSL
FSQGSAQPANTSLGFGSSSSLGATLGSALGGFGTAVANSNTGSGSRRDSLTGSSDLYKRT
SSSLTPIGHSFYNGLSFSSSPGPVGMPLPSQGPGHSQTPPPSLSSHGSSSSLNLGGLTNG
SGRYISAAPGAEAKYRSASSASSLFSPSSTLFSSSRLRYGMSDVMPSGRSRLLEDFRNNR
YPNLQLREIAGHIMEFSQDQHGSRFIQLKLERATPAERQLVFNEILQAAYQLMVDVFGNY
VIQKFFEFGSLEQKLALAERIRGHVLSLALQMYGCRVIQKALEFIPSDQQNEMVRELDGH
VLKCVKDQNGNHVVQKCIECVQPQSLQFIIDAFKGQVFALSTHPYGCRVIQRILEHCLPD
QTLPILEELHQHTEQLVQDQYGNYVIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHKFASN
VVEKCVTHASRTERAVLIDEVCTMNDGPHSALYTMMKDQYANYVVQKMIDVAEPGQRKIV
MHKIRPHIATLRKYTYGKHILAKLEKYYMKNGVDLGPICGPPNGII",PUM1,-,-,1186aa(1-1186),Q14671,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1307,http://db.phasep.pro/browse/","[22-73],[233-272],[485-524],[613-648],[742-773]","[45-58],[94-102],[393-414],[442-457],[475-502],[527-538],[583-614],[625-639],[647-665],[671-695],[762-782],[797-815]",In vitro,150 nM [PUM1];|0.5-50nM[NORAD],"150 mM NaCl, 1 mM MgCl2","20 mM Tris HCl pH 7.5, 1 mM DTT, 10% glycerol",RT,30 min,crowding agent:5% PEG3350;other_molecular: 1 U TEV protease,Confocal microscopy,liquid,"The addition of NORAD at or below its endogenous concentration, however, robustly induced formation of PUM1 droplets"
691,PMID: 34108682,RNAPS0000620,https://pubmed.ncbi.nlm.nih.gov/34108682,RNA + protein,NCBI ID:72,https://www.ncbi.nlm.nih.gov/gene/72,ACTG2,1372nt(1-1372),ACACCAGCCCUCAGUCACUGGGAGAAGAACCUCUCAUACCCUCGGUGCUCCAGUCCCCAGCUCACUCAGCCACACACACCAUGUGUGAAGAGGAGACCACCGCGCUCGUGUGUGACAAUGGCUCUGGCCUGUGCAAGGCAGGCUUCGCAGGAGAUGAUGCCCCCCGGGCUGUCUUCCCCUCCAUUGUGGGCCGCCCUCGCCACCAGAUCUGGCACCACUCCUUCUACAAUGAGCUGCGUGUAGCACCUGAAGAGCACCCCACCCUGCUCACAGAGGCUCCCCUAAAUCCCAAGGCCAACAGGGAAAAGAUGACCCAGAUCAUGUUUGAAACCUUCAAUGUCCCUGCCAUGUACGUCGCCAUUCAAGCUGUGCUCUCCCUCUAUGCCUCUGGCCGCACGACAGGCAUCGUCCUGGAUUCAGGUGAUGGCGUCACCCACAAUGUCCCCAUCUAUGAAGGCUAUGCCCUGCCCCAUGCCAUCAUGCGCCUGGACUUGGCUGGCCGUGACCUCACGGACUACCUCAUGAAGAUCCUCACAGAGAGAGGCUAUUCCUUUGUGACCACAGCUGAGAGAGAAAUUGUGCGAGACAUCAAGGAGAAGCUGUGCUAUGUGGCCCUGGAUUUUGAGAAUGAGAUGGCCACAGCAGCUUCCUCUUCCUCCCUGGAGAAGAGCUAUGAGCUGCCAGAUGGGCAGGUUAUCACCAUUGGCAAUGAGCGCUUCCGCUGCCCUGAGACCCUCUUCCAGCCUUCCUUUAUUGGCAUGGAGUCCGCUGGAAUUCAUGAGACAACCUACAAUUCCAUCAUGAAGUGUGACAUUGACAUCCGUAAGGACUUAUAUGCCAACAAUGUCCUCUCUGGGGGCACCACCAUGUACCCUGGCAUUGCUGACAGGAUGCAGAAGGAGAUCACAGCCCUGGCCCCCAGCACCAUGAAGAUCAAGAUUAUUGCUCCCCCAGAGCGGAAGUACUCAGUCUGGAUCGGGGGCUCUAUCCUGGCCUCUCUCUCCACCUUCCAGCAGAUGUGGAUCAGCAAGCCUGAGUAUGAUGAGGCAGGGCCCUCCAUUGUCCACAGGAAGUGCUUCUAAAGUCAGAACAGGUUCUCCAAGGAUCCCCUCGAGACUACUCUGUUACCAGUCAUGAAACAUUAAAACCUACAAGCCUUACUUCUCUGUGUGGGGCUCUUUUUUCCUGGGCUAUGUCUCAUACACAGUGCUAAGGACUUUUCACACAUUACUUUUAAUCCAUGCAAUAGUGCUGUAAGGUAGGUGCUAUCAUUAUACCCAUAUUACAGAUGAGGAAAUUGAGGCUCAGAGAAGUCAAGGACUUGCGAAGAUCACACAGAUUCCAGAUUAAAAUUCAAGUAUCUGACUGCAAA,mRNA,Homo sapiens,"sp|Q14671|PUM1_HUMAN Pumilio homolog 1 OS=Homo sapiens OX=9606 GN=PUM1 PE=1 SV=3
MSVACVLKRKAVLWQDSFSPHLKHHPQEPANPNMPVVLTSGTGSQAQPQPAANQALAAGT
HSSPVPGSIGVAGRSQDDAMVDYFFQRQHGEQLGGGGSGGGGYNNSKHRWPTGDNIHAEH
QVRSMDELNHDFQALALEGRAMGEQLLPGKKFWETDESSKDGPKGIFLGDQWRDSAWGTS
DHSVSQPIMVQRRPGQSFHVNSEVNSVLSPRSESGGLGVSMVEYVLSSSPGDSCLRKGGF
GPRDADSDENDKGEKKNKGTFDGDKLGDLKEEGDVMDKTNGLPVQNGIDADVKDFSRTPG
NCQNSANEVDLLGPNQNGSEGLAQLTSTNGAKPVEDFSNMESQSVPLDPMEHVGMEPLQF
DYSGTQVPVDSAAATVGLFDYNSQQQLFQRPNALAVQQLTAAQQQQYALAAAHQPHIGLA
PAAFVPNPYIISAAPPGTDPYTAGLAAAATLGPAVVPHQYYGVTPWGVYPASLFQQQAAA
AAAATNSANQQTTPQAQQGQQQVLRGGASQRPLTPNQNQQGQQTDPLVAAAAVNSALAFG
QGLAAGMPGYPVLAPAAYYDQTGALVVNAGARNGLGAPVRLVAPAPVIISSSAAQAAVAA
AAASANGAAGGLAGTTNGPFRPLGTQQPQPQPQQQPNNNLASSSFYGNNSLNSNSQSSSL
FSQGSAQPANTSLGFGSSSSLGATLGSALGGFGTAVANSNTGSGSRRDSLTGSSDLYKRT
SSSLTPIGHSFYNGLSFSSSPGPVGMPLPSQGPGHSQTPPPSLSSHGSSSSLNLGGLTNG
SGRYISAAPGAEAKYRSASSASSLFSPSSTLFSSSRLRYGMSDVMPSGRSRLLEDFRNNR
YPNLQLREIAGHIMEFSQDQHGSRFIQLKLERATPAERQLVFNEILQAAYQLMVDVFGNY
VIQKFFEFGSLEQKLALAERIRGHVLSLALQMYGCRVIQKALEFIPSDQQNEMVRELDGH
VLKCVKDQNGNHVVQKCIECVQPQSLQFIIDAFKGQVFALSTHPYGCRVIQRILEHCLPD
QTLPILEELHQHTEQLVQDQYGNYVIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHKFASN
VVEKCVTHASRTERAVLIDEVCTMNDGPHSALYTMMKDQYANYVVQKMIDVAEPGQRKIV
MHKIRPHIATLRKYTYGKHILAKLEKYYMKNGVDLGPICGPPNGII",PUM1,-,-,1186aa(1-1186),Q14671,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1307,http://db.phasep.pro/browse/","[22-73],[233-272],[485-524],[613-648],[742-773]","[45-58],[94-102],[393-414],[442-457],[475-502],[527-538],[583-614],[625-639],[647-665],[671-695],[762-782],[797-815]",In vitro,150 nM [PUM1];|0.1-20nM[ACTG2 3'UTR],"150 mM NaCl, 1 mM MgCl2","20 mM Tris HCl pH 7.5, 1 mM DTT, 10% glycerol",RT,30 min,crowding agent:5% PEG3350;other_molecular: 1 U TEV protease,Confocal microscopy,solute,"Unlike NORAD, none of these transcripts promoted PUM1 phase separation at or below their physiological concentrations in vitro, although the PUM1 and PUM2 3′ UTRs were able to induce the formation of small droplets at concentrations 4–10 times their physiological levels"
692,PMID: 34108682,RNAPS0000621,https://pubmed.ncbi.nlm.nih.gov/34108682,RNA + protein,NCBI ID:54407,https://www.ncbi.nlm.nih.gov/gene/54407,SLC38A2,4679nt,ACAGCCGCGCGACGCCGCCGCCUUAGAACGCCUUUCCAGUACUGCUAGCAGCAGCCCGACCACGCGUUACCGCACGCUCGCGCCUUUCCCUUGACACGGCGGACGCCGGAGGAUUGGGGCGGCAAUUUGUCUUUUCCUUUUUUAUUAAAAUUAUUUUUCCUGCCUGUUGUUGGAUUUGGGGAAAUUUUUUGUUUGUUUUUUAUGAUUUGUAUUUGACUGAGAGAAACCCACUGAAGACGUCUGCGUGAGAAUAGAGACCACCGAGGCCGACUCGCGGGCCGCUGCACCCACCGCCAAGGACAAAAGGAGCCCAGCGCUACUAGCUGCACCCGAUUCCUCCCAGUGCUUAGCAUGAAGAAGGCCGAAAUGGGACGAUUCAGUAUUUCCCCGGAUGAAGACAGCAGCAGCUACAGUUCCAACAGCGACUUCAACUACUCCUACCCCACCAAGCAAGCUGCUCUGAAAAGCCAUUAUGCAGAUGUAGAUCCUGAAAACCAGAACUUUUUACUUGAAUCGAAUUUGGGGAAGAAGAAGUAUGAAACAGAAUUUAAUUCUCUUGACAUUUGUGUCAAUAUUUUCCCUGUAUUCUGUUCAUCUCCUUUUGAAGACUGCCAAUGAAGGAGGGUCUUUAUUAUAUGAACAAUUGGGAUAUAAGGCAUUUGGAUUAGUUGGAAAGCUUGCAGCAUCUGGAUCAAUUACAAUGCAGAACAUUGGAGCUAUGUCAAGCUACCUCUUCAUAGUGAAAUAUGAGUUGCCUUUGGUGAUCCAGGCAUUAACGAACAUUGAAGAUAAAACUGGAUUGUGGUAUCUGAACGGGAACUAUUUGGUUCUGUUGGUGUCAUUGGUGGUCAUUCUUCCUUUGUCGCUGUUUAGAAAUUUAGGAUAUUUGGGAUAUACCAGUGGCCUUUCCUUGUUGUGUAUGGUGUUCUUUCUGAUUGUGGUCAUUUGCAAGAAAUUUCAGGUUCCGUGUCCUGUGGAAGCUGCUUUGAUAAUUAACGAAACAAUAAACACCACCUUAACACAGCCAACAGCUCUUGUACCUGCUUUGUCACAUAACGUGACUGAAAAUGACUCUUGCAGACCUCACUAUUUUAUUUUCAACUCACAGACUGUCUAUGCUGUGCCAAUUCUGAUCUUUUCAUUUGUCUGUCAUCCUGCUGUUCUUCCCAUCUAUGAAGAACUGAAAGACCGCAGCCGUAGAAGAAUGAUGAAUGUGUCCAAGAUUUCAUUUUUUGCUAUGUUUCUCAUGUAUCUGCUUGCCGCCCUCUUUGGAUACCUAACAUUUUACGAACAUGUUGAGUCAGAAUUGCUUCAUACCUACUCUUCUAUCUUGGGAACUGAUAUUCUUCUUCUCAUUGUCCGUCUGGCUGUGUUAAUGGCUGUGACCCUGACAGUACCAGUAGUUAUUUUCCCAAUCCGGAGUUCUGUAACUCACUUGUUGUGUGCAUCAAAAGAUUUCAGUUGGUGGCGUCAUAGUCUCAUUACAGUGUCUAUCUUGGCAUUUACCAAUUUACUUGUCAUCUUUGUCCCAACUAUUAGGGAUAUCUUUGGUUUUAUUGGUGCAUCUGCAGCUUCUAUGUUGAUUUUUAUUCUUCCUUCUGCCUUCUAUAUCAAGUUGGUGAAGAAAGAACCUAUGAAAUCUGUACAAAAGAUUGGGGCUUUGUUCUUCCUGUUAAGUGGUGUACUGGUGAUGACCGGAAGCAUGGCCUUGAUUGUUUUGGAUUGGGUACACAAUGCACCUGGAGGUGGCCAUUAAUUGGCACCACUCAAACUCAAACUCAGUCCAUCUGAUGCCAGUGUUGAGUAAACUCAACUACUAUGAAAUUUCACCUAAUGUUUUCAGUUUCACUUCCUUUUGAAGUGCAGAUUCCUCGCUGGUUCUUCUGAGUGCAGAAUAAGUGAACUUUUUUGUUUUGUUUUGUUUUUUUAAGAAACUUAUCUGUAUGUUAGAAAUGGAUAUGAACAACAAAACCACGAGUCUCGGGUUAAGGGAAGUGACAAUUUUAUUCCAUUCCAGAGAAUGGACAAACUCUUAACUUUUAUCAAGCCACAUGCUUGGCUGUGUCAUUGUUUAACUUGGAUAUUUUAUGAUUUUACUUGAAUGUGCCUAAUGGAACCAUUUGAUGUGAGAAACAAUUCUUUUUAAUUUACAGCAAAAUAUUGAAUAACCAUUGACAAAAACACUAUUAUUUUUUGUACCAAAAAUACUUAAAGACCUCAGAAGCACUCUUUUACUUUUAAGAAAUUGCUUUUUUGAACUUUAUUCAGAAGCAGUUAUCAAUAAAUUCCAUAAAAUAAUGUCAUUGGUAUUUAAAAAUGAAUAUUAAUAUAAUGAAAUGGUUUGCCUUUUUGUAGGCAUAAUAAGCCAAAUACUUUUUUACCCAAAAUAAUUUUUAGAGAAAAUGAUGUAAUGAAAAAUUGUACCAUGAAUUAGGAGCAUAGUUUUUUCCAUUUAAACGUCACCAUUACUUAAAAGAUGAUUGAUUAUUGCUAUACCAAAUCAGAUGAACUCUGUUCAUCACUUUUCUUCUCUGUCCCCAAACAAUUUGGUUCAUUCAGACUGAAAUGUUUGUGUCUUCAACUUAUUAGAAUGGAAGAUAAUGCAGAUAUUUCUGUGGGAAAUAAAAUAACUAAUUUUGAGGUACCAAAUAGUGCAAUUGGGUAAAACAGGGUUUAUUCAGUUGCAUCUGUCUCCAGUGUUGUAUUGACAGCUCUGGGUCUUUUUUUGGGCCAGCCCUUUUUUGACAUUGCUUCCAGCAGUGGAAAAUGGGCAUUUGAUGGCAAUAGGCCAAAAUUAUUGUGUCCAGAGAGUACACUUUUUCAAAAUGCUCACCUACUGGAAGUGUGAAUUACUUGACAAUGUAUGGCUUAGUUGUGUUCAUGUUUUGUCUACAGUAGAGGUCUAAUCCACAGGUUACACCUAUGUUUGAUAUGAUAUAAGUUCUCUUUGCGUAGGCCACUGGGUUUCUCAUGCAGUAAGCUUUAUAAAAACUCAUUUGCACUGGACUGUCAUCUCAUUCUUGUACAACGUAGAAUUACUUGUUUACAUCCAACAAAUGGUUAGCUAGGGAAAACAGUGCAAACUGAGUGUUAGUAGUCAUUUUGGUCCAACUGCAUGUCAACCCUUCCAUUUCAAUCCCAGUUAGAAAUGAAAAUAAUUACUUUGAAACUUGGCUUUAAGAGCACAUUUAUCGUACGUCACAGUGUAUGGUGAAUAUAUUAUUAAAUAAUGUGGUACUUCGCUCAUCAGGCAUAAUGUCUAAAAUCUAAUAUACAUAAUUCCAUUAAGUGGUUGAAGGAAGCAAAUAAUGGAAUUGUCAAUUGGUCAUCUGGCUGUAAGGUUUGCCCUUGAACUAAAAAUGUUGUUUGGGGCAAGGGCCAGAAAUGUGGAGACAUGGUUUUUGUUACGCAUUCUUGUAUUAUAUGUGACUAAAUUUACAAACAAGAUACAUGUGUAAUUAAAGACCCUUAUGGAACUGGAAGACGUCUUGUAGUGCUACAUUGGGUGAAACCGUUGGUCCAUUUUUGUCUGUUUCUAUGAAGAUAAAAUAAUUGGGGGCCAUCUAGAAAUAGAAAGGCAGUGGGAAGACAGAUUCUACGGCACUGCUUUCAUUUAAUUGGGCUUUAGGCACUCCAUUCGAAUGCAGAACCUCACCUCUAGUUGAGACCAAGAAUUGGCAAAUUUGCAUGAGCUCCUGGAAAGAGUUGCUGACUUUGUAUCUAAGACCUGCCAGGGAAUACCAAGAGUUGUUUCUACAGACUUUUUUUUUUUUUUUUGUAUGGGAGAAGAUACUGUGGCAACCAGGAAGGAAUGGAAAAAAAAUUCUUUUCUCUACAGCAAAUUAAUGUGAGGAAGCUCCUCCAAUCCUCUGGCUAUUUAAGGUUCAAAAUCAAGUGCCUAGGGAAAAUUCCAAUGGAUGAUUUUCUGGGAGCUAUCUUGUCUACCUUGAGGUUCCUGAACAAUGAAUUCCCAUUAAUGAGCAGUCUUCAGUAUUAAAACCACUGUCUUGUCACCUCAUUUUGCAUUACUGUCUUCCGUGGAUGUUUCAGUUACAACUGUAAUGUUAUUUAUAGAACAACAUUAAUCCAUUAAAGCUAACCUAUUUUUCAAUAUUUAUGAUAAUCUAUGUACAUAUAUUGUCUGUCCAUAUGUAUUUGUAAAUAGGUUGUAUAUAAUGUCAGGUUUGGGUCUUGGGUUCAAGUGUAUAUAUUCCUGUAAGUUUCUUAACUGCAUUUUGAUGAAUUCACAUUAUGUAACUAUAAGAAUUGUCCCAAAAGUACCUGUACAGAAAAUUGAAUAUUGAAAAAUUGACAAAUUGUGUACAAACACUAAAAAAAACUUGUUUAAAUUGUAUUUGCAAUAAACAACAUCAAAUUUUUUCAUGAAAUCUUGGUACAAAUUCAGAUCUCUUAUUUAAAAUUUAAAUAAGGAAUACAUUUUCAAAAUGCAGUAAUCAAAAUGUGAUCUAGUGUAAUGAAAUAAAAUGUGAUCUAGUGUAAUGGAAGACCUUUGAGAACCUGGGUGUAUUAACUUUGUGUAUAUAGUGUAAAUAUCCCCACUGUACUGUUAGAGGCCAACAAUUCUAGUAUGGCUUGUUGGCAAAGAGUGCUACACCGUUUCAAUGAAACAAUGUAUGUUUGUUUUAACUGAACUAAAAUAAAUACAUGCUUAAUCCUGA,mRNA,Homo sapiens,"sp|Q14671|PUM1_HUMAN Pumilio homolog 1 OS=Homo sapiens OX=9606 GN=PUM1 PE=1 SV=3
MSVACVLKRKAVLWQDSFSPHLKHHPQEPANPNMPVVLTSGTGSQAQPQPAANQALAAGT
HSSPVPGSIGVAGRSQDDAMVDYFFQRQHGEQLGGGGSGGGGYNNSKHRWPTGDNIHAEH
QVRSMDELNHDFQALALEGRAMGEQLLPGKKFWETDESSKDGPKGIFLGDQWRDSAWGTS
DHSVSQPIMVQRRPGQSFHVNSEVNSVLSPRSESGGLGVSMVEYVLSSSPGDSCLRKGGF
GPRDADSDENDKGEKKNKGTFDGDKLGDLKEEGDVMDKTNGLPVQNGIDADVKDFSRTPG
NCQNSANEVDLLGPNQNGSEGLAQLTSTNGAKPVEDFSNMESQSVPLDPMEHVGMEPLQF
DYSGTQVPVDSAAATVGLFDYNSQQQLFQRPNALAVQQLTAAQQQQYALAAAHQPHIGLA
PAAFVPNPYIISAAPPGTDPYTAGLAAAATLGPAVVPHQYYGVTPWGVYPASLFQQQAAA
AAAATNSANQQTTPQAQQGQQQVLRGGASQRPLTPNQNQQGQQTDPLVAAAAVNSALAFG
QGLAAGMPGYPVLAPAAYYDQTGALVVNAGARNGLGAPVRLVAPAPVIISSSAAQAAVAA
AAASANGAAGGLAGTTNGPFRPLGTQQPQPQPQQQPNNNLASSSFYGNNSLNSNSQSSSL
FSQGSAQPANTSLGFGSSSSLGATLGSALGGFGTAVANSNTGSGSRRDSLTGSSDLYKRT
SSSLTPIGHSFYNGLSFSSSPGPVGMPLPSQGPGHSQTPPPSLSSHGSSSSLNLGGLTNG
SGRYISAAPGAEAKYRSASSASSLFSPSSTLFSSSRLRYGMSDVMPSGRSRLLEDFRNNR
YPNLQLREIAGHIMEFSQDQHGSRFIQLKLERATPAERQLVFNEILQAAYQLMVDVFGNY
VIQKFFEFGSLEQKLALAERIRGHVLSLALQMYGCRVIQKALEFIPSDQQNEMVRELDGH
VLKCVKDQNGNHVVQKCIECVQPQSLQFIIDAFKGQVFALSTHPYGCRVIQRILEHCLPD
QTLPILEELHQHTEQLVQDQYGNYVIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHKFASN
VVEKCVTHASRTERAVLIDEVCTMNDGPHSALYTMMKDQYANYVVQKMIDVAEPGQRKIV
MHKIRPHIATLRKYTYGKHILAKLEKYYMKNGVDLGPICGPPNGII",PUM1,-,-,1186aa(1-1186),Q14671,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1307,http://db.phasep.pro/browse/","[22-73],[233-272],[485-524],[613-648],[742-773]","[45-58],[94-102],[393-414],[442-457],[475-502],[527-538],[583-614],[625-639],[647-665],[671-695],[762-782],[797-815]",In vitro,150 nM [PUM1];|0.1-20nM[SLC38A2 3'UTR],"150 mM NaCl, 1 mM MgCl2","20 mM Tris HCl pH 7.5, 1 mM DTT, 10% glycerol",RT,30 min,crowding agent:5% PEG3350;other_molecular: 1 U TEV protease,Confocal microscopy,solute,"Unlike NORAD, none of these transcripts promoted PUM1 phase separation at or below their physiological concentrations in vitro, although the PUM1 and PUM2 3′ UTRs were able to induce the formation of small droplets at concentrations 4–10 times their physiological levels"
693,PMID: 34108682,RNAPS0000622,https://pubmed.ncbi.nlm.nih.gov/34108682,RNA + protein,NCBI ID:9698,https://www.ncbi.nlm.nih.gov/gene/9698,PUM1,5385nt(1-5385),AGUGGGCCGCCAUGUUGUCGGAGUGAAAGGUAAGGGGGAGCGAGAGCGCCAGAGAGAGAAGAUCGGGGGGCUGAAAUCCAUCUUCAUCCUACCGCUCCGCCCGUGUUGGUGGAAUGAGCGUUGCAUGUGUCUUGAAGAGAAAAGCAGUGCUUUGGCAGGACUCUUUCAGCCCCCACCUGAAACAUCACCCUCAAGAACCAGCUAAUCCCAACAUGCCUGUUGUUUUGACAUCUGGAACAGGGUCGCAAGCGCAGCCACAACCAGCUGCAAAUCAGGCUCUUGCAGCUGGGACUCACUCCAGCCCUGUCCCAGGAUCUAUAGGAGUUGCAGGCCGUUCCCAGGACGACGCUAUGGUGGACUACUUCUUUCAGAGGCAGCAUGGUGAGCAGCUUGGGGGAGGAGGAAGUGGAGGAGGCGGCUAUAAUAAUAGCAAACAUCGAUGGCCUACUGGGGAUAACAUUCAUGCAGAACAUCAGGUGCGUUCCAUGGAUGAACUGAAUCAUGAUUUUCAAGCACUUGCUCUGGAGGGAAGAGCGAUGGGAGAGCAGCUCUUGCCAGGUAAAAAGUUUUGGGAAACAGAUGAAUCCAGCAAAGAUGGACCAAAAGGAAUAUUCCUGGGUGAUCAAUGGCGAGACAGUGCCUGGGGAACAUCAGAUCAUUCAGUUUCCCAGCCAAUCAUGGUGCAGAGAAGACCUGGUCAGAGUUUCCAUGUGAACAGUGAGGUCAAUUCUGUACUGUCCCCACGAUCGGAGAGUGGGGGACUAGGCGUUAGCAUGGUGGAGUAUGUGUUGAGCUCAUCCCCGGGCGAUUCCUGUCUAAGAAAAGGAGGAUUUGGCCCAAGGGAUGCAGACAGUGAUGAAAACGACAAAGGUGAAAAGAAGAACAAGGGUACGUUUGAUGGAGAUAAGCUAGGAGAUUUGAAGGAGGAGGGUGAUGUGAUGGACAAGACCAAUGGUUUACCAGUGCAGAAUGGGAUUGAUGCAGACGUCAAAGAUUUUAGCCGUACCCCUGGUAAUUGCCAGAACUCUGCUAAUGAAGUGGAUCUUCUGGGUCCAAACCAGAAUGGUUCUGAGGGCUUAGCCCAGCUGACCAGCACCAAUGGUGCCAAGCCUGUGGAGGAUUUCUCCAACAUGGAGUCCCAGAGUGUCCCCUUGGACCCCAUGGAACAUGUGGGCAUGGAGCCUCUUCAGUUUGAUUAUUCAGGCACGCAGGUACCUGUGGACUCAGCAGCAGCAACUGUGGGACUUUUUGACUACAAUUCUCAACAACAGCUGUUCCAAAGACCUAAUGCGCUUGCUGUCCAGCAGUUGACAGCUGCUCAGCAGCAGCAGUAUGCACUGGCAGCUGCUCAUCAGCCGCACAUCGGUUUAGCUCCCGCUGCGUUUGUCCCCAAUCCAUACAUCAUCAGCGCUGCUCCCCCAGGGACGGACCCCUACACAGCUGGAUUGGCUGCAGCAGCGACACUAGGCCCAGCUGUGGUCCCUCACCAGUAUUAUGGAGUUACUCCCUGGGGAGUCUACCCUGCCAGUCUUUUCCAGCAGCAAGCUGCCGCUGCCGCUGCAGCAACUAAUUCAGCUAAUCAACAGACCACCCCACAGGCUCAGCAAGGACAGCAGCAGGUUCUCCGUGGAGGAGCCAGCCAACGUCCUUUGACCCCAAACCAGAACCAGCAGGGACAGCAAACGGAUCCCCUUGUGGCAGCUGCAGCAGUGAAUUCUGCCCUUGCAUUUGGACAAGGUCUGGCAGCAGGCAUGCCAGGUUAUCCGGUGUUGGCUCCUGCUGCUUACUAUGACCAAACUGGUGCCCUUGUAGUGAAUGCAGGCGCGAGAAAUGGUCUUGGAGCUCCUGUUCGACUUGUAGCUCCUGCCCCAGUCAUCAUUAGUUCCUCAGCUGCACAAGCAGCUGUUGCAGCAGCCGCAGCUUCAGCAAAUGGAGCAGCUGGUGGUCUUGCUGGAACAACAAAUGGACCAUUUCGCCCUUUAGGAACACAGCAGCCUCAGCCCCAGCCCCAGCAGCAGCCCAAUAACAACCUGGCAUCCAGUUCUUUCUACGGCAACAACUCUCUGAACAGCAAUUCACAGAGCAGCUCCCUCUUCUCCCAGGGCUCUGCCCAGCCUGCCAACACAUCCUUGGGAUUCGGAAGUAGCAGUUCUCUCGGCGCCACCCUGGGAUCCGCCCUUGGAGGGUUUGGAACAGCAGUUGCAAACUCCAACACUGGCAGUGGCUCCCGCCGUGACUCCCUGACUGGCAGCAGUGACCUUUAUAAGAGGACAUCGAGCAGCUUGACCCCCAUUGGACACAGUUUUUAUAACGGCCUUAGCUUUUCCUCCUCUCCUGGACCCGUGGGCAUGCCUCUCCCUAGUCAGGGACCAGGACAUUCACAGACACCACCUCCUUCCCUCUCUUCACAUGGAUCCUCUUCAAGCUUAAACCUGGGAGGACUCACGAAUGGCAGUGGAAGAUACAUCUCUGCUGCUCCAGGCGCUGAAGCCAAGUACCGCAGUGCAAGCAGCGCCUCCAGCCUCUUCAGCCCGAGCAGCACUCUUUUCUCUUCCUCUCGUUUGCGAUAUGGAAUGUCUGAUGUCAUGCCUUCUGGCAGGAGCAGGCUUUUGGAAGAUUUUCGAAACAACCGGUACCCCAAUUUACAACUGCGGGAGAUUGCUGGACAUAUAAUGGAAUUUUCCCAAGACCAGCAUGGGUCCAGAUUCAUUCAGCUGAAACUGGAGCGUGCCACACCAGCUGAGCGCCAGCUUGUCUUCAAUGAAAUCCUCCAGGCUGCCUACCAACUCAUGGUGGAUGUGUUUGGUAAUUACGUCAUUCAGAAGUUCUUUGAAUUUGGCAGUCUUGAACAGAAGCUGGCUUUGGCAGAACGGAUUCGAGGCCACGUCCUGUCAUUGGCACUACAGAUGUAUGGCUGCCGUGUUAUCCAGAAAGCUCUUGAGUUUAUUCCUUCAGACCAGCAGGUAAUUAAUGAGAUGGUUCGGGAACUAGAUGGCCAUGUCUUGAAGUGUGUGAAAGAUCAGAAUGGCAAUCACGUGGUUCAGAAAUGCAUUGAAUGUGUACAGCCCCAGUCUUUGCAAUUUAUCAUCGAUGCGUUUAAGGGACAGGUAUUUGCCUUAUCCACACAUCCUUAUGGCUGCCGAGUGAUUCAGAGAAUCCUGGAGCACUGUCUCCCUGACCAGACACUCCCUAUUUUAGAGGAGCUUCACCAGCACACAGAGCAGCUUGUACAGGAUCAAUAUGGAAAUUAUGUAAUCCAACAUGUACUGGAGCACGGUCGUCCUGAGGAUAAAAGCAAAAUUGUAGCAGAAAUCCGAGGCAAUGUACUUGUAUUGAGUCAGCACAAAUUUGCAAGCAAUGUUGUGGAGAAGUGUGUUACUCACGCCUCACGUACGGAGCGCGCUGUGCUCAUCGAUGAGGUGUGCACCAUGAACGACGGUCCCCACAGUGCCUUAUACACCAUGAUGAAGGACCAGUAUGCCAACUACGUGGUCCAGAAGAUGAUUGACGUGGCGGAGCCAGGCCAGCGGAAGAUCGUCAUGCAUAAGAUCCGGCCCCACAUCGCAACUCUUCGUAAGUACACCUAUGGCAAGCACAUUCUGGCCAAGCUGGAGAAGUACUACAUGAAGAACGGUGUUGACUUAGGGCCCAUCUGUGGCCCCCCUAAUGGUAUCAUCUGAGGCAGUGUCACCCGCUGUUCCCUCAUUCCCGCUGACCUCACUGGCCCACUGGCAAAUCCAACCAGCAACCAGAAAUGUUCUAGUGUAGAGUCUGAGACGGGCAAGUGGUUGCUCCAGGAUUACUCCCUCCUCCAAAAAAGGAAUCAAAUCCACGAGUGGAAAAGCCUUUGUAAAUUUAAUUUUAUUACACAUAACAUGUACUAUUUUUUUUAAUUGACUAAUUGCCCUGCUGUUUUACUGGUGUAUAGGAUACUUGUACAUAGGUAACCAAUGUACAUGGGAGGCCACAUAUUUUGUUCACUGUUGUAUCUAUAUUUCACAUGUGGAAACUUUCAGGGUGGUUGGUUUAACAAAAAAAAAAAGCUUUAAAAAAAAAAGAAAAAAAGGAAAAGGUUUUUAGCUCAUUUGCCUGGCCGGCAAGUUUUGCAAAUAGCUCUUCCCCACCUCCUCAUUUUAGUAAAAAACAAACAAAAACAAAAAAACCUGAGAAGUUUGAAUUGUAGUUAAAUGACCCCAAACUGGCAUUUAACACUGUUUAUAAAAAAUAUAUAUAUAUAUAUAUAUAUAUAUAAUGAAAAAGGUUUCAGAGUUGCUAAAGCUUCAGUUUGUGACAUUAAGUUUAUGAAAUUCUAAAAAAUGCCUUUUUUGGAGACUAUAUUAUGCUGAAGAAGGCUGUUCGUGAGGAGGAGAUGCGAGCACCCAGAACGUCUUUUGAGGCUGGGCGGGUGUGAUUGUUUACUGCCUACUGGAUUUUUUUCUAUUAACAUUGAAAGGUAAAAUCUGAUUAUUUAGCAUGAGAAAAAAAAAUCCAACUCUGCUUUUGGUCUUGCUUCUAUAAAUAUAUAGUGUAUACUUGGUGUAGACUUUGCAUAUAUACAAAUUUGUAGUAUUUUCUUGUUUUGAUGUCUAAUCUGUAUCUAUAAUGUACCCUAGUAGUCGAACAUACUUUUGAUUGUACAAUUGUACAUUUGUAUACCUGUAAUGUAAAUGUGGAGAAGUUUGAAUCAACAUAAACACGUUUUUUGGUAAGAAAAGAGAAUUAGCCAGCCCUGUGCAUUCAGUGUAUAUUCUCACCUUUUAUGGUCGUAGCAUAUAGUGUUGUAUAUUGUAAAUUGUAAUUUCAACCAGAAGUAAAUUUUUUUCUUUUGAAGGAAUAAAUGUUCUUUAUACAGCCUAGUUAAUGUUUAAAAAGAAAAAAAUAGCUUGGUUUUAUUUGUCAUCUAGUCUCAAGUAUAGCGAGAUUCUUUCUAAAUGUUAUUCAAGAUUGAGUUCUCACUAGUGUUUUUUUAAUCCUAAAAAAGUAAUGUUUUGAUUUUGUGACAGUCAAAAGGACGUGCAAAAGUCUAGCCUUGCCCGAGCUUUCCUUACAAUCAGAGCCCCUCUCACCUUGUAAAGUGUGAAUCGCCCUUCCCUUUUGUACAGAAGAUGAACUGUAUUUUGCAUUUUGUCUACUUGUAAGUGAAUGUAACAUACUGUCAAUUUUCCUUGUUUGAAUAUAGAAUUGUAACACUACACGGUGUACAUUUCCAGAGCCUUGUGUAUAUUUCCAAUGAACUUUUUUGCAAGCACACUUGUAACCAUAUGUGUAUAAUUAACAAACCUGUGUAUGCUUAUGCCUGGGCAACUAUUUUUUGUAACUCUUGUGUAGAUUGUCUCUAAACAAUGUGUGAUCUUUAUUUUGAAAAAUACAGAACUUUGGAAUCUG,mRNA,Homo sapiens,"sp|Q14671|PUM1_HUMAN Pumilio homolog 1 OS=Homo sapiens OX=9606 GN=PUM1 PE=1 SV=3
MSVACVLKRKAVLWQDSFSPHLKHHPQEPANPNMPVVLTSGTGSQAQPQPAANQALAAGT
HSSPVPGSIGVAGRSQDDAMVDYFFQRQHGEQLGGGGSGGGGYNNSKHRWPTGDNIHAEH
QVRSMDELNHDFQALALEGRAMGEQLLPGKKFWETDESSKDGPKGIFLGDQWRDSAWGTS
DHSVSQPIMVQRRPGQSFHVNSEVNSVLSPRSESGGLGVSMVEYVLSSSPGDSCLRKGGF
GPRDADSDENDKGEKKNKGTFDGDKLGDLKEEGDVMDKTNGLPVQNGIDADVKDFSRTPG
NCQNSANEVDLLGPNQNGSEGLAQLTSTNGAKPVEDFSNMESQSVPLDPMEHVGMEPLQF
DYSGTQVPVDSAAATVGLFDYNSQQQLFQRPNALAVQQLTAAQQQQYALAAAHQPHIGLA
PAAFVPNPYIISAAPPGTDPYTAGLAAAATLGPAVVPHQYYGVTPWGVYPASLFQQQAAA
AAAATNSANQQTTPQAQQGQQQVLRGGASQRPLTPNQNQQGQQTDPLVAAAAVNSALAFG
QGLAAGMPGYPVLAPAAYYDQTGALVVNAGARNGLGAPVRLVAPAPVIISSSAAQAAVAA
AAASANGAAGGLAGTTNGPFRPLGTQQPQPQPQQQPNNNLASSSFYGNNSLNSNSQSSSL
FSQGSAQPANTSLGFGSSSSLGATLGSALGGFGTAVANSNTGSGSRRDSLTGSSDLYKRT
SSSLTPIGHSFYNGLSFSSSPGPVGMPLPSQGPGHSQTPPPSLSSHGSSSSLNLGGLTNG
SGRYISAAPGAEAKYRSASSASSLFSPSSTLFSSSRLRYGMSDVMPSGRSRLLEDFRNNR
YPNLQLREIAGHIMEFSQDQHGSRFIQLKLERATPAERQLVFNEILQAAYQLMVDVFGNY
VIQKFFEFGSLEQKLALAERIRGHVLSLALQMYGCRVIQKALEFIPSDQQNEMVRELDGH
VLKCVKDQNGNHVVQKCIECVQPQSLQFIIDAFKGQVFALSTHPYGCRVIQRILEHCLPD
QTLPILEELHQHTEQLVQDQYGNYVIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHKFASN
VVEKCVTHASRTERAVLIDEVCTMNDGPHSALYTMMKDQYANYVVQKMIDVAEPGQRKIV
MHKIRPHIATLRKYTYGKHILAKLEKYYMKNGVDLGPICGPPNGII",PUM1,-,-,1186aa(1-1186),Q14671,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1307,http://db.phasep.pro/browse/","[22-73],[233-272],[485-524],[613-648],[742-773]","[45-58],[94-102],[393-414],[442-457],[475-502],[527-538],[583-614],[625-639],[647-665],[671-695],[762-782],[797-815]",In vitro,150 nM [PUM1];|0.1-20nM[PUM1 3'UTR],"150 mM NaCl, 1 mM MgCl2","20 mM Tris HCl pH 7.5, 1 mM DTT, 10% glycerol",RT,30 min,crowding agent:5% PEG3350;other_molecular: 1 U TEV protease,Confocal microscopy,"solute, liquid","Unlike NORAD, none of these transcripts promoted PUM1 phase separation at or below their physiological concentrations in vitro, although the PUM1 and PUM2 3′ UTRs were able to induce the formation of small droplets at concentrations 4–10 times their physiological levels"
694,PMID: 34108682,RNAPS0000623,https://pubmed.ncbi.nlm.nih.gov/34108682,RNA + protein,NCBI ID:23369,https://www.ncbi.nlm.nih.gov/gene/23369,PUM2,6200nt(1-6200),AGGGGAGGGCAGGCGGCGGUGGCAGCCAUGUUGUUGUGAGUCUCUGUGUCUCACCCUCGGUACUUCGGUGGUUCGGAGGAGGAGGGGGAGGAGAAGGAGGAGGUGGGGUGGGGGGGGAGGGUGGUAGGUGGAGAAAGAAGACAUUGCCGCCACCGAAGGCGGAGGAGGGGGAGGACCGCCAAGAGCGACGCCGCCGUGUGCCCAACGGUCGGUGUCCCCGGCUGAGGCAGCGCGGCCGCAGCAGCCCUGUUUGAUCUGUGGAUGAAAUGAAUCAUGAUUUUCAAGCUCUUGCAUUAGAAUCUCGGGGAAUGGGAGAGACCAUUCAAUGUCCCAGCCUAUUAUGGUACAGAGAAGAUCUGGACAGGGUUUUCAUGGAAACAGUGAAGUAAAUGCAAUACUGUCUCCGCGAUCAGAAAGUGGAGGCCUUGGUGUGAGCAUGGUAGAAUAUGUAUUAAGUUCUUCUCCUGCUGAUAAAUUGGAUUCUCGAUUUAGGAAGGGAAAUUUUGGCACUAGAGAUGCUGAAACAGAUGGACCUGAGAAAGGAGAUCAAAAAGGCAAGGCUUCUCCAUUUGAGGAGGACCAAAACAGAGAUCUUAAACAAGGAGAUGAUGAUGAUUCUAAAAUAAAUGGCAGAGGUUUGCCAAAUGGAAUGGAUGCCGAUUGCAAAGAUUUUAAUCGUACUCCUGGAAGUCGUCAAGCCUCUCCAACUGAAGUAGUUGAGCGCUUGGGCCCCAAUACUAAUCCCUCAGAAGGACUGGGGCCUCUUCCUAAUCCUACAGCUAAUAAACCACUUGUUGAAGAAUUUUCAAAUCCUGAAACUCAGAAUCUGGAUGCCAUGGAACAAGUUGGUCUGGAAUCCUUACAGUUUGACUAUCCUGGUAAUCAGGUACCAAUGGACUCUUCAGGAGCUACUGUAGGCCUUUUUGACUACAAUUCCCAGCAGCAGCUCUUUCAGAGGACUAAUGCACUAACAGUUCAACAGUUAACUGCAGCUCAACAGCAGCAAUAUGCAUUAGCAGCAGCUCAGCAGCCACAUAUAGCUGGUGUAUUCUCAGCAGGCCUUGCUCCAGCUGCAUUUGUGCCAAAUCCAUACAUUAUUAGUGCUGCUCCUCCAGGGACCGAUCCGUAUACUGCAGCAGGAUUGGCUGCAGCAGCUACAUUAGCAGGUCCAGCAGUGGUUCCACCUCAGUAUUACGGCGUUCCAUGGGGGGUGUAUCCAGCCAACUUAUUUCAGCAGCAAGCUGCAGCUGCGGCAAAUAACACAGCCAGUCAGCAAGCAGCAUCACAAGCUCAGCCUGGACAGCAACAGGUUCUCCGUGCUGGAGCAGGUCAGCGUCCUCUUACUCCCAAUCAGGGUCAGCAAGGGCAGCAAGCAGAAUCACUUGCGGCAGCUGCAGCAGCAAAUCCAACAUUGGCUUUUGGUCAGGGUCUUGCUACUGGCAUGCCAGGCUAUCAAGUACUAGCUCCAACUGCCUAUUAUGAUCAGACUGGUGCCUUAGUGGUUGGCCCUGGAGCAAGGACUGGCCUUGGAGCUCCAGUUCGGUUAAUGGCUCCAACACCUGUUUUAAUUAGUUCAGCAGCAGCACAAGCUGCAGCAGCAGCAGCAGCUGGAGGAACUGCAAGUAGCCUUACAGGCAGCACAAAUGGUCUGUUUCGGCCAAUUGGCACUCAGCCACCACAGCAGCAGCAACAGCAGCCAAGCACUAAUCUGCAAUCUAAUUCAUUUUAUGGAAGCAGUUCUUUGACUAAUAGCUCCCAGAGUAGUUCUUUAUUUUCUCAUGGACCUGGUCAACCUGGAAGUACAUCUCUUGGCUUUGGAAGUGGUAACUCUUUGGGUGCUGCUAUAGGCUCAGCCCUCAGUGGAUUUGGUUCAUCAGUUGGCAGUUCUGCAAGUAGUAGUGCCACAAGGAGAGAGUCUCUAUCUACUAGCUCUGACUUGUACAAAAGAUCUAGUAGCAGCCUAGCACCCAUAGGGCAACCAUUUUACAAUAGUCUGGGAUUUUCCUCCUCUCCAAGUCCAAUAGGCAUGCCUCUGCCAAGCCAAACUCCAGGACAUUCACUUACGCCACCGCCAUCACUUUCAUCACAUGGAUCCUCAUCCAGUUUGCAUUUAGGAGGACUGACAAAUGGUAGUGGUCGAUAUAUCUCUGCAGCACCUGGAGCAGAAGCAAAAUAUCGAAGUGCUUCAAGCACUUCCAGUCUAUUUAGCUCCAGCAGCCAGCUCUUUCCUCCUUCCCGGCUUCGGUAUAAUAGGUCUGAUAUUAUGCCUUCUGGCCGCAGUAGAUUAUUGGAAGAUUUCAGAAACAACCGCUUCCCAAACCUUCAGCUUAGAGACUUGAUUGGACAUAUAGUUGAGUUUUCUCAAGACCAGCAUGGUUCUAGAUUCAUACAGCAAAAACUAGAGAGAGCUACUCCAGCUGAGCGACAGAUGGUAUUUAAUGAAAUUCUGCAAGCAGCCUAUCAAUUAAUGACUGAUGUUUUUGGCAACUAUGUUAUACAGAAGUUUUUUGAGUUUGGGAGUCUGGAUCAAAAAUUAGCCCUGGCUACUCGUAUUCGUGGUCAUGUUCUACCCUUAGCCUUGCAGAUGUAUGGCUGCCGCGUUAUUCAGAAAGCAUUAGAAUCUAUUUCUUCUGACCAGCAGAGUGAAAUGGUAAAGGAGCUGGAUGGUCAUGUGCUCAAAUGUGUGAAAGAUCAGAAUGGAAACCAUGUUGUACAAAAAUGUAUCGAAUGUGUUCAGCCACAGUCACUACAGUUCAUCAUUGAUGCUUUCAAGGGACAAGUAUUUGUGCUUUCAACUCAUCCUUAUGGCUGCAGAGUAAUUCAGCGCAUCCUAGAGCAUUGCACUGCAGAACAGACCUUACCUAUCUUAGAAGAACUCCACCAACAUACAGAGCAGUUGGUACAGGAUCAGUAUGGCAAUUAUGUUAUUCAGCAUGUACUGGAACACGGUCGACCUGAAGACAAGAGCAAAAUUGUUUCCGAAAUCAGGGGAAAGGUUUUAGCCCUGAGUCAACACAAAUUUGCCAGCAAUGUAGUAGAAAAGUGUGUUACUCAUGCCUCCCGUGCUGAGAGAGCUUUACUGAUUGACGAGGUUUGCUGCCAGAAUGAUGGUCCUCACAGUGCCUUAUACACCAUGAUGAAGGACCAGUAUGCCAAUUACGUGGUUCAAAAGAUGAUUGAUAUGGCUGAACCUGCUCAGAGAAAGAUAAUCAUGCACAAGAUUCGACCUCACAUUACUACUUUGCGCAAAUACACAUACGGGAAGCAUAUACUGGCCAAGUUGGAAAAGUAUUAUUUGAAGAAUAGCCCGGACCUAGGACCUAUUGGAGGACCACCAAAUGGAAUGCUGUAAAUUACAGGAGCAAGAGAAAGAAGAUAAUUUAACCAUGUGAAAAGAAUUUUUUUGUGUGUGAAUUAUCAAAACACAACUCAACUAUGAAUCUUCAAUUUUUUUUUAAAGCAAAACUAUUUAUUGACUUUAUUCAUCCAUUUGUAAAUUUUUUAAGGUUCUUGUGUAUAUUUGGGGGGUGGGGGAUGAAUUAUAAAUUAUAUUCAGCCCUGAGUGGAGACCUAUCAGAUUGGAUUGCUGGCAAAGCACAGAAUGCCUGUAUAUGAUGUAACUGUAUCAAAAAUAAAAAGCUGUCACAUAUUUUGUAAAUUUUUACCUUGUAAAGUCACAAAAAUAGUUUUUAAAGGAAAAAGUACAGUAUUCUUUUAAUAAACUGGCUCACAGUCUGGUAGGUCUACAACCCCAUAGCACAACAGGUUUAUAGAGAUGUAUAUAGAAUUAUAGUCCUUAUUUUUUUCCUUUGCGUGAAACCUUUUAUAACAGAUUAACAAUCAACUGCAUAAAUAUUAUUAAUAUUUUAAAAAGAGUUAAGUUGUAUUUUGAUAAUUCACAAACUAUCAUGCAAAUAACGAGUAAGUAGACAAGAAUAAAGUGGUUUGAGAUGAAAAGAACCUAACAUUAUUUACAGUAGAUGUGGUUUUAAUACAAUUACUGCCCUAAAAUGUCUCUGGCAAUGUACAGAAAUAUUGUAUAUACUUACAUAUGUAAUUGUUGUAAGAGUUAAAUACAAAAUCAUGGUGACACUUCCAAUUAAGUGCACUAAAUGAAAAGUUAAGUCACUUAUUAACUUUUCAGUUUGGUUUGCAAUGAGAAAGAGUGGAAAUUUGUAUUUUGUUUUGCUUAUAGAAUUACAGACAUGUUGAGGAAGUGUUGAGCUUUAUUUUGCUUUUUCAUAGAGGCAGAAAGUAGGAACCAGAUAGAGAUGAAAAGGGGCCACUGAAAAGUGAAUUUGAUAGCUCAGCAUUUAAGCAUGAUUACAUAUUCAGAUAGCUCUUUUUGCUUUCUAUAAAUAUAUGCAUUGUGUGUGUAGUAAUAGAUGUAAGUUUACACUUUGAAAGGAAAUCUUGUUUCAAUGUUUAUUAUAAAAGCCUUGCUAAUUUAGUAGUGAUGCUUUCCUUGGUUGUACAGGUGUACAUUUGUAAACCUUCAUGCUGUAAAUGGAAUUUGUUUUAUCUCUUUGGGAUACAUUUGCAUUUUAGUGUACAUUUACGUCCCUGCCCUCUUUGACCUGGCAAUAUAGUGUUGUAUAAUGUAAAUUUAUUUCUCCAAAUCGAGAGUGAUUUUUUAAAAAUUUUUUAUCUUUAUAUGGUUUCAGAAGUAUGAACCAGCUUUCUUUUUAUUAUUGUGAGAUCAUUUUGUUUUAUAACAUAGUUGUUGACUGUUAAUAUGGACCUGCUAGAAUUUGGAUCACUUUCAAUUGAAGUCAGGGUAUUGUGCAUAAUAGAAAGUAUUGGACUGAGAUAUUUGGUUACCAUGGAGGCCAAUGCUUUUUUCAUCUUAUUAAAUGUGAUGUGACUUUUUUCUUUGUACAGAAGAGUACUGUAUUUUUGAAUAGCCUACUCCCAAGUAAGAGCAAAUCUGUAUGAUAACAUUUUUUCCUCUGGACAUAAGACAUAACAGUAACACGAUGUACAUUUACAAGCGGCCUUAUGUACAUUUCCCAACAAUCUUUUUAAGGCAAAAUUGUGACCAUAUGUGUAUAAUUAAAAUCGUUUUUAAUCCUUUGCCUAUGAAAAUAUUUUGGAAAAAAACUUGCUGUGUAUAUUCAGUUUCUGAAAGAUAAAGAAAGUGCUUUGUAUUUUGUUGAAGUCAGUAUUUUGUAUAAACAUUUAUGUUGACCCACUUAUGUUCAGUGCUGAAAACUAAAAUGAACAUGCUAUUCUGUCAGCUGAAUAUGGAAGAGAUCUUUUUUUACUAGAGAUCUGCAGAAGAAACGCAAUCUUCUGAGCACAAUAUGGAAUCUAAAGGUUUUAUCACUUAGUUGUUCAUAUUAUGAACCUAAAAAUAAUGGCAUAAAGUUUGGGGAUGCCAGGCAUACUUUUUCAUGUUUGGUGUUGAGUUAUUUUACUUUUCUAACCCAACAUUCCUUGGUGAGACCAUUAAAUCCAAACACUUGUCACCGUUCCUUCUCAUAGUCACUCUGGGUCAUCAGCAUGUCCCAGUCACUGCAGCAACGCCUUGUGUUUGUUUCAUUUUUUUAAAACCCACACAAAGCCGCUGUCUCACUUUUUCCUACUUUACCAACCUCAGAGUAUUUCGGCCCGUAUCGAACUUUUGUUCUCAGUAUCAGCCCAUGGUUUCAGGAUCAAAGCUGUCAUGUUGGAGAUUGGUAAUGGCUUUCCUGUCUUUGUACAGUUGAAUUCCUAGUCUUCCUUCAUCCUUGCCCUCUGUUGGCACAGGCAUUAUCUCUGCAAUUUUAGAAAAUGACAAGUAGAGAAUACUACAUUGAGAAACUAAACCCUCUUCUUGGGGUCCUGAUACUCAUUCCCAUUUGUCCCAGUGCUGACAACCCAAUCUUCCCAAUACUUUCAGGCCUGCUCUACAAAAGUACCUGUUCUUGUAGAAAUUUUACAGUCUGCCAUUUUGGGUGCCCACCCCAAUUUUUACCUUUUAGUAAGUUGGCAUGAAAUUUUGGUAAAAUCUGAAAAUCACAUUUCAGAAUAAAACAAUUGGGCAAAACUACCUAGGCUUUACUCUUGAGUGUCUCCUUUUGAUAGGGAUUGUUUCUGGACCAGUUUGUCUAAGUCCUGGCUCUUAUUGGUUCAUAUGAAAUAAUGUUAACUUCACUUCUUUGUAUAUUAUGUAUAAAUUAGAAAAUGAAAAAUGUGUGAAUAACAUUGUAUGAAAUAAA,mRNA,Homo sapiens,"sp|Q14671|PUM1_HUMAN Pumilio homolog 1 OS=Homo sapiens OX=9606 GN=PUM1 PE=1 SV=3
MSVACVLKRKAVLWQDSFSPHLKHHPQEPANPNMPVVLTSGTGSQAQPQPAANQALAAGT
HSSPVPGSIGVAGRSQDDAMVDYFFQRQHGEQLGGGGSGGGGYNNSKHRWPTGDNIHAEH
QVRSMDELNHDFQALALEGRAMGEQLLPGKKFWETDESSKDGPKGIFLGDQWRDSAWGTS
DHSVSQPIMVQRRPGQSFHVNSEVNSVLSPRSESGGLGVSMVEYVLSSSPGDSCLRKGGF
GPRDADSDENDKGEKKNKGTFDGDKLGDLKEEGDVMDKTNGLPVQNGIDADVKDFSRTPG
NCQNSANEVDLLGPNQNGSEGLAQLTSTNGAKPVEDFSNMESQSVPLDPMEHVGMEPLQF
DYSGTQVPVDSAAATVGLFDYNSQQQLFQRPNALAVQQLTAAQQQQYALAAAHQPHIGLA
PAAFVPNPYIISAAPPGTDPYTAGLAAAATLGPAVVPHQYYGVTPWGVYPASLFQQQAAA
AAAATNSANQQTTPQAQQGQQQVLRGGASQRPLTPNQNQQGQQTDPLVAAAAVNSALAFG
QGLAAGMPGYPVLAPAAYYDQTGALVVNAGARNGLGAPVRLVAPAPVIISSSAAQAAVAA
AAASANGAAGGLAGTTNGPFRPLGTQQPQPQPQQQPNNNLASSSFYGNNSLNSNSQSSSL
FSQGSAQPANTSLGFGSSSSLGATLGSALGGFGTAVANSNTGSGSRRDSLTGSSDLYKRT
SSSLTPIGHSFYNGLSFSSSPGPVGMPLPSQGPGHSQTPPPSLSSHGSSSSLNLGGLTNG
SGRYISAAPGAEAKYRSASSASSLFSPSSTLFSSSRLRYGMSDVMPSGRSRLLEDFRNNR
YPNLQLREIAGHIMEFSQDQHGSRFIQLKLERATPAERQLVFNEILQAAYQLMVDVFGNY
VIQKFFEFGSLEQKLALAERIRGHVLSLALQMYGCRVIQKALEFIPSDQQNEMVRELDGH
VLKCVKDQNGNHVVQKCIECVQPQSLQFIIDAFKGQVFALSTHPYGCRVIQRILEHCLPD
QTLPILEELHQHTEQLVQDQYGNYVIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHKFASN
VVEKCVTHASRTERAVLIDEVCTMNDGPHSALYTMMKDQYANYVVQKMIDVAEPGQRKIV
MHKIRPHIATLRKYTYGKHILAKLEKYYMKNGVDLGPICGPPNGII",PUM1,-,-,1186aa(1-1186),Q14671,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1307,http://db.phasep.pro/browse/","[22-73],[233-272],[485-524],[613-648],[742-773]","[45-58],[94-102],[393-414],[442-457],[475-502],[527-538],[583-614],[625-639],[647-665],[671-695],[762-782],[797-815]",In vitro,150 nM [PUM1];|0.1-20nM[PUM2 3'UTR],"150 mM NaCl, 1 mM MgCl2","20 mM Tris HCl pH 7.5, 1 mM DTT, 10% glycerol",RT,30 min,crowding agent:5% PEG3350;other_molecular: 1 U TEV protease,Confocal microscopy,"solute, liquid","Unlike NORAD, none of these transcripts promoted PUM1 phase separation at or below their physiological concentrations in vitro, although the PUM1 and PUM2 3′ UTRs were able to induce the formation of small droplets at concentrations 4–10 times their physiological levels"
695,PMID: 34267352,RNAPS0000625,https://pubmed.ncbi.nlm.nih.gov/34267352,RNA + protein,NCBI ID:735301,https://www.ncbi.nlm.nih.gov/gene/735301,SNHG9,345nt(1-345),GCGGCCCGGGAAUCUACGUCACCCGAAAAGCGACUAUAAACGCCGGCGCCUCCGUCCCCAGCCGCGGCUCGGGAAUCCACCCGAAGAGUGGCUAUAAACGUCCGCGCCUCCAUUGCGCUCUCCUCUUCACUUAGGACACUGGUCCUCCCACGCCUGACACCGACGUCGCCAGGACCGCGGGGUUGGGGGAACUUGGCUGUCCCACGUCUUUCAAAUAAAGCUGUUUUGUCUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,lncRNA,Homo sapiens,"sp|O95835|LATS1_HUMAN Serine/threonine-protein kinase LATS1 OS=Homo sapiens OX=9606 GN=LATS1 PE=1 SV=1
MKRSEKPEGYRQMRPKTFPASNYTVSSRQMLQEIRESLRNLSKPSDAAKAEHNMSKMSTE
DPRQVRNPPKFGTHHKALQEIRNSLLPFANETNSSRSTSEVNPQMLQDLQAAGFDEDMVI
QALQKTNNRSIEAAIEFISKMSYQDPRREQMAAAAARPINASMKPGNVQQSVNRKQSWKG
SKESLVPQRHGPPLGESVAYHSESPNSQTDVGRPLSGSGISAFVQAHPSNGQRVNPPPPP
QVRSVTPPPPPRGQTPPPRGTTPPPPSWEPNSQTKRYSGNMEYVISRISPVPPGAWQEGY
PPPPLNTSPMNPPNQGQRGISSVPVGRQPIIMQSSSKFNFPSGRPGMQNGTGQTDFMIHQ
NVVPAGTVNRQPPPPYPLTAANGQSPSALQTGGSAAPSSYTNGSIPQSMMVPNRNSHNME
LYNISVPGLQTNWPQSSSAPAQSSPSSGHEIPTWQPNIPVRSNSFNNPLGNRASHSANSQ
PSATTVTAITPAPIQQPVKSMRVLKPELQTALAPTHPSWIPQPIQTVQPSPFPEGTASNV
TVMPPVAEAPNYQGPPPPYPKHLLHQNPSVPPYESISKPSKEDQPSLPKEDESEKSYENV
DSGDKEKKQITTSPITVRKNKKDEERRESRIQSYSPQAFKFFMEQHVENVLKSHQQRLHR
KKQLENEMMRVGLSQDAQDQMRKMLCQKESNYIRLKRAKMDKSMFVKIKTLGIGAFGEVC
LARKVDTKALYATKTLRKKDVLLRNQVAHVKAERDILAEADNEWVVRLYYSFQDKDNLYF
VMDYIPGGDMMSLLIRMGIFPESLARFYIAELTCAVESVHKMGFIHRDIKPDNILIDRDG
HIKLTDFGLCTGFRWTHDSKYYQSGDHPRQDSMDFSNEWGDPSSCRCGDRLKPLERRAAR
QHQRCLAHSLVGTPNYIAPEVLLRTGYTQLCDWWSVGVILFEMLVGQPPFLAQTPLETQM
KVINWQTSLHIPPQAKLSPEASDLIIKLCRGPEDRLGKNGADEIKAHPFFKTIDFSSDLR
QQSASYIPKITHPTDTSNFDPVDPDKLWSDDNEEENVNDTLNGWYKNGKHPEHAFYEFTF
RRFFDDNGYPYNYPKPIEYEYINSQGSEQQSDEDDQNTGSEIKNRDLVYV",LATS1,-,-,1130aa(1-1130),O95835,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1421,http://db.phasep.pro/browse/","[1-68],[149-276],[294-321],[365-405],[432-484],[515-601],[1104-1130]","[228-267],[301-314],[434-447],[483-494],[555-560],[1104-1116]",In vitro,-,"15 mM NaCl, 130 mM KCl, 5 mM KH2PO4, 1.5 mM MgCl2","20 mM Tris-HCl, pH 7.5",25˚C,2 h,other_molecular:1 mg/mL BSA,"Differential interference contrast microscopy,Fluorescence microscopy",liquid," To test whether the interaction with SNHG9 induces LATS1 phase separation in vitro, we incubated LATS1-GFP protein with fluorescein-labeled SNHG9 (red). Upon mixing, LATS1 and SNHG9 formed micrometer-sized liquid droplets"
696,PMID: 34267352,RNAPS0000625,https://pubmed.ncbi.nlm.nih.gov/34267352,RNA + protein,NCBI ID:735301,https://www.ncbi.nlm.nih.gov/gene/735301,SNHG9,345nt(1-345),GCGGCCCGGGAAUCUACGUCACCCGAAAAGCGACUAUAAACGCCGGCGCCUCCGUCCCCAGCCGCGGCUCGGGAAUCCACCCGAAGAGUGGCUAUAAACGUCCGCGCCUCCAUUGCGCUCUCCUCUUCACUUAGGACACUGGUCCUCCCACGCCUGACACCGACGUCGCCAGGACCGCGGGGUUGGGGGAACUUGGCUGUCCCACGUCUUUCAAAUAAAGCUGUUUUGUCUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,lncRNA,Homo sapiens,"sp|O95835|LATS1_HUMAN Serine/threonine-protein kinase LATS1 OS=Homo sapiens OX=9606 GN=LATS1 PE=1 SV=1
MKRSEKPEGYRQMRPKTFPASNYTVSSRQMLQEIRESLRNLSKPSDAAKAEHNMSKMSTE
DPRQVRNPPKFGTHHKALQEIRNSLLPFANETNSSRSTSEVNPQMLQDLQAAGFDEDMVI
QALQKTNNRSIEAAIEFISKMSYQDPRREQMAAAAARPINASMKPGNVQQSVNRKQSWKG
SKESLVPQRHGPPLGESVAYHSESPNSQTDVGRPLSGSGISAFVQAHPSNGQRVNPPPPP
QVRSVTPPPPPRGQTPPPRGTTPPPPSWEPNSQTKRYSGNMEYVISRISPVPPGAWQEGY
PPPPLNTSPMNPPNQGQRGISSVPVGRQPIIMQSSSKFNFPSGRPGMQNGTGQTDFMIHQ
NVVPAGTVNRQPPPPYPLTAANGQSPSALQTGGSAAPSSYTNGSIPQSMMVPNRNSHNME
LYNISVPGLQTNWPQSSSAPAQSSPSSGHEIPTWQPNIPVRSNSFNNPLGNRASHSANSQ
PSATTVTAITPAPIQQPVKSMRVLKPELQTALAPTHPSWIPQPIQTVQPSPFPEGTASNV
TVMPPVAEAPNYQGPPPPYPKHLLHQNPSVPPYESISKPSKEDQPSLPKEDESEKSYENV
DSGDKEKKQITTSPITVRKNKKDEERRESRIQSYSPQAFKFFMEQHVENVLKSHQQRLHR
KKQLENEMMRVGLSQDAQDQMRKMLCQKESNYIRLKRAKMDKSMFVKIKTLGIGAFGEVC
LARKVDTKALYATKTLRKKDVLLRNQVAHVKAERDILAEADNEWVVRLYYSFQDKDNLYF
VMDYIPGGDMMSLLIRMGIFPESLARFYIAELTCAVESVHKMGFIHRDIKPDNILIDRDG
HIKLTDFGLCTGFRWTHDSKYYQSGDHPRQDSMDFSNEWGDPSSCRCGDRLKPLERRAAR
QHQRCLAHSLVGTPNYIAPEVLLRTGYTQLCDWWSVGVILFEMLVGQPPFLAQTPLETQM
KVINWQTSLHIPPQAKLSPEASDLIIKLCRGPEDRLGKNGADEIKAHPFFKTIDFSSDLR
QQSASYIPKITHPTDTSNFDPVDPDKLWSDDNEEENVNDTLNGWYKNGKHPEHAFYEFTF
RRFFDDNGYPYNYPKPIEYEYINSQGSEQQSDEDDQNTGSEIKNRDLVYV",LATS1,-,-,1130aa(1-1130),O95835,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1421,http://db.phasep.pro/browse/","[1-68],[149-276],[294-321],[365-405],[432-484],[515-601],[1104-1130]","[228-267],[301-314],[434-447],[483-494],[555-560],[1104-1116]",In vitro,100 nM [SNHG9-sen];|0.01-2µM[LATS1-GFP],"15 mM NaCl, 130 mM KCl, 5 mM KH2PO4, 1.5 mM MgCl2","20 mM Tris-HCl, pH 7.5",25˚C,2 h,other_molecular:1 mg/mL BSA,Fluorescence microscopy,liquid,"Droplet formation was observed when the protein concentration of LATS1-GFP was 0.1 µM in the presence of SNHG9-sense, while no droplet formed at the same protein concentration in the presence of SNHG9-antisense or in the absence of RNA"
697,PMID: 34267352,RNAPS0000626,https://pubmed.ncbi.nlm.nih.gov/34267352,RNA + protein,NCBI ID:735301,https://www.ncbi.nlm.nih.gov/gene/735301,SNHG9-antisense,345nt(1-345),AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUGUUUUGUCGAAAUAAACUUUCUGCACCCUGUCGGUUCAAGGGGGUUGGGGCGCCAGGACCGCUGCAGCCACAGUCCGCACCCUCCUGGUCACAGGAUUCACUUCUCCUCUCGCGUUACCUCCGCGCCUGCAAAUAUCGGUGAGAAGCCCACCUAAGGGCUCGGCGCCGACCCCUGCCUCCGCGGCCGCAAAUAUCAGCGAAAAGCCCACUGCAUCUAAGGGCCCGGCG,lncRNA,Homo sapiens,"sp|O95835|LATS1_HUMAN Serine/threonine-protein kinase LATS1 OS=Homo sapiens OX=9606 GN=LATS1 PE=1 SV=1
MKRSEKPEGYRQMRPKTFPASNYTVSSRQMLQEIRESLRNLSKPSDAAKAEHNMSKMSTE
DPRQVRNPPKFGTHHKALQEIRNSLLPFANETNSSRSTSEVNPQMLQDLQAAGFDEDMVI
QALQKTNNRSIEAAIEFISKMSYQDPRREQMAAAAARPINASMKPGNVQQSVNRKQSWKG
SKESLVPQRHGPPLGESVAYHSESPNSQTDVGRPLSGSGISAFVQAHPSNGQRVNPPPPP
QVRSVTPPPPPRGQTPPPRGTTPPPPSWEPNSQTKRYSGNMEYVISRISPVPPGAWQEGY
PPPPLNTSPMNPPNQGQRGISSVPVGRQPIIMQSSSKFNFPSGRPGMQNGTGQTDFMIHQ
NVVPAGTVNRQPPPPYPLTAANGQSPSALQTGGSAAPSSYTNGSIPQSMMVPNRNSHNME
LYNISVPGLQTNWPQSSSAPAQSSPSSGHEIPTWQPNIPVRSNSFNNPLGNRASHSANSQ
PSATTVTAITPAPIQQPVKSMRVLKPELQTALAPTHPSWIPQPIQTVQPSPFPEGTASNV
TVMPPVAEAPNYQGPPPPYPKHLLHQNPSVPPYESISKPSKEDQPSLPKEDESEKSYENV
DSGDKEKKQITTSPITVRKNKKDEERRESRIQSYSPQAFKFFMEQHVENVLKSHQQRLHR
KKQLENEMMRVGLSQDAQDQMRKMLCQKESNYIRLKRAKMDKSMFVKIKTLGIGAFGEVC
LARKVDTKALYATKTLRKKDVLLRNQVAHVKAERDILAEADNEWVVRLYYSFQDKDNLYF
VMDYIPGGDMMSLLIRMGIFPESLARFYIAELTCAVESVHKMGFIHRDIKPDNILIDRDG
HIKLTDFGLCTGFRWTHDSKYYQSGDHPRQDSMDFSNEWGDPSSCRCGDRLKPLERRAAR
QHQRCLAHSLVGTPNYIAPEVLLRTGYTQLCDWWSVGVILFEMLVGQPPFLAQTPLETQM
KVINWQTSLHIPPQAKLSPEASDLIIKLCRGPEDRLGKNGADEIKAHPFFKTIDFSSDLR
QQSASYIPKITHPTDTSNFDPVDPDKLWSDDNEEENVNDTLNGWYKNGKHPEHAFYEFTF
RRFFDDNGYPYNYPKPIEYEYINSQGSEQQSDEDDQNTGSEIKNRDLVYV",LATS1,-,-,1130aa(1-1130),O95835,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1421,http://db.phasep.pro/browse/","[1-68],[149-276],[294-321],[365-405],[432-484],[515-601],[1104-1130]","[228-267],[301-314],[434-447],[483-494],[555-560],[1104-1116]",In vitro,100 nM [SNHG9-as];|0.01-2µM[LATS1-GFP],"15 mM NaCl, 130 mM KCl, 5 mM KH2PO4, 1.5 mM MgCl2","20 mM Tris-HCl, pH 7.5",25˚C,2 h,other_molecular:1 mg/mL BSA,Fluorescence microscopy,"solute, liquid","Droplet formation was observed when the protein concentration of LATS1-GFP was 0.1 µM in the presence of SNHG9-sense, while no droplet formed at the same protein concentration in the presence of SNHG9-antisense or in the absence of RNA"
698,PMID: 34267352,RNAPS0000625,https://pubmed.ncbi.nlm.nih.gov/34267352,RNA + protein,NCBI ID:735301,https://www.ncbi.nlm.nih.gov/gene/735301,SNHG9,345nt(1-345),GCGGCCCGGGAAUCUACGUCACCCGAAAAGCGACUAUAAACGCCGGCGCCUCCGUCCCCAGCCGCGGCUCGGGAAUCCACCCGAAGAGUGGCUAUAAACGUCCGCGCCUCCAUUGCGCUCUCCUCUUCACUUAGGACACUGGUCCUCCCACGCCUGACACCGACGUCGCCAGGACCGCGGGGUUGGGGGAACUUGGCUGUCCCACGUCUUUCAAAUAAAGCUGUUUUGUCUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,lncRNA,Homo sapiens,"sp|O95835|LATS1_HUMAN Serine/threonine-protein kinase LATS1 OS=Homo sapiens OX=9606 GN=LATS1 PE=1 SV=1
MKRSEKPEGYRQMRPKTFPASNYTVSSRQMLQEIRESLRNLSKPSDAAKAEHNMSKMSTE
DPRQVRNPPKFGTHHKALQEIRNSLLPFANETNSSRSTSEVNPQMLQDLQAAGFDEDMVI
QALQKTNNRSIEAAIEFISKMSYQDPRREQMAAAAARPINASMKPGNVQQSVNRKQSWKG
SKESLVPQRHGPPLGESVAYHSESPNSQTDVGRPLSGSGISAFVQAHPSNGQRVNPPPPP
QVRSVTPPPPPRGQTPPPRGTTPPPPSWEPNSQTKRYSGNMEYVISRISPVPPGAWQEGY
PPPPLNTSPMNPPNQGQRGISSVPVGRQPIIMQSSSKFNFPSGRPGMQNGTGQTDFMIHQ
NVVPAGTVNRQPPPPYPLTAANGQSPSALQTGGSAAPSSYTNGSIPQSMMVPNRNSHNME
LYNISVPGLQTNWPQSSSAPAQSSPSSGHEIPTWQPNIPVRSNSFNNPLGNRASHSANSQ
PSATTVTAITPAPIQQPVKSMRVLKPELQTALAPTHPSWIPQPIQTVQPSPFPEGTASNV
TVMPPVAEAPNYQGPPPPYPKHLLHQNPSVPPYESISKPSKEDQPSLPKEDESEKSYENV
DSGDKEKKQITTSPITVRKNKKDEERRESRIQSYSPQAFKFFMEQHVENVLKSHQQRLHR
KKQLENEMMRVGLSQDAQDQMRKMLCQKESNYIRLKRAKMDKSMFVKIKTLGIGAFGEVC
LARKVDTKALYATKTLRKKDVLLRNQVAHVKAERDILAEADNEWVVRLYYSFQDKDNLYF
VMDYIPGGDMMSLLIRMGIFPESLARFYIAELTCAVESVHKMGFIHRDIKPDNILIDRDG
HIKLTDFGLCTGFRWTHDSKYYQSGDHPRQDSMDFSNEWGDPSSCRCGDRLKPLERRAAR
QHQRCLAHSLVGTPNYIAPEVLLRTGYTQLCDWWSVGVILFEMLVGQPPFLAQTPLETQM
KVINWQTSLHIPPQAKLSPEASDLIIKLCRGPEDRLGKNGADEIKAHPFFKTIDFSSDLR
QQSASYIPKITHPTDTSNFDPVDPDKLWSDDNEEENVNDTLNGWYKNGKHPEHAFYEFTF
RRFFDDNGYPYNYPKPIEYEYINSQGSEQQSDEDDQNTGSEIKNRDLVYV",LATS1,-,-,1130aa(1-1130),O95835,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1421,http://db.phasep.pro/browse/","[1-68],[149-276],[294-321],[365-405],[432-484],[515-601],[1104-1130]","[228-267],[301-314],[434-447],[483-494],[555-560],[1104-1116]",In vitro,0-2nM[SNHG9];|2-8µM[LATS1-GFP],"15 mM NaCl, 130 mM KCl, 5 mM KH2PO4, 1.5 mM MgCl2","20 mM Tris-HCl, pH 7.5",25˚C,2 h,other_molecular:1 mg/mL BSA,Fluorescence microscopy,liquid,"Additionally, our orthogonal experiment suggested that LATS1 underwent phase separation in a dosedependent manner with additional SNHG9"
699,PMID: 34239064,RNAPS0000450,https://pubmed.ncbi.nlm.nih.gov/34239064,RNA + protein,-,-,SARS-CoV-2 virus RNA,29903nt(1-29903),AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGCACCUCAUGGUCAUGUUAUGGUUGAGCUGGUAGCAGAACUCGAAGGCAUUCAGUACGGUCGUAGUGGUGAGACACUUGGUGUCCUUGUCCCUCAUGUGGGCGAAAUACCAGUGGCUUACCGCAAGGUUCUUCUUCGUAAGAACGGUAAUAAAGGAGCUGGUGGCCAUAGUUACGGCGCCGAUCUAAAGUCAUUUGACUUAGGCGACGAGCUUGGCACUGAUCCUUAUGAAGAUUUUCAAGAAAACUGGAACACUAAACAUAGCAGUGGUGUUACCCGUGAACUCAUGCGUGAGCUUAACGGAGGGGCAUACACUCGCUAUGUCGAUAACAACUUCUGUGGCCCUGAUGGCUACCCUCUUGAGUGCAUUAAAGACCUUCUAGCACGUGCUGGUAAAGCUUCAUGCACUUUGUCCGAACAACUGGACUUUAUUGACACUAAGAGGGGUGUAUACUGCUGCCGUGAACAUGAGCAUGAAAUUGCUUGGUACACGGAACGUUCUGAAAAGAGCUAUGAAUUGCAGACACCUUUUGAAAUUAAAUUGGCAAAGAAAUUUGACACCUUCAAUGGGGAAUGUCCAAAUUUUGUAUUUCCCUUAAAUUCCAUAAUCAAGACUAUUCAACCAAGGGUUGAAAAGAAAAAGCUUGAUGGCUUUAUGGGUAGAAUUCGAUCUGUCUAUCCAGUUGCGUCACCAAAUGAAUGCAACCAAAUGUGCCUUUCAACUCUCAUGAAGUGUGAUCAUUGUGGUGAAACUUCAUGGCAGACGGGCGAUUUUGUUAAAGCCACUUGCGAAUUUUGUGGCACUGAGAAUUUGACUAAAGAAGGUGCCACUACUUGUGGUUACUUACCCCAAAAUGCUGUUGUUAAAAUUUAUUGUCCAGCAUGUCACAAUUCAGAAGUAGGACCUGAGCAUAGUCUUGCCGAAUACCAUAAUGAAUCUGGCUUGAAAACCAUUCUUCGUAAGGGUGGUCGCACUAUUGCCUUUGGAGGCUGUGUGUUCUCUUAUGUUGGUUGCCAUAACAAGUGUGCCUAUUGGGUUCCACGUGCUAGCGCUAACAUAGGUUGUAACCAUACAGGUGUUGUUGGAGAAGGUUCCGAAGGUCUUAAUGACAACCUUCUUGAAAUACUCCAAAAAGAGAAAGUCAACAUCAAUAUUGUUGGUGACUUUAAACUUAAUGAAGAGAUCGCCAUUAUUUUGGCAUCUUUUUCUGCUUCCACAAGUGCUUUUGUGGAAACUGUGAAAGGUUUGGAUUAUAAAGCAUUCAAACAAAUUGUUGAAUCCUGUGGUAAUUUUAAAGUUACAAAAGGAAAAGCUAAAAAAGGUGCCUGGAAUAUUGGUGAACAGAAAUCAAUACUGAGUCCUCUUUAUGCAUUUGCAUCAGAGGCUGCUCGUGUUGUACGAUCAAUUUUCUCCCGCACUCUUGAAACUGCUCAAAAUUCUGUGCGUGUUUUACAGAAGGCCGCUAUAACAAUACUAGAUGGAAUUUCACAGUAUUCACUGAGACUCAUUGAUGCUAUGAUGUUCACAUCUGAUUUGGCUACUAACAAUCUAGUUGUAAUGGCCUACAUUACAGGUGGUGUUGUUCAGUUGACUUCGCAGUGGCUAACUAACAUCUUUGGCACUGUUUAUGAAAAACUCAAACCCGUCCUUGAUUGGCUUGAAGAGAAGUUUAAGGAAGGUGUAGAGUUUCUUAGAGACGGUUGGGAAAUUGUUAAAUUUAUCUCAACCUGUGCUUGUGAAAUUGUCGGUGGACAAAUUGUCACCUGUGCAAAGGAAAUUAAGGAGAGUGUUCAGACAUUCUUUAAGCUUGUAAAUAAAUUUUUGGCUUUGUGUGCUGACUCUAUCAUUAUUGGUGGAGCUAAACUUAAAGCCUUGAAUUUAGGUGAAACAUUUGUCACGCACUCAAAGGGAUUGUACAGAAAGUGUGUUAAAUCCAGAGAAGAAACUGGCCUACUCAUGCCUCUAAAAGCCCCAAAAGAAAUUAUCUUCUUAGAGGGAGAAACACUUCCCACAGAAGUGUUAACAGAGGAAGUUGUCUUGAAAACUGGUGAUUUACAACCAUUAGAACAACCUACUAGUGAAGCUGUUGAAGCUCCAUUGGUUGGUACACCAGUUUGUAUUAACGGGCUUAUGUUGCUCGAAAUCAAAGACACAGAAAAGUACUGUGCCCUUGCACCUAAUAUGAUGGUAACAAACAAUACCUUCACACUCAAAGGCGGUGCACCAACAAAGGUUACUUUUGGUGAUGACACUGUGAUAGAAGUGCAAGGUUACAAGAGUGUGAAUAUCACUUUUGAACUUGAUGAAAGGAUUGAUAAAGUACUUAAUGAGAAGUGCUCUGCCUAUACAGUUGAACUCGGUACAGAAGUAAAUGAGUUCGCCUGUGUUGUGGCAGAUGCUGUCAUAAAAACUUUGCAACCAGUAUCUGAAUUACUUACACCACUGGGCAUUGAUUUAGAUGAGUGGAGUAUGGCUACAUACUACUUAUUUGAUGAGUCUGGUGAGUUUAAAUUGGCUUCACAUAUGUAUUGUUCUUUCUACCCUCCAGAUGAGGAUGAAGAAGAAGGUGAUUGUGAAGAAGAAGAGUUUGAGCCAUCAACUCAAUAUGAGUAUGGUACUGAAGAUGAUUACCAAGGUAAACCUUUGGAAUUUGGUGCCACUUCUGCUGCUCUUCAACCUGAAGAAGAGCAAGAAGAAGAUUGGUUAGAUGAUGAUAGUCAACAAACUGUUGGUCAACAAGACGGCAGUGAGGACAAUCAGACAACUACUAUUCAAACAAUUGUUGAGGUUCAACCUCAAUUAGAGAUGGAACUUACACCAGUUGUUCAGACUAUUGAAGUGAAUAGUUUUAGUGGUUAUUUAAAACUUACUGACAAUGUAUACAUUAAAAAUGCAGACAUUGUGGAAGAAGCUAAAAAGGUAAAACCAACAGUGGUUGUUAAUGCAGCCAAUGUUUACCUUAAACAUGGAGGAGGUGUUGCAGGAGCCUUAAAUAAGGCUACUAACAAUGCCAUGCAAGUUGAAUCUGAUGAUUACAUAGCUACUAAUGGACCACUUAAAGUGGGUGGUAGUUGUGUUUUAAGCGGACACAAUCUUGCUAAACACUGUCUUCAUGUUGUCGGCCCAAAUGUUAACAAAGGUGAAGACAUUCAACUUCUUAAGAGUGCUUAUGAAAAUUUUAAUCAGCACGAAGUUCUACUUGCACCAUUAUUAUCAGCUGGUAUUUUUGGUGCUGACCCUAUACAUUCUUUAAGAGUUUGUGUAGAUACUGUUCGCACAAAUGUCUACUUAGCUGUCUUUGAUAAAAAUCUCUAUGACAAACUUGUUUCAAGCUUUUUGGAAAUGAAGAGUGAAAAGCAAGUUGAACAAAAGAUCGCUGAGAUUCCUAAAGAGGAAGUUAAGCCAUUUAUAACUGAAAGUAAACCUUCAGUUGAACAGAGAAAACAAGAUGAUAAGAAAAUCAAAGCUUGUGUUGAAGAAGUUACAACAACUCUGGAAGAAACUAAGUUCCUCACAGAAAACUUGUUACUUUAUAUUGACAUUAAUGGCAAUCUUCAUCCAGAUUCUGCCACUCUUGUUAGUGACAUUGACAUCACUUUCUUAAAGAAAGAUGCUCCAUAUAUAGUGGGUGAUGUUGUUCAAGAGGGUGUUUUAACUGCUGUGGUUAUACCUACUAAAAAGGCUGGUGGCACUACUGAAAUGCUAGCGAAAGCUUUGAGAAAAGUGCCAACAGACAAUUAUAUAACCACUUACCCGGGUCAGGGUUUAAAUGGUUACACUGUAGAGGAGGCAAAGACAGUGCUUAAAAAGUGUAAAAGUGCCUUUUACAUUCUACCAUCUAUUAUCUCUAAUGAGAAGCAAGAAAUUCUUGGAACUGUUUCUUGGAAUUUGCGAGAAAUGCUUGCACAUGCAGAAGAAACACGCAAAUUAAUGCCUGUCUGUGUGGAAACUAAAGCCAUAGUUUCAACUAUACAGCGUAAAUAUAAGGGUAUUAAAAUACAAGAGGGUGUGGUUGAUUAUGGUGCUAGAUUUUACUUUUACACCAGUAAAACAACUGUAGCGUCACUUAUCAACACACUUAACGAUCUAAAUGAAACUCUUGUUACAAUGCCACUUGGCUAUGUAACACAUGGCUUAAAUUUGGAAGAAGCUGCUCGGUAUAUGAGAUCUCUCAAAGUGCCAGCUACAGUUUCUGUUUCUUCACCUGAUGCUGUUACAGCGUAUAAUGGUUAUCUUACUUCUUCUUCUAAAACACCUGAAGAACAUUUUAUUGAAACCAUCUCACUUGCUGGUUCCUAUAAAGAUUGGUCCUAUUCUGGACAAUCUACACAACUAGGUAUAGAAUUUCUUAAGAGAGGUGAUAAAAGUGUAUAUUACACUAGUAAUCCUACCACAUUCCACCUAGAUGGUGAAGUUAUCACCUUUGACAAUCUUAAGACACUUCUUUCUUUGAGAGAAGUGAGGACUAUUAAGGUGUUUACAACAGUAGACAACAUUAACCUCCACACGCAAGUUGUGGACAUGUCAAUGACAUAUGGACAACAGUUUGGUCCAACUUAUUUGGAUGGAGCUGAUGUUACUAAAAUAAAACCUCAUAAUUCACAUGAAGGUAAAACAUUUUAUGUUUUACCUAAUGAUGACACUCUACGUGUUGAGGCUUUUGAGUACUACCACACAACUGAUCCUAGUUUUCUGGGUAGGUACAUGUCAGCAUUAAAUCACACUAAAAAGUGGAAAUACCCACAAGUUAAUGGUUUAACUUCUAUUAAAUGGGCAGAUAACAACUGUUAUCUUGCCACUGCAUUGUUAACACUCCAACAAAUAGAGUUGAAGUUUAAUCCACCUGCUCUACAAGAUGCUUAUUACAGAGCAAGGGCUGGUGAAGCUGCUAACUUUUGUGCACUUAUCUUAGCCUACUGUAAUAAGACAGUAGGUGAGUUAGGUGAUGUUAGAGAAACAAUGAGUUACUUGUUUCAACAUGCCAAUUUAGAUUCUUGCAAAAGAGUCUUGAACGUGGUGUGUAAAACUUGUGGACAACAGCAGACAACCCUUAAGGGUGUAGAAGCUGUUAUGUACAUGGGCACACUUUCUUAUGAACAAUUUAAGAAAGGUGUUCAGAUACCUUGUACGUGUGGUAAACAAGCUACAAAAUAUCUAGUACAACAGGAGUCACCUUUUGUUAUGAUGUCAGCACCACCUGCUCAGUAUGAACUUAAGCAUGGUACAUUUACUUGUGCUAGUGAGUACACUGGUAAUUACCAGUGUGGUCACUAUAAACAUAUAACUUCUAAAGAAACUUUGUAUUGCAUAGACGGUGCUUUACUUACAAAGUCCUCAGAAUACAAAGGUCCUAUUACGGAUGUUUUCUACAAAGAAAACAGUUACACAACAACCAUAAAACCAGUUACUUAUAAAUUGGAUGGUGUUGUUUGUACAGAAAUUGACCCUAAGUUGGACAAUUAUUAUAAGAAAGACAAUUCUUAUUUCACAGAGCAACCAAUUGAUCUUGUACCAAACCAACCAUAUCCAAACGCAAGCUUCGAUAAUUUUAAGUUUGUAUGUGAUAAUAUCAAAUUUGCUGAUGAUUUAAACCAGUUAACUGGUUAUAAGAAACCUGCUUCAAGAGAGCUUAAAGUUACAUUUUUCCCUGACUUAAAUGGUGAUGUGGUGGCUAUUGAUUAUAAACACUACACACCCUCUUUUAAGAAAGGAGCUAAAUUGUUACAUAAACCUAUUGUUUGGCAUGUUAACAAUGCAACUAAUAAAGCCACGUAUAAACCAAAUACCUGGUGUAUACGUUGUCUUUGGAGCACAAAACCAGUUGAAACAUCAAAUUCGUUUGAUGUACUGAAGUCAGAGGACGCGCAGGGAAUGGAUAAUCUUGCCUGCGAAGAUCUAAAACCAGUCUCUGAAGAAGUAGUGGAAAAUCCUACCAUACAGAAAGACGUUCUUGAGUGUAAUGUGAAAACUACCGAAGUUGUAGGAGACAUUAUACUUAAACCAGCAAAUAAUAGUUUAAAAAUUACAGAAGAGGUUGGCCACACAGAUCUAAUGGCUGCUUAUGUAGACAAUUCUAGUCUUACUAUUAAGAAACCUAAUGAAUUAUCUAGAGUAUUAGGUUUGAAAACCCUUGCUACUCAUGGUUUAGCUGCUGUUAAUAGUGUCCCUUGGGAUACUAUAGCUAAUUAUGCUAAGCCUUUUCUUAACAAAGUUGUUAGUACAACUACUAACAUAGUUACACGGUGUUUAAACCGUGUUUGUACUAAUUAUAUGCCUUAUUUCUUUACUUUAUUGCUACAAUUGUGUACUUUUACUAGAAGUACAAAUUCUAGAAUUAAAGCAUCUAUGCCGACUACUAUAGCAAAGAAUACUGUUAAGAGUGUCGGUAAAUUUUGUCUAGAGGCUUCAUUUAAUUAUUUGAAGUCACCUAAUUUUUCUAAACUGAUAAAUAUUAUAAUUUGGUUUUUACUAUUAAGUGUUUGCCUAGGUUCUUUAAUCUACUCAACCGCUGCUUUAGGUGUUUUAAUGUCUAAUUUAGGCAUGCCUUCUUACUGUACUGGUUACAGAGAAGGCUAUUUGAACUCUACUAAUGUCACUAUUGCAACCUACUGUACUGGUUCUAUACCUUGUAGUGUUUGUCUUAGUGGUUUAGAUUCUUUAGACACCUAUCCUUCUUUAGAAACUAUACAAAUUACCAUUUCAUCUUUUAAAUGGGAUUUAACUGCUUUUGGCUUAGUUGCAGAGUGGUUUUUGGCAUAUAUUCUUUUCACUAGGUUUUUCUAUGUACUUGGAUUGGCUGCAAUCAUGCAAUUGUUUUUCAGCUAUUUUGCAGUACAUUUUAUUAGUAAUUCUUGGCUUAUGUGGUUAAUAAUUAAUCUUGUACAAAUGGCCCCGAUUUCAGCUAUGGUUAGAAUGUACAUCUUCUUUGCAUCAUUUUAUUAUGUAUGGAAAAGUUAUGUGCAUGUUGUAGACGGUUGUAAUUCAUCAACUUGUAUGAUGUGUUACAAACGUAAUAGAGCAACAAGAGUCGAAUGUACAACUAUUGUUAAUGGUGUUAGAAGGUCCUUUUAUGUCUAUGCUAAUGGAGGUAAAGGCUUUUGCAAACUACACAAUUGGAAUUGUGUUAAUUGUGAUACAUUCUGUGCUGGUAGUACAUUUAUUAGUGAUGAAGUUGCGAGAGACUUGUCACUACAGUUUAAAAGACCAAUAAAUCCUACUGACCAGUCUUCUUACAUCGUUGAUAGUGUUACAGUGAAGAAUGGUUCCAUCCAUCUUUACUUUGAUAAAGCUGGUCAAAAGACUUAUGAAAGACAUUCUCUCUCUCAUUUUGUUAACUUAGACAACCUGAGAGCUAAUAACACUAAAGGUUCAUUGCCUAUUAAUGUUAUAGUUUUUGAUGGUAAAUCAAAAUGUGAAGAAUCAUCUGCAAAAUCAGCGUCUGUUUACUACAGUCAGCUUAUGUGUCAACCUAUACUGUUACUAGAUCAGGCAUUAGUGUCUGAUGUUGGUGAUAGUGCGGAAGUUGCAGUUAAAAUGUUUGAUGCUUACGUUAAUACGUUUUCAUCAACUUUUAACGUACCAAUGGAAAAACUCAAAACACUAGUUGCAACUGCAGAAGCUGAACUUGCAAAGAAUGUGUCCUUAGACAAUGUCUUAUCUACUUUUAUUUCAGCAGCUCGGCAAGGGUUUGUUGAUUCAGAUGUAGAAACUAAAGAUGUUGUUGAAUGUCUUAAAUUGUCACAUCAAUCUGACAUAGAAGUUACUGGCGAUAGUUGUAAUAACUAUAUGCUCACCUAUAACAAAGUUGAAAACAUGACACCCCGUGACCUUGGUGCUUGUAUUGACUGUAGUGCGCGUCAUAUUAAUGCGCAGGUAGCAAAAAGUCACAACAUUGCUUUGAUAUGGAACGUUAAAGAUUUCAUGUCAUUGUCUGAACAACUACGAAAACAAAUACGUAGUGCUGCUAAAAAGAAUAACUUACCUUUUAAGUUGACAUGUGCAACUACUAGACAAGUUGUUAAUGUUGUAACAACAAAGAUAGCACUUAAGGGUGGUAAAAUUGUUAAUAAUUGGUUGAAGCAGUUAAUUAAAGUUACACUUGUGUUCCUUUUUGUUGCUGCUAUUUUCUAUUUAAUAACACCUGUUCAUGUCAUGUCUAAACAUACUGACUUUUCAAGUGAAAUCAUAGGAUACAAGGCUAUUGAUGGUGGUGUCACUCGUGACAUAGCAUCUACAGAUACUUGUUUUGCUAACAAACAUGCUGAUUUUGACACAUGGUUUAGCCAGCGUGGUGGUAGUUAUACUAAUGACAAAGCUUGCCCAUUGAUUGCUGCAGUCAUAACAAGAGAAGUGGGUUUUGUCGUGCCUGGUUUGCCUGGCACGAUAUUACGCACAACUAAUGGUGACUUUUUGCAUUUCUUACCUAGAGUUUUUAGUGCAGUUGGUAACAUCUGUUACACACCAUCAAAACUUAUAGAGUACACUGACUUUGCAACAUCAGCUUGUGUUUUGGCUGCUGAAUGUACAAUUUUUAAAGAUGCUUCUGGUAAGCCAGUACCAUAUUGUUAUGAUACCAAUGUACUAGAAGGUUCUGUUGCUUAUGAAAGUUUACGCCCUGACACACGUUAUGUGCUCAUGGAUGGCUCUAUUAUUCAAUUUCCUAACACCUACCUUGAAGGUUCUGUUAGAGUGGUAACAACUUUUGAUUCUGAGUACUGUAGGCACGGCACUUGUGAAAGAUCAGAAGCUGGUGUUUGUGUAUCUACUAGUGGUAGAUGGGUACUUAACAAUGAUUAUUACAGAUCUUUACCAGGAGUUUUCUGUGGUGUAGAUGCUGUAAAUUUACUUACUAAUAUGUUUACACCACUAAUUCAACCUAUUGGUGCUUUGGACAUAUCAGCAUCUAUAGUAGCUGGUGGUAUUGUAGCUAUCGUAGUAACAUGCCUUGCCUACUAUUUUAUGAGGUUUAGAAGAGCUUUUGGUGAAUACAGUCAUGUAGUUGCCUUUAAUACUUUACUAUUCCUUAUGUCAUUCACUGUACUCUGUUUAACACCAGUUUACUCAUUCUUACCUGGUGUUUAUUCUGUUAUUUACUUGUACUUGACAUUUUAUCUUACUAAUGAUGUUUCUUUUUUAGCACAUAUUCAGUGGAUGGUUAUGUUCACACCUUUAGUACCUUUCUGGAUAACAAUUGCUUAUAUCAUUUGUAUUUCCACAAAGCAUUUCUAUUGGUUCUUUAGUAAUUACCUAAAGAGACGUGUAGUCUUUAAUGGUGUUUCCUUUAGUACUUUUGAAGAAGCUGCGCUGUGCACCUUUUUGUUAAAUAAAGAAAUGUAUCUAAAGUUGCGUAGUGAUGUGCUAUUACCUCUUACGCAAUAUAAUAGAUACUUAGCUCUUUAUAAUAAGUACAAGUAUUUUAGUGGAGCAAUGGAUACAACUAGCUACAGAGAAGCUGCUUGUUGUCAUCUCGCAAAGGCUCUCAAUGACUUCAGUAACUCAGGUUCUGAUGUUCUUUACCAACCACCACAAACCUCUAUCACCUCAGCUGUUUUGCAGAGUGGUUUUAGAAAAAUGGCAUUCCCAUCUGGUAAAGUUGAGGGUUGUAUGGUACAAGUAACUUGUGGUACAACUACACUUAACGGUCUUUGGCUUGAUGACGUAGUUUACUGUCCAAGACAUGUGAUCUGCACCUCUGAAGACAUGCUUAACCCUAAUUAUGAAGAUUUACUCAUUCGUAAGUCUAAUCAUAAUUUCUUGGUACAGGCUGGUAAUGUUCAACUCAGGGUUAUUGGACAUUCUAUGCAAAAUUGUGUACUUAAGCUUAAGGUUGAUACAGCCAAUCCUAAGACACCUAAGUAUAAGUUUGUUCGCAUUCAACCAGGACAGACUUUUUCAGUGUUAGCUUGUUACAAUGGUUCACCAUCUGGUGUUUACCAAUGUGCUAUGAGGCCCAAUUUCACUAUUAAGGGUUCAUUCCUUAAUGGUUCAUGUGGUAGUGUUGGUUUUAACAUAGAUUAUGACUGUGUCUCUUUUUGUUACAUGCACCAUAUGGAAUUACCAACUGGAGUUCAUGCUGGCACAGACUUAGAAGGUAACUUUUAUGGACCUUUUGUUGACAGGCAAACAGCACAAGCAGCUGGUACGGACACAACUAUUACAGUUAAUGUUUUAGCUUGGUUGUACGCUGCUGUUAUAAAUGGAGACAGGUGGUUUCUCAAUCGAUUUACCACAACUCUUAAUGACUUUAACCUUGUGGCUAUGAAGUACAAUUAUGAACCUCUAACACAAGACCAUGUUGACAUACUAGGACCUCUUUCUGCUCAAACUGGAAUUGCCGUUUUAGAUAUGUGUGCUUCAUUAAAAGAAUUACUGCAAAAUGGUAUGAAUGGACGUACCAUAUUGGGUAGUGCUUUAUUAGAAGAUGAAUUUACACCUUUUGAUGUUGUUAGACAAUGCUCAGGUGUUACUUUCCAAAGUGCAGUGAAAAGAACAAUCAAGGGUACACACCACUGGUUGUUACUCACAAUUUUGACUUCACUUUUAGUUUUAGUCCAGAGUACUCAAUGGUCUUUGUUCUUUUUUUUGUAUGAAAAUGCCUUUUUACCUUUUGCUAUGGGUAUUAUUGCUAUGUCUGCUUUUGCAAUGAUGUUUGUCAAACAUAAGCAUGCAUUUCUCUGUUUGUUUUUGUUACCUUCUCUUGCCACUGUAGCUUAUUUUAAUAUGGUCUAUAUGCCUGCUAGUUGGGUGAUGCGUAUUAUGACAUGGUUGGAUAUGGUUGAUACUAGUUUGUCUGGUUUUAAGCUAAAAGACUGUGUUAUGUAUGCAUCAGCUGUAGUGUUACUAAUCCUUAUGACAGCAAGAACUGUGUAUGAUGAUGGUGCUAGGAGAGUGUGGACACUUAUGAAUGUCUUGACACUCGUUUAUAAAGUUUAUUAUGGUAAUGCUUUAGAUCAAGCCAUUUCCAUGUGGGCUCUUAUAAUCUCUGUUACUUCUAACUACUCAGGUGUAGUUACAACUGUCAUGUUUUUGGCCAGAGGUAUUGUUUUUAUGUGUGUUGAGUAUUGCCCUAUUUUCUUCAUAACUGGUAAUACACUUCAGUGUAUAAUGCUAGUUUAUUGUUUCUUAGGCUAUUUUUGUACUUGUUACUUUGGCCUCUUUUGUUUACUCAACCGCUACUUUAGACUGACUCUUGGUGUUUAUGAUUACUUAGUUUCUACACAGGAGUUUAGAUAUAUGAAUUCACAGGGACUACUCCCACCCAAGAAUAGCAUAGAUGCCUUCAAACUCAACAUUAAAUUGUUGGGUGUUGGUGGCAAACCUUGUAUCAAAGUAGCCACUGUACAGUCUAAAAUGUCAGAUGUAAAGUGCACAUCAGUAGUCUUACUCUCAGUUUUGCAACAACUCAGAGUAGAAUCAUCAUCUAAAUUGUGGGCUCAAUGUGUCCAGUUACACAAUGACAUUCUCUUAGCUAAAGAUACUACUGAAGCCUUUGAAAAAAUGGUUUCACUACUUUCUGUUUUGCUUUCCAUGCAGGGUGCUGUAGACAUAAACAAGCUUUGUGAAGAAAUGCUGGACAACAGGGCAACCUUACAAGCUAUAGCCUCAGAGUUUAGUUCCCUUCCAUCAUAUGCAGCUUUUGCUACUGCUCAAGAAGCUUAUGAGCAGGCUGUUGCUAAUGGUGAUUCUGAAGUUGUUCUUAAAAAGUUGAAGAAGUCUUUGAAUGUGGCUAAAUCUGAAUUUGACCGUGAUGCAGCCAUGCAACGUAAGUUGGAAAAGAUGGCUGAUCAAGCUAUGACCCAAAUGUAUAAACAGGCUAGAUCUGAGGACAAGAGGGCAAAAGUUACUAGUGCUAUGCAGACAAUGCUUUUCACUAUGCUUAGAAAGUUGGAUAAUGAUGCACUCAACAACAUUAUCAACAAUGCAAGAGAUGGUUGUGUUCCCUUGAACAUAAUACCUCUUACAACAGCAGCCAAACUAAUGGUUGUCAUACCAGACUAUAACACAUAUAAAAAUACGUGUGAUGGUACAACAUUUACUUAUGCAUCAGCAUUGUGGGAAAUCCAACAGGUUGUAGAUGCAGAUAGUAAAAUUGUUCAACUUAGUGAAAUUAGUAUGGACAAUUCACCUAAUUUAGCAUGGCCUCUUAUUGUAACAGCUUUAAGGGCCAAUUCUGCUGUCAAAUUACAGAAUAAUGAGCUUAGUCCUGUUGCACUACGACAGAUGUCUUGUGCUGCCGGUACUACACAAACUGCUUGCACUGAUGACAAUGCGUUAGCUUACUACAACACAACAAAGGGAGGUAGGUUUGUACUUGCACUGUUAUCCGAUUUACAGGAUUUGAAAUGGGCUAGAUUCCCUAAGAGUGAUGGAACUGGUACUAUCUAUACAGAACUGGAACCACCUUGUAGGUUUGUUACAGACACACCUAAAGGUCCUAAAGUGAAGUAUUUAUACUUUAUUAAAGGAUUAAACAACCUAAAUAGAGGUAUGGUACUUGGUAGUUUAGCUGCCACAGUACGUCUACAAGCUGGUAAUGCAACAGAAGUGCCUGCCAAUUCAACUGUAUUAUCUUUCUGUGCUUUUGCUGUAGAUGCUGCUAAAGCUUACAAAGAUUAUCUAGCUAGUGGGGGACAACCAAUCACUAAUUGUGUUAAGAUGUUGUGUACACACACUGGUACUGGUCAGGCAAUAACAGUUACACCGGAAGCCAAUAUGGAUCAAGAAUCCUUUGGUGGUGCAUCGUGUUGUCUGUACUGCCGUUGCCACAUAGAUCAUCCAAAUCCUAAAGGAUUUUGUGACUUAAAAGGUAAGUAUGUACAAAUACCUACAACUUGUGCUAAUGACCCUGUGGGUUUUACACUUAAAAACACAGUCUGUACCGUCUGCGGUAUGUGGAAAGGUUAUGGCUGUAGUUGUGAUCAACUCCGCGAACCCAUGCUUCAGUCAGCUGAUGCACAAUCGUUUUUAAACGGGUUUGCGGUGUAAGUGCAGCCCGUCUUACACCGUGCGGCACAGGCACUAGUACUGAUGUCGUAUACAGGGCUUUUGACAUCUACAAUGAUAAAGUAGCUGGUUUUGCUAAAUUCCUAAAAACUAAUUGUUGUCGCUUCCAAGAAAAGGACGAAGAUGACAAUUUAAUUGAUUCUUACUUUGUAGUUAAGAGACACACUUUCUCUAACUACCAACAUGAAGAAACAAUUUAUAAUUUACUUAAGGAUUGUCCAGCUGUUGCUAAACAUGACUUCUUUAAGUUUAGAAUAGACGGUGACAUGGUACCACAUAUAUCACGUCAACGUCUUACUAAAUACACAAUGGCAGACCUCGUCUAUGCUUUAAGGCAUUUUGAUGAAGGUAAUUGUGACACAUUAAAAGAAAUACUUGUCACAUACAAUUGUUGUGAUGAUGAUUAUUUCAAUAAAAAGGACUGGUAUGAUUUUGUAGAAAACCCAGAUAUAUUACGCGUAUACGCCAACUUAGGUGAACGUGUACGCCAAGCUUUGUUAAAAACAGUACAAUUCUGUGAUGCCAUGCGAAAUGCUGGUAUUGUUGGUGUACUGACAUUAGAUAAUCAAGAUCUCAAUGGUAACUGGUAUGAUUUCGGUGAUUUCAUACAAACCACGCCAGGUAGUGGAGUUCCUGUUGUAGAUUCUUAUUAUUCAUUGUUAAUGCCUAUAUUAACCUUGACCAGGGCUUUAACUGCAGAGUCACAUGUUGACACUGACUUAACAAAGCCUUACAUUAAGUGGGAUUUGUUAAAAUAUGACUUCACGGAAGAGAGGUUAAAACUCUUUGACCGUUAUUUUAAAUAUUGGGAUCAGACAUACCACCCAAAUUGUGUUAACUGUUUGGAUGACAGAUGCAUUCUGCAUUGUGCAAACUUUAAUGUUUUAUUCUCUACAGUGUUCCCACCUACAAGUUUUGGACCACUAGUGAGAAAAAUAUUUGUUGAUGGUGUUCCAUUUGUAGUUUCAACUGGAUACCACUUCAGAGAGCUAGGUGUUGUACAUAAUCAGGAUGUAAACUUACAUAGCUCUAGACUUAGUUUUAAGGAAUUACUUGUGUAUGCUGCUGACCCUGCUAUGCACGCUGCUUCUGGUAAUCUAUUACUAGAUAAACGCACUACGUGCUUUUCAGUAGCUGCACUUACUAACAAUGUUGCUUUUCAAACUGUCAAACCCGGUAAUUUUAACAAAGACUUCUAUGACUUUGCUGUGUCUAAGGGUUUCUUUAAGGAAGGAAGUUCUGUUGAAUUAAAACACUUCUUCUUUGCUCAGGAUGGUAAUGCUGCUAUCAGCGAUUAUGACUACUAUCGUUAUAAUCUACCAACAAUGUGUGAUAUCAGACAACUACUAUUUGUAGUUGAAGUUGUUGAUAAGUACUUUGAUUGUUACGAUGGUGGCUGUAUUAAUGCUAACCAAGUCAUCGUCAACAACCUAGACAAAUCAGCUGGUUUUCCAUUUAAUAAAUGGGGUAAGGCUAGACUUUAUUAUGAUUCAAUGAGUUAUGAGGAUCAAGAUGCACUUUUCGCAUAUACAAAACGUAAUGUCAUCCCUACUAUAACUCAAAUGAAUCUUAAGUAUGCCAUUAGUGCAAAGAAUAGAGCUCGCACCGUAGCUGGUGUCUCUAUCUGUAGUACUAUGACCAAUAGACAGUUUCAUCAAAAAUUAUUGAAAUCAAUAGCCGCCACUAGAGGAGCUACUGUAGUAAUUGGAACAAGCAAAUUCUAUGGUGGUUGGCACAACAUGUUAAAAACUGUUUAUAGUGAUGUAGAAAACCCUCACCUUAUGGGUUGGGAUUAUCCUAAAUGUGAUAGAGCCAUGCCUAACAUGCUUAGAAUUAUGGCCUCACUUGUUCUUGCUCGCAAACAUACAACGUGUUGUAGCUUGUCACACCGUUUCUAUAGAUUAGCUAAUGAGUGUGCUCAAGUAUUGAGUGAAAUGGUCAUGUGUGGCGGUUCACUAUAUGUUAAACCAGGUGGAACCUCAUCAGGAGAUGCCACAACUGCUUAUGCUAAUAGUGUUUUUAACAUUUGUCAAGCUGUCACGGCCAAUGUUAAUGCACUUUUAUCUACUGAUGGUAACAAAAUUGCCGAUAAGUAUGUCCGCAAUUUACAACACAGACUUUAUGAGUGUCUCUAUAGAAAUAGAGAUGUUGACACAGACUUUGUGAAUGAGUUUUACGCAUAUUUGCGUAAACAUUUCUCAAUGAUGAUACUCUCUGACGAUGCUGUUGUGUGUUUCAAUAGCACUUAUGCAUCUCAAGGUCUAGUGGCUAGCAUAAAGAACUUUAAGUCAGUUCUUUAUUAUCAAAACAAUGUUUUUAUGUCUGAAGCAAAAUGUUGGACUGAGACUGACCUUACUAAAGGACCUCAUGAAUUUUGCUCUCAACAUACAAUGCUAGUUAAACAGGGUGAUGAUUAUGUGUACCUUCCUUACCCAGAUCCAUCAAGAAUCCUAGGGGCCGGCUGUUUUGUAGAUGAUAUCGUAAAAACAGAUGGUACACUUAUGAUUGAACGGUUCGUGUCUUUAGCUAUAGAUGCUUACCCACUUACUAAACAUCCUAAUCAGGAGUAUGCUGAUGUCUUUCAUUUGUACUUACAAUACAUAAGAAAGCUACAUGAUGAGUUAACAGGACACAUGUUAGACAUGUAUUCUGUUAUGCUUACUAAUGAUAACACUUCAAGGUAUUGGGAACCUGAGUUUUAUGAGGCUAUGUACACACCGCAUACAGUCUUACAGGCUGUUGGGGCUUGUGUUCUUUGCAAUUCACAGACUUCAUUAAGAUGUGGUGCUUGCAUACGUAGACCAUUCUUAUGUUGUAAAUGCUGUUACGACCAUGUCAUAUCAACAUCACAUAAAUUAGUCUUGUCUGUUAAUCCGUAUGUUUGCAAUGCUCCAGGUUGUGAUGUCACAGAUGUGACUCAACUUUACUUAGGAGGUAUGAGCUAUUAUUGUAAAUCACAUAAACCACCCAUUAGUUUUCCAUUGUGUGCUAAUGGACAAGUUUUUGGUUUAUAUAAAAAUACAUGUGUUGGUAGCGAUAAUGUUACUGACUUUAAUGCAAUUGCAACAUGUGACUGGACAAAUGCUGGUGAUUACAUUUUAGCUAACACCUGUACUGAAAGACUCAAGCUUUUUGCAGCAGAAACGCUCAAAGCUACUGAGGAGACAUUUAAACUGUCUUAUGGUAUUGCUACUGUACGUGAAGUGCUGUCUGACAGAGAAUUACAUCUUUCAUGGGAAGUUGGUAAACCUAGACCACCACUUAACCGAAAUUAUGUCUUUACUGGUUAUCGUGUAACUAAAAACAGUAAAGUACAAAUAGGAGAGUACACCUUUGAAAAAGGUGACUAUGGUGAUGCUGUUGUUUACCGAGGUACAACAACUUACAAAUUAAAUGUUGGUGAUUAUUUUGUGCUGACAUCACAUACAGUAAUGCCAUUAAGUGCACCUACACUAGUGCCACAAGAGCACUAUGUUAGAAUUACUGGCUUAUACCCAACACUCAAUAUCUCAGAUGAGUUUUCUAGCAAUGUUGCAAAUUAUCAAAAGGUUGGUAUGCAAAAGUAUUCUACACUCCAGGGACCACCUGGUACUGGUAAGAGUCAUUUUGCUAUUGGCCUAGCUCUCUACUACCCUUCUGCUCGCAUAGUGUAUACAGCUUGCUCUCAUGCCGCUGUUGAUGCACUAUGUGAGAAGGCAUUAAAAUAUUUGCCUAUAGAUAAAUGUAGUAGAAUUAUACCUGCACGUGCUCGUGUAGAGUGUUUUGAUAAAUUCAAAGUGAAUUCAACAUUAGAACAGUAUGUCUUUUGUACUGUAAAUGCAUUGCCUGAGACGACAGCAGAUAUAGUUGUCUUUGAUGAAAUUUCAAUGGCCACAAAUUAUGAUUUGAGUGUUGUCAAUGCCAGAUUACGUGCUAAGCACUAUGUGUACAUUGGCGACCCUGCUCAAUUACCUGCACCACGCACAUUGCUAACUAAGGGCACACUAGAACCAGAAUAUUUCAAUUCAGUGUGUAGACUUAUGAAAACUAUAGGUCCAGACAUGUUCCUCGGAACUUGUCGGCGUUGUCCUGCUGAAAUUGUUGACACUGUGAGUGCUUUGGUUUAUGAUAAUAAGCUUAAAGCACAUAAAGACAAAUCAGCUCAAUGCUUUAAAAUGUUUUAUAAGGGUGUUAUCACGCAUGAUGUUUCAUCUGCAAUUAACAGGCCACAAAUAGGCGUGGUAAGAGAAUUCCUUACACGUAACCCUGCUUGGAGAAAAGCUGUCUUUAUUUCACCUUAUAAUUCACAGAAUGCUGUAGCCUCAAAGAUUUUGGGACUACCAACUCAAACUGUUGAUUCAUCACAGGGCUCAGAAUAUGACUAUGUCAUAUUCACUCAAACCACUGAAACAGCUCACUCUUGUAAUGUAAACAGAUUUAAUGUUGCUAUUACCAGAGCAAAAGUAGGCAUACUUUGCAUAAUGUCUGAUAGAGACCUUUAUGACAAGUUGCAAUUUACAAGUCUUGAAAUUCCACGUAGGAAUGUGGCAACUUUACAAGCUGAAAAUGUAACAGGACUCUUUAAAGAUUGUAGUAAGGUAAUCACUGGGUUACAUCCUACACAGGCACCUACACACCUCAGUGUUGACACUAAAUUCAAAACUGAAGGUUUAUGUGUUGACAUACCUGGCAUACCUAAGGACAUGACCUAUAGAAGACUCAUCUCUAUGAUGGGUUUUAAAAUGAAUUAUCAAGUUAAUGGUUACCCUAACAUGUUUAUCACCCGCGAAGAAGCUAUAAGACAUGUACGUGCAUGGAUUGGCUUCGAUGUCGAGGGGUGUCAUGCUACUAGAGAAGCUGUUGGUACCAAUUUACCUUUACAGCUAGGUUUUUCUACAGGUGUUAACCUAGUUGCUGUACCUACAGGUUAUGUUGAUACACCUAAUAAUACAGAUUUUUCCAGAGUUAGUGCUAAACCACCGCCUGGAGAUCAAUUUAAACACCUCAUACCACUUAUGUACAAAGGACUUCCUUGGAAUGUAGUGCGUAUAAAGAUUGUACAAAUGUUAAGUGACACACUUAAAAAUCUCUCUGACAGAGUCGUAUUUGUCUUAUGGGCACAUGGCUUUGAGUUGACAUCUAUGAAGUAUUUUGUGAAAAUAGGACCUGAGCGCACCUGUUGUCUAUGUGAUAGACGUGCCACAUGCUUUUCCACUGCUUCAGACACUUAUGCCUGUUGGCAUCAUUCUAUUGGAUUUGAUUACGUCUAUAAUCCGUUUAUGAUUGAUGUUCAACAAUGGGGUUUUACAGGUAACCUACAAAGCAACCAUGAUCUGUAUUGUCAAGUCCAUGGUAAUGCACAUGUAGCUAGUUGUGAUGCAAUCAUGACUAGGUGUCUAGCUGUCCACGAGUGCUUUGUUAAGCGUGUUGACUGGACUAUUGAAUAUCCUAUAAUUGGUGAUGAACUGAAGAUUAAUGCGGCUUGUAGAAAGGUUCAACACAUGGUUGUUAAAGCUGCAUUAUUAGCAGACAAAUUCCCAGUUCUUCACGACAUUGGUAACCCUAAAGCUAUUAAGUGUGUACCUCAAGCUGAUGUAGAAUGGAAGUUCUAUGAUGCACAGCCUUGUAGUGACAAAGCUUAUAAAAUAGAAGAAUUAUUCUAUUCUUAUGCCACACAUUCUGACAAAUUCACAGAUGGUGUAUGCCUAUUUUGGAAUUGCAAUGUCGAUAGAUAUCCUGCUAAUUCCAUUGUUUGUAGAUUUGACACUAGAGUGCUAUCUAACCUUAACUUGCCUGGUUGUGAUGGUGGCAGUUUGUAUGUAAAUAAACAUGCAUUCCACACACCAGCUUUUGAUAAAAGUGCUUUUGUUAAUUUAAAACAAUUACCAUUUUUCUAUUACUCUGACAGUCCAUGUGAGUCUCAUGGAAAACAAGUAGUGUCAGAUAUAGAUUAUGUACCACUAAAGUCUGCUACGUGUAUAACACGUUGCAAUUUAGGUGGUGCUGUCUGUAGACAUCAUGCUAAUGAGUACAGAUUGUAUCUCGAUGCUUAUAACAUGAUGAUCUCAGCUGGCUUUAGCUUGUGGGUUUACAAACAAUUUGAUACUUAUAACCUCUGGAACACUUUUACAAGACUUCAGAGUUUAGAAAAUGUGGCUUUUAAUGUUGUAAAUAAGGGACACUUUGAUGGACAACAGGGUGAAGUACCAGUUUCUAUCAUUAAUAACACUGUUUACACAAAAGUUGAUGGUGUUGAUGUAGAAUUGUUUGAAAAUAAAACAACAUUACCUGUUAAUGUAGCAUUUGAGCUUUGGGCUAAGCGCAACAUUAAACCAGUACCAGAGGUGAAAAUACUCAAUAAUUUGGGUGUGGACAUUGCUGCUAAUACUGUGAUCUGGGACUACAAAAGAGAUGCUCCAGCACAUAUAUCUACUAUUGGUGUUUGUUCUAUGACUGACAUAGCCAAGAAACCAACUGAAACGAUUUGUGCACCACUCACUGUCUUUUUUGAUGGUAGAGUUGAUGGUCAAGUAGACUUAUUUAGAAAUGCCCGUAAUGGUGUUCUUAUUACAGAAGGUAGUGUUAAAGGUUUACAACCAUCUGUAGGUCCCAAACAAGCUAGUCUUAAUGGAGUCACAUUAAUUGGAGAAGCCGUAAAAACACAGUUCAAUUAUUAUAAGAAAGUUGAUGGUGUUGUCCAACAAUUACCUGAAACUUACUUUACUCAGAGUAGAAAUUUACAAGAAUUUAAACCCAGGAGUCAAAUGGAAAUUGAUUUCUUAGAAUUAGCUAUGGAUGAAUUCAUUGAACGGUAUAAAUUAGAAGGCUAUGCCUUCGAACAUAUCGUUUAUGGAGAUUUUAGUCAUAGUCAGUUAGGUGGUUUACAUCUACUGAUUGGACUAGCUAAACGUUUUAAGGAAUCACCUUUUGAAUUAGAAGAUUUUAUUCCUAUGGACAGUACAGUUAAAAACUAUUUCAUAACAGAUGCGCAAACAGGUUCAUCUAAGUGUGUGUGUUCUGUUAUUGAUUUAUUACUUGAUGAUUUUGUUGAAAUAAUAAAAUCCCAAGAUUUAUCUGUAGUUUCUAAGGUUGUCAAAGUGACUAUUGACUAUACAGAAAUUUCAUUUAUGCUUUGGUGUAAAGAUGGCCAUGUAGAAACAUUUUACCCAAAAUUACAAUCUAGUCAAGCGUGGCAACCGGGUGUUGCUAUGCCUAAUCUUUACAAAAUGCAAAGAAUGCUAUUAGAAAAGUGUGACCUUCAAAAUUAUGGUGAUAGUGCAACAUUACCUAAAGGCAUAAUGAUGAAUGUCGCAAAAUAUACUCAACUGUGUCAAUAUUUAAACACAUUAACAUUAGCUGUACCCUAUAAUAUGAGAGUUAUACAUUUUGGUGCUGGUUCUGAUAAAGGAGUUGCACCAGGUACAGCUGUUUUAAGACAGUGGUUGCCUACGGGUACGCUGCUUGUCGAUUCAGAUCUUAAUGACUUUGUCUCUGAUGCAGAUUCAACUUUGAUUGGUGAUUGUGCAACUGUACAUACAGCUAAUAAAUGGGAUCUCAUUAUUAGUGAUAUGUACGACCCUAAGACUAAAAAUGUUACAAAAGAAAAUGACUCUAAAGAGGGUUUUUUCACUUACAUUUGUGGGUUUAUACAACAAAAGCUAGCUCUUGGAGGUUCCGUGGCUAUAAAGAUAACAGAACAUUCUUGGAAUGCUGAUCUUUAUAAGCUCAUGGGACACUUCGCAUGGUGGACAGCCUUUGUUACUAAUGUGAAUGCGUCAUCAUCUGAAGCAUUUUUAAUUGGAUGUAAUUAUCUUGGCAAACCACGCGAACAAAUAGAUGGUUAUGUCAUGCAUGCAAAUUACAUAUUUUGGAGGAAUACAAAUCCAAUUCAGUUGUCUUCCUAUUCUUUAUUUGACAUGAGUAAAUUUCCCCUUAAAUUAAGGGGUACUGCUGUUAUGUCUUUAAAAGAAGGUCAAAUCAAUGAUAUGAUUUUAUCUCUUCUUAGUAAAGGUAGACUUAUAAUUAGAGAAAACAACAGAGUUGUUAUUUCUAGUGAUGUUCUUGUUAACAACUAAACGAACAAUGUUUGUUUUUCUUGUUUUAUUGCCACUAGUCUCUAGUCAGUGUGUUAAUCUUACAACCAGAACUCAAUUACCCCCUGCAUACACUAAUUCUUUCACACGUGGUGUUUAUUACCCUGACAAAGUUUUCAGAUCCUCAGUUUUACAUUCAACUCAGGACUUGUUCUUACCUUUCUUUUCCAAUGUUACUUGGUUCCAUGCUAUACAUGUCUCUGGGACCAAUGGUACUAAGAGGUUUGAUAACCCUGUCCUACCAUUUAAUGAUGGUGUUUAUUUUGCUUCCACUGAGAAGUCUAACAUAAUAAGAGGCUGGAUUUUUGGUACUACUUUAGAUUCGAAGACCCAGUCCCUACUUAUUGUUAAUAACGCUACUAAUGUUGUUAUUAAAGUCUGUGAAUUUCAAUUUUGUAAUGAUCCAUUUUUGGGUGUUUAUUACCACAAAAACAACAAAAGUUGGAUGGAAAGUGAGUUCAGAGUUUAUUCUAGUGCGAAUAAUUGCACUUUUGAAUAUGUCUCUCAGCCUUUUCUUAUGGACCUUGAAGGAAAACAGGGUAAUUUCAAAAAUCUUAGGGAAUUUGUGUUUAAGAAUAUUGAUGGUUAUUUUAAAAUAUAUUCUAAGCACACGCCUAUUAAUUUAGUGCGUGAUCUCCCUCAGGGUUUUUCGGCUUUAGAACCAUUGGUAGAUUUGCCAAUAGGUAUUAACAUCACUAGGUUUCAAACUUUACUUGCUUUACAUAGAAGUUAUUUGACUCCUGGUGAUUCUUCUUCAGGUUGGACAGCUGGUGCUGCAGCUUAUUAUGUGGGUUAUCUUCAACCUAGGACUUUUCUAUUAAAAUAUAAUGAAAAUGGAACCAUUACAGAUGCUGUAGACUGUGCACUUGACCCUCUCUCAGAAACAAAGUGUACGUUGAAAUCCUUCACUGUAGAAAAAGGAAUCUAUCAAACUUCUAACUUUAGAGUCCAACCAACAGAAUCUAUUGUUAGAUUUCCUAAUAUUACAAACUUGUGCCCUUUUGGUGAAGUUUUUAACGCCACCAGAUUUGCAUCUGUUUAUGCUUGGAACAGGAAGAGAAUCAGCAACUGUGUUGCUGAUUAUUCUGUCCUAUAUAAUUCCGCAUCAUUUUCCACUUUUAAGUGUUAUGGAGUGUCUCCUACUAAAUUAAAUGAUCUCUGCUUUACUAAUGUCUAUGCAGAUUCAUUUGUAAUUAGAGGUGAUGAAGUCAGACAAAUCGCUCCAGGGCAAACUGGAAAGAUUGCUGAUUAUAAUUAUAAAUUACCAGAUGAUUUUACAGGCUGCGUUAUAGCUUGGAAUUCUAACAAUCUUGAUUCUAAGGUUGGUGGUAAUUAUAAUUACCUGUAUAGAUUGUUUAGGAAGUCUAAUCUCAAACCUUUUGAGAGAGAUAUUUCAACUGAAAUCUAUCAGGCCGGUAGCACACCUUGUAAUGGUGUUGAAGGUUUUAAUUGUUACUUUCCUUUACAAUCAUAUGGUUUCCAACCCACUAAUGGUGUUGGUUACCAACCAUACAGAGUAGUAGUACUUUCUUUUGAACUUCUACAUGCACCAGCAACUGUUUGUGGACCUAAAAAGUCUACUAAUUUGGUUAAAAACAAAUGUGUCAAUUUCAACUUCAAUGGUUUAACAGGCACAGGUGUUCUUACUGAGUCUAACAAAAAGUUUCUGCCUUUCCAACAAUUUGGCAGAGACAUUGCUGACACUACUGAUGCUGUCCGUGAUCCACAGACACUUGAGAUUCUUGACAUUACACCAUGUUCUUUUGGUGGUGUCAGUGUUAUAACACCAGGAACAAAUACUUCUAACCAGGUUGCUGUUCUUUAUCAGGAUGUUAACUGCACAGAAGUCCCUGUUGCUAUUCAUGCAGAUCAACUUACUCCUACUUGGCGUGUUUAUUCUACAGGUUCUAAUGUUUUUCAAACACGUGCAGGCUGUUUAAUAGGGGCUGAACAUGUCAACAACUCAUAUGAGUGUGACAUACCCAUUGGUGCAGGUAUAUGCGCUAGUUAUCAGACUCAGACUAAUUCUCCUCGGCGGGCACGUAGUGUAGCUAGUCAAUCCAUCAUUGCCUACACUAUGUCACUUGGUGCAGAAAAUUCAGUUGCUUACUCUAAUAACUCUAUUGCCAUACCCACAAAUUUUACUAUUAGUGUUACCACAGAAAUUCUACCAGUGUCUAUGACCAAGACAUCAGUAGAUUGUACAAUGUACAUUUGUGGUGAUUCAACUGAAUGCAGCAAUCUUUUGUUGCAAUAUGGCAGUUUUUGUACACAAUUAAACCGUGCUUUAACUGGAAUAGCUGUUGAACAAGACAAAAACACCCAAGAAGUUUUUGCACAAGUCAAACAAAUUUACAAAACACCACCAAUUAAAGAUUUUGGUGGUUUUAAUUUUUCACAAAUAUUACCAGAUCCAUCAAAACCAAGCAAGAGGUCAUUUAUUGAAGAUCUACUUUUCAACAAAGUGACACUUGCAGAUGCUGGCUUCAUCAAACAAUAUGGUGAUUGCCUUGGUGAUAUUGCUGCUAGAGACCUCAUUUGUGCACAAAAGUUUAACGGCCUUACUGUUUUGCCACCUUUGCUCACAGAUGAAAUGAUUGCUCAAUACACUUCUGCACUGUUAGCGGGUACAAUCACUUCUGGUUGGACCUUUGGUGCAGGUGCUGCAUUACAAAUACCAUUUGCUAUGCAAAUGGCUUAUAGGUUUAAUGGUAUUGGAGUUACACAGAAUGUUCUCUAUGAGAACCAAAAAUUGAUUGCCAACCAAUUUAAUAGUGCUAUUGGCAAAAUUCAAGACUCACUUUCUUCCACAGCAAGUGCACUUGGAAAACUUCAAGAUGUGGUCAACCAAAAUGCACAAGCUUUAAACACGCUUGUUAAACAACUUAGCUCCAAUUUUGGUGCAAUUUCAAGUGUUUUAAAUGAUAUCCUUUCACGUCUUGACAAAGUUGAGGCUGAAGUGCAAAUUGAUAGGUUGAUCACAGGCAGACUUCAAAGUUUGCAGACAUAUGUGACUCAACAAUUAAUUAGAGCUGCAGAAAUCAGAGCUUCUGCUAAUCUUGCUGCUACUAAAAUGUCAGAGUGUGUACUUGGACAAUCAAAAAGAGUUGAUUUUUGUGGAAAGGGCUAUCAUCUUAUGUCCUUCCCUCAGUCAGCACCUCAUGGUGUAGUCUUCUUGCAUGUGACUUAUGUCCCUGCACAAGAAAAGAACUUCACAACUGCUCCUGCCAUUUGUCAUGAUGGAAAAGCACACUUUCCUCGUGAAGGUGUCUUUGUUUCAAAUGGCACACACUGGUUUGUAACACAAAGGAAUUUUUAUGAACCACAAAUCAUUACUACAGACAACACAUUUGUGUCUGGUAACUGUGAUGUUGUAAUAGGAAUUGUCAACAACACAGUUUAUGAUCCUUUGCAACCUGAAUUAGACUCAUUCAAGGAGGAGUUAGAUAAAUAUUUUAAGAAUCAUACAUCACCAGAUGUUGAUUUAGGUGACAUCUCUGGCAUUAAUGCUUCAGUUGUAAACAUUCAAAAAGAAAUUGACCGCCUCAAUGAGGUUGCCAAGAAUUUAAAUGAAUCUCUCAUCGAUCUCCAAGAACUUGGAAAGUAUGAGCAGUAUAUAAAAUGGCCAUGGUACAUUUGGCUAGGUUUUAUAGCUGGCUUGAUUGCCAUAGUAAUGGUGACAAUUAUGCUUUGCUGUAUGACCAGUUGCUGUAGUUGUCUCAAGGGCUGUUGUUCUUGUGGAUCCUGCUGCAAAUUUGAUGAAGACGACUCUGAGCCAGUGCUCAAAGGAGUCAAAUUACAUUACACAUAAACGAACUUAUGGAUUUGUUUAUGAGAAUCUUCACAAUUGGAACUGUAACUUUGAAGCAAGGUGAAAUCAAGGAUGCUACUCCUUCAGAUUUUGUUCGCGCUACUGCAACGAUACCGAUACAAGCCUCACUCCCUUUCGGAUGGCUUAUUGUUGGCGUUGCACUUCUUGCUGUUUUUCAGAGCGCUUCCAAAAUCAUAACCCUCAAAAAGAGAUGGCAACUAGCACUCUCCAAGGGUGUUCACUUUGUUUGCAACUUGCUGUUGUUGUUUGUAACAGUUUACUCACACCUUUUGCUCGUUGCUGCUGGCCUUGAAGCCCCUUUUCUCUAUCUUUAUGCUUUAGUCUACUUCUUGCAGAGUAUAAACUUUGUAAGAAUAAUAAUGAGGCUUUGGCUUUGCUGGAAAUGCCGUUCCAAAAACCCAUUACUUUAUGAUGCCAACUAUUUUCUUUGCUGGCAUACUAAUUGUUACGACUAUUGUAUACCUUACAAUAGUGUAACUUCUUCAAUUGUCAUUACUUCAGGUGAUGGCACAACAAGUCCUAUUUCUGAACAUGACUACCAGAUUGGUGGUUAUACUGAAAAAUGGGAAUCUGGAGUAAAAGACUGUGUUGUAUUACACAGUUACUUCACUUCAGACUAUUACCAGCUGUACUCAACUCAAUUGAGUACAGACACUGGUGUUGAACAUGUUACCUUCUUCAUCUACAAUAAAAUUGUUGAUGAGCCUGAAGAACAUGUCCAAAUUCACACAAUCGACGGUUCAUCCGGAGUUGUUAAUCCAGUAAUGGAACCAAUUUAUGAUGAACCGACGACGACUACUAGCGUGCCUUUGUAAGCACAAGCUGAUGAGUACGAACUUAUGUACUCAUUCGUUUCGGAAGAGACAGGUACGUUAAUAGUUAAUAGCGUACUUCUUUUUCUUGCUUUCGUGGUAUUCUUGCUAGUUACACUAGCCAUCCUUACUGCGCUUCGAUUGUGUGCGUACUGCUGCAAUAUUGUUAACGUGAGUCUUGUAAAACCUUCUUUUUACGUUUACUCUCGUGUUAAAAAUCUGAAUUCUUCUAGAGUUCCUGAUCUUCUGGUCUAAACGAACUAAAUAUUAUAUUAGUUUUUCUGUUUGGAACUUUAAUUUUAGCCAUGGCAGAUUCCAACGGUACUAUUACCGUUGAAGAGCUUAAAAAGCUCCUUGAACAAUGGAACCUAGUAAUAGGUUUCCUAUUCCUUACAUGGAUUUGUCUUCUACAAUUUGCCUAUGCCAACAGGAAUAGGUUUUUGUAUAUAAUUAAGUUAAUUUUCCUCUGGCUGUUAUGGCCAGUAACUUUAGCUUGUUUUGUGCUUGCUGCUGUUUACAGAAUAAAUUGGAUCACCGGUGGAAUUGCUAUCGCAAUGGCUUGUCUUGUAGGCUUGAUGUGGCUCAGCUACUUCAUUGCUUCUUUCAGACUGUUUGCGCGUACGCGUUCCAUGUGGUCAUUCAAUCCAGAAACUAACAUUCUUCUCAACGUGCCACUCCAUGGCACUAUUCUGACCAGACCGCUUCUAGAAAGUGAACUCGUAAUCGGAGCUGUGAUCCUUCGUGGACAUCUUCGUAUUGCUGGACACCAUCUAGGACGCUGUGACAUCAAGGACCUGCCUAAAGAAAUCACUGUUGCUACAUCACGAACGCUUUCUUAUUACAAAUUGGGAGCUUCGCAGCGUGUAGCAGGUGACUCAGGUUUUGCUGCAUACAGUCGCUACAGGAUUGGCAACUAUAAAUUAAACACAGACCAUUCCAGUAGCAGUGACAAUAUUGCUUUGCUUGUACAGUAAGUGACAACAGAUGUUUCAUCUCGUUGACUUUCAGGUUACUAUAGCAGAGAUAUUACUAAUUAUUAUGAGGACUUUUAAAGUUUCCAUUUGGAAUCUUGAUUACAUCAUAAACCUCAUAAUUAAAAAUUUAUCUAAGUCACUAACUGAGAAUAAAUAUUCUCAAUUAGAUGAAGAGCAACCAAUGGAGAUUGAUUAAACGAACAUGAAAAUUAUUCUUUUCUUGGCACUGAUAACACUCGCUACUUGUGAGCUUUAUCACUACCAAGAGUGUGUUAGAGGUACAACAGUACUUUUAAAAGAACCUUGCUCUUCUGGAACAUACGAGGGCAAUUCACCAUUUCAUCCUCUAGCUGAUAACAAAUUUGCACUGACUUGCUUUAGCACUCAAUUUGCUUUUGCUUGUCCUGACGGCGUAAAACACGUCUAUCAGUUACGUGCCAGAUCAGUUUCACCUAAACUGUUCAUCAGACAAGAGGAAGUUCAAGAACUUUACUCUCCAAUUUUUCUUAUUGUUGCGGCAAUAGUGUUUAUAACACUUUGCUUCACACUCAAAAGAAAGACAGAAUGAUUGAACUUUCAUUAAUUGACUUCUAUUUGUGCUUUUUAGCCUUUCUGCUAUUCCUUGUUUUAAUUAUGCUUAUUAUCUUUUGGUUCUCACUUGAACUGCAAGAUCAUAAUGAAACUUGUCACGCCUAAACGAACAUGAAAUUUCUUGUUUUCUUAGGAAUCAUCACAACUGUAGCUGCAUUUCACCAAGAAUGUAGUUUACAGUCAUGUACUCAACAUCAACCAUAUGUAGUUGAUGACCCGUGUCCUAUUCACUUCUAUUCUAAAUGGUAUAUUAGAGUAGGAGCUAGAAAAUCAGCACCUUUAAUUGAAUUGUGCGUGGAUGAGGCUGGUUCUAAAUCACCCAUUCAGUACAUCGAUAUCGGUAAUUAUACAGUUUCCUGUUUACCUUUUACAAUUAAUUGCCAGGAACCUAAAUUGGGUAGUCUUGUAGUGCGUUGUUCGUUCUAUGAAGACUUUUUAGAGUAUCAUGACGUUCGUGUUGUUUUAGAUUUCAUCUAAACGAACAAACUAAAAUGUCUGAUAAUGGACCCCAAAAUCAGCGAAAUGCACCCCGCAUUACGUUUGGUGGACCCUCAGAUUCAACUGGCAGUAACCAGAAUGGAGAACGCAGUGGGGCGCGAUCAAAACAACGUCGGCCCCAAGGUUUACCCAAUAAUACUGCGUCUUGGUUCACCGCUCUCACUCAACAUGGCAAGGAAGACCUUAAAUUCCCUCGAGGACAAGGCGUUCCAAUUAACACCAAUAGCAGUCCAGAUGACCAAAUUGGCUACUACCGAAGAGCUACCAGACGAAUUCGUGGUGGUGACGGUAAAAUGAAAGAUCUCAGUCCAAGAUGGUAUUUCUACUACCUAGGAACUGGGCCAGAAGCUGGACUUCCCUAUGGUGCUAACAAAGACGGCAUCAUAUGGGUUGCAACUGAGGGAGCCUUGAAUACACCAAAAGAUCACAUUGGCACCCGCAAUCCUGCUAACAAUGCUGCAAUCGUGCUACAACUUCCUCAAGGAACAACAUUGCCAAAAGGCUUCUACGCAGAAGGGAGCAGAGGCGGCAGUCAAGCCUCUUCUCGUUCCUCAUCACGUAGUCGCAACAGUUCAAGAAAUUCAACUCCAGGCAGCAGUAGGGGAACUUCUCCUGCUAGAAUGGCUGGCAAUGGCGGUGAUGCUGCUCUUGCUUUGCUGCUGCUUGACAGAUUGAACCAGCUUGAGAGCAAAAUGUCUGGUAAAGGCCAACAACAACAAGGCCAAACUGUCACUAAGAAAUCUGCUGCUGAGGCUUCUAAGAAGCCUCGGCAAAAACGUACUGCCACUAAAGCAUACAAUGUAACACAAGCUUUCGGCAGACGUGGUCCAGAACAAACCCAAGGAAAUUUUGGGGACCAGGAACUAAUCAGACAAGGAACUGAUUACAAACAUUGGCCGCAAAUUGCACAAUUUGCCCCCAGCGCUUCAGCGUUCUUCGGAAUGUCGCGCAUUGGCAUGGAAGUCACACCUUCGGGAACGUGGUUGACCUACACAGGUGCCAUCAAAUUGGAUGACAAAGAUCCAAAUUUCAAAGAUCAAGUCAUUUUGCUGAAUAAGCAUAUUGACGCAUACAAAACAUUCCCACCAACAGAGCCUAAAAAGGACAAAAAGAAGAAGGCUGAUGAAACUCAAGCCUUACCGCAGAGACAGAAGAAACAGCAAACUGUGACUCUUCUUCCUGCUGCAGAUUUGGAUGAUUUCUCCAAACAAUUGCAACAAUCCAUGAGCAGUGCUGACUCAACUCAGGCCUAAACUCAUGCAGACCACACAAGGCAGAUGGGCUAUAUAAACGUUUUCGCUUUUCCGUUUACGAUAUAUAGUCUACUCUUGUGCAGAAUGAAUUCUCGUAACUACAUAGCACAAGUAGAUGUAGUUAACUUUAAUCUCACAUAGCAAUCUUUAAUCAGUGUGUAACAUUAGGGAGGACUUGAAAGAGCCACCACAUUUUCACCGAGGCCACGCGGAGUACGAUCGAGUGUACAGUGAACAAUGCUAGGGAGAGCUGCCUAUAUGGAAGAGCCCUAAUGUGUAAAAUUAAUUUUAGUAGUGCUAUCCCCAUGUGAUUUUAAUAGCUUCUUAGGAGAAUGACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,1–5 nM[SARS-CoV-2],"15 mM NaCl, 135 mM KCl, 5 mM phosphate, 1.5 mM MgCl2","20 mM Tris–HCl, pH 7.0",37˚C,-,other_molecular:1 mg ml−1 BSA,Surface plasmon resonance,liquid,"As expected, the SARS2-NP exhibited a high binding capacity for viral RNA, which was substantially reduced in the DD-depleted mutant (Fig. 1n), indicating that the DD is required for SARS2-NP to bind viral RNA"
700,PMID: 34239064,RNAPS0000450,https://pubmed.ncbi.nlm.nih.gov/34239064,RNA + protein,-,-,SARS-CoV-2 virus RNA,29903nt(1-29903),AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGCACCUCAUGGUCAUGUUAUGGUUGAGCUGGUAGCAGAACUCGAAGGCAUUCAGUACGGUCGUAGUGGUGAGACACUUGGUGUCCUUGUCCCUCAUGUGGGCGAAAUACCAGUGGCUUACCGCAAGGUUCUUCUUCGUAAGAACGGUAAUAAAGGAGCUGGUGGCCAUAGUUACGGCGCCGAUCUAAAGUCAUUUGACUUAGGCGACGAGCUUGGCACUGAUCCUUAUGAAGAUUUUCAAGAAAACUGGAACACUAAACAUAGCAGUGGUGUUACCCGUGAACUCAUGCGUGAGCUUAACGGAGGGGCAUACACUCGCUAUGUCGAUAACAACUUCUGUGGCCCUGAUGGCUACCCUCUUGAGUGCAUUAAAGACCUUCUAGCACGUGCUGGUAAAGCUUCAUGCACUUUGUCCGAACAACUGGACUUUAUUGACACUAAGAGGGGUGUAUACUGCUGCCGUGAACAUGAGCAUGAAAUUGCUUGGUACACGGAACGUUCUGAAAAGAGCUAUGAAUUGCAGACACCUUUUGAAAUUAAAUUGGCAAAGAAAUUUGACACCUUCAAUGGGGAAUGUCCAAAUUUUGUAUUUCCCUUAAAUUCCAUAAUCAAGACUAUUCAACCAAGGGUUGAAAAGAAAAAGCUUGAUGGCUUUAUGGGUAGAAUUCGAUCUGUCUAUCCAGUUGCGUCACCAAAUGAAUGCAACCAAAUGUGCCUUUCAACUCUCAUGAAGUGUGAUCAUUGUGGUGAAACUUCAUGGCAGACGGGCGAUUUUGUUAAAGCCACUUGCGAAUUUUGUGGCACUGAGAAUUUGACUAAAGAAGGUGCCACUACUUGUGGUUACUUACCCCAAAAUGCUGUUGUUAAAAUUUAUUGUCCAGCAUGUCACAAUUCAGAAGUAGGACCUGAGCAUAGUCUUGCCGAAUACCAUAAUGAAUCUGGCUUGAAAACCAUUCUUCGUAAGGGUGGUCGCACUAUUGCCUUUGGAGGCUGUGUGUUCUCUUAUGUUGGUUGCCAUAACAAGUGUGCCUAUUGGGUUCCACGUGCUAGCGCUAACAUAGGUUGUAACCAUACAGGUGUUGUUGGAGAAGGUUCCGAAGGUCUUAAUGACAACCUUCUUGAAAUACUCCAAAAAGAGAAAGUCAACAUCAAUAUUGUUGGUGACUUUAAACUUAAUGAAGAGAUCGCCAUUAUUUUGGCAUCUUUUUCUGCUUCCACAAGUGCUUUUGUGGAAACUGUGAAAGGUUUGGAUUAUAAAGCAUUCAAACAAAUUGUUGAAUCCUGUGGUAAUUUUAAAGUUACAAAAGGAAAAGCUAAAAAAGGUGCCUGGAAUAUUGGUGAACAGAAAUCAAUACUGAGUCCUCUUUAUGCAUUUGCAUCAGAGGCUGCUCGUGUUGUACGAUCAAUUUUCUCCCGCACUCUUGAAACUGCUCAAAAUUCUGUGCGUGUUUUACAGAAGGCCGCUAUAACAAUACUAGAUGGAAUUUCACAGUAUUCACUGAGACUCAUUGAUGCUAUGAUGUUCACAUCUGAUUUGGCUACUAACAAUCUAGUUGUAAUGGCCUACAUUACAGGUGGUGUUGUUCAGUUGACUUCGCAGUGGCUAACUAACAUCUUUGGCACUGUUUAUGAAAAACUCAAACCCGUCCUUGAUUGGCUUGAAGAGAAGUUUAAGGAAGGUGUAGAGUUUCUUAGAGACGGUUGGGAAAUUGUUAAAUUUAUCUCAACCUGUGCUUGUGAAAUUGUCGGUGGACAAAUUGUCACCUGUGCAAAGGAAAUUAAGGAGAGUGUUCAGACAUUCUUUAAGCUUGUAAAUAAAUUUUUGGCUUUGUGUGCUGACUCUAUCAUUAUUGGUGGAGCUAAACUUAAAGCCUUGAAUUUAGGUGAAACAUUUGUCACGCACUCAAAGGGAUUGUACAGAAAGUGUGUUAAAUCCAGAGAAGAAACUGGCCUACUCAUGCCUCUAAAAGCCCCAAAAGAAAUUAUCUUCUUAGAGGGAGAAACACUUCCCACAGAAGUGUUAACAGAGGAAGUUGUCUUGAAAACUGGUGAUUUACAACCAUUAGAACAACCUACUAGUGAAGCUGUUGAAGCUCCAUUGGUUGGUACACCAGUUUGUAUUAACGGGCUUAUGUUGCUCGAAAUCAAAGACACAGAAAAGUACUGUGCCCUUGCACCUAAUAUGAUGGUAACAAACAAUACCUUCACACUCAAAGGCGGUGCACCAACAAAGGUUACUUUUGGUGAUGACACUGUGAUAGAAGUGCAAGGUUACAAGAGUGUGAAUAUCACUUUUGAACUUGAUGAAAGGAUUGAUAAAGUACUUAAUGAGAAGUGCUCUGCCUAUACAGUUGAACUCGGUACAGAAGUAAAUGAGUUCGCCUGUGUUGUGGCAGAUGCUGUCAUAAAAACUUUGCAACCAGUAUCUGAAUUACUUACACCACUGGGCAUUGAUUUAGAUGAGUGGAGUAUGGCUACAUACUACUUAUUUGAUGAGUCUGGUGAGUUUAAAUUGGCUUCACAUAUGUAUUGUUCUUUCUACCCUCCAGAUGAGGAUGAAGAAGAAGGUGAUUGUGAAGAAGAAGAGUUUGAGCCAUCAACUCAAUAUGAGUAUGGUACUGAAGAUGAUUACCAAGGUAAACCUUUGGAAUUUGGUGCCACUUCUGCUGCUCUUCAACCUGAAGAAGAGCAAGAAGAAGAUUGGUUAGAUGAUGAUAGUCAACAAACUGUUGGUCAACAAGACGGCAGUGAGGACAAUCAGACAACUACUAUUCAAACAAUUGUUGAGGUUCAACCUCAAUUAGAGAUGGAACUUACACCAGUUGUUCAGACUAUUGAAGUGAAUAGUUUUAGUGGUUAUUUAAAACUUACUGACAAUGUAUACAUUAAAAAUGCAGACAUUGUGGAAGAAGCUAAAAAGGUAAAACCAACAGUGGUUGUUAAUGCAGCCAAUGUUUACCUUAAACAUGGAGGAGGUGUUGCAGGAGCCUUAAAUAAGGCUACUAACAAUGCCAUGCAAGUUGAAUCUGAUGAUUACAUAGCUACUAAUGGACCACUUAAAGUGGGUGGUAGUUGUGUUUUAAGCGGACACAAUCUUGCUAAACACUGUCUUCAUGUUGUCGGCCCAAAUGUUAACAAAGGUGAAGACAUUCAACUUCUUAAGAGUGCUUAUGAAAAUUUUAAUCAGCACGAAGUUCUACUUGCACCAUUAUUAUCAGCUGGUAUUUUUGGUGCUGACCCUAUACAUUCUUUAAGAGUUUGUGUAGAUACUGUUCGCACAAAUGUCUACUUAGCUGUCUUUGAUAAAAAUCUCUAUGACAAACUUGUUUCAAGCUUUUUGGAAAUGAAGAGUGAAAAGCAAGUUGAACAAAAGAUCGCUGAGAUUCCUAAAGAGGAAGUUAAGCCAUUUAUAACUGAAAGUAAACCUUCAGUUGAACAGAGAAAACAAGAUGAUAAGAAAAUCAAAGCUUGUGUUGAAGAAGUUACAACAACUCUGGAAGAAACUAAGUUCCUCACAGAAAACUUGUUACUUUAUAUUGACAUUAAUGGCAAUCUUCAUCCAGAUUCUGCCACUCUUGUUAGUGACAUUGACAUCACUUUCUUAAAGAAAGAUGCUCCAUAUAUAGUGGGUGAUGUUGUUCAAGAGGGUGUUUUAACUGCUGUGGUUAUACCUACUAAAAAGGCUGGUGGCACUACUGAAAUGCUAGCGAAAGCUUUGAGAAAAGUGCCAACAGACAAUUAUAUAACCACUUACCCGGGUCAGGGUUUAAAUGGUUACACUGUAGAGGAGGCAAAGACAGUGCUUAAAAAGUGUAAAAGUGCCUUUUACAUUCUACCAUCUAUUAUCUCUAAUGAGAAGCAAGAAAUUCUUGGAACUGUUUCUUGGAAUUUGCGAGAAAUGCUUGCACAUGCAGAAGAAACACGCAAAUUAAUGCCUGUCUGUGUGGAAACUAAAGCCAUAGUUUCAACUAUACAGCGUAAAUAUAAGGGUAUUAAAAUACAAGAGGGUGUGGUUGAUUAUGGUGCUAGAUUUUACUUUUACACCAGUAAAACAACUGUAGCGUCACUUAUCAACACACUUAACGAUCUAAAUGAAACUCUUGUUACAAUGCCACUUGGCUAUGUAACACAUGGCUUAAAUUUGGAAGAAGCUGCUCGGUAUAUGAGAUCUCUCAAAGUGCCAGCUACAGUUUCUGUUUCUUCACCUGAUGCUGUUACAGCGUAUAAUGGUUAUCUUACUUCUUCUUCUAAAACACCUGAAGAACAUUUUAUUGAAACCAUCUCACUUGCUGGUUCCUAUAAAGAUUGGUCCUAUUCUGGACAAUCUACACAACUAGGUAUAGAAUUUCUUAAGAGAGGUGAUAAAAGUGUAUAUUACACUAGUAAUCCUACCACAUUCCACCUAGAUGGUGAAGUUAUCACCUUUGACAAUCUUAAGACACUUCUUUCUUUGAGAGAAGUGAGGACUAUUAAGGUGUUUACAACAGUAGACAACAUUAACCUCCACACGCAAGUUGUGGACAUGUCAAUGACAUAUGGACAACAGUUUGGUCCAACUUAUUUGGAUGGAGCUGAUGUUACUAAAAUAAAACCUCAUAAUUCACAUGAAGGUAAAACAUUUUAUGUUUUACCUAAUGAUGACACUCUACGUGUUGAGGCUUUUGAGUACUACCACACAACUGAUCCUAGUUUUCUGGGUAGGUACAUGUCAGCAUUAAAUCACACUAAAAAGUGGAAAUACCCACAAGUUAAUGGUUUAACUUCUAUUAAAUGGGCAGAUAACAACUGUUAUCUUGCCACUGCAUUGUUAACACUCCAACAAAUAGAGUUGAAGUUUAAUCCACCUGCUCUACAAGAUGCUUAUUACAGAGCAAGGGCUGGUGAAGCUGCUAACUUUUGUGCACUUAUCUUAGCCUACUGUAAUAAGACAGUAGGUGAGUUAGGUGAUGUUAGAGAAACAAUGAGUUACUUGUUUCAACAUGCCAAUUUAGAUUCUUGCAAAAGAGUCUUGAACGUGGUGUGUAAAACUUGUGGACAACAGCAGACAACCCUUAAGGGUGUAGAAGCUGUUAUGUACAUGGGCACACUUUCUUAUGAACAAUUUAAGAAAGGUGUUCAGAUACCUUGUACGUGUGGUAAACAAGCUACAAAAUAUCUAGUACAACAGGAGUCACCUUUUGUUAUGAUGUCAGCACCACCUGCUCAGUAUGAACUUAAGCAUGGUACAUUUACUUGUGCUAGUGAGUACACUGGUAAUUACCAGUGUGGUCACUAUAAACAUAUAACUUCUAAAGAAACUUUGUAUUGCAUAGACGGUGCUUUACUUACAAAGUCCUCAGAAUACAAAGGUCCUAUUACGGAUGUUUUCUACAAAGAAAACAGUUACACAACAACCAUAAAACCAGUUACUUAUAAAUUGGAUGGUGUUGUUUGUACAGAAAUUGACCCUAAGUUGGACAAUUAUUAUAAGAAAGACAAUUCUUAUUUCACAGAGCAACCAAUUGAUCUUGUACCAAACCAACCAUAUCCAAACGCAAGCUUCGAUAAUUUUAAGUUUGUAUGUGAUAAUAUCAAAUUUGCUGAUGAUUUAAACCAGUUAACUGGUUAUAAGAAACCUGCUUCAAGAGAGCUUAAAGUUACAUUUUUCCCUGACUUAAAUGGUGAUGUGGUGGCUAUUGAUUAUAAACACUACACACCCUCUUUUAAGAAAGGAGCUAAAUUGUUACAUAAACCUAUUGUUUGGCAUGUUAACAAUGCAACUAAUAAAGCCACGUAUAAACCAAAUACCUGGUGUAUACGUUGUCUUUGGAGCACAAAACCAGUUGAAACAUCAAAUUCGUUUGAUGUACUGAAGUCAGAGGACGCGCAGGGAAUGGAUAAUCUUGCCUGCGAAGAUCUAAAACCAGUCUCUGAAGAAGUAGUGGAAAAUCCUACCAUACAGAAAGACGUUCUUGAGUGUAAUGUGAAAACUACCGAAGUUGUAGGAGACAUUAUACUUAAACCAGCAAAUAAUAGUUUAAAAAUUACAGAAGAGGUUGGCCACACAGAUCUAAUGGCUGCUUAUGUAGACAAUUCUAGUCUUACUAUUAAGAAACCUAAUGAAUUAUCUAGAGUAUUAGGUUUGAAAACCCUUGCUACUCAUGGUUUAGCUGCUGUUAAUAGUGUCCCUUGGGAUACUAUAGCUAAUUAUGCUAAGCCUUUUCUUAACAAAGUUGUUAGUACAACUACUAACAUAGUUACACGGUGUUUAAACCGUGUUUGUACUAAUUAUAUGCCUUAUUUCUUUACUUUAUUGCUACAAUUGUGUACUUUUACUAGAAGUACAAAUUCUAGAAUUAAAGCAUCUAUGCCGACUACUAUAGCAAAGAAUACUGUUAAGAGUGUCGGUAAAUUUUGUCUAGAGGCUUCAUUUAAUUAUUUGAAGUCACCUAAUUUUUCUAAACUGAUAAAUAUUAUAAUUUGGUUUUUACUAUUAAGUGUUUGCCUAGGUUCUUUAAUCUACUCAACCGCUGCUUUAGGUGUUUUAAUGUCUAAUUUAGGCAUGCCUUCUUACUGUACUGGUUACAGAGAAGGCUAUUUGAACUCUACUAAUGUCACUAUUGCAACCUACUGUACUGGUUCUAUACCUUGUAGUGUUUGUCUUAGUGGUUUAGAUUCUUUAGACACCUAUCCUUCUUUAGAAACUAUACAAAUUACCAUUUCAUCUUUUAAAUGGGAUUUAACUGCUUUUGGCUUAGUUGCAGAGUGGUUUUUGGCAUAUAUUCUUUUCACUAGGUUUUUCUAUGUACUUGGAUUGGCUGCAAUCAUGCAAUUGUUUUUCAGCUAUUUUGCAGUACAUUUUAUUAGUAAUUCUUGGCUUAUGUGGUUAAUAAUUAAUCUUGUACAAAUGGCCCCGAUUUCAGCUAUGGUUAGAAUGUACAUCUUCUUUGCAUCAUUUUAUUAUGUAUGGAAAAGUUAUGUGCAUGUUGUAGACGGUUGUAAUUCAUCAACUUGUAUGAUGUGUUACAAACGUAAUAGAGCAACAAGAGUCGAAUGUACAACUAUUGUUAAUGGUGUUAGAAGGUCCUUUUAUGUCUAUGCUAAUGGAGGUAAAGGCUUUUGCAAACUACACAAUUGGAAUUGUGUUAAUUGUGAUACAUUCUGUGCUGGUAGUACAUUUAUUAGUGAUGAAGUUGCGAGAGACUUGUCACUACAGUUUAAAAGACCAAUAAAUCCUACUGACCAGUCUUCUUACAUCGUUGAUAGUGUUACAGUGAAGAAUGGUUCCAUCCAUCUUUACUUUGAUAAAGCUGGUCAAAAGACUUAUGAAAGACAUUCUCUCUCUCAUUUUGUUAACUUAGACAACCUGAGAGCUAAUAACACUAAAGGUUCAUUGCCUAUUAAUGUUAUAGUUUUUGAUGGUAAAUCAAAAUGUGAAGAAUCAUCUGCAAAAUCAGCGUCUGUUUACUACAGUCAGCUUAUGUGUCAACCUAUACUGUUACUAGAUCAGGCAUUAGUGUCUGAUGUUGGUGAUAGUGCGGAAGUUGCAGUUAAAAUGUUUGAUGCUUACGUUAAUACGUUUUCAUCAACUUUUAACGUACCAAUGGAAAAACUCAAAACACUAGUUGCAACUGCAGAAGCUGAACUUGCAAAGAAUGUGUCCUUAGACAAUGUCUUAUCUACUUUUAUUUCAGCAGCUCGGCAAGGGUUUGUUGAUUCAGAUGUAGAAACUAAAGAUGUUGUUGAAUGUCUUAAAUUGUCACAUCAAUCUGACAUAGAAGUUACUGGCGAUAGUUGUAAUAACUAUAUGCUCACCUAUAACAAAGUUGAAAACAUGACACCCCGUGACCUUGGUGCUUGUAUUGACUGUAGUGCGCGUCAUAUUAAUGCGCAGGUAGCAAAAAGUCACAACAUUGCUUUGAUAUGGAACGUUAAAGAUUUCAUGUCAUUGUCUGAACAACUACGAAAACAAAUACGUAGUGCUGCUAAAAAGAAUAACUUACCUUUUAAGUUGACAUGUGCAACUACUAGACAAGUUGUUAAUGUUGUAACAACAAAGAUAGCACUUAAGGGUGGUAAAAUUGUUAAUAAUUGGUUGAAGCAGUUAAUUAAAGUUACACUUGUGUUCCUUUUUGUUGCUGCUAUUUUCUAUUUAAUAACACCUGUUCAUGUCAUGUCUAAACAUACUGACUUUUCAAGUGAAAUCAUAGGAUACAAGGCUAUUGAUGGUGGUGUCACUCGUGACAUAGCAUCUACAGAUACUUGUUUUGCUAACAAACAUGCUGAUUUUGACACAUGGUUUAGCCAGCGUGGUGGUAGUUAUACUAAUGACAAAGCUUGCCCAUUGAUUGCUGCAGUCAUAACAAGAGAAGUGGGUUUUGUCGUGCCUGGUUUGCCUGGCACGAUAUUACGCACAACUAAUGGUGACUUUUUGCAUUUCUUACCUAGAGUUUUUAGUGCAGUUGGUAACAUCUGUUACACACCAUCAAAACUUAUAGAGUACACUGACUUUGCAACAUCAGCUUGUGUUUUGGCUGCUGAAUGUACAAUUUUUAAAGAUGCUUCUGGUAAGCCAGUACCAUAUUGUUAUGAUACCAAUGUACUAGAAGGUUCUGUUGCUUAUGAAAGUUUACGCCCUGACACACGUUAUGUGCUCAUGGAUGGCUCUAUUAUUCAAUUUCCUAACACCUACCUUGAAGGUUCUGUUAGAGUGGUAACAACUUUUGAUUCUGAGUACUGUAGGCACGGCACUUGUGAAAGAUCAGAAGCUGGUGUUUGUGUAUCUACUAGUGGUAGAUGGGUACUUAACAAUGAUUAUUACAGAUCUUUACCAGGAGUUUUCUGUGGUGUAGAUGCUGUAAAUUUACUUACUAAUAUGUUUACACCACUAAUUCAACCUAUUGGUGCUUUGGACAUAUCAGCAUCUAUAGUAGCUGGUGGUAUUGUAGCUAUCGUAGUAACAUGCCUUGCCUACUAUUUUAUGAGGUUUAGAAGAGCUUUUGGUGAAUACAGUCAUGUAGUUGCCUUUAAUACUUUACUAUUCCUUAUGUCAUUCACUGUACUCUGUUUAACACCAGUUUACUCAUUCUUACCUGGUGUUUAUUCUGUUAUUUACUUGUACUUGACAUUUUAUCUUACUAAUGAUGUUUCUUUUUUAGCACAUAUUCAGUGGAUGGUUAUGUUCACACCUUUAGUACCUUUCUGGAUAACAAUUGCUUAUAUCAUUUGUAUUUCCACAAAGCAUUUCUAUUGGUUCUUUAGUAAUUACCUAAAGAGACGUGUAGUCUUUAAUGGUGUUUCCUUUAGUACUUUUGAAGAAGCUGCGCUGUGCACCUUUUUGUUAAAUAAAGAAAUGUAUCUAAAGUUGCGUAGUGAUGUGCUAUUACCUCUUACGCAAUAUAAUAGAUACUUAGCUCUUUAUAAUAAGUACAAGUAUUUUAGUGGAGCAAUGGAUACAACUAGCUACAGAGAAGCUGCUUGUUGUCAUCUCGCAAAGGCUCUCAAUGACUUCAGUAACUCAGGUUCUGAUGUUCUUUACCAACCACCACAAACCUCUAUCACCUCAGCUGUUUUGCAGAGUGGUUUUAGAAAAAUGGCAUUCCCAUCUGGUAAAGUUGAGGGUUGUAUGGUACAAGUAACUUGUGGUACAACUACACUUAACGGUCUUUGGCUUGAUGACGUAGUUUACUGUCCAAGACAUGUGAUCUGCACCUCUGAAGACAUGCUUAACCCUAAUUAUGAAGAUUUACUCAUUCGUAAGUCUAAUCAUAAUUUCUUGGUACAGGCUGGUAAUGUUCAACUCAGGGUUAUUGGACAUUCUAUGCAAAAUUGUGUACUUAAGCUUAAGGUUGAUACAGCCAAUCCUAAGACACCUAAGUAUAAGUUUGUUCGCAUUCAACCAGGACAGACUUUUUCAGUGUUAGCUUGUUACAAUGGUUCACCAUCUGGUGUUUACCAAUGUGCUAUGAGGCCCAAUUUCACUAUUAAGGGUUCAUUCCUUAAUGGUUCAUGUGGUAGUGUUGGUUUUAACAUAGAUUAUGACUGUGUCUCUUUUUGUUACAUGCACCAUAUGGAAUUACCAACUGGAGUUCAUGCUGGCACAGACUUAGAAGGUAACUUUUAUGGACCUUUUGUUGACAGGCAAACAGCACAAGCAGCUGGUACGGACACAACUAUUACAGUUAAUGUUUUAGCUUGGUUGUACGCUGCUGUUAUAAAUGGAGACAGGUGGUUUCUCAAUCGAUUUACCACAACUCUUAAUGACUUUAACCUUGUGGCUAUGAAGUACAAUUAUGAACCUCUAACACAAGACCAUGUUGACAUACUAGGACCUCUUUCUGCUCAAACUGGAAUUGCCGUUUUAGAUAUGUGUGCUUCAUUAAAAGAAUUACUGCAAAAUGGUAUGAAUGGACGUACCAUAUUGGGUAGUGCUUUAUUAGAAGAUGAAUUUACACCUUUUGAUGUUGUUAGACAAUGCUCAGGUGUUACUUUCCAAAGUGCAGUGAAAAGAACAAUCAAGGGUACACACCACUGGUUGUUACUCACAAUUUUGACUUCACUUUUAGUUUUAGUCCAGAGUACUCAAUGGUCUUUGUUCUUUUUUUUGUAUGAAAAUGCCUUUUUACCUUUUGCUAUGGGUAUUAUUGCUAUGUCUGCUUUUGCAAUGAUGUUUGUCAAACAUAAGCAUGCAUUUCUCUGUUUGUUUUUGUUACCUUCUCUUGCCACUGUAGCUUAUUUUAAUAUGGUCUAUAUGCCUGCUAGUUGGGUGAUGCGUAUUAUGACAUGGUUGGAUAUGGUUGAUACUAGUUUGUCUGGUUUUAAGCUAAAAGACUGUGUUAUGUAUGCAUCAGCUGUAGUGUUACUAAUCCUUAUGACAGCAAGAACUGUGUAUGAUGAUGGUGCUAGGAGAGUGUGGACACUUAUGAAUGUCUUGACACUCGUUUAUAAAGUUUAUUAUGGUAAUGCUUUAGAUCAAGCCAUUUCCAUGUGGGCUCUUAUAAUCUCUGUUACUUCUAACUACUCAGGUGUAGUUACAACUGUCAUGUUUUUGGCCAGAGGUAUUGUUUUUAUGUGUGUUGAGUAUUGCCCUAUUUUCUUCAUAACUGGUAAUACACUUCAGUGUAUAAUGCUAGUUUAUUGUUUCUUAGGCUAUUUUUGUACUUGUUACUUUGGCCUCUUUUGUUUACUCAACCGCUACUUUAGACUGACUCUUGGUGUUUAUGAUUACUUAGUUUCUACACAGGAGUUUAGAUAUAUGAAUUCACAGGGACUACUCCCACCCAAGAAUAGCAUAGAUGCCUUCAAACUCAACAUUAAAUUGUUGGGUGUUGGUGGCAAACCUUGUAUCAAAGUAGCCACUGUACAGUCUAAAAUGUCAGAUGUAAAGUGCACAUCAGUAGUCUUACUCUCAGUUUUGCAACAACUCAGAGUAGAAUCAUCAUCUAAAUUGUGGGCUCAAUGUGUCCAGUUACACAAUGACAUUCUCUUAGCUAAAGAUACUACUGAAGCCUUUGAAAAAAUGGUUUCACUACUUUCUGUUUUGCUUUCCAUGCAGGGUGCUGUAGACAUAAACAAGCUUUGUGAAGAAAUGCUGGACAACAGGGCAACCUUACAAGCUAUAGCCUCAGAGUUUAGUUCCCUUCCAUCAUAUGCAGCUUUUGCUACUGCUCAAGAAGCUUAUGAGCAGGCUGUUGCUAAUGGUGAUUCUGAAGUUGUUCUUAAAAAGUUGAAGAAGUCUUUGAAUGUGGCUAAAUCUGAAUUUGACCGUGAUGCAGCCAUGCAACGUAAGUUGGAAAAGAUGGCUGAUCAAGCUAUGACCCAAAUGUAUAAACAGGCUAGAUCUGAGGACAAGAGGGCAAAAGUUACUAGUGCUAUGCAGACAAUGCUUUUCACUAUGCUUAGAAAGUUGGAUAAUGAUGCACUCAACAACAUUAUCAACAAUGCAAGAGAUGGUUGUGUUCCCUUGAACAUAAUACCUCUUACAACAGCAGCCAAACUAAUGGUUGUCAUACCAGACUAUAACACAUAUAAAAAUACGUGUGAUGGUACAACAUUUACUUAUGCAUCAGCAUUGUGGGAAAUCCAACAGGUUGUAGAUGCAGAUAGUAAAAUUGUUCAACUUAGUGAAAUUAGUAUGGACAAUUCACCUAAUUUAGCAUGGCCUCUUAUUGUAACAGCUUUAAGGGCCAAUUCUGCUGUCAAAUUACAGAAUAAUGAGCUUAGUCCUGUUGCACUACGACAGAUGUCUUGUGCUGCCGGUACUACACAAACUGCUUGCACUGAUGACAAUGCGUUAGCUUACUACAACACAACAAAGGGAGGUAGGUUUGUACUUGCACUGUUAUCCGAUUUACAGGAUUUGAAAUGGGCUAGAUUCCCUAAGAGUGAUGGAACUGGUACUAUCUAUACAGAACUGGAACCACCUUGUAGGUUUGUUACAGACACACCUAAAGGUCCUAAAGUGAAGUAUUUAUACUUUAUUAAAGGAUUAAACAACCUAAAUAGAGGUAUGGUACUUGGUAGUUUAGCUGCCACAGUACGUCUACAAGCUGGUAAUGCAACAGAAGUGCCUGCCAAUUCAACUGUAUUAUCUUUCUGUGCUUUUGCUGUAGAUGCUGCUAAAGCUUACAAAGAUUAUCUAGCUAGUGGGGGACAACCAAUCACUAAUUGUGUUAAGAUGUUGUGUACACACACUGGUACUGGUCAGGCAAUAACAGUUACACCGGAAGCCAAUAUGGAUCAAGAAUCCUUUGGUGGUGCAUCGUGUUGUCUGUACUGCCGUUGCCACAUAGAUCAUCCAAAUCCUAAAGGAUUUUGUGACUUAAAAGGUAAGUAUGUACAAAUACCUACAACUUGUGCUAAUGACCCUGUGGGUUUUACACUUAAAAACACAGUCUGUACCGUCUGCGGUAUGUGGAAAGGUUAUGGCUGUAGUUGUGAUCAACUCCGCGAACCCAUGCUUCAGUCAGCUGAUGCACAAUCGUUUUUAAACGGGUUUGCGGUGUAAGUGCAGCCCGUCUUACACCGUGCGGCACAGGCACUAGUACUGAUGUCGUAUACAGGGCUUUUGACAUCUACAAUGAUAAAGUAGCUGGUUUUGCUAAAUUCCUAAAAACUAAUUGUUGUCGCUUCCAAGAAAAGGACGAAGAUGACAAUUUAAUUGAUUCUUACUUUGUAGUUAAGAGACACACUUUCUCUAACUACCAACAUGAAGAAACAAUUUAUAAUUUACUUAAGGAUUGUCCAGCUGUUGCUAAACAUGACUUCUUUAAGUUUAGAAUAGACGGUGACAUGGUACCACAUAUAUCACGUCAACGUCUUACUAAAUACACAAUGGCAGACCUCGUCUAUGCUUUAAGGCAUUUUGAUGAAGGUAAUUGUGACACAUUAAAAGAAAUACUUGUCACAUACAAUUGUUGUGAUGAUGAUUAUUUCAAUAAAAAGGACUGGUAUGAUUUUGUAGAAAACCCAGAUAUAUUACGCGUAUACGCCAACUUAGGUGAACGUGUACGCCAAGCUUUGUUAAAAACAGUACAAUUCUGUGAUGCCAUGCGAAAUGCUGGUAUUGUUGGUGUACUGACAUUAGAUAAUCAAGAUCUCAAUGGUAACUGGUAUGAUUUCGGUGAUUUCAUACAAACCACGCCAGGUAGUGGAGUUCCUGUUGUAGAUUCUUAUUAUUCAUUGUUAAUGCCUAUAUUAACCUUGACCAGGGCUUUAACUGCAGAGUCACAUGUUGACACUGACUUAACAAAGCCUUACAUUAAGUGGGAUUUGUUAAAAUAUGACUUCACGGAAGAGAGGUUAAAACUCUUUGACCGUUAUUUUAAAUAUUGGGAUCAGACAUACCACCCAAAUUGUGUUAACUGUUUGGAUGACAGAUGCAUUCUGCAUUGUGCAAACUUUAAUGUUUUAUUCUCUACAGUGUUCCCACCUACAAGUUUUGGACCACUAGUGAGAAAAAUAUUUGUUGAUGGUGUUCCAUUUGUAGUUUCAACUGGAUACCACUUCAGAGAGCUAGGUGUUGUACAUAAUCAGGAUGUAAACUUACAUAGCUCUAGACUUAGUUUUAAGGAAUUACUUGUGUAUGCUGCUGACCCUGCUAUGCACGCUGCUUCUGGUAAUCUAUUACUAGAUAAACGCACUACGUGCUUUUCAGUAGCUGCACUUACUAACAAUGUUGCUUUUCAAACUGUCAAACCCGGUAAUUUUAACAAAGACUUCUAUGACUUUGCUGUGUCUAAGGGUUUCUUUAAGGAAGGAAGUUCUGUUGAAUUAAAACACUUCUUCUUUGCUCAGGAUGGUAAUGCUGCUAUCAGCGAUUAUGACUACUAUCGUUAUAAUCUACCAACAAUGUGUGAUAUCAGACAACUACUAUUUGUAGUUGAAGUUGUUGAUAAGUACUUUGAUUGUUACGAUGGUGGCUGUAUUAAUGCUAACCAAGUCAUCGUCAACAACCUAGACAAAUCAGCUGGUUUUCCAUUUAAUAAAUGGGGUAAGGCUAGACUUUAUUAUGAUUCAAUGAGUUAUGAGGAUCAAGAUGCACUUUUCGCAUAUACAAAACGUAAUGUCAUCCCUACUAUAACUCAAAUGAAUCUUAAGUAUGCCAUUAGUGCAAAGAAUAGAGCUCGCACCGUAGCUGGUGUCUCUAUCUGUAGUACUAUGACCAAUAGACAGUUUCAUCAAAAAUUAUUGAAAUCAAUAGCCGCCACUAGAGGAGCUACUGUAGUAAUUGGAACAAGCAAAUUCUAUGGUGGUUGGCACAACAUGUUAAAAACUGUUUAUAGUGAUGUAGAAAACCCUCACCUUAUGGGUUGGGAUUAUCCUAAAUGUGAUAGAGCCAUGCCUAACAUGCUUAGAAUUAUGGCCUCACUUGUUCUUGCUCGCAAACAUACAACGUGUUGUAGCUUGUCACACCGUUUCUAUAGAUUAGCUAAUGAGUGUGCUCAAGUAUUGAGUGAAAUGGUCAUGUGUGGCGGUUCACUAUAUGUUAAACCAGGUGGAACCUCAUCAGGAGAUGCCACAACUGCUUAUGCUAAUAGUGUUUUUAACAUUUGUCAAGCUGUCACGGCCAAUGUUAAUGCACUUUUAUCUACUGAUGGUAACAAAAUUGCCGAUAAGUAUGUCCGCAAUUUACAACACAGACUUUAUGAGUGUCUCUAUAGAAAUAGAGAUGUUGACACAGACUUUGUGAAUGAGUUUUACGCAUAUUUGCGUAAACAUUUCUCAAUGAUGAUACUCUCUGACGAUGCUGUUGUGUGUUUCAAUAGCACUUAUGCAUCUCAAGGUCUAGUGGCUAGCAUAAAGAACUUUAAGUCAGUUCUUUAUUAUCAAAACAAUGUUUUUAUGUCUGAAGCAAAAUGUUGGACUGAGACUGACCUUACUAAAGGACCUCAUGAAUUUUGCUCUCAACAUACAAUGCUAGUUAAACAGGGUGAUGAUUAUGUGUACCUUCCUUACCCAGAUCCAUCAAGAAUCCUAGGGGCCGGCUGUUUUGUAGAUGAUAUCGUAAAAACAGAUGGUACACUUAUGAUUGAACGGUUCGUGUCUUUAGCUAUAGAUGCUUACCCACUUACUAAACAUCCUAAUCAGGAGUAUGCUGAUGUCUUUCAUUUGUACUUACAAUACAUAAGAAAGCUACAUGAUGAGUUAACAGGACACAUGUUAGACAUGUAUUCUGUUAUGCUUACUAAUGAUAACACUUCAAGGUAUUGGGAACCUGAGUUUUAUGAGGCUAUGUACACACCGCAUACAGUCUUACAGGCUGUUGGGGCUUGUGUUCUUUGCAAUUCACAGACUUCAUUAAGAUGUGGUGCUUGCAUACGUAGACCAUUCUUAUGUUGUAAAUGCUGUUACGACCAUGUCAUAUCAACAUCACAUAAAUUAGUCUUGUCUGUUAAUCCGUAUGUUUGCAAUGCUCCAGGUUGUGAUGUCACAGAUGUGACUCAACUUUACUUAGGAGGUAUGAGCUAUUAUUGUAAAUCACAUAAACCACCCAUUAGUUUUCCAUUGUGUGCUAAUGGACAAGUUUUUGGUUUAUAUAAAAAUACAUGUGUUGGUAGCGAUAAUGUUACUGACUUUAAUGCAAUUGCAACAUGUGACUGGACAAAUGCUGGUGAUUACAUUUUAGCUAACACCUGUACUGAAAGACUCAAGCUUUUUGCAGCAGAAACGCUCAAAGCUACUGAGGAGACAUUUAAACUGUCUUAUGGUAUUGCUACUGUACGUGAAGUGCUGUCUGACAGAGAAUUACAUCUUUCAUGGGAAGUUGGUAAACCUAGACCACCACUUAACCGAAAUUAUGUCUUUACUGGUUAUCGUGUAACUAAAAACAGUAAAGUACAAAUAGGAGAGUACACCUUUGAAAAAGGUGACUAUGGUGAUGCUGUUGUUUACCGAGGUACAACAACUUACAAAUUAAAUGUUGGUGAUUAUUUUGUGCUGACAUCACAUACAGUAAUGCCAUUAAGUGCACCUACACUAGUGCCACAAGAGCACUAUGUUAGAAUUACUGGCUUAUACCCAACACUCAAUAUCUCAGAUGAGUUUUCUAGCAAUGUUGCAAAUUAUCAAAAGGUUGGUAUGCAAAAGUAUUCUACACUCCAGGGACCACCUGGUACUGGUAAGAGUCAUUUUGCUAUUGGCCUAGCUCUCUACUACCCUUCUGCUCGCAUAGUGUAUACAGCUUGCUCUCAUGCCGCUGUUGAUGCACUAUGUGAGAAGGCAUUAAAAUAUUUGCCUAUAGAUAAAUGUAGUAGAAUUAUACCUGCACGUGCUCGUGUAGAGUGUUUUGAUAAAUUCAAAGUGAAUUCAACAUUAGAACAGUAUGUCUUUUGUACUGUAAAUGCAUUGCCUGAGACGACAGCAGAUAUAGUUGUCUUUGAUGAAAUUUCAAUGGCCACAAAUUAUGAUUUGAGUGUUGUCAAUGCCAGAUUACGUGCUAAGCACUAUGUGUACAUUGGCGACCCUGCUCAAUUACCUGCACCACGCACAUUGCUAACUAAGGGCACACUAGAACCAGAAUAUUUCAAUUCAGUGUGUAGACUUAUGAAAACUAUAGGUCCAGACAUGUUCCUCGGAACUUGUCGGCGUUGUCCUGCUGAAAUUGUUGACACUGUGAGUGCUUUGGUUUAUGAUAAUAAGCUUAAAGCACAUAAAGACAAAUCAGCUCAAUGCUUUAAAAUGUUUUAUAAGGGUGUUAUCACGCAUGAUGUUUCAUCUGCAAUUAACAGGCCACAAAUAGGCGUGGUAAGAGAAUUCCUUACACGUAACCCUGCUUGGAGAAAAGCUGUCUUUAUUUCACCUUAUAAUUCACAGAAUGCUGUAGCCUCAAAGAUUUUGGGACUACCAACUCAAACUGUUGAUUCAUCACAGGGCUCAGAAUAUGACUAUGUCAUAUUCACUCAAACCACUGAAACAGCUCACUCUUGUAAUGUAAACAGAUUUAAUGUUGCUAUUACCAGAGCAAAAGUAGGCAUACUUUGCAUAAUGUCUGAUAGAGACCUUUAUGACAAGUUGCAAUUUACAAGUCUUGAAAUUCCACGUAGGAAUGUGGCAACUUUACAAGCUGAAAAUGUAACAGGACUCUUUAAAGAUUGUAGUAAGGUAAUCACUGGGUUACAUCCUACACAGGCACCUACACACCUCAGUGUUGACACUAAAUUCAAAACUGAAGGUUUAUGUGUUGACAUACCUGGCAUACCUAAGGACAUGACCUAUAGAAGACUCAUCUCUAUGAUGGGUUUUAAAAUGAAUUAUCAAGUUAAUGGUUACCCUAACAUGUUUAUCACCCGCGAAGAAGCUAUAAGACAUGUACGUGCAUGGAUUGGCUUCGAUGUCGAGGGGUGUCAUGCUACUAGAGAAGCUGUUGGUACCAAUUUACCUUUACAGCUAGGUUUUUCUACAGGUGUUAACCUAGUUGCUGUACCUACAGGUUAUGUUGAUACACCUAAUAAUACAGAUUUUUCCAGAGUUAGUGCUAAACCACCGCCUGGAGAUCAAUUUAAACACCUCAUACCACUUAUGUACAAAGGACUUCCUUGGAAUGUAGUGCGUAUAAAGAUUGUACAAAUGUUAAGUGACACACUUAAAAAUCUCUCUGACAGAGUCGUAUUUGUCUUAUGGGCACAUGGCUUUGAGUUGACAUCUAUGAAGUAUUUUGUGAAAAUAGGACCUGAGCGCACCUGUUGUCUAUGUGAUAGACGUGCCACAUGCUUUUCCACUGCUUCAGACACUUAUGCCUGUUGGCAUCAUUCUAUUGGAUUUGAUUACGUCUAUAAUCCGUUUAUGAUUGAUGUUCAACAAUGGGGUUUUACAGGUAACCUACAAAGCAACCAUGAUCUGUAUUGUCAAGUCCAUGGUAAUGCACAUGUAGCUAGUUGUGAUGCAAUCAUGACUAGGUGUCUAGCUGUCCACGAGUGCUUUGUUAAGCGUGUUGACUGGACUAUUGAAUAUCCUAUAAUUGGUGAUGAACUGAAGAUUAAUGCGGCUUGUAGAAAGGUUCAACACAUGGUUGUUAAAGCUGCAUUAUUAGCAGACAAAUUCCCAGUUCUUCACGACAUUGGUAACCCUAAAGCUAUUAAGUGUGUACCUCAAGCUGAUGUAGAAUGGAAGUUCUAUGAUGCACAGCCUUGUAGUGACAAAGCUUAUAAAAUAGAAGAAUUAUUCUAUUCUUAUGCCACACAUUCUGACAAAUUCACAGAUGGUGUAUGCCUAUUUUGGAAUUGCAAUGUCGAUAGAUAUCCUGCUAAUUCCAUUGUUUGUAGAUUUGACACUAGAGUGCUAUCUAACCUUAACUUGCCUGGUUGUGAUGGUGGCAGUUUGUAUGUAAAUAAACAUGCAUUCCACACACCAGCUUUUGAUAAAAGUGCUUUUGUUAAUUUAAAACAAUUACCAUUUUUCUAUUACUCUGACAGUCCAUGUGAGUCUCAUGGAAAACAAGUAGUGUCAGAUAUAGAUUAUGUACCACUAAAGUCUGCUACGUGUAUAACACGUUGCAAUUUAGGUGGUGCUGUCUGUAGACAUCAUGCUAAUGAGUACAGAUUGUAUCUCGAUGCUUAUAACAUGAUGAUCUCAGCUGGCUUUAGCUUGUGGGUUUACAAACAAUUUGAUACUUAUAACCUCUGGAACACUUUUACAAGACUUCAGAGUUUAGAAAAUGUGGCUUUUAAUGUUGUAAAUAAGGGACACUUUGAUGGACAACAGGGUGAAGUACCAGUUUCUAUCAUUAAUAACACUGUUUACACAAAAGUUGAUGGUGUUGAUGUAGAAUUGUUUGAAAAUAAAACAACAUUACCUGUUAAUGUAGCAUUUGAGCUUUGGGCUAAGCGCAACAUUAAACCAGUACCAGAGGUGAAAAUACUCAAUAAUUUGGGUGUGGACAUUGCUGCUAAUACUGUGAUCUGGGACUACAAAAGAGAUGCUCCAGCACAUAUAUCUACUAUUGGUGUUUGUUCUAUGACUGACAUAGCCAAGAAACCAACUGAAACGAUUUGUGCACCACUCACUGUCUUUUUUGAUGGUAGAGUUGAUGGUCAAGUAGACUUAUUUAGAAAUGCCCGUAAUGGUGUUCUUAUUACAGAAGGUAGUGUUAAAGGUUUACAACCAUCUGUAGGUCCCAAACAAGCUAGUCUUAAUGGAGUCACAUUAAUUGGAGAAGCCGUAAAAACACAGUUCAAUUAUUAUAAGAAAGUUGAUGGUGUUGUCCAACAAUUACCUGAAACUUACUUUACUCAGAGUAGAAAUUUACAAGAAUUUAAACCCAGGAGUCAAAUGGAAAUUGAUUUCUUAGAAUUAGCUAUGGAUGAAUUCAUUGAACGGUAUAAAUUAGAAGGCUAUGCCUUCGAACAUAUCGUUUAUGGAGAUUUUAGUCAUAGUCAGUUAGGUGGUUUACAUCUACUGAUUGGACUAGCUAAACGUUUUAAGGAAUCACCUUUUGAAUUAGAAGAUUUUAUUCCUAUGGACAGUACAGUUAAAAACUAUUUCAUAACAGAUGCGCAAACAGGUUCAUCUAAGUGUGUGUGUUCUGUUAUUGAUUUAUUACUUGAUGAUUUUGUUGAAAUAAUAAAAUCCCAAGAUUUAUCUGUAGUUUCUAAGGUUGUCAAAGUGACUAUUGACUAUACAGAAAUUUCAUUUAUGCUUUGGUGUAAAGAUGGCCAUGUAGAAACAUUUUACCCAAAAUUACAAUCUAGUCAAGCGUGGCAACCGGGUGUUGCUAUGCCUAAUCUUUACAAAAUGCAAAGAAUGCUAUUAGAAAAGUGUGACCUUCAAAAUUAUGGUGAUAGUGCAACAUUACCUAAAGGCAUAAUGAUGAAUGUCGCAAAAUAUACUCAACUGUGUCAAUAUUUAAACACAUUAACAUUAGCUGUACCCUAUAAUAUGAGAGUUAUACAUUUUGGUGCUGGUUCUGAUAAAGGAGUUGCACCAGGUACAGCUGUUUUAAGACAGUGGUUGCCUACGGGUACGCUGCUUGUCGAUUCAGAUCUUAAUGACUUUGUCUCUGAUGCAGAUUCAACUUUGAUUGGUGAUUGUGCAACUGUACAUACAGCUAAUAAAUGGGAUCUCAUUAUUAGUGAUAUGUACGACCCUAAGACUAAAAAUGUUACAAAAGAAAAUGACUCUAAAGAGGGUUUUUUCACUUACAUUUGUGGGUUUAUACAACAAAAGCUAGCUCUUGGAGGUUCCGUGGCUAUAAAGAUAACAGAACAUUCUUGGAAUGCUGAUCUUUAUAAGCUCAUGGGACACUUCGCAUGGUGGACAGCCUUUGUUACUAAUGUGAAUGCGUCAUCAUCUGAAGCAUUUUUAAUUGGAUGUAAUUAUCUUGGCAAACCACGCGAACAAAUAGAUGGUUAUGUCAUGCAUGCAAAUUACAUAUUUUGGAGGAAUACAAAUCCAAUUCAGUUGUCUUCCUAUUCUUUAUUUGACAUGAGUAAAUUUCCCCUUAAAUUAAGGGGUACUGCUGUUAUGUCUUUAAAAGAAGGUCAAAUCAAUGAUAUGAUUUUAUCUCUUCUUAGUAAAGGUAGACUUAUAAUUAGAGAAAACAACAGAGUUGUUAUUUCUAGUGAUGUUCUUGUUAACAACUAAACGAACAAUGUUUGUUUUUCUUGUUUUAUUGCCACUAGUCUCUAGUCAGUGUGUUAAUCUUACAACCAGAACUCAAUUACCCCCUGCAUACACUAAUUCUUUCACACGUGGUGUUUAUUACCCUGACAAAGUUUUCAGAUCCUCAGUUUUACAUUCAACUCAGGACUUGUUCUUACCUUUCUUUUCCAAUGUUACUUGGUUCCAUGCUAUACAUGUCUCUGGGACCAAUGGUACUAAGAGGUUUGAUAACCCUGUCCUACCAUUUAAUGAUGGUGUUUAUUUUGCUUCCACUGAGAAGUCUAACAUAAUAAGAGGCUGGAUUUUUGGUACUACUUUAGAUUCGAAGACCCAGUCCCUACUUAUUGUUAAUAACGCUACUAAUGUUGUUAUUAAAGUCUGUGAAUUUCAAUUUUGUAAUGAUCCAUUUUUGGGUGUUUAUUACCACAAAAACAACAAAAGUUGGAUGGAAAGUGAGUUCAGAGUUUAUUCUAGUGCGAAUAAUUGCACUUUUGAAUAUGUCUCUCAGCCUUUUCUUAUGGACCUUGAAGGAAAACAGGGUAAUUUCAAAAAUCUUAGGGAAUUUGUGUUUAAGAAUAUUGAUGGUUAUUUUAAAAUAUAUUCUAAGCACACGCCUAUUAAUUUAGUGCGUGAUCUCCCUCAGGGUUUUUCGGCUUUAGAACCAUUGGUAGAUUUGCCAAUAGGUAUUAACAUCACUAGGUUUCAAACUUUACUUGCUUUACAUAGAAGUUAUUUGACUCCUGGUGAUUCUUCUUCAGGUUGGACAGCUGGUGCUGCAGCUUAUUAUGUGGGUUAUCUUCAACCUAGGACUUUUCUAUUAAAAUAUAAUGAAAAUGGAACCAUUACAGAUGCUGUAGACUGUGCACUUGACCCUCUCUCAGAAACAAAGUGUACGUUGAAAUCCUUCACUGUAGAAAAAGGAAUCUAUCAAACUUCUAACUUUAGAGUCCAACCAACAGAAUCUAUUGUUAGAUUUCCUAAUAUUACAAACUUGUGCCCUUUUGGUGAAGUUUUUAACGCCACCAGAUUUGCAUCUGUUUAUGCUUGGAACAGGAAGAGAAUCAGCAACUGUGUUGCUGAUUAUUCUGUCCUAUAUAAUUCCGCAUCAUUUUCCACUUUUAAGUGUUAUGGAGUGUCUCCUACUAAAUUAAAUGAUCUCUGCUUUACUAAUGUCUAUGCAGAUUCAUUUGUAAUUAGAGGUGAUGAAGUCAGACAAAUCGCUCCAGGGCAAACUGGAAAGAUUGCUGAUUAUAAUUAUAAAUUACCAGAUGAUUUUACAGGCUGCGUUAUAGCUUGGAAUUCUAACAAUCUUGAUUCUAAGGUUGGUGGUAAUUAUAAUUACCUGUAUAGAUUGUUUAGGAAGUCUAAUCUCAAACCUUUUGAGAGAGAUAUUUCAACUGAAAUCUAUCAGGCCGGUAGCACACCUUGUAAUGGUGUUGAAGGUUUUAAUUGUUACUUUCCUUUACAAUCAUAUGGUUUCCAACCCACUAAUGGUGUUGGUUACCAACCAUACAGAGUAGUAGUACUUUCUUUUGAACUUCUACAUGCACCAGCAACUGUUUGUGGACCUAAAAAGUCUACUAAUUUGGUUAAAAACAAAUGUGUCAAUUUCAACUUCAAUGGUUUAACAGGCACAGGUGUUCUUACUGAGUCUAACAAAAAGUUUCUGCCUUUCCAACAAUUUGGCAGAGACAUUGCUGACACUACUGAUGCUGUCCGUGAUCCACAGACACUUGAGAUUCUUGACAUUACACCAUGUUCUUUUGGUGGUGUCAGUGUUAUAACACCAGGAACAAAUACUUCUAACCAGGUUGCUGUUCUUUAUCAGGAUGUUAACUGCACAGAAGUCCCUGUUGCUAUUCAUGCAGAUCAACUUACUCCUACUUGGCGUGUUUAUUCUACAGGUUCUAAUGUUUUUCAAACACGUGCAGGCUGUUUAAUAGGGGCUGAACAUGUCAACAACUCAUAUGAGUGUGACAUACCCAUUGGUGCAGGUAUAUGCGCUAGUUAUCAGACUCAGACUAAUUCUCCUCGGCGGGCACGUAGUGUAGCUAGUCAAUCCAUCAUUGCCUACACUAUGUCACUUGGUGCAGAAAAUUCAGUUGCUUACUCUAAUAACUCUAUUGCCAUACCCACAAAUUUUACUAUUAGUGUUACCACAGAAAUUCUACCAGUGUCUAUGACCAAGACAUCAGUAGAUUGUACAAUGUACAUUUGUGGUGAUUCAACUGAAUGCAGCAAUCUUUUGUUGCAAUAUGGCAGUUUUUGUACACAAUUAAACCGUGCUUUAACUGGAAUAGCUGUUGAACAAGACAAAAACACCCAAGAAGUUUUUGCACAAGUCAAACAAAUUUACAAAACACCACCAAUUAAAGAUUUUGGUGGUUUUAAUUUUUCACAAAUAUUACCAGAUCCAUCAAAACCAAGCAAGAGGUCAUUUAUUGAAGAUCUACUUUUCAACAAAGUGACACUUGCAGAUGCUGGCUUCAUCAAACAAUAUGGUGAUUGCCUUGGUGAUAUUGCUGCUAGAGACCUCAUUUGUGCACAAAAGUUUAACGGCCUUACUGUUUUGCCACCUUUGCUCACAGAUGAAAUGAUUGCUCAAUACACUUCUGCACUGUUAGCGGGUACAAUCACUUCUGGUUGGACCUUUGGUGCAGGUGCUGCAUUACAAAUACCAUUUGCUAUGCAAAUGGCUUAUAGGUUUAAUGGUAUUGGAGUUACACAGAAUGUUCUCUAUGAGAACCAAAAAUUGAUUGCCAACCAAUUUAAUAGUGCUAUUGGCAAAAUUCAAGACUCACUUUCUUCCACAGCAAGUGCACUUGGAAAACUUCAAGAUGUGGUCAACCAAAAUGCACAAGCUUUAAACACGCUUGUUAAACAACUUAGCUCCAAUUUUGGUGCAAUUUCAAGUGUUUUAAAUGAUAUCCUUUCACGUCUUGACAAAGUUGAGGCUGAAGUGCAAAUUGAUAGGUUGAUCACAGGCAGACUUCAAAGUUUGCAGACAUAUGUGACUCAACAAUUAAUUAGAGCUGCAGAAAUCAGAGCUUCUGCUAAUCUUGCUGCUACUAAAAUGUCAGAGUGUGUACUUGGACAAUCAAAAAGAGUUGAUUUUUGUGGAAAGGGCUAUCAUCUUAUGUCCUUCCCUCAGUCAGCACCUCAUGGUGUAGUCUUCUUGCAUGUGACUUAUGUCCCUGCACAAGAAAAGAACUUCACAACUGCUCCUGCCAUUUGUCAUGAUGGAAAAGCACACUUUCCUCGUGAAGGUGUCUUUGUUUCAAAUGGCACACACUGGUUUGUAACACAAAGGAAUUUUUAUGAACCACAAAUCAUUACUACAGACAACACAUUUGUGUCUGGUAACUGUGAUGUUGUAAUAGGAAUUGUCAACAACACAGUUUAUGAUCCUUUGCAACCUGAAUUAGACUCAUUCAAGGAGGAGUUAGAUAAAUAUUUUAAGAAUCAUACAUCACCAGAUGUUGAUUUAGGUGACAUCUCUGGCAUUAAUGCUUCAGUUGUAAACAUUCAAAAAGAAAUUGACCGCCUCAAUGAGGUUGCCAAGAAUUUAAAUGAAUCUCUCAUCGAUCUCCAAGAACUUGGAAAGUAUGAGCAGUAUAUAAAAUGGCCAUGGUACAUUUGGCUAGGUUUUAUAGCUGGCUUGAUUGCCAUAGUAAUGGUGACAAUUAUGCUUUGCUGUAUGACCAGUUGCUGUAGUUGUCUCAAGGGCUGUUGUUCUUGUGGAUCCUGCUGCAAAUUUGAUGAAGACGACUCUGAGCCAGUGCUCAAAGGAGUCAAAUUACAUUACACAUAAACGAACUUAUGGAUUUGUUUAUGAGAAUCUUCACAAUUGGAACUGUAACUUUGAAGCAAGGUGAAAUCAAGGAUGCUACUCCUUCAGAUUUUGUUCGCGCUACUGCAACGAUACCGAUACAAGCCUCACUCCCUUUCGGAUGGCUUAUUGUUGGCGUUGCACUUCUUGCUGUUUUUCAGAGCGCUUCCAAAAUCAUAACCCUCAAAAAGAGAUGGCAACUAGCACUCUCCAAGGGUGUUCACUUUGUUUGCAACUUGCUGUUGUUGUUUGUAACAGUUUACUCACACCUUUUGCUCGUUGCUGCUGGCCUUGAAGCCCCUUUUCUCUAUCUUUAUGCUUUAGUCUACUUCUUGCAGAGUAUAAACUUUGUAAGAAUAAUAAUGAGGCUUUGGCUUUGCUGGAAAUGCCGUUCCAAAAACCCAUUACUUUAUGAUGCCAACUAUUUUCUUUGCUGGCAUACUAAUUGUUACGACUAUUGUAUACCUUACAAUAGUGUAACUUCUUCAAUUGUCAUUACUUCAGGUGAUGGCACAACAAGUCCUAUUUCUGAACAUGACUACCAGAUUGGUGGUUAUACUGAAAAAUGGGAAUCUGGAGUAAAAGACUGUGUUGUAUUACACAGUUACUUCACUUCAGACUAUUACCAGCUGUACUCAACUCAAUUGAGUACAGACACUGGUGUUGAACAUGUUACCUUCUUCAUCUACAAUAAAAUUGUUGAUGAGCCUGAAGAACAUGUCCAAAUUCACACAAUCGACGGUUCAUCCGGAGUUGUUAAUCCAGUAAUGGAACCAAUUUAUGAUGAACCGACGACGACUACUAGCGUGCCUUUGUAAGCACAAGCUGAUGAGUACGAACUUAUGUACUCAUUCGUUUCGGAAGAGACAGGUACGUUAAUAGUUAAUAGCGUACUUCUUUUUCUUGCUUUCGUGGUAUUCUUGCUAGUUACACUAGCCAUCCUUACUGCGCUUCGAUUGUGUGCGUACUGCUGCAAUAUUGUUAACGUGAGUCUUGUAAAACCUUCUUUUUACGUUUACUCUCGUGUUAAAAAUCUGAAUUCUUCUAGAGUUCCUGAUCUUCUGGUCUAAACGAACUAAAUAUUAUAUUAGUUUUUCUGUUUGGAACUUUAAUUUUAGCCAUGGCAGAUUCCAACGGUACUAUUACCGUUGAAGAGCUUAAAAAGCUCCUUGAACAAUGGAACCUAGUAAUAGGUUUCCUAUUCCUUACAUGGAUUUGUCUUCUACAAUUUGCCUAUGCCAACAGGAAUAGGUUUUUGUAUAUAAUUAAGUUAAUUUUCCUCUGGCUGUUAUGGCCAGUAACUUUAGCUUGUUUUGUGCUUGCUGCUGUUUACAGAAUAAAUUGGAUCACCGGUGGAAUUGCUAUCGCAAUGGCUUGUCUUGUAGGCUUGAUGUGGCUCAGCUACUUCAUUGCUUCUUUCAGACUGUUUGCGCGUACGCGUUCCAUGUGGUCAUUCAAUCCAGAAACUAACAUUCUUCUCAACGUGCCACUCCAUGGCACUAUUCUGACCAGACCGCUUCUAGAAAGUGAACUCGUAAUCGGAGCUGUGAUCCUUCGUGGACAUCUUCGUAUUGCUGGACACCAUCUAGGACGCUGUGACAUCAAGGACCUGCCUAAAGAAAUCACUGUUGCUACAUCACGAACGCUUUCUUAUUACAAAUUGGGAGCUUCGCAGCGUGUAGCAGGUGACUCAGGUUUUGCUGCAUACAGUCGCUACAGGAUUGGCAACUAUAAAUUAAACACAGACCAUUCCAGUAGCAGUGACAAUAUUGCUUUGCUUGUACAGUAAGUGACAACAGAUGUUUCAUCUCGUUGACUUUCAGGUUACUAUAGCAGAGAUAUUACUAAUUAUUAUGAGGACUUUUAAAGUUUCCAUUUGGAAUCUUGAUUACAUCAUAAACCUCAUAAUUAAAAAUUUAUCUAAGUCACUAACUGAGAAUAAAUAUUCUCAAUUAGAUGAAGAGCAACCAAUGGAGAUUGAUUAAACGAACAUGAAAAUUAUUCUUUUCUUGGCACUGAUAACACUCGCUACUUGUGAGCUUUAUCACUACCAAGAGUGUGUUAGAGGUACAACAGUACUUUUAAAAGAACCUUGCUCUUCUGGAACAUACGAGGGCAAUUCACCAUUUCAUCCUCUAGCUGAUAACAAAUUUGCACUGACUUGCUUUAGCACUCAAUUUGCUUUUGCUUGUCCUGACGGCGUAAAACACGUCUAUCAGUUACGUGCCAGAUCAGUUUCACCUAAACUGUUCAUCAGACAAGAGGAAGUUCAAGAACUUUACUCUCCAAUUUUUCUUAUUGUUGCGGCAAUAGUGUUUAUAACACUUUGCUUCACACUCAAAAGAAAGACAGAAUGAUUGAACUUUCAUUAAUUGACUUCUAUUUGUGCUUUUUAGCCUUUCUGCUAUUCCUUGUUUUAAUUAUGCUUAUUAUCUUUUGGUUCUCACUUGAACUGCAAGAUCAUAAUGAAACUUGUCACGCCUAAACGAACAUGAAAUUUCUUGUUUUCUUAGGAAUCAUCACAACUGUAGCUGCAUUUCACCAAGAAUGUAGUUUACAGUCAUGUACUCAACAUCAACCAUAUGUAGUUGAUGACCCGUGUCCUAUUCACUUCUAUUCUAAAUGGUAUAUUAGAGUAGGAGCUAGAAAAUCAGCACCUUUAAUUGAAUUGUGCGUGGAUGAGGCUGGUUCUAAAUCACCCAUUCAGUACAUCGAUAUCGGUAAUUAUACAGUUUCCUGUUUACCUUUUACAAUUAAUUGCCAGGAACCUAAAUUGGGUAGUCUUGUAGUGCGUUGUUCGUUCUAUGAAGACUUUUUAGAGUAUCAUGACGUUCGUGUUGUUUUAGAUUUCAUCUAAACGAACAAACUAAAAUGUCUGAUAAUGGACCCCAAAAUCAGCGAAAUGCACCCCGCAUUACGUUUGGUGGACCCUCAGAUUCAACUGGCAGUAACCAGAAUGGAGAACGCAGUGGGGCGCGAUCAAAACAACGUCGGCCCCAAGGUUUACCCAAUAAUACUGCGUCUUGGUUCACCGCUCUCACUCAACAUGGCAAGGAAGACCUUAAAUUCCCUCGAGGACAAGGCGUUCCAAUUAACACCAAUAGCAGUCCAGAUGACCAAAUUGGCUACUACCGAAGAGCUACCAGACGAAUUCGUGGUGGUGACGGUAAAAUGAAAGAUCUCAGUCCAAGAUGGUAUUUCUACUACCUAGGAACUGGGCCAGAAGCUGGACUUCCCUAUGGUGCUAACAAAGACGGCAUCAUAUGGGUUGCAACUGAGGGAGCCUUGAAUACACCAAAAGAUCACAUUGGCACCCGCAAUCCUGCUAACAAUGCUGCAAUCGUGCUACAACUUCCUCAAGGAACAACAUUGCCAAAAGGCUUCUACGCAGAAGGGAGCAGAGGCGGCAGUCAAGCCUCUUCUCGUUCCUCAUCACGUAGUCGCAACAGUUCAAGAAAUUCAACUCCAGGCAGCAGUAGGGGAACUUCUCCUGCUAGAAUGGCUGGCAAUGGCGGUGAUGCUGCUCUUGCUUUGCUGCUGCUUGACAGAUUGAACCAGCUUGAGAGCAAAAUGUCUGGUAAAGGCCAACAACAACAAGGCCAAACUGUCACUAAGAAAUCUGCUGCUGAGGCUUCUAAGAAGCCUCGGCAAAAACGUACUGCCACUAAAGCAUACAAUGUAACACAAGCUUUCGGCAGACGUGGUCCAGAACAAACCCAAGGAAAUUUUGGGGACCAGGAACUAAUCAGACAAGGAACUGAUUACAAACAUUGGCCGCAAAUUGCACAAUUUGCCCCCAGCGCUUCAGCGUUCUUCGGAAUGUCGCGCAUUGGCAUGGAAGUCACACCUUCGGGAACGUGGUUGACCUACACAGGUGCCAUCAAAUUGGAUGACAAAGAUCCAAAUUUCAAAGAUCAAGUCAUUUUGCUGAAUAAGCAUAUUGACGCAUACAAAACAUUCCCACCAACAGAGCCUAAAAAGGACAAAAAGAAGAAGGCUGAUGAAACUCAAGCCUUACCGCAGAGACAGAAGAAACAGCAAACUGUGACUCUUCUUCCUGCUGCAGAUUUGGAUGAUUUCUCCAAACAAUUGCAACAAUCCAUGAGCAGUGCUGACUCAACUCAGGCCUAAACUCAUGCAGACCACACAAGGCAGAUGGGCUAUAUAAACGUUUUCGCUUUUCCGUUUACGAUAUAUAGUCUACUCUUGUGCAGAAUGAAUUCUCGUAACUACAUAGCACAAGUAGAUGUAGUUAACUUUAAUCUCACAUAGCAAUCUUUAAUCAGUGUGUAACAUUAGGGAGGACUUGAAAGAGCCACCACAUUUUCACCGAGGCCACGCGGAGUACGAUCGAGUGUACAGUGAACAAUGCUAGGGAGAGCUGCCUAUAUGGAAGAGCCCUAAUGUGUAAAAUUAAUUUUAGUAGUGCUAUCCCCAUGUGAUUUUAAUAGCUUCUUAGGAGAAUGACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|△DD
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△DD,-,413aa(1-413),P0DTC9,-,-,"[1-43],[74-100],[143-147],[150-158],[170-213],[233-269],[361-383],[405-413]",-,In vitro,1–5 nM[SARS-CoV-2],"15 mM NaCl, 135 mM KCl, 5 mM phosphate, 1.5 mM MgCl2","20 mM Tris–HCl, pH 7.0",37˚C,-,other_molecular:1 mg ml−1 BSA,Surface plasmon resonance,liquid,"As expected, the SARS2-NP exhibited a high binding capacity for viral RNA, which was substantially reduced in the DD-depleted mutant (Fig. 1n), indicating that the DD is required for SARS2-NP to bind viral RNA"
701,PMID: 34239064,RNAPS0000450,https://pubmed.ncbi.nlm.nih.gov/34239064,RNA + protein,-,-,SARS-CoV-2 virus RNA,29903nt(1-29903),AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGCACCUCAUGGUCAUGUUAUGGUUGAGCUGGUAGCAGAACUCGAAGGCAUUCAGUACGGUCGUAGUGGUGAGACACUUGGUGUCCUUGUCCCUCAUGUGGGCGAAAUACCAGUGGCUUACCGCAAGGUUCUUCUUCGUAAGAACGGUAAUAAAGGAGCUGGUGGCCAUAGUUACGGCGCCGAUCUAAAGUCAUUUGACUUAGGCGACGAGCUUGGCACUGAUCCUUAUGAAGAUUUUCAAGAAAACUGGAACACUAAACAUAGCAGUGGUGUUACCCGUGAACUCAUGCGUGAGCUUAACGGAGGGGCAUACACUCGCUAUGUCGAUAACAACUUCUGUGGCCCUGAUGGCUACCCUCUUGAGUGCAUUAAAGACCUUCUAGCACGUGCUGGUAAAGCUUCAUGCACUUUGUCCGAACAACUGGACUUUAUUGACACUAAGAGGGGUGUAUACUGCUGCCGUGAACAUGAGCAUGAAAUUGCUUGGUACACGGAACGUUCUGAAAAGAGCUAUGAAUUGCAGACACCUUUUGAAAUUAAAUUGGCAAAGAAAUUUGACACCUUCAAUGGGGAAUGUCCAAAUUUUGUAUUUCCCUUAAAUUCCAUAAUCAAGACUAUUCAACCAAGGGUUGAAAAGAAAAAGCUUGAUGGCUUUAUGGGUAGAAUUCGAUCUGUCUAUCCAGUUGCGUCACCAAAUGAAUGCAACCAAAUGUGCCUUUCAACUCUCAUGAAGUGUGAUCAUUGUGGUGAAACUUCAUGGCAGACGGGCGAUUUUGUUAAAGCCACUUGCGAAUUUUGUGGCACUGAGAAUUUGACUAAAGAAGGUGCCACUACUUGUGGUUACUUACCCCAAAAUGCUGUUGUUAAAAUUUAUUGUCCAGCAUGUCACAAUUCAGAAGUAGGACCUGAGCAUAGUCUUGCCGAAUACCAUAAUGAAUCUGGCUUGAAAACCAUUCUUCGUAAGGGUGGUCGCACUAUUGCCUUUGGAGGCUGUGUGUUCUCUUAUGUUGGUUGCCAUAACAAGUGUGCCUAUUGGGUUCCACGUGCUAGCGCUAACAUAGGUUGUAACCAUACAGGUGUUGUUGGAGAAGGUUCCGAAGGUCUUAAUGACAACCUUCUUGAAAUACUCCAAAAAGAGAAAGUCAACAUCAAUAUUGUUGGUGACUUUAAACUUAAUGAAGAGAUCGCCAUUAUUUUGGCAUCUUUUUCUGCUUCCACAAGUGCUUUUGUGGAAACUGUGAAAGGUUUGGAUUAUAAAGCAUUCAAACAAAUUGUUGAAUCCUGUGGUAAUUUUAAAGUUACAAAAGGAAAAGCUAAAAAAGGUGCCUGGAAUAUUGGUGAACAGAAAUCAAUACUGAGUCCUCUUUAUGCAUUUGCAUCAGAGGCUGCUCGUGUUGUACGAUCAAUUUUCUCCCGCACUCUUGAAACUGCUCAAAAUUCUGUGCGUGUUUUACAGAAGGCCGCUAUAACAAUACUAGAUGGAAUUUCACAGUAUUCACUGAGACUCAUUGAUGCUAUGAUGUUCACAUCUGAUUUGGCUACUAACAAUCUAGUUGUAAUGGCCUACAUUACAGGUGGUGUUGUUCAGUUGACUUCGCAGUGGCUAACUAACAUCUUUGGCACUGUUUAUGAAAAACUCAAACCCGUCCUUGAUUGGCUUGAAGAGAAGUUUAAGGAAGGUGUAGAGUUUCUUAGAGACGGUUGGGAAAUUGUUAAAUUUAUCUCAACCUGUGCUUGUGAAAUUGUCGGUGGACAAAUUGUCACCUGUGCAAAGGAAAUUAAGGAGAGUGUUCAGACAUUCUUUAAGCUUGUAAAUAAAUUUUUGGCUUUGUGUGCUGACUCUAUCAUUAUUGGUGGAGCUAAACUUAAAGCCUUGAAUUUAGGUGAAACAUUUGUCACGCACUCAAAGGGAUUGUACAGAAAGUGUGUUAAAUCCAGAGAAGAAACUGGCCUACUCAUGCCUCUAAAAGCCCCAAAAGAAAUUAUCUUCUUAGAGGGAGAAACACUUCCCACAGAAGUGUUAACAGAGGAAGUUGUCUUGAAAACUGGUGAUUUACAACCAUUAGAACAACCUACUAGUGAAGCUGUUGAAGCUCCAUUGGUUGGUACACCAGUUUGUAUUAACGGGCUUAUGUUGCUCGAAAUCAAAGACACAGAAAAGUACUGUGCCCUUGCACCUAAUAUGAUGGUAACAAACAAUACCUUCACACUCAAAGGCGGUGCACCAACAAAGGUUACUUUUGGUGAUGACACUGUGAUAGAAGUGCAAGGUUACAAGAGUGUGAAUAUCACUUUUGAACUUGAUGAAAGGAUUGAUAAAGUACUUAAUGAGAAGUGCUCUGCCUAUACAGUUGAACUCGGUACAGAAGUAAAUGAGUUCGCCUGUGUUGUGGCAGAUGCUGUCAUAAAAACUUUGCAACCAGUAUCUGAAUUACUUACACCACUGGGCAUUGAUUUAGAUGAGUGGAGUAUGGCUACAUACUACUUAUUUGAUGAGUCUGGUGAGUUUAAAUUGGCUUCACAUAUGUAUUGUUCUUUCUACCCUCCAGAUGAGGAUGAAGAAGAAGGUGAUUGUGAAGAAGAAGAGUUUGAGCCAUCAACUCAAUAUGAGUAUGGUACUGAAGAUGAUUACCAAGGUAAACCUUUGGAAUUUGGUGCCACUUCUGCUGCUCUUCAACCUGAAGAAGAGCAAGAAGAAGAUUGGUUAGAUGAUGAUAGUCAACAAACUGUUGGUCAACAAGACGGCAGUGAGGACAAUCAGACAACUACUAUUCAAACAAUUGUUGAGGUUCAACCUCAAUUAGAGAUGGAACUUACACCAGUUGUUCAGACUAUUGAAGUGAAUAGUUUUAGUGGUUAUUUAAAACUUACUGACAAUGUAUACAUUAAAAAUGCAGACAUUGUGGAAGAAGCUAAAAAGGUAAAACCAACAGUGGUUGUUAAUGCAGCCAAUGUUUACCUUAAACAUGGAGGAGGUGUUGCAGGAGCCUUAAAUAAGGCUACUAACAAUGCCAUGCAAGUUGAAUCUGAUGAUUACAUAGCUACUAAUGGACCACUUAAAGUGGGUGGUAGUUGUGUUUUAAGCGGACACAAUCUUGCUAAACACUGUCUUCAUGUUGUCGGCCCAAAUGUUAACAAAGGUGAAGACAUUCAACUUCUUAAGAGUGCUUAUGAAAAUUUUAAUCAGCACGAAGUUCUACUUGCACCAUUAUUAUCAGCUGGUAUUUUUGGUGCUGACCCUAUACAUUCUUUAAGAGUUUGUGUAGAUACUGUUCGCACAAAUGUCUACUUAGCUGUCUUUGAUAAAAAUCUCUAUGACAAACUUGUUUCAAGCUUUUUGGAAAUGAAGAGUGAAAAGCAAGUUGAACAAAAGAUCGCUGAGAUUCCUAAAGAGGAAGUUAAGCCAUUUAUAACUGAAAGUAAACCUUCAGUUGAACAGAGAAAACAAGAUGAUAAGAAAAUCAAAGCUUGUGUUGAAGAAGUUACAACAACUCUGGAAGAAACUAAGUUCCUCACAGAAAACUUGUUACUUUAUAUUGACAUUAAUGGCAAUCUUCAUCCAGAUUCUGCCACUCUUGUUAGUGACAUUGACAUCACUUUCUUAAAGAAAGAUGCUCCAUAUAUAGUGGGUGAUGUUGUUCAAGAGGGUGUUUUAACUGCUGUGGUUAUACCUACUAAAAAGGCUGGUGGCACUACUGAAAUGCUAGCGAAAGCUUUGAGAAAAGUGCCAACAGACAAUUAUAUAACCACUUACCCGGGUCAGGGUUUAAAUGGUUACACUGUAGAGGAGGCAAAGACAGUGCUUAAAAAGUGUAAAAGUGCCUUUUACAUUCUACCAUCUAUUAUCUCUAAUGAGAAGCAAGAAAUUCUUGGAACUGUUUCUUGGAAUUUGCGAGAAAUGCUUGCACAUGCAGAAGAAACACGCAAAUUAAUGCCUGUCUGUGUGGAAACUAAAGCCAUAGUUUCAACUAUACAGCGUAAAUAUAAGGGUAUUAAAAUACAAGAGGGUGUGGUUGAUUAUGGUGCUAGAUUUUACUUUUACACCAGUAAAACAACUGUAGCGUCACUUAUCAACACACUUAACGAUCUAAAUGAAACUCUUGUUACAAUGCCACUUGGCUAUGUAACACAUGGCUUAAAUUUGGAAGAAGCUGCUCGGUAUAUGAGAUCUCUCAAAGUGCCAGCUACAGUUUCUGUUUCUUCACCUGAUGCUGUUACAGCGUAUAAUGGUUAUCUUACUUCUUCUUCUAAAACACCUGAAGAACAUUUUAUUGAAACCAUCUCACUUGCUGGUUCCUAUAAAGAUUGGUCCUAUUCUGGACAAUCUACACAACUAGGUAUAGAAUUUCUUAAGAGAGGUGAUAAAAGUGUAUAUUACACUAGUAAUCCUACCACAUUCCACCUAGAUGGUGAAGUUAUCACCUUUGACAAUCUUAAGACACUUCUUUCUUUGAGAGAAGUGAGGACUAUUAAGGUGUUUACAACAGUAGACAACAUUAACCUCCACACGCAAGUUGUGGACAUGUCAAUGACAUAUGGACAACAGUUUGGUCCAACUUAUUUGGAUGGAGCUGAUGUUACUAAAAUAAAACCUCAUAAUUCACAUGAAGGUAAAACAUUUUAUGUUUUACCUAAUGAUGACACUCUACGUGUUGAGGCUUUUGAGUACUACCACACAACUGAUCCUAGUUUUCUGGGUAGGUACAUGUCAGCAUUAAAUCACACUAAAAAGUGGAAAUACCCACAAGUUAAUGGUUUAACUUCUAUUAAAUGGGCAGAUAACAACUGUUAUCUUGCCACUGCAUUGUUAACACUCCAACAAAUAGAGUUGAAGUUUAAUCCACCUGCUCUACAAGAUGCUUAUUACAGAGCAAGGGCUGGUGAAGCUGCUAACUUUUGUGCACUUAUCUUAGCCUACUGUAAUAAGACAGUAGGUGAGUUAGGUGAUGUUAGAGAAACAAUGAGUUACUUGUUUCAACAUGCCAAUUUAGAUUCUUGCAAAAGAGUCUUGAACGUGGUGUGUAAAACUUGUGGACAACAGCAGACAACCCUUAAGGGUGUAGAAGCUGUUAUGUACAUGGGCACACUUUCUUAUGAACAAUUUAAGAAAGGUGUUCAGAUACCUUGUACGUGUGGUAAACAAGCUACAAAAUAUCUAGUACAACAGGAGUCACCUUUUGUUAUGAUGUCAGCACCACCUGCUCAGUAUGAACUUAAGCAUGGUACAUUUACUUGUGCUAGUGAGUACACUGGUAAUUACCAGUGUGGUCACUAUAAACAUAUAACUUCUAAAGAAACUUUGUAUUGCAUAGACGGUGCUUUACUUACAAAGUCCUCAGAAUACAAAGGUCCUAUUACGGAUGUUUUCUACAAAGAAAACAGUUACACAACAACCAUAAAACCAGUUACUUAUAAAUUGGAUGGUGUUGUUUGUACAGAAAUUGACCCUAAGUUGGACAAUUAUUAUAAGAAAGACAAUUCUUAUUUCACAGAGCAACCAAUUGAUCUUGUACCAAACCAACCAUAUCCAAACGCAAGCUUCGAUAAUUUUAAGUUUGUAUGUGAUAAUAUCAAAUUUGCUGAUGAUUUAAACCAGUUAACUGGUUAUAAGAAACCUGCUUCAAGAGAGCUUAAAGUUACAUUUUUCCCUGACUUAAAUGGUGAUGUGGUGGCUAUUGAUUAUAAACACUACACACCCUCUUUUAAGAAAGGAGCUAAAUUGUUACAUAAACCUAUUGUUUGGCAUGUUAACAAUGCAACUAAUAAAGCCACGUAUAAACCAAAUACCUGGUGUAUACGUUGUCUUUGGAGCACAAAACCAGUUGAAACAUCAAAUUCGUUUGAUGUACUGAAGUCAGAGGACGCGCAGGGAAUGGAUAAUCUUGCCUGCGAAGAUCUAAAACCAGUCUCUGAAGAAGUAGUGGAAAAUCCUACCAUACAGAAAGACGUUCUUGAGUGUAAUGUGAAAACUACCGAAGUUGUAGGAGACAUUAUACUUAAACCAGCAAAUAAUAGUUUAAAAAUUACAGAAGAGGUUGGCCACACAGAUCUAAUGGCUGCUUAUGUAGACAAUUCUAGUCUUACUAUUAAGAAACCUAAUGAAUUAUCUAGAGUAUUAGGUUUGAAAACCCUUGCUACUCAUGGUUUAGCUGCUGUUAAUAGUGUCCCUUGGGAUACUAUAGCUAAUUAUGCUAAGCCUUUUCUUAACAAAGUUGUUAGUACAACUACUAACAUAGUUACACGGUGUUUAAACCGUGUUUGUACUAAUUAUAUGCCUUAUUUCUUUACUUUAUUGCUACAAUUGUGUACUUUUACUAGAAGUACAAAUUCUAGAAUUAAAGCAUCUAUGCCGACUACUAUAGCAAAGAAUACUGUUAAGAGUGUCGGUAAAUUUUGUCUAGAGGCUUCAUUUAAUUAUUUGAAGUCACCUAAUUUUUCUAAACUGAUAAAUAUUAUAAUUUGGUUUUUACUAUUAAGUGUUUGCCUAGGUUCUUUAAUCUACUCAACCGCUGCUUUAGGUGUUUUAAUGUCUAAUUUAGGCAUGCCUUCUUACUGUACUGGUUACAGAGAAGGCUAUUUGAACUCUACUAAUGUCACUAUUGCAACCUACUGUACUGGUUCUAUACCUUGUAGUGUUUGUCUUAGUGGUUUAGAUUCUUUAGACACCUAUCCUUCUUUAGAAACUAUACAAAUUACCAUUUCAUCUUUUAAAUGGGAUUUAACUGCUUUUGGCUUAGUUGCAGAGUGGUUUUUGGCAUAUAUUCUUUUCACUAGGUUUUUCUAUGUACUUGGAUUGGCUGCAAUCAUGCAAUUGUUUUUCAGCUAUUUUGCAGUACAUUUUAUUAGUAAUUCUUGGCUUAUGUGGUUAAUAAUUAAUCUUGUACAAAUGGCCCCGAUUUCAGCUAUGGUUAGAAUGUACAUCUUCUUUGCAUCAUUUUAUUAUGUAUGGAAAAGUUAUGUGCAUGUUGUAGACGGUUGUAAUUCAUCAACUUGUAUGAUGUGUUACAAACGUAAUAGAGCAACAAGAGUCGAAUGUACAACUAUUGUUAAUGGUGUUAGAAGGUCCUUUUAUGUCUAUGCUAAUGGAGGUAAAGGCUUUUGCAAACUACACAAUUGGAAUUGUGUUAAUUGUGAUACAUUCUGUGCUGGUAGUACAUUUAUUAGUGAUGAAGUUGCGAGAGACUUGUCACUACAGUUUAAAAGACCAAUAAAUCCUACUGACCAGUCUUCUUACAUCGUUGAUAGUGUUACAGUGAAGAAUGGUUCCAUCCAUCUUUACUUUGAUAAAGCUGGUCAAAAGACUUAUGAAAGACAUUCUCUCUCUCAUUUUGUUAACUUAGACAACCUGAGAGCUAAUAACACUAAAGGUUCAUUGCCUAUUAAUGUUAUAGUUUUUGAUGGUAAAUCAAAAUGUGAAGAAUCAUCUGCAAAAUCAGCGUCUGUUUACUACAGUCAGCUUAUGUGUCAACCUAUACUGUUACUAGAUCAGGCAUUAGUGUCUGAUGUUGGUGAUAGUGCGGAAGUUGCAGUUAAAAUGUUUGAUGCUUACGUUAAUACGUUUUCAUCAACUUUUAACGUACCAAUGGAAAAACUCAAAACACUAGUUGCAACUGCAGAAGCUGAACUUGCAAAGAAUGUGUCCUUAGACAAUGUCUUAUCUACUUUUAUUUCAGCAGCUCGGCAAGGGUUUGUUGAUUCAGAUGUAGAAACUAAAGAUGUUGUUGAAUGUCUUAAAUUGUCACAUCAAUCUGACAUAGAAGUUACUGGCGAUAGUUGUAAUAACUAUAUGCUCACCUAUAACAAAGUUGAAAACAUGACACCCCGUGACCUUGGUGCUUGUAUUGACUGUAGUGCGCGUCAUAUUAAUGCGCAGGUAGCAAAAAGUCACAACAUUGCUUUGAUAUGGAACGUUAAAGAUUUCAUGUCAUUGUCUGAACAACUACGAAAACAAAUACGUAGUGCUGCUAAAAAGAAUAACUUACCUUUUAAGUUGACAUGUGCAACUACUAGACAAGUUGUUAAUGUUGUAACAACAAAGAUAGCACUUAAGGGUGGUAAAAUUGUUAAUAAUUGGUUGAAGCAGUUAAUUAAAGUUACACUUGUGUUCCUUUUUGUUGCUGCUAUUUUCUAUUUAAUAACACCUGUUCAUGUCAUGUCUAAACAUACUGACUUUUCAAGUGAAAUCAUAGGAUACAAGGCUAUUGAUGGUGGUGUCACUCGUGACAUAGCAUCUACAGAUACUUGUUUUGCUAACAAACAUGCUGAUUUUGACACAUGGUUUAGCCAGCGUGGUGGUAGUUAUACUAAUGACAAAGCUUGCCCAUUGAUUGCUGCAGUCAUAACAAGAGAAGUGGGUUUUGUCGUGCCUGGUUUGCCUGGCACGAUAUUACGCACAACUAAUGGUGACUUUUUGCAUUUCUUACCUAGAGUUUUUAGUGCAGUUGGUAACAUCUGUUACACACCAUCAAAACUUAUAGAGUACACUGACUUUGCAACAUCAGCUUGUGUUUUGGCUGCUGAAUGUACAAUUUUUAAAGAUGCUUCUGGUAAGCCAGUACCAUAUUGUUAUGAUACCAAUGUACUAGAAGGUUCUGUUGCUUAUGAAAGUUUACGCCCUGACACACGUUAUGUGCUCAUGGAUGGCUCUAUUAUUCAAUUUCCUAACACCUACCUUGAAGGUUCUGUUAGAGUGGUAACAACUUUUGAUUCUGAGUACUGUAGGCACGGCACUUGUGAAAGAUCAGAAGCUGGUGUUUGUGUAUCUACUAGUGGUAGAUGGGUACUUAACAAUGAUUAUUACAGAUCUUUACCAGGAGUUUUCUGUGGUGUAGAUGCUGUAAAUUUACUUACUAAUAUGUUUACACCACUAAUUCAACCUAUUGGUGCUUUGGACAUAUCAGCAUCUAUAGUAGCUGGUGGUAUUGUAGCUAUCGUAGUAACAUGCCUUGCCUACUAUUUUAUGAGGUUUAGAAGAGCUUUUGGUGAAUACAGUCAUGUAGUUGCCUUUAAUACUUUACUAUUCCUUAUGUCAUUCACUGUACUCUGUUUAACACCAGUUUACUCAUUCUUACCUGGUGUUUAUUCUGUUAUUUACUUGUACUUGACAUUUUAUCUUACUAAUGAUGUUUCUUUUUUAGCACAUAUUCAGUGGAUGGUUAUGUUCACACCUUUAGUACCUUUCUGGAUAACAAUUGCUUAUAUCAUUUGUAUUUCCACAAAGCAUUUCUAUUGGUUCUUUAGUAAUUACCUAAAGAGACGUGUAGUCUUUAAUGGUGUUUCCUUUAGUACUUUUGAAGAAGCUGCGCUGUGCACCUUUUUGUUAAAUAAAGAAAUGUAUCUAAAGUUGCGUAGUGAUGUGCUAUUACCUCUUACGCAAUAUAAUAGAUACUUAGCUCUUUAUAAUAAGUACAAGUAUUUUAGUGGAGCAAUGGAUACAACUAGCUACAGAGAAGCUGCUUGUUGUCAUCUCGCAAAGGCUCUCAAUGACUUCAGUAACUCAGGUUCUGAUGUUCUUUACCAACCACCACAAACCUCUAUCACCUCAGCUGUUUUGCAGAGUGGUUUUAGAAAAAUGGCAUUCCCAUCUGGUAAAGUUGAGGGUUGUAUGGUACAAGUAACUUGUGGUACAACUACACUUAACGGUCUUUGGCUUGAUGACGUAGUUUACUGUCCAAGACAUGUGAUCUGCACCUCUGAAGACAUGCUUAACCCUAAUUAUGAAGAUUUACUCAUUCGUAAGUCUAAUCAUAAUUUCUUGGUACAGGCUGGUAAUGUUCAACUCAGGGUUAUUGGACAUUCUAUGCAAAAUUGUGUACUUAAGCUUAAGGUUGAUACAGCCAAUCCUAAGACACCUAAGUAUAAGUUUGUUCGCAUUCAACCAGGACAGACUUUUUCAGUGUUAGCUUGUUACAAUGGUUCACCAUCUGGUGUUUACCAAUGUGCUAUGAGGCCCAAUUUCACUAUUAAGGGUUCAUUCCUUAAUGGUUCAUGUGGUAGUGUUGGUUUUAACAUAGAUUAUGACUGUGUCUCUUUUUGUUACAUGCACCAUAUGGAAUUACCAACUGGAGUUCAUGCUGGCACAGACUUAGAAGGUAACUUUUAUGGACCUUUUGUUGACAGGCAAACAGCACAAGCAGCUGGUACGGACACAACUAUUACAGUUAAUGUUUUAGCUUGGUUGUACGCUGCUGUUAUAAAUGGAGACAGGUGGUUUCUCAAUCGAUUUACCACAACUCUUAAUGACUUUAACCUUGUGGCUAUGAAGUACAAUUAUGAACCUCUAACACAAGACCAUGUUGACAUACUAGGACCUCUUUCUGCUCAAACUGGAAUUGCCGUUUUAGAUAUGUGUGCUUCAUUAAAAGAAUUACUGCAAAAUGGUAUGAAUGGACGUACCAUAUUGGGUAGUGCUUUAUUAGAAGAUGAAUUUACACCUUUUGAUGUUGUUAGACAAUGCUCAGGUGUUACUUUCCAAAGUGCAGUGAAAAGAACAAUCAAGGGUACACACCACUGGUUGUUACUCACAAUUUUGACUUCACUUUUAGUUUUAGUCCAGAGUACUCAAUGGUCUUUGUUCUUUUUUUUGUAUGAAAAUGCCUUUUUACCUUUUGCUAUGGGUAUUAUUGCUAUGUCUGCUUUUGCAAUGAUGUUUGUCAAACAUAAGCAUGCAUUUCUCUGUUUGUUUUUGUUACCUUCUCUUGCCACUGUAGCUUAUUUUAAUAUGGUCUAUAUGCCUGCUAGUUGGGUGAUGCGUAUUAUGACAUGGUUGGAUAUGGUUGAUACUAGUUUGUCUGGUUUUAAGCUAAAAGACUGUGUUAUGUAUGCAUCAGCUGUAGUGUUACUAAUCCUUAUGACAGCAAGAACUGUGUAUGAUGAUGGUGCUAGGAGAGUGUGGACACUUAUGAAUGUCUUGACACUCGUUUAUAAAGUUUAUUAUGGUAAUGCUUUAGAUCAAGCCAUUUCCAUGUGGGCUCUUAUAAUCUCUGUUACUUCUAACUACUCAGGUGUAGUUACAACUGUCAUGUUUUUGGCCAGAGGUAUUGUUUUUAUGUGUGUUGAGUAUUGCCCUAUUUUCUUCAUAACUGGUAAUACACUUCAGUGUAUAAUGCUAGUUUAUUGUUUCUUAGGCUAUUUUUGUACUUGUUACUUUGGCCUCUUUUGUUUACUCAACCGCUACUUUAGACUGACUCUUGGUGUUUAUGAUUACUUAGUUUCUACACAGGAGUUUAGAUAUAUGAAUUCACAGGGACUACUCCCACCCAAGAAUAGCAUAGAUGCCUUCAAACUCAACAUUAAAUUGUUGGGUGUUGGUGGCAAACCUUGUAUCAAAGUAGCCACUGUACAGUCUAAAAUGUCAGAUGUAAAGUGCACAUCAGUAGUCUUACUCUCAGUUUUGCAACAACUCAGAGUAGAAUCAUCAUCUAAAUUGUGGGCUCAAUGUGUCCAGUUACACAAUGACAUUCUCUUAGCUAAAGAUACUACUGAAGCCUUUGAAAAAAUGGUUUCACUACUUUCUGUUUUGCUUUCCAUGCAGGGUGCUGUAGACAUAAACAAGCUUUGUGAAGAAAUGCUGGACAACAGGGCAACCUUACAAGCUAUAGCCUCAGAGUUUAGUUCCCUUCCAUCAUAUGCAGCUUUUGCUACUGCUCAAGAAGCUUAUGAGCAGGCUGUUGCUAAUGGUGAUUCUGAAGUUGUUCUUAAAAAGUUGAAGAAGUCUUUGAAUGUGGCUAAAUCUGAAUUUGACCGUGAUGCAGCCAUGCAACGUAAGUUGGAAAAGAUGGCUGAUCAAGCUAUGACCCAAAUGUAUAAACAGGCUAGAUCUGAGGACAAGAGGGCAAAAGUUACUAGUGCUAUGCAGACAAUGCUUUUCACUAUGCUUAGAAAGUUGGAUAAUGAUGCACUCAACAACAUUAUCAACAAUGCAAGAGAUGGUUGUGUUCCCUUGAACAUAAUACCUCUUACAACAGCAGCCAAACUAAUGGUUGUCAUACCAGACUAUAACACAUAUAAAAAUACGUGUGAUGGUACAACAUUUACUUAUGCAUCAGCAUUGUGGGAAAUCCAACAGGUUGUAGAUGCAGAUAGUAAAAUUGUUCAACUUAGUGAAAUUAGUAUGGACAAUUCACCUAAUUUAGCAUGGCCUCUUAUUGUAACAGCUUUAAGGGCCAAUUCUGCUGUCAAAUUACAGAAUAAUGAGCUUAGUCCUGUUGCACUACGACAGAUGUCUUGUGCUGCCGGUACUACACAAACUGCUUGCACUGAUGACAAUGCGUUAGCUUACUACAACACAACAAAGGGAGGUAGGUUUGUACUUGCACUGUUAUCCGAUUUACAGGAUUUGAAAUGGGCUAGAUUCCCUAAGAGUGAUGGAACUGGUACUAUCUAUACAGAACUGGAACCACCUUGUAGGUUUGUUACAGACACACCUAAAGGUCCUAAAGUGAAGUAUUUAUACUUUAUUAAAGGAUUAAACAACCUAAAUAGAGGUAUGGUACUUGGUAGUUUAGCUGCCACAGUACGUCUACAAGCUGGUAAUGCAACAGAAGUGCCUGCCAAUUCAACUGUAUUAUCUUUCUGUGCUUUUGCUGUAGAUGCUGCUAAAGCUUACAAAGAUUAUCUAGCUAGUGGGGGACAACCAAUCACUAAUUGUGUUAAGAUGUUGUGUACACACACUGGUACUGGUCAGGCAAUAACAGUUACACCGGAAGCCAAUAUGGAUCAAGAAUCCUUUGGUGGUGCAUCGUGUUGUCUGUACUGCCGUUGCCACAUAGAUCAUCCAAAUCCUAAAGGAUUUUGUGACUUAAAAGGUAAGUAUGUACAAAUACCUACAACUUGUGCUAAUGACCCUGUGGGUUUUACACUUAAAAACACAGUCUGUACCGUCUGCGGUAUGUGGAAAGGUUAUGGCUGUAGUUGUGAUCAACUCCGCGAACCCAUGCUUCAGUCAGCUGAUGCACAAUCGUUUUUAAACGGGUUUGCGGUGUAAGUGCAGCCCGUCUUACACCGUGCGGCACAGGCACUAGUACUGAUGUCGUAUACAGGGCUUUUGACAUCUACAAUGAUAAAGUAGCUGGUUUUGCUAAAUUCCUAAAAACUAAUUGUUGUCGCUUCCAAGAAAAGGACGAAGAUGACAAUUUAAUUGAUUCUUACUUUGUAGUUAAGAGACACACUUUCUCUAACUACCAACAUGAAGAAACAAUUUAUAAUUUACUUAAGGAUUGUCCAGCUGUUGCUAAACAUGACUUCUUUAAGUUUAGAAUAGACGGUGACAUGGUACCACAUAUAUCACGUCAACGUCUUACUAAAUACACAAUGGCAGACCUCGUCUAUGCUUUAAGGCAUUUUGAUGAAGGUAAUUGUGACACAUUAAAAGAAAUACUUGUCACAUACAAUUGUUGUGAUGAUGAUUAUUUCAAUAAAAAGGACUGGUAUGAUUUUGUAGAAAACCCAGAUAUAUUACGCGUAUACGCCAACUUAGGUGAACGUGUACGCCAAGCUUUGUUAAAAACAGUACAAUUCUGUGAUGCCAUGCGAAAUGCUGGUAUUGUUGGUGUACUGACAUUAGAUAAUCAAGAUCUCAAUGGUAACUGGUAUGAUUUCGGUGAUUUCAUACAAACCACGCCAGGUAGUGGAGUUCCUGUUGUAGAUUCUUAUUAUUCAUUGUUAAUGCCUAUAUUAACCUUGACCAGGGCUUUAACUGCAGAGUCACAUGUUGACACUGACUUAACAAAGCCUUACAUUAAGUGGGAUUUGUUAAAAUAUGACUUCACGGAAGAGAGGUUAAAACUCUUUGACCGUUAUUUUAAAUAUUGGGAUCAGACAUACCACCCAAAUUGUGUUAACUGUUUGGAUGACAGAUGCAUUCUGCAUUGUGCAAACUUUAAUGUUUUAUUCUCUACAGUGUUCCCACCUACAAGUUUUGGACCACUAGUGAGAAAAAUAUUUGUUGAUGGUGUUCCAUUUGUAGUUUCAACUGGAUACCACUUCAGAGAGCUAGGUGUUGUACAUAAUCAGGAUGUAAACUUACAUAGCUCUAGACUUAGUUUUAAGGAAUUACUUGUGUAUGCUGCUGACCCUGCUAUGCACGCUGCUUCUGGUAAUCUAUUACUAGAUAAACGCACUACGUGCUUUUCAGUAGCUGCACUUACUAACAAUGUUGCUUUUCAAACUGUCAAACCCGGUAAUUUUAACAAAGACUUCUAUGACUUUGCUGUGUCUAAGGGUUUCUUUAAGGAAGGAAGUUCUGUUGAAUUAAAACACUUCUUCUUUGCUCAGGAUGGUAAUGCUGCUAUCAGCGAUUAUGACUACUAUCGUUAUAAUCUACCAACAAUGUGUGAUAUCAGACAACUACUAUUUGUAGUUGAAGUUGUUGAUAAGUACUUUGAUUGUUACGAUGGUGGCUGUAUUAAUGCUAACCAAGUCAUCGUCAACAACCUAGACAAAUCAGCUGGUUUUCCAUUUAAUAAAUGGGGUAAGGCUAGACUUUAUUAUGAUUCAAUGAGUUAUGAGGAUCAAGAUGCACUUUUCGCAUAUACAAAACGUAAUGUCAUCCCUACUAUAACUCAAAUGAAUCUUAAGUAUGCCAUUAGUGCAAAGAAUAGAGCUCGCACCGUAGCUGGUGUCUCUAUCUGUAGUACUAUGACCAAUAGACAGUUUCAUCAAAAAUUAUUGAAAUCAAUAGCCGCCACUAGAGGAGCUACUGUAGUAAUUGGAACAAGCAAAUUCUAUGGUGGUUGGCACAACAUGUUAAAAACUGUUUAUAGUGAUGUAGAAAACCCUCACCUUAUGGGUUGGGAUUAUCCUAAAUGUGAUAGAGCCAUGCCUAACAUGCUUAGAAUUAUGGCCUCACUUGUUCUUGCUCGCAAACAUACAACGUGUUGUAGCUUGUCACACCGUUUCUAUAGAUUAGCUAAUGAGUGUGCUCAAGUAUUGAGUGAAAUGGUCAUGUGUGGCGGUUCACUAUAUGUUAAACCAGGUGGAACCUCAUCAGGAGAUGCCACAACUGCUUAUGCUAAUAGUGUUUUUAACAUUUGUCAAGCUGUCACGGCCAAUGUUAAUGCACUUUUAUCUACUGAUGGUAACAAAAUUGCCGAUAAGUAUGUCCGCAAUUUACAACACAGACUUUAUGAGUGUCUCUAUAGAAAUAGAGAUGUUGACACAGACUUUGUGAAUGAGUUUUACGCAUAUUUGCGUAAACAUUUCUCAAUGAUGAUACUCUCUGACGAUGCUGUUGUGUGUUUCAAUAGCACUUAUGCAUCUCAAGGUCUAGUGGCUAGCAUAAAGAACUUUAAGUCAGUUCUUUAUUAUCAAAACAAUGUUUUUAUGUCUGAAGCAAAAUGUUGGACUGAGACUGACCUUACUAAAGGACCUCAUGAAUUUUGCUCUCAACAUACAAUGCUAGUUAAACAGGGUGAUGAUUAUGUGUACCUUCCUUACCCAGAUCCAUCAAGAAUCCUAGGGGCCGGCUGUUUUGUAGAUGAUAUCGUAAAAACAGAUGGUACACUUAUGAUUGAACGGUUCGUGUCUUUAGCUAUAGAUGCUUACCCACUUACUAAACAUCCUAAUCAGGAGUAUGCUGAUGUCUUUCAUUUGUACUUACAAUACAUAAGAAAGCUACAUGAUGAGUUAACAGGACACAUGUUAGACAUGUAUUCUGUUAUGCUUACUAAUGAUAACACUUCAAGGUAUUGGGAACCUGAGUUUUAUGAGGCUAUGUACACACCGCAUACAGUCUUACAGGCUGUUGGGGCUUGUGUUCUUUGCAAUUCACAGACUUCAUUAAGAUGUGGUGCUUGCAUACGUAGACCAUUCUUAUGUUGUAAAUGCUGUUACGACCAUGUCAUAUCAACAUCACAUAAAUUAGUCUUGUCUGUUAAUCCGUAUGUUUGCAAUGCUCCAGGUUGUGAUGUCACAGAUGUGACUCAACUUUACUUAGGAGGUAUGAGCUAUUAUUGUAAAUCACAUAAACCACCCAUUAGUUUUCCAUUGUGUGCUAAUGGACAAGUUUUUGGUUUAUAUAAAAAUACAUGUGUUGGUAGCGAUAAUGUUACUGACUUUAAUGCAAUUGCAACAUGUGACUGGACAAAUGCUGGUGAUUACAUUUUAGCUAACACCUGUACUGAAAGACUCAAGCUUUUUGCAGCAGAAACGCUCAAAGCUACUGAGGAGACAUUUAAACUGUCUUAUGGUAUUGCUACUGUACGUGAAGUGCUGUCUGACAGAGAAUUACAUCUUUCAUGGGAAGUUGGUAAACCUAGACCACCACUUAACCGAAAUUAUGUCUUUACUGGUUAUCGUGUAACUAAAAACAGUAAAGUACAAAUAGGAGAGUACACCUUUGAAAAAGGUGACUAUGGUGAUGCUGUUGUUUACCGAGGUACAACAACUUACAAAUUAAAUGUUGGUGAUUAUUUUGUGCUGACAUCACAUACAGUAAUGCCAUUAAGUGCACCUACACUAGUGCCACAAGAGCACUAUGUUAGAAUUACUGGCUUAUACCCAACACUCAAUAUCUCAGAUGAGUUUUCUAGCAAUGUUGCAAAUUAUCAAAAGGUUGGUAUGCAAAAGUAUUCUACACUCCAGGGACCACCUGGUACUGGUAAGAGUCAUUUUGCUAUUGGCCUAGCUCUCUACUACCCUUCUGCUCGCAUAGUGUAUACAGCUUGCUCUCAUGCCGCUGUUGAUGCACUAUGUGAGAAGGCAUUAAAAUAUUUGCCUAUAGAUAAAUGUAGUAGAAUUAUACCUGCACGUGCUCGUGUAGAGUGUUUUGAUAAAUUCAAAGUGAAUUCAACAUUAGAACAGUAUGUCUUUUGUACUGUAAAUGCAUUGCCUGAGACGACAGCAGAUAUAGUUGUCUUUGAUGAAAUUUCAAUGGCCACAAAUUAUGAUUUGAGUGUUGUCAAUGCCAGAUUACGUGCUAAGCACUAUGUGUACAUUGGCGACCCUGCUCAAUUACCUGCACCACGCACAUUGCUAACUAAGGGCACACUAGAACCAGAAUAUUUCAAUUCAGUGUGUAGACUUAUGAAAACUAUAGGUCCAGACAUGUUCCUCGGAACUUGUCGGCGUUGUCCUGCUGAAAUUGUUGACACUGUGAGUGCUUUGGUUUAUGAUAAUAAGCUUAAAGCACAUAAAGACAAAUCAGCUCAAUGCUUUAAAAUGUUUUAUAAGGGUGUUAUCACGCAUGAUGUUUCAUCUGCAAUUAACAGGCCACAAAUAGGCGUGGUAAGAGAAUUCCUUACACGUAACCCUGCUUGGAGAAAAGCUGUCUUUAUUUCACCUUAUAAUUCACAGAAUGCUGUAGCCUCAAAGAUUUUGGGACUACCAACUCAAACUGUUGAUUCAUCACAGGGCUCAGAAUAUGACUAUGUCAUAUUCACUCAAACCACUGAAACAGCUCACUCUUGUAAUGUAAACAGAUUUAAUGUUGCUAUUACCAGAGCAAAAGUAGGCAUACUUUGCAUAAUGUCUGAUAGAGACCUUUAUGACAAGUUGCAAUUUACAAGUCUUGAAAUUCCACGUAGGAAUGUGGCAACUUUACAAGCUGAAAAUGUAACAGGACUCUUUAAAGAUUGUAGUAAGGUAAUCACUGGGUUACAUCCUACACAGGCACCUACACACCUCAGUGUUGACACUAAAUUCAAAACUGAAGGUUUAUGUGUUGACAUACCUGGCAUACCUAAGGACAUGACCUAUAGAAGACUCAUCUCUAUGAUGGGUUUUAAAAUGAAUUAUCAAGUUAAUGGUUACCCUAACAUGUUUAUCACCCGCGAAGAAGCUAUAAGACAUGUACGUGCAUGGAUUGGCUUCGAUGUCGAGGGGUGUCAUGCUACUAGAGAAGCUGUUGGUACCAAUUUACCUUUACAGCUAGGUUUUUCUACAGGUGUUAACCUAGUUGCUGUACCUACAGGUUAUGUUGAUACACCUAAUAAUACAGAUUUUUCCAGAGUUAGUGCUAAACCACCGCCUGGAGAUCAAUUUAAACACCUCAUACCACUUAUGUACAAAGGACUUCCUUGGAAUGUAGUGCGUAUAAAGAUUGUACAAAUGUUAAGUGACACACUUAAAAAUCUCUCUGACAGAGUCGUAUUUGUCUUAUGGGCACAUGGCUUUGAGUUGACAUCUAUGAAGUAUUUUGUGAAAAUAGGACCUGAGCGCACCUGUUGUCUAUGUGAUAGACGUGCCACAUGCUUUUCCACUGCUUCAGACACUUAUGCCUGUUGGCAUCAUUCUAUUGGAUUUGAUUACGUCUAUAAUCCGUUUAUGAUUGAUGUUCAACAAUGGGGUUUUACAGGUAACCUACAAAGCAACCAUGAUCUGUAUUGUCAAGUCCAUGGUAAUGCACAUGUAGCUAGUUGUGAUGCAAUCAUGACUAGGUGUCUAGCUGUCCACGAGUGCUUUGUUAAGCGUGUUGACUGGACUAUUGAAUAUCCUAUAAUUGGUGAUGAACUGAAGAUUAAUGCGGCUUGUAGAAAGGUUCAACACAUGGUUGUUAAAGCUGCAUUAUUAGCAGACAAAUUCCCAGUUCUUCACGACAUUGGUAACCCUAAAGCUAUUAAGUGUGUACCUCAAGCUGAUGUAGAAUGGAAGUUCUAUGAUGCACAGCCUUGUAGUGACAAAGCUUAUAAAAUAGAAGAAUUAUUCUAUUCUUAUGCCACACAUUCUGACAAAUUCACAGAUGGUGUAUGCCUAUUUUGGAAUUGCAAUGUCGAUAGAUAUCCUGCUAAUUCCAUUGUUUGUAGAUUUGACACUAGAGUGCUAUCUAACCUUAACUUGCCUGGUUGUGAUGGUGGCAGUUUGUAUGUAAAUAAACAUGCAUUCCACACACCAGCUUUUGAUAAAAGUGCUUUUGUUAAUUUAAAACAAUUACCAUUUUUCUAUUACUCUGACAGUCCAUGUGAGUCUCAUGGAAAACAAGUAGUGUCAGAUAUAGAUUAUGUACCACUAAAGUCUGCUACGUGUAUAACACGUUGCAAUUUAGGUGGUGCUGUCUGUAGACAUCAUGCUAAUGAGUACAGAUUGUAUCUCGAUGCUUAUAACAUGAUGAUCUCAGCUGGCUUUAGCUUGUGGGUUUACAAACAAUUUGAUACUUAUAACCUCUGGAACACUUUUACAAGACUUCAGAGUUUAGAAAAUGUGGCUUUUAAUGUUGUAAAUAAGGGACACUUUGAUGGACAACAGGGUGAAGUACCAGUUUCUAUCAUUAAUAACACUGUUUACACAAAAGUUGAUGGUGUUGAUGUAGAAUUGUUUGAAAAUAAAACAACAUUACCUGUUAAUGUAGCAUUUGAGCUUUGGGCUAAGCGCAACAUUAAACCAGUACCAGAGGUGAAAAUACUCAAUAAUUUGGGUGUGGACAUUGCUGCUAAUACUGUGAUCUGGGACUACAAAAGAGAUGCUCCAGCACAUAUAUCUACUAUUGGUGUUUGUUCUAUGACUGACAUAGCCAAGAAACCAACUGAAACGAUUUGUGCACCACUCACUGUCUUUUUUGAUGGUAGAGUUGAUGGUCAAGUAGACUUAUUUAGAAAUGCCCGUAAUGGUGUUCUUAUUACAGAAGGUAGUGUUAAAGGUUUACAACCAUCUGUAGGUCCCAAACAAGCUAGUCUUAAUGGAGUCACAUUAAUUGGAGAAGCCGUAAAAACACAGUUCAAUUAUUAUAAGAAAGUUGAUGGUGUUGUCCAACAAUUACCUGAAACUUACUUUACUCAGAGUAGAAAUUUACAAGAAUUUAAACCCAGGAGUCAAAUGGAAAUUGAUUUCUUAGAAUUAGCUAUGGAUGAAUUCAUUGAACGGUAUAAAUUAGAAGGCUAUGCCUUCGAACAUAUCGUUUAUGGAGAUUUUAGUCAUAGUCAGUUAGGUGGUUUACAUCUACUGAUUGGACUAGCUAAACGUUUUAAGGAAUCACCUUUUGAAUUAGAAGAUUUUAUUCCUAUGGACAGUACAGUUAAAAACUAUUUCAUAACAGAUGCGCAAACAGGUUCAUCUAAGUGUGUGUGUUCUGUUAUUGAUUUAUUACUUGAUGAUUUUGUUGAAAUAAUAAAAUCCCAAGAUUUAUCUGUAGUUUCUAAGGUUGUCAAAGUGACUAUUGACUAUACAGAAAUUUCAUUUAUGCUUUGGUGUAAAGAUGGCCAUGUAGAAACAUUUUACCCAAAAUUACAAUCUAGUCAAGCGUGGCAACCGGGUGUUGCUAUGCCUAAUCUUUACAAAAUGCAAAGAAUGCUAUUAGAAAAGUGUGACCUUCAAAAUUAUGGUGAUAGUGCAACAUUACCUAAAGGCAUAAUGAUGAAUGUCGCAAAAUAUACUCAACUGUGUCAAUAUUUAAACACAUUAACAUUAGCUGUACCCUAUAAUAUGAGAGUUAUACAUUUUGGUGCUGGUUCUGAUAAAGGAGUUGCACCAGGUACAGCUGUUUUAAGACAGUGGUUGCCUACGGGUACGCUGCUUGUCGAUUCAGAUCUUAAUGACUUUGUCUCUGAUGCAGAUUCAACUUUGAUUGGUGAUUGUGCAACUGUACAUACAGCUAAUAAAUGGGAUCUCAUUAUUAGUGAUAUGUACGACCCUAAGACUAAAAAUGUUACAAAAGAAAAUGACUCUAAAGAGGGUUUUUUCACUUACAUUUGUGGGUUUAUACAACAAAAGCUAGCUCUUGGAGGUUCCGUGGCUAUAAAGAUAACAGAACAUUCUUGGAAUGCUGAUCUUUAUAAGCUCAUGGGACACUUCGCAUGGUGGACAGCCUUUGUUACUAAUGUGAAUGCGUCAUCAUCUGAAGCAUUUUUAAUUGGAUGUAAUUAUCUUGGCAAACCACGCGAACAAAUAGAUGGUUAUGUCAUGCAUGCAAAUUACAUAUUUUGGAGGAAUACAAAUCCAAUUCAGUUGUCUUCCUAUUCUUUAUUUGACAUGAGUAAAUUUCCCCUUAAAUUAAGGGGUACUGCUGUUAUGUCUUUAAAAGAAGGUCAAAUCAAUGAUAUGAUUUUAUCUCUUCUUAGUAAAGGUAGACUUAUAAUUAGAGAAAACAACAGAGUUGUUAUUUCUAGUGAUGUUCUUGUUAACAACUAAACGAACAAUGUUUGUUUUUCUUGUUUUAUUGCCACUAGUCUCUAGUCAGUGUGUUAAUCUUACAACCAGAACUCAAUUACCCCCUGCAUACACUAAUUCUUUCACACGUGGUGUUUAUUACCCUGACAAAGUUUUCAGAUCCUCAGUUUUACAUUCAACUCAGGACUUGUUCUUACCUUUCUUUUCCAAUGUUACUUGGUUCCAUGCUAUACAUGUCUCUGGGACCAAUGGUACUAAGAGGUUUGAUAACCCUGUCCUACCAUUUAAUGAUGGUGUUUAUUUUGCUUCCACUGAGAAGUCUAACAUAAUAAGAGGCUGGAUUUUUGGUACUACUUUAGAUUCGAAGACCCAGUCCCUACUUAUUGUUAAUAACGCUACUAAUGUUGUUAUUAAAGUCUGUGAAUUUCAAUUUUGUAAUGAUCCAUUUUUGGGUGUUUAUUACCACAAAAACAACAAAAGUUGGAUGGAAAGUGAGUUCAGAGUUUAUUCUAGUGCGAAUAAUUGCACUUUUGAAUAUGUCUCUCAGCCUUUUCUUAUGGACCUUGAAGGAAAACAGGGUAAUUUCAAAAAUCUUAGGGAAUUUGUGUUUAAGAAUAUUGAUGGUUAUUUUAAAAUAUAUUCUAAGCACACGCCUAUUAAUUUAGUGCGUGAUCUCCCUCAGGGUUUUUCGGCUUUAGAACCAUUGGUAGAUUUGCCAAUAGGUAUUAACAUCACUAGGUUUCAAACUUUACUUGCUUUACAUAGAAGUUAUUUGACUCCUGGUGAUUCUUCUUCAGGUUGGACAGCUGGUGCUGCAGCUUAUUAUGUGGGUUAUCUUCAACCUAGGACUUUUCUAUUAAAAUAUAAUGAAAAUGGAACCAUUACAGAUGCUGUAGACUGUGCACUUGACCCUCUCUCAGAAACAAAGUGUACGUUGAAAUCCUUCACUGUAGAAAAAGGAAUCUAUCAAACUUCUAACUUUAGAGUCCAACCAACAGAAUCUAUUGUUAGAUUUCCUAAUAUUACAAACUUGUGCCCUUUUGGUGAAGUUUUUAACGCCACCAGAUUUGCAUCUGUUUAUGCUUGGAACAGGAAGAGAAUCAGCAACUGUGUUGCUGAUUAUUCUGUCCUAUAUAAUUCCGCAUCAUUUUCCACUUUUAAGUGUUAUGGAGUGUCUCCUACUAAAUUAAAUGAUCUCUGCUUUACUAAUGUCUAUGCAGAUUCAUUUGUAAUUAGAGGUGAUGAAGUCAGACAAAUCGCUCCAGGGCAAACUGGAAAGAUUGCUGAUUAUAAUUAUAAAUUACCAGAUGAUUUUACAGGCUGCGUUAUAGCUUGGAAUUCUAACAAUCUUGAUUCUAAGGUUGGUGGUAAUUAUAAUUACCUGUAUAGAUUGUUUAGGAAGUCUAAUCUCAAACCUUUUGAGAGAGAUAUUUCAACUGAAAUCUAUCAGGCCGGUAGCACACCUUGUAAUGGUGUUGAAGGUUUUAAUUGUUACUUUCCUUUACAAUCAUAUGGUUUCCAACCCACUAAUGGUGUUGGUUACCAACCAUACAGAGUAGUAGUACUUUCUUUUGAACUUCUACAUGCACCAGCAACUGUUUGUGGACCUAAAAAGUCUACUAAUUUGGUUAAAAACAAAUGUGUCAAUUUCAACUUCAAUGGUUUAACAGGCACAGGUGUUCUUACUGAGUCUAACAAAAAGUUUCUGCCUUUCCAACAAUUUGGCAGAGACAUUGCUGACACUACUGAUGCUGUCCGUGAUCCACAGACACUUGAGAUUCUUGACAUUACACCAUGUUCUUUUGGUGGUGUCAGUGUUAUAACACCAGGAACAAAUACUUCUAACCAGGUUGCUGUUCUUUAUCAGGAUGUUAACUGCACAGAAGUCCCUGUUGCUAUUCAUGCAGAUCAACUUACUCCUACUUGGCGUGUUUAUUCUACAGGUUCUAAUGUUUUUCAAACACGUGCAGGCUGUUUAAUAGGGGCUGAACAUGUCAACAACUCAUAUGAGUGUGACAUACCCAUUGGUGCAGGUAUAUGCGCUAGUUAUCAGACUCAGACUAAUUCUCCUCGGCGGGCACGUAGUGUAGCUAGUCAAUCCAUCAUUGCCUACACUAUGUCACUUGGUGCAGAAAAUUCAGUUGCUUACUCUAAUAACUCUAUUGCCAUACCCACAAAUUUUACUAUUAGUGUUACCACAGAAAUUCUACCAGUGUCUAUGACCAAGACAUCAGUAGAUUGUACAAUGUACAUUUGUGGUGAUUCAACUGAAUGCAGCAAUCUUUUGUUGCAAUAUGGCAGUUUUUGUACACAAUUAAACCGUGCUUUAACUGGAAUAGCUGUUGAACAAGACAAAAACACCCAAGAAGUUUUUGCACAAGUCAAACAAAUUUACAAAACACCACCAAUUAAAGAUUUUGGUGGUUUUAAUUUUUCACAAAUAUUACCAGAUCCAUCAAAACCAAGCAAGAGGUCAUUUAUUGAAGAUCUACUUUUCAACAAAGUGACACUUGCAGAUGCUGGCUUCAUCAAACAAUAUGGUGAUUGCCUUGGUGAUAUUGCUGCUAGAGACCUCAUUUGUGCACAAAAGUUUAACGGCCUUACUGUUUUGCCACCUUUGCUCACAGAUGAAAUGAUUGCUCAAUACACUUCUGCACUGUUAGCGGGUACAAUCACUUCUGGUUGGACCUUUGGUGCAGGUGCUGCAUUACAAAUACCAUUUGCUAUGCAAAUGGCUUAUAGGUUUAAUGGUAUUGGAGUUACACAGAAUGUUCUCUAUGAGAACCAAAAAUUGAUUGCCAACCAAUUUAAUAGUGCUAUUGGCAAAAUUCAAGACUCACUUUCUUCCACAGCAAGUGCACUUGGAAAACUUCAAGAUGUGGUCAACCAAAAUGCACAAGCUUUAAACACGCUUGUUAAACAACUUAGCUCCAAUUUUGGUGCAAUUUCAAGUGUUUUAAAUGAUAUCCUUUCACGUCUUGACAAAGUUGAGGCUGAAGUGCAAAUUGAUAGGUUGAUCACAGGCAGACUUCAAAGUUUGCAGACAUAUGUGACUCAACAAUUAAUUAGAGCUGCAGAAAUCAGAGCUUCUGCUAAUCUUGCUGCUACUAAAAUGUCAGAGUGUGUACUUGGACAAUCAAAAAGAGUUGAUUUUUGUGGAAAGGGCUAUCAUCUUAUGUCCUUCCCUCAGUCAGCACCUCAUGGUGUAGUCUUCUUGCAUGUGACUUAUGUCCCUGCACAAGAAAAGAACUUCACAACUGCUCCUGCCAUUUGUCAUGAUGGAAAAGCACACUUUCCUCGUGAAGGUGUCUUUGUUUCAAAUGGCACACACUGGUUUGUAACACAAAGGAAUUUUUAUGAACCACAAAUCAUUACUACAGACAACACAUUUGUGUCUGGUAACUGUGAUGUUGUAAUAGGAAUUGUCAACAACACAGUUUAUGAUCCUUUGCAACCUGAAUUAGACUCAUUCAAGGAGGAGUUAGAUAAAUAUUUUAAGAAUCAUACAUCACCAGAUGUUGAUUUAGGUGACAUCUCUGGCAUUAAUGCUUCAGUUGUAAACAUUCAAAAAGAAAUUGACCGCCUCAAUGAGGUUGCCAAGAAUUUAAAUGAAUCUCUCAUCGAUCUCCAAGAACUUGGAAAGUAUGAGCAGUAUAUAAAAUGGCCAUGGUACAUUUGGCUAGGUUUUAUAGCUGGCUUGAUUGCCAUAGUAAUGGUGACAAUUAUGCUUUGCUGUAUGACCAGUUGCUGUAGUUGUCUCAAGGGCUGUUGUUCUUGUGGAUCCUGCUGCAAAUUUGAUGAAGACGACUCUGAGCCAGUGCUCAAAGGAGUCAAAUUACAUUACACAUAAACGAACUUAUGGAUUUGUUUAUGAGAAUCUUCACAAUUGGAACUGUAACUUUGAAGCAAGGUGAAAUCAAGGAUGCUACUCCUUCAGAUUUUGUUCGCGCUACUGCAACGAUACCGAUACAAGCCUCACUCCCUUUCGGAUGGCUUAUUGUUGGCGUUGCACUUCUUGCUGUUUUUCAGAGCGCUUCCAAAAUCAUAACCCUCAAAAAGAGAUGGCAACUAGCACUCUCCAAGGGUGUUCACUUUGUUUGCAACUUGCUGUUGUUGUUUGUAACAGUUUACUCACACCUUUUGCUCGUUGCUGCUGGCCUUGAAGCCCCUUUUCUCUAUCUUUAUGCUUUAGUCUACUUCUUGCAGAGUAUAAACUUUGUAAGAAUAAUAAUGAGGCUUUGGCUUUGCUGGAAAUGCCGUUCCAAAAACCCAUUACUUUAUGAUGCCAACUAUUUUCUUUGCUGGCAUACUAAUUGUUACGACUAUUGUAUACCUUACAAUAGUGUAACUUCUUCAAUUGUCAUUACUUCAGGUGAUGGCACAACAAGUCCUAUUUCUGAACAUGACUACCAGAUUGGUGGUUAUACUGAAAAAUGGGAAUCUGGAGUAAAAGACUGUGUUGUAUUACACAGUUACUUCACUUCAGACUAUUACCAGCUGUACUCAACUCAAUUGAGUACAGACACUGGUGUUGAACAUGUUACCUUCUUCAUCUACAAUAAAAUUGUUGAUGAGCCUGAAGAACAUGUCCAAAUUCACACAAUCGACGGUUCAUCCGGAGUUGUUAAUCCAGUAAUGGAACCAAUUUAUGAUGAACCGACGACGACUACUAGCGUGCCUUUGUAAGCACAAGCUGAUGAGUACGAACUUAUGUACUCAUUCGUUUCGGAAGAGACAGGUACGUUAAUAGUUAAUAGCGUACUUCUUUUUCUUGCUUUCGUGGUAUUCUUGCUAGUUACACUAGCCAUCCUUACUGCGCUUCGAUUGUGUGCGUACUGCUGCAAUAUUGUUAACGUGAGUCUUGUAAAACCUUCUUUUUACGUUUACUCUCGUGUUAAAAAUCUGAAUUCUUCUAGAGUUCCUGAUCUUCUGGUCUAAACGAACUAAAUAUUAUAUUAGUUUUUCUGUUUGGAACUUUAAUUUUAGCCAUGGCAGAUUCCAACGGUACUAUUACCGUUGAAGAGCUUAAAAAGCUCCUUGAACAAUGGAACCUAGUAAUAGGUUUCCUAUUCCUUACAUGGAUUUGUCUUCUACAAUUUGCCUAUGCCAACAGGAAUAGGUUUUUGUAUAUAAUUAAGUUAAUUUUCCUCUGGCUGUUAUGGCCAGUAACUUUAGCUUGUUUUGUGCUUGCUGCUGUUUACAGAAUAAAUUGGAUCACCGGUGGAAUUGCUAUCGCAAUGGCUUGUCUUGUAGGCUUGAUGUGGCUCAGCUACUUCAUUGCUUCUUUCAGACUGUUUGCGCGUACGCGUUCCAUGUGGUCAUUCAAUCCAGAAACUAACAUUCUUCUCAACGUGCCACUCCAUGGCACUAUUCUGACCAGACCGCUUCUAGAAAGUGAACUCGUAAUCGGAGCUGUGAUCCUUCGUGGACAUCUUCGUAUUGCUGGACACCAUCUAGGACGCUGUGACAUCAAGGACCUGCCUAAAGAAAUCACUGUUGCUACAUCACGAACGCUUUCUUAUUACAAAUUGGGAGCUUCGCAGCGUGUAGCAGGUGACUCAGGUUUUGCUGCAUACAGUCGCUACAGGAUUGGCAACUAUAAAUUAAACACAGACCAUUCCAGUAGCAGUGACAAUAUUGCUUUGCUUGUACAGUAAGUGACAACAGAUGUUUCAUCUCGUUGACUUUCAGGUUACUAUAGCAGAGAUAUUACUAAUUAUUAUGAGGACUUUUAAAGUUUCCAUUUGGAAUCUUGAUUACAUCAUAAACCUCAUAAUUAAAAAUUUAUCUAAGUCACUAACUGAGAAUAAAUAUUCUCAAUUAGAUGAAGAGCAACCAAUGGAGAUUGAUUAAACGAACAUGAAAAUUAUUCUUUUCUUGGCACUGAUAACACUCGCUACUUGUGAGCUUUAUCACUACCAAGAGUGUGUUAGAGGUACAACAGUACUUUUAAAAGAACCUUGCUCUUCUGGAACAUACGAGGGCAAUUCACCAUUUCAUCCUCUAGCUGAUAACAAAUUUGCACUGACUUGCUUUAGCACUCAAUUUGCUUUUGCUUGUCCUGACGGCGUAAAACACGUCUAUCAGUUACGUGCCAGAUCAGUUUCACCUAAACUGUUCAUCAGACAAGAGGAAGUUCAAGAACUUUACUCUCCAAUUUUUCUUAUUGUUGCGGCAAUAGUGUUUAUAACACUUUGCUUCACACUCAAAAGAAAGACAGAAUGAUUGAACUUUCAUUAAUUGACUUCUAUUUGUGCUUUUUAGCCUUUCUGCUAUUCCUUGUUUUAAUUAUGCUUAUUAUCUUUUGGUUCUCACUUGAACUGCAAGAUCAUAAUGAAACUUGUCACGCCUAAACGAACAUGAAAUUUCUUGUUUUCUUAGGAAUCAUCACAACUGUAGCUGCAUUUCACCAAGAAUGUAGUUUACAGUCAUGUACUCAACAUCAACCAUAUGUAGUUGAUGACCCGUGUCCUAUUCACUUCUAUUCUAAAUGGUAUAUUAGAGUAGGAGCUAGAAAAUCAGCACCUUUAAUUGAAUUGUGCGUGGAUGAGGCUGGUUCUAAAUCACCCAUUCAGUACAUCGAUAUCGGUAAUUAUACAGUUUCCUGUUUACCUUUUACAAUUAAUUGCCAGGAACCUAAAUUGGGUAGUCUUGUAGUGCGUUGUUCGUUCUAUGAAGACUUUUUAGAGUAUCAUGACGUUCGUGUUGUUUUAGAUUUCAUCUAAACGAACAAACUAAAAUGUCUGAUAAUGGACCCCAAAAUCAGCGAAAUGCACCCCGCAUUACGUUUGGUGGACCCUCAGAUUCAACUGGCAGUAACCAGAAUGGAGAACGCAGUGGGGCGCGAUCAAAACAACGUCGGCCCCAAGGUUUACCCAAUAAUACUGCGUCUUGGUUCACCGCUCUCACUCAACAUGGCAAGGAAGACCUUAAAUUCCCUCGAGGACAAGGCGUUCCAAUUAACACCAAUAGCAGUCCAGAUGACCAAAUUGGCUACUACCGAAGAGCUACCAGACGAAUUCGUGGUGGUGACGGUAAAAUGAAAGAUCUCAGUCCAAGAUGGUAUUUCUACUACCUAGGAACUGGGCCAGAAGCUGGACUUCCCUAUGGUGCUAACAAAGACGGCAUCAUAUGGGUUGCAACUGAGGGAGCCUUGAAUACACCAAAAGAUCACAUUGGCACCCGCAAUCCUGCUAACAAUGCUGCAAUCGUGCUACAACUUCCUCAAGGAACAACAUUGCCAAAAGGCUUCUACGCAGAAGGGAGCAGAGGCGGCAGUCAAGCCUCUUCUCGUUCCUCAUCACGUAGUCGCAACAGUUCAAGAAAUUCAACUCCAGGCAGCAGUAGGGGAACUUCUCCUGCUAGAAUGGCUGGCAAUGGCGGUGAUGCUGCUCUUGCUUUGCUGCUGCUUGACAGAUUGAACCAGCUUGAGAGCAAAAUGUCUGGUAAAGGCCAACAACAACAAGGCCAAACUGUCACUAAGAAAUCUGCUGCUGAGGCUUCUAAGAAGCCUCGGCAAAAACGUACUGCCACUAAAGCAUACAAUGUAACACAAGCUUUCGGCAGACGUGGUCCAGAACAAACCCAAGGAAAUUUUGGGGACCAGGAACUAAUCAGACAAGGAACUGAUUACAAACAUUGGCCGCAAAUUGCACAAUUUGCCCCCAGCGCUUCAGCGUUCUUCGGAAUGUCGCGCAUUGGCAUGGAAGUCACACCUUCGGGAACGUGGUUGACCUACACAGGUGCCAUCAAAUUGGAUGACAAAGAUCCAAAUUUCAAAGAUCAAGUCAUUUUGCUGAAUAAGCAUAUUGACGCAUACAAAACAUUCCCACCAACAGAGCCUAAAAAGGACAAAAAGAAGAAGGCUGAUGAAACUCAAGCCUUACCGCAGAGACAGAAGAAACAGCAAACUGUGACUCUUCUUCCUGCUGCAGAUUUGGAUGAUUUCUCCAAACAAUUGCAACAAUCCAUGAGCAGUGCUGACUCAACUCAGGCCUAAACUCAUGCAGACCACACAAGGCAGAUGGGCUAUAUAAACGUUUUCGCUUUUCCGUUUACGAUAUAUAGUCUACUCUUGUGCAGAAUGAAUUCUCGUAACUACAUAGCACAAGUAGAUGUAGUUAACUUUAAUCUCACAUAGCAAUCUUUAAUCAGUGUGUAACAUUAGGGAGGACUUGAAAGAGCCACCACAUUUUCACCGAGGCCACGCGGAGUACGAUCGAGUGUACAGUGAACAAUGCUAGGGAGAGCUGCCUAUAUGGAAGAGCCCUAAUGUGUAAAAUUAAUUUUAGUAGUGCUAUCCCCAUGUGAUUUUAAUAGCUUCUUAGGAGAAUGACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,protein_ptm:deacetylated,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5µM[SARS2-NPNon-Ac];|5µM[SARS-CoV-2],"15 mM NaCl, 135 mM KCl, 5 mM phosphate, 1.5 mM MgCl2","20 mM Tris–HCl, pH 7.0",37˚C,-,other_molecular:1 mg ml−1 BSA,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"SARS2-NP Non-Ac and RNA rapidly formed micrometre-sized liquid droplets and the small liquid droplets quickly fused into larger ones, accompanied by increased fluorescence intensity and a larger equivalent diameter"
702,PMID: 34239064,RNAPS0000450,https://pubmed.ncbi.nlm.nih.gov/34239064,RNA + protein,-,-,SARS-CoV-2 virus RNA,29903nt(1-29903),AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGCACCUCAUGGUCAUGUUAUGGUUGAGCUGGUAGCAGAACUCGAAGGCAUUCAGUACGGUCGUAGUGGUGAGACACUUGGUGUCCUUGUCCCUCAUGUGGGCGAAAUACCAGUGGCUUACCGCAAGGUUCUUCUUCGUAAGAACGGUAAUAAAGGAGCUGGUGGCCAUAGUUACGGCGCCGAUCUAAAGUCAUUUGACUUAGGCGACGAGCUUGGCACUGAUCCUUAUGAAGAUUUUCAAGAAAACUGGAACACUAAACAUAGCAGUGGUGUUACCCGUGAACUCAUGCGUGAGCUUAACGGAGGGGCAUACACUCGCUAUGUCGAUAACAACUUCUGUGGCCCUGAUGGCUACCCUCUUGAGUGCAUUAAAGACCUUCUAGCACGUGCUGGUAAAGCUUCAUGCACUUUGUCCGAACAACUGGACUUUAUUGACACUAAGAGGGGUGUAUACUGCUGCCGUGAACAUGAGCAUGAAAUUGCUUGGUACACGGAACGUUCUGAAAAGAGCUAUGAAUUGCAGACACCUUUUGAAAUUAAAUUGGCAAAGAAAUUUGACACCUUCAAUGGGGAAUGUCCAAAUUUUGUAUUUCCCUUAAAUUCCAUAAUCAAGACUAUUCAACCAAGGGUUGAAAAGAAAAAGCUUGAUGGCUUUAUGGGUAGAAUUCGAUCUGUCUAUCCAGUUGCGUCACCAAAUGAAUGCAACCAAAUGUGCCUUUCAACUCUCAUGAAGUGUGAUCAUUGUGGUGAAACUUCAUGGCAGACGGGCGAUUUUGUUAAAGCCACUUGCGAAUUUUGUGGCACUGAGAAUUUGACUAAAGAAGGUGCCACUACUUGUGGUUACUUACCCCAAAAUGCUGUUGUUAAAAUUUAUUGUCCAGCAUGUCACAAUUCAGAAGUAGGACCUGAGCAUAGUCUUGCCGAAUACCAUAAUGAAUCUGGCUUGAAAACCAUUCUUCGUAAGGGUGGUCGCACUAUUGCCUUUGGAGGCUGUGUGUUCUCUUAUGUUGGUUGCCAUAACAAGUGUGCCUAUUGGGUUCCACGUGCUAGCGCUAACAUAGGUUGUAACCAUACAGGUGUUGUUGGAGAAGGUUCCGAAGGUCUUAAUGACAACCUUCUUGAAAUACUCCAAAAAGAGAAAGUCAACAUCAAUAUUGUUGGUGACUUUAAACUUAAUGAAGAGAUCGCCAUUAUUUUGGCAUCUUUUUCUGCUUCCACAAGUGCUUUUGUGGAAACUGUGAAAGGUUUGGAUUAUAAAGCAUUCAAACAAAUUGUUGAAUCCUGUGGUAAUUUUAAAGUUACAAAAGGAAAAGCUAAAAAAGGUGCCUGGAAUAUUGGUGAACAGAAAUCAAUACUGAGUCCUCUUUAUGCAUUUGCAUCAGAGGCUGCUCGUGUUGUACGAUCAAUUUUCUCCCGCACUCUUGAAACUGCUCAAAAUUCUGUGCGUGUUUUACAGAAGGCCGCUAUAACAAUACUAGAUGGAAUUUCACAGUAUUCACUGAGACUCAUUGAUGCUAUGAUGUUCACAUCUGAUUUGGCUACUAACAAUCUAGUUGUAAUGGCCUACAUUACAGGUGGUGUUGUUCAGUUGACUUCGCAGUGGCUAACUAACAUCUUUGGCACUGUUUAUGAAAAACUCAAACCCGUCCUUGAUUGGCUUGAAGAGAAGUUUAAGGAAGGUGUAGAGUUUCUUAGAGACGGUUGGGAAAUUGUUAAAUUUAUCUCAACCUGUGCUUGUGAAAUUGUCGGUGGACAAAUUGUCACCUGUGCAAAGGAAAUUAAGGAGAGUGUUCAGACAUUCUUUAAGCUUGUAAAUAAAUUUUUGGCUUUGUGUGCUGACUCUAUCAUUAUUGGUGGAGCUAAACUUAAAGCCUUGAAUUUAGGUGAAACAUUUGUCACGCACUCAAAGGGAUUGUACAGAAAGUGUGUUAAAUCCAGAGAAGAAACUGGCCUACUCAUGCCUCUAAAAGCCCCAAAAGAAAUUAUCUUCUUAGAGGGAGAAACACUUCCCACAGAAGUGUUAACAGAGGAAGUUGUCUUGAAAACUGGUGAUUUACAACCAUUAGAACAACCUACUAGUGAAGCUGUUGAAGCUCCAUUGGUUGGUACACCAGUUUGUAUUAACGGGCUUAUGUUGCUCGAAAUCAAAGACACAGAAAAGUACUGUGCCCUUGCACCUAAUAUGAUGGUAACAAACAAUACCUUCACACUCAAAGGCGGUGCACCAACAAAGGUUACUUUUGGUGAUGACACUGUGAUAGAAGUGCAAGGUUACAAGAGUGUGAAUAUCACUUUUGAACUUGAUGAAAGGAUUGAUAAAGUACUUAAUGAGAAGUGCUCUGCCUAUACAGUUGAACUCGGUACAGAAGUAAAUGAGUUCGCCUGUGUUGUGGCAGAUGCUGUCAUAAAAACUUUGCAACCAGUAUCUGAAUUACUUACACCACUGGGCAUUGAUUUAGAUGAGUGGAGUAUGGCUACAUACUACUUAUUUGAUGAGUCUGGUGAGUUUAAAUUGGCUUCACAUAUGUAUUGUUCUUUCUACCCUCCAGAUGAGGAUGAAGAAGAAGGUGAUUGUGAAGAAGAAGAGUUUGAGCCAUCAACUCAAUAUGAGUAUGGUACUGAAGAUGAUUACCAAGGUAAACCUUUGGAAUUUGGUGCCACUUCUGCUGCUCUUCAACCUGAAGAAGAGCAAGAAGAAGAUUGGUUAGAUGAUGAUAGUCAACAAACUGUUGGUCAACAAGACGGCAGUGAGGACAAUCAGACAACUACUAUUCAAACAAUUGUUGAGGUUCAACCUCAAUUAGAGAUGGAACUUACACCAGUUGUUCAGACUAUUGAAGUGAAUAGUUUUAGUGGUUAUUUAAAACUUACUGACAAUGUAUACAUUAAAAAUGCAGACAUUGUGGAAGAAGCUAAAAAGGUAAAACCAACAGUGGUUGUUAAUGCAGCCAAUGUUUACCUUAAACAUGGAGGAGGUGUUGCAGGAGCCUUAAAUAAGGCUACUAACAAUGCCAUGCAAGUUGAAUCUGAUGAUUACAUAGCUACUAAUGGACCACUUAAAGUGGGUGGUAGUUGUGUUUUAAGCGGACACAAUCUUGCUAAACACUGUCUUCAUGUUGUCGGCCCAAAUGUUAACAAAGGUGAAGACAUUCAACUUCUUAAGAGUGCUUAUGAAAAUUUUAAUCAGCACGAAGUUCUACUUGCACCAUUAUUAUCAGCUGGUAUUUUUGGUGCUGACCCUAUACAUUCUUUAAGAGUUUGUGUAGAUACUGUUCGCACAAAUGUCUACUUAGCUGUCUUUGAUAAAAAUCUCUAUGACAAACUUGUUUCAAGCUUUUUGGAAAUGAAGAGUGAAAAGCAAGUUGAACAAAAGAUCGCUGAGAUUCCUAAAGAGGAAGUUAAGCCAUUUAUAACUGAAAGUAAACCUUCAGUUGAACAGAGAAAACAAGAUGAUAAGAAAAUCAAAGCUUGUGUUGAAGAAGUUACAACAACUCUGGAAGAAACUAAGUUCCUCACAGAAAACUUGUUACUUUAUAUUGACAUUAAUGGCAAUCUUCAUCCAGAUUCUGCCACUCUUGUUAGUGACAUUGACAUCACUUUCUUAAAGAAAGAUGCUCCAUAUAUAGUGGGUGAUGUUGUUCAAGAGGGUGUUUUAACUGCUGUGGUUAUACCUACUAAAAAGGCUGGUGGCACUACUGAAAUGCUAGCGAAAGCUUUGAGAAAAGUGCCAACAGACAAUUAUAUAACCACUUACCCGGGUCAGGGUUUAAAUGGUUACACUGUAGAGGAGGCAAAGACAGUGCUUAAAAAGUGUAAAAGUGCCUUUUACAUUCUACCAUCUAUUAUCUCUAAUGAGAAGCAAGAAAUUCUUGGAACUGUUUCUUGGAAUUUGCGAGAAAUGCUUGCACAUGCAGAAGAAACACGCAAAUUAAUGCCUGUCUGUGUGGAAACUAAAGCCAUAGUUUCAACUAUACAGCGUAAAUAUAAGGGUAUUAAAAUACAAGAGGGUGUGGUUGAUUAUGGUGCUAGAUUUUACUUUUACACCAGUAAAACAACUGUAGCGUCACUUAUCAACACACUUAACGAUCUAAAUGAAACUCUUGUUACAAUGCCACUUGGCUAUGUAACACAUGGCUUAAAUUUGGAAGAAGCUGCUCGGUAUAUGAGAUCUCUCAAAGUGCCAGCUACAGUUUCUGUUUCUUCACCUGAUGCUGUUACAGCGUAUAAUGGUUAUCUUACUUCUUCUUCUAAAACACCUGAAGAACAUUUUAUUGAAACCAUCUCACUUGCUGGUUCCUAUAAAGAUUGGUCCUAUUCUGGACAAUCUACACAACUAGGUAUAGAAUUUCUUAAGAGAGGUGAUAAAAGUGUAUAUUACACUAGUAAUCCUACCACAUUCCACCUAGAUGGUGAAGUUAUCACCUUUGACAAUCUUAAGACACUUCUUUCUUUGAGAGAAGUGAGGACUAUUAAGGUGUUUACAACAGUAGACAACAUUAACCUCCACACGCAAGUUGUGGACAUGUCAAUGACAUAUGGACAACAGUUUGGUCCAACUUAUUUGGAUGGAGCUGAUGUUACUAAAAUAAAACCUCAUAAUUCACAUGAAGGUAAAACAUUUUAUGUUUUACCUAAUGAUGACACUCUACGUGUUGAGGCUUUUGAGUACUACCACACAACUGAUCCUAGUUUUCUGGGUAGGUACAUGUCAGCAUUAAAUCACACUAAAAAGUGGAAAUACCCACAAGUUAAUGGUUUAACUUCUAUUAAAUGGGCAGAUAACAACUGUUAUCUUGCCACUGCAUUGUUAACACUCCAACAAAUAGAGUUGAAGUUUAAUCCACCUGCUCUACAAGAUGCUUAUUACAGAGCAAGGGCUGGUGAAGCUGCUAACUUUUGUGCACUUAUCUUAGCCUACUGUAAUAAGACAGUAGGUGAGUUAGGUGAUGUUAGAGAAACAAUGAGUUACUUGUUUCAACAUGCCAAUUUAGAUUCUUGCAAAAGAGUCUUGAACGUGGUGUGUAAAACUUGUGGACAACAGCAGACAACCCUUAAGGGUGUAGAAGCUGUUAUGUACAUGGGCACACUUUCUUAUGAACAAUUUAAGAAAGGUGUUCAGAUACCUUGUACGUGUGGUAAACAAGCUACAAAAUAUCUAGUACAACAGGAGUCACCUUUUGUUAUGAUGUCAGCACCACCUGCUCAGUAUGAACUUAAGCAUGGUACAUUUACUUGUGCUAGUGAGUACACUGGUAAUUACCAGUGUGGUCACUAUAAACAUAUAACUUCUAAAGAAACUUUGUAUUGCAUAGACGGUGCUUUACUUACAAAGUCCUCAGAAUACAAAGGUCCUAUUACGGAUGUUUUCUACAAAGAAAACAGUUACACAACAACCAUAAAACCAGUUACUUAUAAAUUGGAUGGUGUUGUUUGUACAGAAAUUGACCCUAAGUUGGACAAUUAUUAUAAGAAAGACAAUUCUUAUUUCACAGAGCAACCAAUUGAUCUUGUACCAAACCAACCAUAUCCAAACGCAAGCUUCGAUAAUUUUAAGUUUGUAUGUGAUAAUAUCAAAUUUGCUGAUGAUUUAAACCAGUUAACUGGUUAUAAGAAACCUGCUUCAAGAGAGCUUAAAGUUACAUUUUUCCCUGACUUAAAUGGUGAUGUGGUGGCUAUUGAUUAUAAACACUACACACCCUCUUUUAAGAAAGGAGCUAAAUUGUUACAUAAACCUAUUGUUUGGCAUGUUAACAAUGCAACUAAUAAAGCCACGUAUAAACCAAAUACCUGGUGUAUACGUUGUCUUUGGAGCACAAAACCAGUUGAAACAUCAAAUUCGUUUGAUGUACUGAAGUCAGAGGACGCGCAGGGAAUGGAUAAUCUUGCCUGCGAAGAUCUAAAACCAGUCUCUGAAGAAGUAGUGGAAAAUCCUACCAUACAGAAAGACGUUCUUGAGUGUAAUGUGAAAACUACCGAAGUUGUAGGAGACAUUAUACUUAAACCAGCAAAUAAUAGUUUAAAAAUUACAGAAGAGGUUGGCCACACAGAUCUAAUGGCUGCUUAUGUAGACAAUUCUAGUCUUACUAUUAAGAAACCUAAUGAAUUAUCUAGAGUAUUAGGUUUGAAAACCCUUGCUACUCAUGGUUUAGCUGCUGUUAAUAGUGUCCCUUGGGAUACUAUAGCUAAUUAUGCUAAGCCUUUUCUUAACAAAGUUGUUAGUACAACUACUAACAUAGUUACACGGUGUUUAAACCGUGUUUGUACUAAUUAUAUGCCUUAUUUCUUUACUUUAUUGCUACAAUUGUGUACUUUUACUAGAAGUACAAAUUCUAGAAUUAAAGCAUCUAUGCCGACUACUAUAGCAAAGAAUACUGUUAAGAGUGUCGGUAAAUUUUGUCUAGAGGCUUCAUUUAAUUAUUUGAAGUCACCUAAUUUUUCUAAACUGAUAAAUAUUAUAAUUUGGUUUUUACUAUUAAGUGUUUGCCUAGGUUCUUUAAUCUACUCAACCGCUGCUUUAGGUGUUUUAAUGUCUAAUUUAGGCAUGCCUUCUUACUGUACUGGUUACAGAGAAGGCUAUUUGAACUCUACUAAUGUCACUAUUGCAACCUACUGUACUGGUUCUAUACCUUGUAGUGUUUGUCUUAGUGGUUUAGAUUCUUUAGACACCUAUCCUUCUUUAGAAACUAUACAAAUUACCAUUUCAUCUUUUAAAUGGGAUUUAACUGCUUUUGGCUUAGUUGCAGAGUGGUUUUUGGCAUAUAUUCUUUUCACUAGGUUUUUCUAUGUACUUGGAUUGGCUGCAAUCAUGCAAUUGUUUUUCAGCUAUUUUGCAGUACAUUUUAUUAGUAAUUCUUGGCUUAUGUGGUUAAUAAUUAAUCUUGUACAAAUGGCCCCGAUUUCAGCUAUGGUUAGAAUGUACAUCUUCUUUGCAUCAUUUUAUUAUGUAUGGAAAAGUUAUGUGCAUGUUGUAGACGGUUGUAAUUCAUCAACUUGUAUGAUGUGUUACAAACGUAAUAGAGCAACAAGAGUCGAAUGUACAACUAUUGUUAAUGGUGUUAGAAGGUCCUUUUAUGUCUAUGCUAAUGGAGGUAAAGGCUUUUGCAAACUACACAAUUGGAAUUGUGUUAAUUGUGAUACAUUCUGUGCUGGUAGUACAUUUAUUAGUGAUGAAGUUGCGAGAGACUUGUCACUACAGUUUAAAAGACCAAUAAAUCCUACUGACCAGUCUUCUUACAUCGUUGAUAGUGUUACAGUGAAGAAUGGUUCCAUCCAUCUUUACUUUGAUAAAGCUGGUCAAAAGACUUAUGAAAGACAUUCUCUCUCUCAUUUUGUUAACUUAGACAACCUGAGAGCUAAUAACACUAAAGGUUCAUUGCCUAUUAAUGUUAUAGUUUUUGAUGGUAAAUCAAAAUGUGAAGAAUCAUCUGCAAAAUCAGCGUCUGUUUACUACAGUCAGCUUAUGUGUCAACCUAUACUGUUACUAGAUCAGGCAUUAGUGUCUGAUGUUGGUGAUAGUGCGGAAGUUGCAGUUAAAAUGUUUGAUGCUUACGUUAAUACGUUUUCAUCAACUUUUAACGUACCAAUGGAAAAACUCAAAACACUAGUUGCAACUGCAGAAGCUGAACUUGCAAAGAAUGUGUCCUUAGACAAUGUCUUAUCUACUUUUAUUUCAGCAGCUCGGCAAGGGUUUGUUGAUUCAGAUGUAGAAACUAAAGAUGUUGUUGAAUGUCUUAAAUUGUCACAUCAAUCUGACAUAGAAGUUACUGGCGAUAGUUGUAAUAACUAUAUGCUCACCUAUAACAAAGUUGAAAACAUGACACCCCGUGACCUUGGUGCUUGUAUUGACUGUAGUGCGCGUCAUAUUAAUGCGCAGGUAGCAAAAAGUCACAACAUUGCUUUGAUAUGGAACGUUAAAGAUUUCAUGUCAUUGUCUGAACAACUACGAAAACAAAUACGUAGUGCUGCUAAAAAGAAUAACUUACCUUUUAAGUUGACAUGUGCAACUACUAGACAAGUUGUUAAUGUUGUAACAACAAAGAUAGCACUUAAGGGUGGUAAAAUUGUUAAUAAUUGGUUGAAGCAGUUAAUUAAAGUUACACUUGUGUUCCUUUUUGUUGCUGCUAUUUUCUAUUUAAUAACACCUGUUCAUGUCAUGUCUAAACAUACUGACUUUUCAAGUGAAAUCAUAGGAUACAAGGCUAUUGAUGGUGGUGUCACUCGUGACAUAGCAUCUACAGAUACUUGUUUUGCUAACAAACAUGCUGAUUUUGACACAUGGUUUAGCCAGCGUGGUGGUAGUUAUACUAAUGACAAAGCUUGCCCAUUGAUUGCUGCAGUCAUAACAAGAGAAGUGGGUUUUGUCGUGCCUGGUUUGCCUGGCACGAUAUUACGCACAACUAAUGGUGACUUUUUGCAUUUCUUACCUAGAGUUUUUAGUGCAGUUGGUAACAUCUGUUACACACCAUCAAAACUUAUAGAGUACACUGACUUUGCAACAUCAGCUUGUGUUUUGGCUGCUGAAUGUACAAUUUUUAAAGAUGCUUCUGGUAAGCCAGUACCAUAUUGUUAUGAUACCAAUGUACUAGAAGGUUCUGUUGCUUAUGAAAGUUUACGCCCUGACACACGUUAUGUGCUCAUGGAUGGCUCUAUUAUUCAAUUUCCUAACACCUACCUUGAAGGUUCUGUUAGAGUGGUAACAACUUUUGAUUCUGAGUACUGUAGGCACGGCACUUGUGAAAGAUCAGAAGCUGGUGUUUGUGUAUCUACUAGUGGUAGAUGGGUACUUAACAAUGAUUAUUACAGAUCUUUACCAGGAGUUUUCUGUGGUGUAGAUGCUGUAAAUUUACUUACUAAUAUGUUUACACCACUAAUUCAACCUAUUGGUGCUUUGGACAUAUCAGCAUCUAUAGUAGCUGGUGGUAUUGUAGCUAUCGUAGUAACAUGCCUUGCCUACUAUUUUAUGAGGUUUAGAAGAGCUUUUGGUGAAUACAGUCAUGUAGUUGCCUUUAAUACUUUACUAUUCCUUAUGUCAUUCACUGUACUCUGUUUAACACCAGUUUACUCAUUCUUACCUGGUGUUUAUUCUGUUAUUUACUUGUACUUGACAUUUUAUCUUACUAAUGAUGUUUCUUUUUUAGCACAUAUUCAGUGGAUGGUUAUGUUCACACCUUUAGUACCUUUCUGGAUAACAAUUGCUUAUAUCAUUUGUAUUUCCACAAAGCAUUUCUAUUGGUUCUUUAGUAAUUACCUAAAGAGACGUGUAGUCUUUAAUGGUGUUUCCUUUAGUACUUUUGAAGAAGCUGCGCUGUGCACCUUUUUGUUAAAUAAAGAAAUGUAUCUAAAGUUGCGUAGUGAUGUGCUAUUACCUCUUACGCAAUAUAAUAGAUACUUAGCUCUUUAUAAUAAGUACAAGUAUUUUAGUGGAGCAAUGGAUACAACUAGCUACAGAGAAGCUGCUUGUUGUCAUCUCGCAAAGGCUCUCAAUGACUUCAGUAACUCAGGUUCUGAUGUUCUUUACCAACCACCACAAACCUCUAUCACCUCAGCUGUUUUGCAGAGUGGUUUUAGAAAAAUGGCAUUCCCAUCUGGUAAAGUUGAGGGUUGUAUGGUACAAGUAACUUGUGGUACAACUACACUUAACGGUCUUUGGCUUGAUGACGUAGUUUACUGUCCAAGACAUGUGAUCUGCACCUCUGAAGACAUGCUUAACCCUAAUUAUGAAGAUUUACUCAUUCGUAAGUCUAAUCAUAAUUUCUUGGUACAGGCUGGUAAUGUUCAACUCAGGGUUAUUGGACAUUCUAUGCAAAAUUGUGUACUUAAGCUUAAGGUUGAUACAGCCAAUCCUAAGACACCUAAGUAUAAGUUUGUUCGCAUUCAACCAGGACAGACUUUUUCAGUGUUAGCUUGUUACAAUGGUUCACCAUCUGGUGUUUACCAAUGUGCUAUGAGGCCCAAUUUCACUAUUAAGGGUUCAUUCCUUAAUGGUUCAUGUGGUAGUGUUGGUUUUAACAUAGAUUAUGACUGUGUCUCUUUUUGUUACAUGCACCAUAUGGAAUUACCAACUGGAGUUCAUGCUGGCACAGACUUAGAAGGUAACUUUUAUGGACCUUUUGUUGACAGGCAAACAGCACAAGCAGCUGGUACGGACACAACUAUUACAGUUAAUGUUUUAGCUUGGUUGUACGCUGCUGUUAUAAAUGGAGACAGGUGGUUUCUCAAUCGAUUUACCACAACUCUUAAUGACUUUAACCUUGUGGCUAUGAAGUACAAUUAUGAACCUCUAACACAAGACCAUGUUGACAUACUAGGACCUCUUUCUGCUCAAACUGGAAUUGCCGUUUUAGAUAUGUGUGCUUCAUUAAAAGAAUUACUGCAAAAUGGUAUGAAUGGACGUACCAUAUUGGGUAGUGCUUUAUUAGAAGAUGAAUUUACACCUUUUGAUGUUGUUAGACAAUGCUCAGGUGUUACUUUCCAAAGUGCAGUGAAAAGAACAAUCAAGGGUACACACCACUGGUUGUUACUCACAAUUUUGACUUCACUUUUAGUUUUAGUCCAGAGUACUCAAUGGUCUUUGUUCUUUUUUUUGUAUGAAAAUGCCUUUUUACCUUUUGCUAUGGGUAUUAUUGCUAUGUCUGCUUUUGCAAUGAUGUUUGUCAAACAUAAGCAUGCAUUUCUCUGUUUGUUUUUGUUACCUUCUCUUGCCACUGUAGCUUAUUUUAAUAUGGUCUAUAUGCCUGCUAGUUGGGUGAUGCGUAUUAUGACAUGGUUGGAUAUGGUUGAUACUAGUUUGUCUGGUUUUAAGCUAAAAGACUGUGUUAUGUAUGCAUCAGCUGUAGUGUUACUAAUCCUUAUGACAGCAAGAACUGUGUAUGAUGAUGGUGCUAGGAGAGUGUGGACACUUAUGAAUGUCUUGACACUCGUUUAUAAAGUUUAUUAUGGUAAUGCUUUAGAUCAAGCCAUUUCCAUGUGGGCUCUUAUAAUCUCUGUUACUUCUAACUACUCAGGUGUAGUUACAACUGUCAUGUUUUUGGCCAGAGGUAUUGUUUUUAUGUGUGUUGAGUAUUGCCCUAUUUUCUUCAUAACUGGUAAUACACUUCAGUGUAUAAUGCUAGUUUAUUGUUUCUUAGGCUAUUUUUGUACUUGUUACUUUGGCCUCUUUUGUUUACUCAACCGCUACUUUAGACUGACUCUUGGUGUUUAUGAUUACUUAGUUUCUACACAGGAGUUUAGAUAUAUGAAUUCACAGGGACUACUCCCACCCAAGAAUAGCAUAGAUGCCUUCAAACUCAACAUUAAAUUGUUGGGUGUUGGUGGCAAACCUUGUAUCAAAGUAGCCACUGUACAGUCUAAAAUGUCAGAUGUAAAGUGCACAUCAGUAGUCUUACUCUCAGUUUUGCAACAACUCAGAGUAGAAUCAUCAUCUAAAUUGUGGGCUCAAUGUGUCCAGUUACACAAUGACAUUCUCUUAGCUAAAGAUACUACUGAAGCCUUUGAAAAAAUGGUUUCACUACUUUCUGUUUUGCUUUCCAUGCAGGGUGCUGUAGACAUAAACAAGCUUUGUGAAGAAAUGCUGGACAACAGGGCAACCUUACAAGCUAUAGCCUCAGAGUUUAGUUCCCUUCCAUCAUAUGCAGCUUUUGCUACUGCUCAAGAAGCUUAUGAGCAGGCUGUUGCUAAUGGUGAUUCUGAAGUUGUUCUUAAAAAGUUGAAGAAGUCUUUGAAUGUGGCUAAAUCUGAAUUUGACCGUGAUGCAGCCAUGCAACGUAAGUUGGAAAAGAUGGCUGAUCAAGCUAUGACCCAAAUGUAUAAACAGGCUAGAUCUGAGGACAAGAGGGCAAAAGUUACUAGUGCUAUGCAGACAAUGCUUUUCACUAUGCUUAGAAAGUUGGAUAAUGAUGCACUCAACAACAUUAUCAACAAUGCAAGAGAUGGUUGUGUUCCCUUGAACAUAAUACCUCUUACAACAGCAGCCAAACUAAUGGUUGUCAUACCAGACUAUAACACAUAUAAAAAUACGUGUGAUGGUACAACAUUUACUUAUGCAUCAGCAUUGUGGGAAAUCCAACAGGUUGUAGAUGCAGAUAGUAAAAUUGUUCAACUUAGUGAAAUUAGUAUGGACAAUUCACCUAAUUUAGCAUGGCCUCUUAUUGUAACAGCUUUAAGGGCCAAUUCUGCUGUCAAAUUACAGAAUAAUGAGCUUAGUCCUGUUGCACUACGACAGAUGUCUUGUGCUGCCGGUACUACACAAACUGCUUGCACUGAUGACAAUGCGUUAGCUUACUACAACACAACAAAGGGAGGUAGGUUUGUACUUGCACUGUUAUCCGAUUUACAGGAUUUGAAAUGGGCUAGAUUCCCUAAGAGUGAUGGAACUGGUACUAUCUAUACAGAACUGGAACCACCUUGUAGGUUUGUUACAGACACACCUAAAGGUCCUAAAGUGAAGUAUUUAUACUUUAUUAAAGGAUUAAACAACCUAAAUAGAGGUAUGGUACUUGGUAGUUUAGCUGCCACAGUACGUCUACAAGCUGGUAAUGCAACAGAAGUGCCUGCCAAUUCAACUGUAUUAUCUUUCUGUGCUUUUGCUGUAGAUGCUGCUAAAGCUUACAAAGAUUAUCUAGCUAGUGGGGGACAACCAAUCACUAAUUGUGUUAAGAUGUUGUGUACACACACUGGUACUGGUCAGGCAAUAACAGUUACACCGGAAGCCAAUAUGGAUCAAGAAUCCUUUGGUGGUGCAUCGUGUUGUCUGUACUGCCGUUGCCACAUAGAUCAUCCAAAUCCUAAAGGAUUUUGUGACUUAAAAGGUAAGUAUGUACAAAUACCUACAACUUGUGCUAAUGACCCUGUGGGUUUUACACUUAAAAACACAGUCUGUACCGUCUGCGGUAUGUGGAAAGGUUAUGGCUGUAGUUGUGAUCAACUCCGCGAACCCAUGCUUCAGUCAGCUGAUGCACAAUCGUUUUUAAACGGGUUUGCGGUGUAAGUGCAGCCCGUCUUACACCGUGCGGCACAGGCACUAGUACUGAUGUCGUAUACAGGGCUUUUGACAUCUACAAUGAUAAAGUAGCUGGUUUUGCUAAAUUCCUAAAAACUAAUUGUUGUCGCUUCCAAGAAAAGGACGAAGAUGACAAUUUAAUUGAUUCUUACUUUGUAGUUAAGAGACACACUUUCUCUAACUACCAACAUGAAGAAACAAUUUAUAAUUUACUUAAGGAUUGUCCAGCUGUUGCUAAACAUGACUUCUUUAAGUUUAGAAUAGACGGUGACAUGGUACCACAUAUAUCACGUCAACGUCUUACUAAAUACACAAUGGCAGACCUCGUCUAUGCUUUAAGGCAUUUUGAUGAAGGUAAUUGUGACACAUUAAAAGAAAUACUUGUCACAUACAAUUGUUGUGAUGAUGAUUAUUUCAAUAAAAAGGACUGGUAUGAUUUUGUAGAAAACCCAGAUAUAUUACGCGUAUACGCCAACUUAGGUGAACGUGUACGCCAAGCUUUGUUAAAAACAGUACAAUUCUGUGAUGCCAUGCGAAAUGCUGGUAUUGUUGGUGUACUGACAUUAGAUAAUCAAGAUCUCAAUGGUAACUGGUAUGAUUUCGGUGAUUUCAUACAAACCACGCCAGGUAGUGGAGUUCCUGUUGUAGAUUCUUAUUAUUCAUUGUUAAUGCCUAUAUUAACCUUGACCAGGGCUUUAACUGCAGAGUCACAUGUUGACACUGACUUAACAAAGCCUUACAUUAAGUGGGAUUUGUUAAAAUAUGACUUCACGGAAGAGAGGUUAAAACUCUUUGACCGUUAUUUUAAAUAUUGGGAUCAGACAUACCACCCAAAUUGUGUUAACUGUUUGGAUGACAGAUGCAUUCUGCAUUGUGCAAACUUUAAUGUUUUAUUCUCUACAGUGUUCCCACCUACAAGUUUUGGACCACUAGUGAGAAAAAUAUUUGUUGAUGGUGUUCCAUUUGUAGUUUCAACUGGAUACCACUUCAGAGAGCUAGGUGUUGUACAUAAUCAGGAUGUAAACUUACAUAGCUCUAGACUUAGUUUUAAGGAAUUACUUGUGUAUGCUGCUGACCCUGCUAUGCACGCUGCUUCUGGUAAUCUAUUACUAGAUAAACGCACUACGUGCUUUUCAGUAGCUGCACUUACUAACAAUGUUGCUUUUCAAACUGUCAAACCCGGUAAUUUUAACAAAGACUUCUAUGACUUUGCUGUGUCUAAGGGUUUCUUUAAGGAAGGAAGUUCUGUUGAAUUAAAACACUUCUUCUUUGCUCAGGAUGGUAAUGCUGCUAUCAGCGAUUAUGACUACUAUCGUUAUAAUCUACCAACAAUGUGUGAUAUCAGACAACUACUAUUUGUAGUUGAAGUUGUUGAUAAGUACUUUGAUUGUUACGAUGGUGGCUGUAUUAAUGCUAACCAAGUCAUCGUCAACAACCUAGACAAAUCAGCUGGUUUUCCAUUUAAUAAAUGGGGUAAGGCUAGACUUUAUUAUGAUUCAAUGAGUUAUGAGGAUCAAGAUGCACUUUUCGCAUAUACAAAACGUAAUGUCAUCCCUACUAUAACUCAAAUGAAUCUUAAGUAUGCCAUUAGUGCAAAGAAUAGAGCUCGCACCGUAGCUGGUGUCUCUAUCUGUAGUACUAUGACCAAUAGACAGUUUCAUCAAAAAUUAUUGAAAUCAAUAGCCGCCACUAGAGGAGCUACUGUAGUAAUUGGAACAAGCAAAUUCUAUGGUGGUUGGCACAACAUGUUAAAAACUGUUUAUAGUGAUGUAGAAAACCCUCACCUUAUGGGUUGGGAUUAUCCUAAAUGUGAUAGAGCCAUGCCUAACAUGCUUAGAAUUAUGGCCUCACUUGUUCUUGCUCGCAAACAUACAACGUGUUGUAGCUUGUCACACCGUUUCUAUAGAUUAGCUAAUGAGUGUGCUCAAGUAUUGAGUGAAAUGGUCAUGUGUGGCGGUUCACUAUAUGUUAAACCAGGUGGAACCUCAUCAGGAGAUGCCACAACUGCUUAUGCUAAUAGUGUUUUUAACAUUUGUCAAGCUGUCACGGCCAAUGUUAAUGCACUUUUAUCUACUGAUGGUAACAAAAUUGCCGAUAAGUAUGUCCGCAAUUUACAACACAGACUUUAUGAGUGUCUCUAUAGAAAUAGAGAUGUUGACACAGACUUUGUGAAUGAGUUUUACGCAUAUUUGCGUAAACAUUUCUCAAUGAUGAUACUCUCUGACGAUGCUGUUGUGUGUUUCAAUAGCACUUAUGCAUCUCAAGGUCUAGUGGCUAGCAUAAAGAACUUUAAGUCAGUUCUUUAUUAUCAAAACAAUGUUUUUAUGUCUGAAGCAAAAUGUUGGACUGAGACUGACCUUACUAAAGGACCUCAUGAAUUUUGCUCUCAACAUACAAUGCUAGUUAAACAGGGUGAUGAUUAUGUGUACCUUCCUUACCCAGAUCCAUCAAGAAUCCUAGGGGCCGGCUGUUUUGUAGAUGAUAUCGUAAAAACAGAUGGUACACUUAUGAUUGAACGGUUCGUGUCUUUAGCUAUAGAUGCUUACCCACUUACUAAACAUCCUAAUCAGGAGUAUGCUGAUGUCUUUCAUUUGUACUUACAAUACAUAAGAAAGCUACAUGAUGAGUUAACAGGACACAUGUUAGACAUGUAUUCUGUUAUGCUUACUAAUGAUAACACUUCAAGGUAUUGGGAACCUGAGUUUUAUGAGGCUAUGUACACACCGCAUACAGUCUUACAGGCUGUUGGGGCUUGUGUUCUUUGCAAUUCACAGACUUCAUUAAGAUGUGGUGCUUGCAUACGUAGACCAUUCUUAUGUUGUAAAUGCUGUUACGACCAUGUCAUAUCAACAUCACAUAAAUUAGUCUUGUCUGUUAAUCCGUAUGUUUGCAAUGCUCCAGGUUGUGAUGUCACAGAUGUGACUCAACUUUACUUAGGAGGUAUGAGCUAUUAUUGUAAAUCACAUAAACCACCCAUUAGUUUUCCAUUGUGUGCUAAUGGACAAGUUUUUGGUUUAUAUAAAAAUACAUGUGUUGGUAGCGAUAAUGUUACUGACUUUAAUGCAAUUGCAACAUGUGACUGGACAAAUGCUGGUGAUUACAUUUUAGCUAACACCUGUACUGAAAGACUCAAGCUUUUUGCAGCAGAAACGCUCAAAGCUACUGAGGAGACAUUUAAACUGUCUUAUGGUAUUGCUACUGUACGUGAAGUGCUGUCUGACAGAGAAUUACAUCUUUCAUGGGAAGUUGGUAAACCUAGACCACCACUUAACCGAAAUUAUGUCUUUACUGGUUAUCGUGUAACUAAAAACAGUAAAGUACAAAUAGGAGAGUACACCUUUGAAAAAGGUGACUAUGGUGAUGCUGUUGUUUACCGAGGUACAACAACUUACAAAUUAAAUGUUGGUGAUUAUUUUGUGCUGACAUCACAUACAGUAAUGCCAUUAAGUGCACCUACACUAGUGCCACAAGAGCACUAUGUUAGAAUUACUGGCUUAUACCCAACACUCAAUAUCUCAGAUGAGUUUUCUAGCAAUGUUGCAAAUUAUCAAAAGGUUGGUAUGCAAAAGUAUUCUACACUCCAGGGACCACCUGGUACUGGUAAGAGUCAUUUUGCUAUUGGCCUAGCUCUCUACUACCCUUCUGCUCGCAUAGUGUAUACAGCUUGCUCUCAUGCCGCUGUUGAUGCACUAUGUGAGAAGGCAUUAAAAUAUUUGCCUAUAGAUAAAUGUAGUAGAAUUAUACCUGCACGUGCUCGUGUAGAGUGUUUUGAUAAAUUCAAAGUGAAUUCAACAUUAGAACAGUAUGUCUUUUGUACUGUAAAUGCAUUGCCUGAGACGACAGCAGAUAUAGUUGUCUUUGAUGAAAUUUCAAUGGCCACAAAUUAUGAUUUGAGUGUUGUCAAUGCCAGAUUACGUGCUAAGCACUAUGUGUACAUUGGCGACCCUGCUCAAUUACCUGCACCACGCACAUUGCUAACUAAGGGCACACUAGAACCAGAAUAUUUCAAUUCAGUGUGUAGACUUAUGAAAACUAUAGGUCCAGACAUGUUCCUCGGAACUUGUCGGCGUUGUCCUGCUGAAAUUGUUGACACUGUGAGUGCUUUGGUUUAUGAUAAUAAGCUUAAAGCACAUAAAGACAAAUCAGCUCAAUGCUUUAAAAUGUUUUAUAAGGGUGUUAUCACGCAUGAUGUUUCAUCUGCAAUUAACAGGCCACAAAUAGGCGUGGUAAGAGAAUUCCUUACACGUAACCCUGCUUGGAGAAAAGCUGUCUUUAUUUCACCUUAUAAUUCACAGAAUGCUGUAGCCUCAAAGAUUUUGGGACUACCAACUCAAACUGUUGAUUCAUCACAGGGCUCAGAAUAUGACUAUGUCAUAUUCACUCAAACCACUGAAACAGCUCACUCUUGUAAUGUAAACAGAUUUAAUGUUGCUAUUACCAGAGCAAAAGUAGGCAUACUUUGCAUAAUGUCUGAUAGAGACCUUUAUGACAAGUUGCAAUUUACAAGUCUUGAAAUUCCACGUAGGAAUGUGGCAACUUUACAAGCUGAAAAUGUAACAGGACUCUUUAAAGAUUGUAGUAAGGUAAUCACUGGGUUACAUCCUACACAGGCACCUACACACCUCAGUGUUGACACUAAAUUCAAAACUGAAGGUUUAUGUGUUGACAUACCUGGCAUACCUAAGGACAUGACCUAUAGAAGACUCAUCUCUAUGAUGGGUUUUAAAAUGAAUUAUCAAGUUAAUGGUUACCCUAACAUGUUUAUCACCCGCGAAGAAGCUAUAAGACAUGUACGUGCAUGGAUUGGCUUCGAUGUCGAGGGGUGUCAUGCUACUAGAGAAGCUGUUGGUACCAAUUUACCUUUACAGCUAGGUUUUUCUACAGGUGUUAACCUAGUUGCUGUACCUACAGGUUAUGUUGAUACACCUAAUAAUACAGAUUUUUCCAGAGUUAGUGCUAAACCACCGCCUGGAGAUCAAUUUAAACACCUCAUACCACUUAUGUACAAAGGACUUCCUUGGAAUGUAGUGCGUAUAAAGAUUGUACAAAUGUUAAGUGACACACUUAAAAAUCUCUCUGACAGAGUCGUAUUUGUCUUAUGGGCACAUGGCUUUGAGUUGACAUCUAUGAAGUAUUUUGUGAAAAUAGGACCUGAGCGCACCUGUUGUCUAUGUGAUAGACGUGCCACAUGCUUUUCCACUGCUUCAGACACUUAUGCCUGUUGGCAUCAUUCUAUUGGAUUUGAUUACGUCUAUAAUCCGUUUAUGAUUGAUGUUCAACAAUGGGGUUUUACAGGUAACCUACAAAGCAACCAUGAUCUGUAUUGUCAAGUCCAUGGUAAUGCACAUGUAGCUAGUUGUGAUGCAAUCAUGACUAGGUGUCUAGCUGUCCACGAGUGCUUUGUUAAGCGUGUUGACUGGACUAUUGAAUAUCCUAUAAUUGGUGAUGAACUGAAGAUUAAUGCGGCUUGUAGAAAGGUUCAACACAUGGUUGUUAAAGCUGCAUUAUUAGCAGACAAAUUCCCAGUUCUUCACGACAUUGGUAACCCUAAAGCUAUUAAGUGUGUACCUCAAGCUGAUGUAGAAUGGAAGUUCUAUGAUGCACAGCCUUGUAGUGACAAAGCUUAUAAAAUAGAAGAAUUAUUCUAUUCUUAUGCCACACAUUCUGACAAAUUCACAGAUGGUGUAUGCCUAUUUUGGAAUUGCAAUGUCGAUAGAUAUCCUGCUAAUUCCAUUGUUUGUAGAUUUGACACUAGAGUGCUAUCUAACCUUAACUUGCCUGGUUGUGAUGGUGGCAGUUUGUAUGUAAAUAAACAUGCAUUCCACACACCAGCUUUUGAUAAAAGUGCUUUUGUUAAUUUAAAACAAUUACCAUUUUUCUAUUACUCUGACAGUCCAUGUGAGUCUCAUGGAAAACAAGUAGUGUCAGAUAUAGAUUAUGUACCACUAAAGUCUGCUACGUGUAUAACACGUUGCAAUUUAGGUGGUGCUGUCUGUAGACAUCAUGCUAAUGAGUACAGAUUGUAUCUCGAUGCUUAUAACAUGAUGAUCUCAGCUGGCUUUAGCUUGUGGGUUUACAAACAAUUUGAUACUUAUAACCUCUGGAACACUUUUACAAGACUUCAGAGUUUAGAAAAUGUGGCUUUUAAUGUUGUAAAUAAGGGACACUUUGAUGGACAACAGGGUGAAGUACCAGUUUCUAUCAUUAAUAACACUGUUUACACAAAAGUUGAUGGUGUUGAUGUAGAAUUGUUUGAAAAUAAAACAACAUUACCUGUUAAUGUAGCAUUUGAGCUUUGGGCUAAGCGCAACAUUAAACCAGUACCAGAGGUGAAAAUACUCAAUAAUUUGGGUGUGGACAUUGCUGCUAAUACUGUGAUCUGGGACUACAAAAGAGAUGCUCCAGCACAUAUAUCUACUAUUGGUGUUUGUUCUAUGACUGACAUAGCCAAGAAACCAACUGAAACGAUUUGUGCACCACUCACUGUCUUUUUUGAUGGUAGAGUUGAUGGUCAAGUAGACUUAUUUAGAAAUGCCCGUAAUGGUGUUCUUAUUACAGAAGGUAGUGUUAAAGGUUUACAACCAUCUGUAGGUCCCAAACAAGCUAGUCUUAAUGGAGUCACAUUAAUUGGAGAAGCCGUAAAAACACAGUUCAAUUAUUAUAAGAAAGUUGAUGGUGUUGUCCAACAAUUACCUGAAACUUACUUUACUCAGAGUAGAAAUUUACAAGAAUUUAAACCCAGGAGUCAAAUGGAAAUUGAUUUCUUAGAAUUAGCUAUGGAUGAAUUCAUUGAACGGUAUAAAUUAGAAGGCUAUGCCUUCGAACAUAUCGUUUAUGGAGAUUUUAGUCAUAGUCAGUUAGGUGGUUUACAUCUACUGAUUGGACUAGCUAAACGUUUUAAGGAAUCACCUUUUGAAUUAGAAGAUUUUAUUCCUAUGGACAGUACAGUUAAAAACUAUUUCAUAACAGAUGCGCAAACAGGUUCAUCUAAGUGUGUGUGUUCUGUUAUUGAUUUAUUACUUGAUGAUUUUGUUGAAAUAAUAAAAUCCCAAGAUUUAUCUGUAGUUUCUAAGGUUGUCAAAGUGACUAUUGACUAUACAGAAAUUUCAUUUAUGCUUUGGUGUAAAGAUGGCCAUGUAGAAACAUUUUACCCAAAAUUACAAUCUAGUCAAGCGUGGCAACCGGGUGUUGCUAUGCCUAAUCUUUACAAAAUGCAAAGAAUGCUAUUAGAAAAGUGUGACCUUCAAAAUUAUGGUGAUAGUGCAACAUUACCUAAAGGCAUAAUGAUGAAUGUCGCAAAAUAUACUCAACUGUGUCAAUAUUUAAACACAUUAACAUUAGCUGUACCCUAUAAUAUGAGAGUUAUACAUUUUGGUGCUGGUUCUGAUAAAGGAGUUGCACCAGGUACAGCUGUUUUAAGACAGUGGUUGCCUACGGGUACGCUGCUUGUCGAUUCAGAUCUUAAUGACUUUGUCUCUGAUGCAGAUUCAACUUUGAUUGGUGAUUGUGCAACUGUACAUACAGCUAAUAAAUGGGAUCUCAUUAUUAGUGAUAUGUACGACCCUAAGACUAAAAAUGUUACAAAAGAAAAUGACUCUAAAGAGGGUUUUUUCACUUACAUUUGUGGGUUUAUACAACAAAAGCUAGCUCUUGGAGGUUCCGUGGCUAUAAAGAUAACAGAACAUUCUUGGAAUGCUGAUCUUUAUAAGCUCAUGGGACACUUCGCAUGGUGGACAGCCUUUGUUACUAAUGUGAAUGCGUCAUCAUCUGAAGCAUUUUUAAUUGGAUGUAAUUAUCUUGGCAAACCACGCGAACAAAUAGAUGGUUAUGUCAUGCAUGCAAAUUACAUAUUUUGGAGGAAUACAAAUCCAAUUCAGUUGUCUUCCUAUUCUUUAUUUGACAUGAGUAAAUUUCCCCUUAAAUUAAGGGGUACUGCUGUUAUGUCUUUAAAAGAAGGUCAAAUCAAUGAUAUGAUUUUAUCUCUUCUUAGUAAAGGUAGACUUAUAAUUAGAGAAAACAACAGAGUUGUUAUUUCUAGUGAUGUUCUUGUUAACAACUAAACGAACAAUGUUUGUUUUUCUUGUUUUAUUGCCACUAGUCUCUAGUCAGUGUGUUAAUCUUACAACCAGAACUCAAUUACCCCCUGCAUACACUAAUUCUUUCACACGUGGUGUUUAUUACCCUGACAAAGUUUUCAGAUCCUCAGUUUUACAUUCAACUCAGGACUUGUUCUUACCUUUCUUUUCCAAUGUUACUUGGUUCCAUGCUAUACAUGUCUCUGGGACCAAUGGUACUAAGAGGUUUGAUAACCCUGUCCUACCAUUUAAUGAUGGUGUUUAUUUUGCUUCCACUGAGAAGUCUAACAUAAUAAGAGGCUGGAUUUUUGGUACUACUUUAGAUUCGAAGACCCAGUCCCUACUUAUUGUUAAUAACGCUACUAAUGUUGUUAUUAAAGUCUGUGAAUUUCAAUUUUGUAAUGAUCCAUUUUUGGGUGUUUAUUACCACAAAAACAACAAAAGUUGGAUGGAAAGUGAGUUCAGAGUUUAUUCUAGUGCGAAUAAUUGCACUUUUGAAUAUGUCUCUCAGCCUUUUCUUAUGGACCUUGAAGGAAAACAGGGUAAUUUCAAAAAUCUUAGGGAAUUUGUGUUUAAGAAUAUUGAUGGUUAUUUUAAAAUAUAUUCUAAGCACACGCCUAUUAAUUUAGUGCGUGAUCUCCCUCAGGGUUUUUCGGCUUUAGAACCAUUGGUAGAUUUGCCAAUAGGUAUUAACAUCACUAGGUUUCAAACUUUACUUGCUUUACAUAGAAGUUAUUUGACUCCUGGUGAUUCUUCUUCAGGUUGGACAGCUGGUGCUGCAGCUUAUUAUGUGGGUUAUCUUCAACCUAGGACUUUUCUAUUAAAAUAUAAUGAAAAUGGAACCAUUACAGAUGCUGUAGACUGUGCACUUGACCCUCUCUCAGAAACAAAGUGUACGUUGAAAUCCUUCACUGUAGAAAAAGGAAUCUAUCAAACUUCUAACUUUAGAGUCCAACCAACAGAAUCUAUUGUUAGAUUUCCUAAUAUUACAAACUUGUGCCCUUUUGGUGAAGUUUUUAACGCCACCAGAUUUGCAUCUGUUUAUGCUUGGAACAGGAAGAGAAUCAGCAACUGUGUUGCUGAUUAUUCUGUCCUAUAUAAUUCCGCAUCAUUUUCCACUUUUAAGUGUUAUGGAGUGUCUCCUACUAAAUUAAAUGAUCUCUGCUUUACUAAUGUCUAUGCAGAUUCAUUUGUAAUUAGAGGUGAUGAAGUCAGACAAAUCGCUCCAGGGCAAACUGGAAAGAUUGCUGAUUAUAAUUAUAAAUUACCAGAUGAUUUUACAGGCUGCGUUAUAGCUUGGAAUUCUAACAAUCUUGAUUCUAAGGUUGGUGGUAAUUAUAAUUACCUGUAUAGAUUGUUUAGGAAGUCUAAUCUCAAACCUUUUGAGAGAGAUAUUUCAACUGAAAUCUAUCAGGCCGGUAGCACACCUUGUAAUGGUGUUGAAGGUUUUAAUUGUUACUUUCCUUUACAAUCAUAUGGUUUCCAACCCACUAAUGGUGUUGGUUACCAACCAUACAGAGUAGUAGUACUUUCUUUUGAACUUCUACAUGCACCAGCAACUGUUUGUGGACCUAAAAAGUCUACUAAUUUGGUUAAAAACAAAUGUGUCAAUUUCAACUUCAAUGGUUUAACAGGCACAGGUGUUCUUACUGAGUCUAACAAAAAGUUUCUGCCUUUCCAACAAUUUGGCAGAGACAUUGCUGACACUACUGAUGCUGUCCGUGAUCCACAGACACUUGAGAUUCUUGACAUUACACCAUGUUCUUUUGGUGGUGUCAGUGUUAUAACACCAGGAACAAAUACUUCUAACCAGGUUGCUGUUCUUUAUCAGGAUGUUAACUGCACAGAAGUCCCUGUUGCUAUUCAUGCAGAUCAACUUACUCCUACUUGGCGUGUUUAUUCUACAGGUUCUAAUGUUUUUCAAACACGUGCAGGCUGUUUAAUAGGGGCUGAACAUGUCAACAACUCAUAUGAGUGUGACAUACCCAUUGGUGCAGGUAUAUGCGCUAGUUAUCAGACUCAGACUAAUUCUCCUCGGCGGGCACGUAGUGUAGCUAGUCAAUCCAUCAUUGCCUACACUAUGUCACUUGGUGCAGAAAAUUCAGUUGCUUACUCUAAUAACUCUAUUGCCAUACCCACAAAUUUUACUAUUAGUGUUACCACAGAAAUUCUACCAGUGUCUAUGACCAAGACAUCAGUAGAUUGUACAAUGUACAUUUGUGGUGAUUCAACUGAAUGCAGCAAUCUUUUGUUGCAAUAUGGCAGUUUUUGUACACAAUUAAACCGUGCUUUAACUGGAAUAGCUGUUGAACAAGACAAAAACACCCAAGAAGUUUUUGCACAAGUCAAACAAAUUUACAAAACACCACCAAUUAAAGAUUUUGGUGGUUUUAAUUUUUCACAAAUAUUACCAGAUCCAUCAAAACCAAGCAAGAGGUCAUUUAUUGAAGAUCUACUUUUCAACAAAGUGACACUUGCAGAUGCUGGCUUCAUCAAACAAUAUGGUGAUUGCCUUGGUGAUAUUGCUGCUAGAGACCUCAUUUGUGCACAAAAGUUUAACGGCCUUACUGUUUUGCCACCUUUGCUCACAGAUGAAAUGAUUGCUCAAUACACUUCUGCACUGUUAGCGGGUACAAUCACUUCUGGUUGGACCUUUGGUGCAGGUGCUGCAUUACAAAUACCAUUUGCUAUGCAAAUGGCUUAUAGGUUUAAUGGUAUUGGAGUUACACAGAAUGUUCUCUAUGAGAACCAAAAAUUGAUUGCCAACCAAUUUAAUAGUGCUAUUGGCAAAAUUCAAGACUCACUUUCUUCCACAGCAAGUGCACUUGGAAAACUUCAAGAUGUGGUCAACCAAAAUGCACAAGCUUUAAACACGCUUGUUAAACAACUUAGCUCCAAUUUUGGUGCAAUUUCAAGUGUUUUAAAUGAUAUCCUUUCACGUCUUGACAAAGUUGAGGCUGAAGUGCAAAUUGAUAGGUUGAUCACAGGCAGACUUCAAAGUUUGCAGACAUAUGUGACUCAACAAUUAAUUAGAGCUGCAGAAAUCAGAGCUUCUGCUAAUCUUGCUGCUACUAAAAUGUCAGAGUGUGUACUUGGACAAUCAAAAAGAGUUGAUUUUUGUGGAAAGGGCUAUCAUCUUAUGUCCUUCCCUCAGUCAGCACCUCAUGGUGUAGUCUUCUUGCAUGUGACUUAUGUCCCUGCACAAGAAAAGAACUUCACAACUGCUCCUGCCAUUUGUCAUGAUGGAAAAGCACACUUUCCUCGUGAAGGUGUCUUUGUUUCAAAUGGCACACACUGGUUUGUAACACAAAGGAAUUUUUAUGAACCACAAAUCAUUACUACAGACAACACAUUUGUGUCUGGUAACUGUGAUGUUGUAAUAGGAAUUGUCAACAACACAGUUUAUGAUCCUUUGCAACCUGAAUUAGACUCAUUCAAGGAGGAGUUAGAUAAAUAUUUUAAGAAUCAUACAUCACCAGAUGUUGAUUUAGGUGACAUCUCUGGCAUUAAUGCUUCAGUUGUAAACAUUCAAAAAGAAAUUGACCGCCUCAAUGAGGUUGCCAAGAAUUUAAAUGAAUCUCUCAUCGAUCUCCAAGAACUUGGAAAGUAUGAGCAGUAUAUAAAAUGGCCAUGGUACAUUUGGCUAGGUUUUAUAGCUGGCUUGAUUGCCAUAGUAAUGGUGACAAUUAUGCUUUGCUGUAUGACCAGUUGCUGUAGUUGUCUCAAGGGCUGUUGUUCUUGUGGAUCCUGCUGCAAAUUUGAUGAAGACGACUCUGAGCCAGUGCUCAAAGGAGUCAAAUUACAUUACACAUAAACGAACUUAUGGAUUUGUUUAUGAGAAUCUUCACAAUUGGAACUGUAACUUUGAAGCAAGGUGAAAUCAAGGAUGCUACUCCUUCAGAUUUUGUUCGCGCUACUGCAACGAUACCGAUACAAGCCUCACUCCCUUUCGGAUGGCUUAUUGUUGGCGUUGCACUUCUUGCUGUUUUUCAGAGCGCUUCCAAAAUCAUAACCCUCAAAAAGAGAUGGCAACUAGCACUCUCCAAGGGUGUUCACUUUGUUUGCAACUUGCUGUUGUUGUUUGUAACAGUUUACUCACACCUUUUGCUCGUUGCUGCUGGCCUUGAAGCCCCUUUUCUCUAUCUUUAUGCUUUAGUCUACUUCUUGCAGAGUAUAAACUUUGUAAGAAUAAUAAUGAGGCUUUGGCUUUGCUGGAAAUGCCGUUCCAAAAACCCAUUACUUUAUGAUGCCAACUAUUUUCUUUGCUGGCAUACUAAUUGUUACGACUAUUGUAUACCUUACAAUAGUGUAACUUCUUCAAUUGUCAUUACUUCAGGUGAUGGCACAACAAGUCCUAUUUCUGAACAUGACUACCAGAUUGGUGGUUAUACUGAAAAAUGGGAAUCUGGAGUAAAAGACUGUGUUGUAUUACACAGUUACUUCACUUCAGACUAUUACCAGCUGUACUCAACUCAAUUGAGUACAGACACUGGUGUUGAACAUGUUACCUUCUUCAUCUACAAUAAAAUUGUUGAUGAGCCUGAAGAACAUGUCCAAAUUCACACAAUCGACGGUUCAUCCGGAGUUGUUAAUCCAGUAAUGGAACCAAUUUAUGAUGAACCGACGACGACUACUAGCGUGCCUUUGUAAGCACAAGCUGAUGAGUACGAACUUAUGUACUCAUUCGUUUCGGAAGAGACAGGUACGUUAAUAGUUAAUAGCGUACUUCUUUUUCUUGCUUUCGUGGUAUUCUUGCUAGUUACACUAGCCAUCCUUACUGCGCUUCGAUUGUGUGCGUACUGCUGCAAUAUUGUUAACGUGAGUCUUGUAAAACCUUCUUUUUACGUUUACUCUCGUGUUAAAAAUCUGAAUUCUUCUAGAGUUCCUGAUCUUCUGGUCUAAACGAACUAAAUAUUAUAUUAGUUUUUCUGUUUGGAACUUUAAUUUUAGCCAUGGCAGAUUCCAACGGUACUAUUACCGUUGAAGAGCUUAAAAAGCUCCUUGAACAAUGGAACCUAGUAAUAGGUUUCCUAUUCCUUACAUGGAUUUGUCUUCUACAAUUUGCCUAUGCCAACAGGAAUAGGUUUUUGUAUAUAAUUAAGUUAAUUUUCCUCUGGCUGUUAUGGCCAGUAACUUUAGCUUGUUUUGUGCUUGCUGCUGUUUACAGAAUAAAUUGGAUCACCGGUGGAAUUGCUAUCGCAAUGGCUUGUCUUGUAGGCUUGAUGUGGCUCAGCUACUUCAUUGCUUCUUUCAGACUGUUUGCGCGUACGCGUUCCAUGUGGUCAUUCAAUCCAGAAACUAACAUUCUUCUCAACGUGCCACUCCAUGGCACUAUUCUGACCAGACCGCUUCUAGAAAGUGAACUCGUAAUCGGAGCUGUGAUCCUUCGUGGACAUCUUCGUAUUGCUGGACACCAUCUAGGACGCUGUGACAUCAAGGACCUGCCUAAAGAAAUCACUGUUGCUACAUCACGAACGCUUUCUUAUUACAAAUUGGGAGCUUCGCAGCGUGUAGCAGGUGACUCAGGUUUUGCUGCAUACAGUCGCUACAGGAUUGGCAACUAUAAAUUAAACACAGACCAUUCCAGUAGCAGUGACAAUAUUGCUUUGCUUGUACAGUAAGUGACAACAGAUGUUUCAUCUCGUUGACUUUCAGGUUACUAUAGCAGAGAUAUUACUAAUUAUUAUGAGGACUUUUAAAGUUUCCAUUUGGAAUCUUGAUUACAUCAUAAACCUCAUAAUUAAAAAUUUAUCUAAGUCACUAACUGAGAAUAAAUAUUCUCAAUUAGAUGAAGAGCAACCAAUGGAGAUUGAUUAAACGAACAUGAAAAUUAUUCUUUUCUUGGCACUGAUAACACUCGCUACUUGUGAGCUUUAUCACUACCAAGAGUGUGUUAGAGGUACAACAGUACUUUUAAAAGAACCUUGCUCUUCUGGAACAUACGAGGGCAAUUCACCAUUUCAUCCUCUAGCUGAUAACAAAUUUGCACUGACUUGCUUUAGCACUCAAUUUGCUUUUGCUUGUCCUGACGGCGUAAAACACGUCUAUCAGUUACGUGCCAGAUCAGUUUCACCUAAACUGUUCAUCAGACAAGAGGAAGUUCAAGAACUUUACUCUCCAAUUUUUCUUAUUGUUGCGGCAAUAGUGUUUAUAACACUUUGCUUCACACUCAAAAGAAAGACAGAAUGAUUGAACUUUCAUUAAUUGACUUCUAUUUGUGCUUUUUAGCCUUUCUGCUAUUCCUUGUUUUAAUUAUGCUUAUUAUCUUUUGGUUCUCACUUGAACUGCAAGAUCAUAAUGAAACUUGUCACGCCUAAACGAACAUGAAAUUUCUUGUUUUCUUAGGAAUCAUCACAACUGUAGCUGCAUUUCACCAAGAAUGUAGUUUACAGUCAUGUACUCAACAUCAACCAUAUGUAGUUGAUGACCCGUGUCCUAUUCACUUCUAUUCUAAAUGGUAUAUUAGAGUAGGAGCUAGAAAAUCAGCACCUUUAAUUGAAUUGUGCGUGGAUGAGGCUGGUUCUAAAUCACCCAUUCAGUACAUCGAUAUCGGUAAUUAUACAGUUUCCUGUUUACCUUUUACAAUUAAUUGCCAGGAACCUAAAUUGGGUAGUCUUGUAGUGCGUUGUUCGUUCUAUGAAGACUUUUUAGAGUAUCAUGACGUUCGUGUUGUUUUAGAUUUCAUCUAAACGAACAAACUAAAAUGUCUGAUAAUGGACCCCAAAAUCAGCGAAAUGCACCCCGCAUUACGUUUGGUGGACCCUCAGAUUCAACUGGCAGUAACCAGAAUGGAGAACGCAGUGGGGCGCGAUCAAAACAACGUCGGCCCCAAGGUUUACCCAAUAAUACUGCGUCUUGGUUCACCGCUCUCACUCAACAUGGCAAGGAAGACCUUAAAUUCCCUCGAGGACAAGGCGUUCCAAUUAACACCAAUAGCAGUCCAGAUGACCAAAUUGGCUACUACCGAAGAGCUACCAGACGAAUUCGUGGUGGUGACGGUAAAAUGAAAGAUCUCAGUCCAAGAUGGUAUUUCUACUACCUAGGAACUGGGCCAGAAGCUGGACUUCCCUAUGGUGCUAACAAAGACGGCAUCAUAUGGGUUGCAACUGAGGGAGCCUUGAAUACACCAAAAGAUCACAUUGGCACCCGCAAUCCUGCUAACAAUGCUGCAAUCGUGCUACAACUUCCUCAAGGAACAACAUUGCCAAAAGGCUUCUACGCAGAAGGGAGCAGAGGCGGCAGUCAAGCCUCUUCUCGUUCCUCAUCACGUAGUCGCAACAGUUCAAGAAAUUCAACUCCAGGCAGCAGUAGGGGAACUUCUCCUGCUAGAAUGGCUGGCAAUGGCGGUGAUGCUGCUCUUGCUUUGCUGCUGCUUGACAGAUUGAACCAGCUUGAGAGCAAAAUGUCUGGUAAAGGCCAACAACAACAAGGCCAAACUGUCACUAAGAAAUCUGCUGCUGAGGCUUCUAAGAAGCCUCGGCAAAAACGUACUGCCACUAAAGCAUACAAUGUAACACAAGCUUUCGGCAGACGUGGUCCAGAACAAACCCAAGGAAAUUUUGGGGACCAGGAACUAAUCAGACAAGGAACUGAUUACAAACAUUGGCCGCAAAUUGCACAAUUUGCCCCCAGCGCUUCAGCGUUCUUCGGAAUGUCGCGCAUUGGCAUGGAAGUCACACCUUCGGGAACGUGGUUGACCUACACAGGUGCCAUCAAAUUGGAUGACAAAGAUCCAAAUUUCAAAGAUCAAGUCAUUUUGCUGAAUAAGCAUAUUGACGCAUACAAAACAUUCCCACCAACAGAGCCUAAAAAGGACAAAAAGAAGAAGGCUGAUGAAACUCAAGCCUUACCGCAGAGACAGAAGAAACAGCAAACUGUGACUCUUCUUCCUGCUGCAGAUUUGGAUGAUUUCUCCAAACAAUUGCAACAAUCCAUGAGCAGUGCUGACUCAACUCAGGCCUAAACUCAUGCAGACCACACAAGGCAGAUGGGCUAUAUAAACGUUUUCGCUUUUCCGUUUACGAUAUAUAGUCUACUCUUGUGCAGAAUGAAUUCUCGUAACUACAUAGCACAAGUAGAUGUAGUUAACUUUAAUCUCACAUAGCAAUCUUUAAUCAGUGUGUAACAUUAGGGAGGACUUGAAAGAGCCACCACAUUUUCACCGAGGCCACGCGGAGUACGAUCGAGUGUACAGUGAACAAUGCUAGGGAGAGCUGCCUAUAUGGAAGAGCCCUAAUGUGUAAAAUUAAUUUUAGUAGUGCUAUCCCCAUGUGAUUUUAAUAGCUUCUUAGGAGAAUGACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,protein_ptm:acetylated(Lys375),419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5µM[SARS2-NPLys375-Ac];|5µM[SARS-CoV-2],"15 mM NaCl, 135 mM KCl, 5 mM phosphate, 1.5 mM MgCl2","20 mM Tris–HCl, pH 7.0",37˚C,-,other_molecular:1 mg ml−1 BSA,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"In contrast, SARS2-NPLys375-Ac and RNA slowly formed smaller droplets with much less liquid "
703,PMID: 34239064,RNAPS0000450,https://pubmed.ncbi.nlm.nih.gov/34239064,RNA + protein,-,-,SARS-CoV-2 virus RNA,29903nt(1-29903),AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGCACCUCAUGGUCAUGUUAUGGUUGAGCUGGUAGCAGAACUCGAAGGCAUUCAGUACGGUCGUAGUGGUGAGACACUUGGUGUCCUUGUCCCUCAUGUGGGCGAAAUACCAGUGGCUUACCGCAAGGUUCUUCUUCGUAAGAACGGUAAUAAAGGAGCUGGUGGCCAUAGUUACGGCGCCGAUCUAAAGUCAUUUGACUUAGGCGACGAGCUUGGCACUGAUCCUUAUGAAGAUUUUCAAGAAAACUGGAACACUAAACAUAGCAGUGGUGUUACCCGUGAACUCAUGCGUGAGCUUAACGGAGGGGCAUACACUCGCUAUGUCGAUAACAACUUCUGUGGCCCUGAUGGCUACCCUCUUGAGUGCAUUAAAGACCUUCUAGCACGUGCUGGUAAAGCUUCAUGCACUUUGUCCGAACAACUGGACUUUAUUGACACUAAGAGGGGUGUAUACUGCUGCCGUGAACAUGAGCAUGAAAUUGCUUGGUACACGGAACGUUCUGAAAAGAGCUAUGAAUUGCAGACACCUUUUGAAAUUAAAUUGGCAAAGAAAUUUGACACCUUCAAUGGGGAAUGUCCAAAUUUUGUAUUUCCCUUAAAUUCCAUAAUCAAGACUAUUCAACCAAGGGUUGAAAAGAAAAAGCUUGAUGGCUUUAUGGGUAGAAUUCGAUCUGUCUAUCCAGUUGCGUCACCAAAUGAAUGCAACCAAAUGUGCCUUUCAACUCUCAUGAAGUGUGAUCAUUGUGGUGAAACUUCAUGGCAGACGGGCGAUUUUGUUAAAGCCACUUGCGAAUUUUGUGGCACUGAGAAUUUGACUAAAGAAGGUGCCACUACUUGUGGUUACUUACCCCAAAAUGCUGUUGUUAAAAUUUAUUGUCCAGCAUGUCACAAUUCAGAAGUAGGACCUGAGCAUAGUCUUGCCGAAUACCAUAAUGAAUCUGGCUUGAAAACCAUUCUUCGUAAGGGUGGUCGCACUAUUGCCUUUGGAGGCUGUGUGUUCUCUUAUGUUGGUUGCCAUAACAAGUGUGCCUAUUGGGUUCCACGUGCUAGCGCUAACAUAGGUUGUAACCAUACAGGUGUUGUUGGAGAAGGUUCCGAAGGUCUUAAUGACAACCUUCUUGAAAUACUCCAAAAAGAGAAAGUCAACAUCAAUAUUGUUGGUGACUUUAAACUUAAUGAAGAGAUCGCCAUUAUUUUGGCAUCUUUUUCUGCUUCCACAAGUGCUUUUGUGGAAACUGUGAAAGGUUUGGAUUAUAAAGCAUUCAAACAAAUUGUUGAAUCCUGUGGUAAUUUUAAAGUUACAAAAGGAAAAGCUAAAAAAGGUGCCUGGAAUAUUGGUGAACAGAAAUCAAUACUGAGUCCUCUUUAUGCAUUUGCAUCAGAGGCUGCUCGUGUUGUACGAUCAAUUUUCUCCCGCACUCUUGAAACUGCUCAAAAUUCUGUGCGUGUUUUACAGAAGGCCGCUAUAACAAUACUAGAUGGAAUUUCACAGUAUUCACUGAGACUCAUUGAUGCUAUGAUGUUCACAUCUGAUUUGGCUACUAACAAUCUAGUUGUAAUGGCCUACAUUACAGGUGGUGUUGUUCAGUUGACUUCGCAGUGGCUAACUAACAUCUUUGGCACUGUUUAUGAAAAACUCAAACCCGUCCUUGAUUGGCUUGAAGAGAAGUUUAAGGAAGGUGUAGAGUUUCUUAGAGACGGUUGGGAAAUUGUUAAAUUUAUCUCAACCUGUGCUUGUGAAAUUGUCGGUGGACAAAUUGUCACCUGUGCAAAGGAAAUUAAGGAGAGUGUUCAGACAUUCUUUAAGCUUGUAAAUAAAUUUUUGGCUUUGUGUGCUGACUCUAUCAUUAUUGGUGGAGCUAAACUUAAAGCCUUGAAUUUAGGUGAAACAUUUGUCACGCACUCAAAGGGAUUGUACAGAAAGUGUGUUAAAUCCAGAGAAGAAACUGGCCUACUCAUGCCUCUAAAAGCCCCAAAAGAAAUUAUCUUCUUAGAGGGAGAAACACUUCCCACAGAAGUGUUAACAGAGGAAGUUGUCUUGAAAACUGGUGAUUUACAACCAUUAGAACAACCUACUAGUGAAGCUGUUGAAGCUCCAUUGGUUGGUACACCAGUUUGUAUUAACGGGCUUAUGUUGCUCGAAAUCAAAGACACAGAAAAGUACUGUGCCCUUGCACCUAAUAUGAUGGUAACAAACAAUACCUUCACACUCAAAGGCGGUGCACCAACAAAGGUUACUUUUGGUGAUGACACUGUGAUAGAAGUGCAAGGUUACAAGAGUGUGAAUAUCACUUUUGAACUUGAUGAAAGGAUUGAUAAAGUACUUAAUGAGAAGUGCUCUGCCUAUACAGUUGAACUCGGUACAGAAGUAAAUGAGUUCGCCUGUGUUGUGGCAGAUGCUGUCAUAAAAACUUUGCAACCAGUAUCUGAAUUACUUACACCACUGGGCAUUGAUUUAGAUGAGUGGAGUAUGGCUACAUACUACUUAUUUGAUGAGUCUGGUGAGUUUAAAUUGGCUUCACAUAUGUAUUGUUCUUUCUACCCUCCAGAUGAGGAUGAAGAAGAAGGUGAUUGUGAAGAAGAAGAGUUUGAGCCAUCAACUCAAUAUGAGUAUGGUACUGAAGAUGAUUACCAAGGUAAACCUUUGGAAUUUGGUGCCACUUCUGCUGCUCUUCAACCUGAAGAAGAGCAAGAAGAAGAUUGGUUAGAUGAUGAUAGUCAACAAACUGUUGGUCAACAAGACGGCAGUGAGGACAAUCAGACAACUACUAUUCAAACAAUUGUUGAGGUUCAACCUCAAUUAGAGAUGGAACUUACACCAGUUGUUCAGACUAUUGAAGUGAAUAGUUUUAGUGGUUAUUUAAAACUUACUGACAAUGUAUACAUUAAAAAUGCAGACAUUGUGGAAGAAGCUAAAAAGGUAAAACCAACAGUGGUUGUUAAUGCAGCCAAUGUUUACCUUAAACAUGGAGGAGGUGUUGCAGGAGCCUUAAAUAAGGCUACUAACAAUGCCAUGCAAGUUGAAUCUGAUGAUUACAUAGCUACUAAUGGACCACUUAAAGUGGGUGGUAGUUGUGUUUUAAGCGGACACAAUCUUGCUAAACACUGUCUUCAUGUUGUCGGCCCAAAUGUUAACAAAGGUGAAGACAUUCAACUUCUUAAGAGUGCUUAUGAAAAUUUUAAUCAGCACGAAGUUCUACUUGCACCAUUAUUAUCAGCUGGUAUUUUUGGUGCUGACCCUAUACAUUCUUUAAGAGUUUGUGUAGAUACUGUUCGCACAAAUGUCUACUUAGCUGUCUUUGAUAAAAAUCUCUAUGACAAACUUGUUUCAAGCUUUUUGGAAAUGAAGAGUGAAAAGCAAGUUGAACAAAAGAUCGCUGAGAUUCCUAAAGAGGAAGUUAAGCCAUUUAUAACUGAAAGUAAACCUUCAGUUGAACAGAGAAAACAAGAUGAUAAGAAAAUCAAAGCUUGUGUUGAAGAAGUUACAACAACUCUGGAAGAAACUAAGUUCCUCACAGAAAACUUGUUACUUUAUAUUGACAUUAAUGGCAAUCUUCAUCCAGAUUCUGCCACUCUUGUUAGUGACAUUGACAUCACUUUCUUAAAGAAAGAUGCUCCAUAUAUAGUGGGUGAUGUUGUUCAAGAGGGUGUUUUAACUGCUGUGGUUAUACCUACUAAAAAGGCUGGUGGCACUACUGAAAUGCUAGCGAAAGCUUUGAGAAAAGUGCCAACAGACAAUUAUAUAACCACUUACCCGGGUCAGGGUUUAAAUGGUUACACUGUAGAGGAGGCAAAGACAGUGCUUAAAAAGUGUAAAAGUGCCUUUUACAUUCUACCAUCUAUUAUCUCUAAUGAGAAGCAAGAAAUUCUUGGAACUGUUUCUUGGAAUUUGCGAGAAAUGCUUGCACAUGCAGAAGAAACACGCAAAUUAAUGCCUGUCUGUGUGGAAACUAAAGCCAUAGUUUCAACUAUACAGCGUAAAUAUAAGGGUAUUAAAAUACAAGAGGGUGUGGUUGAUUAUGGUGCUAGAUUUUACUUUUACACCAGUAAAACAACUGUAGCGUCACUUAUCAACACACUUAACGAUCUAAAUGAAACUCUUGUUACAAUGCCACUUGGCUAUGUAACACAUGGCUUAAAUUUGGAAGAAGCUGCUCGGUAUAUGAGAUCUCUCAAAGUGCCAGCUACAGUUUCUGUUUCUUCACCUGAUGCUGUUACAGCGUAUAAUGGUUAUCUUACUUCUUCUUCUAAAACACCUGAAGAACAUUUUAUUGAAACCAUCUCACUUGCUGGUUCCUAUAAAGAUUGGUCCUAUUCUGGACAAUCUACACAACUAGGUAUAGAAUUUCUUAAGAGAGGUGAUAAAAGUGUAUAUUACACUAGUAAUCCUACCACAUUCCACCUAGAUGGUGAAGUUAUCACCUUUGACAAUCUUAAGACACUUCUUUCUUUGAGAGAAGUGAGGACUAUUAAGGUGUUUACAACAGUAGACAACAUUAACCUCCACACGCAAGUUGUGGACAUGUCAAUGACAUAUGGACAACAGUUUGGUCCAACUUAUUUGGAUGGAGCUGAUGUUACUAAAAUAAAACCUCAUAAUUCACAUGAAGGUAAAACAUUUUAUGUUUUACCUAAUGAUGACACUCUACGUGUUGAGGCUUUUGAGUACUACCACACAACUGAUCCUAGUUUUCUGGGUAGGUACAUGUCAGCAUUAAAUCACACUAAAAAGUGGAAAUACCCACAAGUUAAUGGUUUAACUUCUAUUAAAUGGGCAGAUAACAACUGUUAUCUUGCCACUGCAUUGUUAACACUCCAACAAAUAGAGUUGAAGUUUAAUCCACCUGCUCUACAAGAUGCUUAUUACAGAGCAAGGGCUGGUGAAGCUGCUAACUUUUGUGCACUUAUCUUAGCCUACUGUAAUAAGACAGUAGGUGAGUUAGGUGAUGUUAGAGAAACAAUGAGUUACUUGUUUCAACAUGCCAAUUUAGAUUCUUGCAAAAGAGUCUUGAACGUGGUGUGUAAAACUUGUGGACAACAGCAGACAACCCUUAAGGGUGUAGAAGCUGUUAUGUACAUGGGCACACUUUCUUAUGAACAAUUUAAGAAAGGUGUUCAGAUACCUUGUACGUGUGGUAAACAAGCUACAAAAUAUCUAGUACAACAGGAGUCACCUUUUGUUAUGAUGUCAGCACCACCUGCUCAGUAUGAACUUAAGCAUGGUACAUUUACUUGUGCUAGUGAGUACACUGGUAAUUACCAGUGUGGUCACUAUAAACAUAUAACUUCUAAAGAAACUUUGUAUUGCAUAGACGGUGCUUUACUUACAAAGUCCUCAGAAUACAAAGGUCCUAUUACGGAUGUUUUCUACAAAGAAAACAGUUACACAACAACCAUAAAACCAGUUACUUAUAAAUUGGAUGGUGUUGUUUGUACAGAAAUUGACCCUAAGUUGGACAAUUAUUAUAAGAAAGACAAUUCUUAUUUCACAGAGCAACCAAUUGAUCUUGUACCAAACCAACCAUAUCCAAACGCAAGCUUCGAUAAUUUUAAGUUUGUAUGUGAUAAUAUCAAAUUUGCUGAUGAUUUAAACCAGUUAACUGGUUAUAAGAAACCUGCUUCAAGAGAGCUUAAAGUUACAUUUUUCCCUGACUUAAAUGGUGAUGUGGUGGCUAUUGAUUAUAAACACUACACACCCUCUUUUAAGAAAGGAGCUAAAUUGUUACAUAAACCUAUUGUUUGGCAUGUUAACAAUGCAACUAAUAAAGCCACGUAUAAACCAAAUACCUGGUGUAUACGUUGUCUUUGGAGCACAAAACCAGUUGAAACAUCAAAUUCGUUUGAUGUACUGAAGUCAGAGGACGCGCAGGGAAUGGAUAAUCUUGCCUGCGAAGAUCUAAAACCAGUCUCUGAAGAAGUAGUGGAAAAUCCUACCAUACAGAAAGACGUUCUUGAGUGUAAUGUGAAAACUACCGAAGUUGUAGGAGACAUUAUACUUAAACCAGCAAAUAAUAGUUUAAAAAUUACAGAAGAGGUUGGCCACACAGAUCUAAUGGCUGCUUAUGUAGACAAUUCUAGUCUUACUAUUAAGAAACCUAAUGAAUUAUCUAGAGUAUUAGGUUUGAAAACCCUUGCUACUCAUGGUUUAGCUGCUGUUAAUAGUGUCCCUUGGGAUACUAUAGCUAAUUAUGCUAAGCCUUUUCUUAACAAAGUUGUUAGUACAACUACUAACAUAGUUACACGGUGUUUAAACCGUGUUUGUACUAAUUAUAUGCCUUAUUUCUUUACUUUAUUGCUACAAUUGUGUACUUUUACUAGAAGUACAAAUUCUAGAAUUAAAGCAUCUAUGCCGACUACUAUAGCAAAGAAUACUGUUAAGAGUGUCGGUAAAUUUUGUCUAGAGGCUUCAUUUAAUUAUUUGAAGUCACCUAAUUUUUCUAAACUGAUAAAUAUUAUAAUUUGGUUUUUACUAUUAAGUGUUUGCCUAGGUUCUUUAAUCUACUCAACCGCUGCUUUAGGUGUUUUAAUGUCUAAUUUAGGCAUGCCUUCUUACUGUACUGGUUACAGAGAAGGCUAUUUGAACUCUACUAAUGUCACUAUUGCAACCUACUGUACUGGUUCUAUACCUUGUAGUGUUUGUCUUAGUGGUUUAGAUUCUUUAGACACCUAUCCUUCUUUAGAAACUAUACAAAUUACCAUUUCAUCUUUUAAAUGGGAUUUAACUGCUUUUGGCUUAGUUGCAGAGUGGUUUUUGGCAUAUAUUCUUUUCACUAGGUUUUUCUAUGUACUUGGAUUGGCUGCAAUCAUGCAAUUGUUUUUCAGCUAUUUUGCAGUACAUUUUAUUAGUAAUUCUUGGCUUAUGUGGUUAAUAAUUAAUCUUGUACAAAUGGCCCCGAUUUCAGCUAUGGUUAGAAUGUACAUCUUCUUUGCAUCAUUUUAUUAUGUAUGGAAAAGUUAUGUGCAUGUUGUAGACGGUUGUAAUUCAUCAACUUGUAUGAUGUGUUACAAACGUAAUAGAGCAACAAGAGUCGAAUGUACAACUAUUGUUAAUGGUGUUAGAAGGUCCUUUUAUGUCUAUGCUAAUGGAGGUAAAGGCUUUUGCAAACUACACAAUUGGAAUUGUGUUAAUUGUGAUACAUUCUGUGCUGGUAGUACAUUUAUUAGUGAUGAAGUUGCGAGAGACUUGUCACUACAGUUUAAAAGACCAAUAAAUCCUACUGACCAGUCUUCUUACAUCGUUGAUAGUGUUACAGUGAAGAAUGGUUCCAUCCAUCUUUACUUUGAUAAAGCUGGUCAAAAGACUUAUGAAAGACAUUCUCUCUCUCAUUUUGUUAACUUAGACAACCUGAGAGCUAAUAACACUAAAGGUUCAUUGCCUAUUAAUGUUAUAGUUUUUGAUGGUAAAUCAAAAUGUGAAGAAUCAUCUGCAAAAUCAGCGUCUGUUUACUACAGUCAGCUUAUGUGUCAACCUAUACUGUUACUAGAUCAGGCAUUAGUGUCUGAUGUUGGUGAUAGUGCGGAAGUUGCAGUUAAAAUGUUUGAUGCUUACGUUAAUACGUUUUCAUCAACUUUUAACGUACCAAUGGAAAAACUCAAAACACUAGUUGCAACUGCAGAAGCUGAACUUGCAAAGAAUGUGUCCUUAGACAAUGUCUUAUCUACUUUUAUUUCAGCAGCUCGGCAAGGGUUUGUUGAUUCAGAUGUAGAAACUAAAGAUGUUGUUGAAUGUCUUAAAUUGUCACAUCAAUCUGACAUAGAAGUUACUGGCGAUAGUUGUAAUAACUAUAUGCUCACCUAUAACAAAGUUGAAAACAUGACACCCCGUGACCUUGGUGCUUGUAUUGACUGUAGUGCGCGUCAUAUUAAUGCGCAGGUAGCAAAAAGUCACAACAUUGCUUUGAUAUGGAACGUUAAAGAUUUCAUGUCAUUGUCUGAACAACUACGAAAACAAAUACGUAGUGCUGCUAAAAAGAAUAACUUACCUUUUAAGUUGACAUGUGCAACUACUAGACAAGUUGUUAAUGUUGUAACAACAAAGAUAGCACUUAAGGGUGGUAAAAUUGUUAAUAAUUGGUUGAAGCAGUUAAUUAAAGUUACACUUGUGUUCCUUUUUGUUGCUGCUAUUUUCUAUUUAAUAACACCUGUUCAUGUCAUGUCUAAACAUACUGACUUUUCAAGUGAAAUCAUAGGAUACAAGGCUAUUGAUGGUGGUGUCACUCGUGACAUAGCAUCUACAGAUACUUGUUUUGCUAACAAACAUGCUGAUUUUGACACAUGGUUUAGCCAGCGUGGUGGUAGUUAUACUAAUGACAAAGCUUGCCCAUUGAUUGCUGCAGUCAUAACAAGAGAAGUGGGUUUUGUCGUGCCUGGUUUGCCUGGCACGAUAUUACGCACAACUAAUGGUGACUUUUUGCAUUUCUUACCUAGAGUUUUUAGUGCAGUUGGUAACAUCUGUUACACACCAUCAAAACUUAUAGAGUACACUGACUUUGCAACAUCAGCUUGUGUUUUGGCUGCUGAAUGUACAAUUUUUAAAGAUGCUUCUGGUAAGCCAGUACCAUAUUGUUAUGAUACCAAUGUACUAGAAGGUUCUGUUGCUUAUGAAAGUUUACGCCCUGACACACGUUAUGUGCUCAUGGAUGGCUCUAUUAUUCAAUUUCCUAACACCUACCUUGAAGGUUCUGUUAGAGUGGUAACAACUUUUGAUUCUGAGUACUGUAGGCACGGCACUUGUGAAAGAUCAGAAGCUGGUGUUUGUGUAUCUACUAGUGGUAGAUGGGUACUUAACAAUGAUUAUUACAGAUCUUUACCAGGAGUUUUCUGUGGUGUAGAUGCUGUAAAUUUACUUACUAAUAUGUUUACACCACUAAUUCAACCUAUUGGUGCUUUGGACAUAUCAGCAUCUAUAGUAGCUGGUGGUAUUGUAGCUAUCGUAGUAACAUGCCUUGCCUACUAUUUUAUGAGGUUUAGAAGAGCUUUUGGUGAAUACAGUCAUGUAGUUGCCUUUAAUACUUUACUAUUCCUUAUGUCAUUCACUGUACUCUGUUUAACACCAGUUUACUCAUUCUUACCUGGUGUUUAUUCUGUUAUUUACUUGUACUUGACAUUUUAUCUUACUAAUGAUGUUUCUUUUUUAGCACAUAUUCAGUGGAUGGUUAUGUUCACACCUUUAGUACCUUUCUGGAUAACAAUUGCUUAUAUCAUUUGUAUUUCCACAAAGCAUUUCUAUUGGUUCUUUAGUAAUUACCUAAAGAGACGUGUAGUCUUUAAUGGUGUUUCCUUUAGUACUUUUGAAGAAGCUGCGCUGUGCACCUUUUUGUUAAAUAAAGAAAUGUAUCUAAAGUUGCGUAGUGAUGUGCUAUUACCUCUUACGCAAUAUAAUAGAUACUUAGCUCUUUAUAAUAAGUACAAGUAUUUUAGUGGAGCAAUGGAUACAACUAGCUACAGAGAAGCUGCUUGUUGUCAUCUCGCAAAGGCUCUCAAUGACUUCAGUAACUCAGGUUCUGAUGUUCUUUACCAACCACCACAAACCUCUAUCACCUCAGCUGUUUUGCAGAGUGGUUUUAGAAAAAUGGCAUUCCCAUCUGGUAAAGUUGAGGGUUGUAUGGUACAAGUAACUUGUGGUACAACUACACUUAACGGUCUUUGGCUUGAUGACGUAGUUUACUGUCCAAGACAUGUGAUCUGCACCUCUGAAGACAUGCUUAACCCUAAUUAUGAAGAUUUACUCAUUCGUAAGUCUAAUCAUAAUUUCUUGGUACAGGCUGGUAAUGUUCAACUCAGGGUUAUUGGACAUUCUAUGCAAAAUUGUGUACUUAAGCUUAAGGUUGAUACAGCCAAUCCUAAGACACCUAAGUAUAAGUUUGUUCGCAUUCAACCAGGACAGACUUUUUCAGUGUUAGCUUGUUACAAUGGUUCACCAUCUGGUGUUUACCAAUGUGCUAUGAGGCCCAAUUUCACUAUUAAGGGUUCAUUCCUUAAUGGUUCAUGUGGUAGUGUUGGUUUUAACAUAGAUUAUGACUGUGUCUCUUUUUGUUACAUGCACCAUAUGGAAUUACCAACUGGAGUUCAUGCUGGCACAGACUUAGAAGGUAACUUUUAUGGACCUUUUGUUGACAGGCAAACAGCACAAGCAGCUGGUACGGACACAACUAUUACAGUUAAUGUUUUAGCUUGGUUGUACGCUGCUGUUAUAAAUGGAGACAGGUGGUUUCUCAAUCGAUUUACCACAACUCUUAAUGACUUUAACCUUGUGGCUAUGAAGUACAAUUAUGAACCUCUAACACAAGACCAUGUUGACAUACUAGGACCUCUUUCUGCUCAAACUGGAAUUGCCGUUUUAGAUAUGUGUGCUUCAUUAAAAGAAUUACUGCAAAAUGGUAUGAAUGGACGUACCAUAUUGGGUAGUGCUUUAUUAGAAGAUGAAUUUACACCUUUUGAUGUUGUUAGACAAUGCUCAGGUGUUACUUUCCAAAGUGCAGUGAAAAGAACAAUCAAGGGUACACACCACUGGUUGUUACUCACAAUUUUGACUUCACUUUUAGUUUUAGUCCAGAGUACUCAAUGGUCUUUGUUCUUUUUUUUGUAUGAAAAUGCCUUUUUACCUUUUGCUAUGGGUAUUAUUGCUAUGUCUGCUUUUGCAAUGAUGUUUGUCAAACAUAAGCAUGCAUUUCUCUGUUUGUUUUUGUUACCUUCUCUUGCCACUGUAGCUUAUUUUAAUAUGGUCUAUAUGCCUGCUAGUUGGGUGAUGCGUAUUAUGACAUGGUUGGAUAUGGUUGAUACUAGUUUGUCUGGUUUUAAGCUAAAAGACUGUGUUAUGUAUGCAUCAGCUGUAGUGUUACUAAUCCUUAUGACAGCAAGAACUGUGUAUGAUGAUGGUGCUAGGAGAGUGUGGACACUUAUGAAUGUCUUGACACUCGUUUAUAAAGUUUAUUAUGGUAAUGCUUUAGAUCAAGCCAUUUCCAUGUGGGCUCUUAUAAUCUCUGUUACUUCUAACUACUCAGGUGUAGUUACAACUGUCAUGUUUUUGGCCAGAGGUAUUGUUUUUAUGUGUGUUGAGUAUUGCCCUAUUUUCUUCAUAACUGGUAAUACACUUCAGUGUAUAAUGCUAGUUUAUUGUUUCUUAGGCUAUUUUUGUACUUGUUACUUUGGCCUCUUUUGUUUACUCAACCGCUACUUUAGACUGACUCUUGGUGUUUAUGAUUACUUAGUUUCUACACAGGAGUUUAGAUAUAUGAAUUCACAGGGACUACUCCCACCCAAGAAUAGCAUAGAUGCCUUCAAACUCAACAUUAAAUUGUUGGGUGUUGGUGGCAAACCUUGUAUCAAAGUAGCCACUGUACAGUCUAAAAUGUCAGAUGUAAAGUGCACAUCAGUAGUCUUACUCUCAGUUUUGCAACAACUCAGAGUAGAAUCAUCAUCUAAAUUGUGGGCUCAAUGUGUCCAGUUACACAAUGACAUUCUCUUAGCUAAAGAUACUACUGAAGCCUUUGAAAAAAUGGUUUCACUACUUUCUGUUUUGCUUUCCAUGCAGGGUGCUGUAGACAUAAACAAGCUUUGUGAAGAAAUGCUGGACAACAGGGCAACCUUACAAGCUAUAGCCUCAGAGUUUAGUUCCCUUCCAUCAUAUGCAGCUUUUGCUACUGCUCAAGAAGCUUAUGAGCAGGCUGUUGCUAAUGGUGAUUCUGAAGUUGUUCUUAAAAAGUUGAAGAAGUCUUUGAAUGUGGCUAAAUCUGAAUUUGACCGUGAUGCAGCCAUGCAACGUAAGUUGGAAAAGAUGGCUGAUCAAGCUAUGACCCAAAUGUAUAAACAGGCUAGAUCUGAGGACAAGAGGGCAAAAGUUACUAGUGCUAUGCAGACAAUGCUUUUCACUAUGCUUAGAAAGUUGGAUAAUGAUGCACUCAACAACAUUAUCAACAAUGCAAGAGAUGGUUGUGUUCCCUUGAACAUAAUACCUCUUACAACAGCAGCCAAACUAAUGGUUGUCAUACCAGACUAUAACACAUAUAAAAAUACGUGUGAUGGUACAACAUUUACUUAUGCAUCAGCAUUGUGGGAAAUCCAACAGGUUGUAGAUGCAGAUAGUAAAAUUGUUCAACUUAGUGAAAUUAGUAUGGACAAUUCACCUAAUUUAGCAUGGCCUCUUAUUGUAACAGCUUUAAGGGCCAAUUCUGCUGUCAAAUUACAGAAUAAUGAGCUUAGUCCUGUUGCACUACGACAGAUGUCUUGUGCUGCCGGUACUACACAAACUGCUUGCACUGAUGACAAUGCGUUAGCUUACUACAACACAACAAAGGGAGGUAGGUUUGUACUUGCACUGUUAUCCGAUUUACAGGAUUUGAAAUGGGCUAGAUUCCCUAAGAGUGAUGGAACUGGUACUAUCUAUACAGAACUGGAACCACCUUGUAGGUUUGUUACAGACACACCUAAAGGUCCUAAAGUGAAGUAUUUAUACUUUAUUAAAGGAUUAAACAACCUAAAUAGAGGUAUGGUACUUGGUAGUUUAGCUGCCACAGUACGUCUACAAGCUGGUAAUGCAACAGAAGUGCCUGCCAAUUCAACUGUAUUAUCUUUCUGUGCUUUUGCUGUAGAUGCUGCUAAAGCUUACAAAGAUUAUCUAGCUAGUGGGGGACAACCAAUCACUAAUUGUGUUAAGAUGUUGUGUACACACACUGGUACUGGUCAGGCAAUAACAGUUACACCGGAAGCCAAUAUGGAUCAAGAAUCCUUUGGUGGUGCAUCGUGUUGUCUGUACUGCCGUUGCCACAUAGAUCAUCCAAAUCCUAAAGGAUUUUGUGACUUAAAAGGUAAGUAUGUACAAAUACCUACAACUUGUGCUAAUGACCCUGUGGGUUUUACACUUAAAAACACAGUCUGUACCGUCUGCGGUAUGUGGAAAGGUUAUGGCUGUAGUUGUGAUCAACUCCGCGAACCCAUGCUUCAGUCAGCUGAUGCACAAUCGUUUUUAAACGGGUUUGCGGUGUAAGUGCAGCCCGUCUUACACCGUGCGGCACAGGCACUAGUACUGAUGUCGUAUACAGGGCUUUUGACAUCUACAAUGAUAAAGUAGCUGGUUUUGCUAAAUUCCUAAAAACUAAUUGUUGUCGCUUCCAAGAAAAGGACGAAGAUGACAAUUUAAUUGAUUCUUACUUUGUAGUUAAGAGACACACUUUCUCUAACUACCAACAUGAAGAAACAAUUUAUAAUUUACUUAAGGAUUGUCCAGCUGUUGCUAAACAUGACUUCUUUAAGUUUAGAAUAGACGGUGACAUGGUACCACAUAUAUCACGUCAACGUCUUACUAAAUACACAAUGGCAGACCUCGUCUAUGCUUUAAGGCAUUUUGAUGAAGGUAAUUGUGACACAUUAAAAGAAAUACUUGUCACAUACAAUUGUUGUGAUGAUGAUUAUUUCAAUAAAAAGGACUGGUAUGAUUUUGUAGAAAACCCAGAUAUAUUACGCGUAUACGCCAACUUAGGUGAACGUGUACGCCAAGCUUUGUUAAAAACAGUACAAUUCUGUGAUGCCAUGCGAAAUGCUGGUAUUGUUGGUGUACUGACAUUAGAUAAUCAAGAUCUCAAUGGUAACUGGUAUGAUUUCGGUGAUUUCAUACAAACCACGCCAGGUAGUGGAGUUCCUGUUGUAGAUUCUUAUUAUUCAUUGUUAAUGCCUAUAUUAACCUUGACCAGGGCUUUAACUGCAGAGUCACAUGUUGACACUGACUUAACAAAGCCUUACAUUAAGUGGGAUUUGUUAAAAUAUGACUUCACGGAAGAGAGGUUAAAACUCUUUGACCGUUAUUUUAAAUAUUGGGAUCAGACAUACCACCCAAAUUGUGUUAACUGUUUGGAUGACAGAUGCAUUCUGCAUUGUGCAAACUUUAAUGUUUUAUUCUCUACAGUGUUCCCACCUACAAGUUUUGGACCACUAGUGAGAAAAAUAUUUGUUGAUGGUGUUCCAUUUGUAGUUUCAACUGGAUACCACUUCAGAGAGCUAGGUGUUGUACAUAAUCAGGAUGUAAACUUACAUAGCUCUAGACUUAGUUUUAAGGAAUUACUUGUGUAUGCUGCUGACCCUGCUAUGCACGCUGCUUCUGGUAAUCUAUUACUAGAUAAACGCACUACGUGCUUUUCAGUAGCUGCACUUACUAACAAUGUUGCUUUUCAAACUGUCAAACCCGGUAAUUUUAACAAAGACUUCUAUGACUUUGCUGUGUCUAAGGGUUUCUUUAAGGAAGGAAGUUCUGUUGAAUUAAAACACUUCUUCUUUGCUCAGGAUGGUAAUGCUGCUAUCAGCGAUUAUGACUACUAUCGUUAUAAUCUACCAACAAUGUGUGAUAUCAGACAACUACUAUUUGUAGUUGAAGUUGUUGAUAAGUACUUUGAUUGUUACGAUGGUGGCUGUAUUAAUGCUAACCAAGUCAUCGUCAACAACCUAGACAAAUCAGCUGGUUUUCCAUUUAAUAAAUGGGGUAAGGCUAGACUUUAUUAUGAUUCAAUGAGUUAUGAGGAUCAAGAUGCACUUUUCGCAUAUACAAAACGUAAUGUCAUCCCUACUAUAACUCAAAUGAAUCUUAAGUAUGCCAUUAGUGCAAAGAAUAGAGCUCGCACCGUAGCUGGUGUCUCUAUCUGUAGUACUAUGACCAAUAGACAGUUUCAUCAAAAAUUAUUGAAAUCAAUAGCCGCCACUAGAGGAGCUACUGUAGUAAUUGGAACAAGCAAAUUCUAUGGUGGUUGGCACAACAUGUUAAAAACUGUUUAUAGUGAUGUAGAAAACCCUCACCUUAUGGGUUGGGAUUAUCCUAAAUGUGAUAGAGCCAUGCCUAACAUGCUUAGAAUUAUGGCCUCACUUGUUCUUGCUCGCAAACAUACAACGUGUUGUAGCUUGUCACACCGUUUCUAUAGAUUAGCUAAUGAGUGUGCUCAAGUAUUGAGUGAAAUGGUCAUGUGUGGCGGUUCACUAUAUGUUAAACCAGGUGGAACCUCAUCAGGAGAUGCCACAACUGCUUAUGCUAAUAGUGUUUUUAACAUUUGUCAAGCUGUCACGGCCAAUGUUAAUGCACUUUUAUCUACUGAUGGUAACAAAAUUGCCGAUAAGUAUGUCCGCAAUUUACAACACAGACUUUAUGAGUGUCUCUAUAGAAAUAGAGAUGUUGACACAGACUUUGUGAAUGAGUUUUACGCAUAUUUGCGUAAACAUUUCUCAAUGAUGAUACUCUCUGACGAUGCUGUUGUGUGUUUCAAUAGCACUUAUGCAUCUCAAGGUCUAGUGGCUAGCAUAAAGAACUUUAAGUCAGUUCUUUAUUAUCAAAACAAUGUUUUUAUGUCUGAAGCAAAAUGUUGGACUGAGACUGACCUUACUAAAGGACCUCAUGAAUUUUGCUCUCAACAUACAAUGCUAGUUAAACAGGGUGAUGAUUAUGUGUACCUUCCUUACCCAGAUCCAUCAAGAAUCCUAGGGGCCGGCUGUUUUGUAGAUGAUAUCGUAAAAACAGAUGGUACACUUAUGAUUGAACGGUUCGUGUCUUUAGCUAUAGAUGCUUACCCACUUACUAAACAUCCUAAUCAGGAGUAUGCUGAUGUCUUUCAUUUGUACUUACAAUACAUAAGAAAGCUACAUGAUGAGUUAACAGGACACAUGUUAGACAUGUAUUCUGUUAUGCUUACUAAUGAUAACACUUCAAGGUAUUGGGAACCUGAGUUUUAUGAGGCUAUGUACACACCGCAUACAGUCUUACAGGCUGUUGGGGCUUGUGUUCUUUGCAAUUCACAGACUUCAUUAAGAUGUGGUGCUUGCAUACGUAGACCAUUCUUAUGUUGUAAAUGCUGUUACGACCAUGUCAUAUCAACAUCACAUAAAUUAGUCUUGUCUGUUAAUCCGUAUGUUUGCAAUGCUCCAGGUUGUGAUGUCACAGAUGUGACUCAACUUUACUUAGGAGGUAUGAGCUAUUAUUGUAAAUCACAUAAACCACCCAUUAGUUUUCCAUUGUGUGCUAAUGGACAAGUUUUUGGUUUAUAUAAAAAUACAUGUGUUGGUAGCGAUAAUGUUACUGACUUUAAUGCAAUUGCAACAUGUGACUGGACAAAUGCUGGUGAUUACAUUUUAGCUAACACCUGUACUGAAAGACUCAAGCUUUUUGCAGCAGAAACGCUCAAAGCUACUGAGGAGACAUUUAAACUGUCUUAUGGUAUUGCUACUGUACGUGAAGUGCUGUCUGACAGAGAAUUACAUCUUUCAUGGGAAGUUGGUAAACCUAGACCACCACUUAACCGAAAUUAUGUCUUUACUGGUUAUCGUGUAACUAAAAACAGUAAAGUACAAAUAGGAGAGUACACCUUUGAAAAAGGUGACUAUGGUGAUGCUGUUGUUUACCGAGGUACAACAACUUACAAAUUAAAUGUUGGUGAUUAUUUUGUGCUGACAUCACAUACAGUAAUGCCAUUAAGUGCACCUACACUAGUGCCACAAGAGCACUAUGUUAGAAUUACUGGCUUAUACCCAACACUCAAUAUCUCAGAUGAGUUUUCUAGCAAUGUUGCAAAUUAUCAAAAGGUUGGUAUGCAAAAGUAUUCUACACUCCAGGGACCACCUGGUACUGGUAAGAGUCAUUUUGCUAUUGGCCUAGCUCUCUACUACCCUUCUGCUCGCAUAGUGUAUACAGCUUGCUCUCAUGCCGCUGUUGAUGCACUAUGUGAGAAGGCAUUAAAAUAUUUGCCUAUAGAUAAAUGUAGUAGAAUUAUACCUGCACGUGCUCGUGUAGAGUGUUUUGAUAAAUUCAAAGUGAAUUCAACAUUAGAACAGUAUGUCUUUUGUACUGUAAAUGCAUUGCCUGAGACGACAGCAGAUAUAGUUGUCUUUGAUGAAAUUUCAAUGGCCACAAAUUAUGAUUUGAGUGUUGUCAAUGCCAGAUUACGUGCUAAGCACUAUGUGUACAUUGGCGACCCUGCUCAAUUACCUGCACCACGCACAUUGCUAACUAAGGGCACACUAGAACCAGAAUAUUUCAAUUCAGUGUGUAGACUUAUGAAAACUAUAGGUCCAGACAUGUUCCUCGGAACUUGUCGGCGUUGUCCUGCUGAAAUUGUUGACACUGUGAGUGCUUUGGUUUAUGAUAAUAAGCUUAAAGCACAUAAAGACAAAUCAGCUCAAUGCUUUAAAAUGUUUUAUAAGGGUGUUAUCACGCAUGAUGUUUCAUCUGCAAUUAACAGGCCACAAAUAGGCGUGGUAAGAGAAUUCCUUACACGUAACCCUGCUUGGAGAAAAGCUGUCUUUAUUUCACCUUAUAAUUCACAGAAUGCUGUAGCCUCAAAGAUUUUGGGACUACCAACUCAAACUGUUGAUUCAUCACAGGGCUCAGAAUAUGACUAUGUCAUAUUCACUCAAACCACUGAAACAGCUCACUCUUGUAAUGUAAACAGAUUUAAUGUUGCUAUUACCAGAGCAAAAGUAGGCAUACUUUGCAUAAUGUCUGAUAGAGACCUUUAUGACAAGUUGCAAUUUACAAGUCUUGAAAUUCCACGUAGGAAUGUGGCAACUUUACAAGCUGAAAAUGUAACAGGACUCUUUAAAGAUUGUAGUAAGGUAAUCACUGGGUUACAUCCUACACAGGCACCUACACACCUCAGUGUUGACACUAAAUUCAAAACUGAAGGUUUAUGUGUUGACAUACCUGGCAUACCUAAGGACAUGACCUAUAGAAGACUCAUCUCUAUGAUGGGUUUUAAAAUGAAUUAUCAAGUUAAUGGUUACCCUAACAUGUUUAUCACCCGCGAAGAAGCUAUAAGACAUGUACGUGCAUGGAUUGGCUUCGAUGUCGAGGGGUGUCAUGCUACUAGAGAAGCUGUUGGUACCAAUUUACCUUUACAGCUAGGUUUUUCUACAGGUGUUAACCUAGUUGCUGUACCUACAGGUUAUGUUGAUACACCUAAUAAUACAGAUUUUUCCAGAGUUAGUGCUAAACCACCGCCUGGAGAUCAAUUUAAACACCUCAUACCACUUAUGUACAAAGGACUUCCUUGGAAUGUAGUGCGUAUAAAGAUUGUACAAAUGUUAAGUGACACACUUAAAAAUCUCUCUGACAGAGUCGUAUUUGUCUUAUGGGCACAUGGCUUUGAGUUGACAUCUAUGAAGUAUUUUGUGAAAAUAGGACCUGAGCGCACCUGUUGUCUAUGUGAUAGACGUGCCACAUGCUUUUCCACUGCUUCAGACACUUAUGCCUGUUGGCAUCAUUCUAUUGGAUUUGAUUACGUCUAUAAUCCGUUUAUGAUUGAUGUUCAACAAUGGGGUUUUACAGGUAACCUACAAAGCAACCAUGAUCUGUAUUGUCAAGUCCAUGGUAAUGCACAUGUAGCUAGUUGUGAUGCAAUCAUGACUAGGUGUCUAGCUGUCCACGAGUGCUUUGUUAAGCGUGUUGACUGGACUAUUGAAUAUCCUAUAAUUGGUGAUGAACUGAAGAUUAAUGCGGCUUGUAGAAAGGUUCAACACAUGGUUGUUAAAGCUGCAUUAUUAGCAGACAAAUUCCCAGUUCUUCACGACAUUGGUAACCCUAAAGCUAUUAAGUGUGUACCUCAAGCUGAUGUAGAAUGGAAGUUCUAUGAUGCACAGCCUUGUAGUGACAAAGCUUAUAAAAUAGAAGAAUUAUUCUAUUCUUAUGCCACACAUUCUGACAAAUUCACAGAUGGUGUAUGCCUAUUUUGGAAUUGCAAUGUCGAUAGAUAUCCUGCUAAUUCCAUUGUUUGUAGAUUUGACACUAGAGUGCUAUCUAACCUUAACUUGCCUGGUUGUGAUGGUGGCAGUUUGUAUGUAAAUAAACAUGCAUUCCACACACCAGCUUUUGAUAAAAGUGCUUUUGUUAAUUUAAAACAAUUACCAUUUUUCUAUUACUCUGACAGUCCAUGUGAGUCUCAUGGAAAACAAGUAGUGUCAGAUAUAGAUUAUGUACCACUAAAGUCUGCUACGUGUAUAACACGUUGCAAUUUAGGUGGUGCUGUCUGUAGACAUCAUGCUAAUGAGUACAGAUUGUAUCUCGAUGCUUAUAACAUGAUGAUCUCAGCUGGCUUUAGCUUGUGGGUUUACAAACAAUUUGAUACUUAUAACCUCUGGAACACUUUUACAAGACUUCAGAGUUUAGAAAAUGUGGCUUUUAAUGUUGUAAAUAAGGGACACUUUGAUGGACAACAGGGUGAAGUACCAGUUUCUAUCAUUAAUAACACUGUUUACACAAAAGUUGAUGGUGUUGAUGUAGAAUUGUUUGAAAAUAAAACAACAUUACCUGUUAAUGUAGCAUUUGAGCUUUGGGCUAAGCGCAACAUUAAACCAGUACCAGAGGUGAAAAUACUCAAUAAUUUGGGUGUGGACAUUGCUGCUAAUACUGUGAUCUGGGACUACAAAAGAGAUGCUCCAGCACAUAUAUCUACUAUUGGUGUUUGUUCUAUGACUGACAUAGCCAAGAAACCAACUGAAACGAUUUGUGCACCACUCACUGUCUUUUUUGAUGGUAGAGUUGAUGGUCAAGUAGACUUAUUUAGAAAUGCCCGUAAUGGUGUUCUUAUUACAGAAGGUAGUGUUAAAGGUUUACAACCAUCUGUAGGUCCCAAACAAGCUAGUCUUAAUGGAGUCACAUUAAUUGGAGAAGCCGUAAAAACACAGUUCAAUUAUUAUAAGAAAGUUGAUGGUGUUGUCCAACAAUUACCUGAAACUUACUUUACUCAGAGUAGAAAUUUACAAGAAUUUAAACCCAGGAGUCAAAUGGAAAUUGAUUUCUUAGAAUUAGCUAUGGAUGAAUUCAUUGAACGGUAUAAAUUAGAAGGCUAUGCCUUCGAACAUAUCGUUUAUGGAGAUUUUAGUCAUAGUCAGUUAGGUGGUUUACAUCUACUGAUUGGACUAGCUAAACGUUUUAAGGAAUCACCUUUUGAAUUAGAAGAUUUUAUUCCUAUGGACAGUACAGUUAAAAACUAUUUCAUAACAGAUGCGCAAACAGGUUCAUCUAAGUGUGUGUGUUCUGUUAUUGAUUUAUUACUUGAUGAUUUUGUUGAAAUAAUAAAAUCCCAAGAUUUAUCUGUAGUUUCUAAGGUUGUCAAAGUGACUAUUGACUAUACAGAAAUUUCAUUUAUGCUUUGGUGUAAAGAUGGCCAUGUAGAAACAUUUUACCCAAAAUUACAAUCUAGUCAAGCGUGGCAACCGGGUGUUGCUAUGCCUAAUCUUUACAAAAUGCAAAGAAUGCUAUUAGAAAAGUGUGACCUUCAAAAUUAUGGUGAUAGUGCAACAUUACCUAAAGGCAUAAUGAUGAAUGUCGCAAAAUAUACUCAACUGUGUCAAUAUUUAAACACAUUAACAUUAGCUGUACCCUAUAAUAUGAGAGUUAUACAUUUUGGUGCUGGUUCUGAUAAAGGAGUUGCACCAGGUACAGCUGUUUUAAGACAGUGGUUGCCUACGGGUACGCUGCUUGUCGAUUCAGAUCUUAAUGACUUUGUCUCUGAUGCAGAUUCAACUUUGAUUGGUGAUUGUGCAACUGUACAUACAGCUAAUAAAUGGGAUCUCAUUAUUAGUGAUAUGUACGACCCUAAGACUAAAAAUGUUACAAAAGAAAAUGACUCUAAAGAGGGUUUUUUCACUUACAUUUGUGGGUUUAUACAACAAAAGCUAGCUCUUGGAGGUUCCGUGGCUAUAAAGAUAACAGAACAUUCUUGGAAUGCUGAUCUUUAUAAGCUCAUGGGACACUUCGCAUGGUGGACAGCCUUUGUUACUAAUGUGAAUGCGUCAUCAUCUGAAGCAUUUUUAAUUGGAUGUAAUUAUCUUGGCAAACCACGCGAACAAAUAGAUGGUUAUGUCAUGCAUGCAAAUUACAUAUUUUGGAGGAAUACAAAUCCAAUUCAGUUGUCUUCCUAUUCUUUAUUUGACAUGAGUAAAUUUCCCCUUAAAUUAAGGGGUACUGCUGUUAUGUCUUUAAAAGAAGGUCAAAUCAAUGAUAUGAUUUUAUCUCUUCUUAGUAAAGGUAGACUUAUAAUUAGAGAAAACAACAGAGUUGUUAUUUCUAGUGAUGUUCUUGUUAACAACUAAACGAACAAUGUUUGUUUUUCUUGUUUUAUUGCCACUAGUCUCUAGUCAGUGUGUUAAUCUUACAACCAGAACUCAAUUACCCCCUGCAUACACUAAUUCUUUCACACGUGGUGUUUAUUACCCUGACAAAGUUUUCAGAUCCUCAGUUUUACAUUCAACUCAGGACUUGUUCUUACCUUUCUUUUCCAAUGUUACUUGGUUCCAUGCUAUACAUGUCUCUGGGACCAAUGGUACUAAGAGGUUUGAUAACCCUGUCCUACCAUUUAAUGAUGGUGUUUAUUUUGCUUCCACUGAGAAGUCUAACAUAAUAAGAGGCUGGAUUUUUGGUACUACUUUAGAUUCGAAGACCCAGUCCCUACUUAUUGUUAAUAACGCUACUAAUGUUGUUAUUAAAGUCUGUGAAUUUCAAUUUUGUAAUGAUCCAUUUUUGGGUGUUUAUUACCACAAAAACAACAAAAGUUGGAUGGAAAGUGAGUUCAGAGUUUAUUCUAGUGCGAAUAAUUGCACUUUUGAAUAUGUCUCUCAGCCUUUUCUUAUGGACCUUGAAGGAAAACAGGGUAAUUUCAAAAAUCUUAGGGAAUUUGUGUUUAAGAAUAUUGAUGGUUAUUUUAAAAUAUAUUCUAAGCACACGCCUAUUAAUUUAGUGCGUGAUCUCCCUCAGGGUUUUUCGGCUUUAGAACCAUUGGUAGAUUUGCCAAUAGGUAUUAACAUCACUAGGUUUCAAACUUUACUUGCUUUACAUAGAAGUUAUUUGACUCCUGGUGAUUCUUCUUCAGGUUGGACAGCUGGUGCUGCAGCUUAUUAUGUGGGUUAUCUUCAACCUAGGACUUUUCUAUUAAAAUAUAAUGAAAAUGGAACCAUUACAGAUGCUGUAGACUGUGCACUUGACCCUCUCUCAGAAACAAAGUGUACGUUGAAAUCCUUCACUGUAGAAAAAGGAAUCUAUCAAACUUCUAACUUUAGAGUCCAACCAACAGAAUCUAUUGUUAGAUUUCCUAAUAUUACAAACUUGUGCCCUUUUGGUGAAGUUUUUAACGCCACCAGAUUUGCAUCUGUUUAUGCUUGGAACAGGAAGAGAAUCAGCAACUGUGUUGCUGAUUAUUCUGUCCUAUAUAAUUCCGCAUCAUUUUCCACUUUUAAGUGUUAUGGAGUGUCUCCUACUAAAUUAAAUGAUCUCUGCUUUACUAAUGUCUAUGCAGAUUCAUUUGUAAUUAGAGGUGAUGAAGUCAGACAAAUCGCUCCAGGGCAAACUGGAAAGAUUGCUGAUUAUAAUUAUAAAUUACCAGAUGAUUUUACAGGCUGCGUUAUAGCUUGGAAUUCUAACAAUCUUGAUUCUAAGGUUGGUGGUAAUUAUAAUUACCUGUAUAGAUUGUUUAGGAAGUCUAAUCUCAAACCUUUUGAGAGAGAUAUUUCAACUGAAAUCUAUCAGGCCGGUAGCACACCUUGUAAUGGUGUUGAAGGUUUUAAUUGUUACUUUCCUUUACAAUCAUAUGGUUUCCAACCCACUAAUGGUGUUGGUUACCAACCAUACAGAGUAGUAGUACUUUCUUUUGAACUUCUACAUGCACCAGCAACUGUUUGUGGACCUAAAAAGUCUACUAAUUUGGUUAAAAACAAAUGUGUCAAUUUCAACUUCAAUGGUUUAACAGGCACAGGUGUUCUUACUGAGUCUAACAAAAAGUUUCUGCCUUUCCAACAAUUUGGCAGAGACAUUGCUGACACUACUGAUGCUGUCCGUGAUCCACAGACACUUGAGAUUCUUGACAUUACACCAUGUUCUUUUGGUGGUGUCAGUGUUAUAACACCAGGAACAAAUACUUCUAACCAGGUUGCUGUUCUUUAUCAGGAUGUUAACUGCACAGAAGUCCCUGUUGCUAUUCAUGCAGAUCAACUUACUCCUACUUGGCGUGUUUAUUCUACAGGUUCUAAUGUUUUUCAAACACGUGCAGGCUGUUUAAUAGGGGCUGAACAUGUCAACAACUCAUAUGAGUGUGACAUACCCAUUGGUGCAGGUAUAUGCGCUAGUUAUCAGACUCAGACUAAUUCUCCUCGGCGGGCACGUAGUGUAGCUAGUCAAUCCAUCAUUGCCUACACUAUGUCACUUGGUGCAGAAAAUUCAGUUGCUUACUCUAAUAACUCUAUUGCCAUACCCACAAAUUUUACUAUUAGUGUUACCACAGAAAUUCUACCAGUGUCUAUGACCAAGACAUCAGUAGAUUGUACAAUGUACAUUUGUGGUGAUUCAACUGAAUGCAGCAAUCUUUUGUUGCAAUAUGGCAGUUUUUGUACACAAUUAAACCGUGCUUUAACUGGAAUAGCUGUUGAACAAGACAAAAACACCCAAGAAGUUUUUGCACAAGUCAAACAAAUUUACAAAACACCACCAAUUAAAGAUUUUGGUGGUUUUAAUUUUUCACAAAUAUUACCAGAUCCAUCAAAACCAAGCAAGAGGUCAUUUAUUGAAGAUCUACUUUUCAACAAAGUGACACUUGCAGAUGCUGGCUUCAUCAAACAAUAUGGUGAUUGCCUUGGUGAUAUUGCUGCUAGAGACCUCAUUUGUGCACAAAAGUUUAACGGCCUUACUGUUUUGCCACCUUUGCUCACAGAUGAAAUGAUUGCUCAAUACACUUCUGCACUGUUAGCGGGUACAAUCACUUCUGGUUGGACCUUUGGUGCAGGUGCUGCAUUACAAAUACCAUUUGCUAUGCAAAUGGCUUAUAGGUUUAAUGGUAUUGGAGUUACACAGAAUGUUCUCUAUGAGAACCAAAAAUUGAUUGCCAACCAAUUUAAUAGUGCUAUUGGCAAAAUUCAAGACUCACUUUCUUCCACAGCAAGUGCACUUGGAAAACUUCAAGAUGUGGUCAACCAAAAUGCACAAGCUUUAAACACGCUUGUUAAACAACUUAGCUCCAAUUUUGGUGCAAUUUCAAGUGUUUUAAAUGAUAUCCUUUCACGUCUUGACAAAGUUGAGGCUGAAGUGCAAAUUGAUAGGUUGAUCACAGGCAGACUUCAAAGUUUGCAGACAUAUGUGACUCAACAAUUAAUUAGAGCUGCAGAAAUCAGAGCUUCUGCUAAUCUUGCUGCUACUAAAAUGUCAGAGUGUGUACUUGGACAAUCAAAAAGAGUUGAUUUUUGUGGAAAGGGCUAUCAUCUUAUGUCCUUCCCUCAGUCAGCACCUCAUGGUGUAGUCUUCUUGCAUGUGACUUAUGUCCCUGCACAAGAAAAGAACUUCACAACUGCUCCUGCCAUUUGUCAUGAUGGAAAAGCACACUUUCCUCGUGAAGGUGUCUUUGUUUCAAAUGGCACACACUGGUUUGUAACACAAAGGAAUUUUUAUGAACCACAAAUCAUUACUACAGACAACACAUUUGUGUCUGGUAACUGUGAUGUUGUAAUAGGAAUUGUCAACAACACAGUUUAUGAUCCUUUGCAACCUGAAUUAGACUCAUUCAAGGAGGAGUUAGAUAAAUAUUUUAAGAAUCAUACAUCACCAGAUGUUGAUUUAGGUGACAUCUCUGGCAUUAAUGCUUCAGUUGUAAACAUUCAAAAAGAAAUUGACCGCCUCAAUGAGGUUGCCAAGAAUUUAAAUGAAUCUCUCAUCGAUCUCCAAGAACUUGGAAAGUAUGAGCAGUAUAUAAAAUGGCCAUGGUACAUUUGGCUAGGUUUUAUAGCUGGCUUGAUUGCCAUAGUAAUGGUGACAAUUAUGCUUUGCUGUAUGACCAGUUGCUGUAGUUGUCUCAAGGGCUGUUGUUCUUGUGGAUCCUGCUGCAAAUUUGAUGAAGACGACUCUGAGCCAGUGCUCAAAGGAGUCAAAUUACAUUACACAUAAACGAACUUAUGGAUUUGUUUAUGAGAAUCUUCACAAUUGGAACUGUAACUUUGAAGCAAGGUGAAAUCAAGGAUGCUACUCCUUCAGAUUUUGUUCGCGCUACUGCAACGAUACCGAUACAAGCCUCACUCCCUUUCGGAUGGCUUAUUGUUGGCGUUGCACUUCUUGCUGUUUUUCAGAGCGCUUCCAAAAUCAUAACCCUCAAAAAGAGAUGGCAACUAGCACUCUCCAAGGGUGUUCACUUUGUUUGCAACUUGCUGUUGUUGUUUGUAACAGUUUACUCACACCUUUUGCUCGUUGCUGCUGGCCUUGAAGCCCCUUUUCUCUAUCUUUAUGCUUUAGUCUACUUCUUGCAGAGUAUAAACUUUGUAAGAAUAAUAAUGAGGCUUUGGCUUUGCUGGAAAUGCCGUUCCAAAAACCCAUUACUUUAUGAUGCCAACUAUUUUCUUUGCUGGCAUACUAAUUGUUACGACUAUUGUAUACCUUACAAUAGUGUAACUUCUUCAAUUGUCAUUACUUCAGGUGAUGGCACAACAAGUCCUAUUUCUGAACAUGACUACCAGAUUGGUGGUUAUACUGAAAAAUGGGAAUCUGGAGUAAAAGACUGUGUUGUAUUACACAGUUACUUCACUUCAGACUAUUACCAGCUGUACUCAACUCAAUUGAGUACAGACACUGGUGUUGAACAUGUUACCUUCUUCAUCUACAAUAAAAUUGUUGAUGAGCCUGAAGAACAUGUCCAAAUUCACACAAUCGACGGUUCAUCCGGAGUUGUUAAUCCAGUAAUGGAACCAAUUUAUGAUGAACCGACGACGACUACUAGCGUGCCUUUGUAAGCACAAGCUGAUGAGUACGAACUUAUGUACUCAUUCGUUUCGGAAGAGACAGGUACGUUAAUAGUUAAUAGCGUACUUCUUUUUCUUGCUUUCGUGGUAUUCUUGCUAGUUACACUAGCCAUCCUUACUGCGCUUCGAUUGUGUGCGUACUGCUGCAAUAUUGUUAACGUGAGUCUUGUAAAACCUUCUUUUUACGUUUACUCUCGUGUUAAAAAUCUGAAUUCUUCUAGAGUUCCUGAUCUUCUGGUCUAAACGAACUAAAUAUUAUAUUAGUUUUUCUGUUUGGAACUUUAAUUUUAGCCAUGGCAGAUUCCAACGGUACUAUUACCGUUGAAGAGCUUAAAAAGCUCCUUGAACAAUGGAACCUAGUAAUAGGUUUCCUAUUCCUUACAUGGAUUUGUCUUCUACAAUUUGCCUAUGCCAACAGGAAUAGGUUUUUGUAUAUAAUUAAGUUAAUUUUCCUCUGGCUGUUAUGGCCAGUAACUUUAGCUUGUUUUGUGCUUGCUGCUGUUUACAGAAUAAAUUGGAUCACCGGUGGAAUUGCUAUCGCAAUGGCUUGUCUUGUAGGCUUGAUGUGGCUCAGCUACUUCAUUGCUUCUUUCAGACUGUUUGCGCGUACGCGUUCCAUGUGGUCAUUCAAUCCAGAAACUAACAUUCUUCUCAACGUGCCACUCCAUGGCACUAUUCUGACCAGACCGCUUCUAGAAAGUGAACUCGUAAUCGGAGCUGUGAUCCUUCGUGGACAUCUUCGUAUUGCUGGACACCAUCUAGGACGCUGUGACAUCAAGGACCUGCCUAAAGAAAUCACUGUUGCUACAUCACGAACGCUUUCUUAUUACAAAUUGGGAGCUUCGCAGCGUGUAGCAGGUGACUCAGGUUUUGCUGCAUACAGUCGCUACAGGAUUGGCAACUAUAAAUUAAACACAGACCAUUCCAGUAGCAGUGACAAUAUUGCUUUGCUUGUACAGUAAGUGACAACAGAUGUUUCAUCUCGUUGACUUUCAGGUUACUAUAGCAGAGAUAUUACUAAUUAUUAUGAGGACUUUUAAAGUUUCCAUUUGGAAUCUUGAUUACAUCAUAAACCUCAUAAUUAAAAAUUUAUCUAAGUCACUAACUGAGAAUAAAUAUUCUCAAUUAGAUGAAGAGCAACCAAUGGAGAUUGAUUAAACGAACAUGAAAAUUAUUCUUUUCUUGGCACUGAUAACACUCGCUACUUGUGAGCUUUAUCACUACCAAGAGUGUGUUAGAGGUACAACAGUACUUUUAAAAGAACCUUGCUCUUCUGGAACAUACGAGGGCAAUUCACCAUUUCAUCCUCUAGCUGAUAACAAAUUUGCACUGACUUGCUUUAGCACUCAAUUUGCUUUUGCUUGUCCUGACGGCGUAAAACACGUCUAUCAGUUACGUGCCAGAUCAGUUUCACCUAAACUGUUCAUCAGACAAGAGGAAGUUCAAGAACUUUACUCUCCAAUUUUUCUUAUUGUUGCGGCAAUAGUGUUUAUAACACUUUGCUUCACACUCAAAAGAAAGACAGAAUGAUUGAACUUUCAUUAAUUGACUUCUAUUUGUGCUUUUUAGCCUUUCUGCUAUUCCUUGUUUUAAUUAUGCUUAUUAUCUUUUGGUUCUCACUUGAACUGCAAGAUCAUAAUGAAACUUGUCACGCCUAAACGAACAUGAAAUUUCUUGUUUUCUUAGGAAUCAUCACAACUGUAGCUGCAUUUCACCAAGAAUGUAGUUUACAGUCAUGUACUCAACAUCAACCAUAUGUAGUUGAUGACCCGUGUCCUAUUCACUUCUAUUCUAAAUGGUAUAUUAGAGUAGGAGCUAGAAAAUCAGCACCUUUAAUUGAAUUGUGCGUGGAUGAGGCUGGUUCUAAAUCACCCAUUCAGUACAUCGAUAUCGGUAAUUAUACAGUUUCCUGUUUACCUUUUACAAUUAAUUGCCAGGAACCUAAAUUGGGUAGUCUUGUAGUGCGUUGUUCGUUCUAUGAAGACUUUUUAGAGUAUCAUGACGUUCGUGUUGUUUUAGAUUUCAUCUAAACGAACAAACUAAAAUGUCUGAUAAUGGACCCCAAAAUCAGCGAAAUGCACCCCGCAUUACGUUUGGUGGACCCUCAGAUUCAACUGGCAGUAACCAGAAUGGAGAACGCAGUGGGGCGCGAUCAAAACAACGUCGGCCCCAAGGUUUACCCAAUAAUACUGCGUCUUGGUUCACCGCUCUCACUCAACAUGGCAAGGAAGACCUUAAAUUCCCUCGAGGACAAGGCGUUCCAAUUAACACCAAUAGCAGUCCAGAUGACCAAAUUGGCUACUACCGAAGAGCUACCAGACGAAUUCGUGGUGGUGACGGUAAAAUGAAAGAUCUCAGUCCAAGAUGGUAUUUCUACUACCUAGGAACUGGGCCAGAAGCUGGACUUCCCUAUGGUGCUAACAAAGACGGCAUCAUAUGGGUUGCAACUGAGGGAGCCUUGAAUACACCAAAAGAUCACAUUGGCACCCGCAAUCCUGCUAACAAUGCUGCAAUCGUGCUACAACUUCCUCAAGGAACAACAUUGCCAAAAGGCUUCUACGCAGAAGGGAGCAGAGGCGGCAGUCAAGCCUCUUCUCGUUCCUCAUCACGUAGUCGCAACAGUUCAAGAAAUUCAACUCCAGGCAGCAGUAGGGGAACUUCUCCUGCUAGAAUGGCUGGCAAUGGCGGUGAUGCUGCUCUUGCUUUGCUGCUGCUUGACAGAUUGAACCAGCUUGAGAGCAAAAUGUCUGGUAAAGGCCAACAACAACAAGGCCAAACUGUCACUAAGAAAUCUGCUGCUGAGGCUUCUAAGAAGCCUCGGCAAAAACGUACUGCCACUAAAGCAUACAAUGUAACACAAGCUUUCGGCAGACGUGGUCCAGAACAAACCCAAGGAAAUUUUGGGGACCAGGAACUAAUCAGACAAGGAACUGAUUACAAACAUUGGCCGCAAAUUGCACAAUUUGCCCCCAGCGCUUCAGCGUUCUUCGGAAUGUCGCGCAUUGGCAUGGAAGUCACACCUUCGGGAACGUGGUUGACCUACACAGGUGCCAUCAAAUUGGAUGACAAAGAUCCAAAUUUCAAAGAUCAAGUCAUUUUGCUGAAUAAGCAUAUUGACGCAUACAAAACAUUCCCACCAACAGAGCCUAAAAAGGACAAAAAGAAGAAGGCUGAUGAAACUCAAGCCUUACCGCAGAGACAGAAGAAACAGCAAACUGUGACUCUUCUUCCUGCUGCAGAUUUGGAUGAUUUCUCCAAACAAUUGCAACAAUCCAUGAGCAGUGCUGACUCAACUCAGGCCUAAACUCAUGCAGACCACACAAGGCAGAUGGGCUAUAUAAACGUUUUCGCUUUUCCGUUUACGAUAUAUAGUCUACUCUUGUGCAGAAUGAAUUCUCGUAACUACAUAGCACAAGUAGAUGUAGUUAACUUUAAUCUCACAUAGCAAUCUUUAAUCAGUGUGUAACAUUAGGGAGGACUUGAAAGAGCCACCACAUUUUCACCGAGGCCACGCGGAGUACGAUCGAGUGUACAGUGAACAAUGCUAGGGAGAGCUGCCUAUAUGGAAGAGCCCUAAUGUGUAAAAUUAAUUUUAGUAGUGCUAUCCCCAUGUGAUUUUAAUAGCUUCUUAGGAGAAUGACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|protein_mutation:K375N
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKNADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,protein_mutation:K375N,419aa(1-419),P0DTC9,-,-,"[1-43],[73-102],[145-149],[152-160],[172-215],[235-271],[366-386],[409-419]",-,In vitro,5-20µM[SARS2-NP–VSV K375N];|200nM[SARS-CoV-2],"15 mM NaCl, 135 mM KCl, 5 mM phosphate, 1.5 mM MgCl2","20 mM Tris–HCl, pH 7.0",37˚C,-,other_molecular:1 mg ml−1 BSA,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"To test whether these viral mutations induce changes in the phase separation of SARS2-NP , we incubated fluorescently labelled K375N and K375E with viral RNA and compared the micrometre-sized liquid droplet formation with that of SARS2-NP WT. Both the K375N and K375E mutants seemed to have compromised LLPS "
704,PMID: 34239064,RNAPS0000450,https://pubmed.ncbi.nlm.nih.gov/34239064,RNA + protein,-,-,SARS-CoV-2 virus RNA,29903nt(1-29903),AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGCACCUCAUGGUCAUGUUAUGGUUGAGCUGGUAGCAGAACUCGAAGGCAUUCAGUACGGUCGUAGUGGUGAGACACUUGGUGUCCUUGUCCCUCAUGUGGGCGAAAUACCAGUGGCUUACCGCAAGGUUCUUCUUCGUAAGAACGGUAAUAAAGGAGCUGGUGGCCAUAGUUACGGCGCCGAUCUAAAGUCAUUUGACUUAGGCGACGAGCUUGGCACUGAUCCUUAUGAAGAUUUUCAAGAAAACUGGAACACUAAACAUAGCAGUGGUGUUACCCGUGAACUCAUGCGUGAGCUUAACGGAGGGGCAUACACUCGCUAUGUCGAUAACAACUUCUGUGGCCCUGAUGGCUACCCUCUUGAGUGCAUUAAAGACCUUCUAGCACGUGCUGGUAAAGCUUCAUGCACUUUGUCCGAACAACUGGACUUUAUUGACACUAAGAGGGGUGUAUACUGCUGCCGUGAACAUGAGCAUGAAAUUGCUUGGUACACGGAACGUUCUGAAAAGAGCUAUGAAUUGCAGACACCUUUUGAAAUUAAAUUGGCAAAGAAAUUUGACACCUUCAAUGGGGAAUGUCCAAAUUUUGUAUUUCCCUUAAAUUCCAUAAUCAAGACUAUUCAACCAAGGGUUGAAAAGAAAAAGCUUGAUGGCUUUAUGGGUAGAAUUCGAUCUGUCUAUCCAGUUGCGUCACCAAAUGAAUGCAACCAAAUGUGCCUUUCAACUCUCAUGAAGUGUGAUCAUUGUGGUGAAACUUCAUGGCAGACGGGCGAUUUUGUUAAAGCCACUUGCGAAUUUUGUGGCACUGAGAAUUUGACUAAAGAAGGUGCCACUACUUGUGGUUACUUACCCCAAAAUGCUGUUGUUAAAAUUUAUUGUCCAGCAUGUCACAAUUCAGAAGUAGGACCUGAGCAUAGUCUUGCCGAAUACCAUAAUGAAUCUGGCUUGAAAACCAUUCUUCGUAAGGGUGGUCGCACUAUUGCCUUUGGAGGCUGUGUGUUCUCUUAUGUUGGUUGCCAUAACAAGUGUGCCUAUUGGGUUCCACGUGCUAGCGCUAACAUAGGUUGUAACCAUACAGGUGUUGUUGGAGAAGGUUCCGAAGGUCUUAAUGACAACCUUCUUGAAAUACUCCAAAAAGAGAAAGUCAACAUCAAUAUUGUUGGUGACUUUAAACUUAAUGAAGAGAUCGCCAUUAUUUUGGCAUCUUUUUCUGCUUCCACAAGUGCUUUUGUGGAAACUGUGAAAGGUUUGGAUUAUAAAGCAUUCAAACAAAUUGUUGAAUCCUGUGGUAAUUUUAAAGUUACAAAAGGAAAAGCUAAAAAAGGUGCCUGGAAUAUUGGUGAACAGAAAUCAAUACUGAGUCCUCUUUAUGCAUUUGCAUCAGAGGCUGCUCGUGUUGUACGAUCAAUUUUCUCCCGCACUCUUGAAACUGCUCAAAAUUCUGUGCGUGUUUUACAGAAGGCCGCUAUAACAAUACUAGAUGGAAUUUCACAGUAUUCACUGAGACUCAUUGAUGCUAUGAUGUUCACAUCUGAUUUGGCUACUAACAAUCUAGUUGUAAUGGCCUACAUUACAGGUGGUGUUGUUCAGUUGACUUCGCAGUGGCUAACUAACAUCUUUGGCACUGUUUAUGAAAAACUCAAACCCGUCCUUGAUUGGCUUGAAGAGAAGUUUAAGGAAGGUGUAGAGUUUCUUAGAGACGGUUGGGAAAUUGUUAAAUUUAUCUCAACCUGUGCUUGUGAAAUUGUCGGUGGACAAAUUGUCACCUGUGCAAAGGAAAUUAAGGAGAGUGUUCAGACAUUCUUUAAGCUUGUAAAUAAAUUUUUGGCUUUGUGUGCUGACUCUAUCAUUAUUGGUGGAGCUAAACUUAAAGCCUUGAAUUUAGGUGAAACAUUUGUCACGCACUCAAAGGGAUUGUACAGAAAGUGUGUUAAAUCCAGAGAAGAAACUGGCCUACUCAUGCCUCUAAAAGCCCCAAAAGAAAUUAUCUUCUUAGAGGGAGAAACACUUCCCACAGAAGUGUUAACAGAGGAAGUUGUCUUGAAAACUGGUGAUUUACAACCAUUAGAACAACCUACUAGUGAAGCUGUUGAAGCUCCAUUGGUUGGUACACCAGUUUGUAUUAACGGGCUUAUGUUGCUCGAAAUCAAAGACACAGAAAAGUACUGUGCCCUUGCACCUAAUAUGAUGGUAACAAACAAUACCUUCACACUCAAAGGCGGUGCACCAACAAAGGUUACUUUUGGUGAUGACACUGUGAUAGAAGUGCAAGGUUACAAGAGUGUGAAUAUCACUUUUGAACUUGAUGAAAGGAUUGAUAAAGUACUUAAUGAGAAGUGCUCUGCCUAUACAGUUGAACUCGGUACAGAAGUAAAUGAGUUCGCCUGUGUUGUGGCAGAUGCUGUCAUAAAAACUUUGCAACCAGUAUCUGAAUUACUUACACCACUGGGCAUUGAUUUAGAUGAGUGGAGUAUGGCUACAUACUACUUAUUUGAUGAGUCUGGUGAGUUUAAAUUGGCUUCACAUAUGUAUUGUUCUUUCUACCCUCCAGAUGAGGAUGAAGAAGAAGGUGAUUGUGAAGAAGAAGAGUUUGAGCCAUCAACUCAAUAUGAGUAUGGUACUGAAGAUGAUUACCAAGGUAAACCUUUGGAAUUUGGUGCCACUUCUGCUGCUCUUCAACCUGAAGAAGAGCAAGAAGAAGAUUGGUUAGAUGAUGAUAGUCAACAAACUGUUGGUCAACAAGACGGCAGUGAGGACAAUCAGACAACUACUAUUCAAACAAUUGUUGAGGUUCAACCUCAAUUAGAGAUGGAACUUACACCAGUUGUUCAGACUAUUGAAGUGAAUAGUUUUAGUGGUUAUUUAAAACUUACUGACAAUGUAUACAUUAAAAAUGCAGACAUUGUGGAAGAAGCUAAAAAGGUAAAACCAACAGUGGUUGUUAAUGCAGCCAAUGUUUACCUUAAACAUGGAGGAGGUGUUGCAGGAGCCUUAAAUAAGGCUACUAACAAUGCCAUGCAAGUUGAAUCUGAUGAUUACAUAGCUACUAAUGGACCACUUAAAGUGGGUGGUAGUUGUGUUUUAAGCGGACACAAUCUUGCUAAACACUGUCUUCAUGUUGUCGGCCCAAAUGUUAACAAAGGUGAAGACAUUCAACUUCUUAAGAGUGCUUAUGAAAAUUUUAAUCAGCACGAAGUUCUACUUGCACCAUUAUUAUCAGCUGGUAUUUUUGGUGCUGACCCUAUACAUUCUUUAAGAGUUUGUGUAGAUACUGUUCGCACAAAUGUCUACUUAGCUGUCUUUGAUAAAAAUCUCUAUGACAAACUUGUUUCAAGCUUUUUGGAAAUGAAGAGUGAAAAGCAAGUUGAACAAAAGAUCGCUGAGAUUCCUAAAGAGGAAGUUAAGCCAUUUAUAACUGAAAGUAAACCUUCAGUUGAACAGAGAAAACAAGAUGAUAAGAAAAUCAAAGCUUGUGUUGAAGAAGUUACAACAACUCUGGAAGAAACUAAGUUCCUCACAGAAAACUUGUUACUUUAUAUUGACAUUAAUGGCAAUCUUCAUCCAGAUUCUGCCACUCUUGUUAGUGACAUUGACAUCACUUUCUUAAAGAAAGAUGCUCCAUAUAUAGUGGGUGAUGUUGUUCAAGAGGGUGUUUUAACUGCUGUGGUUAUACCUACUAAAAAGGCUGGUGGCACUACUGAAAUGCUAGCGAAAGCUUUGAGAAAAGUGCCAACAGACAAUUAUAUAACCACUUACCCGGGUCAGGGUUUAAAUGGUUACACUGUAGAGGAGGCAAAGACAGUGCUUAAAAAGUGUAAAAGUGCCUUUUACAUUCUACCAUCUAUUAUCUCUAAUGAGAAGCAAGAAAUUCUUGGAACUGUUUCUUGGAAUUUGCGAGAAAUGCUUGCACAUGCAGAAGAAACACGCAAAUUAAUGCCUGUCUGUGUGGAAACUAAAGCCAUAGUUUCAACUAUACAGCGUAAAUAUAAGGGUAUUAAAAUACAAGAGGGUGUGGUUGAUUAUGGUGCUAGAUUUUACUUUUACACCAGUAAAACAACUGUAGCGUCACUUAUCAACACACUUAACGAUCUAAAUGAAACUCUUGUUACAAUGCCACUUGGCUAUGUAACACAUGGCUUAAAUUUGGAAGAAGCUGCUCGGUAUAUGAGAUCUCUCAAAGUGCCAGCUACAGUUUCUGUUUCUUCACCUGAUGCUGUUACAGCGUAUAAUGGUUAUCUUACUUCUUCUUCUAAAACACCUGAAGAACAUUUUAUUGAAACCAUCUCACUUGCUGGUUCCUAUAAAGAUUGGUCCUAUUCUGGACAAUCUACACAACUAGGUAUAGAAUUUCUUAAGAGAGGUGAUAAAAGUGUAUAUUACACUAGUAAUCCUACCACAUUCCACCUAGAUGGUGAAGUUAUCACCUUUGACAAUCUUAAGACACUUCUUUCUUUGAGAGAAGUGAGGACUAUUAAGGUGUUUACAACAGUAGACAACAUUAACCUCCACACGCAAGUUGUGGACAUGUCAAUGACAUAUGGACAACAGUUUGGUCCAACUUAUUUGGAUGGAGCUGAUGUUACUAAAAUAAAACCUCAUAAUUCACAUGAAGGUAAAACAUUUUAUGUUUUACCUAAUGAUGACACUCUACGUGUUGAGGCUUUUGAGUACUACCACACAACUGAUCCUAGUUUUCUGGGUAGGUACAUGUCAGCAUUAAAUCACACUAAAAAGUGGAAAUACCCACAAGUUAAUGGUUUAACUUCUAUUAAAUGGGCAGAUAACAACUGUUAUCUUGCCACUGCAUUGUUAACACUCCAACAAAUAGAGUUGAAGUUUAAUCCACCUGCUCUACAAGAUGCUUAUUACAGAGCAAGGGCUGGUGAAGCUGCUAACUUUUGUGCACUUAUCUUAGCCUACUGUAAUAAGACAGUAGGUGAGUUAGGUGAUGUUAGAGAAACAAUGAGUUACUUGUUUCAACAUGCCAAUUUAGAUUCUUGCAAAAGAGUCUUGAACGUGGUGUGUAAAACUUGUGGACAACAGCAGACAACCCUUAAGGGUGUAGAAGCUGUUAUGUACAUGGGCACACUUUCUUAUGAACAAUUUAAGAAAGGUGUUCAGAUACCUUGUACGUGUGGUAAACAAGCUACAAAAUAUCUAGUACAACAGGAGUCACCUUUUGUUAUGAUGUCAGCACCACCUGCUCAGUAUGAACUUAAGCAUGGUACAUUUACUUGUGCUAGUGAGUACACUGGUAAUUACCAGUGUGGUCACUAUAAACAUAUAACUUCUAAAGAAACUUUGUAUUGCAUAGACGGUGCUUUACUUACAAAGUCCUCAGAAUACAAAGGUCCUAUUACGGAUGUUUUCUACAAAGAAAACAGUUACACAACAACCAUAAAACCAGUUACUUAUAAAUUGGAUGGUGUUGUUUGUACAGAAAUUGACCCUAAGUUGGACAAUUAUUAUAAGAAAGACAAUUCUUAUUUCACAGAGCAACCAAUUGAUCUUGUACCAAACCAACCAUAUCCAAACGCAAGCUUCGAUAAUUUUAAGUUUGUAUGUGAUAAUAUCAAAUUUGCUGAUGAUUUAAACCAGUUAACUGGUUAUAAGAAACCUGCUUCAAGAGAGCUUAAAGUUACAUUUUUCCCUGACUUAAAUGGUGAUGUGGUGGCUAUUGAUUAUAAACACUACACACCCUCUUUUAAGAAAGGAGCUAAAUUGUUACAUAAACCUAUUGUUUGGCAUGUUAACAAUGCAACUAAUAAAGCCACGUAUAAACCAAAUACCUGGUGUAUACGUUGUCUUUGGAGCACAAAACCAGUUGAAACAUCAAAUUCGUUUGAUGUACUGAAGUCAGAGGACGCGCAGGGAAUGGAUAAUCUUGCCUGCGAAGAUCUAAAACCAGUCUCUGAAGAAGUAGUGGAAAAUCCUACCAUACAGAAAGACGUUCUUGAGUGUAAUGUGAAAACUACCGAAGUUGUAGGAGACAUUAUACUUAAACCAGCAAAUAAUAGUUUAAAAAUUACAGAAGAGGUUGGCCACACAGAUCUAAUGGCUGCUUAUGUAGACAAUUCUAGUCUUACUAUUAAGAAACCUAAUGAAUUAUCUAGAGUAUUAGGUUUGAAAACCCUUGCUACUCAUGGUUUAGCUGCUGUUAAUAGUGUCCCUUGGGAUACUAUAGCUAAUUAUGCUAAGCCUUUUCUUAACAAAGUUGUUAGUACAACUACUAACAUAGUUACACGGUGUUUAAACCGUGUUUGUACUAAUUAUAUGCCUUAUUUCUUUACUUUAUUGCUACAAUUGUGUACUUUUACUAGAAGUACAAAUUCUAGAAUUAAAGCAUCUAUGCCGACUACUAUAGCAAAGAAUACUGUUAAGAGUGUCGGUAAAUUUUGUCUAGAGGCUUCAUUUAAUUAUUUGAAGUCACCUAAUUUUUCUAAACUGAUAAAUAUUAUAAUUUGGUUUUUACUAUUAAGUGUUUGCCUAGGUUCUUUAAUCUACUCAACCGCUGCUUUAGGUGUUUUAAUGUCUAAUUUAGGCAUGCCUUCUUACUGUACUGGUUACAGAGAAGGCUAUUUGAACUCUACUAAUGUCACUAUUGCAACCUACUGUACUGGUUCUAUACCUUGUAGUGUUUGUCUUAGUGGUUUAGAUUCUUUAGACACCUAUCCUUCUUUAGAAACUAUACAAAUUACCAUUUCAUCUUUUAAAUGGGAUUUAACUGCUUUUGGCUUAGUUGCAGAGUGGUUUUUGGCAUAUAUUCUUUUCACUAGGUUUUUCUAUGUACUUGGAUUGGCUGCAAUCAUGCAAUUGUUUUUCAGCUAUUUUGCAGUACAUUUUAUUAGUAAUUCUUGGCUUAUGUGGUUAAUAAUUAAUCUUGUACAAAUGGCCCCGAUUUCAGCUAUGGUUAGAAUGUACAUCUUCUUUGCAUCAUUUUAUUAUGUAUGGAAAAGUUAUGUGCAUGUUGUAGACGGUUGUAAUUCAUCAACUUGUAUGAUGUGUUACAAACGUAAUAGAGCAACAAGAGUCGAAUGUACAACUAUUGUUAAUGGUGUUAGAAGGUCCUUUUAUGUCUAUGCUAAUGGAGGUAAAGGCUUUUGCAAACUACACAAUUGGAAUUGUGUUAAUUGUGAUACAUUCUGUGCUGGUAGUACAUUUAUUAGUGAUGAAGUUGCGAGAGACUUGUCACUACAGUUUAAAAGACCAAUAAAUCCUACUGACCAGUCUUCUUACAUCGUUGAUAGUGUUACAGUGAAGAAUGGUUCCAUCCAUCUUUACUUUGAUAAAGCUGGUCAAAAGACUUAUGAAAGACAUUCUCUCUCUCAUUUUGUUAACUUAGACAACCUGAGAGCUAAUAACACUAAAGGUUCAUUGCCUAUUAAUGUUAUAGUUUUUGAUGGUAAAUCAAAAUGUGAAGAAUCAUCUGCAAAAUCAGCGUCUGUUUACUACAGUCAGCUUAUGUGUCAACCUAUACUGUUACUAGAUCAGGCAUUAGUGUCUGAUGUUGGUGAUAGUGCGGAAGUUGCAGUUAAAAUGUUUGAUGCUUACGUUAAUACGUUUUCAUCAACUUUUAACGUACCAAUGGAAAAACUCAAAACACUAGUUGCAACUGCAGAAGCUGAACUUGCAAAGAAUGUGUCCUUAGACAAUGUCUUAUCUACUUUUAUUUCAGCAGCUCGGCAAGGGUUUGUUGAUUCAGAUGUAGAAACUAAAGAUGUUGUUGAAUGUCUUAAAUUGUCACAUCAAUCUGACAUAGAAGUUACUGGCGAUAGUUGUAAUAACUAUAUGCUCACCUAUAACAAAGUUGAAAACAUGACACCCCGUGACCUUGGUGCUUGUAUUGACUGUAGUGCGCGUCAUAUUAAUGCGCAGGUAGCAAAAAGUCACAACAUUGCUUUGAUAUGGAACGUUAAAGAUUUCAUGUCAUUGUCUGAACAACUACGAAAACAAAUACGUAGUGCUGCUAAAAAGAAUAACUUACCUUUUAAGUUGACAUGUGCAACUACUAGACAAGUUGUUAAUGUUGUAACAACAAAGAUAGCACUUAAGGGUGGUAAAAUUGUUAAUAAUUGGUUGAAGCAGUUAAUUAAAGUUACACUUGUGUUCCUUUUUGUUGCUGCUAUUUUCUAUUUAAUAACACCUGUUCAUGUCAUGUCUAAACAUACUGACUUUUCAAGUGAAAUCAUAGGAUACAAGGCUAUUGAUGGUGGUGUCACUCGUGACAUAGCAUCUACAGAUACUUGUUUUGCUAACAAACAUGCUGAUUUUGACACAUGGUUUAGCCAGCGUGGUGGUAGUUAUACUAAUGACAAAGCUUGCCCAUUGAUUGCUGCAGUCAUAACAAGAGAAGUGGGUUUUGUCGUGCCUGGUUUGCCUGGCACGAUAUUACGCACAACUAAUGGUGACUUUUUGCAUUUCUUACCUAGAGUUUUUAGUGCAGUUGGUAACAUCUGUUACACACCAUCAAAACUUAUAGAGUACACUGACUUUGCAACAUCAGCUUGUGUUUUGGCUGCUGAAUGUACAAUUUUUAAAGAUGCUUCUGGUAAGCCAGUACCAUAUUGUUAUGAUACCAAUGUACUAGAAGGUUCUGUUGCUUAUGAAAGUUUACGCCCUGACACACGUUAUGUGCUCAUGGAUGGCUCUAUUAUUCAAUUUCCUAACACCUACCUUGAAGGUUCUGUUAGAGUGGUAACAACUUUUGAUUCUGAGUACUGUAGGCACGGCACUUGUGAAAGAUCAGAAGCUGGUGUUUGUGUAUCUACUAGUGGUAGAUGGGUACUUAACAAUGAUUAUUACAGAUCUUUACCAGGAGUUUUCUGUGGUGUAGAUGCUGUAAAUUUACUUACUAAUAUGUUUACACCACUAAUUCAACCUAUUGGUGCUUUGGACAUAUCAGCAUCUAUAGUAGCUGGUGGUAUUGUAGCUAUCGUAGUAACAUGCCUUGCCUACUAUUUUAUGAGGUUUAGAAGAGCUUUUGGUGAAUACAGUCAUGUAGUUGCCUUUAAUACUUUACUAUUCCUUAUGUCAUUCACUGUACUCUGUUUAACACCAGUUUACUCAUUCUUACCUGGUGUUUAUUCUGUUAUUUACUUGUACUUGACAUUUUAUCUUACUAAUGAUGUUUCUUUUUUAGCACAUAUUCAGUGGAUGGUUAUGUUCACACCUUUAGUACCUUUCUGGAUAACAAUUGCUUAUAUCAUUUGUAUUUCCACAAAGCAUUUCUAUUGGUUCUUUAGUAAUUACCUAAAGAGACGUGUAGUCUUUAAUGGUGUUUCCUUUAGUACUUUUGAAGAAGCUGCGCUGUGCACCUUUUUGUUAAAUAAAGAAAUGUAUCUAAAGUUGCGUAGUGAUGUGCUAUUACCUCUUACGCAAUAUAAUAGAUACUUAGCUCUUUAUAAUAAGUACAAGUAUUUUAGUGGAGCAAUGGAUACAACUAGCUACAGAGAAGCUGCUUGUUGUCAUCUCGCAAAGGCUCUCAAUGACUUCAGUAACUCAGGUUCUGAUGUUCUUUACCAACCACCACAAACCUCUAUCACCUCAGCUGUUUUGCAGAGUGGUUUUAGAAAAAUGGCAUUCCCAUCUGGUAAAGUUGAGGGUUGUAUGGUACAAGUAACUUGUGGUACAACUACACUUAACGGUCUUUGGCUUGAUGACGUAGUUUACUGUCCAAGACAUGUGAUCUGCACCUCUGAAGACAUGCUUAACCCUAAUUAUGAAGAUUUACUCAUUCGUAAGUCUAAUCAUAAUUUCUUGGUACAGGCUGGUAAUGUUCAACUCAGGGUUAUUGGACAUUCUAUGCAAAAUUGUGUACUUAAGCUUAAGGUUGAUACAGCCAAUCCUAAGACACCUAAGUAUAAGUUUGUUCGCAUUCAACCAGGACAGACUUUUUCAGUGUUAGCUUGUUACAAUGGUUCACCAUCUGGUGUUUACCAAUGUGCUAUGAGGCCCAAUUUCACUAUUAAGGGUUCAUUCCUUAAUGGUUCAUGUGGUAGUGUUGGUUUUAACAUAGAUUAUGACUGUGUCUCUUUUUGUUACAUGCACCAUAUGGAAUUACCAACUGGAGUUCAUGCUGGCACAGACUUAGAAGGUAACUUUUAUGGACCUUUUGUUGACAGGCAAACAGCACAAGCAGCUGGUACGGACACAACUAUUACAGUUAAUGUUUUAGCUUGGUUGUACGCUGCUGUUAUAAAUGGAGACAGGUGGUUUCUCAAUCGAUUUACCACAACUCUUAAUGACUUUAACCUUGUGGCUAUGAAGUACAAUUAUGAACCUCUAACACAAGACCAUGUUGACAUACUAGGACCUCUUUCUGCUCAAACUGGAAUUGCCGUUUUAGAUAUGUGUGCUUCAUUAAAAGAAUUACUGCAAAAUGGUAUGAAUGGACGUACCAUAUUGGGUAGUGCUUUAUUAGAAGAUGAAUUUACACCUUUUGAUGUUGUUAGACAAUGCUCAGGUGUUACUUUCCAAAGUGCAGUGAAAAGAACAAUCAAGGGUACACACCACUGGUUGUUACUCACAAUUUUGACUUCACUUUUAGUUUUAGUCCAGAGUACUCAAUGGUCUUUGUUCUUUUUUUUGUAUGAAAAUGCCUUUUUACCUUUUGCUAUGGGUAUUAUUGCUAUGUCUGCUUUUGCAAUGAUGUUUGUCAAACAUAAGCAUGCAUUUCUCUGUUUGUUUUUGUUACCUUCUCUUGCCACUGUAGCUUAUUUUAAUAUGGUCUAUAUGCCUGCUAGUUGGGUGAUGCGUAUUAUGACAUGGUUGGAUAUGGUUGAUACUAGUUUGUCUGGUUUUAAGCUAAAAGACUGUGUUAUGUAUGCAUCAGCUGUAGUGUUACUAAUCCUUAUGACAGCAAGAACUGUGUAUGAUGAUGGUGCUAGGAGAGUGUGGACACUUAUGAAUGUCUUGACACUCGUUUAUAAAGUUUAUUAUGGUAAUGCUUUAGAUCAAGCCAUUUCCAUGUGGGCUCUUAUAAUCUCUGUUACUUCUAACUACUCAGGUGUAGUUACAACUGUCAUGUUUUUGGCCAGAGGUAUUGUUUUUAUGUGUGUUGAGUAUUGCCCUAUUUUCUUCAUAACUGGUAAUACACUUCAGUGUAUAAUGCUAGUUUAUUGUUUCUUAGGCUAUUUUUGUACUUGUUACUUUGGCCUCUUUUGUUUACUCAACCGCUACUUUAGACUGACUCUUGGUGUUUAUGAUUACUUAGUUUCUACACAGGAGUUUAGAUAUAUGAAUUCACAGGGACUACUCCCACCCAAGAAUAGCAUAGAUGCCUUCAAACUCAACAUUAAAUUGUUGGGUGUUGGUGGCAAACCUUGUAUCAAAGUAGCCACUGUACAGUCUAAAAUGUCAGAUGUAAAGUGCACAUCAGUAGUCUUACUCUCAGUUUUGCAACAACUCAGAGUAGAAUCAUCAUCUAAAUUGUGGGCUCAAUGUGUCCAGUUACACAAUGACAUUCUCUUAGCUAAAGAUACUACUGAAGCCUUUGAAAAAAUGGUUUCACUACUUUCUGUUUUGCUUUCCAUGCAGGGUGCUGUAGACAUAAACAAGCUUUGUGAAGAAAUGCUGGACAACAGGGCAACCUUACAAGCUAUAGCCUCAGAGUUUAGUUCCCUUCCAUCAUAUGCAGCUUUUGCUACUGCUCAAGAAGCUUAUGAGCAGGCUGUUGCUAAUGGUGAUUCUGAAGUUGUUCUUAAAAAGUUGAAGAAGUCUUUGAAUGUGGCUAAAUCUGAAUUUGACCGUGAUGCAGCCAUGCAACGUAAGUUGGAAAAGAUGGCUGAUCAAGCUAUGACCCAAAUGUAUAAACAGGCUAGAUCUGAGGACAAGAGGGCAAAAGUUACUAGUGCUAUGCAGACAAUGCUUUUCACUAUGCUUAGAAAGUUGGAUAAUGAUGCACUCAACAACAUUAUCAACAAUGCAAGAGAUGGUUGUGUUCCCUUGAACAUAAUACCUCUUACAACAGCAGCCAAACUAAUGGUUGUCAUACCAGACUAUAACACAUAUAAAAAUACGUGUGAUGGUACAACAUUUACUUAUGCAUCAGCAUUGUGGGAAAUCCAACAGGUUGUAGAUGCAGAUAGUAAAAUUGUUCAACUUAGUGAAAUUAGUAUGGACAAUUCACCUAAUUUAGCAUGGCCUCUUAUUGUAACAGCUUUAAGGGCCAAUUCUGCUGUCAAAUUACAGAAUAAUGAGCUUAGUCCUGUUGCACUACGACAGAUGUCUUGUGCUGCCGGUACUACACAAACUGCUUGCACUGAUGACAAUGCGUUAGCUUACUACAACACAACAAAGGGAGGUAGGUUUGUACUUGCACUGUUAUCCGAUUUACAGGAUUUGAAAUGGGCUAGAUUCCCUAAGAGUGAUGGAACUGGUACUAUCUAUACAGAACUGGAACCACCUUGUAGGUUUGUUACAGACACACCUAAAGGUCCUAAAGUGAAGUAUUUAUACUUUAUUAAAGGAUUAAACAACCUAAAUAGAGGUAUGGUACUUGGUAGUUUAGCUGCCACAGUACGUCUACAAGCUGGUAAUGCAACAGAAGUGCCUGCCAAUUCAACUGUAUUAUCUUUCUGUGCUUUUGCUGUAGAUGCUGCUAAAGCUUACAAAGAUUAUCUAGCUAGUGGGGGACAACCAAUCACUAAUUGUGUUAAGAUGUUGUGUACACACACUGGUACUGGUCAGGCAAUAACAGUUACACCGGAAGCCAAUAUGGAUCAAGAAUCCUUUGGUGGUGCAUCGUGUUGUCUGUACUGCCGUUGCCACAUAGAUCAUCCAAAUCCUAAAGGAUUUUGUGACUUAAAAGGUAAGUAUGUACAAAUACCUACAACUUGUGCUAAUGACCCUGUGGGUUUUACACUUAAAAACACAGUCUGUACCGUCUGCGGUAUGUGGAAAGGUUAUGGCUGUAGUUGUGAUCAACUCCGCGAACCCAUGCUUCAGUCAGCUGAUGCACAAUCGUUUUUAAACGGGUUUGCGGUGUAAGUGCAGCCCGUCUUACACCGUGCGGCACAGGCACUAGUACUGAUGUCGUAUACAGGGCUUUUGACAUCUACAAUGAUAAAGUAGCUGGUUUUGCUAAAUUCCUAAAAACUAAUUGUUGUCGCUUCCAAGAAAAGGACGAAGAUGACAAUUUAAUUGAUUCUUACUUUGUAGUUAAGAGACACACUUUCUCUAACUACCAACAUGAAGAAACAAUUUAUAAUUUACUUAAGGAUUGUCCAGCUGUUGCUAAACAUGACUUCUUUAAGUUUAGAAUAGACGGUGACAUGGUACCACAUAUAUCACGUCAACGUCUUACUAAAUACACAAUGGCAGACCUCGUCUAUGCUUUAAGGCAUUUUGAUGAAGGUAAUUGUGACACAUUAAAAGAAAUACUUGUCACAUACAAUUGUUGUGAUGAUGAUUAUUUCAAUAAAAAGGACUGGUAUGAUUUUGUAGAAAACCCAGAUAUAUUACGCGUAUACGCCAACUUAGGUGAACGUGUACGCCAAGCUUUGUUAAAAACAGUACAAUUCUGUGAUGCCAUGCGAAAUGCUGGUAUUGUUGGUGUACUGACAUUAGAUAAUCAAGAUCUCAAUGGUAACUGGUAUGAUUUCGGUGAUUUCAUACAAACCACGCCAGGUAGUGGAGUUCCUGUUGUAGAUUCUUAUUAUUCAUUGUUAAUGCCUAUAUUAACCUUGACCAGGGCUUUAACUGCAGAGUCACAUGUUGACACUGACUUAACAAAGCCUUACAUUAAGUGGGAUUUGUUAAAAUAUGACUUCACGGAAGAGAGGUUAAAACUCUUUGACCGUUAUUUUAAAUAUUGGGAUCAGACAUACCACCCAAAUUGUGUUAACUGUUUGGAUGACAGAUGCAUUCUGCAUUGUGCAAACUUUAAUGUUUUAUUCUCUACAGUGUUCCCACCUACAAGUUUUGGACCACUAGUGAGAAAAAUAUUUGUUGAUGGUGUUCCAUUUGUAGUUUCAACUGGAUACCACUUCAGAGAGCUAGGUGUUGUACAUAAUCAGGAUGUAAACUUACAUAGCUCUAGACUUAGUUUUAAGGAAUUACUUGUGUAUGCUGCUGACCCUGCUAUGCACGCUGCUUCUGGUAAUCUAUUACUAGAUAAACGCACUACGUGCUUUUCAGUAGCUGCACUUACUAACAAUGUUGCUUUUCAAACUGUCAAACCCGGUAAUUUUAACAAAGACUUCUAUGACUUUGCUGUGUCUAAGGGUUUCUUUAAGGAAGGAAGUUCUGUUGAAUUAAAACACUUCUUCUUUGCUCAGGAUGGUAAUGCUGCUAUCAGCGAUUAUGACUACUAUCGUUAUAAUCUACCAACAAUGUGUGAUAUCAGACAACUACUAUUUGUAGUUGAAGUUGUUGAUAAGUACUUUGAUUGUUACGAUGGUGGCUGUAUUAAUGCUAACCAAGUCAUCGUCAACAACCUAGACAAAUCAGCUGGUUUUCCAUUUAAUAAAUGGGGUAAGGCUAGACUUUAUUAUGAUUCAAUGAGUUAUGAGGAUCAAGAUGCACUUUUCGCAUAUACAAAACGUAAUGUCAUCCCUACUAUAACUCAAAUGAAUCUUAAGUAUGCCAUUAGUGCAAAGAAUAGAGCUCGCACCGUAGCUGGUGUCUCUAUCUGUAGUACUAUGACCAAUAGACAGUUUCAUCAAAAAUUAUUGAAAUCAAUAGCCGCCACUAGAGGAGCUACUGUAGUAAUUGGAACAAGCAAAUUCUAUGGUGGUUGGCACAACAUGUUAAAAACUGUUUAUAGUGAUGUAGAAAACCCUCACCUUAUGGGUUGGGAUUAUCCUAAAUGUGAUAGAGCCAUGCCUAACAUGCUUAGAAUUAUGGCCUCACUUGUUCUUGCUCGCAAACAUACAACGUGUUGUAGCUUGUCACACCGUUUCUAUAGAUUAGCUAAUGAGUGUGCUCAAGUAUUGAGUGAAAUGGUCAUGUGUGGCGGUUCACUAUAUGUUAAACCAGGUGGAACCUCAUCAGGAGAUGCCACAACUGCUUAUGCUAAUAGUGUUUUUAACAUUUGUCAAGCUGUCACGGCCAAUGUUAAUGCACUUUUAUCUACUGAUGGUAACAAAAUUGCCGAUAAGUAUGUCCGCAAUUUACAACACAGACUUUAUGAGUGUCUCUAUAGAAAUAGAGAUGUUGACACAGACUUUGUGAAUGAGUUUUACGCAUAUUUGCGUAAACAUUUCUCAAUGAUGAUACUCUCUGACGAUGCUGUUGUGUGUUUCAAUAGCACUUAUGCAUCUCAAGGUCUAGUGGCUAGCAUAAAGAACUUUAAGUCAGUUCUUUAUUAUCAAAACAAUGUUUUUAUGUCUGAAGCAAAAUGUUGGACUGAGACUGACCUUACUAAAGGACCUCAUGAAUUUUGCUCUCAACAUACAAUGCUAGUUAAACAGGGUGAUGAUUAUGUGUACCUUCCUUACCCAGAUCCAUCAAGAAUCCUAGGGGCCGGCUGUUUUGUAGAUGAUAUCGUAAAAACAGAUGGUACACUUAUGAUUGAACGGUUCGUGUCUUUAGCUAUAGAUGCUUACCCACUUACUAAACAUCCUAAUCAGGAGUAUGCUGAUGUCUUUCAUUUGUACUUACAAUACAUAAGAAAGCUACAUGAUGAGUUAACAGGACACAUGUUAGACAUGUAUUCUGUUAUGCUUACUAAUGAUAACACUUCAAGGUAUUGGGAACCUGAGUUUUAUGAGGCUAUGUACACACCGCAUACAGUCUUACAGGCUGUUGGGGCUUGUGUUCUUUGCAAUUCACAGACUUCAUUAAGAUGUGGUGCUUGCAUACGUAGACCAUUCUUAUGUUGUAAAUGCUGUUACGACCAUGUCAUAUCAACAUCACAUAAAUUAGUCUUGUCUGUUAAUCCGUAUGUUUGCAAUGCUCCAGGUUGUGAUGUCACAGAUGUGACUCAACUUUACUUAGGAGGUAUGAGCUAUUAUUGUAAAUCACAUAAACCACCCAUUAGUUUUCCAUUGUGUGCUAAUGGACAAGUUUUUGGUUUAUAUAAAAAUACAUGUGUUGGUAGCGAUAAUGUUACUGACUUUAAUGCAAUUGCAACAUGUGACUGGACAAAUGCUGGUGAUUACAUUUUAGCUAACACCUGUACUGAAAGACUCAAGCUUUUUGCAGCAGAAACGCUCAAAGCUACUGAGGAGACAUUUAAACUGUCUUAUGGUAUUGCUACUGUACGUGAAGUGCUGUCUGACAGAGAAUUACAUCUUUCAUGGGAAGUUGGUAAACCUAGACCACCACUUAACCGAAAUUAUGUCUUUACUGGUUAUCGUGUAACUAAAAACAGUAAAGUACAAAUAGGAGAGUACACCUUUGAAAAAGGUGACUAUGGUGAUGCUGUUGUUUACCGAGGUACAACAACUUACAAAUUAAAUGUUGGUGAUUAUUUUGUGCUGACAUCACAUACAGUAAUGCCAUUAAGUGCACCUACACUAGUGCCACAAGAGCACUAUGUUAGAAUUACUGGCUUAUACCCAACACUCAAUAUCUCAGAUGAGUUUUCUAGCAAUGUUGCAAAUUAUCAAAAGGUUGGUAUGCAAAAGUAUUCUACACUCCAGGGACCACCUGGUACUGGUAAGAGUCAUUUUGCUAUUGGCCUAGCUCUCUACUACCCUUCUGCUCGCAUAGUGUAUACAGCUUGCUCUCAUGCCGCUGUUGAUGCACUAUGUGAGAAGGCAUUAAAAUAUUUGCCUAUAGAUAAAUGUAGUAGAAUUAUACCUGCACGUGCUCGUGUAGAGUGUUUUGAUAAAUUCAAAGUGAAUUCAACAUUAGAACAGUAUGUCUUUUGUACUGUAAAUGCAUUGCCUGAGACGACAGCAGAUAUAGUUGUCUUUGAUGAAAUUUCAAUGGCCACAAAUUAUGAUUUGAGUGUUGUCAAUGCCAGAUUACGUGCUAAGCACUAUGUGUACAUUGGCGACCCUGCUCAAUUACCUGCACCACGCACAUUGCUAACUAAGGGCACACUAGAACCAGAAUAUUUCAAUUCAGUGUGUAGACUUAUGAAAACUAUAGGUCCAGACAUGUUCCUCGGAACUUGUCGGCGUUGUCCUGCUGAAAUUGUUGACACUGUGAGUGCUUUGGUUUAUGAUAAUAAGCUUAAAGCACAUAAAGACAAAUCAGCUCAAUGCUUUAAAAUGUUUUAUAAGGGUGUUAUCACGCAUGAUGUUUCAUCUGCAAUUAACAGGCCACAAAUAGGCGUGGUAAGAGAAUUCCUUACACGUAACCCUGCUUGGAGAAAAGCUGUCUUUAUUUCACCUUAUAAUUCACAGAAUGCUGUAGCCUCAAAGAUUUUGGGACUACCAACUCAAACUGUUGAUUCAUCACAGGGCUCAGAAUAUGACUAUGUCAUAUUCACUCAAACCACUGAAACAGCUCACUCUUGUAAUGUAAACAGAUUUAAUGUUGCUAUUACCAGAGCAAAAGUAGGCAUACUUUGCAUAAUGUCUGAUAGAGACCUUUAUGACAAGUUGCAAUUUACAAGUCUUGAAAUUCCACGUAGGAAUGUGGCAACUUUACAAGCUGAAAAUGUAACAGGACUCUUUAAAGAUUGUAGUAAGGUAAUCACUGGGUUACAUCCUACACAGGCACCUACACACCUCAGUGUUGACACUAAAUUCAAAACUGAAGGUUUAUGUGUUGACAUACCUGGCAUACCUAAGGACAUGACCUAUAGAAGACUCAUCUCUAUGAUGGGUUUUAAAAUGAAUUAUCAAGUUAAUGGUUACCCUAACAUGUUUAUCACCCGCGAAGAAGCUAUAAGACAUGUACGUGCAUGGAUUGGCUUCGAUGUCGAGGGGUGUCAUGCUACUAGAGAAGCUGUUGGUACCAAUUUACCUUUACAGCUAGGUUUUUCUACAGGUGUUAACCUAGUUGCUGUACCUACAGGUUAUGUUGAUACACCUAAUAAUACAGAUUUUUCCAGAGUUAGUGCUAAACCACCGCCUGGAGAUCAAUUUAAACACCUCAUACCACUUAUGUACAAAGGACUUCCUUGGAAUGUAGUGCGUAUAAAGAUUGUACAAAUGUUAAGUGACACACUUAAAAAUCUCUCUGACAGAGUCGUAUUUGUCUUAUGGGCACAUGGCUUUGAGUUGACAUCUAUGAAGUAUUUUGUGAAAAUAGGACCUGAGCGCACCUGUUGUCUAUGUGAUAGACGUGCCACAUGCUUUUCCACUGCUUCAGACACUUAUGCCUGUUGGCAUCAUUCUAUUGGAUUUGAUUACGUCUAUAAUCCGUUUAUGAUUGAUGUUCAACAAUGGGGUUUUACAGGUAACCUACAAAGCAACCAUGAUCUGUAUUGUCAAGUCCAUGGUAAUGCACAUGUAGCUAGUUGUGAUGCAAUCAUGACUAGGUGUCUAGCUGUCCACGAGUGCUUUGUUAAGCGUGUUGACUGGACUAUUGAAUAUCCUAUAAUUGGUGAUGAACUGAAGAUUAAUGCGGCUUGUAGAAAGGUUCAACACAUGGUUGUUAAAGCUGCAUUAUUAGCAGACAAAUUCCCAGUUCUUCACGACAUUGGUAACCCUAAAGCUAUUAAGUGUGUACCUCAAGCUGAUGUAGAAUGGAAGUUCUAUGAUGCACAGCCUUGUAGUGACAAAGCUUAUAAAAUAGAAGAAUUAUUCUAUUCUUAUGCCACACAUUCUGACAAAUUCACAGAUGGUGUAUGCCUAUUUUGGAAUUGCAAUGUCGAUAGAUAUCCUGCUAAUUCCAUUGUUUGUAGAUUUGACACUAGAGUGCUAUCUAACCUUAACUUGCCUGGUUGUGAUGGUGGCAGUUUGUAUGUAAAUAAACAUGCAUUCCACACACCAGCUUUUGAUAAAAGUGCUUUUGUUAAUUUAAAACAAUUACCAUUUUUCUAUUACUCUGACAGUCCAUGUGAGUCUCAUGGAAAACAAGUAGUGUCAGAUAUAGAUUAUGUACCACUAAAGUCUGCUACGUGUAUAACACGUUGCAAUUUAGGUGGUGCUGUCUGUAGACAUCAUGCUAAUGAGUACAGAUUGUAUCUCGAUGCUUAUAACAUGAUGAUCUCAGCUGGCUUUAGCUUGUGGGUUUACAAACAAUUUGAUACUUAUAACCUCUGGAACACUUUUACAAGACUUCAGAGUUUAGAAAAUGUGGCUUUUAAUGUUGUAAAUAAGGGACACUUUGAUGGACAACAGGGUGAAGUACCAGUUUCUAUCAUUAAUAACACUGUUUACACAAAAGUUGAUGGUGUUGAUGUAGAAUUGUUUGAAAAUAAAACAACAUUACCUGUUAAUGUAGCAUUUGAGCUUUGGGCUAAGCGCAACAUUAAACCAGUACCAGAGGUGAAAAUACUCAAUAAUUUGGGUGUGGACAUUGCUGCUAAUACUGUGAUCUGGGACUACAAAAGAGAUGCUCCAGCACAUAUAUCUACUAUUGGUGUUUGUUCUAUGACUGACAUAGCCAAGAAACCAACUGAAACGAUUUGUGCACCACUCACUGUCUUUUUUGAUGGUAGAGUUGAUGGUCAAGUAGACUUAUUUAGAAAUGCCCGUAAUGGUGUUCUUAUUACAGAAGGUAGUGUUAAAGGUUUACAACCAUCUGUAGGUCCCAAACAAGCUAGUCUUAAUGGAGUCACAUUAAUUGGAGAAGCCGUAAAAACACAGUUCAAUUAUUAUAAGAAAGUUGAUGGUGUUGUCCAACAAUUACCUGAAACUUACUUUACUCAGAGUAGAAAUUUACAAGAAUUUAAACCCAGGAGUCAAAUGGAAAUUGAUUUCUUAGAAUUAGCUAUGGAUGAAUUCAUUGAACGGUAUAAAUUAGAAGGCUAUGCCUUCGAACAUAUCGUUUAUGGAGAUUUUAGUCAUAGUCAGUUAGGUGGUUUACAUCUACUGAUUGGACUAGCUAAACGUUUUAAGGAAUCACCUUUUGAAUUAGAAGAUUUUAUUCCUAUGGACAGUACAGUUAAAAACUAUUUCAUAACAGAUGCGCAAACAGGUUCAUCUAAGUGUGUGUGUUCUGUUAUUGAUUUAUUACUUGAUGAUUUUGUUGAAAUAAUAAAAUCCCAAGAUUUAUCUGUAGUUUCUAAGGUUGUCAAAGUGACUAUUGACUAUACAGAAAUUUCAUUUAUGCUUUGGUGUAAAGAUGGCCAUGUAGAAACAUUUUACCCAAAAUUACAAUCUAGUCAAGCGUGGCAACCGGGUGUUGCUAUGCCUAAUCUUUACAAAAUGCAAAGAAUGCUAUUAGAAAAGUGUGACCUUCAAAAUUAUGGUGAUAGUGCAACAUUACCUAAAGGCAUAAUGAUGAAUGUCGCAAAAUAUACUCAACUGUGUCAAUAUUUAAACACAUUAACAUUAGCUGUACCCUAUAAUAUGAGAGUUAUACAUUUUGGUGCUGGUUCUGAUAAAGGAGUUGCACCAGGUACAGCUGUUUUAAGACAGUGGUUGCCUACGGGUACGCUGCUUGUCGAUUCAGAUCUUAAUGACUUUGUCUCUGAUGCAGAUUCAACUUUGAUUGGUGAUUGUGCAACUGUACAUACAGCUAAUAAAUGGGAUCUCAUUAUUAGUGAUAUGUACGACCCUAAGACUAAAAAUGUUACAAAAGAAAAUGACUCUAAAGAGGGUUUUUUCACUUACAUUUGUGGGUUUAUACAACAAAAGCUAGCUCUUGGAGGUUCCGUGGCUAUAAAGAUAACAGAACAUUCUUGGAAUGCUGAUCUUUAUAAGCUCAUGGGACACUUCGCAUGGUGGACAGCCUUUGUUACUAAUGUGAAUGCGUCAUCAUCUGAAGCAUUUUUAAUUGGAUGUAAUUAUCUUGGCAAACCACGCGAACAAAUAGAUGGUUAUGUCAUGCAUGCAAAUUACAUAUUUUGGAGGAAUACAAAUCCAAUUCAGUUGUCUUCCUAUUCUUUAUUUGACAUGAGUAAAUUUCCCCUUAAAUUAAGGGGUACUGCUGUUAUGUCUUUAAAAGAAGGUCAAAUCAAUGAUAUGAUUUUAUCUCUUCUUAGUAAAGGUAGACUUAUAAUUAGAGAAAACAACAGAGUUGUUAUUUCUAGUGAUGUUCUUGUUAACAACUAAACGAACAAUGUUUGUUUUUCUUGUUUUAUUGCCACUAGUCUCUAGUCAGUGUGUUAAUCUUACAACCAGAACUCAAUUACCCCCUGCAUACACUAAUUCUUUCACACGUGGUGUUUAUUACCCUGACAAAGUUUUCAGAUCCUCAGUUUUACAUUCAACUCAGGACUUGUUCUUACCUUUCUUUUCCAAUGUUACUUGGUUCCAUGCUAUACAUGUCUCUGGGACCAAUGGUACUAAGAGGUUUGAUAACCCUGUCCUACCAUUUAAUGAUGGUGUUUAUUUUGCUUCCACUGAGAAGUCUAACAUAAUAAGAGGCUGGAUUUUUGGUACUACUUUAGAUUCGAAGACCCAGUCCCUACUUAUUGUUAAUAACGCUACUAAUGUUGUUAUUAAAGUCUGUGAAUUUCAAUUUUGUAAUGAUCCAUUUUUGGGUGUUUAUUACCACAAAAACAACAAAAGUUGGAUGGAAAGUGAGUUCAGAGUUUAUUCUAGUGCGAAUAAUUGCACUUUUGAAUAUGUCUCUCAGCCUUUUCUUAUGGACCUUGAAGGAAAACAGGGUAAUUUCAAAAAUCUUAGGGAAUUUGUGUUUAAGAAUAUUGAUGGUUAUUUUAAAAUAUAUUCUAAGCACACGCCUAUUAAUUUAGUGCGUGAUCUCCCUCAGGGUUUUUCGGCUUUAGAACCAUUGGUAGAUUUGCCAAUAGGUAUUAACAUCACUAGGUUUCAAACUUUACUUGCUUUACAUAGAAGUUAUUUGACUCCUGGUGAUUCUUCUUCAGGUUGGACAGCUGGUGCUGCAGCUUAUUAUGUGGGUUAUCUUCAACCUAGGACUUUUCUAUUAAAAUAUAAUGAAAAUGGAACCAUUACAGAUGCUGUAGACUGUGCACUUGACCCUCUCUCAGAAACAAAGUGUACGUUGAAAUCCUUCACUGUAGAAAAAGGAAUCUAUCAAACUUCUAACUUUAGAGUCCAACCAACAGAAUCUAUUGUUAGAUUUCCUAAUAUUACAAACUUGUGCCCUUUUGGUGAAGUUUUUAACGCCACCAGAUUUGCAUCUGUUUAUGCUUGGAACAGGAAGAGAAUCAGCAACUGUGUUGCUGAUUAUUCUGUCCUAUAUAAUUCCGCAUCAUUUUCCACUUUUAAGUGUUAUGGAGUGUCUCCUACUAAAUUAAAUGAUCUCUGCUUUACUAAUGUCUAUGCAGAUUCAUUUGUAAUUAGAGGUGAUGAAGUCAGACAAAUCGCUCCAGGGCAAACUGGAAAGAUUGCUGAUUAUAAUUAUAAAUUACCAGAUGAUUUUACAGGCUGCGUUAUAGCUUGGAAUUCUAACAAUCUUGAUUCUAAGGUUGGUGGUAAUUAUAAUUACCUGUAUAGAUUGUUUAGGAAGUCUAAUCUCAAACCUUUUGAGAGAGAUAUUUCAACUGAAAUCUAUCAGGCCGGUAGCACACCUUGUAAUGGUGUUGAAGGUUUUAAUUGUUACUUUCCUUUACAAUCAUAUGGUUUCCAACCCACUAAUGGUGUUGGUUACCAACCAUACAGAGUAGUAGUACUUUCUUUUGAACUUCUACAUGCACCAGCAACUGUUUGUGGACCUAAAAAGUCUACUAAUUUGGUUAAAAACAAAUGUGUCAAUUUCAACUUCAAUGGUUUAACAGGCACAGGUGUUCUUACUGAGUCUAACAAAAAGUUUCUGCCUUUCCAACAAUUUGGCAGAGACAUUGCUGACACUACUGAUGCUGUCCGUGAUCCACAGACACUUGAGAUUCUUGACAUUACACCAUGUUCUUUUGGUGGUGUCAGUGUUAUAACACCAGGAACAAAUACUUCUAACCAGGUUGCUGUUCUUUAUCAGGAUGUUAACUGCACAGAAGUCCCUGUUGCUAUUCAUGCAGAUCAACUUACUCCUACUUGGCGUGUUUAUUCUACAGGUUCUAAUGUUUUUCAAACACGUGCAGGCUGUUUAAUAGGGGCUGAACAUGUCAACAACUCAUAUGAGUGUGACAUACCCAUUGGUGCAGGUAUAUGCGCUAGUUAUCAGACUCAGACUAAUUCUCCUCGGCGGGCACGUAGUGUAGCUAGUCAAUCCAUCAUUGCCUACACUAUGUCACUUGGUGCAGAAAAUUCAGUUGCUUACUCUAAUAACUCUAUUGCCAUACCCACAAAUUUUACUAUUAGUGUUACCACAGAAAUUCUACCAGUGUCUAUGACCAAGACAUCAGUAGAUUGUACAAUGUACAUUUGUGGUGAUUCAACUGAAUGCAGCAAUCUUUUGUUGCAAUAUGGCAGUUUUUGUACACAAUUAAACCGUGCUUUAACUGGAAUAGCUGUUGAACAAGACAAAAACACCCAAGAAGUUUUUGCACAAGUCAAACAAAUUUACAAAACACCACCAAUUAAAGAUUUUGGUGGUUUUAAUUUUUCACAAAUAUUACCAGAUCCAUCAAAACCAAGCAAGAGGUCAUUUAUUGAAGAUCUACUUUUCAACAAAGUGACACUUGCAGAUGCUGGCUUCAUCAAACAAUAUGGUGAUUGCCUUGGUGAUAUUGCUGCUAGAGACCUCAUUUGUGCACAAAAGUUUAACGGCCUUACUGUUUUGCCACCUUUGCUCACAGAUGAAAUGAUUGCUCAAUACACUUCUGCACUGUUAGCGGGUACAAUCACUUCUGGUUGGACCUUUGGUGCAGGUGCUGCAUUACAAAUACCAUUUGCUAUGCAAAUGGCUUAUAGGUUUAAUGGUAUUGGAGUUACACAGAAUGUUCUCUAUGAGAACCAAAAAUUGAUUGCCAACCAAUUUAAUAGUGCUAUUGGCAAAAUUCAAGACUCACUUUCUUCCACAGCAAGUGCACUUGGAAAACUUCAAGAUGUGGUCAACCAAAAUGCACAAGCUUUAAACACGCUUGUUAAACAACUUAGCUCCAAUUUUGGUGCAAUUUCAAGUGUUUUAAAUGAUAUCCUUUCACGUCUUGACAAAGUUGAGGCUGAAGUGCAAAUUGAUAGGUUGAUCACAGGCAGACUUCAAAGUUUGCAGACAUAUGUGACUCAACAAUUAAUUAGAGCUGCAGAAAUCAGAGCUUCUGCUAAUCUUGCUGCUACUAAAAUGUCAGAGUGUGUACUUGGACAAUCAAAAAGAGUUGAUUUUUGUGGAAAGGGCUAUCAUCUUAUGUCCUUCCCUCAGUCAGCACCUCAUGGUGUAGUCUUCUUGCAUGUGACUUAUGUCCCUGCACAAGAAAAGAACUUCACAACUGCUCCUGCCAUUUGUCAUGAUGGAAAAGCACACUUUCCUCGUGAAGGUGUCUUUGUUUCAAAUGGCACACACUGGUUUGUAACACAAAGGAAUUUUUAUGAACCACAAAUCAUUACUACAGACAACACAUUUGUGUCUGGUAACUGUGAUGUUGUAAUAGGAAUUGUCAACAACACAGUUUAUGAUCCUUUGCAACCUGAAUUAGACUCAUUCAAGGAGGAGUUAGAUAAAUAUUUUAAGAAUCAUACAUCACCAGAUGUUGAUUUAGGUGACAUCUCUGGCAUUAAUGCUUCAGUUGUAAACAUUCAAAAAGAAAUUGACCGCCUCAAUGAGGUUGCCAAGAAUUUAAAUGAAUCUCUCAUCGAUCUCCAAGAACUUGGAAAGUAUGAGCAGUAUAUAAAAUGGCCAUGGUACAUUUGGCUAGGUUUUAUAGCUGGCUUGAUUGCCAUAGUAAUGGUGACAAUUAUGCUUUGCUGUAUGACCAGUUGCUGUAGUUGUCUCAAGGGCUGUUGUUCUUGUGGAUCCUGCUGCAAAUUUGAUGAAGACGACUCUGAGCCAGUGCUCAAAGGAGUCAAAUUACAUUACACAUAAACGAACUUAUGGAUUUGUUUAUGAGAAUCUUCACAAUUGGAACUGUAACUUUGAAGCAAGGUGAAAUCAAGGAUGCUACUCCUUCAGAUUUUGUUCGCGCUACUGCAACGAUACCGAUACAAGCCUCACUCCCUUUCGGAUGGCUUAUUGUUGGCGUUGCACUUCUUGCUGUUUUUCAGAGCGCUUCCAAAAUCAUAACCCUCAAAAAGAGAUGGCAACUAGCACUCUCCAAGGGUGUUCACUUUGUUUGCAACUUGCUGUUGUUGUUUGUAACAGUUUACUCACACCUUUUGCUCGUUGCUGCUGGCCUUGAAGCCCCUUUUCUCUAUCUUUAUGCUUUAGUCUACUUCUUGCAGAGUAUAAACUUUGUAAGAAUAAUAAUGAGGCUUUGGCUUUGCUGGAAAUGCCGUUCCAAAAACCCAUUACUUUAUGAUGCCAACUAUUUUCUUUGCUGGCAUACUAAUUGUUACGACUAUUGUAUACCUUACAAUAGUGUAACUUCUUCAAUUGUCAUUACUUCAGGUGAUGGCACAACAAGUCCUAUUUCUGAACAUGACUACCAGAUUGGUGGUUAUACUGAAAAAUGGGAAUCUGGAGUAAAAGACUGUGUUGUAUUACACAGUUACUUCACUUCAGACUAUUACCAGCUGUACUCAACUCAAUUGAGUACAGACACUGGUGUUGAACAUGUUACCUUCUUCAUCUACAAUAAAAUUGUUGAUGAGCCUGAAGAACAUGUCCAAAUUCACACAAUCGACGGUUCAUCCGGAGUUGUUAAUCCAGUAAUGGAACCAAUUUAUGAUGAACCGACGACGACUACUAGCGUGCCUUUGUAAGCACAAGCUGAUGAGUACGAACUUAUGUACUCAUUCGUUUCGGAAGAGACAGGUACGUUAAUAGUUAAUAGCGUACUUCUUUUUCUUGCUUUCGUGGUAUUCUUGCUAGUUACACUAGCCAUCCUUACUGCGCUUCGAUUGUGUGCGUACUGCUGCAAUAUUGUUAACGUGAGUCUUGUAAAACCUUCUUUUUACGUUUACUCUCGUGUUAAAAAUCUGAAUUCUUCUAGAGUUCCUGAUCUUCUGGUCUAAACGAACUAAAUAUUAUAUUAGUUUUUCUGUUUGGAACUUUAAUUUUAGCCAUGGCAGAUUCCAACGGUACUAUUACCGUUGAAGAGCUUAAAAAGCUCCUUGAACAAUGGAACCUAGUAAUAGGUUUCCUAUUCCUUACAUGGAUUUGUCUUCUACAAUUUGCCUAUGCCAACAGGAAUAGGUUUUUGUAUAUAAUUAAGUUAAUUUUCCUCUGGCUGUUAUGGCCAGUAACUUUAGCUUGUUUUGUGCUUGCUGCUGUUUACAGAAUAAAUUGGAUCACCGGUGGAAUUGCUAUCGCAAUGGCUUGUCUUGUAGGCUUGAUGUGGCUCAGCUACUUCAUUGCUUCUUUCAGACUGUUUGCGCGUACGCGUUCCAUGUGGUCAUUCAAUCCAGAAACUAACAUUCUUCUCAACGUGCCACUCCAUGGCACUAUUCUGACCAGACCGCUUCUAGAAAGUGAACUCGUAAUCGGAGCUGUGAUCCUUCGUGGACAUCUUCGUAUUGCUGGACACCAUCUAGGACGCUGUGACAUCAAGGACCUGCCUAAAGAAAUCACUGUUGCUACAUCACGAACGCUUUCUUAUUACAAAUUGGGAGCUUCGCAGCGUGUAGCAGGUGACUCAGGUUUUGCUGCAUACAGUCGCUACAGGAUUGGCAACUAUAAAUUAAACACAGACCAUUCCAGUAGCAGUGACAAUAUUGCUUUGCUUGUACAGUAAGUGACAACAGAUGUUUCAUCUCGUUGACUUUCAGGUUACUAUAGCAGAGAUAUUACUAAUUAUUAUGAGGACUUUUAAAGUUUCCAUUUGGAAUCUUGAUUACAUCAUAAACCUCAUAAUUAAAAAUUUAUCUAAGUCACUAACUGAGAAUAAAUAUUCUCAAUUAGAUGAAGAGCAACCAAUGGAGAUUGAUUAAACGAACAUGAAAAUUAUUCUUUUCUUGGCACUGAUAACACUCGCUACUUGUGAGCUUUAUCACUACCAAGAGUGUGUUAGAGGUACAACAGUACUUUUAAAAGAACCUUGCUCUUCUGGAACAUACGAGGGCAAUUCACCAUUUCAUCCUCUAGCUGAUAACAAAUUUGCACUGACUUGCUUUAGCACUCAAUUUGCUUUUGCUUGUCCUGACGGCGUAAAACACGUCUAUCAGUUACGUGCCAGAUCAGUUUCACCUAAACUGUUCAUCAGACAAGAGGAAGUUCAAGAACUUUACUCUCCAAUUUUUCUUAUUGUUGCGGCAAUAGUGUUUAUAACACUUUGCUUCACACUCAAAAGAAAGACAGAAUGAUUGAACUUUCAUUAAUUGACUUCUAUUUGUGCUUUUUAGCCUUUCUGCUAUUCCUUGUUUUAAUUAUGCUUAUUAUCUUUUGGUUCUCACUUGAACUGCAAGAUCAUAAUGAAACUUGUCACGCCUAAACGAACAUGAAAUUUCUUGUUUUCUUAGGAAUCAUCACAACUGUAGCUGCAUUUCACCAAGAAUGUAGUUUACAGUCAUGUACUCAACAUCAACCAUAUGUAGUUGAUGACCCGUGUCCUAUUCACUUCUAUUCUAAAUGGUAUAUUAGAGUAGGAGCUAGAAAAUCAGCACCUUUAAUUGAAUUGUGCGUGGAUGAGGCUGGUUCUAAAUCACCCAUUCAGUACAUCGAUAUCGGUAAUUAUACAGUUUCCUGUUUACCUUUUACAAUUAAUUGCCAGGAACCUAAAUUGGGUAGUCUUGUAGUGCGUUGUUCGUUCUAUGAAGACUUUUUAGAGUAUCAUGACGUUCGUGUUGUUUUAGAUUUCAUCUAAACGAACAAACUAAAAUGUCUGAUAAUGGACCCCAAAAUCAGCGAAAUGCACCCCGCAUUACGUUUGGUGGACCCUCAGAUUCAACUGGCAGUAACCAGAAUGGAGAACGCAGUGGGGCGCGAUCAAAACAACGUCGGCCCCAAGGUUUACCCAAUAAUACUGCGUCUUGGUUCACCGCUCUCACUCAACAUGGCAAGGAAGACCUUAAAUUCCCUCGAGGACAAGGCGUUCCAAUUAACACCAAUAGCAGUCCAGAUGACCAAAUUGGCUACUACCGAAGAGCUACCAGACGAAUUCGUGGUGGUGACGGUAAAAUGAAAGAUCUCAGUCCAAGAUGGUAUUUCUACUACCUAGGAACUGGGCCAGAAGCUGGACUUCCCUAUGGUGCUAACAAAGACGGCAUCAUAUGGGUUGCAACUGAGGGAGCCUUGAAUACACCAAAAGAUCACAUUGGCACCCGCAAUCCUGCUAACAAUGCUGCAAUCGUGCUACAACUUCCUCAAGGAACAACAUUGCCAAAAGGCUUCUACGCAGAAGGGAGCAGAGGCGGCAGUCAAGCCUCUUCUCGUUCCUCAUCACGUAGUCGCAACAGUUCAAGAAAUUCAACUCCAGGCAGCAGUAGGGGAACUUCUCCUGCUAGAAUGGCUGGCAAUGGCGGUGAUGCUGCUCUUGCUUUGCUGCUGCUUGACAGAUUGAACCAGCUUGAGAGCAAAAUGUCUGGUAAAGGCCAACAACAACAAGGCCAAACUGUCACUAAGAAAUCUGCUGCUGAGGCUUCUAAGAAGCCUCGGCAAAAACGUACUGCCACUAAAGCAUACAAUGUAACACAAGCUUUCGGCAGACGUGGUCCAGAACAAACCCAAGGAAAUUUUGGGGACCAGGAACUAAUCAGACAAGGAACUGAUUACAAACAUUGGCCGCAAAUUGCACAAUUUGCCCCCAGCGCUUCAGCGUUCUUCGGAAUGUCGCGCAUUGGCAUGGAAGUCACACCUUCGGGAACGUGGUUGACCUACACAGGUGCCAUCAAAUUGGAUGACAAAGAUCCAAAUUUCAAAGAUCAAGUCAUUUUGCUGAAUAAGCAUAUUGACGCAUACAAAACAUUCCCACCAACAGAGCCUAAAAAGGACAAAAAGAAGAAGGCUGAUGAAACUCAAGCCUUACCGCAGAGACAGAAGAAACAGCAAACUGUGACUCUUCUUCCUGCUGCAGAUUUGGAUGAUUUCUCCAAACAAUUGCAACAAUCCAUGAGCAGUGCUGACUCAACUCAGGCCUAAACUCAUGCAGACCACACAAGGCAGAUGGGCUAUAUAAACGUUUUCGCUUUUCCGUUUACGAUAUAUAGUCUACUCUUGUGCAGAAUGAAUUCUCGUAACUACAUAGCACAAGUAGAUGUAGUUAACUUUAAUCUCACAUAGCAAUCUUUAAUCAGUGUGUAACAUUAGGGAGGACUUGAAAGAGCCACCACAUUUUCACCGAGGCCACGCGGAGUACGAUCGAGUGUACAGUGAACAAUGCUAGGGAGAGCUGCCUAUAUGGAAGAGCCCUAAUGUGUAAAAUUAAUUUUAGUAGUGCUAUCCCCAUGUGAUUUUAAUAGCUUCUUAGGAGAAUGACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|protein_mutation:K375E
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKEADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,protein_mutation:K375E,419aa(1-419),P0DTC9,-,-,"[1-43],[73-102],[145-149],[152-160],[172-215],[235-271],[365-388],[409-419]",-,In vitro,5-20µM[SARS2-NP–VSV K375E];|200nM[SARS-CoV-2],"15 mM NaCl, 135 mM KCl, 5 mM phosphate, 1.5 mM MgCl2","20 mM Tris–HCl, pH 7.0",37˚C,-,other_molecular:1 mg ml−1 BSA,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"To test whether these viral mutations induce changes in the phase separation of SARS2-NP , we incubated fluorescently labelled K375N and K375E with viral RNA and compared the micrometre-sized liquid droplet formation with that of SARS2-NP WT. Both the K375N and K375E mutants seemed to have compromised LLPS "
705,PMID: 34239064,RNAPS0000450,https://pubmed.ncbi.nlm.nih.gov/34239064,RNA + protein,-,-,SARS-CoV-2 virus RNA,29903nt(1-29903),AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGCACCUCAUGGUCAUGUUAUGGUUGAGCUGGUAGCAGAACUCGAAGGCAUUCAGUACGGUCGUAGUGGUGAGACACUUGGUGUCCUUGUCCCUCAUGUGGGCGAAAUACCAGUGGCUUACCGCAAGGUUCUUCUUCGUAAGAACGGUAAUAAAGGAGCUGGUGGCCAUAGUUACGGCGCCGAUCUAAAGUCAUUUGACUUAGGCGACGAGCUUGGCACUGAUCCUUAUGAAGAUUUUCAAGAAAACUGGAACACUAAACAUAGCAGUGGUGUUACCCGUGAACUCAUGCGUGAGCUUAACGGAGGGGCAUACACUCGCUAUGUCGAUAACAACUUCUGUGGCCCUGAUGGCUACCCUCUUGAGUGCAUUAAAGACCUUCUAGCACGUGCUGGUAAAGCUUCAUGCACUUUGUCCGAACAACUGGACUUUAUUGACACUAAGAGGGGUGUAUACUGCUGCCGUGAACAUGAGCAUGAAAUUGCUUGGUACACGGAACGUUCUGAAAAGAGCUAUGAAUUGCAGACACCUUUUGAAAUUAAAUUGGCAAAGAAAUUUGACACCUUCAAUGGGGAAUGUCCAAAUUUUGUAUUUCCCUUAAAUUCCAUAAUCAAGACUAUUCAACCAAGGGUUGAAAAGAAAAAGCUUGAUGGCUUUAUGGGUAGAAUUCGAUCUGUCUAUCCAGUUGCGUCACCAAAUGAAUGCAACCAAAUGUGCCUUUCAACUCUCAUGAAGUGUGAUCAUUGUGGUGAAACUUCAUGGCAGACGGGCGAUUUUGUUAAAGCCACUUGCGAAUUUUGUGGCACUGAGAAUUUGACUAAAGAAGGUGCCACUACUUGUGGUUACUUACCCCAAAAUGCUGUUGUUAAAAUUUAUUGUCCAGCAUGUCACAAUUCAGAAGUAGGACCUGAGCAUAGUCUUGCCGAAUACCAUAAUGAAUCUGGCUUGAAAACCAUUCUUCGUAAGGGUGGUCGCACUAUUGCCUUUGGAGGCUGUGUGUUCUCUUAUGUUGGUUGCCAUAACAAGUGUGCCUAUUGGGUUCCACGUGCUAGCGCUAACAUAGGUUGUAACCAUACAGGUGUUGUUGGAGAAGGUUCCGAAGGUCUUAAUGACAACCUUCUUGAAAUACUCCAAAAAGAGAAAGUCAACAUCAAUAUUGUUGGUGACUUUAAACUUAAUGAAGAGAUCGCCAUUAUUUUGGCAUCUUUUUCUGCUUCCACAAGUGCUUUUGUGGAAACUGUGAAAGGUUUGGAUUAUAAAGCAUUCAAACAAAUUGUUGAAUCCUGUGGUAAUUUUAAAGUUACAAAAGGAAAAGCUAAAAAAGGUGCCUGGAAUAUUGGUGAACAGAAAUCAAUACUGAGUCCUCUUUAUGCAUUUGCAUCAGAGGCUGCUCGUGUUGUACGAUCAAUUUUCUCCCGCACUCUUGAAACUGCUCAAAAUUCUGUGCGUGUUUUACAGAAGGCCGCUAUAACAAUACUAGAUGGAAUUUCACAGUAUUCACUGAGACUCAUUGAUGCUAUGAUGUUCACAUCUGAUUUGGCUACUAACAAUCUAGUUGUAAUGGCCUACAUUACAGGUGGUGUUGUUCAGUUGACUUCGCAGUGGCUAACUAACAUCUUUGGCACUGUUUAUGAAAAACUCAAACCCGUCCUUGAUUGGCUUGAAGAGAAGUUUAAGGAAGGUGUAGAGUUUCUUAGAGACGGUUGGGAAAUUGUUAAAUUUAUCUCAACCUGUGCUUGUGAAAUUGUCGGUGGACAAAUUGUCACCUGUGCAAAGGAAAUUAAGGAGAGUGUUCAGACAUUCUUUAAGCUUGUAAAUAAAUUUUUGGCUUUGUGUGCUGACUCUAUCAUUAUUGGUGGAGCUAAACUUAAAGCCUUGAAUUUAGGUGAAACAUUUGUCACGCACUCAAAGGGAUUGUACAGAAAGUGUGUUAAAUCCAGAGAAGAAACUGGCCUACUCAUGCCUCUAAAAGCCCCAAAAGAAAUUAUCUUCUUAGAGGGAGAAACACUUCCCACAGAAGUGUUAACAGAGGAAGUUGUCUUGAAAACUGGUGAUUUACAACCAUUAGAACAACCUACUAGUGAAGCUGUUGAAGCUCCAUUGGUUGGUACACCAGUUUGUAUUAACGGGCUUAUGUUGCUCGAAAUCAAAGACACAGAAAAGUACUGUGCCCUUGCACCUAAUAUGAUGGUAACAAACAAUACCUUCACACUCAAAGGCGGUGCACCAACAAAGGUUACUUUUGGUGAUGACACUGUGAUAGAAGUGCAAGGUUACAAGAGUGUGAAUAUCACUUUUGAACUUGAUGAAAGGAUUGAUAAAGUACUUAAUGAGAAGUGCUCUGCCUAUACAGUUGAACUCGGUACAGAAGUAAAUGAGUUCGCCUGUGUUGUGGCAGAUGCUGUCAUAAAAACUUUGCAACCAGUAUCUGAAUUACUUACACCACUGGGCAUUGAUUUAGAUGAGUGGAGUAUGGCUACAUACUACUUAUUUGAUGAGUCUGGUGAGUUUAAAUUGGCUUCACAUAUGUAUUGUUCUUUCUACCCUCCAGAUGAGGAUGAAGAAGAAGGUGAUUGUGAAGAAGAAGAGUUUGAGCCAUCAACUCAAUAUGAGUAUGGUACUGAAGAUGAUUACCAAGGUAAACCUUUGGAAUUUGGUGCCACUUCUGCUGCUCUUCAACCUGAAGAAGAGCAAGAAGAAGAUUGGUUAGAUGAUGAUAGUCAACAAACUGUUGGUCAACAAGACGGCAGUGAGGACAAUCAGACAACUACUAUUCAAACAAUUGUUGAGGUUCAACCUCAAUUAGAGAUGGAACUUACACCAGUUGUUCAGACUAUUGAAGUGAAUAGUUUUAGUGGUUAUUUAAAACUUACUGACAAUGUAUACAUUAAAAAUGCAGACAUUGUGGAAGAAGCUAAAAAGGUAAAACCAACAGUGGUUGUUAAUGCAGCCAAUGUUUACCUUAAACAUGGAGGAGGUGUUGCAGGAGCCUUAAAUAAGGCUACUAACAAUGCCAUGCAAGUUGAAUCUGAUGAUUACAUAGCUACUAAUGGACCACUUAAAGUGGGUGGUAGUUGUGUUUUAAGCGGACACAAUCUUGCUAAACACUGUCUUCAUGUUGUCGGCCCAAAUGUUAACAAAGGUGAAGACAUUCAACUUCUUAAGAGUGCUUAUGAAAAUUUUAAUCAGCACGAAGUUCUACUUGCACCAUUAUUAUCAGCUGGUAUUUUUGGUGCUGACCCUAUACAUUCUUUAAGAGUUUGUGUAGAUACUGUUCGCACAAAUGUCUACUUAGCUGUCUUUGAUAAAAAUCUCUAUGACAAACUUGUUUCAAGCUUUUUGGAAAUGAAGAGUGAAAAGCAAGUUGAACAAAAGAUCGCUGAGAUUCCUAAAGAGGAAGUUAAGCCAUUUAUAACUGAAAGUAAACCUUCAGUUGAACAGAGAAAACAAGAUGAUAAGAAAAUCAAAGCUUGUGUUGAAGAAGUUACAACAACUCUGGAAGAAACUAAGUUCCUCACAGAAAACUUGUUACUUUAUAUUGACAUUAAUGGCAAUCUUCAUCCAGAUUCUGCCACUCUUGUUAGUGACAUUGACAUCACUUUCUUAAAGAAAGAUGCUCCAUAUAUAGUGGGUGAUGUUGUUCAAGAGGGUGUUUUAACUGCUGUGGUUAUACCUACUAAAAAGGCUGGUGGCACUACUGAAAUGCUAGCGAAAGCUUUGAGAAAAGUGCCAACAGACAAUUAUAUAACCACUUACCCGGGUCAGGGUUUAAAUGGUUACACUGUAGAGGAGGCAAAGACAGUGCUUAAAAAGUGUAAAAGUGCCUUUUACAUUCUACCAUCUAUUAUCUCUAAUGAGAAGCAAGAAAUUCUUGGAACUGUUUCUUGGAAUUUGCGAGAAAUGCUUGCACAUGCAGAAGAAACACGCAAAUUAAUGCCUGUCUGUGUGGAAACUAAAGCCAUAGUUUCAACUAUACAGCGUAAAUAUAAGGGUAUUAAAAUACAAGAGGGUGUGGUUGAUUAUGGUGCUAGAUUUUACUUUUACACCAGUAAAACAACUGUAGCGUCACUUAUCAACACACUUAACGAUCUAAAUGAAACUCUUGUUACAAUGCCACUUGGCUAUGUAACACAUGGCUUAAAUUUGGAAGAAGCUGCUCGGUAUAUGAGAUCUCUCAAAGUGCCAGCUACAGUUUCUGUUUCUUCACCUGAUGCUGUUACAGCGUAUAAUGGUUAUCUUACUUCUUCUUCUAAAACACCUGAAGAACAUUUUAUUGAAACCAUCUCACUUGCUGGUUCCUAUAAAGAUUGGUCCUAUUCUGGACAAUCUACACAACUAGGUAUAGAAUUUCUUAAGAGAGGUGAUAAAAGUGUAUAUUACACUAGUAAUCCUACCACAUUCCACCUAGAUGGUGAAGUUAUCACCUUUGACAAUCUUAAGACACUUCUUUCUUUGAGAGAAGUGAGGACUAUUAAGGUGUUUACAACAGUAGACAACAUUAACCUCCACACGCAAGUUGUGGACAUGUCAAUGACAUAUGGACAACAGUUUGGUCCAACUUAUUUGGAUGGAGCUGAUGUUACUAAAAUAAAACCUCAUAAUUCACAUGAAGGUAAAACAUUUUAUGUUUUACCUAAUGAUGACACUCUACGUGUUGAGGCUUUUGAGUACUACCACACAACUGAUCCUAGUUUUCUGGGUAGGUACAUGUCAGCAUUAAAUCACACUAAAAAGUGGAAAUACCCACAAGUUAAUGGUUUAACUUCUAUUAAAUGGGCAGAUAACAACUGUUAUCUUGCCACUGCAUUGUUAACACUCCAACAAAUAGAGUUGAAGUUUAAUCCACCUGCUCUACAAGAUGCUUAUUACAGAGCAAGGGCUGGUGAAGCUGCUAACUUUUGUGCACUUAUCUUAGCCUACUGUAAUAAGACAGUAGGUGAGUUAGGUGAUGUUAGAGAAACAAUGAGUUACUUGUUUCAACAUGCCAAUUUAGAUUCUUGCAAAAGAGUCUUGAACGUGGUGUGUAAAACUUGUGGACAACAGCAGACAACCCUUAAGGGUGUAGAAGCUGUUAUGUACAUGGGCACACUUUCUUAUGAACAAUUUAAGAAAGGUGUUCAGAUACCUUGUACGUGUGGUAAACAAGCUACAAAAUAUCUAGUACAACAGGAGUCACCUUUUGUUAUGAUGUCAGCACCACCUGCUCAGUAUGAACUUAAGCAUGGUACAUUUACUUGUGCUAGUGAGUACACUGGUAAUUACCAGUGUGGUCACUAUAAACAUAUAACUUCUAAAGAAACUUUGUAUUGCAUAGACGGUGCUUUACUUACAAAGUCCUCAGAAUACAAAGGUCCUAUUACGGAUGUUUUCUACAAAGAAAACAGUUACACAACAACCAUAAAACCAGUUACUUAUAAAUUGGAUGGUGUUGUUUGUACAGAAAUUGACCCUAAGUUGGACAAUUAUUAUAAGAAAGACAAUUCUUAUUUCACAGAGCAACCAAUUGAUCUUGUACCAAACCAACCAUAUCCAAACGCAAGCUUCGAUAAUUUUAAGUUUGUAUGUGAUAAUAUCAAAUUUGCUGAUGAUUUAAACCAGUUAACUGGUUAUAAGAAACCUGCUUCAAGAGAGCUUAAAGUUACAUUUUUCCCUGACUUAAAUGGUGAUGUGGUGGCUAUUGAUUAUAAACACUACACACCCUCUUUUAAGAAAGGAGCUAAAUUGUUACAUAAACCUAUUGUUUGGCAUGUUAACAAUGCAACUAAUAAAGCCACGUAUAAACCAAAUACCUGGUGUAUACGUUGUCUUUGGAGCACAAAACCAGUUGAAACAUCAAAUUCGUUUGAUGUACUGAAGUCAGAGGACGCGCAGGGAAUGGAUAAUCUUGCCUGCGAAGAUCUAAAACCAGUCUCUGAAGAAGUAGUGGAAAAUCCUACCAUACAGAAAGACGUUCUUGAGUGUAAUGUGAAAACUACCGAAGUUGUAGGAGACAUUAUACUUAAACCAGCAAAUAAUAGUUUAAAAAUUACAGAAGAGGUUGGCCACACAGAUCUAAUGGCUGCUUAUGUAGACAAUUCUAGUCUUACUAUUAAGAAACCUAAUGAAUUAUCUAGAGUAUUAGGUUUGAAAACCCUUGCUACUCAUGGUUUAGCUGCUGUUAAUAGUGUCCCUUGGGAUACUAUAGCUAAUUAUGCUAAGCCUUUUCUUAACAAAGUUGUUAGUACAACUACUAACAUAGUUACACGGUGUUUAAACCGUGUUUGUACUAAUUAUAUGCCUUAUUUCUUUACUUUAUUGCUACAAUUGUGUACUUUUACUAGAAGUACAAAUUCUAGAAUUAAAGCAUCUAUGCCGACUACUAUAGCAAAGAAUACUGUUAAGAGUGUCGGUAAAUUUUGUCUAGAGGCUUCAUUUAAUUAUUUGAAGUCACCUAAUUUUUCUAAACUGAUAAAUAUUAUAAUUUGGUUUUUACUAUUAAGUGUUUGCCUAGGUUCUUUAAUCUACUCAACCGCUGCUUUAGGUGUUUUAAUGUCUAAUUUAGGCAUGCCUUCUUACUGUACUGGUUACAGAGAAGGCUAUUUGAACUCUACUAAUGUCACUAUUGCAACCUACUGUACUGGUUCUAUACCUUGUAGUGUUUGUCUUAGUGGUUUAGAUUCUUUAGACACCUAUCCUUCUUUAGAAACUAUACAAAUUACCAUUUCAUCUUUUAAAUGGGAUUUAACUGCUUUUGGCUUAGUUGCAGAGUGGUUUUUGGCAUAUAUUCUUUUCACUAGGUUUUUCUAUGUACUUGGAUUGGCUGCAAUCAUGCAAUUGUUUUUCAGCUAUUUUGCAGUACAUUUUAUUAGUAAUUCUUGGCUUAUGUGGUUAAUAAUUAAUCUUGUACAAAUGGCCCCGAUUUCAGCUAUGGUUAGAAUGUACAUCUUCUUUGCAUCAUUUUAUUAUGUAUGGAAAAGUUAUGUGCAUGUUGUAGACGGUUGUAAUUCAUCAACUUGUAUGAUGUGUUACAAACGUAAUAGAGCAACAAGAGUCGAAUGUACAACUAUUGUUAAUGGUGUUAGAAGGUCCUUUUAUGUCUAUGCUAAUGGAGGUAAAGGCUUUUGCAAACUACACAAUUGGAAUUGUGUUAAUUGUGAUACAUUCUGUGCUGGUAGUACAUUUAUUAGUGAUGAAGUUGCGAGAGACUUGUCACUACAGUUUAAAAGACCAAUAAAUCCUACUGACCAGUCUUCUUACAUCGUUGAUAGUGUUACAGUGAAGAAUGGUUCCAUCCAUCUUUACUUUGAUAAAGCUGGUCAAAAGACUUAUGAAAGACAUUCUCUCUCUCAUUUUGUUAACUUAGACAACCUGAGAGCUAAUAACACUAAAGGUUCAUUGCCUAUUAAUGUUAUAGUUUUUGAUGGUAAAUCAAAAUGUGAAGAAUCAUCUGCAAAAUCAGCGUCUGUUUACUACAGUCAGCUUAUGUGUCAACCUAUACUGUUACUAGAUCAGGCAUUAGUGUCUGAUGUUGGUGAUAGUGCGGAAGUUGCAGUUAAAAUGUUUGAUGCUUACGUUAAUACGUUUUCAUCAACUUUUAACGUACCAAUGGAAAAACUCAAAACACUAGUUGCAACUGCAGAAGCUGAACUUGCAAAGAAUGUGUCCUUAGACAAUGUCUUAUCUACUUUUAUUUCAGCAGCUCGGCAAGGGUUUGUUGAUUCAGAUGUAGAAACUAAAGAUGUUGUUGAAUGUCUUAAAUUGUCACAUCAAUCUGACAUAGAAGUUACUGGCGAUAGUUGUAAUAACUAUAUGCUCACCUAUAACAAAGUUGAAAACAUGACACCCCGUGACCUUGGUGCUUGUAUUGACUGUAGUGCGCGUCAUAUUAAUGCGCAGGUAGCAAAAAGUCACAACAUUGCUUUGAUAUGGAACGUUAAAGAUUUCAUGUCAUUGUCUGAACAACUACGAAAACAAAUACGUAGUGCUGCUAAAAAGAAUAACUUACCUUUUAAGUUGACAUGUGCAACUACUAGACAAGUUGUUAAUGUUGUAACAACAAAGAUAGCACUUAAGGGUGGUAAAAUUGUUAAUAAUUGGUUGAAGCAGUUAAUUAAAGUUACACUUGUGUUCCUUUUUGUUGCUGCUAUUUUCUAUUUAAUAACACCUGUUCAUGUCAUGUCUAAACAUACUGACUUUUCAAGUGAAAUCAUAGGAUACAAGGCUAUUGAUGGUGGUGUCACUCGUGACAUAGCAUCUACAGAUACUUGUUUUGCUAACAAACAUGCUGAUUUUGACACAUGGUUUAGCCAGCGUGGUGGUAGUUAUACUAAUGACAAAGCUUGCCCAUUGAUUGCUGCAGUCAUAACAAGAGAAGUGGGUUUUGUCGUGCCUGGUUUGCCUGGCACGAUAUUACGCACAACUAAUGGUGACUUUUUGCAUUUCUUACCUAGAGUUUUUAGUGCAGUUGGUAACAUCUGUUACACACCAUCAAAACUUAUAGAGUACACUGACUUUGCAACAUCAGCUUGUGUUUUGGCUGCUGAAUGUACAAUUUUUAAAGAUGCUUCUGGUAAGCCAGUACCAUAUUGUUAUGAUACCAAUGUACUAGAAGGUUCUGUUGCUUAUGAAAGUUUACGCCCUGACACACGUUAUGUGCUCAUGGAUGGCUCUAUUAUUCAAUUUCCUAACACCUACCUUGAAGGUUCUGUUAGAGUGGUAACAACUUUUGAUUCUGAGUACUGUAGGCACGGCACUUGUGAAAGAUCAGAAGCUGGUGUUUGUGUAUCUACUAGUGGUAGAUGGGUACUUAACAAUGAUUAUUACAGAUCUUUACCAGGAGUUUUCUGUGGUGUAGAUGCUGUAAAUUUACUUACUAAUAUGUUUACACCACUAAUUCAACCUAUUGGUGCUUUGGACAUAUCAGCAUCUAUAGUAGCUGGUGGUAUUGUAGCUAUCGUAGUAACAUGCCUUGCCUACUAUUUUAUGAGGUUUAGAAGAGCUUUUGGUGAAUACAGUCAUGUAGUUGCCUUUAAUACUUUACUAUUCCUUAUGUCAUUCACUGUACUCUGUUUAACACCAGUUUACUCAUUCUUACCUGGUGUUUAUUCUGUUAUUUACUUGUACUUGACAUUUUAUCUUACUAAUGAUGUUUCUUUUUUAGCACAUAUUCAGUGGAUGGUUAUGUUCACACCUUUAGUACCUUUCUGGAUAACAAUUGCUUAUAUCAUUUGUAUUUCCACAAAGCAUUUCUAUUGGUUCUUUAGUAAUUACCUAAAGAGACGUGUAGUCUUUAAUGGUGUUUCCUUUAGUACUUUUGAAGAAGCUGCGCUGUGCACCUUUUUGUUAAAUAAAGAAAUGUAUCUAAAGUUGCGUAGUGAUGUGCUAUUACCUCUUACGCAAUAUAAUAGAUACUUAGCUCUUUAUAAUAAGUACAAGUAUUUUAGUGGAGCAAUGGAUACAACUAGCUACAGAGAAGCUGCUUGUUGUCAUCUCGCAAAGGCUCUCAAUGACUUCAGUAACUCAGGUUCUGAUGUUCUUUACCAACCACCACAAACCUCUAUCACCUCAGCUGUUUUGCAGAGUGGUUUUAGAAAAAUGGCAUUCCCAUCUGGUAAAGUUGAGGGUUGUAUGGUACAAGUAACUUGUGGUACAACUACACUUAACGGUCUUUGGCUUGAUGACGUAGUUUACUGUCCAAGACAUGUGAUCUGCACCUCUGAAGACAUGCUUAACCCUAAUUAUGAAGAUUUACUCAUUCGUAAGUCUAAUCAUAAUUUCUUGGUACAGGCUGGUAAUGUUCAACUCAGGGUUAUUGGACAUUCUAUGCAAAAUUGUGUACUUAAGCUUAAGGUUGAUACAGCCAAUCCUAAGACACCUAAGUAUAAGUUUGUUCGCAUUCAACCAGGACAGACUUUUUCAGUGUUAGCUUGUUACAAUGGUUCACCAUCUGGUGUUUACCAAUGUGCUAUGAGGCCCAAUUUCACUAUUAAGGGUUCAUUCCUUAAUGGUUCAUGUGGUAGUGUUGGUUUUAACAUAGAUUAUGACUGUGUCUCUUUUUGUUACAUGCACCAUAUGGAAUUACCAACUGGAGUUCAUGCUGGCACAGACUUAGAAGGUAACUUUUAUGGACCUUUUGUUGACAGGCAAACAGCACAAGCAGCUGGUACGGACACAACUAUUACAGUUAAUGUUUUAGCUUGGUUGUACGCUGCUGUUAUAAAUGGAGACAGGUGGUUUCUCAAUCGAUUUACCACAACUCUUAAUGACUUUAACCUUGUGGCUAUGAAGUACAAUUAUGAACCUCUAACACAAGACCAUGUUGACAUACUAGGACCUCUUUCUGCUCAAACUGGAAUUGCCGUUUUAGAUAUGUGUGCUUCAUUAAAAGAAUUACUGCAAAAUGGUAUGAAUGGACGUACCAUAUUGGGUAGUGCUUUAUUAGAAGAUGAAUUUACACCUUUUGAUGUUGUUAGACAAUGCUCAGGUGUUACUUUCCAAAGUGCAGUGAAAAGAACAAUCAAGGGUACACACCACUGGUUGUUACUCACAAUUUUGACUUCACUUUUAGUUUUAGUCCAGAGUACUCAAUGGUCUUUGUUCUUUUUUUUGUAUGAAAAUGCCUUUUUACCUUUUGCUAUGGGUAUUAUUGCUAUGUCUGCUUUUGCAAUGAUGUUUGUCAAACAUAAGCAUGCAUUUCUCUGUUUGUUUUUGUUACCUUCUCUUGCCACUGUAGCUUAUUUUAAUAUGGUCUAUAUGCCUGCUAGUUGGGUGAUGCGUAUUAUGACAUGGUUGGAUAUGGUUGAUACUAGUUUGUCUGGUUUUAAGCUAAAAGACUGUGUUAUGUAUGCAUCAGCUGUAGUGUUACUAAUCCUUAUGACAGCAAGAACUGUGUAUGAUGAUGGUGCUAGGAGAGUGUGGACACUUAUGAAUGUCUUGACACUCGUUUAUAAAGUUUAUUAUGGUAAUGCUUUAGAUCAAGCCAUUUCCAUGUGGGCUCUUAUAAUCUCUGUUACUUCUAACUACUCAGGUGUAGUUACAACUGUCAUGUUUUUGGCCAGAGGUAUUGUUUUUAUGUGUGUUGAGUAUUGCCCUAUUUUCUUCAUAACUGGUAAUACACUUCAGUGUAUAAUGCUAGUUUAUUGUUUCUUAGGCUAUUUUUGUACUUGUUACUUUGGCCUCUUUUGUUUACUCAACCGCUACUUUAGACUGACUCUUGGUGUUUAUGAUUACUUAGUUUCUACACAGGAGUUUAGAUAUAUGAAUUCACAGGGACUACUCCCACCCAAGAAUAGCAUAGAUGCCUUCAAACUCAACAUUAAAUUGUUGGGUGUUGGUGGCAAACCUUGUAUCAAAGUAGCCACUGUACAGUCUAAAAUGUCAGAUGUAAAGUGCACAUCAGUAGUCUUACUCUCAGUUUUGCAACAACUCAGAGUAGAAUCAUCAUCUAAAUUGUGGGCUCAAUGUGUCCAGUUACACAAUGACAUUCUCUUAGCUAAAGAUACUACUGAAGCCUUUGAAAAAAUGGUUUCACUACUUUCUGUUUUGCUUUCCAUGCAGGGUGCUGUAGACAUAAACAAGCUUUGUGAAGAAAUGCUGGACAACAGGGCAACCUUACAAGCUAUAGCCUCAGAGUUUAGUUCCCUUCCAUCAUAUGCAGCUUUUGCUACUGCUCAAGAAGCUUAUGAGCAGGCUGUUGCUAAUGGUGAUUCUGAAGUUGUUCUUAAAAAGUUGAAGAAGUCUUUGAAUGUGGCUAAAUCUGAAUUUGACCGUGAUGCAGCCAUGCAACGUAAGUUGGAAAAGAUGGCUGAUCAAGCUAUGACCCAAAUGUAUAAACAGGCUAGAUCUGAGGACAAGAGGGCAAAAGUUACUAGUGCUAUGCAGACAAUGCUUUUCACUAUGCUUAGAAAGUUGGAUAAUGAUGCACUCAACAACAUUAUCAACAAUGCAAGAGAUGGUUGUGUUCCCUUGAACAUAAUACCUCUUACAACAGCAGCCAAACUAAUGGUUGUCAUACCAGACUAUAACACAUAUAAAAAUACGUGUGAUGGUACAACAUUUACUUAUGCAUCAGCAUUGUGGGAAAUCCAACAGGUUGUAGAUGCAGAUAGUAAAAUUGUUCAACUUAGUGAAAUUAGUAUGGACAAUUCACCUAAUUUAGCAUGGCCUCUUAUUGUAACAGCUUUAAGGGCCAAUUCUGCUGUCAAAUUACAGAAUAAUGAGCUUAGUCCUGUUGCACUACGACAGAUGUCUUGUGCUGCCGGUACUACACAAACUGCUUGCACUGAUGACAAUGCGUUAGCUUACUACAACACAACAAAGGGAGGUAGGUUUGUACUUGCACUGUUAUCCGAUUUACAGGAUUUGAAAUGGGCUAGAUUCCCUAAGAGUGAUGGAACUGGUACUAUCUAUACAGAACUGGAACCACCUUGUAGGUUUGUUACAGACACACCUAAAGGUCCUAAAGUGAAGUAUUUAUACUUUAUUAAAGGAUUAAACAACCUAAAUAGAGGUAUGGUACUUGGUAGUUUAGCUGCCACAGUACGUCUACAAGCUGGUAAUGCAACAGAAGUGCCUGCCAAUUCAACUGUAUUAUCUUUCUGUGCUUUUGCUGUAGAUGCUGCUAAAGCUUACAAAGAUUAUCUAGCUAGUGGGGGACAACCAAUCACUAAUUGUGUUAAGAUGUUGUGUACACACACUGGUACUGGUCAGGCAAUAACAGUUACACCGGAAGCCAAUAUGGAUCAAGAAUCCUUUGGUGGUGCAUCGUGUUGUCUGUACUGCCGUUGCCACAUAGAUCAUCCAAAUCCUAAAGGAUUUUGUGACUUAAAAGGUAAGUAUGUACAAAUACCUACAACUUGUGCUAAUGACCCUGUGGGUUUUACACUUAAAAACACAGUCUGUACCGUCUGCGGUAUGUGGAAAGGUUAUGGCUGUAGUUGUGAUCAACUCCGCGAACCCAUGCUUCAGUCAGCUGAUGCACAAUCGUUUUUAAACGGGUUUGCGGUGUAAGUGCAGCCCGUCUUACACCGUGCGGCACAGGCACUAGUACUGAUGUCGUAUACAGGGCUUUUGACAUCUACAAUGAUAAAGUAGCUGGUUUUGCUAAAUUCCUAAAAACUAAUUGUUGUCGCUUCCAAGAAAAGGACGAAGAUGACAAUUUAAUUGAUUCUUACUUUGUAGUUAAGAGACACACUUUCUCUAACUACCAACAUGAAGAAACAAUUUAUAAUUUACUUAAGGAUUGUCCAGCUGUUGCUAAACAUGACUUCUUUAAGUUUAGAAUAGACGGUGACAUGGUACCACAUAUAUCACGUCAACGUCUUACUAAAUACACAAUGGCAGACCUCGUCUAUGCUUUAAGGCAUUUUGAUGAAGGUAAUUGUGACACAUUAAAAGAAAUACUUGUCACAUACAAUUGUUGUGAUGAUGAUUAUUUCAAUAAAAAGGACUGGUAUGAUUUUGUAGAAAACCCAGAUAUAUUACGCGUAUACGCCAACUUAGGUGAACGUGUACGCCAAGCUUUGUUAAAAACAGUACAAUUCUGUGAUGCCAUGCGAAAUGCUGGUAUUGUUGGUGUACUGACAUUAGAUAAUCAAGAUCUCAAUGGUAACUGGUAUGAUUUCGGUGAUUUCAUACAAACCACGCCAGGUAGUGGAGUUCCUGUUGUAGAUUCUUAUUAUUCAUUGUUAAUGCCUAUAUUAACCUUGACCAGGGCUUUAACUGCAGAGUCACAUGUUGACACUGACUUAACAAAGCCUUACAUUAAGUGGGAUUUGUUAAAAUAUGACUUCACGGAAGAGAGGUUAAAACUCUUUGACCGUUAUUUUAAAUAUUGGGAUCAGACAUACCACCCAAAUUGUGUUAACUGUUUGGAUGACAGAUGCAUUCUGCAUUGUGCAAACUUUAAUGUUUUAUUCUCUACAGUGUUCCCACCUACAAGUUUUGGACCACUAGUGAGAAAAAUAUUUGUUGAUGGUGUUCCAUUUGUAGUUUCAACUGGAUACCACUUCAGAGAGCUAGGUGUUGUACAUAAUCAGGAUGUAAACUUACAUAGCUCUAGACUUAGUUUUAAGGAAUUACUUGUGUAUGCUGCUGACCCUGCUAUGCACGCUGCUUCUGGUAAUCUAUUACUAGAUAAACGCACUACGUGCUUUUCAGUAGCUGCACUUACUAACAAUGUUGCUUUUCAAACUGUCAAACCCGGUAAUUUUAACAAAGACUUCUAUGACUUUGCUGUGUCUAAGGGUUUCUUUAAGGAAGGAAGUUCUGUUGAAUUAAAACACUUCUUCUUUGCUCAGGAUGGUAAUGCUGCUAUCAGCGAUUAUGACUACUAUCGUUAUAAUCUACCAACAAUGUGUGAUAUCAGACAACUACUAUUUGUAGUUGAAGUUGUUGAUAAGUACUUUGAUUGUUACGAUGGUGGCUGUAUUAAUGCUAACCAAGUCAUCGUCAACAACCUAGACAAAUCAGCUGGUUUUCCAUUUAAUAAAUGGGGUAAGGCUAGACUUUAUUAUGAUUCAAUGAGUUAUGAGGAUCAAGAUGCACUUUUCGCAUAUACAAAACGUAAUGUCAUCCCUACUAUAACUCAAAUGAAUCUUAAGUAUGCCAUUAGUGCAAAGAAUAGAGCUCGCACCGUAGCUGGUGUCUCUAUCUGUAGUACUAUGACCAAUAGACAGUUUCAUCAAAAAUUAUUGAAAUCAAUAGCCGCCACUAGAGGAGCUACUGUAGUAAUUGGAACAAGCAAAUUCUAUGGUGGUUGGCACAACAUGUUAAAAACUGUUUAUAGUGAUGUAGAAAACCCUCACCUUAUGGGUUGGGAUUAUCCUAAAUGUGAUAGAGCCAUGCCUAACAUGCUUAGAAUUAUGGCCUCACUUGUUCUUGCUCGCAAACAUACAACGUGUUGUAGCUUGUCACACCGUUUCUAUAGAUUAGCUAAUGAGUGUGCUCAAGUAUUGAGUGAAAUGGUCAUGUGUGGCGGUUCACUAUAUGUUAAACCAGGUGGAACCUCAUCAGGAGAUGCCACAACUGCUUAUGCUAAUAGUGUUUUUAACAUUUGUCAAGCUGUCACGGCCAAUGUUAAUGCACUUUUAUCUACUGAUGGUAACAAAAUUGCCGAUAAGUAUGUCCGCAAUUUACAACACAGACUUUAUGAGUGUCUCUAUAGAAAUAGAGAUGUUGACACAGACUUUGUGAAUGAGUUUUACGCAUAUUUGCGUAAACAUUUCUCAAUGAUGAUACUCUCUGACGAUGCUGUUGUGUGUUUCAAUAGCACUUAUGCAUCUCAAGGUCUAGUGGCUAGCAUAAAGAACUUUAAGUCAGUUCUUUAUUAUCAAAACAAUGUUUUUAUGUCUGAAGCAAAAUGUUGGACUGAGACUGACCUUACUAAAGGACCUCAUGAAUUUUGCUCUCAACAUACAAUGCUAGUUAAACAGGGUGAUGAUUAUGUGUACCUUCCUUACCCAGAUCCAUCAAGAAUCCUAGGGGCCGGCUGUUUUGUAGAUGAUAUCGUAAAAACAGAUGGUACACUUAUGAUUGAACGGUUCGUGUCUUUAGCUAUAGAUGCUUACCCACUUACUAAACAUCCUAAUCAGGAGUAUGCUGAUGUCUUUCAUUUGUACUUACAAUACAUAAGAAAGCUACAUGAUGAGUUAACAGGACACAUGUUAGACAUGUAUUCUGUUAUGCUUACUAAUGAUAACACUUCAAGGUAUUGGGAACCUGAGUUUUAUGAGGCUAUGUACACACCGCAUACAGUCUUACAGGCUGUUGGGGCUUGUGUUCUUUGCAAUUCACAGACUUCAUUAAGAUGUGGUGCUUGCAUACGUAGACCAUUCUUAUGUUGUAAAUGCUGUUACGACCAUGUCAUAUCAACAUCACAUAAAUUAGUCUUGUCUGUUAAUCCGUAUGUUUGCAAUGCUCCAGGUUGUGAUGUCACAGAUGUGACUCAACUUUACUUAGGAGGUAUGAGCUAUUAUUGUAAAUCACAUAAACCACCCAUUAGUUUUCCAUUGUGUGCUAAUGGACAAGUUUUUGGUUUAUAUAAAAAUACAUGUGUUGGUAGCGAUAAUGUUACUGACUUUAAUGCAAUUGCAACAUGUGACUGGACAAAUGCUGGUGAUUACAUUUUAGCUAACACCUGUACUGAAAGACUCAAGCUUUUUGCAGCAGAAACGCUCAAAGCUACUGAGGAGACAUUUAAACUGUCUUAUGGUAUUGCUACUGUACGUGAAGUGCUGUCUGACAGAGAAUUACAUCUUUCAUGGGAAGUUGGUAAACCUAGACCACCACUUAACCGAAAUUAUGUCUUUACUGGUUAUCGUGUAACUAAAAACAGUAAAGUACAAAUAGGAGAGUACACCUUUGAAAAAGGUGACUAUGGUGAUGCUGUUGUUUACCGAGGUACAACAACUUACAAAUUAAAUGUUGGUGAUUAUUUUGUGCUGACAUCACAUACAGUAAUGCCAUUAAGUGCACCUACACUAGUGCCACAAGAGCACUAUGUUAGAAUUACUGGCUUAUACCCAACACUCAAUAUCUCAGAUGAGUUUUCUAGCAAUGUUGCAAAUUAUCAAAAGGUUGGUAUGCAAAAGUAUUCUACACUCCAGGGACCACCUGGUACUGGUAAGAGUCAUUUUGCUAUUGGCCUAGCUCUCUACUACCCUUCUGCUCGCAUAGUGUAUACAGCUUGCUCUCAUGCCGCUGUUGAUGCACUAUGUGAGAAGGCAUUAAAAUAUUUGCCUAUAGAUAAAUGUAGUAGAAUUAUACCUGCACGUGCUCGUGUAGAGUGUUUUGAUAAAUUCAAAGUGAAUUCAACAUUAGAACAGUAUGUCUUUUGUACUGUAAAUGCAUUGCCUGAGACGACAGCAGAUAUAGUUGUCUUUGAUGAAAUUUCAAUGGCCACAAAUUAUGAUUUGAGUGUUGUCAAUGCCAGAUUACGUGCUAAGCACUAUGUGUACAUUGGCGACCCUGCUCAAUUACCUGCACCACGCACAUUGCUAACUAAGGGCACACUAGAACCAGAAUAUUUCAAUUCAGUGUGUAGACUUAUGAAAACUAUAGGUCCAGACAUGUUCCUCGGAACUUGUCGGCGUUGUCCUGCUGAAAUUGUUGACACUGUGAGUGCUUUGGUUUAUGAUAAUAAGCUUAAAGCACAUAAAGACAAAUCAGCUCAAUGCUUUAAAAUGUUUUAUAAGGGUGUUAUCACGCAUGAUGUUUCAUCUGCAAUUAACAGGCCACAAAUAGGCGUGGUAAGAGAAUUCCUUACACGUAACCCUGCUUGGAGAAAAGCUGUCUUUAUUUCACCUUAUAAUUCACAGAAUGCUGUAGCCUCAAAGAUUUUGGGACUACCAACUCAAACUGUUGAUUCAUCACAGGGCUCAGAAUAUGACUAUGUCAUAUUCACUCAAACCACUGAAACAGCUCACUCUUGUAAUGUAAACAGAUUUAAUGUUGCUAUUACCAGAGCAAAAGUAGGCAUACUUUGCAUAAUGUCUGAUAGAGACCUUUAUGACAAGUUGCAAUUUACAAGUCUUGAAAUUCCACGUAGGAAUGUGGCAACUUUACAAGCUGAAAAUGUAACAGGACUCUUUAAAGAUUGUAGUAAGGUAAUCACUGGGUUACAUCCUACACAGGCACCUACACACCUCAGUGUUGACACUAAAUUCAAAACUGAAGGUUUAUGUGUUGACAUACCUGGCAUACCUAAGGACAUGACCUAUAGAAGACUCAUCUCUAUGAUGGGUUUUAAAAUGAAUUAUCAAGUUAAUGGUUACCCUAACAUGUUUAUCACCCGCGAAGAAGCUAUAAGACAUGUACGUGCAUGGAUUGGCUUCGAUGUCGAGGGGUGUCAUGCUACUAGAGAAGCUGUUGGUACCAAUUUACCUUUACAGCUAGGUUUUUCUACAGGUGUUAACCUAGUUGCUGUACCUACAGGUUAUGUUGAUACACCUAAUAAUACAGAUUUUUCCAGAGUUAGUGCUAAACCACCGCCUGGAGAUCAAUUUAAACACCUCAUACCACUUAUGUACAAAGGACUUCCUUGGAAUGUAGUGCGUAUAAAGAUUGUACAAAUGUUAAGUGACACACUUAAAAAUCUCUCUGACAGAGUCGUAUUUGUCUUAUGGGCACAUGGCUUUGAGUUGACAUCUAUGAAGUAUUUUGUGAAAAUAGGACCUGAGCGCACCUGUUGUCUAUGUGAUAGACGUGCCACAUGCUUUUCCACUGCUUCAGACACUUAUGCCUGUUGGCAUCAUUCUAUUGGAUUUGAUUACGUCUAUAAUCCGUUUAUGAUUGAUGUUCAACAAUGGGGUUUUACAGGUAACCUACAAAGCAACCAUGAUCUGUAUUGUCAAGUCCAUGGUAAUGCACAUGUAGCUAGUUGUGAUGCAAUCAUGACUAGGUGUCUAGCUGUCCACGAGUGCUUUGUUAAGCGUGUUGACUGGACUAUUGAAUAUCCUAUAAUUGGUGAUGAACUGAAGAUUAAUGCGGCUUGUAGAAAGGUUCAACACAUGGUUGUUAAAGCUGCAUUAUUAGCAGACAAAUUCCCAGUUCUUCACGACAUUGGUAACCCUAAAGCUAUUAAGUGUGUACCUCAAGCUGAUGUAGAAUGGAAGUUCUAUGAUGCACAGCCUUGUAGUGACAAAGCUUAUAAAAUAGAAGAAUUAUUCUAUUCUUAUGCCACACAUUCUGACAAAUUCACAGAUGGUGUAUGCCUAUUUUGGAAUUGCAAUGUCGAUAGAUAUCCUGCUAAUUCCAUUGUUUGUAGAUUUGACACUAGAGUGCUAUCUAACCUUAACUUGCCUGGUUGUGAUGGUGGCAGUUUGUAUGUAAAUAAACAUGCAUUCCACACACCAGCUUUUGAUAAAAGUGCUUUUGUUAAUUUAAAACAAUUACCAUUUUUCUAUUACUCUGACAGUCCAUGUGAGUCUCAUGGAAAACAAGUAGUGUCAGAUAUAGAUUAUGUACCACUAAAGUCUGCUACGUGUAUAACACGUUGCAAUUUAGGUGGUGCUGUCUGUAGACAUCAUGCUAAUGAGUACAGAUUGUAUCUCGAUGCUUAUAACAUGAUGAUCUCAGCUGGCUUUAGCUUGUGGGUUUACAAACAAUUUGAUACUUAUAACCUCUGGAACACUUUUACAAGACUUCAGAGUUUAGAAAAUGUGGCUUUUAAUGUUGUAAAUAAGGGACACUUUGAUGGACAACAGGGUGAAGUACCAGUUUCUAUCAUUAAUAACACUGUUUACACAAAAGUUGAUGGUGUUGAUGUAGAAUUGUUUGAAAAUAAAACAACAUUACCUGUUAAUGUAGCAUUUGAGCUUUGGGCUAAGCGCAACAUUAAACCAGUACCAGAGGUGAAAAUACUCAAUAAUUUGGGUGUGGACAUUGCUGCUAAUACUGUGAUCUGGGACUACAAAAGAGAUGCUCCAGCACAUAUAUCUACUAUUGGUGUUUGUUCUAUGACUGACAUAGCCAAGAAACCAACUGAAACGAUUUGUGCACCACUCACUGUCUUUUUUGAUGGUAGAGUUGAUGGUCAAGUAGACUUAUUUAGAAAUGCCCGUAAUGGUGUUCUUAUUACAGAAGGUAGUGUUAAAGGUUUACAACCAUCUGUAGGUCCCAAACAAGCUAGUCUUAAUGGAGUCACAUUAAUUGGAGAAGCCGUAAAAACACAGUUCAAUUAUUAUAAGAAAGUUGAUGGUGUUGUCCAACAAUUACCUGAAACUUACUUUACUCAGAGUAGAAAUUUACAAGAAUUUAAACCCAGGAGUCAAAUGGAAAUUGAUUUCUUAGAAUUAGCUAUGGAUGAAUUCAUUGAACGGUAUAAAUUAGAAGGCUAUGCCUUCGAACAUAUCGUUUAUGGAGAUUUUAGUCAUAGUCAGUUAGGUGGUUUACAUCUACUGAUUGGACUAGCUAAACGUUUUAAGGAAUCACCUUUUGAAUUAGAAGAUUUUAUUCCUAUGGACAGUACAGUUAAAAACUAUUUCAUAACAGAUGCGCAAACAGGUUCAUCUAAGUGUGUGUGUUCUGUUAUUGAUUUAUUACUUGAUGAUUUUGUUGAAAUAAUAAAAUCCCAAGAUUUAUCUGUAGUUUCUAAGGUUGUCAAAGUGACUAUUGACUAUACAGAAAUUUCAUUUAUGCUUUGGUGUAAAGAUGGCCAUGUAGAAACAUUUUACCCAAAAUUACAAUCUAGUCAAGCGUGGCAACCGGGUGUUGCUAUGCCUAAUCUUUACAAAAUGCAAAGAAUGCUAUUAGAAAAGUGUGACCUUCAAAAUUAUGGUGAUAGUGCAACAUUACCUAAAGGCAUAAUGAUGAAUGUCGCAAAAUAUACUCAACUGUGUCAAUAUUUAAACACAUUAACAUUAGCUGUACCCUAUAAUAUGAGAGUUAUACAUUUUGGUGCUGGUUCUGAUAAAGGAGUUGCACCAGGUACAGCUGUUUUAAGACAGUGGUUGCCUACGGGUACGCUGCUUGUCGAUUCAGAUCUUAAUGACUUUGUCUCUGAUGCAGAUUCAACUUUGAUUGGUGAUUGUGCAACUGUACAUACAGCUAAUAAAUGGGAUCUCAUUAUUAGUGAUAUGUACGACCCUAAGACUAAAAAUGUUACAAAAGAAAAUGACUCUAAAGAGGGUUUUUUCACUUACAUUUGUGGGUUUAUACAACAAAAGCUAGCUCUUGGAGGUUCCGUGGCUAUAAAGAUAACAGAACAUUCUUGGAAUGCUGAUCUUUAUAAGCUCAUGGGACACUUCGCAUGGUGGACAGCCUUUGUUACUAAUGUGAAUGCGUCAUCAUCUGAAGCAUUUUUAAUUGGAUGUAAUUAUCUUGGCAAACCACGCGAACAAAUAGAUGGUUAUGUCAUGCAUGCAAAUUACAUAUUUUGGAGGAAUACAAAUCCAAUUCAGUUGUCUUCCUAUUCUUUAUUUGACAUGAGUAAAUUUCCCCUUAAAUUAAGGGGUACUGCUGUUAUGUCUUUAAAAGAAGGUCAAAUCAAUGAUAUGAUUUUAUCUCUUCUUAGUAAAGGUAGACUUAUAAUUAGAGAAAACAACAGAGUUGUUAUUUCUAGUGAUGUUCUUGUUAACAACUAAACGAACAAUGUUUGUUUUUCUUGUUUUAUUGCCACUAGUCUCUAGUCAGUGUGUUAAUCUUACAACCAGAACUCAAUUACCCCCUGCAUACACUAAUUCUUUCACACGUGGUGUUUAUUACCCUGACAAAGUUUUCAGAUCCUCAGUUUUACAUUCAACUCAGGACUUGUUCUUACCUUUCUUUUCCAAUGUUACUUGGUUCCAUGCUAUACAUGUCUCUGGGACCAAUGGUACUAAGAGGUUUGAUAACCCUGUCCUACCAUUUAAUGAUGGUGUUUAUUUUGCUUCCACUGAGAAGUCUAACAUAAUAAGAGGCUGGAUUUUUGGUACUACUUUAGAUUCGAAGACCCAGUCCCUACUUAUUGUUAAUAACGCUACUAAUGUUGUUAUUAAAGUCUGUGAAUUUCAAUUUUGUAAUGAUCCAUUUUUGGGUGUUUAUUACCACAAAAACAACAAAAGUUGGAUGGAAAGUGAGUUCAGAGUUUAUUCUAGUGCGAAUAAUUGCACUUUUGAAUAUGUCUCUCAGCCUUUUCUUAUGGACCUUGAAGGAAAACAGGGUAAUUUCAAAAAUCUUAGGGAAUUUGUGUUUAAGAAUAUUGAUGGUUAUUUUAAAAUAUAUUCUAAGCACACGCCUAUUAAUUUAGUGCGUGAUCUCCCUCAGGGUUUUUCGGCUUUAGAACCAUUGGUAGAUUUGCCAAUAGGUAUUAACAUCACUAGGUUUCAAACUUUACUUGCUUUACAUAGAAGUUAUUUGACUCCUGGUGAUUCUUCUUCAGGUUGGACAGCUGGUGCUGCAGCUUAUUAUGUGGGUUAUCUUCAACCUAGGACUUUUCUAUUAAAAUAUAAUGAAAAUGGAACCAUUACAGAUGCUGUAGACUGUGCACUUGACCCUCUCUCAGAAACAAAGUGUACGUUGAAAUCCUUCACUGUAGAAAAAGGAAUCUAUCAAACUUCUAACUUUAGAGUCCAACCAACAGAAUCUAUUGUUAGAUUUCCUAAUAUUACAAACUUGUGCCCUUUUGGUGAAGUUUUUAACGCCACCAGAUUUGCAUCUGUUUAUGCUUGGAACAGGAAGAGAAUCAGCAACUGUGUUGCUGAUUAUUCUGUCCUAUAUAAUUCCGCAUCAUUUUCCACUUUUAAGUGUUAUGGAGUGUCUCCUACUAAAUUAAAUGAUCUCUGCUUUACUAAUGUCUAUGCAGAUUCAUUUGUAAUUAGAGGUGAUGAAGUCAGACAAAUCGCUCCAGGGCAAACUGGAAAGAUUGCUGAUUAUAAUUAUAAAUUACCAGAUGAUUUUACAGGCUGCGUUAUAGCUUGGAAUUCUAACAAUCUUGAUUCUAAGGUUGGUGGUAAUUAUAAUUACCUGUAUAGAUUGUUUAGGAAGUCUAAUCUCAAACCUUUUGAGAGAGAUAUUUCAACUGAAAUCUAUCAGGCCGGUAGCACACCUUGUAAUGGUGUUGAAGGUUUUAAUUGUUACUUUCCUUUACAAUCAUAUGGUUUCCAACCCACUAAUGGUGUUGGUUACCAACCAUACAGAGUAGUAGUACUUUCUUUUGAACUUCUACAUGCACCAGCAACUGUUUGUGGACCUAAAAAGUCUACUAAUUUGGUUAAAAACAAAUGUGUCAAUUUCAACUUCAAUGGUUUAACAGGCACAGGUGUUCUUACUGAGUCUAACAAAAAGUUUCUGCCUUUCCAACAAUUUGGCAGAGACAUUGCUGACACUACUGAUGCUGUCCGUGAUCCACAGACACUUGAGAUUCUUGACAUUACACCAUGUUCUUUUGGUGGUGUCAGUGUUAUAACACCAGGAACAAAUACUUCUAACCAGGUUGCUGUUCUUUAUCAGGAUGUUAACUGCACAGAAGUCCCUGUUGCUAUUCAUGCAGAUCAACUUACUCCUACUUGGCGUGUUUAUUCUACAGGUUCUAAUGUUUUUCAAACACGUGCAGGCUGUUUAAUAGGGGCUGAACAUGUCAACAACUCAUAUGAGUGUGACAUACCCAUUGGUGCAGGUAUAUGCGCUAGUUAUCAGACUCAGACUAAUUCUCCUCGGCGGGCACGUAGUGUAGCUAGUCAAUCCAUCAUUGCCUACACUAUGUCACUUGGUGCAGAAAAUUCAGUUGCUUACUCUAAUAACUCUAUUGCCAUACCCACAAAUUUUACUAUUAGUGUUACCACAGAAAUUCUACCAGUGUCUAUGACCAAGACAUCAGUAGAUUGUACAAUGUACAUUUGUGGUGAUUCAACUGAAUGCAGCAAUCUUUUGUUGCAAUAUGGCAGUUUUUGUACACAAUUAAACCGUGCUUUAACUGGAAUAGCUGUUGAACAAGACAAAAACACCCAAGAAGUUUUUGCACAAGUCAAACAAAUUUACAAAACACCACCAAUUAAAGAUUUUGGUGGUUUUAAUUUUUCACAAAUAUUACCAGAUCCAUCAAAACCAAGCAAGAGGUCAUUUAUUGAAGAUCUACUUUUCAACAAAGUGACACUUGCAGAUGCUGGCUUCAUCAAACAAUAUGGUGAUUGCCUUGGUGAUAUUGCUGCUAGAGACCUCAUUUGUGCACAAAAGUUUAACGGCCUUACUGUUUUGCCACCUUUGCUCACAGAUGAAAUGAUUGCUCAAUACACUUCUGCACUGUUAGCGGGUACAAUCACUUCUGGUUGGACCUUUGGUGCAGGUGCUGCAUUACAAAUACCAUUUGCUAUGCAAAUGGCUUAUAGGUUUAAUGGUAUUGGAGUUACACAGAAUGUUCUCUAUGAGAACCAAAAAUUGAUUGCCAACCAAUUUAAUAGUGCUAUUGGCAAAAUUCAAGACUCACUUUCUUCCACAGCAAGUGCACUUGGAAAACUUCAAGAUGUGGUCAACCAAAAUGCACAAGCUUUAAACACGCUUGUUAAACAACUUAGCUCCAAUUUUGGUGCAAUUUCAAGUGUUUUAAAUGAUAUCCUUUCACGUCUUGACAAAGUUGAGGCUGAAGUGCAAAUUGAUAGGUUGAUCACAGGCAGACUUCAAAGUUUGCAGACAUAUGUGACUCAACAAUUAAUUAGAGCUGCAGAAAUCAGAGCUUCUGCUAAUCUUGCUGCUACUAAAAUGUCAGAGUGUGUACUUGGACAAUCAAAAAGAGUUGAUUUUUGUGGAAAGGGCUAUCAUCUUAUGUCCUUCCCUCAGUCAGCACCUCAUGGUGUAGUCUUCUUGCAUGUGACUUAUGUCCCUGCACAAGAAAAGAACUUCACAACUGCUCCUGCCAUUUGUCAUGAUGGAAAAGCACACUUUCCUCGUGAAGGUGUCUUUGUUUCAAAUGGCACACACUGGUUUGUAACACAAAGGAAUUUUUAUGAACCACAAAUCAUUACUACAGACAACACAUUUGUGUCUGGUAACUGUGAUGUUGUAAUAGGAAUUGUCAACAACACAGUUUAUGAUCCUUUGCAACCUGAAUUAGACUCAUUCAAGGAGGAGUUAGAUAAAUAUUUUAAGAAUCAUACAUCACCAGAUGUUGAUUUAGGUGACAUCUCUGGCAUUAAUGCUUCAGUUGUAAACAUUCAAAAAGAAAUUGACCGCCUCAAUGAGGUUGCCAAGAAUUUAAAUGAAUCUCUCAUCGAUCUCCAAGAACUUGGAAAGUAUGAGCAGUAUAUAAAAUGGCCAUGGUACAUUUGGCUAGGUUUUAUAGCUGGCUUGAUUGCCAUAGUAAUGGUGACAAUUAUGCUUUGCUGUAUGACCAGUUGCUGUAGUUGUCUCAAGGGCUGUUGUUCUUGUGGAUCCUGCUGCAAAUUUGAUGAAGACGACUCUGAGCCAGUGCUCAAAGGAGUCAAAUUACAUUACACAUAAACGAACUUAUGGAUUUGUUUAUGAGAAUCUUCACAAUUGGAACUGUAACUUUGAAGCAAGGUGAAAUCAAGGAUGCUACUCCUUCAGAUUUUGUUCGCGCUACUGCAACGAUACCGAUACAAGCCUCACUCCCUUUCGGAUGGCUUAUUGUUGGCGUUGCACUUCUUGCUGUUUUUCAGAGCGCUUCCAAAAUCAUAACCCUCAAAAAGAGAUGGCAACUAGCACUCUCCAAGGGUGUUCACUUUGUUUGCAACUUGCUGUUGUUGUUUGUAACAGUUUACUCACACCUUUUGCUCGUUGCUGCUGGCCUUGAAGCCCCUUUUCUCUAUCUUUAUGCUUUAGUCUACUUCUUGCAGAGUAUAAACUUUGUAAGAAUAAUAAUGAGGCUUUGGCUUUGCUGGAAAUGCCGUUCCAAAAACCCAUUACUUUAUGAUGCCAACUAUUUUCUUUGCUGGCAUACUAAUUGUUACGACUAUUGUAUACCUUACAAUAGUGUAACUUCUUCAAUUGUCAUUACUUCAGGUGAUGGCACAACAAGUCCUAUUUCUGAACAUGACUACCAGAUUGGUGGUUAUACUGAAAAAUGGGAAUCUGGAGUAAAAGACUGUGUUGUAUUACACAGUUACUUCACUUCAGACUAUUACCAGCUGUACUCAACUCAAUUGAGUACAGACACUGGUGUUGAACAUGUUACCUUCUUCAUCUACAAUAAAAUUGUUGAUGAGCCUGAAGAACAUGUCCAAAUUCACACAAUCGACGGUUCAUCCGGAGUUGUUAAUCCAGUAAUGGAACCAAUUUAUGAUGAACCGACGACGACUACUAGCGUGCCUUUGUAAGCACAAGCUGAUGAGUACGAACUUAUGUACUCAUUCGUUUCGGAAGAGACAGGUACGUUAAUAGUUAAUAGCGUACUUCUUUUUCUUGCUUUCGUGGUAUUCUUGCUAGUUACACUAGCCAUCCUUACUGCGCUUCGAUUGUGUGCGUACUGCUGCAAUAUUGUUAACGUGAGUCUUGUAAAACCUUCUUUUUACGUUUACUCUCGUGUUAAAAAUCUGAAUUCUUCUAGAGUUCCUGAUCUUCUGGUCUAAACGAACUAAAUAUUAUAUUAGUUUUUCUGUUUGGAACUUUAAUUUUAGCCAUGGCAGAUUCCAACGGUACUAUUACCGUUGAAGAGCUUAAAAAGCUCCUUGAACAAUGGAACCUAGUAAUAGGUUUCCUAUUCCUUACAUGGAUUUGUCUUCUACAAUUUGCCUAUGCCAACAGGAAUAGGUUUUUGUAUAUAAUUAAGUUAAUUUUCCUCUGGCUGUUAUGGCCAGUAACUUUAGCUUGUUUUGUGCUUGCUGCUGUUUACAGAAUAAAUUGGAUCACCGGUGGAAUUGCUAUCGCAAUGGCUUGUCUUGUAGGCUUGAUGUGGCUCAGCUACUUCAUUGCUUCUUUCAGACUGUUUGCGCGUACGCGUUCCAUGUGGUCAUUCAAUCCAGAAACUAACAUUCUUCUCAACGUGCCACUCCAUGGCACUAUUCUGACCAGACCGCUUCUAGAAAGUGAACUCGUAAUCGGAGCUGUGAUCCUUCGUGGACAUCUUCGUAUUGCUGGACACCAUCUAGGACGCUGUGACAUCAAGGACCUGCCUAAAGAAAUCACUGUUGCUACAUCACGAACGCUUUCUUAUUACAAAUUGGGAGCUUCGCAGCGUGUAGCAGGUGACUCAGGUUUUGCUGCAUACAGUCGCUACAGGAUUGGCAACUAUAAAUUAAACACAGACCAUUCCAGUAGCAGUGACAAUAUUGCUUUGCUUGUACAGUAAGUGACAACAGAUGUUUCAUCUCGUUGACUUUCAGGUUACUAUAGCAGAGAUAUUACUAAUUAUUAUGAGGACUUUUAAAGUUUCCAUUUGGAAUCUUGAUUACAUCAUAAACCUCAUAAUUAAAAAUUUAUCUAAGUCACUAACUGAGAAUAAAUAUUCUCAAUUAGAUGAAGAGCAACCAAUGGAGAUUGAUUAAACGAACAUGAAAAUUAUUCUUUUCUUGGCACUGAUAACACUCGCUACUUGUGAGCUUUAUCACUACCAAGAGUGUGUUAGAGGUACAACAGUACUUUUAAAAGAACCUUGCUCUUCUGGAACAUACGAGGGCAAUUCACCAUUUCAUCCUCUAGCUGAUAACAAAUUUGCACUGACUUGCUUUAGCACUCAAUUUGCUUUUGCUUGUCCUGACGGCGUAAAACACGUCUAUCAGUUACGUGCCAGAUCAGUUUCACCUAAACUGUUCAUCAGACAAGAGGAAGUUCAAGAACUUUACUCUCCAAUUUUUCUUAUUGUUGCGGCAAUAGUGUUUAUAACACUUUGCUUCACACUCAAAAGAAAGACAGAAUGAUUGAACUUUCAUUAAUUGACUUCUAUUUGUGCUUUUUAGCCUUUCUGCUAUUCCUUGUUUUAAUUAUGCUUAUUAUCUUUUGGUUCUCACUUGAACUGCAAGAUCAUAAUGAAACUUGUCACGCCUAAACGAACAUGAAAUUUCUUGUUUUCUUAGGAAUCAUCACAACUGUAGCUGCAUUUCACCAAGAAUGUAGUUUACAGUCAUGUACUCAACAUCAACCAUAUGUAGUUGAUGACCCGUGUCCUAUUCACUUCUAUUCUAAAUGGUAUAUUAGAGUAGGAGCUAGAAAAUCAGCACCUUUAAUUGAAUUGUGCGUGGAUGAGGCUGGUUCUAAAUCACCCAUUCAGUACAUCGAUAUCGGUAAUUAUACAGUUUCCUGUUUACCUUUUACAAUUAAUUGCCAGGAACCUAAAUUGGGUAGUCUUGUAGUGCGUUGUUCGUUCUAUGAAGACUUUUUAGAGUAUCAUGACGUUCGUGUUGUUUUAGAUUUCAUCUAAACGAACAAACUAAAAUGUCUGAUAAUGGACCCCAAAAUCAGCGAAAUGCACCCCGCAUUACGUUUGGUGGACCCUCAGAUUCAACUGGCAGUAACCAGAAUGGAGAACGCAGUGGGGCGCGAUCAAAACAACGUCGGCCCCAAGGUUUACCCAAUAAUACUGCGUCUUGGUUCACCGCUCUCACUCAACAUGGCAAGGAAGACCUUAAAUUCCCUCGAGGACAAGGCGUUCCAAUUAACACCAAUAGCAGUCCAGAUGACCAAAUUGGCUACUACCGAAGAGCUACCAGACGAAUUCGUGGUGGUGACGGUAAAAUGAAAGAUCUCAGUCCAAGAUGGUAUUUCUACUACCUAGGAACUGGGCCAGAAGCUGGACUUCCCUAUGGUGCUAACAAAGACGGCAUCAUAUGGGUUGCAACUGAGGGAGCCUUGAAUACACCAAAAGAUCACAUUGGCACCCGCAAUCCUGCUAACAAUGCUGCAAUCGUGCUACAACUUCCUCAAGGAACAACAUUGCCAAAAGGCUUCUACGCAGAAGGGAGCAGAGGCGGCAGUCAAGCCUCUUCUCGUUCCUCAUCACGUAGUCGCAACAGUUCAAGAAAUUCAACUCCAGGCAGCAGUAGGGGAACUUCUCCUGCUAGAAUGGCUGGCAAUGGCGGUGAUGCUGCUCUUGCUUUGCUGCUGCUUGACAGAUUGAACCAGCUUGAGAGCAAAAUGUCUGGUAAAGGCCAACAACAACAAGGCCAAACUGUCACUAAGAAAUCUGCUGCUGAGGCUUCUAAGAAGCCUCGGCAAAAACGUACUGCCACUAAAGCAUACAAUGUAACACAAGCUUUCGGCAGACGUGGUCCAGAACAAACCCAAGGAAAUUUUGGGGACCAGGAACUAAUCAGACAAGGAACUGAUUACAAACAUUGGCCGCAAAUUGCACAAUUUGCCCCCAGCGCUUCAGCGUUCUUCGGAAUGUCGCGCAUUGGCAUGGAAGUCACACCUUCGGGAACGUGGUUGACCUACACAGGUGCCAUCAAAUUGGAUGACAAAGAUCCAAAUUUCAAAGAUCAAGUCAUUUUGCUGAAUAAGCAUAUUGACGCAUACAAAACAUUCCCACCAACAGAGCCUAAAAAGGACAAAAAGAAGAAGGCUGAUGAAACUCAAGCCUUACCGCAGAGACAGAAGAAACAGCAAACUGUGACUCUUCUUCCUGCUGCAGAUUUGGAUGAUUUCUCCAAACAAUUGCAACAAUCCAUGAGCAGUGCUGACUCAACUCAGGCCUAAACUCAUGCAGACCACACAAGGCAGAUGGGCUAUAUAAACGUUUUCGCUUUUCCGUUUACGAUAUAUAGUCUACUCUUGUGCAGAAUGAAUUCUCGUAACUACAUAGCACAAGUAGAUGUAGUUAACUUUAAUCUCACAUAGCAAUCUUUAAUCAGUGUGUAACAUUAGGGAGGACUUGAAAGAGCCACCACAUUUUCACCGAGGCCACGCGGAGUACGAUCGAGUGUACAGUGAACAAUGCUAGGGAGAGCUGCCUAUAUGGAAGAGCCCUAAUGUGUAAAAUUAAUUUUAGUAGUGCUAUCCCCAUGUGAUUUUAAUAGCUUCUUAGGAGAAUGACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|protein_mutation:K375Q
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKQADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,protein_mutation:K375Q,419aa(1-419),P0DTC9,-,-,"[1-43],[73-102],[145-149],[152-160],[172-215],[235-271],[365-387],[409-419]",-,In vitro,5-20µM[SARS2-NP–VSV K375Q];|200nM[SARS-CoV-2],"15 mM NaCl, 135 mM KCl, 5 mM phosphate, 1.5 mM MgCl2","20 mM Tris–HCl, pH 7.0",37˚C,-,other_molecular:1 mg ml−1 BSA,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"To test whether these viral mutations induce changes in the phase separation of SARS2-NP , we incubated fluorescently labelled K375N and K375E with viral RNA and compared the micrometre-sized liquid droplet formation with that of SARS2-NP WT. Both the K375N and K375E mutants seemed to have compromised LLPS "
706,PMID: 34239064,RNAPS0000450,https://pubmed.ncbi.nlm.nih.gov/34239064,RNA + protein,-,-,SARS-CoV-2 virus RNA,29903nt(1-29903),AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGCACCUCAUGGUCAUGUUAUGGUUGAGCUGGUAGCAGAACUCGAAGGCAUUCAGUACGGUCGUAGUGGUGAGACACUUGGUGUCCUUGUCCCUCAUGUGGGCGAAAUACCAGUGGCUUACCGCAAGGUUCUUCUUCGUAAGAACGGUAAUAAAGGAGCUGGUGGCCAUAGUUACGGCGCCGAUCUAAAGUCAUUUGACUUAGGCGACGAGCUUGGCACUGAUCCUUAUGAAGAUUUUCAAGAAAACUGGAACACUAAACAUAGCAGUGGUGUUACCCGUGAACUCAUGCGUGAGCUUAACGGAGGGGCAUACACUCGCUAUGUCGAUAACAACUUCUGUGGCCCUGAUGGCUACCCUCUUGAGUGCAUUAAAGACCUUCUAGCACGUGCUGGUAAAGCUUCAUGCACUUUGUCCGAACAACUGGACUUUAUUGACACUAAGAGGGGUGUAUACUGCUGCCGUGAACAUGAGCAUGAAAUUGCUUGGUACACGGAACGUUCUGAAAAGAGCUAUGAAUUGCAGACACCUUUUGAAAUUAAAUUGGCAAAGAAAUUUGACACCUUCAAUGGGGAAUGUCCAAAUUUUGUAUUUCCCUUAAAUUCCAUAAUCAAGACUAUUCAACCAAGGGUUGAAAAGAAAAAGCUUGAUGGCUUUAUGGGUAGAAUUCGAUCUGUCUAUCCAGUUGCGUCACCAAAUGAAUGCAACCAAAUGUGCCUUUCAACUCUCAUGAAGUGUGAUCAUUGUGGUGAAACUUCAUGGCAGACGGGCGAUUUUGUUAAAGCCACUUGCGAAUUUUGUGGCACUGAGAAUUUGACUAAAGAAGGUGCCACUACUUGUGGUUACUUACCCCAAAAUGCUGUUGUUAAAAUUUAUUGUCCAGCAUGUCACAAUUCAGAAGUAGGACCUGAGCAUAGUCUUGCCGAAUACCAUAAUGAAUCUGGCUUGAAAACCAUUCUUCGUAAGGGUGGUCGCACUAUUGCCUUUGGAGGCUGUGUGUUCUCUUAUGUUGGUUGCCAUAACAAGUGUGCCUAUUGGGUUCCACGUGCUAGCGCUAACAUAGGUUGUAACCAUACAGGUGUUGUUGGAGAAGGUUCCGAAGGUCUUAAUGACAACCUUCUUGAAAUACUCCAAAAAGAGAAAGUCAACAUCAAUAUUGUUGGUGACUUUAAACUUAAUGAAGAGAUCGCCAUUAUUUUGGCAUCUUUUUCUGCUUCCACAAGUGCUUUUGUGGAAACUGUGAAAGGUUUGGAUUAUAAAGCAUUCAAACAAAUUGUUGAAUCCUGUGGUAAUUUUAAAGUUACAAAAGGAAAAGCUAAAAAAGGUGCCUGGAAUAUUGGUGAACAGAAAUCAAUACUGAGUCCUCUUUAUGCAUUUGCAUCAGAGGCUGCUCGUGUUGUACGAUCAAUUUUCUCCCGCACUCUUGAAACUGCUCAAAAUUCUGUGCGUGUUUUACAGAAGGCCGCUAUAACAAUACUAGAUGGAAUUUCACAGUAUUCACUGAGACUCAUUGAUGCUAUGAUGUUCACAUCUGAUUUGGCUACUAACAAUCUAGUUGUAAUGGCCUACAUUACAGGUGGUGUUGUUCAGUUGACUUCGCAGUGGCUAACUAACAUCUUUGGCACUGUUUAUGAAAAACUCAAACCCGUCCUUGAUUGGCUUGAAGAGAAGUUUAAGGAAGGUGUAGAGUUUCUUAGAGACGGUUGGGAAAUUGUUAAAUUUAUCUCAACCUGUGCUUGUGAAAUUGUCGGUGGACAAAUUGUCACCUGUGCAAAGGAAAUUAAGGAGAGUGUUCAGACAUUCUUUAAGCUUGUAAAUAAAUUUUUGGCUUUGUGUGCUGACUCUAUCAUUAUUGGUGGAGCUAAACUUAAAGCCUUGAAUUUAGGUGAAACAUUUGUCACGCACUCAAAGGGAUUGUACAGAAAGUGUGUUAAAUCCAGAGAAGAAACUGGCCUACUCAUGCCUCUAAAAGCCCCAAAAGAAAUUAUCUUCUUAGAGGGAGAAACACUUCCCACAGAAGUGUUAACAGAGGAAGUUGUCUUGAAAACUGGUGAUUUACAACCAUUAGAACAACCUACUAGUGAAGCUGUUGAAGCUCCAUUGGUUGGUACACCAGUUUGUAUUAACGGGCUUAUGUUGCUCGAAAUCAAAGACACAGAAAAGUACUGUGCCCUUGCACCUAAUAUGAUGGUAACAAACAAUACCUUCACACUCAAAGGCGGUGCACCAACAAAGGUUACUUUUGGUGAUGACACUGUGAUAGAAGUGCAAGGUUACAAGAGUGUGAAUAUCACUUUUGAACUUGAUGAAAGGAUUGAUAAAGUACUUAAUGAGAAGUGCUCUGCCUAUACAGUUGAACUCGGUACAGAAGUAAAUGAGUUCGCCUGUGUUGUGGCAGAUGCUGUCAUAAAAACUUUGCAACCAGUAUCUGAAUUACUUACACCACUGGGCAUUGAUUUAGAUGAGUGGAGUAUGGCUACAUACUACUUAUUUGAUGAGUCUGGUGAGUUUAAAUUGGCUUCACAUAUGUAUUGUUCUUUCUACCCUCCAGAUGAGGAUGAAGAAGAAGGUGAUUGUGAAGAAGAAGAGUUUGAGCCAUCAACUCAAUAUGAGUAUGGUACUGAAGAUGAUUACCAAGGUAAACCUUUGGAAUUUGGUGCCACUUCUGCUGCUCUUCAACCUGAAGAAGAGCAAGAAGAAGAUUGGUUAGAUGAUGAUAGUCAACAAACUGUUGGUCAACAAGACGGCAGUGAGGACAAUCAGACAACUACUAUUCAAACAAUUGUUGAGGUUCAACCUCAAUUAGAGAUGGAACUUACACCAGUUGUUCAGACUAUUGAAGUGAAUAGUUUUAGUGGUUAUUUAAAACUUACUGACAAUGUAUACAUUAAAAAUGCAGACAUUGUGGAAGAAGCUAAAAAGGUAAAACCAACAGUGGUUGUUAAUGCAGCCAAUGUUUACCUUAAACAUGGAGGAGGUGUUGCAGGAGCCUUAAAUAAGGCUACUAACAAUGCCAUGCAAGUUGAAUCUGAUGAUUACAUAGCUACUAAUGGACCACUUAAAGUGGGUGGUAGUUGUGUUUUAAGCGGACACAAUCUUGCUAAACACUGUCUUCAUGUUGUCGGCCCAAAUGUUAACAAAGGUGAAGACAUUCAACUUCUUAAGAGUGCUUAUGAAAAUUUUAAUCAGCACGAAGUUCUACUUGCACCAUUAUUAUCAGCUGGUAUUUUUGGUGCUGACCCUAUACAUUCUUUAAGAGUUUGUGUAGAUACUGUUCGCACAAAUGUCUACUUAGCUGUCUUUGAUAAAAAUCUCUAUGACAAACUUGUUUCAAGCUUUUUGGAAAUGAAGAGUGAAAAGCAAGUUGAACAAAAGAUCGCUGAGAUUCCUAAAGAGGAAGUUAAGCCAUUUAUAACUGAAAGUAAACCUUCAGUUGAACAGAGAAAACAAGAUGAUAAGAAAAUCAAAGCUUGUGUUGAAGAAGUUACAACAACUCUGGAAGAAACUAAGUUCCUCACAGAAAACUUGUUACUUUAUAUUGACAUUAAUGGCAAUCUUCAUCCAGAUUCUGCCACUCUUGUUAGUGACAUUGACAUCACUUUCUUAAAGAAAGAUGCUCCAUAUAUAGUGGGUGAUGUUGUUCAAGAGGGUGUUUUAACUGCUGUGGUUAUACCUACUAAAAAGGCUGGUGGCACUACUGAAAUGCUAGCGAAAGCUUUGAGAAAAGUGCCAACAGACAAUUAUAUAACCACUUACCCGGGUCAGGGUUUAAAUGGUUACACUGUAGAGGAGGCAAAGACAGUGCUUAAAAAGUGUAAAAGUGCCUUUUACAUUCUACCAUCUAUUAUCUCUAAUGAGAAGCAAGAAAUUCUUGGAACUGUUUCUUGGAAUUUGCGAGAAAUGCUUGCACAUGCAGAAGAAACACGCAAAUUAAUGCCUGUCUGUGUGGAAACUAAAGCCAUAGUUUCAACUAUACAGCGUAAAUAUAAGGGUAUUAAAAUACAAGAGGGUGUGGUUGAUUAUGGUGCUAGAUUUUACUUUUACACCAGUAAAACAACUGUAGCGUCACUUAUCAACACACUUAACGAUCUAAAUGAAACUCUUGUUACAAUGCCACUUGGCUAUGUAACACAUGGCUUAAAUUUGGAAGAAGCUGCUCGGUAUAUGAGAUCUCUCAAAGUGCCAGCUACAGUUUCUGUUUCUUCACCUGAUGCUGUUACAGCGUAUAAUGGUUAUCUUACUUCUUCUUCUAAAACACCUGAAGAACAUUUUAUUGAAACCAUCUCACUUGCUGGUUCCUAUAAAGAUUGGUCCUAUUCUGGACAAUCUACACAACUAGGUAUAGAAUUUCUUAAGAGAGGUGAUAAAAGUGUAUAUUACACUAGUAAUCCUACCACAUUCCACCUAGAUGGUGAAGUUAUCACCUUUGACAAUCUUAAGACACUUCUUUCUUUGAGAGAAGUGAGGACUAUUAAGGUGUUUACAACAGUAGACAACAUUAACCUCCACACGCAAGUUGUGGACAUGUCAAUGACAUAUGGACAACAGUUUGGUCCAACUUAUUUGGAUGGAGCUGAUGUUACUAAAAUAAAACCUCAUAAUUCACAUGAAGGUAAAACAUUUUAUGUUUUACCUAAUGAUGACACUCUACGUGUUGAGGCUUUUGAGUACUACCACACAACUGAUCCUAGUUUUCUGGGUAGGUACAUGUCAGCAUUAAAUCACACUAAAAAGUGGAAAUACCCACAAGUUAAUGGUUUAACUUCUAUUAAAUGGGCAGAUAACAACUGUUAUCUUGCCACUGCAUUGUUAACACUCCAACAAAUAGAGUUGAAGUUUAAUCCACCUGCUCUACAAGAUGCUUAUUACAGAGCAAGGGCUGGUGAAGCUGCUAACUUUUGUGCACUUAUCUUAGCCUACUGUAAUAAGACAGUAGGUGAGUUAGGUGAUGUUAGAGAAACAAUGAGUUACUUGUUUCAACAUGCCAAUUUAGAUUCUUGCAAAAGAGUCUUGAACGUGGUGUGUAAAACUUGUGGACAACAGCAGACAACCCUUAAGGGUGUAGAAGCUGUUAUGUACAUGGGCACACUUUCUUAUGAACAAUUUAAGAAAGGUGUUCAGAUACCUUGUACGUGUGGUAAACAAGCUACAAAAUAUCUAGUACAACAGGAGUCACCUUUUGUUAUGAUGUCAGCACCACCUGCUCAGUAUGAACUUAAGCAUGGUACAUUUACUUGUGCUAGUGAGUACACUGGUAAUUACCAGUGUGGUCACUAUAAACAUAUAACUUCUAAAGAAACUUUGUAUUGCAUAGACGGUGCUUUACUUACAAAGUCCUCAGAAUACAAAGGUCCUAUUACGGAUGUUUUCUACAAAGAAAACAGUUACACAACAACCAUAAAACCAGUUACUUAUAAAUUGGAUGGUGUUGUUUGUACAGAAAUUGACCCUAAGUUGGACAAUUAUUAUAAGAAAGACAAUUCUUAUUUCACAGAGCAACCAAUUGAUCUUGUACCAAACCAACCAUAUCCAAACGCAAGCUUCGAUAAUUUUAAGUUUGUAUGUGAUAAUAUCAAAUUUGCUGAUGAUUUAAACCAGUUAACUGGUUAUAAGAAACCUGCUUCAAGAGAGCUUAAAGUUACAUUUUUCCCUGACUUAAAUGGUGAUGUGGUGGCUAUUGAUUAUAAACACUACACACCCUCUUUUAAGAAAGGAGCUAAAUUGUUACAUAAACCUAUUGUUUGGCAUGUUAACAAUGCAACUAAUAAAGCCACGUAUAAACCAAAUACCUGGUGUAUACGUUGUCUUUGGAGCACAAAACCAGUUGAAACAUCAAAUUCGUUUGAUGUACUGAAGUCAGAGGACGCGCAGGGAAUGGAUAAUCUUGCCUGCGAAGAUCUAAAACCAGUCUCUGAAGAAGUAGUGGAAAAUCCUACCAUACAGAAAGACGUUCUUGAGUGUAAUGUGAAAACUACCGAAGUUGUAGGAGACAUUAUACUUAAACCAGCAAAUAAUAGUUUAAAAAUUACAGAAGAGGUUGGCCACACAGAUCUAAUGGCUGCUUAUGUAGACAAUUCUAGUCUUACUAUUAAGAAACCUAAUGAAUUAUCUAGAGUAUUAGGUUUGAAAACCCUUGCUACUCAUGGUUUAGCUGCUGUUAAUAGUGUCCCUUGGGAUACUAUAGCUAAUUAUGCUAAGCCUUUUCUUAACAAAGUUGUUAGUACAACUACUAACAUAGUUACACGGUGUUUAAACCGUGUUUGUACUAAUUAUAUGCCUUAUUUCUUUACUUUAUUGCUACAAUUGUGUACUUUUACUAGAAGUACAAAUUCUAGAAUUAAAGCAUCUAUGCCGACUACUAUAGCAAAGAAUACUGUUAAGAGUGUCGGUAAAUUUUGUCUAGAGGCUUCAUUUAAUUAUUUGAAGUCACCUAAUUUUUCUAAACUGAUAAAUAUUAUAAUUUGGUUUUUACUAUUAAGUGUUUGCCUAGGUUCUUUAAUCUACUCAACCGCUGCUUUAGGUGUUUUAAUGUCUAAUUUAGGCAUGCCUUCUUACUGUACUGGUUACAGAGAAGGCUAUUUGAACUCUACUAAUGUCACUAUUGCAACCUACUGUACUGGUUCUAUACCUUGUAGUGUUUGUCUUAGUGGUUUAGAUUCUUUAGACACCUAUCCUUCUUUAGAAACUAUACAAAUUACCAUUUCAUCUUUUAAAUGGGAUUUAACUGCUUUUGGCUUAGUUGCAGAGUGGUUUUUGGCAUAUAUUCUUUUCACUAGGUUUUUCUAUGUACUUGGAUUGGCUGCAAUCAUGCAAUUGUUUUUCAGCUAUUUUGCAGUACAUUUUAUUAGUAAUUCUUGGCUUAUGUGGUUAAUAAUUAAUCUUGUACAAAUGGCCCCGAUUUCAGCUAUGGUUAGAAUGUACAUCUUCUUUGCAUCAUUUUAUUAUGUAUGGAAAAGUUAUGUGCAUGUUGUAGACGGUUGUAAUUCAUCAACUUGUAUGAUGUGUUACAAACGUAAUAGAGCAACAAGAGUCGAAUGUACAACUAUUGUUAAUGGUGUUAGAAGGUCCUUUUAUGUCUAUGCUAAUGGAGGUAAAGGCUUUUGCAAACUACACAAUUGGAAUUGUGUUAAUUGUGAUACAUUCUGUGCUGGUAGUACAUUUAUUAGUGAUGAAGUUGCGAGAGACUUGUCACUACAGUUUAAAAGACCAAUAAAUCCUACUGACCAGUCUUCUUACAUCGUUGAUAGUGUUACAGUGAAGAAUGGUUCCAUCCAUCUUUACUUUGAUAAAGCUGGUCAAAAGACUUAUGAAAGACAUUCUCUCUCUCAUUUUGUUAACUUAGACAACCUGAGAGCUAAUAACACUAAAGGUUCAUUGCCUAUUAAUGUUAUAGUUUUUGAUGGUAAAUCAAAAUGUGAAGAAUCAUCUGCAAAAUCAGCGUCUGUUUACUACAGUCAGCUUAUGUGUCAACCUAUACUGUUACUAGAUCAGGCAUUAGUGUCUGAUGUUGGUGAUAGUGCGGAAGUUGCAGUUAAAAUGUUUGAUGCUUACGUUAAUACGUUUUCAUCAACUUUUAACGUACCAAUGGAAAAACUCAAAACACUAGUUGCAACUGCAGAAGCUGAACUUGCAAAGAAUGUGUCCUUAGACAAUGUCUUAUCUACUUUUAUUUCAGCAGCUCGGCAAGGGUUUGUUGAUUCAGAUGUAGAAACUAAAGAUGUUGUUGAAUGUCUUAAAUUGUCACAUCAAUCUGACAUAGAAGUUACUGGCGAUAGUUGUAAUAACUAUAUGCUCACCUAUAACAAAGUUGAAAACAUGACACCCCGUGACCUUGGUGCUUGUAUUGACUGUAGUGCGCGUCAUAUUAAUGCGCAGGUAGCAAAAAGUCACAACAUUGCUUUGAUAUGGAACGUUAAAGAUUUCAUGUCAUUGUCUGAACAACUACGAAAACAAAUACGUAGUGCUGCUAAAAAGAAUAACUUACCUUUUAAGUUGACAUGUGCAACUACUAGACAAGUUGUUAAUGUUGUAACAACAAAGAUAGCACUUAAGGGUGGUAAAAUUGUUAAUAAUUGGUUGAAGCAGUUAAUUAAAGUUACACUUGUGUUCCUUUUUGUUGCUGCUAUUUUCUAUUUAAUAACACCUGUUCAUGUCAUGUCUAAACAUACUGACUUUUCAAGUGAAAUCAUAGGAUACAAGGCUAUUGAUGGUGGUGUCACUCGUGACAUAGCAUCUACAGAUACUUGUUUUGCUAACAAACAUGCUGAUUUUGACACAUGGUUUAGCCAGCGUGGUGGUAGUUAUACUAAUGACAAAGCUUGCCCAUUGAUUGCUGCAGUCAUAACAAGAGAAGUGGGUUUUGUCGUGCCUGGUUUGCCUGGCACGAUAUUACGCACAACUAAUGGUGACUUUUUGCAUUUCUUACCUAGAGUUUUUAGUGCAGUUGGUAACAUCUGUUACACACCAUCAAAACUUAUAGAGUACACUGACUUUGCAACAUCAGCUUGUGUUUUGGCUGCUGAAUGUACAAUUUUUAAAGAUGCUUCUGGUAAGCCAGUACCAUAUUGUUAUGAUACCAAUGUACUAGAAGGUUCUGUUGCUUAUGAAAGUUUACGCCCUGACACACGUUAUGUGCUCAUGGAUGGCUCUAUUAUUCAAUUUCCUAACACCUACCUUGAAGGUUCUGUUAGAGUGGUAACAACUUUUGAUUCUGAGUACUGUAGGCACGGCACUUGUGAAAGAUCAGAAGCUGGUGUUUGUGUAUCUACUAGUGGUAGAUGGGUACUUAACAAUGAUUAUUACAGAUCUUUACCAGGAGUUUUCUGUGGUGUAGAUGCUGUAAAUUUACUUACUAAUAUGUUUACACCACUAAUUCAACCUAUUGGUGCUUUGGACAUAUCAGCAUCUAUAGUAGCUGGUGGUAUUGUAGCUAUCGUAGUAACAUGCCUUGCCUACUAUUUUAUGAGGUUUAGAAGAGCUUUUGGUGAAUACAGUCAUGUAGUUGCCUUUAAUACUUUACUAUUCCUUAUGUCAUUCACUGUACUCUGUUUAACACCAGUUUACUCAUUCUUACCUGGUGUUUAUUCUGUUAUUUACUUGUACUUGACAUUUUAUCUUACUAAUGAUGUUUCUUUUUUAGCACAUAUUCAGUGGAUGGUUAUGUUCACACCUUUAGUACCUUUCUGGAUAACAAUUGCUUAUAUCAUUUGUAUUUCCACAAAGCAUUUCUAUUGGUUCUUUAGUAAUUACCUAAAGAGACGUGUAGUCUUUAAUGGUGUUUCCUUUAGUACUUUUGAAGAAGCUGCGCUGUGCACCUUUUUGUUAAAUAAAGAAAUGUAUCUAAAGUUGCGUAGUGAUGUGCUAUUACCUCUUACGCAAUAUAAUAGAUACUUAGCUCUUUAUAAUAAGUACAAGUAUUUUAGUGGAGCAAUGGAUACAACUAGCUACAGAGAAGCUGCUUGUUGUCAUCUCGCAAAGGCUCUCAAUGACUUCAGUAACUCAGGUUCUGAUGUUCUUUACCAACCACCACAAACCUCUAUCACCUCAGCUGUUUUGCAGAGUGGUUUUAGAAAAAUGGCAUUCCCAUCUGGUAAAGUUGAGGGUUGUAUGGUACAAGUAACUUGUGGUACAACUACACUUAACGGUCUUUGGCUUGAUGACGUAGUUUACUGUCCAAGACAUGUGAUCUGCACCUCUGAAGACAUGCUUAACCCUAAUUAUGAAGAUUUACUCAUUCGUAAGUCUAAUCAUAAUUUCUUGGUACAGGCUGGUAAUGUUCAACUCAGGGUUAUUGGACAUUCUAUGCAAAAUUGUGUACUUAAGCUUAAGGUUGAUACAGCCAAUCCUAAGACACCUAAGUAUAAGUUUGUUCGCAUUCAACCAGGACAGACUUUUUCAGUGUUAGCUUGUUACAAUGGUUCACCAUCUGGUGUUUACCAAUGUGCUAUGAGGCCCAAUUUCACUAUUAAGGGUUCAUUCCUUAAUGGUUCAUGUGGUAGUGUUGGUUUUAACAUAGAUUAUGACUGUGUCUCUUUUUGUUACAUGCACCAUAUGGAAUUACCAACUGGAGUUCAUGCUGGCACAGACUUAGAAGGUAACUUUUAUGGACCUUUUGUUGACAGGCAAACAGCACAAGCAGCUGGUACGGACACAACUAUUACAGUUAAUGUUUUAGCUUGGUUGUACGCUGCUGUUAUAAAUGGAGACAGGUGGUUUCUCAAUCGAUUUACCACAACUCUUAAUGACUUUAACCUUGUGGCUAUGAAGUACAAUUAUGAACCUCUAACACAAGACCAUGUUGACAUACUAGGACCUCUUUCUGCUCAAACUGGAAUUGCCGUUUUAGAUAUGUGUGCUUCAUUAAAAGAAUUACUGCAAAAUGGUAUGAAUGGACGUACCAUAUUGGGUAGUGCUUUAUUAGAAGAUGAAUUUACACCUUUUGAUGUUGUUAGACAAUGCUCAGGUGUUACUUUCCAAAGUGCAGUGAAAAGAACAAUCAAGGGUACACACCACUGGUUGUUACUCACAAUUUUGACUUCACUUUUAGUUUUAGUCCAGAGUACUCAAUGGUCUUUGUUCUUUUUUUUGUAUGAAAAUGCCUUUUUACCUUUUGCUAUGGGUAUUAUUGCUAUGUCUGCUUUUGCAAUGAUGUUUGUCAAACAUAAGCAUGCAUUUCUCUGUUUGUUUUUGUUACCUUCUCUUGCCACUGUAGCUUAUUUUAAUAUGGUCUAUAUGCCUGCUAGUUGGGUGAUGCGUAUUAUGACAUGGUUGGAUAUGGUUGAUACUAGUUUGUCUGGUUUUAAGCUAAAAGACUGUGUUAUGUAUGCAUCAGCUGUAGUGUUACUAAUCCUUAUGACAGCAAGAACUGUGUAUGAUGAUGGUGCUAGGAGAGUGUGGACACUUAUGAAUGUCUUGACACUCGUUUAUAAAGUUUAUUAUGGUAAUGCUUUAGAUCAAGCCAUUUCCAUGUGGGCUCUUAUAAUCUCUGUUACUUCUAACUACUCAGGUGUAGUUACAACUGUCAUGUUUUUGGCCAGAGGUAUUGUUUUUAUGUGUGUUGAGUAUUGCCCUAUUUUCUUCAUAACUGGUAAUACACUUCAGUGUAUAAUGCUAGUUUAUUGUUUCUUAGGCUAUUUUUGUACUUGUUACUUUGGCCUCUUUUGUUUACUCAACCGCUACUUUAGACUGACUCUUGGUGUUUAUGAUUACUUAGUUUCUACACAGGAGUUUAGAUAUAUGAAUUCACAGGGACUACUCCCACCCAAGAAUAGCAUAGAUGCCUUCAAACUCAACAUUAAAUUGUUGGGUGUUGGUGGCAAACCUUGUAUCAAAGUAGCCACUGUACAGUCUAAAAUGUCAGAUGUAAAGUGCACAUCAGUAGUCUUACUCUCAGUUUUGCAACAACUCAGAGUAGAAUCAUCAUCUAAAUUGUGGGCUCAAUGUGUCCAGUUACACAAUGACAUUCUCUUAGCUAAAGAUACUACUGAAGCCUUUGAAAAAAUGGUUUCACUACUUUCUGUUUUGCUUUCCAUGCAGGGUGCUGUAGACAUAAACAAGCUUUGUGAAGAAAUGCUGGACAACAGGGCAACCUUACAAGCUAUAGCCUCAGAGUUUAGUUCCCUUCCAUCAUAUGCAGCUUUUGCUACUGCUCAAGAAGCUUAUGAGCAGGCUGUUGCUAAUGGUGAUUCUGAAGUUGUUCUUAAAAAGUUGAAGAAGUCUUUGAAUGUGGCUAAAUCUGAAUUUGACCGUGAUGCAGCCAUGCAACGUAAGUUGGAAAAGAUGGCUGAUCAAGCUAUGACCCAAAUGUAUAAACAGGCUAGAUCUGAGGACAAGAGGGCAAAAGUUACUAGUGCUAUGCAGACAAUGCUUUUCACUAUGCUUAGAAAGUUGGAUAAUGAUGCACUCAACAACAUUAUCAACAAUGCAAGAGAUGGUUGUGUUCCCUUGAACAUAAUACCUCUUACAACAGCAGCCAAACUAAUGGUUGUCAUACCAGACUAUAACACAUAUAAAAAUACGUGUGAUGGUACAACAUUUACUUAUGCAUCAGCAUUGUGGGAAAUCCAACAGGUUGUAGAUGCAGAUAGUAAAAUUGUUCAACUUAGUGAAAUUAGUAUGGACAAUUCACCUAAUUUAGCAUGGCCUCUUAUUGUAACAGCUUUAAGGGCCAAUUCUGCUGUCAAAUUACAGAAUAAUGAGCUUAGUCCUGUUGCACUACGACAGAUGUCUUGUGCUGCCGGUACUACACAAACUGCUUGCACUGAUGACAAUGCGUUAGCUUACUACAACACAACAAAGGGAGGUAGGUUUGUACUUGCACUGUUAUCCGAUUUACAGGAUUUGAAAUGGGCUAGAUUCCCUAAGAGUGAUGGAACUGGUACUAUCUAUACAGAACUGGAACCACCUUGUAGGUUUGUUACAGACACACCUAAAGGUCCUAAAGUGAAGUAUUUAUACUUUAUUAAAGGAUUAAACAACCUAAAUAGAGGUAUGGUACUUGGUAGUUUAGCUGCCACAGUACGUCUACAAGCUGGUAAUGCAACAGAAGUGCCUGCCAAUUCAACUGUAUUAUCUUUCUGUGCUUUUGCUGUAGAUGCUGCUAAAGCUUACAAAGAUUAUCUAGCUAGUGGGGGACAACCAAUCACUAAUUGUGUUAAGAUGUUGUGUACACACACUGGUACUGGUCAGGCAAUAACAGUUACACCGGAAGCCAAUAUGGAUCAAGAAUCCUUUGGUGGUGCAUCGUGUUGUCUGUACUGCCGUUGCCACAUAGAUCAUCCAAAUCCUAAAGGAUUUUGUGACUUAAAAGGUAAGUAUGUACAAAUACCUACAACUUGUGCUAAUGACCCUGUGGGUUUUACACUUAAAAACACAGUCUGUACCGUCUGCGGUAUGUGGAAAGGUUAUGGCUGUAGUUGUGAUCAACUCCGCGAACCCAUGCUUCAGUCAGCUGAUGCACAAUCGUUUUUAAACGGGUUUGCGGUGUAAGUGCAGCCCGUCUUACACCGUGCGGCACAGGCACUAGUACUGAUGUCGUAUACAGGGCUUUUGACAUCUACAAUGAUAAAGUAGCUGGUUUUGCUAAAUUCCUAAAAACUAAUUGUUGUCGCUUCCAAGAAAAGGACGAAGAUGACAAUUUAAUUGAUUCUUACUUUGUAGUUAAGAGACACACUUUCUCUAACUACCAACAUGAAGAAACAAUUUAUAAUUUACUUAAGGAUUGUCCAGCUGUUGCUAAACAUGACUUCUUUAAGUUUAGAAUAGACGGUGACAUGGUACCACAUAUAUCACGUCAACGUCUUACUAAAUACACAAUGGCAGACCUCGUCUAUGCUUUAAGGCAUUUUGAUGAAGGUAAUUGUGACACAUUAAAAGAAAUACUUGUCACAUACAAUUGUUGUGAUGAUGAUUAUUUCAAUAAAAAGGACUGGUAUGAUUUUGUAGAAAACCCAGAUAUAUUACGCGUAUACGCCAACUUAGGUGAACGUGUACGCCAAGCUUUGUUAAAAACAGUACAAUUCUGUGAUGCCAUGCGAAAUGCUGGUAUUGUUGGUGUACUGACAUUAGAUAAUCAAGAUCUCAAUGGUAACUGGUAUGAUUUCGGUGAUUUCAUACAAACCACGCCAGGUAGUGGAGUUCCUGUUGUAGAUUCUUAUUAUUCAUUGUUAAUGCCUAUAUUAACCUUGACCAGGGCUUUAACUGCAGAGUCACAUGUUGACACUGACUUAACAAAGCCUUACAUUAAGUGGGAUUUGUUAAAAUAUGACUUCACGGAAGAGAGGUUAAAACUCUUUGACCGUUAUUUUAAAUAUUGGGAUCAGACAUACCACCCAAAUUGUGUUAACUGUUUGGAUGACAGAUGCAUUCUGCAUUGUGCAAACUUUAAUGUUUUAUUCUCUACAGUGUUCCCACCUACAAGUUUUGGACCACUAGUGAGAAAAAUAUUUGUUGAUGGUGUUCCAUUUGUAGUUUCAACUGGAUACCACUUCAGAGAGCUAGGUGUUGUACAUAAUCAGGAUGUAAACUUACAUAGCUCUAGACUUAGUUUUAAGGAAUUACUUGUGUAUGCUGCUGACCCUGCUAUGCACGCUGCUUCUGGUAAUCUAUUACUAGAUAAACGCACUACGUGCUUUUCAGUAGCUGCACUUACUAACAAUGUUGCUUUUCAAACUGUCAAACCCGGUAAUUUUAACAAAGACUUCUAUGACUUUGCUGUGUCUAAGGGUUUCUUUAAGGAAGGAAGUUCUGUUGAAUUAAAACACUUCUUCUUUGCUCAGGAUGGUAAUGCUGCUAUCAGCGAUUAUGACUACUAUCGUUAUAAUCUACCAACAAUGUGUGAUAUCAGACAACUACUAUUUGUAGUUGAAGUUGUUGAUAAGUACUUUGAUUGUUACGAUGGUGGCUGUAUUAAUGCUAACCAAGUCAUCGUCAACAACCUAGACAAAUCAGCUGGUUUUCCAUUUAAUAAAUGGGGUAAGGCUAGACUUUAUUAUGAUUCAAUGAGUUAUGAGGAUCAAGAUGCACUUUUCGCAUAUACAAAACGUAAUGUCAUCCCUACUAUAACUCAAAUGAAUCUUAAGUAUGCCAUUAGUGCAAAGAAUAGAGCUCGCACCGUAGCUGGUGUCUCUAUCUGUAGUACUAUGACCAAUAGACAGUUUCAUCAAAAAUUAUUGAAAUCAAUAGCCGCCACUAGAGGAGCUACUGUAGUAAUUGGAACAAGCAAAUUCUAUGGUGGUUGGCACAACAUGUUAAAAACUGUUUAUAGUGAUGUAGAAAACCCUCACCUUAUGGGUUGGGAUUAUCCUAAAUGUGAUAGAGCCAUGCCUAACAUGCUUAGAAUUAUGGCCUCACUUGUUCUUGCUCGCAAACAUACAACGUGUUGUAGCUUGUCACACCGUUUCUAUAGAUUAGCUAAUGAGUGUGCUCAAGUAUUGAGUGAAAUGGUCAUGUGUGGCGGUUCACUAUAUGUUAAACCAGGUGGAACCUCAUCAGGAGAUGCCACAACUGCUUAUGCUAAUAGUGUUUUUAACAUUUGUCAAGCUGUCACGGCCAAUGUUAAUGCACUUUUAUCUACUGAUGGUAACAAAAUUGCCGAUAAGUAUGUCCGCAAUUUACAACACAGACUUUAUGAGUGUCUCUAUAGAAAUAGAGAUGUUGACACAGACUUUGUGAAUGAGUUUUACGCAUAUUUGCGUAAACAUUUCUCAAUGAUGAUACUCUCUGACGAUGCUGUUGUGUGUUUCAAUAGCACUUAUGCAUCUCAAGGUCUAGUGGCUAGCAUAAAGAACUUUAAGUCAGUUCUUUAUUAUCAAAACAAUGUUUUUAUGUCUGAAGCAAAAUGUUGGACUGAGACUGACCUUACUAAAGGACCUCAUGAAUUUUGCUCUCAACAUACAAUGCUAGUUAAACAGGGUGAUGAUUAUGUGUACCUUCCUUACCCAGAUCCAUCAAGAAUCCUAGGGGCCGGCUGUUUUGUAGAUGAUAUCGUAAAAACAGAUGGUACACUUAUGAUUGAACGGUUCGUGUCUUUAGCUAUAGAUGCUUACCCACUUACUAAACAUCCUAAUCAGGAGUAUGCUGAUGUCUUUCAUUUGUACUUACAAUACAUAAGAAAGCUACAUGAUGAGUUAACAGGACACAUGUUAGACAUGUAUUCUGUUAUGCUUACUAAUGAUAACACUUCAAGGUAUUGGGAACCUGAGUUUUAUGAGGCUAUGUACACACCGCAUACAGUCUUACAGGCUGUUGGGGCUUGUGUUCUUUGCAAUUCACAGACUUCAUUAAGAUGUGGUGCUUGCAUACGUAGACCAUUCUUAUGUUGUAAAUGCUGUUACGACCAUGUCAUAUCAACAUCACAUAAAUUAGUCUUGUCUGUUAAUCCGUAUGUUUGCAAUGCUCCAGGUUGUGAUGUCACAGAUGUGACUCAACUUUACUUAGGAGGUAUGAGCUAUUAUUGUAAAUCACAUAAACCACCCAUUAGUUUUCCAUUGUGUGCUAAUGGACAAGUUUUUGGUUUAUAUAAAAAUACAUGUGUUGGUAGCGAUAAUGUUACUGACUUUAAUGCAAUUGCAACAUGUGACUGGACAAAUGCUGGUGAUUACAUUUUAGCUAACACCUGUACUGAAAGACUCAAGCUUUUUGCAGCAGAAACGCUCAAAGCUACUGAGGAGACAUUUAAACUGUCUUAUGGUAUUGCUACUGUACGUGAAGUGCUGUCUGACAGAGAAUUACAUCUUUCAUGGGAAGUUGGUAAACCUAGACCACCACUUAACCGAAAUUAUGUCUUUACUGGUUAUCGUGUAACUAAAAACAGUAAAGUACAAAUAGGAGAGUACACCUUUGAAAAAGGUGACUAUGGUGAUGCUGUUGUUUACCGAGGUACAACAACUUACAAAUUAAAUGUUGGUGAUUAUUUUGUGCUGACAUCACAUACAGUAAUGCCAUUAAGUGCACCUACACUAGUGCCACAAGAGCACUAUGUUAGAAUUACUGGCUUAUACCCAACACUCAAUAUCUCAGAUGAGUUUUCUAGCAAUGUUGCAAAUUAUCAAAAGGUUGGUAUGCAAAAGUAUUCUACACUCCAGGGACCACCUGGUACUGGUAAGAGUCAUUUUGCUAUUGGCCUAGCUCUCUACUACCCUUCUGCUCGCAUAGUGUAUACAGCUUGCUCUCAUGCCGCUGUUGAUGCACUAUGUGAGAAGGCAUUAAAAUAUUUGCCUAUAGAUAAAUGUAGUAGAAUUAUACCUGCACGUGCUCGUGUAGAGUGUUUUGAUAAAUUCAAAGUGAAUUCAACAUUAGAACAGUAUGUCUUUUGUACUGUAAAUGCAUUGCCUGAGACGACAGCAGAUAUAGUUGUCUUUGAUGAAAUUUCAAUGGCCACAAAUUAUGAUUUGAGUGUUGUCAAUGCCAGAUUACGUGCUAAGCACUAUGUGUACAUUGGCGACCCUGCUCAAUUACCUGCACCACGCACAUUGCUAACUAAGGGCACACUAGAACCAGAAUAUUUCAAUUCAGUGUGUAGACUUAUGAAAACUAUAGGUCCAGACAUGUUCCUCGGAACUUGUCGGCGUUGUCCUGCUGAAAUUGUUGACACUGUGAGUGCUUUGGUUUAUGAUAAUAAGCUUAAAGCACAUAAAGACAAAUCAGCUCAAUGCUUUAAAAUGUUUUAUAAGGGUGUUAUCACGCAUGAUGUUUCAUCUGCAAUUAACAGGCCACAAAUAGGCGUGGUAAGAGAAUUCCUUACACGUAACCCUGCUUGGAGAAAAGCUGUCUUUAUUUCACCUUAUAAUUCACAGAAUGCUGUAGCCUCAAAGAUUUUGGGACUACCAACUCAAACUGUUGAUUCAUCACAGGGCUCAGAAUAUGACUAUGUCAUAUUCACUCAAACCACUGAAACAGCUCACUCUUGUAAUGUAAACAGAUUUAAUGUUGCUAUUACCAGAGCAAAAGUAGGCAUACUUUGCAUAAUGUCUGAUAGAGACCUUUAUGACAAGUUGCAAUUUACAAGUCUUGAAAUUCCACGUAGGAAUGUGGCAACUUUACAAGCUGAAAAUGUAACAGGACUCUUUAAAGAUUGUAGUAAGGUAAUCACUGGGUUACAUCCUACACAGGCACCUACACACCUCAGUGUUGACACUAAAUUCAAAACUGAAGGUUUAUGUGUUGACAUACCUGGCAUACCUAAGGACAUGACCUAUAGAAGACUCAUCUCUAUGAUGGGUUUUAAAAUGAAUUAUCAAGUUAAUGGUUACCCUAACAUGUUUAUCACCCGCGAAGAAGCUAUAAGACAUGUACGUGCAUGGAUUGGCUUCGAUGUCGAGGGGUGUCAUGCUACUAGAGAAGCUGUUGGUACCAAUUUACCUUUACAGCUAGGUUUUUCUACAGGUGUUAACCUAGUUGCUGUACCUACAGGUUAUGUUGAUACACCUAAUAAUACAGAUUUUUCCAGAGUUAGUGCUAAACCACCGCCUGGAGAUCAAUUUAAACACCUCAUACCACUUAUGUACAAAGGACUUCCUUGGAAUGUAGUGCGUAUAAAGAUUGUACAAAUGUUAAGUGACACACUUAAAAAUCUCUCUGACAGAGUCGUAUUUGUCUUAUGGGCACAUGGCUUUGAGUUGACAUCUAUGAAGUAUUUUGUGAAAAUAGGACCUGAGCGCACCUGUUGUCUAUGUGAUAGACGUGCCACAUGCUUUUCCACUGCUUCAGACACUUAUGCCUGUUGGCAUCAUUCUAUUGGAUUUGAUUACGUCUAUAAUCCGUUUAUGAUUGAUGUUCAACAAUGGGGUUUUACAGGUAACCUACAAAGCAACCAUGAUCUGUAUUGUCAAGUCCAUGGUAAUGCACAUGUAGCUAGUUGUGAUGCAAUCAUGACUAGGUGUCUAGCUGUCCACGAGUGCUUUGUUAAGCGUGUUGACUGGACUAUUGAAUAUCCUAUAAUUGGUGAUGAACUGAAGAUUAAUGCGGCUUGUAGAAAGGUUCAACACAUGGUUGUUAAAGCUGCAUUAUUAGCAGACAAAUUCCCAGUUCUUCACGACAUUGGUAACCCUAAAGCUAUUAAGUGUGUACCUCAAGCUGAUGUAGAAUGGAAGUUCUAUGAUGCACAGCCUUGUAGUGACAAAGCUUAUAAAAUAGAAGAAUUAUUCUAUUCUUAUGCCACACAUUCUGACAAAUUCACAGAUGGUGUAUGCCUAUUUUGGAAUUGCAAUGUCGAUAGAUAUCCUGCUAAUUCCAUUGUUUGUAGAUUUGACACUAGAGUGCUAUCUAACCUUAACUUGCCUGGUUGUGAUGGUGGCAGUUUGUAUGUAAAUAAACAUGCAUUCCACACACCAGCUUUUGAUAAAAGUGCUUUUGUUAAUUUAAAACAAUUACCAUUUUUCUAUUACUCUGACAGUCCAUGUGAGUCUCAUGGAAAACAAGUAGUGUCAGAUAUAGAUUAUGUACCACUAAAGUCUGCUACGUGUAUAACACGUUGCAAUUUAGGUGGUGCUGUCUGUAGACAUCAUGCUAAUGAGUACAGAUUGUAUCUCGAUGCUUAUAACAUGAUGAUCUCAGCUGGCUUUAGCUUGUGGGUUUACAAACAAUUUGAUACUUAUAACCUCUGGAACACUUUUACAAGACUUCAGAGUUUAGAAAAUGUGGCUUUUAAUGUUGUAAAUAAGGGACACUUUGAUGGACAACAGGGUGAAGUACCAGUUUCUAUCAUUAAUAACACUGUUUACACAAAAGUUGAUGGUGUUGAUGUAGAAUUGUUUGAAAAUAAAACAACAUUACCUGUUAAUGUAGCAUUUGAGCUUUGGGCUAAGCGCAACAUUAAACCAGUACCAGAGGUGAAAAUACUCAAUAAUUUGGGUGUGGACAUUGCUGCUAAUACUGUGAUCUGGGACUACAAAAGAGAUGCUCCAGCACAUAUAUCUACUAUUGGUGUUUGUUCUAUGACUGACAUAGCCAAGAAACCAACUGAAACGAUUUGUGCACCACUCACUGUCUUUUUUGAUGGUAGAGUUGAUGGUCAAGUAGACUUAUUUAGAAAUGCCCGUAAUGGUGUUCUUAUUACAGAAGGUAGUGUUAAAGGUUUACAACCAUCUGUAGGUCCCAAACAAGCUAGUCUUAAUGGAGUCACAUUAAUUGGAGAAGCCGUAAAAACACAGUUCAAUUAUUAUAAGAAAGUUGAUGGUGUUGUCCAACAAUUACCUGAAACUUACUUUACUCAGAGUAGAAAUUUACAAGAAUUUAAACCCAGGAGUCAAAUGGAAAUUGAUUUCUUAGAAUUAGCUAUGGAUGAAUUCAUUGAACGGUAUAAAUUAGAAGGCUAUGCCUUCGAACAUAUCGUUUAUGGAGAUUUUAGUCAUAGUCAGUUAGGUGGUUUACAUCUACUGAUUGGACUAGCUAAACGUUUUAAGGAAUCACCUUUUGAAUUAGAAGAUUUUAUUCCUAUGGACAGUACAGUUAAAAACUAUUUCAUAACAGAUGCGCAAACAGGUUCAUCUAAGUGUGUGUGUUCUGUUAUUGAUUUAUUACUUGAUGAUUUUGUUGAAAUAAUAAAAUCCCAAGAUUUAUCUGUAGUUUCUAAGGUUGUCAAAGUGACUAUUGACUAUACAGAAAUUUCAUUUAUGCUUUGGUGUAAAGAUGGCCAUGUAGAAACAUUUUACCCAAAAUUACAAUCUAGUCAAGCGUGGCAACCGGGUGUUGCUAUGCCUAAUCUUUACAAAAUGCAAAGAAUGCUAUUAGAAAAGUGUGACCUUCAAAAUUAUGGUGAUAGUGCAACAUUACCUAAAGGCAUAAUGAUGAAUGUCGCAAAAUAUACUCAACUGUGUCAAUAUUUAAACACAUUAACAUUAGCUGUACCCUAUAAUAUGAGAGUUAUACAUUUUGGUGCUGGUUCUGAUAAAGGAGUUGCACCAGGUACAGCUGUUUUAAGACAGUGGUUGCCUACGGGUACGCUGCUUGUCGAUUCAGAUCUUAAUGACUUUGUCUCUGAUGCAGAUUCAACUUUGAUUGGUGAUUGUGCAACUGUACAUACAGCUAAUAAAUGGGAUCUCAUUAUUAGUGAUAUGUACGACCCUAAGACUAAAAAUGUUACAAAAGAAAAUGACUCUAAAGAGGGUUUUUUCACUUACAUUUGUGGGUUUAUACAACAAAAGCUAGCUCUUGGAGGUUCCGUGGCUAUAAAGAUAACAGAACAUUCUUGGAAUGCUGAUCUUUAUAAGCUCAUGGGACACUUCGCAUGGUGGACAGCCUUUGUUACUAAUGUGAAUGCGUCAUCAUCUGAAGCAUUUUUAAUUGGAUGUAAUUAUCUUGGCAAACCACGCGAACAAAUAGAUGGUUAUGUCAUGCAUGCAAAUUACAUAUUUUGGAGGAAUACAAAUCCAAUUCAGUUGUCUUCCUAUUCUUUAUUUGACAUGAGUAAAUUUCCCCUUAAAUUAAGGGGUACUGCUGUUAUGUCUUUAAAAGAAGGUCAAAUCAAUGAUAUGAUUUUAUCUCUUCUUAGUAAAGGUAGACUUAUAAUUAGAGAAAACAACAGAGUUGUUAUUUCUAGUGAUGUUCUUGUUAACAACUAAACGAACAAUGUUUGUUUUUCUUGUUUUAUUGCCACUAGUCUCUAGUCAGUGUGUUAAUCUUACAACCAGAACUCAAUUACCCCCUGCAUACACUAAUUCUUUCACACGUGGUGUUUAUUACCCUGACAAAGUUUUCAGAUCCUCAGUUUUACAUUCAACUCAGGACUUGUUCUUACCUUUCUUUUCCAAUGUUACUUGGUUCCAUGCUAUACAUGUCUCUGGGACCAAUGGUACUAAGAGGUUUGAUAACCCUGUCCUACCAUUUAAUGAUGGUGUUUAUUUUGCUUCCACUGAGAAGUCUAACAUAAUAAGAGGCUGGAUUUUUGGUACUACUUUAGAUUCGAAGACCCAGUCCCUACUUAUUGUUAAUAACGCUACUAAUGUUGUUAUUAAAGUCUGUGAAUUUCAAUUUUGUAAUGAUCCAUUUUUGGGUGUUUAUUACCACAAAAACAACAAAAGUUGGAUGGAAAGUGAGUUCAGAGUUUAUUCUAGUGCGAAUAAUUGCACUUUUGAAUAUGUCUCUCAGCCUUUUCUUAUGGACCUUGAAGGAAAACAGGGUAAUUUCAAAAAUCUUAGGGAAUUUGUGUUUAAGAAUAUUGAUGGUUAUUUUAAAAUAUAUUCUAAGCACACGCCUAUUAAUUUAGUGCGUGAUCUCCCUCAGGGUUUUUCGGCUUUAGAACCAUUGGUAGAUUUGCCAAUAGGUAUUAACAUCACUAGGUUUCAAACUUUACUUGCUUUACAUAGAAGUUAUUUGACUCCUGGUGAUUCUUCUUCAGGUUGGACAGCUGGUGCUGCAGCUUAUUAUGUGGGUUAUCUUCAACCUAGGACUUUUCUAUUAAAAUAUAAUGAAAAUGGAACCAUUACAGAUGCUGUAGACUGUGCACUUGACCCUCUCUCAGAAACAAAGUGUACGUUGAAAUCCUUCACUGUAGAAAAAGGAAUCUAUCAAACUUCUAACUUUAGAGUCCAACCAACAGAAUCUAUUGUUAGAUUUCCUAAUAUUACAAACUUGUGCCCUUUUGGUGAAGUUUUUAACGCCACCAGAUUUGCAUCUGUUUAUGCUUGGAACAGGAAGAGAAUCAGCAACUGUGUUGCUGAUUAUUCUGUCCUAUAUAAUUCCGCAUCAUUUUCCACUUUUAAGUGUUAUGGAGUGUCUCCUACUAAAUUAAAUGAUCUCUGCUUUACUAAUGUCUAUGCAGAUUCAUUUGUAAUUAGAGGUGAUGAAGUCAGACAAAUCGCUCCAGGGCAAACUGGAAAGAUUGCUGAUUAUAAUUAUAAAUUACCAGAUGAUUUUACAGGCUGCGUUAUAGCUUGGAAUUCUAACAAUCUUGAUUCUAAGGUUGGUGGUAAUUAUAAUUACCUGUAUAGAUUGUUUAGGAAGUCUAAUCUCAAACCUUUUGAGAGAGAUAUUUCAACUGAAAUCUAUCAGGCCGGUAGCACACCUUGUAAUGGUGUUGAAGGUUUUAAUUGUUACUUUCCUUUACAAUCAUAUGGUUUCCAACCCACUAAUGGUGUUGGUUACCAACCAUACAGAGUAGUAGUACUUUCUUUUGAACUUCUACAUGCACCAGCAACUGUUUGUGGACCUAAAAAGUCUACUAAUUUGGUUAAAAACAAAUGUGUCAAUUUCAACUUCAAUGGUUUAACAGGCACAGGUGUUCUUACUGAGUCUAACAAAAAGUUUCUGCCUUUCCAACAAUUUGGCAGAGACAUUGCUGACACUACUGAUGCUGUCCGUGAUCCACAGACACUUGAGAUUCUUGACAUUACACCAUGUUCUUUUGGUGGUGUCAGUGUUAUAACACCAGGAACAAAUACUUCUAACCAGGUUGCUGUUCUUUAUCAGGAUGUUAACUGCACAGAAGUCCCUGUUGCUAUUCAUGCAGAUCAACUUACUCCUACUUGGCGUGUUUAUUCUACAGGUUCUAAUGUUUUUCAAACACGUGCAGGCUGUUUAAUAGGGGCUGAACAUGUCAACAACUCAUAUGAGUGUGACAUACCCAUUGGUGCAGGUAUAUGCGCUAGUUAUCAGACUCAGACUAAUUCUCCUCGGCGGGCACGUAGUGUAGCUAGUCAAUCCAUCAUUGCCUACACUAUGUCACUUGGUGCAGAAAAUUCAGUUGCUUACUCUAAUAACUCUAUUGCCAUACCCACAAAUUUUACUAUUAGUGUUACCACAGAAAUUCUACCAGUGUCUAUGACCAAGACAUCAGUAGAUUGUACAAUGUACAUUUGUGGUGAUUCAACUGAAUGCAGCAAUCUUUUGUUGCAAUAUGGCAGUUUUUGUACACAAUUAAACCGUGCUUUAACUGGAAUAGCUGUUGAACAAGACAAAAACACCCAAGAAGUUUUUGCACAAGUCAAACAAAUUUACAAAACACCACCAAUUAAAGAUUUUGGUGGUUUUAAUUUUUCACAAAUAUUACCAGAUCCAUCAAAACCAAGCAAGAGGUCAUUUAUUGAAGAUCUACUUUUCAACAAAGUGACACUUGCAGAUGCUGGCUUCAUCAAACAAUAUGGUGAUUGCCUUGGUGAUAUUGCUGCUAGAGACCUCAUUUGUGCACAAAAGUUUAACGGCCUUACUGUUUUGCCACCUUUGCUCACAGAUGAAAUGAUUGCUCAAUACACUUCUGCACUGUUAGCGGGUACAAUCACUUCUGGUUGGACCUUUGGUGCAGGUGCUGCAUUACAAAUACCAUUUGCUAUGCAAAUGGCUUAUAGGUUUAAUGGUAUUGGAGUUACACAGAAUGUUCUCUAUGAGAACCAAAAAUUGAUUGCCAACCAAUUUAAUAGUGCUAUUGGCAAAAUUCAAGACUCACUUUCUUCCACAGCAAGUGCACUUGGAAAACUUCAAGAUGUGGUCAACCAAAAUGCACAAGCUUUAAACACGCUUGUUAAACAACUUAGCUCCAAUUUUGGUGCAAUUUCAAGUGUUUUAAAUGAUAUCCUUUCACGUCUUGACAAAGUUGAGGCUGAAGUGCAAAUUGAUAGGUUGAUCACAGGCAGACUUCAAAGUUUGCAGACAUAUGUGACUCAACAAUUAAUUAGAGCUGCAGAAAUCAGAGCUUCUGCUAAUCUUGCUGCUACUAAAAUGUCAGAGUGUGUACUUGGACAAUCAAAAAGAGUUGAUUUUUGUGGAAAGGGCUAUCAUCUUAUGUCCUUCCCUCAGUCAGCACCUCAUGGUGUAGUCUUCUUGCAUGUGACUUAUGUCCCUGCACAAGAAAAGAACUUCACAACUGCUCCUGCCAUUUGUCAUGAUGGAAAAGCACACUUUCCUCGUGAAGGUGUCUUUGUUUCAAAUGGCACACACUGGUUUGUAACACAAAGGAAUUUUUAUGAACCACAAAUCAUUACUACAGACAACACAUUUGUGUCUGGUAACUGUGAUGUUGUAAUAGGAAUUGUCAACAACACAGUUUAUGAUCCUUUGCAACCUGAAUUAGACUCAUUCAAGGAGGAGUUAGAUAAAUAUUUUAAGAAUCAUACAUCACCAGAUGUUGAUUUAGGUGACAUCUCUGGCAUUAAUGCUUCAGUUGUAAACAUUCAAAAAGAAAUUGACCGCCUCAAUGAGGUUGCCAAGAAUUUAAAUGAAUCUCUCAUCGAUCUCCAAGAACUUGGAAAGUAUGAGCAGUAUAUAAAAUGGCCAUGGUACAUUUGGCUAGGUUUUAUAGCUGGCUUGAUUGCCAUAGUAAUGGUGACAAUUAUGCUUUGCUGUAUGACCAGUUGCUGUAGUUGUCUCAAGGGCUGUUGUUCUUGUGGAUCCUGCUGCAAAUUUGAUGAAGACGACUCUGAGCCAGUGCUCAAAGGAGUCAAAUUACAUUACACAUAAACGAACUUAUGGAUUUGUUUAUGAGAAUCUUCACAAUUGGAACUGUAACUUUGAAGCAAGGUGAAAUCAAGGAUGCUACUCCUUCAGAUUUUGUUCGCGCUACUGCAACGAUACCGAUACAAGCCUCACUCCCUUUCGGAUGGCUUAUUGUUGGCGUUGCACUUCUUGCUGUUUUUCAGAGCGCUUCCAAAAUCAUAACCCUCAAAAAGAGAUGGCAACUAGCACUCUCCAAGGGUGUUCACUUUGUUUGCAACUUGCUGUUGUUGUUUGUAACAGUUUACUCACACCUUUUGCUCGUUGCUGCUGGCCUUGAAGCCCCUUUUCUCUAUCUUUAUGCUUUAGUCUACUUCUUGCAGAGUAUAAACUUUGUAAGAAUAAUAAUGAGGCUUUGGCUUUGCUGGAAAUGCCGUUCCAAAAACCCAUUACUUUAUGAUGCCAACUAUUUUCUUUGCUGGCAUACUAAUUGUUACGACUAUUGUAUACCUUACAAUAGUGUAACUUCUUCAAUUGUCAUUACUUCAGGUGAUGGCACAACAAGUCCUAUUUCUGAACAUGACUACCAGAUUGGUGGUUAUACUGAAAAAUGGGAAUCUGGAGUAAAAGACUGUGUUGUAUUACACAGUUACUUCACUUCAGACUAUUACCAGCUGUACUCAACUCAAUUGAGUACAGACACUGGUGUUGAACAUGUUACCUUCUUCAUCUACAAUAAAAUUGUUGAUGAGCCUGAAGAACAUGUCCAAAUUCACACAAUCGACGGUUCAUCCGGAGUUGUUAAUCCAGUAAUGGAACCAAUUUAUGAUGAACCGACGACGACUACUAGCGUGCCUUUGUAAGCACAAGCUGAUGAGUACGAACUUAUGUACUCAUUCGUUUCGGAAGAGACAGGUACGUUAAUAGUUAAUAGCGUACUUCUUUUUCUUGCUUUCGUGGUAUUCUUGCUAGUUACACUAGCCAUCCUUACUGCGCUUCGAUUGUGUGCGUACUGCUGCAAUAUUGUUAACGUGAGUCUUGUAAAACCUUCUUUUUACGUUUACUCUCGUGUUAAAAAUCUGAAUUCUUCUAGAGUUCCUGAUCUUCUGGUCUAAACGAACUAAAUAUUAUAUUAGUUUUUCUGUUUGGAACUUUAAUUUUAGCCAUGGCAGAUUCCAACGGUACUAUUACCGUUGAAGAGCUUAAAAAGCUCCUUGAACAAUGGAACCUAGUAAUAGGUUUCCUAUUCCUUACAUGGAUUUGUCUUCUACAAUUUGCCUAUGCCAACAGGAAUAGGUUUUUGUAUAUAAUUAAGUUAAUUUUCCUCUGGCUGUUAUGGCCAGUAACUUUAGCUUGUUUUGUGCUUGCUGCUGUUUACAGAAUAAAUUGGAUCACCGGUGGAAUUGCUAUCGCAAUGGCUUGUCUUGUAGGCUUGAUGUGGCUCAGCUACUUCAUUGCUUCUUUCAGACUGUUUGCGCGUACGCGUUCCAUGUGGUCAUUCAAUCCAGAAACUAACAUUCUUCUCAACGUGCCACUCCAUGGCACUAUUCUGACCAGACCGCUUCUAGAAAGUGAACUCGUAAUCGGAGCUGUGAUCCUUCGUGGACAUCUUCGUAUUGCUGGACACCAUCUAGGACGCUGUGACAUCAAGGACCUGCCUAAAGAAAUCACUGUUGCUACAUCACGAACGCUUUCUUAUUACAAAUUGGGAGCUUCGCAGCGUGUAGCAGGUGACUCAGGUUUUGCUGCAUACAGUCGCUACAGGAUUGGCAACUAUAAAUUAAACACAGACCAUUCCAGUAGCAGUGACAAUAUUGCUUUGCUUGUACAGUAAGUGACAACAGAUGUUUCAUCUCGUUGACUUUCAGGUUACUAUAGCAGAGAUAUUACUAAUUAUUAUGAGGACUUUUAAAGUUUCCAUUUGGAAUCUUGAUUACAUCAUAAACCUCAUAAUUAAAAAUUUAUCUAAGUCACUAACUGAGAAUAAAUAUUCUCAAUUAGAUGAAGAGCAACCAAUGGAGAUUGAUUAAACGAACAUGAAAAUUAUUCUUUUCUUGGCACUGAUAACACUCGCUACUUGUGAGCUUUAUCACUACCAAGAGUGUGUUAGAGGUACAACAGUACUUUUAAAAGAACCUUGCUCUUCUGGAACAUACGAGGGCAAUUCACCAUUUCAUCCUCUAGCUGAUAACAAAUUUGCACUGACUUGCUUUAGCACUCAAUUUGCUUUUGCUUGUCCUGACGGCGUAAAACACGUCUAUCAGUUACGUGCCAGAUCAGUUUCACCUAAACUGUUCAUCAGACAAGAGGAAGUUCAAGAACUUUACUCUCCAAUUUUUCUUAUUGUUGCGGCAAUAGUGUUUAUAACACUUUGCUUCACACUCAAAAGAAAGACAGAAUGAUUGAACUUUCAUUAAUUGACUUCUAUUUGUGCUUUUUAGCCUUUCUGCUAUUCCUUGUUUUAAUUAUGCUUAUUAUCUUUUGGUUCUCACUUGAACUGCAAGAUCAUAAUGAAACUUGUCACGCCUAAACGAACAUGAAAUUUCUUGUUUUCUUAGGAAUCAUCACAACUGUAGCUGCAUUUCACCAAGAAUGUAGUUUACAGUCAUGUACUCAACAUCAACCAUAUGUAGUUGAUGACCCGUGUCCUAUUCACUUCUAUUCUAAAUGGUAUAUUAGAGUAGGAGCUAGAAAAUCAGCACCUUUAAUUGAAUUGUGCGUGGAUGAGGCUGGUUCUAAAUCACCCAUUCAGUACAUCGAUAUCGGUAAUUAUACAGUUUCCUGUUUACCUUUUACAAUUAAUUGCCAGGAACCUAAAUUGGGUAGUCUUGUAGUGCGUUGUUCGUUCUAUGAAGACUUUUUAGAGUAUCAUGACGUUCGUGUUGUUUUAGAUUUCAUCUAAACGAACAAACUAAAAUGUCUGAUAAUGGACCCCAAAAUCAGCGAAAUGCACCCCGCAUUACGUUUGGUGGACCCUCAGAUUCAACUGGCAGUAACCAGAAUGGAGAACGCAGUGGGGCGCGAUCAAAACAACGUCGGCCCCAAGGUUUACCCAAUAAUACUGCGUCUUGGUUCACCGCUCUCACUCAACAUGGCAAGGAAGACCUUAAAUUCCCUCGAGGACAAGGCGUUCCAAUUAACACCAAUAGCAGUCCAGAUGACCAAAUUGGCUACUACCGAAGAGCUACCAGACGAAUUCGUGGUGGUGACGGUAAAAUGAAAGAUCUCAGUCCAAGAUGGUAUUUCUACUACCUAGGAACUGGGCCAGAAGCUGGACUUCCCUAUGGUGCUAACAAAGACGGCAUCAUAUGGGUUGCAACUGAGGGAGCCUUGAAUACACCAAAAGAUCACAUUGGCACCCGCAAUCCUGCUAACAAUGCUGCAAUCGUGCUACAACUUCCUCAAGGAACAACAUUGCCAAAAGGCUUCUACGCAGAAGGGAGCAGAGGCGGCAGUCAAGCCUCUUCUCGUUCCUCAUCACGUAGUCGCAACAGUUCAAGAAAUUCAACUCCAGGCAGCAGUAGGGGAACUUCUCCUGCUAGAAUGGCUGGCAAUGGCGGUGAUGCUGCUCUUGCUUUGCUGCUGCUUGACAGAUUGAACCAGCUUGAGAGCAAAAUGUCUGGUAAAGGCCAACAACAACAAGGCCAAACUGUCACUAAGAAAUCUGCUGCUGAGGCUUCUAAGAAGCCUCGGCAAAAACGUACUGCCACUAAAGCAUACAAUGUAACACAAGCUUUCGGCAGACGUGGUCCAGAACAAACCCAAGGAAAUUUUGGGGACCAGGAACUAAUCAGACAAGGAACUGAUUACAAACAUUGGCCGCAAAUUGCACAAUUUGCCCCCAGCGCUUCAGCGUUCUUCGGAAUGUCGCGCAUUGGCAUGGAAGUCACACCUUCGGGAACGUGGUUGACCUACACAGGUGCCAUCAAAUUGGAUGACAAAGAUCCAAAUUUCAAAGAUCAAGUCAUUUUGCUGAAUAAGCAUAUUGACGCAUACAAAACAUUCCCACCAACAGAGCCUAAAAAGGACAAAAAGAAGAAGGCUGAUGAAACUCAAGCCUUACCGCAGAGACAGAAGAAACAGCAAACUGUGACUCUUCUUCCUGCUGCAGAUUUGGAUGAUUUCUCCAAACAAUUGCAACAAUCCAUGAGCAGUGCUGACUCAACUCAGGCCUAAACUCAUGCAGACCACACAAGGCAGAUGGGCUAUAUAAACGUUUUCGCUUUUCCGUUUACGAUAUAUAGUCUACUCUUGUGCAGAAUGAAUUCUCGUAACUACAUAGCACAAGUAGAUGUAGUUAACUUUAAUCUCACAUAGCAAUCUUUAAUCAGUGUGUAACAUUAGGGAGGACUUGAAAGAGCCACCACAUUUUCACCGAGGCCACGCGGAGUACGAUCGAGUGUACAGUGAACAAUGCUAGGGAGAGCUGCCUAUAUGGAAGAGCCCUAAUGUGUAAAAUUAAUUUUAGUAGUGCUAUCCCCAUGUGAUUUUAAUAGCUUCUUAGGAGAAUGACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5-20µM[SARS2-NP];|200nM[SARS-CoV-2],"15 mM NaCl, 135 mM KCl, 5 mM phosphate, 1.5 mM MgCl2","20 mM Tris–HCl, pH 7.0",37˚C,-,other_molecular:1 mg ml−1 BSA,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"To test whether these viral mutations induce changes in the phase separation of SARS2-NP , we incubated fluorescently labelled K375N and K375E with viral RNA and compared the micrometre-sized liquid droplet formation with that of SARS2-NP WT. Both the K375N and K375E mutants seemed to have compromised LLPS "
